Effects O
of O
docosahexaenoic B
acid I
and O
methylmercury B
on O
child O
' O
s O
brain O
development O
due O
to O
consumption O
of O
fish O
by O
Finnish O
mother O
during O
pregnancy O
: O
a O
probabilistic O
modeling O
approach O
. O

Fish O
contains O
both O
beneficial O
substances O
e O
. O
g O
. O
docosahexaenoic B
acids I
but O
also O
harmful O
compounds O
e O
. O
g O
. O
methylmercury B
. O

The O
increased O
activities O
of O
the O
most O
important O
intestinal O
efflux O
( O
P O
- O
glycoprotein O
- O
Pgp O
, O
Multidrug O
Resistance O
Associated O
Protein O
2 O
- O
MRP O
- O
2 O
, O
Breast O
Cancer O
Resistance O
Protein O
- O
BCRP O
) O
and O
uptake O
( O
MonoCarboxylate B
Transporter O
1 O
- O
MCT1 O
, O
Organic O
Anion O
Transporting O
Polypeptide O
- O
OATP O
, O
Peptide O
transporter O
1 O
- O
PepT1 O
) O
transporters O
were O
caused O
by O
changes O
in O
electrophysiological O
membrane O
properties O
and O
by O
allosteric O
modifications O
. O

Because O
clinical O
studies O
investigating O
interactions O
between O
garlic O
and O
human O
immunodeficiency O
virus O
protease O
inhibitors O
saquinavir B
and O
ritonavir B
have O
already O
been O
performed O
, O
we O
used O
these O
in O
vivo O
data O
to O
evaluate O
the O
in O
vitro O
results O
and O
the O
reliability O
of O
the O
models O
employed O
as O
screening O
tools O
for O
forecasting O
the O
potential O
of O
first O
- O
pass O
intestinal O
metabolism O
changes O
. O

We O
also O
assessed O
the O
probability O
of O
pharmacokinetic O
interactions O
with O
garlic O
of O
the O
novel O
drug O
darunavir B
and O
other O
cardiovascular O
drugs O
. O

Endothelial O
nitric B
oxide I
synthase O
genotypes O
and O
haplotypes O
modify O
the O
responses O
to O
sildenafil B
in O
patients O
with O
erectile O
dysfunction O
. O

Erectile O
dysfunction O
( O
ED O
) O
is O
usually O
treated O
with O
sildenafil B
. O

Although O
genetic O
polymorphisms O
in O
the O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
gene O
may O
impair O
endogenous O
NO B
formation O
, O
there O
is O
little O
information O
about O
how O
eNOS O
polymorphisms O
and O
haplotypes O
affect O
the O
responses O
to O
sildenafil B
. O

The O
clinical O
responses O
to O
sildenafil B
were O
evaluated O
and O
the O
patients O
were O
classified O
as O
good O
responders O
( O
GR O
) O
or O
poor O
responders O
( O
PR O
) O
when O
their O
changes O
in O
five O
- O
item O
version O
of O
International O
Index O
for O
Erectile O
Function O
questionnaire O
were O
above O
or O
below O
the O
median O
value O
. O

Our O
findings O
show O
evidence O
that O
eNOS O
polymorphisms O
affect O
the O
responses O
of O
PED O
and O
clinical O
ED O
patients O
to O
sildenafil B
. O

On O
the O
benefit O
of O
magnetic O
magnesium B
nanocarrier O
in O
cardiovascular O
toxicity O
of O
aluminum O
phosphide O
. O

Later O
lipid O
peroxidation O
, O
antioxidant O
power O
, O
ATP B
/ O
ADP B
ratio O
, O
and O
Mg B
concentration O
in O
the O
heart O
were O
evaluated O
. O

We O
found O
a O
considerable O
increase O
in O
antioxidant O
power O
, O
Mg B
level O
in O
the O
plasma O
and O
the O
heart O
and O
a O
reduction O
in O
lipid O
peroxidation O
and O
ADP B
/ O
ATP B
ratio O
at O
various O
doses O
of O
( O
25 O
) O
MgPMC16 O
, O
but O
( O
25 O
) O
MgPMC16 O
- O
0 O
. O
025 O
+ O
Bicarb O
was O
the O
most O
effective O
combination O
therapy O
. O

The O
results O
of O
this O
study O
support O
that O
( O
25 O
) O
MgPMC16 O
can O
increase O
heart O
energy O
by O
active O
transport O
of O
Mg B
inside O
the O
cardiac O
cells O
. O
( O
25 O
) O
MgPMC16 O
seems O
ameliorating O
AlP O
- O
induced O
toxicity O
and O
cardiac O
failure O
necessitating O
further O
studies O
. O

Hyperthermia O
- O
exposed O
rats O
were O
killed O
under O
50 O
mg O
/ O
kg O
ketamine B
anaesthesia O
and O
tissue O
samples O
were O
obtained O
for O
biochemical O
and O
histopathological O
investigations O
. O

Hyperthermia O
treatment O
significantly O
decreased O
the O
testicular O
antioxidant O
system O
, O
including O
decreases O
in O
the O
glutathione B
level O
, O
superoxide B
dismutase O
, O
and O
glutathione B
peroxidase O
activities O
. O

Our O
data O
indicate O
a O
significant O
reduction O
in O
the O
expression O
of O
proliferating O
cell O
nuclear O
antigen O
and O
an O
enhancement O
in O
the O
activity O
of O
terminal O
deoxynucleotidyl O
transferase O
dUTP B
nick O
end O
labelling O
after O
scrotal O
hyperthermia O
. O

In O
order O
to O
study O
the O
mechanism O
of O
the O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
valproic B
acid I
( O
VPA B
) O
and O
suberoylanilide B
hydroxamic I
acid I
( O
SAHA B
) O
in O
breast O
cancer O
, O
we O
generated O
and O
validated O
genomic O
profiles O
of O
drug O
response O
using O
a O
series O
of O
breast O
cancer O
cell O
lines O
sensitive O
to O
each O
drug O
. O

These O
genomic O
profiles O
were O
then O
used O
to O
model O
drug O
response O
in O
human O
breast O
tumors O
and O
show O
significant O
correlation O
between O
VPA B
and O
SAHA B
response O
profiles O
in O
multiple O
breast O
tumor O
data O
sets O
, O
highlighting O
their O
similar O
mechanism O
of O
action O
. O

The O
genes O
deregulated O
by O
VPA B
and O
SAHA B
converge O
on O
the O
cell O
cycle O
pathway O
( O
Bayes O
factor O
5 O
. O
21 O
and O
5 O
. O
94 O
, O
respectively O
; O
P O
- O
value O
10 O
( O
- O
8 O
. O
6 O
) O
and O
10 O
( O
- O
9 O
) O
, O
respectively O
) O
. O

In O
particular O
, O
VPA B
and O
SAHA B
upregulate O
key O
cyclin O
- O
dependent O
kinase O
( O
CDK O
) O
inhibitors O
. O

Together O
, O
these O
results O
led O
us O
to O
hypothesize O
that O
VPA B
and O
SAHA B
may O
interact O
synergistically O
with O
CDK O
inhibitors O
such O
as O
PD O
- O
033299 O
. O

The O
main O
isolated O
compounds O
were O
triterpenes B
( O
alpha O
- O
amyrin O
, O
beta O
- O
amyrin O
, O
lupeol B
, O
betulin O
, O
betulinic B
acid I
, O
uvaol O
, O
erythrodiol O
and O
oleanolic B
acid I
) O
and O
phenolic B
acid I
derivatives O
from O
4 B
- I
hydroxybenzoic I
acid I
( O
gallic O
and O
protocatechuic O
acids O
and O
isocorilagin O
) O
. O

In O
the O
germination O
assays O
, O
high O
inhibitory O
allelopathic O
effects O
of O
the O
extracts O
and O
isocorilagin O
were O
observed O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
activity O
of O
isocorilagin O
was O
higher O
than O
those O
of O
the O
standards O
used O
( O
Trolox B
and O
butylated B
hydroxyanisole I
) O
. O

The O
urine O
fluoride B
levels O
and O
plasma O
TOS O
and O
TAC O
levels O
were O
measured O
. O

The O
urine O
fluoride B
levels O
of O
fluorosis O
patients O
were O
significantly O
higher O
than O
control O
subjects O
as O
expected O
( O
1 O
. O
91 O
+ O
/ O
- O
0 O
. O
15 O
vs O
. O
0 O
. O
49 O
+ O
/ O
- O
0 O
. O
13 O
mg O
/ O
L O
, O
respectively O
; O
p O
< O
0 O
. O
001 O
) O
. O

TAC O
was O
significantly O
lower O
in O
fluorosis O
group O
than O
in O
control O
group O
( O
1 O
. O
60 O
+ O
/ O
- O
0 O
. O
36 O
vs O
. O
1 O
. O
82 O
+ O
/ O
- O
0 O
. O
51 O
mmol O
Trolox B
Eq O
/ O
L O
, O
respectively O
; O
p O
= O
0 O
. O
004 O
) O
. O

Correlation O
analysis O
in O
all O
the O
groups O
indicated O
that O
TAC O
was O
negatively O
correlated O
with O
urine O
fluoride B
( O
r O
= O
- O
0 O
. O
25 O
, O
p O
= O
0 O
. O
003 O
) O
, O
TOS O
was O
positively O
correlated O
with O
urine O
fluoride B
( O
r O
= O
0 O
. O
34 O
, O
p O
< O
0 O
. O
001 O
) O
and O
OSI O
was O
positively O
correlated O
with O
urine O
fluoride B
( O
r O
= O
0 O
. O
36 O
, O
p O
< O
0 O
. O
001 O
) O
. O

Impact O
of O
aqueous O
doash O
extract O
on O
urinary O
mutagenicity O
in O
rats O
exposed O
to O
heterocyclic B
amines I
. O

The O
2 O
- O
amino O
- O
3 O
- O
methylimidazo O
[ O
4 O
, O
5 O
- O
f O
] O
quinoline O
( O
IQ O
) O
and O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
are O
the O
most O
abundant O
of O
the O
heterocyclic B
amine I
carcinogens O
present O
in O
cooked O
food O
. O

In O
the O
present O
study O
, O
the O
potential O
of O
doash O
tea O
to O
influence O
carcinogen O
metabolism O
was O
investigated O
indirectly O
using O
heterocyclic B
amines I
as O
model O
mutagens O
, O
IQ O
and O
PhIP B
. O

Rats O
were O
treated O
with O
different O
doses O
of O
IQ O
( O
1 O
, O
3 O
, O
5 O
and O
10 O
mg O
/ O
kg O
) O
or O
PhIP B
( O
1 O
, O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
. O

The O
selected O
dosage O
was O
5 O
mg O
/ O
kg O
for O
both O
heterocyclic B
amines I
. O

Results O
obtained O
revealed O
that O
rats O
treated O
with O
doash O
tea O
and O
given O
a O
single O
dose O
of O
the O
heterocyclic B
amines I
, O
whether O
for O
1 O
day O
( O
short O
- O
term O
) O
or O
for O
1 O
month O
( O
long O
term O
) O
, O
showed O
a O
statistically O
significant O
decrease O
in O
their O
excretion O
of O
indirect O
mutagens O
( O
IQ O
or O
PhIP B
) O
. O

Following O
treatment O
of O
the O
rats O
with O
a O
single O
oral O
dose O
of O
IQ O
or O
PhIP B
, O
the O
highest O
mutagenic O
activity O
determined O
in O
the O
presence O
of O
an O
activation O
system O
was O
excreted O
in O
the O
urine O
after O
24 O
h O
, O
with O
much O
lower O
levels O
of O
mutagencity O
being O
excreted O
during O
subsequent O
elimination O
from O
the O
body O
. O

No O
mutagenicity O
was O
observed O
in O
the O
absence O
of O
an O
activation O
system O
that O
is O
direct O
- O
acting O
mutagenicity O
using O
( O
IQ O
and O
PhIP B
) O
. O

Human O
organic O
cation O
transporter O
3 O
( O
OCT3 O
and O
SLC22A3 O
) O
mediates O
the O
uptake O
of O
many O
important O
endogenous O
amines B
and O
basic O
drugs O
in O
a O
variety O
of O
tissues O
. O

Accumulation O
profiles O
of O
fatty B
acids I
and O
alpha B
- I
tocopherol I
were O
analysed O
at O
three O
ripening O
stages O
in O
the O
seed O
oils O
of O
Primula O
and O
Echium O
species O
. O

Total O
seed O
oils O
were O
increased O
considerably O
with O
maturation O
, O
while O
alpha B
- I
tocopherol I
contents O
decreased O
in O
both O
species O
. O

Increased O
levels O
of O
ALA B
and O
oleic B
acid I
, O
and O
decrease O
in O
linoleic O
and O
palmitic O
acids O
at O
late O
ripening O
stages O
of O
Primula O
sibthorpii O
, O
and O
slightly O
fluctuations O
of O
all O
examined O
fatty B
acids I
in O
Echium O
italicum O
were O
observed O
. O

Considerable O
amounts O
of O
alpha B
- I
tocopherol I
( O
27 O
. O
4 O
mg O
/ O
100 O
g O
) O
, O
linoleic B
acid I
( O
42 O
. O
76 O
% O
) O
and O
ALA B
( O
25 O
. O
46 O
% O
) O
and O
GLA O
( O
4 O
. O
11 O
% O
) O
were O
detected O
in O
Ribes O
alpinum O
. O

The O
ubiquitous O
serine B
/ O
threonine B
protein O
phosphatase O
1 O
( O
PP1 O
) O
regulates O
diverse O
, O
essential O
cellular O
processes O
such O
as O
cell O
cycle O
progression O
, O
protein O
synthesis O
, O
muscle O
contraction O
, O
carbohydrate B
metabolism O
, O
transcription O
and O
neuronal O
signaling O
. O

Protective O
effect O
of O
vitamin B
E I
and O
epicatechin B
against O
nicotine B
- O
induced O
oxidative O
stress O
in O
rats O
. O

Nicotine B
is O
a O
major O
pharmacologically O
active O
and O
addictive O
component O
of O
tobacco O
smoke O
, O
which O
is O
regarded O
to O
be O
a O
primary O
risk O
factor O
in O
the O
development O
of O
cardiovascular O
and O
pulmonary O
diseases O
. O

Epicatechin B
is O
one O
of O
the O
most O
potent O
antioxidants O
present O
in O
the O
human O
diet O
. O

Vitamin B
E I
is O
a O
major O
lipid O
- O
soluble O
antioxidant O
vitamin O
and O
free O
radical O
scavenger O
, O
presents O
as O
an O
integral O
component O
of O
cellular O
membranes O
and O
has O
important O
biological O
functions O
. O

The O
primary O
mechanism O
by O
which O
vitamin B
E I
is O
proposed O
to O
prevent O
cancer O
is O
through O
their O
antioxidant O
properties O
. O

The O
goal O
of O
this O
study O
is O
to O
evaluate O
the O
effect O
of O
epicatechin B
alone O
or O
combined O
with O
vitamin B
E I
in O
inhibiting O
the O
oxidative O
stress O
induced O
by O
nicotine B
in O
rats O
. O

Results O
obtained O
indicated O
that O
there O
was O
a O
significant O
elevation O
in O
the O
levels O
of O
malondialdhyde O
( O
MDA B
) O
in O
nicotine B
injected O
rats O
. O

The O
combined O
treatment O
( O
epicatechin B
+ O
Vit B
E I
) O
group O
showed O
a O
potential O
reduction O
of O
these O
parameters O
more O
than O
individual O
treatment O
. O

The O
activities O
of O
superoxide B
dismutase O
, O
catalase O
and O
glutathione B
peroxidase O
were O
found O
significantly O
higher O
in O
combined O
treated O
than O
untreated O
rats O
. O

In O
nicotine B
group O
, O
a O
negative O
significant O
correlation O
between O
reduced O
glutathione B
and O
MDA B
( O
r O
= O
- O
0 O
. O
92 O
) O
was O
observed O
. O

In O
conclusion O
, O
these O
results O
suggested O
that O
the O
supplementation O
of O
diet O
with O
epicatechin B
and O
vitamin B
E I
provided O
antioxidant O
defense O
with O
strong O
chemopreventive O
activity O
against O
nicotine B
- O
induced O
carcinogenesis O
. O

Prevention O
of O
cytotoxicity O
of O
nickel B
by O
quercetin B
: O
the O
role O
of O
reactive O
oxygen B
species O
and O
histone O
acetylation O
. O

Excessive O
exposure O
to O
nickel B
may O
cause O
health O
effects O
on O
the O
blood O
, O
lung O
, O
nose O
, O
kidney O
, O
reproductive O
system O
, O
skin O
and O
the O
unborn O
child O
. O

In O
the O
present O
study O
, O
we O
found O
that O
Ni B
( I
2 I
+ I
) I
exposure O
led O
to O
a O
time O
- O
and O
dose O
- O
dependent O
proliferation O
arrest O
and O
death O
in O
human O
leukemia O
HL O
- O
60 O
cells O
. O

In O
the O
presence O
of O
1 O
mM O
Ni B
( I
2 I
+ I
) I
, O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
( O
indicated O
by O
the O
level O
of O
malondialdehyde B
) O
increased O
to O
323 O
% O
and O
histone O
acetylation O
decreased O
to O
32 O
% O
. O

Interestingly O
, O
quercetin B
( O
QU O
) O
dose O
dependently O
prevented O
Ni B
( I
2 I
+ I
) I
- O
induced O
cell O
proliferation O
arrest O
and O
death O
from O
0 O
to O
80 O
mu O
M O
but O
showed O
similar O
activity O
of O
scavenging O
ROS O
at O
the O
concentrations O
of O
20 O
, O
40 O
and O
80 O
micro O
M O
. O

When O
the O
effect O
of O
QU O
on O
histone O
acetylation O
was O
studied O
, O
QU O
significantly O
prevented O
Ni B
( I
2 I
+ I
) I
- O
induced O
histone O
hypoacetylation O
at O
40 O
or O
80 O
micro O
M O
. O

Moreover O
, O
increase O
in O
histone O
acetylation O
by O
trichostatin B
A I
could O
also O
significantly O
enhance O
the O
protection O
effect O
of O
QU O
at O
10 O
or O
20 O
micro O
M O
but O
not O
at O
higher O
concentrations O
. O

Thus O
, O
our O
results O
further O
confirmed O
the O
critical O
role O
of O
ROS O
and O
histone O
hypoacetylation O
in O
the O
cytotoxicity O
of O
Ni B
( I
2 I
+ I
) I
exposure O
and O
proved O
that O
QU O
is O
a O
potentially O
useful O
native O
dietary O
compound O
to O
efficiently O
prevent O
Ni B
( I
2 I
+ I
) I
- O
caused O
cytotoxicity O
through O
both O
diminishing O
ROS O
generation O
and O
increasing O
histone O
acetylation O
. O

Cadmium B
concentrations O
in O
shrimp O
( O
Penaeus O
semisulcatus O
and O
Penaeus O
monodon O
) O
caught O
from O
the O
coastal O
areas O
in O
Southern O
Iran O
. O

This O
study O
was O
undertaken O
to O
determine O
the O
concentration O
of O
cadmium B
in O
two O
shrimp O
species O
, O
namely O
, O
Penaeus O
semisulcatus O
and O
Penaeus O
monodon O
caught O
from O
the O
coastal O
areas O
in O
southern O
Iran O
. O

Cadmium B
concentration O
was O
determined O
by O
graphite B
furnace O
atomic O
absorption O
spectrophotometry O
in O
91 O
shrimp O
samples O
after O
nitric B
acid I
/ O
perchloric O
acid O
digestion O
. O

The O
mean O
+ O
/ O
- O
SD O
of O
cadmium B
concentrations O
in O
shrimp O
samples O
were O
0 O
. O
128 O
+ O
/ O
- O
0 O
. O
144 O
( O
mu O
g O
/ O
g O
) O
. O

The O
cadmium B
concentrations O
ranged O
from O
0 O
. O
010 O
to O
0 O
. O
96 O
mu O
g O
/ O
g O
of O
the O
muscle O
tissues O
of O
shrimp O
. O

Higher O
cadmium B
concentration O
in O
shrimp O
samples O
was O
found O
in O
summer O
( O
significant O
p O
< O
0 O
. O
05 O
) O
. O

The O
results O
show O
that O
the O
mean O
concentration O
of O
cadmium B
in O
shrimp O
is O
lower O
than O
the O
maximum O
allowed O
levels O
according O
to O
International O
standards O
, O
although O
the O
concentration O
of O
cadmium B
in O
only O
one O
sample O
was O
more O
than O
the O
amount O
recommended O
by O
Food O
and O
Agriculture O
Organization O
. O

Therefore O
, O
no O
risk O
to O
the O
consumer O
arises O
from O
the O
cadmium B
contents O
of O
the O
shrimp O
caught O
in O
these O
areas O
. O

The O
host O
molecule O
1 O
, O
1 O
, O
6 O
, O
6 O
- O
tetraphenylhexa O
- O
2 O
, O
4 O
- O
diyne O
- O
1 O
, O
6 O
- O
diol O
( O
A O
) O
was O
used O
to O
selectively O
recognise O
the O
guest O
molecule O
patchouli O
alcohol O
( O
B O
) O
in O
the O
essential O
oil O
of O
Pogostemon O
cablin O
( O
Blanco O
) O
Benth O
through O
two O
strong O
hydrogen B
bonding O
. O

In O
this O
experiment O
, O
a O
total O
of O
100 O
male O
albino O
rats O
of O
Spargue O
Dawley O
strain O
were O
divided O
into O
10 O
groups O
: O
G O
( O
1 O
) O
was O
fed O
basal O
diet O
and O
served O
as O
control O
, O
G O
( O
2 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
( O
blue O
dye O
, O
No O
. O
2 O
, O
124 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O
3 O
) O
: O
basal O
diet O
+ O
carmoisine O
( O
red O
dye O
, O
No O
. O
3 O
, O
70 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O
4 O
) O
: O
basal O
diet O
+ O
tartrazine O
( O
yellow O
dye O
, O
FD O
& O
C O
yellow O
No O
. O
5 O
, O
75 O
mg O
/ O
kg O
diet O
) O
, O
G O
( O

5 O
) O
: O
basal O
diet O
+ O
trans O
- O
anethole O
( O
4 O
. O
5 O
g O
/ O
kg O
diet O
) O
G O
( O
6 O
) O
: O
basal O
diet O
+ O
propylene B
glycol I
( O
0 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
7 O
) O
: O
basal O
diet O
+ O
vanillin B
( O
1 O
. O
25 O
g O
/ O
kg O
diet O
) O
, O
G O
( O
8 O
) O
: O
basal O
diet O
+ O
Brilliant B
blue I
+ O
propylene B
glycol I
, O
G O
( O
9 O
) O
: O
basal O
diet O
+ O
carmoisine O
+ O
trans O
- O
anethole O
, O
G O
( O
10 O
) O
: O
basal O
diet O
+ O
tartrazine O
+ O
vanillin B
for O
42 O
successive O
days O

Also O
there O
was O
a O
significant O
decrease O
in O
reduced O
glutathione B
content O
; O
glutathione B
- O
S B
- O
transferase O
and O
superoxide B
dismutase O
activities O
in O
both O
blood O
and O
liver O
compared O
to O
control O
group O
. O

On O
the O
other O
hand O
, O
a O
significant O
increase O
in O
serum O
alanine B
aminotransferase O
, O
aspartate B
aminotransferase O
, O
alkaline O
phosphatase O
activities O
, O
bilirubin B
, O
urea B
, O
creatinine B
, O
total O
protein O
and O
albumin O
were O
observed O
in O
all O
test O
groups O
when O
compared O
to O
control O
group O
. O

Steroids B
and O
phenolic B
constituents O
from O
the O
fruiting O
bodies O
of O
the O
basidiomycete O
Sarcodon O
joedes O
. O

Nine O
secondary O
metabolites O
, O
including O
four O
steroids B
, O
four O
phenolics B
and O
one O
cerebroside O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
fruiting O
bodies O
of O
the O
basidiomycete O
Sarcodon O
joedes O
. O

The O
isolated O
compounds O
were O
identified O
by O
spectroscopic O
analyses O
as O
( O
22E O
, O
24R O
) O
- O
6 O
beta O
- O
methoxyergosta O
- O
7 O
, O
22 O
- O
diene O
- O
3 O
beta O
, O
5 O
alpha O
- O
diol O
( O
1 O
) O
, O
2 O
' O
, O
3 O
' O
- O
diacetoxy O
- O
3 O
, O
4 O
, O
5 O
' O
, O
6 O
' O
, O
4 O
' O
' O
- O
pentahydroxy O
- O
p O
- O
terphenyl O
( O
2 O
) O
, O
cerebroside O
B O
( O
3 O
) O
, O
ergosta O
- O
7 O
, O
22 O
- O
dien O
- O
3 O
beta O
- O
ol O
( O
4 O
) O
, O
ergosterol B
peroxide I
( O
5 O

) O
, O
( O
22E O
, O
24R O
) O
- O
3 O
beta O
- O
hydroxy O
- O
ergosta O
- O
5 O
, O
22 O
- O
dien O
- O
7 O
- O
one O
( O
6 O
) O
, O
benzoic B
acid I
( O
7 O
) O
, O
methyl O
p O
- O
hydroxybenzoate O
( O
8 O
) O
and O
3 O
, O
4 O
- O
dihydroxybenzoic O
acid O
( O
9 O
) O
. O

In O
vitro O
evaluation O
of O
the O
protective O
effects O
of O
4 O
- O
thujanol O
against O
mitomycin B
- I
C I
and O
cyclophosphamide B
- O
induced O
genotoxic O
damage O
in O
human O
peripheral O
lymphocytes O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
protective O
effects O
of O
4 O
- O
thujanol O
against O
the O
genotoxic O
effects O
induced O
by O
mitomycin B
C I
( O
MMC B
) O
and O
cyclophosphamide B
( O
CP O
) O
in O
human O
lymphocytes O
, O
using O
the O
chromosome O
aberrations O
, O
sister O
chromatid O
exchanges O
, O
and O
micronucleus O
tests O
, O
in O
the O
absence O
and O
in O
the O
presence O
of O
S9 O
mix O
, O
respectively O
. O

The O
cells O
were O
treated O
with O
0 O
. O
25 O
micro O
g O
/ O
mL O
MMC B
and O
28 O
micro O
g O
/ O
mL O
CP O
as O
alone O
and O
cotreated O
with O
13 O
+ O
0 O
. O
25 O
, O
26 O
+ O
0 O
. O
25 O
, O
and O
52 O
+ O
0 O
. O
25 O
micro O
g O
/ O
mL O
4 O
- O
thujanol O
+ O
MMC B
and O
with O
13 O
+ O
28 O
, O
26 O
+ O
28 O
, O
and O
52 O
+ O
28 O
micro O
g O
/ O
mL O
4 O
- O
thujanol O
+ O
CP O
as O
a O
mixture O
. O

The O
present O
study O
showed O
that O
4 O
- O
thujanol O
was O
unable O
to O
reduce O
the O
genetic O
damage O
induced O
by O
MMC B
, O
in O
the O
absence O
of O
S9 O
mix O
. O

In O
general O
, O
4 O
- O
thujanol O
+ O
MMC B
and O
4 O
- O
thujanol O
+ O
CP O
decreased O
the O
mitotic O
index O
, O
proliferation O
index O
and O
nuclear O
division O
index O
to O
the O
same O
extent O
or O
more O
than O
those O
of O
individual O
exposure O
of O
MMC B
or O
CP O
. O

In O
conclusion O
, O
4 O
- O
thujanol O
significantly O
reduced O
( O
p O
< O
0 O
. O
001 O
) O
the O
genotoxic O
damage O
induced O
by O
CP O
but O
not O
MMC B
when O
compared O
with O
the O
respective O
positive O
control O
alone O
. O

Chlorogenic B
acid I
, O
rutin B
and O
hyperoside B
content O
in O
Fragaria O
vesca O
, O
F O
. O
viridis O
and O
F O
. O
moschata O
in O
Lithuania O
. O

The O
main O
objective O
of O
this O
study O
was O
to O
establish O
the O
variation O
pattern O
in O
the O
content O
of O
chlorogenic B
acid I
, O
rutin B
and O
hyperoside B
in O
leaves O
and O
fruits O
of O
the O
native O
Lithuanian O
species O
. O

F O
. O
vesca O
fruits O
had O
the O
highest O
rutin B
( O
1 O
. O
38 O
+ O
/ O
- O
0 O
. O
19 O
mg O
g O
( O
- O
1 O
) O
DM O
) O
, O
hyperoside B
( O
0 O
. O
69 O
+ O
/ O
- O
0 O
. O
10 O
mg O
g O
( O
- O
1 O
) O
DM O
) O
and O
chlorogenic B
acid I
( O
2 O
. O
25 O
+ O
/ O
- O
0 O
. O
34 O
mg O
g O
( O
- O
1 O
) O
DM O
) O
content O
, O
followed O
by O
F O
. O
viridis O
and O
F O
. O
moschata O
. O

Our O
results O
showed O
that O
the O
leaves O
should O
be O
taken O
into O
account O
as O
important O
rutin B
and O
hyperoside B
contributors O
for O
strawberries O
. O

Cyclo O
- O
( O
His O
, O
Leu O
) O
: O
a O
new O
microbial O
diketopiperazine B
from O
a O
terrestrial O
Bacillus O
subtilis O
strain O
B38 O
. O

In O
continuation O
of O
our O
search O
for O
bioactive O
secondary O
metabolites O
from O
terrestrial O
Bacillus O
spp O
. O
, O
a O
new O
microbial O
diketopiperazine B
, O
cis O
- O
cyclo O
- O
( O
His O
, O
Leu O
) O
( O
1 O
) O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
a O
strain O
B O
. O
subtilis O
B38 O
, O
together O
with O
cis O
- O
cyclo O
- O
( O
Phe O
, O
Phe O
) O
( O
2 O
) O
, O
tryptophane O
( O
3 O
) O
, O
cis O
- O
cyclo O
- O
( O
Leu O
, O
Tyr O
) O
( O
4 O
) O
, O
cis O
- O
cyclo O
- O
( O

The O
recently O
discovered O
pleckstrin O
homology O
( O
PH O
) O
domain O
leucine B
- O
rich O
repeat O
protein O
phosphatase O
( O
PHLPP O
) O
family O
is O
emerging O
as O
a O
central O
component O
in O
suppressing O
cell O
survival O
pathways O
. O

This O
review O
summarizes O
the O
targets O
and O
cellular O
actions O
of O
PHLPP O
, O
with O
emphasis O
on O
its O
role O
as O
a O
tumour O
suppressor O
in O
the O
oncogenic O
phosphoinositide B
3 O
- O
kinase O
( O
PI3K O
) O
/ O
Akt O
signalling O
cascade O
. O

The O
essential O
oil O
contained O
approximately O
79 O
. O
91 O
% O
monoterpenoids O
and O
18 O
. O
25 O
% O
sesquiterpenoids B
. O

alpha O
- O
Thujone O
( O
36 O
. O
35 O
% O
) O
, O
beta O
- O
thujone O
( O
9 O
. O
37 O
% O
) O
, O
germacrene O
D O
( O
6 O
. O
32 O
% O
) O
, O
4 O
- O
terpineol O
( O
6 O
. O
31 O
% O
) O
, O
beta O
- O
caryophyllene O
( O
5 O
. O
43 O
% O
) O
, O
camphene O
( O
5 O
. O
47 O
% O
) O
and O
borneol B
( O
4 O
. O
12 O
% O
) O
were O
identified O
as O
the O
major O
constituents O
. O

The O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
has O
an O
essential O
role O
in O
multiple O
signaling O
pathways O
, O
including O
cell O
proliferation O
and O
migration O
, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine B
kinase O
( O
TK O
) O
domain O
. O

They O
display O
sensitivity O
to O
TK O
inhibitors O
, O
including O
gefitinib B
and O
erlotinib B
. O

In O
this O
study O
, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M O
mutation O
confers O
gefitinib B
resistance O
on O
the O
G719S O
mutant O
. O

The O
G719S O
/ O
T790M O
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib B
- O
binding O
affinity O
. O

The O
T790M O
mutation O
increases O
the O
ATP B
affinity O
of O
the O
G719S O
mutant O
, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant O
. O

The O
Met790 O
side O
chain O
of O
the O
G719S O
/ O
T790M O
double O
mutant O
, O
in O
the O
apo O
form O
and O
gefitinib B
- O
and O
AMPPNP O
- O
bound O
forms O
, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands O
. O

Notably O
, O
the O
introduction O
of O
the O
F723A O
mutation O
greatly O
enhanced O
the O
gefitinib B
sensitivity O
of O
the O
wild O
- O
type O
EGFR O
in O
vivo O
, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active O
- O
site O
cleft O
results O
in O
enhanced O
gefitinib B
sensitivity O
. O

Modulated O
release O
of O
5 B
- I
fluorouracil I
from O
pH O
- O
sensitive O
and O
colon O
targeted O
pellets O
: O
an O
industrially O
feasible O
approach O
. O

5 B
- I
Fluorouracil I
( O
5 B
- I
FU I
) O
loaded O
pellets O
were O
prepared O
by O
extrusion O
- O
spheronization O
using O
Avicel O
( O
( O
R O
) O
) O
PH101 O
as O
a O
spheronization O
aid O
and O
hydroxypropylmethylc O
K4M O
( O
HPMC O
K4M O
) O
solution O
as O
a O
binder O
. O

Hence O
, O
the O
present O
study O
provides O
constructive O
results O
for O
colon O
targeting O
of O
5 B
- I
FU I
pellets O
with O
industrially O
feasible O
processes O
. O

Oncogenic O
mutations O
in O
PIK3CA O
, O
which O
encodes O
the O
phosphoinositide B
- O
3 O
- O
kinase O
( O
PI3K O
) O
catalytic O
subunit O
p110 O
alpha O
, O
occur O
in O
~ O
25 O
% O
of O
human O
breast O
cancers O
. O

Whole O
- O
exome O
analysis O
of O
the O
Pik3ca O
( O
H1047R O
) O
- O
driven O
mammary O
tumors O
identified O
multiple O
mutations O
, O
including O
Trp53 B
mutations O
that O
appeared O
spontaneously O
during O
the O
development O
of O
adenocarinoma O
and O
spindle O
cell O
tumors O
. O

WNT6 O
knock O
- O
down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 O
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline B
chemotherapeutics O
epirubicin O
( O
Epi O
) O
and O
doxorubicin B
( O
Dox B
) O
. O

In O
GC O
patients O
, O
WNT6 O
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status O
, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
( O
Epi O
, O
cisplatin B
, O
5 B
- I
fluorouracil I
) O
chemotherapy O
. O

These O
results O
showed O
that O
WNT6 O
and O
Cav1 O
are O
upregulated O
by O
chemotherapeutics O
and O
enhance O
the O
resistance O
of O
GC O
cells O
to O
anthracycline B
drugs O
. O

Three O
new O
compounds O
; O
epi O
- O
mukulin O
, O
( O
Z O
) O
- O
Delta O
( O
1 O
, O
2 O
) O
dehydroguggulsterone O
and O
Delta O
( O
6 O
, O
7 O
) O
dehydro O
- O
20 O
- O
hydroxygugglsterone O
were O
isolated O
from O
the O
n B
- I
hexane I
- O
soluble O
fraction O
( O
HSF O
) O
of O
the O
methanol B
extract O
of O
guggul O
, O
the O
oleogum O
resin O
of O
Commiphora O
wightii O
together O
with O
six O
known O
compounds O
: O
diasesartemin O
, O
( O
+ O
) O
- O
epi O
- O
magnolin O
, O
( O
+ O
) O
- O
diayangambin O
, O

Under O
the O
assay O
conditions O
, O
diasesartemin O
( O
IC O
( O
50 O
) O
= O
60 O
. O
6 O
+ O
/ O
- O
0 O
. O
01 O
micro O
M O
) O
was O
found O
to O
be O
more O
potent O
than O
the O
positive O
control O
, O
acarbose B
( O
IC O
( O
50 O
) O
= O
92 O
. O
94 O
+ O
/ O
- O
0 O
. O
01 O
micro O
M O
) O
; O
a O
known O
alpha O
- O
glucosidase O
inhibitor O
( O
p O
< O
0 O
. O
05 O
) O
. O

However O
, O
syringic O
acid O
was O
found O
only O
in O
RSG O
, O
while O
chlorogenic B
acid I
was O
found O
only O
in O
RSC O
. O

Progesterone B
, O
estradiol B
and O
testosterone B
have O
been O
shown O
to O
control O
reactive O
gliosis O
in O
different O
models O
of O
CNS O
injury O
, O
modifying O
the O
number O
of O
reactive O
astrocytes O
and O
reactive O
microglia O
and O
the O
expression O
of O
anti O
- O
inflammatory O
and O
proinflammatory O
mediators O
. O

The O
actions O
of O
gonadal O
hormones O
on O
reactive O
gliosis O
involve O
different O
mechanisms O
, O
including O
the O
modulation O
of O
the O
activity O
of O
steroid B
receptors O
, O
such O
as O
estrogen B
receptors O
alpha O
and O
beta O
, O
the O
regulation O
of O
nuclear O
factor O
- O
kappa O
B O
mediated O
transcription O
of O
inflammatory O
molecules O
and O
the O
recruitment O
of O
the O
transcriptional O
corepressor O
c O
- O
terminal O
binding O
protein O
to O
proinflammatory O
promoters O
. O

In O
addition O
, O
the O
Parkinson O
' O
s O
disease O
related O
gene O
parkin O
and O
the O
endocannabinoid O
system O
also O
participate O
in O
the O
regulation O
of O
reactive O
gliosis O
by O
estradiol B
. O

The O
known O
compounds O
were O
identified O
as O
beta B
- I
sitosterol I
, O
stigmasterol B
and O
lupeol B
by O
comparing O
their O
spectral O
data O
with O
those O
reported O
in O
the O
literature O
. O

Berberine B
inhibits O
myofibroblast O
differentiation O
in O
nasal O
polyp O
- O
derived O
fibroblasts O
via O
the O
p38 O
pathway O
. O

The O
purposes O
of O
this O
study O
were O
to O
determine O
whether O
berberine B
has O
any O
effect O
on O
phenotype O
changes O
and O
extracellular O
matrix O
( O
ECM O
) O
production O
in O
nasal O
polyp O
- O
derived O
fibroblasts O
( O
NPDFs O
) O
and O
to O
investigate O
the O
underlying O
molecular O
mechanism O
. O

NPDFs O
were O
pre O
- O
treated O
with O
berberine B
prior O
to O
induction O
by O
transforming O
growth O
factor O
( O
TGF O
) O
- O
beta O
1 O
. O

In O
TGF O
- O
beta O
1 O
- O
induced O
NPDFs O
, O
berberine B
significantly O
inhibited O
the O
expression O
of O
alpha O
- O
SMA O
and O
collagen O
type O
I O
mRNA O
and O
reduced O
alpha O
- O
SMA O
and O
collagen O
protein O
levels O
. O

Berberine B
only O
suppressed O
the O
expression O
of O
pp38 O
among O
the O
evaluated O
signaling O
molecules O
. O

SB203580 B
( O
a O
specific O
inhibitor O
of O
p38 O
kinase O
) O
markedly O
suppressed O
the O
increased O
expression O
of O
collagen O
type O
I O
and O
alpha O
- O
SMA O
in O
TGF O
- O
beta O
1 O
- O
induced O
NPDFs O
. O

Berberine B
exerts O
suppressive O
effects O
on O
phenotype O
changes O
and O
ECM O
production O
in O
NPDFs O
via O
p38 O
signaling O
pathway O
interference O
. O

The O
molecular O
mechanism O
is O
predominantly O
based O
on O
an O
increased O
expression O
of O
the O
endothelial O
and O
inducible O
nitric B
oxide I
( O
NO B
) O
synthase O
with O
a O
consecutive O
rapid O
supply O
of O
NO B
as O
well O
as O
an O
increased O
content O
of O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
in O
the O
wound O
. O

However O
, O
we O
show O
that O
membrane O
blebs O
, O
which O
are O
strongly O
enriched O
in O
phospho B
- O
cofilin O
, O
are O
not O
responsible O
for O
the O
poor O
anchoring O
of O
the O
spindle O
. O

We O
investigated O
the O
effects O
of O
three O
preparations O
of O
Panax O
ginseng O
, O
Panax O
notoginseng O
, O
isolated O
ginsenosides B
, O
and O
the O
polyacetylene B
panaxynol O
on O
Trypanosoma O
brucei O
brucei O
and O
the O
human O
cancer O
cell O
line O
HeLa O
. O

Hexane B
extracts O
and O
the O
pure O
panaxynol O
were O
toxic O
and O
at O
the O
same O
time O
highly O
selective O
against O
T O
. O

b O
. O
brucei O
, O
whereas O
methanol B
extracts O
and O
12 O
isolated O
ginsenosides B
were O
significantly O
less O
toxic O
and O
showed O
only O
weak O
selectivity O
. O

Androgenic O
and O
spermatogenic O
activity O
of O
alkylamide O
- O
rich O
ethanol B
solution O
extract O
of O
Anacyclus O
pyrethrum O
DC O
. O

Aphrodisiac O
activity O
may O
be O
due O
to O
an O
increase O
in O
the O
production O
or O
effect O
of O
androgens B
, O
so O
this O
study O
sought O
to O
evaluate O
the O
androgenic O
and O
spermatogenic O
potential O
of O
the O
alkylamide O
- O
rich O
ethanol B
solution O
extract O
. O

The O
ethanol B
solution O
extract O
of O
A O
. O
pyrethrum O
was O
administered O
to O
groups O
of O
rats O
in O
50 O
, O
100 O
, O
and O
150 O
mg O
/ O
kg O
doses O
for O
a O
period O
of O
28 O
days O
, O
and O
the O
action O
was O
compared O
with O
control O
and O
testosterone B
- O
treated O
rats O
. O

Extract O
administration O
at O
all O
the O
doses O
produced O
significant O
increase O
in O
body O
weight O
, O
sperm O
count O
, O
motility O
, O
and O
viability O
along O
with O
serum O
testosterone B
, O
luteinizing O
hormone O
, O
and O
follicle O
- O
stimulating O
hormone O
concentrations O
. O

Seminal O
fructose B
content O
was O
also O
significantly O
increased O
after O
28 O
days O
of O
treatment O
. O

Our O
results O
suggest O
that O
the O
ethanol B
solution O
extract O
of O
the O
roots O
of O
A O
. O
pyrethrum O
has O
androgenic O
potential O
and O
may O
improve O
male O
fertility O
by O
enhancing O
spermatogenesis O
. O

Here O
we O
utilize O
transgenic O
and O
allograft O
breast O
cancer O
models O
to O
demonstrate O
that O
increased O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
signalling O
can O
be O
a O
significant O
contributor O
to O
breast O
cancer O
progression O
in O
vivo O
. O

Actions O
of O
Xanthurenic B
acid I
, O
a O
putative O
endogenous O
Group O
II O
metabotropic O
glutamate B
receptor O
agonist O
, O
on O
sensory O
transmission O
in O
the O
thalamus O
. O

Xanthurenic B
acid I
( O
XA O
) O
, O
a O
molecule O
arising O
from O
tryptophan B
metabolism O
by O
transamination O
of O
3 O
- O
hydroxykynurenine O
, O
has O
recently O
been O
identified O
as O
an O
endogenous O
Group O
II O
( O
mGlu2 O
and O
mGlu3 O
) O
metabotropic O
glutamate B
( O
mGlu O
) O
receptor O
ligand O
in O
vitro O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Sol O
- O
flame O
synthesis O
: O
a O
general O
strategy O
to O
decorate O
nanowires O
with O
metal B
oxide I
/ O
noble O
metal O
nanoparticles O
. O

Moreover O
, O
the O
sol O
- O
flame O
method O
is O
simple O
and O
general O
, O
with O
which O
we O
have O
successfully O
decorated O
various O
NWs O
with O
binary O
/ O
ternary O
metal B
oxide I
and O
even O
noble O
metal O
NPs O
. O

This O
work O
reports O
the O
chemical O
composition O
of O
the O
essential O
oil O
of O
Lippia O
sidoides O
( O
EOLS O
) O
and O
evaluation O
of O
the O
topical O
effect O
of O
EOLS O
and O
thymol B
against O
different O
irritant O
agents O
in O
vivo O
. O

The O
essential O
oil O
was O
obtained O
by O
hydrodistillation O
, O
and O
gas O
chromatography O
/ O
mass O
spectrometry O
analysis O
identified O
the O
main O
constituents O
: O
thymol B
( O
84 O
. O
9 O
% O
) O
and O
p O
- O
cymene O
( O
5 O
. O
33 O
% O
) O
. O

The O
antiinflammatory O
activity O
was O
evaluated O
using O
the O
mouse O
models O
of O
acute O
ear O
inflammation O
induced O
by O
croton O
oil O
, O
arachidonic B
acid I
, O
phenol B
or O
histamine B
, O
and O
chronic O
inflammation O
induced O
by O
croton O
oil O
. O

The O
topical O
application O
of O
EOLS O
or O
thymol B
at O
a O
dose O
of O
2 O
mg O
/ O
ear O
significantly O
reduced O
( O
p O
< O
0 O
. O
001 O
) O
ear O
edema O
induced O
with O
arachidonic B
acid I
by O
45 O
. O
1 O
% O
and O
47 O
. O
4 O
% O
and O
reduced O
ear O
edema O
induced O
with O
phenol B
by O
33 O
. O
2 O
% O
( O
p O
< O
0 O
. O
05 O
) O
and O
54 O
. O
7 O
% O
( O
p O
< O
0 O
. O
01 O
) O
in O
acute O
ear O
edema O
. O

However O
, O
a O
proinflammatory O
effect O
of O
EOLS O
and O
thymol B
was O
evidenced O
when O
it O
was O
applied O
for O
more O
than O
1 O
day O
. O

There O
were O
no O
statistical O
differences O
in O
antiedematogenic O
activity O
between O
EOLS O
and O
thymol B
. O

In O
conclusion O
, O
the O
results O
indicate O
that O
thymol B
is O
the O
constituent O
responsible O
for O
the O
topical O
antiinflammatory O
activity O
of O
EOLS O
. O

The O
free O
acid O
derivatives O
as O
they O
are O
good O
candidates O
as O
antiinflammatory O
drugs O
are O
able O
to O
antagonize O
the O
multiple O
neutrophil O
functions O
evoked O
by O
N O
- O
formyl O
- O
L O
- O
methionyl O
- O
L O
- O
leucyl O
- O
Lphenylalanine O
( O
fMLF B
) O
, O
i O
. O
e O
. O
chemotaxis O
, O
superoxide B
anion O
production O
and O
lysozyme O
release O
. O

The O
second O
series O
of O
peptides O
derives O
from O
the O
endogenous O
protein O
kinase O
C O
( O
PKC O
) O
inhibitor O
PKI55 O
, O
a O
55 O
- O
amino B
acid I
protein O
, O
whose O
synthesis O
is O
induced O
by O
PKC O
activation O
, O
so O
that O
a O
feedback O
loop O
of O
inhibition O
is O
established O
. O

In O
vitro O
experiments O
showed O
that O
PKI55 O
inhibits O
recombinant O
PKC O
isoforms O
alpha O
, O
beta O
1 O
, O
beta O
2 O
, O
gamma O
, O
delta O
, O
zeta O
, O
; O
to O
identify O
the O
minimal O
amino B
acid I
sequence O
of O
PKI55 O
protein O
maintaining O
the O
inhibitory O
effects O
on O
PKC O
, O
peptides O
derived O
from O
both O
C B
- O
and O
N B
- O
terminal O
sequences O
have O
been O
synthesized O
. O

The O
N B
- O
terminal O
peptides O
5 O
( O
MLYKLHDVCRQLWFSC O
) O
, O
8 O
( O
CRQLWFSC O
) O
and O
9 O
( O
CRQLW O
) O
, O
that O
in O
human O
neutrophils O
retain O
the O
inhibitory O
activity O
on O
PKC O
, O
decrease O
the O
chemotaxis O
, O
and O
, O
in O
mice O
, O
display O
anti O
- O
inflammatory O
and O
analgesic O
action O
, O
after O
both O
central O
and O
peripheral O
administration O
of O
very O
low O
doses O
. O

A O
review O
on O
the O
development O
in O
the O
field O
of O
NIDDM O
based O
thiazolidinedione B
PPAR O
gamma O
agonists O
. O

The O
present O
work O
aims O
towards O
examining O
the O
functional O
and O
structural O
features O
that O
facilitate O
the O
binding O
of O
small O
molecules O
based O
on O
Thiazolidinedione B
pharmacophore O
to O
PPARs O
. O

The O
intent O
of O
this O
article O
is O
to O
review O
all O
the O
reported O
thiazolidinediones B
and O
associated O
groups O
of O
PPAR O
gamma O
ligands O
. O

A O
new O
triterpenoid B
from O
the O
rhizomes O
of O
Nelumbo O
nucifera O
. O

A O
new O
triterpenoid B
, O
2 O
alpha O
, O
24 O
- O
diacetoxy O
- O
3 O
beta O
- O
hydroxyolean O
- O
12 O
- O
en O
- O
28 O
- O
oic O
acid O
( O
1 O
) O
, O
was O
characterised O
from O
the O
rhizomes O
of O
Nelumbo O
nucifera O
Gaertn O
by O
spectroscopic O
and O
chemical O
methods O
along O
with O
four O
known O
compounds O
, O
hyptatic O
acid O
- O
A O
( O
2 O
alpha O
, O
3 O
beta O
, O
24 O
- O
trihydroxyolean O
- O
12 O
- O
en O
- O
28 O
- O
oic O
acid O
) O
( O
2 O
) O
, O
maslinic O
acid O
( O
2 O
alpha O
, O
3 O
beta O
- O

dihydroxyoleane O
- O
12 O
- O
ene O
- O
28 O
- O
oic O
acid O
) O
, O
betulin O
and O
lupeol B
. O

Vasodilatory O
effects O
of O
cinnamic B
acid I
via O
the O
nitric B
oxide I
- O
cGMP B
- O
PKG O
pathway O
in O
rat O
thoracic O
aorta O
. O

Cinnamic B
acid I
( O
CA O
) O
and O
its O
derivatives O
have O
a O
broad O
therapeutic O
spectrum O
that O
includes O
antimicrobial O
, O
antifungal O
, O
and O
antitumoral O
activities O
. O

In O
addition O
, O
vascular O
strips O
and O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
were O
used O
in O
organ O
bath O
, O
Western O
blot O
, O
nitrite B
, O
and O
cyclic O
guanosine O
monophosphate O
( O
cGMP B
) O
measurements O
. O

CA O
relaxed O
phenylephrine B
- O
precontracted O
aortic O
strips O
in O
an O
endothelium O
- O
dependent O
manner O
. O

Pretreatment O
of O
the O
endothelium O
- O
intact O
aortic O
strips O
with O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
10 O
( O
- O
4 O
) O
M O
) O
, O
1 O
H O
- O
[ O
1 O
, O
2 O
, O
4 O
] O
- O
oxadiazolole O
- O
[ O
4 O
, O
3 O
- O
a O
] O
quinoxalin O
- O
10 O
- O
one O
, O
( O
10 O
( O
- O
6 O
) O
M O
) O
and O
methylene B
blue I
( O
10 O
( O
- O
5 O
) O
M O
) O
inhibited O
CA O
- O
induced O
vasorelaxation O
. O

CA O
also O
increased O
the O
phosphorylation O
of O
endothelial O
nitric B
oxide I
synthase O
and O
nitric B
oxide I
generation O
in O
a O
concentration O
- O
dependent O
manner O
in O
HUVECs O
. O

In O
addition O
, O
cGMP B
generation O
and O
cGMP B
- O
dependent O
protein O
kinase O
G O
( O
PKG O
) O
expression O
in O
aortic O
strips O
were O
increased O
by O
CA O
treatment O
. O

Furthermore O
, O
CA O
- O
induced O
vasorelaxation O
was O
inhibited O
by O
the O
PKG O
inhibitor O
KT5823 O
( O
0 O
. O
3 O
mu O
M O
) O
and O
the O
Ca B
( I
2 I
+ I
) I
- O
activated O
K B
( I
+ I
) I
channel O
inhibitor O
tetraethylammonium B
( O
10 O
( O
- O
3 O
) O
M O
) O
. O

These O
findings O
suggest O
that O
CA O
exerts O
an O
endothelium O
- O
dependent O
vasodilation O
effect O
via O
the O
nitric B
oxide I
- O
cGMP B
- O
PKG O
- O
mediated O
pathway O
in O
rat O
thoracic O
aorta O
. O

The O
mechanisms O
underlying O
neuronal O
- O
glia O
network O
dysfunctions O
induced O
by O
brain O
inflammation O
are O
also O
discussed O
, O
highlighting O
novel O
neuromodulatory O
effects O
of O
classical O
inflammatory O
mediators O
such O
as O
cytokines O
and O
prostaglandins B
. O

Targeting O
metabotropic O
glutamate B
receptor O
subtype O
mGluR5 O
has O
emerged O
as O
a O
cognitive O
- O
enhancing O
strategy O
in O
neuropsychiatric O
disorders O
, O
but O
synaptic O
and O
cellular O
actions O
of O
mGluR5 O
in O
the O
mPFC O
remain O
to O
be O
determined O
. O

Both O
the O
prototypical O
mGluR5 O
agonist O
CHPG O
and O
a O
positive O
allosteric O
modulator O
( O
PAM O
) O
for O
mGluR5 O
( O
VU0360172 B
) O
increased O
synaptically O
evoked O
spiking O
( O
E O
- O
S O
coupling O
) O
in O
mPFC O
pyramidal O
cells O
. O

The O
facilitatory O
effects O
of O
CHPG O
and O
VU0360172 B
were O
inhibited O
by O
an O
mGluR5 O
antagonist O
( O
MTEP B
) O
. O

CHPG O
, O
but O
not O
VU0360172 B
, O
increased O
neuronal O
excitability O
( O
frequency O
- O
current O
[ O
F O
- O
I O
] O
function O
) O
. O

VU0360172 B
, O
but O
not O
CHPG O
, O
increased O
evoked O
excitatory O
synaptic O
currents O
( O
EPSCs O
) O
and O
amplitude O
, O
but O
not O
frequency O
, O
of O
miniature O
EPSCs O
, O
indicating O
a O
postsynaptic O
action O
. O

VU0360172 B
, O
but O
not O
CHPG O
, O
decreased O
evoked O
inhibitory O
synaptic O
currents O
( O
IPSCs O
) O
through O
an O
action O
that O
involved O
cannabinoid O
receptor O
CB1 O
, O
because O
a O
CB1 O
receptor O
antagonist O
( O
AM281 O
) O
blocked O
the O
inhibitory O
effect O
of O
VU0360172 B
on O
synaptic O
inhibition O
. O

VU0360172 B
also O
increased O
and O
prolonged O
CB1 O
- O
mediated O
depolarization O
- O
induced O
suppression O
of O
synaptic O
inhibition O
( O
DSI O
) O
. O

This O
effect O
can O
be O
accomplished O
by O
increasing O
excitability O
with O
an O
orthosteric O
agonist O
( O
CHPG O
) O
or O
by O
increasing O
excitatory O
synaptic O
drive O
and O
CB1 O
- O
mediated O
presynaptic O
suppression O
of O
synaptic O
inhibition O
( O
" O
dis O
- O
inhibition O
" O
) O
with O
a O
PAM O
( O
VU0360172 B
) O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Extracts O
of O
Scutellaria O
baicalensis O
reduced O
body O
weight O
and O
blood O
triglyceride B
in O
db O
/ O
db O
Mice O
. O

In O
obese O
db O
/ O
db O
mice O
, O
SBE O
treatment O
also O
reduced O
plasma O
alanine B
aminotransferase O
levels O
. O

In O
the O
livers O
of O
db O
/ O
db O
mice O
, O
SBE O
promoted O
5 B
' I
AMP I
- O
activated O
protein O
kinase O
activity O
and O
restored O
metabolic O
process O
and O
insulin O
signaling O
pathways O
. O

The O
methanol B
extract O
of O
the O
tubers O
of O
Polygonum O
perfoliatum O
L O
. O
afforded O
a O
new O
lignan B
: O
8 O
- O
oxo O
- O
pinoresinol O
( O
1 O
) O
, O
and O
five O
known O
compounds O
3 O
' O
, O
5 O
- O
dihydroxy O
- O
3 O
, O
4 O
' O
, O
5 O
' O
, O
7 O
- O
tetramethoxy O
- O
flavone O
( O
2 O
) O
, O
catechin B
( O
3 O
) O
, O
quercetin B
( O
4 O
) O
, O
quercetin O
- O
3 O
- O
O O
- O
beta O
- O
D O
- O
glucuronide O
( O
5 O
) O
and O
rutin B
( O
6 O
) O
. O

Tonic O
GABA B
( O
A O
) O
receptor O
- O
mediated O
signalling O
in O
temporal O
lobe O
epilepsy O
. O

The O
tonic O
activation O
of O
extrasynaptic O
GABAA O
receptors O
by O
extracellular O
GABA B
provides O
a O
powerful O
means O
of O
regulating O
neuronal O
excitability O
. O

However O
, O
the O
network O
consequences O
of O
a O
commonly O
used O
approach O
to O
augment O
tonic O
GABAA O
receptor O
- O
mediated O
conductances O
by O
global O
manipulation O
of O
extracellular O
GABA B
are O
difficult O
to O
predict O
without O
understanding O
how O
epileptogenesis O
alters O
the O
pharmacology O
and O
GABA B
sensitivity O
of O
tonic O
inhibition O
, O
and O
how O
manipulation O
of O
tonic O
conductances O
modulates O
the O
output O
of O
individual O
neurons O
. O

Metabotropic O
glutamate B
7 O
( O
mGlu7 O
) O
receptor O
: O
a O
target O
for O
medication O
development O
for O
the O
treatment O
of O
cocaine B
dependence O
. O

Brain O
glutamate B
has O
been O
shown O
to O
play O
an O
important O
role O
in O
reinstatement O
to O
drug O
seeking O
, O
a O
behavior O
considered O
to O
be O
of O
relevance O
to O
relapse O
to O
drug O
taking O
in O
humans O
. O

Therefore O
, O
glutamate B
receptors O
, O
in O
particular O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
, O
have O
become O
important O
targets O
for O
medication O
development O
for O
the O
treatment O
of O
drug O
dependence O
. O

In O
this O
review O
article O
, O
we O
focus O
on O
the O
mGlu7 O
receptor O
subtype O
, O
and O
discuss O
recent O
findings O
with O
AMN082 B
, O
a O
selective O
mGlu7 O
receptor O
allosteric O
agonist O
, O
in O
animal O
models O
with O
relevance O
to O
drug O
dependence O
. O

Systemic O
or O
local O
administration O
of O
AMN082 B
into O
the O
nucleus O
accumbens O
( O
NAc O
) O
, O
a O
critical O
brain O
region O
involved O
in O
reward O
and O
drug O
dependence O
processes O
, O
inhibited O
the O
reinforcing O
and O
motivational O
effects O
of O
cocaine B
, O
heroin B
and O
ethanol B
, O
as O
assessed O
by O
the O
intravenous O
drug O
self O
- O
administration O
procedure O
. O

In O
addition O
, O
AMN082 B
inhibited O
the O
reward O
- O
enhancing O
effects O
induced O
by O
cocaine B
, O
as O
assessed O
in O
the O
intracranial O
self O
- O
stimulation O
procedure O
, O
and O
cocaine B
- O
or O
cue O
- O
induced O
reinstatement O
of O
drug O
- O
seeking O
behavior O
. O

In O
vivo O
microdialysis O
studies O
indicated O
that O
systemic O
or O
intra O
- O
NAc O
administration O
of O
AMN082 B
significantly O
decreased O
extracellular O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
and O
elevated O
extracellular O
glutamate B
, O
but O
had O
no O
effect O
on O
extracellular O
dopamine B
in O
the O
NAc O
, O
suggesting O
that O
a O
non O
- O
dopaminergic O
mechanism O
underlies O
the O
effects O
of O
AMN082 B
on O
the O
actions O
of O
cocaine B
. O

Further O
, O
data O
indicated O
that O
AMN082 B
- O
induced O
changes O
in O
glutamate B
were O
the O
net O
effect O
of O
two O
actions O
: O
one O
is O
the O
direct O
inhibition O
of O
glutamate B
release O
by O
activation O
of O
mGlu7 O
receptors O
on O
glutamatergic O
neurons O
; O
another O
is O
the O
indirect O
increases O
of O
glutamate B
release O
mediated O
by O
decreases O
in O
GABA B
transmission O
. O

These O
increases O
in O
extracellular O
glutamate B
functionally O
antagonized O
cocaine B
- O
induced O
inhibition O
of O
NAc O
- O
ventral O
pallidum O
GABAergic O
neurotransmission O
, O
and O
therefore O
, O
the O
rewarding O
effects O
of O
cocaine B
. O

In O
addition O
, O
elevated O
extracellular O
glutamate B
activated O
presynaptic O
mGlu2 O
/ O
3 O
autoreceptors O
which O
in O
turn O
inhibited O
cocaine B
priming O
- O
or O
cue O
- O
induced O
enhancement O
of O
glutamate B
release O
and O
reinstatement O
of O
drug O
- O
seeking O
behavior O
. O

AMN082 B
or O
other O
mGlu7 O
receptor O
allosteric O
agonists O
may O
have O
potential O
as O
novel O
pharmacotherapies O
for O
cocaine B
addiction O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

The O
synergistic O
apoptotic O
interaction O
of O
panaxadiol O
and O
epigallocatechin B
gallate I
in O
human O
colorectal O
cancer O
cells O
. O

Panaxadiol O
( O
PD O
) O
is O
a O
purified O
sapogenin O
of O
ginseng O
saponins B
, O
which O
exhibits O
anticancer O
activity O
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
, O
a O
major O
catechin B
in O
green O
tea O
, O
is O
a O
strong O
botanical O
antioxidant O
. O

In O
this O
study O
, O
we O
investigated O
the O
possible O
synergistic O
anticancer O
effects O
of O
PD O
and O
EGCG B
on O
human O
colorectal O
cancer O
cells O
and O
explored O
the O
potential O
role O
of O
apoptosis O
in O
the O
synergistic O
activities O
. O

When O
PD O
( O
10 O
and O
20 O
micro O
m O
) O
was O
combined O
with O
EGCG B
( O
10 O
, O
20 O
, O
and O
30 O
micro O
m O
) O
, O
significantly O
enhanced O
antiproliferative O
effects O
were O
observed O
in O
both O
cell O
lines O
. O

Combining O
20 O
micro O
m O
of O
PD O
with O
20 O
and O
30 O
micro O
m O
of O
EGCG B
significantly O
decreased O
S O
- O
phase O
fractions O
of O
cells O
. O

In O
the O
apoptotic O
assay O
, O
the O
combination O
of O
PD O
and O
EGCG B
significantly O
increased O
the O
percentage O
of O
apoptotic O
cells O
compared O
with O
PD O
alone O
( O
p O
< O
0 O
. O
01 O
) O
. O

The O
synergistic O
apoptotic O
effects O
were O
also O
supported O
by O
docking O
analysis O
, O
which O
demonstrated O
that O
PD O
and O
EGCG B
bound O
in O
two O
different O
sites O
of O
the O
annexin O
V O
protein O
. O

Data O
from O
this O
study O
suggested O
that O
apoptosis O
might O
play O
an O
important O
role O
in O
the O
EGCG B
- O
enhanced O
antiproliferative O
effects O
of O
PD O
on O
human O
colorectal O
cancer O
cells O
. O

Models O
of O
both O
type O
1 O
( O
C57BL O
/ O
6 O
mice O
with O
streptozotocin B
- O
induced O
diabetes O
) O
and O
type O
2 O
diabetes O
( O
db O
/ O
db O
mice O
) O
and O
age O
- O
matched O
and O
sex O
- O
matched O
controls O
were O
examined O
. O

Guava O
leaf O
tea O
( O
GLT O
) O
contains O
guava O
leaf O
polyphenol B
( O
Gvpp O
) O
, O
which O
regulates O
the O
absorption O
of O
dietary O
carbohydrate B
from O
the O
intestines O
. O

Borderline O
diabetics O
, O
who O
are O
at O
high O
risk O
of O
development O
of O
diabetes O
, O
take O
GLT O
to O
suppress O
a O
rapid O
increase O
of O
blood O
sugar B
level O
after O
meals O
. O

However O
, O
patients O
with O
diabetes O
in O
whom O
diabetic O
drugs O
or O
warfarin B
as O
a O
blood O
thinner O
are O
prescribed O
also O
take O
GLT O
with O
the O
expectation O
of O
glycemic O
control O
. O

Therefore O
, O
we O
studied O
whether O
GLT O
had O
potential O
for O
inhibition O
or O
induction O
of O
cytochrome O
P450 O
( O
CYP O
) O
and O
an O
influence O
on O
the O
action O
of O
warfarin B
. O

Extract O
of O
guava O
leaf O
( O
GvEx O
) O
consists O
of O
carbohydrate B
and O
polyphenols B
, O
which O
are O
Gvpp O
, O
quercetin B
, O
and O
ellagic B
acid I
. O

These O
polyphenols B
, O
but O
not O
GvEx O
, O
showed O
a O
certain O
level O
of O
inhibition O
of O
human O
- O
cDNA O
- O
expressed O
CYPs O
. O

In O
a O
comparison O
of O
GLT O
and O
grapefruit O
juice O
, O
GLT O
showed O
weaker O
inhibition O
of O
CYP O
activities O
and O
of O
midazolam B
1 O
' O
- O
hydroxylation O
than O
grapefruit O
juice O
. O

When O
rats O
were O
concomitantly O
treated O
with O
GLT O
and O
warfarin B
, O
the O
prolongation O
of O
clotting O
time O
of O
blood O
by O
warfarin B
was O
not O
influenced O
. O

It O
contains O
a O
complex O
mixture O
of O
terpenoids B
, O
hydrocarbons B
, O
phenolic B
compounds O
, O
acid O
derivatives O
and O
ketones B
. O

The O
effects O
of O
temperature O
and O
salinity O
on O
17 O
- O
alpha O
- O
ethynylestradiol O
uptake O
and O
its O
relationship O
to O
oxygen B
consumption O
in O
the O
model O
euryhaline O
teleost O
( O
Fundulus O
heteroclitus O
) O
. O

The O
synthetic O
estrogen B
17 O
- O
alpha O
- O
ethynylestradiol O
( O
EE2 B
) O
, O
a O
component O
of O
birth O
control O
and O
hormone O
replacement O
therapy O
, O
is O
discharged O
into O
the O
environment O
via O
wastewater O
treatment O
plant O
( O
WWTP O
) O
effluents O
. O

The O
present O
study O
employed O
radiolabeled O
EE2 B
to O
examine O
impacts O
of O
temperature O
and O
salinity O
on O
EE2 B
uptake O
in O
male O
killifish O
( O
Fundulus O
heteroclitus O
) O
. O

Fish O
were O
exposed O
to O
a O
nominal O
concentration O
of O
100ng O
/ O
L O
EE2 B
for O
2h O
. O

The O
rate O
of O
EE2 B
uptake O
was O
constant O
over O
the O
2h O
period O
. O

Oxygen B
consumption O
rates O
( O
MO O
( O
2 O
) O
) O
, O
whole O
body O
uptake O
rates O
, O
and O
tissue O
- O
specific O
EE2 B
distribution O
were O
determined O
. O

In O
killifish O
acclimated O
to O
18 O
degrees O
C O
at O
16ppt O
( O
50 O
% O
sea O
water O
) O
, O
MO O
( O
2 O
) O
and O
EE2 B
uptake O
were O
both O
lower O
after O
24h O
exposure O
to O
10 O
degrees O
C O
and O
4 O
degrees O
C O
, O
and O
increased O
after O
24h O
exposure O
to O
26 O
degrees O
C O
. O

Transfer O
to O
fresh O
water O
( O
FW O
) O
for O
24h O
lowered O
EE2 B
uptake O
rate O
, O
and O
long O
- O
term O
acclimation O
to O
fresh O
water O
reduced O
it O
by O
70 O
% O
. O

Both O
long O
- O
term O
acclimation O
to O
100 O
% O
sea O
water O
( O
32ppt O
) O
and O
a O
24h O
transfer O
to O
100 O
% O
sea O
water O
also O
reduced O
EE2 B
uptake O
rate O
by O
50 O
% O
relative O
to O
16ppt O
. O

Tissue O
- O
specific O
accumulation O
of O
EE2 B
was O
highest O
( O
40 O
- O
60 O
% O
of O
the O
total O
) O
in O
the O
liver O
plus O
gall O
bladder O
across O
all O
exposures O
, O
and O
the O
vast O
majority O
of O
this O
was O
in O
the O
bile O
at O
2h O
, O
regardless O
of O
temperature O
or O
salinity O
. O

Killifish O
chronically O
exposed O
( O
15 O
days O
) O
to O
100ng O
/ O
L O
EE2 B
displayed O
no O
difference O
in O
EE2 B
uptake O
rate O
or O
tissue O
- O
specific O
distribution O
. O

However O
, O
drinking O
accounted O
for O
less O
than O
30 O
% O
of O
gut O
accumulation O
, O
and O
therefore O
a O
negligible O
percentage O
of O
whole O
body O
EE2 B
uptake O
rates O
. O

In O
general O
, O
there O
were O
strong O
positive O
relationships O
between O
EE2 B
uptake O
rates O
and O
MO O
( O
2 O
) O
, O
suggesting O
similar O
uptake O
pathways O
of O
these O
lipophilic O
molecules O
across O
the O
gills O
. O

These O
data O
will O
be O
useful O
in O
developing O
a O
predictive O
model O
of O
how O
key O
environmental O
parameter O
variations O
( O
salinity O
, O
temperature O
, O
dissolved O
oxygen B
) O
affect O
EE2 B
uptake O
in O
estuarine O
fish O
, O
to O
determine O
optimal O
timing O
and O
location O
of O
WWTP O
discharges O
. O

One O
new O
antitumour O
cassane O
- O
type O
diterpene B
from O
Caesalpinia O
crista O
. O

1 O
alpha O
- O
acetoxy O
- O
5 O
alpha O
, O
7 O
beta O
- O
dihydroxycassa O
- O
11 O
, O
13 O
( O
15 O
) O
- O
diene O
- O
16 O
, O
12 O
- O
lactone O
, O
a O
new O
cassane O
- O
type O
diterpene B
was O
isolated O
from O
Caesalpinia O
crista O
. O

MUC1 O
- O
C O
interacts O
with O
EGFR O
( O
epidermal O
growth O
factor O
receptor O
) O
, O
ErbB2 O
and O
other O
receptor O
tyrosine B
kinases O
at O
the O
cell O
membrane O
and O
contributes O
to O
activation O
of O
the O
PI3K O
< O
E232 O
> O
AKT O
and O
mitogen O
- O
activated O
protein O
kinase O
kinase O
( O
MEK O
) O
< O
E232 O
> O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
pathways O
. O

beta O
- O
eudesmol O
- O
induced O
apoptosis O
was O
accompanied O
by O
cleavage O
of O
caspase O
- O
3 O
, O
caspase O
- O
9 O
, O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
; O
downregulation O
of O
Bcl O
- O
2 O
expression O
; O
release O
of O
cytochrome O
c O
from O
mitochondria O
; O
and O
decrease O
in O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
. O

Activation O
of O
c O
- O
Jun O
N B
- O
terminal O
kinases O
( O
JNK O
) O
mitogen O
- O
activated O
protein O
kinases O
was O
observed O
in O
beta O
- O
eudesmol O
- O
treated O
HL60 O
cells O
, O
and O
the O
inhibitor O
of O
JNK O
blocked O
the O
beta O
- O
eudesmol O
- O
induced O
apoptosis O
, O
downregulation O
of O
Bcl O
- O
2 O
, O
and O
the O
loss O
of O
MMP O
. O

The O
structure O
of O
the O
new O
saponin B
, O
glinoside O
C O
( O
1 O
) O
, O
was O
established O
as O
16 O
- O
O O
- O
( O
beta O
- O
D O
- O
glucopyranosyl O
) O
- O
3 O
beta O
, O
12 O
beta O
, O
16 O
beta O
, O
21 O
alpha O
, O
22 O
- O
pentahydroxy O
hopane O
by O
extensive O
use O
of O
1 O
- O
D O
, O
2 O
- O
D O
NMR O
and O
mass O
spectral O
techniques O
. O

Optimization O
of O
PLGA B
nanoparticles O
formulation O
containing O
L O
- O
DOPA O
by O
applying O
the O
central O
composite O
design O
. O

The O
aim O
of O
this O
work O
was O
to O
prepare O
L O
- O
DOPA O
loaded O
poly O
( O
D O
, O
L O
- O
lactide O
- O
co O
- O
glycolide O
) O
( O
PLGA B
) O
nanoparticles O
by O
a O
modified O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
( O
1 O
) O
/ O
O O
/ O
W O
( O
2 O
) O
) O
emulsification O
solvent O
evaporation O
method O
. O

A O
central O
composite O
design O
was O
applied O
for O
optimization O
of O
the O
formulation O
parameters O
and O
for O
studying O
the O
effects O
of O
three O
independent O
variables O
: O
PLGA B
concentration O
, O
polyvinyl B
alcohol I
( O
PVA B
) O
concentration O
and O
organic O
solvent O
removal O
rate O
on O
the O
particle O
size O
and O
the O
entrapment O
efficiency O
( O
response O
variables O
) O
. O

It O
was O
found O
that O
the O
optimum O
values O
of O
the O
responses O
could O
be O
obtained O
at O
higher O
concentration O
of O
PLGA B
( O
5 O
% O
, O
w O
/ O
v O
) O
and O
PVA B
( O
6 O
% O
, O
w O
/ O
v O
) O
; O
and O
faster O
organic O
solvent O
removal O
rate O
( O
700 O
rpm O
) O
. O

FTIR O
investigation O
confirmed O
that O
the O
L O
- O
DOPA O
and O
PLGA B
polymer O
maintained O
its O
backbone O
structure O
in O
the O
fabrication O
of O
nanoparticles O
. O

The O
results O
suggested O
that O
PLGA B
nanoparticles O
might O
represent O
a O
promising O
formulation O
for O
brain O
delivery O
of O
L O
- O
DOPA O
. O

The O
preparation O
of O
L O
- O
DOPA O
loaded O
PLGA B
nanoparticles O
can O
be O
optimized O
by O
the O
central O
composite O
design O
. O

Impact O
of O
early O
- O
life O
stress O
, O
on O
group O
III O
mGlu O
receptor O
levels O
in O
the O
rat O
hippocampus O
: O
effects O
of O
ketamine B
, O
electroconvulsive O
shock O
therapy O
and O
fluoxetine B
treatment O
. O

The O
group O
III O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
( O
mGlu O
( O
4 O
, O
7 O
) O
and O
( O
8 O
) O
receptors O
) O
in O
particular O
are O
beginning O
to O
show O
promise O
in O
this O
respect O
. O

In O
this O
study O
we O
investigated O
the O
effects O
of O
three O
antidepressant O
treatments O
( O
fluoxetine B
, O
ketamine B
and O
electroconvulsive O
shock O
therapy O
( O
ECT O
) O
) O
. O

Ketamine B
is O
an O
NMDA B
receptor O
antagonist O
which O
possess O
a O
rapid O
antidepressant O
therapeutic O
profile O
and O
moreover O
is O
effective O
in O
cases O
of O
treatment O
- O
resistant O
depression O
. O

Furthermore O
, O
ECT O
is O
also O
a O
therapeutic O
strategy O
possessing O
increased O
efficacy O
compared O
to O
conventional O
monoamine B
based O
therapies O
. O

To O
redress O
this O
deficit O
we O
investigated O
the O
effects O
these O
treatments O
and O
the O
prototypical O
selective O
serotonin B
reuptake O
inhibitor O
( O
SSRI O
) O
fluoxetine B
would O
have O
on O
hippocampal O
group O
III O
mGlu O
receptor O
mRNA O
levels O
in O
na O
i O
ve O
Sprague O
- O
Dawley O
rats O
and O
rats O
which O
had O
undergone O
early O
- O
life O
stress O
in O
the O
form O
of O
the O
maternal O
separation O
( O
MS O
) O
procedure O
. O

We O
found O
MS O
significantly O
reduced O
mGlu O
( O
4 O
) O
receptor O
expression O
and O
fluoxetine B
reversed O
this O
MS O
induced O
change O
. O

ECT O
and O
ketamine B
treatment O
significantly O
reduced O
mGlu O
( O
4 O
) O
receptor O
expression O
in O
non O
- O
separated O
( O
NS O
) O
animals O
while O
having O
no O
effect O
in O
MS O
animals O
. O

Fluoxetine B
and O
ECT O
significantly O
increased O
mGlu O
( O
7 O
) O
receptor O
expression O
in O
NS O
animals O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

The O
results O
obtained O
suggest O
that O
the O
presence O
of O
the O
allyl B
group O
is O
fundamental O
for O
the O
antimicrobial O
activity O
of O
these O
sulfide B
derivatives O
when O
they O
are O
present O
in O
Allium O
or O
in O
other O
species O
( O
DADS O
inhibition O
zone O
on O
S O
. O
aureus O
15 O
. O
9 O
mm O
, O
P O
. O
aeruginosa O
21 O
. O
9 O
mm O
, O
E O
. O
coli O
11 O
. O
4 O
mm O
) O
. O

Flavonoids B
and O
saponins B
from O
Zizyphus O
incurva O
. O

( O
Rhamnaceae O
) O
along O
with O
eight O
known O
compounds O
: O
six O
flavonoids B
and O
two O
saponins B
. O

Rapid O
characterisation O
of O
flavonoids B
from O
Sophora O
alopecuroides O
L O
. O
by O
HPLC O
/ O
DAD O
/ O
ESI O
- O
MSn O
. O

An O
HPLC O
/ O
DAD O
/ O
ESI O
- O
MSn O
method O
was O
established O
to O
characterise O
flavonoids B
in O
the O
seeds O
of O
Sophora O
alopecuroides O
L O
. O

All O
the O
flavonoids B
exhibited O
abundant O
[ O
M O
- O
H B
] O
- O
ions O
, O
which O
triggered O
data O
- O
dependent O
multistage O
mass O
spectrometry O
fragmentations O
. O

Characteristic O
UV O
spectra O
were O
used O
to O
confirm O
flavonoid B
subtypes O
. O

In O
total O
, O
22 O
flavonoids B
and O
two O
phenolic B
compounds O
were O
detected O
and O
identified O
. O

This O
method O
accomplished O
rapid O
profiling O
of O
flavonoid B
constituents O
in O
S O
. O
alopecuroides O
L O
. O

cAMP B
regulation O
of O
airway O
smooth O
muscle O
function O
. O

Moreover O
, O
the O
use O
of O
long O
- O
acting O
beta O
- O
agonists O
combined O
with O
inhaled O
corticosteroids B
constitutes O
an O
important O
maintenance O
therapy O
for O
these O
diseases O
. O

The O
presumed O
cellular O
mechanism O
of O
action O
involves O
the O
generation O
of O
intracellular O
cAMP B
, O
which O
in O
turn O
can O
activate O
the O
effector O
molecules O
cAMP B
- O
dependent O
protein O
kinase O
( O
PKA O
) O
and O
Epac O
. O

Other O
agents O
such O
as O
prostaglandin B
E I
( I
2 I
) I
and O
phosphodiesterase O
inhibitors O
that O
also O
increase O
intracellular O
cAMP B
levels O
in O
ASM O
, O
can O
also O
antagonize O
ASM O
contraction O
, O
and O
inhibit O
other O
ASM O
functions O
including O
proliferation O
and O
migration O
. O

Therefore O
, O
beta O
( O
2 O
) O
ARs O
and O
cAMP B
are O
key O
players O
in O
combating O
the O
pathophysiology O
of O
airway O
narrowing O
and O
remodeling O
. O

However O
, O
limitations O
of O
beta O
- O
agonist O
therapy O
due O
to O
drug O
tachyphylaxis O
related O
to O
beta O
( O
2 O
) O
AR O
desensitization O
, O
and O
recent O
findings O
regarding O
the O
manner O
in O
which O
beta O
( O
2 O
) O
ARs O
and O
cAMP B
signal O
, O
have O
raised O
new O
and O
interesting O
questions O
about O
these O
well O
- O
studied O
molecules O
. O

In O
this O
review O
we O
discuss O
current O
concepts O
regarding O
beta O
( O
2 O
) O
ARs O
and O
cAMP B
in O
the O
regulation O
of O
ASM O
cell O
functions O
and O
their O
therapeutic O
roles O
in O
asthma O
and O
COPD O
. O

The O
anti O
- O
hyperthermic O
effect O
of O
Lu O
AF21934 O
( O
5 O
mg O
/ O
kg O
) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine B
receptor O
antagonist O
flumazenil B
( O
10 O
mg O
/ O
kg O
) O
and O
was O
not O
serotonin B
- O
dependent O
, O
as O
it O
persisted O
in O
serotonin B
- O
deficient O
mice O
and O
upon O
blockade O
of O
either O
5 B
- I
HT I
( O
1A O
) O
receptors O
by O
WAY100635 O
, O
or O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
receptors O
by O
ritanserin O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Four O
chemotypes O
were O
identified O
: O
piperitone O
oxide O
, O
piperitenone O
oxide O
, O
piperitone O
- O
menthone B
and O
pulegone B
. O

In O
this O
study O
, O
we O
screened O
308 O
extracts O
from O
102 O
species O
for O
cytostatic O
and O
cytotoxic O
activity O
against O
a O
panel O
of O
six O
tumor O
cell O
lines O
using O
a O
24 O
- O
h O
sulphorhodamine B
B I
assay O
. O

The O
interaction O
between O
mGluR1 O
and O
the O
calcium B
channel O
Cav O
2 O
. O
1 O
preserves O
coupling O
in O
the O
presence O
of O
long O
Homer O
proteins O
. O

Group O
I O
metabotropic O
glutamate B
receptors O
( O
mGluR1 O
and O
5 O
) O
are O
G O
protein O
coupled O
receptors O
that O
regulate O
neuronal O
activity O
in O
a O
number O
of O
ways O
. O

This O
localization O
is O
in O
turn O
dependent O
on O
the O
Homer O
family O
of O
scaffolding O
proteins O
which O
bind O
to O
a O
small O
motif O
on O
the O
distal O
C B
- O
termini O
of O
mGluR1 O
and O
5 O
, O
localize O
the O
receptors O
near O
the O
PSD O
, O
strengthen O
coupling O
to O
post O
- O
synaptic O
effectors O
and O
simultaneously O
uncouple O
the O
mGluRs O
from O
extra O
- O
synaptic O
effectors O
such O
as O
voltage O
dependent O
ion O
channels O
. O

Here O
the O
selectivity O
of O
this O
uncoupling O
process O
was O
examined O
by O
testing O
the O
ability O
of O
Homer O
- O
2b O
to O
uncouple O
mGluR1 O
from O
multiple O
voltage O
dependent O
calcium B
channels O
including O
Ca B
( O
V2 O
. O
2 O
) O
( O
N O
- O
type O
) O
, O
Ca B
( O
V3 O
. O
2 O
) O
( O
T O
- O
type O
) O
, O
and O
Ca B
( O
V2 O
. O
1 O
) O
( O
P O
/ O
Q O
- O
type O
) O
expressed O
in O
rat O
sympathetic O
neurons O
from O
the O
superior O
cervical O
ganglion O
( O
SCG O
) O
. O

Uncoupling O
from O
this O
channel O
was O
achieved O
by O
co O
- O
expression O
of O
an O
mGluR1 O
C B
- O
terminal O
protein O
designed O
to O
disrupt O
a O
previously O
described O
direct O
interaction O
between O
these O
two O
proteins O
, O
suggesting O
that O
this O
interaction O
allows O
incorporation O
of O
Ca B
( O
V2 O
. O
1 O
) O
into O
the O
mGluR1 O
/ O
Homer O
signaling O
complex O
, O
thereby O
preserving O
modulation O
in O
the O
presence O
of O
scaffolding O
Homer O
proteins O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Pharmacological O
profiling O
of O
native O
group O
II O
metabotropic O
glutamate B
receptors O
in O
primary O
cortical O
neuronal O
cultures O
using O
a O
FLIPR O
. O

The O
group O
II O
metabotropic O
glutamate B
( O
mGlu O
) O
receptors O
comprised O
of O
the O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
have O
gained O
recognition O
in O
recent O
years O
as O
potential O
targets O
for O
psychiatric O
disorders O
, O
including O
anxiety O
and O
schizophrenia O
. O

We O
have O
utilised O
dissociated O
primary O
cortical O
neuronal O
cultures O
, O
which O
after O
7 O
days O
in O
vitro O
have O
formed O
functional O
synaptic O
connections O
and O
display O
periodic O
and O
spontaneous O
synchronised O
calcium B
( O
Ca B
( I
2 I
+ I
) I
) O
oscillations O
in O
response O
to O
intrinsic O
action O
potential O
bursts O
. O

We O
herein O
demonstrate O
that O
in O
addition O
to O
non O
- O
selective O
group O
II O
mGlu O
receptor O
agonists O
, O
( O
2R O
, O
4R O
) O
- O
APDC O
, O
LY379268 B
and O
DCG B
- I
IV I
, O
a O
selective O
mGlu2 O
agonist O
, O
LY541850 B
, O
and O
mGlu2 O
positive O
allosteric O
modulators O
, O
BINA O
and O
CBiPES O
, O
inhibit O
the O
frequency O
of O
synchronised O
Ca B
( I
2 I
+ I
) I
oscillations O
in O
primary O
cultures O
of O
rat O
and O
mouse O
cortical O
neurons O
. O

Use O
of O
cultures O
from O
wild O
- O
type O
, O
mGlu2 O
( O
- O
/ O
- O
) O
, O
mGlu3 O
( O
- O
/ O
- O
) O
and O
mGlu2 O
/ O
3 O
( O
- O
/ O
- O
) O
mice O
allowed O
us O
to O
further O
probe O
the O
contribution O
of O
mGlu2 O
and O
mGlu3 O
, O
and O
revealed O
LY541850 B
to O
be O
a O
partial O
mGlu2 O
agonist O
and O
a O
full O
mGlu3 O
antagonist O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Glycine B
release O
is O
regulated O
by O
metabotropic O
glutamate B
receptors O
sensitive O
to O
mGluR2 O
/ O
3 O
ligands O
and O
activated O
by O
N O
- O
acetylaspartylglutam O
( O
NAAG O
) O
. O

The O
presence O
of O
metabotropic O
glutamate B
receptors O
( O
mGluRs O
) O
of O
group O
II O
modulating O
glycine B
exocytosis O
from O
glycinergic O
nerve O
endings O
of O
mouse O
spinal O
cord O
was O
investigated O
. O

Purified O
synaptosomes O
were O
selectively O
prelabeled O
with O
[ O
( O
3 O
) O
H O
] O
glycine O
through O
the O
neuronal O
transporter O
GlyT2 O
and O
subsequently O
depolarized O
by O
superfusion O
with O
12 O
mM O
KCl B
. O

The O
selective O
mGluR2 O
/ O
3 O
agonist O
LY379268 B
inhibited O
the O
K B
( I
+ I
) I
- O
evoked O
overflow O
of O
[ O
( O
3 O
) O
H O
] O
glycine O
in O
a O
concentration O
- O
dependent O
manner O
( O
EC O
( O
50 O
) O
about O
0 O
. O
2 O
nM O
) O
. O

The O
effect O
of O
LY379268 B
was O
prevented O
by O
the O
selective O
mGluR2 O
/ O
3 O
antagonist O
LY341495 O
( O
IC O
( O
50 O
) O
about O
1 O
nM O
) O
. O

In O
contrast O
, O
glutamate B
was O
ineffective O
up O
to O
0 O
. O
1 O
nM O
, O
excluding O
that O
glutamate B
contamination O
of O
commercial O
NAAG O
samples O
is O
responsible O
for O
the O
reported O
activity O
of O
NAAG O
at O
mGluR3 O
. O

The O
effect O
of O
a O
combination O
of O
maximally O
effective O
concentrations O
of O
LY379268 B
and O
NAAG O
exhibited O
no O
additivity O
. O

The O
non O
- O
hydrolysable O
NAAG O
analogue O
N O
- O
acetylaspartyl O
- O
beta O
- O
linked O
glutamate O
( O
beta O
- O
NAAG O
) O
antagonized O
NAAG O
and O
LY379268 B
. O

In O
conclusion O
, O
our O
results O
show O
that O
glycinergic O
nerve O
endings O
in O
spinal O
cord O
are O
endowed O
with O
group O
II O
mGluRs O
mediating O
inhibition O
of O
glycine B
exocytosis O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Attenuation O
of O
methamphetamine B
seeking O
by O
the O
mGluR2 O
/ O
3 O
agonist O
LY379268 B
in O
rats O
with O
histories O
of O
restricted O
and O
escalated O
self O
- O
administration O
. O

Recent O
findings O
implicate O
group O
II O
metabotropic O
glutamate B
receptors O
( O
mGluR O
( O
2 O
/ O
3 O
) O
) O
in O
the O
reinforcing O
effects O
of O
psychostimulants O
and O
have O
identified O
these O
receptors O
as O
potential O
treatment O
targets O
for O
drug O
addiction O
. O

Here O
, O
we O
investigated O
the O
effects O
of O
mGluR O
( O
2 O
/ O
3 O
) O
stimulation O
on O
cue O
- O
and O
drug O
- O
primed O
reinstatement O
in O
rats O
with O
different O
histories O
of O
methamphetamine B
( O
METH B
) O
self O
- O
administration O
training O
, O
under O
two O
conditions O
: O
16 O
daily O
sessions O
of O
short O
access O
( O
90 O
min O
/ O
day O
, O
ShA O
) O
, O
or O
8 O
daily O
sessions O
of O
short O
access O
followed O
by O
8 O
sessions O
of O
long O
access O
( O
6 O
h O
/ O
day O
, O
LgA O
) O
. O

Following O
self O
- O
administration O
and O
subsequent O
extinction O
training O
, O
rats O
were O
pretreated O
with O
the O
selective O
mGluR O
( O
2 O
/ O
3 O
) O
agonist O
LY379268 B
( O
variable O
dose O
, O
0 O
- O
3 O
mg O
/ O
kg O
) O
, O
exposed O
to O
METH B
- O
paired O
cues O
or O
a O
priming O
injection O
of O
METH B
( O
1 O
mg O
/ O
kg O
) O
, O
and O
tested O
for O
reinstatement O
of O
METH B
- O
seeking O
behavior O
. O

LgA O
rats O
self O
- O
administered O
greater O
amounts O
of O
METH B
during O
the O
second O
half O
of O
training O
, O
but O
when O
pretreated O
with O
vehicle O
, O
ShA O
and O
LgA O
rats O
showed O
cue O
- O
and O
drug O
- O
primed O
reinstatement O
at O
equivalent O
response O
rates O
. O

However O
, O
LgA O
rats O
demonstrated O
greater O
sensitivity O
to O
mGluR O
( O
2 O
/ O
3 O
) O
stimulation O
with O
attenuated O
responding O
during O
cue O
- O
induced O
reinstatement O
after O
0 O
. O
3 O
mg O
/ O
kg O
and O
higher O
doses O
of O
LY379268 B
, O
whereas O
ShA O
rats O
decreased O
cue O
- O
induced O
reinstatement O
behavior O
following O
1 O
. O
0 O
mg O
/ O
kg O
and O
3 O
. O
0 O
mg O
/ O
kg O
LY379268 B
. O

Additionally O
, O
both O
LgA O
and O
ShA O
rats O
exhibited O
decreased O
METH B
- O
primed O
reinstatement O
behavior O
following O
0 O
. O
3 O
mg O
/ O
kg O
and O
higher O
doses O
of O
LY379268 B
. O

A O
separate O
group O
of O
control O
rats O
was O
trained O
to O
self O
- O
administer O
sucrose O
pellets O
, O
and O
demonstrated O
attenuated O
cue O
- O
induced O
sucrose O
- O
seeking O
behavior O
following O
1 O
. O
0 O
and O
3 O
. O
0 O
mg O
/ O
kg O
LY379268 B
. O

Together O
, O
the O
results O
indicate O
that O
LY379268 B
has O
differential O
attenuating O
effects O
on O
cue O
- O
induced O
reinstatement O
behavior O
in O
rats O
with O
different O
histories O
of O
METH B
intake O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Two O
new O
phenolic B
glycosides I
from O
Inula O
cappa O
DC O
. O

Two O
new O
phenolic B
glycosides I
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
roots O
of O
Inula O
cappa O
DC O
. O

In O
vitro O
characterization O
of O
organophosphorus B
compound O
hydrolysis O
by O
native O
and O
recombinant O
human O
prolidase O
. O

Human O
prolidase O
is O
a O
binuclear O
metalloenzyme O
, O
which O
can O
potentially O
function O
as O
a O
catalytic O
bioscavenger O
for O
organophosphorus B
( O
OP O
) O
nerve O
agents O
. O

Both O
enzymes O
efficiently O
hydrolyzed O
diisopropylfluoropho O
, O
sarin B
, O
soman B
, O
tabun B
and O
cyclosarin B
, O
but O
were O
much O
less O
efficient O
at O
hydrolyzing O
paraoxon B
and O
methyl O
paraoxon O
. O

Theoretical O
study O
of O
the O
pH O
- O
dependent O
antioxidant O
properties O
of O
vitamin B
C I
. O

Molecules O
acting O
as O
antioxidants O
capable O
of O
scavenging O
reactive O
oxygen B
species O
( O
ROS O
) O
are O
of O
utmost O
importance O
in O
the O
living O
cell O
. O

Vitamin B
C I
is O
known O
to O
be O
one O
of O
these O
molecules O
. O

In O
this O
study O
we O
have O
analyzed O
the O
reactivity O
of O
vitamin B
C I
toward O
the O
[ O
Formula O
: O
see O
text O
] O
and O
[ O
Formula O
: O
see O
text O
] O
ROS O
species O
, O
in O
all O
acidic O
, O
neutral O
and O
basic O
media O
. O

Two O
reaction O
types O
have O
been O
studied O
in O
each O
case O
: O
addition O
to O
the O
ring O
atoms O
, O
and O
hydrogen B
/ O
proton O
abstraction O
. O

In O
all O
three O
media O
, O
vitamin B
C I
reactions O
with O
two O
hydroxyl B
radicals O
show O
a O
wide O
variety O
of O
possible O
products O
. O

Hyperinakin O
, O
a O
new O
anti O
- O
inflammatory O
phloroglucinol B
derivative O
from O
Hypericum O
nakamurai O
. O

Phytochemical O
investigation O
of O
Hypericum O
nakamurai O
( O
Masamune O
) O
Robson O
has O
led O
to O
the O
isolation O
of O
three O
phloroglucinol B
derivatives O
1 O
- O
3 O
. O

Single O
- O
nucleotide B
polymorphisms O
( O
SNPs O
) O
in O
chromosomal O
DNA O
are O
contributing O
factors O
dictating O
natural O
susceptibility O
of O
humans O
to O
disease O
. O

This O
mini O
- O
review O
evaluates O
the O
theoretical O
potential O
of O
a O
pharmacological O
enhancement O
strategy O
of O
cognitive O
remediation O
training O
with O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
agonists O
. O

We O
also O
examined O
mGlu1 O
/ O
5 O
receptor O
signaling O
by O
in O
vivo O
measurement O
of O
DHPG B
- O
stimulated O
polyphosphoinositide B
hydrolysis O
. O

Stimulation O
of O
( O
3 O
) O
H O
- O
inositolmonophosphat O
formation O
induced O
by O
i O
. O
c O
. O
v O
. O
injection O
of O
DHPG B
was O
enhanced O
by O
about O
50 O
% O
in O
the O
hippocampus O
of O
cLH O
rats O
. O

Correspondingly O
, O
DHPG B
- O
induced O
long O
- O
term O
depression O
( O
LTD O
) O
at O
Schaffer O
collateral O
/ O
CA1 O
pyramidal O
cell O
synapses O
was O
amplified O
in O
hippocampal O
slices O
of O
cLH O
rats O
, O
whereas O
LTD O
induced O
by O
low O
frequency O
stimulation O
of O
the O
Schaffer O
collaterals O
did O
not O
change O
. O

However O
, O
chronic O
treatment O
of O
cLH O
rats O
with O
MPEP B
did O
not O
reverse O
learned O
helplessness O
, O
indicating O
that O
the O
enhanced O
mGlu5 O
receptor O
function O
is O
not O
the O
only O
player O
in O
the O
behavioral O
phenotype O
of O
this O
genetic O
model O
of O
depression O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

A O
variant O
in O
the O
carboxyl B
- O
terminus O
of O
connexin O
40 O
alters O
GAP O
junctions O
and O
increases O
risk O
for O
tetralogy O
of O
Fallot O
. O

A O
heterozygous O
nucleotide B
change O
( O
c O
. O
793C O
> O
T O
) O
in O
exon O
2 O
of O
the O
gene O
leading O
to O
the O
p O
. O
Pro265Ser O
variant O
at O
the O
carboxyl B
- O
terminus O
of O
the O
protein O
was O
found O
in O
two O
unrelated O
sporadic O
patients O
, O
one O
with O
classic O
anatomy O
and O
one O
with O
pulmonary O
atresia O
. O

A O
comparison O
between O
the O
temperatures O
within O
imploding O
acoustic O
cavitation O
bubbles O
and O
the O
extent O
of O
sonoluminescence O
( O
SL O
) O
quenching O
by O
C O
( O
1 O
) O
- O
C O
( O
5 O
) O
aliphatic B
alcohols I
in O
1 O
- O
ethyl O
- O
3 O
- O
methylimidazolium O
ethylsulfate O
( O
[ O
EMIM O
] O
[ O
EtSO O
( O
4 O
) O
] O
, O
a O
well O
known O
imidazolium B
based O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
) O
, O
has O
been O
made O
at O
an O
ultrasound O
frequency O
of O
213 O
kHz O
. O

The O
temperatures O
obtained O
ranged O
from O
3500 O
+ O
/ O
- O
200K O
, O
in O
neat O
[ O
EMIM O
] O
[ O
EtSO O
( O
4 O
) O
] O
, O
to O
about O
3200 O
+ O
/ O
- O
200K O
in O
RTIL O
- O
alcohol B
containing O
solutions O
. O

It O
was O
also O
found O
that O
the O
SL O
intensity O
decreased O
with O
increasing O
concentration O
( O
up O
to O
1M O
) O
of O
the O
alcohols B
to O
a O
greater O
extent O
compared O
with O
the O
relative O
changes O
to O
the O
bubble O
temperatures O
. O

Both O
the O
extent O
of O
the O
reduction O
in O
the O
bubble O
temperatures O
and O
the O
SL O
quenching O
were O
much O
smaller O
than O
those O
obtained O
in O
comparable O
aqueous O
solutions O
containing O
aliphatic B
alcohols I
. O

Possible O
reasons O
for O
the O
differences O
in O
the O
observed O
trends O
between O
water O
/ O
alcohol B
and O
[ O
EMIM O
] O
[ O
EtSO O
( O
4 O
) O
] O
/ O
alcohol B
systems O
under O
sonication O
at O
213 O
kHz O
are O
discussed O
. O

Mounting O
evidence O
suggests O
a O
possible O
role O
for O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
in O
the O
neuropathophysiology O
of O
autism O
spectrum O
disorders O
( O
ASD O
) O
, O
but O
the O
extent O
of O
this O
impairment O
is O
unclear O
. O

A O
non O
- O
invasive O
, O
in O
vivo O
measure O
of O
GABA B
involves O
transcranial O
magnetic O
stimulation O
( O
TMS O
) O
of O
the O
primary O
motor O
cortex O
to O
probe O
cortical O
inhibition O
. O

There O
was O
, O
however O
, O
evidence O
for O
short O
interval O
cortical O
inhibition O
( O
SICI O
) O
deficits O
among O
those O
ASD O
participants O
who O
had O
experienced O
early O
language O
delay O
, O
suggesting O
that O
GABA B
may O
be O
implicated O
in O
an O
ASD O
subtype O
. O

The O
current O
findings O
do O
not O
support O
a O
broad O
role O
for O
GABA B
in O
the O
neuropathophysiology O
of O
ASD O
, O
but O
provide O
further O
indication O
that O
GABAA O
could O
be O
involved O
in O
ASD O
where O
there O
is O
a O
delay O
in O
language O
acquisition O
. O

As O
first O
- O
line O
treatment O
of O
tics O
risperidone B
( O
best O
evidence O
level O
for O
atypical O
antipsychotics O
) O
or O
tiapride O
( O
largest O
clinical O
experience O
in O
Europe O
and O
low O
rate O
of O
adverse O
reactions O
) O
are O
recommended O
. O

In O
TS O
patients O
with O
comorbid O
attention O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
atomoxetine B
, O
stimulants O
or O
clonidine B
should O
be O
considered O
, O
or O
, O
if O
tics O
are O
severe O
, O
a O
combination O
of O
stimulants O
and O
risperidone B
. O

When O
mild O
to O
moderate O
tics O
are O
associated O
with O
obsessive O
- O
compulsive O
symptoms O
, O
depression O
or O
anxiety O
sulpiride B
monotherapy O
can O
be O
helpful O
. O

In O
more O
severe O
cases O
the O
combination O
of O
risperidone B
and O
a O
selective O
serotonin B
reuptake O
inhibitor O
should O
be O
given O
. O

For O
many O
addictions O
, O
including O
cocaine B
, O
methamphetamine B
, O
and O
marijuana O
addiction O
, O
there O
are O
no O
approved O
pharmacological O
treatments O
. O

A O
number O
of O
cognitive O
enhancing O
agents O
, O
including O
galantamine B
, O
modafinil B
, O
atomoxetine B
, O
methylphenidate B
, O
and O
guanfacine O
, O
have O
shown O
promising O
findings O
in O
human O
studies O
. O

Pinosylvin O
Induces O
Cell O
Survival O
, O
Migration O
and O
Anti O
- O
Adhesiveness O
of O
Endothelial O
Cells O
via O
Nitric B
Oxide I
Production O
. O

Pinosylvin O
is O
a O
phenolic B
compound O
mainly O
found O
in O
the O
Pinus O
species O
. O

When O
BAECs O
were O
treated O
with O
pinosylvin O
, O
etoposide B
- O
or O
starvation O
- O
induced O
apoptosis O
was O
shown O
to O
be O
significantly O
reduced O
. O

Moreover O
, O
pinosylvin O
was O
shown O
to O
activate O
endothelial O
nitric B
oxide I
synthetase O
( O
eNOS O
) O
. O

The O
pinosylvin O
- O
induced O
cell O
proliferation O
was O
declined O
by O
treatment O
with O
L B
- I
NAME I
, O
an O
eNOS O
inhibitor O
. O

We O
investigated O
GSK O
- O
3 O
inhibitors O
based O
on O
2 O
different O
scaffolds O
in O
order O
to O
elucidate O
the O
demands O
of O
the O
ATP B
- O
binding O
pocket O
[ O
1 O
] O
. O

VP1 O
. O
1 O
. O
5 O
facilitated O
pre O
- O
pulse O
inhibition O
( O
PPI O
) O
, O
reversed O
amphetamine B
- O
but O
not O
MK B
- I
801 I
- O
induced O
PPI O
deficit O
. O

The O
drug O
was O
able O
to O
ameliorate O
the O
disrupted O
latent O
inhibition O
( O
LI O
) O
induced O
by O
the O
increased O
number O
of O
conditioning O
trials O
and O
reversed O
amphetamine B
- O
induced O
LI O
deficit O
, O
supporting O
further O
its O
antipsychotic O
effects O
. O

PDE10A O
is O
highly O
expressed O
in O
the O
brain O
and O
functions O
to O
metabolically O
inactivate O
the O
important O
second O
messengers O
cAMP B
and O
cGMP B
. O

THPP O
- O
1 O
significantly O
increased O
phosphorylation O
of O
proteins O
in O
the O
striatum O
involved O
in O
synaptic O
plasticity O
, O
including O
the O
a O
- O
amino O
- O
3 O
- O
hydroxy O
- O
5 O
- O
methylisoxazole O
- O
4 O
- O
proprionic O
acid O
receptor O
( O
AMPA B
) O
GluR1 O
subunit O
, O
extracellular O
receptor O
kinase O
( O
ERK O
) O
, O
and O
cAMP B
- O
response O
element O
binding O
protein O
( O
CREB O
) O
. O

THPP O
- O
1 O
produced O
dose O
- O
dependent O
effects O
in O
preclinical O
assays O
predictive O
of O
antipsychotic O
activity O
including O
attenuation O
of O
MK B
- I
801 I
- O
induced O
psychomotor O
activation O
and O
condition O
avoidance O
responding O
in O
rats O
. O

At O
similar O
plasma O
exposures O
, O
THPP O
- O
1 O
significantly O
increased O
object O
recognition O
memory O
in O
rat O
and O
attenuated O
a O
ketamine B
- O
induced O
deficit O
in O
the O
object O
retrieval O
detour O
task O
in O
rhesus O
monkey O
. O

Quetiapine B
ameliorates O
stress O
- O
induced O
cognitive O
inflexibility O
in O
rats O
. O

The O
antidepressant O
action O
of O
quetiapine B
has O
been O
demonstrated O
in O
clinical O
and O
preclinical O
studies O
. O

Therefore O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
whether O
quetiapine B
would O
prevent O
and O
/ O
or O
reverse O
stress O
- O
induced O
cognitive O
impairments O
in O
a O
rat O
model O
of O
prefrontal O
cortex O
( O
PFC O
) O
- O
dependent O
attentional O
set O
- O
shifting O
task O
( O
ASST O
) O
. O

Because O
quetiapine B
augmentation O
to O
selective O
serotonin B
reuptake O
inhibitors O
( O
SSRIs O
) O
has O
recently O
been O
proven O
to O
be O
beneficial O
in O
neuropsychiatric O
disorders O
, O
a O
separate O
experiment O
was O
designed O
to O
assess O
the O
impact O
of O
combined O
administration O
of O
inactive O
doses O
of O
quetiapine B
and O
escitalopram B
on O
ASST O
performance O
in O
rats O
. O

Quetiapine B
( O
2 O
. O
5 O
mg O
/ O
kg O
, O
PO O
) O
given O
to O
rats O
prior O
to O
the O
restraint O
sessions O
completely O
prevented O
this O
stress O
- O
induced O
cognitive O
inflexibility O
. O

Similar O
effect O
was O
demonstrated O
after O
pretreatment O
with O
the O
alpha O
1 O
- O
adrenoceptor O
antagonist O
, O
prazosin B
( O
1 O
mg O
/ O
kg O
, O
IP O
) O
. O

Moreover O
, O
acute O
administration O
of O
quetiapine B
before O
the O
test O
reversed O
set O
- O
shifting O
deficits O
in O
stressed O
rats O
( O
0 O
. O
63 O
, O
1 O
. O
25 O
and O
2 O
. O
5 O
mg O
/ O
kg O
, O
PO O
) O
and O
improved O
ED O
performance O
of O
cognitively O
unimpaired O
control O
animals O
( O
1 O
. O
25 O
and O
2 O
. O
5 O
mg O
/ O
kg O
, O
PO O
) O
. O

Finally O
, O
the O
combined O
administration O
of O
inactive O
doses O
of O
quetiapine B
( O
0 O
. O
63 O
and O
0 O
. O
3 O
mg O
/ O
kg O
in O
control O
and O
stressed O
rats O
, O
respectively O
) O
and O
escitalopram B
( O
0 O
. O
3 O
mg O
/ O
kg O
, O
IP O
) O
facilitated O
set O
- O
shifting O
performance O
in O
either O
control O
or O
stressed O
rats O
. O

In O
conclusion O
, O
quetiapine B
administration O
either O
prevented O
or O
reversed O
stress O
- O
induced O
cognitive O
inflexibility O
in O
rats O
. O

In O
addition O
to O
promoting O
of O
set O
- O
shifting O
by O
itself O
, O
quetiapine B
also O
enhanced O
the O
procognitive O
efficacy O
of O
escitalopram B
. O

The O
potential O
contribution O
of O
the O
antagonism O
at O
alpha O
1 O
- O
adrenoceptors O
to O
the O
mechanisms O
underlying O
the O
protective O
action O
of O
quetiapine B
requires O
further O
evaluation O
. O

Modified O
- O
release O
prednisone B
decreases O
complaints O
and O
fatigue O
compared O
to O
standard O
prednisolone B
in O
patients O
with O
adrenal O
insufficiency O
. O

Patients O
on O
morning O
dose O
prednisolone B
( O
5 O
mg O
) O
were O
included O
, O
switched O
to O
modified O
- O
release O
prednisone B
( O
5 O
mg O
) O
at O
10 O
PM O
for O
3 O
months O
, O
and O
then O
switched O
back O
on O
standard O
prednisolone B
. O

Modified O
- O
release O
prednisone B
showed O
significant O
improvement O
in O
one O
of O
4 O
scales O
of O
GBB O
- O
24 O
and O
positive O
trends O
to O
better O
scores O
in O
3 O
of O
4 O
scales O
. O

Modified O
- O
release O
prednisone B
showed O
decreased O
complaints O
and O
fatigue O
compared O
to O
standard O
prednisolone B
indicating O
importance O
of O
glucocorticoid O
increase O
in O
early O
morning O
hours O
before O
waking O
. O

Bioactivity O
of O
Diosmetin O
Glycosides O
Isolated O
from O
the O
Epicarp O
of O
Date O
Fruits O
, O
Phoenix O
dactylifera O
, O
on O
the O
Biochemical O
Profile O
of O
Alloxan B
Diabetic O
Male O
Rats O
. O

The O
new O
natural O
flavonoid B
compounds O
- O
diosmetin O
7 O
- O
O O
- O
beta O
- O
L O
- O
arabinofuranosyl O
( O
1 O
- O
- O
> O
2 O
) O
beta O
- O
D O
- O
apiofuranoside O
( O
1 O
) O
and O
diosmetin O
7 O
- O
O O
- O
beta O
- O
D O
- O
apiofuranoside O
( O
2 O
) O
- O
were O
isolated O
from O
the O
acetone B
extract O
of O
date O
fruits O
epicarp O
belonging O
to O
family O
Arecaceae O
( O
Palmae O
) O
. O

These O
compounds O
were O
assessed O
for O
their O
biological O
activity O
on O
alloxan B
diabetic O
rats O
. O

wt O
were O
orally O
administrated O
to O
alloxan B
diabetic O
rats O
for O
30 O
days O
. O

The O
treatment O
of O
diabetic O
rats O
with O
these O
compounds O
resulted O
in O
marked O
improvement O
of O
the O
different O
biochemical O
results O
, O
i O
. O
e O
. O
the O
serum O
glucose B
level O
( O
highly O
significant O
, O
from O
330 O
+ O
5 O
. O
5 O
mg O
/ O
dL O
to O
140 O
+ O
1 O
. O
2 O
mg O
/ O
dL O
) O
treated O
with O
( O
1 O
) O
; O
liver O
functions O
markedly O
developed O
both O
by O
AST O
and O
ALT O
levels O
, O
( O
reduced O
significantly O
from O
68 O
. O
3 O
+ O
4 O
. O
8 O
mu O
/ O
L O
to O
54 O
+ O
5 O
. O
5 O
mu O
/ O
L O
and O
from O
61 O
. O
0 O
+ O
3 O
. O
6 O
mu O
/ O
L O
to O
40 O
. O
1 O
+ O
3 O
. O
6 O
mu O
/ O
L O
, O
respectively O

) O
treated O
with O
( O
2 O
) O
, O
accompanying O
with O
mild O
decrease O
in O
both O
cholesterol B
and O
triglycerides B
levels O
with O
( O
1 O
) O
or O
( O
2 O
) O
. O

Decrease O
of O
TBARS O
level O
was O
observed O
in O
whole O
blood O
when O
treated O
with O
( O
1 O
) O
or O
( O
2 O
) O
, O
while O
levels O
of O
glutathione B
peroxidase O
and O
superoxide B
dismutase O
were O
increased O
in O
liver O
. O

Serum O
testosterone B
level O
was O
highly O
significantly O
increased O
( O
from O
705 O
. O
1 O
+ O
3 O
. O
6 O
mg O
/ O
100 O
ml O
to O
720 O
+ O
4 O
. O
7 O
mg O
/ O
100 O
ml O
) O
, O
total O
acid O
phosphatase O
and O
prostate O
acid O
phosphatase O
activities O
were O
highly O
significantly O
decreased O
( O
from O
16 O
. O
9 O
+ O
0 O
. O
28 O
mu O
/ O
L O
to O
10 O
. O
7 O
+ O
1 O
. O
2 O
mu O
/ O
L O
and O
from O
9 O
. O
7 O
+ O
0 O
. O
7 O
mu O
/ O
L O
to O
6 O
. O
5 O
+ O
1 O
mu O
/ O
L O
, O
respectively O
) O
for O
compound O
( O
1 O
) O
. O

Pharmacological O
activation O
of O
AMP O
activated O
kinase O
( O
AMPK O
) O
by O
metformin B
has O
proven O
to O
be O
a O
beneficial O
therapeutic O
approach O
for O
the O
treatment O
of O
type O
II O
diabetes O
. O

Despite O
improved O
glucose B
regulation O
achieved O
by O
administration O
of O
small O
molecule O
activators O
of O
AMPK O
, O
the O
potential O
negative O
impact O
of O
enhanced O
AMPK O
activity O
on O
insulin O
secretion O
by O
the O
pancreatic O
beta O
cell O
is O
an O
important O
consideration O
. O

In O
this O
review O
, O
we O
discuss O
our O
current O
understanding O
of O
the O
role O
of O
AMPK O
in O
central O
functions O
of O
the O
pancreatic O
beta O
cell O
, O
including O
glucose B
- O
stimulated O
insulin O
secretion O
( O
GSIS O
) O
, O
proliferation O
, O
and O
survival O
. O

Human O
neuronal O
coenzyme O
Q10 O
deficiency O
results O
in O
global O
loss O
of O
mitochondrial O
respiratory O
chain O
activity O
, O
increased O
mitochondrial O
oxidative O
stress O
and O
reversal O
of O
ATP B
synthase O
activity O
: O
implications O
for O
pathogenesis O
and O
treatment O
. O

The O
aetiology O
of O
the O
neurological O
presentation O
of O
CoQ O
( O
10 O
) O
deficiency O
has O
yet O
to O
be O
fully O
elucidated O
and O
therefore O
in O
order O
to O
investigate O
these O
phenomena O
we O
have O
established O
a O
neuronal O
cell O
model O
of O
CoQ O
( O
10 O
) O
deficiency O
by O
treatment O
of O
neuronal O
SH O
- O
SY5Y O
cell O
line O
with O
para B
- I
aminobenzoic I
acid I
( O
PABA O
) O
. O

Reduction O
of O
neuronal O
CoQ O
( O
10 O
) O
status O
was O
accompanied O
by O
a O
progressive O
decrease O
in O
mitochondrial O
respiratory O
chain O
enzyme O
activities O
, O
with O
a O
67 O
. O
5 O
% O
decrease O
in O
cellular O
ATP B
production O
at O
46 O
% O
residual O
CoQ O
( O
10 O
) O
. O

Dasatinib B
exhibited O
nanomolar O
affinity O
whereas O
broad O
coverage O
inhibitors O
such O
as O
sunitinib B
and O
staurosporine B
derivatives O
did O
not O
show O
any O
effect O
. O

Nicotine B
improves O
performance O
in O
an O
attentional O
set O
shifting O
task O
in O
rats O
. O

A O
large O
number O
of O
studies O
in O
both O
humans O
and O
experimental O
animals O
have O
demonstrated O
nicotine B
- O
induced O
improvements O
in O
various O
aspects O
of O
cognitive O
function O
, O
including O
attention O
and O
memory O
. O

The O
prefrontal O
cortex O
( O
PFC O
) O
is O
thought O
to O
be O
critically O
involved O
in O
the O
modulation O
of O
executive O
function O
and O
these O
attentional O
processes O
are O
enhanced O
by O
nicotine B
acting O
at O
nicotinic O
acetylcholine B
receptors O
. O

The O
effects O
of O
nicotine B
on O
attentional O
flexibility O
were O
therefore O
evaluated O
using O
the O
rodent O
attentional O
set O
shifting O
task O
in O
rats O
. O

Nicotine B
injected O
both O
acutely O
and O
following O
repeated O
pre O
- O
exposure O
significantly O
improved O
both O
intradimensional O
and O
extradimensional O
set O
shifting O
performance O
in O
the O
task O
. O

Further O
investigation O
of O
the O
acute O
effects O
of O
nicotine B
demonstrated O
this O
improvement O
in O
attentional O
flexibility O
to O
be O
dose O
- O
dependent O
. O

These O
results O
implicate O
the O
nicotinic O
receptor O
system O
in O
the O
mediation O
of O
processes O
underlying O
cognitive O
flexibility O
and O
suggest O
that O
nicotine B
improves O
attentional O
flexibility O
in O
rats O
, O
both O
within O
and O
between O
perceptual O
dimensions O
of O
a O
compound O
stimulus O
. O

Nicotine B
- O
induced O
alterations O
in O
prefrontal O
circuitry O
may O
underlie O
these O
effects O
on O
cognitive O
flexibility O
. O

Recent O
evidence O
suggests O
that O
a O
substantial O
portion O
of O
the O
passive O
stiffness O
of O
an O
in O
vitro O
preparation O
of O
tracheal O
smooth O
muscle O
is O
calcium B
sensitive O
and O
is O
regulated O
by O
Rho O
- O
kinase O
, O
although O
the O
underlying O
mechanism O
and O
the O
details O
of O
regulation O
for O
the O
development O
of O
this O
intracellular O
passive O
stiffness O
are O
still O
largely O
unknown O
. O

Natural O
anthocyanins B
from O
phytoresources O
and O
their O
chemical O
researches O
. O

Anthocyanins B
are O
a O
class O
of O
naturally O
occurring O
polyphenols B
which O
have O
been O
most O
widely O
studied O
in O
recent O
decades O
for O
the O
rapid O
development O
of O
relative O
techniques O
. O

This O
article O
first O
reviews O
the O
various O
anthocyanin B
resources O
including O
fruits O
, O
flowers O
, O
vegetables O
and O
beverages O
. O

Besides O
the O
direct O
extraction O
from O
natural O
resources O
, O
anthocyanins B
can O
also O
be O
obtained O
by O
semi O
- O
or O
total O
synthesis O
. O

After O
the O
introduction O
of O
new O
representative O
anthocyanins B
found O
in O
the O
past O
few O
years O
and O
the O
major O
relationships O
between O
structures O
and O
stability O
, O
modern O
separation O
and O
analysis O
technologies O
in O
related O
studies O
were O
summarised O
, O
which O
play O
an O
important O
role O
in O
chemical O
researches O
of O
anthocyanins B
. O

Role O
of O
metabotropic O
glutamate B
receptor O
1 O
in O
the O
basolateral O
amygdala O
- O
driven O
prefrontal O
cortical O
deactivation O
in O
inflammatory O
pain O
in O
the O
rat O
. O

We O
have O
here O
investigated O
the O
role O
of O
group O
I O
metabotropic O
glutamate B
receptors O
( O
mGluRs O
) O
in O
the O
basolateral O
amygdala O
( O
BLA O
) O
pre O
- O
infra O
- O
limbic O
( O
PL O
- O
IL O
) O
divisions O
of O
the O
medial O
prefrontal O
cortex O
( O
mPFC O
) O
neuron O
connections O
after O
carrageenan O
- O
induced O
inflammatory O
pain O
in O
the O
rat O
. O

Intra O
- O
plantar O
injection O
of O
carrageenan O
decreased O
either O
spontaneous O
or O
mechanically O
/ O
electrically O
evoked O
activity O
of O
PL O
cortex O
pyramidal O
neurons O
which O
responded O
with O
excitation O
in O
a O
way O
prevented O
by O
CPCOOEt O
, O
a O
selective O
mGluR1 O
antagonist O
, O
though O
not O
by O
MPEP B
, O
a O
selective O
mGluR5 O
antagonist O
. O

Accordingly O
, O
intra O
- O
BLA O
microinjection O
of O
DHPG B
, O
a O
group O
I O
mGluR O
agonist O
, O
caused O
PL O
cortex O
neuron O
activity O
depression O
, O
antagonized O
by O
CPCCOEt B
. O

CPCOOEt O
, O
but O
not O
MPEP B
, O
reduced O
also O
carrageenan O
- O
induced O
mechanical O
allodynia O
. O

The O
PL O
cortex O
cell O
deactivation O
in O
inflammatory O
pain O
condition O
was O
associated O
with O
increased O
GABA B
( O
conversely O
glutamate B
was O
decreased O
) O
in O
the O
PL O
/ O
IL O
cortex O
. O

The O
local O
application O
of O
bicuculline B
, O
a O
GABA B
( O
A O
) O
receptor O
selective O
antagonist O
, O
reduced O
mechanical O
allodynia O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
' O
Metabotropic O
Glutamate B
Receptors O
' O
. O

Emerging O
role O
of O
AMP B
- O
activated O
protein O
kinase O
in O
endocrine O
control O
of O
metabolism O
in O
the O
liver O
. O

This O
review O
summarizes O
the O
emerging O
role O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
in O
mediating O
endocrine O
regulation O
of O
metabolic O
fluxes O
in O
the O
liver O
. O

Rats O
treated O
with O
insulin O
plus O
hCG O
displayed O
abnormal O
estrous O
cycles O
with O
increasing O
androgen B
biosynthesis O
. O

AMPAKINE O
compounds O
are O
a O
novel O
class O
of O
pharmacological O
agents O
that O
act O
as O
positive O
modulators O
of O
AMPA B
receptors O
to O
enhance O
excitatory O
glutamatergic O
neurotransmission O
. O

Here O
we O
evaluate O
the O
actions O
of O
AMPA B
compounds O
in O
adult O
male O
and O
female O
BTBR O
mice O
, O
a O
well O
characterized O
mouse O
model O
of O
autism O
. O

Preliminary O
data O
with O
CX546 O
, O
in O
which O
beta B
- I
cyclodextrin I
was O
the O
vehicle O
, O
revealed O
behavioral O
effects O
of O
the O
acute O
intraperitoneal O
and O
oral O
administration O
of O
vehicle O
alone O
. O

Androgen B
insensitivity O
syndrome O
. O

Androgen B
insensitivity O
syndrome O
( O
AIS O
) O
is O
a O
disorder O
caused O
by O
a O
mutation O
of O
the O
gene O
encoding O
the O
androgen B
receptor O
( O
AR O
; O
Xq11 O
- O
q12 O
) O
. O

Deep O
understanding O
of O
the O
interaction O
between O
thienorphine O
and O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
isoforms O
. O

Silibinin O
protects O
H9c2 O
cardiac O
cells O
from O
oxidative O
stress O
and O
inhibits O
phenylephrine B
- O
induced O
hypertrophy O
: O
potential O
mechanisms O
. O

Recent O
in O
vitro O
and O
in O
vivo O
studies O
indicate O
the O
involvement O
of O
reactive O
oxygen B
species O
in O
the O
hypertrophic O
response O
. O

In O
this O
study O
, O
silibinin O
, O
a O
plant O
flavonolignan O
extracted O
from O
milk O
thistle O
with O
potent O
antioxidant O
activity O
, O
was O
evaluated O
for O
its O
effects O
in O
( O
a O
) O
preventing O
hydrogen B
peroxide I
( O
H2O2 B
) O
- O
induced O
cellular O
damage O
and O
( O
b O
) O
blocking O
the O
phenylephrine B
- O
induced O
hypertrophic O
response O
. O

Pretreatment O
of O
H9c2 O
cells O
with O
silibinin O
resulted O
in O
better O
protection O
of O
H9c2 O
cells O
under O
conditions O
of O
H2O2 B
- O
induced O
cellular O
stress O
compared O
to O
untreated O
cells O
as O
indicated O
by O
cell O
viability O
and O
DNA O
fragmentation O
assays O
. O

Furthermore O
, O
silibinin O
attenuated O
the O
phenylephrine B
- O
induced O
hypertrophic O
response O
as O
evidenced O
by O
the O
measurement O
of O
cell O
surface O
, O
up O
- O
regulation O
of O
atrial O
natriuretic O
peptide O
and O
increase O
of O
cellular O
protein O
levels O
. O

Moreover O
, O
silibinin O
repressed O
the O
phenylephrine B
- O
induced O
phosphorylation O
of O
ERK1 O
/ O
2 O
kinases O
, O
while O
it O
appeared O
to O
inhibit O
the O
weakly O
activated O
by O
phenylephrine B
phosphorylation O
of O
Akt O
. O

Based O
on O
our O
results O
, O
silibinin O
may O
attenuate O
the O
phenylephrine B
- O
induced O
hypertrophic O
response O
of O
H9c2 O
cells O
via O
antioxidant O
mechanisms O
involving O
mainly O
the O
inhibition O
of O
the O
intracellular O
signaling O
pathways O
mediated O
by O
ERK1 O
/ O
2 O
MAPKs O
and O
Akt O
. O

Modafinil B
effects O
on O
cognition O
and O
emotion O
in O
schizophrenia O
and O
its O
neurochemical O
modulation O
in O
the O
brain O
. O

Modafinil B
is O
a O
central O
nervous O
system O
wake O
promoting O
agent O
used O
for O
the O
treatment O
of O
excessive O
daytime O
sleeping O
. O

Here O
, O
we O
review O
the O
effects O
of O
modafinil B
in O
human O
cognition O
and O
emotion O
and O
its O
specific O
actions O
on O
symptoms O
in O
patients O
with O
schizophrenia O
and O
whether O
these O
are O
consistently O
effective O
throughout O
the O
literature O
. O

We O
also O
performed O
a O
systematic O
review O
on O
the O
effects O
of O
modafinil B
on O
neurotransmitter O
signalling O
in O
different O
areas O
of O
the O
brain O
in O
order O
to O
better O
understand O
the O
neuromechanisms O
of O
its O
cognitive O
and O
emotional O
enhancing O
properties O
. O

A O
review O
of O
its O
effects O
in O
schizophrenia O
suggests O
that O
modafinil B
facilitates O
cognitive O
functions O
, O
with O
pro O
- O
mnemonic O
effects O
and O
problem O
solving O
improvements O
. O

The O
systematic O
review O
on O
the O
neurochemical O
modulation O
of O
the O
modafinil B
suggests O
that O
its O
mnemonic O
enhancing O
properties O
might O
be O
the O
result O
of O
glutamatergic O
and O
dopaminergic O
increased O
neuronal O
activation O
in O
the O
hippocampus O
and O
in O
the O
prefrontal O
cortex O
respectively O
. O

Other O
neurotransmitters O
were O
also O
activated O
by O
modafinil B
in O
various O
limbic O
brain O
areas O
, O
suggesting O
that O
the O
drug O
acts O
on O
these O
brain O
regions O
to O
influence O
emotional O
responses O
. O

These O
reviews O
seek O
to O
delineate O
the O
neuronal O
mechanisms O
by O
which O
modafinil B
affects O
cognitive O
and O
emotional O
function O
. O

A O
search O
for O
alternative O
mechanisms O
that O
may O
operate O
dependently O
or O
independently O
with O
the O
well O
- O
established O
excitotoxic O
mechanism O
has O
led O
researchers O
to O
the O
discovery O
of O
newly O
described O
non O
- O
glutamate B
mechanisms O
. O

It O
is O
well O
established O
that O
both O
estrogen B
loss O
and O
type O
II O
diabetes O
mellitus O
( O
DMII O
) O
can O
impair O
bone O
metabolism O
, O
but O
whether O
estrogen B
loss O
exacerbates O
the O
effects O
of O
DMII O
is O
unclear O
. O

Therefore O
, O
we O
determined O
if O
ovariectomy O
( O
OVX O
) O
of O
rats O
on O
a O
long O
- O
term O
high O
- O
fat O
/ O
sugar B
diet O
and O
injection O
of O
a O
low O
dose O
of O
streptozotocin B
( O
DMII O
) O
decreased O
bone O
mineral O
density O
( O
BMD O
) O
more O
than O
OVX O
or O
DMII O
alone O
. O

As O
hypothesized O
, O
BMD O
and O
plasma O
estrogen B
levels O
were O
decreased O
more O
in O
DOVX O
rats O
than O
in O
rats O
following O
OVX O
( O
NOVX O
) O
or O
DMII O
( O
DS O
) O
alone O
. O

In O
conclusion O
, O
these O
data O
demonstrate O
that O
estrogen B
loss O
and O
DMII O
induced O
by O
a O
high O
- O
fat O
/ O
sugar B
diet O
interact O
to O
produce O
osteoporosis O
and O
support O
the O
hypothesis O
that O
the O
bone O
loss O
may O
be O
mediated O
at O
least O
in O
part O
by O
concurrent O
decreases O
in O
the O
insulin O
signaling O
proteins O
in O
bone O
. O

Classical O
antipsychotics O
, O
e O
. O
g O
. O
haloperidol B
, O
chlorpromazine B
, O
are O
potent O
at O
controlling O
the O
positive O
symptoms O
of O
schizophrenia O
but O
frequently O
elicit O
extrapyramidal O
motor O
side O
- O
effects O
. O

The O
introduction O
of O
atypical O
antipsychotics O
such O
as O
risperidone B
, O
olanzapine B
and O
clozapine B
has O
obviated O
this O
problem O
, O
but O
none O
of O
the O
current O
drugs O
seem O
to O
improve O
the O
cognitive O
deficits O
accompanying O
schizophrenia O
. O

Egis O
- O
11150 O
displayed O
high O
affinity O
for O
adrenergic O
alpha O
( O
1 O
) O
, O
alpha O
( O
2c O
) O
, O
5 B
- I
HT I
( O
2A O
) O
5 O
- O
HT O
7 O
, O
moderate O
affinity O
for O
adrenergic O
alpha O
( O
2a O
) O
and O
D O
2 O
receptors O
. O

Phencyclidine B
- O
induced O
hypermotility O
in O
mice O
and O
inhibition O
of O
conditioned O
avoidance O
response O
in O
rats O
were O
assessed O
to O
estimate O
efficacy O
against O
the O
positive O
and O
social O
withdrawal O
test O
in O
rats O
was O
used O
to O
predict O
efficacy O
against O
the O
negative O
symptoms O
of O
schizophrenia O
. O

Passive O
- O
avoidance O
learning O
, O
novel O
object O
recognition O
and O
radial O
maze O
tests O
in O
rats O
were O
used O
to O
assess O
pro O
- O
cognitive O
activity O
, O
while O
phencyclidine B
- O
induced O
disruption O
of O
prepulse O
inhibition O
in O
mice O
was O
examined O
to O
test O
for O
effects O
on O
attention O
. O

Propranolol B
restores O
cognitive O
deficits O
and O
improves O
amyloid O
and O
Tau O
pathologies O
in O
a O
senescence O
- O
accelerated O
mouse O
model O
. O

In O
the O
present O
study O
we O
tested O
whether O
propranolol B
, O
a O
beta O
- O
receptor O
antagonist O
commonly O
used O
as O
antihypertensive O
drug O
, O
could O
ameliorate O
the O
cognitive O
impairments O
and O
increases O
in O
AD O
- O
related O
markers O
shown O
by O
the O
senescence O
- O
accelerated O
mouse O
prone O
- O
8 O
( O
SAMP8 O
) O
. O

Propranolol B
administration O
( O
5 O
mg O
/ O
kg O
for O
3 O
weeks O
) O
to O
6 O
- O
month O
- O
old O
SAMP8 O
mice O
attenuated O
cognitive O
memory O
impairments O
shown O
by O
these O
mice O
in O
the O
novel O
object O
recognition O
test O
. O

All O
these O
effects O
were O
reversed O
by O
propranolol B
treatment O
. O

Tau O
hyperphosphorylation O
( O
PHF O
- O
1 O
epitope O
) O
shown O
by O
SAMP8 O
mice O
at O
this O
age O
was O
also O
decreased O
in O
the O
hippocampus O
of O
propranolol B
- O
treated O
mice O
, O
an O
effect O
probably O
related O
to O
a O
decrease O
in O
JNK1 O
expression O
. O

Interestingly O
, O
propranolol B
also O
phosphorylated O
Akt O
in O
SAMP8 O
mice O
, O
which O
was O
associated O
with O
an O
increase O
of O
glycogen O
synthase O
kinase O
- O
3 O
beta O
phosphorylation O
, O
contributing O
therefore O
to O
the O
reductions O
in O
Tau O
hyperphosphorylation O
. O

Synaptic O
pathology O
in O
SAMP8 O
mice O
, O
as O
shown O
by O
decreases O
in O
synaptophysin O
and O
BDNF O
, O
was O
also O
counteracted O
by O
propranolol B
treatment O
. O

Overall O
, O
propranolol B
might O
be O
beneficial O
in O
age O
- O
related O
brain O
dysfunction O
and O
could O
be O
an O
emerging O
candidate O
for O
the O
treatment O
of O
other O
neurodegenerative O
diseases O
. O

Sour O
Cherry O
Seed O
Kernel O
Extract O
Increases O
Heme B
Oxygenase O
- O
1 O
Expression O
and O
Decreases O
Representation O
of O
CD3 O
+ O
TNF O
- O
alpha O
+ O
and O
CD3 O
+ O
IL O
- O
8 O
+ O
Subpopulations O
in O
Peripheral O
Blood O
Leukocyte O
Cultures O
from O
Type O
2 O
Diabetes O
Patients O
. O

Cultures O
were O
evaluated O
by O
two O
- O
color O
flow O
cytometry O
for O
percent O
representation O
of O
CD3 O
+ O
IL8 O
+ O
and O
CD3 O
+ O
TNF O
- O
alpha O
+ O
cells O
which O
express O
interleukin O
- O
8 O
( O
IL O
- O
8 O
) O
, O
and O
tumor O
necrosis O
factor O
- O
alpha O
, O
( O
TNF O
- O
alpha O
+ O
) O
respectively O
, O
and O
by O
enzyme O
- O
linked O
immunoassay O
for O
lymphocyte O
- O
associated O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
, O
known O
to O
be O
induced O
by O
SCE O
) O
. O

Combined O
effects O
of O
treatment O
with O
vitamin B
C I
, O
vitamin B
E I
and O
selenium B
on O
the O
skin O
of O
diabetic O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
vitamin B
C I
, O
vitamin B
E I
and O
selenium B
( O
Se B
) O
on O
the O
skin O
tissue O
of O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

Diabetes O
was O
induced O
by O
intraperitoneal O
injection O
of O
65 O
mg O
/ O
kg O
streptozotocin B
. O

Vitamin B
C I
( O
250 O
mg O
/ O
kg O
) O
, O
vitamin B
E I
( O
250 O
mg O
/ O
kg O
) O
and O
Se B
( O
0 O
. O
2 O
mg O
/ O
kg O
) O
were O
given O
by O
gavage O
technique O
to O
rats O
of O
one O
diabetic O
and O
one O
control O
group O
for O
30 O
days O
. O

In O
the O
diabetic O
group O
, O
the O
levels O
of O
serum O
urea B
and O
creatinine B
, O
skin O
lipid O
peroxidation O
and O
nonenzymatic O
glycosylation O
levels O
increased O
, O
but O
skin O
glutathione B
levels O
decreased O
. O

Treatment O
with O
vitamin B
C I
, O
vitamin B
E I
and O
Se B
reversed O
these O
effects O
. O

The O
present O
study O
showed O
that O
vitamin B
C I
, O
vitamin B
E I
and O
Se B
exerted O
antioxidant O
effects O
and O
consequently O
may O
prevent O
skin O
damage O
caused O
by O
streptozotocin B
- O
induced O
diabetes O
. O

Dopamine B
D O
2 O
- O
agonist O
rotigotine O
effects O
on O
cortical O
excitability O
and O
central O
cholinergic O
transmission O
in O
Alzheimer O
' O
s O
disease O
patients O
. O

Dopamine B
is O
a O
neurotransmitter O
involved O
in O
several O
brain O
functions O
ranging O
from O
emotions O
control O
, O
movement O
organization O
to O
memory O
formation O
. O

Several O
recent O
line O
of O
research O
instead O
indicates O
a O
clear O
role O
for O
dopamine B
in O
both O
amyloid O
beta O
formation O
as O
well O
as O
in O
cognitive O
decline O
progression O
. O

In O
particular O
it O
has O
been O
shown O
that O
dopamine B
D O
2 O
- O
like O
receptors O
( O
namely O
D O
3 O
and O
D O
2 O
) O
could O
be O
mostly O
responsible O
for O
dopamine B
dysfunction O
in O
AD O
. O

Here O
we O
aimed O
to O
study O
the O
effects O
of O
the O
dopamine B
agonist O
Rotigotine O
on O
cortical O
excitability O
and O
on O
central O
cholinergic O
transmission O
in O
cases O
of O
AD O
. O

Rotigotine O
is O
a O
dopamine B
agonist O
with O
a O
pharmacological O
profile O
with O
high O
affinity O
for O
D O
3 O
and O
D O
2 O
receptors O
. O

These O
unexpected O
effects O
might O
depend O
on O
the O
dopamine B
D O
2 O
- O
like O
receptors O
dysfunction O
previously O
described O
in O
AD O
brains O
. O

The O
absorption O
process O
in O
animals O
of O
TAK O
- O
491 O
, O
designed O
as O
ester B
- O
based O
prodrug O
with O
medoxomil O
moiety O
, O
was O
evaluated O
. O

These O
metabolic O
features O
of O
TAK O
- O
491 O
were O
similar O
to O
olmesartan B
medoxomil I
, O
suggesting O
the O
hydrolytic O
pathway O
and O
enzymes O
for O
TAK O
- O
491 O
when O
catalyzing O
to O
TAK O
- O
536 O
would O
be O
the O
same O
as O
olmesartan B
medoxomil I
. O

Synthesis O
, O
characterization O
, O
screening O
and O
docking O
analysis O
of O
4 O
- O
anilinoquinazoline O
derivatives O
as O
tyrosine B
kinase O
inhibitors O
. O

We O
report O
here O
the O
design O
and O
synthesis O
of O
a O
series O
of O
4 O
- O
anilinoquinazoline O
derivatives O
, O
of O
which O
7 O
compounds O
were O
crystallographically O
characterized O
, O
as O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
inhibitors O
by O
modifications O
on O
the O
aniline B
ring O
or O
at O
the O
6 O
- O
alkoxy O
site O
of O
the O
6 O
, O
7 O
- O
dimethoxy O
- O
4 O
- O
anilinoquinazoline O
pharmacophore O
. O

Docking O
studies O
indicated O
that O
all O
4 O
- O
anilinoquinazoline O
derivatives O
could O
be O
inserted O
into O
the O
ATP B
- O
binding O
pocket O
of O
the O
EGFR O
via O
indirect O
docking O
, O
and O
that O
the O
modifications O
at O
the O
3 O
' O
- O
position O
of O
the O
anilino O
group O
and O
6 O
- O
alkoxy O
site O
of O
the O
quinazoline B
ring O
have O
little O
interference O
with O
the O
formation O
of O
the O
two O
essential O
H B
- O
bonds O
between O
the O
N3 O
of O
the O
quinazoline B
ring O
and O
Thr766 O
through O
a O
water O
molecule O
, O
and O
the O
N1 O
of O
the O
quinazoline B
ring O
and O
N B
- I
H I
of O
Met769 O
. O

The O
displacing O
of O
the O
phenyl B
at O
4 O
- O
position O
with O
pyridinyl O
dramatically O
reduces O
the O
activity O
of O
the O
quinazoline B
pharmacophore O
, O
the O
resulting O
derivative O
( O
10 O
) O
being O
the O
least O
active O
compound O
. O

The O
docking O
results O
also O
showed O
that O
the O
formation O
of O
new O
H B
- O
bonds O
between O
the O
N B
- I
H I
of O
the O
ethylenediamine O
group O
linked O
to O
the O
6 O
- O
alkoxy O
site O
and O
Asp776 O
/ O
Cys773 O
in O
the O
binding O
pocket O
of O
EGFR O
makes O
compounds O
19 O
( O
IC50 O
= O
12 O
. O
1 O
+ O
/ O
- O
1 O
. O
6 O
nM O
) O
and O
20 O
( O
IC50 O
= O
13 O
. O
6 O
+ O
/ O
- O
0 O
. O
8 O
nM O
) O
the O
most O
potent O
EGFR O
inhibitors O
in O
this O
class O
and O
worthy O
of O
further O
modification O
to O
obtain O
more O
potent O
anticancer O
compounds O
. O

A O
particular O
emphasis O
is O
placed O
on O
protein O
NMR O
and O
hydrogen B
/ O
deuterium B
exchange O
( O
HDX O
) O
techniques O
and O
how O
they O
provide O
complementary O
information O
that O
, O
when O
combined O
with O
crystallography O
, O
provide O
detailed O
insight O
into O
the O
function O
of O
nuclear O
receptors O
. O

Gelucires O
are O
polyethylene B
glycol I
( O
PEG B
) O
glycerides O
composed O
of O
mono O
- O
, O
di O
- O
and O
triglycerides O
and O
mono O
- O
and O
diesters O
of O
PEG B
. O

Modeling O
the O
structure O
and O
proton O
transfer O
pathways O
of O
the O
mutant O
His B
- O
107 O
- O
Tyr B
of O
human O
carbonic O
anhydrase O
II O
. O

We O
present O
molecular O
modeling O
of O
the O
structure O
and O
possible O
proton O
transfer O
pathways O
from O
the O
surface O
of O
the O
protein O
to O
the O
zinc B
- O
bound O
water O
molecule O
in O
the O
active O
site O
of O
the O
mutant O
His B
- O
107 O
- O
Tyr B
of O
human O
carbonic O
anhydrase O
II O
( O
HCAII O
) O
. O

While O
many O
of O
the O
structures O
investigated O
do O
not O
reveal O
a O
complete O
path O
between O
the O
zinc B
bound O
water O
and O
His B
- O
64 O
, O
several O
others O
do O
indicate O
the O
presence O
of O
a O
transient O
connection O
even O
when O
His B
- O
64 O
is O
present O
in O
its O
outward O
conformation O
. O

Competing O
contributions O
from O
His B
- O
64 O
sidechain O
rotation O
from O
its O
outward O
conformation O
are O
also O
evaluated O
in O
terms O
of O
optimal O
path O
analysis O
. O

Oxysterol B
generation O
and O
liver O
X O
receptor O
- O
dependent O
reverse O
cholesterol B
transport O
: O
not O
all O
roads O
lead O
to O
Rome O
. O

Cell O
cholesterol B
metabolism O
is O
a O
tightly O
regulated O
process O
, O
dependent O
in O
part O
on O
activation O
of O
nuclear O
liver O
X O
receptors O
( O
LXRs O
) O
to O
increase O
expression O
of O
genes O
mediating O
removal O
of O
excess O
cholesterol B
from O
cells O
in O
the O
reverse O
cholesterol B
transport O
pathway O
. O

LXRs O
are O
thought O
to O
be O
activated O
predominantly O
by O
oxysterols B
generated O
enzymatically O
from O
cholesterol B
in O
different O
cell O
organelles O
. O

Defects O
resulting O
in O
slowed O
release O
of O
cholesterol B
from O
late O
endosomes O
and O
lysosomes O
or O
reduction O
in O
sterol B
- O
27 O
- O
hydroxylase O
activity O
lead O
to O
specific O
blocks O
in O
oxysterol B
production O
and O
impaired O
LXR O
- O
dependent O
gene O
activation O
. O

This O
block O
does O
not O
appear O
to O
be O
compensated O
by O
oxysterol B
production O
in O
other O
cell O
compartments O
. O

The O
purpose O
of O
this O
review O
is O
to O
summarize O
current O
knowledge O
about O
oxysterol B
- O
dependent O
activation O
by O
LXR O
of O
genes O
involved O
in O
reverse O
cholesterol B
transport O
, O
and O
what O
these O
defects O
of O
cell O
cholesterol B
homeostasis O
can O
teach O
us O
about O
the O
critical O
pathways O
of O
oxysterol B
generation O
for O
expression O
of O
LXR O
- O
dependent O
genes O
. O

The O
mGlu O
5 O
positive O
allosteric O
modulator O
LSN2463359 O
differentially O
modulates O
motor O
, O
instrumental O
and O
cognitive O
effects O
of O
NMDA B
receptor O
antagonists O
in O
the O
rat O
. O

Metabotropic O
glutamate B
5 O
( O
mGlu O
5 O
) O
receptors O
are O
known O
to O
functionally O
interact O
with O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
receptors O
at O
both O
neuronal O
and O
behavioural O
levels O
, O
in O
a O
manner O
that O
may O
be O
of O
relevance O
to O
the O
treatment O
of O
schizophrenia O
. O

We O
have O
previously O
described O
a O
novel O
mGlu O
5 O
positive O
allosteric O
modulator O
( O
PAM O
) O
, O
LSN2463359 O
and O
provided O
evidence O
of O
its O
ability O
to O
attenuate O
aspects O
of O
the O
behavioural O
response O
to O
administration O
of O
the O
competitive O
NMDA B
receptor O
antagonist O
, O
SDZ O
220 O
, O
581 O
. O

In O
addition O
, O
LSN2463359 O
was O
found O
to O
selectively O
attenuate O
reversal O
learning O
deficits O
observed O
in O
the O
neurodevelopmental O
MAM O
E17 O
model O
but O
not O
in O
the O
acute O
phencyclidine B
( O
PCP B
) O
model O
. O

In O
the O
present O
study O
, O
the O
interactions O
between O
this O
mGlu O
5 O
PAM O
and O
the O
NMDA B
receptor O
were O
explored O
further O
by O
assessing O
the O
effects O
of O
LSN2463359 O
against O
some O
of O
the O
motor O
, O
instrumental O
and O
cognitive O
effects O
induced O
by O
the O
non O
- O
competitive O
NMDA B
receptor O
antagonists O
PCP B
and O
MK B
- I
801 I
, O
the O
competitive O
NMDA B
receptor O
antagonist O
SDZ O
220 O
, O
581 O
and O
the O
GluN2B O
selective O
NMDA B
receptor O
antagonist O
, O
Ro O
63 O
- O
1908 O
. O

LSN2463359 O
had O
either O
no O
or O
minor O
impact O
on O
locomotor O
hyperactivity O
induced O
by O
either O
PCP B
or O
SDZ O
220 O
, O
581 O
. O

In O
contrast O
, O
LSN2463359 O
failed O
to O
alter O
both O
of O
the O
instrumental O
effects O
induced O
by O
the O
open O
channel O
blockers O
PCP B
and O
MK B
- I
801 I
. O

In O
addition O
, O
although O
PCP B
and O
SDZ O
220 O
, O
581 O
induced O
similar O
deficits O
in O
a O
discrimination O
and O
reversal O
learning O
task O
, O
LSN2463359 O
was O
again O
only O
able O
to O
reverse O
the O
deficit O
induced O
by O
SDZ O
220 O
, O
581 O
. O

The O
results O
indicate O
that O
the O
interactions O
between O
mGlu O
5 O
and O
NMDA B
receptors O
are O
dependent O
on O
both O
the O
mechanism O
of O
the O
blockade O
of O
the O
receptor O
and O
the O
behavioural O
domain O
under O
investigation O
. O

Our O
work O
has O
implications O
for O
the O
preclinical O
use O
of O
NMDA B
receptor O
antagonists O
in O
the O
prediction O
of O
potential O
therapeutic O
efficacy O
in O
the O
search O
for O
novel O
treatments O
for O
schizophrenia O
. O

The O
demonstrated O
functional O
interaction O
of O
metabotropic O
glutamate B
5 O
( O
mGlu O
5 O
) O
receptors O
with O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
receptors O
has O
prompted O
speculation O
that O
their O
activation O
may O
offer O
a O
potential O
treatment O
for O
aspects O
of O
schizophrenia O
. O

Both O
compounds O
are O
potent O
and O
selective O
potentiators O
of O
human O
and O
rat O
mGlu O
5 O
receptors O
in O
vitro O
, O
displaying O
curve O
shift O
ratios O
of O
two O
to O
three O
fold O
in O
the O
concentration O
- O
response O
relationship O
to O
glutamate O
or O
the O
glutamate B
receptor O
agonist O
, O
DHPG B
, O
with O
no O
detectable O
intrinsic O
agonist O
properties O
. O

In O
contrast O
, O
the O
previously O
described O
mGlu O
5 O
PAMs O
CDPPB O
and O
ADX47273 B
showed O
relatively O
poor O
evidence O
of O
in O
vivo O
target O
engagement O
in O
either O
receptor O
occupancy O
assays O
or O
EEG O
disturbance O
. O

Wake O
- O
promoting O
doses O
of O
LSN2463359 O
and O
LSN2814617 O
attenuated O
deficits O
in O
performance O
induced O
by O
the O
competitive O
NMDA B
receptor O
antagonist O
SDZ O
220 O
, O
581 O
in O
two O
tests O
of O
operant O
behaviour O
: O
the O
variable O
interval O
30 O
s O
task O
and O
the O
DMTP O
task O
. O

Size O
of O
TiO B
( I
2 I
) I
nanoparticles O
influences O
their O
phototoxicity O
: O
an O
in O
vitro O
investigation O
. O

To O
uncover O
the O
size O
influence O
of O
TiO B
( I
2 I
) I
nanoparticles O
on O
their O
potential O
toxicity O
, O
the O
cytotoxicity O
of O
different O
- O
sized O
TiO B
( I
2 I
) I
nanoparticles O
with O
and O
without O
photoactivation O
was O
tested O
. O

It O
was O
demonstrated O
that O
without O
photoactivation O
, O
TiO B
( I
2 I
) I
nanoparticles O
were O
inert O
up O
to O
100 O
mu O
g O
/ O
ml O
. O

On O
the O
contrary O
, O
with O
photoactivation O
, O
the O
toxicity O
of O
TiO B
( I
2 I
) I
nanoparticles O
significantly O
increased O
, O
which O
correlated O
well O
with O
the O
specific O
surface O
area O
of O
the O
particles O
. O

Our O
results O
also O
suggest O
that O
the O
generation O
of O
hydroxyl B
radicals O
and O
reactive O
oxygen B
species O
( O
ROS O
) O
- O
mediated O
damage O
to O
the O
surface O
- O
adsorbed O
biomolecules O
could O
be O
the O
two O
major O
reasons O
for O
the O
cytotoxicity O
of O
TiO B
( I
2 I
) I
nanoparticles O
after O
photoactivation O
. O

To O
further O
investigate O
the O
influence O
of O
the O
generation O
of O
hydroxyl B
radicals O
and O
adsorption O
of O
protein O
, O
poly O
( O
ethylene O
- O
alt O
- O
maleic O
anhydride O
) O
( O
PEMA O
) O
and O
chitosan O
were O
used O
to O
coat O
TiO B
( I
2 I
) I
nanoparticles O
. O

The O
results O
confirmed O
that O
surface O
coating O
of O
TiO B
( I
2 I
) I
nanoparticles O
could O
reduce O
such O
toxicity O
after O
photoactivation O
, O
by O
hindering O
adsorption O
of O
biomolecules O
and O
generation O
of O
hydroxyl B
radical O
( O
. B
OH I
) O
during O
photoactivation O
. O

Fibroblast O
growth O
factor O
23 O
inhibits O
extrarenal O
synthesis O
of O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
in O
human O
monocytes O
. O

Vitamin B
D I
is O
a O
potent O
stimulator O
of O
monocyte O
innate O
immunity O
, O
and O
this O
effect O
is O
mediated O
via O
intracrine O
conversion O
of O
25 B
- I
hydroxyvitamin I
D I
( O
25OHD B
) O
to O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
) O
. O

In O
the O
kidney O
, O
synthesis O
of O
1 O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
is O
suppressed O
by O
fibroblast O
growth O
factor O
23 O
( O
FGF23 O
) O
, O
via O
transcriptional O
suppression O
of O
the O
vitamin B
D I
- O
activating O
enzyme O
1 O
alpha O
- O
hydroxylase O
( O
CYP27B1 O
) O
. O

In O
PBMCm O
this O
was O
associated O
with O
downregulation O
of O
25OHD B
to O
1 O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
metabolism O
, O
and O
concomitant O
suppression O
of O
intracrine O
induced O
24 O
- O
hydroxylase O
( O
CYP24A1 O
) O
and O
antibacterial O
cathelicidin O
( O
LL37 O
) O
. O

Elevated O
expression O
of O
FGF23 O
may O
therefore O
play O
a O
crucial O
role O
in O
defining O
immune O
responses O
to O
vitamin B
D I
and O
this O
, O
in O
turn O
, O
may O
be O
a O
key O
determinant O
of O
infection O
in O
patients O
with O
chronic O
kidney O
disease O
( O
CKD O
) O
. O

A O
crown B
- I
ether I
loop O
- O
derivatized O
oligothiophene O
doubly O
attached O
on O
gold O
surface O
as O
cation O
- O
binding O
switchable O
molecular O
junction O
. O

UV O
- O
vis O
spectroscopy O
and O
cyclic O
voltammetry O
show O
that O
the O
corresponding O
dithioester O
precursor O
can O
complex O
Pb B
( I
2 I
+ I
) I
in O
solution O
and O
that O
this O
property O
is O
maintained O
for O
monolayers O
of O
the O
dithiol B
on O
gold O
. O

Current O
- O
voltage O
measurements O
by O
eutectic O
GaIn O
drop O
contact O
on O
the O
monolayer O
show O
a O
significant O
increase O
( O
up O
to O
1 O
. O
6 O
x O
10 O
( O
3 O
) O
times O
) O
of O
the O
current O
at O
low O
bias O
after O
Pb B
( I
2 I
+ I
) I
complexation O
. O

Atypical O
femoral O
fractures O
( O
AFF O
) O
associated O
with O
long O
- O
term O
bisphosphonates B
( O
LTB O
) O
are O
a O
growing O
concern O
. O

Bisphosphonate B
exposure O
was O
on O
average O
5 O
. O
5 O
years O
( O
range O
5 O
to O
12 O
years O
) O
for O
the O
AFF O
and O
5 O
. O
4 O
years O
( O
range O
5 O
to O
8 O
years O
) O
for O
the O
LTB O
groups O
. O

These O
results O
suggest O
that O
bisphosphonate B
therapy O
probably O
does O
not O
put O
the O
majority O
of O
patients O
at O
risk O
for O
AFF O
. O

Biotransformation O
of O
serotonin B
derivatives O
by O
the O
larvae O
of O
common O
cutworm O
( O
Spodoptera O
litura O
) O
. O

Seven O
serotonin B
derivatives O
( O
1 O
- O
7 O
) O
were O
biotransformed O
using O
larvae O
of O
Spodoptera O
litura O
. O

N O
- O
p O
- O
methoxy O
cinnamoyl O
serotonin O
( O
3 O
) O
was O
converted O
into O
its O
O B
- O
demethylated O
compound O
, O
N O
- O
p O
- O
coumaroyl O
serotonin O
( O
2 O
) O
. O

A O
proposed O
mechanism O
for O
the O
reaction O
indicates O
that O
the O
ethyl B
side O
of O
the O
ester O
is O
eliminated O
as O
ethylene B
through O
a O
concerted O
six O
- O
membered O
cyclic O
transition O
state O
, O
and O
the O
unstable O
intermediate O
glycidic O
acid O
decarboxylates O
rapidly O
to O
give O
the O
corresponding O
aldehyde B
. O

For O
2 O
- O
phpy O
, O
C B
- I
H I
bond O
activation O
in O
the O
[ O
NiCl O
( O
phpy O
) O
( O
2 O
) O
] O
( O
+ O
) O
complex O
is O
significant O
, O
whereas O
this O
route O
is O
almost O
suppressed O
for O
the O
corresponding O
complexes O
of O
3 O
- O
and O
4 O
- O
phpy O
and O
only O
occurs O
at O
elevated O
energies O
. O

A O
significant O
dose O
- O
dependent O
relationship O
between O
mercury B
exposure O
from O
dental O
amalgams O
and O
kidney O
integrity O
biomarkers O
: O
A O
further O
assessment O
of O
the O
Casa O
Pia O
children O
' O
s O
dental O
amalgam O
trial O
. O

Amalgams O
are O
about O
50 O
% O
mercury B
( O
Hg B
) O
, O
and O
Hg B
is O
known O
to O
significantly O
accumulate O
in O
the O
kidney O
. O

It O
was O
hypothesized O
that O
because O
Hg B
accumulates O
in O
the O
proximal O
tubules O
( O
PTs O
) O
, O
glutathione B
- O
S B
- O
transferases O
( O
GST O
) O
- O
alpha O
( O
suggestive O
of O
kidney O
damage O
at O
the O
level O
of O
PT O
) O
would O
be O
expected O
to O
be O
more O
related O
to O
Hg B
exposure O
than O
GST O
- O
pi O
( O
suggestive O
of O
kidney O
damage O
at O
the O
level O
of O
the O
distal O
tubules O
) O
. O

Our O
study O
determined O
whether O
there O
was O
a O
significant O
dose O
- O
dependent O
correlation O
between O
increasing O
Hg B
exposure O
from O
dental O
amalgams O
and O
GST O
- O
alpha O
and O
GST O
- O
pi O
as O
biomarkers O
of O
kidney O
integrity O
. O

Overall O
, O
the O
present O
study O
, O
using O
a O
different O
and O
more O
sensitive O
statistical O
model O
than O
the O
parent O
study O
, O
revealed O
a O
statistically O
significant O
dose O
- O
dependent O
correlation O
between O
cumulative O
exposure O
to O
Hg B
from O
dental O
amalgams O
and O
urinary O
levels O
of O
GST O
- O
alpha O
, O
after O
covariate O
adjustment O
; O
where O
as O
, O
a O
nonsignificant O
relationship O
was O
observed O
with O
urinary O
levels O
of O
GST O
- O
pi O
. O

Manganese B
( O
Mn B
) O
is O
recognized O
an O
essential O
nutrient O
, O
permanganate O
( O
MnO4 O
( O
- O
) O
) O
and O
manganous O
( O
Mn B
( I
+ I
2 I
) I
) O
ions O
are O
caustic O
, O
and O
the O
acute O
toxicity O
of O
KMnO O
( O
4 O
) O
is O
defined O
by O
its O
oxidant O
/ O
irritant O
properties O
and O
by O
the O
toxicity O
of O
Mn B
. O

Based O
on O
clinical O
experience O
with O
200 O
mg O
/ O
L O
KMnO O
( O
4 O
) O
, O
a O
Do O
Not O
Consume O
concentration O
of O
7 O
mg O
/ O
L O
KMnO O
( O
4 O
) O
( O
equivalent O
to O
2 O
mg O
Mn B
/ O
L O
) O
is O
recommended O
. O

Recognizing O
limited O
empirical O
data O
from O
which O
to O
calculate O
an O
ocular O
reference O
value O
, O
a O
skin O
contact O
' O
Do O
Not O
Use O
' O
concentration O
of O
30 O
mg O
Mn B
/ O
L O
is O
recommended O
based O
on O
the O
skin O
irritation O
in O
some O
patients O
after O
a O
10 O
- O
min O
contact O
with O
100 O
mg O
KMnO4 O
/ O
L O
. O

Cresyl O
saligenin O
phosphate O
makes O
multiple O
adducts O
on O
free O
histidine B
, O
but O
does O
not O
form O
an O
adduct O
on O
histidine B
438 O
of O
human O
butyrylcholinesteras O
. O

CBDP O
irreversibly O
inhibits O
butyrylcholinesteras O
( O
BChE O
) O
in O
human O
plasma O
by O
forming O
adducts O
on O
the O
active O
site O
serine B
( O
Ser B
- O
198 O
) O
. O

The O
active O
site O
histidine B
( O
His B
- O
438 O
) O
was O
hypothesized O
to O
abstract O
o O
- O
hydroxybenzyl O
moiety O
from O
the O
initial O
adduct O
on O
Ser B
- O
198 O
. O

Mass O
spectral O
analysis O
of O
CBDP O
- O
inhibited O
BChE O
digested O
with O
Glu B
- O
C O
showed O
an O
o O
- O
hydroxybenzyl O
adduct O
( O
+ O
106amu O
) O
on O
lysine B
499 O
, O
a O
residue O
far O
from O
the O
active O
site O
, O
but O
not O
on O
His B
- O
438 O
. O

Nevertheless O
, O
the O
nitrogen B
of O
the O
imidazole B
ring O
of O
free O
l O
- O
histidine O
formed O
a O
variety O
of O
adducts O
upon O
reaction O
with O
CBDP O
, O
including O
the O
o O
- O
hydroxybenzyl O
adduct O
, O
suggesting O
that O
histidine B
- O
CBDP O
adducts O
may O
form O
on O
other O
proteins O
. O

Organochlorine B
pesticide O
levels O
and O
risk O
of O
Alzheimer O
' O
s O
disease O
in O
north O
Indian O
population O
. O

A O
case O
control O
study O
of O
70 O
patients O
of O
AD O
and O
75 O
controls O
was O
done O
to O
examine O
the O
association O
between O
organochlorine B
pesticides O
( O
OCPs O
) O
and O
risk O
of O
AD O
. O

OCPs O
( O
hexachlorocyclohexan O
( O
HCH O
) O
, O
aldrin O
, O
dieldrin B
, O
endosulfan B
, O
pp O
' O
- O
dichlorodiphenyldich O
( O
pp O
' O
- O
DDE O
) O
, O
op O
' O
- O
DDE O
, O
pp O
' O
- O
dichlorodiphenyltric O
( O
pp O
' O
- O
DDT O
) O
, O
op O
' O
- O
DDT O
, O
pp O
' O
- O
dichlorodiphenyldich O
( O
pp O
' O
- O
DDD O
) O
and O
op O
' O
- O
DDD O
) O
were O
extracted O
from O
blood O
and O
quantitatively O
estimated O
using O
gas O
chromatography O
. O

A O
Mann O
- O
Whitney O
U O
test O
revealed O
significant O
difference O
in O
beta O
- O
HCH O
levels O
( O
U O
= O
1237 O
. O
00 O
, O
W O
= O
4087 O
. O
00 O
, O
z O
= O
- O
6 O
. O
296 O
, O
p O
= O
0 O
. O
000 O
, O
r O
= O
- O
0 O
. O
71 O
) O
, O
dieldrin B
levels O
( O
U O
= O
1449 O
. O
00 O
, O
W O
= O
4299 O
. O
00 O
, O
z O
= O
- O
5 O
. O
809 O
, O
p O
= O
0 O
. O
000 O
, O
r O
= O
- O
0 O
. O
68 O
) O
and O
pp O
' O
- O
DDE O
levels O
( O
U O
= O
2062 O
. O
00 O
, O
W O
= O
4912 O
. O
00 O
, O
z O
= O
- O
2 O
. O
698 O
, O
p O
= O

In O
conclusion O
, O
this O
study O
supports O
epidemiological O
studies O
that O
associate O
exposure O
to O
pesticides O
with O
increased O
risk O
of O
AD O
, O
and O
we O
identified O
the O
specific O
pesticides O
beta O
- O
HCH O
, O
dieldrin B
and O
pp O
' O
- O
DDE O
that O
are O
associated O
with O
the O
risk O
of O
AD O
in O
the O
north O
Indian O
population O
. O

Therapeutic O
efficacy O
of O
silymarin O
from O
milk O
thistle O
in O
reducing O
manganese B
- O
induced O
hepatic O
damage O
and O
apoptosis O
in O
rats O
. O

Oxidative O
stress O
has O
been O
proposed O
as O
a O
possible O
mechanism O
involved O
in O
manganese B
( O
Mn B
) O
toxicity O
. O

The O
present O
study O
investigated O
the O
beneficial O
role O
of O
silymarin O
, O
a O
natural O
flavonoid B
, O
in O
Mn B
- O
induced O
hepatotoxicity O
focusing O
on O
histopathology O
and O
biochemical O
approaches O
. O

Exposure O
to O
Mn B
resulted O
in O
a O
significant O
elevation O
of O
the O
plasma O
marker O
enzyme O
activities O
and O
bilirubin B
level O
related O
to O
liver O
dysfunction O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
hepatic O
oxidative O
stress O
indices O
. O

This O
metal O
reduced O
the O
activities O
of O
superoxide B
dismutase O
, O
catalase O
and O
glutathione B
peroxidase O
and O
nonenzymatic O
antioxidant O
levels O
such O
as O
reduced O
glutathione B
, O
total O
sulfhydryl B
groups O
and O
vitamin B
C I
. O

Coadministration O
of O
silymarin O
alleviated O
Mn B
oxidative O
damage O
effects O
by O
inhibiting O
ROS O
generation O
. O

Histological O
studies O
also O
supported O
the O
beneficial O
role O
of O
silymarin O
against O
Mn B
- O
induced O
hepatic O
damages O
. O

Combining O
all O
, O
results O
suggested O
that O
silymarin O
could O
protect O
hepatic O
tissues O
against O
Mn B
- O
induced O
oxidative O
stress O
probably O
through O
its O
antioxidant O
activity O
. O

Therefore O
, O
its O
supplementation O
could O
provide O
a O
new O
approach O
for O
the O
reduction O
in O
hepatic O
complication O
due O
to O
Mn B
poisoning O
. O

Effect O
of O
copper B
overload O
on O
the O
survival O
of O
HepG2 O
and O
A O
- O
549 O
human O
- O
derived O
cells O
. O

We O
investigated O
the O
effect O
of O
copper B
( O
Cu B
) O
overload O
( O
20 O
- O
160 O
micro O
M O
/ O
24 O
h O
) O
in O
two O
cell O
lines O
of O
human O
hepatic O
( O
HepG2 O
) O
and O
pulmonary O
( O
A O
- O
549 O
) O
origin O
by O
determining O
lipid O
and O
protein O
damage O
and O
the O
response O
of O
the O
antioxidant O
defence O
system O
. O

A O
- O
549 O
cells O
were O
more O
sensitive O
to O
Cu B
overload O
than O
HepG2 O
cells O
. O

A O
marked O
increase O
was O
observed O
in O
both O
the O
cell O
lines O
in O
the O
nitrate B
plus O
nitrite B
concentration O
, O
protein O
carbonyls B
and O
thiobarbituric B
acid I
reactive O
substances O
( O
TBARS O
) O
. O

The O
TBARS O
increase O
was O
consistent O
with O
an O
increment O
in O
saturated B
fatty I
acids I
at O
the O
expense O
of O
polyunsaturated O
acids O
in O
a O
Cu B
concentration O
- O
dependent O
fashion O
. O

Antioxidant O
enzymes O
were O
stimulated O
by O
Cu B
overload O
. O

Superoxide B
dismutase O
activity O
increased O
significantly O
in O
both O
the O
cell O
lines O
, O
with O
greater O
increases O
in O
HepG2 O
than O
in O
A O
- O
549 O
cells O
. O

Dose O
- O
dependent O
decreases O
in O
alpha B
- I
tocopherol I
and O
ferric B
reducing O
ability O
were O
observed O
. O

Total O
glutathione B
content O
was O
lower O
in O
A O
- O
549 O
cells O
and O
higher O
in O
HepG2 O
. O

Calpain O
and O
caspase O
- O
3 O
were O
differentially O
activated O
in O
a O
dose O
- O
dependent O
manner O
under O
copper B
- O
induced O
reactive O
oxygen B
species O
production O
. O

We O
conclude O
that O
Cu B
exposure O
of O
human O
lung O
- O
and O
liver O
- O
derived O
cells O
should O
be O
considered O
a O
reliable O
experimental O
system O
for O
detailed O
study O
of O
mechanism O
/ O
mechanisms O
by O
which O
Cu B
overload O
exerts O
its O
deleterious O
effects O
. O

In O
the O
present O
study O
, O
we O
have O
used O
MTT B
reduction O
of O
the O
whole O
tissue O
to O
clarify O
whether O
the O
production O
of O
this O
complex O
3 O
- O
D O
- O
model O
is O
transferable O
into O
other O
laboratories O
and O
whether O
these O
tissues O
can O
be O
constructed O
reproducibly O
. O

High O
levels O
of O
arachidonic B
acid I
and O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
in O
breast O
cancer O
tissues O
are O
associated O
with O
promoting O
cancer O
cell O
proliferation O
. O

Fatty B
acids I
are O
endogenous O
ligands O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
( O
PPAR O
alpha O
) O
, O
which O
is O
linked O
to O
the O
regulation O
of O
fatty B
acid I
uptake O
, O
lipid O
metabolism O
and O
breast O
cancer O
cell O
growth O
. O

This O
study O
was O
designed O
to O
screen O
candidate O
fatty B
acids I
from O
breast O
cancer O
tissue O
and O
to O
investigate O
the O
effects O
of O
these O
candidate O
fatty B
acids I
on O
PPAR O
alpha O
expression O
, O
cell O
growth O
and O
cell O
cycle O
progression O
in O
breast O
cancer O
cell O
lines O
. O

One O
breast O
cancer O
tissue O
and O
one O
reference O
tissue O
were O
each O
taken O
from O
30 O
individual O
breasts O
to O
examine O
for O
fatty B
acid I
composition O
and O
PPAR O
alpha O
expression O
. O

We O
found O
that O
arachidonic B
acid I
( O
AA O
) O
and O
PPAR O
alpha O
were O
highly O
expressed O
in O
the O
breast O
cancer O
tissues O
. O

Vitamin B
E I
deficiency O
impairs O
the O
somatostatinergic O
receptor O
- O
effector O
system O
and O
leads O
to O
phosphotyrosine B
phosphatase O
overactivation O
and O
cell O
death O
in O
the O
rat O
hippocampus O
. O

Vitamin B
E I
plays O
an O
essential O
role O
in O
maintaining O
the O
structure O
and O
function O
of O
the O
nervous O
system O
, O
and O
its O
deficiency O
, O
commonly O
associated O
with O
fat O
malabsorption O
diseases O
, O
may O
reduce O
neuronal O
survival O
. O

We O
previously O
demonstrated O
that O
the O
somatostatinergic O
system O
, O
implicated O
in O
neuronal O
survival O
control O
, O
can O
be O
modulated O
by O
alpha B
- I
tocopherol I
in O
the O
rat O
dentate O
gyrus O
, O
increasing O
cyclic O
adenosine O
monophosphate O
response O
element O
binding O
protein O
phosphorylation O
. O

To O
gain O
a O
better O
understanding O
of O
the O
molecular O
actions O
of O
tocopherols B
and O
examine O
the O
link O
among O
vitamin B
E I
, O
somatostatin B
and O
neuronal O
survival O
, O
we O
have O
investigated O
the O
effects O
of O
a O
deficiency O
and O
subsequent O
administration O
of O
tocopherol B
on O
the O
somatostatin B
signaling O
pathway O
and O
neuronal O
survival O
in O
the O
rat O
hippocampus O
. O

No O
changes O
in O
somatostatin B
expression O
were O
detected O
in O
vitamin B
- I
E I
- O
deficient O
rats O
. O

These O
rats O
, O
however O
, O
showed O
a O
significant O
increase O
in O
the O
somatostatin B
receptor O
density O
and O
dissociation O
constant O
, O
which O
correlated O
with O
a O
significant O
increase O
in O
the O
protein O
levels O
of O
somatostatin B
receptors O
. O

Nevertheless O
, O
vitamin B
E I
deficiency O
impaired O
the O
ability O
of O
the O
somatostatin B
receptors O
to O
couple O
to O
the O
effectors O
adenylyl B
cyclase O
and O
phosphotyrosine B
phosphatase O
by O
diminishing O
Gi O
protein O
functionality O
. O

Furthermore O
, O
vitamin B
E I
deficiency O
significantly O
increased O
phosphotyrosine B
phosphatase O
activity O
and O
PTP O
eta O
expression O
, O
as O
well O
as O
PKC O
delta O
activation O
, O
and O
decreased O
extracellular O
- O
signal O
- O
regulated O
kinase O
phosphorylation O
. O

Subsequent O
alpha B
- I
tocopherol I
administration O
partially O
or O
completely O
reversed O
all O
these O
values O
to O
control O
levels O
. O

Altogether O
, O
our O
results O
prove O
the O
importance O
of O
vitamin B
E I
homeostasis O
in O
the O
somatostatin B
receptor O
- O
effector O
system O
and O
suggest O
a O
possible O
mechanism O
by O
which O
this O
vitamin O
may O
regulate O
the O
neuronal O
cell O
survival O
in O
the O
adult O
hippocampus O
. O

Avobenzone O
presented O
a O
pronounced O
phototoxicity O
and O
vitamin B
A I
presented O
a O
tendency O
to O
a O
weak O
phototoxic O
potential O
. O

Amongst O
the O
different O
procedures O
evaluated O
, O
the O
use O
of O
a O
SDS B
0 O
. O
1 O
% O
PBS O
solution O
to O
remove O
the O
sticky O
and O
greasy O
test O
material O
prior O
to O
the O
normal O
washing O
procedures O
was O
found O
to O
be O
the O
most O
suitable O
adaptation O
to O
ensure O
efficient O
removal O
of O
greasy O
and O
sticky O
in O
- O
house O
controls O
without O
affecting O
the O
results O
of O
the O
negative O
control O
. O

The O
predictive O
capacity O
of O
the O
refined O
SDS B
0 O
. O
1 O
% O
washing O
procedure O
, O
was O
investigated O
by O
using O
twelve O
oily O
and O
viscous O
compounds O
having O
known O
skin O
irritation O
effects O
supported O
by O
raw O
and O
/ O
or O
peer O
reviewed O
in O
vivo O
data O
. O

In O
addition O
, O
when O
exposed O
to O
non O
- O
irritant O
oily O
and O
viscous O
materials O
, O
tissues O
rinsed O
with O
0 O
. O
1 O
% O
SDS B
generally O
showed O
increased O
viabilities O
accompanied O
by O
decreased O
variabilities O
as O
compared O
to O
the O
normal O
washing O
procedures O
. O

In O
conclusion O
, O
the O
use O
of O
a O
refined O
washing O
procedure O
making O
use O
of O
SDS B
0 O
. O
1 O
% O
in O
PBS O
was O
found O
a O
suitable O
procedure O
to O
ensure O
efficient O
removal O
of O
greasy O
and O
sticky O
materials O
, O
leading O
to O
an O
increased O
predictive O
capacity O
and O
decreased O
variability O
of O
the O
tissue O
responses O
while O
maintaining O
its O
sensitivity O
and O
not O
affecting O
untreated O
tissues O
morphology O
and O
viability O
. O

Group O
II O
metabotropic O
glutamate B
receptor O
type O
2 O
allosteric O
potentiators O
prevent O
sodium O
lactate O
- O
induced O
panic O
- O
like O
response O
in O
panic O
- O
vulnerable O
rats O
. O

Rats O
with O
chronic O
inhibition O
of O
GABA B
synthesis O
by O
infusion O
of O
l O
- O
allyglycine O
, O
a O
glutamic B
acid I
decarboxylase O
inhibitor O
, O
into O
their O
dorsomedial O
/ O
perifornical O
hypothalamus O
are O
anxious O
and O
exhibit O
panic O
- O
like O
cardio O
- O
respiratory O
responses O
to O
treatment O
with O
intravenous O
( O
i O
. O
v O
. O
) O
sodium O
lactate O
( O
NaLac O
) O
infusions O
, O
in O
a O
manner O
similar O
to O
what O
occurs O
in O
patients O
with O
panic O
disorder O
. O

We O
previously O
showed O
that O
either O
NMDA B
receptor O
antagonists O
or O
metabotropic O
glutamate B
receptor O
type O
2 O
/ O
3 O
receptor O
agonists O
can O
block O
such O
a O
NaLac O
response O
, O
suggesting O
that O
a O
glutamate B
mechanism O
is O
contributing O
to O
this O
panic O
- O
like O
state O
. O

Using O
this O
animal O
model O
of O
panic O
, O
we O
tested O
the O
efficacy O
of O
CBiPES O
and O
THIIC O
, O
which O
are O
selective O
group O
II O
metabotropic O
glutamate B
type O
2 O
receptor O
allosteric O
potentiators O
( O
at O
10 O
- O
30 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
, O
in O
preventing O
NaLac O
- O
induced O
panic O
- O
like O
behavioral O
and O
cardiovascular O
responses O
. O

The O
positive O
control O
was O
alprazolam B
( O
3mg O
/ O
kg O
i O
. O
p O
. O
) O
, O
a O
clinically O
effective O
anti O
- O
panic O
benzodiazepine B
. O

As O
predicted O
, O
panic O
- O
prone O
rats O
given O
a O
NaLac O
challenge O
displayed O
NaLac O
- O
induced O
panic O
- O
like O
cardiovascular O
( O
i O
. O
e O
. O
tachycardia O
and O
hypertensive O
) O
responses O
and O
" O
anxiety O
" O
( O
i O
. O
e O
. O
decreased O
social O
interaction O
time O
) O
and O
" O
flight O
" O
( O
i O
. O
e O
. O
increased O
locomotion O
) O
- O
associated O
behaviors O
; O
however O
, O
systemic O
injection O
of O
the O
panic O
- O
prone O
rats O
with O
CBiPES O
, O
THIIC O
or O
alprazolam B
prior O
to O
the O
NaLac O
dose O
blocked O
all O
NaLac O
- O
induced O
panic O
- O
like O
behaviors O
and O
cardiovascular O
responses O
. O

These O
data O
suggested O
that O
in O
a O
rat O
animal O
model O
, O
selective O
group O
II O
metabotropic O
glutamate B
type O
2 O
receptor O
allosteric O
potentiators O
show O
an O
anti O
- O
panic O
efficacy O
similar O
to O
alprazolam B
. O

High O
multivitamin O
intakes O
during O
pregnancy O
and O
postweaning O
obesogenic O
diets O
interact O
to O
affect O
the O
relationship O
between O
expression O
of O
PPAR O
genes O
and O
glucose B
regulation O
in O
the O
offspring O
. O

High O
multivitamin O
intake O
( O
HV O
) O
during O
pregnancy O
increases O
body O
fat O
and O
weight O
and O
alters O
glucose B
and O
fatty B
acid I
metabolism O
in O
Wistar O
rat O
offspring O
. O

This O
study O
investigated O
the O
expression O
of O
peroxisome O
- O
proliferator O
activated O
receptors O
( O
PPARs O
) O
genes O
involved O
in O
regulation O
of O
glucose B
and O
fatty B
acid I
metabolism O
in O
their O
tissues O
. O

In O
conclusion O
, O
the O
HV O
diet O
during O
pregnancy O
interacts O
with O
postweaning O
diets O
in O
determining O
the O
expression O
of O
PPARs O
genes O
in O
a O
tissue O
- O
and O
age O
- O
dependent O
manner O
and O
uncouples O
the O
relationship O
between O
these O
genes O
and O
glucose B
regulation O
and O
fat O
mass O
in O
the O
rat O
offspring O
. O

Phospho B
- O
Akt O
protein O
levels O
were O
not O
altered O
. O

In O
SU5416 O
- O
treated O
situation O
, O
cell O
viability O
was O
not O
different O
before O
and O
after O
administration O
of O
either O
p21 O
siRNA O
or O
LY294002 B
whereas O
it O
was O
lessened O
after O
co O
- O
administration O
of O
p21 O
siRNA O
and O
LY294002 B
. O

While O
CHOP O
plasmid O
transfection O
diminished O
p21 O
and O
phospho B
- O
Akt O
protein O
levels O
, O
CHOP O
siRNA O
transfection O
did O
not O
alter O
the O
protein O
levels O
. O

Lead O
- O
induced O
ER O
calcium B
release O
and O
inhibitory O
effects O
of O
methionine O
choline O
in O
cultured O
rat O
hippocampal O
neurons O
. O

Long O
term O
potentiation O
in O
the O
hippocampus O
, O
a O
potential O
neural O
substrate O
for O
learning O
and O
memory O
, O
is O
thought O
to O
be O
linked O
to O
calcium B
- O
triggered O
intracellular O
events O
. O

In O
this O
study O
, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb B
( I
2 I
+ I
) I
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium B
concentration O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
) O
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine O
choline O
; O
understanding O
these O
effects O
would O
help O
explain O
the O
lead O
- O
induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O
relief O
strategies O
. O

The O
results O
showed O
that O
Pb B
( I
2 I
+ I
) I
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
and O
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
ER O
) O
linearly O
in O
a O
time O
- O
and O
concentration O
- O
dependant O
manner O
, O
and O
Pb B
( I
2 I
+ I
) I
addition O
after O
the O
applying O
of O
a O
ryanodine B
receptor O
( O
RyR O
) O
antagonist O
and O
an O
inositol O
- O
1 O
, O
4 O
, O
5 O
- O
triphosphate O
receptor O
( O
IP O
( O
3 O
) O
R O
) O
antagonist O
did O
not O
increase O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

The O
addition O
of O
10 O
, O
20 O
, O
or O
40 O
mmol O
/ O
L O
methionine O
choline O
simultaneously O
with O
addition O
of O
10 O
mu O
mol O
/ O
L O
Pb B
( I
2 I
+ I
) I
decreased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
culture O
medium O
by O
39 O
. O
0 O
% O
, O
66 O
. O
0 O
% O
, O
and O
61 O
. O
6 O
% O
, O
respectively O
, O
in O
a O
concentration O
- O
dependant O
manner O
in O
a O
certain O
dose O
range O
. O

Our O
results O
suggest O
that O
Pb B
( I
2 I
+ I
) I
induces O
ER O
calcium B
release O
to O
increase O
the O
resting O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
; O
and O
methionine O
choline O
inhibit O
this O
increase O
in O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
. O

Interactions O
between O
bufadienolides O
derived O
from O
toad O
venom O
and O
verapamil B
in O
langendorff O
- O
perfused O
guinea O
- O
pig O
hearts O
. O

We O
aimed O
to O
investigate O
the O
influence O
of O
verapamil B
( O
a O
P O
- O
gp O
inhibitor O
) O
- O
- O
bufadienolides O
interaction O
on O
cardiotoxicity O
and O
bufadienolide O
uptake O
by O
the O
isolated O
heart O
. O

The O
study O
was O
performed O
in O
Langendorff O
isolated O
perfused O
guinea O
- O
pig O
hearts O
by O
bufadienolides O
infusion O
in O
the O
absence O
and O
presence O
of O
verapamil B
( O
250 O
, O
500ng O
/ O
ml O
) O
. O

In O
the O
present O
of O
verapamil B
, O
the O
wide O
QRS O
duration O
and O
lightly O
rapid O
heart O
rate O
( O
HR O
) O
were O
markedly O
reduced O
in O
the O
early O
stage O
of O
bufadienolide O
intoxication O
. O

Furthermore O
, O
the O
contents O
of O
a O
variety O
of O
bufadienolide O
compounds O
in O
the O
verapamil B
+ O
bufadienolide O
group O
were O
significantly O
higher O
when O
cardiac O
arrest O
occurred O
. O

Although O
verapamil B
reduced O
the O
bufadienolide O
- O
induced O
ventricular O
arrhythmias O
, O
verapamil B
worsened O
heart O
block O
and O
lethal O
bradycardia O
of O
bufadienolides O
partly O
via O
increasing O
the O
uptake O
of O
bufadienolides O
in O
heart O
tissue O
, O
which O
could O
compromise O
the O
protective O
effects O
of O
verapamil B
against O
bufadienolide O
intoxication O
. O

These O
results O
suggested O
that O
the O
verapamil B
may O
produce O
dangerous O
interactions O
with O
drugs O
containing O
bufadienolides O
. O

Octanol B
- O
water O
partition O
coefficients O
and O
in O
silico O
prediction O
of O
intestinal O
absorption O
and O
blood O
- O
brain O
barrier O
passage O
are O
also O
considered O
. O

Amino B
acid I
sequence O
of O
the O
ligand O
- O
binding O
domain O
of O
the O
aryl B
hydrocarbon I
receptor O
1 O
predicts O
sensitivity O
of O
wild O
birds O
to O
effects O
of O
dioxin B
- O
like O
compounds O
. O

The O
sensitivity O
of O
avian O
species O
to O
the O
toxic O
effects O
of O
dioxin B
- O
like O
compounds O
( O
DLCs O
) O
varies O
up O
to O
1000 O
- O
fold O
among O
species O
, O
and O
this O
variability O
has O
been O
associated O
with O
interspecies O
differences O
in O
aryl B
hydrocarbon I
receptor O
1 O
ligand O
- O
binding O
domain O
( O
AHR1 O
LBD O
) O
sequence O
. O

In O
the O
present O
study O
, O
the O
AHR1 O
LBD O
sequences O
of O
86 O
avian O
species O
were O
studied O
, O
and O
differences O
at O
amino B
acid I
sites O
256 O
, O
257 O
, O
297 O
, O
324 O
, O
337 O
, O
and O
380 O
were O
identified O
. O

Site O
- O
directed O
mutagenesis O
, O
the O
LRG O
assay O
, O
and O
homology O
modeling O
highlighted O
the O
importance O
of O
each O
amino B
acid I
site O
in O
AHR1 O
sensitivity O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
and O
other O
DLCs O
. O

The O
results O
of O
the O
study O
revealed O
that O
( O
1 O
) O
only O
amino B
acids I
at O
sites O
324 O
and O
380 O
affect O
the O
sensitivity O
of O
AHR1 O
expression O
constructs O
of O
the O
86 O
avian O
species O
to O
DLCs O
and O
( O
2 O
) O
in O
vitro O
luciferase O
activity O
of O
AHR1 O
constructs O
containing O
only O
the O
LBD O
of O
the O
species O
of O
interest O
is O
significantly O
correlated O
( O
r O
( O
2 O
) O
= O
0 O
. O
93 O
, O
p O
< O
0 O
. O
0001 O
) O
with O
in O
ovo O
toxicity O
data O
for O
those O
species O
. O

These O
results O
indicate O
promise O
for O
the O
use O
of O
AHR1 O
LBD O
amino B
acid I
sequences O
independently O
, O
or O
combined O
with O
the O
LRG O
assay O
, O
to O
predict O
avian O
species O
sensitivity O
to O
DLCs O
. O

Moreover O
, O
SH B
groups O
and O
non O
- O
covalent O
interactions O
of O
GISG O
also O
changed O
after O
HUS O
pre O
- O
treatments O
. O

By O
applying O
modern O
proteomic O
technologies O
together O
with O
a O
target O
peptide O
containing O
all O
amino B
acids I
, O
the O
assay O
permits O
the O
profiling O
of O
all O
amino B
acid I
specific O
allergen O
- O
peptide O
interactions O
. O

Moreover O
, O
potentially O
crucial O
allergen O
- O
specific O
Cys B
- O
modifications O
are O
qualitatively O
monitored O
by O
mass O
spectrometry O
and O
confirmed O
by O
a O
dual O
peptide O
approach O
. O

An O
extreme O
as O
well O
as O
a O
moderate O
human O
contact O
sensitizer O
produced O
Cys B
- O
specific O
mass O
shifts O
, O
whereas O
a O
skin O
irritant O
did O
not O
. O

Additionally O
, O
more O
specific O
mechanisms O
exist O
where O
xenobiotics O
act O
as O
ligands O
, O
including O
the O
aryl B
hydrocarbon I
receptor O
, O
metal O
- O
responsive O
transcription O
factor O
- O
1 O
and O
the O
nuclear O
receptor O
family O
of O
transcription O
factors O
. O

We O
previously O
demonstrated O
marked O
differences O
in O
neurotransmitter O
changes O
produced O
by O
developmental O
lead O
( O
Pb B
) O
exposure O
+ O
/ O
- O
prenatal O
stress O
( O
PS O
) O
depending O
upon O
whether O
or O
not O
rats O
had O
been O
given O
BE O
( O
Cory O
- O
Slechta O
, O
D O
. O

Brain O
monoamines B
and O
amino B
acids I
differed O
significantly O
in O
relation O
to O
BE O
, O
even O
in O
control O
animals O
, O
as O
did O
the O
trajectory O
of O
effects O
of O
Pb B
+ O
/ O
- O
PS O
, O
particularly O
in O
frontal O
cortex O
, O
hippocampus O
( O
both O
genders O
) O
, O
and O
midbrain O
( O
males O
) O
. O

In O
males O
, O
Pb B
+ O
/ O
- O
PS O
- O
related O
changes O
in O
neurotransmitters O
correlated O
with O
behavioral O
performance O
. O

alpha O
- O
Amino O
- O
alpha O
' O
- O
Halomethylketones O
: O
Synthetic O
Methodologies O
and O
Pharmaceutical O
Applications O
as O
Serine B
and O
Cysteine B
Protease O
Inhibitors O
. O

alpha O
- O
Amino O
- O
alpha O
' O
- O
halomethylketones O
are O
interesting O
scaffolds O
bearing O
( O
at O
least O
) O
two O
sequential O
electrophilic O
carbons B
that O
by O
interacting O
with O
the O
nucleophilic O
moieties O
of O
several O
enzymes O
, O
represent O
the O
ideal O
candidates O
for O
in O
vivo O
and O
in O
vitro O
inhibition O
studies O
. O

In O
this O
work O
a O
summary O
of O
their O
use O
as O
optimal O
inhibitors O
of O
physiologically O
relevant O
serine B
and O
cysteine B
proteases O
is O
given O
with O
a O
particular O
emphasis O
on O
recently O
established O
SAR O
studies O
. O

Galantamine B
is O
a O
reversible O
, O
competitive O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
and O
allosteric O
potentiating O
ligand O
of O
nicotinic O
acetylcholine B
receptors O
( O
nAChR O
- O
APL O
) O
that O
shares O
many O
common O
structural O
elements O
with O
morphinan O
- O
based O
opioids O
. O

The O
structurally O
diverse O
opioids O
codeine O
and O
eseroline O
, O
like O
galantamine B
, O
are O
also O
nAChR O
- O
APL O
that O
have O
greatly O
diminished O
affinity O
for O
AChE O
, O
representing O
potential O
lead O
compounds O
for O
selective O
nAChR O
- O
APL O
development O
. O

Adhesion O
of O
osteoblasts O
to O
a O
vertically O
aligned O
TiO2 B
nanotube O
surface O
. O

The O
adhesion O
of O
cells O
to O
vertically O
aligned O
TiO2 B
nanotubes O
is O
reviewed O
. O

It O
is O
shown O
that O
adhesion O
and O
spreading O
of O
osteoblasts O
on O
vertically O
aligned O
TiO2 B
nanotube O
surfaces O
depend O
on O
the O
diameter O
of O
the O
nanotubes O
. O

Manganese B
- O
enhanced O
magnetic O
resonance O
imaging O
detects O
declining O
pancreatic O
beta O
- O
cell O
mass O
in O
a O
cyclophosphamide B
- O
accelerated O
mouse O
model O
of O
type O
1 O
diabetes O
. O

Magnetic O
resonance O
imaging O
has O
detected O
gross O
differences O
in O
BCM O
between O
healthy O
and O
diabetic O
mice O
using O
the O
contrast O
agent O
manganese B
, O
which O
labels O
functional O
beta O
- O
cells O
and O
increases O
the O
water O
proton O
relaxation O
rate O
( O
R1 O
) O
, O
but O
its O
ability O
to O
measure O
gradations O
in O
BCM O
during O
disease O
progression O
is O
unknown O
. O

Our O
objective O
was O
to O
test O
the O
hypothesis O
that O
measurements O
of O
the O
manganese B
- O
enhanced O
pancreatic O
R1 O
could O
detect O
decreasing O
BCM O
in O
a O
mouse O
model O
of O
type O
1 O
diabetes O
. O

We O
used O
cyclophosphamide B
- O
accelerated O
BDC2 O
. O
5 O
T O
- O
cell O
receptor O
transgenic O
nonobese O
diabetic O
mice O
, O
which O
experience O
development O
of O
type O
1 O
diabetes O
during O
a O
7 O
- O
day O
time O
period O
after O
cyclophosphamide B
injection O
, O
whereas O
transgene O
- O
negative O
mice O
do O
not O
. O

We O
measured O
the O
manganese B
- O
enhanced O
pancreatic O
R1 O
before O
cyclophosphamide B
injection O
( O
day O
0 O
) O
and O
on O
days O
3 O
, O
4 O
, O
5 O
, O
and O
7 O
afterward O
. O

Changes O
in O
R1 O
in O
transgene O
- O
positive O
mice O
occurred O
before O
elevations O
in O
blood O
glucose B
, O
a O
clinical O
indicator O
of O
diabetes O
, O
suggesting O
potential O
for O
early O
noninvasive O
detection O
of O
changes O
in O
functional O
BCM O
. O

Bcl O
- O
2 O
and O
Bcl O
- O
xL O
suppress O
glucose B
signaling O
in O
pancreatic O
beta O
- O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
chemical O
and O
genetic O
loss O
- O
of O
- O
function O
of O
antiapoptotic O
Bcl O
- O
2 O
and O
Bcl O
- O
x O
( O
L O
) O
significantly O
augments O
glucose B
- O
dependent O
metabolic O
and O
Ca B
( I
2 I
+ I
) I
signals O
in O
primary O
pancreatic O
beta O
- O
cells O
. O

Antagonism O
of O
Bcl O
- O
2 O
/ O
Bcl O
- O
x O
( O
L O
) O
by O
two O
distinct O
small O
- O
molecule O
compounds O
rapidly O
hyperpolarized O
beta O
- O
cell O
mitochondria O
, O
increased O
cytosolic O
Ca B
( I
2 I
+ I
) I
, O
and O
stimulated O
insulin O
release O
via O
the O
ATP B
- O
dependent O
pathway O
in O
beta O
- O
cell O
under O
substimulatory O
glucose B
conditions O
. O

Pancreatic O
beta O
- O
cells O
from O
Bcl O
- O
2 O
( O
- O
/ O
- O
) O
mice O
responded O
to O
glucose B
with O
significantly O
increased O
NAD B
( I
P I
) I
H I
levels O
and O
cytosolic O
Ca B
( I
2 I
+ I
) I
signals O
, O
as O
well O
as O
significantly O
augmented O
insulin O
secretion O
. O

Inducible O
deletion O
of O
Bcl O
- O
x O
( O
L O
) O
in O
adult O
mouse O
beta O
- O
cells O
also O
increased O
glucose B
- O
stimulated O
NAD B
( I
P I
) I
H I
and O
Ca B
( I
2 I
+ I
) I
responses O
and O
resulted O
in O
an O
improvement O
of O
in O
vivo O
glucose B
tolerance O
in O
the O
conditional O
Bcl O
- O
x O
( O
L O
) O
knockout O
animals O
. O

Our O
work O
suggests O
that O
prosurvival O
Bcl O
proteins O
normally O
dampen O
the O
beta O
- O
cell O
response O
to O
glucose B
and O
thus O
reveals O
these O
core O
apoptosis O
proteins O
as O
integrators O
of O
cell O
death O
and O
physiology O
in O
pancreatic O
beta O
- O
cells O
. O

Here O
, O
we O
report O
unexpected O
rearrangements O
to O
the O
insulin O
/ O
IGF O
- O
1 O
pathway O
, O
whereby O
the O
insulin O
- O
like O
receptor O
DAF O
- O
2 O
and O
3 O
- O
phosphoinositide B
- O
dependent O
protein O
kinase O
PDK O
- O
1 O
oppose O
AKT O
- O
1 O
to O
promote O
DNA O
damage O
- O
induced O
apoptosis O
. O

In O
addition O
, O
daf O
- O
2 O
and O
pdk O
- O
1 O
mutants O
have O
reduced O
levels O
of O
phospho B
- O
MPK O
- O
1 O
/ O
ERK O
in O
their O
germ O
cells O
, O
indicating O
that O
the O
insulin O
/ O
IGF O
- O
1 O
pathway O
promotes O
Ras O
signaling O
in O
the O
germline O
. O

Inactivation O
of O
anoctamin O
- O
6 O
/ O
Tmem16f O
, O
a O
regulator O
of O
phosphatidylserine B
scrambling O
in O
osteoblasts O
, O
leads O
to O
decreased O
mineral O
deposition O
in O
skeletal O
tissues O
. O

During O
vertebrate O
skeletal O
development O
, O
osteoblasts O
produce O
a O
mineralized O
bone O
matrix O
by O
deposition O
of O
hydroxyapatite B
crystals O
in O
the O
extracellular O
matrix O
. O

Anoctamin6 O
/ O
Tmem16F O
( O
Ano6 O
) O
belongs O
to O
a O
conserved O
family O
of O
transmembrane O
proteins O
with O
chloride B
channel O
properties O
. O

In O
addition O
, O
Ano6 O
has O
been O
linked O
to O
phosphatidylserine B
( O
PS O
) O
scrambling O
in O
the O
plasma O
membrane O
. O

Furthermore O
, O
we O
demonstrate O
that O
calcium B
- O
dependent O
PS O
scrambling O
is O
impaired O
in O
osteoblasts O
. O

Our O
study O
is O
the O
first O
to O
our O
knowledge O
to O
reveal O
the O
requirement O
of O
Ano6 O
in O
PS O
scrambling O
in O
osteoblasts O
, O
supporting O
a O
function O
of O
PS O
exposure O
in O
the O
deposition O
of O
hydroxyapatite B
. O

Fragrance O
chemicals O
lyral O
and O
lilial O
decrease O
viability O
of O
HaCat O
cells O
' O
by O
increasing O
free O
radical O
production O
and O
lowering O
intracellular O
ATP B
level O
: O
protection O
by O
antioxidants O
. O

Lyral O
and O
lilial O
: O
( O
a O
) O
decreased O
the O
viability O
of O
HaCat O
cells O
with O
a O
50 O
% O
cell O
death O
at O
100 O
and O
60 O
nM O
respectively O
; O
( O
b O
) O
decreased O
significantly O
in O
a O
dose O
dependant O
manner O
the O
intracellular O
ATP B
level O
following O
12 O
- O
h O
of O
treatment O
; O
( O
c O
) O
inhibited O
complexes O
I O
and O
II O
of O
electron O
transport O
chain O
in O
liver O
sub O
- O
mitochondrial O
particles O
; O
and O
( O
d O
) O
increased O
reactive O
oxygen B
species O
generation O
that O
was O
reversed O
by O
N B
- I
acetyl I
cysteine I
and O
trolox B
and O
the O
natural O
antioxidant O
lipoic B
acid I
, O
without O
influencing O
the O
level O
of O
free O

and O
/ O
or O
oxidized O
glutathione B
. O

Lipoic B
acid I
protected O
HaCat O
cells O
against O
the O
decrease O
in O
viability O
induced O
by O
either O
compound O
. O

Dehydrogenation O
of O
lyral O
and O
lilial O
produce O
alpha O
, O
beta O
- O
unsaturated O
aldehydes O
, O
that O
reacts O
with O
lipoic B
acid I
requiring O
proteins O
resulting O
in O
their O
inhibition O
. O

We O
propose O
lyral O
and O
lilial O
as O
toxic O
to O
mitochondria O
that O
have O
a O
direct O
effect O
on O
electron O
transport O
chain O
, O
increase O
ROS O
production O
, O
derange O
mitochondrial O
membrane O
potential O
, O
and O
decrease O
cellular O
ATP B
level O
, O
leading O
thus O
to O
cell O
death O
. O

Silver B
nanoparticles O
induce O
toxicity O
in O
A549 O
cells O
via O
ROS O
- O
dependent O
and O
ROS O
- O
independent O
pathways O
. O

Silver B
nanoparticles O
( O
AgNPs O
) O
are O
incorporated O
into O
a O
large O
number O
of O
consumer O
and O
medical O
products O
. O

The O
present O
study O
evaluated O
the O
in O
vitro O
mechanisms O
of O
AgNP O
( O
< O
100 O
nm O
) O
toxicity O
in O
relationship O
to O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
in O
A549 O
cells O
. O

Pretreatment O
of O
the O
A549 O
cells O
with O
N B
- I
acetyl I
- I
cysteine I
( O
NAC B
) O
, O
an O
antioxidant O
, O
decreased O
the O
effects O
of O
AgNPs O
on O
the O
reduced O
cell O
viability O
, O
change O
in O
the O
MMP O
and O
proportion O
of O
cells O
in O
the O
sub O
- O
G1population O
, O
but O
had O
no O
effect O
on O
the O
AgNP O
- O
mediated O
S O
phase O
arrest O
or O
down O
- O
regulation O
of O
PCNA O
. O

Low O
calorie O
and O
carbohydrate B
diet O
: O
to O
improve O
the O
cardiovascular O
risk O
indicators O
in O
overweight O
or O
obese O
adults O
with O
prediabetes O
. O

Our O
objective O
was O
to O
evaluate O
the O
effects O
of O
a O
moderate O
calorie O
and O
carbohydrate B
- O
restricted O
diet O
on O
cardiovascular O
risk O
indicators O
in O
overweight O
or O
obese O
patients O
with O
prediabetes O
. O

A O
clinical O
trial O
was O
conducted O
in O
which O
86 O
subjects O
presenting O
with O
overweight O
or O
obesity O
and O
prediabetes O
received O
a O
personalized O
diet O
of O
1 O
, O
200 O
to O
1 O
, O
700 O
calories O
with O
a O
distribution O
of O
50 O
% O
carbohydrates B
, O
20 O
% O
proteins O
, O
and O
30 O
% O
fat O
. O

Glucose B
, O
total O
cholesterol B
, O
high O
density O
lipoprotein O
cholesterol B
and O
low O
density O
cholesterol B
, O
and O
triglycerides B
were O
measured O
. O

systolic O
( O
120 O
. O
9 O
+ O
/ O
- O
14 O
. O
2 O
- O
112 O
. O
4 O
+ O
/ O
- O
11 O
. O
5 O
mmHg O
) O
( O
124 O
. O
1 O
+ O
/ O
- O
11 O
. O
9 O
- O
115 O
. O
7 O
+ O
/ O
- O
14 O
. O
0 O
mmHg O
) O
, O
diastolic O
blood O
pressures O
( O
79 O
. O
0 O
+ O
/ O
- O
9 O
. O
3 O
- O
71 O
. O
8 O
+ O
/ O
- O
8 O
. O
3 O
mmHg O
) O
( O
80 O
. O
4 O
+ O
/ O
- O
9 O
. O
0 O
- O
73 O
. O
7 O
+ O
/ O
- O
13 O
. O
1 O
mmHg O
) O
, O
glucose B
( O
106 O
. O
0 O
+ O
/ O
- O
8 O
. O
9 O
- O
95 O
. O
9 O
+ O
/ O
- O
7 O

The O
restrictions O
in O
the O
calorie O
and O
carbohydrate B
diet O
decrease O
the O
cardiovascular O
risk O
indicators O
in O
overweight O
or O
obese O
adults O
with O
prediabetes O
. O

1 O
. O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
are O
a O
group O
of O
drug O
- O
metabolizing O
enzymes O
that O
catalyse O
the O
conjugation O
of O
endogeonous O
compounds O
and O
xenobiotics O
to O
yield O
hydrophilic O
glucuronides O
which O
subsequently O
undergo O
excretion O
. O

The O
peptide O
sequence O
synthesized O
was O
in O
the O
reverse O
order O
of O
the O
human O
peptide O
with O
the O
stable O
isotope O
- O
labels O
in O
the O
amino B
acid I
arginine B
( O
( O
13 O
) O
C6 O
( O
15 O
) O
N4 O
) O
resulting O
in O
an O
increase O
in O
the O
mass O
of O
the O
SIL O
peptide O
of O
10 O
amu O
, O
from O
1753 O
to O
1763 O
. O

A O
dose O
response O
study O
to O
assess O
effects O
after O
dietary O
administration O
of O
diisononyl O
phthalate O
( O
DINP B
) O
in O
gestation O
and O
lactation O
on O
male O
rat O
sexual O
development O
. O

Male O
rat O
sexual O
development O
was O
evaluated O
after O
dietary O
administration O
of O
0 O
, O
760 O
, O
3800 O
, O
11 O
, O
400 O
ppm O
diisononyl O
phthalate O
( O
DiNP B
) O
and O
7600 O
ppm O
dibutyl B
phthalate I
( O
DBP O
) O
from O
gestation O
day O
( O
GD O
) O
12 O
to O
postnatal O
day O
( O
PND O
) O
14 O
. O

Maternal O
weight O
was O
reduced O
on O
GD O
20 O
, O
PND O
2 O
and O
14 O
at O
11 O
, O
400 O
ppm O
DiNP B
. O

Pup O
weight O
was O
reduced O
on O
PND O
2 O
and O
14 O
at O
11 O
, O
400 O
and O
3800 O
ppm O
DiNP B
. O

DiNP B
induced O
MNGs O
( O
3800 O
ppm O
) O
and O
LCAs O
( O
11 O
, O
400 O
ppm O
) O
on O
PND O
2 O
, O
and O
reduced O
AGD O
( O
11 O
, O
400 O
ppm O
) O
on O
PND O
14 O
. O

DiNP B
did O
not O
alter O
AGD O
, O
nipple O
retention O
or O
reproductive O
tract O
malformations O
on O
PND O
49 O
. O

Global O
endpoint O
analysis O
showed O
no O
evidence O
of O
a O
rat O
" O
phthalate B
syndrome O
" O
on O
PND O
49 O
with O
DiNP B
administration O
. O

Lithium B
treatment O
induces O
proteasomal O
degradation O
of O
over O
- O
expressed O
acetylcholinesterase O
( O
AChE O
- O
S O
) O
and O
inhibit O
GSK3 O
beta O
. O

Lithium B
is O
one O
of O
the O
most O
widely O
used O
mood O
- O
stabilizing O
agents O
for O
the O
treatment O
of O
bipolar O
disorder O
. O

Lithium B
is O
also O
a O
potent O
inhibitor O
of O
glycogen O
synthase O
kinase O
- O
3 O
beta O
( O
GSK3 O
beta O
) O
activity O
, O
which O
is O
linked O
to O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
. O

Cells O
treated O
with O
lithium B
exhibited O
rapid O
proteasomal O
degradation O
of O
AChE O
- O
S O
. O

Furthermore O
treatment O
of O
the O
cells O
with O
MG132 B
, O
an O
inhibitor O
of O
the O
26S O
proteasome O
, O
prevented O
the O
destabilizing O
effect O
of O
lithium B
on O
AChE O
- O
S O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
regulation O
of O
AChE O
- O
S O
protein O
stability O
may O
be O
an O
important O
biological O
target O
of O
lithium B
therapy O
. O

Toxicity O
of O
terpenes B
on O
fibroblast O
cells O
compared O
to O
their O
hemolytic O
potential O
and O
increase O
in O
erythrocyte O
membrane O
fluidity O
. O

Terpenes B
are O
considered O
potent O
skin O
permeation O
enhancers O
with O
low O
toxicity O
. O

Electron O
paramagnetic O
resonance O
( O
EPR O
) O
spectroscopy O
of O
the O
spin O
label O
5 O
- O
doxyl O
stearic O
acid O
( O
5 O
- O
DSA O
) O
was O
used O
to O
monitor O
the O
effect O
of O
sesquiterpene B
nerolidol O
and O
various O
monoterpenes O
on O
membrane O
fluidity O
in O
erythrocyte O
and O
fibroblast O
cells O
. O

In O
addition O
, O
the O
hemolytic O
levels O
and O
cytotoxic O
effects O
on O
cultured O
fibroblast O
cells O
were O
also O
measured O
to O
investigate O
possible O
relationships O
between O
the O
cellular O
irritation O
potentials O
of O
terpenes B
and O
the O
ability O
to O
modify O
membrane O
fluidity O
. O

All O
terpenes B
increased O
cell O
membrane O
fluidity O
with O
no O
significant O
differences O
between O
the O
monoterpenes O
, O
but O
the O
effect O
of O
sesquiterpene B
was O
significantly O
greater O
than O
that O
of O
the O
monoterpenes O
. O

The O
IC O
( O
50 O
) O
values O
for O
the O
terpenes B
in O
the O
cytotoxicity O
assay O
indicated O
that O
1 O
, O
8 O
- O
cineole O
showed O
lower O
cytotoxicity O
and O
alpha B
- I
terpineol I
and O
nerolidol O
showed O
higher O
cytotoxicity O
. O

The O
correlation O
between O
the O
hemolytic O
effect O
and O
the O
IC O
( O
50 O
) O
values O
for O
fibroblast O
viability O
was O
low O
( O
R O
= O
0 O
. O
61 O
) O
; O
however O
, O
in O
both O
tests O
, O
nerolidol O
was O
among O
the O
most O
aggressive O
of O
terpenes B
and O
1 O
, O
8 O
- O
cineole O
was O
among O
the O
least O
aggressive O
. O

Obtaining O
information O
concerning O
the O
toxicity O
and O
potency O
of O
terpenes B
could O
aid O
in O
the O
design O
of O
topical O
formulations O
optimized O
to O
facilitate O
drug O
absorption O
for O
the O
treatment O
of O
many O
skin O
diseases O
. O

A O
probable O
clinically O
significant O
interaction O
between O
warfarin B
and O
cloxacillin O
: O
three O
case O
reports O
. O

The O
administration O
of O
cloxacillin O
reduced O
the O
effect O
of O
warfarin B
, O
and O
subsequent O
increases O
in O
warfarin B
doses O
were O
unable O
to O
overcome O
this O
effect O
. O

CONCLUSION O
: O
A O
decrease O
in O
warfarin B
anticoagulation O
effects O
was O
detected O
in O
our O
three O
patients O
following O
cloxacillin O
therapy O
for O
infective O
endocarditis O
. O

Thus O
, O
in O
situations O
where O
anticoagulants O
are O
indicated O
in O
patients O
with O
infective O
endocarditis O
, O
it O
would O
be O
better O
to O
replace O
warfarin B
with O
low O
- O
molecular O
- O
weight O
or O
unfractionated O
heparin O
. O

An O
assessment O
of O
pure O
, O
hybrid O
, O
meta O
, O
and O
hybrid O
- O
meta O
GGA O
density O
functional O
theory O
methods O
for O
open O
- O
shell O
systems O
: O
the O
case O
of O
the O
nonheme O
iron B
enzyme O
8R O
- O
LOX O
. O

Plasma O
TNF O
- O
alpha O
, O
total O
cholesterol B
( O
TC O
) O
, O
triglyceride B
( O
TG O
) O
, O
LDL O
- O
cholesterol B
( O
LDL O
- O
C O
) O
, O
and O
HDL O
- O
cholesterol B
( O
HDL O
- O
C O
) O
were O
determined O
at O
the O
end O
of O
this O
treatment O
. O

Renal O
damage O
was O
identified O
by O
histologic O
observation O
and O
the O
higher O
of O
serum O
blood O
urea B
nitrogen B
( O
BUN O
) O
and O
creatinine B
. O

Etanercept O
shows O
renal O
protection O
from O
histological O
identification O
and O
recovery O
of O
serum O
BUN O
and O
creatinine B
levels O
. O

Loss O
of O
A O
( O
1 O
) O
adenosine B
receptor O
attenuates O
alpha O
- O
naphthylisothiocyana O
- O
induced O
cholestatic O
liver O
injury O
in O
mice O
. O

The O
A O
( O
1 O
) O
adenosine B
receptor O
( O
A O
( O
1 O
) O
AR O
) O
was O
postulated O
to O
participate O
in O
the O
pathogenesis O
of O
hepatic O
fibrosis O
induced O
by O
experimental O
extrahepatic O
cholestasis O
; O
however O
, O
the O
contribution O
of O
A O
( O
1 O
) O
AR O
to O
intrahepatic O
cholestatic O
liver O
injury O
remains O
unknown O
. O

Bile B
acid I
accumulation O
in O
liver O
and O
serum O
was O
markedly O
diminished O
in O
A O
( O
1 O
) O
AR O
( O
- O
/ O
- O
) O
mice O
compared O
with O
wild O
- O
type O
( O
WT O
) O
mice O
. O

However O
, O
biliary O
and O
urinary O
outputs O
of O
bile B
acids I
were O
significantly O
enhanced O
in O
A O
( O
1 O
) O
AR O
( O
- O
/ O
- O
) O
mice O
. O

In O
the O
liver O
, O
mRNA O
expression O
of O
genes O
related O
to O
bile B
acid I
transport O
( O
Bsep O
and O
Mdr2 O
) O
and O
hydroxylation O
( O
Cyp3a11 O
) O
was O
increased O
in O
A O
( O
1 O
) O
AR O
( O
- O
/ O
- O
) O
mice O
. O

Methamphetamine B
- O
induced O
nitric B
oxide I
promotes O
vesicular O
transport O
in O
blood O
- O
brain O
barrier O
endothelial O
cells O
. O

Methamphetamine B
' O
s O
( O
METH B
) O
neurotoxicity O
is O
thought O
to O
be O
in O
part O
due O
to O
its O
ability O
to O
induce O
blood O
- O
brain O
barrier O
( O
BBB O
) O
dysfunction O
. O

Here O
, O
we O
investigated O
the O
effect O
of O
METH B
on O
barrier O
properties O
of O
cultured O
rat O
primary O
brain O
microvascular O
endothelial O
cells O
( O
BMVECs O
) O
. O

Transendothelial O
flux O
doubled O
in O
response O
to O
METH B
, O
irrespective O
of O
the O
size O
of O
tracer O
used O
. O

At O
the O
same O
time O
, O
transendothelial O
electrical O
resistance O
was O
unchanged O
as O
was O
the O
ultrastructural O
appearance O
of O
inter O
- O
endothelial O
junctions O
and O
the O
distribution O
of O
key O
junction O
proteins O
, O
suggesting O
that O
METH B
promoted O
vesicular O
but O
not O
junctional O
transport O
. O

Indeed O
, O
METH B
significantly O
increased O
uptake O
of O
horseradish O
peroxidase O
into O
vesicular O
structures O
. O

METH B
also O
enhanced O
transendothelial O
migration O
of O
lymphocytes O
indicating O
that O
the O
endothelial O
barrier O
against O
both O
molecules O
and O
cells O
was O
compromised O
. O

Barrier O
breakdown O
was O
only O
observed O
in O
response O
to O
METH B
at O
low O
micromolar O
concentrations O
, O
with O
enhanced O
vesicular O
uptake O
peaking O
at O
1 O
mu O
M O
METH B
. O

The O
BMVEC O
response O
to O
METH B
also O
involved O
rapid O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
and O
its O
inhibition O
abrogated O
METH B
- O
induced O
permeability O
and O
lymphocyte O
migration O
, O
indicating O
that O
nitric B
oxide I
was O
a O
key O
mediator O
of O
BBB O
disruption O
in O
response O
to O
METH B
. O

This O
study O
underlines O
the O
key O
role O
of O
nitric B
oxide I
in O
BBB O
function O
and O
describes O
a O
novel O
mechanism O
of O
drug O
- O
induced O
fluid O
- O
phase O
transcytosis O
at O
the O
BBB O
. O

Centrally O
acting O
oximes B
in O
reactivation O
of O
tabun B
- O
phosphoramidated O
AChE O
. O

Organophosphates B
( O
OP O
) O
inhibit O
acetylcholinesterase O
( O
AChE O
, O
EC O
3 O
. O
1 O
. O
1 O
. O
7 O
) O
, O
both O
in O
peripheral O
tissues O
and O
central O
nervous O
system O
( O
CNS O
) O
, O
causing O
adverse O
and O
sometimes O
fatal O
effects O
due O
to O
the O
accumulation O
of O
neurotransmitter O
acetylcholine B
( O
ACh B
) O
. O

A O
directed O
library O
of O
thirty O
uncharged O
oximes B
that O
contain O
tertiary O
amine O
or O
imidazole B
protonable O
functional O
groups O
that O
should O
cross O
the O
BBB O
as O
unionized O
species O
was O
tested O
as O
tabun B
- O
hAChE O
conjugate O
reactivators O
along O
with O
three O
reference O
oximes B
: O
DAM O
( O
diacetylmonoxime O
) O
, O
MINA O
( O
monoisonitrosoaceton O
) O
, O
and O
2 B
- I
PAM I
. O

The O
oxime B
RS150D O
[ O
N O
- O
( O
( O
1 O
- O
( O
3 O
- O
( O
2 O
- O
( O
( O
hydroxyimino O
) O
methyl O
) O
- O
1H O
- O
imidazol O
- O
1 O
- O
yl O
) O
propyl O
) O
- O
1H O
- O
1 O
, O
2 O
, O
3 O
- O
triazol O
- O
4 O
- O
yl O
) O
methyl O
) O
benzamide O
] O
was O
highlighted O
as O
the O
most O
promising O
reactivator O
of O
the O
tabun B
- O
hAChE O
conjugate O
. O

We O
also O
observed O
that O
oximes B
RS194B B
[ O
N O
- O
( O
2 O
- O
( O
azepan O
- O
1 O
- O
yl O
) O
ethyl O
) O
- O
2 O
- O
( O
hydroxyimino O
) O
acetamide O
] O
and O
RS41A B
[ O
2 O
- O
( O
hydroxyimino O
) O
- O
N O
- O
( O
2 O
- O
( O
pyrrolidin O
- O
1 O
- O
yl O
) O
ethyl O
) O
acetamide O
] O
, O
which O
emerged O
as O
lead O
uncharged O
reactivators O
of O
phosphylated O
hAChE O
with O
other O
OPs O
( O
sarin B
, O
cyclosarin B
and O
VX O
) O
, O
exhibited O
only O
moderate O
reactivation O

potency O
for O
tabun B
inhibited O
hAChE O
. O

This O
implies O
that O
geometry O
of O
oxime B
access O
to O
the O
phosphorus B
atom O
conjugated O
to O
the O
active O
serine B
is O
an O
important O
criterion O
for O
efficient O
reactivation O
, O
along O
with O
the O
chemical O
nature O
of O
the O
conjugated O
moiety O
: O
phosphorate O
, O
phosphonate B
, O
or O
phosphoramidate B
. O

The O
phosphoramidated O
- O
hAChE O
choline B
- O
binding O
site O
mutant O
Y337A O
showed O
three O
- O
times O
enhanced O
reactivation O
capacity O
with O
non O
- O
triazole B
imidazole B
containing O
aldoximes O
( O
RS113B O
, O
RS113A O
and O
RS115A O
) O
and O
acetamide O
derivative O
( O
RS194B B
) O
than O
with O
2PAM B
. O

Increased O
nuclear O
thioredoxin O
- O
1 O
potentiates O
cadmium B
- O
induced O
cytotoxicity O
. O

Cadmium B
( O
Cd B
) O
is O
a O
widely O
dispersed O
environmental O
agent O
that O
causes O
oxidative O
toxicity O
through O
mechanisms O
that O
are O
sensitive O
to O
thioredoxin O
- O
1 O
( O
Trx1 O
) O
. O

These O
observations O
indicate O
that O
oxidative O
toxicity O
caused O
by O
low O
- O
dose O
Cd B
could O
involve O
disruption O
of O
actin O
- O
Trx1 O
interaction O
, O
nuclear O
Trx1 O
translocation O
, O
and O
potentiation O
of O
proinflammatory O
cell O
death O
mechanisms O
. O

In O
this O
study O
, O
we O
investigated O
the O
role O
of O
nuclei O
- O
localized O
Trx1 O
in O
Cd B
- O
induced O
inflammation O
and O
cytotoxicity O
using O
in O
vitro O
and O
in O
vivo O
models O
. O

The O
results O
show O
that O
Cd B
stimulated O
nuclear O
translocation O
of O
Trx1 O
and O
p65 O
of O
NF O
- O
kappa O
B O
. O

Elevation O
of O
Trx1 O
in O
nuclei O
in O
in O
vitro O
cells O
and O
kidney O
of O
transgenic O
mice O
potentiated O
Cd B
- O
stimulated O
NF O
- O
kappa O
B O
activation O
and O
cell O
death O
. O

Cd B
- O
stimulated O
Trx1 O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
activation O
were O
inhibited O
by O
cytochalasin O
D O
, O
an O
inhibitor O
of O
actin O
polymerization O
, O
suggesting O
that O
actin O
regulates O
Trx1 O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
activation O
by O
Cd B
. O

A O
nuclear O
- O
targeted O
dominant O
negative O
form O
of O
Trx1 O
blocked O
Cd B
- O
stimulated O
NF O
- O
kappa O
B O
activation O
and O
decreased O
cell O
death O
. O

Addition O
of O
zinc B
, O
known O
to O
antagonize O
Cd B
toxicity O
by O
increasing O
metallothionein O
, O
had O
no O
effect O
on O
Cd B
- O
stimulated O
nuclear O
translocation O
of O
Trx1 O
and O
NF O
- O
kappa O
B O
activation O
. O

Taken O
together O
, O
the O
results O
show O
that O
nuclear O
translocation O
and O
accumulation O
of O
redox O
- O
active O
Trx1 O
in O
nuclei O
play O
an O
important O
role O
in O
Cd B
- O
induced O
inflammation O
and O
cell O
death O
. O

The O
influence O
of O
pH O
on O
phosphatidylethanola B
monolayer O
at O
the O
air O
/ O
aqueous O
solution O
interface O
. O

The O
dependence O
of O
the O
interfacial O
tension O
of O
a O
phosphatidylethanola B
( O
PE O
) O
monolayer O
on O
the O
pH O
of O
the O
aqueous O
solution O
has O
been O
studied O
. O

A O
simple O
model O
of O
the O
influence O
of O
pH O
on O
the O
phosphatidylethanola B
monolayer O
at O
the O
air O
/ O
hydrophobic O
chains O
of O
PE O
is O
presented O
. O

The O
contributions O
of O
additive O
phosphatidylethanola B
forms O
( O
both O
interfacial O
tension O
values O
and O
molecular O
area O
values O
) O
depend O
on O
pH O
. O

The O
interfacial O
tension O
values O
and O
the O
molecular O
area O
values O
for O
PEH O
( O
+ O
) O
and O
PEOH O
( O
- O
) O
forms O
of O
phosphatidylethanola B
were O
calculated O
. O

A O
new O
flavonoid B
and O
other O
polar O
compounds O
from O
Galeopsis O
angustifolia O
Ehrh O
. O

ex O
Hoffm O
. O
indicates O
that O
the O
main O
components O
are O
iridoids B
and O
flavonoids B
. O

Six O
compounds O
were O
identified O
: O
a O
new O
flavonoid B
, O
3 O
' O
- O
hydroxy O
- O
isoscutellarein O
7 O
- O
O O
- O
[ O
6 O
' O
' O
' O
acetyl O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O
( O
1 O
- O
- O
> O
2 O
) O
- O
beta O
- O
D O
- O
glucopyranoside O
] O
; O
three O
iridoid B
glucosides I
: O
harpagide O
, O
acetyl O
harpagide O
and O
for O
the O
first O
time O
in O
this O
species O
, O
8 O
- O
epi O
- O
loganin O
; O
two O
known O
acetylated O
flavonoid O
glycosides O
: O
3 O
' O
- O
hydroxy O
- O
4 O

Both O
flavonoids B
and O
iridoids B
are O
present O
in O
high O
amount O
; O
respectively O
, O
16 O
. O
7 O
% O
and O
4 O
. O
5 O
% O
of O
the O
crude O
extract O
. O

The O
progression O
and O
exacerbations O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
are O
intimately O
associated O
with O
tobacco O
smoke O
/ O
biomass O
fuel O
- O
induced O
oxidative O
and O
aldehyde B
/ O
carbonyl B
stress O
. O

Alterations O
in O
redox O
signaling O
proinflammatory O
kinases O
and O
transcription O
factors O
, O
steroid B
resistance O
, O
unfolded O
protein O
response O
, O
mucus O
hypersecretion O
, O
extracellular O
matrix O
remodeling O
, O
autophagy O
/ O
apoptosis O
, O
epigenetic O
changes O
, O
cellular O
senescence O
/ O
aging O
, O
endothelial O
dysfunction O
, O
autoimmunity O
, O
and O
skeletal O
muscle O
dysfunction O
are O
some O
of O
the O
pathological O
hallmarks O
of O
COPD O
. O

Identification O
of O
various O
antioxidant O
agents O
, O
such O
as O
thiol B
molecules O
( O
glutathione B
and O
mucolytic O
drugs O
, O
such O
as O
N O
- O
acetyl O
- O
Lcysteine O
, O
N O
- O
acystelyn O
, O
erdosteine B
, O
fudosteine B
, O
ergothioneine O
, O
and O
carbocysteine O
lysine O
salt O
) O
, O
dietary O
natural O
productderived O
polyphenols B
and O
other O
compounds O
( O
curcumin B
, O
resveratrol B
, O
green O
tea O
catechins B
, O
quercetin O
sulforaphane O
, O
lycopene B
, O

acai O
, O
alpha B
- I
lipoic I
acid I
, O
tocotrienols O
, O
and O
apocynin B
) O
have O
made O
it O
possible O
to O
modulate O
various O
biochemical O
aspects O
of O
COPD O
. O

Various O
researches O
and O
clinical O
trials O
have O
revealed O
that O
these O
antioxidants O
can O
detoxify O
free O
radicals O
and O
oxidants O
, O
control O
expression O
of O
redox O
and O
glutathione B
biosynthesis O
genes O
, O
chromatin O
remodeling O
, O
and O
ultimately O
inflammatory O
gene O
expression O
. O

This O
includes O
specific O
spin O
traps O
like O
alpha O
- O
phenyl O
- O
N O
- O
tert O
- O
butyl O
nitrone O
, O
a O
catalytic O
antioxidant O
( O
ECSOD O
mimetic O
) O
, O
porphyrins B
( O
AEOL O
10150 O
and O
AEOL O
10113 O
) O
, O
and O
a O
superoxide B
dismutase O
mimetic O
M40419 O
, O
lipid O
peroxidation O
and O
protein O
carbonylation O
blockers O
/ O
inhibitors O
, O
such O
as O
edaravone O
and O
lazaroids O
/ O
tirilazad O
, O
myeloperoxidase O
inhibitors O
, O
as O
well O
as O
specialized O
pro O
- O
resolving O

mediators O
/ O
inflammatory O
resolving O
lipid O
mediators O
, O
omega B
- I
3 I
fatty I
acids I
, O
vitamin B
D I
, O
and O
hydrogen B
sulfide I
. O

These O
strategies O
using O
external O
stimuli O
to O
obtain O
addressability O
, O
thus O
hold O
promising O
alternatives O
to O
other O
conducting O
materials O
such O
as O
carbon B
nanotubes O
for O
further O
technological O
applications O
in O
nanosciences O
. O

A O
total O
of O
171 O
structures O
comprising O
alkaloids O
, O
terpenoids B
, O
phenolics B
and O
other O
metabolites O
are O
listed O
in O
this O
review O
, O
including O
information O
on O
their O
antiplasmodial O
and O
cytotoxic O
activity O
. O

Activity O
- O
guided O
fractionation O
of O
seeds O
of O
Solanum O
indicum O
for O
anti O
- O
HBV O
activity O
led O
to O
the O
isolation O
of O
two O
novel O
coumarinolignoid O
alkaloids O
( O
indicumines O
A O
- O
B O
, O
1 O
- O
2 O
) O
and O
two O
new O
coumarinolignoids O
( O
indicumines O
C O
- O
D O
, O
3 O
- O
4 O
) O
, O
together O
with O
four O
known O
coumarins B
( O
5 O
- O
8 O
) O
. O

The O
role O
of O
residues O
T248 O
, O
Y249 O
and O
T422 O
in O
the O
function O
of O
human O
pregnane B
X O
receptor O
. O

The O
pregnane B
X O
receptor O
( O
PXR O
) O
is O
a O
key O
xenobiotic O
receptor O
that O
regulates O
the O
expression O
of O
numerous O
drug O
- O
metabolizing O
enzymes O
. O

Site O
- O
directed O
mutagenesis O
analysis O
was O
performed O
to O
generate O
phospho B
- O
deficient O
and O
phospho B
- O
mimetic O
mutants O
. O

Circadian O
rhythm O
of O
salivary O
cortisol B
in O
infants O
with O
congenital O
heart O
disease O
. O

Perioperative O
events O
include O
disrupted O
glucose B
homeostasis O
, O
capillary O
leak O
, O
and O
fluid O
retention O
. O

The O
hypothalamic O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
has O
an O
important O
role O
in O
homeostasis O
in O
that O
the O
secretion O
of O
cortisol B
contributes O
to O
the O
response O
to O
stress O
, O
glucose B
regulation O
, O
blood O
volume O
control O
, O
and O
immune O
regulation O
. O

We O
investigated O
the O
diurnal O
rhythm O
of O
the O
HPA O
axis O
in O
infants O
with O
CHD O
by O
measuring O
salivary O
cortisol B
in O
the O
morning O
( O
0600 O
- O
0900 O
h O
- O
circadian O
peak O
) O
and O
evening O
( O
2100 O
- O
2400 O
h O
- O
circadian O
nadir O
) O
. O

Morning O
salivary O
cortisol B
was O
similar O
between O
the O
two O
groups O
[ O
acyanotic O
7 O
. O
0 O
nmol O
/ O
L O
( O
1 O
. O
8 O
- O
23 O
. O
1 O
) O
; O
cyanotic O
9 O
. O
7 O
nmol O
/ O
L O
( O
0 O
. O
9 O
- O
15 O
. O
6 O
) O
; O
p O
= O
0 O
. O
68 O
] O
. O

Evening O
salivary O
cortisol B
was O
similar O
between O
the O
two O
groups O
[ O
acyanotic O
0 O
. O
9 O
nmol O
/ O
L O
( O
0 O
. O
2 O
- O
8 O
. O
5 O
) O
; O
cyanotic O
1 O
. O
4 O
nmol O
/ O
L O
( O
0 O
. O
5 O
- O
14 O
. O
9 O
) O
; O
p O
= O
0 O
. O
32 O
] O
. O

By O
12 O
weeks O
of O
age O
, O
infants O
with O
hypoxia O
secondary O
to O
cyanotic O
CHD O
have O
a O
normal O
cortisol B
diurnal O
rhythm O
. O

Peptide O
reactivity O
was O
measured O
by O
monitoring O
unreacted O
peptides O
with O
UV O
- O
Vis O
spectrophotometer O
using O
5 B
, I
5 I
' I
- I
dithiobis I
- I
2 I
- I
nitrobenzoic I
acid I
as O
a O
detection O
reagent O
for O
the O
free O
thiol B
group O
of O
cysteine B
- O
containing O
peptide O
or O
fluorometer O
using O
fluorescamine O
( O
TM O
) O
as O
a O
detection O
reagent O
for O
the O
free O
amine O
group O
of O
lysine B
- O
containing O
peptide O
. O

Chemicals O
were O
categorized O
as O
sensitizers O
when O
they O
induced O
more O
than O
10 O
% O
depletion O
of O
cysteine B
- O
containing O
peptide O
or O
20 O
% O
depletion O
of O
lysine B
- O
containing O
peptide O
. O

Enhancement O
of O
social O
novelty O
discrimination O
by O
positive O
allosteric O
modulators O
at O
metabotropic O
glutamate B
5 O
receptors O
: O
adolescent O
administration O
prevents O
adult O
- O
onset O
deficits O
induced O
by O
neonatal O
treatment O
with O
phencyclidine B
. O

Metabotropic O
glutamate B
- O
5 O
receptors O
( O
mGluR5 O
) O
, O
which O
physically O
and O
functionally O
interact O
with O
N B
- I
methyl I
- I
D I
- I
Aspartate I
( O
NMDA B
) O
receptors O
, O
likewise O
control O
cognitive O
processes O
and O
have O
been O
proposed O
as O
targets O
for O
novel O
classes O
of O
antipsychotic O
agent O
. O

Since O
social O
cognition O
is O
impaired O
in O
schizophrenia O
and O
disrupted O
by O
NMDA B
receptor O
antagonists O
like O
dizocilpine O
, O
we O
evaluated O
its O
potential O
modulation O
by O
mGluR5 O
. O

Acute O
administration O
( O
0 O
. O
63 O
- O
40 O
mg O
/ O
kg O
) O
of O
the O
mGluR5 O
positive O
allosteric O
modulators O
( O
PAMs O
) O
, O
3 O
- O
cyano O
- O
N O
- O
( O
1 O
, O
3 O
- O
diphenyl O
- O
1H O
- O
pyrazol O
- O
5 O
- O
yl O
) O
benzamide O
( O
CDPPB O
) O
and O
ADX47273 B
, O
reversed O
a O
delay O
- O
induced O
impairment O
in O
social O
novelty O
discrimination O
( O
SND O
) O
in O
adult O
rats O
. O

Supporting O
an O
interrelationship O
between O
mGluR5 O
and O
NMDA B
receptors O
, O
enhancement O
of O
SND O
by O
CDPPB O
was O
blocked O
by O
dizocilpine O
( O
0 O
. O
08 O
mg O
/ O
kg O
) O
while O
, O
reciprocally O
, O
dizocilpine O
- O
induced O
impairment O
in O
SND O
was O
attenuated O
by O
CDPPB O
( O
10 O
mg O
/ O
kg O
) O
. O

The O
SND O
deficit O
elicited O
by O
post O
- O
natal O
administration O
of O
phencyclidine B
( O
10 O
mg O
/ O
kg O
, O
days O
7 O
- O
11 O
) O
was O
reversed O
by O
CDPPB O
or O
ADX47273 B
in O
adults O
at O
week O
8 O
. O

This O
phencyclidine B
- O
induced O
impairment O
in O
cognition O
emerged O
in O
adult O
rats O
from O
week O
7 O
on O
, O
and O
chronic O
, O
pre O
- O
symptomatic O
treatment O
of O
adolescent O
rats O
with O
CDPPB O
over O
weeks O
5 O
- O
6 O
( O
10 O
mg O
/ O
kg O
per O
day O
) O
prevented O
the O
appearance O
of O
SND O
deficits O
in O
adults O
until O
at O
least O
week O
13 O
. O

In O
conclusion O
, O
as O
evaluated O
by O
a O
SND O
procedure O
, O
mGluR5 O
PAMs O
promote O
social O
cognition O
via O
actions O
expressed O
in O
interaction O
with O
NMDA B
receptors O
and O
exerted O
in O
frontal O
cortex O
. O

Swim O
training O
of O
monosodium B
L I
- I
glutamate I
- O
obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine B
phosphorylation O
in O
pancreatic O
islets O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose B
homoeostasis O
and O
of O
the O
insulin O
receptor O
( O
IR O
) O
and O
insulin O
receptor O
substrate O
- O
1 O
( O
IRS O
- O
1 O
) O
signalling O
in O
pancreatic O
islets O
from O
MSG B
- O
obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O

Swim O
training O
of O
90 O
- O
day O
- O
old O
MSG B
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS O
- O
1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose B
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O

The O
results O
showed O
that O
IR O
tyrosine B
phosphorylation O
( O
pIR O
) O
was O
reduced O
by O
42 O
% O
in O
MSG B
- O
obese O
mice O
( O
MSG B
, O
6 O
. O
7 O
+ O
/ O
- O
0 O
. O
2 O
arbitrary O
units O
( O
a O
. O
u O
. O
) O
; O
control O
, O
11 O
. O
5 O
+ O
/ O
- O
0 O
. O
4 O
a O
. O
u O
. O
) O
; O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG B
mice O
without O
affecting O
control O
mice O
( O
MSG B
, O
11 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
; O
control O
, O
12 O
. O
8 O
+ O
/ O
- O
0 O
. O
2 O
a O
. O
u O
. O
) O
. O

Although O
the O
treatment O
with O
MSG B
increased O
IRS O
- O
1 O
tyrosine B
phosphorylation O
( O
pIRS O
- O
1 O
) O
by O
96 O
% O
( O
MSG B
, O
17 O
. O
02 O
+ O
/ O
- O
0 O
. O
6 O
; O
control O
, O
8 O
. O
7 O
+ O
/ O
- O
0 O
. O
2 O
a O
. O
u O
. O
) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
( O
control O
, O
13 O
. O
6 O
+ O
/ O
- O
0 O
. O
1 O
; O
MSG B
, O
22 O
. O
2 O
+ O
/ O
- O
1 O
. O
1 O
a O
. O
u O
. O
) O
. O

Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine B
phosphorylation O
of O
IRS O
- O
1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

Friedelin B
and O
lanosterol B
from O
Garcinia O
prainiana O
stimulated O
glucose B
uptake O
and O
adipocytes O
differentiation O
in O
3T3 O
- O
L1 O
adipocytes O
. O

Friedelin B
and O
lanosterol B
have O
been O
isolated O
from O
twigs O
of O
Garcinia O
prainiana O
. O

In O
the O
MTT B
assay O
, O
it O
was O
found O
that O
the O
compounds O
had O
no O
cytotoxic O
effects O
up O
to O
25 O
micro O
M O
. O

In O
the O
presence O
of O
adipogenic O
cocktail O
( O
MDI O
) O
, O
it O
was O
found O
that O
friedelin B
and O
lanosterol B
enhanced O
intracellular O
fat O
accumulation O
by O
2 O
. O
02 O
and O
2 O
. O
18 O
- O
fold O
, O
respectively O
, O
compared O
with O
the O
vehicle O
- O
treated O
cells O
. O

It O
was O
found O
that O
friedelin B
was O
able O
to O
stimulate O
glucose B
uptake O
up O
to O
1 O
. O
8 O
- O
fold O
compared O
with O
insulin O
- O
treated O
cells O
. O

It O
was O
suggested O
that O
friedelin B
and O
lanosterol B
may O
be O
beneficial O
to O
mimic O
insulin O
action O
that O
would O
be O
useful O
in O
the O
treatment O
of O
diabetes O
type O
2 O
patients O
. O

Cost O
- O
effectiveness O
of O
alendronate B
for O
the O
treatment O
of O
osteopenic O
postmenopausal O
women O
in O
Japan O
. O

The O
objective O
of O
this O
study O
was O
to O
estimate O
the O
cost O
- O
effectiveness O
of O
alendronate B
to O
prevent O
fractures O
in O
osteopenic O
postmenopausal O
women O
without O
a O
history O
of O
fracture O
in O
Japan O
. O

An O
individual O
simulation O
model O
was O
developed O
to O
predict O
lifetime O
costs O
and O
quality O
- O
adjusted O
life O
years O
( O
QALYs O
) O
of O
5 O
years O
of O
preventive O
alendronate B
therapy O
versus O
no O
preventive O
therapy O
. O

For O
70 O
- O
year O
- O
old O
women O
with O
a O
BMD O
of O
70 O
% O
of O
the O
YAM O
having O
one O
of O
the O
following O
risk O
factors O
: O
a O
family O
history O
of O
hip O
fracture O
, O
high O
alcohol B
intake O
, O
or O
current O
smoking O
, O
the O
incremental O
cost O
- O
effectiveness O
ratio O
( O
ICER O
) O
of O
alendronate B
was O
$ O
92 O
, O
937 O
, O
$ O
126 O
, O
251 O
, O
and O
$ O
129 O
, O
067 O
per O
QALY O
, O
respectively O
. O

Probabilistic O
sensitivity O
analysis O
for O
the O
base O
case O
showed O
that O
in O
the O
presence O
of O
one O
, O
two O
, O
and O
three O
risk O
factors O
, O
alendronate B
was O
cost O
- O
effective O
in O
0 O
. O
2 O
% O
to O
2 O
. O
6 O
% O
, O
13 O
. O
1 O
% O
to O
56 O
. O
1 O
% O
, O
and O
99 O
. O
1 O
% O
of O
the O
simulations O
, O
respectively O
, O
if O
society O
is O
willing O
to O
pay O
$ O
50 O
, O
000 O
per O
QALY O
. O

Additional O
analysis O
indicated O
that O
alendronate B
can O
be O
a O
good O
value O
in O
osteopenic O
women O
if O
the O
10 O
- O
year O
probability O
for O
a O
osteoporotic O
hip O
or O
vertebral O
fracture O
is O
more O
than O
26 O
. O
2 O
% O
. O

Our O
results O
indicate O
that O
whether O
to O
treat O
osteopenia O
with O
alendronate B
should O
be O
determined O
on O
the O
basis O
of O
age O
, O
BMD O
, O
and O
number O
of O
clinical O
risk O
factors O
in O
terms O
of O
cost O
- O
effectiveness O
. O

Targeted O
disruption O
of O
inducible O
nitric B
oxide I
synthase O
protects O
against O
aging O
, O
S B
- O
nitrosation O
, O
and O
insulin O
resistance O
in O
muscle O
of O
male O
mice O
. O

Accumulating O
evidence O
has O
demonstrated O
that O
S B
- O
nitrosation O
of O
proteins O
plays O
a O
critical O
role O
in O
several O
human O
diseases O
. O

Here O
, O
we O
explored O
the O
role O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
in O
the O
S B
- O
nitrosation O
of O
proteins O
involved O
in O
the O
early O
steps O
of O
the O
insulin O
- O
signaling O
pathway O
and O
insulin O
resistance O
in O
the O
skeletal O
muscle O
of O
aged O
mice O
. O

Aging O
increased O
iNOS O
expression O
and O
S B
- O
nitrosation O
of O
major O
proteins O
involved O
in O
insulin O
signaling O
, O
thereby O
reducing O
insulin O
sensitivity O
in O
skeletal O
muscle O
. O

Conversely O
, O
aged O
iNOS O
- O
null O
mice O
were O
protected O
from O
S B
- O
nitrosation O
- O
induced O
insulin O
resistance O
. O

Moreover O
, O
pharmacological O
treatment O
with O
an O
iNOS O
inhibitor O
and O
acute O
exercise O
reduced O
iNOS O
- O
induced O
S B
- O
nitrosation O
and O
increased O
insulin O
sensitivity O
in O
the O
muscle O
of O
aged O
animals O
. O

These O
findings O
indicate O
that O
the O
insulin O
resistance O
observed O
in O
aged O
mice O
is O
mainly O
mediated O
through O
the O
S B
- O
nitrosation O
of O
the O
insulin O
- O
signaling O
pathway O
. O

Both O
microtubule O
and O
actin O
are O
required O
for O
insulin O
- O
induced O
glucose B
uptake O
. O

Disruption O
of O
microtubule O
prevented O
insulin O
- O
induced O
actin O
remodeling O
and O
distal O
insulin O
signal O
transduction O
, O
with O
reduction O
in O
surface O
glucose B
transporter O
isoform O
4 O
( O
GLUT4 O
) O
and O
glucose B
uptake O
. O

Though O
microtubule O
mediated O
actin O
remodeling O
through O
PKC O
zeta O
, O
reorganization O
of O
microtubule O
depended O
on O
tyrosine B
phosphorylation O
of O
insulin O
receptor O
, O
the O
mechanism O
is O
different O
from O
insulin O
- O
induced O
actin O
remodeling O
, O
which O
relied O
on O
the O
activity O
of O
PI3 O
- O
kinase O
and O
PKC O
zeta O
. O

Selective O
regulation O
of O
nicotine B
and O
polyamines B
biosynthesis O
in O
tobacco O
cells O
by O
enantiomers O
of O
ornithine B
. O

Ornithine B
( O
Orn O
) O
plays O
a O
main O
role O
in O
the O
biosynthesis O
of O
many O
amino B
acids I
, O
nicotinic O
alkaloids O
, O
and O
polyamines B
in O
tobacco O
. O

This O
investigation O
describes O
the O
impact O
of O
Orn O
enantiomers O
on O
the O
production O
and O
distribution O
of O
free O
, O
conjugated O
, O
and O
bound O
polyamines B
, O
as O
well O
as O
nicotine B
in O
tobacco O
cells O
. O

Putrescine B
was O
abundantly O
produced O
by O
exogenous O
L O
- O
ornithine O
( O
L O
- O
Orn O
) O
, O
and O
both O
spermidine B
and O
spermine B
were O
significantly O
accumulated O
in O
D O
- O
ornithine O
( O
D O
- O
Orn O
) O
- O
supplied O
tobacco O
cells O
. O

Furthermore O
, O
nicotine B
production O
was O
highly O
upregulated O
by O
L O
- O
Orn O
, O
while O
the O
addition O
of O
D O
- O
Orn O
had O
no O
effect O
on O
the O
nicotine B
content O
of O
tobacco O
cells O
. O

It O
was O
observed O
that O
transcript O
expression O
of O
S B
- I
adenosylmethionine I
decarboxylase O
, O
as O
the O
key O
enzyme O
of O
spermidine B
/ O
spermine B
biosynthesis O
, O
is O
coincident O
with O
their O
metabolic O
levels O
and O
is O
highly O
upregulated O
by O
D O
- O
Orn O
, O
as O
opposed O
to O
L O
- O
Orn O
. O

Regarding O
these O
observations O
, O
it O
is O
proposed O
that O
L O
- O
and O
D O
- O
Orn O
function O
differently O
in O
the O
same O
biological O
pathways O
in O
which O
the O
latter O
, O
D O
- O
Orn O
specifically O
regulates O
important O
polyamines B
in O
the O
plant O
cells O
. O

Here O
, O
TFF2 O
was O
purified O
from O
the O
human O
corpus O
and O
antrum O
, O
respectively O
, O
by O
size O
- O
exclusion O
chromatography O
, O
and O
the O
N B
- O
linked O
glycan O
structure O
at O
N O
- O
15 O
of O
the O
mature O
peptide O
was O
determined O
. O

As O
a O
hallmark O
, O
the O
unusual O
monofucosylated O
N O
, O
N O
' O
- O
diacetylhexosediamin O
( O
tentatively O
assigned O
as O
GalNAc O
beta O
1 O
- O
- O
> O
4GlcNAc O
, O
LacdiNAc O
) O
modification O
was O
detected O
as O
the O
terminal O
structure O
of O
a O
bi O
- O
antennary O
complex O
type O
N B
- O
glycan O
exhibiting O
also O
core O
fucosylation O
. O

Replicate O
analyses O
did O
not O
show O
microheterogeneities O
in O
the O
fraction O
of O
peptide O
- O
N B
- O
glycosidase O
F O
cleaved O
and O
permethylated O
N B
- O
glycans O
when O
analyzed O
by O
matrix O
- O
assisted O
laser O
desorption O
ionization O
( O
MALDI O
) O
mass O
spectrometry O
( O
MS O
) O
. O

The O
tryptic O
TFF2 O
N B
- O
glycopeptide O
p34 O
- O
39 O
( O
LSPHNR O
N B
- O
glycosylated O
with O
Fuc3Hex3HexNAc6 O
) O
was O
identified O
by O
both O
ESI O
- O
tandem O
mass O
spectrometry O
and O
MALDI O
- O
post O
- O
source O
decay O
analysis O
. O

Cannabinoid O
CB O
1 O
receptor O
in O
the O
modulation O
of O
stress O
coping O
behavior O
in O
mice O
: O
the O
role O
of O
serotonin B
and O
different O
forebrain O
neuronal O
subpopulations O
. O

The O
aim O
of O
this O
work O
was O
to O
investigate O
the O
involvement O
of O
serotonin B
( O
5 B
- I
HT I
) O
and O
catecholamines B
, O
as O
well O
as O
the O
role O
of O
glutamatergic O
and O
GABAergic O
cannabinoid O
type O
1 O
( O
CB O
( O
1 O
) O
) O
receptor O
, O
in O
responses O
to O
the O
antidepressant O
- O
like O
doses O
of O
the O
CB O
( O
1 O
) O
receptor O
agonist O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
THC B
) O
and O
the O
antagonist O
rimonabant B
in O
the O
forced O
swim O
test O
( O
FST O
) O
. O

Mice O
received O
acute O
injections O
of O
low O
doses O
of O
THC B
( O
0 O
. O
1 O
or O
0 O
. O
5 O
mg O
/ O
kg O
) O
or O
high O
dose O
of O
rimonabant B
( O
3 O
or O
10 O
mg O
/ O
kg O
) O
after O
treatment O
with O
the O
5 B
- I
HT I
synthesis O
inhibitor O
pCPA O
( O
100 O
mg O
/ O
kg O
, O
4 O
days O
) O
, O
the O
5 B
- I
HT I
( O
1A O
) O
receptor O
antagonist O
WAY100635 O
( O
1 O
mg O
/ O
kg O
, O
acute O
) O
or O
the O
non O
- O
selective O
blocker O
of O
catecholamine B
synthesis O
, O
AMPT O
( O
20 O
mg O
/ O
kg O
, O
acute O
) O
. O

THC B
and O
rimonabant B
were O
also O
tested O
in O
mutant O
mice O
lacking O
CB O
( O
1 O
) O
receptor O
in O
specific O
forebrain O
neuronal O
subpopulations O
. O

Both O
THC B
and O
rimonabant B
induced O
antidepressant O
- O
like O
effects O
, O
quantified O
as O
immobility O
in O
the O
FST O
. O

However O
, O
only O
THC B
effects O
were O
reversed O
by O
pCPA O
or O
WAY100635 O
. O

In O
contrast O
, O
only O
AMPT O
could O
attenuate O
the O
rimonabant B
effect O
. O

The O
effect O
of O
THC B
persisted O
in O
mutant O
mice O
with O
CB O
( O
1 O
) O
receptor O
inactivation O
in O
GABAergic O
neurons O
, O
whereas O
rimonabant B
effects O
were O
alleviated O
in O
these O
mutants O
. O

The O
antidepressant O
- O
like O
action O
of O
THC B
depends O
on O
serotonergic O
neurotransmission O
, O
whereas O
rimonabant B
effects O
are O
mediated O
by O
CB O
( O
1 O
) O
receptor O
on O
GABAergic O
neurons O
and O
by O
catecholamine B
signaling O
. O

The O
risky O
cocktail O
: O
what O
combination O
effects O
can O
we O
expect O
between O
ecstasy B
and O
other O
amphetamines B
? O

The O
recreational O
and O
illicit O
use O
of O
amphetaminic O
designer O
compounds O
, O
specially O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
; O
Ecstasy B
) O
, O
is O
of O
concern O
worldwide O
. O

The O
present O
study O
was O
aimed O
at O
predicting O
the O
cytotoxic O
effects O
of O
mixtures O
of O
four O
amphetaminic O
derivatives O
: O
MDMA B
, O
methamphetamine B
, O
4 O
- O
methylthioamphetamin O
and O
d B
- I
amphetamine I
in O
a O
human O
hepatoma O
cell O
line O
. O

Concentration O
- O
response O
curves O
for O
all O
single O
- O
mixture O
components O
were O
recorded O
by O
the O
MTT B
assay O
. O

By O
comparing O
the O
predicted O
calculations O
with O
the O
experimentally O
observed O
effects O
, O
we O
concluded O
that O
CA O
accurately O
predicts O
the O
combination O
of O
amphetamines B
, O
which O
act O
together O
to O
generate O
additive O
effects O
over O
a O
large O
range O
of O
concentrations O
. O

A O
possible O
metabolic O
interaction O
, O
which O
could O
explain O
such O
deviation O
, O
was O
investigated O
, O
and O
it O
was O
observed O
that O
at O
higher O
mixture O
concentrations O
increased O
MDMA B
metabolism O
could O
be O
contributing O
to O
divergences O
from O
additivity O
. O

Resistin O
knockout O
mice O
exhibit O
impaired O
adipocyte O
glucose B
- O
dependent O
insulinotropic O
polypeptide O
receptor O
( O
GIPR O
) O
expression O
. O

Glucose B
- O
dependent O
insulinotropic O
polypeptide O
( O
GIP O
) O
is O
an O
incretin O
hormone O
that O
also O
plays O
a O
regulatory O
role O
in O
fat O
metabolism O
. O

In O
3T3 O
- O
L1 O
cells O
, O
resistin O
was O
demonstrated O
to O
be O
a O
key O
mediator O
of O
GIP O
stimulation O
of O
lipoprotein O
lipase O
( O
LPL O
) O
activity O
, O
involving O
activation O
of O
protein O
kinase O
B O
( O
PKB O
) O
and O
reduced O
phosphorylation O
of O
liver O
kinase O
B1 O
( O
LKB1 O
) O
and O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
. O

Analysis O
of O
primary O
adipocytes O
isolated O
from O
Retn O
( O
- O
/ O
- O
) O
, O
Retn O
( O
+ O
/ O
- O
) O
, O
and O
Retn O
( O
+ O
/ O
+ O
) O
mice O
found O
that O
GIP O
stimulated O
the O
PKB O
/ O
LKB1 O
/ O
AMPK O
/ O
LPL O
pathway O
and O
fatty B
acid I
uptake O
only O
in O
Retn O
( O
+ O
/ O
+ O
) O
adipocytes O
, O
suggesting O
that O
GIP O
signaling O
and O
/ O
or O
GIP O
responsiveness O
were O
compromised O
in O
Retn O
( O
+ O
/ O
- O
) O
and O
Retn O
( O
- O
/ O
- O
) O
adipocytes O
. O

In O
addition O
, O
genes O
encoding O
tumor O
necrosis O
factor O
( O
TNF O
) O
, O
TNF O
receptor O
2 O
( O
TNFR2 O
) O
, O
and O
the O
signaling O
proteins O
stress O
- O
activated O
protein O
kinase O
( O
SAPK O
) O
/ O
Jun O
NH B
( I
2 I
) I
- O
terminal O
kinase O
( O
JNK O
) O
, O
were O
downregulated O
, O
and O
phosphorylated O
levels O
of O
SAPK O
/ O
JNK O
/ O
c O
- O
Jun O
were O
decreased O
in O
Retn O
( O
- O
/ O
- O
) O
mice O
. O

Chromatin O
immunoprecipitation O
assays O
were O
used O
to O
identify O
a O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
( O
TPA B
) O
- O
response O
element O
( O
TRE O
- O
III O
) O
responsible O
for O
c O
- O
Jun O
- O
mediated O
transcriptional O
activation O
of O
Gipr O
. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
chronic O
fluorosis O
on O
the O
dynamics O
( O
including O
fusion O
and O
fission O
proteins O
) O
, O
fragmentation O
, O
and O
distribution O
of O
mitochondria O
in O
the O
cortical O
neurons O
of O
the O
rat O
brain O
in O
an O
attempt O
to O
elucidate O
molecular O
mechanisms O
underlying O
the O
brain O
damage O
associated O
with O
excess O
accumulation O
of O
fluoride B
. O

Sixty O
Sprague O
- O
Dawley O
rats O
were O
divided O
randomly O
into O
three O
groups O
of O
20 O
each O
, O
that O
is O
, O
the O
untreated O
control O
group O
( O
drinking O
water O
naturally O
containing O
< O
0 O
. O
5 O
mg O
fluoride B
/ O
l O
, O
NaF B
) O
, O
the O
low O
- O
fluoride B
group O
( O
whose O
drinking O
water O
was O
supplemented O
with O
10 O
mg O
fluoride B
/ O
l O
) O
and O
the O
high O
- O
fluoride B
group O
( O
50 O
mg O
fluoride B
/ O
l O
) O
. O

We O
examined O
in O
cats O
the O
1 O
) O
ulcerogenic O
effects O
of O
selective O
COX O
- O
1 O
( O
SC O
- O
560 O
, O
ketorolac B
) O
and O
COX O
- O
2 O
( O
celecoxib B
, O
meloxicam B
) O
inhibitors O
on O
the O
gastrointestinal O
mucosa O
, O
2 O
) O
effect O
of O
feeding O
and O
cimetidine O
on O
the O
expression O
of O
COX O
isoforms O
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
level O
in O
the O
duodenum O
, O
and O
3 O
) O
localization O
of O
COX O
isoforms O
in O
the O
duodenum O
. O

Localization O
and O
expression O
of O
COX O
isoforms O
( O
by O
immunohistochemistry O
, O
Western O
blot O
) O
and O
PGE B
( I
2 I
) I
level O
( O
by O
enzyme O
immunoassay O
) O
were O
examined O
. O

Coadministration O
of O
SC O
- O
560 O
and O
celecoxib B
produced O
marked O
lesions O
in O
the O
small O
intestine O
. O

Second O
, O
feeding O
increased O
both O
the O
expression O
of O
COX O
isoforms O
and O
PGE B
( I
2 I
) I
level O
in O
the O
duodenum O
, O
and O
the O
effects O
were O
markedly O
inhibited O
by O
pretreatment O
with O
cimetidine O
. O

pH O
- O
and O
thermo O
- O
sensitive O
pluronic B
/ O
poly B
( I
acrylic I
acid I
) I
in O
situ O
hydrogels O
for O
sustained O
release O
of O
an O
anticancer O
drug O
. O

In O
this O
study O
, O
we O
developed O
oral O
in O
situ O
gelling O
formulations O
composed O
of O
pluronic B
( O
Plu O
) O
and O
polyacrylic O
acid O
( O
PAA B
) O
for O
the O
delivery O
of O
an O
anticancer O
drug O
, O
epirubicin O
( O
Epi O
) O
. O

We O
investigated O
various O
Plu O
/ O
PAA B
/ O
Epi O
formulations O
for O
their O
physicochemical O
properties O
and O
in O
vitro O
permeation O
and O
accumulation O
, O
as O
well O
as O
for O
in O
vivo O
pharmacokinetic O
and O
antitumor O
efficacy O
. O

A O
scanning O
electron O
microscopic O
( O
SEM O
) O
image O
of O
Plu O
14 O
% O
/ O
PAA B
0 O
. O
75 O
% O
/ O
Epi O
hydrogel O
showed O
a O
sponge O
- O
like O
structure O
. O

Consistent O
with O
this O
role O
, O
emerging O
evidence O
indicates O
that O
signals O
arising O
from O
apoptotic O
and O
old O
/ O
or O
dysfunctional O
osteocytes O
are O
seminal O
culprits O
in O
the O
pathogenesis O
of O
involutional O
, O
post O
- O
menopausal O
, O
steroid B
- O
, O
and O
immobilization O
- O
induced O
osteoporosis O
. O

The O
changes O
in O
tissue O
concentrations O
of O
11 O
elements O
( O
Ca B
, O
Cd B
, O
Cr B
, O
Cu B
, O
Fe B
, O
Hg B
, O
Ni B
, O
Pb B
, O
Se B
, O
V B
, O
and O
Zn B
) O
were O
investigated O
in O
a O
longitudinal O
study O
during O
the O
lactation O
period O
and O
during O
the O
post O
- O
weaning O
fast O
period O
. O

Maternal O
transfer O
through O
the O
milk O
was O
observed O
for O
all O
trace O
elements O
, O
except O
for O
Cd B
. O

Examining O
the O
contamination O
levels O
showed O
that O
this O
grey O
seal O
population O
seems O
more O
highly O
exposed O
to O
Pb B
than O
other O
phocid O
populations O
( O
2 O
. O
2 O
mg O
/ O
kg O
dw O
of O
grey O
seal O
hair O
) O
. O

In O
contrast O
, O
blood O
and O
hair O
levels O
reflected O
a O
lower O
Hg B
exposure O
in O
grey O
seals O
from O
the O
Isle O
of O
May O
than O
in O
harbour O
seals O
from O
the O
southeastern O
North O
Sea O
. O

The O
first O
one O
is O
a O
new O
simple O
formulation O
of O
long O
circulating O
contrast O
agents O
, O
formulated O
from O
a O
commercial O
iodinated O
oil O
, O
and O
resulting O
in O
CT O
contrast O
agents O
containing O
more O
than O
twice O
the O
iodine B
concentration O
commercial O
contrast O
agents O
. O

The O
second O
point O
is O
a O
methodological O
aspect O
, O
utilizing O
tangential O
filtration O
for O
reducing O
the O
residual O
surfactants O
in O
the O
bulk O
phase O
and O
serving O
as O
well O
for O
concentrating O
droplets O
( O
and O
iodine B
) O
in O
the O
suspension O
. O

Medium O
and O
high O
oxidation O
state O
metal O
/ O
non O
- O
metal O
fluoride O
and O
oxide B
- O
fluoride B
complexes O
with O
neutral O
donor O
ligands O
. O

While O
most O
high O
and O
medium O
oxidation O
state O
( O
O O
. O
S O
. O
> O
= O
3 O
) O
metal O
and O
non O
- O
metal O
fluorides O
and O
oxide B
fluorides O
are O
strong O
Lewis O
acids O
, O
exploration O
of O
their O
coordination O
chemistry O
with O
neutral O
ligands O
has O
been O
limited O
and O
mostly O
non O
- O
systematic O
. O

This O
is O
despite O
the O
very O
different O
properties O
conferred O
on O
the O
acceptor O
centre O
by O
the O
small O
electronegative O
fluoride B
ligands O
compared O
to O
the O
heavier O
halides O
. O

Current O
knowledge O
of O
the O
coordination O
chemistry O
of O
d O
, O
f O
and O
p O
- O
block O
fluorides O
and O
oxide B
fluorides O
with O
neutral O
ligands O
( O
with O
donor O
atoms O
drawn O
from O
Groups O
15 O
and O
16 O
and O
including O
N O
- O
heterocyclic O
carbenes O
) O
is O
then O
presented O
and O
discussed O
, O
and O
the O
differences O
in O
properties O
compared O
to O
complexes O
containing O
the O
heavier O
halides O
are O
illustrated O
. O

Caffeine B
, O
extraversion O
and O
working O
memory O
. O

Research O
has O
shown O
that O
extraverts O
performing O
a O
working O
memory O
task O
benefit O
more O
from O
caffeine B
than O
do O
introverts O
. O

The O
present O
study O
aimed O
to O
replicate O
this O
and O
extend O
our O
knowledge O
by O
using O
a O
lower O
dose O
of O
caffeine B
( O
65 O
mg O
) O
and O
a O
range O
of O
tasks O
related O
to O
different O
components O
of O
working O
memory O
. O

In O
addition O
, O
tasks O
assessing O
psychomotor O
speed O
and O
the O
encoding O
of O
new O
information O
were O
included O
to O
determine O
whether O
caffeine B
- O
extraversion O
interactions O
were O
restricted O
to O
working O
memory O
tasks O
. O

The O
results O
showed O
that O
caffeine B
interacted O
with O
extraversion O
in O
the O
predicted O
direction O
for O
serial O
recall O
and O
running O
memory O
tasks O
. O

Caffeine B
improved O
simple O
reaction O
time O
and O
the O
speed O
of O
encoding O
of O
new O
information O
, O
effects O
which O
were O
not O
modified O
by O
extraversion O
. O

These O
results O
suggest O
possible O
biological O
mechanisms O
underlying O
effects O
of O
caffeine B
on O
cognitive O
performance O
. O

Quantitative O
analysis O
of O
the O
interaction O
of O
constitutive O
androstane B
receptor O
with O
chemicals O
and O
steroid B
receptor O
coactivator O
1 O
using O
surface O
plasmon O
resonance O
biosensor O
systems O
: O
a O
case O
study O
of O
the O
Baikal O
seal O
( O
Pusa O
sibirica O
) O
and O
the O
mouse O
. O

The O
constitutive O
androstane B
receptor O
( O
CAR O
) O
not O
only O
displays O
a O
high O
basal O
transcriptional O
activity O
but O
also O
acts O
as O
a O
ligand O
- O
dependent O
transcriptional O
factor O
. O

The O
objectives O
of O
this O
study O
are O
to O
establish O
a O
high O
- O
throughput O
tool O
to O
screen O
CAR O
ligands O
and O
to O
clarify O
how O
CAR O
proteins O
from O
the O
Baikal O
seal O
( O
bsCAR O
) O
and O
the O
mouse O
( O
mCAR O
) O
interact O
with O
chemicals O
and O
steroid B
receptor O
coactivator O
1 O
( O
SRC1 O
) O
. O

Androstanol O
and O
androstenol O
, O
estrone B
, O
17 B
beta I
- I
estradiol I
, O
TCPOBOP O
, O
and O
CITCO O
showed O
compound O
- O
specific O
but O
similar O
affinities O
for O
both O
CARs O
. O

Both O
drugs O
and O
food O
have O
powerful O
reinforcing O
effects O
, O
which O
are O
in O
part O
mediated O
by O
abrupt O
dopamine B
increases O
in O
the O
brain O
reward O
centres O
. O

The O
abrupt O
dopamine B
increases O
, O
in O
vulnerable O
individuals O
, O
can O
override O
the O
brain O
' O
s O
homeostatic O
control O
mechanisms O
. O

This O
study O
was O
conducted O
to O
investigate O
the O
potential O
of O
bambangan O
( O
Mangifera O
pajang O
) O
fruit O
extracts O
in O
the O
protection O
against O
oxidative O
damage O
caused O
by O
tert B
- I
butyl I
hydroperoxide I
in O
the O
human O
hepatocellular O
HepG2 O
cell O
line O
. O

Quercetin B
was O
used O
as O
a O
positive O
control O
. O

The O
results O
showed O
that O
only O
the O
kernel O
extract O
of O
M O
. O
pajang O
and O
quercetin B
displayed O
cytoprotective O
activity O
in O
HepG2 O
cells O
, O
with O
EC O
( O
50 O
) O
values O
of O
1 O
. O
2 O
and O
5 O
. O
3 O
mu O
g O
/ O
ml O
, O
respectively O
. O

Expression O
of O
quinone B
reductase O
, O
glutathione B
reductase O
and O
methionine O
sulfoxide O
reductase O
A O
proteins O
were O
significantly O
up O
- O
regulated O
by O
quercetin B
, O
suggesting O
their O
involvement O
in O
the O
cytoprotective O
activity O
of O
quercetin B
. O

However O
, O
expressions O
of O
only O
glutathione B
reductase O
and O
methionine O
sulfoxide O
reductase O
A O
proteins O
were O
significantly O
up O
- O
regulated O
by O
the O
kernel O
extract O
, O
again O
suggesting O
their O
involvement O
in O
the O
cytoprotective O
activity O
of O
bambangan O
kernel O
extract O
. O

Stability O
of O
bioactive O
polyphenols B
from O
honey O
during O
different O
extraction O
methods O
. O

The O
LC O
- O
MS O
/ O
MS O
technique O
was O
applied O
to O
the O
stability O
study O
of O
several O
flavonoids B
and O
phenolic B
acids I
in O
honey O
samples O
during O
the O
ultrasonic O
extraction O
( O
USE O
) O
and O
microwave O
- O
assisted O
extraction O
( O
MAE O
) O
. O

Phenolic B
compounds O
from O
the O
standard O
mixture O
were O
stable O
under O
ultrasounds O
action O
with O
the O
mean O
recovery O
of O
( O
90 O
. O
4 O
% O
+ O
/ O
- O
7 O
. O
1 O
% O
) O
, O
but O
during O
microwave O
- O
assisted O
extraction O
the O
benzoic B
acid I
derivatives O
and O
aglycones O
of O
flavonoids B
showed O
lower O
recovery O
( O
70 O
- O
80 O
% O
) O
. O

In O
honey O
matrix O
, O
the O
phenolic B
acids I
and O
the O
glycosides O
exhibited O
the O
high O
stability O
for O
MAE O
and O
USE O
treatments O
. O

In O
the O
presence O
of O
an O
artificial O
sugar B
matrix O
, O
flavonols B
were O
almost O
completely O
degraded O
after O
successive O
treatment O
under O
MAE O
and O
USE O
conditions O
. O

The O
obtained O
results O
indicated O
that O
standard O
addition O
method O
for O
flavonoids B
quantification O
in O
honey O
samples O
should O
not O
be O
recommended O
. O

Application O
of O
the O
USE O
conditions O
provided O
higher O
and O
/ O
or O
similar O
extraction O
yields O
for O
phenolic B
acids I
than O
usually O
applied O
shaking O
with O
solvent O
. O

Phenolic B
acids I
and O
glycosides O
such O
as O
quercetrin O
, O
rutin B
and O
hesperidin B
appeared O
to O
be O
stable O
under O
such O
conditions O
. O

A O
novel O
one O
- O
step O
microbial O
transformation O
of O
betulin O
to O
betulinic B
acid I
catalysed O
by O
Cunninghamella O
blakesleeana O
. O

Betulinic B
acid I
and O
its O
derivatives O
are O
potential O
bioactive O
compounds O
present O
in O
nature O
. O

This O
study O
investigated O
the O
biotransformation O
of O
betulin O
to O
betulinic B
acid I
by O
Cunninghamella O
blakesleeana O
cells O
. O

LC O
- O
MS O
analysis O
demonstrated O
that O
betulin O
could O
be O
transformed O
into O
at O
least O
five O
products O
from O
cultured O
C O
. O
blakesleeana O
cells O
, O
among O
which O
betulinic B
acid I
was O
the O
most O
important O
. O

Bioefficacy O
of O
EPA B
- O
DHA B
from O
lipids O
recovered O
from O
fish O
processing O
wastes O
through O
biotechnological O
approaches O
. O

The O
effect O
of O
fish O
oil O
recovered O
from O
fish O
visceral O
waste O
( O
FVW O
- O
FO O
) O
on O
serum O
and O
liver O
lipids O
, O
activity O
of O
HMG B
- I
CoA I
reductase O
in O
liver O
microsomes O
and O
EPA B
+ O
DHA B
incorporation O
in O
liver O
, O
heart O
and O
brain O
were O
evaluated O
. O

Rats O
were O
fed O
different O
concentrations O
of O
FVW O
- O
FO O
providing O
1 O
. O
25 O
% O
, O
2 O
. O
50 O
% O
, O
5 O
. O
0 O
% O
EPA B
+ O
DHA B
recovered O
by O
either O
fermentation O
or O
enzymatic O
hydrolysis O
for O
8weeks O
. O

Feeding O
FVW O
- O
FO O
reduce O
triacylglycerols B
( O
5 O
. O
96 O
- O
20 O
. O
3 O
% O
) O
, O
total O
cholesterol B
( O
7 O
. O
9 O
- O
21 O
. O
5 O
% O
) O
and O
LDL O
( O
7 O
. O
39 O
- O
21 O
. O
7 O
% O
) O
cholesterol B
levels O
in O
serum O
compared O
to O
group O
fed O
on O
a O
control O
diet O
( O
groundnut O
oil O
) O
. O

The O
activity O
of O
HMG B
- I
CoA I
reductase O
was O
reduced O
( O
p O
< O
0 O
. O
05 O
) O
in O
the O
FVW O
- O
FO O
fed O
groups O
compared O
to O
the O
control O
. O

EPA B
+ O
DHA B
level O
in O
serum O
, O
liver O
, O
brain O
and O
heart O
increased O
with O
increments O
in O
dietary O
EPA B
+ O
DHA B
. O

Results O
show O
the O
hypolipidemic O
property O
of O
FVW O
- O
FO O
and O
reduced O
HMG B
- I
CoA I
reductase O
activity O
which O
is O
proportional O
to O
the O
incorporation O
of O
EPA B
+ O
DHA B
. O

Phytochemical O
investigation O
of O
the O
n B
- I
butanol I
( O
n B
- I
BuOH I
) O
fraction O
of O
this O
plant O
led O
to O
the O
isolation O
of O
four O
new O
2 O
, O
6 O
- O
dideoxyhexose O
- O
C O
- O
glycosyl O
flavones O
, O
including O
luteolin O
- O
8 O
- O
C O
- O
beta O
- O
digitoxopyranosyl O
- O
4 O
' O
- O
O O
- O
beta O
- O
d O
- O
glucopyranoside O
( O
1 O
) O
, O
apigenin O
- O
8 O
- O
C O
- O
beta O
- O
digitoxopyranoside O
( O
2 O
) O
, O
apigenin O
- O
8 O
- O
C O
- O
beta O
- O
boivinopyranoside O
( O

All O
compounds O
were O
evaluated O
for O
their O
neurite O
outgrowth O
enhancing O
activities O
and O
the O
results O
indicated O
that O
luteolin B
( O
7 O
) O
enhanced O
NGF O
- O
induced O
neurite O
outgrowth O
in O
PC12 O
cells O
at O
50 O
. O
0 O
mu O
M O
. O

For O
the O
quantitative O
estimation O
of O
triterpenic O
acids O
in O
the O
crude O
extracts O
an O
NMR O
based O
methodology O
was O
used O
and O
compared O
with O
the O
HPLC O
measurements O
, O
both O
applied O
for O
the O
first O
time O
, O
for O
the O
case O
of O
betulinic B
acid I
. O

Decrease O
of O
RINm5F O
viability O
was O
mediated O
by O
nitric B
oxide I
( O
NO B
) O
- O
induced O
apoptosis O
. O

Importantly O
, O
these O
extracts O
potentiated O
NO B
and O
TNF O
- O
alpha O
release O
from O
macrophages O
therefore O
enhancing O
their O
cytocidal O
action O
. O

The O
rosemary O
extract O
developed O
more O
pronounced O
antioxidant O
, O
cytotoxic O
and O
immunomodifying O
activities O
, O
probably O
due O
to O
the O
presence O
of O
betulinic B
acid I
and O
a O
higher O
concentration O
of O
carnosic O
acid O
in O
its O
phytochemical O
profile O
. O

In O
the O
present O
study O
, O
six O
cyanobacteria O
isolates O
were O
evaluated O
for O
the O
PAL O
enzyme O
activity O
, O
and O
their O
methanol B
extracts O
were O
assessed O
for O
the O
total O
phenolic B
amount O
and O
other O
antioxidant O
parameters O
. O

BASO673 O
isolates O
with O
high O
levels O
of O
total O
phenols B
( O
66 O
. O
0 O
+ O
/ O
- O
1 O
. O
2 O
mu O
g O
/ O
mg O
, O
78 O
. O
1 O
+ O
/ O
- O
1 O
. O
8 O
mu O
g O
/ O
mg O
, O
respectively O
) O
also O
showed O
high O
levels O
of O
PAL O
activities O
( O
20 O
. O
5 O
+ O
/ O
- O
3 O
. O
1U O
/ O
mg O
protein O
, O
17 O
. O
2 O
+ O
/ O
- O
2 O
. O
3U O
/ O
mg O
protein O
, O
respectively O
) O
and O
strong O
antioxidant O
activities O
. O

To O
understand O
the O
effect O
of O
l O
- O
phenylalanine O
( O
l O
- O
phe O
) O
on O
the O
PAL O
activity O
, O
total O
phenolic B
amount O
, O
and O
phenolic B
constituents O
, O
isolates O
were O
evaluated O
with O
100mg O
/ O
l O
l O
- O
phe O
. O

While O
PAL O
activities O
exhibited O
no O
significant O
change O
with O
l O
- O
phe O
addition O
, O
total O
phenolic B
amount O
of O
the O
isolates O
significantly O
increased O
. O

HPLC O
analysis O
revealed O
gallic B
acid I
, O
trans O
- O
cinnamic O
acid O
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
as O
the O
main O
compounds O
. O

Results O
suggested O
that O
the O
two O
isolate O
mights O
be O
an O
important O
source O
for O
the O
l O
- O
phe O
inducible O
phenolic B
compounds O
. O

A O
metabolite O
profiling O
approach O
was O
used O
to O
study O
the O
effect O
of O
moderate O
- O
intensity O
pulsed O
electric O
field O
( O
MIPEF O
) O
treatments O
on O
the O
individual O
polyphenol B
and O
carotenoid O
contents O
of O
tomato O
fruit O
after O
refrigeration O
at O
4 O
degrees O
C O
for O
24h O
. O

Twenty O
four O
hours O
after O
MIPEF O
treatments O
, O
an O
increase O
was O
observed O
in O
hydroxycinnamic B
acids I
and O
flavanones B
, O
whereas O
flavonols B
, O
coumaric O
and O
ferulic O
acid O
- O
O O
- O
glucoside O
were O
not O
affected O
. O

MIPEF O
treatments O
, O
conducted O
at O
1 O
. O
2kV O
/ O
cm O
and O
30 O
pulses O
, O
led O
to O
the O
greatest O
increases O
in O
chlorogenic O
( O
152 O
% O
) O
, O
caffeic O
acid O
- O
O O
- O
glucoside O
( O
170 O
% O
) O
and O
caffeic B
( O
140 O
% O
) O
acids O
. O

On O
the O
other O
hand O
, O
treatments O
at O
1 O
. O
2kV O
/ O
cm O
and O
5 O
pulses O
led O
to O
maximum O
increases O
of O
alpha B
- I
carotene I
, O
9 O
- O
and O
13 O
- O
cis O
- O
lycopene O
, O
which O
increased O
by O
93 O
% O
, O
94 O
% O
and O
140 O
% O
, O
respectively O
. O

Therefore O
, O
MIPEF O
could O
stimulate O
synthesis O
of O
secondary O
metabolites O
and O
contribute O
to O
production O
of O
tomatoes O
with O
high O
individual O
polyphenol B
and O
carotenoid O
contents O
. O

Amino B
acid I
composition O
, O
antinutrients O
and O
allergens O
in O
the O
peanut O
protein O
fraction O
obtained O
by O
an O
aqueous O
enzymatic O
process O
. O

The O
aqueous O
fraction O
( O
AF O
) O
obtained O
by O
EAE O
had O
a O
better O
essential O
amino B
acid I
profile O
than O
the O
residues O
obtained O
by O
solvent O
extraction O
( O
Rs O
) O
and O
cold O
pressing O
( O
Rc O
) O
. O

AF O
had O
an O
extremely O
low O
phytate B
content O
and O
was O
rich O
in O
peptides O
, O
which O
could O
be O
used O
as O
a O
food O
supplement O
. O

Dimethyl O
sulphide O
, O
1 O
- O
penten O
- O
3 O
- O
ol O
, O
1 O
- O
hexen O
- O
3 O
- O
ol O
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
during O
storage O
, O
whereas O
pentanal O
, O
hexanal O
, O
heptanal O
, O
octanal B
and O
3 O
- O
undecen O
- O
2 O
- O
one O
decreased O
. O

The O
DPPH B
- O
radical O
scavenging O
assay O
exhibited O
high O
antioxidant O
activities O
in O
three O
plants O
( O
more O
than O
80 O
% O
at O
50 O
mu O
g O
) O
. O

The O
F O
. O
vulgaris O
showed O
high O
content O
of O
carvacrol B
( O
29 O
. O
8 O
% O
) O
as O
main O
component O
. O

The O
contents O
of O
carvacrol B
and O
fumaric O
acid O
in O
the O
methanolic O
- O
water O
extracts O
were O
1119 O
and O
1966mg O
/ O
l O
respectively O
. O

The O
hypocholesterolemic O
effects O
of O
two O
low O
calorie O
structured O
lipids O
( O
SL1 O
and O
SL2 O
) O
containing O
essential O
fatty B
acids I
, O
prepared O
by O
lipase O
catalysed O
interesterification O
of O
ethyl O
behenate O
respectively O
with O
sunflower O
and O
soybean O
oils O
were O
studied O
in O
rats O
and O
rabbits O
. O

However O
, O
the O
structured O
lipids O
beneficially O
lowered O
serum O
and O
liver O
lipids O
, O
particularly O
cholesterol B
, O
LDL O
cholesterol B
, O
triglycerides B
and O
also O
maintains O
the O
essential O
fatty B
acid I
status O
in O
serum O
and O
liver O
. O

These O
observations O
coincided O
with O
reduced O
levels O
of O
serum O
cholesterol B
particularly O
LDL O
cholesterol B
observed O
in O
experimental O
groups O
. O

Effects O
of O
solvent O
and O
alkaline O
earth O
metals O
on O
the O
heat O
- O
induced O
precipitation O
process O
of O
sodium B
caseinate O
. O

The O
precipitation O
temperatures O
of O
sodium B
caseinate O
in O
H B
( I
2 I
) I
O I
and O
D O
( O
2 O
) O
O O
in O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Sr O
( O
2 O
+ O
) O
and O
Ba B
( I
2 I
+ I
) I
were O
investigated O
through O
fluorescence O
, O
turbidity O
and O
conductivity O
experiments O
. O

As O
for O
the O
ability O
of O
the O
divalent O
cations O
( O
1 O
- O
17 O
. O
5mM O
) O
to O
induce O
the O
precipitation O
process O
in O
H B
( I
2 I
) I
O I
, O
the O
sequence O
Ba B
( I
2 I
+ I
) I
> O
= O
Ca B
( I
2 I
+ I
) I
> O
Mg B
( I
2 I
+ I
) I
> O
Sr O
( O
2 O
+ O
) O
was O
found O
. O

In O
D O
( O
2 O
) O
O O
, O
the O
order O
of O
ion O
ability O
to O
induce O
caseinate O
precipitation O
was O
Ba B
( I
2 I
+ I
) I
> O
Ca B
( I
2 I
+ I
) I
> O
Sr O
( O
2 O
+ O
) O
> O
Mg B
( I
2 I
+ I
) I
. O

The O
different O
hydrophobicity O
between O
D O
( O
2 O
) O
O O
and O
H B
( I
2 I
) I
O I
was O
shown O
to O
affect O
significantly O
the O
T O
( O
Ps O
) O
of O
caseinate O
in O
the O
presence O
of O
calcium B
, O
strontium O
and O
barium O
. O

The O
presence O
of O
lysine B
and O
the O
major O
component O
lauric B
acid I
derivative O
, O
as O
indicated O
by O
electrospray O
ionisation O
- O
mass O
spectrometry O
( O
ESI O
- O
MS O
) O
direct O
infusion O
and O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectroscopy O
, O
may O
have O
contributed O
to O
the O
antibacterial O
effect O
of O
purified O
PKC O
fraction O
. O

This O
study O
suggests O
that O
the O
antibacterial O
PKC O
compound O
may O
be O
not O
a O
pure O
peptide O
but O
instead O
a O
peptide O
- O
containing O
compound O
high O
in O
lauric B
acid I
derivative O
. O

Effects O
of O
vitamin B
D I
on O
antigen O
- O
specific O
and O
non O
- O
antigen O
- O
specific O
immune O
modulation O
: O
relevance O
for O
type O
1 O
diabetes O
. O

Vitamin B
D I
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 O
- O
hydroxyvitamin O
D O
3 O
( O
25 O
( O
OH O
) O
D O
3 O
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
( O
1 B
, I
25 I
( I
OH I
) I
2 I
D I
3 I
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium B
absorption O
from O
the O
gut O
. O

Importantly O
, O
in O
humans O
, O
vitamin B
D I
is O
mainly O
derived O
from O
endogenous O
production O
of O
vitamin B
D I
3 I
from O
ultraviolet O
( O
UV O
) O
radiation O
exposure O
to O
the O
skin O
while O
a O
small O
part O
( O
< O
10 O
% O
) O
is O
obtained O
via O
dietary O
intake O
of O
dairy O
products O
and O
fatty O
fish O
( O
1 O
) O
. O

Taking O
these O
factors O
into O
account O
, O
geographic O
distribution O
and O
seasonality O
, O
skin O
pigmentation O
, O
age O
, O
and O
lifestyle O
may O
predispose O
certain O
populations O
to O
be O
at O
a O
higher O
risk O
of O
developing O
vitamin B
D I
insufficiency O
or O
deficiency O
( O
2 O
) O
. O

The O
first O
valid O
reports O
correlating O
the O
importance O
of O
an O
adequate O
vitamin B
D I
status O
to O
optimal O
human O
health O
originate O
from O
the O
early O
part O
of O
the O
20th O
century O
, O
when O
vitamin B
D I
was O
described O
to O
prevent O
and O
treat O
the O
bone O
disease O
rickets O
. O

Since O
then O
, O
the O
findings O
that O
vitamin B
D I
receptors O
( O
VDR O
) O
are O
present O
in O
many O
body O
tissues O
and O
that O
vitamin B
D I
metabolizing O
enzymes O
can O
be O
found O
in O
various O
cells O
outside O
the O
kidney O
, O
including O
the O
intestine O
, O
prostate O
, O
immune O
cells O
, O
and O
within O
the O
skin O
itself O
( O
reviewed O
in O
reference O
3 O
) O
, O
have O
revolutionized O
the O
vitamin B
D I
business O
. O

In O
this O
review O
, O
we O
will O
mainly O
focus O
on O
vitamin B
D I
as O
a O
component O
of O
immune O
regulation O
and O
on O
the O
role O
of O
vitamin B
D I
in O
antigen O
- O
specific O
and O
non O
- O
specific O
therapies O
with O
potential O
relevance O
for O
type O
1 O
diabetes O
( O
T1D O
) O
. O

Testosterone B
( O
T O
) O
levels O
of O
prepubertal O
rats O
diminished O
at O
high O
dose O
DHP O
and O
middle O
dose O
DCHP O
groups O
. O

Modeling O
the O
binding O
mechanism O
of O
Alzheimer O
' O
s O
A O
beta O
1 O
- O
4 O
2 O
to O
nicotinic O
acetylcholine B
receptors O
based O
on O
similarity O
with O
snake O
alpha O
- O
neurotoxins O
. O

For O
over O
a O
decade O
, O
it O
has O
been O
known O
that O
amyloid O
beta O
( O
A O
beta O
) O
peptides O
of O
Alzheimer O
' O
s O
disease O
bind O
to O
the O
nicotinic O
alpha O
7 O
acetylcholine B
receptor O
( O
AChR O
) O
with O
picomolar O
affinity O
, O
and O
that O
snake O
alpha O
- O
neurotoxins O
competitively O
inhibit O
this O
binding O
. O

The O
binding O
mechanism O
involves O
residue O
( O
A O
beta O
) O
K28 O
( O
similar O
to O
( O
ATX O
) O
R32 O
) O
which O
forms O
cation O
/ O
pi O
interactions O
in O
the O
acetylcholine B
binding O
site O
, O
and O
residues O
( O
A O
beta O
) O
G29 O
- O
( O
A O
beta O
) O
I32 O
[ O
GAII O
] O
( O
similar O
to O
( O
ATX O
) O
G33 O
- O
( O
ATX O
) O
I36 O
[ O
GTII O
] O
) O
which O
form O
an O
intermolecular O
beta O
- O
sheet O
with O
residues O
( O
alpha O
7 O
) O
F189 O
- O
( O
alpha O
7 O
) O
E191 O
of O
AChR O
. O

Electrical O
detection O
of O
spin O
precession O
in O
freely O
suspended O
graphene B
spin O
valves O
on O
cross O
- O
linked O
poly B
( I
methyl I
methacrylate I
) I
. O

Spin O
injection O
and O
detection O
is O
achieved O
in O
freely O
suspended O
graphene B
using O
cobalt B
electrodes O
and O
a O
nonlocal O
spin O
- O
valve O
geometry O
. O

The O
devices O
are O
fabricated O
with O
a O
single O
electron O
- O
beam O
- O
resist O
poly B
( I
methyl I
methacrylate I
) I
process O
that O
minimizes O
both O
the O
fabrication O
steps O
and O
the O
number O
of O
( O
aggressive O
) O
chemicals O
used O
, O
greatly O
reducing O
contamination O
and O
increasing O
the O
yield O
of O
high O
- O
quality O
, O
mechanically O
stable O
devices O
. O

As O
- O
grown O
devices O
can O
present O
mobilities O
exceeding O
10 O
( O
4 O
) O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
at O
room O
temperature O
and O
, O
because O
the O
contacts O
deposited O
on O
graphene B
are O
only O
exposed O
to O
acetone B
and O
isopropanol O
, O
the O
method O
is O
compatible O
with O
almost O
any O
contacting O
material O
. O

Fitting O
of O
Hanle O
spin O
precession O
data O
in O
bilayer O
and O
multilayer O
graphene B
yields O
a O
spin O
relaxation O
time O
of O
~ O
125 O
- O
250 O
ps O
and O
a O
spin O
diffusion O
length O
of O
1 O
. O
7 O
- O
1 O
. O
9 O
mu O
m O
at O
room O
temperature O
. O

A O
broad O
variety O
of O
ligands O
was O
employed O
, O
affording O
novel O
and O
previously O
inaccessible O
cycloheptatrienyl O
( O
sandwich O
) O
complexes O
of O
the O
type O
[ O
( O
eta O
( O
7 O
) O
- O
C O
( O
7 O
) O
H O
( O
7 O
) O
) O
Zr O
( O
Y O
) O
] O
; O
Y O
comprises O
pentadienyl O
, O
cyclopentadienyl B
, O
allyl B
, O
phospholyl O
, O
boratabenzene O
, O
imidazolin O
- O
2 O
- O
iminato O
and O
amido O
systems O
. O

The O
cycloheptatrienyl O
ring O
in O
these O
systems O
usually O
acts O
as O
an O
" O
innocent O
spectator O
ligand O
" O
, O
but O
reactivity O
can O
arise O
from O
the O
second O
ligand O
Y O
or O
the O
Lewis O
acidity O
of O
the O
, O
formally O
, O
Zr B
( I
+ I
iv I
) I
center O
, O
which O
was O
probed O
in O
selected O
examples O
and O
put O
in O
perspective O
to O
related O
studies O
. O

Portal O
vein O
glucose B
entry O
triggers O
a O
coordinated O
cellular O
response O
that O
potentiates O
hepatic O
glucose B
uptake O
and O
storage O
in O
normal O
but O
not O
high O
- O
fat O
/ O
high O
- O
fructose B
- O
fed O
dogs O
. O

The O
cellular O
events O
mediating O
the O
pleiotropic O
actions O
of O
portal O
vein O
glucose B
( O
PoG O
) O
delivery O
on O
hepatic O
glucose B
disposition O
have O
not O
been O
clearly O
defined O
. O

Likewise O
, O
the O
molecular O
defects O
associated O
with O
postprandial O
hyperglycemia O
and O
impaired O
hepatic O
glucose B
uptake O
( O
HGU O
) O
following O
consumption O
of O
a O
high O
- O
fat O
, O
high O
- O
fructose B
diet O
( O
HFFD O
) O
are O
unknown O
. O

These O
data O
reveal O
new O
insight O
into O
the O
molecular O
physiology O
of O
the O
portal O
glucose B
signaling O
mechanism O
under O
normal O
conditions O
and O
to O
the O
pathophysiology O
of O
aberrant O
postprandial O
hepatic O
glucose B
disposition O
evident O
under O
a O
diet O
- O
induced O
glucose B
- O
intolerant O
condition O
. O

1 O
. O
In O
this O
study O
, O
hydrophilic O
interaction O
liquid O
chromatography O
( O
HILIC O
) O
, O
radiochemical O
activity O
monitoring O
and O
linear O
trap O
quadrupole O
orbitrap O
mass O
spectrometry O
( O
MS O
) O
and O
tandem O
mass O
spectrometry O
( O
MS O
/ O
MS O
) O
were O
used O
to O
identify O
the O
metabolites O
of O
a O
highly O
polar O
novel O
gamma B
- I
aminobutyric I
acid I
type O
- O
B O
receptor O
agonist O
, O
lesogaberan O
, O
in O
rats O
. O

M1 O
was O
identified O
as O
the O
N B
- O
acetylated O
species O
[ O
( O
2R O
) O
- O
3 O
- O
acetamido O
- O
2 O
- O
fluoropropyl O
] O
- O
phosphinic O
acid O
, O
and O
M6 O
as O
[ O
( O
2R O
) O
- O
3 O
- O
amino O
- O
2 O
- O
fluoropropyl O
] O
- O
phosphonic O
acid O
. O

Metabolites O
M2 O
and O
M5 O
were O
the O
alcohol B
and O
carboxylic B
acid I
species O
3 O
- O
hydroxypropyl O
- O
phosphinic O
acid O
and O
3 O
- O
hydroxyphosphonoyl O
- O
propanoic O
acid O
, O
respectively O
, O
both O
of O
which O
had O
lost O
the O
fluorine B
atom O
present O
in O
the O
parent O
compound O
. O

M3 O
was O
the O
corresponding O
carboxylic B
acid I
species O
retaining O
the O
fluorine B
atom O
, O
( O
2R O
) O
- O
2 O
- O
fluoro O
- O
3 O
- O
hydroxyphosphonoyl O
- O
propanoic O
acid O
. O

It O
is O
important O
to O
prepare O
the O
slices O
in O
a O
cold O
preservation O
solution O
, O
to O
prepare O
the O
slices O
at O
a O
correct O
thickness O
, O
and O
to O
incubate O
the O
slices O
in O
a O
system O
where O
the O
slice O
rotates O
in O
out O
of O
the O
oxygen B
atmosphere O
and O
medium O
. O

Prenatal O
exposure O
to O
polychlorinated B
biphenyls I
and O
dioxins O
from O
the O
maternal O
diet O
may O
be O
associated O
with O
immunosuppressive O
effects O
that O
persist O
into O
early O
childhood O
. O

We O
investigated O
whether O
prenatal O
exposure O
from O
the O
maternal O
diet O
to O
the O
toxicants O
polychlorinated B
biphenyls I
( O
PCBs B
) O
and O
dioxins O
is O
associated O
with O
the O
development O
of O
immune O
- O
related O
diseases O
in O
childhood O
. O

Maternal O
exposure O
to O
PCBs B
and O
dioxins O
was O
found O
to O
be O
associated O
with O
an O
increased O
risk O
of O
wheeze O
and O
more O
frequent O
upper O
respiratory O
tract O
infections O
. O

Furthermore O
, O
maternal O
exposure O
to O
PCBs B
and O
dioxins O
was O
found O
to O
be O
associated O
with O
reduced O
antibody O
response O
to O
a O
measles O
vaccine O
. O

Our O
results O
suggest O
that O
prenatal O
dietary O
exposure O
to O
PCBs B
and O
dioxins O
may O
increase O
the O
risk O
of O
wheeze O
and O
the O
susceptibility O
to O
infectious O
diseases O
in O
early O
childhood O
. O

The O
only O
treatment O
related O
significant O
changes O
were O
reduced O
concentrations O
of O
fasting O
blood O
glucose B
( O
up O
to O
17 O
. O
6 O
% O
) O
and O
cholesterol B
( O
up O
to O
22 O
. O
0 O
% O
) O
, O
typical O
benefits O
of O
dietary O
fiber O
, O
in O
males O
treated O
with O
3 O
. O
75 O
and O
5 O
% O
rice O
hull O
fiber O
. O

It O
is O
based O
on O
coexpression O
of O
( O
1 O
) O
a O
protein O
of O
interest O
, O
fused O
with O
the O
bacterial O
biotin B
ligase O
BirA O
, O
together O
with O
( O
2 O
) O
a O
histone O
fused O
to O
a O
biotin B
acceptor O
peptide O
( O
BAP O
) O
, O
which O
is O
specifically O
biotinylated O
by O
BirA O
- O
fusion O
in O
the O
proximity O
of O
the O
protein O
of O
interest O
. O

Finally O
, O
biotin B
pulse O
- O
chase O
experiments O
show O
that O
the O
H4 O
acetylation O
pattern O
starts O
to O
resemble O
the O
acetylation O
pattern O
of O
total O
H4 O
after O
the O
proximity O
of O
chromatin O
to O
RAD18 O
has O
been O
lost O
. O

Here O
, O
we O
show O
the O
reduction O
mechanism O
of O
A O
beta O
production O
using O
the O
butanol B
extract O
of O
Ecklonia O
cava O
through O
the O
examination O
of O
expression O
and O
activity O
of O
alpha O
- O
, O
beta O
- O
, O
and O
gamma O
- O
secretase O
. O

PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V O
/ O
propidium B
iodide I
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase O
- O
9 O
and O
caspase O
- O
3 O
proteins O
. O

DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen B
species O
. O

Hexagonal O
tris O
( O
o O
- O
phenylenedioxy O
) O
cyclotriphosphazene O
( O
TPP B
) O
is O
used O
as O
ahost O
for O
organizing O
dipolar O
molecular O
rotor O
guests O
into O
regular O
trigonal O
arrays O
. O

Inclusion O
of O
molecular O
rotors O
with O
transversely O
dipolar O
rotators O
into O
TPP B
channels O
is O
followed O
by O
solid O
- O
state O
nuclear O
magnetic O
resonance O
, O
diifferential O
scanning O
calorimetry O
, O
X O
- O
ray O
diffraction O
, O
and O
dielectric O
spectroscopy O
. O

With O
advances O
in O
polymerization O
techniques O
as O
well O
as O
selective O
chemical O
modification O
of O
carbohydrates B
, O
glycopolymers O
and O
glyco O
- O
nanoparticles O
are O
emerging O
as O
an O
important O
class O
of O
materials O
with O
tailored O
properties O
or O
novel O
nanotechnology O
- O
based O
platforms O
for O
a O
number O
of O
applications O
. O

Glyco O
- O
nanoparticles O
, O
due O
to O
their O
versatile O
nature O
, O
could O
offer O
a O
platform O
for O
the O
design O
of O
carbohydrate B
- O
based O
vaccines O
and O
possibly O
allow O
the O
development O
of O
new O
single O
- O
dose O
vaccines O
in O
disease O
areas O
of O
unmet O
need O
. O

This O
paper O
surveys O
the O
emerging O
roles O
of O
carbohydrate B
- O
based O
polymeric O
and O
nanomaterials O
for O
biomolecular O
recognition O
processes O
and O
vaccine O
development O
. O

Interactions O
between O
CYP2E1 O
and O
CYP2B4 O
: O
effects O
on O
affinity O
for O
NADPH B
- O
cytochrome O
P450 O
reductase O
and O
substrate O
metabolism O
. O

However O
, O
CYP2B4 O
is O
not O
an O
inhibitor O
of O
CYP2E1 O
- O
mediated O
p B
- I
nitrophenol I
hydroxylation O
. O

When O
these O
inhibition O
studies O
were O
performed O
with O
the O
artificial O
oxidant O
tert B
- I
butyl I
hydroperoxide I
, O
CYP2E1 O
did O
not O
significantly O
inhibit O
CYP2B4 O
activity O
. O

Amino B
acid I
residues O
at O
the O
N O
- O
and O
C O
- O
termini O
are O
essential O
for O
the O
folding O
of O
active O
human O
butyrylcholinesteras O
polypeptide O
. O

Human O
serum O
butyrylcholinesteras O
( O
HuBChE O
) O
is O
currently O
the O
most O
suitable O
bioscavenger O
for O
the O
prophylaxis O
of O
highly O
toxic O
organophosphate B
( O
OP O
) O
nerve O
agents O
. O

Studies O
have O
indicated O
that O
the O
three O
- O
dimensional O
structure O
and O
the O
domains O
of O
HuBChE O
( O
acyl B
pocket O
, O
lip O
of O
the O
active O
center O
gorge O
, O
and O
the O
anionic O
substrate O
- O
binding O
domain O
) O
that O
are O
critical O
for O
the O
binding O
of O
substrate O
are O
also O
essential O
for O
the O
selectivity O
and O
binding O
of O
inhibitors O
including O
OPs O
. O

Tartrate B
- O
resistant O
acid O
phosphatase O
( O
TRAP O
) O
staining O
revealed O
increased O
osteoclast O
numbers O
in O
tibias O
of O
2 O
- O
month O
- O
old O
Col1a1 O
- O
Cnn1 O
mice O
, O
and O
increased O
numbers O
of O
osteoclasts O
co O
- O
cultured O
with O
Col1a1 O
- O
Cnn1 O
osteoblasts O
. O

Although O
acetylcholinesterase O
( O
AChE O
) O
is O
primarily O
a O
hydrolytic O
enzyme O
, O
metabolising O
the O
neurotransmitter O
acetylcholine B
in O
cholinergic O
synapses O
, O
it O
also O
has O
some O
non O
- O
catalytic O
functions O
in O
the O
brain O
which O
are O
far O
less O
well O
characterised O
. O

Since O
AChE O
does O
not O
possess O
a O
transmembrane O
domain O
, O
its O
anchorage O
in O
the O
membrane O
is O
established O
via O
the O
Proline B
Rich O
Membrane O
Anchor O
( O
PRiMA O
) O
, O
a O
transmembrane O
protein O
. O

In O
an O
effort O
to O
understand O
the O
shedding O
process O
of O
AChE O
, O
we O
have O
used O
several O
pharmacological O
treatments O
, O
which O
showed O
that O
it O
is O
likely O
to O
be O
mediated O
in O
part O
by O
an O
EDTA B
- O
and O
batimastat O
- O
sensitive O
, O
but O
GM6001 O
- O
insensitive O
metalloprotease O
, O
with O
the O
possible O
additional O
involvement O
of O
a O
thiol B
isomerase O
. O

Cellular O
release O
of O
AChE O
by O
SH O
- O
SY5Y O
is O
significantly O
enhanced O
by O
the O
muscarinic O
acetylcholine B
receptor O
( O
mAChR O
) O
agonists O
carbachol B
or O
muscarine O
, O
with O
the O
effect O
of O
carbachol B
blocked O
by O
the O
mAChR O
antagonist O
atropine O
. O

Here O
, O
we O
review O
briefly O
some O
of O
the O
major O
ideas O
and O
advances O
of O
this O
field O
, O
and O
report O
on O
some O
recent O
progress O
from O
our O
own O
experimental O
work O
, O
e O
. O
g O
. O
that O
( O
i O
) O
non O
- O
neural O
ChEs O
have O
pronounced O
, O
predominantly O
enzymatic O
effects O
on O
early O
embryonic O
( O
limb O
) O
development O
in O
chick O
and O
mouse O
, O
that O
( O
ii O
) O
retinal O
R28 O
cells O
of O
the O
rat O
overexpressing O
synaptic O
AChE O
present O
a O
significantly O
decreased O
cell O
proliferation O
, O
and O
that O
( O
iii O
) O
in O
developing O
chick O
retina O
ACh B
- O
synthesizing O
and O
ACh B
- O
degrading O
cells O
originate O
from O
the O
same O
postmitotic O
precursor O

We O
suggest O
that O
such O
distinct O
distributions O
of O
ChAT O
( O
+ O
) O
vs O
. O
AChE O
( O
+ O
) O
cells O
in O
the O
inner O
half O
retina O
provide O
graded O
distributions O
of O
ACh B
, O
which O
can O
direct O
cell O
differentiation O
and O
network O
formation O
. O

Gold O
nanoparticle O
aggregate O
carbon B
nanotube O
functionalized O
colloidal O
particles O
serve O
as O
an O
efficient O
platform O
for O
probing O
the O
intracellular O
environment O
. O

Sex O
and O
dose O
- O
dependent O
effects O
of O
developmental O
exposure O
to O
bisphenol B
A I
on O
anxiety O
and O
spatial O
learning O
in O
deer O
mice O
( O
Peromyscus O
maniculatus O
bairdii O
) O
offspring O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
a O
widely O
produced O
, O
endocrine O
disrupting O
compound O
that O
is O
pervasive O
in O
the O
environment O
. O

Data O
suggest O
that O
developmental O
exposure O
to O
BPA B
during O
sexual O
differentiation O
of O
the O
brain O
leads O
to O
later O
behavioral O
consequences O
in O
offspring O
. O

Outbred O
deer O
mice O
( O
Peromyscus O
maniculatus O
bairdii O
) O
are O
an O
excellent O
animal O
model O
for O
such O
studies O
as O
they O
exhibit O
well O
- O
defined O
sex O
- O
and O
steroid B
- O
dependent O
behaviors O
. O

Here O
, O
dams O
during O
gestation O
and O
lactation O
were O
fed O
with O
a O
phytoestrogen O
- O
free O
control O
diet O
, O
the O
same O
diet O
supplemented O
with O
either O
ethinyl B
estradiol I
( O
0 O
. O
1 O
ppb O
) O
, O
or O
one O
of O
the O
three O
doses O
of O
BPA B
( O
50 O
mg O
, O
5 O
mg O
, O
50 O
mu O
g O
/ O
kg O
feed O
weight O
) O
. O

Relative O
to O
controls O
, O
males O
exposed O
to O
the O
two O
upper O
but O
not O
the O
lowest O
dose O
of O
BPA B
demonstrated O
similar O
impairments O
in O
spatial O
learning O
, O
increased O
anxiety O
and O
reduced O
exploratory O
behaviors O
as O
ethinyl B
estradiol I
- O
exposed O
males O
, O
while O
females O
exposed O
to O
ethinyl B
estradiol I
, O
but O
not O
to O
BPA B
, O
consistently O
exhibited O
masculinized O
spatial O
abilities O
. O

We O
also O
determined O
whether O
dams O
maintained O
chronically O
on O
the O
upper O
dose O
of O
BPA B
contained O
environmentally O
relevant O
concentrations O
of O
BPA B
in O
their O
blood O
. O

While O
serum O
concentrations O
of O
unconjugated O
BPA B
in O
controls O
were O
below O
the O
minimum O
level O
of O
detection O
, O
those O
from O
dams O
on O
the O
BPA B
diet O
were O
comparable O
( O
5 O
. O
48 O
+ O
/ O
- O
2 O
. O
07 O
ng O
/ O
ml O
) O
to O
concentrations O
that O
have O
been O
observed O
in O
humans O
. O

Together O
, O
these O
studies O
demonstrate O
that O
developmental O
exposure O
to O
environmentally O
relevant O
concentrations O
of O
BPA B
can O
disrupt O
adult O
behaviors O
in O
a O
dose O
- O
and O
sex O
- O
dependent O
manner O
. O

Using O
an O
electrochemical O
deposition O
method O
, O
the O
bubble O
- O
ejecting O
nanojets O
were O
grown O
within O
the O
alumina B
template O
, O
which O
is O
commercially O
available O
. O

These O
fabricated O
nanosized O
devices O
have O
typical O
dimensions O
of O
300 O
nm O
( O
diameter O
) O
by O
4 O
. O
5 O
mu O
m O
( O
length O
) O
, O
and O
they O
are O
able O
to O
move O
in O
a O
hydrogen B
peroxide I
fuel O
solution O
with O
velocities O
up O
to O
approximately O
40 O
body O
lengths O
per O
second O
. O

Fenhexamid O
and O
fludioxonil O
showed O
endocrine O
disruptor O
activity O
as O
antiandrogens O
in O
an O
androgen B
receptor O
reporter O
assay O
in O
engineered O
human O
breast O
cancer O
cells O
. O

Induction O
of O
miR O
- O
21 O
was O
inhibited O
by O
the O
estrogen B
receptor O
antagonist O
fulvestrant B
, O
by O
androgen B
receptor O
antagonist O
bicalutamide B
, O
by O
actinomycin B
D I
and O
cycloheximide B
, O
and O
by O
inhibitors O
of O
the O
mitogen O
- O
activated O
protein O
kinases O
and O
phosphoinositide B
3 O
- O
kinase O
pathways O
. O

Fenhexamid O
activation O
was O
inhibited O
by O
the O
arylhydrocarbon B
receptor O
antagonist O
alpha O
- O
napthoflavone O
. O

Fenhexamid O
and O
fludioxonil O
did O
not O
affect O
dihydrotestosterone B
- O
induced O
miR O
- O
21 O
expression O
. O

Fludioxonil O
, O
but O
not O
fenhexamid O
, O
inhibited O
MCF O
- O
7 O
cell O
viability O
, O
and O
both O
inhibited O
estradiol B
- O
induced O
cell O
proliferation O
and O
reduced O
cell O
motility O
. O

Benzo B
[ I
a I
] I
pyrene I
- O
induced O
transcriptomic O
responses O
in O
primary O
hepatocytes O
and O
in O
vivo O
liver O
: O
toxicokinetics O
is O
essential O
for O
in O
vivo O
- O
in O
vitro O
comparisons O
. O

Recently O
, O
the O
differential O
gene O
expression O
response O
in O
wild O
- O
type O
and O
cancer O
- O
prone O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
primary O
mouse O
hepatocytes O
after O
exposure O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
) O
revealed O
downregulation O
of O
cancer O
- O
related O
pathways O
in O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
hepatocytes O
only O
. O

Here O
, O
we O
investigated O
pathway O
regulation O
upon O
in O
vivo O
B B
[ I
a I
] I
P I
exposure O
of O
wild O
- O
type O
and O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
mice O
. O

In O
order O
to O
be O
able O
to O
make O
a O
meaningful O
in O
vivo O
- O
in O
vitro O
comparison O
we O
estimated O
internal O
in O
vivo O
B B
[ I
a I
] I
P I
concentrations O
using O
DNA O
adduct O
levels O
and O
physiologically O
based O
kinetic O
modeling O
. O

However O
, O
we O
were O
unable O
to O
detect O
cancer O
- O
related O
pathways O
in O
either O
wild O
- O
type O
or O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
exposed O
livers O
, O
which O
were O
previously O
found O
to O
be O
induced O
by O
B B
[ I
a I
] I
P I
in O
Xpa O
( O
- O
/ O
- O
) O
p53 O
( O
+ O
/ O
- O
) O
primary O
hepatocytes O
. O

In O
conclusion O
, O
we O
showed O
parallels O
in O
gene O
expression O
responses O
between O
livers O
and O
primary O
hepatocytes O
upon O
exposure O
to O
equivalent O
concentrations O
of O
B B
[ I
a I
] I
P I
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
environmentally O
relevant O
concentrations O
of O
the O
commonly O
used O
insecticide O
, O
malathion B
, O
would O
alter O
predator O
avoidance O
behavior O
in O
a O
freshwater O
gastropod O
that O
could O
translate O
to O
increased O
predation O
risk O
. O

We O
exposed O
adult O
Physa O
pomilia O
snails O
to O
0 O
, O
0 O
. O
25 O
, O
or O
1 O
. O
0 O
mg O
/ O
L O
malathion B
for O
2 O
, O
24 O
, O
or O
48 O
h O
and O
evaluated O
predator O
avoidance O
using O
a O
behavioral O
assay O
in O
which O
snails O
were O
exposed O
to O
cues O
from O
predatory O
crayfish O
. O

We O
found O
a O
significant O
reduction O
in O
predator O
avoidance O
in O
snails O
exposed O
to O
both O
concentrations O
of O
malathion B
after O
48 O
h O
of O
exposure O
. O

To O
evaluate O
whether O
observed O
effects O
of O
malathion B
on O
predator O
avoidance O
actually O
increased O
susceptibility O
of O
snails O
to O
predators O
, O
we O
conducted O
a O
predator O
challenge O
experiment O
. O

Snails O
exposed O
to O
0 O
. O
25 O
mg O
/ O
L O
malathion B
for O
48 O
h O
were O
significantly O
more O
susceptible O
to O
predation O
. O

That O
increased O
predation O
risk O
was O
evident O
48 O
h O
after O
initial O
malathion B
exposures O
is O
a O
unique O
result O
because O
most O
studies O
have O
evaluated O
behavioral O
responses O
soon O
after O
( O
< O
12 O
h O
) O
initiation O
of O
pesticide O
exposure O
. O

A O
suite O
of O
biomarkers O
including O
acetylcholinesterase O
, O
ethoxyresorufin B
O B
- O
deethylase O
, O
glutathione B
S B
- O
transferase O
, O
glutathione B
peroxidase O
and O
superoxide B
dismutase O
activities O
in O
fish O
after O
7 O
, O
14 O
, O
21 O
and O
28 O
days O
of O
exposure O
in O
situ O
, O
as O
well O
as O
pharmaceuticals O
and O
metals O
in O
water O
, O
were O
determined O
during O
the O
field O
exposure O
period O
. O

IBR O
values O
were O
in O
good O
agreement O
with O
copper B
and O
caffeine B
concentrations O
. O

Protein O
expression O
of O
Ugt1a6 O
also O
decreased O
and O
corresponded O
with O
reduced O
in O
vitro O
glucuronidation O
of O
bisphenol B
A I
in O
S9 O
fractions O
from O
livers O
of O
pregnant O
mice O
. O

Conversely O
, O
Sult1a1 O
, O
2a1 O
/ O
2 O
, O
and O
3a1 O
mRNAs O
increased O
100 O
to O
500 O
% O
at O
various O
time O
points O
in O
pregnant O
and O
lactating O
mice O
and O
corresponded O
with O
enhanced O
in O
vitro O
sulfation O
of O
acetaminophen B
in O
liver O
S9 O
fractions O
. O

Overall O
, O
dendrite O
lengths O
were O
positively O
correlated O
with O
plasma O
estradiol B
levels O
in O
females O
exposed O
to O
males O
, O
but O
not O
in O
unpaired O
females O
. O

Human O
ether B
- O
a O
- O
go O
- O
go O
- O
related O
gene O
channel O
blockers O
and O
its O
structural O
analysis O
for O
drug O
design O
. O

The O
human O
ether B
- O
a O
- O
go O
- O
go O
- O
related O
gene O
( O
hERG O
) O
is O
a O
K B
+ I
channel O
protein O
mainly O
expressed O
in O
the O
heart O
and O
the O
nervous O
systems O
and O
its O
blockade O
by O
non O
- O
cardiovascular O
acting O
drugs O
resulted O
in O
tachycardia O
and O
sudden O
death O
. O

The O
quinolizidine O
alkaloids O
( O
natural O
products O
) O
such O
as O
oxymatrine B
, O
sophoridine O
, O
sophocarpine O
and O
matrine O
carry O
the O
common O
molecular O
structure O
of O
O O
= O
C O
= O
N O
- O
C O
- O
C O
- O
C O
- O
N O
that O
possessed O
positive O
ionotropic O
effect O
and O
hERG O
blocking O
activity O
. O

The O
isoquinoline B
alkaloid I
, O
neferine O
( O
Nef O
) O
induces O
a O
concentration O
- O
dependent O
decrease O
in O
current O
amplitude O
( O
IC50 O
of O
7 O
. O
419 O
MM O
) O
. O

In O
vitro O
synergistic O
interaction O
between O
amide B
piplartine O
and O
antimicrobial O
peptide O
dermaseptin O
against O
Schistosoma O
mansoni O
schistosomula O
and O
adult O
worms O
. O

Schistosomiasis O
is O
one O
of O
the O
world O
' O
s O
major O
public O
health O
problems O
, O
and O
praziquantel B
is O
the O
only O
available O
drug O
to O
treat O
this O
notable O
neglected O
disease O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
in O
vitro O
activities O
of O
the O
amide B
piplartine O
and O
the O
antimicrobial O
peptide O
dermaseptin O
01 O
administered O
singly O
or O
in O
combination O
against O
Schistosoma O
mansoni O
of O
different O
ages O
including O
3 O
- O
hour O
- O
old O
and O
7 O
- O
day O
- O
old O
schistosomula O
and O
49 O
- O
day O
- O
old O
adult O
schistosomes O
as O
well O
as O
on O
egg O
output O
by O
adult O
worms O
. O

To O
broaden O
our O
knowledge O
about O
the O
toxicity O
of O
metals O
in O
marine O
elasmobranchs O
, O
cannulated O
spiny O
dogfish O
( O
Squalus O
acanthias O
) O
were O
exposed O
to O
20 O
mu O
M O
and O
100 O
mu O
M O
lead O
( O
Pb B
) O
. O

Since O
we O
wanted O
to O
focus O
on O
sub O
lethal O
ion O
- O
osmoregulatory O
and O
respiratory O
disturbances O
, O
arterial O
blood O
samples O
were O
analysed O
for O
pH O
( O
a O
) O
, O
PaO O
( O
2 O
) O
, O
haematocrit O
and O
total O
CO B
( I
2 I
) I
values O
at O
several O
time O
points O
. O

Plasma O
was O
used O
to O
determine O
urea B
, O
TMAO O
, O
lactate B
and O
ion O
concentrations O
. O

After O
96 O
h O
, O
Pb B
concentrations O
were O
determined O
in O
a O
number O
of O
tissues O
, O
such O
as O
gill O
, O
rectal O
gland O
, O
skin O
and O
liver O
. O

To O
further O
investigate O
ion O
and O
osmoregulation O
, O
Na B
( I
+ I
) I
/ O
K B
( I
+ I
) I
- O
ATPase O
activities O
in O
gill O
and O
rectal O
gland O
were O
analysed O
as O
well O
as O
rates O
of O
ammonia B
and O
urea B
excretion O
. O

Pb B
strongly O
accumulated O
in O
gills O
and O
especially O
in O
skin O
. O

After O
2 O
days O
, O
plasma O
Na B
and O
Cl B
concentrations O
were O
reduced O
compared O
to O
controls O
at O
100 O
mu O
M O
Pb B
and O
urea B
excretion O
rates O
were O
elevated O
. O

Pb B
caused O
impaired O
Na B
( I
+ I
) I
/ O
K B
( I
+ I
) I
- O
ATPase O
activity O
in O
gills O
, O
but O
not O
in O
rectal O
gland O
. O

We O
conclude O
that O
spiny O
dogfish O
experienced O
relatively O
low O
ion O
- O
osmoregulatory O
and O
respiratory O
distress O
when O
exposed O
to O
lead O
, O
particularly O
when O
compared O
to O
effects O
of O
other O
metals O
such O
as O
silver B
. O

These O
elasmobranchs O
appear O
to O
be O
able O
to O
minimize O
the O
disturbance O
and O
maintain O
physiological O
homeostasis O
during O
an O
acute O
Pb B
exposure O
. O

An O
omics O
based O
assessment O
of O
cadmium B
toxicity O
in O
the O
green O
alga O
Chlamydomonas O
reinhardtii O
. O

The O
effects O
of O
cadmium B
were O
assessed O
in O
the O
freshwater O
alga O
Chlamydomonas O
reinhardtii O
. O

Algae O
were O
exposed O
to O
concentrations O
of O
0 O
, O
8 O
. O
1 O
or O
114 O
. O
8 O
mu O
M O
of O
cadmium B
and O
growth O
rates O
, O
gene O
transcription O
and O
metabolite O
profiles O
were O
examined O
after O
48 O
and O
72 O
h O
of O
exposure O
. O

In O
algae O
exposed O
to O
8 O
. O
1 O
mu O
M O
Cd B
, O
several O
genes O
were O
differentially O
transcribed O
after O
48 O
h O
but O
no O
adverse O
growth O
related O
effects O
were O
detected O
. O

In O
contrast O
, O
all O
effects O
were O
more O
pronounced O
at O
the O
114 O
. O
8 O
mu O
M O
cadmium B
exposure O
. O

Metabolites O
involved O
in O
the O
glutathione B
synthesis O
pathway O
( O
an O
important O
antioxidant O
defense O
) O
were O
also O
affected O
but O
the O
effects O
of O
cadmium B
were O
found O
to O
be O
more O
pronounced O
at O
the O
transcript O
level O
than O
in O
the O
metabolome O
, O
suggesting O
that O
the O
former O
exhibits O
greater O
sensitivity O
toward O
cadmium B
exposure O
. O

Vinblastine B
( O
Vin O
) O
was O
employed O
to O
select O
for O
a O
Vin O
- O
resistant O
HCV O
replicon O
( O
313 O
- O
11 O
) O
from O
the O
parental O
cell O
line O
( O
377 O
- O
2 O
) O
. O

Addition O
of O
the O
P O
- O
gp O
inhibitor O
, O
tariquidar B
, O
increased O
the O
uptake O
of O
a O
radiolabeled O
HCV O
replication O
inhibitor O
by O
14 O
- O
fold O
in O
the O
313 O
- O
11 O
replicon O
cell O
line O
. O

Multifunctional O
targets O
of O
dietary O
polyphenols B
in O
disease O
: O
a O
case O
for O
the O
chemokine O
network O
and O
energy O
metabolism O
. O

The O
CCL2 O
/ O
CCR2 O
pathway O
and O
the O
energy O
sensor O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
are O
attractive O
therapeutic O
targets O
as O
a O
part O
of O
preventive O
management O
of O
disease O
. O

Several O
effects O
of O
polyphenols B
are O
useful O
in O
this O
scenario O
, O
including O
a O
reduction O
in O
the O
activities O
of O
cytokines O
and O
modulation O
of O
cellular O
metabolism O
through O
histone O
deacetylase O
inhibitors O
, O
AMPK O
activators O
, O
calorie O
- O
restriction O
mimetics O
or O
epigenetic O
regulators O
. O

Hence O
, O
improvement O
in O
food O
through O
enrichment O
with O
polyphenols B
with O
demonstrated O
activity O
may O
represent O
a O
major O
advance O
in O
the O
design O
of O
diets O
with O
both O
industrial O
and O
sanitary O
value O
. O

In O
this O
study O
, O
an O
analytical O
method O
to O
determine O
enniatins O
A O
, O
A1 O
, O
B O
and O
B1 O
( O
ENs O
) O
, O
beauvericin B
( O
BEA O
) O
and O
fusaproliferin O
( O
FUS O
) O
based O
on O
Ultra O
- O
Turrax O
extraction O
followed O
by O
liquid O
chromatography O
coupled O
to O
triple O
quadrupole O
mass O
spectrometer O
detector O
( O
MS O
/ O
MS O
QqQ O
) O
, O
was O
applied O
for O
the O
analysis O
of O
pasta O
. O

This O
nucleus O
was O
exploited O
based O
on O
the O
well O
- O
known O
quinazoline B
core O
and O
its O
interactions O
with O
several O
protein O
kinases O
. O

Cells O
were O
exposed O
to O
contact O
allergens O
( O
2 O
- O
bromo O
- O
2 O
- O
bromomethyl O
glutaronitrile O
, O
cinnamaldehyde B
, O
citral B
, O
diethylmaleate O
, O
dinitrochlorobenzene O
, O
glyoxal B
, O
2 B
- I
mercaptobenzothiazol I
, O
nickel B
sulfate I
, O
4 O
- O
nitrobenzylbromide O
, O
oxazolone O
, O
penicillin O
G O
, O
resorcinol B
, O
tetramethylthiuram B
disulfide I
) O
, O
to O
pre O
- O
pro O
- O
haptens O
( O

cinnamyl B
alcohol I
, O
eugenol B
, O
isoeugenol B
, O
p O
- O
phenylediamine O
) O
, O
to O
respiratory O
allergens O
( O
ammonium B
hexachloroplatinate I
, O
diphenylmethane O
diisocyanate O
, O
glutaraldehyde B
, O
hexamethylenediisocy O
, O
maleic O
anhydride O
, O
trimellitic B
anhydride I
) O
and O
to O
irritants O
( O
benzaldehyde O
, O
cholorobenzene O
, O
diethylphtalate O
, O
hydrobenzoic O
acid O
, O
lactic B
acid I
, O
octanoic B
acid I
, O

phenol B
, O
salicylic B
acid I
, O
sodium O
lauryl O
sulphate O
, O
sulfamic O
acid O
) O
. O

At O
not O
- O
cytotoxic O
concentrations O
( O
cell O
viability O
higher O
of O
80 O
% O
, O
as O
assessed O
by O
MTT B
reduction O
assay O
) O
, O
all O
contact O
sensitizers O
, O
including O
pre O
- O
pro O
- O
haptens O
, O
induced O
a O
dose O
- O
related O
increase O
in O
IL O
- O
18 O
, O
whereas O
both O
irritants O
, O
with O
the O
exception O
of O
sulfamic O
acid O
, O
and O
respiratory O
allergens O
failed O
. O

Assay O
of O
vtg O
, O
ERs O
and O
PPARs O
as O
endpoint O
for O
the O
rapid O
in O
vitro O
screening O
of O
the O
harmful O
effect O
of O
Di B
- I
( I
2 I
- I
ethylhexyl I
) I
- I
phthalate I
( O
DEHP B
) O
and O
phthalic O
acid O
( O
PA O
) O
in O
zebrafish O
primary O
hepatocyte O
cultures O
. O

In O
the O
last O
years O
the O
concern O
about O
the O
negative O
effects O
of O
phthalates B
on O
reproduction O
significantly O
increased O
. O

Considering O
that O
, O
at O
date O
data O
available O
dealing O
with O
the O
adverse O
outcome O
of O
Di B
- I
( I
2 I
- I
ethylhexyl I
) I
- I
phthalate I
( O
DEHP B
) O
on O
the O
reproduction O
of O
several O
species O
are O
still O
contrasting O
, O
in O
this O
study O
, O
the O
effects O
induced O
by O
DEHP B
( O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
1 O
, O
10 O
and O
100 O
nM O
) O
and O
its O
active O
metabolite O
, O
phthalic O
acid O
( O
PA O
) O
( O
0 O
. O
01 O
, O
0 O
. O
1 O
, O
1 O
and O
10 O
mu O
M O
) O
, O
were O
analyzed O
in O
zebrafish O
, O
Danio O
rerio O
, O
primary O
hepatocyte O
cultures O
, O
using O
target O
molecules O

involved O
in O
fish O
reproduction O
( O
vitellogenin O
- O
- O
vtg O
and O
estrogen B
receptors O
- O
- O
ER O
alpha O
, O
beta O
1 O
and O
beta O
2 O
) O
and O
metabolism O
( O
peroxisome O
proliferators O
activated O
receptors O
- O
- O
PPAR O
alpha O
, O
beta O
, O
gamma O
) O
. O

Moreover O
, O
since O
many O
toxicological O
studies O
revealed O
a O
sex O
specific O
response O
to O
toxicants O
, O
male O
and O
female O
primary O
hepatocyte O
cultures O
were O
set O
up O
to O
elucidate O
the O
possible O
gender O
specific O
effects O
of O
two O
common O
environmental O
phthalates B
. O

The O
increase O
of O
vtg O
levels O
observed O
in O
the O
culture O
media O
of O
male O
or O
female O
hepatocytes O
strongly O
evidenced O
the O
phthalates B
E2 O
- O
like O
action O
. O

In O
conclusion O
, O
this O
study O
enforces O
the O
role O
of O
vtg O
as O
biomarker O
for O
evaluate O
the O
presence O
of O
environmental O
doses O
of O
DEHP B
and O
PA O
. O

Considering O
the O
similar O
gender O
modulation O
observed O
for O
vtg O
and O
PPARs O
, O
these O
molecules O
could O
be O
used O
for O
the O
rapid O
screening O
of O
the O
presence O
of O
DEHP B
and O
PA O
. O

Noteworthy O
the O
gender O
specific O
modulation O
observed O
for O
ERs O
opens O
a O
debate O
on O
the O
estrogenic O
mechanism O
of O
action O
of O
DEHP B
and O
PA O
and O
their O
role O
on O
vtg O
induction O
. O

NFD O
abrogated O
EGF O
- O
induced O
phosphorylation O
of O
EGF O
receptor O
( O
EGFR O
) O
and O
phosphatidylinositol B
3 O
- O
kinase O
( O
PI3K O
) O
/ O
Akt O
. O

The O
specific O
PI3K O
inhibitor O
, O
wortmannin B
, O
blocked O
significantly O
EGF O
- O
induced O
cell O
migration O
and O
invasion O
. O

Furthermore O
, O
the O
EGFR O
inhibitor O
AG1478 B
inhibited O
EGF O
- O
induced O
MMP O
- O
9 O
expression O
, O
cell O
migration O
and O
invasion O
, O
as O
well O
as O
the O
activation O
of O
PI3K O
/ O
Akt O
, O
suggesting O
that O
PI3K O
/ O
Akt O
activation O
occur O
downstream O
of O
EGFR O
activation O
. O

The O
association O
of O
serum O
25 B
- I
hydroxyvitamin I
D I
and O
vertebral O
fractures O
in O
patients O
with O
type O
2 O
diabetes O
. O

Vitamin B
D I
is O
an O
important O
regulator O
of O
bone O
health O
. O

Previous O
studies O
examining O
the O
association O
between O
vitamin B
D I
deficiency O
and O
osteoporotic O
fractures O
have O
reported O
conflicting O
results O
. O

The O
relationship O
between O
vitamin B
D I
status O
and O
risk O
of O
vertebral O
fractures O
in O
diabetic O
patients O
is O
unknown O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
whether O
low O
serum O
25 B
- I
hydroxyvitamin I
D I
[ O
25 O
( O
OH O
) O
D O
] O
levels O
were O
associated O
with O
vertebral O
fractures O
in O
patients O
with O
type O
2 O
diabetes O
. O

However O
, O
there O
was O
no O
significant O
association O
between O
vitamin B
D I
status O
and O
the O
prevalence O
of O
vertebral O
fractures O
in O
women O
( O
14 O
. O
4 O
% O
vs O
. O
19 O
. O
2 O
% O
vs O
. O
26 O
. O
6 O
% O
, O
p O
for O
trend O
= O
0 O
. O
111 O
) O
. O

Ketamine B
- O
induced O
neuronal O
damage O
and O
altered O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
function O
in O
rat O
primary O
forebrain O
culture O
. O

Ketamine B
, O
a O
noncompetitive O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonist O
, O
is O
frequently O
used O
in O
pediatric O
general O
anesthesia O
. O

Accumulating O
evidence O
from O
animal O
experiments O
has O
demonstrated O
that O
ketamine B
causes O
neuronal O
cell O
death O
during O
the O
brain O
growth O
spurt O
. O

To O
elucidate O
the O
underlying O
mechanisms O
associated O
with O
ketamine B
- O
induced O
neuronal O
toxicity O
and O
search O
for O
approaches O
or O
agents O
to O
prevent O
ketamine B
' O
s O
adverse O
effects O
on O
the O
developing O
brain O
, O
a O
primary O
nerve O
cell O
culture O
system O
was O
utilized O
. O

Neurons O
harvested O
from O
the O
forebrain O
of O
newborn O
rats O
were O
maintained O
under O
normal O
control O
conditions O
or O
exposed O
to O
either O
ketamine B
( O
10 O
micro O
M O
) O
or O
ketamine B
plus O
L B
- I
carnitine I
( O
an O
antioxidant O
; O
1 O
- O
100 O
micro O
M O
) O
for O
24h O
, O
followed O
by O
a O
24 O
- O
h O
withdrawal O
period O
. O

Ketamine B
exposure O
resulted O
in O
elevated O
NMDA B
receptor O
( O
NR1 O
) O
expression O
, O
increased O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
as O
indicated O
by O
higher O
levels O
of O
8 B
- I
oxoguanine I
production O
, O
and O
enhanced O
neuronal O
damage O
. O

Coadministration O
of O
L B
- I
carnitine I
significantly O
diminished O
ROS O
generation O
and O
provided O
near O
complete O
protection O
of O
neurons O
from O
ketamine B
- O
induced O
cell O
death O
. O

NMDA B
receptors O
regulate O
channels O
that O
are O
highly O
permeable O
to O
calcium B
, O
and O
calcium B
imaging O
data O
demonstrated O
that O
neurons O
exposed O
to O
ketamine B
had O
a O
significantly O
elevated O
amplitude O
of O
calcium B
influx O
and O
higher O
intracellular O
free O
calcium B
concentrations O
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
evoked O
by O
NMDA B
( O
50 O
micro O
M O
) O
, O
compared O
with O
control O
neurons O
. O

These O
findings O
suggest O
that O
prolonged O
ketamine B
exposure O
produces O
an O
increase O
in O
NMDA B
receptor O
expression O
( O
compensatory O
upregulation O
) O
, O
which O
allows O
for O
a O
higher O
/ O
toxic O
influx O
of O
calcium B
into O
neurons O
once O
ketamine B
is O
removed O
from O
the O
system O
, O
leading O
to O
elevated O
ROS O
generation O
and O
neuronal O
cell O
death O
. O

L B
- I
Carnitine I
appears O
to O
be O
a O
promising O
agent O
in O
preventing O
or O
reversing O
ketamine B
' O
s O
toxic O
effects O
on O
neurons O
at O
an O
early O
developmental O
stage O
. O

Resonance O
Raman O
spectral O
imaging O
of O
intracellular O
uptake O
of O
beta B
- I
carotene I
loaded O
poly O
( O
D O
, O
L O
- O
lactide O
- O
co O
- O
glycolide O
) O
nanoparticles O
. O

For O
this O
purpose O
, O
the O
particles O
were O
loaded O
with O
beta B
- I
carotene I
. O

beta B
- I
Carotene I
as O
a O
provitamin O
is O
not O
soluble O
in O
water O
and O
is O
thus O
usually O
of O
low O
bioavailability O
, O
which O
is O
enhanced O
by O
encapsulation O
into O
the O
nanoparticles O
. O

Activation O
of O
group O
I O
metabotropic O
glutamate B
receptors O
potentiates O
heteromeric O
kainate B
receptors O
. O

Kainate B
receptors O
( O
KARs O
) O
, O
a O
family O
of O
ionotropic O
glutamate B
receptors O
, O
are O
widely O
expressed O
in O
the O
central O
nervous O
system O
and O
are O
critically O
involved O
in O
synaptic O
transmission O
. O

KAR O
activation O
is O
influenced O
by O
metabotropic O
glutamate B
receptor O
( O
mGlu O
) O
signaling O
, O
but O
the O
underlying O
mechanisms O
are O
not O
understood O
. O

In O
hippocampal O
and O
cortical O
cultures O
, O
the O
calcium B
signal O
caused O
by O
activation O
of O
native O
KARs O
was O
potentiated O
by O
activation O
of O
group O
I O
mGlu O
receptors O
. O

The O
potentiation O
of O
heteromeric O
KARs O
by O
mGlu1 O
activation O
was O
attenuated O
by O
GDP O
beta O
S O
, O
blocked O
by O
an O
inhibitor O
of O
phospholipase O
C O
or O
the O
calcium B
chelator O
1 O
, O
2 O
- O
bis O
( O
o O
- O
aminophenoxy O
) O
ethane O
- O
N O
, O
N O
, O
N O
' O
, O
N O
' O
- O
tetraacetic O
acid O
( O
BAPTA B
) O
, O
prolonged O
by O
the O
phosphatase O
inhibitor O
okadaic O
acid O
, O
but O
unaffected O
by O
the O
tyrosine B
kinase O
inhibitor O
lavendustin O
A O
. O

Protein O
kinase O
C O
( O
PKC O
) O
inhibition O
reduced O
the O
potentiation O
by O
mGlu1 O
of O
GluK2 O
/ O
GluK5 O
, O
and O
conversely O
, O
direct O
activation O
of O
PKC O
by O
phorbol B
12 I
- I
myristate I
, I
13 I
- I
acetate I
potentiated O
GluK2 O
/ O
GluK5 O
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
identified O
three O
serines O
( O
Ser833 O
, O
Ser836 O
, O
and O
Ser840 O
) O
within O
the O
membrane O
proximal O
region O
of O
the O
GluK5 O
C B
- O
terminal O
domain O
that O
, O
in O
combination O
, O
are O
required O
for O
mGlu1 O
- O
mediated O
potentiation O
of O
KARs O
. O

Together O
, O
these O
data O
suggest O
that O
phosphorylation O
of O
key O
residues O
in O
the O
C B
- O
terminal O
domain O
changes O
the O
overall O
charge O
of O
this O
domain O
, O
resulting O
in O
potentiated O
agonist O
responses O
. O

beta O
- O
Adrenergic O
agonists O
mediate O
enhancement O
of O
beta O
1 O
- O
adrenergic O
receptor O
N B
- O
terminal O
cleavage O
and O
stabilization O
in O
vivo O
and O
in O
vitro O
. O

Previously O
, O
we O
have O
shown O
that O
the O
human O
( O
h O
) O
beta O
( O
1 O
) O
AR O
is O
cleaved O
in O
its O
N B
terminus O
by O
a O
metalloproteinase O
, O
both O
constitutively O
and O
in O
a O
receptor O
activation O
- O
dependent O
manner O
. O

By O
using O
flow O
cytometry O
and O
Western O
blotting O
, O
we O
demonstrated O
that O
isoproterenol B
, O
S O
- O
propranolol O
, O
CGP O
- O
12177 O
[ O
4 O
- O
[ O
3 O
- O
[ O
( O
1 O
, O
1 O
- O
dimethylethyl O
) O
amino O
] O
2 O
- O
hydroxypropoxy O
] O
- O
1 O
, O
3 O
- O
dihydro O
- O
2H O
- O
benzimidazol O
- O
2 O
- O
one O
] O
, O
pindolol O
, O
and O
timolol B
, O
which O
displayed O
agonistic O
properties O
toward O
the O
beta O
( O
1 O
) O
AR O
in O
either O
the O
adenylyl B
cyclase O
or O

The O
orphan O
nuclear O
receptor O
estrogen B
- O
related O
receptor O
alpha O
( O
ERR O
alpha O
) O
directs O
the O
transcription O
of O
nuclear O
genes O
involved O
in O
energy O
homeostasis O
control O
and O
the O
regulation O
of O
mitochondrial O
mass O
and O
function O
. O

Cell O
treatment O
with O
the O
nuclear O
export O
inhibitor O
leptomycin O
B O
did O
not O
prevent O
AM251 O
- O
induced O
destabilization O
of O
ERR O
alpha O
protein O
, O
whereas O
proteasome O
inhibition O
with O
MG132 B
stabilized O
and O
maintained O
its O
DNA O
- O
binding O
function O
, O
indicative O
of O
ERR O
alpha O
being O
a O
target O
of O
nuclear O
proteasomal O
complexes O
. O

AM251 O
induced O
SUMO O
- O
2 O
, O
3 O
incorporation O
in O
ERR O
alpha O
in O
conjunction O
with O
increased O
protein O
kinase O
C O
activity O
, O
whose O
activation O
by O
phorbol B
ester I
also O
promoted O
ERR O
alpha O
protein O
loss O
. O

Metformin B
directly O
inhibits O
ghrelin O
secretion O
through O
AMP B
- O
activated O
protein O
kinase O
in O
rat O
primary O
gastric O
cells O
. O

The O
antidiabetic O
drug O
Metformin B
causes O
weight O
loss O
in O
both O
diabetic O
and O
non O
- O
diabetic O
individuals O
. O

Metformin B
treatment O
is O
also O
associated O
with O
lower O
circulating O
levels O
of O
the O
orexigenic O
hormone O
ghrelin O
. O

To O
test O
whether O
Metformin B
directly O
affects O
ghrelin O
cells O
, O
rat O
primary O
stomach O
cells O
were O
treated O
with O
Metformin B
and O
the O
levels O
of O
ghrelin O
secretion O
, O
proghrelin O
gene O
expression O
and O
activation O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
were O
examined O
. O

Metformin B
significantly O
reduced O
ghrelin O
secretion O
and O
proghrelin O
mRNA O
production O
and O
both O
these O
effects O
were O
blocked O
by O
co O
- O
incubation O
with O
the O
AMPK O
inhibitor O
compound O
C O
. O

Finally O
, O
Metformin B
treatment O
caused O
a O
significant O
increase O
in O
the O
level O
of O
phosphorylated O
( O
active O
) O
AMPK O
. O

Our O
results O
show O
that O
Metformin B
directly O
inhibits O
stomach O
ghrelin O
production O
and O
secretion O
through O
AMPK O
. O

This O
reduction O
in O
ghrelin O
secretion O
may O
be O
one O
of O
the O
key O
components O
in O
Metformin B
' O
s O
mechanism O
of O
weight O
loss O
. O

In O
EPD O
, O
TiO B
( I
2 I
) I
nanoparticles O
were O
used O
to O
enhance O
the O
surface O
energy O
and O
create O
nanoporous O
structures O
, O
while O
BDA O
was O
employed O
to O
produce O
microporous O
structures O
. O

Voluntary O
exercise O
does O
not O
ameliorate O
spatial O
learning O
and O
memory O
deficits O
induced O
by O
chronic O
administration O
of O
nandrolone B
decanoate I
in O
rats O
. O

Chronic O
exposure O
to O
the O
anabolic O
androgenic O
steroids B
( O
AAS O
) O
nandrolone B
decanoate I
( O
ND O
) O
in O
supra O
- O
physiological O
doses O
is O
associated O
with O
learning O
and O
memory O
impairments O
. O

Rosiglitazone B
disrupts O
endosteal O
bone O
formation O
during O
distraction O
osteogenesis O
by O
local O
adipocytic O
infiltration O
. O

Rosiglitazone B
( O
Rosi O
) O
is O
a O
drug O
in O
the O
thiazolidinedione B
class O
for O
treatment O
of O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
, O
which O
binds O
and O
activates O
PPAR O
gamma O
nuclear O
receptor O
in O
fat O
cells O
, O
sensitizing O
them O
to O
insulin O
. O

Rosi O
treatment O
decreased O
levels O
of O
non O
- O
fasted O
glucose B
and O
insulin O
and O
improved O
insulin O
sensitivity O
in O
the O
A O
( O
vy O
) O
/ O
a O
mice O
, O
but O
had O
no O
effect O
in O
a O
/ O
a O
mice O
, O
indicating O
antidiabetic O
efficacy O
of O
Rosi O
at O
the O
tested O
dose O
. O

Perfluorooctane B
sulfonate I
( O
PFOS B
) O
affects O
hormone O
receptor O
activity O
, O
steroidogenesis O
, O
and O
expression O
of O
endocrine O
- O
related O
genes O
in O
vitro O
and O
in O
vivo O
. O

Perfluorooctane B
sulfonate I
( O
PFOS B
) O
is O
a O
widespread O
and O
persistent O
chemical O
in O
the O
environment O
. O

We O
investigated O
the O
endocrine O
- O
disrupting O
effects O
of O
PFOS B
using O
a O
combination O
of O
in O
vitro O
and O
in O
vivo O
assays O
. O

Reporter O
gene O
assays O
were O
used O
to O
detect O
receptor O
- O
mediated O
( O
anti O
- O
) O
estrogenic O
, O
( O
anti O
- O
) O
androgenic O
, O
and O
( O
anti O
- O
) O
thyroid B
hormone I
activities O
. O

The O
effect O
of O
PFOS B
on O
steroidogenesis O
was O
assessed O
both O
at O
hormone O
levels O
in O
the O
supernatant O
and O
at O
expression O
levels O
of O
hormone O
- O
induced O
genes O
in O
the O
H295R O
cell O
. O

A O
zebrafish O
- O
based O
short O
- O
term O
screening O
method O
was O
developed O
to O
detect O
the O
effect O
of O
PFOS B
on O
endocrine O
function O
in O
vivo O
. O

The O
results O
indicate O
that O
PFOS B
can O
act O
as O
an O
estrogen B
receptor O
agonist O
and O
thyroid B
hormone I
receptor O
antagonist O
. O

Exposure O
to O
PFOS B
decreased O
supernatant O
testosterone B
( O
T O
) O
, O
increased O
estradiol B
( O
E2 O
) O
concentrations O
in O
H295R O
cell O
medium O
and O
altered O
the O
expression O
of O
several O
genes O
involved O
in O
steroidogenesis O
. O

In O
addition O
, O
PFOS B
increased O
early O
thyroid O
development O
gene O
( O
hhex O
and O
pax8 O
) O
expression O
in O
a O
concentration O
- O
dependent O
manner O
, O
decreased O
steroidogenic O
enzyme O
gene O
( O
CYP17 O
, O
CYP19a O
, O
CYP19b O
) O
expression O
, O
and O
changed O
the O
expression O
pattern O
of O
estrogen B
receptor O
production O
genes O
( O
esr1 O
, O
esr2b O
) O
after O
500 O
micro O
g O
/ O
L O
PFOS B
treatment O
in O
zebrafish O
embryos O
. O

These O
results O
indicate O
that O
PFOS B
has O
the O
ability O
to O
act O
as O
an O
endocrine O
disruptor O
both O
in O
vitro O
and O
in O
vivo O
by O
disrupting O
the O
function O
of O
nuclear O
hormone O
receptors O
, O
interfering O
with O
steroidogenesis O
, O
and O
altering O
the O
expression O
of O
endocrine O
- O
related O
genes O
in O
zebrafish O
embryo O
. O

Unchanged O
drug O
and O
a O
carboxylate B
metabolite O
( O
M1 O
) O
were O
the O
major O
components O
in O
plasma O
, O
accounting O
for O
66 O
. O
0 O
and O
23 O
. O
4 O
% O
of O
total O
plasma O
radioactivity O
area O
under O
the O
curve O
, O
respectively O
. O

Gold O
hollow O
nanospheres O
( O
AuHSs O
) O
and O
gold O
hollow O
nanocubes O
( O
AuHCs O
) O
were O
synthesized O
by O
the O
galvanic O
replacement O
technique O
using O
silver B
nano O
templates O
. O

This O
value O
decreases O
for O
both O
shapes O
when O
the O
nanoparticles O
are O
assembled O
on O
a O
quartz B
substrate O
by O
using O
the O
Langmuir O
- O
Blodgett O
technique O
. O

The O
calculation O
also O
showed O
that O
the O
plasmon O
field O
distributions O
of O
both O
AuHCs O
and O
AuHSs O
were O
distorted O
by O
the O
quartz B
substrate O
in O
a O
different O
manner O
. O

It O
is O
also O
observed O
that O
the O
surface O
- O
enhanced O
Raman O
spectrum O
of O
thiophenol B
is O
stronger O
when O
measured O
on O
AuHCs O
than O
on O
AuHSs O
. O

Noncanonical O
suppression O
of O
GH O
- O
dependent O
isoforms O
of O
cytochrome O
P450 O
by O
the O
somatostatin B
analog O
octreotide O
. O

Octreotide O
is O
a O
potent O
somatostatin B
analog O
therapeutically O
used O
to O
treat O
several O
conditions O
including O
hyper O
GH O
secretion O
in O
patients O
with O
acromegaly O
. O

Agonists O
and O
positive O
allosteric O
modulators O
( O
PAMs O
) O
of O
alpha O
7 O
nicotinic O
acetylcholine B
receptors O
( O
nAChRs O
) O
are O
currently O
being O
considered O
as O
novel O
therapeutic O
approaches O
for O
managing O
cognitive O
deficits O
in O
schizophrenia O
and O
Alzheimer O
' O
s O
disease O
. O

We O
tested O
two O
types O
of O
PAMS O
, O
type O
I O
( O
NS1738 O
) O
and O
type O
II O
( O
PNU B
- I
120596 I
) O
in O
carrageenan O
- O
induced O
inflammatory O
pain O
and O
chronic O
constriction O
injury O
( O
CCI O
) O
neuropathic O
pain O
models O
. O

We O
found O
that O
both O
NS1738 O
and O
PNU B
- I
120596 I
significantly O
reduced O
thermal O
hyperalgesia O
, O
while O
only O
PNU B
- I
120596 I
significantly O
reduced O
edema O
caused O
by O
a O
hind O
paw O
infusion O
of O
carrageenan O
. O

Importantly O
, O
PNU B
- I
120596 I
reversed O
established O
thermal O
hyperalgesia O
and O
edema O
induced O
by O
carrageenan O
. O

In O
the O
CCI O
model O
, O
PNU B
- I
120596 I
had O
long O
- O
lasting O
( O
up O
to O
6 O
h O
) O
, O
dose O
- O
dependent O
anti O
- O
hyperalgesic O
and O
anti O
- O
allodynic O
effects O
after O
a O
single O
injection O
, O
while O
NS1738 O
was O
inactive O
. O

Systemic O
administration O
of O
the O
alpha O
7 O
nAChR O
antagonist O
MLA B
reversed O
PNU B
- I
120596 I
' O
s O
effects O
, O
suggesting O
the O
involvement O
of O
central O
and O
peripheral O
alpha O
7 O
nAChRs O
. O

Furthermore O
, O
PNU B
- I
120596 I
enhanced O
an O
ineffective O
dose O
of O
selective O
agonist O
PHA O
- O
543613 O
to O
produce O
anti O
- O
allodynic O
effects O
in O
the O
CCI O
model O
. O

Our O
results O
indicate O
that O
the O
type O
II O
alpha O
7 O
nAChRs O
PAM O
PNU B
- I
120596 I
, O
but O
not O
the O
type O
I O
alpha O
7 O
nAChRs O
PAM O
NS1738 O
, O
shows O
significant O
anti O
- O
edematous O
and O
anti O
- O
allodynic O
effects O
in O
inflammatory O
and O
CCI O
pain O
models O
in O
mice O
. O

Tandem O
inverse O
- O
electron O
- O
demand O
hetero O
- O
/ O
retro O
- O
Diels O
- O
Alder O
reactions O
for O
aromatic O
nitrogen B
heterocycle O
synthesis O
. O

The O
merged O
inverse O
- O
electron O
- O
demand O
hetero O
- O
Diels O
- O
Alder O
( O
ihDA O
) O
/ O
retro O
- O
Diels O
- O
Alder O
( O
rDA O
) O
reaction O
sequence O
can O
be O
used O
to O
rapidly O
synthesise O
highly O
functionalised O
nitrogen B
heteroaromatics O
. O

Some O
of O
these O
, O
like O
dichlorvos B
, O
induced O
multiple O
stress O
genes O
in O
a O
concentration O
- O
dependent O
manner O
. O

Unusually O
, O
endosulfan B
induced O
only O
one O
gene O
( O
cyp O
- O
34A9 O
) O
to O
very O
high O
levels O
( O
8 O
- O
10 O
- O
fold O
) O
even O
at O
the O
lowest O
test O
concentration O
, O
with O
a O
clear O
plateau O
at O
higher O
doses O
. O

Other O
pesticides O
, O
like O
diuron O
, O
did O
not O
alter O
reporter O
gene O
expression O
detectably O
even O
at O
the O
highest O
test O
concentration O
attainable O
, O
while O
others O
( O
such O
as O
glyphosate B
) O
did O
so O
only O
at O
very O
high O
concentrations O
. O

Soluble O
organic O
contaminants O
present O
in O
the O
pore O
water O
were O
extracted O
with O
acetone B
and O
dichloromethane B
, O
then O
after O
evaporation O
of O
the O
solvents O
, O
the O
organic O
residues O
were O
redissolved O
in O
ultrapure O
water O
to O
reconstitute O
the O
soluble O
organic O
components O
of O
the O
original O
soil O
pore O
water O
. O

Primary O
aldosteronism O
( O
PA O
) O
is O
one O
of O
the O
commonest O
forms O
of O
curable O
hypertension O
, O
and O
use O
of O
the O
plasma O
aldosterone B
- O
to O
- O
renin O
ratio O
as O
a O
screening O
test O
has O
led O
to O
a O
more O
efficient O
identification O
of O
this O
condition O
. O

Both O
animal O
and O
human O
studies O
have O
indicated O
that O
PA O
is O
associated O
with O
a O
variety O
of O
cardiovascular O
and O
renal O
complications O
that O
reflect O
the O
capability O
of O
elevated O
aldosterone B
to O
induce O
tissue O
damage O
exceeding O
that O
induced O
by O
hypertension O
itself O
. O

Unilateral O
adrenalectomy O
or O
administration O
of O
mineralocorticoid O
receptor O
antagonists O
are O
the O
current O
options O
for O
treating O
an O
aldosterone B
- O
producing O
adenoma O
or O
idiopathic O
adrenal O
hyperplasia O
. O

Bis O
( O
12 O
) O
- O
hupyridone O
, O
a O
novel O
acetylcholinesterase O
inhibitor O
, O
protects O
against O
glutamate B
- O
induced O
neuronal O
excitotoxicity O
via O
activating O
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
/ O
phosphoinositide B
3 O
- O
kinase O
/ O
Akt O
cascade O
. O

Bis O
( O
12 O
) O
- O
hupyridone O
( O
B12H O
) O
, O
derived O
from O
the O
Chinese O
medicinal O
component O
huperzine B
A I
, O
was O
originally O
designed O
as O
a O
novel O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
. O

In O
this O
paper O
, O
we O
report O
that O
B12H O
( O
24 O
- O
h O
pretreatment O
) O
effectively O
blocked O
glutamate B
- O
induced O
neuronal O
excitotoxicity O
in O
cerebellar O
granule O
neurons O
( O
CGNs O
) O
. O

However O
, O
the O
huge O
discrepancy O
between O
the O
EC50 O
value O
and O
IC50 O
value O
of O
B12H O
, O
to O
protect O
against O
neuronal O
toxicity O
( O
0 O
. O
09 O
mu O
M O
) O
and O
to O
block O
the O
NMDA B
receptor O
( O
21 O
. O
8 O
mu O
M O
) O
respectively O
, O
suggests O
that O
the O
neuroprotection O
of O
B12H O
might O
be O
not O
primarily O
due O
to O
the O
blockade O
of O
the O
NMDA B
receptor O
. O

Pretreatment O
by O
specific O
antagonists O
of O
alpha7 O
- O
nicotinic O
acetylcholine B
receptor O
( O
alpha O
7nAChR O
) O
, O
but O
not O
muscarinic O
acetylcholine B
receptor O
( O
mAChR O
) O
or O
alpha O
4 O
beta O
2nAChR O
, O
decreased O
the O
neuroprotection O
of O
B12H O
. O

Furthermore O
, O
B12H O
restored O
the O
suppressed O
activation O
of O
the O
Akt O
pathway O
caused O
by O
glutamate B
as O
evidenced O
by O
the O
decreased O
expressions O
of O
pSer473 O
- O
Akt O
and O
pSer9 O
- O
GSK3 O
beta O
. O

All O
these O
results O
suggest O
that O
B12H O
substantially O
protected O
CGNs O
against O
glutamate B
- O
induced O
neuronal O
excitotoxicity O
via O
activating O
alpha O
7nAChR O
/ O
PI3 O
- O
K O
/ O
Akt O
cascade O
. O

Finally O
, O
we O
observed O
that O
Ts2 O
or O
Ts6 O
injection O
in O
5 O
- O
lipoxygenase O
( O
LO O
) O
deficient O
mice O
and O
in O
wild O
type O
( O
WT O
) O
129sv O
mice O
pre O
- O
treated O
with O
LTs O
and O
PGs O
inhibitors O
( O
MK O
- O
886 O
and O
celecoxib B
, O
respectively O
) O
a O
reduction O
the O
influx O
of O
leukocytes O
occurs O
in O
comparison O
to O
WT O
. O

Growth O
differentiation O
factor O
15 O
stimulates O
rapamycin B
- O
sensitive O
ovarian O
cancer O
cell O
growth O
and O
invasion O
. O

Further O
, O
proliferation O
, O
growth O
, O
and O
invasion O
of O
GDF15 O
stable O
clones O
were O
blocked O
by O
rapamycin B
. O

These O
data O
indicate O
that O
GDF15 O
over O
- O
expression O
, O
which O
occurred O
in O
a O
majority O
of O
human O
ovarian O
cancers O
, O
promoted O
rapamycin B
- O
sensitive O
invasion O
and O
growth O
of O
ovarian O
cancer O
cells O
. O

In O
addition O
, O
the O
effect O
of O
a O
new O
polymeric O
excipient O
Soluplus B
( O
R O
) O
( O
polyvinyl O
caprolactam O
- O
polyvinyl O
acetate O
- O
polyethylene O
glycol O
graft O
copolymer O
) O
on O
oral O
bioavailability O
of O
piroxicam O
was O
investigated O
. O

The O
use O
of O
Soluplus B
( O
R O
) O
was O
found O
to O
enhance O
the O
dissolution O
and O
oral O
bioavailability O
of O
piroxicam O
in O
rats O
. O

Fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptor O
activation O
in O
TE O
- O
671 O
cells O
and O
inhibition O
of O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
by O
optical O
isomers O
of O
the O
piperidine O
alkaloid O
coniine O
. O

Coniine O
is O
an O
optically O
active O
toxic O
piperidine O
alkaloid O
and O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
agonist O
found O
in O
poison O
hemlock O
( O
Conium O
maculatum O
L O
. O
) O
. O

The O
present O
study O
compared O
( O
- O
) O
- O
coniine O
, O
( O
+ O
) O
- O
coniine O
, O
and O
nicotine B
for O
the O
ability O
to O
inhibit O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
and O
in O
TE O
- O
671 O
cells O
that O
express O
fetal O
muscle O
- O
type O
nAChR O
. O

The O
pyridine B
alkaloid I
nicotine B
did O
not O
inhibit O
fetal O
movement O
in O
a O
day O
40 O
pregnant O
goat O
model O
, O
suggesting O
agonist O
specificity O
for O
the O
inhibition O
of O
fetal O
movement O
. O

Systematic O
modifications O
of O
two O
torsion O
angles O
leading O
to O
324 O
and O
144 O
starting O
geometries O
for O
the O
compound O
I O
and O
each O
disaccharide B
were O
used O
to O
generate O
adiabatic O
maps O
using O
B3LYP O
/ O
6 O
- O
31G O
( O
d O
) O
. O

Effects O
of O
silver B
nanoparticles O
on O
the O
liver O
and O
hepatocytes O
in O
vitro O
. O

Silver B
( O
Ag B
) O
NPs O
are O
highly O
relevant O
for O
human O
exposure O
due O
to O
their O
use O
in O
food O
contact O
materials O
, O
dietary O
supplements O
, O
and O
antibacterial O
wound O
treatments O
. O

Therefore O
, O
this O
study O
used O
a O
simple O
hepatocytes O
model O
combined O
with O
an O
in O
vivo O
injection O
model O
to O
simulate O
the O
passage O
of O
a O
small O
amount O
of O
NPs O
into O
the O
bloodstream O
following O
exposure O
, O
e O
. O
g O
. O
, O
via O
ingestion O
or O
inhalation O
, O
and O
examined O
the O
potential O
of O
Ag B
NPs O
of O
20 O
nm O
diameter O
to O
cause O
toxicity O
, O
inflammation O
, O
and O
oxidative O
stress O
in O
the O
liver O
following O
in O
vivo O
exposures O
of O
female O
Wistar O
rats O
via O
iv O
injection O
to O
50 O
mu O
g O
of O
NPs O
and O
in O
vitro O
exposures O
using O
the O
human O
hepatocyte O
cell O
line O

We O
found O
that O
Ag B
NPs O
were O
highly O
cytotoxic O
to O
hepatocytes O
( O
LC O
( O
50 O
) O
lactate B
dehydrogenase O
: O
2 O
. O
5 O
mu O
g O
/ O
cm O
( O
2 O
) O
) O
and O
affected O
hepatocyte O
homeostasis O
by O
reducing O
albumin O
release O
. O

At O
sublethal O
concentrations O
with O
normal O
cell O
or O
tissue O
morphology O
, O
Ag B
NPs O
were O
detected O
in O
cytoplasm O
and O
nuclei O
of O
hepatocytes O
. O

We O
observed O
similar O
effects O
of O
Ag B
NPs O
on O
inflammatory O
mediator O
expression O
in O
vitro O
and O
in O
vivo O
with O
increase O
of O
interleukin O
- O
8 O
( O
IL O
- O
8 O
) O
/ O
macrophage O
inflammatory O
protein O
2 O
, O
IL O
- O
1RI O
, O
and O
tumor O
necrosis O
factor O
- O
alpha O
expression O
in O
both O
models O
and O
increased O
IL O
- O
8 O
protein O
release O
in O
vitro O
. O

This O
article O
presents O
evidence O
of O
the O
potential O
toxicity O
and O
inflammogenic O
potential O
of O
Ag B
NPs O
in O
the O
liver O
following O
ingestion O
. O

Comment O
on O
real O
- O
time O
observation O
on O
dynamic O
growth O
/ O
dissolution O
of O
conductive O
filaments O
in O
oxide B
- O
electrolyte O
- O
based O
ReRAM O
. O

Filament O
formation O
and O
dissolution O
in O
the O
system O
Ag O
( O
Cu O
) O
/ O
ZrO B
( I
2 I
) I
/ O
Pt B
were O
observed O
by O
Liu O
et O
al O
. O

Extracellular O
loop O
II O
modulates O
GTP B
sensitivity O
of O
the O
prostaglandin B
EP3 O
receptor O
. O

Unlike O
the O
majority O
of O
G O
protein O
- O
coupled O
receptors O
, O
the O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
E O
- O
prostanoid O
3 O
( O
EP3 O
) O
receptor O
binds O
agonist O
with O
high O
affinity O
that O
is O
insensitive O
to O
the O
presence O
of O
guanosine O
5 O
[ O
prime O
] O
- O
O O
- O
( O
3 O
- O
thio O
) O
triphosphate O
( O
GTP O
gamma O
S O
) O
. O

Seven O
point O
mutations O
were O
introduced O
into O
the O
conserved O
motif O
in O
the O
second O
extracellular O
loop O
( O
ECII O
) O
of O
EP3 O
, O
resulting O
in O
acquisition O
of O
GTP B
- O
sensitive O
agonist O
binding O
. O

Loss O
of O
agonist O
binding O
was O
observed O
on O
intact O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
W203A O
receptor O
, O
conditions O
where O
high O
GTP B
levels O
are O
present O
; O
however O
, O
high O
affinity O
binding O
[ O
( O
3 O
) O
H O
] O
PGE O
( O
2 O
) O
was O
observed O
in O
broken O
cell O
preparations O
washed O
free O
of O
GTP B
. O

Moreover O
, O
mutation O
of O
ECII O
can O
alter O
this O
coupled O
equilibrium O
from O
GTP B
- O
insensitive O
agonist O
binding O
to O
more O
conventional O
GTP B
- O
sensitive O
binding O
. O

This O
suggests O
that O
for O
the O
mutant O
receptors O
, O
ECII O
plays O
a O
critical O
role O
in O
linking O
the O
agonist O
bound O
receptor O
conformation O
to O
the O
G O
protein O
nucleotide B
bound O
state O
. O

Mesoscopic O
model O
parametrization O
of O
hydrogen B
bonds O
and O
stacking O
interactions O
of O
RNA O
from O
melting O
temperatures O
. O

Here O
, O
we O
extend O
the O
technique O
to O
RNA O
and O
show O
that O
the O
new O
parameters O
correctly O
reproduce O
known O
properties O
such O
as O
the O
stronger O
hydrogen B
bonds O
of O
AU O
base O
pairs O
. O

Additionally O
, O
we O
calculated O
the O
site O
- O
dependent O
base O
pair O
oscillation O
to O
explain O
why O
RNA O
shows O
larger O
oscillation O
amplitudes O
despite O
having O
stronger O
AU O
hydrogen B
bonds O
. O

Carbaryl B
exposure O
and O
recovery O
modify O
the O
interrenal O
and O
thyroidal O
activities O
and O
the O
mitochondria O
- O
rich O
cell O
function O
in O
the O
climbing O
perch O
Anabas O
testudineus O
Bloch O
. O

We O
examined O
the O
effects O
of O
carbaryl B
( O
1 O
- O
naphthyl O
methylcarbamate O
; O
sevin O
) O
, O
a O
carbamate B
pesticide O
, O
on O
interrenal O
and O
thyroid O
activities O
and O
mitochondrial O
rich O
( O
MR O
) O
cell O
function O
in O
climbing O
perch O
to O
understand O
the O
physiological O
basis O
of O
toxicity O
acclimation O
in O
this O
fish O
to O
the O
chemical O
stressor O
. O

Carbaryl B
exposure O
( O
5 O
- O
20 O
mg O
L O
( O
- O
1 O
) O
) O
for O
48 O
h O
increased O
cortisol B
and O
glucose B
, O
but O
decreased O
the O
T O
( O
3 O
) O
level O
without O
affecting O
T O
( O
4 O
) O
concentration O
in O
the O
plasma O
. O

These O
responses O
of O
the O
carbaryl B
- O
exposed O
fish O
were O
nullified O
and O
a O
rise O
in O
plasma O
T O
( O
4 O
) O
occurred O
in O
these O
fish O
when O
they O
were O
kept O
for O
96 O
h O
recovery O
in O
clean O
water O
. O

A O
tight O
plasma O
mineral O
control O
was O
indicated O
in O
the O
carbaryl B
- O
exposed O
fish O
as O
reflected O
by O
the O
unchanged O
plasma O
Na B
, O
K B
, O
Ca B
and O
inorganic O
phosphate B
levels O
. O

The O
ouabain B
- O
sensitive O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
- O
ATPase O
activity O
showed O
an O
increase O
in O
the O
gills O
but O
the O
intestinal O
and O
renal O
tissues O
showed O
little O
response O
to O
carbaryl B
treatment O
. O

However O
, O
substantial O
increases O
in O
the O
intestinal O
and O
renal O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
- O
ATPase O
activities O
occurred O
in O
the O
recovery O
fish O
. O

The O
MR O
cells O
in O
the O
branchial O
epithelia O
showed O
a O
strong O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
- O
ATPase O
immunoreactivity O
to O
carbaryl B
treatment O
indicating O
an O
activated O
MR O
cell O
function O
. O

The O
numerical O
MR O
cell O
density O
remained O
unchanged O
, O
but O
stretching O
of O
secondary O
gill O
lamellae O
as O
part O
of O
gill O
remodeling O
occurred O
during O
carbaryl B
exposure O
. O

The O
increased O
surface O
of O
these O
lamellae O
with O
abundant O
MR O
cells O
as O
a O
result O
of O
its O
migration O
into O
the O
lamellar O
surface O
points O
to O
marked O
structural O
and O
functional O
modifications O
of O
these O
cells O
in O
the O
carbaryl B
- O
treated O
fish O
which O
is O
likely O
to O
a O
target O
for O
carbaryl B
action O
. O

Our O
data O
thus O
provide O
evidence O
that O
carbaryl B
exposure O
and O
its O
recovery O
evoke O
interrenal O
and O
thyroid O
disruption O
in O
this O
fish O
leading O
to O
a O
modified O
osmotic O
response O
including O
an O
altered O
MR O
cell O
function O
. O

To O
address O
the O
question O
about O
costs O
of O
living O
in O
polluted O
areas O
, O
biomarkers O
linked O
to O
metabolism O
were O
measured O
in O
Pterostichus O
oblongopunctatus O
( O
Coleoptera O
: O
Carabidae O
) O
collected O
along O
two O
metal O
- O
pollution O
gradients O
in O
the O
vicinity O
of O
the O
two O
largest O
Polish O
zinc B
smelters O
: O
' O
Boles O
l O
aw O
' O
and O
' O
Miasteczko O
S O
l O
a O
skie O
' O
in O
southern O
Poland O
. O

Both O
gradients O
covered O
a O
broad O
range O
of O
Zn B
and O
Cd B
concentrations O
in O
the O
humus O
layer O
( O
109 O
- O
6151 O
and O
1 O
. O
48 O
- O
71 O
. O
4 O
mg O
kg O
( O
- O
1 O
) O
, O
respectively O
) O
and O
body O
metal O
concentrations O
increased O
with O
increasing O
soil O
metal O
concentrations O
. O

The O
whole O
- O
organism O
respiration O
rate O
was O
measured O
as O
oxygen B
consumption O
with O
Micro O
- O
Oxymax O
respirometer O
, O
and O
cellular O
energy O
consumption O
- O
as O
the O
activity O
of O
electron O
transport O
system O
, O
which O
is O
linked O
to O
cellular O
respiration O
rate O
. O

Linaclotide O
, O
a O
potent O
guanylate B
cyclase O
C O
agonist O
, O
is O
a O
therapeutic O
peptide O
approved O
in O
the O
United O
States O
for O
the O
treatment O
of O
irritable O
bowel O
syndrome O
with O
constipation O
and O
chronic O
idiopathic O
constipation O
. O

The O
disulfide B
bonds O
of O
both O
peptides O
are O
reduced O
in O
the O
small O
intestine O
, O
where O
they O
are O
subsequently O
proteolyzed O
and O
degraded O
. O

MM O
- O
419447 O
exhibits O
high O
- O
affinity O
binding O
in O
vitro O
to O
T84 O
cells O
, O
resulting O
in O
a O
significant O
, O
concentration O
- O
dependent O
accumulation O
of O
intracellular O
cyclic O
guanosine O
- O
3 O
' O
, O
5 O
' O
- O
monophosphate O
( O
cGMP B
) O
. O

In O
rat O
models O
of O
gastrointestinal O
function O
, O
orally O
dosed O
MM O
- O
419447 O
significantly O
increased O
fluid O
secretion O
into O
small O
intestinal O
loops O
, O
increased O
intraluminal O
cGMP B
, O
and O
caused O
a O
dose O
- O
dependent O
acceleration O
in O
gastrointestinal O
transit O
. O

Lanthanum O
( O
III O
) O
regulates O
the O
nitrogen B
assimilation O
in O
soybean O
seedlings O
under O
ultraviolet O
- O
B O
radiation O
. O

Here O
, O
the O
regulation O
effects O
of O
lanthanum O
( O
La O
( O
III O
) O
) O
on O
nitrogen B
assimilation O
in O
soybean O
seedlings O
( O
Glycine O
max O
L O
. O
) O
under O
ultraviolet O
- O
B O
radiation O
were O
investigated O
to O
elucidate O
the O
regulation O
mechanism O
of O
REEs O
on O
plants O
under O
UV O
- O
B O
radiation O
. O

UV O
- O
B O
radiation O
led O
to O
the O
inhibition O
in O
the O
activities O
of O
the O
key O
enzymes O
( O
nitrate B
reductase O
, O
glutamine B
synthetase O
, O
glutamate B
synthase O
) O
in O
the O
nitrogen B
assimilation O
, O
the O
decrease O
in O
the O
contents O
of O
nitrate B
and O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino B
acid I
in O
soybean O
seedlings O
. O

The O
pretreatment O
with O
20 O
mg O
L O
( O
- O
1 O
) O
La O
( O
III O
) O
could O
alleviate O
the O
effects O
of O
UV O
- O
B O
radiation O
on O
the O
activities O
of O
nitrate B
reductase O
, O
glutamine B
synthetase O
, O
glutamate B
synthase O
, O
and O
glutamate B
dehydrogenase O
, O
promoting O
amino B
acid I
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O

The O
results O
indicated O
that O
the O
pretreatment O
with O
20 O
mg O
L O
( O
- O
1 O
) O
La O
( O
III O
) O
could O
alleviate O
the O
inhibition O
of O
UV O
- O
B O
radiation O
on O
nitrogen B
assimilation O
in O
soybean O
seedlings O
. O

On O
days O
1 O
and O
8 O
, O
BALB O
/ O
c O
mice O
received O
dermal O
applications O
with O
toluene B
- I
2 I
, I
4 I
- I
diisocyanate I
( O
TDI B
) O
or O
vehicle O
( O
acetone B
olive O
oil O
) O
, O
followed O
by O
two O
ip O
injections O
of O
cyclophosphamide B
( O
CP O
, O
days O
11 O
and O
13 O
) O
, O
or O
one O
iv O
injection O
of O
antigranulocyte O
receptor O
1 O
( O
aGR1 O
, O
day O
13 O
) O
monoclonal O
antibody O
( O
mAb O
) O
, O
or O
two O
ip O
injections O
of O
Ly6G O
- O
specific O
mAb O
( O
1A8 O
, O
days O
13 O
and O
14 O
) O

On O
day O
15 O
, O
the O
mice O
were O
challenged O
( O
oropharyngeal O
administration O
) O
with O
TDI B
or O
vehicle O
. O

The O
next O
day O
, O
we O
assessed O
methacholine B
airway O
hyperreactivity O
( O
AHR O
) O
; O
bronchoalveolar O
lavage O
differential O
cell O
count O
; O
histopathology O
and O
total O
serum O
IgE O
; O
and O
auricular O
lymphocyte O
subpopulations O
and O
release O
of O
interleukin O
( O
IL O
) O
- O
2 O
, O
IL O
- O
4 O
, O
IL O
- O
10 O
, O
IL O
- O
13 O
, O
and O
gamma O
interferon O
by O
these O
lymphocytes O
. O

Injection O
of O
aGR1 O
or O
1A8 O
led O
to O
significantly O
changed O
cytokine O
release O
patterns O
in O
TDI B
- O
treated O
mice O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
fundamentals O
, O
applications O
, O
and O
recent O
advances O
of O
injectable O
thermosensitive O
hydrogel O
as O
DDSs O
, O
including O
chitosan O
and O
related O
derivatives O
, O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
based O
( O
PNIPAAM B
) O
copolymers O
, O
poly B
( I
ethylene I
oxide I
) I
/ O
poly O
( O
propylene O
oxide O
) O
( O
PEO B
/ O
PPO O
) O
copolymers O
and O
its O
derivatives O
, O
and O
poly B
( I
ethylene I
glycol I
) I
/ O
biodegradable O
polyester B
copolymers O
. O

OBF O
regulation O
can O
be O
improved O
by O
magnesium B
, O
calcium B
channel O
blockers O
as O
well O
as O
with O
carbonic O
anhydrase O
inhibitors O
. O

Upregulation O
of O
phagocyte O
- O
like O
NADPH B
oxidase O
by O
cytokines O
in O
pancreatic O
beta O
- O
cells O
: O
attenuation O
of O
oxidative O
and O
nitrosative O
stress O
by O
2 O
- O
bromopalmitate O
. O

Phagocyte O
- O
like O
NADPH B
oxidase O
( O
Nox2 O
) O
has O
been O
shown O
to O
play O
regulatory O
roles O
in O
the O
metabolic O
dysfunction O
of O
the O
islet O
beta O
- O
cell O
under O
the O
duress O
of O
glucolipotoxic O
conditions O
and O
exposure O
to O
proinflammatory O
cytokines O
. O

2 O
- O
Bromopalmitate O
( O
2 O
- O
BP O
) O
, O
a O
known O
inhibitor O
of O
protein O
palmitoylation O
, O
markedly O
attenuated O
cytokine O
- O
induced O
, O
Nox2 O
- O
mediated O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
and O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
- O
mediated O
nitric B
oxide I
( O
NO B
) O
generation O
. O

Together O
, O
our O
findings O
identify O
palmitoyltransferase O
as O
a O
target O
for O
inhibition O
of O
cytomix O
- O
induced O
oxidative O
( O
ROS O
generation O
) O
and O
nitrosative O
( O
NO B
generation O
) O
stress O
in O
the O
pancreatic O
beta O
- O
cell O
. O

The O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
is O
a O
serine B
/ O
threonine B
kinase O
that O
in O
the O
brain O
, O
regulates O
several O
important O
physiological O
functions O
such O
as O
neuronal O
development O
and O
synaptic O
plasticity O
, O
and O
also O
seems O
to O
be O
involved O
in O
many O
pathologies O
, O
including O
epilepsy O
and O
psychiatric O
disorders O
. O

Here O
, O
we O
investigated O
for O
the O
first O
time O
, O
the O
effect O
of O
some O
treatment O
schedules O
( O
i O
. O
e O
. O
early O
chronic O
, O
sub O
- O
chronic O
and O
acute O
) O
with O
the O
specific O
mTOR O
inhibitor O
rapamycin B
, O
on O
the O
development O
of O
absence O
seizures O
and O
seizure O
parameters O
as O
well O
as O
depressive O
- O
like O
behavior O
in O
WAG O
/ O
Rij O
rats O
, O
a O
genetic O
model O
of O
absence O
epilepsy O
, O
epileptogenesis O
and O
mild O
- O
depression O
comorbidity O
. O

In O
addition O
, O
we O
studied O
the O
possible O
interaction O
between O
rapamycin B
treatment O
and O
the O
effects O
of O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
endotoxin O
administration O
, O
which O
is O
known O
to O
aggravate O
absence O
seizures O
through O
generation O
of O
increased O
neuroinflammatory O
responses O
. O

We O
found O
that O
rapamycin B
( O
early O
chronic O
treatment O
for O
17 O
weeks O
, O
starting O
at O
P45 O
) O
exhibited O
clear O
antiepileptogenic O
properties O
also O
in O
this O
animal O
epilepsy O
model O
; O
however O
, O
this O
effect O
was O
accompanied O
by O
unexpected O
prodepressant O
effects O
. O

The O
rapamycin B
/ O
LPS O
co O
- O
administration O
studies O
showed O
that O
rapamycin B
blocked O
or O
prevented O
the O
LPS O
- O
dependent O
increase O
in O
absence O
seizures O
, O
suggesting O
an O
anti O
- O
inflammatory O
- O
like O
protective O
action O
. O

In O
conclusion O
, O
we O
have O
demonstrated O
a O
novel O
antiepileptogenic O
effect O
of O
rapamycin B
in O
a O
well O
- O
established O
animal O
model O
of O
absence O
epilepsy O
, O
and O
we O
suggest O
that O
this O
effect O
may O
be O
mediated O
by O
the O
inhibition O
of O
inflammatory O
processes O
that O
are O
developed O
in O
the O
brain O
of O
these O
specific O
animals O
during O
epileptogenesis O
and O
during O
seizures O
. O

The O
pyridyl B
group O
in O
ligand O
design O
for O
selective O
metal O
ion O
complexation O
and O
sensing O
. O

Preorganization O
of O
polypyridyl O
ligands O
ranging O
from O
bidentate O
to O
tetradentate O
by O
bridging O
benzo O
groups O
, O
as O
are O
present O
in O
1 B
, I
10 I
- I
phenanthroline I
( O
phen O
) O
compared O
to O
2 O
, O
2 O
' O
- O
bipyridyl O
( O
bpy B
) O
, O
is O
discussed O
. O

The O
role O
of O
solvation O
is O
considered O
in O
relation O
to O
the O
relative O
affinity O
of O
ligands O
containing O
pyridyl B
groups O
for O
divalent O
and O
trivalent O
metal O
ions O
in O
aqueous O
solution O
. O

The O
effects O
of O
steric O
clashes O
between O
H B
atoms O
on O
polypyridyl O
ligands O
in O
decreasing O
complex O
stability O
are O
evaluated O
, O
as O
well O
as O
the O
effect O
of O
chelate O
ring O
size O
on O
metal O
ion O
selectivity O
. O

Phen O
ligands O
with O
other O
donor O
groups O
present O
at O
the O
2 O
and O
9 O
positions O
, O
such O
as O
alcohols B
, O
amides B
, O
carboxylates B
, O
and O
oximes B
are O
discussed O
. O

The O
design O
of O
pyridyl B
- O
based O
ligands O
for O
the O
separation O
of O
Am O
( O
III O
) O
from O
lanthanide O
( O
III O
) O
ions O
is O
considered O
, O
as O
well O
as O
ligands O
for O
the O
removal O
of O
metal O
ions O
such O
as O
Cu B
( I
II I
) I
or O
Zn B
( I
II I
) I
in O
neurological O
diseases O
such O
as O
Alzheimer O
' O
s O
. O

The O
design O
of O
pyridyl B
- O
based O
fluorescent O
sensors O
for O
selective O
sensing O
of O
metal O
ions O
is O
examined O
in O
terms O
of O
the O
role O
of O
spin O
- O
orbit O
coupling O
constants O
( O
zeta O
) O
, O
paramagnetism O
, O
and O
steric O
effects O
in O
the O
development O
of O
selective O
fluorescent O
sensors O
that O
operate O
via O
chelation O
enhanced O
fluorescence O
( O
CHEF O
) O
. O

It O
is O
concluded O
that O
for O
lighter O
metal O
ions O
with O
smaller O
zeta O
values O
such O
as O
Zn B
( I
II I
) I
and O
Ca B
( I
II I
) I
, O
and O
to O
a O
lesser O
extent O
Cd B
( I
II I
) I
, O
that O
the O
CHEF O
effect O
can O
be O
achieved O
with O
pyridyl B
- O
containing O
fluorophores O
that O
coordinate O
directly O
to O
the O
metal O
ion O
. O

The O
way O
in O
which O
steric O
effects O
can O
be O
used O
to O
decrease O
the O
CHEF O
effect O
in O
Zn B
( I
II I
) I
relative O
to O
Cd B
( I
II I
) I
to O
enable O
selective O
sensing O
of O
the O
latter O
is O
analyzed O
. O

For O
heavier O
metal O
ions O
such O
as O
Hg B
( I
II I
) I
and O
Pb B
( I
II I
) I
, O
because O
of O
their O
large O
zeta O
values O
which O
quench O
fluorescence O
, O
it O
is O
concluded O
that O
the O
fluorophore O
should O
be O
tethered O
to O
the O
metal O
- O
binding O
part O
of O
the O
sensor O
, O
and O
prevented O
from O
binding O
to O
the O
metal O
ion O
by O
steric O
and O
electronic O
factors O
. O

How O
Hg B
( I
II I
) I
can O
quench O
the O
CHEF O
effect O
by O
pi O
- O
contact O
with O
fluorophores O
such O
as O
the O
anthracenyl O
group O
, O
which O
at O
first O
sight O
might O
not O
seem O
able O
to O
bond O
with O
metal O
ions O
, O
is O
examined O
. O

Apoptosis O
initiation O
of O
beta B
- I
ionone I
in O
SGC O
- O
7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K O
- O
AKT O
pathway O
. O

beta B
- I
ionone I
has O
been O
shown O
to O
hold O
potent O
anti O
- O
proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O

To O
investigate O
the O
effects O
of O
beta B
- I
ionone I
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol B
3 O
- O
kinase O
( O
PI3K O
) O
- O
AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC O
- O
7901 O
cells O
. O

The O
results O
demonstrated O
that O
beta B
- I
ionone I
- O
induced O
apoptosis O
in O
a O
dose O
- O
dependent O
manner O
in O
SGC O
- O
7901 O
cells O
treated O
with O
beta B
- I
ionone I
( O
25 O
, O
50 O
, O
100 O
and O
200 O
mu O
mol O
/ O
L O
) O
for O
24 O
h O
. O

beta B
- I
ionone I
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved O
- O
caspase O
- O
3 O
and O
inhibit O
bcl O
- O
2 O
expression O
in O
SGC O
- O
7901 O
cells O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
significantly O
decreased O
levels O
of O
p O
- O
PI3K O
and O
p O
- O
AKT O
expression O
were O
observed O
in O
SGC O
- O
7901 O
cells O
after O
beta B
- I
ionone I
treatments O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
( O
P O
< O
0 O
. O
01 O
) O
. O

Thus O
, O
the O
apoptosis O
induction O
in O
SGC O
- O
7901 O
cells O
by O
beta B
- I
ionone I
may O
be O
regulated O
through O
a O
PI3K O
- O
AKT O
pathway O
. O

These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
beta B
- I
ionone I
to O
induce O
apoptosis O
initiation O
in O
SGC O
- O
7901 O
cells O
. O

Enhanced O
carcinogenicity O
by O
coexposure O
to O
arsenic B
and O
iron B
and O
a O
novel O
remediation O
system O
for O
the O
elements O
in O
well O
drinking O
water O
. O

Various O
carcinomas O
including O
skin O
cancer O
are O
explosively O
increasing O
in O
arsenicosis O
patients O
who O
drink O
arsenic B
- O
polluted O
well O
water O
, O
especially O
in O
Bangladesh O
. O

Although O
well O
drinking O
water O
in O
the O
cancer O
- O
prone O
areas O
contains O
various O
elements O
, O
very O
little O
is O
known O
about O
the O
effects O
of O
elements O
except O
arsenic B
on O
carcinogenicity O
. O

In O
order O
to O
clarify O
the O
carcinogenic O
effects O
of O
coexposure O
to O
arsenic B
and O
iron B
, O
anchorage O
- O
independent O
growth O
and O
invasion O
in O
human O
untransformed O
HaCaT O
and O
transformed O
A431 O
keratinocytes O
were O
examined O
. O

Since O
the O
mean O
ratio O
of O
arsenic B
and O
iron B
in O
well O
water O
was O
1 O
: O
10 O
in O
cancer O
- O
prone O
areas O
of O
Bangladesh O
, O
effects O
of O
1 O
mu O
M O
arsenic B
and O
10 O
mu O
M O
iron B
were O
investigated O
. O

Iron B
synergistically O
promoted O
arsenic B
- O
mediated O
anchorage O
- O
independent O
growth O
in O
untransformed O
and O
transformed O
keratinocytes O
. O

Iron B
additionally O
increased O
invasion O
in O
both O
types O
of O
keratinocytes O
. O

Our O
results O
suggest O
that O
iron B
promotes O
arsenic B
- O
mediated O
transformation O
of O
untransformed O
keratinocytes O
and O
progression O
of O
transformed O
keratinocytes O
. O

We O
then O
developed O
a O
low O
- O
cost O
and O
high O
- O
performance O
adsorbent O
composed O
of O
a O
hydrotalcite O
- O
like O
compound O
for O
arsenic B
and O
iron B
. O

Thus O
, O
we O
not O
only O
demonstrated O
for O
the O
first O
time O
increased O
carcinogenicity O
by O
coexposure O
to O
arsenic B
and O
iron B
but O
also O
proposed O
a O
novel O
remediation O
system O
for O
well O
drinking O
water O
. O

The O
effect O
of O
oxygen B
heteroatoms O
on O
the O
single O
molecule O
conductance O
of O
saturated O
chains O
. O

Single O
molecule O
conductance O
measurements O
on O
alkanedithiols O
and O
alkoxydithiols O
( O
dithiolated O
oligoethers O
) O
were O
performed O
using O
the O
STM O
- O
controlled O
break O
junction O
method O
in O
order O
to O
ascertain O
how O
the O
oxygen B
heteroatoms O
in O
saturated O
linear O
chains O
impact O
the O
molecular O
conductance O
. O

Comparisons O
with O
electronic O
structure O
calculations O
and O
previous O
work O
on O
alkanes B
indicate O
that O
the O
conductance O
of O
the O
oligoethers O
is O
lower O
than O
that O
of O
alkane O
chains O
with O
the O
same O
length O
. O

Efficacy O
of O
asiatic O
acid O
, O
a O
pentacyclic O
triterpene O
on O
attenuating O
the O
key O
enzymes O
activities O
of O
carbohydrate B
metabolism O
in O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

Asiatic O
acid O
( O
AA O
) O
, O
a O
triterpenoid B
derivative O
of O
Centella O
asiatica O
, O
has O
shown O
significant O
biological O
effects O
of O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O

Aim O
of O
this O
investigation O
was O
to O
evaluate O
the O
antihyperglycemic O
effect O
of O
AA O
on O
the O
activities O
of O
hepatic O
enzymes O
of O
carbohydrate B
metabolism O
in O
streptozotocin B
( O
STZ B
) O
- O
induced O
diabetic O
rats O
. O

To O
induce O
diabetes O
mellitus O
, O
rats O
were O
injected O
with O
streptozotocin B
intraperitoneally O
at O
a O
single O
dose O
of O
40 O
mg O
/ O
kg O
b O
. O
w O
. O

Diabetic O
rats O
showed O
significant O
( O
p O
< O
0 O
. O
05 O
) O
increased O
in O
plasma O
glucose B
, O
glycosylated O
hemoglobin O
and O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
in O
circulating O
insulin O
and O
hemoglobin O
. O

The O
altered O
activities O
of O
key O
enzymes O
such O
as O
glucose B
- O
6 O
- O
phosphatase O
and O
fructose B
- O
1 O
, O
6 O
- O
bisphosphatase O
of O
carbohydrate B
metabolism O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
whereas O
hexokinase O
, O
pyruvate B
kinase O
, O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
and O
glycogen O
content O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
in O
the O
liver O
of O
diabetic O
rats O
and O
also O
increased O
activities O
of O
aspartate B
transaminase O
( O
AST O
) O
, O
alanine B
transaminase O
( O
ALT O
) O
and O
alkaline O

Oral O
administration O
of O
AA O
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
and O
glibenclamide B
( O
600 O
mu O
g O
/ O
kg O
b O
. O
w O
. O
) O
to O
diabetic O
rats O
for O
45 O
days O
prevented O
the O
above O
alteration O
and O
reverted O
to O
near O
normalcy O
. O

In O
this O
search O
, O
AA O
found O
to O
be O
potential O
bioactive O
compound O
to O
regulate O
the O
carbohydrate B
metabolism O
by O
modulating O
the O
key O
regulatory O
enzymes O
in O
diabetic O
rats O
. O

Manganese B
- O
containing O
fungicides O
like O
Mancozeb O
have O
been O
associated O
with O
neurodegenerative O
conditions O
like O
Parkinson O
' O
s O
disease O
. O

The O
dopamine B
- O
mediated O
swim O
to O
crawl O
locomotory O
transition O
behavior O
is O
exquisitely O
vulnerable O
to O
Mancozeb O
, O
with O
functional O
impairment O
preceding O
markers O
of O
neuronal O
structural O
damage O
. O

The O
damage O
is O
partially O
rescued O
in O
mutants O
lacking O
the O
divalent O
metal O
transporter O
, O
SMF O
- O
1 O
, O
demonstrating O
that O
some O
, O
but O
not O
all O
, O
of O
the O
damage O
is O
mediated O
by O
manganese B
. O

Increasing O
concentrations O
of O
Mancozeb O
recruit O
additional O
behavioral O
dysfunction O
, O
notably O
serotonin B
- O
mediated O
egg O
- O
laying O
behavior O
, O
but O
without O
evident O
serotonergic O
neuronal O
structural O
damage O
. O

Moreover O
, O
new O
information O
is O
presented O
about O
the O
possible O
connection O
between O
naphthodianthrones O
and O
phenolic B
biosynthesis O
. O

Adolescent O
male O
rats O
are O
less O
sensitive O
than O
adults O
to O
the O
anxiogenic O
and O
serotonin B
- O
releasing O
effects O
of O
fenfluramine B
. O

Fenfluramine B
( O
2 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
produced O
greater O
anxiogenic O
effects O
in O
adult O
rats O
in O
both O
the O
light O
/ O
dark O
and O
elevated O
plus O
maze O
tests O
for O
anxiety O
- O
like O
behavior O
, O
and O
stimulated O
greater O
increases O
in O
extracellular O
serotonin B
in O
the O
adult O
medial O
prefrontal O
cortex O
( O
mPFC O
) O
( O
1 O
, O
2 O
. O
5 O
, O
and O
10 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

Local O
infusion O
of O
100 O
mM O
potassium O
chloride O
into O
the O
mPFC O
also O
stimulated O
greater O
serotonin B
efflux O
in O
adult O
rats O
. O

Adult O
rats O
had O
higher O
tissue O
serotonin B
content O
than O
adolescents O
in O
the O
prefrontal O
cortex O
, O
amygdala O
, O
and O
hippocampus O
, O
but O
the O
rate O
of O
serotonin B
synthesis O
was O
similar O
between O
age O
groups O
. O

Serotonin B
transporter O
( O
SERT O
) O
immunoreactivity O
and O
SERT O
radioligand O
binding O
were O
comparable O
between O
age O
groups O
in O
all O
three O
brain O
regions O
. O

These O
data O
suggest O
that O
lower O
tissue O
serotonin B
stores O
in O
adolescents O
limit O
fenfluramine B
- O
stimulated O
serotonin B
release O
and O
so O
contribute O
to O
the O
lesser O
anxiogenic O
effects O
of O
fenfluramine B
. O

Arsenic B
trioxide I
- O
induced O
hERG O
K B
( I
+ I
) I
channel O
deficiency O
can O
be O
rescued O
by O
matrine O
and O
oxymatrine B
through O
up O
- O
regulating O
transcription O
factor O
Sp1 O
expression O
. O

The O
human O
ether B
- O
a O
- O
go O
- O
go O
- O
related O
gene O
( O
hERG O
) O
encodes O
the O
rapidly O
activating O
, O
delayed O
rectifier O
potassium B
channel O
( O
IKr O
) O
important O
for O
cardiac O
repolarization O
. O

Arsenic B
trioxide I
( O
As B
( I
2 I
) I
O I
( I
3 I
) I
) O
, O
which O
is O
used O
to O
treat O
acute O
promyelocytic O
leukemia O
, O
can O
cause O
LQTS O
type O
2 O
( O
LQT2 O
) O
by O
reducing O
the O
hERG O
current O
through O
the O
diversion O
of O
hERG O
trafficking O
to O
the O
cytoplasmic O
membrane O
. O

Our O
aim O
was O
to O
develop O
cardioprotective O
agents O
to O
decrease O
As B
( I
2 I
) I
O I
( I
3 I
) I
- O
induced O
cardiotoxicity O
. O

Long O
- O
term O
treatment O
with O
1 O
mu O
M O
matrine O
or O
oxymatrine B
increased O
expression O
of O
the O
hERG O
protein O
and O
rescued O
the O
hERG O
surface O
expression O
disrupted O
by O
As B
( I
2 I
) I
O I
( I
3 I
) I
. O

In O
addition O
, O
Matrine O
and O
oxymatrine B
significantly O
shortened O
action O
potential O
duration O
prolonged O
by O
As B
( I
2 I
) I
O I
( I
3 I
) I
in O
guinea O
pig O
ventricular O
myocytes O
. O

Therefore O
, O
matrine O
and O
oxymatrine B
may O
have O
the O
potential O
to O
cure O
LQT2 O
as O
a O
potassium B
channel O
activator O
by O
promoting O
hERG O
channel O
activation O
and O
increasing O
hERG O
channel O
expression O
. O

TNF O
- O
alpha O
- O
mediated O
NF O
- O
kappa O
B O
survival O
signaling O
impairment O
by O
cisplatin B
enhances O
JNK O
activation O
allowing O
synergistic O
apoptosis O
of O
renal O
proximal O
tubular O
cells O
. O

Cisplatin B
- O
induced O
nephrotoxicity O
is O
an O
important O
limiting O
factor O
for O
cisplatin B
use O
. O

Tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
is O
known O
to O
contribute O
to O
cisplatin B
- O
induced O
nephrotoxicity O
by O
inducing O
an O
inflammatory O
process O
aggravating O
the O
primary O
injury O
, O
thereby O
resulting O
in O
acute O
kidney O
injury O
( O
AKI O
) O
. O

The O
present O
study O
investigates O
the O
pathways O
synergistically O
activated O
by O
cisplatin B
and O
TNF O
- O
alpha O
responsible O
for O
TNF O
- O
alpha O
- O
enhanced O
cisplatin B
- O
induced O
renal O
cell O
injury O
. O

To O
do O
so O
, O
immortalized O
renal O
proximal O
tubular O
epithelial O
cells O
( O
IM O
- O
PTECs O
) O
were O
co O
- O
treated O
with O
TNF O
- O
alpha O
and O
cisplatin B
. O

Under O
these O
conditions O
, O
cisplatin B
induced O
dose O
- O
dependent O
apoptosis O
in O
IM O
- O
PTECs O
, O
which O
was O
significantly O
enhanced O
by O
TNF O
- O
alpha O
. O

Transcriptomic O
analysis O
revealed O
that O
cisplatin B
inhibited O
the O
typical O
TNF O
- O
alpha O
response O
and O
cisplatin B
/ O
TNF O
- O
alpha O
treatment O
up O
- O
regulated O
cell O
death O
pathways O
while O
it O
down O
- O
regulated O
survival O
pathways O
compared O
to O
cisplatin B
alone O
. O

In O
concordance O
, O
the O
gene O
expression O
levels O
of O
kidney O
injury O
markers O
combined O
with O
activation O
of O
specific O
inflammatory O
mediators O
were O
enhanced O
by O
cisplatin B
/ O
TNF O
- O
alpha O
treatment O
, O
resembling O
the O
in O
vivo O
cisplatin B
- O
induced O
nephrotoxicity O
response O
. O

Furthermore O
, O
combined O
cisplatin B
/ O
TNF O
- O
alpha O
treatment O
inhibited O
NF O
- O
kappa O
B O
nuclear O
translocation O
and O
NF O
- O
kappa O
B O
- O
mediated O
gene O
transcription O
leading O
to O
enhanced O
and O
prolonged O
JNK O
and O
c O
- O
Jun O
phosphorylation O
. O

This O
led O
to O
an O
alteration O
in O
the O
transcription O
of O
the O
NF O
- O
kappa O
B O
- O
induced O
anti O
- O
apoptotic O
genes O
c O
- O
IAP2 O
, O
Bcl O
- O
XL O
, O
Bruce O
and O
Bcl2 O
and O
pro O
- O
apoptotic O
genes O
Bfk O
and O
Xaf1 O
and O
consequently O
to O
sensitization O
of O
the O
IM O
- O
PTECs O
toward O
cisplatin B
/ O
TNF O
- O
alpha O
- O
induced O
toxicity O
. O

In O
conclusion O
, O
our O
findings O
support O
a O
model O
whereby O
renal O
cells O
exposed O
to O
both O
cisplatin B
and O
TNF O
- O
alpha O
switch O
into O
a O
more O
pro O
- O
apoptotic O
and O
inflammatory O
program O
by O
altering O
their O
NF O
- O
kappa O
B O
/ O
JNK O
/ O
c O
- O
Jun O
balance O
. O

There O
is O
growing O
evidence O
that O
aminobisphosphonates B
like O
ibandronate O
show O
anticancer O
activity O
by O
an O
unknown O
mechanism O
. O

Further O
we O
found O
stimulation O
of O
FAS O
- O
expression O
as O
a O
result O
of O
epigenetic O
DNA O
demethylation O
that O
was O
due O
to O
down O
- O
regulation O
of O
DNMT1 O
, O
which O
was O
rescued O
by O
re O
- O
isoprenylation O
by O
both O
geranylgeranyl B
- I
pyrophosphate I
and O
farnesylpyrophosphat O
. O

Data O
suggest O
that O
bisphosphonates B
via O
modulation O
of O
the O
activity O
of O
small O
- O
GTPases O
induce O
apoptosis O
in O
neoplastic O
cells O
by O
DNA O
- O
CpG B
- O
demethylation O
and O
stimulation O
of O
FAS O
- O
expression O
. O

Combined O
administration O
of O
ornithine B
and O
phenylacetate B
( O
OP O
) O
is O
proposed O
as O
a O
novel O
treatment O
of O
hyperammonemia O
and O
hepatic O
encephalopathy O
. O

Ornithine B
is O
believed O
to O
increase O
ammonia B
fixation O
into O
glutamine B
in O
muscle O
tissue O
and O
glutamine B
is O
subsequently O
thought O
to O
react O
with O
phenylacetate B
forming O
phenylacetylglutamin O
( O
PAGN O
) O
which O
is O
excreted O
in O
urine O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
the O
interorgan O
metabolism O
of O
ornithine B
and O
ammonia B
in O
cirrhotic O
rats O
treated O
with O
OP O
in O
order O
to O
obtain O
an O
understanding O
of O
the O
underlying O
mechanisms O
of O
the O
beneficial O
effect O
of O
the O
treatment O
, O
which O
are O
largely O
unknown O
. O

[ O
2 O
, O
5 O
- O
( O
15 O
) O
N O
] O
Ornithine O
or O
( O
15 O
) O
NH O
( O
4 O
) O
( O
+ O
) O
were O
administered O
intravenously O
and O
the O
incorporation O
of O
( B
15 I
) I
N I
in O
amino B
acids I
as O
well O
as O
the O
content O
of O
the O
amino B
acids I
were O
subsequently O
determined O
in O
plasma O
, O
skeletal O
muscle O
, O
liver O
and O
kidney O
. O

In O
BDL O
rats O
, O
OP O
treatment O
reduced O
arterial O
ammonia B
concentration O
and O
increased O
that O
of O
glutamine B
30 O
min O
after O
the O
treatment O
but O
not O
after O
15 O
h O
. O

OP O
treatment O
did O
not O
increase O
( B
15 I
) I
N I
labeling O
in O
glutamine B
from O
[ O
2 O
, O
5 O
- O
( O
15 O
) O
N O
] O
ornithine O
and O
( O
15 O
) O
NH O
( O
4 O
) O
( O
+ O
) O
in O
skeletal O
muscle O
or O
liver O
. O

However O
, O
the O
extent O
of O
glutamine B
labeling O
from O
[ O
2 O
, O
5 O
- O
( O
15 O
) O
N O
] O
ornithine O
or O
( O
15 O
) O
NH O
( O
4 O
) O
( O
+ O
) O
was O
similar O
in O
arterial O
blood O
and O
liver O
and O
higher O
than O
that O
in O
skeletal O
muscle O
. O

These O
findings O
suggest O
that O
the O
effect O
of O
OP O
was O
related O
to O
hepatic O
metabolism O
of O
ornithine B
. O

PAGN O
could O
not O
be O
detected O
in O
urine O
or O
blood O
in O
any O
of O
the O
rats O
which O
may O
explain O
why O
OP O
treatment O
only O
reduced O
arterial O
ammonia B
transiently O
. O

Inflammatory O
glomerular O
kidney O
diseases O
are O
often O
accompanied O
with O
a O
massive O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
that O
affect O
the O
function O
of O
the O
glomerular O
filtration O
barrier O
and O
contribute O
to O
mesangiolysis O
via O
the O
induction O
of O
cell O
death O
in O
mesangial O
cells O
. O

To O
this O
end O
, O
protein O
lysates O
of O
human O
podocytes O
were O
treated O
with O
or O
without O
hydrogen B
peroxide I
( O
250 O
mu O
M O
) O
. O

To O
demonstrate O
whether O
PDGF O
- O
BB O
induced O
ROS O
formation O
affects O
PKA O
dependent O
pathways O
, O
the O
effects O
of O
PDGF O
- O
BB O
on O
phosphorylation O
of O
serine B
157 O
of O
vasodilator O
stimulated O
protein O
( O
VASP O
) O
a O
classical O
target O
of O
PKA O
were O
analysed O
. O

Interestingly O
PDGF O
- O
BB O
induced O
VASP O
phosphorylation O
in O
a O
ROS O
dependent O
manner O
but O
independent O
of O
changes O
in O
cAMP B
levels O
. O

Chloroacetic O
acid O
( O
CA O
) O
, O
a O
toxic O
chlorinated O
analog O
of O
acetic B
acid I
, O
is O
widely O
used O
in O
chemical O
industries O
as O
an O
herbicide O
, O
detergent O
, O
and O
disinfectant O
, O
and O
chemical O
intermediates O
that O
are O
formed O
during O
the O
synthesis O
of O
various O
products O
. O

Treatment O
of O
Neuro O
- O
2a O
cells O
with O
CA O
significantly O
reduced O
the O
number O
of O
viable O
cells O
( O
in O
a O
dose O
- O
dependent O
manner O
with O
a O
range O
from O
0 O
. O
1 O
to O
3mM O
) O
, O
increased O
the O
generation O
of O
ROS O
, O
and O
reduced O
the O
intracellular O
levels O
of O
glutathione B
depletion O
. O

These O
CA O
- O
induced O
apoptosis O
- O
related O
signals O
were O
markedly O
prevented O
by O
the O
antioxidant O
N B
- I
acetylcysteine I
( O
NAC B
) O
. O

Pretreatment O
with O
NAC B
and O
specific O
p38 O
- O
MAPK O
inhibitor O
( O
SB203580 B
) O
, O
but O
not O
JNK O
inhibitor O
( O
SP600125 B
) O
effectively O
abrogated O
the O
phosphorylation O
of O
p38 O
- O
MAPK O
and O
attenuated O
the O
apoptotic O
signals O
( O
including O
: O
decrease O
in O
cytotoxicity O
, O
caspase O
- O
3 O
/ O
- O
7 O
activation O
, O
the O
cytosolic O
cytochrome O
c O
release O
, O
and O
the O
reversed O
alteration O
of O
Bcl O
- O
2 O
and O
Bax O
mRNA O
) O
in O
CA O
- O
treated O
Neuro O
- O
2a O
cells O
. O

Active O
self O
- O
healing O
encapsulation O
of O
vaccine O
antigens O
in O
PLGA B
microspheres O
. O

Herein O
, O
we O
describe O
the O
detailed O
development O
of O
a O
simple O
and O
effective O
method O
to O
microencapsulate O
vaccine O
antigens O
in O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
by O
simple O
mixing O
of O
preformed O
active O
self O
- O
microencapsulating O
( O
SM O
) O
PLGA B
microspheres O
in O
a O
low O
concentration O
aqueous O
antigen O
solution O
at O
modest O
temperature O
( O
10 O
- O
38 O
degrees O
C O
) O
. O

The O
microsphere O
formulation O
parameters O
and O
loading O
conditions O
to O
provide O
optimal O
active O
self O
- O
healing O
microencapsulation O
of O
vaccine O
antigens O
in O
PLGA B
was O
investigated O
. O

Active O
self O
- O
healing O
encapsulation O
of O
two O
antigens O
, O
ovalbumin O
and O
tetanus O
toxoid O
( O
TT O
) O
, O
in O
PLGA B
microspheres O
was O
adjusted O
by O
preparing O
blank O
microspheres O
containing O
different O
vaccine O
adjuvants O
( O
aluminum O
hydroxide O
( O
Al B
( I
OH I
) I
3 I
) O
or O
calcium O
phosphate O
) O
. O

Active O
loading O
of O
vaccine O
antigen O
in O
Al B
( I
OH I
) I
3 I
- O
PLGA B
microspheres O
was O
found O
to O
: O
a O
) O
increase O
with O
an O
increasing O
loading O
of O
Al B
( I
OH I
) I
3 I
( O
0 O
. O
88 O
- O
3 O
wt O
. O
% O
) O
and O
addition O
of O
porosigen O
, O
b O
) O
decrease O
when O
the O
inner O
Al B
( I
OH I
) I
3 I
/ O
trehalose O
phase O
to O
1 O
mL O
outer O
oil O
phase O
and O
size O
of O
microspheres O
was O
respectively O
> O
0 O
. O
2 O
mL O
and O
63 O
mu O
m O
, O
and O
c O
) O
change O
negligibly O
by O
PLGA B
concentration O
and O
initial O
incubation O
( O
loading O
) O
temperature O
. O

Encapsulation O
of O
protein O
sorbing O
Al B
( I
OH I
) I
3 I
in O
PLGA B
microspheres O
resulted O
in O
suppression O
of O
self O
- O
healing O
of O
PLGA B
pores O
, O
which O
was O
then O
overcome O
by O
improving O
polymer O
chain O
mobility O
, O
which O
in O
turn O
was O
accomplished O
by O
coincorporating O
hydrophobic O
plasticizers O
in O
PLGA B
. O

Active O
self O
- O
healing O
microencapsulation O
of O
manufacturing O
process O
- O
labile O
TT O
in O
PLGA B
was O
found O
to O
: O
a O
) O
obviate O
micronization O
- O
and O
organic O
solvent O
- O
induced O
TT O
degradation O
, O
b O
) O
improve O
antigen O
loading O
( O
1 O
. O
4 O
- O
1 O
. O
8 O
wt O
. O
% O
TT O
) O
and O
encapsulation O
efficiency O
( O
~ O
97 O
% O
) O
, O
c O
) O
provide O
nearly O
homogeneous O
distribution O
and O
stabilization O
of O
antigen O
in O
polymer O
, O
and O
d O
) O
provide O
improved O
in O
vitro O
controlled O
release O
of O
antigenic O
TT O
. O

Recent O
studies O
propose O
that O
N O
- O
arachidonyl O
glycine O
( O
NAGly O
) O
, O
a O
carboxylic B
analogue O
of O
anandamide B
, O
is O
an O
endogenous O
ligand O
of O
the O
G O
alpha O
( O
i O
/ O
o O
) O
protein O
- O
coupled O
receptor O
18 O
( O
GPR18 O
) O
. O

GPR18 O
was O
heterologously O
expressed O
in O
rat O
sympathetic O
neurons O
, O
and O
the O
modulation O
of O
N B
- O
type O
( O
Ca B
( O
v O
) O
2 O
. O
2 O
) O
calcium B
channels O
was O
examined O
. O

Application O
of O
NAGly O
on O
GPR18 O
- O
expressing O
neurons O
did O
not O
inhibit O
calcium B
currents O
but O
instead O
potentiated O
currents O
in O
a O
voltage O
- O
dependent O
manner O
, O
similar O
to O
what O
has O
previously O
been O
reported O
( O
Guo O
et O
al O
. O
, O
2008 O
; O
J O
Neurophysiol O
, O
100 O
: O
1147 O
) O
. O

Other O
proposed O
agonists O
of O
GPR18 O
, O
including O
anandamide B
and O
abnormal O
cannabidiol B
, O
also O
failed O
to O
induce O
inhibition O
of O
calcium B
currents O
. O

Mutants O
of O
GPR18 O
, O
designed O
to O
constitutively O
activate O
receptors O
, O
did O
not O
tonically O
inhibit O
calcium B
currents O
, O
indicating O
a O
lack O
of O
GPR18 O
activation O
or O
coupling O
to O
endogenous O
G O
proteins O
. O

Other O
downstream O
effectors O
of O
G O
alpha O
( O
i O
/ O
o O
) O
- O
coupled O
receptors O
, O
G O
protein O
- O
coupled O
inwardly O
rectifying O
potassium B
channels O
and O
adenylate B
cyclase O
, O
were O
not O
modulated O
by O
GPR18 O
signaling O
. O

Effects O
of O
Korean O
red O
ginseng O
extracts O
on O
neural O
tube O
defects O
and O
impairment O
of O
social O
interaction O
induced O
by O
prenatal O
exposure O
to O
valproic B
acid I
. O

Using O
the O
prenatal O
valproic B
acid I
( O
VPA B
) O
- O
injection O
model O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
in O
rats O
, O
which O
produces O
social O
impairrment O
and O
altered O
seizure O
susceptibility O
as O
in O
human O
ASD O
patients O
as O
well O
as O
mild O
neural O
tube O
defects O
like O
crooked O
tail O
phenotype O
, O
we O
examined O
whether O
chronic O
administration O
of O
red O
ginseng O
extract O
may O
rescue O
the O
social O
impairment O
and O
crooked O
tail O
phenotype O
in O
prenatally O
VPA B
- O
exposed O
rat O
offspring O
. O

VPA B
- O
induced O
impairment O
in O
social O
interactions O
tested O
using O
sociability O
and O
social O
preference O
paradigms O
as O
well O
as O
crooked O
tail O
phenotypes O
were O
significantly O
improved O
by O
administration O
of O
Korean O
red O
ginseng O
( O
KRG O
) O
in O
a O
dose O
dependent O
manner O
. O

Rat O
offspring O
prenatally O
exposed O
to O
VPA B
showed O
higher O
sensitivity O
to O
electric O
shock O
seizure O
and O
increased O
locomotor O
activity O
in O
open O
- O
field O
test O
. O

These O
results O
suggest O
that O
KRG O
may O
modulate O
neurobehavioral O
and O
structural O
organization O
of O
nervous O
system O
adversely O
affected O
by O
prenatal O
exposure O
to O
VPA B
. O

The O
crystal O
structure O
of O
human O
telomeric O
DNA O
complexed O
with O
berberine B
: O
an O
interesting O
case O
of O
stacked O
ligand O
to O
G O
- O
tetrad O
ratio O
higher O
than O
1 O
: O
1 O
. O

The O
first O
crystal O
structure O
of O
human O
telomeric O
DNA O
in O
complex O
with O
the O
natural O
alkaloid O
berberine B
, O
produced O
by O
different O
plant O
families O
and O
used O
in O
folk O
medicine O
for O
millennia O
, O
was O
solved O
by O
X O
- O
ray O
diffraction O
method O
. O

However O
, O
the O
present O
crystal O
structure O
highlighted O
for O
the O
first O
time O
, O
the O
presence O
of O
two O
berberine B
molecules O
in O
the O
two O
binding O
sites O
, O
directly O
interacting O
with O
each O
tetrad O
. O

Arsenic B
increases O
Pi O
- O
mediated O
vascular O
calcification O
and O
induces O
premature O
senescence O
in O
vascular O
smooth O
muscle O
cells O
. O

Several O
mechanisms O
have O
been O
proposed O
to O
explain O
the O
vascular O
toxicity O
of O
arsenic B
. O

Rat O
aortic O
VSMC O
were O
treated O
with O
1 O
- O
100 O
micro O
M O
of O
either O
sodium O
arsenate O
( O
As B
( I
V I
) I
) O
, O
sodium B
arsenite I
( O
As B
( I
III I
) I
) O
, O
monomethylarsonic B
acid I
, O
or O
dimethylarsinic B
acid I
. O

None O
of O
the O
treatments O
induced O
VSMC O
calcification O
in O
the O
presence O
of O
1mM O
inorganic O
phosphate B
( O
Pi O
) O
, O
but O
1 O
micro O
M O
As B
( I
III I
) I
did O
increase O
calcification O
when O
induced O
with O
2 O
. O
5mM O
Pi O
. O

A O
lactate B
dehydrogenase O
assay O
revealed O
that O
this O
increase O
was O
explained O
by O
a O
rise O
in O
cytotoxicity O
due O
to O
simultaneous O
incubation O
with O
1 O
micro O
M O
As B
( I
III I
) I
and O
2 O
. O
5mM O
Pi O
. O

This O
calcification O
increase O
was O
also O
observed O
in O
the O
aortas O
of O
a O
vascular O
calcification O
model O
: O
5 O
/ O
6 O
nephrectomized O
rats O
fed O
with O
a O
high O
Pi O
diet O
and O
treated O
with O
vitamin B
D I
( I
3 I
) I
. O

Several O
known O
mechanisms O
that O
might O
explain O
arsenic B
toxicity O
in O
our O
experimental O
model O
were O
discarded O
: O
apoptosis O
, O
oxidative O
stress O
, O
and O
inflammasome O
activation O
. O

Nevertheless O
, O
both O
senescence O
- O
associated O
beta O
- O
galactosidase O
activity O
and O
p21 O
expression O
were O
increased O
by O
As B
( I
III I
) I
, O
which O
reveals O
the O
induction O
of O
SIPS O
. O

As B
( I
III I
) I
also O
caused O
dedifferentiation O
of O
VSMC O
, O
as O
shown O
by O
the O
reduced O
expression O
of O
the O
VSMC O
markers O
SM22 O
alpha O
and O
calponin O
. O

Senescence O
and O
gene O
expression O
were O
also O
observed O
in O
the O
aortas O
of O
healthy O
rats O
treated O
with O
50 O
ppm O
As B
( I
V I
) I
in O
drinking O
water O
for O
1 O
month O
. O

In O
conclusion O
, O
both O
premature O
senescence O
in O
aortic O
VSMC O
with O
phenotypic O
dedifferentiation O
and O
the O
increase O
of O
Pi O
- O
induced O
calcification O
are O
novel O
mechanisms O
of O
arsenic B
vasculotoxicity O
. O

Differential O
influences O
of O
ethanol B
on O
early O
exposure O
to O
racemic O
methylphenidate B
compared O
with O
dexmethylphenidate O
in O
humans O
. O

Coadministration O
of O
dl O
- O
MPH O
with O
ethanol B
results O
in O
elevated O
d O
- O
MPH O
plasma O
concentrations O
accompanied O
by O
CES1 O
- O
mediated O
enantioselective O
transesterification O
of O
l O
- O
MPH O
to O
l O
- O
ethylphenidate O
( O
EPH O
) O
. O

The O
present O
study O
tested O
the O
hypothesis O
that O
administration O
of O
the O
pure O
isomer O
dexmethylphenidate O
( O
d O
- O
MPH O
) O
will O
overcome O
the O
influence O
of O
ethanol B
on O
d O
- O
MPH O
absorption O
by O
eliminating O
competitive O
CES1 O
- O
mediated O
presystemic O
metabolism O
of O
l O
- O
MPH O
to O
l O
- O
EPH O
. O

Twenty O
- O
four O
healthy O
volunteers O
received O
dl O
- O
MPH O
( O
0 O
. O
3 O
mg O
/ O
kg O
) O
or O
d O
- O
MPH O
( O
0 O
. O
15 O
mg O
/ O
kg O
) O
, O
with O
or O
without O
ethanol B
( O
0 O
. O
6 O
g O
/ O
kg O
) O
. O

During O
the O
absorption O
phase O
of O
dl O
- O
MPH O
, O
concomitant O
ethanol B
significantly O
elevated O
d O
- O
MPH O
plasma O
concentrations O
( O
44 O
- O
99 O
% O
; O
P O
< O
0 O
. O
005 O
) O
. O

Furthermore O
, O
immediately O
following O
the O
ethanol B
drink O
the O
subjective O
effects O
of O
" O
high O
, O
" O
" O
good O
, O
" O
" O
like O
, O
" O
" O
stimulated O
, O
" O
and O
overall O
" O
effect O
" O
were O
significantly O
potentiated O
( O
P O
< O
= O
0 O
. O
01 O
) O
. O

Ethanol B
combined O
with O
pure O
d O
- O
MPH O
did O
not O
elevate O
plasma O
d O
- O
MPH O
concentrations O
during O
the O
absorption O
phase O
, O
and O
the O
ethanol B
- O
induced O
potentiation O
of O
subjective O
effects O
was O
delayed O
relative O
to O
dl O
- O
MPH O
- O
ethanol B
. O

Ethanol B
increased O
the O
d O
- O
MPH O
area O
under O
the O
curve O
( O
AUC O
) O
( O
0 O
- O
inf O
) O
by O
21 O
% O
following O
dl O
- O
MPH O
( O
P O
< O
0 O
. O
001 O
) O
and O
14 O
% O
for O
d O
- O
MPH O
( O
P O
= O
0 O
. O
001 O
) O
. O

In O
men O
receiving O
d O
- O
MPH O
- O
ethanol B
, O
the O
d O
- O
MPH O
absorption O
partial O
AUC O
( O
0 O
. O
5 O
- O
2 O
hours O
) O
was O
2 O
. O
1 O
times O
greater O
and O
the O
time O
to O
maximum O
concentration O
( O
T O
( O
max O
) O
) O
occurred O
1 O
. O
1 O
hours O
earlier O
than O
in O
women O
, O
consistent O
with O
an O
increased O
rate O
of O
d O
- O
MPH O
absorption O
reducing O
hepatic O
extraction O
. O

Methotrexate B
- O
conjugated O
and O
hyperbranched O
polyglycerol B
- O
grafted O
Fe B
3 I
O I
4 I
magnetic O
nanoparticles O
for O
targeted O
anticancer O
effects O
. O

Superparamagnetic O
nanoparticles O
grafted O
with O
hyperbranched O
polyglycerol B
( O
HPG O
) O
and O
conjugated O
with O
methotrexate B
( O
MTX B
) O
( O
MNP O
- O
g O
- O
HPG O
- O
MTX B
) O
were O
synthesized O
via O
a O
sol O
- O
gel O
reaction O
followed O
by O
thiol O
- O
ene O
click O
chemistry O
and O
esterification O
reaction O
. O

The O
successful O
grafting O
of O
MTX B
and O
HPG O
onto O
the O
nanoparticles O
was O
confirmed O
by O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
, O
Fourier O
transform O
infrared O
( O
FT O
- O
IR O
) O
spectroscopy O
, O
and O
UV O
- O
visible O
spectroscopy O
. O

The O
HPG O
- O
graft O
layer O
confers O
the O
magnetic O
nanoparticles O
with O
good O
dispersibility O
and O
stability O
in O
aqueous O
medium O
and O
macrophage O
- O
evasive O
property O
while O
the O
MTX B
acts O
as O
a O
chemotherapeutic O
drug O
as O
well O
as O
a O
tumor O
targeting O
ligand O
. O

The O
dose O
- O
dependent O
targeting O
and O
anticancer O
effect O
of O
the O
MNP O
- O
g O
- O
HPG O
- O
MTX B
nanoparticles O
were O
evaluated O
, O
and O
the O
results O
showed O
that O
depending O
on O
the O
amount O
of O
conjugated O
MTX B
and O
the O
concentration O
of O
the O
incubated O
nanoparticles O
, O
the O
uptake O
of O
MNP O
- O
g O
- O
HPG O
- O
MTX B
nanoparticles O
by O
human O
head O
and O
neck O
cancer O
( O
KB O
) O
cells O
can O
be O
eight O
times O
or O
more O
higher O
than O
those O
by O
3T3 O
fibroblasts O
and O
RAW O
macrophages O
. O

As O
a O
result O
, O
the O
MNP O
- O
g O
- O
HPG O
- O
MTX B
nanoparticles O
are O
capable O
of O
killing O
~ O
50 O
% O
of O
the O
KB O
cells O
while O
at O
the O
same O
time O
exhibiting O
low O
cytotoxicity O
towards O
3T3 O
fibroblasts O
and O
RAW O
macrophages O
. O

Large O
- O
area O
fabrication O
of O
periodic O
sub O
- O
15 O
nm O
- O
width O
single O
- O
layer O
graphene B
nanorings O
. O

A O
periodically O
aligned O
array O
of O
graphene B
nanorings O
( O
GRNRs O
) O
with O
a O
sub O
- O
15 O
nm O
linewidth O
at O
a O
pitch O
of O
450 O
nm O
is O
fabricated O
with O
a O
large O
area O
, O
9 O
cm O
( O
2 O
) O
, O
through O
conventional O
nanoimprint O
lithography O
coupled O
with O
sophisticated O
metal O
deposition O
and O
plasma O
- O
etching O
processes O
. O

Effects O
of O
bisphenol B
A I
on O
growth O
and O
nitrogen B
nutrition O
of O
roots O
of O
soybean O
seedlings O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
environmental O
endocrine O
disruptor O
that O
seriously O
threatens O
ecological O
systems O
. O

Plants O
are O
the O
primary O
producers O
in O
ecological O
systems O
, O
but O
little O
information O
is O
available O
concerning O
the O
toxic O
effect O
of O
BPA B
on O
plants O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
BPA B
on O
the O
growth O
and O
nitrogen B
nutrition O
of O
roots O
of O
soybean O
seedlings O
were O
investigated O
by O
using O
a O
root O
automatic O
scan O
apparatus O
and O
biochemical O
methods O
. O

It O
was O
found O
that O
when O
soybean O
seedlings O
were O
treated O
with O
1 O
. O
5 O
mg O
/ O
L O
BPA B
, O
the O
growth O
of O
roots O
was O
improved O
, O
the O
content O
of O
nitrate B
in O
roots O
was O
increased O
, O
the O
content O
of O
ammonium O
in O
roots O
was O
decreased O
, O
and O
the O
activities O
of O
nitrate B
reductase O
and O
nitrite B
reductase O
in O
roots O
were O
not O
changed O
. O

The O
opposite O
effects O
were O
observed O
in O
roots O
treated O
with O
17 O
. O
2 O
mg O
/ O
L O
and O
50 O
. O
0 O
mg O
/ O
L O
BPA B
, O
except O
for O
an O
increase O
in O
the O
content O
of O
nitrate B
in O
roots O
treated O
with O
17 O
. O
2 O
mg O
/ O
L O
BPA B
and O
a O
decrease O
in O
the O
activities O
of O
nitrate B
reductase O
and O
nitrite B
reductase O
in O
roots O
of O
soybeans O
seedlings O
. O

Statistical O
analysis O
indicated O
that O
the O
change O
in O
the O
nitrogen B
nutrition O
of O
roots O
of O
soybean O
seedlings O
treated O
with O
BPA B
was O
one O
reason O
why O
the O
growth O
of O
roots O
was O
changed O
. O

The O
authors O
suggest O
that O
the O
potential O
environmental O
and O
ecological O
risk O
of O
BPA B
to O
plants O
should O
receive O
more O
consideration O
. O

In O
this O
work O
, O
we O
pinpoint O
a O
loop O
within O
the O
Esa1 O
Tudor O
domain O
and O
a O
short O
basic O
region O
at O
the O
N B
terminus O
of O
the O
Epl1 O
EPcA O
domain O
as O
necessary O
for O
this O
nucleosomal O
HAT O
activity O
. O

We O
also O
show O
that O
this O
Esa1 O
Tudor O
domain O
loop O
region O
is O
positioned O
close O
to O
nucleosomal O
DNA O
and O
that O
the O
Epl1 O
EPcA O
basic O
region O
is O
in O
proximity O
to O
the O
N B
- O
terminal O
histone O
H2A O
tail O
, O
the O
globular O
region O
of O
histone O
H4 O
, O
and O
also O
to O
nucleosomal O
DNA O
when O
Piccolo O
NuA4 O
interacts O
with O
the O
nucleosome O
. O

alpha O
/ O
beta O
- O
Hydrolase O
domain O
- O
containing O
6 O
( O
ABHD6 O
) O
represents O
a O
potentially O
attractive O
therapeutic O
target O
for O
indirectly O
potentiating O
2 B
- I
arachidonoylglycerol I
signaling O
; O
however O
, O
the O
enzyme O
is O
currently O
largely O
uncharacterized O
. O

Toosendanin O
( O
TSN O
) O
, O
a O
triterpenoid B
isolated O
from O
Melia O
toosendan O
Sieb O
. O

Cell O
apoptosis O
induced O
by O
TSN O
was O
confirmed O
by O
Annexin O
V O
- O
FITC B
/ O
propidium B
iodide I
staining O
. O

Nano O
- O
titanium B
dioxide I
induces O
genotoxicity O
and O
apoptosis O
in O
human O
lung O
cancer O
cell O
line O
, O
A549 O
. O

The O
increased O
inhaled O
application O
of O
titanium B
dioxide I
nanoparticles O
( O
TiO B
( I
2 I
) I
NPs O
) O
increases O
the O
potential O
pulmonary O
health O
risks O
. O

The O
present O
investigations O
were O
carried O
out O
to O
study O
the O
TiO B
( I
2 I
) I
NPs O
- O
induced O
apoptosis O
, O
oxidative O
stress O
and O
genotoxicity O
in O
the O
human O
lung O
cancer O
cell O
line O
, O
A549 O
, O
a O
widely O
used O
cell O
system O
for O
pulmonary O
toxicity O
studies O
. O

Tetrazolium O
bromide O
salt O
and O
lactate B
dehydrogenase O
release O
assays O
were O
used O
to O
study O
the O
cytotoxicity O
. O

Cells O
exposed O
to O
TiO B
( I
2 I
) I
NPs O
( O
10 O
and O
50 O
mu O
g O
/ O
ml O
) O
for O
6 O
- O
24 O
h O
shows O
significant O
induction O
in O
oxidative O
stress O
, O
that O
is O
, O
the O
production O
of O
reactive O
oxygen B
species O
and O
malondialdehyde B
and O
decrease O
in O
the O
activity O
of O
catalase O
and O
glutathione B
. O

TiO B
( I
2 I
) I
NPs O
exposure O
also O
induces O
the O
formation O
of O
apoptotic O
bodies O
and O
micronucleus O
as O
marker O
of O
genotoxicity O
. O

TiO B
( I
2 I
) I
NPs O
exposure O
could O
not O
pose O
significant O
effects O
on O
Bax O
expression O
. O

Data O
indicate O
that O
nano O
- O
TiO B
( I
2 I
) I
induces O
oxidative O
stress O
, O
genotoxicity O
and O
apoptosis O
in O
human O
lung O
cancer O
cell O
line O
, O
A549 O
. O

Our O
result O
also O
identifies O
the O
mechanisms O
involved O
in O
TiO B
( I
2 I
) I
NP O
- O
induced O
changes O
in O
A549 O
cells O
. O

Perhaps O
, O
reporting O
for O
the O
first O
time O
, O
the O
association O
of O
TiO B
( I
2 I
) I
NPs O
- O
induced O
genotoxicity O
and O
apoptosis O
at O
transcriptional O
and O
translational O
level O
in O
the O
human O
lung O
cancer O
cell O
line O
, O
A549 O
cells O
. O

The O
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
subtype O
is O
abundantly O
expressed O
in O
the O
central O
nervous O
system O
and O
in O
the O
periphery O
. O

Recent O
evidence O
suggests O
that O
alpha O
7 O
nAChR O
subtypes O
, O
which O
can O
be O
activated O
by O
an O
endogenous O
cholinergic O
tone O
, O
comprising O
acetylcholine B
and O
the O
alpha O
7 O
nAChR O
agonist O
choline B
, O
play O
an O
important O
role O
in O
subchronic O
pain O
and O
inflammation O
. O

Testing O
type O
I O
[ O
N O
- O
( O
5 O
- O
chloro O
- O
2 O
- O
hydroxyphenyl O
) O
- O
N O
' O
- O
[ O
2 O
- O
chloro O
- O
5 O
- O
( O
trifluoromethyl O
) O
phenyl O
] O
( O
NS1738 O
) O
] O
and O
type O
II O
[ O
1 O
- O
( O
5 O
- O
chloro O
- O
2 O
, O
4 O
- O
dimethoxy O
- O
phenyl O
) O
- O
3 O
- O
( O
5 O
- O
methyl O
- O
isoxazol O
- O
3 O
- O
yl O
) O
( O
PNU B
- I
120596 I
) O
] O
alpha O
7 O
nAChR O
PAMs O
in O
acute O
and O
persistent O
pain O
, O
we O
found O

that O
, O
although O
neither O
reduced O
acute O
thermal O
pain O
, O
only O
PNU B
- I
120596 I
dose O
- O
dependently O
attenuated O
paw O
- O
licking O
behavior O
in O
the O
formalin B
test O
. O

The O
long O
- O
acting O
effect O
of O
PNU B
- I
120596 I
in O
this O
test O
was O
in O
discordance O
with O
its O
pharmacokinetic O
profile O
in O
mice O
, O
which O
suggests O
the O
involvement O
of O
postreceptor O
signaling O
mechanisms O
. O

Our O
results O
with O
selective O
mitogen O
- O
activated O
protein O
kinase O
kinase O
inhibitor O
1 O
, O
4 O
- O
diamino O
- O
2 O
, O
3 O
- O
dicyano O
- O
1 O
, O
4 O
- O
bis O
( O
o O
- O
aminophenylmercapto O
) O
butadiene O
monoethanolate O
( O
U0126 B
) O
argues O
for O
an O
important O
role O
of O
extracellular O
signal O
- O
regulated O
kinase O
- O
1 O
/ O
2 O
pathways O
activation O
in O
PNU B
- I
120596 I
' O
s O
antinociceptive O
effects O
. O

The O
alpha O
7 O
antagonist O
MLA B
, O
administered O
intrathecally O
, O
reversed O
PNU B
- I
120596 I
' O
s O
effects O
, O
confirming O
PNU B
- I
120596 I
' O
s O
action O
, O
in O
part O
, O
through O
central O
alpha O
7 O
nAChRs O
. O

Importantly O
, O
tolerance O
to O
PNU B
- I
120596 I
was O
not O
developed O
after O
subchronic O
treatment O
of O
the O
drug O
. O

Surprisingly O
, O
PNU B
- I
120596 I
' O
s O
antinociceptive O
effects O
were O
blocked O
by O
NS1738 O
. O

Our O
results O
indicate O
that O
type O
II O
alpha O
7 O
nAChR O
PAM O
PNU B
- I
120596 I
, O
but O
not O
type O
I O
alpha O
7 O
nAChR O
PAM O
NS1738 O
, O
shows O
significant O
antinociception O
effects O
in O
persistent O
pain O
models O
in O
mice O
. O

A O
new O
cyclometallated O
iridium O
( O
III O
) O
complex O
with O
the O
2 O
, O
2 O
' O
- O
biquinoline O
N B
- O
donor O
ligand O
has O
been O
synthesized O
and O
characterized O
. O

PD O
treatment O
of O
BDL O
- O
operated O
mice O
decreased O
serum O
alanine B
aminotransferase O
, O
serum O
aspartate B
aminotransferase O
, O
and O
total O
bilirubin B
levels O
by O
up O
to O
37 O
% O
, O
31 O
% O
, O
and O
41 O
% O
, O
respectively O
, O
in O
comparison O
with O
the O
levels O
in O
mice O
that O
underwent O
BDL O
alone O
. O

PD O
treatment O
attenuated O
oxidative O
stress O
, O
as O
evidenced O
by O
an O
increase O
in O
anti O
- O
oxidative O
enzyme O
levels O
glutathione B
and O
superoxide B
dismutase O
together O
with O
a O
decrease O
in O
lipid O
peroxidation O
and O
oxidative O
stress O
indices O
levels O
of O
malondialdehyde B
and O
nitric B
oxide I
. O

In O
addition O
, O
nuclear O
factor O
- O
kappa O
B O
and O
inducible O
nitric B
oxide I
synthase O
levels O
significantly O
decreased O
after O
PD O
treatment O
, O
as O
did O
the O
levels O
of O
hepatocyte O
apoptosis O
. O

Endocrine O
disruptive O
potential O
of O
endosulfan B
on O
the O
reproductive O
axis O
of O
Cichlasoma O
dimerus O
( O
Perciformes O
, O
Cichlidae O
) O
. O

Endosulfan B
( O
ES O
) O
, O
a O
persistent O
organochlorine B
pesticide O
, O
is O
widely O
used O
despite O
its O
toxicity O
to O
non O
- O
target O
animals O
. O

The O
aim O
of O
the O
present O
work O
was O
to O
assess O
the O
endocrine O
disruptive O
potential O
of O
endosulfan B
on O
the O
pituitary O
gonadotropins O
levels O
and O
on O
the O
testes O
function O
due O
to O
ES O
in O
the O
South O
American O
freshwater O
fish O
Cichlasoma O
dimerus O
, O
using O
in O
vitro O
and O
in O
vivo O
approaches O
. O

Antiarrhythmic O
effects O
of O
( O
- O
) O
- O
epicatechin O
- O
3 O
- O
gallate O
, O
a O
novel O
sodium B
channel O
agonist O
in O
cultured O
neonatal O
rat O
ventricular O
myocytes O
. O

( O
- O
) O
- O
Epicatechin O
- O
3 O
- O
gallate O
( O
ECG O
) O
, O
a O
polyphenol B
extracted O
from O
green O
tea O
, O
has O
been O
proposed O
as O
an O
effective O
compound O
for O
improving O
cardiac O
contractility O
. O

By O
using O
the O
whole O
- O
cell O
patch O
- O
clamp O
configurations O
, O
we O
found O
ECG O
enhanced O
the O
slowly O
inactivating O
component O
of O
voltage O
- O
gated O
Na B
( I
+ I
) I
currents O
( O
I O
( O
Na B
) O
) O
in O
a O
concentration O
- O
dependent O
manner O
( O
0 O
. O
1 O
- O
100 O
mu O
M O
) O
with O
an O
EC O
( O
50 O
) O
value O
of O
3 O
. O
8 O
mu O
M O
. O

ECG O
not O
only O
shifted O
the O
current O
- O
voltage O
relationship O
of O
peak O
I O
( O
Na B
) O
to O
the O
hyperpolarizing O
direction O
but O
also O
accelerated O
I O
( O
Na B
) O
recovery O
kinetics O
. O

Working O
at O
a O
concentration O
level O
of O
I O
( O
Na B
) O
enhancement O
, O
ECG O
has O
no O
notable O
effect O
on O
voltage O
- O
gated O
K B
( I
+ I
) I
currents O
and O
L O
- O
type O
Ca B
( I
2 I
+ I
) I
currents O
. O

The O
expression O
of O
dominant O
cardiac O
sodium B
channel O
subunit O
, O
Nav1 O
. O
5 O
, O
was O
consistently O
detected O
throughout O
the O
culture O
periods O
. O

Our O
results O
reveal O
how O
ECG O
, O
the O
novel O
I O
( O
Na B
) O
agonist O
, O
may O
act O
as O
a O
promising O
candidate O
in O
clinical O
applications O
on O
cardiac O
arrhythmias O
. O

Sodium B
/ O
iodide B
symporter O
is O
expressed O
in O
the O
majority O
of O
seminomas O
and O
embryonal O
testicular O
carcinomas O
. O

Expression O
of O
Na B
( I
+ I
) I
/ O
I B
( I
- I
) I
symporter O
( O
NIS O
( O
SLC5A5 O
) O
) O
, O
the O
glycoprotein O
responsible O
for O
iodide B
transport O
, O
has O
been O
demonstrated O
in O
normal O
testicular O
tissue O
. O

In O
NTERA O
cells O
treated O
with O
the O
histone O
deacetylase O
inhibitors O
SAHA B
and O
valproic B
acid I
, O
a O
significant O
increase O
in O
NIS O
mRNA O
( O
about O
60 O
- O
and O
30 O
- O
fold O
vs O
control O
, O
P O
< O
0 O
. O
001 O
and O
P O
< O
0 O
. O
01 O
respectively O
) O
and O
protein O
levels O
, O
resulting O
in O
enhanced O
ability O
to O
uptake O
radioiodine O
, O
was O
observed O
. O

The O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
possible O
association O
between O
sex O
, O
polymorphisms O
in O
the O
CYP2C8 O
and O
CYP2C9 O
genes O
, O
and O
the O
pharmacokinetics O
of O
losartan B
, O
valsartan O
, O
candesartan B
, O
and O
telmisartan B
. O

The O
study O
population O
comprised O
246 O
healthy O
volunteers O
from O
seven O
single O
- O
dose O
clinical O
trials O
: O
64 O
from O
two O
candesartan B
studies O
, O
43 O
from O
a O
telmisartan B
study O
, O
36 O
from O
a O
losartan B
study O
, O
and O
103 O
from O
three O
valsartan O
studies O
. O

Sex O
only O
affected O
telmisartan B
pharmacokinetics O
, O
since O
women O
showed O
a O
higher O
telmisartan B
C O
( O
max O
) O
than O
men O
( O
590 O
. O
5 O
+ O
/ O
- O
75 O
. O
8 O
ng O
/ O
ml O
versus O
282 O
. O
1 O
+ O
/ O
- O
30 O
. O
8 O
ng O
/ O
ml O
; O
P O
< O
= O
0 O
. O
01 O
) O
. O

CYP2C9 O
variants O
were O
associated O
only O
with O
losartan B
pharmacokinetics O
: O
the O
half O
- O
life O
of O
losartan B
was O
higher O
in O
CYP2C9 O
* O
3 O
allele O
carriers O
( O
3 O
. O
1 O
+ O
/ O
- O
0 O
. O
4 O
hours O
) O
than O
in O
volunteers O
with O
the O
wild O
- O
type O
genotype O
( O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
1 O
hours O
) O
( O
P O
< O
= O
0 O
. O
05 O
) O
. O

These O
results O
suggest O
that O
genotypes O
for O
CYP2C9 O
and O
CYP2C8 O
are O
relevant O
to O
the O
pharmacokinetics O
of O
losartan B
and O
valsartan O
, O
respectively O
, O
but O
not O
the O
pharmacokinetics O
of O
candesartan B
or O
telmisartan B
. O

Mapping O
of O
Saccharomyces O
cerevisiae O
metabolites O
in O
fermenting O
wheat O
straight O
- O
dough O
reveals O
succinic B
acid I
as O
pH O
- O
determining O
factor O
. O

Here O
, O
the O
yeast O
carbon B
metabolism O
was O
mapped O
during O
bread O
straight O
- O
dough O
fermentation O
. O

Ethanol B
and O
carbon B
dioxide I
concentrations O
reached O
up O
to O
60 O
mmol O
/ O
100g O
flour O
. O

Interestingly O
, O
high O
levels O
of O
glycerol B
( O
up O
to O
10 O
mmol O
/ O
100g O
flour O
) O
and O
succinic B
acid I
( O
up O
to O
1 O
. O
6 O
mmol O
/ O
100g O
flour O
) O
were O
produced O
during O
dough O
fermentation O
. O

Further O
tests O
showed O
that O
, O
contrary O
to O
current O
belief O
, O
the O
pH O
decrease O
in O
fermenting O
dough O
is O
primarily O
caused O
by O
the O
production O
of O
succinic B
acid I
by O
the O
yeast O
instead O
of O
carbon B
dioxide I
dissolution O
or O
bacterial O
organic O
acids O
. O

Preparative O
separation O
and O
purification O
of O
sulforaphene B
from O
radish O
seeds O
by O
high O
- O
speed O
countercurrent O
chromatography O
. O

Sulforaphene B
, O
a O
kind O
of O
isothiocyanates B
, O
derived O
from O
glucoraphenin O
which O
is O
the O
important O
ingredient O
of O
radish O
( O
Raphanus O
sativus O
L O
. O
) O
seeds O
, O
has O
shown O
significant O
pharmacological O
activities O
. O

In O
this O
paper O
, O
the O
separation O
and O
purification O
of O
sulforaphene B
from O
radish O
seeds O
, O
was O
achieved O
by O
high O
- O
speed O
countercurrent O
chromatography O
( O
HSCCC O
) O
. O

A O
two O
- O
phase O
solvent O
system O
consisted O
of O
n B
- I
hexane I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
35 O
: O
100 O
: O
35 O
: O
100 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
was O
applied O
. O

From O
about O
1000 O
mg O
amount O
of O
the O
crude O
plant O
extract O
, O
249 O
. O
4 O
mg O
of O
pure O
sulforaphene B
was O
obtained O
by O
one O
- O
step O
separation O
on O
a O
280 O
ml O
HSCCC O
column O
. O

The O
purified O
sulforaphene B
was O
at O
a O
high O
purity O
of O
96 O
. O
9 O
% O
and O
the O
mass O
recovery O
was O
more O
than O
95 O
% O
. O

The O
purity O
of O
sulforaphene B
was O
determined O
by O
HPLC O
analysis O
and O
its O
chemical O
structure O
was O
assessed O
by O
MS O
, O
( B
1 I
) I
H I
NMR O
, O
( B
13 I
) I
C I
NMR O
and O
DEPT O
- O
135 O
NMR O
. O

Lead O
and O
cadmium B
concentrations O
in O
goat O
, O
cow O
, O
sheep O
, O
and O
buffalo O
milks O
from O
different O
regions O
of O
Iran O
. O

In O
total O
, O
137 O
goat O
, O
cow O
, O
sheep O
, O
and O
buffalo O
milk O
samples O
were O
collected O
in O
different O
regions O
of O
Iran O
and O
analysed O
to O
determine O
concentrations O
of O
lead O
and O
cadmium B
by O
a O
graphite B
furnace O
atomic O
absorption O
spectrometric O
method O
. O

The O
mean O
recovery O
of O
the O
analytical O
method O
was O
96 O
. O
3 O
% O
and O
104 O
% O
for O
cadmium B
and O
lead O
, O
respectively O
. O

The O
mean O
lead O
and O
cadmium B
contents O
obtained O
from O
137 O
samples O
were O
1 O
. O
93 O
+ O
/ O
- O
1 O
. O
48 O
( O
range O
: O
0 O
. O
18 O
- O
6 O
. O
11 O
ng O
/ O
ml O
) O
and O
9 O
. O
51 O
+ O
/ O
- O
4 O
. O
93 O
ng O
/ O
ml O
( O
range O
: O
1 O
. O
84 O
ng O
/ O
ml O
- O
30 O
. O
50 O
ng O
/ O
ml O
) O
, O
respectively O
. O

The O
mean O
concentrations O
of O
cadmium B
and O
lead O
in O
animals O
aged O
< O
= O
3 O
years O
( O
n O
= O
80 O
; O
1 O
. O
40 O
+ O
/ O
- O
1 O
. O
05 O
ng O
/ O
ml O
and O
7 O
. O
91 O
+ O
/ O
- O
3 O
. O
60 O
ng O
/ O
ml O
, O
respectively O
) O
were O
lower O
than O
in O
animals O
aged O
> O
3 O
years O
( O
n O
= O
58 O
; O
2 O
. O
69 O
+ O
/ O
- O
1 O
. O
67 O
ng O
/ O
ml O
and O
11 O
. O
8 O
+ O
/ O
- O
5 O
. O
71 O
ng O
/ O
ml O
, O
respectively O
) O
. O

The O
upper O
detergent O
- O
poor O
phase O
extract O
was O
subsequently O
fractionated O
by O
40 O
- O
80 O
% O
ammonium O
sulfate O
and O
chromatographed O
on O
HiTrap O
Phenyl B
Sepharose O
and O
Superdex O
200 O
HR O
10 O
/ O
30 O
. O

A O
single O
prominent O
protein O
band O
appeared O
on O
native O
- O
PAGE O
and O
SDS B
- O
PAGE O
implying O
that O
the O
mPPO O
is O
a O
monomeric O
protein O
with O
estimated O
molecular O
weight O
of O
38kDa O
. O

The O
K O
( O
m O
) O
and O
V O
( O
max O
) O
values O
were O
calculated O
to O
be O
5 O
. O
46 O
mM O
and O
0 O
. O
98 O
U O
/ O
ml O
/ O
min O
, O
respectively O
, O
when O
catechol B
was O
used O
as O
substrate O
. O

Among O
the O
chemical O
inhibitors O
tested O
, O
l O
- O
cysteine O
showed O
the O
best O
inhibitory O
effect O
, O
with O
an O
IC O
( O
50 O
) O
of O
1 O
. O
3 O
+ O
/ O
- O
0 O
. O
002 O
mM O
followed O
by O
ascorbic B
acid I
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
06 O
mM O
) O
, O
glutathione B
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
07 O
mM O
) O
, O
EDTA B
( O
100 O
+ O
/ O
- O
0 O
. O
02 O
mM O
) O
and O
citric B
acid I
( O
186 O
+ O
/ O
- O
0 O
. O
16 O
mM O
) O
. O

Toona O
sinensis O
and O
its O
major O
bioactive O
compound O
gallic B
acid I
inhibit O
LPS O
- O
induced O
inflammation O
in O
nuclear O
factor O
- O
kappa O
B O
transgenic O
mice O
as O
evaluated O
by O
in O
vivo O
bioluminescence O
imaging O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
anti O
- O
inflammatory O
effects O
of O
a O
nutritious O
vegetable O
Toona O
sinensis O
( O
leaf O
extracts O
, O
TS O
) O
and O
its O
major O
bioactive O
compound O
gallic B
acid I
( O
GA O
) O
by O
analysing O
LPS O
- O
induced O
NF O
- O
kappa O
B O
activation O
in O
transgenic O
mice O
, O
using O
bioluminescence O
imaging O
. O

HPLC O
confirmatory O
method O
development O
for O
the O
determination O
of O
seven O
quinolones B
in O
salmon O
tissue O
( O
Salmo O
salar O
L O
. O
) O
validated O
according O
to O
the O
European O
Union O
Decision O
2002 O
/ O
657 O
/ O
EC O
. O

A O
confirmatory O
high O
pressure O
liquid O
chromatographic O
method O
for O
the O
determination O
of O
seven O
quinolone B
antibiotics O
in O
tissue O
of O
Atlantic O
salmon O
( O
Salmo O
salar O
L O
. O
) O
was O
developed O
. O

Ciprofloxacin B
( O
CIP B
) O
, O
danofloxacin O
( O
DAN O
) O
, O
enrofloxacin O
( O
ENR O
) O
, O
sarafloxacin O
( O
SAR B
) O
, O
oxolinic O
acid O
( O
OXO B
) O
, O
nalidixic O
acid O
( O
NAL O
) O
and O
flumequine O
( O
FLU O
) O
were O
separated O
on O
a O
Perfectsil O
ODS O
- O
2 O
120 O
( O
250 O
mm O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O
0 O
. O
1 O
% O
trifluoroacetic B
acid I
( O
pH O
= O
1 O
) O

, O
acetonitrile B
and O
methanol B
at O
25 O
degrees O
C O
within O
22 O
min O
. O

Analytes O
were O
monitored O
at O
255 O
nm O
( O
for O
the O
determination O
of O
OXO B
, O
NAL O
and O
FLU O
) O
and O
275 O
nm O
( O
for O
CIP B
, O
DAN O
, O
ENR O
and O
SAR B
) O
by O
means O
of O
photodiode O
array O
detector O
. O

Examined O
quinolones B
were O
isolated O
from O
salmon O
tissue O
by O
extraction O
with O
citrate B
buffer O
solution O
( O
pH O
= O
4 O
. O
7 O
) O
and O
purified O
by O
solid O
phase O
extraction O
using O
Oasis O
HLB O
( O
200mg O
/ O
6 O
mL O
) O
cartridges O
. O

Suspended O
cells O
of O
Glycyrrhiza O
( O
CG O
) O
possessed O
a O
similar O
content O
of O
flavonoids B
and O
a O
lower O
content O
of O
triterpenes B
, O
when O
compared O
with O
its O
field O
cultivated O
equivalent O
( O
NG O
) O
. O

Xylene B
- O
induced O
ear O
oedema O
and O
ovalbumin O
- O
induced O
mouse O
paw O
oedema O
were O
applied O
, O
to O
compare O
the O
effects O
of O
CG O
and O
NG O
on O
the O
acute O
inflammatory O
response O
. O

Quantitative O
determination O
of O
fatty B
acid I
chain O
composition O
in O
pork O
meat O
products O
by O
high O
resolution O
1H B
NMR O
spectroscopy O
. O

High O
resolution O
( B
1 I
) I
H I
NMR O
spectroscopy O
was O
proposed O
for O
the O
determination O
of O
the O
fatty B
acid I
chain O
profile O
of O
lipids O
in O
pork O
meat O
products O
during O
ripening O
. O

Quantitative O
NMR O
analysis O
provided O
the O
fatty B
acid I
chain O
profiles O
of O
total O
lipid O
extracts O
. O

In O
all O
cases O
, O
oleyl O
chains O
were O
predominant O
, O
and O
high O
amounts O
of O
polyunsaturated B
fatty I
acid I
chains O
were O
observed O
. O

Identification O
of O
a O
novel O
phenolic B
compound O
in O
litchi O
( O
Litchi O
chinensis O
Sonn O
. O
) O
pericarp O
and O
bioactivity O
evaluation O
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol B
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic B
, O
2 O
- O
( O
2 O
- O
hydroxyl O
- O
5 O
- O
( O
methoxycarbonyl O
) O
phenoxy O
) O
benzoic O
acid O
, O
together O
with O
kaempferol B
, O
isolariciresinol O
, O
stigmasterol B
, O
butylated B
hydroxytoluene I
, O
3 O
, O
4 O
- O
dihydroxyl O
benzoate O
, O
methyl O
shikimate O
and O
ethyl O
shikimate O
. O

Antioxidant O
activities O
of O
the O
eight O
compounds O
were O
determined O
by O
a O
DPPH B
radical O
scavenging O
assay O
and O
the O
results O
showed O
that O
2 O
- O
( O
2 O
- O
hydroxy O
- O
5 O
- O
( O
methoxycarbonyl O
) O
phenoxy O
) O
benzoic O
acid O
, O
kaempferol B
, O
isolariciresinol O
, O
butylated B
hydroxytoluene I
and O
3 O
, O
4 O
- O
dihydroxy O
benzoate O
exhibited O
good O
antioxidant O
activities O
. O

An O
interesting O
finding O
was O
that O
butylated B
hydroxytoluene I
was O
detected O
as O
a O
natural O
antioxidant O
in O
this O
work O
, O
which O
was O
usually O
taken O
as O
a O
synthesized O
antioxidant O
. O

Solvent O
choice O
was O
the O
most O
important O
factor O
in O
the O
extraction O
of O
resveratrols O
, O
and O
mixed O
methanol B
and O
ethyl B
acetate I
[ O
50 O
: O
50 O
( O
v O
/ O
v O
) O
] O
had O
much O
higher O
extraction O
efficiency O
than O
the O
other O
five O
solvents O
tested O
. O

For O
extracting O
resveratrols O
, O
1g O
of O
berry O
skins O
or O
leaf O
tissue O
extracted O
in O
10 O
mL O
methanol B
and O
ethyl B
acetate I
[ O
50 O
: O
50 O
( O
v O
/ O
v O
) O
] O
for O
24h O
at O
25 O
degrees O
C O
in O
darkness O
was O
the O
optimized O
extraction O
condition O
. O

The O
optimized O
analytical O
method O
for O
HPLC O
was O
a O
multi O
- O
step O
gradient O
elution O
using O
acetonitrile B
and O
water O
. O

The O
resveratrol B
content O
of O
' O
Beta O
' O
was O
between O
that O
of O
' O
Zhi O
168 O
' O
and O
' O
Saint O
- O
Emilion O
' O
. O

C O
. O
nobile O
proved O
to O
be O
an O
equilibrated O
valuable O
herb O
rich O
in O
carbohydrates B
and O
proteins O
, O
and O
poor O
in O
fat O
, O
providing O
tocopherols B
, O
carotenoids O
and O
essential O
fatty B
acids I
( O
C18 O
: O
2n6 O
and O
C18 O
: O
3n3 O
) O
. O

Moreover O
, O
the O
herb O
and O
its O
infusion O
are O
a O
source O
of O
phenolic B
compounds O
( O
flavonoids B
such O
as O
flavonols B
and O
flavones B
, O
phenolic B
acids I
and O
derivatives O
) O
and O
organic O
acids O
( O
oxalic O
, O
quinic O
, O
malic O
, O
citric O
and O
fumaric O
acids O
) O
that O
showed O
antioxidant O
and O
antitumour O
activities O
, O
without O
hepatotoxicity O
. O

The O
most O
abundant O
compounds O
in O
the O
plant O
extract O
and O
infusion O
were O
5 O
- O
O O
- O
caffeoylquinic O
acid O
and O
an O
apigenin B
derivative O
. O

Besides O
enniatins O
A O
, O
A1 O
, O
B O
and O
B1 O
, O
also O
deoxynivalenol B
and O
its O
conjugated O
form O
( O
deoxynivalenol O
- O
3 O
- O
glucoside O
) O
were O
determined O
in O
almost O
all O
tested O
cereal O
- O
based O
samples O
. O

CS O
exposure O
caused O
significant O
lung O
damage O
, O
as O
evidenced O
by O
higher O
levels O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
neutrophil O
infiltration O
, O
dityrosine O
and O
4 O
- O
HNE O
, O
as O
well O
as O
lower O
levels O
of O
Mn B
- O
superoxide B
dismutase O
and O
catalase O
expression O
. O

The O
solution O
at O
pH O
3 O
. O
2 O
and O
0 O
% O
ethanol B
resulted O
the O
most O
effective O
as O
it O
led O
to O
the O
extraction O
of O
a O
higher O
number O
and O
amount O
of O
free O
and O
glycosilated O
volatile O
compounds O
. O

The O
enzyme O
activity O
was O
measured O
using O
ABTS B
as O
a O
chromogenic O
substrate O
( O
pH O
6 O
. O
0 O
) O
. O

The O
degree O
of O
LPO O
purification O
was O
monitored O
by O
SDS B
- O
PAGE O
and O
its O
R O
( O
z O
) O
( O
A O
( O
412 O
) O
/ O
A O
( O
280 O
) O
) O
value O
. O

Infusion O
and O
decoction O
of O
wild O
German O
chamomile O
: O
bioactivity O
and O
characterization O
of O
organic O
acids O
and O
phenolic B
compounds O
. O

Herein O
, O
the O
methanol B
extract O
of O
Matricaria O
recutita O
L O
. O

The O
decoction O
exhibited O
no O
antitumour O
activity O
( O
GI O
( O
50 O
) O
> O
400 O
mu O
g O
/ O
mL O
) O
which O
could O
indicate O
that O
this O
bioactivity O
might O
be O
related O
to O
compounds O
( O
including O
phenolic B
compounds O
) O
that O
were O
not O
extracted O
or O
that O
were O
affected O
by O
the O
decoction O
procedure O
. O

Both O
plant O
methanol B
extract O
and O
infusion O
showed O
inhibitory O
activity O
to O
the O
growth O
of O
HCT O
- O
15 O
( O
GI O
( O
50 O
) O
250 O
. O
24 O
and O
298 O
. O
23 O
mu O
g O
/ O
mL O
, O
respectively O
) O
and O
HeLa O
( O
GI O
( O
50 O
) O
259 O
. O
36 O
and O
277 O
. O
67 O
mu O
g O
/ O
mL O
, O
respectively O
) O
cell O
lines O
, O
without O
hepatotoxicity O
( O
GI O
( O
50 O
) O
> O
400 O
mu O
g O
/ O
mL O
) O
. O

Otherwise O
, O
the O
plant O
methanol B
extract O
contained O
the O
highest O
amounts O
of O
both O
phenolic B
acids I
( O
3 O
. O
99 O
g O
/ O
100g O
dw O
) O
and O
flavonoids B
( O
2 O
. O
59 O
g O
/ O
100g O
dw O
) O
. O

Many O
major O
components O
( O
> O
50 O
) O
of O
beeswax O
, O
odd O
and O
even O
hydrocarbons B
, O
oleofin O
, O
palmitate O
, O
oleate O
and O
hydroxypalmitate O
monoesters O
were O
detected O
, O
and O
for O
the O
first O
time O
palmitate O
and O
oleate O
monoesters O
esterified O
with O
1 O
- O
octadecanol O
and O
1 O
- O
eicosanol O
are O
reported O
to O
be O
present O
in O
beeswax O
. O

Unsupervised O
pattern O
recognition O
procedures O
, O
cluster O
analysis O
and O
principal O
component O
analysis O
, O
were O
used O
to O
find O
data O
patterns O
and O
successfully O
differentiate O
authentic O
and O
paraffin B
adulterated O
beeswax O
based O
on O
the O
chemical O
profile O
obtained O
. O

The O
discrimination O
power O
of O
the O
chemometric O
unsupervised O
methods O
for O
detection O
of O
paraffin B
adulterated O
beeswax O
was O
superior O
to O
the O
discriminating O
power O
of O
classical O
analytical O
parameters O
. O

Using O
linear O
discriminant O
analysis O
, O
classification O
rules O
for O
authentic O
and O
paraffin B
adulterated O
beeswax O
samples O
were O
developed O
. O

Folates B
, O
such O
as O
[ O
6S O
] O
- O
5 O
- O
methyltetrahydrofoli O
acid O
, O
have O
been O
introduced O
in O
the O
market O
both O
in O
vitamin O
pills O
and O
in O
fortified O
foods O
. O

Results O
suggest O
that O
stereoisomeric O
difference O
could O
influence O
the O
antioxidant O
activity O
of O
5 O
- O
MTHF O
and O
hence O
should O
be O
taken O
into O
account O
when O
folates B
are O
added O
to O
foodstuffs O
to O
improve O
their O
nutritional O
value O
. O

When O
viscera O
extract O
from O
hybrid O
catfish O
was O
used O
for O
the O
production O
of O
protein O
hydrolysate O
from O
toothed O
ponyfish O
muscle O
, O
extract O
concentration O
, O
reaction O
time O
, O
and O
fish O
muscle O
/ O
buffer O
ratio O
affected O
the O
hydrolysis O
and O
nitrogen B
recovery O
( O
NR O
) O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
protein O
hydrolysate O
contained O
a O
high O
amount O
of O
essential O
amino B
acids I
( O
48 O
. O
22 O
% O
) O
and O
had O
arginine B
and O
lysine B
as O
the O
dominant O
amino B
acids I
. O

Simultaneous O
separation O
and O
purification O
of O
total O
polyphenols B
, O
chlorogenic B
acid I
and O
phlorizin B
from O
thinned O
young O
apples O
. O

An O
efficient O
preparative O
separation O
of O
polyphenols B
from O
thinned O
young O
apples O
( O
TYA O
) O
has O
been O
developed O
in O
the O
present O
study O
. O

X O
- O
5 O
resin O
was O
verified O
to O
offer O
the O
best O
adsorption O
capacity O
and O
desorption O
ratio O
for O
total O
polyphenols B
among O
the O
eight O
macroporous O
resins O
investigated O
. O

Influential O
factors O
, O
such O
as O
pH O
value O
and O
concentration O
of O
feeding O
solution O
, O
strippant O
, O
and O
adsorption O
isotherm O
to O
the O
separation O
of O
total O
polyphenols B
, O
were O
successively O
investigated O
on O
X O
- O
5 O
resin O
. O

After O
one O
run O
treatment O
, O
the O
phenolic B
content O
was O
increased O
2 O
. O
12 O
- O
fold O
from O
35 O
. O
17 O
% O
to O
74 O
. O
64 O
% O
, O
with O
a O
recovery O
yield O
of O
89 O
. O
35 O
% O
. O

Chlorogenic B
acid I
and O
phlorizin B
were O
selectively O
purified O
using O
X O
- O
5 O
and O
polyamide B
resins O
. O

The O
contents O
of O
chlorogenic B
acid I
and O
phlorizin B
were O
15 O
. O
20 O
% O
and O
97 O
. O
52 O
% O
with O
recovery O
yields O
of O
89 O
. O
16 O
% O
and O
64 O
. O
95 O
% O
, O
respectively O
. O

LSF O
water O
- O
soluble O
fractions O
had O
higher O
( O
P O
< O
= O
0 O
. O
05 O
) O
free O
amino B
groups O
, O
GABA B
content O
, O
antioxidant O
and O
angiotensin O
I O
- O
converting O
enzyme O
inhibitory O
( O
ACEI O
) O
activities O
than O
SSF O
. O

In O
addition O
, O
GABA B
and O
ACEI O
activity O
of O
LSF O
increased O
in O
a O
time O
- O
dependent O
manner O
. O

Proteolysis O
by O
BS O
was O
limited O
, O
with O
slight O
changes O
in O
free O
amino B
groups O
, O
while O
GABA B
, O
total O
phenolic B
compounds O
and O
antioxidant O
capacity O
increased O
throughout O
fermentation O
. O

Higher O
antihypertensive O
potential O
was O
observed O
in O
NF O
( O
96 O
h O
) O
characterised O
by O
the O
highest O
GABA B
content O
( O
10 O
. O
42 O
mg O
/ O
g O
extract O
) O
, O
ACE O
- O
inhibitory O
potency O
( O
expressed O
as O
IC O
( O
50 O
) O
) O
of O
0 O
. O
18 O
mg O
protein O
/ O
ml O
and O
antioxidant O
capacity O
of O
0 O
. O
26 O
mmol O
Trolox B
equivalents O
/ O
g O
extract O
. O

Fucoxanthin B
content O
and O
antioxidant O
properties O
of O
Undaria O
pinnatifida O
. O

This O
study O
investigated O
the O
fucoxanthin B
content O
of O
New O
Zealand O
( O
NZ O
) O
Undaria O
pinnatifida O
harvested O
from O
two O
locations O
in O
the O
Marlborough O
Sounds O
, O
New O
Zealand O
across O
its O
growing O
season O
. O

Fucoxanthin B
content O
and O
antioxidant O
properties O
of O
processed O
New O
Zealand O
U O
. O
pinnatifida O
and O
commercial O
wakame O
from O
Japan O
and O
Korea O
were O
further O
compared O
. O

Results O
showed O
that O
U O
. O
pinnatifida O
harvested O
from O
Port O
Underwood O
had O
higher O
fucoxanthin B
content O
in O
the O
blade O
compared O
to O
Pelorus O
Sound O
. O

The O
sporophyll O
also O
contained O
a O
significant O
amount O
of O
fucoxanthin B
throughout O
the O
harvest O
season O
, O
although O
lower O
than O
in O
the O
blade O
. O

Two O
antioxidant O
measurement O
methods O
, O
DPPH B
and O
CUPRAC O
, O
were O
utilised O
to O
measure O
antioxidant O
activities O
. O

Processed O
NZ O
U O
. O
pinnatifida O
had O
a O
lower O
fucoxanthin B
content O
and O
antioxidant O
activity O
than O
freeze O
- O
dried O
Undaria O
. O

Fucoxanthin B
content O
and O
antioxidant O
activities O
of O
NZ O
processed O
U O
. O
pinnatifida O
were O
not O
significantly O
different O
from O
other O
commercial O
samples O
from O
Japan O
and O
Korea O
. O

Structure O
and O
composition O
of O
model O
cheeses O
influence O
sodium B
NMR O
mobility O
, O
kinetics O
of O
sodium B
release O
and O
sodium B
partition O
coefficients O
. O

The O
mobility O
and O
release O
of O
sodium B
ions O
were O
assessed O
in O
model O
cheeses O
with O
three O
different O
lipid O
/ O
protein O
ratios O
, O
with O
or O
without O
added O
NaCl B
. O

( O
23 O
) O
Na O
nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectroscopy O
was O
used O
to O
study O
the O
molecular O
mobility O
of O
sodium B
ions O
in O
model O
cheeses O
through O
measurements O
of O
the O
relaxation O
and O
creation O
times O
. O

Greater O
mobility O
was O
observed O
in O
cheeses O
containing O
a O
lower O
protein O
content O
and O
with O
added O
NaCl B
. O

The O
kinetics O
of O
sodium B
release O
from O
the O
cheese O
to O
an O
aqueous O
phase O
was O
correlated O
with O
the O
mobility O
of O
sodium B
ions O
. O

The O
highest O
rates O
of O
sodium B
release O
were O
observed O
with O
a O
lower O
protein O
content O
and O
with O
added O
NaCl B
. O

The O
water O
/ O
cheese O
partition O
coefficients O
of O
sodium B
increased O
when O
NaCl B
was O
added O
or O
the O
protein O
content O
was O
higher O
. O

The O
study O
highlighted O
the O
effect O
of O
model O
cheese O
characteristics O
on O
molecular O
and O
macroscopic O
behaviours O
of O
sodium B
. O

A O
combination O
of O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Huperzine I
A I
improves O
protection O
against O
soman O
toxicity O
compared O
to O
[ B
+ I
] I
- I
Huperzine I
A I
in O
guinea O
pigs O
. O

[ B
- I
] I
- I
Huperzine I
A I
( O
[ O
- O
] O
- O
Hup O
A O
) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE O
inhibitor O
that O
penetrates O
the O
blood O
- O
brain O
barrier O
. O

[ O
+ O
] O
- O
Hup O
A O
block O
the O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino B
acid I
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O

We O
investigated O
a O
combination O
of O
[ O
+ O
] O
- O
Hup O
A O
with O
a O
small O
dose O
of O
[ O
- O
] O
- O
Hup O
A O
( O
[ O
+ O
] O
and O
[ O
- O
] O
- O
Hup O
A O
) O
against O
soman B
toxicity O
. O

Organophosphorus B
compound O
esterase O
profiles O
as O
predictors O
of O
therapeutic O
and O
toxic O
effects O
. O

Certain O
organophosphorus B
compounds O
( O
OPCs O
) O
inhibit O
various O
serine B
esterases O
( O
EOHs O
) O
via O
phosphorylation O
of O
their O
active O
site O
serines O
. O

The O
general O
formula O
of O
the O
OPCs O
was O
( O
RO O
) O
2P O
( O
O O
) O
X O
, O
where O
R O
= O
alkyl B
, O
X O
= O
- O
SCH O
( O
Hal O
) O
COOEt O
( O
Hal O
= O
Cl B
, O
Br B
) O
, O
- O
SCHCl2 O
, O
- O
SCH2Br O
, O
- O
OCH O
( O
CF3 O
) O
R O
( O
1 O
) O
( O
R O
( O
1 O
) O
= O
C6H5 O
, O
CF3 B
, O
COOEt O
, O
COOMe O
) O
. O

New O
tools O
in O
diagnosis O
and O
biomonitoring O
of O
intoxications O
with O
organophosphorothioa O
: O
Case O
studies O
with O
chlorpyrifos B
and O
diazinon B
. O

Organophosphate B
( O
OP O
) O
pesticides O
are O
neurotoxic O
compounds O
that O
are O
widely O
used O
in O
agriculture O
. O

These O
adducts O
can O
be O
analyzed O
by O
means O
of O
fluoride B
reactivation O
or O
by O
analysis O
with O
LC O
- O
MS O
/ O
MS O
of O
the O
pepsin O
or O
pronase O
digest O
of O
butyrylcholinesteras O
and O
albumin O
, O
respectively O
. O

The O
utility O
of O
these O
methods O
is O
illustrated O
through O
the O
analysis O
of O
plasma O
samples O
obtained O
from O
patients O
taken O
1 O
- O
49days O
after O
ingestion O
of O
the O
organophosphate B
pesticides O
chlorpyrifos B
and O
/ O
or O
diazinon B
. O

Strategies O
for O
the O
selection O
of O
catalytic O
antibodies O
against O
organophosphorus B
nerve O
agents O
. O

Among O
the O
strategies O
aimed O
at O
biocompatible O
means O
for O
organophosphorus B
nerve O
agents O
neutralization O
, O
immunoglobulins O
have O
attracted O
attention O
in O
the O
1990 O
' O
s O
and O
2000 O
' O
s O
both O
for O
their O
ability O
to O
immobilize O
the O
toxicants O
, O
but O
also O
for O
their O
ability O
to O
be O
turned O
into O
enzymatically O
active O
antibodies O
known O
as O
catalytic O
antibodies O
or O
abzymes O
( O
antibodies O
- O
enzymes O
) O
. O

Helenalin O
- O
induced O
apoptosis O
is O
dependent O
on O
production O
of O
reactive O
oxygen B
species O
and O
independent O
of O
induction O
of O
endoplasmic O
reticulum O
stress O
in O
renal O
cell O
carcinoma O
. O

Helenalin O
, O
a O
sesquiterpene B
lactone I
, O
exhibits O
anti O
- O
inflammatory O
and O
anti O
- O
tumor O
activities O
. O

Helenalin O
increased O
production O
of O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Furthermore O
, O
ROS O
scavengers O
, O
N O
- O
acetylcystine O
( O
NAC B
) O
, O
and O
glutathione O
ethyl O
ester O
( O
GEE O
) O
, O
reduced O
helenalin O
- O
induced O
apoptosis O
. O

Dietary O
quercetin B
ameliorates O
nonalcoholic O
steatohepatitis O
induced O
by O
a O
high O
- O
fat O
diet O
in O
gerbils O
. O

Dietary O
quercetin B
is O
highly O
abundant O
in O
edible O
plants O
, O
which O
possesses O
a O
wide O
range O
of O
pharmacological O
properties O
. O

This O
study O
was O
to O
investigate O
hepatoprotective O
effects O
of O
quercetin B
in O
the O
nonalcoholic O
steatohepatitis O
( O
NASH O
) O
gerbils O
induced O
by O
a O
high O
- O
fat O
diet O
( O
HFD O
) O
, O
and O
to O
evaluate O
its O
regulatory O
mechanism O
on O
hepatic O
inflammatory O
response O
. O

The O
results O
showed O
that O
oral O
administration O
of O
quercetin B
at O
doses O
of O
30 O
- O
60 O
mg O
/ O
kg O
to O
hyperlipidemia O
rats O
for O
14 O
days O
were O
highly O
effective O
in O
decreasing O
the O
levels O
of O
serum O
total O
cholesterol B
( O
TC O
) O
, O
triglycerides B
( O
TG O
) O
, O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
, O
alanine B
aminotransferase O
( O
ALT O
) O
and O
aspartate B
aminotransferase O
( O
AST O
) O
. O

Thus O
, O
dietary O
quercetin B
had O
significant O
therapeutic O
benefits O
and O
could O
be O
explored O
as O
a O
potential O
promising O
candidate O
for O
the O
prevention O
of O
NASH O
. O

Neuroprotective O
role O
of O
ATP B
- O
sensitive O
potassium B
channels O
in O
cerebral O
ischemia O
. O

ATP B
- O
sensitive O
potassium B
( O
K B
( O
ATP B
) O
) O
channels O
are O
weak O
, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity O
, O
thus O
modulating O
many O
cellular O
functions O
. O

An O
increase O
in O
the O
ADP B
/ O
ATP B
ratio O
opens O
K B
( O
ATP B
) O
channels O
, O
leading O
to O
membrane O
hyperpolarization O
. O

K B
( O
ATP B
) O
channels O
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain O
, O
including O
the O
hippocampus O
and O
cortex O
. O

In O
vivo O
animal O
studies O
confirmed O
that O
knocking O
out O
the O
Kir6 O
. O
2 O
subunit O
of O
the O
K B
( O
ATP B
) O
channels O
increases O
ischemic O
infarction O
, O
and O
overexpression O
of O
the O
Kir6 O
. O
2 O
subunit O
reduces O
neuronal O
injury O
from O
ischemic O
insults O
. O

These O
findings O
provide O
the O
basis O
for O
a O
practical O
strategy O
whereby O
activation O
of O
endogenous O
K B
( O
ATP B
) O
channels O
reduces O
cellular O
damage O
resulting O
from O
cerebral O
ischemic O
stroke O
. O

K B
( O
ATP B
) O
channel O
modulators O
may O
prove O
to O
be O
clinically O
useful O
as O
part O
of O
a O
combination O
therapy O
for O
stroke O
management O
in O
the O
future O
. O

Using O
dissociated O
hippocampal O
neuronal O
cultures O
, O
we O
identified O
a O
critical O
and O
cell O
autonomous O
role O
for O
the O
receptor O
tyrosine B
kinase O
EphA4 O
in O
mediating O
activity O
- O
induced O
homeostatic O
down O
- O
regulation O
of O
excitatory O
synaptic O
strength O
. O

First O
- O
principles O
calculations O
of O
lithium B
- O
ion O
migration O
at O
a O
coherent O
grain O
boundary O
in O
a O
cathode O
material O
, O
LiCoO O
( O
2 O
) O
. O

This O
study O
suggests O
that O
internal O
interfaces O
in O
LiCoO O
( O
2 O
) O
strongly O
affect O
the O
battery O
voltage O
, O
battery O
capacity O
, O
and O
power O
density O
of O
this O
material O
, O
which O
is O
of O
particular O
concern O
if O
it O
is O
used O
in O
all O
- O
solid O
- O
state O
Li B
- O
ion O
batteries O
. O

Pathways O
related O
to O
glutathione B
biosynthesis O
and O
metabolism O
were O
the O
primary O
pathways O
consistent O
with O
cross O
- O
species O
differences O
in O
tumor O
incidence O
. O

In O
this O
mouse O
strain O
with O
' O
fully O
humanized O
' O
CYP3A O
genes O
, O
the O
kinetics O
of O
triazolam B
metabolism O
, O
CYP3A O
- O
mediated O
mechanism O
- O
based O
inactivation O
effects O
and O
formation O
of O
fetal O
- O
specific O
metabolites O
of O
dehydroepiandrostero B
observed O
in O
humans O
were O
well O
reproduced O
. O

Enhancement O
on O
oral O
absorption O
of O
paclitaxel B
by O
multifunctional O
pluronic O
micelles O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
synthesize O
Pluronic O
F127 O
- O
polyethylenimine O
- O
folate O
( O
PF127 O
- O
PEI O
- O
FA O
) O
copolymer O
, O
construct O
a O
mixed O
micelle O
system O
with O
PF127 O
- O
PEI O
- O
FA O
copolymer O
and O
Pluronic O
P123 O
( O
PP123 O
) O
and O
to O
evaluate O
the O
potential O
of O
these O
mixed O
micelles O
as O
an O
oral O
drug O
delivery O
system O
for O
paclitaxel B
( O
PTX B
) O
. O

The O
results O
of O
intestinal O
absorption O
revealed O
that O
the O
PTX B
- O
loaded O
micelles O
displayed O
superior O
permeability O
across O
intestinal O
barrier O
than O
free O
drug O
and O
PF127 O
- O
PEI O
- O
FA O
/ O
PP123 O
mixed O
micelles O
exhibited O
the O
strongest O
permeability O
across O
intestinal O
barrier O
. O

The O
presence O
of O
verapamil B
and O
Pluronic B
both O
improved O
the O
intestinal O
absorption O
of O
PTX B
, O
which O
further O
certified O
the O
effect O
of O
Pluronic B
on O
P O
- O
gp O
inhibition O
. O

Pharmacokinetic O
study O
demonstrated O
that O
the O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
( O
AUC O
( O
0 O
- O
- O
> O
36 O
h O
) O
) O
of O
PTX B
- O
loaded O
micelles O
was O
three O
times O
greater O
than O
the O
PTX B
solution O
( O
dissolved O
in O
a O
50 O
/ O
50 O
( O
vol O
/ O
vol O
) O
mixture O
of O
Cremophore O
EL O
/ O
dehydrated O
ethanol B
) O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
general O
PF127 O
- O
PEI O
- O
FA O
/ O
PP123 O
mixed O
micelles O
were O
proved O
to O
be O
potential O
oral O
drug O
delivery O
system O
for O
PTX B
. O

Is O
polycystic O
ovary O
syndrome O
, O
a O
state O
of O
relative O
estrogen B
excess O
, O
a O
real O
risk O
factor O
for O
estrogen B
- O
dependant O
malignancies O
? O

Chronic O
anovulation O
combined O
with O
relative O
estrogen B
excess O
and O
consequent O
prolonged O
stimulatory O
effect O
on O
the O
endometrium O
can O
lead O
to O
the O
pathogenesis O
of O
hormonal O
dependant O
carcinoma O
. O

This O
article O
provides O
a O
critical O
literature O
review O
of O
the O
relationship O
between O
PCOS O
and O
the O
incidence O
of O
estrogen B
- O
dependant O
gynecological O
tumours O
, O
and O
it O
then O
discusses O
whether O
the O
commonly O
cited O
risk O
factor O
association O
can O
be O
substantiated O
by O
high O
quality O
studies O
which O
comply O
with O
the O
requirements O
of O
" O
evidence O
- O
based O
medicine O
. O
" O

Precipitation O
of O
Ibuprofen O
Sodium O
using O
compressed O
carbon B
dioxide I
as O
antisolvent O
. O

Brain O
tissues O
were O
collected O
and O
analyzed O
by O
western O
blot O
, O
enzyme O
immunoassay O
, O
spectrophotometric O
assays O
and O
terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP B
end O
- O
labeling O
( O
TUNEL O
) O
staining O
. O

Additionally O
, O
it O
decreased O
the O
levels O
of O
malondialdehyde B
and O
elevated O
total O
superoxide B
dismutase O
activity O
, O
which O
was O
accompanied O
by O
reductions O
of O
NADPH B
oxidase O
subunit O
gp91 O
( O
phox O
) O
and O
inducible O
nitric B
oxide I
synthase O
in O
the O
brain O
of O
SHR O
. O

Cell O
cycle O
regulation O
by O
glucosamine B
in O
human O
pulmonary O
epithelial O
cells O
. O

Glucosamine B
, O
a O
commonly O
used O
supplemental O
compound O
, O
has O
recently O
begun O
to O
be O
regarded O
as O
a O
potential O
anti O
- O
inflammatory O
molecule O
. O

This O
study O
aimed O
to O
uncover O
how O
glucosamine B
impacts O
on O
cellular O
proliferation O
in O
human O
alveolar O
epithelial O
cells O
( O
A549 O
) O
and O
bronchial O
epithelial O
cells O
( O
HBECs O
) O
. O

With O
trypan B
blue I
- O
exclusion O
assay O
, O
we O
observed O
that O
glucosamine B
( O
10 O
, O
20 O
, O
50 O
mM O
) O
caused O
a O
decrease O
in O
cell O
number O
at O
24 O
and O
48 O
h O
; O
with O
a O
flow O
cytometric O
analysis O
, O
we O
also O
noted O
an O
enhanced O
cell O
accumulation O
within O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
at O
24 O
h O
and O
induction O
of O
late O
apoptosis O
at O
24 O
and O
48 O
h O
by O
glucosamine B
( O
10 O
, O
20 O
, O
50 O
mM O
) O
in O
A549 O
cells O
and O
HBECs O
. O

Examination O
of O
phosphorylation O
in O
retinoblastoma O
( O
Rb O
) O
protein O
, O
we O
found O
an O
inhibitory O
effect O
by O
glucosamine B
at O
20 O
and O
50 O
mM O
. O

Glucosamine B
at O
50 O
mM O
was O
demonstrated O
to O
elevate O
both O
the O
mRNA O
and O
protein O
expression O
of O
p53 O
and O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
but O
also O
caused O
a O
reduction O
in O
p21 O
protein O
expression O
. O

In O
addition O
, O
glucosamine B
attenuated O
p21 O
protein O
stability O
via O
the O
proteasomal O
proteolytic O
pathway O
, O
as O
well O
as O
inducing O
p21 O
nuclear O
accumulation O
. O

Altogether O
, O
our O
results O
suggest O
that O
a O
high O
dose O
of O
glucosamine B
may O
inhibit O
cell O
proliferation O
through O
apoptosis O
and O
disturb O
cell O
cycle O
progression O
with O
a O
halt O
at O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
, O
and O
that O
this O
occurs O
, O
at O
least O
in O
part O
, O
by O
a O
reduction O
in O
Rb O
phosphorylation O
together O
with O
modulation O
of O
p21 O
, O
p53 O
and O
HO O
- O
1 O
expression O
, O
and O
nuclear O
p21 O
accumulation O
. O

Prediction O
of O
crizotinib B
- O
midazolam B
interaction O
using O
the O
Simcyp O
population O
- O
based O
simulator O
: O
comparison O
of O
CYP3A O
time O
- O
dependent O
inhibition O
between O
human O
liver O
microsomes O
versus O
hepatocytes O
. O

Crizotinib B
( O
Xalkori O
) O
is O
an O
orally O
available O
potent O
inhibitor O
of O
multiple O
tyrosine B
kinases O
, O
including O
anaplastic O
lymphoma O
kinase O
and O
mesenchymal O
- O
epithelial O
transition O
factor O
. O

Objectives O
of O
the O
present O
study O
were O
as O
follows O
: O
1 O
) O
to O
characterize O
crizotinib B
time O
- O
dependent O
inhibition O
( O
TDI O
) O
potency O
for O
CYP3A O
in O
human O
liver O
microsomes O
( O
HLM O
) O
and O
cryopreserved O
human O
hepatocytes O
suspended O
in O
human O
plasma O
( O
HSP O
) O
; O
2 O
) O
to O
characterize O
crizotinib B
enzyme O
induction O
potency O
on O
CYP3A4 O
in O
cryopreserved O
human O
hepatocytes O
; O
3 O
) O
to O
predict O
crizotinib B
steady O
- O
state O
plasma O
concentrations O
in O
patients O
( O
e O
. O
g O
. O
, O
autoinhibition O

and O
autoinduction O
) O
using O
the O
mechanistic O
dynamic O
model O
, O
Simcyp O
population O
- O
based O
simulator O
; O
and O
4 O
) O
to O
predict O
a O
clinical O
crizotinib B
- O
midazolam B
interaction O
using O
the O
dynamic O
model O
as O
well O
as O
the O
static O
mathematical O
model O
. O

Crizotinib B
inactivation O
constant O
( O
K O
( O
I O
) O
) O
and O
maximum O
inactivation O
rate O
constant O
( O
k O
( O
inact O
) O
) O
for O
TDI O
were O
estimated O
as O
, O
respectively O
, O
0 O
. O
37 O
micro O
M O
and O
6 O
. O
9 O
h O
( O
- O
1 O
) O
in O
HLM O
and O
0 O
. O
89 O
micro O
M O
and O
0 O
. O
78 O
h O
( O
- O
1 O
) O
in O
HSP O
. O

Thus O
, O
crizotinib B
inactivation O
efficiency O
( O
k O
( O
inact O
) O
/ O
K O
( O
I O
) O
) O
was O
~ O
20 O
- O
fold O
lower O
in O
HSP O
relative O
to O
HLM O
. O

Crizotinib B
E O
( O
max O
) O
and O
EC O
( O
50 O
) O
for O
CYP3A4 O
induction O
( O
measured O
as O
mRNA O
expression O
) O
were O
estimated O
as O
6 O
. O
4 O
- O
to O
29 O
- O
fold O
and O
0 O
. O
47 O
to O
3 O
. O
1 O
micro O
M O
, O
respectively O
. O

Based O
on O
these O
in O
vitro O
parameters O
, O
the O
predicted O
crizotinib B
steady O
- O
state O
area O
under O
plasma O
concentration O
- O
time O
curve O
( O
AUC O
) O
with O
HLM O
- O
TDI O
was O
2 O
. O
1 O
- O
fold O
higher O
than O
the O
observed O
AUC O
, O
whereas O
that O
with O
HSP O
- O
TDI O
was O
consistent O
with O
the O
observed O
result O
( O
< O
= O
1 O
. O
1 O
- O
fold O
) O
. O

The O
increase O
in O
midazolam B
AUC O
with O
coadministration O
of O
crizotinib B
( O
21 O
- O
fold O
) O
was O
significantly O
overpredicted O
using O
HLM O
- O
TDI O
, O
whereas O
the O
prediction O
using O
HSP O
- O
TDI O
( O
3 O
. O
6 O
- O
fold O
) O
was O
consistent O
with O
the O
observed O
result O
( O
3 O
. O
7 O
- O
fold O
) O
. O

Arsenic B
and O
arsenic B
species O
in O
cultured O
oyster O
( O
Crassostrea O
gigas O
and O
C O
. O
corteziensis O
) O
from O
coastal O
lagoons O
of O
the O
SE O
Gulf O
of O
California O
, O
Mexico O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
bioavailability O
of O
arsenic B
( O
As B
) O
through O
cultured O
oyster O
Crassostrea O
gigas O
and O
Crassostrea O
corteziensis O
from O
four O
coastal O
lagoons O
( O
SE O
Gulf O
of O
California O
) O
. O

Organisms O
were O
collected O
in O
two O
seasons O
( O
rainy O
and O
dry O
season O
) O
, O
and O
they O
were O
analyzed O
for O
total O
arsenic B
and O
chemical O
speciation O
of O
this O
element O
. O

The O
concentrations O
of O
As B
in O
oyster O
soft O
tissue O
fluctuated O
between O
5 O
. O
44 O
and O
9 O
. O
56 O
mu O
g O
/ O
g O
for O
rainy O
season O
and O
6 O
. O
46 O
and O
8 O
. O
33 O
mu O
g O
/ O
g O
for O
dry O
season O
( O
dry O
weight O
) O
in O
C O
. O
gigas O
. O

In O
C O
. O
corteziensis O
, O
the O
As B
concentrations O
were O
< O
5 O
mu O
g O
/ O
g O
for O
both O
seasons O
( O
dry O
weight O
) O
. O

Arsenic B
speciation O
indicated O
arsenobetaine O
as O
the O
major O
arseno O
- O
compound O
accounting O
for O
43 O
. O
2 O
- O
76 O
. O
3 O
% O
of O
total O
content O
of O
As B
. O

Lower O
contributions O
were O
obtained O
for O
non O
- O
extractable O
As B
( O
11 O
. O
3 O
- O
17 O
. O
5 O
% O
) O
and O
other O
molecules O
such O
as O
arsenocholine O
and O
methyl O
- O
arsonate O
( O
< O
5 O
% O
) O
. O

Inorganic O
arsenic B
was O
detectable O
in O
only O
two O
samples O
, O
at O
concentrations O
lower O
than O
< O
0 O
. O
1 O
mu O
g O
/ O
g O
. O

These O
As B
data O
are O
the O
first O
generated O
for O
these O
mollusks O
in O
NW O
Mexico O
and O
indicate O
that O
C O
. O
gigas O
and O
C O
. O
corteziensis O
farmed O
in O
this O
area O
are O
safe O
for O
human O
consumption O
in O
terms O
of O
arseno O
- O
compounds O
. O

We O
report O
the O
bindings O
of O
several O
lipids O
cholesterol B
( O
Chol O
) O
, O
1 O
, O
2 O
- O
dioleoyl O
- O
3 O
- O
trimethylammonium O
- O
propane O
( O
DOTAP B
) O
, O
dioctadecyldimethyla O
( O
DDAB O
) O
, O
and O
dioleoylphosphatidyl O
( O
DOPE B
) O
to O
dendrimers O
of O
different O
compositions O
such O
as O
mPEG O
- O
PAMAM O
( O
G3 O
) O
, O
mPEG O
- O
PAMAM O
( O
G4 O
) O
, O
and O
PAMAM B
( O
G4 O
) O
under O
physiological O
conditions O
. O

The O
free O
binding O
energies O
from O
docking O
were O
- O
5 O
. O
15 O
( O
cholesterol B
) O
, O
- O
5 O
. O
79 O
( O
DDAB O
) O
, O
and O
- O
5 O
. O
36 O
kcal O
/ O
mol O
( O
DOTAP B
) O
with O
the O
order O
of O
stability O
DDAB O
- O
PAMAM O
- O
G O
- O
4 O
> O
DOTAP O
- O
PAMAM O
- O
G4 O
> O
cholesterol B
- O
PAMAM O
- O
G4 O
, O
consistent O
with O
the O
spectroscopic O
results O
. O

We O
identified O
two O
genes O
in O
the O
glycolytic O
pathway O
( O
phosphoglycerate O
kinase O
1 O
( O
PGK1 O
) O
and O
pyruvate B
kinase O
M2 O
( O
PKM2 O
) O
) O
at O
the O
ATP B
production O
steps O
and O
experimentally O
validated O
their O
repression O
by O
PPAR O
gamma O
in O
two O
breast O
cancer O
cell O
lines O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
. O

Further O
analysis O
suggested O
that O
this O
repression O
leads O
to O
decrease O
in O
ATP B
levels O
and O
apoptosis O
. O

Precision O
- O
cut O
liver O
slices O
from O
humans O
and O
other O
species O
have O
been O
used O
to O
study O
pathways O
of O
phase O
I O
( O
e O
. O
g O
. O
cytochrome O
P450 O
- O
dependent O
biotransformations O
) O
and O
II O
( O
e O
. O
g O
. O
conjugation O
with O
D O
- O
glucuronic O
acid O
, O
sulphate B
and O
glutathione B
) O
metabolism O
of O
a O
wide O
range O
of O
xenobiotics O
. O

The O
objective O
of O
this O
study O
was O
to O
develop O
a O
controlled O
delivery O
system O
for O
PEGylated O
octreotide O
using O
a O
Poloxamer B
based O
in O
situ O
gel O
forming O
polymer O
. O

The O
designed O
drug O
delivery O
system O
contained O
low O
concentration O
of O
Poloxamer B
407 I
( O
P407 B
) O
( O
< O
0 O
. O
16 O
% O
) O
with O
polyvinyl B
alcohol I
( O
PVA B
) O
as O
a O
polymeric O
additive O
. O

Rheological O
measurements O
of O
gel O
vehicle O
formulations O
indicated O
that O
the O
in O
situ O
gel O
forming O
system O
with O
optimum O
sol O
- O
gel O
transition O
temperature O
of O
28 O
. O
7 O
degrees O
C O
could O
be O
formed O
using O
a O
combination O
of O
P407 B
and O
PVA B
at O
ratio O
of O
15 O
- O
10 O
% O
( O
w O
/ O
v O
) O
. O

The O
effect O
of O
formulation O
additives O
such O
as O
buffering O
agents O
on O
rheological O
behavior O
demonstrated O
that O
sodium O
bicarbonate O
and O
lactic B
acid I
have O
opposite O
effect O
on O
sol O
- O
gel O
transition O
temperature O
of O
the O
system O
. O

The O
in O
vitro O
release O
profiles O
of O
octreotide O
and O
PEGylated O
octreotide O
from O
the O
selected O
P407 B
/ O
PVA B
formulations O
were O
measured O
using O
a O
membrane O
- O
less O
device O
. O

Tissue O
histopathological O
studies O
confirmed O
the O
biocompatibility O
of O
the O
delivery O
system O
for O
PEGylated O
octreotide O
, O
supporting O
the O
suitability O
of O
P407 B
/ O
PVA B
mixture O
as O
an O
injectable O
drug O
delivery O
system O
. O

Glycogen O
synthase O
, O
a O
key O
enzyme O
in O
muscle O
glycogen O
synthesis O
, O
is O
extensively O
regulated O
, O
both O
allosterically O
( O
by O
glucose B
- I
6 I
- I
phosphate I
, O
ATP B
, O
and O
others O
) O
and O
covalently O
( O
by O
phosphorylation O
) O
. O

LARGE2 O
generates O
the O
same O
xylose B
- O
and O
glucuronic B
acid I
- O
containing O
glycan O
structures O
as O
LARGE O
. O

It O
is O
a O
bifunctional O
glycosyltransferase O
using O
uridine B
diphosphate I
( O
UDP B
) O
- O
xylose B
( O
Xyl O
) O
and O
UDP B
- O
glucuronic B
acid I
( O
GlcA B
) O
as O
donor O
sugars B
to O
produce O
a O
xyloglucuronan O
with O
alternating O
Xyl O
and O
GlcA B
residues O
. O

Reversible O
and O
cyclical O
transformations O
between O
solid O
and O
hollow O
nanostructures O
in O
confined O
reactions O
of O
manganese O
oxide O
and O
silica B
within O
nanosized O
spheres O
. O

Annealing O
of O
MnO B
@ O
SiO B
( I
2 I
) I
nanospheres O
in O
a O
reducing O
gas O
environment O
resulted O
in O
the O
transformation O
of O
the O
core O
- O
shell O
structure O
into O
a O
hollow O
structure O
as O
a O
result O
of O
outward O
diffusion O
of O
MnO B
species O
into O
the O
thermodynamically O
more O
stable O
silicate B
phase O
. O

When O
the O
hollow O
silicate B
nanospheres O
were O
oxidized O
, O
the O
interior O
cavities O
were O
refilled O
with O
a O
Mn O
( O
3 O
) O
O O
( O
4 O
) O
phase O
segregated O
from O
the O
silicate B
phase O
, O
and O
the O
hollow O
structure O
reverted O
to O
the O
initial O
core O
- O
shell O
structure O
. O

More O
interestingly O
, O
when O
catalytically O
active O
Pt B
nanocrystals O
were O
introduced O
into O
the O
manganese O
oxide O
/ O
silica B
system O
, O
the O
Mn O
( O
3 O
) O
O O
( O
4 O
) O
was O
readily O
reduced O
to O
the O
chemically O
reactive O
MnO B
, O
even O
at O
low O
temperature O
, O
which O
enabled O
reconversion O
of O
the O
solid O
nanospheres O
with O
a O
Mn O
( O
3 O
) O
O O
( O
4 O
) O
core O
to O
hollow O
nanostructures O
during O
reductive O
annealing O
. O

Therefore O
, O
when O
MnO B
@ O
SiO B
( I
2 I
) I
/ O
Pt B
( I
II I
) I
nanospheres O
were O
subjected O
to O
an O
oxidation O
/ O
reduction O
cycle O
by O
repeatedly O
switching O
the O
flowing O
gas O
between O
air O
and O
hydrogen B
, O
the O
nanospheres O
underwent O
a O
reversible O
change O
between O
solid O
and O
hollow O
structures O
, O
depending O
on O
the O
gas O
environment O
. O

Polydatin O
ameliorates O
renal O
injury O
by O
attenuating O
oxidative O
stress O
- O
related O
inflammatory O
responses O
in O
fructose B
- O
induced O
urate B
nephropathic O
mice O
. O

A O
series O
of O
studies O
have O
recently O
demonstrated O
that O
the O
oxidative O
stress O
, O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
activation O
and O
the O
subsequent O
coordinated O
inflammatory O
responses O
played O
an O
important O
role O
in O
the O
pathogenesis O
of O
urate B
nephropathy O
( O
UN O
) O
. O

In O
this O
study O
, O
polydatin O
showed O
inhibitory O
activities O
on O
xanthine B
oxidase O
to O
repress O
the O
level O
of O
serum O
uric B
acid I
in O
vivo O
and O
in O
vitro O
. O

Further O
investigations O
revealed O
that O
polydatin O
displayed O
little O
toxic O
effects O
and O
significantly O
ameliorated O
the O
renal O
function O
in O
fructose B
- O
induced O
UN O
mice O
. O

The O
nephroprotective O
activities O
of O
polydatin O
was O
not O
only O
due O
to O
the O
effects O
on O
remarkably O
attenuating O
the O
oxidative O
stress O
induced O
by O
uric B
acid I
, O
but O
also O
on O
markedly O
suppressing O
the O
oxidative O
stress O
- O
related O
inflammatory O
cascade O
, O
including O
decreasing O
the O
expressions O
of O
NF O
- O
kappa O
B O
p65 O
, O
COX O
- O
2 O
and O
iNOS O
proteins O
and O
inhibiting O
the O
productions O
of O
TNF O
- O
alpha O
, O
PGE O
( O
2 O
) O
and O
IL O
- O
1 O
beta O
. O

Alleviation O
effects O
of O
magnesium B
on O
copper B
toxicity O
and O
accumulation O
in O
grapevine O
roots O
evaluated O
with O
biotic O
ligand O
models O
. O

Copper B
toxicity O
and O
accumulation O
in O
plants O
are O
affected O
by O
physicochemical O
characteristics O
of O
soil O
solutions O
such O
as O
the O
concentrations O
of O
coexistent O
cations O
( O
e O
. O
g O
. O
, O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
K B
( I
+ I
) I
, O
Na B
( I
+ I
) I
, O
and O
H B
( I
+ I
) I
) O
. O

The O
alleviation O
effects O
of O
Mg B
on O
Cu B
toxicity O
and O
accumulation O
in O
grapevine O
roots O
were O
the O
main O
concerns O
in O
this O
study O
and O
were O
investigated O
by O
using O
a O
hydroponic O
experiment O
of O
grapevine O
cuttings O
. O

The O
BLM O
approach O
, O
which O
incorporated O
competition O
of O
Mg B
( I
2 I
+ I
) I
with O
Cu B
( I
2 I
+ I
) I
to O
occupy O
the O
biotic O
ligands O
on O
root O
surfaces O
, O
was O
developed O
to O
predict O
Cu B
rhizotoxicity O
and O
accumulation O
by O
grapevine O
roots O
. O

In O
the O
results O
, O
the O
effective O
activity O
of O
Cu B
, O
{ O
Cu B
( I
2 I
+ I
) I
} O
, O
resulting O
in O
a O
50 O
% O
reduction O
of O
root O
elongation O
( O
EA O
( O
50 O
) O
) O
, O
linearly O
increased O
with O
increments O
of O
Mg B
activity O
, O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

In O
addition O
, O
the O
Cu B
concentration O
in O
root O
, O
Cu B
( O
root O
) O
, O
was O
retarded O
by O
an O
increase O
of O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

The O
linear O
model O
was O
significantly O
fitted O
to O
the O
relationship O
between O
{ O
Cu B
( I
2 I
+ I
) I
} O
/ O
Cu B
( O
root O
) O
and O
{ O
Mg B
( I
2 I
+ I
) I
} O
. O

According O
to O
the O
concept O
of O
BLM O
, O
the O
present O
results O
revealed O
that O
the O
amelioration O
effects O
of O
Mg B
on O
Cu B
toxicity O
and O
accumulation O
in O
roots O
could O
arise O
from O
competition O
between O
Mg B
( I
2 I
+ I
) I
and O
Cu B
( I
2 I
+ I
) I
on O
the O
binding O
sites O
( O
i O
. O
e O
. O
, O
the O
biotic O
ligands O
) O
. O

Then O
, O
the O
developed O
Cu B
- O
BLMs O
incorporating O
the O
Mg B
( I
2 I
+ I
) I
competition O
effectiveness O
were O
validated O
provide O
accurate O
predictions O
of O
Cu B
toxicity O
and O
accumulation O
in O
grapevine O
roots O
. O

Bilayer O
lipid O
membranes O
( O
BLMs O
) O
are O
prepared O
in O
the O
device O
upon O
spontaneous O
and O
instantaneous O
thinning O
of O
the O
lipid O
solution O
in O
a O
100 O
- O
mu O
m O
dry O
- O
etched O
aperture O
in O
a O
12 O
. O
5 O
- O
mu O
m O
thick O
Teflon B
foil O
. O

Furthermore O
, O
the O
potential O
of O
this O
platform O
is O
demonstrated O
for O
( O
i O
) O
the O
in O
- O
depth O
characterization O
of O
BLMs O
comprising O
both O
synthetic O
and O
natural O
lipids O
( O
1 O
, O
2 O
- O
diphytanoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
( O
DPhPC O
) O
and O
L B
- I
alpha I
- I
phosphatidylcholine I
( O
L O
- O
alpha O
- O
PC O
) O
/ O
cholesterol B
, O
respectively O
) O
in O
terms O
of O
seal O
resistance O
, O
capacitance O
, O
surface O
area O
, O
specific O
capacitance O
, O
and O
membrane O
hydrophobic O
thickness O
; O
( O
ii O
) O
confocal O
microscopy O
imaging O

of O
phase O
separation O
in O
sphingomyelin B
/ O
L O
- O
alpha O
- O
PC O
/ O
cholesterol B
ternary O
membranes O
; O
( O
iii O
) O
electrical O
measurements O
of O
individual O
nanopores O
( O
alpha O
- O
hemolysin O
, O
gramicidin O
) O
; O
and O
( O
iv O
) O
indirect O
assessment O
of O
the O
alteration O
of O
membrane O
properties O
upon O
exposure O
to O
chemical O
stimuli O
using O
the O
natural O
nanopore O
gramicidin O
as O
a O
sensor O
. O

Sweet O
' O
n O
low O
in O
stereo O
: O
A O
Wharton O
reaction O
was O
employed O
along O
with O
a O
diastereoselective O
palladium B
- O
catalyzed O
glycosylation O
and O
other O
post O
- O
glycosylation O
transformations O
to O
synthesize O
digitoxin O
analogues O
. O

Cytotoxic O
evaluation O
against O
a O
panel O
of O
cancer O
cell O
lines O
uncovered O
the O
stereochemical O
and O
substitutional O
limits O
of O
the O
C3 O
' O
/ O
C4 O
' O
- O
hydroxy O
functionality O
in O
digitoxin O
monosaccharide B
. O

Neuronal O
androgen B
receptor O
regulates O
insulin O
sensitivity O
via O
suppression O
of O
hypothalamic O
NF O
- O
kappa O
B O
- O
mediated O
PTP1B O
expression O
. O

Clinical O
investigations O
highlight O
the O
increased O
incidence O
of O
metabolic O
syndrome O
in O
prostate O
cancer O
( O
PCa O
) O
patients O
receiving O
androgen B
deprivation O
therapy O
( O
ADT O
) O
. O

Studies O
using O
global O
androgen B
receptor O
( O
AR O
) O
knockout O
mice O
demonstrate O
that O
AR O
deficiency O
results O
in O
the O
development O
of O
insulin O
resistance O
in O
males O
. O

Neuronal O
AR O
regulates O
hypothalamic O
insulin O
signaling O
by O
repressing O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
- O
mediated O
induction O
of O
protein O
- O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
. O

Glomerular O
gene O
expression O
was O
profiled O
in O
patients O
with O
early O
type O
2 O
DN O
and O
in O
three O
mouse O
models O
( O
streptozotocin B
DBA O
/ O
2 O
, O
C57BLKS O
db O
/ O
db O
, O
and O
eNOS O
- O
deficient O
C57BLKS O
db O
/ O
db O
mice O
) O
. O

Three O
shared O
human O
- O
mouse O
cross O
- O
species O
glomerular O
transcriptional O
networks O
containing O
143 O
( O
Human O
- O
DBA O
STZ B
) O
, O
97 O
( O
Human O
- O
BKS O
db O
/ O
db O
) O
, O
and O
162 O
( O
Human O
- O
BKS O
eNOS O
( O
- O
/ O
- O
) O
db O
/ O
db O
) O
gene O
nodes O
were O
generated O
. O

Furthermore O
, O
despite O
elevated O
glucose B
concentrations O
, O
carriers O
of O
GCK O
mutations O
showed O
lower O
levels O
of O
free O
fatty B
acids I
and O
triglycerides B
than O
healthy O
control O
subjects O
. O

Elevated O
levels O
of O
fatty B
acids I
are O
known O
to O
associate O
with O
beta O
- O
cell O
dysfunction O
, O
insulin O
resistance O
, O
and O
increased O
incidence O
of O
late O
complications O
. O

Intrahypothalamic O
estradiol B
regulates O
glucose B
metabolism O
via O
the O
sympathetic O
nervous O
system O
in O
female O
rats O
. O

Long O
- O
term O
reduced O
hypothalamic O
estrogen B
signaling O
leads O
to O
increased O
food O
intake O
and O
decreased O
locomotor O
activity O
and O
energy O
expenditure O
, O
and O
ultimately O
results O
in O
obesity O
and O
insulin O
resistance O
. O

In O
the O
current O
study O
, O
we O
aimed O
to O
determine O
the O
acute O
obesity O
- O
independent O
effects O
of O
hypothalamic O
estrogen B
signaling O
on O
glucose B
metabolism O
. O

We O
studied O
endogenous O
glucose B
production O
( O
EGP O
) O
and O
insulin O
sensitivity O
during O
selective O
modulation O
of O
systemic O
or O
intrahypothalamic O
estradiol B
( O
E2 O
) O
signaling O
in O
rats O
1 O
week O
after O
ovariectomy O
( O
OVX O
) O
. O

OVX O
caused O
a O
17 O
% O
decrease O
in O
plasma O
glucose B
, O
which O
was O
completely O
restored O
by O
systemic O
E2 O
. O

Likewise O
, O
the O
administration O
of O
E2 O
by O
microdialysis O
, O
either O
in O
the O
hypothalamic O
paraventricular O
nucleus O
( O
PVN O
) O
or O
in O
the O
ventromedial O
nucleus O
( O
VMH O
) O
, O
restored O
plasma O
glucose B
. O

The O
infusion O
of O
an O
E2 O
antagonist O
via O
reverse O
microdialysis O
into O
the O
PVN O
or O
VMH O
attenuated O
the O
effect O
of O
systemic O
E2 O
on O
plasma O
glucose B
. O

In O
conclusion O
, O
intrahypothalamic O
estrogen B
regulates O
peripheral O
and O
hepatic O
insulin O
sensitivity O
via O
sympathetic O
signaling O
to O
the O
liver O
. O

Comparative O
analysis O
of O
four O
oxidized O
guanine B
lesions O
from O
reactions O
of O
DNA O
with O
peroxynitrite B
, O
singlet O
oxygen B
, O
and O
gamma O
- O
radiation O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
dose O
- O
response O
relationship O
for O
the O
formation O
of O
the O
above O
four O
products O
arising O
in O
calf O
thymus O
DNA O
exposed O
to O
gamma O
irradiation O
, O
photoactivated O
rose O
bengal O
, O
and O
two O
sources O
of O
peroxynitrite B
. O

Inactivation O
of O
Escherichia O
coli O
by O
sonoelectrocatalytic O
disinfection O
using O
TiO2 B
as O
electrode O
. O

This O
is O
the O
first O
study O
to O
demonstrate O
sonoelectrocatalytic O
disinfection O
using O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
as O
an O
anode O
for O
effective O
inactivation O
of O
Escherichia O
coli O
. O

In O
brief O
, O
a O
non O
- O
woven O
TiO B
( I
2 I
) I
fabric O
used O
as O
an O
anode O
and O
a O
platinum B
cathode O
were O
immersed O
in O
an O
E O
. O
coli O
suspension O
in O
which O
a O
positive O
potential O
was O
applied O
to O
TiO B
( I
2 I
) I
concomitant O
with O
ultrasound O
( O
US O
) O
irradiation O
. O

One O
was O
disinfection O
by O
applying O
a O
positive O
potential O
to O
a O
TiO B
( I
2 I
) I
electrode O
, O
but O
without O
US O
irradiation O
( O
electrochemical O
disinfection O
) O
. O

The O
other O
was O
disinfection O
without O
applying O
a O
potential O
, O
but O
with O
US O
irradiation O
in O
the O
presence O
of O
TiO B
( I
2 I
) I
( O
sonocatalytic O
disinfection O
) O
. O

This O
synergistically O
enhanced O
inactivation O
rate O
of O
E O
. O
coli O
cells O
was O
attributable O
to O
effective O
reaction O
of O
the O
sonocatalytically O
generated O
OH B
radicals O
with O
E O
. O
coli O
cells O
at O
the O
surface O
of O
the O
TiO B
( I
2 I
) I
anode O
, O
which O
resulted O
from O
the O
electroadsorption O
of O
E O
. O
coli O
cells O
toward O
the O
TiO B
( I
2 I
) I
anode O
. O

Abamectin O
( O
ABA O
) O
, O
which O
belongs O
to O
the O
family O
of O
avermectins B
, O
is O
used O
as O
a O
parasiticide O
; O
however O
, O
ABA O
poisoning O
can O
impair O
liver O
function O
. O

In O
a O
previous O
study O
using O
isolated O
rat O
liver O
mitochondria O
, O
we O
observed O
that O
ABA O
inhibited O
the O
activity O
of O
adenine B
nucleotide I
translocator O
and O
FoF1 O
- O
ATPase O
. O

The O
toxicity O
of O
ABA O
was O
assessed O
by O
monitoring O
oxygen B
consumption O
and O
mitochondrial O
membrane O
potential O
, O
intracellular O
ATP B
concentration O
, O
cell O
viability O
, O
intracellular O
Ca B
( I
2 I
+ I
) I
homeostasis O
, O
release O
of O
cytochrome O
c O
, O
caspase O
3 O
activity O
and O
necrotic O
cell O
death O
. O

ABA O
reduces O
cellular O
respiration O
in O
cells O
energized O
with O
glutamate B
and O
malate B
or O
succinate B
. O

The O
hepatocytes O
that O
were O
previously O
incubated O
with O
proadifen O
, O
a O
cytochrome O
P450 O
inhibitor O
, O
are O
more O
sensitive O
to O
the O
compound O
as O
observed O
by O
a O
rapid O
decrease O
in O
the O
mitochondrial O
membrane O
potential O
accompanied O
by O
reductions O
in O
ATP B
concentration O
and O
cell O
viability O
and O
a O
disruption O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
homeostasis O
followed O
by O
necrosis O
. O

Our O
results O
indicate O
that O
ABA O
biotransformation O
reduces O
its O
toxicity O
, O
and O
its O
toxic O
action O
is O
related O
to O
the O
inhibition O
of O
mitochondrial O
activity O
, O
which O
leads O
to O
decreased O
synthesis O
of O
ATP B
followed O
by O
cell O
death O
. O

Gene O
polymorphisms O
of O
the O
4 O
- O
( O
methylnitrosamino O
) O
- O
1 O
- O
( O
3 O
- O
pyridyl O
) O
- O
1 O
- O
butanone O
( O
NNK O
) O
metabolism O
- O
related O
enzymes O
- O
cytochrome O
P450 O
( O
CYP O
) O
monooxygenase O
2A13 O
( O
CYP2A13 O
) O
and O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
- O
2B7 O
could O
contribute O
to O
the O
levels O
of O
NNK O
- O
related O
metabolites O
in O
urine O
, O
thereby O
increasing O
the O
susceptibility O
to O
urothelial O

Subjects O
carrying O
the O
UGT2B7 O
268 O
His B
/ O
Tyr B
or O
Tyr B
/ O
Tyr B
genotype O
had O
significantly O
lower O
total O
NNAL O
than O
those O
carrying O
His B
/ O
His B
genotype O
. O

In O
the O
future O
, O
large O
- O
scale O
studies O
will O
be O
required O
to O
verify O
the O
association O
between O
the O
single O
nucleotide B
polymorphisms O
of O
NNK O
metabolism O
- O
related O
enzymes O
and O
UC O
risk O
. O

Novel O
potassium B
channel O
blocker O
venom O
peptides O
from O
Mesobuthus O
gibbosus O
( O
Scorpiones O
: O
Buthidae O
) O
. O

Venom O
fractions O
were O
tested O
in O
electrophysiological O
assays O
on O
a O
panel O
of O
six O
K B
( I
+ I
) I
channels O
( O
K B
( O
v O
) O
1 O
. O
1 O
- O
1 O
. O
6 O
) O
by O
using O
the O
two O
- O
electrode O
voltage O
clamp O
technique O
. O

Three O
new O
alpha O
- O
KTx O
peptides O
were O
found O
and O
called O
MegKTx1 O
, O
MegKTx2 O
and O
MegKTx3 O
( O
M O
. O
gibbosus O
, O
K B
( I
+ I
) I
channel O
toxin O
number O
1 O
- O
3 O
) O
. O

Superoxide B
anion O
mediates O
the O
L O
- O
selectin O
down O
- O
regulation O
induced O
by O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
in O
human O
neutrophils O
. O

In O
this O
work O
we O
studied O
both O
the O
functional O
effect O
of O
NSAIDs O
on O
the O
neutrophils O
/ O
endothelial O
cells O
dynamic O
interaction O
, O
and O
the O
potential O
involvement O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
in O
the O
NSAIDs O
- O
mediated O
down O
- O
regulation O
of O
L O
- O
selectin O
. O

When O
human O
neutrophils O
were O
incubated O
with O
diclofenac B
, O
a O
significant O
reduction O
in O
the O
number O
of O
cells O
that O
rolled O
on O
activated O
endothelial O
cells O
was O
observed O
. O

Different O
NSAIDs O
( O
flufenamic B
acid I
, O
meclofenamic O
acid O
, O
diclofenac B
, O
indomethacin B
, O
nimesulide B
, O
flurbiprofen O
, O
meloxicam B
, O
phenylbutazone O
, O
piroxicam O
, O
ketoprofen B
and O
aspirin B
) O
caused O
variable O
increase O
in O
neutrophil O
intracellular O
ROS O
concentration O
, O
which O
was O
inversely O
proportional O
to O
the O
change O
produced O
in O
L O
- O
selectin O
surface O
expression O
. O

Pre O
- O
incubation O
of O
neutrophils O
with O
superoxide B
dismutase O
, O
but O
not O
with O
catalase O
, O
showed O
both O
a O
significant O
protective O
effect O
on O
the O
L O
- O
selectin O
down O
- O
regulation O
induced O
by O
several O
NSAIDs O
and O
a O
diminished O
effect O
of O
diclofenac B
on O
neutrophil O
rolling O
. O

Interestingly O
, O
diclofenac B
and O
flufenamic B
acid I
but O
not O
piroxicam O
significantly O
increased O
the O
extracellular O
superoxide B
anion O
production O
by O
neutrophils O
, O
and O
inhibition O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
( O
NADPH B
) O
- O
oxidase O
activity O
with O
diphenyleneiodonium B
prevented O
the O
down O
- O
regulation O
of O
L O
- O
selectin O
by O
diclofenac B
. O

In O
accordance O
with O
these O
results O
, O
neutrophils O
from O
patients O
with O
chronic O
granulomatous O
disease O
, O
a O
hereditary O
disease O
in O
which O
neutrophils O
show O
a O
reduced O
capacity O
to O
form O
superoxide B
radicals O
, O
exhibited O
a O
lower O
down O
- O
regulation O
of O
L O
- O
selectin O
( O
IC50 O
: O
15 O
. O
3 O
mu O
g O
/ O
ml O
) O
compared O
to O
normal O
controls O
( O
IC50 O
: O
5 O
. O
6 O
mu O
g O
/ O
ml O
) O
in O
response O
to O
diclofenac B
. O

CONCLUSION O
: O
A O
group O
of O
NSAIDs O
is O
capable O
of O
interfering O
with O
the O
ability O
of O
neutrophils O
to O
interact O
with O
endothelial O
cells O
by O
triggering O
L O
- O
selectin O
- O
shedding O
through O
the O
NADPH B
- O
oxidase O
- O
dependent O
generation O
of O
superoxide B
anion O
at O
the O
plasma O
membrane O
. O

Our O
previous O
study O
found O
that O
proteasome O
inhibitor O
( O
MG132 B
) O
treatment O
attenuated O
cardiac O
fibrosis O
and O
heart O
failure O
during O
the O
early O
and O
middle O
stages O
of O
pressure O
overload O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
effects O
and O
possible O
mechanisms O
of O
MG132 B
on O
cardiac O
fibrosis O
and O
dysfunction O
during O
the O
late O
stages O
of O
pressure O
overload O
. O

Male O
Sprague O
Dawley O
rats O
with O
abdominal O
aortic O
constriction O
( O
AAC O
) O
or O
a O
sham O
operation O
received O
an O
intraperitoneal O
injection O
of O
MG132 B
( O
0 O
. O
1 O
mg O
kg O
- O
( O
1 O
) O
day O
- O
( O
1 O
) O
) O
or O
vehicle O
for O
16 O
weeks O
. O

Ang O
II O
- O
stimulated O
adult O
rat O
cardiac O
fibroblasts O
were O
utilized O
to O
examine O
the O
effects O
of O
MG132 B
on O
collagen O
synthesis O
and O
the O
relationship O
between O
the O
renin O
- O
angiotensin O
- O
aldosterone B
system O
( O
RAAS O
) O
and O
the O
UPS O
. O

MG132 B
treatment O
attenuated O
ventricular O
dysfunction O
by O
suppressing O
cardiac O
fibrosis O
rather O
than O
inhibiting O
cardiac O
hypertrophy O
during O
the O
late O
- O
stages O
of O
pressure O
overload O
. O

We O
also O
found O
that O
Ang O
II O
activates O
UPS O
in O
the O
heart O
and O
MG132 B
attenuates O
Ang O
II O
- O
induced O
collagen O
synthesis O
via O
suppression O
of O
the O
NF O
- O
kappa O
B O
/ O
TGF O
- O
beta O
/ O
Smad2 O
signaling O
pathways O
. O

Under O
the O
drug O
screening O
process O
of O
synthetic O
diphenylpyrazole O
derivatives O
, O
we O
discovered O
compound O
yuwen02f1 O
possesses O
anti O
- O
inflammatory O
effects O
in O
decreasing O
the O
release O
of O
pro O
- O
inflammatory O
cytokines O
including O
TNF O
alpha O
and O
IL O
- O
6 O
, O
nitric B
oxide I
, O
reactive O
oxygen B
species O
( O
ROS O
) O
as O
well O
as O
inhibiting O
migration O
of O
LPS O
- O
stimulated O
phagocytes O
. O

These O
results O
suggest O
that O
yuwen02f1 O
is O
a O
potential O
anti O
- O
inflammatory O
agent O
for O
alleviating O
syndromes O
of O
acute O
and O
chronic O
inflammatory O
diseases O
as O
evidenced O
by O
attenuating O
the O
generation O
of O
cytokines O
and O
down O
- O
regulating O
the O
expression O
of O
iNOS O
and O
COX O
- O
2 O
through O
the O
blockade O
of O
ROS O
generation O
and O
NADPH B
oxidase O
, O
NF O
kappa O
B O
and O
MAPK O
activation O
pathways O
in O
LPS O
- O
stimulated O
phagocytes O
. O

Protective O
effects O
of O
erythropoietin O
on O
astrocytic O
swelling O
after O
oxygen B
- O
glucose B
deprivation O
and O
reoxygenation O
: O
mediation O
through O
AQP4 O
expression O
and O
MAPK O
pathway O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
human O
erythropoietin O
( O
rhEPO O
) O
reduces O
the O
astrocytic O
swelling O
created O
by O
oxygen B
- O
glucose B
deprivation O
followed O
by O
reoxygenation O
( O
OGD O
/ O
Reox O
) O
in O
vitro O
and O
whether O
this O
effect O
can O
be O
mediated O
through O
the O
modulation O
of O
aquaporin4 O
( O
AQP4 O
) O
expression O
in O
the O
plasma O
membrane O
( O
PM O
) O
and O
phosphorylation O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
pathway O
( O
MAPK O
) O
pathway O
. O

Differential O
responses O
in O
ammonia B
excretion O
, O
sodium B
fluxes O
and O
gill O
permeability O
explain O
different O
sensitivities O
to O
acute O
high O
environmental O
ammonia B
in O
three O
freshwater O
teleosts O
. O

We O
examined O
the O
acute O
physiological O
responses O
to O
high O
environmental O
ammonia B
( O
HEA O
) O
, O
particularly O
the O
linkages O
between O
branchial O
ammonia B
fluxes O
and O
unidirectional O
Na B
( I
+ I
) I
fluxes O
, O
as O
well O
as O
urea B
excretion O
, O
cortisol B
, O
and O
indicators O
of O
gill O
permeability O
in O
three O
freshwater O
teleosts O
differing O
in O
their O
sensitivities O
to O
ammonia B
; O
the O
highly O
sensitive O
salmonid O
Oncorhynchus O
mykiss O
( O
rainbow O
trout O
) O
, O
the O
less O
sensitive O
cyprinid O
Cyprinus O
carpio O
( O
common O
carp O
) O
and O
the O
highly O
resistant O
cyprinid O

Fish O
were O
acutely O
exposed O
to O
two O
sub O
- O
lethal O
ammonia B
concentrations O
( O
as O
NH O
( O
4 O
) O
HCO O
( O
3 O
) O
) O
at O
pH O
7 O
. O
9 O
: O
1 O
mM O
for O
a O
period O
of O
12 O
h O
, O
identical O
for O
all O
species O
, O
and O
5 O
mM O
for O
the O
cyprinids O
and O
1 O
. O
4 O
mM O
for O
the O
trout O
for O
3 O
h O
. O

Elevation O
of O
plasma O
cortisol B
at O
both O
levels O
of O
HEA O
was O
apparent O
in O
all O
species O
. O

At O
1 O
mM O
, O
ammonia B
excretion O
( O
J O
( O
amm O
) O
) O
was O
inhibited O
to O
a O
greater O
extent O
in O
trout O
than O
cyprinids O
and O
concurrently O
a O
significantly O
higher O
plasma O
ammonia B
level O
was O
evident O
in O
trout O
. O

Goldfish O
showed O
a O
significant O
increase O
in O
urea B
excretion O
rate O
( O
J O
( O
urea B
) O
) O
during O
HEA O
exposure O
. O

In O
carp O
and O
trout O
, O
neither O
level O
of O
HEA O
elevated O
J O
( O
urea B
) O
but O
urea B
production O
was O
increased O
as O
evidenced O
by O
a O
considerable O
elevation O
of O
plasma O
urea B
. O

At O
1mM O
HEA O
, O
Na B
( I
+ I
) I
imbalance O
became O
progressively O
more O
severe O
in O
trout O
and O
carp O
due O
to O
a O
stimulation O
of O
unidirectional O
Na B
( I
+ I
) I
efflux O
( O
J O
( O
out O
) O
( O
Na B
) O
) O
without O
a O
concomitant O
increase O
in O
unidirectional O
Na B
( I
+ I
) I
influx O
( O
J O
( O
in O
) O
( O
Na B
) O
) O
. O

Additionally O
, O
a O
transient O
reduction O
of O
J O
( O
in O
) O
( O
Na B
) O
was O
evident O
in O
trout O
. O

Goldfish O
showed O
an O
opposite O
trend O
for O
J O
( O
out O
) O
( O
Na B
) O
with O
reduced O
efflux O
rates O
and O
a O
positive O
Na B
( I
+ I
) I
balance O
during O
the O
first O
few O
hours O
of O
HEA O
. O

However O
, O
after O
12 O
h O
of O
exposure O
, O
both O
J O
( O
in O
) O
( O
Na B
) O
and O
J O
( O
out O
) O
( O
Na B
) O
were O
also O
increased O
in O
both O
carp O
and O
goldfish O
, O
whereas O
only O
J O
( O
out O
) O
( O
Na B
) O
was O
increased O
in O
trout O
, O
leading O
to O
a O
net O
Na B
( I
+ I
) I
loss O
. O

Na B
( I
+ I
) I
homeostasis O
was O
entirely O
disrupted O
in O
all O
three O
species O
when O
subjected O
to O
the O
5 O
or O
1 O
. O
4 O
mM O
ammonia B
for O
3 O
h O
: O
J O
( O
in O
) O
( O
Na B
) O
was O
significantly O
inhibited O
while O
considerable O
activation O
of O
J O
( O
out O
) O
( O
Na B
) O
was O
observed O
. O

Diffusive O
water O
efflux O
rates O
and O
net O
K B
( I
+ I
) I
loss O
rates O
across O
the O
gills O
were O
enhanced O
during O
HEA O
only O
in O
trout O
, O
indicating O
an O
increment O
in O
gill O
transcellular O
permeability O
. O

Transepithelial O
potential O
was O
increased O
in O
all O
the O
species O
during O
ammonia B
exposure O
, O
but O
to O
the O
least O
extent O
in O
goldfish O
. O

Overall O
, O
for O
several O
different O
physiological O
systems O
, O
trout O
were O
most O
disturbed O
, O
and O
goldfish O
were O
least O
disturbed O
by O
HEA O
, O
helping O
to O
explain O
the O
differential O
ammonia B
tolerance O
of O
the O
three O
species O
. O

Despite O
the O
widespread O
use O
of O
these O
drugs O
, O
approximately O
30 O
% O
of O
asthma O
sufferers O
exhibit O
some O
degree O
of O
steroid B
insensitivity O
or O
are O
refractory O
to O
inhaled O
GCs O
. O

In O
this O
work O
, O
the O
metabolism O
of O
four O
frequently O
prescribed O
inhaled O
GCs O
, O
triamcinolone B
acetonide I
, O
flunisolide O
, O
budesonide B
, O
and O
fluticasone B
propionate I
, O
by O
the O
CYP3A O
family O
of O
enzymes O
was O
studied O
to O
identify O
differences O
in O
their O
rates O
of O
clearance O
and O
to O
identify O
their O
metabolites O
. O

CYP3A5 O
, O
which O
is O
particularly O
relevant O
to O
GC O
metabolism O
in O
the O
lungs O
, O
was O
also O
shown O
to O
efficiently O
metabolize O
triamcinolone B
acetonide I
, O
budesonide B
, O
and O
fluticasone B
propionate I
. O

Common O
metabolites O
included O
6 O
beta O
- O
hydroxylation O
and O
Delta O
( O
6 O
) O
- O
dehydrogenation O
for O
triamcinolone B
acetonide I
, O
budesonide B
, O
and O
flunisolide O
. O

Metabolism O
also O
occurred O
on O
the O
D O
- O
ring O
substituents O
, O
including O
the O
21 O
- O
carboxy O
metabolites O
for O
triamcinolone B
acetonide I
and O
flunisolide O
. O

IsoDGR O
- O
tagged O
albumin O
binds O
tumor O
vessels O
and O
can O
be O
exploited O
as O
a O
carrier O
for O
the O
preparation O
of O
tumor O
vasculature O
- O
selective O
nanomedicines O
, O
such O
as O
gold O
nanoparticles O
( O
Au B
) O
carrying O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
) O
, O
a O
potent O
vascular O
damaging O
agent O
. O

Enhancing O
the O
photocatalytic O
activity O
of O
anatase O
TiO2 B
by O
improving O
the O
specific O
facet O
- O
induced O
spontaneous O
separation O
of O
photogenerated O
electrons O
and O
holes O
. O

Recently O
, O
it O
has O
been O
proven O
that O
directional O
flow O
of O
photogenerated O
charge O
carriers O
occurs O
on O
specific O
facets O
of O
TiO B
( I
2 I
) I
nanocrystals O
. O

Herein O
, O
we O
demonstrate O
that O
the O
photocatalytic O
activity O
of O
anatase O
TiO B
( I
2 I
) I
nanocrystals O
in O
both O
photoreduction O
and O
photooxidation O
processes O
can O
be O
enhanced O
by O
selectively O
depositing O
Pt B
nanoparticles O
on O
the O
{ O
101 O
} O
facets O
, O
which O
strengthens O
spontaneously O
surface O
- O
induced O
separation O
between O
photogenerated O
electrons O
and O
holes O
in O
the O
photocatalysis O
process O
. O

An O
optimal O
ratio O
of O
the O
oxidative O
{ O
001 O
} O
facets O
to O
the O
reductive O
{ O
101 O
} O
facets O
exists O
with O
regard O
to O
the O
photocatalysis O
of O
the O
faceted O
TiO B
( I
2 I
) I
nanocrystals O
, O
and O
this O
is O
crucial O
for O
balancing O
the O
recombination O
and O
redox O
reaction O
rates O
of O
photogenerated O
electrons O
and O
holes O
. O

Noncompetitive O
, O
voltage O
- O
dependent O
NMDA B
receptor O
antagonism O
by O
hydrophobic O
anions O
. O

NMDA B
receptor O
( O
NMDAR O
) O
antagonists O
are O
dissociative O
anesthetics O
, O
drugs O
of O
abuse O
, O
and O
are O
of O
therapeutic O
interest O
in O
neurodegeneration O
and O
neuropsychiatric O
disease O
. O

We O
recently O
showed O
that O
the O
hydrophobic O
anion O
dipicrylamine O
( O
DPA O
) O
negatively O
regulates O
GABA B
( O
A O
) O
receptor O
function O
by O
a O
mechanism O
indistinguishable O
from O
that O
of O
sulfated O
neurosteroids O
. O

Because O
sulfated O
neurosteroids B
also O
modulate O
NMDARs O
, O
here O
we O
examined O
the O
effects O
of O
DPA O
on O
NMDAR O
function O
. O

In O
rat O
hippocampal O
neurons O
DPA O
inhibited O
currents O
gated O
by O
300 O
micro O
M O
NMDA B
with O
an O
IC O
( O
50 O
) O
of O
2 O
. O
3 O
micro O
M O
. O

Overall O
, O
we O
conclude O
that O
DPA O
noncompetitively O
inhibits O
NMDA B
- O
induced O
current O
by O
a O
novel O
voltage O
- O
dependent O
mechanism O
and O
represents O
a O
new O
class O
of O
anionic O
NMDAR O
antagonists O
. O

Structural O
optimization O
of O
2 O
, O
5 O
- O
thiophene O
amides O
as O
highly O
potent O
and O
selective O
17 B
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
2 O
inhibitors O
for O
the O
treatment O
of O
osteoporosis O
. O

We O
report O
here O
the O
optimization O
of O
human O
17 O
beta O
- O
HSD2 O
inhibitors O
in O
the O
2 O
, O
5 O
- O
thiophene O
amide O
class O
by O
varying O
the O
size O
of O
the O
linker O
( O
n O
equals O
0 O
and O
2 O
) O
between O
the O
amide B
moiety O
and O
the O
phenyl B
group O
. O

The O
four O
most O
active O
compounds O
showed O
an O
IC O
5 O
0 O
of O
around O
60 O
nM O
and O
a O
very O
good O
selectivity O
toward O
17 O
beta O
- O
HSD1 O
, O
17 O
beta O
- O
HSD4 O
, O
17 O
beta O
- O
HSD5 O
, O
11 O
beta O
- O
HSD1 O
, O
11 O
beta O
- O
HSD2 O
and O
the O
estrogen B
receptors O
alpha O
and O
beta O
. O

Here O
, O
we O
provide O
an O
overview O
of O
the O
present O
knowledge O
of O
the O
role O
of O
nucleotides B
in O
nociception O
, O
with O
a O
particular O
emphasis O
on O
G O
protein O
- O
coupled O
P2Y O
receptors O
and O
their O
involvement O
in O
the O
communication O
between O
first O
- O
and O
second O
- O
order O
neurons O
in O
sensory O
nerve O
pathways O
and O
surrounding O
glial O
cells O
. O

Endometrial O
cancer O
is O
associated O
with O
enhanced O
cell O
proliferation O
due O
to O
high O
concentrations O
of O
estrogens B
, O
and O
decreased O
cell O
differentiation O
due O
to O
low O
levels O
of O
progesterone B
and O
retinoic B
acid I
. O

It O
is O
also O
associated O
with O
aberrant O
inflammatory O
responses O
and O
concomitant O
increased O
production O
of O
prostaglandins B
. O

Effects O
of O
arsenite B
in O
astrocytes O
on O
neuronal O
signaling O
transduction O
. O

The O
main O
purpose O
of O
this O
study O
was O
to O
test O
the O
hypothesis O
that O
arsenite B
induces O
neurotoxicity O
via O
effects O
on O
astrocytes O
. O

Astrocytes O
were O
exposed O
to O
0 O
, O
5 O
or O
10 O
mu O
M O
arsenite B
in O
medium O
for O
24 O
h O
, O
and O
then O
astrocyte O
- O
conditioned O
medium O
( O
ACM O
) O
was O
collected O
after O
incubation O
with O
fresh O
medium O
for O
6 O
h O
. O

Primary O
neuron O
cultures O
were O
divided O
into O
four O
groups O
due O
to O
ACM O
, O
which O
were O
neurons O
without O
ACM O
exposure O
( O
group O
I O
) O
and O
neurons O
exposed O
to O
ACM O
from O
0 O
, O
5 O
or O
10 O
mu O
M O
arsenite B
treated O
astrocytes O
( O
group O
II O
- O
IV O
) O
. O

Protein O
expression O
of O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptors O
( O
NR1 O
, O
NR2A O
, O
NR2B O
) O
, O
calmodulin O
- O
dependent O
protein O
kinase O
II O
( O
CaMKII O
) O
and O
adenylate B
cyclase O
( O
AC O
) O
in O
neurons O
were O
measured O
after O
incubation O
with O
ACM O
for O
4 O
, O
8 O
or O
12 O
h O
. O

Taken O
together O
, O
findings O
from O
this O
study O
suggested O
that O
arsenic B
in O
astrocytes O
might O
impair O
synaptic O
formation O
through O
disturbing O
astrocytic O
effects O
on O
neuronal O
signal O
transduction O
. O

Toxicity O
of O
the O
synthetic O
polymeric O
3 O
- O
alkylpyridinium O
salt O
( O
APS3 O
) O
is O
due O
to O
specific O
block O
of O
nicotinic O
acetylcholine B
receptors O
. O

Finally O
, O
APS3 O
efficiently O
blocked O
acetylcholine B
- O
activated O
membrane O
inward O
currents O
flowing O
through O
Torpedo O
nicotinic O
acetylcholine B
receptors O
( O
nAChRs O
) O
incorporated O
to O
Xenopus O
oocytes O
, O
with O
an O
IC O
( O
50 O
) O
of O
0 O
. O
19 O
mu O
M O
. O

Characteristic O
molecular O
signature O
for O
the O
early O
detection O
and O
prediction O
of O
polycyclic B
aromatic I
hydrocarbons I
in O
rat O
liver O
. O

Among O
the O
various O
environmental O
toxicants O
, O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
are O
an O
important O
class O
of O
environmental O
pollutant O
, O
and O
many O
PAHs B
are O
known O
or O
suspected O
carcinogens O
. O

In O
the O
present O
study O
, O
to O
investigate O
whether O
characteristic O
expression O
profiles O
of O
PAHs B
exist O
in O
rat O
liver O
and O
whether O
a O
characteristic O
molecular O
signature O
can O
discriminate O
and O
predict O
among O
different O
PAHs B
at O
an O
early O
exposure O
time O
, O
we O
analyzed O
the O
genome O
- O
wide O
expression O
profiles O
of O
rat O
livers O
exposed O
to O
PAHs B
[ O
benzo B
[ I
a I
] I
anthracene I
( O
BA O
) O
, O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
, O
phenanthrene B
( O
PA O
) O
and O
naphthalene B
( O
NT O
) O
] O
. O

At O
early O
time O
- O
point O
PAH B
exposure O
, O
large O
- O
scale O
gene O
expression O
analysis O
resulted O
in O
characteristic O
molecular O
signatures O
for O
each O
PAH B
, O
and O
supervised O
analysis O
identified O
1183 O
outlier O
genes O
as O
a O
distinct O
molecular O
signature O
discerning O
PAHs B
from O
the O
normal O
control O
group O
. O

We O
identified O
158 O
outlier O
genes O
as O
early O
predictive O
and O
surrogate O
markers O
for O
predicting O
each O
tested O
PAH B
by O
combination O
of O
two O
different O
multi O
- O
classification O
algorithms O
with O
100 O
% O
accuracy O
through O
a O
leave O
- O
one O
out O
cross O
- O
validation O
method O
. O

In O
conclusion O
, O
the O
characteristic O
gene O
expression O
signatures O
from O
a O
rat O
model O
system O
could O
be O
used O
as O
predictable O
and O
discernible O
gene O
- O
based O
biomarkers O
for O
the O
detection O
and O
prediction O
of O
PAHs B
, O
and O
these O
molecular O
markers O
may O
provide O
insights O
into O
the O
underlying O
mechanisms O
for O
genotoxicity O
of O
exposure O
to O
PAHs B
from O
environmental O
aspect O
. O

Linking O
GABA B
( O
A O
) O
receptor O
subunits O
to O
alcohol B
- O
induced O
conditioned O
taste O
aversion O
and O
recovery O
from O
acute O
alcohol B
intoxication O
. O

GABA B
type O
A O
receptors O
( O
GABA B
( O
A O
) O
- O
R O
) O
are O
important O
for O
ethanol B
actions O
and O
it O
is O
of O
interest O
to O
link O
individual O
subunits O
with O
specific O
ethanol B
behaviors O
. O

We O
studied O
null O
mutant O
mice O
for O
six O
different O
GABA B
( O
A O
) O
- O
R O
subunits O
( O
alpha O
1 O
, O
alpha O
2 O
, O
alpha O
3 O
, O
alpha O
4 O
, O
alpha O
5 O
and O
delta O
) O
. O

Only O
mice O
lacking O
the O
alpha O
2 O
subunit O
showed O
reduction O
of O
conditioned O
taste O
aversion O
( O
CTA O
) O
to O
ethanol B
. O

These O
results O
are O
in O
agreement O
with O
data O
from O
knock O
- O
in O
mice O
with O
mutation O
of O
the O
ethanol B
- O
sensitive O
site O
in O
the O
alpha O
2 O
- O
subunit O
( O
Blednov O
et O
al O
. O
, O
2011 O
) O
. O

All O
together O
, O
they O
indicate O
that O
aversive O
property O
of O
ethanol B
is O
dependent O
on O
ethanol B
action O
on O
alpha O
2 O
- O
containing O
GABA B
( O
A O
) O
- O
R O
. O

Deletion O
of O
the O
alpha O
2 O
- O
subunit O
led O
to O
faster O
recovery O
whereas O
absence O
of O
the O
alpha O
3 O
- O
subunit O
slowed O
recovery O
from O
ethanol B
- O
induced O
incoordination O
( O
rotarod O
) O
. O

However O
, O
no O
differences O
in O
recovery O
were O
found O
in O
motor O
- O
incoordinating O
effects O
of O
an O
alpha O
1 O
- O
selective O
modulator O
( O
zolpidem B
) O
or O
an O
alpha O
4 O
- O
selective O
agonist O
( O
gaboxadol O
) O
. O

Therefore O
, O
recovery O
of O
rotarod O
incoordination O
is O
under O
control O
of O
two O
GABA B
( O
A O
) O
- O
R O
subunits O
: O
alpha O
2 O
and O
alpha O
3 O
. O

For O
motor O
activity O
, O
alpha O
3 O
null O
mice O
demonstrated O
higher O
activation O
by O
ethanol B
( O
1 O
g O
/ O
kg O
) O
whereas O
both O
alpha O
2 O
( O
- O
/ O
- O
) O
and O
alpha O
3 O
( O
- O
/ O
Y O
) O
knockout O
mice O
were O
less O
sensitive O
to O
ethanol B
- O
induced O
reduction O
of O
motor O
activity O
( O
1 O
. O
5 O
g O
/ O
kg O
) O
. O

These O
studies O
demonstrate O
that O
the O
effects O
of O
ethanol B
at O
GABAergic O
synapses O
containing O
alpha O
2 O
subunit O
are O
important O
for O
specific O
behavioral O
effects O
of O
ethanol B
which O
may O
be O
relevant O
to O
the O
genetic O
linkage O
of O
the O
alpha O
2 O
subunit O
with O
human O
alcoholism O
. O

Nitric B
oxide I
synthase O
/ O
nitric B
oxide I
( O
NOS O
/ O
NO B
) O
system O
in O
the O
RVLM O
modulates O
cardiovascular O
activities O
. O

Our O
experiments O
were O
designed O
to O
test O
the O
hypothesis O
that O
orexin O
- O
A O
( O
OXA O
) O
is O
involved O
in O
the O
mechanism O
of O
stress O
- O
induced O
hypertension O
( O
SIH O
) O
by O
adjusting O
NOS O
/ O
NO B
system O
in O
the O
RVLM O
. O

The O
double O
- O
staining O
immunohistochemical O
evidence O
showed O
that O
OX1R O
immunoreactive O
( O
OX1R O
- O
IR O
) O
cells O
and O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
or O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
immunoreactive O
( O
IR O
) O
cells O
were O
co O
- O
localizated O
in O
the O
RVLM O
. O

Microinjection O
into O
the O
RVLM O
of O
both O
control O
and O
SIHR O
groups O
of O
7 O
- O
Ni O
( O
0 O
. O
05 O
pmol O
/ O
100 O
nl O
, O
nNOS O
inhibitor O
) O
or O
Methylene B
Blue I
[ O
100 O
pmol O
/ O
100 O
nl O
, O
an O
inhibitor O
of O
soluble O
guanylate B
cyclase O
( O
sGC O
) O
] O
suppressed O
the O
OXA O
- O
induced O
increase O
of O
SBP O
and O
HR O
, O
whereas O
microinjection O
of O
AG O
( O
1 O
, O
10 O
, O
100 O
pmol O
/ O
100 O
nl O
) O
had O
no O
obvious O
effects O
on O
the O
OXA O
- O
induced O
increase O
of O
SBP O
and O
HR O
. O

The O
cardiovascular O
effects O
of O
OXA O
in O
the O
RVLM O
may O
be O
induced O
by O
nNOS O
- O
derived O
NO B
, O
which O
activated O
sGC O
- O
associated O
signaling O
pathway O
. O

Uncontaminated O
low O
( O
3 O
% O
) O
, O
medium O
( O
11 O
% O
) O
, O
and O
high O
( O
38 O
- O
48 O
% O
) O
carbon B
content O
soils O
from O
Macquarie O
Island O
were O
used O
to O
examine O
the O
influence O
of O
soil O
carbon B
on O
toxicity O
. O

Earthworms O
were O
sensitive O
to O
fresh O
SAB O
, O
with O
significant O
avoidance O
at O
181 O
mg O
/ O
kg O
; O
acute O
14 O
- O
d O
survival O
median O
lethal O
concentration O
( O
LC50 O
) O
of O
103 O
mg O
/ O
kg O
for O
low O
carbon B
soil O
; O
and O
juvenile O
production O
median O
effective O
concentration O
( O
EC50 O
) O
of O
317 O
mg O
/ O
kg O
for O
high O
carbon B
soil O
. O

Earthworms O
were O
less O
sensitive O
to O
aged O
SAB O
than O
to O
fresh O
SAB O
in O
high O
carbon B
soil O
for O
juvenile O
production O
( O
EC50 O
of O
1 O
, O
753 O
and O
317 O
mg O
/ O
kg O
, O
respectively O
) O
, O
but O
were O
more O
sensitive O
for O
adult O
survival O
( O
LC50 O
of O
2 O
, O
322 O
and O
1 O
, O
364 O
mg O
/ O
kg O
, O
respectively O
) O
. O

Extraction O
of O
sediment O
- O
associated O
polycyclic B
aromatic I
hydrocarbons I
with O
granular O
activated O
carbon B
. O

Addition O
of O
activated O
carbon B
( O
AC O
) O
to O
sediments O
has O
been O
proposed O
as O
a O
method O
to O
reduce O
ecotoxicological O
risks O
of O
sediment O
- O
bound O
contaminants O
. O

The O
present O
study O
explores O
the O
effectiveness O
of O
granular O
AC O
( O
GAC O
) O
in O
extracting O
polycyclic O
aromatic O
hydrocarbon O
( O
PAH B
) O
from O
highly O
contaminated O
sediments O
. O

Four O
candidate O
GAC O
materials O
were O
screened O
in O
terms O
of O
PAH B
extraction O
efficiency O
using O
single O
- O
step O
24 O
- O
h O
GAC O
extractions O
, O
with O
traditional O
24 O
- O
h O
Tenax O
extraction O
as O
a O
reference O
. O

Subsequently O
, O
sorption O
of O
native O
PAHs B
to O
the O
best O
performing O
GAC O
1240W O
( O
0 O
. O
45 O
- O
1 O
. O
70 O
mm O
) O
was O
studied O
for O
sediment O
only O
and O
for O
GAC O
- O
sediment O
mixtures O
at O
different O
GAC O
- O
sediment O
weight O
ratios O
, O
using O
76 O
- O
micro O
m O
polyoxymethylene O
( O
POM O
) O
passive O
samplers O
. O

Granular O
AC O
sorption O
parameters O
for O
PAHs B
were O
determined O
by O
subtracting O
the O
contribution O
of O
PAH B
sorption O
to O
sediment O
from O
PAH B
sorption O
to O
the O
GAC O
- O
sediment O
mixture O
. O

It O
appears O
that O
the O
binding O
of O
PAHs B
and O
the O
effectiveness O
of O
GAC O
to O
reduce O
sediment O
porewater O
concentrations O
were O
highly O
dependent O
on O
the O
GAC O
- O
sediment O
mixing O
ratio O
and O
hydrophobicity O
of O
the O
PAH B
. O

Despite O
the O
considerable O
fouling O
of O
GAC O
by O
organic O
matter O
and O
oil O
, O
50 O
to O
90 O
% O
of O
the O
most O
available O
PAH B
was O
extracted O
by O
the O
GAC O
during O
a O
28 O
- O
d O
contact O
time O
, O
at O
a O
dose O
as O
low O
as O
4 O
% O
, O
which O
also O
is O
a O
feasible O
dose O
in O
field O
- O
scale O
applications O
aimed O
at O
cleaning O
the O
sediment O
by O
GAC O
addition O
and O
removal O
. O

Upon O
adriamycin B
( O
ADR O
) O
exposure O
, O
p53 O
as O
well O
as O
RUNX1 O
were O
strongly O
induced O
in O
p53 O
- O
proficient O
HCT116 O
and O
U2OS O
cells O
, O
which O
were O
closely O
associated O
with O
significant O
transactivation O
of O
p53 O
target O
genes O
, O
such O
as O
p21 O
( O
WAF O
) O
( O
1 O
) O
, O
BAX O
, O
NOXA O
, O
and O
PUMA O
. O

Furthermore O
, O
RUNX1 O
was O
associated O
with O
p300 O
histone O
acetyltransferase O
, O
and O
ADR O
- O
dependent O
acetylation O
of O
p53 O
at O
Lys B
- O
373 O
/ O
382 O
was O
markedly O
inhibited O
in O
RUNX1 O
knockdown O
cells O
. O

Hydrogen B
sulfide I
increases O
nitric B
oxide I
production O
with O
calcium B
- O
dependent O
activation O
of O
endothelial O
nitric B
oxide I
synthase O
in O
endothelial O
cells O
. O

Hydrogen B
sulfide I
( O
H B
( I
2 I
) I
S I
) O
was O
recently O
discovered O
to O
be O
synthesized O
in O
mammalian O
tissues O
by O
several O
different O
enzymes O
. O

Numerous O
studies O
have O
shown O
that O
H B
( I
2 I
) I
S I
has O
vasodilator O
and O
antihypertensive O
effects O
in O
the O
cardiovascular O
system O
. O

However O
, O
intracellular O
mechanisms O
of O
the O
H B
( I
2 I
) I
S I
- O
induced O
vasodilation O
and O
its O
interactions O
with O
other O
endothelium O
- O
derived O
relaxing O
factors O
, O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
remain O
unclear O
. O

We O
investigated O
whether O
H B
( I
2 I
) I
S I
directly O
regulates O
endothelial O
NO B
synthase O
( O
eNOS O
) O
activity O
and O
NO B
production O
in O
endothelial O
cells O
. O

NaHS B
, O
a O
H B
( I
2 I
) I
S I
donor O
, O
dose O
- O
dependently O
increased O
NO B
production O
in O
cultured O
endothelial O
cells O
. O

This O
effect O
was O
abolished O
by O
a O
calcium B
chelator O
( O
BAPTA B
- I
AM I
) O
, O
but O
not O
by O
the O
absence O
of O
extracellular O
calcium B
. O

The O
NaHS B
- O
induced O
NO B
production O
was O
partially O
blocked O
by O
inhibitors O
of O
ryanodine B
receptor O
( O
dantrolene O
) O
or O
inositol O
1 O
, O
4 O
, O
5 O
- O
triphosphate O
receptor O
( O
xestospongin B
C I
) O
. O

NaHS B
significantly O
increased O
intracellular O
calcium B
concentrations O
, O
and O
this O
effect O
was O
attenuated O
by O
dantrolene O
or O
xestospongin B
C I
. O

NaHS B
induced O
phosphorylation O
of O
eNOS O
at O
the O
activating O
phosphoserine O
residue O
1179 O
. O

The O
NaHS B
- O
induced O
eNOS O
phosphorylation O
and O
NO B
production O
were O
not O
affected O
by O
a O
PI3K O
/ O
Akt O
inhibitor O
( O
wortmannin B
) O
. O

The O
data O
of O
this O
study O
suggest O
that O
H B
( I
2 I
) I
S I
directly O
acts O
on O
endothelial O
cells O
to O
induce O
eNOS O
activation O
and O
NO B
production O
by O
releasing O
calcium B
from O
the O
intracellular O
store O
in O
endoplasmic O
reticulum O
, O
which O
may O
explain O
one O
of O
mechanisms O
of O
its O
vasodilator O
function O
. O

Efficient O
serum O
- O
resistant O
lipopolyplexes O
targeted O
to O
the O
folate B
receptor O
. O

In O
this O
work O
, O
we O
have O
developed O
and O
evaluated O
a O
new O
targeted O
lipopolyplex O
( O
LPP O
) O
, O
by O
combining O
polyethylenimine B
( O
PEI B
) O
, O
1 O
, O
2 O
- O
dioleoyl O
- O
3 O
- O
( O
trimethylammonium O
) O
propane O
( O
DOTAP B
) O
/ O
Chol O
liposomes O
, O
the O
plasmids O
pCMVLuc O
/ O
pCMVIL O
- O
12 O
, O
and O
the O
ligand O
folic B
acid I
( O
FA O
) O
, O
able O
to O
transfect O
HeLa O
and O
B16 O
- O
F10 O
cells O
in O
the O
presence O
of O
very O
high O
concentration O
of O
serum O
( O
60 O
% O
FBS O
) O
. O

The O
combination O
of O
folic B
acid I
with O
lipopolyplexes O
also O
enhanced O
significantly O
the O
transfection O
activity O
of O
the O
therapeutic O
gene O
interleukin O
- O
12 O
( O
IL O
- O
12 O
) O
, O
without O
any O
significant O
cytotoxicity O
. O

The O
specificity O
of O
the O
folate B
receptor O
( O
FR O
) O
- O
mediated O
gene O
transfer O
was O
corroborated O
by O
employing O
a O
folate B
receptor O
deficient O
cell O
line O
( O
HepG2 O
) O
. O

Ferulic B
acid I
modulates O
fluoride B
- O
induced O
oxidative O
hepatotoxicity O
in O
male O
Wistar O
rats O
. O

The O
present O
study O
is O
aimed O
to O
evaluate O
the O
protective O
effect O
of O
ferulic B
acid I
( O
FA O
) O
on O
fluoride B
- O
induced O
oxidative O
hepatotoxicity O
in O
male O
Wistar O
rats O
. O

Fluoride B
( O
25 O
mg O
/ O
L O
) O
was O
given O
orally O
to O
induce O
hepatotoxicity O
for O
12 O
weeks O
. O

Hepatic O
damage O
were O
assessed O
using O
status O
of O
pathophysiological O
markers O
like O
serum O
marker O
enzymes O
like O
aspartate B
transaminase O
, O
alanine B
transaminase O
, O
alkaline O
phosphatase O
, O
acid O
phosphatase O
, O
gamma O
glutamyl O
transferase O
, O
lactate B
dehydrogenase O
, O
bilirubin B
, O
lipid O
profile O
, O
total O
protein O
content O
levels O
, O
and O
histopathological O
studies O
. O

Treatment O
with O
FA O
significantly O
reduced O
the O
degree O
of O
histological O
aberrations O
and O
rescued O
lipid O
peroxidation O
, O
as O
observed O
from O
reduced O
levels O
of O
lipid O
hydroperoxides O
, O
nitric B
oxide I
, O
restored O
levels O
of O
enzymic O
and O
non O
- O
enzymic O
antioxidants O
, O
and O
total O
protein O
content O
, O
with O
a O
concomitant O
decline O
in O
the O
levels O
of O
marker O
enzymes O
and O
lipid O
profile O
in O
fluoride B
- O
induced O
rats O
. O

These O
results O
suggest O
that O
ferulic B
acid I
has O
the O
ability O
to O
protect O
fluoride B
- O
induced O
hepatic O
damage O
. O

Interestingly O
, O
inhibitors O
against O
the O
mitogen O
- O
activated O
protein O
kinase O
and O
phosphoinositide B
- O
3 O
- O
kinase O
signaling O
pathways O
significantly O
decreased O
the O
induction O
of O
ABCG2 O
by O
PRL O
without O
altering O
STAT5 O
recruitment O
to O
the O
GAS O
element O
. O

A O
series O
of O
2 O
- O
( O
substituted O
phenyl O
/ O
benzyl O
- O
amino O
) O
- O
6 O
- O
( O
4 O
- O
chlorophenyl O
) O
- O
5 O
- O
( O
methoxycarbonyl O
) O
- O
4 O
- O
methyl O
- O
3 O
, O
6 O
- O
dihydropyrimidin O
- O
1 O
- O
ium O
chlorides O
7 O
- O
13 O
and O
15 O
was O
synthesized O
in O
their O
hydrochloride B
salt O
form O
. O

The O
title O
compounds O
were O
characterized O
by O
FT O
- O
IR O
, O
NMR O
( O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
) O
and O
elemental O
analysis O
. O

They O
were O
evaluated O
for O
their O
in O
vitro O
antitubercular O
activity O
against O
Mycobacterium O
tuberculosis O
H37Rv O
, O
multidrug O
resistance O
tuberculosis O
and O
extensively O
drug O
resistance O
tuberculosis O
by O
agar O
diffusion O
method O
and O
tested O
for O
the O
cytotoxic O
action O
on O
peripheral O
blood O
mononuclear O
cells O
by O
MTT B
assay O
. O

A O
dual O
role O
of O
Se B
on O
Cd B
toxicity O
: O
evidences O
from O
the O
uptake O
of O
Cd B
and O
some O
essential O
elements O
and O
the O
growth O
responses O
in O
paddy O
rice O
. O

This O
study O
was O
carried O
out O
to O
investigate O
the O
effects O
of O
selenium B
( O
Se B
) O
on O
the O
uptake O
and O
translocation O
of O
cadmium B
( O
Cd B
) O
and O
essential O
elements O
in O
paddy O
rice O
( O
Oryza O
sativa O
L O
. O
, O
Shuangyou O
998 O
) O
. O

Selenium B
could O
alleviate O
/ O
aggravate O
Cd B
toxicity O
in O
paddy O
rice O
, O
which O
depended O
on O
the O
dosages O
of O
Se B
and O
/ O
or O
Cd B
. O

When O
Cd B
treatment O
level O
was O
as O
low O
as O
35 O
. O
6 O
mu O
M O
, O
< O
= O
12 O
. O
7 O
mu O
M O
Se B
could O
inhibit O
the O
uptake O
of O
Cd B
in O
paddy O
rice O
and O
increase O
the O
biomass O
of O
paddy O
rice O
; O
however O
, O
with O
Cd B
levels O
reaching O
89 O
- O
178 O
mu O
M O
, O
the O
addition O
of O
Se B
resulted O
in O
increases O
in O
Cd B
uptake O
and O
exacerbated O
the O
growth O
of O
paddy O
rice O
. O

Cd B
always O
inhibited O
the O
uptake O
of O
Se B
. O

Cd B
alone O
suppressed O
the O
uptake O
of O
Ca B
, O
Mg B
, O
Mn B
, O
Cu B
, O
and O
Zn B
; O
however O
, O
Se B
reversed O
the O
decreases O
in O
the O
concentrations O
of O
the O
said O
elements O
, O
suggesting O
an O
element O
regulation O
mechanism O
to O
relieve O
Cd B
toxicity O
. O

Without O
Cd B
in O
the O
solution O
, O
low O
doses O
of O
Se B
increased O
the O
biomasses O
of O
shoots O
and O
roots O
at O
the O
expense O
of O
the O
more O
or O
less O
decreases O
in O
the O
concentrations O
of O
Ca B
, O
Mg B
, O
K B
, O
Fe B
, O
Mn B
, O
Cu B
, O
and O
shoot O
Zn B
, O
indicating O
an O
antagonistic O
effect O
of O
Se B
on O
these O
cations O
. O

The O
presence O
of O
Cd B
could O
also O
reverse O
these O
decreases O
especially O
at O
the O
highest O
treatment O
levels O
for O
both O
Se B
and O
Cd B
, O
also O
suggesting O
an O
element O
regulation O
mechanism O
responsible O
for O
the O
detoxification O
of O
high O
dosages O
of O
Se B
. O

Consequently O
, O
when O
Se B
is O
used O
to O
alleviate O
Cd B
toxicity O
, O
attention O
must O
be O
paid O
to O
the O
Cd B
pollution O
extent O
and O
doses O
of O
Se B
supplement O
. O

Involvement O
of O
lysosomal O
exocytosis O
in O
the O
excretion O
of O
mesoporous O
silica B
nanoparticles O
and O
enhancement O
of O
the O
drug O
delivery O
effect O
by O
exocytosis O
inhibition O
. O

The O
exocytosis O
of O
phosphonate B
modified O
mesoporous O
silica B
nanoparticles O
( O
P O
- O
MSNs O
) O
is O
demonstrated O
and O
lysosomal O
exocytosis O
is O
identified O
as O
the O
mechanism O
responsible O
for O
this O
event O
. O

Slowing O
down O
P O
- O
MSN O
exocytosis O
enhances O
the O
drug O
delivery O
effect O
of O
CPT B
- O
loaded O
P O
- O
MSNs O
by O
improving O
cell O
killing O
. O

Overexpression O
of O
ATP B
- O
binding O
cassette O
transporter O
ABCG2 O
as O
a O
potential O
mechanism O
of O
acquired O
resistance O
to O
vemurafenib B
in O
BRAF O
( O
V600E O
) O
mutant O
cancer O
cells O
. O

The O
discovery O
of O
constitutive O
activation O
of O
the O
BRAF O
kinase O
caused O
by O
activating O
BRAF O
( O
V600E O
) O
kinase O
mutation O
in O
most O
melanoma O
patients O
led O
to O
the O
discovery O
of O
the O
first O
potent O
BRAF O
( O
V600E O
) O
signaling O
inhibitor O
, O
vemurafenib B
. O

Vemurafenib B
was O
effective O
in O
treating O
advanced O
melanoma O
patients O
and O
was O
proposed O
for O
the O
treatment O
of O
other O
BRAF O
( O
V600E O
) O
mutant O
cancers O
as O
well O
. O

Unfortunately O
, O
the O
success O
of O
vemurafenib B
was O
hampered O
by O
the O
rapid O
development O
of O
acquired O
resistance O
in O
different O
types O
of O
BRAF O
( O
V600E O
) O
mutant O
cancer O
cells O
. O

It O
becomes O
important O
to O
identify O
and O
evaluate O
all O
of O
the O
potential O
mechanisms O
of O
cellular O
resistance O
to O
vemurafenib B
. O

In O
this O
study O
, O
we O
characterized O
the O
interactions O
of O
vemurafenib B
with O
three O
major O
ATP B
- O
binding O
cassette O
( O
ABC O
) O
transporters O
, O
ABCB1 O
, O
ABCC1 O
and O
ABCG2 O
. O

We O
found O
that O
vemurafenib B
stimulated O
the O
ATPase O
activity O
and O
potently O
inhibited O
drug O
efflux O
mediated O
by O
ABCB1 O
and O
ABCG2 O
. O

Vemurafenib B
also O
restored O
drug O
sensitivity O
in O
ABCG2 O
- O
overexpressing O
cells O
. O

Moreover O
, O
we O
revealed O
that O
in O
the O
presence O
of O
functional O
ABCG2 O
, O
BRAF O
kinase O
inhibition O
by O
vemurafenib B
is O
reduced O
in O
BRAF O
( O
V600E O
) O
mutant O
A375 O
cells O
. O

Taken O
together O
, O
our O
findings O
indicate O
that O
ABCG2 O
confers O
resistance O
to O
vemurafenib B
in O
A375 O
cells O
, O
suggesting O
involvement O
of O
this O
transporter O
in O
acquired O
resistance O
to O
vemurafenib B
. O

Thus O
, O
combination O
chemotherapy O
targeting O
multiple O
pathways O
could O
be O
an O
effective O
therapeutic O
strategy O
to O
overcome O
acquired O
resistance O
to O
vemurafenib B
for O
cancers O
harboring O
the O
BRAF O
( O
V600E O
) O
mutation O
. O

The O
cytotoxic O
antimetabolites O
, O
5 O
- O
flurouracil O
and O
mitomycin B
C I
both O
prolong O
success O
but O
with O
the O
increased O
risk O
of O
blinding O
complications O
. O

A O
novel O
antioxidant O
regenerating O
system O
consisting O
of O
cellobiose O
dehydrogenase O
( O
CDH O
) O
, O
cellobiose O
, O
and O
phenolic B
antioxidants O
with O
potential O
application O
for O
continuous O
quenching O
of O
free O
radical O
species O
in O
chronic O
wounds O
was O
developed O
. O

This O
antioxidant O
regenerating O
system O
, O
continuously O
quenched O
in O
situ O
produced O
. B
NO I
, O
O B
( I
2 I
) I
( I
. I
- I
) I
and O
OH B
. I
radicals O
and O
the O
produced O
oxidized O
phenolic B
antioxidants O
were O
regenerated O
back O
to O
their O
original O
parent O
compounds O
by O
CDH O
using O
cellobiose O
as O
electron O
donor O
. O

This O
system O
therefore O
prevented O
the O
accumulation O
of O
oxidized O
phenolic B
antioxidants O
. O

Interestingly O
, O
this O
study O
also O
challenges O
the O
relevance O
of O
using O
total O
antioxidant O
capacities O
values O
of O
plant O
crude O
extracts O
obtained O
using O
biologically O
none O
relevant O
radical O
species O
like O
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
) O
) O
, O
Trolox B
Equivalent O
Antioxidant O
Capacity O
( O
TEAC O
) O
, O
etc O
. O
when O
applied O
as O
medicinal O
remedies O
. O

This O
is O
because O
methoxylated O
phenolic O
antioxidants O
like O
sinapic B
acid I
, O
ferulic B
acid I
; O
2 O
, O
6 O
- O
dimethoxyphenol O
readily O
donate O
their O
electrons O
to O
these O
radicals O
( O
DPPH B
, O
TEAC O
, O
etc O
. O
) O
, O
thereby O
greatly O
influencing O
the O
total O
antioxidant O
values O
although O
this O
study O
showed O
that O
they O
are O
not O
at O
all O
effective O
in O
quenching O
O B
( I
2 I
) I
( I
. I
- I
) I
radicals O
and O
again O
are O
not O
the O
most O
effective O
quenchers O
of O
NO B
and O
OH B
radicals O
as O
demonstrated O
during O
this O
study O
. O

Combination O
treatment O
with O
progesterone B
and O
vitamin B
D I
hormone O
is O
more O
effective O
than O
monotherapy O
in O
ischemic O
stroke O
: O
The O
role O
of O
BDNF O
/ O
TrkB O
/ O
Erk1 O
/ O
2 O
signaling O
in O
neuroprotection O
. O

We O
investigated O
whether O
combinatorial O
post O
- O
injury O
treatment O
with O
progesterone B
( O
P4 O
) O
and O
vitamin B
D I
hormone O
( O
VDH O
) O
would O
reduce O
ischemic O
injury O
more O
effectively O
than O
P4 O
alone O
in O
an O
oxygen B
glucose B
deprivation O
( O
OGD O
) O
model O
in O
primary O
cortical O
neurons O
and O
in O
a O
transient O
middle O
cerebral O
artery O
occlusion O
( O
tMCAO O
) O
model O
in O
rats O
. O

VDH O
, O
but O
not O
P4 O
, O
upregulated O
heme B
oxygenase O
- O
1 O
, O
suggesting O
a O
pathway O
for O
the O
neuroprotective O
effects O
of O
VDH O
differing O
from O
that O
of O
P4 O
. O

The O
combination O
of O
P4 O
and O
VDH O
activated O
brain O
- O
derived O
neurotrophic O
factor O
and O
its O
specific O
receptor O
, O
tyrosine B
kinase O
receptor O
- O
B O
. O

The O
nonfermentable O
dietary O
fiber O
hydroxypropyl B
methylcellulose O
modulates O
intestinal O
microbiota O
. O

To O
determine O
whether O
the O
nonfermentable O
fiber O
hydroxypropyl B
methylcellulose O
( O
HPMC O
) O
could O
alter O
the O
intestinal O
microbiota O
and O
whether O
such O
changes O
correlated O
with O
metabolic O
improvements O
, O
C57B O
/ O
L6 O
mice O
were O
normalized O
to O
a O
high O
- O
fat O
diet O
( O
HFD O
) O
, O
then O
either O
maintained O
on O
HFD O
( O
control O
) O
, O
or O
switched O
to O
HFD O
supplemented O
with O
10 O
% O
HPMC O
, O
or O
a O
low O
- O
fat O
diet O
( O
LFD O
) O
. O

Compared O
to O
control O
treatment O
, O
both O
LFD O
and O
HPMC O
reduced O
weight O
gain O
( O
11 O
. O
8 O
and O
5 O
. O
7 O
g O
, O
respectively O
) O
, O
plasma O
cholesterol B
( O
23 O
. O
1 O
and O
19 O
. O
6 O
% O
) O
, O
and O
liver O
triglycerides B
( O
73 O
. O
1 O
and O
44 O
. O
6 O
% O
) O
, O
and O
, O
as O
revealed O
by O
454 O
- O
pyrosequencing O
of O
the O
microbial O
16S O
rRNA O
gene O
, O
decreased O
microbial O
alpha O
- O
diversity O
and O
differentially O
altered O
intestinal O
microbiota O
. O

Inhibition O
of O
glycogen O
synthase O
kinase O
- O
3 O
ameliorates O
beta O
- O
amyloid O
pathology O
and O
restores O
lysosomal O
acidification O
and O
mammalian O
target O
of O
rapamycin B
activity O
in O
the O
Alzheimer O
disease O
mouse O
model O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Analyses O
of O
5XFAD O
hemi O
- O
brain O
samples O
indicated O
that O
L803 O
- O
mts O
restored O
the O
activity O
of O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
and O
inhibited O
autophagy O
. O

Lysosomal O
acidification O
was O
impaired O
in O
the O
5XFAD O
brains O
as O
indicated O
by O
reduced O
cathepsin O
D O
activity O
and O
decreased O
N B
- O
glycoyslation O
of O
the O
vacuolar O
ATPase O
subunit O
V0a1 O
, O
a O
modification O
required O
for O
lysosomal O
acidification O
. O

Among O
the O
artemisinin B
- O
based O
combination O
therapy O
( O
ACT O
) O
regimens O
, O
artemisinin B
derivative O
, O
artemether O
in O
combination O
with O
lumefantrine O
( O
artemether O
- O
lumefantrine O
, O
AL O
) O
has O
achieved O
excellent O
results O
in O
the O
fight O
against O
malarial O
scourge O
. O

Animals O
were O
randomly O
divided O
into O
four O
groups O
: O
those O
administered O
1 O
% O
Tween B
80 I
( O
control O
) O
, O
those O
administered O
artemether O
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
, O
those O
administered O
lumefantrine O
( O
24 O
mg O
/ O
kg O
body O
weight O
) O
, O
and O
those O
coadministered O
artemether O
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
and O
lumefantrine O
( O
24 O
mg O
/ O
kg O
body O
weight O
) O
. O

While O
reduced O
glutathione B
, O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
( O
G6PD O
) O
and O
catalase O
activities O
were O
reduced O
, O
glutathione B
peroxidase O
and O
glutathione B
- O
s O
- O
transferase O
activities O
increased O
in O
all O
the O
treated O
groups O
compared O
to O
the O
control O
group O
. O

The O
drugs O
caused O
significant O
( O
p O
< O
0 O
. O
05 O
) O
elevation O
of O
malondialdehyde B
( O
MDA B
) O
levels O
compared O
to O
the O
control O
group O
. O

In O
order O
to O
investigate O
possible O
fibril O
remodeling O
mechanisms O
using O
this O
approach O
, O
we O
performed O
comparative O
studies O
on O
the O
structural O
features O
of O
the O
different O
amyloid O
- O
beta O
( O
A O
beta O
) O
aggregates O
remodeled O
from O
A O
beta O
fibrils O
by O
three O
biocompatible O
small O
molecules O
: O
methylene B
blue I
; O
brilliant O
blue O
G O
; O
and O
erythrosine O
B O
. O

In O
contrast O
, O
incubation O
of O
the O
A O
beta O
fibrils O
with O
methylene B
blue I
perturbs O
fibrillar O
structure O
, O
leading O
to O
amorphous O
A O
beta O
aggregates O
. O

Thus O
, O
the O
effects O
of O
psychotropic O
drugs O
such O
as O
antipsychotics O
and O
antidepressants O
have O
been O
understood O
to O
modulate O
synaptic O
regulation O
via O
receptors O
and O
transporters O
of O
neurotransmitters O
such O
as O
dopamine B
and O
serotonin B
. O

Therefore O
, O
in O
this O
review O
, O
at O
first O
, O
we O
summarize O
recent O
findings O
of O
interaction O
between O
microglia O
and O
neurotransmitters O
such O
as O
dopamine B
, O
serotonin B
, O
norepinephrine B
, O
acetylcholine B
and O
glutamate B
. O

In O
this O
concise O
review O
, O
we O
discuss O
the O
major O
findings O
on O
three O
neurotransmitters O
, O
namely O
dopamine B
, O
serotonin B
and O
glutamate B
. O

The O
most O
promising O
radioligand O
for O
D O
( O
2 O
) O
/ O
D O
( O
3 O
) O
neuroreceptor O
imaging O
is O
the O
agonist O
[ O
( O
11 O
) O
C O
] O
PHNO O
, O
with O
higher O
in O
vivo O
affinity O
for O
D O
( O
3 O
) O
than O
D O
( O
2 O
) O
receptors O
, O
which O
can O
be O
used O
to O
measure O
amphetamine B
- O
induced O
release O
of O
dopamine B
, O
and O
therefore O
a O
potential O
model O
of O
dopaminergic O
alterations O
in O
schizophrenia O
. O

Recent O
development O
of O
selective O
radiotracers O
allow O
imaging O
of O
the O
serotonin B
transporter O
( O
SERT O
) O
using O
positron O
emission O
tomography O
( O
PET O
) O
with O
selective O
tracers O
such O
as O
[ O
( O
11 O
) O
C O
] O
DASB O
. O

Serotonin B
receptors O
of O
type O
6 O
( O
5 O
- O
HT6 O
) O
: O
from O
neuroscience O
to O
clinical O
pharmacology O
. O

The O
serotonin B
( O
5 B
- I
HT I
) O
receptors O
of O
type O
6 O
( O
5 O
- O
HT6 O
) O
are O
quite O
different O
from O
all O
other O
5 B
- I
HT I
receptors O
, O
as O
they O
include O
a O
short O
third O
cytoplasmatic O
loop O
and O
a O
long O
C B
- O
terminal O
tail O
, O
and O
one O
intron O
located O
in O
the O
middle O
of O
the O
third O
cytoplasmatic O
loop O
. O

A O
lot O
of O
controversies O
still O
exist O
regarding O
their O
binding O
affinity O
, O
effects O
of O
5 O
- O
HT6 O
ligands O
on O
brain O
catecholamines B
, O
behavioral O
syndromes O
regulated O
by O
them O
, O
and O
brain O
distribution O
. O

Schizophrenia O
is O
a O
brain O
disorder O
and O
various O
theories O
other O
than O
the O
dopamine B
hypothesis O
have O
been O
developed O
to O
describe O
its O
underlying O
neurobiology O
. O

Gamma B
- I
aminobutyric I
- I
acid I
- O
receptors O
and O
glutamtergic O
N B
- I
Methyl I
- I
D I
- I
aspartic I
- I
acid I
- O
receptors O
are O
most O
likely O
to O
be O
involved O
in O
this O
complex O
interplay O
, O
which O
may O
reflect O
a O
disturbed O
signal O
- O
to O
- O
noise O
ratio O
in O
schizophrenia O
patients O
. O

Distinct O
roles O
of O
methamphetamine B
in O
modulating O
spatial O
memory O
consolidation O
, O
retrieval O
, O
reconsolidation O
and O
the O
accompanying O
changes O
of O
ERK O
and O
CREB O
activation O
in O
hippocampus O
and O
prefrontal O
cortex O
. O

The O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
and O
the O
transcription O
factor O
cAMP B
response O
element O
- O
binding O
protein O
( O
CREB O
) O
were O
involved O
in O
neuroplastic O
changes O
associated O
with O
learning O
and O
memory O
. O

In O
the O
current O
study O
, O
we O
used O
a O
Morris O
water O
maze O
to O
examine O
the O
effect O
of O
methamphetamine B
( O
METH B
) O
on O
different O
processes O
of O
spatial O
memory O
in O
mice O
. O

We O
found O
that O
1 O
. O
0 O
mg O
/ O
kg O
dose O
of O
METH B
facilitated O
spatial O
memory O
consolidation O
when O
it O
was O
injected O
immediately O
after O
the O
last O
learning O
trial O
. O

In O
contrast O
, O
the O
same O
dose O
of O
METH B
had O
no O
effect O
on O
spatial O
memory O
retrieval O
when O
it O
was O
injected O
30 O
min O
before O
the O
test O
. O

Furthermore O
, O
1 O
. O
0 O
mg O
/ O
kg O
dose O
of O
METH B
injected O
immediately O
after O
retrieval O
had O
no O
effect O
on O
spatial O
memory O
reconsolidation O
. O

Activation O
of O
both O
ERK O
and O
CREB O
in O
the O
hippocampus O
was O
found O
following O
memory O
consolidation O
but O
not O
after O
retrieval O
or O
reconsolidation O
in O
METH B
- O
treated O
mouse O
groups O
. O

In O
contrast O
, O
activation O
of O
both O
ERK O
and O
CREB O
in O
the O
PFC O
was O
found O
following O
memory O
retrieval O
but O
not O
other O
processes O
in O
METH B
- O
treated O
mouse O
groups O
. O

These O
results O
suggested O
that O
METH B
facilitated O
spatial O
memory O
consolidation O
but O
not O
retrieval O
or O
reconsolidation O
. O

Moreover O
, O
activation O
of O
the O
ERK O
and O
CREB O
signaling O
pathway O
in O
the O
hippocampus O
might O
be O
involved O
in O
METH B
- O
induced O
spatial O
memory O
changes O
. O

Acyclovir B
( O
ACV B
) O
is O
one O
of O
the O
drugs O
of O
choice O
for O
the O
treatment O
of O
epidermal O
, O
ocular O
or O
systemic O
herpetic O
infections O
. O

In O
order O
to O
cope O
with O
all O
these O
requirements O
, O
micro O
- O
particles O
( O
MPs O
) O
and O
nano O
- O
particles O
( O
NPs O
) O
containing O
ACV B
have O
been O
developed O
using O
cross O
- O
linked O
chitosan O
with O
tripolyphosphate O
( O
TPP B
) O
due O
to O
the O
biocompatibility O
, O
bio O
- O
adhesion O
ability O
and O
the O
potential O
power O
as O
penetration O
enhancer O
of O
this O
polymer O
. O

FTIR O
and O
X O
- O
ray O
results O
suggested O
an O
electrostatic O
interaction O
ACV B
- O
Chitosan O
that O
made O
ACV B
be O
molecularly O
dispersed O
within O
the O
polymer O
matrix O
. O

From O
the O
diffusion O
profiles O
, O
it O
was O
found O
that O
the O
amounts O
of O
ACV B
effectively O
diffused O
in O
24h O
were O
30 O
, O
430 O
and O
80 O
mu O
g O
for O
the O
ACV B
solution O
, O
MP O
and O
NP O
respectively O
. O

SMI O
results O
showed O
that O
chitosan O
- O
based O
particles O
induced O
moderate O
irritation O
and O
mild O
tissue O
damage O
, O
what O
supposes O
that O
ACV B
- O
MP O
constitute O
a O
promising O
alternative O
for O
further O
development O
of O
an O
antiviral O
formulation O
. O

A O
novel O
permeation O
enhancer O
: O
N O
- O
succinyl O
chitosan O
on O
the O
intranasal O
absorption O
of O
isosorbide B
dinitrate I
in O
rats O
. O

The O
purpose O
of O
this O
paper O
is O
to O
study O
the O
potential O
of O
N O
- O
succinyl O
chitosan O
as O
a O
novel O
permeation O
enhancer O
for O
the O
intranasal O
absorption O
of O
isosorbide B
dinitrate I
( O
ISDN B
) O
. O

An O
in O
situ O
nasal O
perfusion O
technique O
in O
rats O
was O
utilized O
to O
investigate O
the O
effect O
of O
NSCS O
substitution O
degree O
, O
NSCS O
molecular O
weight O
and O
concentration O
on O
the O
intranasal O
absorption O
of O
ISDN B
. O

It O
was O
found O
that O
all O
the O
NSCS O
investigated O
improved O
the O
intranasal O
absorption O
of O
ISDN B
remarkably O
. O

Both O
in O
situ O
and O
in O
vivo O
studies O
demonstrated O
that O
NSCS O
is O
more O
effective O
than O
chitosan O
in O
promoting O
intranasal O
absorption O
of O
ISDN B
. O

Therefore O
, O
temperature O
profiles O
of O
mannitol B
, O
sucrose B
, O
or O
trehalose O
were O
recorded O
with O
various O
prototypes O
of O
the O
optical O
fiber O
sensors O
( O
OFSs O
) O
and O
compared O
to O
data O
obtained O
with O
conventional O
TCs O
or O
Pirani O
/ O
capacitance O
manometry O
with O
respect O
to O
the O
endpoint O
of O
primary O
drying O
. O

Triclosan B
exposure O
alters O
postembryonic O
development O
in O
a O
Pacific O
tree O
frog O
( O
Pseudacris O
regilla O
) O
Amphibian O
Metamorphosis O
Assay O
( O
TREEMA O
) O
. O

The O
Amphibian O
Metamorphosis O
Assay O
( O
AMA O
) O
, O
developed O
for O
Xenopus O
laevis O
, O
is O
designed O
to O
identify O
chemicals O
that O
disrupt O
thyroid B
hormone I
( O
TH O
) O
- O
mediated O
biological O
processes O
. O

We O
adapted O
the O
AMA O
for O
use O
on O
an O
ecologically O
- O
relevant O
North O
American O
species O
, O
the O
Pacific O
tree O
frog O
( O
Pseudacris O
regilla O
) O
, O
and O
applied O
molecular O
endpoints O
to O
evaluate O
the O
effects O
of O
the O
antibacterial O
agent O
, O
triclosan B
( O
TCS B
) O
. O

Premetamorphic O
( O
Gosner O
stage O
26 O
- O
28 O
) O
tadpoles O
were O
immersed O
for O
21 O
days O
in O
solvent O
control O
, O
1 O
. O
5 O
mu O
g O
/ O
L O
thyroxine B
( O
T O
( O
4 O
) O
) O
, O
0 O
. O
3 O
, O
3 O
and O
30 O
mu O
g O
/ O
L O
( O
nominal O
) O
TCS B
, O
or O
combined O
T O
( O
4 O
) O
/ O
TCS B
treatments O
. O

We O
observed O
TCS B
- O
induced O
perturbations O
in O
all O
of O
the O
molecular O
and O
morphological O
endpoints O
indicating O
that O
TCS B
exposure O
disrupts O
coordination O
of O
postembryonic O
tadpole O
development O
. O

Although O
TCS B
alone O
( O
3 O
and O
30 O
mu O
g O
/ O
L O
) O
was O
protective O
against O
tadpole O
mortality O
, O
this O
protection O
was O
lost O
in O
the O
presence O
of O
T O
( O
4 O
) O
. O

Human O
paraoxonase O
double O
mutants O
hydrolyze O
V O
and O
G O
class O
organophosphorus B
nerve O
agents O
. O

Variants O
of O
human O
paraoxonase O
1 O
( O
PON1 O
) O
are O
being O
developed O
as O
catalytic O
bioscavengers O
for O
the O
organophosphorus B
chemical O
warfare O
agents O
( O
OP O
) O
. O

We O
improved O
upon O
these O
activities O
either O
by O
substituting O
a O
tryptophan B
( O
F347W O
) O
near O
the O
putative O
active O
site O
residues O
for O
enhanced O
substrate O
binding O
or O
by O
reducing O
a O
bulky O
group O
( O
Y71A O
) O
at O
the O
periphery O
of O
the O
putative O
enzyme O
active O
site O
. O

When O
compared O
to O
H115W O
alone O
, O
we O
found O
that O
H115W O
/ O
Y71A O
and O
H115W O
/ O
F347W O
maintained O
VX O
catalytic O
efficiency O
but O
showed O
mixed O
results O
for O
the O
capacity O
to O
hydrolyze O
paraoxon B
. O

Contrary O
to O
previous O
reports O
, O
we O
show O
that O
H115W O
can O
hydrolyze O
soman B
, O
and O
the O
double O
mutant O
H115W O
/ O
Y71A O
is O
nearly O
4 O
- O
fold O
more O
efficient O
than O
H115W O
for O
paraoxon B
hydrolysis O
. O

We O
also O
observed O
modest O
stereoselectivity O
for O
hydrolysis O
of O
the O
P O
( O
- O
) O
stereoisomer O
of O
tabun B
by O
H115W O
/ O
F347W O
. O

Expression O
of O
cAMP B
- O
responsive O
element O
binding O
proteins O
( O
CREBs O
) O
in O
fast O
- O
and O
slow O
- O
twitch O
muscles O
: O
A O
signaling O
pathway O
to O
account O
for O
the O
synaptic O
expression O
of O
collagen O
- O
tailed O
subunit O
( O
ColQ O
) O
of O
acetylcholinesterase O
at O
the O
rat O
neuromuscular O
junction O
. O

ColQ O
- O
1a O
is O
expressed O
at O
the O
neuromuscular O
junction O
( O
NMJ O
) O
in O
fast O
- O
twitch O
muscle O
, O
and O
this O
expression O
depends O
on O
trophic O
factors O
supplied O
by O
motor O
neurons O
signaling O
via O
a O
cAMP B
- O
dependent O
pathway O
in O
muscle O
. O

To O
further O
elucidate O
the O
molecular O
basis O
of O
ColQ O
- O
1a O
' O
s O
synaptic O
expression O
, O
here O
we O
investigated O
the O
expression O
and O
localization O
of O
cAMP B
- O
responsive O
element O
binding O
protein O
( O
CREB O
) O
at O
the O
synaptic O
and O
extra O
- O
synaptic O
regions O
of O
fast O
- O
and O
slow O
- O
twitch O
muscles O
from O
adult O
rats O
. O

These O
results O
reveal O
, O
for O
the O
first O
time O
, O
the O
differential O
distribution O
of O
P O
- O
CREB O
in O
fast O
- O
and O
slow O
- O
twitch O
muscles O
, O
which O
might O
support O
the O
crucial O
role O
of O
cAMP B
- O
dependent O
signaling O
in O
controlling O
the O
synapse O
- O
specific O
expression O
of O
ColQ O
- O
1a O
in O
fast O
- O
twitch O
muscles O
. O

The O
determination O
of O
exogenous O
formaldehyde B
in O
blood O
of O
rats O
during O
and O
after O
inhalation O
exposure O
. O

Formaldehyde B
( O
FA O
) O
is O
suspected O
of O
being O
associated O
with O
the O
development O
of O
leukemia O
. O

In O
order O
to O
differentiate O
between O
exogenous O
and O
endogenous O
FA O
the O
rats O
were O
exposed O
to O
stable O
isotope O
( O
( B
13 I
) I
C I
) O
labeled O
FA O
by O
inhalation O
. O

Analysis O
of O
microRNA O
and O
gene O
expression O
profiling O
in O
triazole B
fungicide O
- O
treated O
HepG2 O
cell O
line O
. O

In O
the O
present O
study O
, O
we O
investigated O
differential O
expression O
of O
miRNAs O
in O
response O
to O
three O
triazole B
fungicides O
( O
myclobutanil O
, O
propiconazole O
, O
and O
triadimefon B
) O
. O

The O
human O
hepatoma O
cell O
line O
( O
HepG2 O
) O
was O
treated O
with O
the O
above O
triazoles B
for O
3 O
h O
or O
48 O
h O
. O

Overall O
, O
this O
study O
provides O
an O
array O
of O
potential O
biomarkers O
for O
the O
above O
triazole B
fungicides O
. O

Furthermore O
, O
these O
miRNAs O
induced O
by O
triazoles B
could O
be O
the O
foundation O
for O
the O
development O
of O
a O
miRNA O
- O
based O
toxic O
biomarker O
library O
that O
can O
predict O
environmental O
toxicity O
. O

Hydroxysafflor B
yellow I
a I
inhibits O
lipopolysaccharide O
- O
induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O

Hydroxysafflor B
yellow I
A I
( O
HSYA B
) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O

The O
present O
study O
investigated O
the O
effects O
of O
HSYA B
on O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O

A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA B
( O
1 O
, O
4 O
and O
16 O
mu O
mol O
/ O
L O
) O
. O

HSYA B
suppressed O
the O
expression O
of O
TLR O
- O
4 O
, O
Myd88 O
, O
ICAM O
- O
1 O
, O
TNF O
alpha O
, O
IL O
- O
1 O
beta O
and O
IL O
- O
6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O

HSYA B
treatment O
also O
decreased O
NF O
- O
kappa O
B O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen O
- O
activated O
protein O
kinase O
( O
p38 O
MAPK O
) O
. O

These O
findings O
suggest O
that O
HSYA B
effectively O
inhibits O
LPS O
- O
induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

The O
products O
of O
the O
Yellow O
cocoon O
( O
C O
) O
gene O
and O
the O
Flesh O
( O
F O
) O
gene O
of O
the O
silkworm O
Bombyx O
mori O
determine O
the O
selectivity O
for O
transport O
of O
lutein B
and O
beta B
- I
carotene I
, O
respectively O
, O
to O
the O
silk O
gland O
. O

Here O
, O
we O
elucidated O
the O
molecular O
identity O
of O
the O
F O
gene O
product O
by O
positional O
cloning O
, O
as O
SCRB15 O
, O
a O
paralog O
of O
Cameo2 O
with O
26 O
% O
amino B
acid I
identity O
. O

Transgenic O
expression O
of O
SCRB15 O
in O
the O
middle O
silk O
gland O
using O
the O
binary O
GAL4 O
- O
UAS O
expression O
system O
enhanced O
selective O
beta B
- I
carotene I
uptake O
by O
the O
middle O
silk O
gland O
, O
while O
transgenic O
expression O
of O
Cameo2 O
enhanced O
selective O
lutein B
uptake O
under O
the O
same O
GAL4 O
driver O
. O

One O
scaffold O
strand O
is O
dominating O
the O
field O
: O
M13mp18 O
, O
a O
bacteriophage O
- O
derived O
vector O
7249 O
nucleotides B
in O
length O
. O

RBCK1 O
, O
an O
E3 O
ubiquitin O
ligase O
, O
interacts O
with O
and O
ubiquinates O
the O
human O
pregnane B
X O
receptor O
. O

The O
pregnane B
X O
receptor O
( O
PXR O
, O
NR1I2 O
) O
plays O
a O
pivotal O
role O
in O
the O
disposition O
and O
detoxification O
of O
numerous O
foreign O
and O
endogenous O
chemicals O
by O
increasing O
transcription O
of O
numerous O
target O
genes O
, O
including O
phase O
I O
and O
II O
drug O
- O
metabolizing O
enzymes O
and O
transporters O
. O

In O
the O
present O
study O
, O
yeast O
two O
- O
hybrid O
screening O
identified O
an O
E3 O
ubiquitin O
ligase O
, O
RBCK1 O
( O
Ring O
- O
B O
- O
box O
- O
coiled O
- O
coil O
protein O
interacting O
with O
protein O
kinase O
C O
- O
1 O
) O
, O
as O
a O
human O
pregnane B
X O
receptor O
( O
hPXR O
) O
- O
interacting O
protein O
. O

Simultaneous O
ectopic O
overexpression O
of O
RBCK1 O
and O
PXR O
decreased O
PXR O
levels O
in O
AD O
- O
293 O
cells O
, O
and O
this O
decrease O
was O
inhibited O
by O
the O
proteasomal O
inhibitor O
MG B
- I
132 I
( O
carbobenzoxy O
- O
Leu O
- O
Leu O
- O
leucinal O
) O
. O

Of O
importance O
, O
ectopic O
overexpression O
and O
silencing O
of O
endogenous O
RBCK1 O
in O
primary O
human O
hepatocytes O
resulted O
in O
a O
decrease O
and O
increase O
, O
respectively O
, O
in O
endogenous O
PXR O
protein O
levels O
and O
in O
the O
induction O
of O
PXR O
target O
genes O
by O
rifampicin B
. O

The O
effect O
of O
C B
- O
vacancy O
on O
hydrogen B
storage O
and O
characterization O
of O
H2 B
modes O
on O
Ti B
functionalized O
C60 O
fullerene O
a O
first O
principles O
study O
. O

Density O
functional O
theory O
calculations O
were O
performed O
to O
examine O
the O
effect O
of O
a O
C B
vacancy O
on O
the O
physisorption O
of O
H B
( I
2 I
) I
onto O
Ti B
- O
functionalized O
C O
( O
60 O
) O
fullerene O
when O
H B
( I
2 I
) I
is O
oriented O
along O
the O
x O
- O
, O
y O
- O
, O
and O
z O
- O
axes O
of O
the O
fullerene B
. O

The O
effect O
of O
the O
C B
vacancy O
on O
the O
physisorption O
modes O
of O
H B
( I
2 I
) I
was O
investigated O
as O
a O
function O
of O
H B
( I
2 I
) I
binding O
energy O
within O
the O
energy O
window O
( O
- O
0 O
. O
2 O
to O
- O
0 O
. O
6 O
eV O
) O
targeted O
by O
the O
Department O
of O
Energy O
( O
DOE O
) O
, O
and O
as O
functions O
of O
a O
variety O
of O
other O
physicochemical O
properties O
. O

The O
results O
indicate O
that O
the O
preferential O
orientations O
of O
H B
( I
2 I
) I
in O
the O
defect O
- O
free O
( O
i O
. O
e O
. O
, O
no O
C B
vacancy O
) O
C O
( O
60 O
) O
TiH O
( O
2 O
) O
complex O
are O
along O
the O
x O
- O
and O
y O
- O
axes O
of O
C B
( I
60 I
) I
( O
with O
adsorption O
energies O
of O
- O
0 O
. O
23 O
and O
- O
0 O
. O
21 O
eV O
, O
respectively O
) O
, O
making O
these O
orientations O
the O
most O
suitable O
ones O
for O
hydrogen B
storage O
, O
in O
contrast O
to O
the O
results O
obtained O
for O
defect O
- O
containing O
fullerenes O
. O

The O
defect O
- O
containing O
( O
i O
. O
e O
. O
, O
containing O
a O
C B
vacancy O
) O
C O
( O
59 O
) O
TiH O
( O
2 O
) O
complex O
do O
not O
exhibit O
adsorption O
energies O
within O
the O
targeted O
energy O
range O
. O

Charge O
transfer O
occurs O
from O
Ti B
3d O
to O
C B
2p O
of O
the O
fullerene B
. O

The O
binding O
of O
H B
( I
2 I
) I
is O
dominated O
by O
the O
pairwise O
support O
- O
metal O
interaction O
energy O
E O
( O
i O
) O
( O
Cn O
. O
. O
. O
Ti B
) O
, O
and O
the O
role O
of O
the O
fullerene B
is O
not O
restricted O
to O
supporting O
the O
metal O
. O

The O
C B
vacancy O
enhances O
the O
adsorption O
energy O
of O
Ti B
, O
in O
contrast O
to O
that O
of O
H B
( I
2 I
) I
. O

When O
stably O
expressed O
in O
transfected O
rat O
basophilic O
leukemia O
( O
RBL O
- O
2H3 O
) O
cells O
, O
mFpr1 O
was O
readily O
activated O
by O
N B
- O
formylated O
peptides O
derived O
from O
Listeria O
monocytogenes O
( O
fMIVTLF O
) O
, O
Staphylococcus O
aureus O
( O
fMIFL O
) O
, O
and O
mitochondria O
( O
fMMYALF O
) O
. O

The O
role O
of O
voltage O
- O
gated O
potassium B
channels O
Kv2 O
. O
1 O
and O
Kv2 O
. O
2 O
in O
the O
regulation O
of O
insulin O
and O
somatostatin O
release O
from O
pancreatic O
islets O
. O

The O
voltage O
- O
gated O
potassium B
channels O
Kv2 O
. O
1 O
and O
Kv2 O
. O
2 O
are O
highly O
expressed O
in O
pancreatic O
islets O
, O
yet O
their O
contribution O
to O
islet O
hormone O
secretion O
is O
not O
fully O
understood O
. O

Pancreatic O
beta O
- O
cells O
from O
Kv2 O
. O
1 O
( O
- O
/ O
- O
) O
mice O
possess O
reduced O
Kv O
current O
and O
display O
greater O
glucose B
- O
stimulated O
insulin O
secretion O
( O
GSIS O
) O
relative O
to O
WT O
beta O
- O
cells O
. O

However O
, O
in O
WT O
mice O
neither O
inhibitor O
improved O
glucose B
tolerance O
in O
vivo O
. O

GxTX O
- O
1E O
and O
RY796 O
enhanced O
somatostatin B
release O
in O
isolated O
human O
and O
mouse O
islets O
and O
in O
situ O
perfused O
pancreata O
from O
WT O
and O
Kv2 O
. O
1 O
( O
- O
/ O
- O
) O
mice O
. O

Kv2 O
. O
2 O
silencing O
in O
mouse O
islets O
by O
adenovirus O
- O
small O
hairpin O
RNA O
( O
shRNA O
) O
specifically O
enhanced O
islet O
somatostatin B
, O
but O
not O
insulin O
, O
secretion O
. O

In O
mice O
lacking O
somatostatin B
receptor O
5 O
, O
GxTX O
- O
1E O
stimulated O
insulin O
secretion O
and O
improved O
glucose B
tolerance O
. O

Collectively O
, O
these O
data O
show O
that O
Kv2 O
. O
1 O
regulates O
insulin O
secretion O
in O
beta O
- O
cells O
and O
Kv2 O
. O
2 O
modulates O
somatostatin B
release O
in O
delta O
- O
cells O
. O

Effects O
of O
a O
bioassay O
- O
derived O
ivermectin B
lowest O
observed O
effect O
concentration O
on O
life O
- O
cycle O
traits O
of O
the O
nematode O
Caenorhabditis O
elegans O
. O

The O
pharmaceutical O
ivermectin B
is O
used O
to O
treat O
parasitic O
infections O
, O
such O
as O
those O
caused O
by O
nematodes O
. O

While O
several O
studies O
have O
demonstrated O
the O
severe O
effects O
of O
ivermectin B
on O
non O
- O
target O
organisms O
, O
little O
is O
known O
about O
the O
drug O
' O
s O
impact O
on O
free O
- O
living O
nematodes O
. O

In O
the O
present O
work O
, O
a O
full O
life O
- O
cycle O
experiment O
was O
conducted O
to O
estimate O
how O
an O
ivermectin B
lowest O
observed O
effect O
concentration O
derived O
from O
a O
Caenorhabditis O
elegans O
bioassay O
( O
endpoint O
reproduction O
) O
might O
translate O
into O
effects O
at O
the O
population O
level O
of O
this O
free O
- O
living O
nematode O
. O

The O
experiment O
revealed O
that O
a O
4 O
- O
day O
bioassay O
is O
protective O
enough O
for O
C O
. O
elegans O
with O
respect O
to O
ivermectin B
' O
s O
effects O
on O
fecundity O
. O

Compounds O
1 O
, O
2 O
, O
10 O
, O
and O
11 O
contain O
a O
24 O
- O
aldehyde B
, O
which O
is O
rare O
for O
triterpene O
saponins O
from O
Ilex O
. O

Two O
- O
stage O
metal O
- O
catalyst O
- O
free O
growth O
of O
high O
- O
quality O
polycrystalline O
graphene B
films O
on O
silicon B
nitride I
substrates O
. O

By O
using O
two O
- O
stage O
, O
metal O
- O
catalyst O
- O
free O
chemical O
vapor O
deposition O
( O
CVD O
) O
, O
it O
is O
demonstrated O
that O
high O
- O
quality O
polycrystalline O
graphene B
films O
can O
directly O
grow O
on O
silicon B
nitride I
substrates O
. O

The O
carrier O
mobility O
can O
reach O
about O
1500 O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
, O
which O
is O
about O
three O
times O
the O
value O
of O
those O
grown O
on O
SiO B
( I
2 I
) I
/ O
Si B
substrates O
, O
and O
also O
is O
better O
than O
some O
examples O
of O
metal O
- O
catalyzed O
graphene B
, O
reflecting O
the O
good O
quality O
of O
the O
graphene B
lattice O
. O

Coal B
mining O
activities O
have O
been O
implicated O
as O
sources O
that O
increase O
stream O
specific O
conductance O
in O
Central O
Appalachia O
. O

The O
present O
study O
characterized O
potential O
sources O
of O
elevated O
ionic O
strength O
for O
small O
subwatersheds O
within O
the O
Coal B
, O
Upper O
Kanawha O
, O
Gauley O
, O
and O
New O
Rivers O
in O
West O
Virginia O
. O

In O
most O
catchments O
, O
HCO B
3 I
( I
- I
) I
and O
SO B
4 I
( I
2 I
- I
) I
concentrations O
were O
greater O
than O
Cl B
( I
- I
) I
concentration O
. O

Interestingly O
, O
the O
enzymes O
described O
herein O
were O
highly O
similar O
to O
methylenedioxy O
bridge O
- O
forming O
enzymes O
from O
alkaloid O
biosynthesis O
, O
whereas O
candidates O
more O
similar O
to O
lignan B
biosynthetic O
enzymes O
were O
catalytically O
inactive O
with O
the O
substrates O
employed O
. O

Phosphorylation O
of O
dopamine B
transporter O
serine B
7 O
modulates O
cocaine B
analog O
binding O
. O

As O
an O
approach O
to O
elucidating O
dopamine B
transporter O
( O
DAT O
) O
phosphorylation O
characteristics O
, O
we O
examined O
in O
vitro O
phosphorylation O
of O
a O
recombinant O
rat O
DAT O
N B
- O
terminal O
peptide O
( O
NDAT O
) O
using O
purified O
protein O
kinases O
. O

We O
found O
that O
NDAT O
becomes O
phosphorylated O
at O
single O
distinct O
sites O
by O
protein O
kinase O
A O
( O
Ser B
- O
7 O
) O
and O
calcium B
- O
calmodulin O
- O
dependent O
protein O
kinase O
II O
( O
Ser B
- O
13 O
) O
and O
at O
multiple O
sites O
( O
Ser B
- O
4 O
, O
Ser B
- O
7 O
, O
and O
Ser B
- O
13 O
) O
by O
protein O
kinase O
C O
( O
PKC O
) O
, O
implicating O
these O
residues O
as O
potential O
sites O
of O
DAT O
phosphorylation O
by O
these O
kinases O
. O

Mapping O
of O
rat O
striatal O
DAT O
phosphopeptides O
by O
two O
- O
dimensional O
thin O
layer O
chromatography O
revealed O
basal O
and O
PKC O
- O
stimulated O
phosphorylation O
of O
the O
same O
peptide O
fragments O
and O
comigration O
of O
PKC O
- O
stimulated O
phosphopeptide O
fragments O
with O
NDAT O
Ser B
- O
7 O
phosphopeptide O
markers O
. O

We O
further O
confirmed O
by O
site O
- O
directed O
mutagenesis O
and O
mass O
spectrometry O
that O
Ser B
- O
7 O
is O
a O
site O
for O
PKC O
- O
stimulated O
phosphorylation O
in O
heterologously O
expressed O
rat O
and O
human O
DATs O
. O

Mutation O
of O
Ser B
- O
7 O
and O
nearby O
residues O
strongly O
reduced O
the O
affinity O
of O
rat O
DAT O
for O
the O
cocaine B
analog O
( O
- O
) O
- O
2 O
beta O
- O
carbomethoxy O
- O
3 O
beta O
- O
( O
4 O
- O
fluorophenyl O
) O
tropane O
( O
CFT O
) O
, O
whereas O
in O
rat O
striatal O
tissue O
, O
conditions O
that O
promote O
DAT O
phosphorylation O
caused O
increased O
CFT O
affinity O
. O

Ser B
- O
7 O
mutation O
also O
affected O
zinc B
modulation O
of O
CFT O
binding O
, O
with O
Ala B
and O
Asp B
substitutions O
inducing O
opposing O
effects O
. O

These O
results O
identify O
Ser B
- O
7 O
as O
a O
major O
site O
for O
basal O
and O
PKC O
- O
stimulated O
phosphorylation O
of O
native O
and O
expressed O
DAT O
and O
suggest O
that O
Ser B
- O
7 O
phosphorylation O
modulates O
transporter O
conformational O
equilibria O
, O
shifting O
the O
transporter O
between O
high O
and O
low O
affinity O
cocaine B
binding O
states O
. O

Multiple O
geochemical O
markers O
, O
including O
aliphatic O
hydrocarbons O
( O
n B
- I
alkanes I
) O
, O
linear O
alkylbenzenes O
( O
LABs O
) O
, O
and O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
were O
employed O
to O
relate O
sediment O
organic O
chemical O
pollution O
in O
the O
coastal O
zone O
off O
South O
China O
to O
socioeconomic O
development O
there O
. O

Concentrations O
of O
Sigma O
n O
- O
C O
( O
15 O
- O
35 O
) O
( O
n B
- I
alkanes I
with O
15 O
- O
35 O
carbon B
atoms O
) O
, O
Sigma O
LAB O
( O
sum O
of O
C O
( O
10 O
) O
to O
C O
( O
13 O
) O
LABs O
) O
, O
and O
Sigma O
( O
26 O
) O
PAH B
( O
sum O
of O
26 O
PAH B
compounds O
) O
ranged O
from O
110 O
to O
3 O
, O
160 O
, O
11 O
to O
160 O
, O
and O
26 O
to O
600 O
ng O
/ O
g O
, O
with O
medians O
of O
730 O
, O
40 O
, O
and O
230 O
ng O
/ O
g O
, O
respectively O
. O

Natural O
hydrocarbons B
were O
mainly O
derived O
from O
terrestrial O
higher O
plant O
waxes O
, O
and O
in O
minor O
amounts O
from O
aquatic O
plankton O
and O
bacteria O
. O

In O
addition O
, O
anthropogenic O
hydrocarbons B
were O
derived O
largely O
from O
vehicular O
emissions O
and O
combustion O
of O
domestic O
coal O
and O
biomass O
and O
to O
a O
lesser O
extent O
from O
oil O
spills O
. O

Eastern O
and O
western O
coastal O
sediments O
contained O
higher O
levels O
of O
LABs O
but O
lower O
levels O
of O
PAHs B
than O
those O
of O
the O
Pearl O
River O
Estuary O
, O
a O
coastal O
area O
of O
the O
Pearl O
River O
Delta O
. O

However O
, O
greater O
amounts O
of O
energy O
are O
consumed O
in O
the O
latter O
region O
to O
produce O
more O
combustion O
- O
derived O
PAH B
contamination O
. O

Large O
area O
resist O
- O
free O
soft O
lithographic O
patterning O
of O
graphene B
. O

Large O
area O
low O
- O
cost O
patterning O
is O
a O
challenging O
problem O
in O
graphene B
research O
. O

A O
resist O
- O
free O
, O
single O
- O
step O
, O
large O
area O
and O
cost O
effective O
soft O
lithographic O
patterning O
strategy O
is O
presented O
for O
graphene B
. O

The O
technique O
is O
applicable O
on O
any O
arbitrary O
substrate O
that O
needs O
to O
be O
covered O
with O
a O
graphene B
film O
and O
provides O
a O
viable O
route O
to O
large O
- O
area O
patterning O
of O
graphene B
for O
device O
applications O
. O

The O
molecular O
structure O
of O
the O
blue O
mussel O
Mytilus O
edulis O
whole O
anchoring O
threads O
was O
studied O
by O
two O
- O
dimensional O
( B
13 I
) I
C I
solid O
- O
state O
NMR O
on O
fully O
labeled O
fibers O
. O

The O
spectra O
are O
dominated O
by O
residues O
in O
collagen O
environments O
, O
as O
determined O
from O
chemical O
shift O
analysis O
, O
and O
a O
complete O
two O
- O
dimensional O
assignment O
( O
including O
minor O
amino B
acids I
) O
was O
possible O
. O

The O
abundant O
glycine B
and O
alanine B
residues O
can O
be O
resolved O
in O
up O
to O
five O
different O
structural O
environments O
. O

Alanine B
peaks O
could O
be O
assigned O
to O
collagen O
triple O
- O
helices O
, O
beta O
- O
sheets O
( O
parallel O
and O
antiparallel O
) O
, O
beta O
- O
turns O
, O
and O
unordered O
structures O
. O

The O
human O
genome O
codes O
for O
13 O
members O
of O
a O
family O
of O
filament O
- O
forming O
GTP B
- O
binding O
proteins O
known O
as O
septins O
. O

This O
construct O
( O
SEPT3 O
- O
GC O
) O
, O
which O
includes O
the O
GTP B
- O
binding O
and O
C B
- O
terminal O
domains O
, O
purifies O
as O
a O
nucleotide B
- O
free O
monomer O
, O
allowing O
for O
its O
characterization O
in O
terms O
of O
GTP B
- O
binding O
and O
hydrolysis O
. O

In O
the O
present O
study O
we O
describe O
these O
two O
interfaces O
and O
relate O
the O
structure O
to O
its O
tendency O
to O
form O
monomers O
and O
its O
efficiency O
in O
the O
hydrolysis O
of O
GTP B
. O

Thus O
, O
we O
present O
information O
on O
three O
important O
receptor O
families O
, O
the O
integrins O
, O
the O
receptor O
tyrosine B
kinases O
, O
and O
the O
G O
protein O
- O
coupled O
receptors O
in O
terms O
of O
their O
suitability O
for O
targeted O
delivery O
of O
oligonucleotides O
. O

A O
possible O
mechanism O
of O
acid O
- O
catalyzed O
degradation O
of O
compound O
1 O
in O
methanol B
was O
proposed O
, O
consisting O
of O
a O
fast O
protonation O
, O
followed O
by O
a O
committed O
step O
of O
hydroxyl B
group O
removal O
. O

Ipsilateral O
feeding O
- O
specific O
circuits O
between O
the O
nucleus O
accumbens O
shell O
and O
the O
lateral O
hypothalamus O
: O
regulation O
by O
glutamate B
and O
GABA B
receptor O
subtypes O
. O

Activation O
of O
GABA B
( O
A O
) O
receptors O
or O
blockade O
of O
AMPA B
and O
kainate B
receptors O
within O
the O
AcbSh O
induces O
feeding O
, O
as O
does O
blockade O
of O
GABA B
( O
A O
) O
receptors O
or O
activation O
of O
NMDA B
receptors O
in O
the O
LH O
. O

DNQX O
( O
1 O
. O
25 O
mu O
g O
) O
or O
muscimol B
( O
100 O
ng O
) O
infused O
into O
the O
AcbSh O
unilaterally O
elicited O
feeding O
, O
and O
this O
elicited O
intake O
was O
suppressed O
by O
bilateral O
LH O
injection O
of O
d O
- O
AP5 O
( O
2 O
mu O
g O
) O
or O
muscimol B
( O
25 O
ng O
) O
. O

The O
effectiveness O
of O
d O
- O
AP5 O
or O
muscimol B
infusion O
into O
either O
the O
LH O
site O
ipsilateral O
or O
contralateral O
to O
the O
AcbSh O
injection O
was O
compared O
. O

Ipsilateral O
LH O
injection O
of O
d O
- O
AP5 O
or O
muscimol B
was O
significantly O
more O
effective O
than O
contralateral O
injection O
in O
suppressing O
food O
intake O
initiated O
by O
AcbSh O
injection O
of O
DNQX O
or O
muscimol B
. O

These O
results O
add O
to O
the O
prior O
evidence O
that O
inhibition O
of O
the O
LH O
through O
pharmacological O
modulation O
of O
NMDA B
or O
GABA B
( O
A O
) O
receptors O
specifically O
suppresses O
feeding O
initiated O
by O
AcbSh O
inhibition O
, O
and O
that O
these O
two O
regions O
communicate O
via O
an O
ipsilateral O
circuit O
to O
specifically O
regulate O
feeding O
. O

Pathophysiological O
roles O
of O
aldo O
- O
keto O
reductases O
( O
AKR1C1 O
and O
AKR1C3 O
) O
in O
development O
of O
cisplatin B
resistance O
in O
human O
colon O
cancers O
. O

Cisplatin B
( O
cis O
- O
diamminedichloroplat O
, O
CDDP B
) O
is O
widely O
used O
for O
treatment O
of O
patients O
with O
solid O
tumors O
formed O
in O
various O
organs O
including O
the O
lung O
, O
prostate O
and O
cervix O
, O
but O
is O
much O
less O
sensitive O
in O
colon O
and O
breast O
cancers O
. O

One O
major O
factor O
implicated O
in O
the O
ineffectiveness O
has O
been O
suggested O
to O
be O
acquisition O
of O
the O
CDDP B
resistance O
. O

Here O
, O
we O
established O
the O
CDDP B
- O
resistant O
phenotypes O
of O
human O
colon O
HCT15 O
cells O
by O
continuously O
exposing O
them O
to O
incremental O
concentrations O
of O
the O
drug O
, O
and O
monitored O
expressions O
of O
aldo O
- O
keto O
reductases O
( O
AKRs O
) O
1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
and O
1C3 O
. O

Among O
the O
six O
AKRs O
, O
AKR1C1 O
and O
AKR1C3 O
are O
highly O
induced O
with O
the O
CDDP B
resistance O
. O

The O
resistance O
lowered O
the O
sensitivity O
toward O
cellular O
damages O
evoked O
by O
oxidative O
stress O
- O
derived O
aldehydes B
, O
4 O
- O
hydroxy O
- O
2 O
- O
nonenal O
and O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
that O
are O
detoxified O
by O
AKR1C1 O
and O
AKR1C3 O
. O

Overexpression O
of O
AKR1C1 O
or O
AKR1C3 O
in O
the O
parental O
HCT15 O
cells O
mitigated O
the O
cytotoxicity O
of O
the O
aldehydes B
and O
CDDP B
. O

Knockdown O
of O
both O
AKR1C1 O
and O
AKR1C3 O
in O
the O
resistant O
cells O
or O
treatment O
of O
the O
cells O
with O
specific O
inhibitors O
of O
the O
AKRs O
increased O
the O
sensitivity O
to O
CDDP B
toxicity O
. O

Thus O
, O
the O
two O
AKRs O
participate O
in O
the O
mechanism O
underlying O
the O
CDDP B
resistance O
probably O
via O
detoxification O
of O
the O
aldehydes B
resulting O
from O
enhanced O
oxidative O
stress O
. O

Pretreatment O
of O
the O
resistant O
cells O
with O
a O
potent O
proteasome O
inhibitor O
Z O
- O
Leu O
- O
Leu O
- O
Leu O
- O
al O
augmented O
the O
CDDP B
sensitization O
elicited O
by O
the O
AKR O
inhibitors O
. O

Collectively O
, O
these O
results O
suggest O
the O
involvement O
of O
up O
- O
regulated O
AKR1C1 O
, O
AKR1C3 O
and O
proteasome O
in O
CDDP B
resistance O
of O
colon O
cancers O
and O
support O
a O
chemotherapeutic O
role O
for O
their O
inhibitors O
. O

Local O
structure O
and O
dynamics O
of O
benzene B
confined O
in O
the O
IRMOF O
- O
1 O
nanocavity O
as O
studied O
by O
molecular O
dynamics O
simulation O
. O

The O
local O
structure O
and O
dynamic O
behaviour O
of O
a O
benzene B
molecular O
assembly O
confined O
within O
the O
nano O
- O
cavities O
of O
a O
zinc B
- O
based O
metal O
- O
organic O
framework O
, O
[ O
Zn O
( O
4 O
) O
O O
( O
CO O
( O
2 O
) O
C O
( O
6 O
) O
H O
( O
4 O
) O
CO O
( O
2 O
) O
) O
( O
3 O
) O
] O
( O
n O
) O
( O
IRMOF O
- O
1 O
) O
, O
were O
investigated O
by O
means O
of O
molecular O
dynamics O
( O
MD O
) O
simulations O
. O

The O
local O
structure O
of O
the O
confined O
benzene B
molecules O
was O
evaluated O
using O
radial O
distribution O
functions O
. O

The O
sites O
for O
adsorption O
of O
benzene B
in O
IRMOF O
- O
1 O
were O
well O
defined O
by O
the O
simulation O
. O

The O
diffusion O
coefficients O
at O
ambient O
temperature O
suggested O
that O
the O
mobility O
of O
the O
confined O
benzene B
was O
high O
, O
comparable O
to O
the O
bulk O
fluid O
. O

Decreasing O
the O
temperature O
gave O
rise O
to O
the O
aggregation O
of O
benzene B
in O
the O
IRMOF O
- O
1 O
frameworks O
. O

Molecular O
aggregation O
was O
attributed O
to O
the O
localization O
of O
benzene B
in O
the O
large O
and O
the O
small O
cavities O
of O
IRMOF O
- O
1 O
, O
respectively O
. O

Both O
the O
translational O
diffusion O
coefficient O
and O
the O
trajectory O
of O
benzene B
provided O
evidence O
that O
the O
localization O
of O
benzene B
in O
the O
large O
and O
the O
small O
cavities O
takes O
place O
at O
ca O
. O

Furthermore O
, O
at O
high O
benzene B
loading O
, O
the O
migration O
of O
benzene B
in O
the O
small O
cavities O
was O
prevented O
( O
frozen O
) O
below O
135 O
K O
. O

Thus O
, O
the O
translational O
degree O
of O
freedom O
of O
the O
benzene B
molecules O
changed O
drastically O
, O
depending O
on O
the O
temperature O
. O

A O
series O
of O
coarse O
grained O
molecular O
dynamics O
simulations O
of O
lipid O
bilayers O
with O
carbon B
nanoparticles O
different O
in O
size O
have O
been O
performed O
. O

A O
VUV O
photoionization O
study O
of O
the O
multichannel O
reaction O
of O
phenyl B
radicals O
with O
1 O
, O
3 O
- O
butadiene O
under O
combustion O
relevant O
conditions O
. O

We O
studied O
the O
reaction O
of O
phenyl B
radicals O
( O
C O
( O
6 O
) O
H O
( O
5 O
) O
) O
with O
1 O
, O
3 O
- O
butadiene O
( O
H O
( O
2 O
) O
CCHCHCH O
( O
2 O
) O
) O
exploiting O
a O
high O
temperature O
chemical O
reactor O
under O
combustion O
- O
like O
conditions O
( O
300 O
Torr O
, O
873 O
K O
) O
. O

Our O
data O
suggest O
that O
the O
atomic O
hydrogen B
( O
H B
) O
, O
methyl B
( O
CH B
( I
3 I
) I
) O
, O
and O
vinyl B
( O
C O
( O
2 O
) O
H O
( O
3 O
) O
) O
losses O
are O
open O
with O
estimated O
branching O
ratios O
of O
about O
86 O
+ O
/ O
- O
4 O
% O
, O
8 O
+ O
/ O
- O
2 O
% O
, O
and O
6 O
+ O
/ O
- O
2 O
% O
, O
respectively O
. O

These O
fits O
indicate O
the O
formation O
of O
three O
C O
( O
10 O
) O
H O
( O
10 O
) O
isomers O
( O
trans O
- O
1 O
, O
3 O
- O
butadienylbenzene O
, O
1 O
, O
4 O
- O
dihydronaphthalene O
, O
1 O
- O
methylindene O
) O
, O
three O
C O
( O
9 O
) O
H O
( O
8 O
) O
isomers O
( O
indene B
, O
phenylallene O
, O
1 O
- O
phenyl O
- O
1 O
- O
methylacetylene O
) O
, O
and O
a O
C O
( O
8 O
) O
H O
( O
8 O
) O
isomer O
( O
styrene B
) O
. O

A O
comparison O
with O
results O
from O
recent O
crossed O
molecular O
beam O
studies O
of O
the O
1 O
, O
3 O
- O
butadiene O
- O
phenyl O
radical O
reaction O
and O
electronic O
structure O
calculations O
suggests O
that O
trans O
- O
1 O
, O
3 O
- O
butadienylbenzene O
( O
130 O
amu O
) O
, O
1 O
, O
4 O
- O
dihydronaphthalene O
( O
130 O
amu O
) O
, O
and O
styrene B
( O
104 O
amu O
) O
are O
reaction O
products O
formed O
as O
a O
consequence O
of O
a O
bimolecular O
reaction O
between O
the O
phenyl B
radical O
and O
1 O
, O
3 O
- O
butadiene O
. O

1 O
- O
Methylindene O
( O
130 O
amu O
) O
, O
indene B
( O
116 O
amu O
) O
, O
phenylallene O
( O
116 O
amu O
) O
, O
and O
1 O
- O
phenyl O
- O
1 O
- O
methylacetylene O
( O
116 O
amu O
) O
are O
synthesized O
upon O
reaction O
of O
the O
phenyl B
radical O
with O
three O
C O
( O
4 O
) O
H O
( O
6 O
) O
isomers O
: O
1 O
, O
2 O
- O
butadiene O
( O
H O
( O
2 O
) O
CCCH O
( O
CH O
( O
3 O
) O
) O
) O
, O
1 O
- O
butyne O
( O
HCCC O
( O
2 O
) O
H O
( O
5 O
) O
) O
, O
and O
2 O
- O
butyne O
( O
CH O
( O
3 O
) O
CCCH O
( O

3 O
) O
) O
; O
these O
C O
( O
4 O
) O
H O
( O
6 O
) O
isomers O
can O
be O
formed O
from O
1 O
, O
3 O
- O
butadiene O
via O
hydrogen B
atom O
assisted O
isomerization O
reactions O
or O
via O
thermal O
rearrangements O
of O
1 O
, O
3 O
- O
butadiene O
involving O
hydrogen B
shifts O
in O
the O
high O
temperature O
chemical O
reactor O
. O

Previous O
reports O
have O
identified O
a O
role O
for O
the O
tyrosine B
kinase O
receptor O
EphB4 O
and O
its O
ligand O
, O
ephrinB2 O
, O
as O
potential O
mediators O
of O
both O
bone O
formation O
by O
osteoblasts O
and O
bone O
resorption O
by O
osteoclasts O
. O

Efavirenz O
( O
EFV B
) O
is O
one O
of O
the O
most O
commonly O
prescribed O
antiretrovirals O
for O
use O
in O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
infection O
. O

EFV B
is O
extensively O
metabolized O
by O
cytochrome O
P450 O
to O
a O
number O
of O
oxygenated O
products O
; O
however O
, O
the O
pharmacologic O
activity O
and O
distribution O
of O
these O
metabolites O
in O
anatomic O
compartments O
have O
yet O
to O
be O
explored O
. O

The O
systemic O
distribution O
of O
EFV B
oxidative O
metabolites O
was O
examined O
in O
blood O
plasma O
, O
seminal O
plasma O
, O
and O
cerebrospinal O
fluid O
from O
subjects O
on O
an O
EFV B
- O
based O
regimen O
. O

Interestingly O
, O
protein O
- O
free O
concentrations O
of O
metabolites O
were O
only O
detectable O
in O
seminal O
plasma O
, O
where O
a O
novel O
dihdyroxylated O
metabolite O
of O
EFV B
was O
also O
detected O
. O

This O
accumulation O
of O
protein O
- O
free O
EFV B
metabolites O
was O
demonstrated O
to O
be O
the O
result O
of O
differential O
protein O
binding O
in O
seminal O
plasma O
compared O
with O
that O
of O
blood O
plasma O
. O

In O
addition O
, O
the O
oxidative O
metabolites O
of O
EFV B
did O
not O
present O
with O
any O
significant O
pharmacologic O
activity O
toward O
HIV O
- O
1 O
as O
measured O
using O
an O
HIV O
green O
fluorescent O
protein O
single O
- O
round O
infectivity O
assay O
. O

Once O
released O
by O
HIV O
( O
+ O
) O
cells O
, O
p17 O
binds O
heparan O
sulfate B
proteoglycans O
( O
HSPGs O
) O
and O
CXCR1 O
on O
leukocytes O
causing O
their O
dysfunction O
. O

Two O
stretches O
of O
basic O
amino B
acids I
( O
basic O
motifs O
) O
are O
present O
in O
p17 O
N B
and O
C B
termini O
. O

Neutralization O
( O
Arg O
- O
- O
> O
Ala B
substitution O
) O
of O
the O
N B
- O
terminal O
, O
but O
not O
of O
the O
C B
- O
terminal O
basic O
motif O
, O
causes O
the O
loss O
of O
p17 O
heparin O
- O
binding O
capacity O
. O

The O
N B
- O
terminal O
heparin O
- O
binding O
motif O
of O
p17 O
partially O
overlaps O
the O
CXCR1 O
- O
binding O
domain O
. O

Competition O
experiments O
demonstrated O
that O
free O
heparin O
and O
heparan O
sulfate B
( O
HS O
) O
, O
but O
not O
selectively O
2 O
- O
O B
- O
, O
6 O
- O
O B
- O
, O
and O
N O
- O
O O
desulfated O
heparins O
, O
prevent O
p17 O
binding O
to O
substrate O
- O
immobilized O
heparin O
, O
indicating O
that O
the O
sulfate B
groups O
of O
the O
glycosaminoglycan O
mediate O
p17 O
interaction O
. O

Evaluation O
of O
the O
p17 O
antagonist O
activity O
of O
a O
panel O
of O
biotechnological O
heparins O
derived O
by O
chemical O
sulfation O
of O
the O
Escherichia O
coli O
K5 O
polysaccharide O
revealed O
that O
the O
highly O
N B
, O
O B
- O
sulfated O
derivative O
prevents O
the O
binding O
of O
p17 O
to O
both O
heparin O
and O
CXCR1 O
, O
thus O
inhibiting O
p17 O
- O
driven O
chemotactic O
migration O
of O
human O
monocytes O
with O
an O
efficiency O
that O
is O
higher O
than O
those O
of O
heparin O
and O
HS O
. O

Positive O
allosteric O
modulator O
of O
alpha O
7 O
nicotinic O
- O
acetylcholine B
receptors O
, O
PNU B
- I
120596 I
augments O
the O
effects O
of O
donepezil B
on O
learning O
and O
memory O
in O
aged O
rodents O
and O
non O
- O
human O
primates O
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
an O
adjunctive O
treatment O
strategy O
to O
memory O
enhancement O
, O
namely O
combining O
the O
commonly O
prescribed O
acetylcholinesterase O
inhibitor O
( O
AChEI O
) O
donepezil B
, O
with O
a O
positive O
allosteric O
modulator O
( O
PAM O
) O
of O
alpha O
7 O
nicotinic O
- O
acetylcholine B
receptors O
( O
alpha O
7 O
- O
nAChRs O
) O
, O
PNU B
- I
120596 I
. O

In O
all O
three O
experiments O
a O
similar O
drug O
response O
was O
observed O
, O
namely O
that O
donepezil B
administered O
alone O
improved O
task O
performance O
in O
a O
dose O
- O
dependent O
manner O
; O
that O
PNU B
- I
120596 I
administered O
alone O
was O
without O
significant O
effect O
, O
but O
that O
the O
combination O
of O
PNU B
- I
120596 I
with O
a O
subthreshold O
dose O
of O
donepezil B
was O
effective O
. O

The O
positive O
effect O
of O
the O
drug O
combination O
appeared O
to O
be O
alpha O
7 O
- O
nAChR O
mediated O
given O
that O
it O
was O
blocked O
in O
the O
NOR O
task O
by O
the O
selective O
alpha O
7 O
- O
nAChR O
antagonist O
methyllycaconitine B
( O
MLA B
) O
. O

Collectively O
, O
these O
data O
indicate O
that O
PNU B
- I
120596 I
increases O
the O
effective O
dose O
range O
of O
donepezil B
in O
learning O
/ O
memory O
- O
related O
tasks O
in O
young O
and O
age O
- O
impaired O
animal O
models O
. O

The O
results O
suggest O
that O
alpha O
7 O
- O
nAChR O
- O
selective O
PAMs O
like O
PNU B
- I
120596 I
have O
potential O
as O
adjunctive O
treatments O
with O
acetylcholinesterase O
inhibitors O
( O
e O
. O
g O
. O
, O
donepezil B
) O
for O
age O
- O
related O
illnesses O
such O
as O
AD O
as O
well O
memory O
disorders O
not O
necessarily O
associated O
with O
advanced O
age O
. O

1H B
NMR O
spectra O
of O
ethane O
- O
1 O
, O
2 O
- O
diol O
and O
other O
vicinal B
diols I
in O
benzene B
: O
GIAO O
/ O
DFT O
shift O
calculations O
. O

The O
proton O
NMR O
spectra O
of O
several O
1 O
, O
2 O
- O
diols O
in O
benzene B
have O
been O
analysed O
so O
as O
to O
associate O
each O
magnetically O
nonequivalent O
proton O
with O
its O
chemical O
shift O
. O

The O
shifts O
and O
coupling O
constants O
of O
the O
OH B
and O
methylene B
protons O
of O
ethane O
- O
1 O
, O
2 O
- O
diol O
have O
been O
determined O
in O
a O
wide O
range O
of O
solvents O
. O

The O
conformer O
distribution O
and O
the O
proton O
NMR O
shifts O
of O
these O
1 O
, O
2 O
- O
diols O
in O
benzene B
have O
been O
computed O
on O
the O
basis O
of O
density O
functional O
theory O
. O

Overall O
, O
the O
computed O
NMR O
shifts O
are O
in O
good O
agreement O
with O
experimental O
values O
for O
the O
OH B
protons O
but O
remain O
systematically O
high O
for O
CH B
protons O
. O

To O
date O
, O
main O
available O
oral O
antidiabetic O
medications O
target O
either O
insulin O
resistance O
( O
metformin B
, O
glitazones B
) O
, O
or O
insulin O
deficiency O
( O
sulfonylureas B
, O
glinides O
) O
, O
but O
leading O
to O
shortfalls O
in O
medication O
. O

We O
recently O
reported O
that O
levulinate O
( O
4 O
- O
ketopentanoate O
) O
is O
converted O
in O
the O
liver O
to O
4 O
- O
hydroxypentanoate O
, O
a O
drug O
of O
abuse O
, O
and O
that O
the O
formation O
of O
4 O
- O
hydroxypentanoate O
is O
stimulated O
by O
ethanol B
oxidation O
. O

We O
also O
identified O
3 O
parallel O
beta O
- O
oxidation O
pathways O
by O
which O
levulinate O
and O
4 O
- O
hydroxypentanoate O
are O
catabolized O
to O
propionyl O
- O
CoA O
and O
acetyl B
- I
CoA I
. O

We O
now O
report O
that O
levulinate O
forms O
three O
seven O
- O
carbon B
cyclical O
CoA O
esters O
by O
processes O
starting O
with O
the O
elongation O
of O
levulinyl O
- O
CoA O
by O
acetyl B
- I
CoA I
to O
3 O
, O
6 O
- O
diketoheptanoyl O
- O
CoA O
. O

The O
second O
cyclization O
process O
yields O
a O
methyl O
- O
pyrrolyl O
- O
acetyl O
- O
CoA O
containing O
a O
nitrogen B
atom O
derived O
from O
the O
epsilon O
- O
nitrogen O
of O
lysine B
but O
without O
carbons B
from O
lysine B
. O

The O
cyclic O
CoA O
esters O
were O
identified O
in O
rat O
livers O
perfused O
with O
levulinate O
and O
in O
livers O
and O
brains O
from O
rats O
gavaged O
with O
calcium O
levulinate O
+ O
/ O
- O
ethanol B
. O

Lastly O
, O
3 O
, O
6 O
- O
diketoheptanoyl O
- O
CoA O
, O
like O
2 O
, O
5 O
- O
diketohexane O
, O
pyrrolates O
free O
lysine B
and O
, O
presumably O
, O
lysine B
residues O
from O
proteins O
. O

Large O
- O
sized O
, O
2D O
single O
crystals O
of O
perylene B
are O
grown O
by O
both O
solution O
- O
cast O
and O
physical O
vapor O
transport O
methods O
. O

3D O
- O
QSAR O
- O
assisted O
drug O
design O
: O
identification O
of O
a O
potent O
quinazoline B
- O
based O
Aurora O
kinase O
inhibitor O
. O

Three O
different O
3D O
- O
QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole B
( O
Model O
I O
) O
and O
furanopyrimidine O
( O
Model O
II O
) O
compounds O
with O
IC O
( O
50 O
) O
values O
toward O
Aurora O
kinase O
A O
ranging O
from O
33 O
nM O
to O
10 O
. O
5 O
mu O
M O
. O

Based O
on O
these O
suggestions O
, O
the O
rational O
redesign O
of O
furanopyrimidine O
24 O
( O
clog O
P O
= O
7 O
. O
41 O
; O
Aurora O
A O
IC O
( O
50 O
) O
= O
43 O
nM O
; O
HCT O
- O
116 O
IC O
( O
50 O
) O
= O
400 O
nM O
) O
led O
to O
the O
identification O
of O
quinazoline B
67 O
( O
clog O
P O
= O
5 O
. O
28 O
; O
Aurora O
A O
IC O
( O
50 O
) O
= O
25 O
nM O
; O
HCT O
- O
116 O
IC O
( O
50 O
) O
= O
23 O
nM O
) O
. O

This O
study O
provided O
a O
systematic O
review O
of O
recent O
U O
. O
S O
. O
studies O
on O
the O
price O
elasticity O
of O
demand O
for O
sugar B
- O
sweetened O
beverages O
( O
SSBs O
) O
, O
fast O
food O
, O
and O
fruits O
and O
vegetables O
, O
as O
well O
as O
the O
direct O
associations O
of O
prices O
/ O
taxes O
with O
body O
weight O
outcomes O
. O

Cannabinoid O
agonists O
increase O
the O
interaction O
between O
beta O
- O
Arrestin O
2 O
and O
ERK1 O
/ O
2 O
and O
upregulate O
beta O
- O
Arrestin O
2 O
and O
5 B
- I
HT I
( O
2A O
) O
receptors O
. O

We O
have O
recently O
reported O
that O
selective O
cannabinoid O
2 O
( O
CB O
( O
2 O
) O
) O
receptor O
agonists O
upregulate O
5 B
- I
HT I
( O
2A O
) O
receptors O
by O
enhancing O
ERK1 O
/ O
2 O
signaling O
in O
prefrontal O
cortex O
( O
PFCx O
) O
. O

Increased O
activity O
of O
cortical O
5 B
- I
HT I
( O
2A O
) O
receptors O
has O
been O
associated O
with O
several O
neuropsychiatric O
disorders O
such O
as O
anxiety O
and O
schizophrenia O
. O

Sprague O
- O
Dawley O
rats O
treated O
with O
a O
non O
- O
selective O
cannabinoid O
agonist O
( O
CP55940 B
, O
50 O
mu O
g O
/ O
kg O
, O
7 O
days O
, O
i O
. O
p O
. O
) O
showed O
enhanced O
co O
- O
immunoprecipitation O
of O
beta O
- O
Arrestin O
2 O
and O
ERK1 O
/ O
2 O
, O
enhanced O
pERK O
protein O
levels O
, O
and O
enhanced O
expression O
of O
beta O
- O
Arrestin O
2 O
mRNA O
and O
protein O
levels O
in O
PFCx O
. O

Our O
results O
suggest O
that O
sustained O
activation O
of O
CB O
( O
2 O
) O
receptors O
would O
enhance O
beta O
- O
Arrestin O
2 O
expression O
possibly O
contributing O
to O
its O
increased O
interaction O
with O
ERK1 O
/ O
2 O
, O
thereby O
driving O
the O
upregulation O
of O
5 B
- I
HT I
( O
2A O
) O
receptors O
. O

Beneficial O
effects O
of O
polyphenols B
on O
cardiovascular O
disease O
. O

In O
recent O
years O
, O
numerous O
studies O
have O
demonstrated O
the O
health O
benefits O
of O
polyphenols B
, O
and O
special O
attention O
has O
been O
paid O
to O
their O
beneficial O
effects O
against O
cardiovascular O
disease O
, O
the O
leading O
cause O
of O
death O
in O
the O
world O
today O
. O

Polyphenols B
present O
vasodilator O
effects O
and O
are O
able O
to O
improve O
lipid O
profiles O
and O
attenuate O
the O
oxidation O
of O
low O
density O
lipoproteins O
. O

It O
has O
been O
suggested O
that O
most O
of O
these O
effects O
are O
a O
consequence O
of O
the O
antioxidant O
properties O
of O
polyphenols B
, O
but O
this O
idea O
is O
not O
completely O
accepted O
, O
and O
many O
other O
mechanisms O
have O
been O
proposed O
recently O
to O
explain O
the O
health O
effects O
of O
these O
compounds O
. O

In O
fact O
, O
different O
signaling O
pathways O
have O
been O
linked O
to O
polyphenols B
. O

This O
review O
brings O
together O
some O
recent O
studies O
which O
establish O
the O
beneficial O
properties O
of O
polyphenols B
for O
cardiovascular O
disease O
and O
analyzes O
the O
mechanisms O
involved O
in O
these O
properties O
. O

SS O
rats O
had O
lower O
plasma O
testosterone B
concentrations O
than O
CTL O
rats O
( O
p O
= O
0 O
. O
05 O
) O
, O
but O
did O
not O
differ O
in O
androgen B
receptor O
, O
estrogen B
receptor O
alpha O
, O
or O
Fos O
immunoreactive O
cell O
counts O
in O
the O
medial O
preoptic O
area O
. O

Angiotensin O
AT2 O
receptor O
activates O
the O
cyclic B
- I
AMP I
signaling O
pathway O
in O
eel O
. O

A O
unique O
angiotensin O
type O
2 O
receptor O
( O
AT2 O
) O
that O
induces O
a O
cAMP B
signaling O
pathway O
was O
cloned O
and O
characterized O
for O
the O
first O
time O
in O
fish O
, O
Anguilla O
japonica O
. O

Various O
angiotensin O
( O
Ang O
) O
peptides O
, O
including O
Ang O
II O
, O
Ang O
III O
, O
and O
Ang O
IV O
, O
were O
detected O
in O
the O
spleen O
by O
a O
radioimmunoassay O
coupled O
with O
HPLC O
separation O
, O
and O
these O
endogenous O
peptides O
stimulated O
a O
cAMP B
signaling O
, O
which O
has O
no O
crosstalk O
with O
cGMP B
pathway O
. O

Intraindividual O
and O
interindividual O
variabilities O
in O
endogenous O
cortisol B
6 O
beta O
- O
hydroxylation O
clearance O
as O
an O
index O
for O
in O
vivo O
CYP3A O
phenotyping O
in O
humans O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
in O
vivo O
activity O
of O
cytochrome O
P450 O
3A O
( O
CYP3A O
) O
in O
49 O
healthy O
Japanese O
subjects O
aged O
22 O
- O
58 O
years O
using O
endogenous O
cortisol B
6 O
beta O
- O
hydroxylation O
clearance O
[ O
CLm O
( O
6 O
beta O
) O
] O
, O
a O
novel O
biomarker O
for O
CYP3A O
phenotyping O
. O

Some O
novel O
alpha O
and O
beta O
ionone O
based O
chalcones B
and O
their O
dihydropyrazolidines O
/ O
pyrazolidines O
have O
been O
synthesized O
and O
evaluated O
for O
their O
in O
vitro O
and O
in O
vivo O
antileishmanial O
activities O
against O
Leishmania O
donovani O
. O

Design O
, O
synthesis O
and O
inhibitory O
activities O
of O
naringenin B
derivatives O
on O
human O
colon O
cancer O
cells O
. O

Based O
on O
the O
previous O
result O
, O
several O
naringenin B
derivatives O
modified O
at O
position O
7 O
with O
bulky O
substituents O
were O
designed O
and O
synthesized O
, O
and O
their O
inhibitory O
effects O
on O
HCT116 O
human O
colon O
cancer O
cells O
were O
tested O
using O
a O
clonogenic O
assay O
. O

The O
half O
maximal O
inhibitory O
concentrations O
( O
IC O
( O
50 O
) O
) O
of O
five O
naringenin B
derivatives O
ranged O
between O
1 O
. O
20 O
mu O
M O
and O
20 O
. O
01 O
mu O
M O
which O
are O
much O
better O
than O
naringenin B
used O
as O
a O
control O
. O

To O
elucidate O
the O
possible O
interaction O
between O
naringenin B
derivatives O
and O
CDK2 O
, O
in O
silico O
docking O
study O
was O
performed O
. O

This O
result O
demonstrates O
the O
rationale O
for O
the O
different O
inhibitory O
activities O
of O
the O
naringenin B
derivatives O
. O

Here O
we O
compare O
the O
TAzP O
probe O
with O
other O
rigid O
or O
flexible O
probes O
with O
respect O
to O
target O
tagging O
efficiency O
, O
hydrophobic O
parameters O
, O
aqueous O
solubility O
, O
and O
dihedral O
angles O
around O
the O
biaryl B
linkage O
by O
a O
combination O
of O
empirical O
and O
calculation O
methods O
. O

The O
rigid O
biaryl B
linkage O
of O
the O
TAzP O
probe O
has O
a O
skewed O
conformation O
that O
influences O
its O
aqueous O
solubility O
. O

Herein O
we O
report O
a O
next O
generation O
muscarinic O
receptor O
4 O
( O
M O
( O
4 O
) O
) O
positive O
allosteric O
modulator O
( O
PAM O
) O
, O
ML253 O
which O
exhibits O
nanomolar O
activity O
at O
both O
the O
human O
( O
EC O
( O
50 O
) O
= O
56 O
nM O
) O
and O
rat O
( O
EC O
( O
50 O
) O
= O
176 O
nM O
) O
receptors O
and O
excellent O
efficacy O
by O
the O
left O
- O
ward O
shift O
of O
the O
ACh B
concentration O
response O
curve O
( O
fold O
shift O
, O
human O
= O
106 O
; O
rat O
= O
50 O
) O
. O

In O
addition O
, O
ML253 O
is O
selective O
against O
the O
four O
other O
muscarinic O
subtypes O
, O
displays O
excellent O
CNS O
exposure O
and O
is O
active O
in O
an O
amphetamine B
- O
induced O
hyperlocomotion O
assay O
. O

Protein O
tyrosine B
phosphatase O
1B O
inhibitory O
effect O
by O
dammarane B
- O
type O
triterpenes B
from O
hydrolyzate O
of O
total O
Gynostemma O
pentaphyllum O
saponins B
. O

Protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
is O
an O
important O
factor O
in O
non O
- O
insulin O
- O
dependent O
diabetes O
mellitus O
( O
type O
- O
2 O
diabetes O
) O
, O
and O
a O
promising O
target O
for O
treatment O
of O
diabetes O
and O
obesity O
. O

Therefore O
, O
the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
inhibitory O
activities O
of O
constituents O
( O
three O
new O
together O
with O
twelve O
known O
triterpenes B
compounds O
) O
isolated O
from O
the O
hydrolyzate O
of O
total O
saponins B
from O
Gynostemma O
pentaphyllum O
. O

The O
circadian O
rhythm O
of O
corticosterone B
( O
CORT B
) O
secretion O
from O
the O
adrenal O
cortex O
is O
regulated O
by O
the O
suprachiasmatic O
nucleus O
( O
SCN O
) O
, O
which O
is O
entrained O
to O
the O
light O
- O
dark O
cycle O
. O

Since O
the O
circadian O
CORT B
rhythm O
is O
associated O
with O
circadian O
expression O
of O
the O
steroidogenic O
acute O
regulatory O
( O
StAR O
) O
protein O
, O
we O
investigated O
the O
24h O
pattern O
of O
hormonal O
secretion O
( O
ACTH O
and O
CORT B
) O
, O
steroidogenic O
gene O
expression O
( O
StAR O
, O
SF O
- O
1 O
, O
DAX1 O
and O
Nurr77 O
) O
and O
the O
expression O
of O
genes O
involved O
in O
ACTH O
signalling O
( O
MC2R O
and O
MRAP O
) O
in O
rats O
entrained O
to O
a O
normal O
light O
- O
dark O
cycle O
. O

We O
found O
that O
circadian O
changes O
in O
ACTH O
and O
CORT B
were O
associated O
with O
the O
circadian O
expression O
of O
all O
gene O
targets O
; O
with O
SF O
- O
1 O
, O
Nurr77 O
and O
MRAP O
peaking O
in O
the O
evening O
, O
and O
DAX1 O
and O
MC2R O
peaking O
in O
the O
morning O
. O

Since O
disruption O
of O
normal O
SCN O
activity O
by O
exposure O
to O
constant O
light O
abolishes O
the O
circadian O
rhythm O
of O
CORT B
in O
the O
rat O
, O
we O
also O
investigated O
whether O
the O
AM O
- O
PM O
variation O
of O
our O
target O
genes O
was O
also O
disrupted O
in O
rats O
exposed O
to O
constant O
light O
conditions O
for O
5weeks O
. O

We O
found O
that O
the O
disruption O
of O
the O
AM O
- O
PM O
variation O
of O
ACTH O
and O
CORT B
secretion O
in O
rats O
exposed O
to O
constant O
light O
was O
accompanied O
by O
a O
loss O
of O
AM O
- O
PM O
variation O
in O
StAR O
, O
SF O
- O
1 O
and O
DAX1 O
, O
and O
a O
reversed O
AM O
- O
PM O
variation O
in O
Nurr77 O
, O
MC2R O
and O
MRAP O
. O

We O
propose O
that O
ACTH O
regulates O
the O
secretion O
of O
CORT B
via O
the O
circadian O
control O
of O
steroidogenic O
gene O
pathways O
that O
become O
dysregulated O
under O
the O
influence O
of O
constant O
light O
. O

Synthesis O
and O
anti O
- O
tumor O
evaluation O
of O
novel O
25 O
- O
hydroxyprotopanaxadi O
analogs O
incorporating O
natural O
amino B
acids I
. O

In O
the O
current O
study O
, O
derivatives O
of O
25 O
- O
hydroxyprotopanaxadi O
( O
25 O
- O
OH O
- O
PPD O
) O
were O
prepared O
and O
their O
in O
vitro O
anti O
- O
tumor O
activities O
were O
tested O
on O
six O
different O
human O
tumor O
cell O
lines O
by O
standard O
MTT B
assay O
. O

The O
results O
showed O
that O
combining O
an O
ester B
group O
combined O
with O
the O
presence O
of O
an O
amino B
acid I
moiety O
led O
to O
a O
10 O
- O
fold O
improved O
anti O
- O
tumor O
activity O
. O

Pulmonary O
delivery O
of O
an O
aerosolized O
recombinant O
human O
butyrylcholinesteras O
pretreatment O
protects O
against O
aerosolized O
paraoxon B
in O
macaques O
. O

Butyrylcholinesteras O
( O
BChE O
) O
is O
the O
leading O
pretreatment O
candidate O
against O
exposure O
to O
organophosphates B
( O
OPs O
) O
, O
which O
pose O
an O
ever O
increasing O
public O
and O
military O
health O
. O

In O
contrast O
to O
parenteral O
delivery O
of O
rBChE O
, O
which O
currently O
requires O
posttranslational O
modification O
for O
good O
plasma O
stability O
, O
an O
unmodified O
aer O
- O
rBChE O
pretreatment O
given O
1 O
- O
40h O
prior O
to O
> O
1 O
LD50 O
of O
aer O
- O
paraoxon B
( O
Px O
) O
was O
able O
to O
prevent O
inhibition O
of O
circulating O
cholinesterase O
in O
a O
dose O
- O
dependent O
manner O
. O

These O
studies O
are O
the O
first O
to O
show O
protection O
by O
rBChE O
against O
a O
pesticide O
such O
as O
paraoxon B
when O
delivered O
directly O
into O
the O
lung O
and O
bode O
well O
for O
the O
use O
of O
a O
non O
- O
invasive O
and O
consumer O
friendly O
method O
of O
rHuBChE O
delivery O
as O
a O
human O
treatment O
to O
counteract O
OP O
toxicity O
. O

Aspidin O
PB O
, O
a O
phloroglucinol B
derivative O
, O
induces O
apoptosis O
in O
human O
hepatocarcinoma O
HepG2 O
cells O
by O
modulating O
PI3K O
/ O
Akt O
/ O
GSK3 O
beta O
pathway O
. O

Aspidin O
PB O
, O
a O
phloroglucinol B
derivative O
isolated O
from O
Dryopteris O
fragrans O
( O
L O
. O
) O
Schott O
, O
has O
been O
previously O
reported O
to O
exert O
high O
biological O
activities O
. O

After O
treatment O
with O
aspidin O
PB O
for O
72 O
h O
, O
48 O
h O
and O
24 O
h O
using O
MTT B
assay O
, O
the O
IC O
( O
50 O
) O
values O
were O
10 O
. O
59 O
mu O
M O
, O
20 O
. O
86 O
mu O
M O
and O
46 O
. O
59 O
mu O
M O
, O
respectively O
. O

Aspidin O
PB O
was O
capable O
to O
induce O
apoptosis O
, O
as O
measured O
by O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
, O
acridine O
orange O
( O
AO O
) O
staining O
and O
propidium B
iodide I
( O
PI O
) O
/ O
annexin O
V O
- O
FITC B
double O
staining O
. O

Similarly O
, O
the O
effects O
of O
aspidin O
PB O
on O
PI3K O
, O
Akt O
, O
GSK3 O
beta O
, O
NAG O
- O
1 O
expression O
were O
abolished O
by O
treatment O
with O
the O
PI3K O
inhibitor O
, O
wortmannin B
. O

Inhibition O
of O
CIP2A O
determines O
erlotinib B
- O
induced O
apoptosis O
in O
hepatocellular O
carcinoma O
. O

Erlotinib B
is O
a O
small O
- O
molecular O
inhibitor O
of O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
. O

Here O
, O
we O
identify O
that O
cancerous O
inhibitor O
of O
protein O
phosphatase O
2A O
( O
CIP2A O
) O
is O
a O
major O
determinant O
mediating O
erlotinib B
- O
induced O
apoptosis O
in O
hepatocellular O
carcinoma O
( O
HCC O
) O
. O

Erlotinib B
showed O
differential O
effects O
on O
apoptosis O
in O
4 O
human O
HCC O
cell O
lines O
. O

Erlotinib B
induced O
significant O
apoptosis O
in O
Hep3B O
and O
PLC5 O
cell O
lines O
; O
however O
, O
Huh O
- O
7 O
and O
HA59T O
cell O
lines O
showed O
resistance O
to O
erlotinib B
- O
induced O
apoptosis O
at O
all O
tested O
doses O
. O

Down O
- O
regulation O
of O
CIP2A O
, O
a O
cellular O
inhibitor O
of O
protein O
phosphatase O
2A O
( O
PP2A O
) O
, O
mediated O
the O
apoptotic O
effect O
of O
erlotinib B
in O
HCC O
. O

Erlotinib B
inhibited O
CIP2A O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
in O
all O
sensitive O
HCC O
cells O
whereas O
no O
alterations O
in O
CIP2A O
were O
found O
in O
resistant O
cells O
. O

Overexpression O
of O
CIP2A O
upregulated O
phospho B
- O
Akt O
and O
protected O
Hep3B O
cells O
from O
erlotinib B
- O
induced O
apoptosis O
. O

In O
addition O
, O
silencing O
CIP2A O
by O
siRNA O
restored O
the O
effects O
of O
erlotinib B
in O
Huh O
- O
7 O
cells O
. O

Moreover O
, O
adding O
okadaic O
acid O
, O
a O
PP2A O
inhibitor O
, O
abolished O
the O
effects O
of O
erlotinib B
on O
apoptosis O
in O
Hep3B O
cells O
; O
and O
forskolin B
, O
a O
PP2A O
agonist O
enhanced O
the O
effect O
of O
erlotinib B
in O
resistant O
HA59T O
cells O
. O

Combining O
Akt O
inhibitor O
MK O
- O
2206 O
with O
erlotinib B
restored O
the O
sensitivity O
of O
HA59T O
cells O
to O
erlotinib B
. O

Furthermore O
, O
in O
vivo O
xenograft O
data O
showed O
that O
erlotinib B
inhibited O
the O
growth O
of O
PLC5 O
tumor O
but O
had O
no O
effect O
on O
Huh O
- O
7 O
tumor O
. O

Erlotinib B
downregulated O
CIP2A O
and O
upregulated O
PP2A O
activity O
in O
PLC5 O
tumors O
, O
but O
not O
in O
Huh O
- O
7 O
tumors O
. O

In O
conclusion O
, O
inhibition O
of O
CIP2A O
determines O
the O
effects O
of O
erlotinib B
on O
apoptosis O
in O
HCC O
. O

CIP2A O
may O
be O
useful O
as O
a O
therapeutic O
biomarker O
for O
predicting O
clinical O
response O
to O
erlotinib B
in O
HCC O
treatment O
. O

This O
study O
examined O
the O
protective O
effects O
of O
boldine O
against O
high O
glucose B
- O
induced O
oxidative O
stress O
in O
rat O
aortic O
endothelial O
cells O
( O
RAEC O
) O
and O
its O
mechanisms O
of O
vasoprotection O
related O
to O
diabetic O
endothelial O
dysfunction O
. O

In O
RAEC O
exposed O
to O
high O
glucose B
( O
30 O
mM O
) O
for O
48 O
h O
, O
pre O
- O
treatment O
with O
boldine O
reduced O
the O
elevated O
ROS O
and O
nitrotyrosine O
formation O
, O
and O
preserved O
nitric B
oxide I
( O
NO B
) O
production O
. O

Pre O
- O
incubation O
with O
beta O
- O
NAPDH O
reduced O
the O
acetylcholine B
- O
induced O
endothelium O
- O
dependent O
relaxation O
; O
this O
attenuation O
was O
reversed O
by O
boldine O
. O

Compared O
with O
control O
, O
endothelium O
- O
dependent O
relaxation O
in O
the O
aortas O
of O
streptozotocin B
( O
STZ B
) O
- O
treated O
diabetic O
rats O
was O
significantly O
improved O
by O
both O
acute O
( O
1 O
mu O
M O
, O
30 O
min O
) O
and O
chronic O
( O
20mg O
/ O
kg O
/ O
daily O
, O
i O
. O
p O
. O
, O
7 O
days O
) O
treatment O
with O
boldine O
. O

Intracellular O
superoxide B
and O
peroxynitrite B
formation O
measured O
by O
DHE O
fluorescence O
or O
chemiluminescence O
assay O
were O
higher O
in O
sections O
of O
aortic O
rings O
from O
diabetic O
rats O
compared O
with O
control O
. O

Chronic O
boldine O
treatment O
normalized O
ROS O
over O
- O
production O
in O
the O
diabetic O
group O
and O
this O
correlated O
with O
reduction O
of O
NAD B
( I
P I
) I
H I
oxidase O
subunits O
, O
NOX2 O
and O
p47 O
( O
phox O
) O
. O

The O
present O
study O
shows O
that O
boldine O
reversed O
the O
increased O
ROS O
formation O
in O
high O
glucose B
- O
treated O
endothelial O
cells O
and O
restored O
endothelial O
function O
in O
STZ B
- O
induced O
diabetes O
by O
inhibiting O
oxidative O
stress O
and O
thus O
increasing O
NO B
bioavailability O
. O

Spermatozoa O
were O
exposed O
ex O
vivo O
to O
an O
alkylating O
agent O
( O
methyl B
methanesulfonate I
) O
before O
in O
vitro O
fertilization O
and O
DNA O
damage O
was O
assessed O
by O
the O
alkaline O
comet O
assay O
. O

Two O
new O
C O
- O
benzylated O
dihydrochalcone O
derivatives O
, O
4 O
, O
2 O
' O
, O
4 O
' O
- O
trihydroxy O
- O
6 O
' O
- O
methoxy O
- O
3 O
' O
( O
2 O
' O
' O
- O
hydroxybenzyl O
) O
dihydrochalcone O
( O
1 O
) O
and O
2 O
' O
, O
4 O
' O
- O
dihydroxy O
- O
4 O
, O
6 O
' O
- O
dimethoxy O
- O
3 O
' O
( O
2 O
' O
' O
- O
hydroxybenzyl O
) O
dihydrochalcone O
( O
2 O
) O
, O
along O
with O
six O
known O
flavonoid B
derivatives O
( O
3 O
- O
8 O
) O
, O
a O

The O
structures O
of O
the O
compounds O
were O
elucidated O
by O
spectroscopic O
analysis O
, O
mainly O
1D O
and O
2D O
NMR O
techniques O
( O
1H B
, O
13C B
, O
COSY O
, O
HMQC O
, O
and O
HMBC O
) O
, O
as O
well O
as O
by O
comparison O
with O
literature O
data O
. O

Facile O
and O
clean O
release O
of O
vertical O
Si B
nanowires O
by O
wet O
chemical O
etching O
based O
on O
alkali O
hydroxides O
. O

A O
simple O
method O
to O
release O
Si B
nanowires O
( O
SiNWs O
) O
from O
a O
substrate O
, O
with O
their O
original O
length O
almost O
intact O
, O
is O
demonstrated O
. O

By O
exploiting O
the O
unique O
chemistry O
involved O
for O
the O
fabrication O
of O
vertical O
arrays O
of O
SiNWs O
in O
metal O
- O
assisted O
chemical O
etching O
( O
MaCE O
) O
based O
either O
on O
HF B
/ O
AgNO3 B
or O
HF B
/ O
H2O2 B
chemistries O
, O
wet O
etching O
with O
alkali O
hydroxides O
such O
as O
NaOH B
or O
KOH B
preferentially O
attacks O
the O
bottom O
part O
of O
the O
vertical O
SiNWs O
. O

A O
protective O
layer O
of O
Si B
oxide B
is O
found O
to O
exist O
on O
the O
outer O
wall O
of O
the O
SiNWs O
and O
to O
play O
the O
key O
role O
of O
etch O
mask O
during O
the O
release O
- O
etching O
by O
alkali O
hydroxides O
. O

The O
clean O
release O
of O
SiNWs O
also O
enables O
the O
repeated O
use O
of O
the O
Si B
substrate O
for O
the O
fabrication O
of O
vertical O
SiNW O
arrays O
by O
MaCE O
. O

Enantioseparation O
of O
four O
organophosphonate B
derivatives O
on O
N O
- O
( O
3 O
, O
5 O
- O
dinitrobenzoyl O
) O
- O
L O
- O
leucine O
- O
n O
- O
propylamide O
stationary O
phase O
by O
molecular O
modeling O
. O

Four O
groups O
of O
organophosphonate B
derivatives O
enantiomers O
were O
separated O
on O
N O
- O
( O
3 O
, O
5 O
- O
dinitrobenzoyl O
) O
- O
S O
- O
leucine O
chiral O
stationary O
phase O
. O

Stochastic O
and O
potentiometric O
microsensors O
based O
on O
porphyrins B
and O
polymeric O
surfactants O
such O
as O
polysodium O
N O
- O
undecanoyl O
- O
L O
- O
leucylvanilate O
and O
polysodium O
N O
- O
undecanoyl O
- O
L O
- O
vanilate O
were O
developed O
for O
enantioselective O
assay O
of O
pipecolic O
acid O
. O

The O
matrices O
used O
for O
the O
design O
of O
the O
stochastic O
sensors O
were O
diamond B
paste O
and O
graphite B
paste O
, O
while O
the O
matrix O
used O
for O
the O
design O
of O
potentiometric O
sensors O
was O
carbon B
paste O
. O

The O
acidity O
of O
the O
backbone O
amides B
, O
as O
reflected O
in O
hydrogen B
exchange O
rates O
, O
is O
exquisitely O
sensitive O
to O
the O
surrounding O
charge O
and O
dielectric O
volume O
distribution O
. O

The O
most O
recently O
deposited O
NOE O
- O
based O
ubiquitin O
structure O
and O
the O
original O
NMR O
structure O
of O
CI2 O
fail O
to O
provide O
statistically O
significant O
predictions O
of O
hydrogen B
exchange O
. O

Effects O
of O
ozone B
and O
fine O
particulate O
matter O
( O
PM O
( O
2 O
. O
5 O
) O
) O
on O
rat O
system O
inflammation O
and O
cardiac O
function O
. O

In O
order O
to O
understand O
the O
toxic O
mechanisms O
of O
cardiovascular O
system O
injuries O
induced O
by O
ambient O
PM O
( O
2 O
. O
5 O
) O
and O
/ O
or O
ozone B
, O
a O
subacute O
toxicological O
animal O
experiment O
was O
designed O
with O
exposure O
twice O
a O
week O
for O
3 O
continuous O
weeks O
. O

Wistar O
rats O
were O
randomly O
categorized O
into O
8 O
groups O
( O
n O
= O
6 O
) O
: O
1 O
control O
group O
, O
3 O
groups O
exposed O
to O
fine O
particulate O
matters O
( O
PM O
( O
2 O
. O
5 O
) O
) O
alone O
at O
3 O
doses O
( O
0 O
. O
2 O
, O
0 O
. O
8 O
, O
or O
3 O
. O
2 O
mg O
/ O
rat O
) O
, O
1 O
group O
to O
ozone B
( O
0 O
. O
81 O
ppm O
) O
alone O
and O
3 O
groups O
to O
ozone B
plus O
PM O
( O
2 O
. O
5 O
) O
at O
3 O
doses O
( O
0 O
. O
2 O
, O
0 O
. O
8 O
, O
or O
3 O
. O
2 O
mg O
/ O
rat O
) O
. O

Biomarkers O
of O
systemic O
inflammation O
and O
injuries O
( O
CRP O
, O
IL O
- O
6 O
, O
LDH O
, O
CK O
) O
, O
heart O
oxidative O
stress O
( O
MDA B
, O
SOD O
) O
and O
endothelial O
function O
( O
ET O
- O
1 O
, O
VEGF O
) O
were O
analyzed O
after O
the O
6th O
exposure O
. O

Results O
showed O
that O
PM O
( O
2 O
. O
5 O
) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA B
, O
CK O
, O
ET O
- O
1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
( O
HRV O
) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
( O
ANS O
) O
function O
. O

Ozone B
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O

Ozone B
plus O
PM O
( O
2 O
. O
5 O
) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL O
- O
6 O
, O
CK O
, O
LDH O
and O
MDA B
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose O
- O
response O
way O
. O

Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM O
( O
2 O
. O
5 O
) O
with O
and O
without O
ozone B
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O

In O
conclusion O
, O
PM O
( O
2 O
. O
5 O
) O
alone O
exposure O
could O
cause O
inflammation O
, O
endothelial O
function O
and O
ANS O
injuries O
, O
and O
ozone B
potentiated O
these O
effects O
induced O
by O
PM O
( O
2 O
. O
5 O
) O
. O

Dynamics O
of O
silver B
nanoparticle O
formation O
and O
agglomeration O
inside O
the O
cavitation O
bubble O
after O
pulsed O
laser O
ablation O
in O
liquid O
. O

Limits O
of O
metastability O
in O
amorphous O
ices O
: O
2H B
- O
NMR O
relaxation O
. O

The O
high O
- O
frequency O
reorientation O
dynamics O
of O
O O
- O
( O
2 O
) O
H O
bonds O
is O
investigated O
in O
various O
amorphous O
ices O
including O
eHDA O
( O
expanded O
high O
density O
amorphous O
ice O
) O
, O
LDA O
- O
II O
( O
low O
density O
amorphous O
ice O
II O
) O
and O
HGW O
( O
hyperquenched O
glassy O
water O
) O
using O
( B
2 I
) I
H I
- O
NMR O
spin O
- O
lattice O
relaxation O
as O
a O
local O
probe O
. O

Nanoporous O
silicon B
networks O
as O
anodes O
for O
lithium B
ion O
batteries O
. O

Nanoporous O
silicon B
( O
Si B
) O
networks O
with O
controllable O
porosity O
and O
thickness O
are O
fabricated O
by O
a O
simple O
and O
scalable O
electrochemical O
process O
, O
and O
then O
released O
from O
Si B
wafers O
and O
transferred O
to O
flexible O
and O
conductive O
substrates O
. O

These O
nanoporous O
Si B
networks O
serve O
as O
high O
performance O
Li B
- O
ion O
battery O
electrodes O
, O
with O
an O
initial O
discharge O
capacity O
of O
2570 O
mA O
h O
g O
( O
- O
1 O
) O
, O
above O
1000 O
mA O
h O
g O
( O
- O
1 O
) O
after O
200 O
cycles O
without O
any O
electrolyte O
additives O
. O

Significant O
progress O
has O
been O
made O
recently O
in O
the O
development O
of O
Organic O
Ionic O
Plastic O
Crystals O
( O
OIPCs O
) O
, O
a O
unique O
family O
of O
solid O
state O
electrolytes O
with O
applications O
in O
electrochemical O
devices O
such O
as O
lithium B
batteries O
and O
dye O
- O
sensitised O
solar O
cells O
. O

However O
, O
the O
complex O
mechanisms O
of O
conduction O
through O
these O
materials O
, O
both O
in O
their O
pure O
state O
and O
in O
the O
presence O
of O
a O
small O
amount O
of O
a O
second O
component O
( O
such O
as O
lithium B
salts O
to O
enable O
their O
use O
in O
lithium B
batteries O
) O
are O
still O
not O
fully O
understood O
. O

In O
parallel O
, O
the O
applicability O
of O
these O
materials O
as O
electrolytes O
for O
dye O
- O
sensitised O
solar O
cells O
and O
lithium B
batteries O
is O
being O
more O
widely O
demonstrated O
. O

We O
have O
now O
used O
the O
special O
features O
of O
unsymmetrically O
substituted O
allyl B
derivatives O
to O
obtain O
unprecedented O
insight O
into O
ion O
pair O
dynamics O
. O

By O
employing O
chiral O
high O
- O
performance O
liquid O
chromatography O
, O
it O
was O
possible O
to O
follow O
the O
time O
- O
dependent O
concentrations O
of O
all O
four O
isomeric O
esters B
( O
two O
regioisomeric O
pairs O
of O
enantiomers O
) O
and O
all O
four O
isomeric O
alcohols B
generated O
during O
the O
hydrolysis O
of O
enantiopure O
1 O
- O
( O
4 O
- O
chlorophenyl O
) O
- O
3 O
- O
phenylallyl O
and O
3 O
- O
( O
4 O
- O
chlorophenyl O
) O
- O
1 O
- O
phenylallyl O
4 O
- O
nitrobenzoates O
. O

Numerical O
simulation O
of O
chemical O
reactions O
inside O
an O
isolated O
spherical O
bubble O
of O
oxygen B
has O
been O
performed O
for O
various O
ambient O
bubble O
radii O
at O
different O
frequencies O
and O
acoustic O
amplitudes O
to O
study O
the O
effects O
of O
these O
two O
parameters O
on O
the O
range O
of O
ambient O
radius O
for O
an O
active O
bubble O
in O
sonochemical O
reactions O
. O

Decolourization O
of O
direct O
azo B
dye O
, O
direct O
blue O
15 O
( O
DB15 O
) O
, O
by O
an O
advanced O
Fenton O
process O
coupled O
with O
ultrasonic O
irradiation O
( O
Fenton O
/ O
US O
) O
was O
investigated O
. O

Experimental O
results O
showed O
that O
the O
optimum O
conditions O
for O
decolourization O
were O
pH O
3 O
. O
0 O
, O
Fe O
( O
0 O
) O
1g O
/ O
L O
, O
H B
( I
2 I
) I
O I
( I
2 I
) I
5 O
. O
15 O
x O
10 O
( O
- O
3 O
) O
mol O
/ O
L O
with O
ultrasound O
density O
of O
120W O
/ O
L O
at O
60kHz O
. O

Although O
the O
solutions O
containing O
H O
( O
2 O
) O
CO O
( O
3 O
) O
, O
Cl B
( I
- I
) I
, O
ClO O
( O
4 O
) O
( O
- O
) O
, O
NO B
( I
3 I
) I
( I
- I
) I
and O
SO B
( I
4 I
) I
( I
2 I
- I
) I
ions O
did O
not O
have O
a O
significant O
effect O
on O
the O
decolouration O
, O
the O
H O
( O
2 O
) O
PO O
( O
4 O
) O
( O
- O
) O
ion O
did O
decrease O
the O
decolouration O
rate O
. O

This O
study O
demonstrates O
that O
a O
Fenton O
/ O
US O
process O
can O
effectively O
decolour O
the O
direct O
azo B
dye O
DB15 O
in O
wastewater O
. O

The O
study O
shows O
that O
the O
stability O
of O
the O
two O
complexes O
with O
bidentate O
ligands O
is O
associated O
with O
their O
high O
hydrogen B
bonding O
stability O
and O
existence O
of O
stronger O
non O
- O
covalent O
metal O
- O
ligand O
bonds O
. O

Highlights O
on O
contemporary O
recognition O
and O
sensing O
of O
fluoride B
anion O
in O
solution O
and O
in O
the O
solid O
state O
. O

The O
fluoride B
anion O
has O
recently O
gained O
well O
deserved O
attention O
among O
the O
scientific O
community O
for O
its O
importance O
in O
many O
fields O
of O
human O
activities O
, O
but O
also O
for O
concerns O
on O
its O
effect O
on O
health O
and O
the O
environment O
. O

Although O
surprisingly O
overlooked O
in O
systematic O
studies O
in O
the O
past O
, O
fluoride B
has O
nowadays O
become O
a O
topical O
target O
in O
the O
field O
of O
anion O
recognition O
. O

A O
multitude O
of O
scientific O
reports O
are O
published O
every O
year O
where O
the O
establishment O
of O
efficient O
and O
specific O
interaction O
with O
fluoride B
is O
sought O
in O
polar O
and O
aqueous O
media O
. O

Also O
, O
dissociated O
phospho B
- O
rpS3 O
translocated O
into O
nucleus O
and O
bound O
with O
NF O
- O
kappa O
B O
complex O
( O
p65 O
and O
p50 O
) O
, O
contributing O
to O
p65 O
DNA O
binding O
property O
and O
specificity O
. O

N O
, O
N O
- O
dihydroxypyromelliti O
( O
NDHPI O
) O
and O
N O
, O
N O
' O
, O
N O
' O
' O
- O
trihydroxyisocyanuri O
acid O
( O
THICA O
) O
have O
been O
recently O
demonstrated O
to O
act O
as O
better O
carbon B
- O
radical O
- O
producing O
catalysts O
than O
the O
popular O
N O
- O
hydroxyphthalimide O
( O
NHPI O
) O
. O

Besides O
, O
the O
more O
remarkable O
catalytic O
efficiencies O
of O
NDHPI O
and O
THICA O
compared O
to O
NHPI O
can O
be O
ascribed O
to O
the O
lower O
barriers O
and O
the O
endothermicity O
in O
the O
H B
- O
abstraction O
processes O
by O
their O
radicals O
, O
especially O
by O
their O
multi O
- O
radicals O
which O
show O
stronger O
electron O
- O
withdrawing O
effects O
. O

High O
- O
dose O
resveratrol B
supplementation O
in O
obese O
men O
: O
an O
investigator O
- O
initiated O
, O
randomized O
, O
placebo O
- O
controlled O
clinical O
trial O
of O
substrate O
metabolism O
, O
insulin O
sensitivity O
, O
and O
body O
composition O
. O

Based O
on O
animal O
and O
in O
vitro O
studies O
, O
resveratrol B
reverts O
these O
risk O
factors O
via O
stimulation O
of O
silent O
mating O
type O
information O
regulation O
2 O
homolog O
1 O
( O
SIRT1 O
) O
, O
but O
data O
in O
human O
subjects O
are O
scarce O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
metabolic O
effects O
of O
high O
- O
dose O
resveratrol B
in O
obese O
human O
subjects O
. O

In O
a O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blinded O
, O
and O
parallel O
- O
group O
design O
, O
24 O
obese O
but O
otherwise O
healthy O
men O
were O
randomly O
assigned O
to O
4 O
weeks O
of O
resveratrol B
or O
placebo O
treatment O
. O

Extensive O
metabolic O
examinations O
including O
assessment O
of O
glucose B
turnover O
and O
insulin O
sensitivity O
( O
hyperinsulinemic O
euglycemic O
clamp O
) O
were O
performed O
before O
and O
after O
the O
treatment O
. O

Endogenous O
glucose B
production O
and O
the O
turnover O
and O
oxidation O
rates O
of O
glucose B
remained O
unchanged O
. O

Resveratrol B
supplementation O
also O
had O
no O
effect O
on O
blood O
pressure O
; O
resting O
energy O
expenditure O
; O
oxidation O
rates O
of O
lipid O
; O
ectopic O
or O
visceral O
fat O
content O
; O
or O
inflammatory O
and O
metabolic O
biomarkers O
. O

The O
lack O
of O
effect O
disagrees O
with O
persuasive O
data O
obtained O
from O
rodent O
models O
and O
raises O
doubt O
about O
the O
justification O
of O
resveratrol B
as O
a O
human O
nutritional O
supplement O
in O
metabolic O
disorders O
. O

In O
pregnant O
women O
, O
the O
diabetic O
condition O
results O
in O
a O
three O
- O
to O
fivefold O
increased O
risk O
for O
fetal O
cardiac O
malformations O
as O
a O
result O
of O
elevated O
glucose B
concentrations O
and O
the O
resultant O
osmotic O
stress O
in O
the O
developing O
embryo O
and O
fetus O
. O

Pulsed O
hyperglycemia O
induced O
by O
daily O
administration O
of O
glucose B
during O
3 O
days O
of O
development O
caused O
daily O
spikes O
in O
plasma O
glucose B
concentration O
. O

In O
a O
second O
model O
, O
sustained O
hyperglycemia O
was O
induced O
with O
a O
single O
injection O
of O
glucose B
into O
the O
yolk O
on O
day O
0 O
. O

The O
sustained O
model O
raised O
the O
average O
plasma O
glucose B
concentration O
from O
70 O
mg O
/ O
dL O
to O
180 O
mg O
/ O
dL O
and O
led O
to O
decreased O
gene O
expression O
of O
glucose B
transporter O
GLUT1 O
. O

Annotated O
trait O
- O
associated O
genomic O
loci O
, O
for O
which O
most O
are O
single O
- O
nucleotide B
polymorphisms O
derived O
from O
genome O
- O
wide O
association O
studies O
, O
may O
be O
valuable O
resources O
for O
experimental O
scientists O
. O

The O
chemopreventive O
effect O
of O
beta B
- I
cryptoxanthin I
from O
mandarin O
on O
human O
stomach O
cells O
( O
BGC O
- O
823 O
) O
. O

beta B
- I
Cryptoxanthin I
, O
a O
provitaminic O
carotenoid O
, O
present O
in O
many O
fruits O
and O
vegetables O
, O
has O
been O
associated O
with O
decreased O
risk O
of O
chronic O
diseases O
, O
including O
cancer O
. O

The O
influence O
of O
beta B
- I
cryptoxanthin I
derived O
from O
mandarin O
on O
the O
proliferation O
of O
the O
stomach O
tumor O
cell O
line O
BGC O
- O
823 O
was O
tested O
using O
MTT B
and O
cell O
count O
assay O
at O
72 O
h O
and O
dose O
- O
response O
( O
from O
0 O
. O
01 O
to O
20 O
mu O
M O
) O
. O

beta B
- I
Cryptoxanthin I
suppressed O
the O
cell O
migration O
by O
the O
scratch O
assay O
. O

Furthermore O
, O
beta B
- I
cryptoxanthin I
induced O
an O
accumulation O
of O
cells O
in O
the O
G1 O
/ O
G0 O
phase O
of O
the O
cell O
cycle O
( O
as O
detected O
by O
flow O
cytometry O
) O
, O
which O
was O
in O
accordance O
with O
an O
increased O
expression O
of O
p21 O
and O
down O
regulations O
of O
cyclin O
D1 O
and O
cyclin O
E O
, O
detected O
by O
Western O
blot O
analysis O
, O
and O
beta B
- I
cryptoxanthin I
increased O
the O
mRNA O
levels O
of O
retinoic B
acid I
receptor O
beta O
( O
RAR O
beta O
) O
with O
the O
treatment O
at O
10 O
mu O
M O
for O
24 O
h O
. O

Collectively O
, O
the O
above O
findings O
suggest O
that O
beta B
- I
cryptoxanthin I
could O
be O
therapeutic O
in O
the O
treatment O
of O
stomach O
cancer O
cell O
in O
vitro O
. O

The O
multisensor O
, O
developed O
at O
laboratory O
, O
is O
composed O
by O
14 O
sensing O
elements O
of O
tin O
dioxide O
thin O
layers O
( O
doped O
with O
Cr B
and O
In B
, O
and O
undoped O
) O
deposited O
by O
the O
reactive O
sputtering O
technique O
. O

The O
free O
, O
bound O
and O
total O
phenolic O
contents O
were O
66 O
. O
17 O
- O
226 O
. O
03 O
, O
11 O
. O
18 O
- O
40 O
. O
54 O
, O
and O
101 O
. O
51 O
- O
259 O
. O
18 O
mg O
of O
gallic B
acid I
equivalents O
/ O
100 O
g O
, O
respectively O
. O

The O
free O
, O
bound O
and O
total O
flavonoid B
contents O
were O
16 O
. O
68 O
- O
110 O
. O
33 O
, O
10 O
. O
48 O
- O
22 O
. O
75 O
, O
and O
39 O
. O
43 O
- O
129 O
. O
86 O
mg O
of O
catechin B
equivalents O
/ O
100 O
g O
, O
respectively O
. O

Free O
phenolics B
and O
flavonoids B
contributed O
averagely O
80 O
. O
1 O
% O
and O
75 O
% O
to O
their O
total O
contents O
, O
respectively O
. O

Six O
individual O
phenolics B
( O
gallic B
acid I
, O
chlorogenic B
acid I
, O
( B
+ I
) I
- I
catechin I
, O
caffeic B
acid I
, O
( B
- I
) I
- I
epicatechin I
, O
and O
rutin B
) O
were O
detected O
in O
litchi O
pulp O
by O
HPLC O
. O

Significant O
varietal O
discrepancy O
in O
antioxidant O
activity O
was O
also O
found O
by O
FRAP O
and O
DPPH B
scavenging O
capacity O
methods O
. O

Antioxidant O
activity O
was O
significantly O
correlated O
with O
phenolic O
and O
flavonoid B
contents O
. O

Thus O
, O
phenolics B
and O
flavonoids B
exist O
mainly O
in O
the O
free O
form O
in O
litchi O
pulp O
. O

The O
production O
of O
TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
and O
nitric B
oxide I
also O
increased O
. O

Correlations O
between O
the O
dietary O
fibre O
components O
, O
associated O
bioactive O
components O
( O
e O
. O
g O
. O
tocols O
, O
sterols B
, O
phenolic B
acids I
and O
folates B
) O
and O
agronomic O
properties O
previously O
determined O
on O
the O
same O
samples O
were O
found O
with O
multivariate O
analysis O
( O
PCA O
) O
. O

The O
second O
PC O
described O
the O
variation O
in O
kernel O
weight O
and O
other O
bran O
components O
such O
as O
alkylresorcinols B
, O
tocols O
and O
sterols B
. O

The O
selective O
interaction O
of O
lectins O
with O
carbohydrate B
components O
from O
bacterial O
cells O
surface O
was O
used O
as O
the O
recognition O
principle O
for O
the O
detection O
. O

Development O
and O
validation O
of O
an O
HPLC O
method O
for O
the O
determination O
of O
six O
penicillin B
and O
three O
amphenicol O
antibiotics O
in O
gilthead O
seabream O
( O
Sparus O
Aurata O
) O
tissue O
according O
to O
the O
European O
Union O
Decision O
2002 O
/ O
657 O
/ O
EC O
. O

A O
confirmatory O
high O
performance O
liquid O
chromatography O
method O
for O
the O
determination O
of O
six O
penicillin B
antibiotics O
and O
three O
amphenicol O
antibiotics O
in O
gilthead O
seabream O
( O
Sparus O
Aurata O
) O
tissue O
was O
developed O
. O

Ampicillin B
( O
AMP B
) O
, O
penicillin O
G O
( O
PG O
) O
, O
penicillin O
V O
( O
PV O
) O
, O
oxacillin B
( O
OXA O
) O
, O
cloxacillin O
( O
CLO O
) O
, O
dicloxacillin O
( O
DICLO O
) O
, O
thiamphenicol O
( O
TAP O
) O
, O
florfenicol O
( O
FFC O
) O
and O
chloramphenicol O
( O
CAP O
) O
were O
separated O
on O
an O
Inertsil O
, O
C O
( O
8 O
) O
( O
250 O
x O
4 O
mm O
, O
5 O
mu O
m O
) O
column O
by O
gradient O
elution O
with O
a O
mobile O
phase O
consisting O
of O

ammonium B
acetate I
0 O
. O
05 O
M O
and O
acetonitrile B
at O
25 O
degrees O
C O
. O

Diode O
array O
detection O
with O
monitoring O
at O
225 O
nm O
( O
for O
the O
determination O
of O
AMP B
, O
PG O
, O
PV O
, O
TAP O
and O
FFC O
) O
, O
240 O
nm O
( O
for O
OXA O
, O
CLO O
and O
DICLO O
) O
and O
278 O
nm O
( O
for O
CAP O
) O
was O
applied O
. O

Metabolite O
profiling O
of O
ginsenoside B
Re I
in O
rat O
urine O
and O
faeces O
after O
oral O
administration O
. O

Following O
oral O
administration O
of O
ginsenoside B
Re I
, O
the O
compound O
and O
its O
metabolites O
were O
identified O
and O
quantified O
in O
rat O
urine O
and O
faeces O
by O
liquid O
chromatography O
coupled O
with O
triple O
quadrupole O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
. O

Ginsenoside B
Re I
( O
200 O
mg O
/ O
kg O
) O
was O
orally O
administered O
to O
rats O
by O
gastric O
intubation O
, O
and O
urine O
and O
faeces O
samples O
were O
then O
collected O
during O
the O
next O
24 O
h O
using O
metabolic O
cages O
. O

The O
precursor O
- O
product O
ion O
pairs O
used O
for O
LC O
- O
MS O
/ O
MS O
analysis O
were O
: O
m O
/ O
z O
945 O
- O
- O
> O
475 O
for O
ginsenoside B
Re I
, O
799 O
- O
- O
> O
637 O
for O
ginsenoside B
Rg1 I
, O
783 O
- O
- O
> O
475 O
for O
ginsenoside O
Rg2 O
, O
637 O
- O
- O
> O
475 O
for O
ginsenosides O
Rh1 O
and O
F1 O
, O
475 O
- O
- O
> O
391 O
for O
protopanaxatriol B
, O
and O
779 O
- O
- O
> O
641 O
for O
digoxin O
( O
internal O
standard O
) O
. O

The O
major O
ginsenosides B
excreted O
in O
urine O
were O
ginsenosides O
Re O
and O
Rg1 O
, O
and O
only O
minimal O
amounts O
of O
ginsenosides O
Rg2 O
and O
Rh1 O
were O
found O
. O

Greater O
amounts O
of O
ginsenoside B
metabolites O
were O
detected O
in O
the O
faeces O
samples O
; O
biotransformation O
to O
ginsenoside B
Rg1 I
was O
predominant O
but O
further O
deglycosylated O
metabolites O
including O
ginsenoside O
F1 O
and O
protopanaxatriol B
were O
additionally O
detected O
. O

The O
total O
recovery O
of O
ginsenosides B
over O
24 O
h O
was O
approximately O
46 O
% O
. O

Thirteen O
anthocyanins B
were O
identified O
in O
the O
purple O
- O
fleshed O
sweet O
potato O
cultivar O
Jihei O
No O
. O
1 O
. O

The O
main O
anthocyanins B
were O
3 O
- O
sophoroside O
- O
5 O
- O
glucoside O
derivatives O
from O
cyanidin B
and O
peonidin B
, O
acylated O
with O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
or O
caffeic B
acid I
. O

A O
unique O
anthocyanin B
, O
delphinidin O
- O
3 O
, O
5 O
- O
diglucoside O
was O
also O
found O
. O

The O
thermal O
stability O
of O
purple O
- O
fleshed O
sweet O
potato O
anthocyanins B
( O
PSPAs O
) O
followed O
a O
first O
- O
order O
kinetics O
model O
. O

The O
enrichment O
and O
degradation O
kinetics O
of O
anthocyanins B
in O
these O
matrices O
were O
investigated O
at O
80 O
, O
90 O
, O
and O
100 O
degrees O
C O
. O

A O
higher O
stability O
of O
anthocyanins B
was O
obtained O
in O
aqueous O
solutions O
with O
pH O
3 O
and O
4 O
and O
in O
apple O
and O
pear O
juices O
. O

Rapid O
analysis O
of O
sugars B
in O
honey O
by O
processing O
Raman O
spectrum O
using O
chemometric O
methods O
and O
artificial O
neural O
networks O
. O

The O
aim O
of O
this O
study O
was O
to O
quantify O
glucose B
, O
fructose B
, O
sucrose B
and O
maltose O
contents O
of O
honey O
samples O
using O
Raman O
spectroscopy O
as O
a O
rapid O
method O
. O

By O
performing O
a O
single O
measurement O
, O
quantifications O
of O
sugar B
contents O
have O
been O
said O
to O
be O
unaffordable O
according O
to O
the O
molecular O
similarities O
between O
sugar B
molecules O
in O
honey O
matrix O
. O

Model O
solutions O
of O
four O
sugars B
were O
processed O
with O
PCA O
and O
significant O
separation O
was O
observed O
. O

This O
operation O
, O
done O
with O
the O
spectral O
features O
by O
using O
PLS O
and O
ANN O
methods O
, O
led O
to O
the O
discriminant O
analysis O
of O
sugar B
contents O
. O

The O
correlation O
coefficient O
values O
between O
actual O
and O
predicted O
values O
of O
glucose B
, O
fructose B
, O
sucrose B
and O
maltose O
were O
determined O
as O
0 O
. O
964 O
, O
0 O
. O
965 O
, O
0 O
. O
968 O
and O
0 O
. O
949 O
for O
PLS O
and O
0 O
. O
965 O
, O
0 O
. O
965 O
, O
0 O
. O
978 O
and O
0 O
. O
956 O
for O
ANN O
, O
respectively O
. O

The O
requirement O
of O
rapid O
analysis O
of O
sugar B
contents O
of O
commercial O
honeys O
has O
been O
met O
by O
the O
data O
processed O
within O
this O
article O
. O

Dextrans O
and O
glucooligosaccharide O
( O
GLOS O
) O
are O
produced O
by O
lactic B
acid I
bacteria O
( O
LAB O
) O
during O
sourdough O
fermentation O
. O

In O
this O
study O
accumulation O
of O
eight O
heavy O
metals O
( O
Cu B
, O
Ni B
, O
Zn B
, O
Cr B
, O
Fe B
, O
Mn B
, O
Co B
and O
Pb B
) O
in O
green O
vegetables O
like O
Allium O
cepa O
, O
Allium O
sativum O
, O
Solanum O
lycopersicum O
and O
Solanum O
melongena O
, O
irrigated O
with O
wastewater O
in O
Mardan O
are O
studied O
using O
Atomic O
Absorption O
spectrophotometer O
. O

The O
most O
heavily O
contaminated O
vegetable O
was O
wastewater O
irrigated O
A O
. O
cepa O
, O
where O
the O
accumulation O
of O
Mn B
( O
28 O
. O
05 O
mg O
kg O
( O
- O
1 O
) O
) O
in O
the O
edible O
parts O
was O
50 O
- O
fold O
greater O
than O
A O
. O
cepa O
irrigated O
with O
tube O
well O
water O
irrigated O
soil O
. O

The O
casein O
fraction O
of O
13 O
Portuguese O
PDO O
cheeses O
were O
analysed O
using O
Urea B
- O
PAGE O
and O
reverse O
phase O
- O
high O
performance O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
and O
then O
subjected O
to O
chemometric O
evaluation O
. O

Peptide O
mapping O
using O
Urea B
- O
PAGE O
followed O
by O
CA O
revealed O
two O
major O
clusters O
according O
to O
the O
similarity O
of O
the O
proteolytic O
profile O
of O
the O
cheeses O
. O

The O
C B
, O
N B
, O
O B
, O
and O
S B
isotopic O
compositions O
of O
egg O
components O
from O
7 O
different O
production O
systems O
were O
measured O
. O

The O
application O
of O
Near O
- O
Infrared O
Reflectance O
Spectroscopy O
( O
NIRS O
) O
to O
detect O
melamine B
adulteration O
of O
soya O
bean O
meal O
. O

Soya O
bean O
products O
are O
used O
widely O
in O
the O
animal O
feed O
industry O
as O
a O
protein O
based O
feed O
ingredient O
and O
have O
been O
found O
to O
be O
adulterated O
with O
melamine B
. O

Dehulled O
soya O
( O
GM O
and O
non O
- O
GM O
) O
, O
soya O
hulls O
and O
toasted O
soya O
were O
contaminated O
with O
melamine B
and O
spectra O
were O
generated O
using O
Near O
Infrared O
Reflectance O
Spectroscopy O
( O
NIRS O
) O
. O

A O
panel O
of O
reporter O
gene O
assays O
( O
RGAs O
) O
coupled O
with O
a O
single O
solid O
phase O
extraction O
( O
SPE O
) O
step O
was O
developed O
and O
used O
to O
screen O
bottled O
mineral O
water O
for O
the O
presence O
of O
four O
classes O
of O
endocrine O
disruptors O
( O
EDs O
) O
, O
oestrogens B
, O
androgens B
, O
progestagens O
and O
glucocorticoids O
. O

Oestrogenic O
, O
androgenic O
, O
progestagenic O
and O
glucocorticoid O
activity O
was O
found O
in O
38 O
% O
, O
38 O
% O
, O
36 O
% O
and O
55 O
% O
of O
the O
samples O
, O
respectively O
at O
an O
average O
concentration O
of O
10 O
ng O
/ O
l O
17 B
beta I
- I
estradiol I
equivalent O
( O
EEQ O
) O
, O
26 O
ng O
/ O
l O
testosterone B
equivalent O
( O
TEQ O
) O
, O
123 O
ng O
/ O
l O
progesterone B
equivalent O
( O
PEQ O
) O
and O
13 O
. O
5 O
ng O
/ O
l O
hydrocortisone B
equivalent O
( O
HEQ O
) O
. O

Chrysin B
suppresses O
renal O
carcinogenesis O
via O
amelioration O
of O
hyperproliferation O
, O
oxidative O
stress O
and O
inflammation O
: O
plausible O
role O
of O
NF O
- O
kappa O
B O
. O

Flavonoid B
family O
is O
a O
rich O
source O
of O
polyphenolic B
compounds O
and O
hence O
possess O
strong O
antioxidant O
and O
anti O
inflammatory O
properties O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
efficacy O
of O
chrysin B
; O
a O
bio O
- O
active O
flavonoid B
as O
an O
anticancer O
agent O
. O

Renal O
cancer O
was O
initiated O
by O
single O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
N O
- O
nitrosodiethylamine O
( O
DEN B
200 O
mg O
/ O
kg O
BW O
body O
weight O
) O
and O
promoted O
by O
twice O
weekly O
administration O
of O
ferric O
nitrilotriacetate O
( O
Fe O
- O
NTA O
) O
9 O
mg O
Fe B
/ O
kg O
BW O
for O
16 O
wk O
. O

In O
the O
present O
study O
, O
we O
report O
the O
chemopreventive O
effects O
of O
chrysin B
against O
( O
Fe O
- O
NTA O
) O
induced O
renal O
oxidative O
stress O
, O
inflammation O
, O
hyperproliferative O
response O
, O
and O
two O
- O
stage O
renal O
carcinogenesis O
. O

To O
ascertain O
the O
molecular O
mechanism O
implicated O
in O
the O
antitumor O
promoting O
activity O
of O
chrysin B
, O
its O
effect O
was O
investigated O
on O
markers O
of O
tumor O
promotion O
and O
inflammation O
: O
ornithine B
decarboxylase O
( O
ODC O
) O
activity O
, O
proliferating O
cell O
nuclear O
antigen O
( O
PCNA O
) O
, O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclo O
- O
oxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
expression O
, O
and O
on O
levels O
of O
proinflammatory O
cytokines O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O

TNF O
- O
alpha O
) O
, O
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
. O

Pretreatment O
of O
animals O
with O
chrysin B
at O
both O
doses O
( O
20 O
and O
40 O
mg O
/ O
kg O
body O
weight O
) O
markedly O
inhibited O
all O
. O

Further O
, O
Fe O
- O
NTA O
enhances O
renal O
lipid O
peroxidation O
, O
with O
concomitant O
reduction O
in O
reduced O
glutathione B
content O
( O
GSH B
) O
, O
antioxidant O
enzymes O
, O
and O
phase O
II O
metabolizing O
enzymes O
. O

It O
induces O
serum O
toxicity O
markers O
, O
viz O
. O
, O
blood O
urea B
nitrogen B
( O
BUN O
) O
, O
creatinine B
and O
lactate B
dehydrogenase O
( O
LDH O
) O
. O

Prophylactic O
treatment O
of O
animals O
with O
chrysin B
before O
the O
administration O
of O
Fe O
- O
NTA O
was O
effective O
in O
modulating O
oxidative O
and O
renal O
injury O
markers O
and O
resulted O
in O
the O
diminution O
of O
Fe O
- O
NTA O
mediated O
injury O
. O

These O
results O
suggest O
chrysin B
as O
an O
effective O
chemopreventive O
agent O
having O
the O
capability O
to O
obstruct O
DEN B
initiated O
and O
Fe O
- O
NTA O
promoted O
renal O
cancer O
in O
the O
rat O
model O
. O

To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium B
selenite I
and O
barricade O
function O
of O
blood O
- O
retinal O
barrier O
( O
BRB O
) O
were O
investigated O
. O

In O
terms O
of O
IC O
( O
50 O
) O
values O
, O
cucurbitacins O
I O
and O
E O
presented O
a O
higher O
toxicity O
compared O
to O
that O
of O
cucurbitacin O
D O
( O
MTT B
assay O
) O
. O

Cucurbitacin O
E O
was O
readily O
hydrolyzed O
by O
human O
hepatic O
microsomes O
, O
leading O
to O
cucurbitacin B
I I
( O
K O
( O
m O
) O
22 O
mu O
M O
, O
V O
( O
max O
) O
571 O
nmol O
/ O
mg O
proteins O
/ O
min O
) O
. O

In O
terms O
of O
V O
( O
max O
) O
/ O
K O
( O
m O
) O
, O
the O
cucurbitacin O
E O
was O
the O
best O
substrate O
of O
UDP B
- O
glucuronosyltransfer O
. O

This O
study O
shows O
that O
cucurbitacins O
I O
, O
D O
and O
E O
present O
a O
potent O
cytotoxic O
activity O
toward O
the O
chondrosarcoma O
SW O
1353 O
cell O
line O
and O
are O
metabolized O
as O
sulfate B
and O
glucuronide B
conjugates O
. O

The O
classic O
approach O
of O
targeting O
the O
ATP B
active O
site O
has O
recently O
come O
up O
against O
selectivity O
issues O
, O
which O
can O
be O
considerably O
reduced O
by O
following O
an O
allosteric O
modulation O
approach O
. O

The O
present O
study O
suggested O
that O
high O
RI O
alpha O
expression O
could O
contribute O
to O
monoclonal O
proliferation O
of O
parathyroid O
cells O
by O
impairing O
the O
cAMP B
/ O
PKA O
signaling O
pathway O
. O

Selenium B
( O
Se B
) O
seed O
priming O
induced O
growth O
and O
biochemical O
changes O
in O
wheat O
under O
water O
deficit O
conditions O
. O

One O
- O
hour O
priming O
significantly O
increased O
root O
length O
stress O
tolerance O
index O
, O
dry O
matter O
stress O
tolerance O
index O
, O
and O
total O
biomass O
of O
seedlings O
; O
however O
, O
no O
significant O
effect O
of O
changing O
duration O
of O
Se B
seed O
priming O
was O
observed O
on O
plant O
height O
stress O
tolerance O
index O
and O
shoot O
/ O
root O
ratio O
. O

Among O
cultivars O
, O
Kohistan O
- O
97 O
was O
found O
to O
be O
more O
responsive O
to O
Se B
seed O
treatment O
as O
1 O
h O
priming O
at O
100 O
mu O
M O
significantly O
increased O
its O
total O
biomass O
by O
43 O
% O
as O
compared O
to O
control O
treatment O
. O

Although O
biomass O
of O
seedlings O
was O
not O
affected O
with O
Se B
seed O
priming O
under O
normal O
conditions O
, O
but O
it O
increased O
significantly O
with O
increase O
in O
rates O
of O
Se B
under O
drought O
stress O
conditions O
. O

One O
- O
hour O
priming O
at O
75 O
mu O
M O
increased O
the O
total O
sugar B
content O
and O
total O
free O
amino B
acids I
in O
both O
wheat O
cultivars O
. O

Bisphenol B
A I
inhibits O
voltage O
- O
activated O
Ca B
( I
2 I
+ I
) I
channels O
in O
vitro O
: O
mechanisms O
and O
structural O
requirements O
. O

Bisphenol B
A I
( O
BPA B
) O
, O
a O
high O
volume O
production O
chemical O
compound O
attracts O
growing O
attention O
as O
a O
health O
- O
relevant O
xenobiotic O
in O
humans O
. O

In O
this O
study O
we O
show O
that O
BPA B
acts O
as O
a O
potent O
blocker O
of O
voltage O
- O
activated O
Ca B
( I
2 I
+ I
) I
channels O
. O

We O
determined O
the O
mechanisms O
of O
block O
and O
the O
structural O
elements O
of O
BPA B
essential O
for O
its O
action O
. O

Macroscopic O
Ba B
( I
2 I
+ I
) I
/ O
Ca B
( I
2 I
+ I
) I
currents O
through O
native O
L O
- O
, O
N O
- O
, O
P O
/ O
Q O
- O
, O
T O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
in O
rat O
endocrine O
GH O
( O
3 O
) O
cells O
, O
mouse O
dorsal O
root O
ganglion O
neurons O
or O
cardiac O
myocytes O
, O
and O
recombinant O
human O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
expressed O
in O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
were O
rapidly O
and O
reversibly O
inhibited O
by O
BPA B
with O
similar O
potency O
( O
EC O
( O
50 O
) O
values O
: O
26 O
- O
35 O
mu O
M O
) O
. O

Pharmacological O
and O
biophysical O
analysis O
of O
R O
- O
type O
Ca B
( I
2 I
+ I
) I
channels O
revealed O
that O
BPA B
interacts O
with O
the O
extracellular O
part O
of O
the O
channel O
protein O
. O

This O
indicates O
that O
BPA B
interacts O
with O
the O
channel O
in O
its O
resting O
state O
by O
directly O
binding O
to O
an O
external O
site O
outside O
the O
pore O
- O
forming O
region O
. O

Structure O
- O
effect O
analyses O
of O
various O
phenolic B
and O
bisphenolic O
compounds O
revealed O
that O
1 O
) O
a O
double O
- O
alkylated O
( O
R O
- O
C O
( O
CH O
( O
3 O
) O
) O
( O
2 O
) O
- O
R O
, O
R O
- O
C O
( O
CH O
( O
3 O
) O
) O
( O
CH O
( O
2 O
) O
CH O
( O
3 O
) O
) O
- O
R O
) O
, O
or O
double O
- O
trifluoromethylated O
sp O
( O
3 O
) O
- O
hybridized O
carbon B
atom O
between O
the O
two O
aromatic O
rings O
and O
2 O
) O
the O
two O
aromatic O
moieties O
in O
angulated O
orientation O
are O
optimal O
for O
BPA B
' O
s O
effectiveness O
. O

Since O
BPA B
highly O
pollutes O
the O
environment O
and O
is O
incorporated O
into O
the O
human O
organism O
, O
our O
data O
may O
provide O
a O
basis O
for O
future O
studies O
relevant O
for O
human O
health O
and O
development O
. O

We O
show O
that O
bismuth B
nanostructures O
form O
three O
- O
dimensional O
patterns O
governed O
by O
two O
- O
dimensional O
electronic O
effects O
. O

Polymethoxyflavones O
as O
agents O
that O
prevent O
formation O
of O
cataract O
: O
nobiletin B
congeners O
show O
potent O
growth O
inhibitory O
effects O
in O
human O
lens O
epithelial O
cells O
. O

Nobiletin B
, O
one O
of O
the O
most O
abundant O
polymethoxyflavones O
( O
PMFs O
) O
in O
citrus O
peel O
, O
and O
its O
synthetic O
congeners O
displayed O
a O
potent O
inhibition O
of O
LEC O
proliferation O
. O

A O
preconcentration O
method O
was O
developed O
by O
using O
a O
new O
aminothioazole O
- O
containing O
sulfonamide B
resin O
in O
solid O
phase O
extraction O
for O
the O
determination O
of O
lead O
and O
nickel B
in O
milk O
and O
yoghurt O
samples O
. O

The O
optimum O
parameters O
for O
Pb B
and O
Ni B
were O
found O
to O
be O
3 O
. O
5 O
, O
30 O
min O
and O
2 O
. O
5 O
mL O
for O
pH O
, O
contact O
time O
, O
eluate O
volume O
, O
respectively O
. O

The O
enhancement O
of O
350 O
- O
and O
50 O
- O
fold O
in O
the O
sensitivity O
of O
Pb B
and O
Ni B
were O
achieved O
by O
combination O
of O
the O
slotted O
tube O
atom O
trap O
- O
atomic O
absorption O
spectrometry O
with O
the O
optimised O
preconcentration O
method O
, O
respectively O
. O

Limits O
of O
detection O
were O
found O
to O
be O
0 O
. O
15 O
ng O
mL O
- O
( O
1 O
) O
for O
Pb B
and O
0 O
. O
75 O
ng O
mL O
- O
( O
1 O
) O
for O
Ni B
. O

The O
lead O
concentrations O
in O
the O
studied O
samples O
were O
found O
to O
be O
in O
the O
range O
of O
15 O
- O
61 O
ng O
Pb B
mL O
- O
( O
1 O
) O
for O
milk O
and O
21 O
- O
42 O
ng O
Pb B
g O
- O
( O
1 O
) O
for O
yoghurt O
samples O
. O

Sitosterol B
as O
an O
antioxidant O
in O
frying O
oils O
. O

The O
antioxidative O
effect O
of O
sitosterol B
at O
1 O
, O
2 O
and O
5 O
% O
levels O
, O
in O
triolein O
, O
refined O
canola O
, O
high O
oleic O
sunflower O
and O
flaxseed O
oils O
, O
continuously O
heated O
for O
a O
period O
of O
up O
to O
72 O
h O
at O
frying O
temperature O
of O
180 O
degrees O
C O
, O
was O
studied O
. O

High O
Pressure O
Size O
Exclusion O
Chromatography O
( O
HPSEC O
) O
was O
used O
to O
monitor O
changes O
in O
peak O
areas O
of O
triacylglycerol B
( O
TG O
) O
polymer O
, O
monomer O
and O
ester B
hydrolysis O
products O
. O

The O
presence O
of O
enhanced O
levels O
of O
sitosterol B
was O
found O
to O
significantly O
decrease O
TG O
polymer O
formation O
in O
triolein O
and O
the O
vegetable O
oil O
samples O
after O
heating O
at O
180 O
degrees O
C O
for O
a O
period O
of O
72 O
h O
. O

A O
corresponding O
increase O
in O
the O
level O
of O
intact O
TG O
monomer O
and O
the O
extent O
of O
TG O
ester O
hydrolysis O
was O
observed O
in O
all O
samples O
with O
enhanced O
levels O
of O
sitosterol B
. O

Conversion O
of O
sterol B
to O
steradiene O
, O
by O
the O
1 O
, O
2 O
elimination O
of O
water O
, O
may O
be O
responsible O
for O
the O
antioxidative O
effect O
of O
sitosterol B
at O
frying O
temperatures O
. O

Oat O
, O
( O
Avena O
sativa O
) O
is O
an O
excellent O
source O
of O
mixed O
linkage O
beta O
- O
glucans O
( O
( O
1 O
- O
- O
> O
3 O
) O
( O
1 O
- O
- O
> O
4 O
) O
- O
beta O
- O
D O
- O
glucan O
) O
, O
a O
dietary O
fibre O
with O
cholesterol B
lowering O
properties O
. O

Geographical O
provenance O
of O
palm O
oil O
by O
fatty B
acid I
and O
volatile O
compound O
fingerprinting O
techniques O
. O

In O
this O
study O
the O
application O
of O
fatty B
acid I
and O
volatile O
organic O
compound O
fingerprinting O
in O
combination O
with O
chemometrics O
have O
been O
applied O
to O
verify O
the O
geographical O
origin O
of O
crude O
palm O
oil O
( O
continental O
scale O
) O
. O

The O
fatty B
acid I
fingerprinting O
model O
revealed O
three O
misclassified O
samples O
. O

The O
verification O
of O
the O
geographical O
origin O
of O
crude O
palm O
oil O
is O
feasible O
by O
fatty B
acid I
and O
volatile O
compound O
fingerprinting O
. O

Fluorescent O
ligands O
for O
adenosine B
receptors O
. O

Interest O
is O
increasing O
in O
developing O
fluorescent O
ligands O
for O
characterization O
of O
adenosine B
receptors O
( O
ARs O
) O
, O
which O
hold O
a O
promise O
of O
usefulness O
in O
the O
drug O
discovery O
process O
. O

The O
choice O
of O
dye O
moiety O
( O
e O
. O
g O
. O
Alexa B
Fluor I
488 I
) O
, O
attachment O
point O
and O
linker O
length O
can O
alter O
the O
selectivity O
and O
potency O
of O
the O
parent O
molecule O
. O

Fluorescent O
derivatives O
of O
adenosine B
agonists O
and O
antagonists O
( O
e O
. O
g O
. O
XAC O
and O
other O
heterocyclic O
antagonist O
scaffolds O
) O
have O
been O
synthesized O
and O
characterized O
pharmacologically O
. O

Investigating O
the O
binding O
interactions O
of O
galantamine B
with O
beta O
- O
amyloid O
peptide O
. O

The O
anti O
- O
Alzheimer O
' O
s O
agent O
galantamine B
is O
known O
to O
possess O
anti O
- O
amyloid O
properties O
. O

We O
studied O
the O
binding O
interactions O
of O
galantamine B
with O
amyloid O
peptide O
dimer O
( O
A O
beta O
( O
1 O
- O
40 O
) O
) O
through O
molecular O
docking O
and O
molecular O
dynamics O
simulations O
. O

Galantamine B
' O
s O
binding O
site O
within O
the O
amyloid O
peptide O
dimer O
was O
identified O
by O
docking O
experiments O
and O
the O
most O
stable O
complex O
was O
analyzed O
by O
molecular O
dynamics O
simulation O
. O

These O
studies O
show O
that O
galantamine B
was O
interacting O
with O
the O
central O
region O
of O
the O
amyloid O
dimer O
( O
Lys16 O
- O
Ala21 O
) O
and O
the O
C B
- O
terminal O
region O
( O
Ile31 O
- O
Val36 O
) O
with O
minimum O
structural O
drift O
of O
C O
alpha O
atom O
in O
those O
regions O
. O

Furthermore O
, O
galantamine B
' O
s O
binding O
mode O
disrupts O
the O
key O
pi O
- O
pi O
stacking O
interaction O
between O
aromatic O
rings O
of O
Phe19 O
( O
chain O
A O
) O
and O
Phe19 O
( O
chain O
B O
) O
and O
intermolecular O
hydrogen B
bonds O
seen O
in O
unbound O
peptide O
dimer O
. O

Noticeably O
, O
the O
azepine O
tertiary O
nitrogen B
of O
galantamine B
was O
in O
close O
proximity O
to O
backbone O
CO B
of O
Leu34 O
( O
distance O
< O
3 O
. O
5 O
A O
) O
to O
stabilize O
the O
dimer O
conformation O
. O

In O
summary O
, O
the O
results O
indicate O
that O
galantamine B
binding O
to O
amyloid O
peptide O
dimer O
leads O
to O
a O
significant O
conformational O
change O
at O
the O
turn O
region O
( O
Asp23 O
- O
Gly29 O
) O
that O
disrupts O
interactions O
between O
individual O
beta O
- O
strands O
and O
promotes O
a O
nontoxic O
conformation O
of O
A O
beta O
( O
1 O
- O
40 O
) O
to O
prevent O
the O
formation O
of O
neurotoxic O
oligomers O
. O

Detection O
of O
designer O
steroid B
methylstenbolone O
in O
" O
nutritional O
supplement O
" O
using O
gas O
chromatography O
and O
tandem O
mass O
spectrometry O
: O
elucidation O
of O
its O
urinary O
metabolites O
. O

Usually O
, O
the O
steroids B
intentionally O
added O
to O
the O
" O
nutritional O
supplements O
" O
are O
testosterone B
analogues O
with O
some O
structural O
modifications O
. O

In O
this O
study O
, O
the O
analyzed O
product O
was O
bought O
online O
and O
a O
new O
anabolic O
steroid B
known O
as O
methylstenbolone O
( O
2 O
, O
17 O
alpha O
- O
dimethyl O
- O
17 O
beta O
- O
hydroxy O
- O
5 O
alpha O
- O
androst O
- O
1 O
- O
en O
- O
3 O
- O
one O
) O
was O
detected O
, O
as O
described O
on O
label O
. O

Generally O
, O
anabolic O
steroids B
are O
extensively O
metabolized O
, O
thus O
in O
- O
depth O
knowledge O
of O
their O
metabolism O
is O
mandatory O
for O
doping O
control O
purposes O
. O

For O
this O
reason O
, O
a O
human O
excretion O
study O
was O
carried O
out O
with O
four O
volunteers O
after O
a O
single O
oral O
dose O
to O
determine O
the O
urinary O
metabolites O
of O
the O
steroid B
. O

Urine O
samples O
were O
submitted O
to O
enzymatic O
hydrolysis O
of O
glucuconjugated O
metabolites O
followed O
by O
liquid O
- O
liquid O
extraction O
and O
analysis O
of O
the O
trimethylsilyl B
derivatives O
by O
gas O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
. O

Tigecycline O
( O
Tig O
) O
, O
a O
glycylcycline O
antibiotic O
and O
an O
analog O
of O
Minocycline B
, O
is O
shown O
to O
exert O
anti O
- O
inflammatory O
effects O
that O
are O
distinct O
from O
its O
anti O
- O
microbial O
activity O
. O

The O
results O
showed O
that O
tigecycline O
significantly O
attenuated O
the O
expression O
and O
the O
release O
of O
nuclear O
factor O
- O
kappa O
beta O
( O
NF O
- O
kappa O
B O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
1beta O
( O
IL O
- O
1 O
beta O
) O
, O
as O
well O
as O
nitric B
oxide I
( O
NO B
) O
levels O
in O
LPS O
- O
induced O
PC12 O
cells O
. O

Bradykinetic O
alcohol B
dehydrogenases O
make O
yeast O
fitter O
for O
growth O
in O
the O
presence O
of O
allyl O
alcohol O
. O

Previous O
studies O
showed O
that O
fitter O
yeast O
( O
Saccharomyces O
cerevisiae O
) O
that O
can O
grow O
by O
fermenting O
glucose B
in O
the O
presence O
of O
allyl O
alcohol O
, O
which O
is O
oxidized O
by O
alcohol B
dehydrogenase O
I O
( O
ADH1 O
) O
to O
toxic O
acrolein B
, O
had O
mutations O
in O
the O
ADH1 O
gene O
that O
led O
to O
decreased O
ADH O
activity O
. O

These O
yeast O
may O
grow O
more O
slowly O
due O
to O
slower O
reduction O
of O
acetaldehyde B
and O
a O
higher O
NADH B
/ O
NAD B
( I
+ I
) I
ratio O
, O
which O
should O
decrease O
the O
oxidation O
of O
allyl O
alcohol O
. O

The O
H44R O
substitution O
( O
affecting O
interactions O
with O
the O
coenzyme O
pyrophosphate B
) O
was O
previously O
shown O
to O
decrease O
affinity O
for O
coenzymes O
2 O
- O
4 O
- O
fold O
and O
turnover O
numbers O
( O
V O
/ O
Et O
) O
by O
4 O
- O
6 O
- O
fold O
. O

The O
E67Q O
substitution O
near O
the O
catalytic O
zinc B
was O
shown O
previously O
to O
increase O
the O
Michaelis O
constant O
for O
acetaldehyde B
and O
to O
decrease O
turnover O
for O
ethanol B
oxidation O
. O

Effect O
of O
volume O
ratio O
of O
ultrafiltrate O
to O
sample O
solution O
on O
the O
analysis O
of O
free O
drug O
and O
measurement O
of O
free O
carbamazepine B
in O
clinical O
drug O
monitoring O
. O

We O
used O
carbamazepine B
as O
a O
model O
drug O
and O
studied O
the O
effect O
of O
different O
centrifugation O
times O
on O
ultrafitrate O
volume O
and O
the O
related O
effects O
on O
unbound O
carbamazepine B
measurement O
. O

Therefore O
, O
this O
method O
was O
successfully O
employed O
to O
quantify O
the O
free O
fraction O
of O
carbamazepine B
in O
clinical O
samples O
. O

Determination O
of O
aflatoxins O
, O
deoxynivalenol B
, O
ochratoxin B
A I
and O
zearalenone B
in O
wheat O
and O
oat O
based O
bran O
supplements O
sold O
in O
the O
Spanish O
market O
. O

The O
aflatoxins O
( O
AFs O
) O
, O
deoxynivalenol B
( O
DON B
) O
, O
ochratoxin B
A I
( O
OTA O
) O
and O
zearalenone B
( O
ZEA B
) O
are O
mycotoxins O
produced O
by O
fungal O
species O
which O
can O
contaminate O
, O
alone O
or O
simultaneously O
, O
cereal O
- O
based O
raw O
materials O
. O

The O
results O
showed O
a O
major O
presence O
of O
DON B
in O
the O
analyzed O
samples O
, O
with O
levels O
above O
the O
EU O
legislation O
in O
some O
samples O
. O

Presence O
of O
DON B
was O
more O
frequent O
in O
wheat O
samples O
, O
compared O
to O
oats O
ones O
( O
p O
< O
0 O
. O
05 O
) O
. O

Co O
- O
occurrence O
was O
frequently O
found O
between O
the O
Fusarium O
mycotoxins O
( O
ZEA B
and O
DON B
) O
. O

Due O
to O
the O
high O
levels O
of O
DON B
in O
the O
analyzed O
samples O
, O
a O
calculation O
of O
DON B
intake O
has O
been O
made O
and O
it O
has O
been O
demonstrated O
that O
bran O
can O
account O
for O
an O
important O
percentage O
of O
DON B
exposure O
in O
the O
total O
diet O
. O

Paclobutrazol O
( O
PBZ O
) O
is O
a O
triazole B
- O
containing O
fungicide O
which O
is O
widely O
used O
in O
agriculture O
. O

Acute O
toxicity O
can O
follow O
its O
extensive O
use O
but O
it O
is O
generally O
weaker O
than O
traditional O
pesticides O
such O
as O
organochlorine B
and O
organophosphorus B
. O

After O
PBZ O
exposure O
for O
50 O
days O
, O
hepatic O
lipid O
droplets O
were O
enlarged O
and O
the O
hepatic O
total O
lipid O
, O
triglyceride B
, O
total O
cholesterol B
and O
free O
fatty O
acid O
content O
had O
increased O
in O
a O
dose O
dependent O
manner O
compared O
to O
the O
control O
. O

The O
mRNA O
expression O
of O
lipid O
metabolism O
associated O
genes O
such O
as O
peroxisome O
proliferator O
- O
activated O
receptors O
( O
PPARs O
) O
, O
androgen B
receptor O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
fatty B
acid I
synthesis O
, O
fatty B
acid I
bing O
protein O
4 O
, O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
and O
stearoyl B
- I
CoA I
desaturase O
were O
up O
- O
regulated O
by O
PBZ O
exposure O
. O

These O
results O
indicated O
that O
triazole B
- O
containing O
fungicides O
might O
affect O
the O
metabolism O
and O
health O
of O
fish O
via O
the O
multi O
- O
signal O
pathways O
of O
nuclear O
receptors O
such O
as O
PPARs O
and O
LXR O
. O

Hierarchical O
assembly O
of O
ultrathin O
hexagonal O
SnS2 O
nanosheets O
onto O
electrospun O
TiO2 B
nanofibers O
: O
enhanced O
photocatalytic O
activity O
based O
on O
photoinduced O
interfacial O
charge O
transfer O
. O

Well O
- O
designed O
hierarchical O
nanostructures O
with O
one O
dimensional O
( O
1D O
) O
TiO B
( I
2 I
) I
nanofibers O
( O
120 O
- O
350 O
nm O
in O
diameter O
and O
several O
micrometers O
in O
length O
) O
and O
ultrathin O
hexagonal O
SnS O
( O
2 O
) O
nanosheets O
( O
40 O
- O
70 O
nm O
in O
lateral O
size O
and O
4 O
- O
8 O
nm O
in O
thickness O
) O
were O
successfully O
synthesized O
by O
combining O
the O
electrospinning O
technique O
( O
for O
TiO B
( I
2 I
) I
nanofibers O
) O
and O
a O
hydrothermal O
growth O
method O
( O
for O
SnS O
( O
2 O
) O
nanosheets O
) O
. O

The O
single O
- O
crystalline O
SnS O
( O
2 O
) O
nanosheets O
with O
a O
2D O
layered O
structure O
were O
uniformly O
grown O
onto O
the O
electrospun O
TiO B
( I
2 I
) I
nanofibers O
consisted O
of O
either O
anatase O
( O
A O
) O
phase O
or O
anatase O
- O
rutile O
( O
AR O
) O
mixed O
phase O
TiO B
( I
2 I
) I
nanoparticles O
. O

Moreover O
, O
the O
as O
- O
prepared O
SnS O
( O
2 O
) O
/ O
TiO B
( I
2 I
) I
hierarchical O
nanostructures O
as O
nanoheterojunction O
photocatalysts O
exhibited O
excellent O
UV O
and O
visible O
light O
photocatalytic O
activities O
for O
the O
degradation O
of O
organic O
dyes O
( O
rhodamine B
B I
and O
methyl B
orange I
) O
and O
phenols B
( O
4 B
- I
nitrophenol I
) O
, O
remarkably O
superior O
to O
the O
TiO B
( I
2 I
) I
nanofibers O
and O
the O
SnS O
( O
2 O
) O
nanosheets O
, O
mainly O
owing O
to O
the O
photoinduced O
interfacial O
charge O
transfer O
based O
on O
the O

photosynergistic O
effect O
of O
the O
SnS O
( O
2 O
) O
/ O
TiO B
( I
2 I
) I
heterojunction O
. O

Chronic O
arsenic B
exposure O
in O
nanomolar O
concentrations O
compromises O
wound O
response O
and O
intercellular O
signaling O
in O
airway O
epithelial O
cells O
. O

Paracrine O
ATP B
signaling O
in O
the O
lung O
epithelium O
participates O
in O
a O
variety O
of O
innate O
immune O
functions O
, O
including O
mucociliary O
clearance O
, O
bactericide O
production O
, O
and O
as O
an O
initiating O
signal O
in O
wound O
repair O
. O

We O
evaluated O
the O
effects O
of O
chronic O
low O
- O
dose O
arsenic B
relevant O
to O
U O
. O
S O
. O
drinking O
water O
standards O
( O
i O
. O
e O
. O
, O
10 O
ppb O
[ O
130nM O
] O
) O
on O
airway O
epithelial O
cells O
. O

Immortalized O
human O
bronchial O
epithelial O
cells O
( O
16HBE14o O
- O
) O
were O
exposed O
to O
0 O
, O
130 O
, O
or O
330nM O
arsenic B
( O
as O
Na O
- O
arsenite O
) O
for O
4 O
- O
5 O
weeks O
and O
examined O
for O
wound O
repair O
efficiency O
and O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
. O

We O
found O
that O
chronic O
arsenic B
exposure O
at O
these O
low O
doses O
slows O
wound O
repair O
and O
reduces O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
. O

We O
further O
show O
that O
arsenic B
compromises O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
by O
altering O
both O
Ca B
( I
2 I
+ I
) I
release O
from O
intracellular O
stores O
( O
via O
metabotropic O
P2Y O
receptors O
) O
and O
Ca B
( I
2 I
+ I
) I
influx O
mechanisms O
( O
via O
ionotropic O
P2X O
receptors O
) O
. O

To O
better O
model O
the O
effects O
of O
arsenic B
on O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
under O
conditions O
of O
natural O
exposure O
, O
we O
cultured O
tracheal O
epithelial O
cells O
obtained O
from O
mice O
exposed O
to O
control O
or O
50 O
ppb O
Na O
- O
arsenite O
supplemented O
drinking O
water O
for O
4 O
weeks O
. O

Tracheal O
epithelial O
cells O
from O
arsenic B
- O
exposed O
mice O
displayed O
reduced O
ATP B
- O
mediated O
Ca B
( I
2 I
+ I
) I
signaling O
dynamics O
similar O
to O
our O
in O
vitro O
chronic O
exposure O
. O

Our O
findings O
demonstrate O
that O
chronic O
arsenic B
exposure O
at O
levels O
that O
are O
commonly O
found O
in O
drinking O
water O
( O
i O
. O
e O
. O
, O
10 O
- O
50 O
ppb O
) O
alters O
cellular O
mechanisms O
critical O
to O
airway O
innate O
immunity O
. O

1 O
. O
In O
this O
article O
, O
metabolites O
of O
ginkgolic O
acid O
( O
GA O
) O
( O
15 O
: O
1 O
) O
in O
rats O
plasma O
, O
bile O
, O
urine O
and O
faeces O
after O
oral O
administration O
have O
been O
investigated O
for O
the O
first O
time O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
( O
HPLC O
- O
MS O
/ O
MS O
) O
with O
the O
aid O
of O
on O
- O
line O
hydrogen B
/ O
deuterium B
( O
H B
/ O
D B
) O
exchange O
technique O
and O
beta O
- O
glucuronidase O
hydrolysis O
experiments O
. O

4 O
. O
The O
results O
indicated O
that O
M1 O
and O
M2 O
with O
parent O
compound O
( O
M0 O
) O
were O
mainly O
eliminated O
in O
faeces O
and O
three O
glucuronide B
metabolites O
( O
M3 O
, O
M4 O
and O
M5 O
) O
excreted O
in O
bile O
as O
the O
predominant O
forms O
after O
oral O
administration O
of O
GA O
( O
15 O
: O
1 O
) O
to O
rats O
. O

A O
nanorod O
is O
first O
aligned O
along O
the O
edge O
of O
a O
small O
trench O
in O
a O
silicon B
substrate O
, O
and O
then O
one O
end O
of O
the O
nanorod O
is O
fixed O
on O
the O
substrate O
. O

By O
small O
- O
angle O
approximation O
, O
the O
shear O
modulus O
of O
the O
ZnO B
NR O
, O
which O
has O
a O
radius O
of O
166 O
nm O
and O
a O
length O
of O
4 O
mu O
m O
, O
is O
measured O
to O
be O
8 O
. O
1 O
+ O
/ O
- O
1 O
. O
9 O
GPa O
. O

From O
an O
atypical O
wake O
- O
promoting O
agent O
to O
potent O
histamine B
- O
3 O
receptor O
inverse O
agonists O
. O

Utilizing O
atypical O
wake O
- O
promoting O
agent O
modafinil B
( O
inactive O
in O
both O
rH O
( O
3 O
) O
and O
hH O
( O
3 O
) O
binding O
assays O
) O
as O
a O
launching O
pad O
, O
a O
series O
of O
sulfinyl O
- O
and O
sulfone B
- O
derived O
H O
( O
3 O
) O
receptor O
inverse O
agonists O
were O
developed O
. O

In O
addition O
, O
we O
identified O
a O
single O
amino B
acid I
in O
YopK O
that O
is O
essential O
for O
translocation O
rate O
regulation O
but O
is O
dispensable O
for O
maintaining O
fidelity O
of O
translocation O
. O

Identification O
of O
a O
novel O
benzimidazole B
derivative O
as O
a O
highly O
potent O
NPY O
Y5 O
receptor O
antagonist O
with O
an O
anti O
- O
obesity O
profile O
. O

Optimization O
of O
HTS O
hit O
1 O
for O
NPY O
Y5 O
receptor O
binding O
affinity O
, O
CYP450 O
inhibition O
, O
solubility O
and O
metabolic O
stability O
led O
to O
the O
identification O
of O
some O
orally O
available O
oxygen B
- O
linker O
derivatives O
for O
in O
vivo O
study O
. O

Testosterone B
positively O
associated O
with O
both O
male O
mating O
effort O
and O
paternal O
behavior O
in O
savanna O
baboons O
( O
Papio O
cynocephalus O
) O
. O

Testosterone B
( O
T O
) O
is O
often O
positively O
associated O
with O
male O
sexual O
behavior O
and O
negatively O
associated O
with O
paternal O
care O
. O

Silexan O
, O
an O
essential O
oil O
from O
flowers O
of O
Lavandula O
angustifolia O
, O
is O
not O
recognized O
as O
benzodiazepine B
- O
like O
in O
rats O
trained O
to O
discriminate O
a O
diazepam B
cue O
. O

Based O
on O
the O
observed O
clinical O
effects O
, O
it O
has O
been O
speculated O
that O
lavender O
oil O
may O
exert O
benzodiazepine B
- O
like O
action O
including O
the O
known O
dependence O
and O
abuse O
potential O
of O
this O
class O
of O
drugs O
. O

Twelve O
adult O
, O
male O
, O
Sprague O
- O
Dawley O
rats O
were O
trained O
to O
discriminate O
the O
benzodiazepine B
drug O
diazepam B
( O
2 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
from O
saline O
using O
a O
two O
- O
lever O
operant O
procedure O
. O

After O
approximately O
40 O
training O
sessions O
the O
majority O
of O
rats O
learned O
the O
discrimination O
and O
pre O
- O
treatment O
with O
ascending O
doses O
of O
diazepam B
( O
0 O
. O
3 O
- O
2 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
produced O
a O
dose O
related O
generalization O
to O
the O
diazepam B
cue O
. O

In O
these O
same O
animals O
Silexan O
was O
administered O
to O
see O
if O
animals O
recognized O
the O
drug O
as O
" O
diazepam B
- O
like O
" O
i O
. O
e O
. O
generalized O
to O
diazepam B
or O
" O
saline O
- O
like O
" O
. O

In O
sum O
, O
Silexan O
has O
no O
diazepam B
- O
like O
interoceptive O
property O
in O
adult O
, O
male O
rats O
. O

This O
suggests O
that O
Silexan O
does O
not O
share O
the O
potential O
of O
benzodiazepines B
to O
induce O
the O
development O
of O
tolerance O
, O
dependence O
and O
addiction O
. O

Combination O
of O
phenylpropanoids O
with O
5 B
- I
fluorouracil I
as O
anti O
- O
cancer O
agents O
against O
human O
cervical O
cancer O
( O
HeLa O
) O
cell O
line O
. O

The O
effect O
of O
eight O
phenylpropanoids O
in O
combination O
with O
5 B
- I
fluorouracil I
against O
the O
cervical O
cancer O
cells O
( O
HeLa O
) O
is O
reported O
here O
. O

The O
cytotoxic O
activity O
of O
these O
phenylpropanoids O
against O
HeLa O
cells O
is O
in O
the O
order O
of O
eugenol B
> O
ferulic O
> O
cinnamic O
> O
caffeic B
> O
chlorogenic B
> O
p O
- O
coumaric O
> O
3 O
, O
4 O
- O
dimethoxycinnamic O
> O
2 O
, O
4 O
, O
5 O
- O
trimethoxycinnamic O
acids O
. O

Eugenol B
, O
ferulic O
and O
caffeic O
acids O
interacted O
synergistically O
with O
the O
drug O
, O
in O
bringing O
about O
a O
reduction O
in O
the O
amount O
of O
the O
latter O
. O

Flow O
cytometry O
results O
indicated O
that O
the O
combination O
of O
eugenol B
and O
5 B
- I
fluorouracil I
increased O
the O
number O
of O
cells O
in O
the O
S O
and O
G2 O
/ O
M O
phases O
when O
compared O
to O
treatment O
with O
the O
individual O
compounds O
alone O
. O

3D O
- O
quantitative O
structure O
activity O
relationship O
studies O
indicate O
the O
importance O
of O
electrostatic O
region O
near O
the O
substitutions O
present O
in O
the O
benzene B
ring O
and O
near O
the O
double O
bond O
of O
the O
compounds O
for O
anticancer O
and O
hemolytic O
activities O
, O
respectively O
. O

For O
this O
purpose O
, O
the O
combined O
effect O
of O
23 O
- O
methyl O
- O
6 O
- O
O O
- O
desmethylauricepyron O
( O
1 O
) O
, O
quercetin B
( O
2 O
) O
and O
3 O
- O
O O
- O
methylquercetin O
( O
3 O
) O
, O
obtained O
through O
bioguided O
fractionation O
from O
A O
. O
satureioides O
ethanol B
extract O
, O
was O
evaluated O
against O
Staphylococcus O
aureus O
and O
Escherichia O
coli O
. O

In O
first O
place O
, O
the O
antibacterial O
effect O
of O
the O
combination O
of O
flavonols B
2 O
and O
3 O
was O
assessed O
, O
as O
these O
showed O
individual O
effectiveness O
lower O
than O
or O
equal O
to O
that O
of O
the O
fraction O
from O
which O
they O
were O
obtained O
. O

When O
the O
flavonols B
were O
applied O
together O
at O
concentrations O
below O
their O
minimum O
inhibitory O
concentration O
( O
MIC O
) O
values O
, O
a O
synergistic O
effect O
( O
FICI O
< O
0 O
. O
30 O
) O
against O
S O
. O
aureus O
was O
observed O
. O

pH O
- O
responsive O
composite O
microspheres O
based O
on O
magnetic O
mesoporous O
silica B
nanoparticle O
for O
drug O
delivery O
. O

pH O
- O
responsive O
composite O
microspheres O
, O
consisting O
of O
a O
core O
of O
Fe3O4 B
nanoparticle O
, O
a O
sandwiched O
layer O
of O
mesoporous O
silica B
and O
a O
shell O
of O
crosslinked O
poly O
( O
methacrylic O
acid O
) O
( O
PMAA O
) O
, O
were O
successfully O
synthesized O
via O
distillation O
precipitation O
polymerization O
. O

Doxorubicin O
hydrochloride O
( O
DOX B
) O
was O
applied O
as O
a O
model O
drug O
, O
and O
the O
behavior O
of O
drug O
storage O
/ O
release O
was O
investigated O
. O

The O
cumulative O
release O
of O
DOX B
- O
loaded O
composite O
microsphere O
in O
vitro O
showed O
that O
the O
drug O
release O
rate O
was O
much O
faster O
below O
its O
pKa O
than O
that O
of O
above O
its O
pKa O
. O

Microstructured O
, O
functional O
PVA B
hydrogels O
through O
bioconjugation O
with O
oligopeptides O
under O
physiological O
conditions O
. O

In O
this O
work O
, O
bioconjugation O
techniques O
are O
developed O
to O
achieve O
peptide O
functionalization O
of O
poly B
( I
vinyl I
alcohol I
) I
, O
PVA B
, O
as O
both O
a O
polymer O
in O
solution O
and O
within O
microstructured O
physical O
hydrogels O
, O
in O
both O
cases O
under O
physiological O
conditions O
. O

PVA B
is O
unique O
in O
that O
it O
is O
one O
of O
very O
few O
polymers O
with O
excellent O
biocompatibility O
and O
safety O
and O
has O
FDA O
approval O
for O
clinical O
uses O
in O
humans O
. O

However O
, O
decades O
of O
development O
have O
documented O
only O
scant O
opportunities O
in O
bioconjugation O
with O
PVA B
. O

To O
address O
these O
limitations O
, O
PVA B
is O
synthesized O
with O
terminal O
thiol B
groups O
and O
conjugated O
with O
thiolated O
peptides O
using O
PVA B
in O
solution O
. O

Further O
, O
microstructured O
, O
surface O
- O
adhered O
PVA B
physical O
hydrogels O
are O
assembled O
, O
the O
available O
conjugation O
sites O
within O
the O
hydrogels O
are O
quantified O
, O
and O
quantitative O
kinetic O
data O
are O
collected O
on O
peptide O
conjugation O
to O
the O
hydrogels O
. O

The O
success O
of O
bioconjugation O
in O
the O
gel O
phase O
is O
quantified O
through O
the O
use O
of O
a O
cell O
- O
adhesive O
peptide O
and O
visualization O
of O
cell O
adhesion O
on O
PVA B
hydrogels O
as O
cell O
culture O
substrates O
. O

Taken O
together O
, O
the O
presented O
data O
establish O
a O
novel O
paradigm O
in O
bioconjugation O
and O
functionalization O
of O
PVA B
physical O
hydrogels O
. O

Coupled O
with O
an O
excellent O
safety O
profile O
of O
PVA B
, O
these O
results O
deliver O
a O
superior O
biomaterial O
for O
diverse O
biomedical O
applications O
. O

Novel O
Three O
- O
Dimensional O
Nanoporous O
Alumina B
as O
a O
Template O
for O
Hierarchical O
TiO2 B
Nanotube O
Arrays O
. O

By O
using O
extremely O
rough O
, O
chemically O
etched O
microstructured O
aluminium B
foils O
, O
anodization O
in O
phosphoric B
acid I
under O
very O
harsh O
conditions O
, O
e O
. O
g O
. O
, O
10 O
wt O
% O
phosphoric B
acid I
and O
room O
temperature O
, O
can O
be O
repeatedly O
accomplished O
without O
suffering O
from O
breakdown O
. O

As O
a O
result O
, O
an O
alumina B
membrane O
with O
a O
three O
- O
dimensionally O
distributed O
nanopore O
structure O
is O
formed O
, O
which O
can O
be O
used O
as O
a O
general O
template O
to O
fabricate O
hierarchical O
micro O
- O
/ O
nano O
- O
structures O
. O

Six O
compounds O
with O
exponents O
ranging O
from O
0 O
. O
7 O
to O
1 O
. O
1 O
for O
both O
CL O
and O
V O
( O
ss O
) O
[ O
antipyrine O
, O
caffeine B
, O
epiroprim O
, O
propafenone O
, O
theophylline B
, O
and O
verapamil B
] O
displayed O
higher O
predictability O
. O

Its O
effect O
on O
the O
metabolic O
clearance O
of O
midazolam B
using O
cryopreserved O
hepatocytes O
was O
also O
monitored O
. O

The O
potential O
of O
S O
. O
frutescens O
to O
inhibit O
human O
ATP B
- O
binding O
cassette O
transporters O
( O
P O
- O
gp O
and O
BCRP O
) O
and O
the O
human O
organic O
anion O
transporting O
polypeptide O
( O
OATP1B1 O
and O
OATP1B3 O
) O
activity O
was O
assessed O
using O
cell O
lines O
overexpressing O
the O
transporter O
proteins O
. O

IC O
( O
50 O
) O
= O
35 O
. O
9 O
micro O
g O
/ O
ml O
) O
, O
and O
CYP3A4 O
/ O
5 O
( O
IC O
( O
50 O
) O
= O
17 O
. O
5 O
micro O
g O
/ O
ml O
[ O
with O
midazolam1 O
' O
- O
hydroxylation O
] O
; O
IC O
( O
50 O
) O
= O
28 O
. O
3 O
micro O
g O
/ O
ml O
[ O
with O
testosterone B
6 O
beta O
- O
hydroxylation O
] O
) O
. O

S O
. O
frutescens O
also O
delays O
the O
production O
of O
midazolam B
metabolites O
in O
the O
hepatocytes O
, O
decreasing O
its O
clearance O
by O
40 O
% O
. O

In O
humans O
, O
the O
disease O
phenotype O
is O
modified O
by O
a O
methionine B
/ O
valine B
polymorphism O
at O
codon O
129 O
of O
the O
prion O
protein O
gene O
. O

Using O
a O
combination O
of O
hydrogen B
/ O
deuterium B
exchange O
coupled O
to O
NMR O
spectroscopy O
, O
hydroxyl B
radical O
probing O
detected O
by O
mass O
spectrometry O
, O
and O
site O
- O
directed O
mutagenesis O
, O
we O
demonstrate O
that O
stop O
mutants O
of O
the O
human O
prion O
protein O
have O
a O
conserved O
amyloid O
core O
. O

Bioresorbable O
surface O
- O
adhered O
enzymatic O
microreactors O
based O
on O
physical O
hydrogels O
of O
poly B
( I
vinyl I
alcohol I
) I
. O

Hydrogel O
biomaterials O
based O
on O
poly B
( I
vinyl I
alcohol I
) I
, O
PVA B
, O
have O
an O
extensive O
history O
of O
biomedical O
applications O
, O
yet O
in O
their O
current O
form O
suffer O
from O
significant O
shortcomings O
, O
such O
as O
a O
lack O
of O
mechanism O
of O
biodegradation O
and O
poor O
opportunities O
in O
controlled O
drug O
release O
. O

We O
investigate O
physical O
hydrogels O
of O
PVA B
as O
surface O
- O
adhered O
materials O
and O
present O
biodegradable O
matrices O
equipped O
with O
innovative O
tools O
in O
substrate O
- O
mediated O
drug O
release O
. O

Toward O
the O
final O
goal O
, O
PVA B
chains O
with O
narrow O
polydispersities O
( O
1 O
. O
1 O
- O
1 O
. O
2 O
) O
and O
molecular O
weights O
of O
5 O
, O
10 O
, O
and O
28 O
kDa O
are O
synthesized O
via O
controlled O
radical O
polymerization O
( O
RAFT O
) O
. O

Taken O
together O
, O
we O
present O
, O
to O
the O
best O
of O
our O
knowledge O
, O
the O
first O
example O
of O
bioresorbable O
physical O
hydrogel O
based O
on O
PVA B
with O
engineered O
opportunities O
in O
substrate O
- O
mediated O
enzymatic O
activity O
and O
envisioned O
utility O
in O
surface O
- O
mediated O
drug O
delivery O
and O
tissue O
engineering O
. O

Catechol B
- O
initiated O
polyethers O
: O
multifunctional O
hydrophilic O
ligands O
for O
PEGylation O
and O
functionalization O
of O
metal B
oxide I
nanoparticles O
. O

Bifunctional O
CA O
- O
PEG B
( O
catechol B
- O
poly B
( I
ethylene I
glycol I
) I
) O
and O
multifunctional O
CA O
- O
PEG B
- O
PGA O
/ O
PEVGE O
( O
poly O
( O
glycidyl O
amine O
) O
/ O
poly O
( O
ethylene O
glycol O
vinyl O
glycidyl O
ether O
) O
) O
ligands O
for O
the O
functionalization O
and O
solubilization O
of O
nanoparticles O
are O
introduced O
. O

Tunable O
polymers O
with O
polydispersities O
< O
1 O
. O
25 O
and O
molecular O
weights O
in O
the O
range O
500 O
- O
7700 O
g O
mol O
( O
- O
1 O
) O
containing O
a O
catechol B
moiety O
for O
conjugation O
to O
metal B
oxide I
nanoparticles O
were O
prepared O
. O

The O
functional O
PEG B
ligands O
were O
synthesized O
starting O
from O
the O
acetonide O
- O
protected O
catechol B
initiator O
2 O
, O
2 O
- O
dimethyl O
- O
1 O
, O
3 O
- O
benzodioxole O
- O
5 O
- O
propanol O
( O
CA O
- O
OH B
) O
for O
oxyanionic O
polymerization O
. O

CA O
- O
OH B
was O
used O
both O
for O
homopolymerization O
of O
ethylene B
oxide I
( O
EO O
) O
as O
well O
as O
copolymerization O
with O
functional O
epoxides O
N O
, O
N O
- O
diallyl O
glycidyl O
amine O
( O
DAGA O
) O
, O
releasing O
primary O
amino O
groups O
and O
ethylene O
glycol O
vinyl O
glycidyl O
ether O
( O
EVGE O
) O
, O
exhibiting O
a O
double O
bond O
for O
click O
- O
type O
reactions O
, O
to O
generate O
CA O
- O
PEG B
and O
CA O
- O
PEG B
- O
PGA O
/ O
PEVGE O
. O

We O
demonstrate O
the O
potential O
of O
the O
functional O
ligands O
by O
binding O
to O
MnO B
nanoparticles O
, O
rendering O
the O
PEGylated O
nanoparticles O
highly O
stable O
in O
aqueous O
environment O
. O

Furthermore O
, O
addressability O
of O
the O
functional O
groups O
has O
been O
proven O
, O
for O
example O
, O
by O
coupling O
with O
fluoresceine O
isothiocyanate O
( O
FITC B
) O
, O
to O
allow O
for O
optical O
monitoring O
of O
the O
nanoparticle O
fate O
in O
biological O
systems O
. O

New O
molecular O
and O
cellular O
targets O
for O
chemoprevention O
and O
treatment O
of O
skin O
tumors O
by O
plant O
polyphenols B
: O
a O
critical O
review O
. O

In O
the O
last O
two O
decades O
, O
natural O
plant O
derived O
polyphenols B
( O
PPs O
, O
resveratrol B
, O
silibinin O
, O
green O
tea O
polyphenols B
, O
flavonoids B
, O
anthocyanins B
, O
etc O
. O
) O
have O
been O
drawing O
particular O
interest O
as O
emerging O
active O
substances O
in O
dermatological O
/ O
cosmeceutical O
compositions O
for O
the O
prevention O
, O
slowing O
, O
or O
reversion O
of O
skin O
tumorigenesis O
( O
chemoprevention O
) O
. O

Novel O
therapeutic O
targets O
as O
different O
as O
epidermal O
stem O
cells O
, O
cellular O
senescence O
, O
epigenetic O
enzymes O
involved O
in O
carcinogenesis O
, O
epidermal O
growth O
factor O
and O
aryl B
hydrocarbon I
receptors O
, O
and O
metabolic O
CYP1 O
subfamily O
enzymes O
are O
highlighted O
. O

Colchicine B
semisynthetics O
: O
chemotherapeutics O
for O
cancer O
? O

Nitrogen B
- O
containing O
bioactive O
alkaloids O
of O
plant O
origin O
play O
a O
significant O
role O
in O
human O
health O
and O
medicine O
. O

Gloriosa O
superba O
biosynthesizes O
substantial O
quantities O
of O
colchicine B
, O
a O
bioactive O
molecule O
for O
gout O
treatment O
. O

Colchicine B
also O
has O
antimitotic O
activity O
, O
preventing O
growth O
of O
cancer O
cells O
by O
interacting O
with O
microtubules O
, O
which O
could O
lead O
to O
the O
design O
of O
better O
cancer O
therapeutics O
. O

Further O
, O
several O
colchicine B
semisynthetics O
are O
less O
toxic O
than O
colchicine B
. O

Research O
is O
being O
conducted O
on O
effective O
, O
less O
toxic O
colchicine B
semisynthetic O
formulations O
with O
potential O
drug O
delivery O
strategies O
directly O
targeting O
multiple O
solid O
cancers O
. O

This O
article O
reviews O
the O
dynamic O
state O
of O
anticancer O
drug O
development O
from O
colchicine B
semisynthetics O
and O
natural O
colchicine B
production O
and O
briefly O
discusses O
colchicine B
biosynthesis O
. O

Plant O
Kingdom O
could O
be O
considered O
a O
rich O
source O
of O
the O
most O
diverse O
structures O
( O
e O
. O
g O
. O
there O
are O
more O
than O
12 O
, O
000 O
known O
alkaloids O
, O
more O
than O
8 O
, O
000 O
phenolic B
compounds O
and O
over O
25 O
, O
000 O
different O
terpenoids B
) O
, O
many O
of O
which O
were O
proven O
to O
possess O
strong O
antimicrobial O
properties O
( O
e O
. O
g O
. O
thymol B
, O
eurabienol O
, O
etc O
. O
) O
. O

What O
is O
also O
important O
is O
that O
the O
development O
of O
bacterial O
resistance O
toward O
natural O
plant O
products O
( O
that O
are O
generally O
regarded O
as O
eco O
- O
friendly O
) O
has O
been O
thus O
far O
documented O
in O
a O
very O
limited O
number O
of O
cases O
( O
e O
. O
g O
. O
for O
reserpine B
) O
. O

Galanthamine B
, O
contained O
in O
the O
bulbs O
and O
flowers O
of O
Galanthus O
and O
related O
genera O
like O
Narcissus O
, O
represents O
a O
good O
example O
. O

Starting O
from O
Galanthamine B
, O
properties O
of O
Melissa O
species O
, O
Salvia O
officinalis O
, O
Arnica O
chamissonis O
and O
Ruta O
graveolens O
are O
discussed O
to O
point O
to O
the O
role O
of O
these O
plants O
as O
potential O
sources O
for O
the O
development O
of O
therapeutic O
agents O
for O
AD O
. O

Likewise O
, O
non O
steroidal B
anti O
- O
inflammatory O
drugs O
and O
anticonvulsants O
, O
also O
have O
limited O
safety O
and O
tolerability O
profile O
in O
the O
management O
of O
chronic O
pains O
. O

Bacopa O
monnieri O
, O
a O
renowned O
ayurvedic O
medicine O
has O
a O
strong O
antidepressant O
effect O
and O
significant O
antinociceptive O
effect O
, O
which O
is O
comparable O
to O
the O
effect O
of O
morphine B
via O
adenosinergic O
, O
opioidergic O
, O
and O
adrenergic O
mechanisms O
. O

Apart O
from O
its O
effect O
of O
augmenting O
morphine B
analgesia O
, O
BM O
also O
inhibits O
opioid O
- O
withdrawal O
induced O
hyperalgesia O
, O
and O
acquisition O
and O
expression O
of O
morphine B
tolerance O
. O

Pharmacological O
characterization O
of O
1 O
- O
nitrosocyclohexyl O
acetate O
, O
a O
long O
- O
acting O
nitroxyl B
donor O
that O
shows O
vasorelaxant O
and O
antiaggregatory O
effects O
. O

Nitroxyl B
( O
HNO O
) O
donors O
have O
potential O
benefit O
in O
the O
treatment O
of O
heart O
failure O
and O
other O
cardiovascular O
diseases O
. O

The O
mechanism O
of O
action O
of O
HNO O
was O
examined O
by O
applying O
NCA O
in O
the O
absence O
and O
presence O
of O
the O
HNO O
scavenger O
glutathione B
( O
GSH B
) O
and O
inhibitors O
of O
soluble O
guanylyl O
cyclase O
( O
sGC O
) O
, O
adenylyl B
cyclase O
( O
AC O
) O
, O
calcitonin O
gene O
- O
related O
peptide O
receptor O
( O
CGRP O
) O
, O
and O
K B
( I
+ I
) I
channels O
. O

The O
concentration O
- O
response O
was O
markedly O
decreased O
in O
the O
presence O
of O
excess O
GSH B
; O
the O
nitric B
oxide I
scavenger O
2 B
- I
( I
4 I
- I
carboxyphenyl I
) I
- I
4 I
, I
4 I
, I
5 I
, I
5 I
- I
tetramethylimidazoli I
- I
1 I
- I
oxyl I
- I
3 I
- I
oxide I
had O
no O
effect O
. O

Inhibitors O
of O
sGC O
, O
CGRP O
, O
and O
voltage O
- O
dependent O
K B
( I
+ I
) I
channels O
each O
significantly O
impaired O
the O
vasodilator O
response O
to O
NCA O
. O

In O
contrast O
, O
inhibitors O
of O
AC O
, O
ATP B
- O
sensitive O
K B
( I
+ I
) I
channels O
, O
or O
high O
- O
conductance O
Ca B
( I
2 I
+ I
) I
- O
activated O
K B
( I
+ I
) I
channels O
did O
not O
change O
the O
effects O
of O
NCA O
. O

NCA O
significantly O
reduced O
contractile O
response O
and O
platelet O
aggregation O
mediated O
by O
the O
thromboxane O
A O
( O
2 O
) O
mimetic O
9 O
, O
11 O
- O
dideoxy O
- O
11 O
alpha O
, O
9 O
alpha O
- O
epoxymethanoprostagl O
F O
( O
2 O
) O
( O
alpha O
) O
in O
a O
cGMP B
- O
dependent O
manner O
. O

Liver O
X O
Receptors O
and O
female O
reproduction O
: O
when O
cholesterol B
meets O
fertility O
! O

The O
role O
of O
cholesterol B
in O
female O
reproductive O
physiology O
has O
been O
suspected O
for O
a O
long O
time O
, O
while O
the O
molecular O
bases O
were O
unknown O
. O

Cholesterol B
is O
the O
precursor O
of O
ovarian O
steroid B
biosynthesis O
and O
is O
also O
essential O
for O
fertility O
. O

In O
the O
uterus O
, O
cholesterol B
is O
essential O
to O
achieve O
correct O
contractions O
at O
term O
, O
but O
an O
excessive O
uterine O
cholesterol B
concentration O
has O
been O
associated O
with O
contractility O
defects O
. O

Liver O
X O
Receptor O
( O
LXR O
) O
alpha O
and O
LXR O
beta O
are O
nuclear O
receptors O
activated O
by O
oxysterols B
, O
oxidized O
derivatives O
of O
cholesterol B
. O

Since O
their O
discovery O
, O
the O
role O
of O
LXR O
in O
the O
control O
of O
cholesterol B
homeostasis O
has O
been O
widely O
described O
. O

Beyond O
their O
cholesterol B
- O
lowering O
role O
, O
more O
recent O
data O
have O
linked O
these O
nuclear O
receptors O
to O
various O
physiological O
processes O
. O

This O
review O
will O
try O
to O
enlighten O
on O
the O
LXR O
as O
a O
molecular O
link O
between O
dietary O
cholesterol B
and O
reproductive O
diseases O
in O
women O
. O

It O
was O
found O
that O
tea O
polyphenols B
( O
TP O
) O
, O
tea O
polysaccharides O
( O
TPS O
) O
, O
caffeine B
( O
Caf B
) O
, O
protein O
( O
Pro O
) O
, O
amino B
acids I
( O
AA O
) O
were O
accumulated O
in O
several O
fractions O
after O
solvent O
extraction O
despite O
not O
being O
separated O
completely O
. O

Meanwhile O
, O
95 O
% O
ethanol B
precipitate O
( O
EP O
) O
and O
ethyl B
acetate I
fraction O
( O
EF O
) O
possessed O
remarkable O
antioxidant O
activity O
and O
potent O
inhibitory O
effects O
against O
alpha O
- O
glycosidase O
in O
vitro O
. O

Furthermore O
, O
all O
the O
extracts O
( O
50 O
mg O
/ O
kg O
BW O
) O
showed O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
effect O
on O
postprandial O
hyperglycemia O
in O
diabetic O
mice O
as O
compared O
with O
a O
model O
group O
, O
and O
the O
suppression O
of O
EP O
was O
not O
significantly O
( O
p O
> O
0 O
. O
05 O
) O
different O
from O
that O
of O
acarbose B
at O
the O
same O
dosage O
( O
50 O
mg O
/ O
kg O
BW O
) O
, O
which O
indicate O
that O
these O
fractions O
could O
be O
developed O
as O
potential O
anti O
- O
diabetic O
agents O
. O

GnRH O
caused O
a O
sustained O
increase O
in O
nuclear O
beta O
- O
catenin O
levels O
, O
which O
was O
significantly O
reduced O
by O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
inhibition O
. O

l O
- O
DOPA O
modifies O
the O
antidepressant O
- O
like O
effects O
of O
reboxetine B
and O
fluoxetine B
in O
rats O
. O

Nowadays O
the O
most O
widely O
used O
antidepressants O
are O
selective O
serotonin B
reuptake O
inhibitors O
( O
SSRI O
) O
or O
noradrenaline B
reuptake O
inhibitors O
( O
NRI O
) O
, O
however O
, O
these O
take O
four O
to O
eight O
weeks O
to O
exert O
their O
effects O
and O
each O
drug O
is O
efficacious O
only O
in O
60 O
- O
70 O
% O
of O
patients O
. O

In O
an O
attempt O
to O
improve O
the O
efficacy O
of O
antidepressants O
, O
new O
drugs O
that O
also O
modify O
dopamine B
levels O
are O
being O
developed O
. O

However O
, O
l O
- O
DOPA O
enhanced O
the O
neuronal O
response O
to O
reboxetine B
in O
the O
LC O
and O
increased O
its O
antidepressant O
- O
like O
effects O
but O
counteracted O
the O
effect O
of O
fluoxetine B
on O
neurons O
in O
the O
LC O
and O
decreased O
its O
antidepressant O
- O
like O
effect O
. O

The O
sensitivity O
of O
neurons O
in O
the O
DRN O
to O
reboxetine B
and O
fluoxetine B
was O
not O
altered O
by O
the O
administration O
of O
l O
- O
DOPA O
. O

New O
targeted O
therapies O
include O
5 B
- I
HT I
( O
1F O
) O
receptor O
agonists O
, O
calcitonin O
gene O
- O
related O
peptide O
( O
CGRP O
) O
antagonists O
, O
nitric B
oxide I
synthetase O
inhibitors O
, O
and O
ion O
channel O
antagonists O
. O

Impairment O
of O
novel O
object O
recognition O
in O
adulthood O
after O
neonatal O
exposure O
to O
diazinon B
. O

Diazinon B
is O
an O
organophosphate B
pesticide O
that O
is O
still O
heavily O
used O
in O
agriculture O
, O
home O
gardening O
, O
and O
indoor O
pest O
control O
in O
Japan O
. O

The O
present O
study O
investigated O
the O
effect O
of O
neonatal O
exposure O
to O
diazinon B
on O
hippocampus O
- O
dependent O
novel O
object O
recognition O
test O
performance O
and O
the O
expression O
of O
the O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
and O
its O
signal O
transduction O
pathway O
- O
related O
genes O
in O
the O
hippocampi O
of O
young O
adult O
and O
adult O
mice O
. O

Male O
offspring O
of O
C3H O
/ O
HeN O
mice O
were O
subcutaneously O
treated O
with O
0 O
, O
0 O
. O
5 O
, O
or O
5 O
mg O
/ O
kg O
of O
diazinon B
for O
4 O
consecutive O
days O
beginning O
on O
postnatal O
day O
( O
PND O
) O
8 O
. O

The O
hippocampi O
were O
collected O
on O
PND O
50 O
or O
PND O
85 O
after O
the O
completion O
of O
the O
novel O
object O
recognition O
test O
, O
and O
the O
expression O
levels O
of O
neurotrophins O
and O
the O
NMDA B
receptor O
and O
its O
signal O
transduction O
pathway O
- O
related O
genes O
were O
examined O
using O
real O
- O
time O
RT O
- O
PCR O
. O

Diazinon B
- O
injected O
mice O
exhibited O
a O
poor O
ability O
to O
discriminate O
between O
novel O
and O
familiar O
objects O
during O
both O
the O
PND O
49 O
and O
the O
PND O
84 O
tests O
. O

The O
NMDA B
receptor O
subunits O
NR1 O
and O
NR2B O
and O
the O
related O
protein O
kinase O
calcium B
/ O
calmodulin O
- O
dependent O
protein O
kinase O
( O
CaMK O
) O
- O
IV O
and O
the O
transcription O
factor O
cyclic B
AMP I
responsive O
element O
binding O
protein O
( O
CREB O
) O
- O
1 O
mRNA O
levels O
were O
reduced O
in O
the O
PND O
50 O
mice O
. O

However O
, O
no O
significant O
changes O
in O
the O
expressions O
of O
the O
NMDA B
subunits O
and O
their O
signal O
transduction O
molecules O
were O
observed O
in O
the O
hippocampi O
of O
the O
PND O
85 O
mice O
. O

These O
results O
indicate O
that O
neonatal O
diazinon B
exposure O
impaired O
the O
hippocampus O
- O
dependent O
novel O
object O
recognition O
ability O
, O
accompanied O
by O
a O
modulation O
in O
the O
expressions O
of O
the O
NMDA B
receptor O
and O
neurotrophin O
in O
young O
adult O
and O
adult O
mice O
. O

The O
role O
of O
native O
salinity O
regime O
on O
grass O
shrimp O
( O
Palaemonetes O
pugio O
) O
sensitivity O
to O
cadmium B
. O

This O
study O
investigated O
if O
grass O
shrimp O
( O
Palaemonetes O
pugio O
) O
populations O
from O
different O
salinity O
regimes O
differed O
in O
sensitivity O
to O
cadmium B
( O
Cd B
) O
. O

After O
acclimation O
, O
groups O
were O
exposed O
to O
equivalent O
free O
- O
ion O
Cd B
concentration O
( O
4 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
mg O
/ O
L O
, O
Cd B
( I
2 I
+ I
) I
) O
in O
their O
respective O
acclimated O
salinity O
to O
compare O
survival O
among O
salinity O
treatments O
. O

Results O
of O
Kaplan O
- O
Meier O
survival O
analysis O
indicated O
that O
3 O
. O
0 O
ppt O
- O
- O
> O
3 O
. O
0 O
ppt O
shrimp O
were O
more O
sensitive O
to O
Cd B
( I
2 I
+ I
) I
than O
any O
other O
group O
( O
p O
< O
0 O
. O
0001 O
) O
. O

Additionally O
, O
3 O
. O
0 O
ppt O
- O
- O
> O
13 O
. O
5 O
ppt O
shrimp O
were O
less O
sensitive O
to O
Cd B
( I
2 I
+ I
) I
than O
were O
24 O
. O
0 O
ppt O
- O
- O
> O
13 O
. O
5 O
ppt O
shrimp O
( O
p O
= O
0 O
. O
0013 O
) O
. O

These O
results O
suggest O
that O
sensitivity O
of O
grass O
shrimp O
to O
Cd B
is O
dependent O
upon O
the O
salinity O
during O
exposure O
, O
and O
the O
salinity O
regime O
from O
which O
the O
tested O
population O
originated O
. O

Long O
- O
term O
therapy O
with O
certain O
drugs O
, O
especially O
cytochrome O
P450 O
( O
P450 O
; O
CYP O
) O
- O
inducing O
agents O
, O
confers O
an O
increased O
risk O
of O
osteomalacia O
that O
is O
attributed O
to O
vitamin B
D I
deficiency O
. O

Human O
CYP24A1 O
, O
CYP3A4 O
, O
and O
CYP27B1 O
catalyze O
the O
inactivation O
and O
activation O
of O
vitamin B
D I
and O
have O
been O
implicated O
in O
the O
adverse O
drug O
response O
. O

In O
this O
study O
, O
the O
inducibility O
of O
these O
enzymes O
and O
monohydroxylation O
of O
25 O
- O
hydroxyvitamin O
D3 O
( O
25OHD3 B
) O
were O
evaluated O
after O
exposure O
to O
P450 O
- O
inducing O
drugs O
. O

With O
human O
hepatocytes O
, O
treatment O
with O
phenobarbital B
, O
hyperforin O
, O
carbamazepine B
, O
and O
rifampin O
significantly O
increased O
the O
levels O
of O
CYP3A4 O
, O
but O
not O
CYP24A1 O
or O
CYP27B1 O
mRNA O
. O

In O
addition O
, O
rifampin O
pretreatment O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
formation O
of O
the O
major O
metabolite O
of O
25OHD3 B
, O
4 O
beta O
, O
25 O
( O
OH O
) O
2 O
D3 O
. O

24R O
, O
25 O
( O
OH O
) O
2 O
D3 O
was O
the O
predominant O
monohydroxy O
metabolite O
produced O
from O
25OHD3 B
, O
but O
its O
formation O
was O
unaffected O
by O
the O
inducers O
. O

Examination O
of O
the O
plasma O
monohydroxy O
metabolite O
/ O
25OHD3 B
ratios O
indicated O
selective O
induction O
of O
the O
CYP3A4 O
- O
dependent O
4 O
beta O
- O
hydroxylation O
pathway O
of O
25OHD3 B
elimination O
. O

Bioengineered O
chimeric O
spider O
silk O
- O
uranium B
binding O
proteins O
. O

Here O
, O
novel O
functional O
hybrid O
biomaterials O
for O
specific O
interactions O
with O
heavy O
metals O
are O
designed O
by O
bioengineering O
consensus O
sequence O
repeats O
from O
spider O
silk O
of O
Nephila O
clavipes O
with O
repeats O
of O
a O
uranium B
peptide O
recognition O
motif O
from O
a O
mutated O
33 O
- O
residue O
of O
calmodulin O
protein O
from O
Paramecium O
tetraurelia O
. O

The O
self O
- O
assembly O
features O
of O
the O
silk O
to O
control O
nanoscale O
organic O
/ O
inorganic O
material O
interfaces O
provides O
new O
biomaterials O
for O
uranium B
recovery O
. O

With O
subsequent O
enzymatic O
digestion O
of O
the O
silk O
to O
concentrate O
the O
sequestered O
metals O
, O
options O
can O
be O
envisaged O
to O
use O
these O
new O
chimeric O
protein O
systems O
in O
environmental O
engineering O
, O
including O
to O
remediate O
environments O
contaminated O
by O
uranium B
. O

Interparticle O
dispersion O
, O
membrane O
curvature O
, O
and O
penetration O
induced O
by O
single O
- O
walled O
carbon B
nanotubes O
wrapped O
with O
lipids O
and O
PEGylated O
lipids O
. O

Single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
wrapped O
with O
different O
types O
of O
lipids O
and O
polyethylene B
glycol I
( O
PEG B
) O
- O
grafted O
lipids O
were O
simulated O
with O
lipid O
bilayers O
. O

Simulations O
were O
carried O
out O
with O
the O
previously O
parametrized O
coarse O
- O
grained O
( O
CG O
) O
SWNT O
and O
PEG B
force O
fields O
that O
had O
captured O
the O
experimentally O
observed O
conformations O
of O
self O
- O
assembled O
SWNT O
- O
lipid O
complexes O
and O
phase O
behavior O
of O
PEG B
- O
grafted O
lipids O
. O

Simulations O
of O
multiple O
copies O
of O
the O
SWNT O
in O
water O
show O
that O
all O
pure O
SWNTs O
aggregate O
, O
lipid O
- O
wrapped O
SWNTs O
partially O
aggregate O
, O
but O
those O
wrapped O
with O
lipids O
grafted O
to O
PEG B
( O
M O
( O
w O
) O
= O
550 O
) O
completely O
disperse O
, O
indicating O
the O
effect O
of O
short O
PEG B
chains O
on O
interparticle O
aggregation O
, O
in O
agreement O
with O
experiment O
. O

Starting O
with O
initial O
SWNT O
orientation O
parallel O
to O
the O
bilayer O
surface O
, O
SWNTs O
wrapped O
with O
lysophospholipids O
and O
PEG B
( O
M O
( O
w O
) O
= O
550 O
) O
- O
grafted O
lipids O
insert O
into O
the O
hydrophobic O
region O
of O
the O
bilayer O
, O
while O
SWNTs O
wrapped O
with O
phospholipids O
and O
longer O
PEG B
( O
M O
( O
w O
) O
= O
2000 O
) O
- O
grafted O
lipids O
do O
not O
. O

These O
indicate O
that O
SWNTs O
insert O
because O
of O
the O
hydrophobic O
interaction O
with O
the O
bilayer O
tails O
, O
but O
the O
tight O
wrapping O
of O
charged O
lipid O
headgroups O
and O
long O
hydrophilic O
PEG B
chains O
can O
weaken O
the O
hydrophobic O
interaction O
and O
inhibit O
SWNT O
insertion O
. O

Our O
findings O
indicate O
that O
interparticle O
aggregation O
, O
SWNT O
penetration O
, O
and O
membrane O
curvature O
can O
be O
modulated O
by O
the O
SWNT O
- O
lipid O
structure O
and O
the O
PEG B
length O
. O

Radiosynthesis O
and O
evaluation O
of O
[ O
( O
1 O
) O
( O
1 O
) O
C O
- O
carbonyl O
] O
- O
labeled O
carbamates B
as O
fatty B
acid I
amide B
hydrolase O
radiotracers O
for O
positron O
emission O
tomography O
. O

Fatty B
acid I
amide B
hydrolase O
( O
FAAH O
) O
plays O
a O
key O
role O
in O
regulating O
the O
tone O
of O
the O
endocannabinoid O
system O
. O

Brain O
extraction O
measurements O
showed O
that O
binding O
to O
FAAH O
was O
irreversible O
and O
kinetically O
different O
for O
the O
two O
classes O
of O
carbamates B
. O

Upon O
heating O
of O
the O
solutions O
the O
lamellar O
spacing O
increases O
, O
with O
significant O
differences O
in O
the O
presence O
of O
NaCl B
or O
CaCl B
( I
2 I
) I
as O
compared O
to O
the O
standard O
solution O
. O

Analysis O
of O
15N O
- O
1H B
NMR O
relaxation O
in O
proteins O
by O
a O
combined O
experimental O
and O
molecular O
dynamics O
simulation O
approach O
: O
picosecond O
- O
nanosecond O
dynamics O
of O
the O
Rho O
GTPase O
binding O
domain O
of O
plexin O
- O
B1 O
in O
the O
dimeric O
state O
indicates O
allosteric O
pathways O
. O

Peptide O
groups O
in O
the O
alpha O
- O
helices O
and O
the O
beta O
- O
strands O
of O
the O
dimer O
( O
the O
beta O
- O
strands O
of O
the O
monomer O
) O
experience O
strong O
and O
highly O
asymmetric O
local O
ordering O
centered O
approximately O
at O
the O
C O
( O
i O
- O
1 O
) O
( O
alpha O
) O
- O
C O
( O
i O
) O
( O
alpha O
) O
axes O
( O
N B
- I
H I
bonds O
) O
. O

N B
- I
H I
fluctuations O
occur O
on O
the O
picosecond O
time O
scale O
. O

Amplified O
fluorescent O
sensing O
of O
DNA O
using O
graphene B
oxide I
and O
a O
conjugated O
cationic O
polymer O
. O

We O
explore O
the O
interactions O
between O
a O
fluorescein B
( O
FAM O
) O
- O
labeled O
single O
- O
stranded O
DNA O
( O
P O
) O
, O
graphene B
oxide I
( O
GO O
) O
, O
and O
a O
cationic O
conjugated O
polymer O
, O
poly O
[ O
( O
9 O
, O
9 O
- O
bis O
( O
6 O
' O
- O
N O
, O
N O
, O
N O
- O
trimethylammonium O
) O
hexyl O
) O
- O
fluorenylene O
phenylene O
dibromide O
] O
( O
PFP O
) O
. O

To O
explore O
the O
hitherto O
successful O
derivatization O
of O
the O
alpha B
- I
carbon I
of O
fosmidomycin O
, O
a O
series O
of O
new O
alpha O
- O
substituted O
analogues O
was O
prepared O
. O

This O
was O
done O
by O
introduction O
of O
a O
heteroatom O
( O
N B
or O
O B
) O
in O
alpha O
- O
position O
to O
the O
phosphonate B
and O
using O
the O
resultant O
OH B
and O
NH B
2 I
groups O
as O
a O
handle O
for O
appending O
a O
variety O
of O
substituents O
by O
means O
of O
several O
functional O
groups O
such O
as O
ether B
, O
amide B
, O
urea B
, O
and O
1 O
, O
4 O
- O
triazole O
. O

The O
synthesized O
boron O
- O
dipyrromethene O
- O
based O
fluorescence O
dyes O
have O
one O
or O
two O
sulfonate B
groups O
, O
which O
confer O
solubility O
in O
aqueous O
media O
, O
and O
a O
dinitrophenyl O
group O
as O
a O
redox O
reaction O
site O
. O

These O
probes O
produce O
the O
corresponding O
fluorescent O
products O
via O
multiple O
interfacial O
electron O
transfer O
processes O
, O
allowing O
us O
to O
investigate O
the O
photoinduced O
redox O
reactions O
over O
individual O
pristine O
and O
Au B
- O
nanoparticle O
- O
deposited O
TiO B
( I
2 I
) I
nanoparticles O
at O
the O
single O
- O
particle O
, O
single O
- O
molecule O
levels O
. O

The O
minimum O
probe O
concentration O
to O
detect O
single O
- O
product O
molecules O
on O
a O
single O
TiO B
( I
2 I
) I
nanoparticle O
was O
found O
to O
be O
in O
the O
nanomolar O
range O
( O
< O
10 O
nM O
) O
in O
acidic O
solution O
. O

Furthermore O
, O
super O
- O
resolution O
mapping O
of O
the O
reaction O
sites O
revealed O
that O
visible O
- O
light O
- O
induced O
reduction O
reactions O
preferentially O
occurred O
on O
the O
TiO B
( I
2 I
) I
surface O
within O
a O
distance O
of O
a O
few O
tens O
of O
nanometers O
around O
the O
deposited O
Au B
nanoparticles O
. O

A O
self O
- O
assembled O
nanogel O
, O
derived O
from O
an O
acid O
- O
labile O
cholesteryl O
- O
modified O
pullulan O
( O
acL O
- O
CHP O
) O
, O
was O
prepared O
by O
grafting O
vinyl O
ether O
- O
cholesterol B
substituents O
onto O
a O
100 O
kD O
pullulan O
main O
chain O
polymer O
backbone O
. O

These O
findings O
suggest O
that O
stimuli O
- O
responsive O
, O
self O
- O
assembled O
nanogels O
can O
release O
protein O
cargo O
in O
a O
manner O
that O
is O
controlled O
by O
the O
degradation O
rate O
of O
the O
cholesterol B
- O
pullulan O
grafting O
moiety O
. O

Native O
cellulose O
nanofibrils O
, O
purified O
from O
wood O
and O
sea O
tunicate O
, O
were O
fully O
dispersed O
in O
water O
via O
a O
topochemical O
modification O
of O
cellulose O
nanofibrils O
using O
2 B
, I
2 I
, I
6 I
, I
6 I
- I
tetramethylpiperidin I
- I
1 I
- I
oxyl I
( O
TEMPO B
) O
as O
a O
catalyst O
. O

The O
strength O
values O
estimated O
for O
the O
cellulose O
nanofibrils O
in O
the O
present O
study O
are O
comparable O
with O
those O
of O
commercially O
available O
multiwalled O
carbon B
nanotubes O
. O

Synergistic O
activity O
and O
mechanism O
of O
action O
of O
ceftazidime B
and O
apigenin B
combination O
against O
ceftazidime B
- O
resistant O
Enterobacter O
cloacae O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
examine O
the O
antibacterial O
and O
synergistic O
effect O
of O
naturally O
occurring O
flavonoids B
, O
apigenin B
, O
quercetin B
, O
naringenin B
and O
ceftazidime B
when O
use O
singly O
and O
in O
combination O
against O
ceftazidime B
- O
resistant O
Enterobacter O
cloacae O
strains O
by O
minimum O
inhibitory O
concentration O
( O
MIC O
) O
, O
checkerboard O
and O
viable O
count O
methods O
. O

These O
findings O
were O
confirmed O
by O
MICs O
that O
these O
strains O
were O
resistant O
to O
ceftazidime B
, O
cefepime O
and O
flomoxef O
at O
> O
1024 O
, O
16 O
- O
24 O
, O
> O
256 O
mu O
g O
/ O
ml O
respectively O
, O
while O
susceptible O
to O
imipenem O
at O
1 O
- O
2 O
mu O
g O
/ O
ml O
. O

The O
synergistic O
activity O
was O
observed O
at O
ceftazidime B
plus O
either O
apigenin B
or O
naringenin B
combinations O
with O
FIC O
indixes O
between O
< O
0 O
. O
01 O
and O
< O
0 O
. O
27 O
against O
these O
strains O
, O
whereas O
ceftazidime B
plus O
clavulanic O
acid O
or O
quercetin B
did O
not O
exhibit O
synergy O
. O

The O
modulation O
of O
ceftazidime B
- O
resistance O
by O
apigenin B
or O
narigenin O
significantly O
enhanced O
the O
activities O
of O
ceftazidime B
. O

The O
5 O
, O
7 O
- O
OH O
group O
of O
A O
ring O
and O
one O
4 O
' O
- O
OH O
group O
of O
the O
B O
ring O
in O
apigenin B
and O
naringenin B
are O
important O
for O
synergistic O
activity O
. O

Viable O
counts O
showed O
that O
the O
killing O
of O
ceftazidime B
- O
resistant O
E O
. O
cloacae O
DMST O
21394 O
( O
CREC O
) O
cells O
by O
3 O
mu O
g O
/ O
ml O
ceftazidime B
was O
potentiated O
by O
3 O
mu O
g O
/ O
ml O
apigenin B
to O
low O
levels O
( O
10 O
( O
3 O
) O
cfu O
/ O
ml O
) O
over O
6h O
. O

Electronmicroscopy O
clearly O
showed O
that O
ceftazidime B
3 O
mu O
g O
/ O
ml O
in O
combination O
with O
3 O
mu O
g O
/ O
ml O
of O
apigenin B
also O
caused O
marked O
morphological O
damage O
of O
cell O
wall O
, O
cell O
shape O
and O
plasma O
membrane O
of O
this O
strain O
. O

Enzymes O
assays O
indicated O
that O
apigenin B
showed O
marked O
inhibitory O
activity O
against O
penicillinase O
type O
IV O
from O
E O
. O
cloacae O
. O

The O
results O
for O
outer O
membrane O
( O
OM O
) O
permeabilization O
in O
both O
nitrocefin O
( O
NCF O
) O
assay O
and O
crystal O
violet O
uptake O
showed O
that O
the O
combination O
of O
ceftazidime B
plus O
apigenin B
significantly O
altered O
OM O
permeabilisation O
of O
CREC O
compared O
to O
control O
or O
single O
treatment O
of O
these O
agents O
. O

Both O
o O
- O
nitrophenyl O
- O
beta O
- O
D O
- O
galactoside O
( O
ONPG O
) O
uptake O
and O
release O
of O
UV O
- O
absorbing O
material O
concentrations O
results O
exhibited O
that O
ceftazidime B
and O
apigenin B
combination O
damaged O
CREC O
cytoplasmic O
membrane O
( O
CM O
) O
and O
caused O
subsequent O
leakage O
of O
intracellular O
constituents O
. O

From O
the O
results O
, O
it O
can O
be O
concluded O
that O
apigenin B
and O
naringenin B
have O
the O
synergistic O
effect O
with O
ceftazidime B
to O
reverse O
bacterial O
resistance O
to O
this O
cephalosporin B
against O
CREC O
. O

This O
activity O
may O
be O
involved O
three O
mechanisms O
of O
action O
by O
apigenin B
. O

Apigenin B
and O
naringenin B
have O
a O
sufficient O
margin O
of O
safety O
for O
therapeutic O
use O
. O

For O
this O
reason O
, O
apigenin B
and O
naringenin B
offer O
for O
the O
development O
of O
a O
valuable O
adjunct O
to O
ceftazidime B
against O
CREC O
, O
which O
currently O
almost O
cephalosporins O
resistance O
. O

Microsomal O
prostaglandin B
E I
synthase O
- O
1 O
( O
mPGES O
- O
1 O
) O
is O
an O
inducible O
prostaglandin B
E I
synthase O
that O
catalyzes O
the O
conversion O
of O
prostaglandin B
PGH O
( O
2 O
) O
to O
PGE B
( I
2 I
) I
and O
represents O
a O
novel O
target O
for O
therapeutic O
treatment O
of O
inflammatory O
disorders O
. O

The O
accuracy O
of O
DNA O
synthesis O
depends O
on O
the O
accuracy O
of O
the O
polymerase O
as O
well O
as O
the O
quality O
and O
concentration O
( O
s O
) O
of O
the O
available O
5 O
' O
- O
deoxynucleoside O
- O
triphosphate O
DNA O
precursors O
( O
dNTPs B
) O
. O

The O
relationships O
between O
dNTPs B
and O
error O
rates O
have O
been O
studied O
in O
vitro O
, O
but O
only O
limited O
insights O
exist O
into O
these O
correlations O
during O
in O
vivo O
replication O
. O

These O
strains O
, O
defective O
in O
dCTP O
deaminase O
and O
nucleoside B
diphosphate I
kinase O
, O
respectively O
, O
are O
characterized O
by O
both O
disturbances O
of O
dNTP B
pools O
and O
a O
mutator O
phenotype O
. O
ndk O
strains O
have O
been O
studied O
before O
, O
but O
were O
included O
in O
this O
study O
, O
as O
controversies O
exist O
regarding O
the O
source O
of O
its O
mutator O
phenotype O
. O

The O
two O
strains O
also O
display O
differential O
mutability O
for O
rifampicin B
- O
resistant O
mutants O
. O

Overall O
, O
our O
analysis O
reveals O
for O
both O
strains O
a O
satisfactory O
correlation O
between O
dNTP B
pool O
alterations O
and O
the O
replication O
error O
rates O
, O
and O
also O
suggests O
that O
a O
minimal O
explanation O
for O
the O
ndk O
mutator O
does O
not O
require O
assumptions O
beyond O
the O
predicted O
effect O
of O
the O
dNTP B
pools O
. O

Parametrisation O
of O
the O
free O
energy O
of O
ATP B
binding O
to O
wild O
- O
type O
and O
mutant O
Kir6 O
. O
2 O
potassium B
channels O
. O

ATP B
- O
sensitive O
K B
( I
+ I
) I
( O
K B
( O
ATP B
) O
) O
channels O
, O
comprised O
of O
pore O
- O
forming O
Kir6 O
. O
x O
and O
regulatory O
SURx O
subunits O
, O
play O
important O
roles O
in O
many O
cellular O
functions O
; O
because O
of O
their O
sensitivity O
to O
inhibition O
by O
intracellular O
ATP B
, O
K B
( O
ATP B
) O
channels O
provide O
a O
link O
between O
cell O
metabolism O
and O
membrane O
electrical O
activity O
. O

We O
constructed O
structural O
homology O
models O
of O
Kir6 O
. O
2 O
and O
a O
series O
of O
Kir6 O
. O
2 O
channels O
carrying O
mutations O
within O
the O
putative O
ATP B
- O
binding O
site O
. O

Computational O
docking O
was O
carried O
out O
to O
determine O
the O
conformation O
of O
ATP B
in O
its O
binding O
site O
. O

The O
Linear O
Interaction O
Energy O
( O
LIE O
) O
method O
was O
used O
to O
estimate O
the O
free O
- O
energy O
of O
ATP B
binding O
to O
wild O
- O
type O
and O
mutant O
Kir6 O
. O
2 O
channels O
. O

Comparisons O
of O
the O
theoretical O
binding O
free O
energies O
for O
ATP B
with O
those O
determined O
from O
mutational O
experiments O
enabled O
the O
identification O
of O
the O
most O
probable O
conformation O
of O
ATP B
bound O
to O
the O
Kir6 O
. O
2 O
channel O
. O

A O
set O
of O
LIE O
parameters O
was O
defined O
that O
may O
enable O
prediction O
of O
the O
effects O
of O
additional O
Kir6 O
. O
2 O
mutations O
within O
the O
ATP B
binding O
site O
on O
the O
affinity O
for O
ATP B
. O

Achyrofuran O
is O
an O
antibacterial O
agent O
capable O
of O
killing O
methicillin B
- O
resistant O
vancomycin B
- O
intermediate O
Staphylococcus O
aureus O
in O
the O
nanomolar O
range O
. O

Currently O
, O
there O
is O
a O
pressing O
need O
for O
novel O
antibacterial O
agents O
against O
drug O
- O
resistant O
bacteria O
, O
especially O
those O
which O
have O
been O
common O
in O
our O
communities O
and O
hospitals O
, O
such O
as O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
. O

In O
the O
search O
for O
the O
active O
principle O
( O
s O
) O
that O
confers O
these O
antimicrobial O
activities O
, O
we O
have O
processed O
the O
dichloromethane B
extract O
from O
the O
aerial O
parts O
of O
the O
plant O
. O

We O
determined O
the O
MIC O
to O
be O
around O
0 O
. O
1 O
mu O
M O
( O
0 O
. O
07 O
mu O
g O
/ O
ml O
) O
for O
the O
reference O
methicillin B
- O
resistant O
and O
vancomycin B
- O
intermediate O
S O
. O
aureus O
strain O
NRS402 O
. O

beta O
- O
phenylethyl O
isothiocyanate O
reverses O
platinum B
resistance O
by O
a O
GSH B
- O
dependent O
mechanism O
in O
cancer O
cells O
with O
epithelial O
- O
mesenchymal O
transition O
phenotype O
. O

Platinum B
( O
Pt B
) O
- O
based O
chemotherapy O
is O
an O
important O
regimen O
in O
the O
clinical O
treatment O
of O
cancer O
, O
but O
development O
of O
drug O
resistance O
presents O
a O
major O
challenge O
. O

One O
key O
mechanism O
involved O
in O
resistance O
to O
Pt B
drugs O
is O
the O
decrease O
of O
intracellular O
Pt B
due O
to O
the O
drug O
efflux O
through O
the O
glutathione B
( O
GSH B
) O
- O
mediated O
export O
, O
and O
this O
is O
particularly O
significant O
in O
cancer O
cells O
with O
stem O
- O
cell O
like O
properties O
. O

In O
the O
present O
study O
, O
we O
showed O
that O
two O
Pt B
- O
resistant O
human O
cancer O
cell O
lines O
exhibited O
stem O
- O
cell O
like O
EMT O
properties O
, O
had O
high O
cellular O
GSH B
and O
accumulated O
significantly O
less O
cellular O
Pt B
compared O
to O
their O
parental O
cells O
, O
and O
failed O
to O
undergo O
apoptosis O
when O
exposed O
to O
Pt B
at O
the O
drug O
concentrations O
toxic O
to O
the O
parental O
cells O
. O

Importantly O
, O
we O
found O
that O
the O
natural O
compound O
beta O
- O
phenylethyl O
isothiocyanate O
( O
PEITC B
) O
was O
able O
to O
effectively O
abolish O
this O
drug O
resistant O
mechanism O
by O
effective O
depletion O
of O
cellular O
GSH B
, O
leading O
to O
a O
significant O
increase O
in O
cellular O
Pt B
as O
well O
as O
DNA O
- O
bound O
Pt B
. O

A O
combination O
of O
PEITC B
and O
Pt B
showed O
a O
striking O
synergistic O
anticancer O
activity O
both O
in O
vitro O
and O
in O
vivo O
, O
as O
evidenced O
by O
an O
increase O
in O
drug O
- O
induced O
apoptosis O
, O
a O
loss O
of O
colony O
formation O
capacity O
, O
and O
significant O
suppression O
of O
tumor O
growth O
in O
mice O
. O

Taken O
together O
, O
our O
study O
shows O
a O
promising O
therapeutic O
strategy O
to O
overcome O
drug O
resistance O
to O
platinum B
- O
based O
chemotherapy O
and O
may O
potentially O
have O
broad O
implications O
in O
clinical O
treatment O
of O
cancer O
. O

Analysis O
by O
substituted O
cysteine B
scanning O
mutagenesis O
of O
the O
fourth O
transmembrane O
domain O
of O
the O
CXCR4 O
receptor O
in O
its O
inactive O
and O
active O
state O
. O

In O
this O
study O
, O
we O
used O
the O
substituted O
- O
cysteine B
accessibility O
method O
( O
SCAM O
) O
to O
identify O
specific O
residues O
of O
the O
fourth O
transmembrane O
domain O
( O
TM4 O
) O
that O
contribute O
to O
the O
formation O
of O
the O
binding O
pocket O
of O
CXCR4 O
in O
its O
inactive O
and O
active O
state O
. O

We O
successively O
substituted O
each O
residue O
from O
E179 O
( O
( O
4 O
. O
68 O
) O
) O
to O
K154 O
( O
( O
4 O
. O
43 O
) O
) O
with O
cysteine B
and O
expressed O
the O
mutants O
in O
COS O
- O
7 O
cells O
. O

Mutant O
receptors O
were O
then O
alkylated O
with O
methanethiosulfonate O
- O
ethylammonium O
( O
MTSEA O
) O
, O
and O
binding O
inhibition O
was O
monitored O
using O
the O
CXCR4 O
antagonist O
FC131 B
[ O
cyclo O
( O
- O
D O
- O
Tyr O
( O
1 O
) O
- O
Arg O
( O
2 O
) O
- O
Arg O
( O
3 O
) O
- O
Nal O
( O
4 O
) O
- O
Gly O
( O
5 O
) O
- O
) O
] O
, O
which O
displays O
anti O
- O
HIV O
activity O
. O

MTSEA O
treatment O
resulted O
in O
a O
significant O
reduction O
of O
FC131 B
binding O
to O
D171C O
( O
( O
4 O
. O
60 O
) O
) O
and O
P170C O
( O
( O
4 O
. O
59 O
) O
) O
. O

To O
assess O
TM4 O
accessibility O
in O
an O
active O
state O
of O
CXCR4 O
, O
TM4 O
cysteine B
mutants O
were O
transposed O
within O
the O
constitutively O
active O
mutant O
N119S O
( O
( O
3 O
. O
35 O
) O
) O
. O

MTSEA O
treatment O
of O
TM4 O
mutants O
N119S O
- O
S178C O
( O
( O
4 O
. O
67 O
) O
) O
, O
N119S O
- O
V177C O
( O
( O
4 O
. O
66 O
) O
) O
and O
N119S O
- O
I173C O
( O
( O
4 O
. O
62 O
) O
) O
resulted O
in O
a O
significant O
reduction O
in O
FC131 B
binding O
. O

Protection O
assays O
using O
FC131 B
prior O
to O
MTSEA O
treatment O
significantly O
reduced O
the O
alkylation O
of O
all O
MTSEA O
- O
sensitive O
mutants O
. O

We O
have O
determined O
their O
influence O
on O
the O
beta O
- O
amyloid O
( O
beta O
A O
) O
aggregation O
process O
, O
beta O
- O
secretase O
and O
acethylcholinesteras O
activities O
on O
cell O
- O
free O
systems O
, O
on O
the O
redox O
and O
lipid O
peroxidation O
status O
, O
and O
on O
the O
vulnerability O
to O
apoptotic O
death O
in O
an O
APPswe O
neuroblastoma O
cell O
line O
, O
before O
and O
after O
hydrogen B
peroxide I
treatment O
. O

We O
have O
discovered O
that O
2 O
- O
arylvinylboronic O
acids O
and O
some O
of O
their O
esters B
possess O
a O
set O
of O
properties O
which O
makes O
them O
highly O
useful O
as O
neuroprotective O
agents O
affecting O
multiple O
biological O
targets O
involved O
in O
AD O
. O

As O
indicator O
for O
the O
impairment O
of O
skin O
barrier O
by O
freezing O
cholesterol B
dissolution O
was O
determined O
in O
the O
solvents O
in O
exposure O
chambers O
of O
diffusion O
cells O
. O

Cholesterol B
dissolved O
from O
the O
skin O
indicates O
no O
significant O
differences O
between O
freshly O
excised O
and O
frozen O
stored O
skin O
. O

Structural O
determinants O
of O
substrate O
specificity O
in O
aldehyde B
dehydrogenases O
. O

Within O
the O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
, O
proteins O
belonging O
to O
the O
ALDH9 O
, O
ALDH10 O
, O
ALDH25 O
, O
ALDH26 O
and O
ALDH27 O
families O
display O
activity O
as O
omega O
- O
aminoaldehyde O
dehydrogenases O
( O
AMADHs O
) O
. O

These O
enzymes O
participate O
in O
polyamine B
, O
choline B
and O
arginine B
catabolism O
, O
as O
well O
as O
in O
synthesis O
of O
several O
osmoprotectants O
and O
carnitine B
. O

In O
order O
to O
ascertain O
the O
degree O
of O
conservation O
of O
these O
residues O
among O
AMADHs O
and O
to O
evaluate O
their O
possible O
relevance O
in O
determining O
the O
aminoaldehyde O
specificity O
, O
we O
compared O
the O
known O
amino B
acid I
sequences O
of O
every O
ALDH O
family O
that O
have O
at O
least O
one O
member O
with O
known O
crystal O
structure O
, O
as O
well O
as O
the O
electrostatic O
potential O
surface O
of O
the O
aldehyde B
binding O
sites O
of O
these O
structures O
. O

In O
addition O
, O
all O
AMADHs O
exhibit O
a O
negative O
electrostatic O
potential O
surface O
in O
the O
aldehyde B
- O
entrance O
tunnel O
, O
due O
to O
side O
- O
chain O
carboxyl B
and O
hydroxyl B
groups O
or O
main O
- O
chain O
carbonyl B
groups O
. O

Finally O
, O
our O
comparative O
sequence O
analyses O
revealed O
that O
the O
residues O
equivalent O
to O
Asp121 O
and O
Phe170 O
are O
highly O
conserved O
in O
many O
ALDH O
families O
irrespective O
of O
their O
substrate O
specificity O
- O
suggesting O
that O
they O
perform O
a O
role O
in O
catalysis O
additional O
or O
different O
to O
binding O
of O
the O
substrate O
- O
and O
that O
the O
positions O
Met124 O
, O
Cys301 O
, O
and O
Cys303 O
are O
hot O
spots O
changed O
during O
evolution O
to O
confer O
aldehyde B
specificity O
to O
several O
ALDH O
families O
. O

Micelles O
of O
zinc B
protoporphyrin I
conjugated O
to O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
for O
imaging O
and O
light O
- O
induced O
antitumor O
effects O
in O
vivo O
. O

We O
synthesized O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
polymer O
conjugated O
with O
zinc B
protoporphyrin I
( O
HPMA B
- O
ZnPP B
) O
and O
evaluated O
its O
application O
for O
tumor O
detection O
by O
imaging O
and O
treatment O
by O
light O
exposure O
using O
in O
mouse O
sarcoma O
model O
. O

To O
characterize O
HPMA B
- O
ZnPP B
micelle O
, O
we O
measured O
its O
micellar O
size O
, O
surface O
charge O
, O
stability O
, O
photochemical O
, O
biochemical O
properties O
and O
tissue O
distribution O
. O

In O
vivo O
anti O
- O
tumor O
effect O
and O
fluorescence O
imaging O
were O
carried O
out O
to O
validate O
the O
tumor O
selective O
accumulation O
and O
therapeutic O
effect O
by O
inducing O
singlet O
oxygen B
by O
light O
exposure O
. O

HPMA B
- O
ZnPP B
was O
highly O
water O
soluble O
and O
formed O
micelles O
spontaneously O
having O
hydrophobic O
clustered O
head O
group O
of O
ZnPP B
, O
in O
aqueous O
solution O
, O
with O
a O
hydrodynamic O
diameter O
of O
82 O
. O
8 O
+ O
/ O
- O
41 O
. O
8 O
nm O
and O
zeta O
- O
potential O
of O
+ O
1 O
. O
12 O
mV O
. O

HPMA B
- O
ZnPP B
had O
a O
long O
plasma O
half O
- O
life O
and O
effectively O
and O
selectively O
accumulated O
in O
tumors O
. O

Although O
HPMA B
- O
ZnPP B
alone O
had O
no O
toxicity O
in O
S O
- O
180 O
tumor O
- O
bearing O
mice O
, O
light O
- O
irradiation O
significantly O
suppressed O
tumor O
growth O
in O
vivo O
, O
similar O
to O
the O
cytotoxicity O
to O
HeLa O
cells O
in O
vitro O
upon O
endoscopic O
light O
- O
irradiation O
. O

HPMA B
- O
ZnPP B
can O
visualize O
tumors O
by O
fluorescence O
after O
i O
. O
v O
. O
injection O
, O
which O
suggests O
that O
this O
micelle O
may O
be O
useful O
for O
both O
tumor O
imaging O
and O
therapy O
. O

Hexylsubstituted O
poly O
( O
lactic O
acid O
) O
( O
hexPLA O
) O
is O
a O
viscous O
polymer O
, O
which O
degrades O
in O
the O
presence O
of O
water O
similar O
to O
the O
structure O
related O
poly B
( I
lactic I
acid I
) I
. O

This O
first O
in O
vivo O
study O
toward O
the O
biocompatibility O
of O
hexPLA O
implants O
in O
rats O
over O
3 O
months O
in O
comparison O
to O
in O
situ O
forming O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
formulations O
is O
presented O
here O
. O

In O
contrast O
to O
the O
PLGA B
formulations O
, O
hexPLA O
did O
not O
provoke O
an O
encapsulation O
of O
the O
implant O
with O
extracellular O
matrix O
. O

Nanogel O
surfaces O
decorated O
with O
alginate O
( O
alg O
) O
or O
mannosylated O
alginate O
( O
alg O
- O
man B
) O
, O
were O
used O
for O
targeting O
particular O
DC O
receptors O
. O

When O
receptors O
interacting O
directly O
with O
ova O
were O
blocked O
, O
this O
altered O
the O
uptake O
of O
alg O
- O
nanogels O
and O
alg O
- O
man B
- O
nanogels O
carrying O
ova O
. O

Nanogel O
- O
delivered O
ova O
with O
mannose B
surface O
decoration O
was O
superior O
to O
free O
ova O
for O
inducing O
interferon O
- O
gamma O
production O
by O
T O
- O
lymphocytes O
. O

Food O
reward O
- O
sensitive O
interaction O
of O
ghrelin O
and O
opioid O
receptor O
pathways O
in O
mesolimbic O
dopamine B
system O
. O

The O
goal O
of O
the O
study O
was O
to O
investigate O
the O
roles O
of O
mu O
and O
kappa O
opioid O
receptors O
in O
systemic O
ghrelin O
- O
mediated O
regulation O
of O
the O
mesolimbic O
dopamine B
system O
. O

Extracellular O
dopamine B
levels O
were O
quantified O
in O
the O
nucleus O
accumbens O
( O
NAc O
) O
and O
receptor O
- O
specific O
compounds O
were O
infused O
into O
the O
ventral O
tegmental O
area O
( O
VTA O
) O
using O
dual O
- O
probe O
microdialysis O
. O

Consumption O
of O
regular O
or O
palatable O
food O
without O
systemic O
ghrelin O
administration O
induced O
an O
increase O
in O
dopamine B
levels O
in O
the O
NAc O
via O
activation O
of O
mu O
opioid O
receptors O
in O
the O
VTA O
. O

Systemic O
ghrelin O
administration O
( O
3 O
nmol O
, O
i O
. O
v O
. O
) O
followed O
by O
no O
food O
induced O
a O
decrease O
in O
dopamine B
levels O
via O
activation O
of O
kappa O
opioid O
receptors O
in O
the O
VTA O
. O

Systemic O
ghrelin O
administration O
followed O
by O
consumption O
of O
regular O
food O
induced O
an O
increase O
in O
dopamine B
levels O
via O
preferential O
activation O
of O
mu O
opioid O
receptors O
, O
whereas O
systemic O
ghrelin O
administration O
followed O
by O
consumption O
of O
palatable O
food O
suppressed O
the O
increase O
in O
dopamine B
levels O
via O
preferential O
activation O
of O
kappa O
opioid O
receptors O
. O

Thus O
, O
natural O
food O
reward O
and O
systemic O
ghrelin O
activate O
mu O
and O
kappa O
opioid O
receptor O
pathways O
in O
the O
VTA O
, O
respectively O
, O
resulting O
in O
opposite O
influences O
on O
dopamine B
release O
in O
the O
NAc O
. O

Furthermore O
, O
systemic O
ghrelin O
induces O
switching O
of O
the O
dominant O
opioid O
receptor O
pathway O
for O
highly O
rewarding O
food O
from O
mu O
to O
kappa O
, O
resulting O
in O
suppression O
of O
the O
mesolimbic O
dopamine B
system O
. O

Since O
its O
characterisation O
in O
2001 O
, O
the O
mGlu8 O
- O
selective O
agonist O
DCPG B
has O
been O
widely O
used O
to O
explore O
the O
potential O
functional O
role O
of O
this O
group O
III O
mGlu O
receptor O
within O
the O
central O
nervous O
system O
. O

However O
, O
there O
is O
evidence O
that O
DCPG B
exerts O
off O
- O
target O
effects O
at O
higher O
concentrations O
, O
limiting O
its O
use O
as O
an O
mGlu8 O
- O
selective O
agonist O
. O

Here O
, O
we O
have O
used O
field O
recordings O
in O
rat O
hippocampal O
slices O
to O
investigate O
the O
effects O
of O
DCPG B
in O
the O
lateral O
perforant O
path O
( O
LPP O
) O
, O
a O
pathway O
known O
to O
express O
high O
levels O
of O
mGlu8 O
. O

We O
show O
that O
DCPG B
does O
inhibit O
excitatory O
transmission O
in O
this O
pathway O
, O
but O
produces O
a O
biphasic O
concentration O
- O
response O
curve O
suggesting O
activation O
of O
two O
distinct O
receptor O
types O
. O

In O
addition O
, O
higher O
concentrations O
of O
DCPG B
also O
depress O
excitatory O
transmission O
in O
the O
medial O
perforant O
path O
( O
MPP O
) O
, O
a O
pathway O
expressing O
very O
low O
levels O
of O
mGlu8 O
receptors O
. O

Experiments O
in O
slices O
from O
mice O
lacking O
mGlu8 O
receptors O
indicate O
that O
concentrations O
of O
DCPG B
> O
1 O
mu O
M O
produce O
large O
non O
- O
selective O
effects O
in O
both O
the O
LPP O
and O
MPP O
. O

Taken O
together O
, O
our O
results O
confirm O
the O
mGlu8 O
- O
selectivity O
of O
DCPG B
at O
submicromolar O
concentrations O
, O
but O
suggest O
that O
care O
must O
be O
taken O
when O
employing O
higher O
concentrations O
of O
the O
agonist O
, O
which O
may O
additionally O
activate O
mGlu2 O
receptors O
, O
especially O
at O
synapses O
where O
their O
expression O
is O
high O
. O

MDCPG O
may O
be O
a O
useful O
tool O
in O
determining O
whether O
observable O
DCPG B
effects O
are O
attributable O
to O
mGlu8 O
, O
versus O
mGlu2 O
, O
receptor O
activation O
. O

Water O
analyses O
revealed O
aluminum B
, O
iron B
and O
zinc B
as O
well O
as O
organochlorine B
( O
aldrin O
/ O
dieldrin B
, O
endosulfan B
, O
heptachlor O
/ O
heptachlor O
epoxide O
and O
metolachlor B
) O
contamination O
at O
all O
of O
the O
sites O
, O
with O
the O
exception O
of O
FU10 O
. O

Copper B
, O
chrome O
, O
iron B
and O
zinc B
were O
detected O
in O
the O
gills O
of O
both O
species O
, O
and O
aldrin O
/ O
dieldrin B
, O
endosulfan B
and O
heptachlor O
/ O
heptachlor O
epoxide O
were O
detected O
in O
the O
gills O
of O
fish O
from O
all O
of O
the O
sites O
, O
with O
the O
exception O
of O
FU10 O
. O

The O
organochlorine B
contamination O
at O
FU20 O
and O
FU50 O
was O
associated O
with O
variable O
changes O
in O
the O
MRCs O
and O
inhibition O
of O
Na B
( I
+ I
) I
/ O
K B
( I
+ I
) I
- O
ATPase O
( O
NKA O
) O
activity O
, O
especially O
in O
P O
. O
maculatus O
. O

Equol O
( O
EQ O
) O
, O
a O
potent O
biologically O
active O
metabolite O
of O
the O
soy O
isoflavone B
daidzein B
, O
interacts O
with O
estrogen B
receptors O
( O
ERs O
) O
, O
however O
, O
as O
suggested O
recently O
, O
EQ O
may O
also O
exert O
anti O
- O
androgenic O
actions O
in O
androgen B
regulated O
tissues O
like O
prostate O
and O
seminal O
vesicles O
in O
adult O
male O
rats O
. O

Therefore O
, O
we O
investigated O
the O
effects O
of O
EQ O
on O
androgen B
- O
and O
estrogen B
- O
regulated O
gene O
expressions O
in O
the O
pituitary O
and O
circulating O
luteinizing O
hormone O
( O
LH O
) O
and O
prolactin O
( O
PRL O
) O
levels O
in O
adult O
male O
rats O
. O

As O
reference O
compound O
, O
the O
pure O
anti O
- O
androgenic O
drug O
flutamide B
( O
FLUT O
) O
was O
employed O
at O
a O
dose O
of O
100 O
mg O
/ O
kg O
BW O
/ O
day O
. O

The O
present O
findings O
revealed O
that O
the O
pituitary O
mechanisms O
involved O
in O
the O
effects O
of O
EQ O
and O
FLUT O
were O
different O
due O
to O
the O
opposite O
changes O
in O
the O
mRNA O
expression O
levels O
of O
estrogen B
receptor O
subtype O
alpha O
( O
ER O
alpha O
) O
- O
, O
truncated O
estrogen B
receptor O
product O
- O
1 O
( O
TERP O
- O
1 O
) O
- O
and O
- O
2 O
( O
TERP O
- O
2 O
) O
- O
, O
gonadotropin O
releasing O
hormone O
receptor O
( O
GnRH O
receptor O
) O
- O
, O
beta O
- O
subunit O
of O
LH O
( O
LH O
beta O
) O
- O
, O
and O
gonadotropin O
alpha O
subunit O
( O
alpha O
- O
subunit O
) O
genes O
. O

However O
, O
EQ O
did O
not O
exert O
anti O
- O
androgenic O
effects O
on O
male O
rat O
pituitary O
function O
as O
observed O
at O
the O
levels O
of O
mRNA O
expression O
of O
androgen B
- O
and O
estrogen B
- O
regulated O
genes O
and O
circulating O
pituitary O
hormones O
. O

Retinoic B
acid I
biosynthesis O
catalyzed O
by O
retinal O
dehydrogenases O
relies O
on O
a O
rate O
- O
limiting O
conformational O
transition O
associated O
with O
substrate O
recognition O
. O

Retinoic B
acid I
( O
RA O
) O
, O
a O
metabolite O
of O
vitamin B
A I
, O
exerts O
pleiotropic O
effects O
throughout O
life O
in O
vertebrate O
organisms O
. O

The O
last O
step O
of O
retinoic B
acid I
biosynthesis O
is O
irreversibly O
catalyzed O
by O
the O
NAD B
- O
dependent O
retinal O
dehydrogenases O
( O
RALDH O
) O
, O
which O
are O
members O
of O
the O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
. O

This O
study O
addresses O
the O
molecular O
basis O
of O
retinal O
recognition O
in O
human O
ALDH1A1 O
( O
or O
RALDH1 O
) O
and O
rat O
ALDH1A2 O
( O
or O
RALDH2 O
) O
, O
through O
the O
comparison O
of O
the O
catalytic O
behavior O
of O
retinal O
analogs O
and O
use O
of O
the O
fluorescence O
properties O
of O
retinol B
. O

Use O
of O
the O
fluorescence O
resonance O
energy O
transfer O
upon O
retinol B
interaction O
with O
RALDHs O
provides O
evidence O
that O
retinal O
recognition O
occurs O
in O
two O
steps O
: O
binding O
into O
the O
substrate O
access O
channel O
, O
and O
a O
slower O
structural O
reorganization O
with O
a O
rate O
constant O
of O
the O
same O
magnitude O
as O
the O
kcat O
for O
retinal O
oxidation O
: O
0 O
. O
18 O
vs O
. O
0 O
. O
07 O
and O
0 O
. O
25 O
vs O
. O
0 O
. O
1 O
s O
( O
- O
1 O
) O
for O
ALDH1A1 O
and O
ALDH1A2 O
, O
respectively O
. O

Inhibition O
of O
human O
alcohol B
and O
aldehyde B
dehydrogenases O
by O
cimetidine O
and O
assessment O
of O
its O
effects O
on O
ethanol B
metabolism O
. O

Previous O
studies O
have O
reported O
that O
cimetidine O
, O
an O
H2 O
- O
receptor O
antagonist O
used O
to O
treat O
gastric O
and O
duodenal O
ulcers O
, O
can O
inhibit O
alcohol B
dehydrogenases O
( O
ADHs O
) O
and O
ethanol B
metabolism O
. O

Human O
alcohol B
dehydrogenases O
and O
aldehyde B
dehydrogenases O
( O
ALDHs O
) O
, O
the O
principal O
enzymes O
responsible O
for O
metabolism O
of O
ethanol B
, O
are O
complex O
enzyme O
families O
that O
exhibit O
functional O
polymorphisms O
among O
ethnic O
groups O
and O
distinct O
tissue O
distributions O
. O

We O
investigated O
the O
inhibition O
by O
cimetidine O
of O
alcohol B
oxidation O
by O
recombinant O
human O
ADH1A O
, O
ADH1B1 O
, O
ADH1B2 O
, O
ADH1B3 O
, O
ADH1C1 O
, O
ADH1C2 O
, O
ADH2 O
, O
and O
ADH4 O
, O
and O
aldehyde B
oxidation O
by O
ALDH1A1 O
and O
ALDH2 O
at O
pH O
7 O
. O
5 O
and O
a O
cytosolic O
NAD B
( I
+ I
) I
concentration O
. O

The O
metabolic O
interactions O
between O
cimetidine O
and O
ethanol B
/ O
acetaldehyde B
were O
assessed O
by O
computer O
simulation O
using O
the O
inhibition O
equations O
and O
the O
determined O
kinetic O
constants O
. O

At O
therapeutic O
drug O
levels O
( O
0 O
. O
015 O
mM O
) O
and O
physiologically O
relevant O
concentrations O
of O
ethanol B
( O
10 O
mM O
) O
and O
acetaldehyde B
( O
10 O
mu O
M O
) O
in O
target O
tissues O
, O
cimetidine O
could O
weakly O
inhibit O
( O
< O
5 O
% O
) O
the O
activities O
of O
ADH1B2 O
and O
ADH1B3 O
in O
liver O
, O
ADH2 O
in O
liver O
and O
small O
intestine O
, O
ADH4 O
in O
stomach O
, O
and O
ALDH1A1 O
in O
the O
three O
tissues O
, O
but O
not O
significantly O
affect O
ADH1A O
, O
ADH1B1 O
, O
ADH1C1 O
/ O
2 O
, O
or O
ALDH2 O
. O

The O
quantitative O
effects O
of O
cimetidine O
on O
metabolism O
of O
ethanol B
and O
other O
physiological O
substrates O
of O
ADHs O
need O
further O
investigation O
. O

Enrichment O
of O
fruit O
juices O
with O
pine O
bark O
extract O
( O
PBE O
) O
could O
be O
a O
strategy O
to O
compensate O
for O
phenolic B
losses O
during O
the O
gastrointestinal O
digestion O
. O

The O
digestion O
of O
both O
PBE O
- O
enriched O
pineapple O
and O
red O
fruit O
juice O
led O
to O
significant O
changes O
in O
most O
of O
the O
analysed O
phenolic B
compounds O
. O

The O
in O
vitro O
inflammatory O
state O
showed O
cell O
barrier O
dysfunction O
and O
overproduction O
of O
IL O
- O
8 O
, O
nitric B
oxide I
( O
NO B
) O
and O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

In O
the O
inflamed O
cells O
, O
incubation O
with O
nondigested O
samples O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
the O
production O
of O
IL O
- O
8 O
and O
NO B
compared O
with O
digested O
samples O
. O

Nine O
mycotoxins O
including O
six O
aspergillic O
acid O
group O
toxins O
, O
aluminiumneoaspergil O
( O
1 O
) O
, O
zirconiumneoaspergil O
( O
2 O
) O
, O
aspergilliamide O
( O
3 O
) O
, O
ferrineoaspergillin O
( O
5 O
) O
, O
flavacol O
( O
6 O
) O
, O
neoaspergillic O
acid O
( O
7 O
) O
, O
and O
three O
ochratoxins O
, O
ochratoxin O
A O
n O
- O
butyl O
ester O
( O
4 O
) O
, O
ochratoxin B
A I
( O
8 O
) O
, O
ochratoxin O
A O
methyl O
ester O
( O
9 O
) O
, O
were O
isolated O
from O

This O
was O
the O
first O
report O
about O
zirconium B
complex O
obtained O
from O
nature O
and O
ochratoxins O
isolated O
from O
marine O
environment O
. O

B O
- O
cell O
receptor O
( O
BCR O
) O
associated O
kinases O
including O
spleen O
tyrosine B
kinase O
( O
SYK O
) O
contribute O
to O
the O
pathogenesis O
of O
B O
- O
cell O
malignancies O
. O

Ticlopidine O
, O
a O
cholestatic O
liver O
injury O
- O
inducible O
drug O
, O
causes O
dysfunction O
of O
bile O
formation O
via O
diminished O
biliary O
secretion O
of O
phospholipids O
: O
involvement O
of O
biliary O
- O
excreted O
glutathione B
- O
conjugated O
ticlopidine O
metabolites O
. O

These O
results O
suggest O
that O
glutathione B
- O
conjugated O
TIC O
metabolites O
( O
TIC O
- O
SGs O
) O
, O
which O
were O
formed O
in O
the O
liver O
after O
P450s O
- O
mediated O
metabolism O
and O
were O
excreted O
extensively O
into O
bile O
by O
MRP2 O
, O
mediated O
the O
observed O
alterations O
of O
the O
bile O
composition O
. O

Administration O
of O
TIC O
caused O
significant O
liver O
injuries O
in O
SD O
rats O
, O
with O
decreased O
biliary O
phospholipids O
, O
but O
not O
in O
EHBR O
, O
consistent O
with O
the O
in O
vitro O
observation O
that O
phospholipid O
- O
bile B
acid I
- O
mixed O
micelles O
moderated O
the O
cytotoxic O
effects O
of O
bile B
acids I
. O

Further O
analyses O
revealed O
that O
TIC O
- O
SGs O
did O
not O
directly O
inhibit O
multidrug O
resistance O
3 O
P O
- O
glycoprotein O
( O
MDR3 O
/ O
ABCB4 O
) O
- O
mediated O
phosphatidylcholine B
efflux O
in O
vitro O
. O

Because O
the O
diminished O
biliary O
secretion O
of O
phospholipids O
with O
TIC O
administration O
was O
restored O
by O
taurocholate B
infusion O
in O
SD O
rats O
, O
the O
decreased O
biliary O
concentration O
of O
bile B
acids I
, O
due O
to O
the O
stimulation O
of O
bile B
acid I
- O
independent O
bile O
flow O
driven O
by O
TIC O
- O
SGs O
, O
might O
have O
indirectly O
attenuated O
phospholipid O
secretion O
. O

Apomorphine B
is O
a O
bimodal O
modulator O
of O
TRPA1 O
channels O
. O

Apomorphine B
is O
a O
non O
- O
narcotic O
derivative O
of O
morphine B
, O
which O
acts O
as O
a O
dopamine B
agonist O
and O
is O
clinically O
used O
to O
treat O
" O
off O
- O
states O
" O
in O
patients O
suffering O
from O
Parkinson O
' O
s O
disease O
. O

Adverse O
effects O
of O
apomorphine B
treatment O
include O
severe O
emesis O
and O
nausea O
, O
and O
ulceration O
and O
pain O
at O
the O
injection O
site O
. O

We O
wanted O
to O
test O
whether O
sensory O
transient O
receptor O
potential O
( O
TRP O
) O
channels O
are O
a O
molecular O
target O
for O
apomorphine B
. O

Here O
, O
we O
show O
that O
rTRPV1 O
, O
rTRPV2 O
, O
rTRPV3 O
, O
and O
mTRPV4 O
, O
as O
well O
as O
hTRPM8 O
, O
and O
rTRPM3 O
, O
which O
are O
expressed O
in O
dorsal O
root O
ganglion O
neurons O
, O
are O
insensitive O
toward O
apomorphine B
treatment O
. O

On O
the O
contrary O
, O
human O
TRPA1 O
could O
be O
concentration O
- O
dependently O
modulated O
by O
apomorphine B
. O

Whereas O
the O
addition O
of O
apomorphine B
in O
the O
low O
micromolar O
range O
produced O
an O
irreversible O
activation O
of O
the O
channel O
, O
application O
of O
higher O
concentrations O
caused O
a O
reversible O
voltage O
- O
dependent O
inhibition O
of O
heterologously O
expressed O
TRPA1 O
channels O
, O
resulting O
from O
a O
reduction O
of O
single O
- O
channel O
open O
times O
. O

In O
addition O
, O
we O
provide O
evidence O
that O
apomorphine B
also O
acts O
on O
endogenous O
TRPA1 O
in O
cultured O
dorsal O
root O
ganglion O
neurons O
from O
rats O
and O
in O
the O
enterochromaffin O
model O
cell O
line O
QGP O
- O
1 O
, O
from O
which O
serotonin B
is O
released O
upon O
activation O
of O
TRPA1 O
. O

Our O
study O
shows O
that O
human O
TRPA1 O
is O
a O
target O
for O
apomorphine B
, O
suggesting O
that O
an O
activation O
of O
TRPA1 O
might O
contribute O
to O
adverse O
side O
effects O
such O
as O
nausea O
and O
painful O
injections O
, O
which O
can O
occur O
during O
treatment O
with O
apomorphine B
. O

Human O
stearoyl B
- I
CoA I
desaturase O
1 O
( O
SCD O
- O
1 O
) O
gene O
expression O
is O
negatively O
regulated O
by O
thyroid B
hormone I
without O
direct O
binding O
of O
thyroid B
hormone I
receptor O
to O
the O
gene O
promoter O
. O

Stearoyl B
- I
CoA I
desaturase O
- O
1 O
( O
SCD O
- O
1 O
) O
plays O
a O
pivotal O
role O
in O
an O
increase O
of O
triglyceride B
by O
an O
excess O
of O
dietary O
carbohydrate B
intake O
. O

Dietary O
carbohydrates B
increase O
SCD O
- O
1 O
gene O
expression O
in O
liver O
by O
sterol B
response O
element O
binding O
protein O
( O
SREBP O
) O
- O
1c O
- O
dependent O
and O
SREBP O
- O
1c O
- O
independent O
pathways O
. O

Previous O
report O
demonstrated O
that O
thyroid B
hormone I
( O
TH O
) O
negatively O
regulates O
mouse O
SCD O
- O
1 O
gene O
promoter O
before O
SREBP O
- O
1c O
was O
revealed O
. O

We O
identified O
the O
vRNA O
sequences O
involved O
in O
five O
of O
these O
interactions O
at O
the O
nucleotide B
level O
, O
and O
in O
two O
cases O
, O
we O
validated O
the O
existence O
of O
the O
interaction O
using O
compensatory O
mutations O
in O
the O
interacting O
sequences O
. O

Cell O
- O
based O
screening O
identifies O
paroxetine B
as O
an O
inhibitor O
of O
diabetic O
endothelial O
dysfunction O
. O

We O
have O
conducted O
a O
phenotypic O
screening O
in O
endothelial O
cells O
exposed O
to O
elevated O
extracellular O
glucose B
( O
an O
in O
vitro O
model O
of O
hyperglycemia O
) O
to O
identify O
compounds O
that O
prevent O
hyperglycemia O
- O
induced O
reactive O
oxygen B
species O
( O
ROS O
) O
formation O
without O
adversely O
affecting O
cell O
viability O
. O

Follow O
- O
up O
studies O
focused O
on O
paroxetine B
, O
a O
clinically O
used O
antidepressant O
compound O
that O
has O
not O
been O
previously O
implicated O
in O
the O
context O
of O
hyperglycemia O
or O
diabetes O
. O

Paroxetine B
reduced O
hyperglycemia O
- O
induced O
mitochondrial O
ROS O
formation O
, O
mitochondrial O
protein O
oxidation O
, O
and O
mitochondrial O
and O
nuclear O
DNA O
damage O
, O
without O
interfering O
with O
mitochondrial O
electron O
transport O
or O
cellular O
bioenergetics O
. O

The O
ability O
of O
paroxetine B
to O
improve O
hyperglycemic O
endothelial O
cell O
injury O
was O
unique O
among O
serotonin B
reuptake O
blockers O
and O
can O
be O
attributed O
to O
its O
antioxidant O
effect O
, O
which O
primarily O
resides O
within O
its O
sesamol B
moiety O
. O

Paroxetine B
maintained O
the O
ability O
of O
vascular O
rings O
to O
respond O
to O
the O
endothelium O
- O
dependent O
relaxant O
acetylcholine B
, O
both O
during O
in O
vitro O
hyperglycemia O
and O
ex O
vivo O
, O
in O
a O
rat O
model O
of O
streptozotocin B
- O
induced O
diabetes O
. O

Thus O
, O
the O
current O
work O
identifies O
a O
novel O
pharmacological O
action O
of O
paroxetine B
as O
a O
protector O
of O
endothelial O
cells O
against O
hyperglycemic O
injury O
and O
raises O
the O
potential O
of O
repurposing O
of O
this O
drug O
for O
the O
experimental O
therapy O
of O
diabetic O
cardiovascular O
complications O
. O

Gamma O
- O
radiolysis O
- O
assisted O
cobalt B
oxide I
nanoparticle O
formation O
. O

The O
resulting O
concentrations O
of O
H B
( I
2 I
) I
, O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
Co B
( I
II I
) I
and O
Co B
( I
III I
) I
species O
in O
solution O
and O
the O
chemical O
composition O
and O
sizes O
of O
particles O
that O
were O
formed O
were O
measured O
as O
a O
function O
of O
irradiation O
time O
. O

The O
radiolytic O
oxidation O
of O
Co B
( I
II I
) I
to O
Co B
( I
III I
) I
was O
completed O
in O
100 O
min O
and O
the O
chemical O
composition O
of O
the O
final O
particles O
was O
identified O
as O
Co O
( O
3 O
) O
O O
( O
4 O
) O
by O
XPS O
, O
Raman O
and O
UV O
- O
Vis O
spectroscopy O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
mean O
blood O
glucose B
level O
during O
TPN O
infusion O
is O
associated O
with O
increased O
mortality O
in O
noncritically O
ill O
hospitalized O
patients O
. O

The O
daily O
mean O
TPN O
values O
were O
1 O
. O
630 O
+ O
/ O
- O
323 O
kcal O
, O
3 O
. O
2 O
+ O
/ O
- O
0 O
. O
7 O
g O
carbohydrates B
/ O
kg O
, O
1 O
. O
26 O
+ O
/ O
- O
0 O
. O
3 O
g O
amino B
acids I
/ O
kg O
, O
and O
0 O
. O
9 O
+ O
/ O
- O
0 O
. O
2 O
g O
lipids O
/ O
kg O
. O

Multiple O
logistic O
regression O
analysis O
showed O
that O
the O
patients O
who O
had O
mean O
blood O
glucose B
levels O
> O
180 O
mg O
/ O
dL O
during O
the O
TPN O
infusion O
had O
a O
risk O
of O
mortality O
that O
was O
5 O
. O
6 O
times O
greater O
than O
those O
with O
mean O
blood O
glucose B
levels O
< O
140 O
mg O
/ O
dL O
( O
95 O
% O
CI O
1 O
. O
47 O
- O
21 O
. O
4 O
mg O
/ O
dL O
) O
after O
adjusting O
for O
age O
, O
sex O
, O
nutritional O
state O
, O
presence O
of O
diabetes O
or O
hyperglycemia O
before O
starting O
TPN O
, O
diagnosis O
, O
prior O
comorbidity O
, O
carbohydrates B
infused O
, O
use O
of O
steroid B
therapy O
, O
SD O
of O
blood O
glucose B
level O
, O

CONCLUSIONS O
Hyperglycemia O
( O
mean O
blood O
glucose B
level O
> O
180 O
mg O
/ O
dL O
) O
in O
noncritically O
ill O
patients O
who O
receive O
TPN O
is O
associated O
with O
a O
higher O
risk O
of O
in O
- O
hospital O
mortality O
. O

Effect O
of O
nuclear O
vibrations O
, O
temperature O
, O
co O
- O
adsorbed O
water O
, O
and O
dye O
orientation O
on O
light O
absorption O
, O
charge O
injection O
and O
recombination O
conditions O
in O
organic O
dyes O
on O
TiO2 B
. O

We O
study O
the O
effect O
of O
nuclear O
motions O
at O
different O
temperatures O
, O
including O
the O
effect O
of O
a O
dye O
molecule O
' O
s O
orientation O
with O
respect O
to O
the O
oxide B
surface O
, O
on O
factors O
determining O
the O
performance O
of O
dye O
sensitized O
solar O
cells O
: O
light O
absorption O
, O
electron O
injection O
, O
and O
back O
- O
donation O
. O

We O
perform O
ab O
initio O
molecular O
dynamics O
simulations O
of O
aminophenyl O
acid O
dyes O
NK1 O
and O
NK7 O
, O
differing O
by O
the O
electron O
donating O
group O
, O
in O
a O
vacuum O
and O
adsorbed O
in O
mono O
- O
and O
bi O
- O
dentate O
modes O
on O
a O
dry O
and O
a O
water O
- O
covered O
anatase O
( O
101 O
) O
surface O
of O
TiO B
( I
2 I
) I
, O
at O
300 O
and O
350 O
K O
. O

This O
effect O
is O
preserved O
in O
dyes O
on O
dry O
TiO B
( I
2 I
) I
but O
largely O
disappears O
in O
the O
presence O
of O
water O
. O

It O
depends O
on O
the O
adsorption O
mode O
and O
the O
presence O
of O
H B
( I
2 I
) I
O I
but O
is O
almost O
the O
same O
for O
300 O
and O
350 O
K O
. O

Recombination O
to O
the O
dye O
cation O
is O
expected O
to O
be O
much O
enhanced O
by O
the O
approach O
of O
the O
dye O
oxidation O
equivalent O
hole O
to O
the O
surface O
during O
dye O
wagging O
around O
TiO B
( I
2 I
) I
. O

The O
dynamics O
of O
Delta O
G O
( O
t O
) O
are O
explained O
by O
uncorrelated O
evolution O
of O
the O
energies O
of O
the O
dye O
excited O
state O
and O
the O
conduction O
band O
minimum O
of O
the O
oxide B
due O
to O
their O
respective O
vibrations O
, O
and O
are O
almost O
independent O
of O
dye O
orientation O
. O

These O
enzymes O
convert O
proline B
residues O
within O
the O
repeat O
regions O
of O
collagen O
polypeptides O
to O
4 O
- O
hydroxyproline O
, O
a O
modification O
essential O
for O
the O
stability O
of O
the O
final O
triple O
helix O
. O

C O
- O
P4H O
are O
most O
often O
oligomeric O
complexes O
, O
with O
enzymatic O
activity O
contributed O
by O
the O
alpha O
subunits O
, O
and O
the O
beta O
subunits O
formed O
by O
protein O
disulfide B
isomerase O
( O
PDI O
) O
. O

Altered O
UDP B
- O
glucuronosyltransfer O
and O
sulfotransferase O
expression O
and O
function O
during O
progressive O
stages O
of O
human O
nonalcoholic O
fatty O
liver O
disease O
. O

The O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
and O
sulfotransferases O
( O
SULTs O
) O
represent O
major O
phase O
II O
drug O
- O
metabolizing O
enzymes O
that O
are O
also O
responsible O
for O
maintaining O
cellular O
homeostasis O
by O
metabolism O
of O
several O
endogenous O
molecules O
. O

We O
identified O
upregulation O
of O
UGT1A9 O
, O
2B10 O
, O
and O
3A1 O
and O
SULT1C4 O
mRNA O
in O
both O
stages O
of O
NASH O
, O
whereas O
UGT2A3 O
, O
2B15 O
, O
and O
2B28 O
and O
SULT1A1 O
, O
2B1 O
, O
and O
4A1 O
as O
well O
as O
3 B
' I
- I
phosphoadenosine I
- I
5 I
' I
- I
phosphosulfate I
synthase O
1 O
were O
increased O
in O
NASH O
( O
not O
fatty O
/ O
cirrhosis O
) O
only O
. O

Measurement O
of O
the O
glucuronidation O
and O
sulfonation O
of O
acetaminophen B
( O
APAP B
) O
revealed O
no O
alterations O
in O
glucuronidation O
; O
however O
, O
SULT O
activity O
was O
increased O
in O
steatosis O
compared O
with O
normal O
samples O
, O
but O
then O
decreased O
in O
NASH O
compared O
with O
steatosis O
. O

In O
conclusion O
, O
the O
expression O
of O
specific O
UGT O
and O
SULT O
isoforms O
appears O
to O
be O
differentially O
regulated O
, O
whereas O
sulfonation O
of O
APAP B
is O
disrupted O
during O
progression O
of O
NAFLD O
. O

SERS O
performance O
of O
gold O
nanotubes O
obtained O
by O
sputtering O
onto O
polycarbonate B
track O
- O
etched O
membranes O
. O

Here O
is O
shown O
an O
alternative O
easy O
and O
inexpensive O
synthetic O
approach O
to O
a O
SERS O
- O
substrate O
comprised O
of O
gold O
nanotubes O
obtained O
by O
the O
sputtering O
onto O
polycarbonate B
track O
- O
etched O
membranes O
used O
as O
template O
. O

Further O
analysis O
showed O
that O
the O
larger O
enhancements O
came O
from O
coalesced O
gold O
nanotubes O
and O
detection O
of O
the O
dye O
rhodamine B
6G I
at O
concentrations O
as O
low O
as O
0 O
. O
1 O
nM O
was O
possible O
. O

The O
proposed O
methodology O
could O
be O
easily O
adapted O
to O
other O
metals O
, O
such O
as O
silver B
and O
copper B
. O

Advanced O
gecko O
- O
foot O
- O
mimetic O
dry O
adhesives O
based O
on O
carbon B
nanotubes O
. O

Vertically O
aligned O
carbon B
nanotube O
( O
VA O
- O
CNT O
) O
arrays O
, O
resembling O
gecko O
' O
s O
adhesive O
foot O
hairs O
with O
additional O
superior O
mechanical O
, O
chemical O
and O
electrical O
properties O
, O
have O
been O
demonstrated O
to O
be O
a O
promising O
candidate O
for O
advanced O
fibrillar O
dry O
adhesives O
. O

The O
more O
empirical O
formulations O
to O
the O
efficiency O
limits O
provide O
estimates O
of O
10 O
- O
12 O
% O
, O
but O
the O
more O
fundamental O
descriptions O
suggest O
limits O
of O
20 O
- O
24 O
% O
to O
be O
reachable O
in O
single O
junctions O
, O
similar O
to O
the O
highest O
efficiencies O
obtained O
for O
crystalline O
silicon B
p O
- O
n O
junction O
solar O
cells O
. O

Exploring O
the O
polyamine B
regulatory O
site O
of O
the O
NMDA B
receptor O
: O
a O
parallel O
synthesis O
approach O
. O

The O
elongated O
structures O
of O
polyamine B
inverse O
agonists O
such O
as O
1 O
, O
12 O
- O
diaminododecane O
( O
N12N O
) O
and O
5 O
- O
( O
4 O
- O
aminobutyl O
) O
- O
2 O
- O
thiopheneoctanamine O
( O
N4T8N O
) O
lend O
themselves O
to O
a O
combinatorial O
chemistry O
approach O
to O
explore O
a O
potential O
polyamine B
pharmacophore O
at O
the O
NMDA B
receptor O
. O

Solid O
- O
phase O
parallel O
synthesis O
based O
on O
cross O
- O
linked O
polystyrene B
and O
a O
Wang O
anchor O
allowed O
the O
low O
- O
scale O
preparation O
of O
four O
small O
libraries O
based O
on O
the O
combination O
of O
two O
amino B
acid I
residues O
( O
out O
of O
Gly B
, O
Leu B
, O
Phe B
, O
Lys B
, O
phenylglycine O
, O
Tyr B
, O
Trp B
, O
His B
, O
and O
Arg O
) O
. O

The O
obtained O
compounds O
were O
tested O
as O
modulators O
of O
[ O
( O
3 O
) O
H O
] O
MK O
- O
801 O
binding O
to O
rat O
brain O
membranes O
and O
of O
NMDA B
- O
induced O
currents O
in O
cultured O
rat O
hippocampal O
neurons O
. O

Compounds O
with O
two O
Lys B
residues O
acted O
as O
binding O
stimulators O
( O
agonists O
) O
and O
had O
stimulatory O
and O
inhibitory O
effects O
on O
NMDA B
- O
induced O
currents O
, O
depending O
on O
the O
holding O
potential O
. O

High O
sensitivity O
of O
binding O
inhibition O
to O
spermine B
was O
conferred O
by O
a O
Tyr B
residue O
, O
whereas O
a O
His B
residue O
favored O
high O
potency O
at O
acidic O
pH O
. O

Guided O
by O
the O
principles O
of O
dislocation O
theory O
, O
we O
use O
the O
first O
- O
principles O
calculations O
to O
determine O
the O
structure O
and O
properties O
of O
dislocations O
and O
grain O
boundaries O
( O
GB O
) O
in O
single O
- O
layer O
transition O
metal O
disulfides O
MS O
( O
2 O
) O
( O
M O
= O
Mo B
or O
W B
) O
. O

In O
sharp O
contrast O
to O
other O
two O
- O
dimensional O
materials O
( O
truly O
planar O
graphene B
and O
h O
- O
BN O
) O
, O
here O
the O
edge O
dislocations O
extend O
in O
third O
dimension O
, O
forming O
concave O
dreidel O
- O
shaped O
polyhedra O
. O

Terpenoids B
from O
Incarvillea O
arguta O
. O

One O
new O
monoterpenoid O
, O
( O
+ O
) O
- O
argutoid O
A O
( O
1 O
) O
, O
three O
new O
iridoids B
, O
( O
- O
) O
- O
incarvoid O
A O
( O
2 O
) O
, O
( O
+ O
) O
- O
incarvoid O
B O
( O
3 O
) O
, O
and O
incarvoid O
C O
( O
4 O
) O
, O
and O
five O
known O
compounds O
were O
isolated O
from O
Incarvillea O
arguta O
. O

Amino B
acid I
- O
based O
zwitterionic O
poly O
( O
serine O
methacrylate O
) O
as O
an O
antifouling O
material O
. O

A O
serine B
- O
based O
zwitterionic O
poly O
( O
serine O
methacrylate O
) O
( O
pSerMA O
) O
was O
developed O
in O
this O
work O
to O
be O
used O
as O
a O
potential O
antifouling O
material O
. O

With O
the O
optimal O
film O
thickness O
, O
the O
adsorptions O
from O
bovine O
serum O
albumin O
, O
human O
serum O
, O
and O
human O
plasma O
onto O
the O
pSerMA O
- O
grafted O
surfaces O
, O
as O
evaluated O
by O
a O
surface O
plasmon O
resonance O
( O
SPR O
) O
biosensor O
, O
were O
1 O
. O
8 O
, O
9 O
. O
2 O
, O
and O
12 O
. O
9 O
ng O
/ O
cm O
( O
2 O
) O
, O
respectively O
, O
comparable O
to O
the O
traditional O
antifouling O
material O
such O
as O
poly B
( I
ethylene I
glycol I
) I
. O

This O
is O
the O
first O
work O
to O
develop O
an O
amino B
acid I
- O
based O
zwitterionic O
polymer O
as O
an O
antifouling O
material O
, O
demonstrating O
that O
pSerMA O
is O
a O
promising O
alternative O
to O
the O
traditional O
ethylene B
glycol I
- O
based O
antifouling O
materials O
. O

Discriminating O
the O
endogenous O
and O
exogenous O
urinary O
estrogens B
in O
human O
by O
isotopic O
ratio O
mass O
spectrometry O
and O
its O
potential O
clinical O
value O
. O

Estrogens B
were O
prohibited O
in O
the O
food O
producing O
animals O
by O
European O
Union O
( O
96 O
/ O
22 O
/ O
EC O
directive O
) O
and O
added O
to O
the O
Report O
on O
Carcinogens O
in O
United O
States O
since O
2002 O
. O

The O
endogenous O
estrogens B
were O
separated O
from O
urines O
of O
18 O
adult O
men O
and O
women O
. O

The O
exogenous O
estrogens B
were O
chemical O
reference O
standards O
and O
over O
the O
counter O
preparations O
. O

Two O
patients O
of O
dysfunctional O
uterine O
bleeding O
( O
DUB O
) O
administered O
exogenous O
estradiol B
and O
the O
urines O
were O
collected O
for O
72 O
h O
. O

The O
urinary O
estrogens B
were O
separated O
by O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
and O
confirmed O
. O

The O
exogenous O
and O
exogenous O
estrogens B
were O
analyzed O
by O
gas O
chromatography O
combustion O
isotope O
ratio O
mass O
spectrometry O
( O
GC O
- O
C O
- O
IRMS O
) O
to O
determine O
the O
( B
13 I
) I
C I
/ O
( O
12 O
) O
C O
ratio O
( O
delta O
( B
13 I
) I
C I
/ O
1000 O
) O
. O

The O
delta O
( B
13 I
) I
C I
/ O
1000 O
values O
of O
reference O
standard O
of O
E1 O
, O
E2 O
, O
and O
E3 O
were O
- O
29 O
. O
36 O
+ O
/ O
- O
0 O
. O
72 O
, O
- O
27 O
. O
98 O
+ O
/ O
- O
0 O
. O
35 O
, O
- O
27 O
. O
62 O
+ O
/ O
- O
0 O
. O
51 O
, O
respectively O
. O

The O
delta O
( B
13 I
) I
C I
/ O
1000 O
values O
of O
the O
endogenous O
E1 O
, O
E2 O
, O
and O
E3 O
were O
- O
21 O
. O
62 O
+ O
/ O
- O
1 O
. O
07 O
, O
- O
22 O
. O
14 O
+ O
/ O
- O
0 O
. O
98 O
, O
and O
- O
21 O
. O
88 O
+ O
/ O
- O
1 O
. O
16 O
, O
with O
P O
< O
0 O
. O
01 O
( O
t O
- O
test O
) O
. O

Two O
DUB O
patients O
' O
urinary O
estradiol B
delta O
( B
13 I
) I
C I
/ O
1000 O
values O
was O
depleted O
to O
- O
28 O
. O
02 O
+ O
/ O
- O
0 O
. O
33 O
after O
the O
administration O
. O

The O
progesterone B
, O
17 B
alpha I
- I
hydroxyprogesterone I
, O
pregnanediol O
, O
as O
well O
as O
desogestrel O
and O
ethinylestradiol B
from O
contraceptives O
were O
also O
determined O
. O

Stable O
carbon B
isotope O
analysis O
can O
distinguish O
the O
endogenous O
and O
exogenous O
urinary O
estrogen B
in O
human O
. O

Here O
, O
a O
novel O
bovine O
monocyte O
chemotactic O
factor O
( O
boMCF O
- O
1 O
) O
was O
isolated O
from O
commercial O
bovine O
serum O
by O
a O
four O
step O
purification O
procedure O
including O
adsorption O
to O
silicic B
acid I
, O
heparin O
affinity O
and O
cation O
- O
exchange O
chromatography O
and O
reversed O
phase O
HPLC O
. O

Homogeneous O
boMCF O
- O
1 O
was O
characterized O
as O
a O
7717Da O
protein O
by O
mass O
spectrometry O
and O
identified O
by O
Edman O
degradation O
as O
the O
predicted O
product O
of O
bovine O
macrophage O
inflammatory O
protein O
- O
1 O
alpha O
gene O
( O
boMIP O
- O
1 O
alpha O
/ O
CCL3 O
) O
isoform O
2 O
( O
lacking O
three O
NH B
2 I
- O
terminal O
amino B
acids I
) O
, O
belonging O
to O
the O
MIP O
subfamily O
of O
CC O
chemokines O
. O

Dopamine B
- O
secreting O
PC12 O
cells O
were O
housed O
within O
newly O
formulated O
alginate O
- O
glutamine B
degradable O
polylysine O
( O
A O
- O
GD O
- O
PLL B
) O
microcapsules O
. O

The O
A O
- O
GD O
- O
PLL B
microcapsules O
provided O
a O
3 O
- O
D O
microenvironment O
for O
good O
spatial O
cell O
growth O
, O
viability O
and O
proliferation O
. O

The O
microcapsules O
were O
subsequently O
placed O
within O
a O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
- O
coated O
poly O
( O
epsilon O
- O
caprolactone O
) O
( O
PCL B
) O
chamber O
covered O
with O
a O
PEG O
- O
grafted O
PCL O
nanoporous O
membrane O
formed O
by O
phase O
inversion O
. O

To O
enhance O
PC12 O
cell O
growth O
and O
to O
assist O
in O
controlled O
degradation O
of O
both O
the O
PC12 O
cells O
and O
the O
device O
construct O
, O
small O
PCL B
capsules O
containing O
neural O
growth O
factor O
( O
PCL B
- O
NGF O
) O
and O
a O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
pellet O
containing O
glutamine B
( O
PLGA B
- O
GLN B
) O
were O
also O
placed O
within O
the O
PCL B
chamber O
. O

Release O
of O
NGF O
from O
the O
PCL B
- O
NGF O
capsules O
facilitated O
cell O
proliferation O
and O
viability O
, O
while O
the O
controlled O
release O
of O
GLN B
from O
the O
PLGA B
- O
GLN B
pellet O
resulted O
in O
A O
- O
GD O
- O
PLL B
microcapsule O
degradation O
and O
eventual O
PC12 O
cell O
death O
following O
a O
pre O
- O
specified O
period O
of O
time O
( O
4 O
weeks O
in O
this O
study O
) O
. O

In O
vivo O
, O
our O
device O
was O
found O
to O
be O
well O
tolerated O
and O
we O
successfully O
demonstrated O
the O
controlled O
release O
of O
dopamine B
over O
a O
period O
of O
four O
weeks O
. O

Eight O
selected O
metals O
( O
As B
, O
Hg B
, O
Cd B
, O
Cr B
, O
Cu B
, O
Ni B
, O
Pb B
and O
Zn B
) O
were O
determined O
in O
the O
water O
dissolved O
phase O
( O
DP O
) O
, O
suspended O
particulate O
matter O
( O
SPM O
) O
and O
sediment O
samples O
. O

Dynamic O
bioavailability O
of O
copper B
in O
soil O
estimated O
by O
uptake O
and O
elimination O
kinetics O
in O
the O
springtail O
Folsomia O
candida O
. O

This O
study O
aimed O
to O
assess O
the O
bioavailability O
of O
copper B
in O
soil O
, O
by O
measuring O
its O
uptake O
kinetics O
into O
a O
representative O
soil O
invertebrate O
, O
the O
collembolan O
Folsomia O
candida O
. O

The O
animals O
were O
exposed O
to O
25 O
or O
100 O
mu O
g O
Cu B
g O
( O
- O
1 O
) O
dry O
LUFA O
2 O
. O
2 O
soil O
at O
nominal O
pH O
( O
CaCl2 B
) O
4 O
. O
5 O
, O
5 O
. O
5 O
, O
or O
6 O
. O
5 O
during O
14 O
days O
after O
which O
they O
were O
transferred O
to O
clean O
soil O
for O
14 O
days O
elimination O
. O

Copper B
was O
present O
in O
the O
animals O
at O
a O
basal O
physiological O
level O
of O
40 O
- O
90 O
mu O
g O
g O
( O
- O
1 O
) O
dry O
weight O
, O
on O
top O
of O
this O
uptake O
and O
elimination O
kinetics O
were O
observed O
. O

Multiple O
linear O
regressions O
showed O
that O
the O
pH O
effect O
on O
copper B
uptake O
was O
only O
significant O
when O
taking O
into O
account O
cation O
exchange O
capacity O
, O
or O
calcium B
and O
dissolved O
organic O
carbon B
levels O
in O
the O
pore O
water O
. O

Copper B
concentrations O
in O
the O
animals O
however O
, O
never O
were O
higher O
than O
185 O
mu O
g O
g O
( O
- O
1 O
) O
dry O
weight O
, O
independent O
of O
exposure O
level O
and O
pH O
, O
suggesting O
homeostatic O
regulation O
. O

These O
results O
show O
that O
the O
chemical O
composition O
of O
the O
pore O
water O
does O
affect O
bioavailability O
of O
copper B
in O
soil O
, O
but O
that O
copper B
uptake O
in O
collembolans O
is O
dominated O
by O
homeostatic O
regulation O
rather O
than O
by O
soil O
properties O
like O
pH O
. O

A O
photoinduced O
charge O
transfer O
composite O
of O
graphene B
oxide I
and O
ferrocene B
. O

We O
demonstrate O
the O
formation O
of O
a O
photoinduced O
charge O
transfer O
composite O
with O
graphene B
oxide I
( O
GO O
) O
and O
ferrocene B
( O
Fc O
) O
molecules O
. O

Regions O
on O
adenylyl B
cyclase O
VII O
required O
for O
selective O
regulation O
by O
the O
G13 O
pathway O
. O

Regulation O
of O
multiple O
adenylyl B
cyclases O
( O
AC O
) O
provides O
unique O
inputs O
to O
mediate O
the O
synthesis O
of O
cAMP B
, O
a O
ubiquitous O
second O
messenger O
that O
controls O
many O
aspects O
of O
cellular O
function O
. O

On O
stimulation O
by O
G O
( O
s O
) O
, O
the O
activities O
of O
ACs O
can O
be O
further O
selectively O
modulated O
by O
other O
pathways O
to O
ensure O
precise O
control O
of O
intracellular O
cAMP B
responses O
to O
specific O
stimuli O
. O

Although O
both O
enzymes O
could O
fully O
restore O
regulation O
of O
cAMP B
by O
G O
beta O
gamma O
, O
activation O
of O
the O
G O
( O
13 O
) O
pathway O
preferentially O
synergized O
with O
AC7 O
. O

Exchange O
of O
domains O
between O
the O
two O
isoforms O
indicates O
that O
the O
C1b O
domain O
and O
the O
N B
- O
terminus O
of O
the O
C1a O
domain O
are O
important O
for O
directing O
selective O
regulation O
of O
AC7 O
by O
the O
G O
( O
13 O
) O
pathway O
. O

Moreover O
, O
VK2 O
- O
2 O
, O
3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine B
- O
166 O
residue O
of O
Bak O
. O

Enantioresolution O
of O
chiral O
derivatives O
of O
xanthones B
on O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
and O
L O
- O
phenylglycine O
stationary O
phases O
and O
chiral O
recognition O
mechanism O
by O
docking O
approach O
for O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
. O

The O
resolution O
of O
seven O
enantiomeric O
pairs O
of O
chiral O
derivatives O
of O
xanthones B
( O
CDXs O
) O
on O
( O
S O
, O
S O
) O
- O
Whelk O
- O
O1 O
and O
L O
- O
phenylglycine O
chiral O
stationary O
phases O
( O
CSPs O
) O
was O
systematically O
investigated O
using O
multimodal O
elution O
conditions O
( O
normal O
- O
phase O
, O
polar O
- O
organic O
, O
and O
reversed O
- O
phase O
) O
. O

Involvement O
of O
UDP B
- O
glucuronosyltransfer O
UGT1A9 O
and O
UGT2B7 O
in O
ethanol B
glucuronidation O
, O
and O
interactions O
with O
common O
drugs O
of O
abuse O
. O

Ethyl O
glucuronide O
( O
EtG O
) O
determination O
is O
increasingly O
used O
in O
clinical O
and O
forensic O
toxicology O
to O
document O
ethanol B
consumption O
. O

Activities O
of O
human O
liver O
( O
HLM O
) O
, O
kidney O
( O
HKM O
) O
, O
and O
intestinal O
( O
HIM O
) O
microsomes O
, O
as O
well O
as O
of O
12 O
major O
human O
recombinant O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
, O
toward O
ethanol B
( O
50 O
and O
500 O
mM O
) O
were O
evaluated O
in O
vitro O
using O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

Interaction O
of O
morphine B
, O
codeine O
, O
lorazepam B
, O
oxazepam O
, O
nicotine B
, O
cotinine B
, O
cannabinol O
, O
and O
cannabidiol B
( O
5 O
, O
10 O
, O
15 O
mg O
/ O
l O
) O
with O
ethanol B
( O
1 O
. O
15 O
, O
4 O
. O
6 O
, O
11 O
. O
5 O
g O
/ O
l O
; O
i O
. O
e O
. O
, O
25 O
, O
100 O
, O
250 O
mM O
) O
glucuronidation O
was O
assessed O
using O
pooled O
HLM O
. O

Ethanol B
glucuronidation O
intrinsic O
clearance O
( O
Cl O
( O
int O
) O
) O
was O
4 O
and O
12 O
. O
7 O
times O
higher O
for O
HLM O
than O
for O
HKM O
and O
HIM O
, O
respectively O
. O

Only O
cannabinol O
and O
cannabidiol B
significantly O
affected O
ethanol B
glucuronidation O
. O

Cannabinol O
increased O
ethanol B
glucuronidation O
in O
a O
concentration O
- O
dependent O
manner O
, O
whereas O
cannabidiol B
significantly O
inhibited O
EtG O
formation O
in O
a O
noncompetitive O
manner O
( O
IC O
( O
50 O
) O
= O
1 O
. O
17 O
mg O
/ O
l O
; O
inhibition O
constant O
( O
K O
( O
i O
) O
) O
= O
3 O
. O
1 O
mg O
/ O
l O
) O
. O

UGT1A9 O
and O
2B7 O
are O
the O
main O
enzymes O
involved O
in O
ethanol B
glucuronidation O
. O

In O
addition O
, O
our O
results O
suggest O
that O
cannabinol O
and O
cannabidiol B
could O
significantly O
alter O
ethanol B
glucuronidation O
. O

Mutation O
of O
a O
zinc B
- O
binding O
residue O
in O
the O
glycine B
receptor O
alpha O
1 O
subunit O
changes O
ethanol B
sensitivity O
in O
vitro O
and O
alcohol B
consumption O
in O
vivo O
. O

Ethanol B
is O
a O
widely O
used O
drug O
, O
yet O
an O
understanding O
of O
its O
sites O
and O
mechanisms O
of O
action O
remains O
incomplete O
. O

Among O
the O
protein O
targets O
of O
ethanol B
are O
glycine B
receptors O
( O
GlyRs O
) O
, O
which O
are O
potentiated O
by O
millimolar O
concentrations O
of O
ethanol B
. O

In O
addition O
, O
zinc B
ions O
also O
modulate O
GlyR O
function O
, O
and O
recent O
evidence O
suggests O
that O
physiologic O
concentrations O
of O
zinc B
enhance O
ethanol B
potentiation O
of O
GlyRs O
. O

Here O
, O
we O
first O
built O
a O
homology O
model O
of O
a O
zinc B
- O
bound O
GlyR O
using O
the O
D80 O
position O
as O
a O
coordination O
site O
for O
a O
zinc B
ion O
. O

Next O
, O
we O
investigated O
in O
vitro O
the O
effects O
of O
zinc B
on O
ethanol B
action O
at O
recombinant O
wild O
- O
type O
( O
WT O
) O
and O
mutant O
alpha O
1 O
GlyRs O
containing O
the O
D80A O
substitution O
, O
which O
eliminates O
zinc B
potentiation O
. O

At O
D80A O
GlyRs O
, O
the O
effects O
of O
50 O
and O
200 O
mM O
ethanol B
were O
reduced O
as O
compared O
with O
WT O
receptors O
. O

Also O
, O
in O
contrast O
to O
what O
was O
seen O
with O
WT O
GlyRs O
, O
neither O
adding O
nor O
chelating O
zinc B
changed O
the O
magnitude O
of O
ethanol B
enhancement O
of O
mutant O
D80A O
receptors O
. O

The O
KI O
mice O
showed O
decreased O
ethanol B
consumption O
and O
preference O
, O
and O
they O
displayed O
increased O
startle O
responses O
compared O
with O
their O
WT O
littermates O
. O

Other O
behavioral O
tests O
, O
including O
ethanol B
- O
induced O
motor O
incoordination O
and O
strychnine B
- O
induced O
convulsions O
, O
revealed O
no O
differences O
between O
the O
KI O
and O
WT O
mice O
. O

Together O
, O
our O
findings O
indicate O
that O
zinc B
is O
critical O
in O
determining O
the O
effects O
of O
ethanol B
at O
GlyRs O
and O
suggest O
that O
zinc B
binding O
at O
the O
D80 O
position O
may O
be O
important O
for O
mediating O
some O
of O
the O
behavioral O
effects O
of O
ethanol B
action O
at O
GlyRs O
. O

Expression O
and O
activity O
of O
nitric B
oxide I
synthase O
isoforms O
in O
methamphetamine B
- O
induced O
striatal O
dopamine B
toxicity O
. O

Nitric B
oxide I
is O
implicated O
in O
methamphetamine B
( O
METH B
) O
- O
induced O
neurotoxicity O
; O
however O
, O
the O
source O
of O
the O
nitric B
oxide I
has O
not O
been O
identified O
. O

Previous O
work O
has O
also O
revealed O
that O
animals O
with O
partial O
dopamine B
loss O
induced O
by O
a O
neurotoxic O
regimen O
of O
methamphetamine B
fail O
to O
exhibit O
further O
decreases O
in O
striatal O
dopamine B
when O
re O
- O
exposed O
to O
methamphetamine B
7 O
- O
30 O
days O
later O
. O

The O
current O
study O
examined O
nitric B
oxide I
synthase O
expression O
and O
activity O
and O
protein O
nitration O
in O
striata O
of O
animals O
administered O
saline O
or O
neurotoxic O
regimens O
of O
methamphetamine B
at O
postnatal O
days O
60 O
and O
/ O
or O
90 O
, O
resulting O
in O
four O
treatment O
groups O
: O
Saline O
: O
Saline O
, O
METH B
: O
Saline O
, O
Saline O
: O
METH B
, O
and O
METH B
: O
METH B
. O

Acute O
administration O
of O
methamphetamine B
on O
postnatal O
day O
90 O
( O
Saline O
: O
METH B
and O
METH B
: O
METH B
) O
increased O
nitric B
oxide I
production O
, O
as O
evidenced O
by O
increased O
protein O
nitration O
. O

Methamphetamine B
did O
not O
, O
however O
, O
change O
the O
expression O
of O
endothelial O
or O
inducible O
isoforms O
of O
nitric B
oxide I
synthase O
, O
nor O
did O
it O
change O
the O
number O
of O
cells O
positive O
for O
neuronal O
nitric B
oxide I
synthase O
mRNA O
expression O
or O
the O
amount O
of O
neuronal O
nitric B
oxide I
synthase O
mRNA O
per O
cell O
. O

However O
, O
nitric B
oxide I
synthase O
activity O
in O
striatal O
interneurons O
was O
increased O
in O
the O
Saline O
: O
METH B
and O
METH B
: O
METH B
animals O
. O

These O
data O
suggest O
that O
increased O
nitric B
oxide I
production O
after O
a O
neurotoxic O
regimen O
of O
methamphetamine B
results O
from O
increased O
nitric B
oxide I
synthase O
activity O
, O
rather O
than O
an O
induction O
of O
mRNA O
, O
and O
that O
constitutively O
expressed O
neuronal O
nitric B
oxide I
synthase O
is O
the O
most O
likely O
source O
of O
nitric B
oxide I
after O
methamphetamine B
administration O
. O

Of O
interest O
, O
animals O
rendered O
resistant O
to O
further O
methamphetamine B
- O
induced O
dopamine B
depletions O
still O
show O
equivalent O
degrees O
of O
methamphetamine B
- O
induced O
nitric B
oxide I
production O
, O
suggesting O
that O
nitric B
oxide I
production O
alone O
in O
response O
to O
methamphetamine B
is O
not O
sufficient O
to O
induce O
acute O
neurotoxic O
injury O
. O

The O
CBC O
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser B
- O
2 O
of O
the O
C B
- O
terminal O
domain O
( O
CTD O
) O
of O
RNA O
polymerase O
II O
. O

Surfactant O
- O
free O
microemulsion O
composed O
of O
oleic B
acid I
, O
n O
- O
propanol O
, O
and O
H2O B
. O

Herein O
, O
we O
report O
a O
surfactant O
- O
free O
microemulsion O
( O
denoted O
as O
SFME O
) O
, O
consisting O
of O
oleic B
acid I
( O
oil O
phase O
) O
, O
water O
, O
and O
n O
- O
propanol O
without O
the O
amphiphilic O
molecular O
structure O
of O
a O
traditional O
surfactant O
. O

The O
electrical O
conductivity O
measurement O
was O
employed O
to O
investigate O
the O
microregions O
of O
the O
single O
- O
phase O
microemulsion O
region O
, O
and O
three O
different O
microregions O
, O
that O
is O
, O
water O
- O
in O
- O
oleic B
acid I
( O
W O
/ O
O O
) O
, O
a O
bicontinuous O
( O
B O
. O
C O
. O
) O
region O
, O
and O
oleic B
acid I
- O
in O
- O
water O
( O
O O
/ O
W O
) O
, O
were O
identified O
, O
which O
were O
further O
confirmed O
by O
freeze O
- O
fracture O
and O
cryogenic O
transmission O
electron O
microscopy O
( O
FF O
- O
TEM O
and O
Cryo O
- O
TEM O
) O
observations O
. O

The O
polarity O
and O
the O
salt O
solubility O
of O
water O
domains O
in O
the O
W O
/ O
O O
SFME O
were O
investigated O
by O
UV O
- O
visible O
spectroscopy O
using O
methyl B
orange I
and O
potassium O
ferricyanide O
as O
probes O
, O
respectively O
. O

The O
chloromaleimide O
group O
of O
this O
compound O
is O
thought O
to O
act O
as O
a O
Michael O
acceptor O
and O
react O
with O
the O
thiol B
group O
on O
C319 O
of O
RAD51 O
, O
using O
a O
conjugate O
addition O
- O
elimination O
mechanism O
. O

In O
order O
to O
reduce O
the O
likelihood O
of O
off O
- O
target O
effects O
and O
to O
improve O
compound O
stability O
in O
biological O
systems O
, O
we O
developed O
an O
analogue O
of O
compound O
1 O
that O
lacks O
maleimide B
- O
based O
reactivity O
but O
retains O
RAD51 O
inhibitory O
activity O
. O

We O
aim O
to O
" O
tilt O
" O
the O
stability O
of O
the O
H1 O
loop O
structure O
from O
a O
noncanonical O
conformation O
to O
a O
( O
humanized O
) O
type O
1 O
canonical O
conformation O
by O
studying O
the O
effect O
of O
selected O
mutations O
to O
the O
amino B
acid I
sequence O
of O
the O
H1 O
, O
H2 O
, O
and O
proximal O
residues O
. O

Peptidyl O
- O
prolyl B
cis O
/ O
trans O
- O
isomerase O
A1 O
( O
Pin1 O
) O
is O
a O
target O
for O
modification O
by O
lipid O
electrophiles O
. O

Oxyradical O
damage O
to O
phospholipids O
results O
in O
the O
production O
of O
reactive O
aldehydes B
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O

4 B
- I
Hydroxynonenal I
( O
HNE O
) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys B
, O
His B
, O
or O
Lys B
residues O
. O

Here O
, O
we O
demonstrate O
that O
peptidyl O
- O
prolyl B
cis O
/ O
trans O
- O
isomerase O
A1 O
( O
Pin1 O
) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer B
/ O
pThr B
- O
Pro B
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O

Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI O
- O
TOF O
/ O
TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His B
- O
157 O
and O
Cys B
- O
113 O
. O

Time O
and O
concentration O
dependencies O
indicate O
that O
Cys B
- O
113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O

Pin1 O
was O
adducted O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
treated O
with O
8 O
- O
alkynyl O
- O
HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin B
followed O
by O
streptavidin O
- O
based O
pulldown O
and O
Western O
blotting O
with O
anti O
- O
Pin1 O
antibody O
. O

Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys B
- O
113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA O
- O
MB O
- O
231 O
cells O
. O

Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols B
. O

Initial O
NMR O
studies O
showed O
that O
6DBF7 O
binds O
to O
gal O
- O
1 O
on O
one O
side O
of O
the O
beta O
- O
sandwich O
away O
from O
the O
lectin O
' O
s O
carbohydrate B
binding O
site O
. O

Although O
an O
alanine B
scan O
of O
6DBF7 O
showed O
that O
the O
two O
cationic O
groups O
( O
lysines B
) O
in O
the O
partial O
peptide O
are O
crucial O
to O
its O
angiostatic O
activity O
, O
it O
is O
the O
hydrophobic O
face O
of O
the O
amphipath O
that O
appears O
to O
interact O
directly O
with O
the O
surface O
of O
gal O
- O
1 O
. O

In O
particular O
, O
substitution O
of O
the O
C B
- O
terminal O
Asp B
for O
alanine B
and O
branched O
alkyl B
side O
chains O
( O
Val B
, O
Leu B
, O
Ile B
) O
for O
linear O
ones O
( O
Nle B
, O
Nva O
) O
rendered O
the O
greatest O
improvements O
in O
activity O
. O

Flow O
cytometry O
with O
gal O
- O
1 O
( O
- O
/ O
- O
) O
splenocytes O
showed O
that O
6DBF7 O
and O
two O
of O
its O
more O
potent O
analogs O
( O
DB16 O
and O
DB21 O
) O
can O
fully O
inhibit O
fluorescein B
isothiocyanate I
- O
gal O
- O
1 O
binding O
. O

Moreover O
, O
heteronuclear O
single O
- O
quantum O
coherence O
NMR O
titrations O
showed O
that O
the O
presence O
of O
DB16 O
decreases O
gal O
- O
1 O
affinity O
for O
lactose B
, O
indicating O
that O
the O
peptidomimetic O
targets O
gal O
- O
1 O
as O
a O
noncompetitive O
, O
allosteric O
inhibitor O
of O
glycan O
binding O
. O

Fish O
and O
macroinvertebrate O
assemblages O
, O
fish O
biomarkers O
( O
i O
. O
e O
. O
, O
polycyclic O
aromatic O
hydrocarbon O
[ O
PAH B
] O
metabolite O
levels O
in O
white O
sucker O
[ O
Castostomus O
commersoni O
] O
and O
common O
carp O
[ O
Cyprinus O
carpio O
] O
bile O
and O
DNA O
damage O
) O
, O
sediment O
chemistry O
, O
and O
water O
quality O
were O
assessed O
at O
five O
locations O
relative O
to O
the O
primary O
source O
of O
historical O
PAH B
contamination O
- O
upstream O
( O
RM O
9 O
. O
2 O
) O
, O
adjacent O
( O
RM O
6 O
. O
5 O
) O
, O
and O
downstream O
( O
RMs O
5 O
. O
7 O
, O
4 O
. O
4 O

Overall O
, O
the O
biomarker O
results O
were O
consistent O
with O
the O
sediment O
PAH B
results O
, O
showing O
a O
pattern O
of O
low O
levels O
of O
PAH B
bile O
metabolites O
and O
DNA O
damage O
at O
the O
upstream O
( O
reference O
or O
background O
location O
) O
, O
as O
well O
as O
the O
remediated O
section O
, O
high O
levels O
at O
the O
two O
immediate O
downstream O
sites O
, O
and O
somewhat O
lower O
levels O
at O
the O
furthest O
downstream O
site O
. O

Results O
show O
that O
remediation O
was O
effective O
in O
reducing O
sediment O
contaminant O
concentrations O
and O
exposure O
of O
fish O
to O
PAHs B
and O
in O
improving O
fish O
assemblages O
( O
60 O
% O
increase O
in O
index O
of O
biotic O
integrity O
scores O
) O
in O
remediated O
river O
sections O
. O

Additional O
remedial O
investigation O
and O
potentially O
further O
remediation O
is O
needed O
to O
improve O
the O
downstream O
benthic O
fish O
community O
, O
which O
is O
still O
heavily O
exposed O
to O
PAH B
contaminants O
. O

A O
maternal O
" O
junk O
- O
food O
" O
diet O
reduces O
sensitivity O
to O
the O
opioid O
antagonist O
naloxone B
in O
offspring O
postweaning O
. O

Administration O
of O
the O
opioid O
antagonist O
naloxone B
to O
offspring O
given O
a O
palatable O
diet O
postweaning O
significantly O
reduced O
fat O
intake O
in O
control O
offspring O
( O
males O
: O
7 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
vs O
. O
5 O
. O
4 O
+ O
/ O
- O
0 O
. O
6 O
g O
/ O
kg O
/ O
d O
; O
females O
: O
6 O
. O
9 O
+ O
/ O
- O
0 O
. O
3 O
vs O
. O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
g O
/ O
kg O
/ O
d O
; O
P O
< O
0 O
. O
05 O
) O
, O
but O
not O
in O
male O
JF O
offspring O
( O
8 O
. O
6 O
+ O
/ O
- O
0 O
. O
6 O
vs O
. O
7 O
. O
1 O
+ O
/ O
- O
0 O
. O
5 O
g O
/ O
kg O
/ O

Naloxone B
treatment O
did O
not O
affect O
intake O
of O
standard O
rodent O
feed O
in O
control O
or O
JF O
offspring O
. O

Peptides O
derived O
from O
the O
C B
- O
terminal O
heptad O
repeat O
( O
C O
peptides O
) O
of O
HIV O
- O
1 O
gp41 O
are O
potent O
inhibitors O
against O
virus O
entry O
. O

We O
then O
generated O
a O
24 O
- O
mer O
peptide O
termed O
MT O
- O
SC22EK O
by O
incorporating O
the O
M O
- O
T O
hook O
structure O
to O
the O
N B
terminus O
of O
the O
poorly O
active O
short O
C O
peptide O
SC22EK O
. O

The O
high O
- O
resolution O
crystal O
structure O
of O
MT O
- O
SC22EK O
reveals O
the O
N B
- O
terminal O
M O
- O
T O
hook O
conformation O
folded O
by O
incorporated O
Met626 O
and O
Thr627 O
and O
identifies O
the O
C B
- O
terminal O
boundary O
critical O
for O
the O
anti O
- O
HIV O
activity O
. O

Design O
and O
assessment O
of O
a O
microfluidic O
network O
system O
for O
oxygen B
transport O
in O
engineered O
tissue O
. O

Oxygen B
and O
nutrients O
cannot O
be O
delivered O
to O
cells O
residing O
in O
the O
interior O
of O
large O
- O
volume O
scaffolds O
via O
diffusion O
alone O
. O

We O
proposed O
a O
process O
to O
design O
a O
microfluidic O
network O
by O
combining O
an O
oxygen B
transport O
simulation O
with O
biomimetic O
principles O
governing O
biological O
vascular O
trees O
. O

Novobiocin O
is O
the O
first O
Hsp90 O
C O
- O
terminal O
inhibitor O
ever O
identified O
and O
recent O
structure O
- O
activity O
relationship O
studies O
on O
the O
noviose O
sugar B
identified O
several O
commercially O
available O
amines B
as O
suitable O
surrogates O
. O

Enhancement O
of O
electrical O
and O
thermomechanical O
properties O
of O
silver B
nanowire O
composites O
by O
the O
introduction O
of O
nonconductive O
nanoparticles O
: O
experiment O
and O
simulation O
. O

We O
illustrate O
a O
novel O
but O
facile O
strategy O
to O
improve O
the O
electrical O
conductivity O
and O
the O
thermomechanical O
property O
of O
silver B
nanowire O
/ O
polymer O
nanocomposites O
. O

We O
find O
that O
one O
may O
increase O
the O
electrical O
conductivity O
of O
silver B
nanowire O
/ O
polymer O
nanocomposites O
by O
up O
to O
about O
8 O
orders O
of O
magnitude O
by O
introducing O
silica B
nanoparticles O
with O
nanocomposites O
. O

The O
electrical O
percolation O
threshold O
volume O
fraction O
of O
silver B
nanowires O
decreases O
from O
0 O
. O
12 O
to O
0 O
. O
02 O
. O

Thermomechanical O
properties O
also O
improve O
as O
silica B
nanoparticles O
are O
introduced O
. O

We O
carry O
out O
extensive O
Monte O
Carlo O
simulations O
to O
elucidate O
the O
effects O
of O
silica B
nanoparticles O
at O
a O
molecular O
level O
and O
find O
that O
van O
der O
Waals O
attractive O
interaction O
between O
silica B
nanoparticles O
and O
silver B
nanowires O
dominates O
over O
the O
depletion O
- O
induced O
interaction O
between O
silver B
nanowires O
, O
thus O
improving O
the O
dispersion O
of O
silver B
nanowires O
. O

Without O
silica B
nanoparticles O
, O
silver B
nanowires O
tend O
to O
aggregate O
, O
which O
is O
why O
additional O
silver B
nanowires O
are O
required O
for O
a O
desired O
electrical O
conductivity O
. O

On O
the O
other O
hand O
, O
with O
silica B
nanoparticles O
mixed O
, O
the O
electrical O
percolating O
network O
is O
likely O
to O
form O
at O
a O
smaller O
volume O
fraction O
of O
silver B
nanowires O
. O

RT O
- O
qPCR O
was O
used O
to O
quantify O
the O
transcription O
of O
genes O
encoding O
catalase O
( O
cat O
) O
, O
a O
cytosolic O
superoxide B
dismutase O
( O
Cu B
/ O
Zn B
- O
sod O
) O
, O
a O
selenium B
- O
dependent O
glutathione B
peroxidase O
( O
gpx O
) O
, O
a O
glutathione B
reductase O
( O
gred O
) O
, O
the O
retinoid B
X O
receptor O
( O
rxr O
) O
, O
two O
heat O
shock O
proteins O
( O
hsp40 O
and O
hsp70 O
) O
, O
cortactin O
( O
cor O
) O
and O
the O
two O
ribosomal O
genes O
r18S O
and O

Enzymatic O
activities O
of O
SOD O
, O
Gpx O
, O
Gred O
and O
glutathione B
S B
- O
transferase O
( O
GST O
) O
were O
investigated O
in O
the O
GDC O
using O
spectrophoto O
/ O
fluorometric O
methods O
. O

In O
the O
GDC O
, O
earlier O
responses O
were O
observed O
and O
the O
fold O
- O
change O
magnitude O
was O
generally O
much O
higher O
: O
transcription O
of O
all O
target O
genes O
increased O
significantly O
( O
or O
non O
- O
significantly O
for O
cat O
) O
after O
5 O
h O
of O
exposure O
, O
and O
went O
back O
to O
control O
levels O
afterwards O
, O
suggesting O
the O
onset O
of O
an O
early O
response O
to O
oxidative O
stress O
associated O
to O
the O
unbalance O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
in O
hepatocytes O
. O

Synthesis O
and O
SAR O
of O
aminothiazole B
fused O
benzazepines O
as O
selective O
dopamine B
D2 O
partial O
agonists O
. O

Dopamine B
( O
D O
( O
2 O
) O
) O
partial O
agonists O
( O
D2PAs O
) O
have O
been O
regarded O
as O
a O
potential O
treatment O
for O
schizophrenia O
patients O
with O
expected O
better O
side O
effect O
profiles O
than O
currently O
marketed O
antipsychotics O
. O

Herein O
we O
report O
the O
synthesis O
and O
SAR O
of O
a O
series O
of O
aminothiazole B
fused O
benzazepines O
as O
selective O
D O
( O
2 O
) O
partial O
agonists O
. O

One O
of O
the O
key O
compounds O
, O
8h O
, O
has O
good O
in O
vitro O
/ O
in O
vivo O
ADME O
characteristics O
, O
and O
is O
active O
in O
a O
rat O
amphetamine B
- O
induced O
locomotor O
activity O
model O
. O

The O
series O
consisted O
of O
3 O
- O
( O
benzylamino O
) O
- O
5 O
- O
cyanopyrazine O
- O
2 O
- O
carboxamides O
and O
3 O
- O
( O
benzylamino O
) O
pyrazine O
- O
2 O
, O
5 O
- O
dicarbonitriles O
with O
various O
substituents O
on O
the O
phenyl B
ring O
. O

Novel O
2 O
' O
- O
fluoro O
- O
6 O
' O
- O
methylene O
- O
carbocyclic O
adenosine O
( O
FMCA O
) O
monophosphate B
prodrug O
( O
FMCAP O
) O
was O
synthesized O
and O
evaluated O
for O
its O
in O
vitro O
anti O
- O
HBV O
potency O
against O
a O
lamivudine O
- O
entecavir O
resistant O
clone O
( O
L180M O
+ O
M204V O
+ O
S202G O
) O
. O

The O
monophosphate B
prodrug O
( O
FMCAP O
) O
demonstrated O
greater O
than O
12 O
- O
fold O
( O
12 O
x O
) O
increase O
in O
anti O
- O
HBV O
activity O
without O
increased O
cellular O
toxicity O
. O

Mode O
of O
action O
studies O
by O
molecular O
modeling O
indicate O
that O
the O
2 B
' I
- I
fluoro I
moiety O
by O
hydrogen B
bond O
as O
well O
as O
the O
Van O
der O
Waals O
interaction O
of O
the O
carbocyclic O
ring O
with O
the O
phenylalanine B
moiety O
of O
the O
polymerase O
promote O
the O
positive O
binding O
, O
even O
in O
the O
drug O
- O
resistant O
mutants O
. O

A O
new O
paradigm O
has O
emerged O
that O
invokes O
osteocyte O
apoptosis O
as O
a O
critical O
event O
in O
the O
recruitment O
of O
osteoclasts O
to O
a O
specific O
site O
in O
response O
to O
skeletal O
unloading O
, O
fatigue O
damage O
, O
estrogen B
deficiency O
and O
perhaps O
in O
other O
states O
where O
bone O
must O
be O
removed O
. O

Bisphenol B
A I
interferes O
with O
thyroid O
specific O
gene O
expression O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
endocrine O
- O
disrupting O
chemical O
that O
leads O
to O
low O
- O
dose O
human O
exposure O
due O
to O
its O
ability O
to O
leach O
from O
chemically O
derived O
products O
, O
as O
polycarbonate B
plastics O
and O
epoxy B
resin O
. O

In O
addition O
to O
its O
known O
xeno O
- O
endocrine O
action O
, O
BPA B
exerts O
a O
wide O
range O
of O
metabolic O
effects O
. O

Despite O
the O
documented O
BPA B
exposure O
outcomes O
on O
synthesis O
of O
thyroid B
hormones I
, O
there O
are O
not O
any O
data O
available O
on O
its O
actions O
on O
the O
thyroid O
follicular O
cells O
, O
site O
of O
synthesis O
of O
the O
thyroid B
hormones I
. O

Recently O
, O
it O
has O
been O
shown O
that O
several O
environmental O
pollutants O
, O
as O
BPA B
, O
can O
exert O
a O
thyroid O
disrupting O
activity O
. O

In O
this O
study O
, O
we O
employed O
in O
vitro O
and O
in O
vivo O
( O
zebrafish O
) O
models O
to O
examine O
the O
effects O
of O
BPA B
in O
regulating O
the O
expression O
of O
genes O
involved O
in O
the O
thyroid B
hormone I
synthesis O
and O
of O
their O
transcriptional O
regulators O
at O
BPA B
doses O
as O
low O
as O
10 O
( O
- O
9 O
) O
M O
, O
a O
dose O
that O
is O
environmentally O
pertinent O
and O
far O
below O
the O
one O
detected O
in O
infants O
plasma O
. O

In O
both O
systems O
we O
could O
detect O
an O
altered O
expression O
of O
the O
genes O
involved O
in O
thyroid B
hormones I
synthesis O
and O
of O
thyroid O
specific O
transcriptional O
factors O
in O
BPA B
dose O
and O
time O
dependent O
manner O
. O

Our O
results O
suggest O
that O
BPA B
exerts O
a O
direct O
effect O
on O
thyroid O
follicular O
cell O
. O

We O
show O
that O
these O
cells O
can O
" O
sense O
" O
very O
low O
amount O
of O
BPA B
. O

Thus O
they O
, O
potentially O
, O
represent O
an O
ideal O
in O
vitro O
system O
to O
develop O
assays O
to O
detect O
BPA B
and O
other O
pollutants O
with O
thyroid O
disrupting O
activity O
at O
level O
far O
below O
the O
ones O
considered O
to O
be O
environmental O
relevant O
. O

Moreover O
, O
this O
report O
may O
provide O
new O
insight O
into O
the O
mode O
of O
BPA B
- O
induced O
deregulation O
of O
physiological O
processes O
as O
well O
as O
on O
the O
extensively O
debated O
molecular O
pathways O
underlying O
its O
biological O
activities O
. O

Analysis O
of O
both O
primary O
and O
secondary O
water O
molecule O
losses O
from O
each O
sized O
complex O
provides O
thermochemistry O
for O
the O
sequential O
hydration O
energies O
of O
Mg B
( I
2 I
+ I
) I
for O
x O
= O
2 O
- O
10 O
and O
the O
first O
experimental O
values O
for O
x O
= O
2 O
- O
4 O
. O

Boron B
- O
based O
inhibitors O
of O
acyl B
protein O
thioesterases O
1 O
and O
2 O
. O

Inhibition O
of O
the O
Ras O
- O
depalmitoylating O
enzyme O
acyl B
protein O
thioesterases O
APT1 O
and O
- O
2 O
is O
a O
new O
approach O
to O
modulating O
the O
Ras O
cycle O
. O

Three O
- O
Dimensional O
CdS B
- O
Titanate O
Composite O
Nanomaterials O
for O
Enhanced O
Visible O
- O
Light O
- O
Driven O
Hydrogen B
Evolution O
. O

3D O
Hierarchical O
echinus O
- O
like O
titanate O
spheres O
( O
HETSs O
) O
, O
serving O
as O
the O
supporting O
material O
for O
CdS B
nanoparticles O
, O
are O
synthesized O
via O
a O
fast O
one O
- O
step O
hydrothermal O
method O
. O

The O
obtained O
3D O
CdS B
- O
HETS O
composite O
materials O
show O
enhanced O
H2 B
generation O
under O
visible O
light O
irradiation O
. O

Here O
, O
we O
develop O
an O
improved O
version O
of O
FINDSITE O
, O
FINDSITE O
( O
filt O
) O
, O
that O
filters O
out O
false O
positive O
ligands O
in O
threading O
identified O
templates O
by O
a O
better O
binding O
site O
detection O
procedure O
that O
includes O
information O
about O
the O
binding O
site O
amino B
acid I
similarity O
. O

Polyethylenimine B
( O
PEI B
) O
is O
one O
of O
the O
most O
broadly O
used O
polycations O
for O
gene O
delivery O
due O
to O
its O
high O
transfection O
efficiency O
and O
commercial O
availability O
but O
materials O
are O
cytotoxic O
and O
often O
polydisperse O
. O

In O
this O
study O
, O
well O
- O
defined O
poly B
( I
glycidyl I
methacrylate I
) I
( O
P O
( O
GMA O
) O
) O
homopolymers O
were O
synthesized O
using O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
followed O
by O
decoration O
using O
three O
different O
types O
of O
oligoamines O
, O
i O
. O
e O
. O
, O
tetraethylenepentami B
( O
TEPA B
) O
, O
pentaethylenehexamin O
( O
PEHA O
) O
, O
and O
tris O
( O
2 O
- O
aminoethyl O
) O
amine O
( O
TREN O
) O
, O
respectively O
, O
to O
generate O
various O
P O
( O
GMA O
- O
oligoamine O
) O

The O
optimal O
polymer O
, O
P O
( O
GMA O
- O
TEPA O
) O
( O
50 O
) O
, O
provided O
comparable O
transfection O
efficiency O
but O
lower O
cytotoxicity O
than O
PEI B
. O

P O
( O
GMA O
- O
TEPA O
) O
( O
50 O
) O
was O
then O
used O
as O
the O
cationic O
block O
in O
diblock O
copolymers O
containing O
hydrophilic O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
and O
oligo O
( O
ethylene O
glycol O
) O
monomethyl O
ether O
methacrylate O
( O
OEGMA B
) O
. O

However O
, O
the O
presence O
of O
the O
HPMA B
/ O
OEGMA B
block O
significantly O
decreased O
the O
transfection O
efficacy O
of O
P O
( O
GMA O
- O
TEPA O
) O
( O
50 O
) O
homopolycation O
. O

PKAA O
was O
designed O
to O
have O
acid O
- O
cleavable O
ketal O
linkages O
in O
the O
backbone O
of O
cationic O
biodegradable O
poly B
( I
amidoamine I
) I
. O

A O
mouse O
model O
of O
acetaminophen B
( O
APAP B
) O
- O
induced O
acute O
liver O
failure O
was O
used O
to O
evaluate O
in O
vivo O
siRNA O
delivery O
efficacy O
of O
PKAA O
. O

PKAA O
/ O
anti O
- O
TNF O
- O
alpha O
siRNA O
nanocomplexes O
significantly O
reduced O
the O
ALT O
( O
alanine B
transaminase O
) O
and O
the O
hepatic O
cellular O
damages O
in O
APAP B
- O
intoxicated O
mice O
. O

5 O
' O
- O
Beta O
enzylglycinyl O
- O
amiloride O
( O
UCD38B O
) O
and O
glycinyl O
- O
amiloride O
( O
UCD74A O
) O
are O
cell O
- O
permeant O
and O
cell O
- O
impermeant O
derivatives O
of O
amiloride B
, O
respectively O
, O
and O
used O
here O
to O
identify O
the O
cellular O
mechanisms O
of O
action O
underlying O
their O
antiglioma O
effects O
. O

Cell O
impermeant O
UCD74A O
inhibits O
plasmalemmal O
urokinase O
plasminogen O
activator O
( O
uPA O
) O
and O
the O
type O
1 O
sodium B
- O
proton O
exchanger O
with O
potencies O
analogous O
to O
UCD38B O
, O
but O
is O
cytostatic O
. O

These O
drug O
mechanism O
of O
action O
studies O
demonstrate O
that O
UCD38B O
induces O
a O
cell O
cycle O
- O
independent O
, O
caspase O
- O
independent O
necroptotic O
glioma O
cell O
death O
that O
is O
mediated O
by O
AIF O
and O
independent O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
H2AX O
activation O
. O

The O
three O
- O
step O
approach O
of O
CliEn O
- O
seq O
involves O
in O
vivo O
synthesis O
of O
S O
- O
adenosyl O
- O
L O
- O
methionine O
( O
SAM B
) O
analogues O
from O
cell O
- O
permeable O
methionine B
analogues O
by O
engineered O
SAM B
synthetase O
( O
methionine B
adenosyltransferase O
or O
MAT O
) O
, O
in O
situ O
chromatin O
modification O
by O
engineered O
PMTs O
, O
subsequent O
enrichment O
and O
sequencing O
of O
the O
uniquely O
modified O
chromatins O
. O

PENs O
, O
which O
have O
segments O
that O
are O
either O
gold O
or O
" O
empty O
" O
( O
solvent O
- O
filled O
) O
surrounded O
by O
a O
silica B
shell O
, O
were O
produced O
from O
striped O
metal O
nanowires O
by O
first O
coating O
with O
silica B
and O
then O
removing O
sacrificial O
segments O
by O
acid O
etching O
. O

Thermoresponsive O
xyloglucan O
was O
produced O
after O
partial O
galactose B
removal O
by O
a O
24 O
h O
reaction O
with O
beta O
- O
galactosidase O
. O

The O
obtained O
polymer O
( O
T24 O
) O
was O
then O
activated O
by O
reaction O
with O
4 O
- O
nitrophenyl O
chloroformate O
( O
NPC O
) O
in O
order O
to O
graft O
a O
cyclic O
peptide O
presenting O
an O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
motif O
. O

The O
association O
constants O
for O
the O
formation O
of O
anion O
- O
pi O
complexes O
in O
acetonitrile B
are O
in O
the O
range O
of O
239 O
to O
16950 O
M O
( O
- O
1 O
) O
, O
following O
the O
order O
of O
1 O
. O
NO B
( I
3 I
) I
( I
- I
) I
> O
1 O
. O
BF O
( O
4 O
) O
( O
- O
) O
> O
1 O
. O
PF O
( O
6 O
) O
( O
- O
) O
> O
1 O
. O
SCN O
( O
- O
) O
. O

X O
- O
ray O
molecular O
structures O
of O
the O
complexes O
showed O
that O
two O
opposing O
triazine B
rings O
of O
tetraoxacalix O
[ O
2 O
] O
arene O
[ O
2 O
] O
triazine O
act O
as O
a O
pair O
of O
tweezers O
to O
interact O
with O
the O
included O
anions O
through O
cooperative O
anion O
- O
pi O
and O
lone O
- O
pair O
electron O
- O
pi O
interactions O
. O

Assessment O
of O
the O
antineoplastic O
potential O
of O
chalcones B
in O
animal O
models O
. O

One O
part O
of O
chemical O
space O
that O
is O
endowed O
with O
interesting O
biological O
properties O
is O
the O
area O
of O
the O
chalcones B
. O

With O
this O
review O
, O
we O
provide O
a O
comprehensive O
overview O
of O
the O
numerous O
in O
vivo O
animal O
studies O
on O
the O
antineoplastic O
potential O
of O
both O
natural O
and O
synthetic O
members O
of O
this O
flavonoid B
subclass O
( O
covering O
: O
up O
to O
mid O
- O
2011 O
) O
. O

We O
hope O
that O
this O
overview O
may O
stimulate O
deeper O
investigations O
into O
the O
biochemical O
mechanisms O
by O
which O
chalcones B
exert O
their O
antineoplastic O
action O
. O

As O
a O
result O
, O
in O
the O
foreseeable O
future O
, O
chalcones B
may O
prove O
suitable O
lead O
molecules O
or O
early O
drug O
candidates O
for O
the O
prevention O
or O
treatment O
of O
various O
neoplastic O
diseases O
. O

Copolymers O
containing O
moieties O
of O
similar O
pi O
- O
electron O
donating O
and O
/ O
or O
accepting O
capabilities O
, O
e O
. O
g O
. O
, O
thiophene B
( O
T O
) O
- O
methoxythiophene O
( O
OT O
) O
, O
exhibit O
a O
linear O
dependence O
of O
electronic O
properties O
( O
especially O
, O
HOMO O
/ O
LUMO O
, O
band O
gap O
, O
and O
bandwidth O
) O
on O
the O
D O
/ O
A O
content O
. O

In O
contrast O
, O
for O
strong O
D O
/ O
A O
contrast O
systems O
, O
e O
. O
g O
. O
, O
thiophene B
( O
T O
) O
- O
thienopyrazine O
( O
TP O
) O
, O
the O
electronic O
properties O
vary O
nonlinearly O
with O
D O
/ O
A O
compositions O
. O

Chemically O
induced O
reduction O
of O
proteasome O
activity O
was O
associated O
with O
lower O
glucose B
- O
stimulated O
insulin O
secretion O
, O
which O
was O
partly O
reproduced O
by O
palmitate O
exposure O
. O

Dual O
action O
spirobicycloimidazol O
- O
2 O
, O
4 O
- O
diones O
: O
antidiabetic O
agents O
and O
inhibitors O
of O
aldose B
reductase O
- O
an O
enzyme O
involved O
in O
diabetic O
complications O
. O

The O
synthesized O
compounds O
were O
screened O
for O
in O
vivo O
antidiabetic O
activity O
and O
aldose B
reductase O
inhibition O
. O

Here O
we O
identify O
the O
SWI O
/ O
SNF O
ATP B
- O
dependent O
nucleosome O
- O
remodeling O
complex O
as O
a O
component O
of O
the O
RNA O
- O
mediated O
transcriptional O
silencing O
pathway O
. O

We O
further O
propose O
that O
guiding O
ATP B
- O
dependent O
chromatin O
- O
remodeling O
complexes O
may O
be O
a O
more O
general O
function O
of O
lncRNAs O
. O

As O
a O
mechanism O
of O
action O
, O
the O
knockdown O
of O
TLR4 O
with O
small O
interfering O
RNA O
decreased O
the O
ADP O
- O
induced O
production O
of O
nitric B
oxide I
and O
IL O
- O
12 O
by O
DCs O
, O
suggesting O
the O
membrane O
receptor O
candidate O
of O
ADP O
. O

Poly O
( O
ethylene O
glycol O
) O
- O
block O
- O
poly O
( O
epsilon O
- O
caprolactone O
) O
micelles O
for O
combination O
drug O
delivery O
: O
evaluation O
of O
paclitaxel B
, O
cyclopamine O
and O
gossypol B
in O
intraperitoneal O
xenograft O
models O
of O
ovarian O
cancer O
. O

Poly O
( O
ethylene O
glycol O
) O
- O
block O
- O
poly O
( O
epsilon O
- O
caprolactone O
) O
( O
PEG O
- O
b O
- O
PCL O
) O
micelles O
were O
loaded O
with O
paclitaxel B
( O
cytotoxic O
agent O
) O
, O
cyclopamine O
( O
hedgehog O
inhibitor O
) O
, O
and O
gossypol B
( O
Bcl O
- O
2 O
inhibitor O
) O
. O

3 O
- O
Drug O
PEG O
- O
b O
- O
PCL O
micelles O
were O
not O
significantly O
more O
potent O
in O
2 O
- O
D O
cell O
culture O
in O
comparison O
to O
paclitaxel B
; O
however O
, O
they O
disaggregated O
ES O
- O
2 O
tumor O
spheroids O
, O
whereas O
single O
drugs O
or O
2 O
- O
drug O
combinations O
only O
slowed O
growth O
of O
ES O
- O
2 O
tumor O
spheroids O
or O
had O
no O
noticeable O
effects O
. O

In O
ES O
- O
2 O
and O
SKOV3 O
xenograft O
models O
, O
3 O
- O
drug O
PEG O
- O
b O
- O
PCL O
micelles O
had O
significantly O
less O
tumor O
burden O
than O
paclitaxel B
based O
on O
bioluminescence O
imaging O
, O
3 O
' O
- O
deoxy O
- O
3 O
' O
- O
( O
18 O
) O
F O
- O
fluorothymidine O
( O
( O
18 O
) O
F O
- O
FLT O
) O
PET O
imaging O
, O
and O
overall O
survival O
. O

( O
18 O
) O
F O
- O
FLT O
- O
PET O
images O
clearly O
showed O
that O
3 O
- O
drug O
PEG O
- O
b O
- O
PCL O
micelles O
dramatically O
reduce O
tumor O
volumes O
over O
paclitaxel B
and O
vehicle O
controls O
. O

In O
summary O
, O
PEG O
- O
b O
- O
PCL O
micelles O
enable O
the O
IP O
combination O
drug O
delivery O
of O
paclitaxel B
, O
cyclopamine O
and O
gossypol B
, O
resulting O
in O
tumor O
growth O
inhibition O
and O
prolonged O
survival O
over O
paclitaxel B
alone O
. O

The O
loss O
of O
facilitation O
is O
readily O
induced O
by O
physiologically O
relevant O
pairing O
protocols O
at O
immature O
synapses O
and O
is O
dependent O
on O
activation O
of O
NMDA B
- O
receptors O
but O
not O
L O
- O
type O
calcium B
channels O
. O

Development O
and O
evaluation O
of O
colloidal O
modified O
nanolipid O
carrier O
: O
Application O
to O
topical O
delivery O
of O
tacrolimus B
, O
Part O
II O
- O
In O
vivo O
assessment O
, O
drug O
targeting O
, O
efficacy O
, O
and O
safety O
in O
treatment O
for O
atopic O
dermatitis O
. O

Tacrolimus B
, O
although O
effective O
against O
AD O
, O
is O
a O
challenging O
molecule O
due O
to O
low O
solubility O
, O
low O
- O
penetration O
, O
poor O
- O
bioavailability O
, O
and O
toxicity O
. O

Part O
I O
of O
this O
paper O
, O
reported O
novel O
modified O
nanolipid O
carrier O
system O
for O
topical O
delivery O
of O
tacrolimus B
( O
T O
- O
MNLC O
) O
, O
offering O
great O
opportunity O
to O
load O
low O
- O
solubility O
drug O
with O
improved O
entrapment O
efficiency O
, O
enhanced O
stability O
and O
improved O
skin O
deposition O
. O

Results O
obtained O
exposing O
cells O
for O
72 O
h O
to O
AuNPs O
5 O
and O
15 O
nm O
citrate B
stabilized O
, O
revealed O
cytotoxic O
effects O
only O
for O
AuNPs O
5 O
nm O
at O
concentration O
> O
= O
50 O
mu O
M O
if O
measured O
by O
colony O
forming O
efficiency O
( O
CFE O
) O
. O

Ameliorating O
effects O
of O
extracellular O
polymeric O
substances O
excreted O
by O
Thalassiosira O
pseudonana O
on O
algal O
toxicity O
of O
CdSe B
quantum O
dots O
. O

Here O
, O
we O
examined O
the O
toxicity O
of O
functionalized O
CdSe B
/ O
ZnS B
QDs O
( O
amine B
- O
and O
carboxyl B
- O
) O
by O
exposing O
them O
for O
five O
days O
to O
Thalassiosira O
pseudonana O
( O
marine O
diatom O
) O
grown O
under O
different O
nutrient O
- O
conditions O
( O
enriched O
versus O
nitrogen B
- O
limited O
media O
) O
. O

The O
partitioning O
of O
QDs O
was O
analyzed O
by O
monitoring O
the O
concentration O
of O
Cd B
in O
different O
size O
fractions O
of O
the O
cultures O
( O
i O
. O
e O
. O
, O
filtrate O
, O
< O
0 O
. O
22 O
mu O
m O
and O
permeate O
, O
< O
3 O
kDa O
) O
. O

We O
found O
that O
the O
Cd B
release O
of O
QDs O
in O
the O
T O
. O
pseudonana O
culture O
was O
dependent O
on O
the O
nutrient O
conditions O
and O
nature O
of O
QDs O
' O
surface O
coating O
. O

Both O
amine B
- O
and O
carboxyl B
- O
functionalized O
QDs O
exhibited O
higher O
rates O
of O
Cd B
release O
in O
N O
- O
limited O
cultures O
than O
in O
nutrient O
enriched O
cultures O
. O

The O
results O
also O
showed O
that O
amine B
- O
functionalized O
QDs O
aggregate O
with O
minimal O
Cd B
release O
, O
independent O
of O
nutrient O
conditions O
. O

The O
increasing O
production O
of O
proteins O
induced O
by O
QDs O
suggests O
that O
extracellular O
proteins O
might O
be O
involved O
in O
the O
detoxification O
of O
QDs O
to O
T O
. O
pseudonana O
via O
the O
Cd B
release O
of O
QDs O
. O

17 B
beta I
estradiol I
regulation O
of O
connexin O
43 O
- O
based O
gap O
junction O
and O
mechanosensitivity O
through O
classical O
estrogen B
receptor O
pathway O
in O
osteocyte O
- O
like O
MLO O
- O
Y4 O
cells O
. O

Although O
estrogen B
involves O
in O
the O
adaptive O
responses O
of O
bone O
cells O
to O
mechanical O
loadings O
, O
its O
effects O
on O
osteocytic O
Cx43 O
- O
based O
gap O
junction O
intercellular O
communication O
( O
GJIC O
) O
remain O
obscure O
. O

We O
found O
that O
17 B
beta I
estradiol I
( O
E2 O
) O
up O
- O
regulated O
Cx43 O
, O
and O
enhanced O
GJIC O
in O
osteocyte O
- O
like O
MLO O
- O
Y4 O
cells O
in O
fluorescence O
recovery O
after O
photobleaching O
( O
FRAP O
) O
assay O
. O

Both O
blocking O
of O
classical O
estrogen B
receptors O
( O
ER O
alpha O
/ O
beta O
) O
by O
fulvestrant O
and O
ER O
alpha O
knockdown O
by O
small O
interfering O
RNA O
inhibited O
E2 O
- O
mediated O
Cx43 O
increase O
, O
while O
a O
GPR30 O
- O
specific O
agonist O
G O
- O
1 O
failed O
to O
promote O
Cx43 O
expression O
. O

Furthermore O
, O
the O
influence O
of O
doping O
different O
elements O
on O
the O
Sn B
position O
in O
this O
Heusler O
material O
system O
is O
investigated O
. O

Halogen B
- O
bonding O
- O
triggered O
supramolecular O
gel O
formation O
. O

The O
use O
of O
hydrogen B
bonding O
to O
assemble O
supramolecular O
gels O
in O
organic O
solvents O
is O
well O
established O
. O

In O
contrast O
, O
the O
use O
of O
halogen B
bonding O
to O
trigger O
supramolecular O
gel O
formation O
in O
a O
two O
- O
component O
gel O
( O
' O
co O
- O
gel O
' O
) O
is O
essentially O
unexplored O
, O
and O
forms O
the O
basis O
for O
this O
study O
. O

Here O
, O
we O
show O
that O
halogen B
bonding O
between O
a O
pyridyl B
substituent O
in O
a O
bis O
( O
pyridyl O
urea O
) O
and O
1 O
, O
4 O
- O
diiodotetrafluoroben O
brings O
about O
gelation O
, O
even O
in O
polar O
media O
such O
as O
aqueous O
methanol B
and O
aqueous O
dimethylsulfoxide B
. O

This O
demonstrates O
that O
halogen B
bonding O
is O
sufficiently O
strong O
to O
interfere O
with O
competing O
gel O
- O
inhibitory O
interactions O
and O
create O
a O
' O
tipping O
point O
' O
in O
gel O
assembly O
. O

Using O
this O
concept O
, O
we O
have O
prepared O
a O
halogen B
bond O
donor O
bis B
( I
urea I
) I
gelator O
that O
forms O
co O
- O
gels O
with O
halogen B
bond O
acceptors O
. O

Drug O
- O
drug O
interactions O
between O
rosuvastatin B
and O
oral O
antidiabetic O
drugs O
occurring O
at O
the O
level O
of O
OATP1B1 O
. O

Rosuvastatin B
is O
an O
OATP1B1 O
substrate O
and O
often O
concomitantly O
prescribed O
with O
oral O
antidiabetics O
in O
the O
clinic O
. O

Uptake O
of O
rosuvastatin B
in O
HEK O
- O
OATP1B1 O
cells O
( O
K O
( O
m O
) O
13 O
. O
1 O
+ O
/ O
- O
0 O
. O
43 O
mu O
M O
) O
was O
nearly O
absent O
in O
HEK O
- O
OATP1B1 O
* O
15 O
cells O
. O

Interestingly O
, O
several O
oral O
antidiabetics O
( O
glyburide O
, O
glimepiride O
, O
troglitazone B
, O
pioglitazone B
, O
glipizide O
, O
gliclazide B
, O
and O
tolbutamide B
) O
, O
but O
not O
metformin B
, O
were O
identified O
as O
significant O
inhibitors O
of O
the O
OATP1B1 O
- O
mediated O
transport O
of O
rosuvastatin B
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
several O
oral O
antidiabetic O
drugs O
affect O
the O
OATP1B1 O
- O
mediated O
uptake O
of O
rosuvastatin B
in O
vitro O
. O

The O
next O
step O
will O
be O
to O
translate O
these O
data O
to O
the O
clinical O
situation O
, O
as O
it O
remains O
to O
be O
established O
whether O
the O
studied O
oral O
antidiabetics O
indeed O
affect O
the O
clinical O
pharmacokinetic O
profile O
of O
rosuvastatin B
in O
patients O
. O

Optical O
and O
electrical O
detection O
of O
single O
- O
molecule O
translocation O
through O
carbon B
nanotubes O
. O

Ion O
current O
through O
a O
single O
- O
walled O
carbon B
nanotube O
( O
SWCNT O
) O
was O
monitored O
at O
the O
same O
time O
as O
fluorescence O
was O
recorded O
from O
charged O
dye O
molecules O
translocating O
through O
the O
SWCNT O
. O

Ion O
current O
peaks O
( O
as O
opposed O
to O
blockades O
) O
were O
produced O
by O
both O
positively O
( O
Rhodamine B
6G I
) O
and O
negatively O
( O
Alexa O
546 O
) O
charged O
molecules O
, O
showing O
that O
the O
charge O
filtering O
responsible O
for O
the O
current O
bursts O
is O
caused O
by O
the O
molecules O
themselves O
. O

Reduced O
antinociception O
of O
opioids O
in O
rats O
and O
mice O
by O
vaccination O
with O
immunogens O
containing O
oxycodone B
and O
hydrocodone O
haptens O
. O

An O
oxycodone B
hapten O
containing O
a O
tetraglycine O
linker O
at O
the O
C6 O
position O
( O
6OXY O
( O
Gly O
) O
( O
4 O
) O
OH O
) O
conjugated O
to O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
has O
shown O
early O
proof O
- O
of O
- O
efficacy O
in O
rodents O
as O
a O
candidate O
immunogen O
( O
6OXY O
( O
Gly O
) O
( O
4 O
) O
- O
KLH O
) O
for O
the O
treatment O
of O
oxycodone B
abuse O
. O

In O
this O
study O
, O
oxycodone B
- O
based O
and O
hydrocodone O
- O
based O
haptens O
were O
conjugated O
to O
KLH O
to O
generate O
immunogens O
that O
would O
recognize O
both O
oxycodone B
and O
hydrocodone O
. O

Vaccination O
with O
6OXY O
( O
Gly O
) O
( O
4 O
) O
- O
KLH O
increased O
drug O
binding O
in O
serum O
, O
reduced O
drug O
distribution O
to O
brain O
, O
and O
blunted O
analgesia O
for O
both O
oxycodone B
and O
hydrocodone O
. O

Amide B
conjugation O
showed O
higher O
haptenation O
ratios O
and O
greater O
efficacy O
than O
thioether B
conjugation O
to O
maleimide B
activated O
KLH O
( O
mKLH O
) O
. O

Interactions O
of O
NO2 B
with O
Zr O
- O
based O
MOF O
: O
effects O
of O
the O
size O
of O
organic O
linkers O
on O
NO2 B
adsorption O
at O
ambient O
conditions O
. O

Zirconium B
- O
based O
metal O
organic O
framework O
( O
Zr O
- O
MOF O
) O
, O
UiO O
- O
66 O
and O
UiO O
- O
67 O
, O
were O
synthesized O
and O
used O
as O
adsorbents O
of O
NO B
( I
2 I
) I
at O
ambient O
temperatures O
in O
either O
dry O
or O
moist O
conditions O
. O

The O
samples O
were O
characterized O
before O
and O
after O
exposure O
to O
NO B
( I
2 I
) I
by O
X O
- O
ray O
diffraction O
, O
scanning O
electron O
microscopy O
, O
N B
( I
2 I
) I
- O
adsorption O
at O
77 O
K O
, O
thermal O
analysis O
, O
and O
infrared O
spectroscopy O
. O

The O
results O
indicate O
the O
important O
effect O
of O
a O
ligand O
size O
on O
the O
adsorption O
of O
NO B
( I
2 I
) I
on O
Zr O
- O
MOF O
materials O
. O

While O
the O
large O
size O
of O
the O
4 O
, O
4 O
- O
benzenebiphenyldicar O
acid O
( O
BDPC O
) O
ligand O
has O
a O
positive O
impact O
on O
the O
adsorption O
of O
NO B
( I
2 I
) I
on O
UiO O
- O
67 O
in O
moist O
conditions O
, O
the O
opposite O
effect O
is O
found O
in O
dry O
conditions O
. O

The O
small O
pore O
sizes O
of O
UiO O
- O
66 O
favor O
the O
NO B
( I
2 I
) I
removal O
in O
dry O
conditions O
via O
dispersive O
forces O
. O

Upon O
interaction O
of O
NO B
( I
2 I
) I
molecules O
with O
the O
Zr O
- O
MOF O
in O
dry O
conditions O
, O
the O
bond O
between O
the O
organic O
linker O
and O
metallic O
oxide B
center O
is O
broken O
, O
leading O
to O
the O
formation O
of O
nitrate B
and O
nitrite B
species O
. O

Moreover O
, O
organic O
ligands O
also O
contribute O
to O
the O
NO B
( I
2 I
) I
reactive O
adsorption O
via O
nitration O
reaction O
. O

Androgens B
promote O
prostate O
cancer O
cell O
growth O
through O
induction O
of O
autophagy O
. O

Androgens B
regulate O
both O
the O
physiological O
development O
of O
the O
prostate O
and O
the O
pathology O
of O
prostatic O
diseases O
. O

However O
, O
the O
mechanisms O
by O
which O
androgens B
exert O
their O
regulatory O
activities O
on O
these O
processes O
are O
poorly O
understood O
. O

In O
this O
study O
, O
we O
have O
determined O
that O
androgens B
regulate O
overall O
cell O
metabolism O
and O
cell O
growth O
, O
in O
part O
, O
by O
increasing O
autophagy O
in O
prostate O
cancer O
cells O
. O

Importantly O
, O
inhibition O
of O
autophagy O
using O
either O
pharmacological O
or O
molecular O
inhibitors O
significantly O
abrogated O
androgen B
- O
induced O
prostate O
cancer O
cell O
growth O
. O

Mechanistically O
, O
androgen B
- O
mediated O
autophagy O
appears O
to O
promote O
cell O
growth O
by O
augmenting O
intracellular O
lipid O
accumulation O
, O
an O
effect O
previously O
demonstrated O
to O
be O
necessary O
for O
prostate O
cancer O
cell O
growth O
. O

Further O
, O
autophagy O
and O
subsequent O
cell O
growth O
is O
potentiated O
, O
in O
part O
, O
by O
androgen B
- O
mediated O
increases O
in O
reactive O
oxygen B
species O
. O

Regulation O
of O
H2O2 B
stress O
- O
responsive O
genes O
through O
a O
novel O
transcription O
factor O
in O
the O
protozoan O
pathogen O
Entamoeba O
histolytica O
. O

As O
part O
of O
the O
host O
' O
s O
innate O
immune O
response O
, O
the O
release O
of O
reactive O
oxygen B
and O
nitrogen B
species O
by O
phagocytes O
represents O
a O
major O
obstacle O
to O
the O
establishment O
of O
infection O
. O

The O
ability O
of O
the O
human O
parasite O
Entamoeba O
histolytica O
to O
survive O
reactive O
oxygen B
and O
nitrogen B
species O
is O
central O
to O
its O
pathogenic O
potential O
and O
contributes O
to O
disease O
outcome O
. O

In O
order O
to O
define O
the O
transcriptional O
network O
associated O
with O
oxidative O
stress O
, O
we O
utilized O
the O
MEME O
and O
MAST O
programs O
to O
analyze O
the O
promoter O
regions O
of O
57 O
amoebic O
genes O
that O
had O
increased O
expression O
specifically O
in O
response O
to O
H B
( I
2 I
) I
O I
( I
2 I
) I
exposure O
. O

We O
functionally O
characterized O
an O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
regulatory O
motif O
( O
HRM O
) O
( O
( O
1 O
) O
AAACCTCAATGAAGA O
( O
15 O
) O
) O
, O
which O
was O
enriched O
in O
these O
promoters O
and O
specifically O
bound O
amoebic O
nuclear O
protein O
( O
s O
) O
. O

Assays O
with O
promoter O
- O
luciferase O
fusions O
established O
the O
importance O
of O
key O
residues O
and O
that O
the O
HRM O
motif O
directly O
impacted O
the O
ability O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
responsive O
promoters O
to O
drive O
gene O
expression O
. O

Overexpression O
and O
down O
- O
regulation O
of O
EHI O
_ O
108720 O
demonstrated O
the O
specificity O
of O
EHI O
_ O
108720 O
protein O
binding O
to O
the O
HRM O
, O
and O
overexpression O
increased O
basal O
expression O
from O
an O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
responsive O
wild O
- O
type O
promoter O
but O
not O
from O
its O
mutant O
counterpart O
. O

Ceramides B
are O
sphingolipids B
that O
modulate O
a O
variety O
of O
cellular O
responses O
including O
cell O
death O
, O
autophagy O
, O
insulin O
signaling O
, O
and O
inflammation O
. O

In O
this O
study O
we O
investigated O
the O
intersection O
between O
TLR4 O
- O
mediated O
inflammatory O
signaling O
and O
saturated B
fatty I
acids I
with O
regard O
to O
ceramide O
generation O
. O

Primary O
macrophages O
treated O
with O
lipopolysaccharide O
( O
LPS O
) O
did O
not O
produce O
C16 O
ceramide O
, O
whereas O
palmitate O
exposure O
led O
to O
a O
modest O
increase O
in O
this O
sphingolipid B
. O

The O
through O
- O
space O
spin O
- O
spin O
couplings O
between O
( B
19 I
) I
F I
and O
( B
1 I
) I
H I
/ O
( B
13 I
) I
C I
nuclei O
have O
been O
observed O
in O
solution O
. O

When O
ether B
vapor O
was O
allowed O
to O
diffuse O
into O
a O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solution O
of O
an O
enantiomer O
of O
a O
hexa O
- O
peri O
- O
hexabenzocoronene O
( O
HBC O
) O
derivative O
carrying O
a O
chiral O
( O
BINAP O
) O
Pt O
( O
II O
) O
- O
appended O
coordination O
metallacycle O
( O
HBC O
( O
Py O
) O
( O
[ O
( O
R O
) O
- O
Pt O
] O
) O
or O
HBC O
( O
Py O
) O
( O
[ O
( O
S O
) O
- O
Pt O
] O
) O
) O
, O
screw O
- O
sense O
- O
selective O
assembly O
took O
place O
to O
give O
optically O
active O
nanotubes O
( O
NT O
( O

Py B
) O
( O
[ O
( O
R O
) O
- O
Pt O
] O
) O
or O
NT O
( O
Py B
) O
( O
[ O
( O
S O
) O
- O
Pt O
] O
) O
) O
with O
helical O
chirality O
, O
which O
were O
enriched O
in O
either O
left O
- O
handed O
( O
M O
) O
- O
NT O
( O
Py B
) O
( O
[ O
( O
R O
) O
- O
Pt O
] O
) O
or O
right O
- O
handed O
( O
P O
) O
- O
NT O
( O
Py B
) O
( O
[ O
( O
S O
) O
- O
Pt O
] O
) O
, O
depending O
on O
the O
absolute O
configuration O
of O
the O
( O
BINAP O
) O
Pt O
( O
II O
) O
pendant O
. O

When O
MeOH B
was O
used O
instead O
of O
ether O
for O
the O
vapor O
- O
diffusion O
- O
induced O
assembly O
, O
nanocoils O
formed O
along O
with O
the O
nanotubes O
. O

Removal O
of O
the O
( O
BINAP O
) O
Pt O
( O
II O
) O
pendants O
from O
NT O
( O
Py B
) O
( O
[ O
( O
R O
) O
- O
Pt O
] O
) O
or O
NT O
( O
Py B
) O
( O
[ O
( O
S O
) O
- O
Pt O
] O
) O
with O
ethylenediamine O
yielded O
metal O
- O
free O
nanotubes O
( O
NT O
( O
Py B
) O
) O
that O
remained O
optically O
active O
even O
upon O
heating O
without O
any O
change O
in O
the O
circular O
dichroism O
spectral O
profile O
. O

No O
helical O
inversion O
took O
place O
when O
NT O
( O
Py B
) O
derived O
from O
HBC O
( O
Py O
) O
( O
[ O
( O
R O
) O
- O
Pt O
] O
) O
or O
HBC O
( O
Py O
) O
( O
[ O
( O
S O
) O
- O
Pt O
] O
) O
was O
allowed O
to O
complex O
with O
( O
BINAP O
) O
Pt O
( O
II O
) O
with O
an O
absolute O
configuration O
opposite O
to O
the O
original O
one O
. O

Chemical O
Modification O
of O
Lysozyme O
, O
Glucose B
6 I
- I
Phosphate I
Dehydrogenase O
, O
and O
Bovine O
Eye O
Lens O
Proteins O
Induced O
by O
Peroxyl B
Radicals O
: O
Role O
of O
Oxidizable O
Amino B
Acid I
Residues O
. O

Chemical O
and O
structural O
alterations O
to O
lysozyme O
( O
LYSO O
) O
, O
glucose B
6 I
- I
phosphate I
dehydrogenase O
( O
G6PD O
) O
, O
and O
bovine O
eye O
lens O
proteins O
( O
BLP O
) O
promoted O
by O
peroxyl B
radicals O
generated O
by O
the O
thermal O
decomposition O
of O
2 O
, O
2 O
' O
- O
azobis O
( O
2 O
- O
amidinopropane O
) O
hydrochloride O
( O
AAPH B
) O
under O
aerobic O
conditions O
were O
investigated O
. O

SDS B
- O
PAGE O
analysis O
of O
the O
AAPH B
- O
treated O
proteins O
revealed O
the O
occurrence O
of O
protein O
aggregation O
, O
cross O
- O
linking O
, O
and O
fragmentation O
; O
BLP O
, O
which O
are O
naturally O
organized O
in O
globular O
assemblies O
, O
were O
the O
most O
affected O
proteins O
. O

Transmission O
electron O
microscopy O
( O
TEM O
) O
analysis O
of O
BLP O
shows O
the O
formation O
of O
complex O
protein O
aggregates O
after O
treatment O
with O
AAPH B
. O

These O
structural O
modifications O
were O
accompanied O
by O
the O
formation O
of O
protein O
carbonyl B
groups O
and O
protein O
hydroperoxides O
. O

The O
yield O
of O
carbonyls B
was O
lower O
than O
that O
for O
protein O
hydroperoxide B
generation O
and O
was O
unrelated O
to O
protein O
fragmentation O
. O

The O
oxidized O
proteins O
were O
also O
characterized O
by O
significant O
oxidation O
of O
Met B
, O
Trp B
, O
and O
Tyr B
( O
but O
not O
other O
) O
residues O
, O
and O
low O
levels O
of O
dityrosine O
. O

As O
the O
dityrosine O
yield O
is O
too O
low O
to O
account O
for O
the O
observed O
cross O
- O
linking O
, O
we O
propose O
that O
aggregation O
is O
associated O
with O
tryptophan B
oxidation O
and O
Trp B
- O
derived O
cross O
- O
links O
. O

It O
is O
also O
proposed O
that O
Trp B
oxidation O
products O
play O
a O
fundamental O
role O
in O
nonrandom O
fragmentation O
and O
carbonyl B
group O
formation O
particularly O
for O
LYSO O
and O
G6PD O
. O

These O
data O
point O
to O
a O
complex O
mechanism O
of O
peroxyl B
- O
radical O
mediated O
modification O
of O
proteins O
with O
monomeric O
( O
LYSO O
) O
, O
dimeric O
( O
G6PD O
) O
, O
and O
multimeric O
( O
BLP O
) O
structural O
organization O
, O
which O
not O
only O
results O
in O
oxidation O
of O
protein O
side O
chains O
but O
also O
gives O
rise O
to O
radical O
- O
mediated O
protein O
cross O
- O
links O
and O
fragmentation O
, O
with O
Trp B
species O
being O
critical O
intermediates O
. O

We O
have O
used O
DSF O
to O
demonstrate O
that O
the O
binding O
of O
these O
compounds O
is O
independent O
of O
the O
presence O
or O
absence O
of O
the O
C B
- O
terminal O
tail O
region O
of O
CDK9 O
, O
unlike O
the O
binding O
of O
the O
CDK9 O
- O
selective O
inhibitor O
5 O
, O
6 O
- O
dichlorobenzimidazon O
- O
1 O
- O
beta O
- O
d O
- O
ribofuranoside O
( O
DRB O
) O
. O

INTRODUCTION O
: O
The O
mTOR O
( O
mechanistic O
target O
of O
rapamycin B
, O
formerly O
known O
as O
mammalian O
target O
of O
rapamycin B
) O
kinase O
is O
centrally O
involved O
in O
the O
regulation O
of O
cell O
growth O
and O
metabolism O
in O
response O
to O
intra O
- O
and O
extracellular O
energetic O
stimuli O
and O
growth O
factors O
. O

The O
importance O
of O
mTOR O
in O
health O
and O
diseases O
has O
fueled O
the O
development O
of O
molecules O
that O
inhibit O
mTOR O
signaling O
, O
including O
rapalogs O
( O
sirolimus B
, O
temsirolimus O
, O
everolimus O
and O
deforolimus O
) O
, O
which O
complex O
with O
FK506 O
- O
binding O
protein O
12 O
( O
FK O
- O
BP12 O
) O
to O
inhibit O
mTOR O
complex O
1 O
( O
MTORC1 O
) O
activity O
in O
an O
allosteric O
manner O
, O
or O
the O
more O
recent O
ATP B
- O
competitive O
mTOR O
inhibitors O
( O
mTORi O
) O
, O
which O
target O
the O
catalytic O
site O
of O
the O
enzyme O
. O

Zhou O
and O
co O
- O
workers O
( O
Zhou O
et O
al O
. O
, O
Nano O
Lett O
. O
2008 O
, O
8 O
( O
3 O
) O
, O
859 O
- O
865 O
) O
designed O
, O
synthesized O
, O
and O
tested O
a O
combinatorial O
library O
of O
80 O
surface O
modified O
, O
that O
is O
decorated O
, O
multi O
- O
walled O
carbon B
nanotubes O
for O
their O
composite O
nanotoxicity O
using O
six O
endpoints O
all O
based O
on O
a O
common O
0 O
to O
100 O
activity O
scale O
. O

This O
critical O
commentary O
reviews O
scanning O
techniques O
, O
which O
employ O
natural O
and O
non O
- O
proteinogenic O
amino B
acids I
to O
facilitate O
understanding O
of O
structural O
requirements O
for O
peptide O
biological O
activity O
. O

In O
the O
male O
brain O
, O
the O
medial O
preoptic O
nucleus O
( O
POM O
) O
is O
known O
to O
be O
a O
critical O
relay O
for O
the O
activation O
of O
sexual O
behaviour O
, O
with O
the O
aromatisation O
of O
testosterone B
into O
17 B
beta I
- I
oestradiol I
( O
E2 O
) O
playing O
a O
key O
role O
. O

By O
examining O
the O
relative O
effects O
of O
corticosterone B
( O
CORT B
) O
, O
arginine O
vasotocin O
( O
AVT O
, O
the O
avian O
homologue O
to O
arginine B
vasopressin I
) O
and O
corticotrophin O
- O
releasing O
factor O
( O
CRF O
) O
, O
the O
present O
study O
aimed O
to O
define O
the O
hormone O
profile O
regulating O
stress O
- O
induced O
increases O
in O
AA O
in O
the O
POM O
. O

We O
found O
that O
CORT B
, O
AVT O
and O
CRF O
all O
appear O
to O
play O
some O
role O
in O
these O
changes O
in O
the O
male O
brain O
. O

These O
data O
further O
demonstrate O
the O
high O
degree O
of O
specificity O
( O
nuclei O
- O
, O
sex O
- O
and O
hormone O
- O
specific O
effects O
) O
in O
this O
system O
, O
highlighting O
the O
complexity O
of O
the O
stress O
- O
aromatase O
link O
and O
suggesting O
modes O
through O
which O
the O
nongenomic O
modulation O
of O
this O
enzyme O
can O
result O
in O
targeted O
, O
rapid O
changes O
in O
local O
oestrogen B
concentrations O
. O

CTLL O
- O
2 O
cells O
were O
exposed O
for O
6 O
h O
to O
two O
model O
immunotoxic O
compounds O
: O
( O
1 O
) O
the O
mycotoxin O
deoxynivalenol B
( O
DON B
, O
1 O
and O
2 O
mu O
M O
) O
, O
a O
ribotoxic O
stress O
inducer O
, O
and O
( O
2 O
) O
the O
organotin B
compound O
tributyltin O
oxide O
( O
TBTO O
, O
100 O
and O
200 O
nM O
) O
, O
an O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
inducer O
. O

Remarkably O
, O
DON B
( O
2 O
mu O
M O
) O
downregulated O
genes O
involved O
in O
T O
cell O
activation O
, O
ER O
stress O
and O
apoptosis O
, O
which O
is O
opposite O
to O
results O
obtained O
before O
for O
DON B
- O
exposed O
Jurkat O
cells O
and O
mouse O
primary O
thymocytes O
. O

Furthermore O
, O
the O
results O
for O
DON B
in O
CTLL O
- O
2 O
cells O
are O
also O
opposite O
to O
the O
results O
obtained O
for O
TBTO O
in O
CTLL O
- O
2 O
cells O
. O

In O
agreement O
with O
the O
lack O
of O
induction O
of O
ER O
stress O
and O
apoptosis O
, O
viability O
assays O
showed O
that O
CTLL O
- O
2 O
cells O
are O
much O
more O
resistant O
to O
the O
toxicity O
of O
DON B
than O
Jurkat O
cells O
and O
primary O
thymocytes O
. O

Based O
on O
the O
results O
for O
TBTO O
and O
DON B
, O
the O
CTLL O
- O
2 O
cell O
line O
does O
not O
yield O
an O
added O
value O
for O
immunotoxicity O
compared O
to O
the O
human O
Jurkat O
T O
cell O
line O
. O

These O
species O
were O
produced O
upon O
electron O
bombardment O
of O
a O
mixture O
of O
naphthalene B
( O
C O
( O
10 O
) O
H O
( O
8 O
) O
) O
and O
p O
- O
H O
( O
2 O
) O
during O
matrix O
deposition O
. O

Compared O
with O
spectra O
recorded O
previously O
with O
IR O
photodissociation O
of O
Ar B
- O
tagged O
C O
( O
10 O
) O
H O
( O
9 O
) O
( O
+ O
) O
or O
IR O
multiphoton O
dissociation O
of O
C O
( O
10 O
) O
H O
( O
9 O
) O
( O
+ O
) O
, O
our O
method O
has O
the O
advantages O
of O
producing O
high O
- O
resolution O
IR O
spectra O
with O
a O
wide O
spectral O
coverage O
, O
true O
IR O
intensity O
and O
excellent O
ratio O
of O
signal O
to O
noise O
; O
both O
protonated O
species O
and O
their O
neutral O
counterparts O
are O
produced O
with O
little O
interference O
from O
other O
fragments O
. O

Further O
study O
on O
other O
Oatp1a2 O
substrates O
showed O
that O
the O
high O
affinity O
component O
for O
E O
- O
3 O
- O
S O
is O
responsible O
for O
the O
interaction O
with O
taurocholate B
, O
bromsulphthalein O
, O
and O
rifampicin B
and O
is O
sensitive O
to O
proton O
concentration O
change O
, O
whereas O
the O
low O
affinity O
binding O
site O
is O
only O
involved O
in O
the O
binding O
of O
the O
antitumor O
drug O
methotrexate B
and O
had O
no O
response O
to O
change O
of O
pH O
. O

The O
in O
vitro O
anticancer O
effects O
of O
this O
salt O
were O
evaluated O
in O
HCT O
- O
116 O
human O
colon O
cancer O
cells O
using O
a O
3 O
- O
( O
4 O
, O
5 O
- O
dimethyl O
- O
2 O
- O
thiazolyl O
) O
- O
2 O
, O
5 O
- O
diphenyltetrazolium O
bromide O
( O
MTT B
) O
assay O
. O

HldA O
is O
structurally O
similar O
to O
members O
of O
the O
PfkB O
carbohydrate B
kinase O
family O
and O
appears O
to O
catalyze O
heptose O
phosphorylation O
via O
an O
in O
- O
line O
mechanism O
mediated O
mainly O
by O
a O
conserved O
aspartate B
, O
Asp270 O
. O

Moreover O
, O
we O
report O
the O
structures O
of O
HldA O
in O
complex O
with O
two O
potent O
inhibitors O
in O
which O
both O
inhibitors O
adopt O
a O
folded O
conformation O
and O
occupy O
the O
nucleotide B
- O
binding O
sites O
. O

Novel O
betulinic B
acid I
derivative O
5 O
' O
- O
chloro O
- O
2 O
, O
3 O
- O
didehydroindolo O
[ O
2 O
' O
, O
3 O
' O
: O
2 O
, O
3 O
] O
betulinic O
acid O
( O
DRF O
- O
4012 O
) O
is O
a O
new O
effective O
lupane O
type O
triterpenes B
with O
greater O
anticancer O
activity O
and O
efficacy O
than O
betulinic B
acid I
and O
currently O
under O
advanced O
preclinical O
investigation O
phase O
. O

Incubation O
of O
luotonin O
A O
with O
pooled O
human O
liver O
microsomes O
in O
the O
presence O
of O
NADPH B
- O
generating O
system O
resulted O
in O
the O
formation O
of O
four O
metabolites O
and O
the O
structures O
of O
each O
metabolite O
were O
tentatively O
characterized O
on O
the O
basis O
of O
electrospray O
tandem O
mass O
spectra O
. O

CYP1A2 O
was O
primarily O
involved O
in O
hydroxylation O
of O
the O
quinolone B
moiety O
( O
M1 O
andM3 O
) O
, O
while O
CYP3A4 O
was O
mainly O
responsible O
for O
hydroxylation O
of O
the O
quinazoline B
moiety O
of O
luotonin O
A O
( O
M2 O
and O
M4 O
) O
in O
human O
liver O
microsomes O
. O

The O
measurement O
conditions O
for O
the O
radioactivity O
for O
low O
BG O
LSC O
were O
investigated O
and O
metabolite O
profiling O
in O
rat O
plasma O
after O
single O
oral O
administration O
of O
( B
14 I
) I
C I
- O
labeled O
compounds O
was O
performed O
. O

Kisspeptin O
is O
a O
54 O
- O
amino B
acid I
peptide O
which O
is O
encoded O
by O
the O
KiSS O
- O
1 O
gene O
and O
activates O
the O
G O
protein O
- O
coupled O
receptor O
GPR54 O
. O

In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
( O
LH O
) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O
( O
FSH O
) O
and O
testosterone B
without O
side O
effects O
in O
both O
males O
and O
in O
females O
particularly O
in O
the O
preovulatatory O
phase O
of O
the O
menstrual O
cycle O
. O

Molecular O
nonwoven O
fabrics O
in O
the O
form O
of O
ultrathin O
layer O
- O
by O
- O
layer O
( O
LbL O
) O
helical O
polymer O
films O
with O
covalent O
cross O
- O
linking O
were O
assembled O
on O
substrates O
by O
an O
alternate O
ester B
- O
amide B
exchange O
reaction O
between O
poly O
( O
gamma O
- O
methyl O
l O
- O
glutamate O
) O
( O
PMLG O
) O
and O
cross O
- O
linking O
agent O
ethylene O
diamine O
or O
4 O
, O
4 O
' O
- O
diamino O
azobenzene O
. O

The O
regular O
growth O
of O
helical O
monolayers O
without O
excessive O
adsorption O
and O
the O
formation O
of O
amide B
bonds O
were O
confirmed O
by O
ultraviolet O
- O
visible O
( O
UV O
- O
vis O
) O
spectrophotometry O
, O
quartz B
crystal O
microbalance O
( O
QCM O
) O
, O
ellipsometry O
, O
and O
infrared O
reflection O
- O
absorption O
spectroscopy O
( O
IR O
- O
RAS O
) O
measurements O
. O

The O
ages O
of O
divergence O
of O
the O
main O
lineages O
and O
the O
crown O
age O
of O
the O
subfamily O
were O
estimated O
by O
using O
sequences O
of O
the O
interphotoreceptor O
retinoid B
binding O
protein O
and O
cytochrome O
b O
genes O
for O
a O
dense O
sigmodontine O
and O
muroid O
sampling O
. O

Genipin B
stimulates O
glucose B
transport O
in O
C2C12 O
myotubes O
via O
an O
IRS O
- O
1 O
and O
calcium B
- O
dependent O
mechanism O
. O

Genipin B
, O
a O
compound O
derived O
from O
Gardenia O
jasminoides O
Ellis O
fruits O
, O
has O
been O
used O
over O
the O
years O
in O
traditional O
Chinese O
medicine O
to O
treat O
symptoms O
of O
type O
2 O
diabetes O
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
genipin B
on O
glucose B
uptake O
and O
signaling O
pathways O
in O
C O
( O
2 O
) O
C O
( O
12 O
) O
myotubes O
. O

Our O
study O
demonstrates O
that O
genipin B
stimulated O
glucose B
uptake O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

In O
myotubes O
, O
genipin B
promoted O
glucose B
transporter O
4 O
( O
GLUT4 O
) O
translocation O
to O
the O
cell O
surface O
, O
which O
was O
observed O
by O
analyzing O
their O
distribution O
in O
subcellular O
membrane O
fraction O
, O
and O
increased O
the O
phosphorylation O
of O
insulin O
receptor O
substrate O
- O
1 O
( O
IRS O
- O
1 O
) O
, O
AKT O
, O
and O
GSK3 O
beta O
. O

Meanwhile O
, O
genipin B
increased O
ATP B
levels O
, O
closed O
K B
( O
ATP B
) O
channels O
, O
and O
then O
increased O
the O
concentration O
of O
calcium B
in O
the O
cytoplasm O
in O
C O
( O
2 O
) O
C O
( O
12 O
) O
myotubes O
. O

Genipin B
- O
stimulated O
glucose B
uptake O
could O
be O
blocked O
by O
both O
the O
PI3 O
- O
K O
inhibitor O
wortmannin B
and O
calcium B
chelator O
EGTA B
. O

Moreover O
, O
genipin B
increases O
the O
level O
of O
reactive O
oxygen B
species O
and O
ATP B
in O
C O
( O
2 O
) O
C O
( O
12 O
) O
myotubes O
. O

These O
results O
suggest O
that O
genipin B
activates O
IRS O
- O
1 O
, O
PI3 O
- O
K O
, O
and O
downstream O
signaling O
pathway O
and O
increases O
concentrations O
of O
calcium B
, O
resulting O
in O
GLUT4 O
translocation O
and O
glucose B
uptake O
increase O
in O
C O
( O
2 O
) O
C O
( O
12 O
) O
myotubes O
. O

Electrophoresis O
of O
randomly O
and O
vertically O
embedded O
graphene B
nanosheets O
in O
activated O
carbon B
film O
as O
a O
counter O
electrode O
for O
dye O
- O
sensitized O
solar O
cells O
. O

A O
new O
approach O
has O
been O
developed O
to O
randomly O
and O
vertically O
embed O
the O
graphene B
nanosheets O
( O
GNs O
) O
in O
the O
activated O
carbon B
( O
AC O
) O
film O
in O
an O
applied O
electric O
field O
. O

The O
activated O
carbon B
( O
AC O
) O
nanoparticles O
in O
suspension O
during O
electrophoresis O
play O
an O
important O
role O
in O
supporting O
the O
GNs O
perpendicular O
to O
the O
FTO B
( O
fluorine O
- O
doped O
tin O
oxide O
) O
glass O
. O

Insufficient O
amount O
of O
AC O
nanoparticles O
might O
result O
in O
a O
deposition O
of O
GNs O
parallel O
to O
the O
FTO B
glass O
, O
leading O
to O
incomplete O
utilization O
of O
the O
surface O
area O
accessible O
to O
electrolyte O
ions O
. O

Heterogeneous O
oxidation O
of O
a O
phosphocholine O
on O
synthetic O
sea O
salt O
by O
ozone B
at O
room O
temperature O
. O

The O
ozonolysis O
of O
1 O
- O
palmitoyl O
- O
2 O
- O
oleoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
( O
POPC B
) O
adsorbed O
on O
salt O
mixtures O
as O
models O
for O
sea O
- O
salt O
particles O
was O
studied O
in O
real O
time O
using O
diffuse O
reflection O
infrared O
Fourier O
transform O
spectrometry O
( O
DRIFTS O
) O
at O
room O
temperature O
with O
and O
without O
added O
water O
vapor O
. O

The O
salt O
substrates O
were O
a O
mixture O
of O
MgCl O
( O
2 O
) O
. O
6H O
( O
2 O
) O
O O
with O
NaCl B
or O
a O
commercially O
available O
synthetic O
sea O
salt O
. O

Ozone B
concentrations O
ranged O
from O
( O
0 O
. O
25 O
to O
3 O
. O
9 O
) O
x O
10 O
( O
13 O
) O
molecules O
cm O
( O
- O
3 O
) O
( O
0 O
. O
1 O
- O
1 O
. O
6 O
ppm O
) O
. O

The O
major O
products O
identified O
by O
FTIR O
and O
confirmed O
using O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
( O
MALDI O
) O
mass O
spectrometry O
were O
the O
secondary O
ozonide O
( O
SOZ O
) O
and O
a O
phospholipid O
aldehyde B
and O
carboxylic B
acid I
formed O
by O
scission O
of O
the O
double O
bond O
. O

The O
presence O
of O
water O
vapor O
decreased O
the O
yield O
of O
SOZ O
relative O
to O
the O
products O
formed O
by O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
C B
scission O
, O
but O
also O
increased O
the O
availability O
of O
the O
double O
bond O
for O
reaction O
, O
particularly O
on O
the O
less O
hygroscopic O
commercial O
sea O
- O
salt O
substrate O
. O

We O
find O
that O
: O
( O
i O
) O
Ti B
and O
Cu B
in O
( O
TiO O
( O
2 O
) O
) O
( O
x O
) O
( O
Cu O
( O
2 O
) O
O O
) O
( O
y O
) O
alloys O
have O
similar O
local O
environments O
as O
in O
bulk O
TiO B
( I
2 I
) I
and O
Cu O
( O
2 O
) O
O O
except O
for O
( O
TiO B
( I
2 I
) I
) O
( O
Cu O
( O
2 O
) O
O O
) O
which O
has O
some O
trigonal O
- O
planar O
Cu B
ions O
. O

( O
ii O
) O
The O
predicted O
optical O
band O
gaps O
are O
around O
2 O
. O
1 O
eV O
( O
590 O
nm O
) O
, O
thus O
having O
much O
better O
performance O
in O
the O
absorption O
of O
visible O
light O
compared O
with O
both O
binary O
oxides B
. O

In O
this O
work O
, O
we O
show O
for O
the O
first O
time O
4 O
- O
fold O
tuning O
of O
unfolded O
, O
single O
- O
file O
translocation O
time O
through O
small O
, O
amine B
- O
functionalized O
solid O
- O
state O
nanopores O
by O
varying O
the O
solution O
pH O
in O
situ O
. O

The O
chemical O
universe O
database O
GDB O
- O
17 O
contains O
166 O
. O
4 O
billion O
molecules O
of O
up O
to O
17 O
atoms O
of O
C B
, O
N B
, O
O B
, O
S B
, O
and O
halogens B
obeying O
rules O
for O
chemical O
stability O
, O
synthetic O
feasibility O
, O
and O
medicinal O
chemistry O
. O

Tailorable O
cell O
culture O
platforms O
from O
enzymatically O
cross O
- O
linked O
multifunctional O
poly B
( I
ethylene I
glycol I
) I
- O
based O
hydrogels O
. O

Herein O
we O
describe O
a O
process O
for O
making O
hydrogels O
composed O
of O
hydroxyphenyl O
propionic O
acid O
( O
HPA O
) O
conjugated O
, O
branched O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
via O
an O
enzyme O
mediated O
, O
oxidative O
cross O
- O
linking O
method O
. O

Functionalization O
of O
the O
branched O
PEG B
with O
HPA O
at O
varying O
degrees O
of O
substitution O
was O
confirmed O
via O
attenuated O
total O
reflectance O
Fourier O
transform O
infrared O
spectroscopy O
( O
ATR O
- O
FTIR O
) O
and O
( B
1 I
) I
H I
NMR O
. O

The O
versatility O
of O
this O
hydrogel O
system O
was O
exemplified O
through O
variations O
in O
the O
degree O
of O
HPA O
substitution O
, O
polymer O
concentration O
, O
and O
the O
concentration O
of O
cross O
- O
linking O
reagents O
( O
horseradish O
peroxidase O
and O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
, O
which O
resulted O
in O
a O
range O
of O
mechanical O
properties O
and O
gelation O
kinetics O
for O
these O
gels O
. O

The O
main O
biological O
functions O
of O
these O
173 O
genes O
include O
signaling O
by O
Nerve O
Growth O
Factor O
, O
DNA O
Repair O
, O
Integrin O
Cell O
Surface O
Interactions O
, O
Biological O
Oxidations O
, O
Apoptosis O
, O
Synaptic O
Transmission O
, O
Cell O
Cycle O
Checkpoints O
, O
and O
Arachidonic B
Acid I
Metabolism O
. O

Central O
nervous O
system O
damage O
due O
to O
acute O
paraquat B
poisoning O
: O
an O
experimental O
study O
with O
rat O
model O
. O

Paraquat B
( O
PQ O
) O
is O
a O
common O
herbicide O
and O
PQ O
poisoning O
is O
a O
major O
medical O
problem O
in O
Asia O
. O

In O
SN O
and O
hippocampus O
, O
we O
detected O
increased O
oxidative O
stress O
in O
the O
neurons O
based O
on O
NeuN O
/ O
8 B
- I
OHdG I
immunofluorescence O
double O
labeling O
and O
laser O
cofocal O
microscopy O
. O

The O
uptake O
and O
distribution O
of O
selenium B
in O
three O
aquatic O
plants O
grown O
in O
Se B
( I
IV I
) I
solution O
. O

The O
uptake O
of O
Se B
( I
IV I
) I
by O
Myriophyllum O
spicatum O
, O
Ceratophyllum O
demersum O
and O
Potamogeton O
perfoliatus O
, O
and O
the O
effects O
of O
Se B
( I
IV I
) I
on O
their O
physiological O
and O
biochemical O
characteristics O
were O
studied O
. O

Plants O
were O
cultivated O
outdoors O
under O
semi O
- O
controlled O
conditions O
in O
water O
solution O
containing O
Na O
selenite O
( O
20 O
mu O
g O
Se B
L O
( O
- O
1 O
) O
and O
10 O
mg O
Se B
L O
( O
- O
1 O
) O
) O
. O

The O
higher O
concentration O
of O
Se B
lowered O
the O
photochemical O
efficiency O
of O
PSII O
in O
all O
species O
studied O
, O
while O
the O
lower O
concentration O
had O
no O
effect O
on O
any O
species O
. O

The O
higher O
concentration O
of O
Se B
lowered O
respiratory O
potential O
in O
M O
. O
spicatum O
. O

The O
response O
of O
M O
. O
spicatum O
and O
C O
. O
demersum O
to O
Se B
( I
IV I
) I
regarding O
chlorophylls B
was O
variable O
, O
however O
in O
the O
majority O
of O
cases O
, O
there O
was O
a O
trend O
of O
increasing O
the O
amount O
of O
chlorophylls B
, O
while O
in O
P O
. O
perfoliatus O
the O
amount O
of O
chlorophyll B
a I
decreased O
. O

The O
concentration O
of O
Se B
in O
plants O
cultured O
in O
10 O
mg O
Se B
( I
IV I
) I
L O
( O
- O
1 O
) O
ranged O
from O
436 O
to O
839 O
mu O
g O
Se B
g O
( O
- O
1 O
) O
DM O
in O
M O
. O
spicatum O
, O
319 O
to O
988 O
mu O
g O
Se B
g O
( O
- O
1 O
) O
DM O
in O
C O
. O
demersum O
and O
310 O
to O
661 O
mu O
g O
Se B
g O
( O
- O
1 O
) O
DM O
in O
P O
. O
perfoliatus O
. O

The O
amount O
of O
soluble O
Se B
compounds O
in O
enzyme O
extracts O
of O
high O
Se B
treatment O
was O
27 O
% O
in O
M O
. O
spicatum O
, O
41 O
% O
in O
C O
. O
demersum O
and O
35 O
% O
in O
P O
. O
perfoliatus O
. O

Se B
compounds O
were O
determined O
using O
HPLC O
- O
ICP O
- O
MS O
. O

It O
was O
observed O
that O
the O
applied O
Se B
( I
IV I
) I
was O
mainly O
transformed O
to O
insoluble O
Se B
. O

More O
detailed O
case O
studies O
on O
oily O
fish O
and O
phytosterols B
are O
presented O
in O
companion O
papers O
. O

Additionally O
, O
SKN O
- O
caused O
cell O
death O
was O
reversed O
by O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
scavenger O
N B
- I
acetylcysteine I
( O
NAC B
) O
whereas O
TNF O
alpha O
- O
mediated O
necrosis O
was O
successfully O
protected O
by O
butylated B
hydroxyanisole I
( O
BHA B
) O
, O
implying O
that O
ROS O
may O
be O
differentially O
derived O
from O
death O
inducing O
agents O
. O

Nucleoside B
reverse O
- O
transcriptase O
inhibitor O
( O
NRTI O
) O
drugs O
are O
a O
major O
component O
of O
highly O
- O
active O
antiretroviral O
therapy O
( O
HAART O
) O
. O

We O
employed O
the O
standard O
version O
of O
the O
wing O
SMART O
in O
Drosophila O
melanogaster O
to O
obtain O
more O
detailed O
knowledge O
about O
the O
genotoxic O
profile O
of O
NRTI O
combinations O
of O
AZT B
+ O
ddI O
, O
AZT B
+ O
3TC O
and O
AZT B
+ O
d4T O
. O

The O
combinations O
AZT B
+ O
ddI O
and O
AZT B
+ O
3TC O
were O
shown O
to O
induce O
recombination O
rates O
ranging O
from O
86 O
. O
38 O
% O
to O
98 O
. O
36 O
% O
while O
AZT B
+ O
d4T O
showed O
a O
large O
discrepancy O
between O
recombination O
and O
mutation O
percentages O
. O

The O
combination O
index O
demonstrated O
that O
3TC O
and O
d4T O
produced O
antagonism O
while O
ddI O
showed O
synergistic O
effects O
in O
combination O
with O
AZT B
. O

We O
determined O
the O
kinetic O
parameters O
KM O
, O
kcat O
and O
kcat O
/ O
KM O
for O
oxidation O
of O
CBCP O
- O
ol O
and O
reduction O
of O
CBCP O
- O
one O
by O
AKR1C O
enzymes O
in O
the O
presence O
of O
NAD B
( I
+ I
) I
/ O
NADP B
( I
+ I
) I
and O
NADH B
/ O
NADPH B
, O
respectively O
. O

The O
catalytic O
efficiencies O
for O
the O
oxidation O
of O
CBCP O
- O
ol O
in O
the O
presence O
of O
NAD B
( I
+ I
) I
or O
NADP B
( I
+ I
) I
were O
in O
general O
higher O
when O
compared O
to O
the O
catalytic O
efficiencies O
for O
reduction O
of O
CBCP O
- O
one O
in O
the O
presence O
of O
NADH B
or O
NADPH B
. O

When O
NADPH B
was O
used O
, O
as O
compared O
to O
NADH B
, O
the O
reductions O
of O
CBCP O
- O
one O
by O
AKR1C1 O
, O
AKR1C2 O
and O
AKR1C3 O
were O
14 O
- O
, O
51 O
- O
and O
31 O
- O
fold O
more O
efficient O
, O
respectively O
. O

When O
comparing O
to O
oxidations O
of O
the O
well O
- O
known O
artificial O
substrates O
, O
1 O
- O
acenaphthenol O
and O
S O
- O
tetralol O
, O
we O
observed O
similar O
catalytic O
efficiencies O
as O
for O
CBCP O
- O
ol O
oxidation O
with O
NAD B
( I
+ I
) I
and O
NADP B
( I
+ I
) I
. O

The O
comparison O
of O
CBCP O
- O
one O
reduction O
with O
NADPH B
to O
reductions O
of O
physiological O
substrates O
revealed O
in O
general O
higher O
efficiencies O
, O
except O
for O
reduction O
of O
9 O
- O
cis O
- O
retinaldehyde O
by O
AKR1C3 O
. O

This O
NADPH B
- O
dependent O
reduction O
of O
CBCP O
- O
one O
was O
then O
used O
to O
re O
- O
evaluate O
inhibitory O
potencies O
of O
the O
known O
inhibitors O
of O
the O
target O
AKR1C3 O
and O
the O
anti O
- O
target O
AKR1C2 O
, O
medroxyprogesterone B
acetate I
and O
ursodeoxycholic O
acid O
, O
respectively O
, O
showing O
Ki O
constants O
similar O
to O
the O
reported O
values O
. O

Our O
data O
thus O
confirm O
that O
the O
new O
enzymatic O
assays O
with O
two O
cyclopentane B
substrates O
CBP O
- O
ol O
and O
CBP O
- O
one O
, O
and O
especially O
reduction O
of O
CBCP O
- O
one O
with O
NADPH B
, O
are O
appropriate O
for O
the O
evaluation O
of O
AKR1C O
inhibitors O
. O

Effects O
of O
p53 O
knockout O
on O
ochratoxin B
A I
- O
induced O
genotoxicity O
in O
p53 O
- O
deficient O
gpt O
delta O
mice O
. O

Ochratoxin B
A I
( O
OTA O
) O
is O
a O
mycotoxin O
produced O
by O
fungal O
species O
and O
is O
carcinogenic O
targeting O
the O
S3 O
segment O
of O
the O
renal O
proximal O
tubules O
in O
rodents O
. O

The O
present O
study O
used O
an O
intensive O
longitudinal O
design O
to O
examine O
whether O
mental O
rotation O
performance O
varies O
according O
to O
a O
monthly O
cycle O
in O
both O
males O
and O
females O
and O
whether O
these O
variations O
are O
related O
to O
variations O
in O
progesterone B
, O
estradiol B
, O
and O
testosterone B
levels O
. O

For O
males O
and O
females O
, O
estradiol B
and O
testosterone B
were O
significantly O
linearly O
and O
quadratically O
related O
to O
interindividual O
variation O
in O
performance O
at O
the O
beginning O
of O
the O
study O
( O
progesterone B
was O
linearly O
related O
to O
performance O
for O
females O
) O
. O

The O
association O
between O
testosterone B
and O
performance O
differed O
across O
sexes O
: O
for O
males O
, O
it O
had O
an O
inverse O
U O
- O
shape O
, O
for O
females O
it O
was O
U O
- O
shaped O
. O

Only O
estradiol B
levels O
were O
significantly O
elevated O
at O
the O
lowest O
point O
of O
the O
cycle O
in O
mental O
rotation O
performance O
in O
females O
. O

Effects O
of O
oxygen B
and O
glucose B
deprivation O
on O
synaptic O
transmission O
in O
rat O
dentate O
gyrus O
: O
role O
of O
A O
( O
2A O
) O
adenosine B
receptors O
. O

Our O
aim O
was O
to O
determine O
the O
synaptic O
and O
proliferative O
response O
of O
the O
DG O
to O
severe O
oxygen B
and O
glucose B
deprivation O
( O
OGD O
) O
in O
acute O
rat O
hippocampal O
slices O
and O
to O
investigate O
the O
contribution O
of O
A O
( O
2A O
) O
adenosine B
receptor O
antagonism O
to O
recovery O
of O
synaptic O
activity O
after O
OGD O
. O

Selective O
antagonism O
of O
A O
( O
2A O
) O
adenosine B
receptors O
by O
ZM241385 O
significantly O
prevents O
or O
delays O
the O
appearance O
of O
AD O
and O
protects O
from O
the O
irreversible O
block O
of O
neurotransmission O
induced O
by O
9 O
- O
min O
OGD O
in O
the O
DG O
. O

The O
effects O
of O
9 O
- O
min O
OGD O
on O
proliferation O
and O
maturation O
of O
cells O
localized O
in O
the O
subgranular O
zone O
of O
DG O
in O
slices O
prepared O
from O
5 B
- I
bromo I
- I
2 I
' I
- I
deoxyuridine I
( O
BrdU B
) O
treated O
rats O
was O
investigated O
. O

The O
number O
of O
BrdU B
( I
+ I
) I
cells O
was O
significantly O
decreased O
6 O
h O
after O
9 O
- O
min O
OGD O
and O
this O
effect O
was O
antagonized O
by O
ZM241385 O
. O

After O
24 O
h O
from O
the O
end O
of O
9 O
- O
min O
OGD O
, O
the O
number O
of O
BrdU B
( I
+ I
) I
cells O
returned O
to O
that O
found O
before O
OGD O
and O
increased O
arborization O
of O
tertiary O
dendrites O
of O
DCX O
( O
+ O
) O
cells O
was O
observed O
. O

The O
adenosine B
A O
( O
2A O
) O
antagonist O
ZM241385 O
protects O
from O
synaptic O
failure O
and O
from O
decreased O
proliferation O
of O
immature O
neuronal O
cells O
at O
a O
precocious O
time O
after O
OGD O
. O

Psychostimulant O
pharmacological O
profile O
of O
paraxanthine B
, O
the O
main O
metabolite O
of O
caffeine B
in O
humans O
. O

Caffeine B
induces O
locomotor O
activation O
by O
its O
ability O
to O
block O
adenosine B
receptors O
. O

Caffeine B
is O
metabolized O
to O
several O
methylxanthines O
, O
with O
paraxanthine B
being O
the O
main O
metabolite O
in O
humans O
. O

In O
this O
study O
we O
show O
that O
in O
rats O
paraxanthine B
has O
a O
stronger O
locomotor O
activating O
effect O
than O
caffeine B
or O
the O
two O
other O
main O
metabolites O
of O
caffeine B
, O
theophylline B
and O
theobromine B
. O

As O
previously O
described O
for O
caffeine B
, O
the O
locomotor O
activating O
doses O
of O
paraxanthine B
more O
efficiently O
counteract O
the O
locomotor O
depressant O
effects O
of O
an O
adenosine B
A O
( O
1 O
) O
than O
an O
adenosine B
A O
( O
2A O
) O
receptor O
agonist O
. O

In O
drug O
discrimination O
experiments O
in O
rats O
trained O
to O
discriminate O
a O
maximal O
locomotor O
activating O
dose O
of O
caffeine B
, O
paraxanthine B
, O
unlike O
theophylline B
, O
generalized O
poorly O
to O
caffeine B
suggesting O
the O
existence O
of O
additional O
mechanisms O
other O
than O
adenosine B
antagonism O
in O
the O
behavioral O
effects O
of O
paraxanthine B
. O

Pretreatment O
with O
the O
nitric B
oxide I
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
( O
l B
- I
NAME I
) O
reduced O
the O
locomotor O
activating O
effects O
of O
paraxanthine B
, O
but O
not O
caffeine B
. O

On O
the O
other O
hand O
, O
pretreatment O
with O
the O
selective O
cGMP B
- O
preferring O
phosphodiesterase O
PDE9 O
inhibitor O
BAY O
73 O
- O
6691 O
, O
increased O
locomotor O
activity O
induced O
by O
caffeine B
, O
but O
not O
paraxanthine B
. O

Ex O
vivo O
experiments O
demonstrated O
that O
paraxanthine B
, O
but O
not O
caffeine B
, O
can O
induce O
cGMP B
accumulation O
in O
the O
rat O
striatum O
. O

Finally O
, O
in O
vivo O
microdialysis O
experiments O
showed O
that O
paraxanthine B
, O
but O
not O
caffeine B
, O
significantly O
increases O
extracellular O
levels O
of O
dopamine B
in O
the O
dorsolateral O
striatum O
, O
which O
was O
blocked O
by O
l B
- I
NAME I
. O

These O
findings O
indicate O
that O
inhibition O
of O
cGMP B
- O
preferring O
PDE O
is O
involved O
in O
the O
locomotor O
activating O
effects O
of O
the O
acute O
administration O
of O
paraxanthine B
. O

The O
present O
results O
demonstrate O
a O
unique O
psychostimulant O
profile O
of O
paraxanthine B
, O
which O
might O
contribute O
to O
the O
reinforcing O
effects O
of O
caffeine B
in O
humans O
. O

The O
molecular O
mystique O
of O
tetrodotoxin B
. O

In O
many O
respects O
tetrodotoxin B
( O
TTX B
) O
is O
the O
quintessential O
natural O
toxin O
. O

It O
is O
widely O
distributed O
in O
marine O
and O
terrestrial O
ecosystems O
where O
it O
plays O
a O
role O
in O
the O
chemical O
ecology O
of O
predator O
- O
prey O
relationships O
and O
drives O
evolutionary O
selection O
of O
TTX B
- O
resistance O
( O
Hanifin O
, O
2010 O
; O
Williams O
, O
2010 O
; O
Zimmer O
and O
Ferrer O
, O
2007 O
) O
. O

Lastly O
, O
TTX B
has O
acquired O
a O
certain O
mystique O
in O
scientific O
lore O
attributable O
to O
many O
fascinating O
aspects O
of O
its O
natural O
history O
and O
molecular O
interactions O
as O
presented O
in O
selected O
summary O
below O
. O

Anti O
- O
tumor O
efficacy O
of O
chitosan O
- O
g O
- O
poly B
( I
ethylene I
glycol I
) I
nanocapsules O
containing O
docetaxel B
: O
anti O
- O
TMEFF O
- O
2 O
functionalized O
nanocapsules O
vs O
. O
non O
- O
functionalized O
nanocapsules O
. O

The O
development O
and O
evaluation O
of O
PEGylated O
chitosan O
( O
CS O
) O
nanocapsules O
( O
NCs O
) O
conjugated O
to O
a O
monoclonal O
antibody O
anti O
- O
TMEFF O
- O
2 O
( O
CS O
- O
PEG B
- O
anti O
- O
TMEFF O
- O
2 O
mAb O
NCs O
) O
for O
targeted O
delivery O
of O
docetaxel B
( O
DCX O
) O
is O
presented O
. O

CS O
- O
PEG B
- O
Biotin B
NCs O
, O
displaying O
biotin B
tags O
at O
their O
surface O
, O
were O
obtained O
and O
efficiently O
functionalized O
with O
an O
anti O
- O
TMEFF O
- O
2 O
mAb O
through O
a O
convenient O
avidin O
- O
biotin B
approach O
. O

Cell O
cycle O
analysis O
after O
treatment O
with O
different O
DCX O
- O
loaded O
CS O
- O
PEG B
NC O
formulations O
indicated O
that O
the O
encapsulated O
drug O
remained O
fully O
active O
, O
showing O
a O
similar O
functional O
behavior O
to O
free O
DCX O
. O

In O
vivo O
efficacy O
studies O
using O
a O
non O
- O
small O
cell O
lung O
carcinoma O
xenograft O
revealed O
that O
CS O
- O
PEG B
- O
anti O
- O
TMEFF O
- O
2 O
NCs O
resulted O
as O
effective O
as O
free O
DCX O
( O
Taxotere B
( O
R O
) O
) O
. O

Thus O
, O
while O
free O
DCX O
exhibited O
a O
fast O
and O
short O
effect O
on O
tumor O
volume O
reduction O
, O
CS O
- O
PEG B
- O
anti O
- O
TMEFF O
- O
2 O
mAb O
NCs O
showed O
a O
delayed O
and O
prolonged O
action O
, O
with O
no O
significant O
side O
effects O
of O
treatments O
. O

Two O
new O
trisaccharide O
intermediates O
of O
phenylethanoid O
glycosides O
, O
peiioside O
A O
( O
1 O
) O
/ O
A O
( O
2 O
) O
( O
1a O
/ O
1b O
) O
and O
peiioside O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
n B
- I
BuOH I
fraction O
of O
MeOH B
extract O
of O
the O
stems O
of O
Callicarpa O
peii O
H O
. O
T O
. O

Fluorescent O
25 O
nm O
polystyrene B
nanospheres O
were O
chosen O
as O
nanoobjects O
to O
be O
dispensed O
because O
they O
enable O
both O
the O
in O
situ O
monitoring O
of O
the O
process O
by O
optical O
microscopy O
and O
the O
ex O
situ O
high O
- O
resolution O
characterization O
of O
the O
pattern O
by O
e O
. O
g O
. O
scanning O
electron O
microscopy O
. O

Both O
CpG B
methylation O
and O
activation O
- O
induced O
deaminase O
are O
required O
for O
the O
fragility O
of O
the O
human O
bcl O
- O
2 O
major O
breakpoint O
region O
: O
implications O
for O
the O
timing O
of O
the O
breaks O
in O
the O
t O
( O
14 O
; O
18 O
) O
translocation O
. O

A O
theory O
to O
explain O
the O
striking O
propensity O
of O
the O
MBR O
breaks O
at O
three O
CpG B
clusters O
within O
the O
175 O
- O
bp O
MBR O
region O
invoked O
activation O
- O
induced O
deaminase O
( O
AID O
) O
. O

Consistent O
with O
the O
essential O
elements O
of O
the O
theory O
, O
we O
found O
that O
the O
MBR O
breakage O
process O
is O
indeed O
highly O
dependent O
on O
DNA O
methylation O
at O
the O
CpG B
sites O
and O
highly O
dependent O
on O
the O
AID O
enzyme O
to O
create O
lesions O
at O
peak O
locations O
within O
the O
MBR O
. O

Interestingly O
, O
breakage O
of O
the O
phosphodiester B
bonds O
at O
the O
AID O
- O
initiated O
MBR O
lesions O
is O
RAG O
dependent O
, O
but O
, O
unexpectedly O
, O
most O
are O
also O
dependent O
on O
Artemis O
. O

This O
raises O
the O
possibility O
that O
activated O
Artemis O
, O
derived O
from O
the O
unjoined O
D O
to O
J O
( O
H O
) O
DNA O
ends O
at O
the O
IgH O
locus O
on O
chromosome O
14 O
, O
nicks O
AID O
- O
generated O
TG O
mismatches O
at O
methyl O
CpG B
sites O
, O
and O
this O
would O
explain O
why O
the O
breaks O
at O
the O
chromosome O
18 O
MBR O
occur O
within O
the O
same O
time O
window O
as O
those O
on O
chromosome O
14 O
. O

Plant O
homeodomain O
( O
PHD O
) O
- O
type O
zinc B
fingers O
play O
an O
important O
role O
in O
recognizing O
chromatin O
modifications O
and O
recruiting O
regulatory O
proteins O
to O
specific O
genes O
. O

AF10 O
has O
mostly O
been O
studied O
in O
the O
context O
of O
the O
leukemic O
MLL O
- O
AF10 O
fusion O
protein O
, O
which O
lacks O
the O
N B
- O
terminal O
PHD O
fingers O
of O
AF10 O
. O

In O
this O
study O
, O
we O
used O
genetic O
and O
biochemical O
approaches O
to O
examine O
the O
PHD1 O
- O
PHD2 O
region O
of O
the O
Caenorhabditis O
elegans O
ortholog O
of O
AF10 O
, O
zinc B
finger O
protein O
1 O
( O
ZFP O
- O
1 O
) O
. O

We O
demonstrate O
that O
the O
PHD1 O
- O
PHD2 O
region O
is O
essential O
for O
viability O
and O
that O
the O
first O
PHD O
finger O
contributes O
to O
the O
preferred O
binding O
of O
PHD1 O
- O
PHD2 O
to O
lysine B
4 O
- O
methylated O
histone O
H3 O
tails O
. O

Similar O
results O
were O
obtained O
in O
preincubation O
studies O
using O
fexofenadine B
. O

Antioxidant O
and O
immunomodulatory O
activity O
of O
selenium B
exopolysaccharide O
produced O
by O
Lactococcus O
lactis O
subsp O
. O
lactis O
. O

Selenium O
chloride O
oxide O
( O
SeCl O
( O
2 O
) O
O O
) O
was O
added O
to O
the O
EPS O
to O
synthesize O
selenium B
- O
exopolysaccharide O
( O
Se B
- O
EPS O
) O
. O

The O
in O
vitro O
and O
in O
vivo O
antioxidant O
and O
in O
vivo O
immunomodulatory O
activity O
of O
EPS O
and O
Se B
- O
EPS O
were O
compared O
. O

EPS O
and O
Se B
- O
EPS O
scavenged O
superoxide B
anions O
and O
hydroxyl B
radicals O
. O

They O
also O
increased O
catalase O
( O
CAT O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
and O
glutathione B
peroxidase O
( O
GSH B
- O
Px O
) O
activity O
, O
while O
decreasing O
malondialdehyde B
( O
MDA B
) O
levels O
in O
serum O
and O
in O
the O
livers O
of O
mice O
. O

Se B
- O
EPS O
showed O
stronger O
in O
vitro O
and O
in O
vivo O
antioxidant O
activity O
than O
were O
shown O
by O
EPS O
. O

The O
in O
vivo O
immunoenhancement O
activity O
of O
EPS O
and O
Se B
- O
EPS O
induced O
by O
cyclophosphamide B
( O
CY O
) O
treatment O
in O
immunosuppressed O
mice O
was O
researched O
. O

EPS O
and O
Se B
- O
EPS O
treatments O
increased O
macrophage O
phagocytosis O
, O
spleen O
and O
thymus O
indices O
and O
haemolytic O
complement O
activity O
( O
HC O
( O
50 O
) O
) O
. O

Se B
- O
EPS O
showed O
stronger O
immunomodulatory O
activity O
than O
did O
EPS O
. O

Salt O
- O
soluble O
protein O
, O
surface O
reactive O
sulfhydryl B
content O
, O
and O
surface O
hydrophobicity O
of O
Alaska O
pollock O
, O
Pacific O
whiting O
, O
and O
threadfin O
bream O
surimi O
were O
characterised O
, O
as O
affected O
by O
various O
comminution O
conditions O
. O

Surface O
reactive O
sulfhydryl B
( O
SRSH O
) O
contents O
of O
the O
three O
fish O
species O
behaved O
differently O
. O

The O
SH B
groups O
were O
oxidized O
to O
disulphide B
bonds O
when O
higher O
chopping O
temperature O
was O
applied O
. O

Menthol B
, O
menthone B
, O
pulegone B
and O
eucalyptol O
were O
identified O
as O
the O
major O
components O
. O

This O
study O
showed O
that O
beta O
- O
CDs O
were O
the O
most O
versatile O
CDs O
and O
that O
beta B
- I
CD I
polymers O
could O
perform O
the O
controlled O
release O
of O
aroma O
compounds O
. O

Effects O
of O
ozone B
microbubble O
treatment O
on O
removal O
of O
residual O
pesticides O
and O
quality O
of O
persimmon O
leaves O
. O

This O
study O
investigated O
the O
effects O
of O
ozone B
microbubble O
( O
OMCB O
) O
treatment O
on O
the O
removal O
of O
residual O
fenitrothion B
( O
FT O
) O
and O
benomyl O
pesticides O
from O
red O
and O
green O
persimmon O
leaves O
, O
and O
also O
the O
treatment O
effect O
on O
the O
leaf O
colours O
, O
physical O
properties O
and O
flavour O
. O

The O
influence O
of O
pectolytic O
enzyme O
addition O
and O
prefermentative O
mash O
heating O
during O
the O
winemaking O
process O
on O
the O
phenolic B
composition O
of O
Okuzgozu O
red O
wine O
. O

The O
effects O
of O
pectolytic O
enzyme O
addition O
and O
mash O
heating O
prior O
to O
fermentation O
on O
the O
phenolic B
component O
of O
Okuzgozu O
red O
wine O
during O
the O
winemaking O
and O
ageing O
processes O
were O
investigated O
. O

In O
general O
, O
the O
highest O
concentration O
of O
total O
phenolics B
was O
found O
in O
the O
mash O
- O
heated O
wines O
, O
whereas O
the O
total O
flavan B
- I
3 I
- I
ol I
and O
total O
anthocyanin B
contents O
in O
all O
of O
the O
wines O
, O
decreased O
notably O
during O
the O
winemaking O
and O
ageing O
processes O
. O

As O
determined O
by O
HPLC O
, O
hydroxycinnamic B
acids I
were O
the O
major O
phenolic B
acids I
in O
the O
red O
wines O
. O

After O
6 O
months O
in O
the O
bottle O
, O
the O
enzyme O
- O
treated O
wines O
had O
lower O
phenolic B
acid I
concentrations O
than O
had O
the O
control O
and O
mash O
- O
heated O
wines O
, O
but O
no O
significant O
( O
p O
< O
0 O
. O
05 O
) O
differences O
were O
found O
in O
the O
concentration O
of O
total O
phenolic B
acids I
between O
the O
control O
and O
mash O
- O
heated O
wines O
. O

All O
of O
the O
phenolic B
acid I
levels O
decreased O
with O
the O
winemaking O
and O
ageing O
processes O
whereas O
only O
gallic B
acid I
increased O
. O

The O
wines O
treated O
by O
the O
pectolytic O
enzyme O
addition O
had O
a O
lower O
monomeric O
flavan B
- I
3 I
- I
ol I
content O
than O
had O
the O
other O
wines O
, O
and O
the O
amount O
of O
monomeric O
anthocyanins B
extracted O
did O
not O
increase O
with O
the O
addition O
of O
enzymes O
. O

Sequence O
analysis O
showed O
that O
DKXTH1 O
and O
DKXTH2 O
contained O
a O
putative O
open O
reading O
frame O
of O
861 O
and O
876 O
bp O
encoding O
polypeptides O
of O
287 O
and O
292 O
amino B
acid I
residues O
, O
respectively O
, O
which O
contained O
the O
conserved O
DEIDFEFLG O
motif O
of O
XTH O
, O
a O
potential O
N O
- O
linked O
glycosylation O
signal O
site O
. O

1 O
- O
Methylcyclopropene O
( O
1 O
- O
MCP O
) O
and O
gibberellic O
acid O
( O
GA O
( O
3 O
) O
) O
treatments O
delayed O
the O
softening O
and O
ethylene B
peak O
of O
persimmon O
fruit O
, O
as O
well O
as O
suppressed O
the O
expression O
of O
both O
XTH O
genes O
, O
especially O
DKXTH1 O
. O

These O
results O
indicated O
that O
the O
expression O
of O
both O
XTH O
genes O
might O
be O
ethylene B
dependent O
action O
, O
and O
closely O
related O
to O
softening O
of O
persimmon O
in O
the O
early O
( O
DKXTH1 O
) O
and O
later O
( O
DKXTH2 O
) O
ripening O
stages O
. O

Production O
of O
the O
alpha O
- O
glycosidase O
inhibitor O
1 B
- I
deoxynojirimycin I
from O
Bacillus O
species O
. O

1 B
- I
Deoxynojirimycin I
( O
DNJ B
) O
, O
a O
potent O
alpha O
- O
glycosidase O
inhibitor O
, O
has O
therapeutic O
applications O
in O
treatments O
of O
HIV O
, O
Gaucher O
' O
s O
disease O
, O
and O
diabetes O
. O

DNJ B
has O
been O
extracted O
from O
natural O
sources O
( O
mulberry O
leaves O
) O
for O
therapeutic O
purposes O
; O
however O
, O
DNJ B
ingredients O
are O
in O
limited O
supply O
and O
are O
costly O
to O
obtain O
on O
a O
large O
scale O
. O

Since O
certain O
strains O
of O
Bacillus O
and O
Streptomyces O
species O
reportedly O
produce O
DNJ B
, O
they O
may O
serve O
as O
potential O
sources O
for O
high O
- O
yield O
DNJ B
production O
. O

In O
this O
study O
, O
we O
obtained O
evidence O
for O
a O
DNJ B
production O
in O
Bacillus O
subtilis O
DSM704 O
by O
hydrophilic O
interaction O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

In O
addition O
, O
from O
a O
screen O
of O
750 O
microorganisms O
, O
we O
identified O
additional O
Bacillus O
strains O
( O
Bacillus O
amyloliquefaciens O
AS385 O
and O
Bacillus O
subtilis O
B4 O
) O
that O
produce O
DNJ B
in O
large O
quantities O
. O

Investigation O
of O
the O
effect O
of O
various O
culture O
conditions O
, O
using O
Bacillus O
subtilis O
DSM704 O
and O
the O
DNJ B
high O
- O
production O
Bacillus O
strains O
, O
provided O
evidence O
for O
the O
importance O
of O
sorbitol B
supplementation O
on O
the O
yield O
of O
the O
DNJ B
precursor O
, O
2 O
- O
amino O
- O
2 O
- O
deoxy O
- O
D O
- O
mannitol O
, O
thereby O
increasing O
DNJ B
production O
. O

The O
role O
of O
sorbitol B
in O
increased O
DNJ B
production O
was O
supported O
by O
an O
observed O
increase O
in O
mRNA O
expression O
of O
the O
biosynthetic O
gene O
, O
gabT1 O
. O

When O
Bacillus O
amyloliquefaciens O
AS385 O
was O
cultured O
in O
medium O
supplemented O
with O
sorbitol B
, O
extracellular O
DNJ B
concentration O
reached O
a O
maximum O
of O
460 O
mg O
/ O
l O
of O
medium O
( O
equivalent O
to O
9 O
. O
20mg O
/ O
g O
of O
freeze O
- O
dried O
medium O
) O
, O
indicating O
that O
this O
strain O
can O
serve O
as O
a O
source O
for O
food O
- O
and O
drug O
- O
grade O
products O
. O

These O
findings O
not O
only O
lead O
to O
a O
further O
understanding O
of O
the O
DNJ B
biosynthetic O
pathway O
, O
but O
also O
suggest O
a O
method O
for O
microbial O
mass O
production O
of O
DNJ B
for O
therapeutic O
applications O
. O

Grape O
seed O
procyanidin B
extract O
modulates O
proliferation O
and O
apoptosis O
of O
pancreatic O
beta O
- O
cells O
. O

Grape O
seed O
procyanidin B
extract O
( O
GSPE O
) O
modulates O
glucose B
homeostasis O
and O
insulinemia O
in O
several O
animal O
models O
. O

We O
tested O
the O
effects O
of O
GSPE O
in O
the O
INS O
- O
1E O
pancreatic O
beta O
- O
cell O
line O
, O
either O
under O
basal O
or O
altered O
conditions O
with O
high O
glucose B
, O
insulin O
or O
palmitate O
levels O
. O

GSPE O
enhanced O
the O
pro O
- O
apoptotic O
effect O
of O
high O
glucose B
and O
showed O
clear O
antiproliferative O
effects O
under O
high O
glucose B
, O
insulin O
and O
palmitate O
conditions O
. O

The O
objective O
of O
the O
study O
was O
to O
investigate O
how O
blending O
of O
triacylglycerols B
and O
diacylglycerols O
affected O
the O
melting O
and O
crystallisation O
properties O
in O
a O
solid O
fat O
system O
. O

Lard O
- O
based O
diacylglycerols O
( O
DAGs B
) O
were O
blended O
with O
lard O
in O
various O
concentrations O
( O
0 O
% O
, O
1 O
% O
, O
5 O
% O
, O
10 O
% O
, O
20 O
% O
, O
50 O
% O
, O
60 O
% O
, O
70 O
% O
, O
80 O
% O
, O
90 O
% O
, O
and O
100 O
% O
) O
. O

In O
general O
, O
the O
effects O
of O
DAGs B
were O
found O
to O
be O
dependent O
on O
concentration O
. O

The O
DP O
was O
significantly O
( O
P O
< O
0 O
. O
0001 O
) O
decreased O
when O
DAGs B
were O
added O
to O
the O
lard O
from O
5 O
- O
50 O
% O
, O
whereas O
the O
DP O
was O
increased O
( O
P O
< O
0 O
. O
0001 O
) O
when O
the O
blends O
contained O
more O
than O
60 O
% O
DAGs B
. O

The O
DSC O
thermograms O
showed O
that O
DAGs B
changed O
the O
melting O
and O
crystallisation O
profiles O
of O
lard O
. O

The O
melting O
peaks O
and O
off O
- O
set O
points O
generally O
shifted O
slightly O
towards O
higher O
temperatures O
as O
the O
content O
of O
DAGs B
increased O
above O
50 O
% O
. O

The O
beta O
form O
was O
more O
pronounced O
in O
the O
blends O
with O
high O
concentrations O
of O
DAGs B
. O

Blending O
of O
TAGs B
and O
DAGs B
may O
serve O
as O
a O
solution O
to O
achieve O
specific O
functional O
properties O
in O
products O
containing O
solid O
fats O
. O

Reduction O
of O
acrylamide B
formation O
by O
vanadium B
salt O
in O
potato O
French O
fries O
and O
chips O
. O

The O
effects O
of O
vanadyl O
sulphate O
on O
the O
formation O
of O
acrylamide B
have O
been O
studied O
in O
fried O
potato O
products O
, O
such O
as O
French O
fries O
and O
chips O
. O

Acrylamide B
formation O
was O
inhibited O
by O
30 O
. O
3 O
% O
, O
53 O
. O
3 O
% O
and O
89 O
. O
3 O
% O
when O
the O
sliced O
potato O
strips O
were O
soaked O
in O
0 O
. O
001 O
, O
0 O
. O
01 O
and O
0 O
. O
1 O
M O
vanadyl O
sulphate O
( O
VOSO O
( O
4 O
) O
) O
solutions O
, O
respectively O
, O
for O
60 O
min O
before O
frying O
. O

Moreover O
, O
57 O
. O
7 O
% O
, O
71 O
. O
4 O
% O
and O
92 O
. O
5 O
% O
inhibition O
of O
acrylamide B
formation O
was O
observed O
when O
chips O
were O
soaked O
in O
the O
respective O
vanadyl O
sulphate O
solution O
before O
frying O
. O

In O
a O
separate O
model O
reaction O
, O
a O
solution O
containing O
an O
equimolar O
concentration O
of O
L O
- O
asparagine O
and O
D B
- I
glucose I
showed O
a O
significant O
inhibition O
of O
acrylamide B
formation O
when O
heated O
at O
150 O
degrees O
C O
for O
30 O
min O
in O
the O
presence O
of O
vanadyl O
sulphate O
( O
VOSO O
( O
4 O
) O
) O
. O

The O
results O
indicate O
that O
the O
binding O
of O
VO O
( O
2 O
+ O
) O
to O
asparagine B
and O
the O
decrease O
in O
the O
pH O
of O
the O
potato O
samples O
resulted O
in O
a O
significant O
reduction O
of O
acrylamide B
formation O
in O
fried O
potato O
products O
. O

Determination O
of O
fluorine B
in O
milk O
samples O
via O
calcium O
- O
monofluoride O
by O
electrothermal O
molecular O
absorption O
spectrometry O
. O

The O
determination O
of O
fluorine B
in O
milk O
samples O
via O
the O
molecular O
absorption O
of O
calcium O
mono O
- O
fluoride O
( O
CaF B
) O
was O
performed O
using O
a O
HR O
- O
CS O
- O
ETAAS O
. O

For O
this O
purpose O
, O
calcium B
was O
pipetted O
to O
graphite B
furnace O
together O
with O
samples O
. O

The O
amount O
of O
Ca B
and O
the O
graphite B
furnace O
program O
were O
optimised O
. O

Fluorine B
was O
determined O
in O
pyrolytically O
coated O
platforms O
at O
606 O
. O
440 O
nm O
applying O
a O
pyrolysis O
temperature O
of O
700 O
degrees O
C O
and O
a O
molecule O
forming O
temperature O
of O
2250 O
degrees O
C O
. O

Finally O
, O
applying O
standard O
addition O
technique O
, O
F B
contents O
of O
several O
milk O
samples O
were O
determined O
. O

Therefore O
, O
in O
order O
to O
tolerate O
the O
errors O
, O
the O
F B
contents O
of O
several O
milk O
samples O
were O
determined O
applying O
standard O
addition O
technique O
. O

However O
, O
since O
the O
ingredients O
of O
milk O
samples O
change O
for O
different O
kinds O
, O
the O
F B
in O
each O
sample O
was O
determined O
from O
its O
own O
standard O
addition O
curve O
. O

The O
range O
of O
F B
content O
for O
the O
milk O
samples O
were O
0 O
. O
027 O
- O
0 O
. O
543 O
mu O
g O
mL O
( O
- O
1 O
) O
. O

The O
limit O
of O
detection O
and O
characteristic O
mass O
of O
the O
method O
were O
0 O
. O
26 O
and O
0 O
. O
13 O
ng O
of O
F B
, O
respectively O
. O

In O
this O
paper O
a O
combination O
of O
NIR O
spectroscopy O
and O
FTIR O
and O
Raman O
microspectroscopy O
was O
used O
to O
elucidate O
the O
effects O
of O
different O
salts O
( O
NaCl B
, O
KCl B
and O
MgSO O
( O
4 O
) O
) O
on O
structural O
proteins O
and O
their O
hydration O
in O
muscle O
tissue O
. O

The O
evidence O
for O
this O
was O
given O
by O
connecting O
the O
underlying O
FTIR O
bands O
of O
the O
amide B
I O
region O
( O
1700 O
- O
1600 O
cm O
( O
- O
1 O
) O
) O
and O
the O
water O
region O
( O
3500 O
- O
3000 O
cm O
( O
- O
1 O
) O
) O
with O
water O
vibrations O
obtained O
by O
NIR O
spectroscopy O
. O

Influence O
of O
nitrogen B
supply O
on O
the O
production O
of O
higher O
alcohols B
/ O
esters B
and O
expression O
of O
flavour O
- O
related O
genes O
in O
cacha O
c O
a O
fermentation O
. O

This O
study O
provides O
the O
first O
attempt O
to O
analyse O
the O
influence O
of O
ammonium O
supplements O
on O
sugar B
- O
cane O
juice O
fermentation O
and O
the O
flavour O
profile O
in O
a O
cacha O
c O
a O
industrial O
process O
. O

The O
objective O
was O
to O
find O
a O
relationship O
between O
higher O
alcohol B
/ O
ester B
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cacha O
c O
a O
fermentation O
. O

Sugar B
- O
cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen B
( O
81 O
mg O
N O
/ O
L O
) O
, O
was O
further O
supplemented O
with O
mid O
- O
range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O

Overall O
, O
higher O
alcohol B
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O

The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol B
acyl B
- O
transferase O
EEB1 O
and O
the O
acyl B
esterase O
IAH1 O
. O

Near O
native O
binding O
of O
a O
fluorescent O
serotonin B
conjugate O
to O
serotonin B
type O
3 O
receptors O
. O

Described O
is O
the O
synthesis O
of O
5 O
- O
hydroxytryptamine O
- O
tetramethylrhodamine O
( O
5HT O
* O
) O
; O
an O
indole O
nitrogen O
linked O
fluorescent O
conjugate O
of O
serotonin B
. O

Through O
a O
series O
fluorescence O
quenching O
experiments O
and O
experiments O
in O
the O
presence O
of O
a O
known O
competitive O
antagonist O
( O
Granisetron O
) O
, O
it O
was O
shown O
that O
5HT O
* O
specifically O
binds O
to O
purified O
homo O
- O
pentameric O
type O
- O
3 O
human O
serotonin B
receptors O
( O
5HT O
( O
3A O
) O
) O
. O

To O
date O
, O
ATP B
- O
mimetic O
kinase O
inhibitors O
have O
focused O
primarily O
on O
monocyclic O
and O
bicyclic O
heterocyclic O
cores O
. O

The O
modified O
monomers O
designed O
for O
these O
studies O
all O
share O
a O
common O
feature O
, O
they O
lack O
the O
naturally O
occurring O
3 B
' I
- I
hydroxyl I
group O
found O
in O
2 O
- O
deoxyribonucleosides O
. O

Synthesis O
of O
new O
N O
- O
( O
arylcyclopropyl O
) O
acetamides O
and O
N O
- O
( O
arylvinyl O
) O
acetamides O
as O
conformationally O
- O
restricted O
ligands O
for O
melatonin B
receptors O
. O

N O
- O
( O
Arylcyclopropyl O
) O
acetamides O
and O
N O
- O
( O
arylvinyl O
) O
acetamides O
or O
methyl O
ureas O
have O
been O
prepared O
as O
constrained O
analogues O
of O
melatonin B
. O

The O
affinity O
of O
these O
new O
compounds O
for O
chicken O
brain O
melatonin B
receptors O
and O
recombinant O
human O
MT O
( O
1 O
) O
and O
MT O
( O
2 O
) O
receptors O
was O
evaluated O
using O
2 O
- O
[ O
( O
125 O
) O
I O
] O
- O
iodomelatonin O
as O
radioligand O
. O

Strict O
ethylenic B
or O
cyclopropyl B
analogues O
of O
the O
commercialized O
agonist O
agomelatine B
( O
Valdoxan O
( O
R O
) O
) O
were O
equipotent O
to O
agomelatine B
in O
binding O
bioassays O
. O

However O
, O
the O
ethylenic B
analogue O
was O
more O
effective O
than O
the O
cyclopropyl B
one O
in O
the O
melanophore O
aggregation O
bioassay O
, O
but O
was O
still O
less O
potent O
than O
the O
disubstituted O
2 O
, O
7 O
- O
dimethoxy O
- O
naphtalenic O
compounds O
. O

Non O
- O
benzimidazole B
containing O
inhibitors O
of O
respiratory O
syncytial O
virus O
. O

Several O
non O
- O
benzimidazole B
containing O
inhibitors O
of O
respiratory O
syncytial O
virus O
are O
described O
. O

Core O
template O
modification O
, O
analysis O
of O
antiviral O
activity O
, O
physicochemistry O
and O
optimisation O
of O
properties O
led O
to O
the O
thiazole B
- O
imidazole B
13 O
, O
that O
showed O
a O
good O
potency O
and O
pharmacokinetic O
profile O
in O
the O
rat O
. O

Triazole B
- O
based O
inhibitors O
of O
geranylgeranyltransf O
II O
. O

The O
compounds O
were O
prepared O
through O
use O
of O
click O
chemistry O
to O
assemble O
a O
central O
triazole B
that O
links O
a O
polar O
head O
group O
to O
a O
hydrophobic O
tail O
. O

The O
resulting O
compounds O
were O
tested O
for O
their O
ability O
to O
inhibit O
GGTase O
II O
in O
an O
in O
vitro O
enzyme O
assay O
and O
also O
were O
tested O
for O
cytotoxic O
activity O
in O
an O
MTT B
assay O
with O
the O
human O
myeloma O
RPMI O
- O
8226 O
cell O
line O
. O

The O
most O
potent O
enzyme O
inhibitor O
was O
the O
triazole B
with O
a O
geranylgeranyl O
tail O
, O
which O
suggests O
that O
inhibitors O
that O
can O
access O
the O
enzyme O
region O
that O
holds O
the O
isoprenoid B
tail O
will O
display O
greater O
activity O
. O

Protective O
effect O
of O
ganodermanondiol O
isolated O
from O
the O
Lingzhi O
mushroom O
against O
tert B
- I
butyl I
hydroperoxide I
- O
induced O
hepatotoxicity O
through O
Nrf2 O
- O
mediated O
antioxidant O
enzymes O
. O

The O
present O
study O
examined O
the O
protective O
effects O
of O
ganodermanondiol O
against O
tert B
- I
butyl I
hydroperoxide I
( O
t O
- O
BHP O
) O
- O
induced O
hepatotoxicity O
. O

Ganodermanondiol O
protected O
human O
liver O
- O
derived O
HepG2 O
cells O
through O
nuclear O
factor O
- O
E2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
pathway O
- O
dependent O
heme B
oxygenase O
- O
1 O
expressions O
. O

Moreover O
, O
ganodermanondiol O
increased O
cellular O
glutathione B
levels O
and O
the O
expression O
of O
the O
glutamine B
- O
cysteine B
ligase O
gene O
in O
a O
dose O
- O
dependent O
manner O
. O

Furthermore O
, O
ganodermanondiol O
exposure O
enhanced O
the O
phosphorylation O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
upstream O
kinase O
activators O
, O
LKB1 O
and O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinase O
- O
II O
( O
CaMKII O
) O
. O

DPEP O
induced O
dose O
- O
dependent O
reduction O
of O
the O
protein O
levels O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
and O
concomitant O
reduction O
in O
the O
production O
of O
NO B
and O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
. O

We O
investigated O
the O
mechanism O
by O
which O
DPEP O
inhibits O
NO B
and O
PGE B
( I
2 I
) I
by O
examining O
the O
level O
of O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
activation O
within O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
pathway O
, O
which O
is O
an O
inflammation O
- O
induced O
signaling O
pathway O
in O
RAW O
264 O
. O
7 O
cells O
. O

Radioprotection O
by O
two O
phenolic B
compounds O
: O
chlorogenic O
and O
quinic O
acid O
, O
on O
X O
- O
ray O
induced O
DNA O
damage O
in O
human O
blood O
lymphocytes O
in O
vitro O
. O

The O
present O
study O
was O
designed O
to O
determine O
the O
radioprotective O
effect O
of O
two O
phytochemicals O
, O
namely O
, O
quinic B
acid I
and O
chlorogenic B
acid I
, O
against O
X O
- O
ray O
irradiation O
- O
induced O
genomic O
instability O
in O
non O
- O
tumorigenic O
human O
blood O
lymphocytes O
. O

The O
protective O
ability O
of O
two O
phenolic B
acids I
against O
radiation O
- O
induced O
DNA O
damage O
was O
assessed O
using O
the O
alkaline O
comet O
assay O
in O
human O
blood O
lymphocytes O
isolated O
from O
two O
healthy O
human O
donors O
. O

The O
results O
of O
the O
alkaline O
comet O
assay O
revealed O
that O
quinic B
acid I
and O
chlorogenic B
acid I
decreased O
the O
DNA O
damage O
induced O
by O
X O
- O
ray O
irradiation O
and O
provided O
a O
significant O
radioprotective O
effect O
. O

Quinic B
acid I
decreased O
the O
presence O
of O
irradiation O
- O
induced O
DNA O
damage O
by O
5 O
. O
99 O
- O
53 O
. O
57 O
% O
and O
chlorogenic B
acid I
by O
4 O
. O
49 O
- O
48 O
. O
15 O
% O
, O
as O
determined O
by O
the O
alkaline O
comet O
assay O
. O

The O
results O
show O
that O
quinic B
acid I
and O
chlorogenic B
acid I
may O
act O
as O
radioprotective O
compounds O
. O

Future O
studies O
should O
focus O
on O
determining O
the O
mechanism O
by O
which O
these O
phenolic B
acids I
provide O
radioprotection O
. O

In O
~ O
50 O
% O
of O
the O
visits O
, O
stimulant O
drugs O
like O
cocaine B
and O
amphetamine B
- O
like O
substances O
( O
e O
. O
g O
. O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
, O
the O
main O
active O
ingredient O
of O
ecstasy B
) O
) O
are O
involved O
, O
whereas O
in O
~ O
60 O
% O
multiple O
drugs O
are O
involved O
. O

These O
drugs O
induce O
higher O
dopamine B
and O
serotonin B
levels O
resulting O
in O
drug O
- O
induced O
toxicity O
. O

Since O
GABA B
receptors O
( O
GABA B
- O
R O
) O
provide O
the O
main O
inhibitory O
input O
on O
dopaminergic O
and O
serotonergic O
neurons O
, O
drug O
- O
induced O
inhibition O
of O
GABA B
- O
R O
could O
contribute O
to O
higher O
neurotransmitter O
levels O
and O
thus O
toxicity O
. O

We O
therefore O
investigated O
the O
effects O
of O
combinations O
of O
commonly O
abused O
stimulant O
drugs O
( O
cocaine B
, O
MDMA B
, O
3 O
, O
4 O
- O
methylenedioxyamphet O
( O
MDA B
) O
and O
meta O
- O
chlorophenylpiperazi O
( O
mCPP O
) O
) O
on O
the O
function O
of O
the O
human O
alpha O
1 O
beta O
2 O
gamma O
2 O
GABAA O
receptor O
( O
hGABAA O
- O
R O
) O
, O
expressed O
in O
Xenopus O
oocytes O
, O
using O
the O
two O
- O
electrode O
voltage O
- O
clamp O
technique O
. O

These O
drugs O
concentration O
- O
dependently O
inhibited O
the O
GABA B
- O
evoked O
current O
( O
mCPP O
> O
cocaine B
> O
MDMA B
> O
MDA B
) O
. O

Most O
drug O
combinations O
decreased O
the O
GABA B
- O
evoked O
current O
stronger O
than O
the O
single O
drug O
. O

Additivity O
was O
observed O
during O
combined O
exposure O
to O
low O
concentrations O
of O
cocaine B
and O
mCPP O
as O
well O
as O
during O
combined O
exposure O
to O
MDA B
with O
cocaine B
or O
mCPP O
. O

However O
, O
combinations O
containing O
MDMA B
mainly O
resulted O
in O
sub O
- O
additivity O
or O
no O
additivity O
. O

At O
drug O
concentrations O
relevant O
for O
clinical O
toxicology O
, O
co O
- O
exposure O
to O
> O
= O
2 O
drugs O
can O
decrease O
the O
GABA B
- O
evoked O
current O
in O
an O
additive O
manner O
. O

Thus O
, O
in O
patients O
exposed O
to O
multiple O
drugs O
, O
inhibitory O
GABA B
- O
ergic O
input O
is O
reduced O
more O
prominently O
, O
likely O
resulting O
in O
higher O
brain O
dopamine B
levels O
. O

As O
this O
will O
increase O
the O
risk O
for O
drug O
- O
induced O
toxicity O
, O
treatment O
of O
drug O
- O
intoxicated O
patients O
with O
drugs O
that O
enhance O
GABA B
- O
ergic O
input O
should O
be O
further O
optimized O
. O

HPLC O
analysis O
was O
applied O
to O
quantify O
five O
flavonoids B
from O
peppers O
. O

Apigenin B
was O
identified O
as O
main O
constituent O
. O

The O
antioxidant O
activity O
was O
evaluated O
by O
DPPH B
, O
ABTS B
, O
beta B
- I
carotene I
bleaching O
test O
and O
Fe B
- O
chelating O
activity O
assay O
. O

Roggiano O
peppers O
exhibited O
the O
highest O
antioxidant O
activity O
using O
beta B
- I
carotene I
bleaching O
test O
with O
IC O
( O
50 O
) O
values O
of O
38 O
. O
1 O
and O
24 O
. O
9 O
mu O
g O
/ O
mL O
for O
total O
extract O
and O
n B
- I
hexane I
fraction O
, O
respectively O
. O

GC O
- O
MS O
analysis O
of O
lipophilic O
fraction O
revealed O
the O
presence O
of O
fatty B
acids I
and O
vitamin B
E I
as O
major O
components O
. O

In O
the O
inhibition O
of O
the O
carbohydrate B
- O
hydrolyzing O
enzymes O
fresh O
Senise O
peppers O
exerted O
the O
strongest O
activity O
against O
alpha O
- O
amylase O
with O
an O
IC O
( O
50 O
) O
value O
of O
55 O
. O
3 O
mu O
g O
/ O
mL O
. O

Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis O
- O
inducing O
factor O
in O
aldosterone B
- O
induced O
primary O
cultured O
cardiomyocytes O
. O

In O
this O
study O
, O
aldosterone B
( O
ALD O
) O
- O
induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O

Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
( O
EGTA B
) O
( O
0 O
. O
5 O
mM O
) O
, O
calpeptin O
( O
2 O
. O
5 O
mu O
M O
) O
, O
and O
spironoclactone O
( O
10 O
mu O
M O
) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O

Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT B
and O
LDH O
leakage O
ratio O
. O

The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase O
- O
3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA B
in O
the O
presence O
of O
ALD O
. O

Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA B
but O
not O
due O
to O
calpeptin O
. O

DHA B
supplementation O
: O
current O
implications O
in O
pregnancy O
and O
childhood O
. O

Dietary O
supplementation O
with O
omega O
- O
3 O
long O
chain O
fatty O
acids O
including O
docosahexaenoic B
acid I
( O
DHA B
) O
has O
increased O
in O
popularity O
in O
recent O
years O
and O
adequate O
DHA B
supplementation O
during O
pregnancy O
and O
early O
childhood O
is O
of O
clinical O
importance O
. O

Some O
evidence O
has O
been O
built O
for O
the O
neuro O
- O
cognitive O
benefits O
of O
supplementation O
with O
long O
chain O
polyunsaturated O
fatty O
acids O
( O
LCPUFA O
) O
such O
as O
DHA B
during O
pregnancy O
; O
however O
, O
recent O
data O
indicate O
that O
the O
anti O
- O
inflammatory O
properties O
may O
be O
of O
at O
least O
equal O
significance O
. O

Adequate O
DHA B
availability O
in O
the O
fetus O
/ O
infant O
optimizes O
brain O
and O
retinal O
maturation O
in O
part O
by O
influencing O
neurotransmitter O
pathways O
. O

Our O
goal O
is O
to O
review O
the O
current O
findings O
on O
DHA B
supplementation O
, O
specifically O
in O
pregnancy O
and O
infant O
neurodevelopment O
, O
as O
a O
pharmacologic O
agent O
with O
both O
preventative O
and O
therapeutic O
value O
. O

Given O
the O
overall O
benefits O
of O
DHA B
, O
maternal O
and O
infant O
supplementation O
may O
improve O
neurological O
outcomes O
especially O
in O
vulernable O
populations O
. O

Expression O
profiles O
of O
hippocampal O
regenerative O
sprouting O
- O
related O
genes O
and O
their O
regulation O
by O
E O
- O
64d O
in O
a O
developmental O
rat O
model O
of O
penicillin B
- O
induced O
recurrent O
epilepticus O
. O

In O
the O
present O
study O
, O
the O
potential O
protective O
mechanism O
of O
E O
- O
64d O
on O
hippocampal O
aberrant O
mossy O
fiber O
sprouting O
was O
examined O
in O
a O
developmental O
rat O
model O
of O
penicillin B
- O
induced O
recurrent O
epilepticus O
. O

A O
seizure O
was O
induced O
by O
penicillin B
every O
other O
day O
in O
Sprague O
- O
Dawley O
rats O
from O
postnatal O
day O
21 O
( O
P21 O
) O
. O

The O
results O
of O
the O
present O
study O
suggest O
that O
E O
- O
64d O
, O
an O
elective O
inhibitor O
of O
calpain O
and O
autophagy O
, O
is O
potentially O
useful O
in O
the O
treatment O
of O
developmental O
seizure O
- O
induced O
brain O
damage O
both O
by O
regulating O
abnormal O
zinc B
signal O
transduction O
and O
through O
the O
modulation O
of O
altered O
lipid O
metabolism O
via O
ApoE O
/ O
clusterin O
pathway O
in O
hippocampus O
. O

Its O
dominant O
active O
constituents O
are O
anthraquinones B
including O
emodin B
, O
aloe O
- O
emodin O
, O
rhein O
, O
etc O
. O

Rhein O
naturally O
occurs O
in O
anthraquinone B
( O
1 O
, O
3 O
, O
8 O
- O
trihydroxy O
- O
6 O
- O
methyl O
anthraquinone O
) O
, O
which O
is O
found O
in O
R O
. O
palmatum O
L O
. O
and O
related O
plants O
such O
as O
rhubarb O
. O

All O
fungal O
isolates O
were O
fermented O
in O
liquid O
PDA O
medium O
and O
their O
extracts O
were O
preliminarily O
analyzed O
by O
antibacterial O
reactions O
, O
magnesium O
acetate O
- O
methanol B
reagent O
and O
Borntraiger O
' O
s O
reaction O
, O
and O
the O
strain O
reselection O
was O
made O
by O
thin O
- O
layer O
chromatography O
( O
TLC O
) O
, O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
and O
LC O
- O
MS O
to O
identify O
the O
fermentation O
products O
of O
the O
selected O
strains O
and O
confirmed O
through O
a O
comparison O
with O
authentic O
standards O
. O

Phytochemical O
analysis O
of O
the O
triterpenoids B
with O
cytotoxicity O
and O
QR O
inducing O
properties O
from O
the O
total O
tea O
seed O
saponin B
of O
Camellia O
sinensis O
. O

The O
tea O
seed O
triterpene O
saponin O
( O
TS O
) O
from O
Camellia O
sinensis O
was O
found O
to O
exhibit O
better O
antitumor O
activity O
in O
vivo O
in O
S180 O
implanted O
ICR O
mice O
and O
QR O
inducing O
activity O
for O
hepa O
lclc7 O
cells O
respectively O
compared O
with O
the O
total O
tea O
seed O
saponin B
( O
TTS O
) O
, O
hydrolysate O
of O
the O
TTS O
and O
tea O
seed O
flavonoid O
glycosides O
( O
TF O
) O
. O

The O
preliminary O
structure O
- O
activity O
relationship O
in O
the O
anti O
- O
tumor O
activity O
and O
QR O
inducing O
activity O
of O
tea O
saponins B
was O
discussed O
briefly O
. O

The O
synthetic O
sample O
showed O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
entirely O
different O
from O
those O
in O
the O
literature O
, O
revealing O
that O
the O
initially O
assigned O
structure O
was O
incorrect O
. O

DNA O
polymerase O
minor O
groove O
interactions O
modulate O
mutagenic O
bypass O
of O
a O
templating O
8 B
- I
oxoguanine I
lesion O
. O

A O
major O
base O
lesion O
resulting O
from O
oxidative O
stress O
is O
8 O
- O
oxo O
- O
7 O
, O
8 O
- O
dihydro O
- O
2 O
' O
- O
deoxyguanosine O
( O
8 B
- I
oxoG I
) O
that O
has O
ambiguous O
coding O
potential O
. O

Error O
- O
free O
DNA O
synthesis O
involves O
8 B
- I
oxoG I
adopting O
an O
anti O
- O
conformation O
to O
base O
pair O
with O
cytosine B
whereas O
mutagenic O
bypass O
involves O
8 B
- I
oxoG I
adopting O
a O
syn O
- O
conformation O
to O
base O
pair O
with O
adenine B
. O

During O
base O
excision O
repair O
of O
this O
mispair O
, O
DNA O
polymerase O
( O
pol O
) O
beta O
is O
confronted O
with O
gap O
filling O
opposite O
8 B
- I
oxoG I
. O

Kinetic O
studies O
demonstrate O
that O
this O
substitution O
results O
in O
an O
increased O
fidelity O
opposite O
8 B
- I
oxoG I
. O

Structural O
studies O
with O
R283K O
pol O
beta O
show O
that O
the O
binary O
DNA O
complex O
has O
8 B
- I
oxoG I
in O
equilibrium O
between O
anti O
- O
and O
syn O
- O
forms O
. O

Ternary O
complexes O
with O
incoming O
dCTP O
resemble O
the O
wild O
- O
type O
enzyme O
, O
with O
templating O
anti O
- O
8 O
- O
oxoG O
base O
pairing O
with O
incoming O
cytosine B
. O

In O
contrast O
to O
wild O
- O
type O
pol O
beta O
, O
the O
ternary O
complex O
of O
the O
R283K O
mutant O
with O
an O
incoming O
dATP O
- O
analogue O
and O
templating O
8 B
- I
oxoG I
resembles O
a O
G O
- O
A O
mismatched O
structure O
with O
8 B
- I
oxoG I
adopting O
an O
anti O
- O
conformation O
. O

These O
results O
demonstrate O
that O
the O
incoming O
nucleotide B
is O
unable O
to O
induce O
a O
syn O
- O
8 O
- O
oxoG O
conformation O
without O
minor O
groove O
DNA O
polymerase O
interactions O
that O
influence O
templating O
( O
anti O
- O
/ O
syn O
- O
equilibrium O
) O
of O
8 B
- I
oxoG I
while O
modulating O
fidelity O
. O

Effect O
of O
long O
- O
term O
co O
- O
administration O
of O
Wuzhi O
tablet O
( O
Schisandra O
sphenanthera O
extract O
) O
and O
prednisone B
on O
the O
pharmacokinetics O
of O
tacrolimus B
. O

Tacrolimus B
( O
TAC B
) O
is O
an O
immunosuppressant O
that O
has O
been O
widely O
used O
alone O
or O
in O
combination O
with O
prednisone B
( O
PRED O
) O
to O
prevent O
acute O
rejection O
after O
organ O
transplantation O
. O

Wuzhi O
tablet O
( O
WZ O
, O
Schisandra O
sphenanthera O
extract O
) O
is O
often O
prescribed O
with O
TAC B
to O
prevent O
drug O
- O
induced O
hepatitis O
. O

We O
recently O
reported O
that O
WZ O
could O
significantly O
increase O
TAC B
blood O
exposure O
by O
inhibiting O
P O
- O
gp O
- O
mediated O
efflux O
and O
CYP3A O
- O
mediated O
metabolism O
of O
TAC B
. O

Therefore O
, O
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
long O
- O
term O
treatment O
of O
WZ O
and O
PRED O
on O
the O
pharmacokinetics O
of O
TAC B
in O
rats O
. O

After O
14 O
days O
of O
co O
- O
administration O
of O
WZ O
and O
PRED O
, O
the O
AUC O
( O
0 O
- O
24h O
) O
of O
oral O
TAC B
was O
increased O
( O
from O
59 O
. O
6 O
+ O
/ O
- O
37 O
. O
3 O
to O
95 O
. O
3 O
+ O
/ O
- O
39 O
. O
4 O
ng O
h O
/ O
ml O
, O
p O
= O
0 O
. O
18 O
) O
and O
the O
clearance O
was O
decreased O
( O
from O
38 O
. O
4 O
+ O
/ O
- O
28 O
. O
4 O
to O
17 O
. O
7 O
+ O
/ O
- O
6 O
. O
4 O
l O
/ O
h O
/ O
kg O
, O
p O
= O
0 O
. O
15 O
) O
. O

When O
only O
co O
- O
administered O
with O
WZ O
, O
AUC O
( O
0 O
- O
24h O
) O
of O
TAC B
was O
demonstrated O
a O
significantly O
increase O
( O
from O
59 O
. O
6 O
+ O
/ O
- O
37 O
. O
3 O
to O
135 O
. O
9 O
+ O
/ O
- O
34 O
. O
8 O
ng O
h O
/ O
ml O
, O
p O
< O
0 O
. O
05 O
) O
. O

The O
concomitant O
administration O
of O
PRED O
resulted O
in O
a O
reduction O
in O
the O
systemic O
exposure O
of O
TAC B
and O
an O
increase O
in O
its O
clearance O
, O
though O
neither O
was O
statistically O
significant O
. O

Thus O
, O
our O
study O
suggested O
that O
the O
presence O
of O
WZ O
and O
PRED O
still O
could O
increase O
the O
systemic O
exposure O
of O
TAC B
in O
rats O
. O

Knockdown O
of O
HCA1 O
using O
siRNA O
resulted O
in O
an O
increase O
in O
lipid O
accumulation O
as O
assessed O
by O
quantification O
of O
Nile B
Red I
staining O
and O
TLC O
analysis O
. O

Anti O
- O
inflammatory O
sesquiterpene B
derivatives O
from O
the O
leaves O
of O
Tripterygium O
wilfordii O
. O

Twelve O
new O
dihydroagarofuran O
sesquiterpene O
polyol O
esters O
, O
triptersinines O
A O
- O
L O
( O
1 O
- O
12 O
) O
, O
and O
eight O
known O
sesquiterpene B
pyridine O
alkaloids O
were O
isolated O
from O
the O
leaves O
of O
Tripterygium O
wilfordii O
. O

Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
spectroscopic O
analyses O
, O
including O
UV O
, O
IR O
, O
and O
NMR O
experiments O
( O
( B
1 I
) I
H I
- O
( B
1 I
) I
H I
COSY O
, O
NOESY O
, O
HSQC O
, O
and O
HMBC O
) O
. O

Furthermore O
, O
in O
an O
in O
vitro O
bioassay O
, O
compounds O
1 O
, O
9 O
, O
11 O
, O
13 O
, O
14 O
, O
and O
18 O
showed O
moderate O
inhibitory O
effects O
on O
nitric B
oxide I
production O
in O
LPS O
- O
induced O
macrophages O
at O
5 O
mu O
M O
; O
all O
compounds O
were O
inactive O
when O
tested O
against O
five O
human O
cancer O
cell O
lines O
( O
IC O
( O
50 O
) O
values O
> O
1 O
mu O
M O
) O
. O

Bioassay O
- O
guided O
isolation O
of O
proanthocyanidins B
with O
antiangiogenic O
activities O
. O

Highly O
ordered O
cobalt B
- O
phthalocyanine B
chains O
on O
fractional O
atomic O
steps O
: O
one O
- O
dimensionality O
and O
electron O
hybridization O
. O

Here O
we O
show O
that O
highly O
ordered O
cobalt B
- O
phthalocyanine B
chains O
can O
be O
self O
- O
assembled O
on O
a O
metal O
surface O
using O
fractional O
atomic O
steps O
as O
a O
template O
. O

We O
also O
demonstrate O
that O
the O
substrate O
surface O
electrons O
, O
which O
can O
be O
confined O
by O
cobalt B
- O
phthalocyanine B
molecules O
, O
can O
propagate O
along O
the O
step O
arrays O
and O
can O
hybridize O
with O
the O
molecular O
orbitals O
. O

Pantothenic O
acid O
is O
an O
essential O
nutrient O
required O
to O
synthesize O
coenzyme O
A O
, O
a O
cofactor O
involved O
in O
many O
biological O
processes O
such O
as O
fatty B
acid I
synthesis O
and O
oxidation O
of O
pyruvate B
to O
fuel O
the O
citric B
acid I
cycle O
. O

Hydrolysis O
of O
pantetheine O
also O
liberates O
cysteamine B
, O
a O
known O
antioxidant O
. O

Theoretical O
characterization O
of O
X O
- O
ray O
absorption O
, O
emission O
, O
and O
photoelectron O
spectra O
of O
nitrogen B
doped O
along O
graphene B
edges O
. O

K O
- O
edge O
X O
- O
ray O
absorption O
( O
XAS O
) O
, O
emission O
( O
XES O
) O
, O
and O
photoelectron O
( O
XPS O
) O
spectra O
of O
nitrogen B
doped O
along O
graphene B
edges O
are O
systematically O
investigated O
by O
using O
first O
- O
principles O
methods O
. O

In O
this O
study O
we O
considered O
pyridinium B
- O
like O
, O
pyridine B
- O
like O
, O
cyanide B
- O
like O
, O
and O
amine B
- O
like O
nitrogens O
at O
armchair O
and O
zigzag O
edges O
and O
pyrrole B
- O
like O
nitrogen B
at O
armchair O
edge O
as O
well O
as O
graphite B
- O
like O
nitrogen B
at O
graphene B
interior O
site O
. O

Our O
results O
indicate O
that O
nitrogen B
configuration O
and O
its O
location O
( O
armchair O
or O
zigzag O
edge O
) O
in O
nitrogen O
- O
doped O
graphene O
can O
be O
identified O
via O
the O
spectral O
analysis O
. O

In O
vitro O
studies O
have O
suggested O
that O
the O
effects O
of O
some O
solvents O
might O
be O
due O
to O
the O
formation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

This O
study O
assesses O
hydroxyl B
radical O
( O
OH B
) O
generation O
and O
measures O
malondialdehyde B
( O
MDA B
) O
levels O
in O
the O
cerebral O
tissue O
of O
rats O
exposed O
to O
six O
solvents O
( O
n B
- I
hexane I
, O
n O
- O
octane O
, O
toluene B
, O
n O
- O
butylbenzene O
, O
cyclohexane B
and O
1 O
, O
2 O
, O
4 O
- O
trimethylcyclohexane O
) O
. O

We O
assessed O
OH B
production O
by O
quantifying O
the O
rate O
of O
formation O
of O
3 O
, O
4 O
- O
dihydroxybenzoic O
acid O
using O
a O
trapping O
agent O
, O
4 B
- I
hydroxybenzoic I
acid I
, O
infused O
via O
the O
microdialysis O
probe O
, O
into O
the O
prefrontal O
cortex O
of O
rats O
exposed O
intraperitoneally O
to O
the O
solvents O
. O

Extracellular O
MDA B
was O
quantified O
in O
microdialysates O
collected O
from O
the O
prefrontal O
cortex O
of O
rats O
exposed O
, O
6h O
/ O
day O
for O
ten O
days O
, O
to O
1000ppm O
of O
the O
solvents O
( O
except O
for O
n O
- O
butylbenzene O
, O
generated O
at O
830ppm O
) O
in O
inhalation O
chambers O
. O

Tissue O
levels O
of O
free O
and O
total O
MDA B
were O
measured O
in O
different O
brain O
structures O
for O
rats O
acutely O
( O
intraperitoneal O
route O
) O
and O
sub O
- O
acutely O
( O
inhalation O
) O
exposed O
to O
solvents O
. O

None O
of O
the O
six O
solvents O
studied O
increased O
the O
production O
of O
hydroxyl B
radicals O
in O
the O
prefrontal O
cortex O
after O
acute O
administration O
. O

Nor O
did O
they O
increase O
extracellular O
or O
tissue O
levels O
of O
MDA B
after O
10 O
days O
' O
inhalation O
exposure O
. O

On O
the O
other O
hand O
, O
a O
decrease O
in O
the O
concentrations O
of O
free O
MDA B
in O
brain O
structures O
was O
observed O
after O
acute O
administration O
of O
n B
- I
hexane I
, O
1 O
, O
2 O
, O
4 O
- O
trimethylcyclohexane O
, O
toluene B
and O
n O
- O
butylbenzene O
. O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
involve O
stimulation O
of O
the O
soluble O
guanylate B
cyclase O
- O
cGMP B
pathway O
. O

1 B
- I
Nitro I
- I
2 I
- I
phenylethane I
is O
the O
first O
organic O
NO B
2 I
- O
containing O
molecule O
isolated O
from O
plants O
. O

The O
underlying O
mechanism O
involved O
in O
the O
vasodilator O
effect O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
was O
investigated O
in O
rat O
aorta O
. O

The O
vasorelaxant O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
did O
not O
depend O
on O
endothelial O
layer O
integrity O
, O
and O
the O
effects O
were O
refractory O
to O
L O
- O
N O
( O
G O
) O
- O
nitroarginine O
methyl O
ester O
( O
L B
- I
NAME I
) O
- O
induced O
nitric B
oxide I
synthase O
inhibition O
. O

Vasorelaxation O
was O
similarly O
resistant O
to O
treatment O
with O
indomethacin B
, O
cis O
- O
N O
- O
( O
2 O
- O
phenylcyclopentyl O
) O
- O
azacyclotridec O
- O
1 O
- O
en O
- O
2 O
- O
amine O
hydrochloride O
( O
MDL O
- O
12330A O
) O
, O
and O
KT5720 O
, O
indicating O
that O
neither O
prostaglandin B
release O
nor O
adenylyl B
cyclase O
activation O
is O
involved O
. O

Conversely O
, O
methylene B
blue I
- O
and O
ODQ B
- O
induced O
guanylate B
cyclase O
inhibition O
reduced O
the O
vasorelaxation O
induced O
by O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
. O

The O
pharmacological O
blockade O
of O
K B
( I
+ I
) I
channels O
with O
tetraethylammonium B
, O
glybenclamide O
, O
and O
4 O
- O
aminopyridine O
also O
blunted O
vasorelaxation O
induced O
by O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
. O

The O
effects O
of O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
were O
reversed O
by O
1H O
- O
[ O
1 O
, O
2 O
, O
4 O
] O
oxadiazolo O
[ O
4 O
, O
3 O
- O
a O
] O
quinoxalin O
- O
1 O
- O
one O
( O
ODQ B
) O
and O
comparable O
to O
the O
effects O
induced O
by O
sodium B
nitroprusside I
. O

In O
silico O
analysis O
using O
an O
Ns O
H O
- O
NOX O
subunit O
of O
guanylate B
cyclase O
revealed O
a O
pocket O
on O
the O
macromolecule O
surface O
where O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
preferentially O
docked O
. O

In O
vitro O
, O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
increased O
cyclic O
guanosine O
3 O
' O
, O
5 O
' O
- O
monophosphate O
( O
cGMP B
) O
levels O
in O
rat O
aortic O
rings O
, O
an O
effect O
also O
reversed O
by O
ODQ B
. O

In O
conclusion O
, O
1 B
- I
nitro I
- I
2 I
- I
phenylethane I
produces O
vasodilator O
effects O
by O
stimulating O
the O
soluble O
guanylate B
cyclase O
- O
cGMP B
pathway O
. O

Antidiabetic O
effect O
of O
secoisolariciresinol O
diglucoside O
in O
streptozotocin B
- O
induced O
diabetic O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
antihyperglycemic O
activity O
of O
synthetic O
Secoisolariciresinol O
diglucoside O
( O
SDG O
) O
in O
streptozotocin B
( O
STZ B
) O
- O
induced O
diabetic O
rats O
. O

The O
synthetic O
SDG O
in O
a O
single O
- O
dose O
( O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
two O
- O
day O
study O
showed O
dose O
- O
dependent O
reduction O
in O
glucose B
levels O
with O
maximum O
effect O
of O
64 O
. O
62 O
% O
at O
48 O
h O
post O
drug O
treatment O
( O
p O
< O
0 O
. O
05 O
) O
, O
which O
is O
comparable O
to O
that O
of O
the O
standard O
drug O
tolbutamide B
( O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
. O

In O
a O
multi O
- O
dose O
fourteen O
- O
day O
study O
, O
lower O
doses O
of O
SDG O
( O
5 O
and O
10 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
exhibited O
moderate O
reduction O
in O
glucose B
levels O
, O
lipid O
profile O
, O
restoration O
of O
antioxidant O
enzymes O
and O
improvement O
of O
the O
insulin O
and O
c O
- O
peptide O
levels O
which O
shows O
the O
regeneration O
of O
beta O
- O
cell O
which O
secretes O
insulin O
. O

Results O
of O
the O
present O
investigation O
suggest O
that O
diabetes O
is O
associated O
with O
an O
increase O
in O
oxidative O
stress O
as O
shown O
by O
increase O
in O
serum O
malondialdehyde B
( O
MDA B
) O
, O
decreased O
levels O
of O
catalase O
( O
CAT O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
and O
glutathione B
( O
GSH B
) O
. O

Also O
, O
diabetes O
is O
associated O
with O
an O
increase O
in O
serum O
total O
cholesterol B
as O
well O
as O
triglycerides B
levels O
and O
decrease O
in O
insulin O
and O
c O
- O
peptide O
levels O
. O

And O
, O
also O
maintaining O
tissue O
function O
which O
results O
in O
improving O
the O
sensitivity O
and O
response O
of O
target O
cells O
in O
STZ B
- O
induced O
diabetic O
rats O
to O
insulin O
. O

Feeding O
of O
selenium B
alone O
or O
in O
combination O
with O
glucoraphanin O
differentially O
affects O
intestinal O
and O
hepatic O
antioxidant O
and O
phase O
II O
enzymes O
in O
growing O
rats O
. O

The O
anti O
- O
carcinogenic O
effects O
of O
sulforaphane B
( O
SFN B
) O
are O
based O
on O
the O
up O
- O
regulation O
of O
antioxidant O
enzymes O
( O
AE O
) O
and O
phase O
II O
enzymes O
( O
PIIE O
) O
through O
the O
transcription O
factor O
Nrf2 O
. O

Current O
knowledge O
on O
the O
roles O
of O
the O
SFN B
precursor O
glucoraphanin O
( O
GRA O
) O
on O
these O
processes O
is O
limited O
. O

Anti O
- O
carcinogenic O
effects O
of O
Se B
depending O
on O
glutathione B
peroxidase O
( O
GPx O
) O
activity O
have O
also O
been O
reported O
. O

We O
studied O
effects O
and O
possible O
synergisms O
of O
Se B
and O
GRA O
on O
the O
expression O
and O
activity O
of O
a O
broad O
spectrum O
of O
AE O
and O
PIIE O
in O
jejunum O
, O
colon O
and O
the O
liver O
of O
rats O
fed O
diets O
differing O
in O
Se B
and O
GRA O
concentration O
. O

In O
all O
organs O
, O
GPx1 O
mRNA O
expression O
was O
70 O
% O
to O
90 O
% O
lower O
in O
Se B
deficiency O
than O
in O
Se B
sufficiency O
. O

GPx2 O
expression O
increased O
in O
jejunum O
and O
liver O
under O
Se B
deficiency O
and O
decreased O
in O
the O
colon O
. O

Se B
deficiency O
increased O
most O
colonic O
AE O
and O
PIIE O
compared O
to O
Se B
adequacy O
. O

Adequate O
and O
in O
particular O
supranutritive O
Se B
combined O
with O
GRA O
increased O
colonic O
AE O
and O
PIIE O
expression O
up O
to O
3 O
. O
72 O
- O
fold O
. O

In O
the O
liver O
Se B
deficiency O
raised O
the O
expression O
of O
AE O
and O
PIIE O
up O
to O
4 O
. O
49 O
- O
fold O
. O

GRA O
attenuated O
liver O
AE O
and O
PIIE O
response O
in O
Se B
deficiency O
. O

We O
conclude O
that O
: O
( O
1 O
) O
GPx1 O
sensitively O
indicates O
Se B
deficiency O
; O
( O
2 O
) O
the O
influence O
of O
Se B
and O
Nrf2 O
/ O
Keap1 O
on O
GPx2 O
expression O
depends O
on O
the O
organ O
; O
( O
3 O
) O
GRA O
combined O
with O
supranutritive O
Se B
may O
effectively O
protect O
against O
inflammation O
and O
colon O
cancer O
; O
( O
4 O
) O
future O
investigations O
on O
AE O
and O
PIIE O
expression O
should O
consider O
the O
role O
of O
Keap1 O
to O
a O
higher O
extent O
. O

Specific O
conserved O
C B
- O
terminal O
amino B
acids I
of O
Caenorhabditis O
elegans O
HMP O
- O
1 O
/ O
alpha O
- O
catenin O
modulate O
F O
- O
actin O
binding O
independently O
of O
vinculin O
. O

Although O
the O
C B
- O
terminal O
F O
- O
actin O
- O
binding O
domain O
of O
alpha O
- O
catenin O
has O
been O
shown O
to O
be O
crucial O
for O
its O
function O
, O
a O
more O
detailed O
in O
vivo O
analysis O
of O
discrete O
regions O
and O
residues O
required O
for O
actin O
binding O
has O
not O
been O
performed O
. O

Using O
Caenorhabditis O
elegans O
as O
a O
model O
system O
, O
we O
have O
characterized O
mutations O
in O
hmp O
- O
1 O
/ O
alpha O
- O
catenin O
that O
identify O
HMP O
- O
1 O
residues O
687 O
- O
742 O
and O
826 O
- O
927 O
, O
as O
well O
as O
amino B
acid I
802 O
, O
as O
critical O
to O
the O
localization O
of O
junctional O
proximal O
actin O
during O
epidermal O
morphogenesis O
. O

Using O
homology O
modeling O
, O
we O
show O
that O
these O
amino B
acids I
are O
positioned O
at O
key O
conserved O
sites O
within O
predicted O
alpha O
- O
helices O
in O
the O
C B
terminus O
. O

Our O
studies O
are O
the O
first O
to O
identify O
key O
conserved O
amino B
acids I
in O
the O
C B
terminus O
of O
alpha O
- O
catenin O
that O
modulate O
F O
- O
actin O
binding O
in O
living O
embryos O
of O
a O
simple O
metazoan O
. O

Previous O
work O
from O
our O
group O
has O
demonstrated O
that O
hybrid O
structures O
resulting O
from O
cinnamic B
acid I
conjugation O
with O
heterocyclic O
moieties O
from O
well O
- O
known O
antimalarials O
present O
improved O
antimalarial O
activity O
. O

Now O
, O
we O
report O
the O
synthesis O
and O
SAR O
analysis O
of O
an O
expanded O
series O
of O
cinnamic B
acid I
derivatives O
displaying O
remarkably O
high O
activities O
against O
both O
blood O
- O
and O
liver O
- O
stage O
malaria O
parasites O
. O

Bistable O
magnetoresistance O
switching O
in O
exchange O
- O
coupled O
CoFe O
2 O
O O
4 O
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
by O
self O
- O
assembly O
and O
thermal O
annealing O
. O

In O
this O
work O
, O
we O
report O
the O
self O
- O
assembly O
of O
binary O
nanocrystal O
superlattices O
composed O
of O
magnetically O
hard O
CoFe O
2 O
O O
4 O
nanocrystals O
and O
magnetically O
soft O
Fe B
3 I
O I
4 I
nanocrystals O
. O

Both O
NaZn O
1 O
3 O
- O
and O
MgZn O
2 O
- O
type O
CoFe O
2 O
O O
4 O
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
have O
been O
formed O
by O
the O
liquid O
- O
air O
interfacial O
assembly O
approach O
. O

The O
exchange O
- O
coupled O
CoFe O
2 O
O O
4 O
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
show O
single O
- O
phase O
magnetization O
switching O
behavior O
and O
magnetoresistance O
switching O
behavior O
below O
200 O
K O
. O

The O
NaZn O
1 O
3 O
- O
type O
CoFe O
2 O
O O
4 O
- O
- O
Fe B
3 I
O I
4 I
binary O
nanocrystal O
superlattices O
annealed O
at O
500 O
degrees O
C O
even O
exhibit O
bistable O
magnetoresistance O
switching O
behavior O
at O
room O
temperature O
constituting O
a O
simple O
nonvolatile O
memory O
function O
. O

beta O
- O
Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
A O
beta O
fibril O
aggregation O
inhibition O
activity O
with O
a O
nearly O
similar O
potential O
as O
the O
reference O
compound O
rifampicin B
, O
which O
makes O
them O
promising O
anti O
- O
Alzheimer O
drug O
candidates O
. O

Synthesis O
and O
biological O
evaluation O
of O
analogues O
of O
the O
kinase O
inhibitor O
nilotinib B
as O
Abl O
and O
Kit O
inhibitors O
. O

The O
importance O
of O
the O
trifluoromethyl O
group O
in O
the O
polypharmacological O
profile O
of O
nilotinib B
was O
investigated O
. O

Molecular O
editing O
of O
nilotinib B
led O
to O
the O
design O
, O
synthesis O
and O
biological O
evaluation O
of O
analogues O
where O
the O
trifluoromethyl O
group O
was O
replaced O
by O
a O
proton O
, O
fluorine B
and O
a O
methyl B
group O
. O

While O
these O
analogues O
were O
less O
active O
than O
nilotinib B
toward O
Abl O
, O
their O
activity O
toward O
Kit O
was O
comparable O
, O
with O
the O
monofluorinated O
analogue O
being O
the O
most O
active O
. O

Docking O
of O
nilotinib B
and O
of O
analogues O
2a O
- O
c O
to O
the O
binding O
pocket O
of O
Abl O
and O
of O
Kit O
showed O
that O
the O
lack O
of O
shape O
complementarity O
in O
Kit O
is O
compensated O
by O
the O
stabilizing O
effect O
from O
its O
juxtamembrane O
region O
. O

In O
a O
recent O
disclosure O
, O
we O
described O
the O
discovery O
of O
dimeric O
, O
prolinamide B
- O
based O
NS5A O
replication O
complex O
inhibitors O
exhibiting O
excellent O
potency O
towards O
an O
HCV O
genotype O
1b O
replicon O
. O

Endophytic O
fungi O
from O
Miquelia O
dentata O
Bedd O
. O
, O
produce O
the O
anti O
- O
cancer O
alkaloid O
, O
camptothecine B
. O

Camptothecine B
( O
Campothecin O
, O
CPT B
) O
, O
a O
quinoline O
alkaloid O
, O
is O
a O
potent O
inhibitor O
of O
eukaryotic O
topoisomerase O
I O
. O

Several O
semi O
- O
synthetic O
derivatives O
of O
CPT B
are O
in O
clinical O
use O
against O
ovarian O
, O
small O
lung O
and O
refractory O
ovarian O
cancers O
. O

While O
CPT B
is O
produced O
by O
several O
plant O
species O
belonging O
to O
the O
Asterid O
clade O
, O
in O
recent O
years O
, O
efforts O
have O
been O
made O
to O
isolate O
endophytic O
fungi O
from O
some O
of O
these O
plants O
as O
possible O
alternative O
sources O
of O
CPT B
. O

In O
this O
study O
we O
report O
the O
isolation O
of O
three O
endophytic O
fungi O
from O
fruit O
and O
seed O
regions O
of O
Miquelia O
dentata O
( O
Icacinaceae O
) O
, O
that O
produce O
CPT B
, O
9 O
- O
methoxy O
CPT O
( O
9 O
- O
MeO O
- O
CPT O
) O
and O
10 O
- O
hydroxy O
CPT O
( O
10 O
- O
OH O
- O
CPT O
) O
. O

( O
Sacc O
. O
) O
produced O
CPT B
, O
9 O
- O
MeO O
- O
CPT O
and O
10 O
- O
OH O
- O
CPT O
in O
mycelial O
mats O
in O
shake O
flasks O
containing O
potato O
dextrose O
broth O
. O

Methanolic O
and O
ethyl B
acetate I
extracts O
of O
these O
fungal O
species O
were O
cytotoxic O
to O
colon O
and O
breast O
cancer O
cell O
lines O
. O

The O
cytoplasmic O
Elmo1 O
: O
Dock180 O
complex O
acts O
as O
a O
guanine B
nucleotide B
exchange O
factor O
( O
GEF O
) O
for O
the O
small O
GTPase O
Rac O
and O
functions O
downstream O
of O
the O
phagocytic O
receptor O
BAI1 O
during O
apoptotic O
cell O
clearance O
, O
and O
in O
the O
entry O
of O
Salmonella O
and O
Shigella O
into O
cells O
. O

Jaceosidin O
, O
a O
flavonoid B
derived O
from O
Artemisia O
princeps O
( O
Japanese O
mugwort O
) O
, O
has O
been O
shown O
to O
inhibit O
the O
growth O
of O
several O
human O
cancer O
cells O
, O
However O
, O
the O
exact O
mechanism O
for O
the O
cytotoxic O
effect O
of O
jaceosidin O
is O
not O
completely O
understood O
. O

We O
demonstrated O
that O
jaceosidin O
is O
a O
more O
potent O
inhibitor O
of O
cell O
growth O
than O
cisplatin B
in O
human O
endometrial O
cancer O
cells O
. O

In O
contrast O
, O
jaceosidin O
- O
induced O
cytotoxicity O
in O
normal O
endometrial O
cells O
was O
lower O
than O
that O
observed O
for O
cisplatin B
. O

Moreover O
, O
jaceosidin O
treatment O
resulted O
in O
phosphorylation O
of O
ERK O
, O
and O
pretreatment O
with O
the O
ERK O
inhibitor O
, O
PD98059 B
, O
attenuated O
cell O
growth O
inhibition O
by O
jaceosidin O
. O

Inactivation O
of O
AMPK O
alpha O
in O
both O
transformed O
and O
nontransformed O
cells O
promotes O
a O
metabolic O
shift O
to O
aerobic O
glycolysis O
, O
increased O
allocation O
of O
glucose B
carbon B
into O
lipids O
, O
and O
biomass O
accumulation O
. O

Ptaquiloside O
reduces O
NK O
cell O
activities O
by O
enhancing O
metallothionein O
expression O
, O
which O
is O
prevented O
by O
selenium B
. O

Moreover O
, O
our O
previous O
studies O
showed O
that O
the O
immunosuppressive O
effects O
of O
ptaquiloside O
, O
its O
main O
toxic O
agent O
, O
were O
prevented O
by O
selenium B
in O
mouse O
natural O
killer O
( O
NK O
) O
cells O
. O

Here O
, O
we O
performed O
gene O
expression O
microarray O
analysis O
in O
splenic O
NK O
cells O
from O
mice O
treated O
for O
14 O
days O
with O
ptaquiloside O
( O
5 O
. O
3 O
mg O
/ O
kg O
) O
and O
/ O
or O
selenium B
( O
1 O
. O
3 O
mg O
/ O
kg O
) O
to O
identify O
gene O
transcripts O
altered O
by O
ptaquiloside O
that O
could O
be O
linked O
to O
the O
immunosuppression O
and O
that O
would O
be O
prevented O
by O
selenium B
. O

Considering O
the O
immunosuppressive O
effect O
of O
ptaquiloside O
, O
we O
hypothesized O
that O
two O
genes O
involved O
in O
cellular O
ion O
homeostasis O
, O
metallothionein O
1 O
( O
Mt1 O
) O
and O
metallothionein O
2 O
( O
Mt2 O
) O
, O
could O
be O
implicated O
because O
Mt1 O
and O
Mt2 O
are O
responsible O
for O
zinc B
homeostasis O
, O
and O
a O
reduction O
of O
free O
intracellular O
zinc B
impairs O
NK O
functions O
. O

We O
confirm O
these O
hypotheses O
and O
show O
increased O
expression O
of O
metallothionein O
in O
splenic O
NK O
cells O
and O
reduction O
in O
free O
intracellular O
zinc B
following O
treatment O
with O
ptaquiloside O
that O
were O
completely O
prevented O
by O
selenium B
co O
- O
treatment O
. O

Thus O
PDA O
- O
66 O
is O
a O
new O
anti O
- O
mitotic O
compound O
with O
an O
indole B
- O
core O
with O
the O
potential O
to O
be O
used O
for O
cancer O
therapy O
. O

alpha B
- I
Terpineol I
induces O
fatty O
liver O
in O
mice O
mediated O
by O
the O
AMP B
- O
activated O
kinase O
and O
sterol B
response O
element O
binding O
protein O
pathway O
. O

alpha B
- I
Terpineol I
is O
a O
monoterpene B
alcoholic B
component O
of O
Melaleuca O
alternifolia O
, O
Salvia O
officinalis O
and O
Carthamus O
tinctorius O
that O
is O
used O
widely O
as O
a O
flavor O
and O
essential O
oil O
in O
food O
. O

The O
present O
study O
showed O
that O
alpha B
- I
terpineol I
induces O
fatty O
liver O
via O
the O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
- O
mTOR O
- O
sterol B
regulatory O
element O
- O
binding O
protein O
- O
1 O
( O
SREBP O
- O
1 O
) O
pathway O
. O

alpha B
- I
Terpineol I
- O
treated O
hepatocytes O
had O
significantly O
increased O
neutral O
lipid O
accumulation O
. O

alpha B
- I
Terpineol I
suppressed O
AMPK O
phosphorylation O
, O
and O
increased O
p70S6 O
kinase O
( O
p70S6K O
) O
phosphorylation O
and O
SREBP O
- O
1 O
activation O
. O

Inhibition O
of O
mTOR O
signaling O
by O
co O
- O
treatment O
with O
rapamycin B
or O
co O
- O
transfection O
with O
dominant O
negative O
p70S6K O
blocked O
completely O
the O
effects O
of O
alpha B
- I
terpineol I
. O

alpha B
- I
Terpineol I
oral O
administration O
to O
mice O
for O
2weeks O
led O
to O
decreased O
AMPK O
phosphorylation O
and O
increased O
SREBP O
- O
1 O
activation O
in O
the O
liver O
, O
followed O
by O
hepatic O
lipid O
accumulation O
. O

Conversely O
, O
rapamycin B
co O
- O
treatment O
reversed O
alpha B
- I
terpineol I
- O
induced O
SREBP O
- O
1 O
activation O
and O
fatty O
liver O
in O
mice O
. O

These O
data O
provide O
evidence O
that O
alpha B
- I
terpineol I
causes O
fatty O
liver O
, O
an O
effect O
mediated O
by O
the O
AMPK O
/ O
mTOR O
/ O
SREBP O
- O
1 O
pathway O
. O

Multi O
- O
walled O
carbon B
nanotube O
increases O
the O
excitability O
of O
hippocampal O
CA1 O
neurons O
through O
inhibition O
of O
potassium B
channels O
in O
rat O
' O
s O
brain O
slices O
. O

This O
study O
was O
to O
investigate O
the O
neurotoxicity O
of O
multi O
- O
walled O
carbon B
nanotube O
( O
MWCNT O
) O
by O
measuring O
neuronal O
excitability O
in O
rat O
hippocampal O
neurons O
and O
exploring O
the O
underlying O
mechanism O
. O

Furthermore O
, O
voltage O
- O
activated O
potassium B
currents O
were O
recorded O
. O

It O
was O
found O
that O
MWCNT O
produced O
a O
concentration O
- O
dependent O
inhibition O
in O
amplitudes O
of O
I O
( O
A O
) O
and O
I O
( O
K B
) O
. O

In O
addition O
, O
MWCNT O
had O
effect O
on O
the O
activation O
kinetics O
of O
I O
( O
A O
) O
and O
I O
( O
K B
) O
with O
V O
( O
h O
) O
being O
shifted O
to O
the O
negative O
potential O
at O
high O
concentration O
, O
while O
I O
( O
A O
) O
inactivation O
curve O
was O
considerably O
shifted O
to O
the O
hyperpolarize O
potential O
with O
V O
( O
h O
) O
being O
increased O
. O

The O
results O
suggest O
that O
MWCNT O
increases O
the O
excitability O
of O
hippocampal O
CA1 O
neurons O
by O
inhibiting O
voltage O
- O
gated O
potassium B
current O
. O

Bile B
acids I
in O
the O
colon O
, O
from O
healthy O
to O
cytotoxic O
molecules O
. O

Bile B
acids I
are O
natural O
detergents O
mainly O
involved O
in O
facilitating O
the O
absorption O
of O
dietary O
fat O
in O
the O
intestine O
. O

In O
addition O
to O
this O
absorptive O
function O
, O
bile B
acids I
are O
also O
essential O
in O
the O
maintenance O
of O
the O
intestinal O
epithelium O
homeostasis O
. O

To O
accomplish O
this O
regulatory O
function O
, O
bile B
acids I
may O
induce O
programmed O
cell O
death O
fostering O
the O
renewal O
of O
the O
epithelium O
. O

Bile B
acids I
may O
induce O
apoptosis O
in O
colonocytes O
through O
different O
mechanisms O
. O

In O
contrast O
to O
hepatocytes O
, O
the O
extrinsic O
apoptotic O
pathway O
seems O
to O
have O
a O
low O
relevance O
regarding O
bile B
acid I
cytotoxicity O
in O
the O
colon O
. O

In O
addition O
, O
bile B
acids I
may O
also O
act O
as O
regulatory O
molecules O
involved O
in O
different O
cell O
signaling O
pathways O
in O
colon O
cells O
. O

On O
the O
other O
hand O
, O
there O
is O
increasing O
evidence O
that O
the O
continuous O
exposure O
to O
certain O
hydrophobic O
bile B
acids I
, O
due O
to O
a O
fat O
- O
rich O
diet O
or O
pathological O
conditions O
, O
may O
induce O
oxidative O
DNA O
damage O
that O
, O
in O
turn O
, O
may O
lead O
to O
colorectal O
carcinogenesis O
as O
a O
consequence O
of O
the O
appearance O
of O
cell O
populations O
resistant O
to O
bile B
acid I
- O
induced O
apoptosis O
. O

Finally O
, O
some O
bile B
acids I
, O
such O
as O
UDCA O
, O
or O
low O
concentrations O
of O
hydrophobic O
bile B
acids I
, O
can O
protect O
colon O
cells O
against O
apoptosis O
induced O
by O
high O
concentrations O
of O
cytotoxic O
bile B
acids I
, O
suggesting O
a O
dual O
behavior O
of O
these O
agents O
as O
pro O
- O
death O
or O
pro O
- O
survival O
molecules O
. O

In O
vitro O
evaluation O
of O
cytochrome O
P450 O
induction O
and O
the O
inhibition O
potential O
of O
mitragynine B
, O
a O
stimulant O
alkaloid O
. O

Mitragynine B
, O
an O
euphoric O
compound O
was O
evaluated O
for O
its O
effects O
on O
the O
expression O
of O
mRNAs O
encoding O
CYP1A2 O
, O
CYP2D6 O
and O
CYP3A4 O
and O
protein O
expression O
and O
resultant O
enzymatic O
activity O
. O

The O
effects O
of O
mitragynine B
on O
human O
CYP3A4 O
protein O
expression O
were O
determined O
using O
an O
optimized O
hCYP3A4 O
- O
HepG2 O
cell O
- O
based O
assay O
. O

An O
in O
silico O
computational O
method O
to O
predict O
the O
binding O
conformation O
of O
mitragynine B
to O
the O
active O
site O
of O
the O
CYP3A4 O
enzyme O
was O
performed O
and O
further O
validated O
using O
in O
vitro O
CYP3A4 O
inhibition O
assays O
. O

Mitragynine B
was O
found O
to O
induce O
mRNA O
and O
protein O
expression O
of O
CYP1A2 O
. O

Thus O
, O
mitragynine B
is O
a O
significant O
in O
vitro O
CYP1A2 O
inducer O
. O

NF O
- O
kappa O
B O
- O
associated O
mechanisms O
underlying O
the O
response O
of O
embryonic O
cells O
to O
Doxorubicin B
. O

Therefore O
, O
we O
tried O
to O
assess O
the O
involvement O
of O
the O
p65 O
subunit O
of O
NF O
- O
kappa O
B O
in O
the O
embryonic O
response O
to O
the O
anti O
- O
cancer O
drug O
Doxorubicin B
( O
DOX B
) O
. O

Thus O
, O
exposure O
of O
p65 O
knockout O
( O
p65 O
( O
- O
/ O
- O
) O
) O
or O
wild O
type O
( O
WT O
) O
mouse O
embryonic O
fibroblasts O
( O
MEFs O
) O
to O
DOX B
resulted O
in O
a O
decrease O
in O
cell O
survival O
, O
culture O
density O
and O
cell O
proliferation O
, O
which O
was O
found O
to O
be O
more O
prominent O
in O
p65 O
( O
- O
/ O
- O
) O
MEFs O
. O

Those O
phenomena O
were O
accompanied O
by O
a O
DOX B
- O
induced O
increase O
in O
the O
proportion O
of O
apoptotic O
cells O
, O
which O
was O
demonstrated O
only O
in O
p65 O
( O
- O
/ O
- O
) O
cells O
and O
a O
G2 O
/ O
M O
arrest O
, O
which O
was O
found O
to O
be O
more O
prominent O
in O
WT O
cells O
. O

Furthermore O
, O
DOX B
- O
treated O
WT O
and O
p65 O
( O
- O
/ O
- O
) O
MEFs O
differed O
in O
their O
expression O
of O
various O
apoptosis O
- O
associated O
molecules O
, O
when O
the O
former O
demonstrated O
a O
decrease O
in O
the O
percentage O
of O
p65 O
- O
positive O
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O
of O
p53 O
- O
positive O
cells O
, O
while O
a O
decreased O
percentage O
of O
I O
kappa O
B O
alpha O
- O
positive O
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O
of O
bcl O
- O
2 O
- O
positive O
cells O
was O
detected O
among O
the O
latter O
. O

The O
fact O
that O
the O
response O
of O
the O
cells O
to O
the O
teratogen O
was O
clearly O
p65 O
- O
dependent O
implicates O
this O
molecule O
to O
be O
involved O
in O
the O
response O
of O
the O
embryonic O
cells O
to O
DOX B
. O

Mice O
overexpressing O
PGC O
- O
1 O
alpha O
exhibited O
at O
adult O
age O
impaired O
glucose B
tolerance O
associated O
with O
reduced O
insulin O
secretion O
, O
decreased O
beta O
- O
cell O
mass O
, O
and O
beta O
- O
cell O
hypotrophy O
. O

G6PC2 O
: O
A O
Negative O
Regulator O
of O
Basal O
Glucose B
- O
Stimulated O
Insulin O
Secretion O
. O

Elevated O
fasting O
blood O
glucose B
( O
FBG O
) O
is O
associated O
with O
increased O
risk O
for O
the O
development O
of O
type O
2 O
diabetes O
and O
cardiovascular O
- O
associated O
mortality O
. O

Genome O
- O
wide O
association O
studies O
( O
GWAS O
) O
have O
linked O
polymorphisms O
in O
G6PC2 O
with O
variations O
in O
FBG O
and O
body O
fat O
, O
although O
not O
insulin O
sensitivity O
or O
glucose B
tolerance O
. O

G6PC2 O
encodes O
an O
islet O
- O
specific O
, O
endoplasmic O
reticulum O
- O
resident O
glucose B
- O
6 O
- O
phosphatase O
catalytic O
subunit O
. O

G6pc2 O
deletion O
had O
little O
effect O
on O
insulin O
sensitivity O
and O
glucose B
tolerance O
, O
whereas O
body O
fat O
was O
reduced O
in O
female O
G6pc2 O
knockout O
( O
KO O
) O
mice O
on O
both O
a O
chow O
and O
high O
- O
fat O
diet O
, O
observations O
that O
are O
all O
consistent O
with O
human O
GWAS O
data O
. O

G6pc2 O
deletion O
resulted O
in O
a O
leftward O
shift O
in O
the O
dose O
- O
response O
curve O
for O
glucose B
- O
stimulated O
insulin O
secretion O
( O
GSIS O
) O
. O

As O
a O
consequence O
, O
under O
fasting O
conditions O
in O
which O
plasma O
insulin O
levels O
were O
identical O
, O
blood O
glucose B
levels O
were O
reduced O
in O
G6pc2 O
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O

Glucose B
- O
6 O
- O
phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium B
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O
mice O
. O

These O
data O
suggest O
that O
G6pc2 O
represents O
a O
novel O
, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose B
- I
6 I
- I
phosphate I
, O
thereby O
reducing O
glycolytic O
flux O
. O

They O
also O
can O
be O
cured O
by O
selective O
partial O
pancreatectomy O
; O
however O
, O
unlike O
those O
with O
a O
KATP O
focal O
lesion O
, O
they O
show O
clinical O
sensitivity O
to O
diazoxide B
. O

In O
pathological O
region O
, O
IS O
was O
elevated O
at O
1 O
mmol O
/ O
L O
and O
was O
further O
increased O
by O
15 O
mmol O
/ O
L O
glucose B
. O

Diazoxide B
suppressed O
IS O
and O
tolbutamide B
antagonized O
the O
inhibition O
. O

The O
most O
conspicuous O
anomaly O
was O
a O
large O
stimulation O
of O
IS O
by O
1 O
mmol O
/ O
L O
glucose B
. O

Both O
abnormalities O
, O
attributed O
to O
somatic O
genetic O
events O
, O
may O
account O
for O
inappropriate O
IS O
at O
low O
glucose B
levels O
by O
a O
subset O
of O
beta O
- O
cells O
. O

Naphthoquinones B
( O
e O
. O
g O
. O
diospyrin O
and O
7 O
- O
methyljuglone O
) O
have O
been O
shown O
to O
have O
therapeutic O
potential O
, O
particularly O
against O
Mycobacterium O
tuberculosis O
. O

Our O
evidence O
strongly O
suggests O
that O
the O
compounds O
bind O
to O
the O
N B
- O
terminal O
domain O
of O
GyrB O
, O
which O
contains O
the O
ATPase O
active O
site O
, O
but O
are O
not O
competitive O
inhibitors O
of O
the O
ATPase O
reaction O
. O

We O
propose O
that O
naphthoquinones B
bind O
to O
GyrB O
at O
a O
novel O
site O
close O
to O
the O
ATPase O
site O
. O

The O
thymine B
analog O
5 O
- O
chlorouridine O
, O
first O
reported O
in O
the O
1950s O
as O
anti O
- O
tumor O
agent O
, O
is O
known O
as O
an O
effective O
mutagen O
, O
clastogen O
and O
toxicant O
as O
well O
as O
an O
effective O
inducer O
of O
sister O
- O
chromatid O
exchange O
. O

Considering O
this O
problem O
, O
novel O
BpT O
analogues O
were O
designed O
bearing O
hydrophobic O
, O
electron O
- O
donating O
substituents O
at O
the O
para O
position O
of O
the O
phenyl B
group O
( O
RBpT O
) O
. O

Besting O
vitamin B
E I
: O
sidechain O
substitution O
is O
key O
to O
the O
reactivity O
of O
naphthyridinol O
antioxidants O
in O
lipid O
bilayers O
. O

A O
series O
of O
naphthyridinol O
analogs O
of O
alpha B
- I
tocopherol I
( O
alpha O
- O
TOH O
, O
right O
) O
with O
varying O
sidechain O
substitution O
was O
synthesized O
to O
determine O
how O
systematic O
changes O
in O
the O
lipophilicity O
of O
these O
potent O
antioxidants O
impact O
their O
radical O
- O
trapping O
activities O
in O
lipid O
bilayers O
, O
regenerability O
by O
water O
- O
soluble O
reductants O
, O
and O
binding O
to O
human O
tocopherol B
transport O
protein O
( O
TTP O
) O
. O

The O
activities O
of O
the O
naphthyridinols O
were O
assayed O
in O
phosphatidylcholine B
unilamellar O
liposomes O
using O
a O
recently O
developed O
high O
- O
throughput O
assay O
that O
employs O
a O
boron O
dipyrromethene O
conjugate O
of O
alpha O
- O
TOH O
( O
H O
( O
2 O
) O
B O
- O
PMHC O
) O
that O
undergoes O
fluorescence O
enhancement O
upon O
oxidation O
. O

The O
naphthyridinols O
afforded O
a O
dose O
- O
dependent O
protection O
of O
H O
( O
2 O
) O
B O
- O
PMHC O
consistent O
with O
unprecedented O
peroxyl B
radical O
- O
trapping O
activity O
in O
lipid O
bilayers O
. O

While O
sidechain O
length O
and O
/ O
or O
branching O
had O
no O
effect O
on O
their O
apparent O
reactivity O
, O
it O
dramatically O
impacted O
reaction O
stoichiometry O
, O
with O
more O
lipophilic O
compounds O
trapping O
two O
peroxyl B
radicals O
and O
more O
hydrophilic O
compounds O
trapping O
significantly O
less O
than O
one O
. O

The O
cooperativity O
of O
a O
lipophilic O
naphthyridinol O
with O
water O
- O
soluble O
reducing O
agents O
was O
also O
studied O
in O
liposomes O
using O
H O
( O
2 O
) O
B O
- O
PMHC O
and O
revealed O
superior O
regenerability O
by O
each O
of O
ascorbate B
, O
N B
- I
acetylcysteine I
, O
and O
urate B
when O
compared O
to O
alpha O
- O
TOH O
. O

Binding O
assays O
with O
human O
TTP O
, O
a O
key O
determinant O
of O
the O
bioavailability O
of O
the O
tocopherols B
, O
reveal O
that O
the O
naphthyiridinols O
can O
be O
very O
good O
ligands O
for O
the O
protein O
. O

In O
fact O
, O
naphthyridinols O
with O
sidechains O
of O
eight O
or O
more O
carbons B
had O
affinities O
for O
TTP O
which O
were O
similar O
to O
, O
and O
in O
one O
case O
10 O
- O
fold O
better O
than O
, O
alpha O
- O
TOH O
. O

Potential O
antipsoriatic O
effect O
of O
chondroitin O
sulfate B
through O
inhibition O
of O
NF O
- O
kappa O
B O
and O
STAT3 O
in O
human O
keratinocytes O
. O

Chondroitin O
sulfate B
( O
CS O
) O
is O
a O
natural O
glycosaminoglycan O
, O
formed O
by O
the O
1 O
- O
3 O
linkage O
of O
d O
- O
glucuronic O
acid O
to O
N B
- I
acetylgalactosamine I
, O
present O
in O
the O
extracellular O
matrix O
. O

Effects O
of O
glyphosate B
- O
based O
herbicides O
on O
embryo O
- O
larval O
development O
and O
metamorphosis O
in O
the O
Pacific O
oyster O
, O
Crassostrea O
gigas O
. O

In O
this O
context O
, O
the O
present O
study O
aimed O
to O
assess O
the O
toxicity O
of O
glyphosate B
, O
its O
by O
- O
product O
, O
aminomethylphosphoni O
acid O
( O
AMPA B
) O
and O
two O
commercial O
formulations O
, O
Roundup O
Express O
( O
( O
R O
) O
) O
( O
R O
( O
EX O
) O
) O
and O
Roundup O
All O
e O
es O
et O
Terrasses O
( O
( O
R O
) O
) O
( O
R O
( O
AT O
) O
) O
, O
containing O
glyphosate B
as O
the O
active O
ingredient O
, O
on O
the O
early O
life O
stages O
of O
the O
Pacific O
oyster O
, O
Crassostrea O
gigas O
. O

During O
embryo O
- O
larval O
development O
, O
no O
mortalities O
were O
recorded O
at O
any O
of O
the O
concentrations O
of O
glyphosate B
and O
AMPA B
, O
whereas O
no O
embryos O
or O
D O
- O
shaped O
larvae O
could O
be O
observed O
after O
exposure O
to O
10 O
, O
000 O
mu O
g O
L O
( O
- O
1 O
) O
of O
R O
( O
EX O
) O
or O
R O
( O
AT O
) O
. O

The O
EC O
( O
50 O
) O
values O
were O
28 O
, O
315 O
and O
40 O
, O
617 O
mu O
g O
L O
( O
- O
1 O
) O
for O
glyphosate B
and O
its O
metabolite O
, O
respectively O
, O
but O
much O
lowered O
values O
of O
1133 O
and O
1675 O
mu O
g O
L O
( O
- O
1 O
) O
for O
R O
( O
EX O
) O
and O
R O
( O
AT O
) O
, O
respectively O
. O

Metamorphosis O
tests O
also O
revealed O
a O
significant O
difference O
between O
molecules O
, O
as O
the O
EC O
( O
50 O
) O
values O
exceeded O
100 O
, O
000 O
mu O
g O
L O
( O
- O
1 O
) O
for O
glyphosate B
and O
AMPA B
but O
were O
as O
low O
as O
6366 O
and O
6060 O
mu O
g O
L O
( O
- O
1 O
) O
for O
the O
commercial O
formulations O
, O
which O
appeared O
relatively O
more O
toxic O
. O

Overall O
, O
the O
embryo O
- O
larval O
development O
of O
C O
. O
gigas O
was O
more O
sensitive O
to O
glyphosate B
- O
based O
herbicides O
compared O
to O
various O
endpoints O
studied O
in O
regulatory O
model O
organisms O
, O
and O
embryos O
and O
D O
- O
shaped O
larvae O
were O
more O
sensitive O
compared O
to O
pediveliger O
larvae O
. O

Concentration O
of O
tacrolimus B
and O
major O
metabolites O
in O
kidney O
transplant O
recipients O
as O
a O
function O
of O
diabetes O
mellitus O
and O
cytochrome O
P450 O
3A O
gene O
polymorphism O
. O

Disposition O
of O
tacrolimus B
and O
its O
major O
metabolites O
, O
13 O
- O
O O
- O
desmethyl O
tacrolimus O
and O
15 O
- O
O O
- O
desmethyl O
tacrolimus O
, O
was O
evaluated O
in O
stable O
kidney O
transplant O
recipients O
in O
relation O
to O
diabetes O
mellitus O
and O
genetic O
polymorphism O
of O
cytochrome O
P450 O
( O
CYP O
) O
3A O
. O

In O
addition O
, O
single O
nucleotide B
polymorphisms O
of O
the O
following O
genes O
: O
CYP3A4 O
( O
CYP3A4 O
: O
CYP3A4 O
* O
1B O
, O
- O
392A O
> O
G O
) O
, O
3A5 O
( O
CYP3A5 O
: O
CYP3A5 O
* O
3 O
, O
6986A O
> O
G O
) O
and O
P O
- O
glycoprotein O
( O
ABCB1 O
: O
3435C O
> O
T O
) O
were O
characterized O
. O

Dose O
- O
normalized O
concentrations O
of O
tacrolimus B
or O
metabolites O
were O
higher O
in O
diabetic O
patients O
. O

CYP3A4 O
* O
1B O
carriers O
and O
CYP3A5 O
expressers O
, O
independently O
or O
when O
assessed O
as O
a O
combined O
CYP3A4 O
- O
3A5 O
genotype O
, O
had O
significantly O
lower O
dose O
- O
normalized O
pre O
- O
dose O
( O
C O
( O
0 O
) O
/ O
dose O
) O
and O
2 O
- O
hour O
post O
- O
dose O
( O
C O
( O
2 O
) O
/ O
dose O
) O
concentrations O
of O
tacrolimus B
and O
metabolites O
. O

Genetic O
polymorphism O
of O
CYP3A5 O
or O
CYP3A4 O
influence O
tacrolimus B
or O
metabolites O
dose O
- O
normalized O
concentrations O
but O
not O
metabolite O
to O
parent O
concentration O
ratios O
. O

The O
effect O
of O
diabetes O
on O
tacrolimus B
metabolism O
is O
subject O
to O
debate O
and O
requires O
a O
larger O
sample O
size O
of O
genetically O
stratified O
subjects O
. O

Statistical O
analyses O
of O
protein O
sequence O
alignments O
identify O
structures O
and O
mechanisms O
in O
signal O
activation O
of O
sensor O
histidine B
kinases O
. O

Statistical O
analyses O
of O
genome O
sequence O
- O
derived O
protein O
sequence O
data O
can O
identify O
amino B
acid I
residues O
that O
interact O
between O
proteins O
or O
between O
domains O
of O
a O
protein O
. O

These O
statistical O
methods O
are O
based O
on O
evolution O
- O
directed O
amino B
acid I
variation O
responding O
to O
structural O
and O
functional O
constraints O
in O
proteins O
. O

When O
applied O
to O
two O
- O
component O
systems O
, O
several O
research O
groups O
have O
shown O
they O
can O
be O
used O
to O
identify O
the O
amino B
acid I
interactions O
between O
response O
regulators O
and O
histidine B
kinases O
and O
the O
specificity O
therein O
. O

Recently O
, O
statistical O
studies O
between O
the O
HisKA O
and O
HATPase O
- O
ATP B
- O
binding O
domains O
of O
histidine B
kinases O
identified O
amino B
acid I
interactions O
for O
both O
the O
inactive O
and O
the O
active O
catalytic O
states O
of O
such O
kinases O
. O

This O
conformation O
requires O
an O
unwinding O
of O
a O
portion O
of O
the O
C B
- O
terminal O
helix O
of O
the O
HisKA O
domain O
that O
destroys O
the O
inactive O
state O
residue O
contacts O
and O
suggests O
how O
signal O
- O
binding O
determines O
the O
equilibrium O
between O
the O
inactive O
and O
active O
states O
of O
histidine B
kinases O
. O

Morin O
inhibits O
STAT3 O
tyrosine B
705 O
phosphorylation O
in O
tumor O
cells O
through O
activation O
of O
protein O
tyrosine B
phosphatase O
SHP1 O
. O

Pervanadate O
reversed O
the O
effects O
of O
morin O
on O
STAT3 O
phosphorylation O
, O
indicating O
the O
role O
of O
a O
protein O
tyrosine B
phosphatase O
. O

Suppression O
of O
STAT3 O
correlated O
with O
the O
down O
- O
regulation O
of O
various O
gene O
products O
linked O
to O
tumor O
survival O
, O
proliferation O
, O
and O
angiogenesis O
and O
led O
to O
sensitization O
of O
tumor O
cells O
to O
thalidomide B
and O
bortezomib B
. O

Comparing O
the O
activities O
of O
morin O
with O
those O
of O
four O
structurally O
related O
flavonols B
demonstrated O
the O
importance O
of O
hydroxyl B
groups O
in O
the O
B O
ring O
in O
inhibiting O
STAT3 O
activation O
. O

Blood O
pressure O
and O
levels O
of O
Fe B
, O
Ca B
, O
Mg B
, O
Zn B
, O
Cu B
, O
Na B
and O
K B
in O
the O
hair O
of O
young O
Bantu O
men O
from O
Tanzania O
. O

In O
this O
paper O
, O
blood O
pressure O
figures O
have O
been O
linked O
to O
the O
levels O
of O
Fe B
, O
Ca B
, O
Mg B
, O
Zn B
, O
Cu B
, O
Na B
and O
K B
in O
hair O
. O

Mussel O
- O
inspired O
adhesive O
binders O
for O
high O
- O
performance O
silicon B
nanoparticle O
anodes O
in O
lithium B
- O
ion O
batteries O
. O

Conjugation O
of O
mussel O
- O
inspired O
catechol B
groups O
to O
various O
polymer O
backbones O
results O
in O
materials O
suitable O
as O
silicon B
anode O
binders O
. O

The O
unique O
wetness O
- O
resistant O
adhesion O
provided O
by O
the O
catechol B
groups O
allows O
the O
silicon B
nanoparticle O
electrodes O
to O
maintain O
their O
structure O
throughout O
the O
repeated O
volume O
expansion O
and O
shrinkage O
during O
lithiation O
cycling O
, O
thus O
facilitating O
substantially O
improved O
specific O
capacities O
and O
cycle O
lives O
of O
lithium B
- O
ion O
batteries O
. O

Relative O
importance O
of O
direct O
and O
trophic O
uranium B
exposures O
in O
the O
crayfish O
Orconectes O
limosus O
: O
Implication O
for O
predicting O
uranium B
bioaccumulation O
and O
its O
associated O
toxicity O
. O

The O
authors O
address O
concerns O
relating O
to O
increasing O
uranium B
( O
U O
) O
concentrations O
( O
from O
12 O
micro O
g O
/ O
L O
to O
2 O
mg O
/ O
L O
) O
in O
the O
freshwater O
ecosystem O
caused O
by O
anthropogenic O
activities O
. O

The O
objective O
of O
the O
present O
study O
is O
to O
compare O
uranium B
bioaccumulation O
levels O
in O
tissues O
and O
in O
the O
subcellular O
environment O
. O

Results O
indicated O
that O
adsorption O
of O
uranium B
on O
the O
cuticle O
represents O
the O
main O
contribution O
of O
total O
uranium B
accumulation O
to O
the O
animal O
. O

Accumulation O
in O
the O
gills O
should O
be O
considered O
only O
as O
a O
marker O
of O
waterborne O
uranium B
exposure O
. O

Moreover O
, O
no O
significant O
difference O
in O
the O
subcellular O
distribution O
of O
uranium B
( O
50 O
% O
) O
in O
HP O
was O
observed O
between O
animals O
that O
had O
been O
exposed O
to O
both O
types O
of O
treatment O
. O

A O
potential O
toxic O
effect O
after O
uranium B
accumulation O
could O
therefore O
exist O
after O
trophic O
exposure O
. O

This O
confirms O
the O
need O
to O
focus O
further O
studies O
on O
the O
metal O
( O
uranium B
) O
risk O
assessment O
. O

Photoactivable O
amino B
acid I
bioisosteres O
and O
mass O
spectrometry O
: O
snapshots O
of O
in O
vivo O
3D O
protein O
structures O
. O

A O
reactive O
photo O
- O
leucine B
can O
clamp O
the O
front O
residues O
in O
beta O
- O
turn O
and O
beta O
- O
hairpin O
domains O
, O
thus O
allowing O
us O
to O
look O
into O
the O
specific O
native O
3D O
structure O
of O
proteins O
. O

Contrary O
to O
the O
expectation O
of O
relatively O
weak O
basis O
set O
dependence O
for O
DFT O
, O
the O
basis O
set O
effects O
are O
large O
, O
for O
example O
, O
more O
than O
10 O
kcal O
mol O
( O
- O
1 O
) O
difference O
from O
converged O
basis O
for O
the O
activation O
energy O
with O
" O
small O
" O
basis O
sets O
( O
DZ O
/ O
6 O
- O
31G O
* O
* O
for O
Ir B
/ O
other O
atoms O
, O
or O
SVP O
) O
and O
still O
more O
than O
6 O
kcal O
mol O
( O
- O
1 O
) O
for O
def2 O
- O
TZVPP O
/ O
6 O
- O
31G O
* O
* O
. O

Aiming O
to O
build O
a O
reference O
proteome O
database O
, O
we O
generated O
three O
proteome O
data O
sets O
from O
MNCs O
using O
a O
combination O
of O
SDS B
- O
PAGE O
and O
nanoflow O
LC O
- O
MS O
. O

Bifunctional O
nanoparticles O
constructed O
using O
one O
- O
pot O
encapsulation O
of O
a O
fluorescent O
polymer O
and O
magnetic O
( O
Fe3O4 B
) O
nanoparticles O
in O
a O
silica B
shell O
. O

Integration O
of O
biocompatible O
silica B
with O
a O
fluorescent O
polymer O
( O
PDDF O
) O
and O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
Fe3 O
O4 O
) O
to O
form O
uniform O
core O
- O
shell O
nanostructures O
has O
the O
great O
potential O
to O
form O
particles O
for O
use O
in O
multimodal O
bioimaging O
applications O
. O

Core O
- O
shell O
nanoparticles O
( O
PDDF O
/ O
Fe3 O
O4 O
@ O
SiO2 B
) O
exhibit O
fluorescent O
and O
magnetic O
properties O
that O
are O
favorable O
for O
their O
use O
in O
magnetic O
separation O
and O
guiding O
applications O
, O
as O
well O
as O
optical O
and O
magnetic O
resonance O
( O
MR O
) O
imaging O
capabilities O
. O

With O
the O
biological O
analysis O
in O
an O
in O
vitro O
intracellular O
permeation O
and O
cytotoxicity O
test O
, O
chemical O
conjugation O
of O
the O
surface O
using O
folic B
acid I
( O
FA O
) O
molecules O
can O
provide O
the O
nanoparticles O
with O
cell O
- O
targeting O
properties O
, O
localizing O
the O
nanoparticles O
to O
folate B
receptors O
( O
FRs O
) O
on O
target O
KB O
cells O
that O
over O
- O
express O
the O
FRs O
. O

The O
effect O
of O
the O
surface O
heterogeneity O
on O
the O
in O
vivo O
biodistribution O
was O
systematically O
investigated O
through O
in O
vivo O
tracking O
of O
the O
( B
125 I
) I
I I
- O
labeled O
MSMs O
determined O
by O
Gamma O
counter O
. O

Tetrahydropyrroloqui O
type O
dual O
inhibitors O
of O
aromatase O
/ O
aldosterone B
synthase O
as O
a O
novel O
strategy O
for O
breast O
cancer O
patients O
with O
elevated O
cardiovascular O
risks O
. O

The O
application O
of O
aromatase O
inhibitors O
to O
postmenopausal O
breast O
cancer O
patients O
increases O
the O
risk O
of O
cardiovascular O
diseases O
( O
CVD O
) O
, O
which O
is O
believed O
to O
be O
caused O
by O
the O
abnormally O
high O
concentrations O
of O
aldosterone B
as O
a O
consequence O
of O
the O
estrogen B
deficiency O
. O

Dual O
inhibitors O
of O
aromatase O
( O
CYP19 O
) O
and O
aldosterone B
synthase O
( O
CYP11B2 O
) O
are O
therefore O
proposed O
as O
a O
novel O
strategy O
for O
the O
adjuvant O
therapy O
to O
reduce O
the O
CVD O
risk O
for O
these O
patients O
. O

Interestingly O
, O
the O
substituents O
on O
the O
methylene B
bridge O
showed O
strong O
influences O
on O
the O
inhibitory O
activities O
leading O
to O
opposite O
effects O
, O
that O
is O
, O
a O
given O
substituent O
showed O
an O
increase O
in O
inhibition O
of O
one O
enzyme O
, O
while O
it O
led O
to O
a O
decrease O
for O
the O
other O
enzyme O
. O

The O
structure O
of O
the O
new O
brevipolide O
J O
( O
10 O
) O
was O
characterized O
through O
NMR O
and O
MS O
data O
as O
having O
the O
same O
6 O
- O
heptyl O
- O
5 O
, O
6 O
- O
dihydro O
- O
2H O
- O
pyran O
- O
2 O
- O
one O
framework O
possessing O
the O
cyclopropane B
moiety O
of O
all O
brevipolides O
but O
substituted O
by O
an O
isoferuloyl O
group O
instead O
of O
the O
p O
- O
methoxycinnamoyl O
moiety O
found O
in O
8 O
and O
9 O
. O

Ltd O
. O
claims O
pyrazole B
- O
based O
antagonists O
of O
the O
orexin O
- O
1 O
and O
orexin O
- O
2 O
receptors O
. O

Structurally O
, O
the O
claimed O
compounds O
represent O
a O
variation O
on O
established O
DORA O
SAR O
themes O
and O
translate O
features O
of O
clinical O
compounds O
into O
a O
pyrazole B
- O
based O
scaffold O
. O

Highly O
sensitive O
fluorescent O
and O
colorimetric O
pH O
sensor O
based O
on O
polyethylenimine B
- O
capped O
silver B
nanoclusters O
. O

Silver B
nanoclusters O
capped O
by O
hyperbranched O
polyethylenimine B
( O
PEI B
) O
have O
been O
developed O
as O
a O
highly O
sensitive O
fluorescent O
and O
colorimetric O
pH O
sensor O
. O

The O
probe O
responds O
rapidly O
to O
pH O
fluctuations O
and O
has O
such O
absorption O
characteristics O
that O
the O
color O
changes O
from O
the O
colorless O
or O
a O
nearly O
colorless O
state O
to O
a O
colored O
state O
with O
increasing O
acidity O
, O
so O
PEI B
- O
capped O
Ag B
nanoclusters O
could O
be O
used O
as O
a O
color O
indicator O
for O
colorimetric O
pH O
detection O
. O

Quantitatively O
, O
the O
fluorescence O
intensity O
of O
PEI B
- O
capped O
Ag B
nanoclusters O
exhibits O
a O
linear O
fashion O
over O
the O
pH O
range O
of O
5 O
. O
02 O
- O
7 O
. O
96 O
and O
increases O
by O
around O
10 O
- O
fold O
approximately O
with O
greater O
fluorescence O
at O
higher O
pH O
values O
. O

The O
repulsion O
development O
and O
conformational O
change O
of O
PEI B
with O
decreasing O
pH O
induce O
the O
aggregation O
of O
Ag B
nanoclusters O
, O
leading O
to O
an O
obvious O
color O
change O
and O
fluorescence O
quenching O
of O
Ag B
nanoclusters O
at O
low O
pH O
values O
. O

As O
expected O
, O
the O
pH O
probe O
is O
also O
sensitive O
to O
the O
different O
buffer O
solutions O
, O
except O
for O
those O
containing O
some O
anions O
that O
could O
react O
with O
Ag B
nanoclusters O
. O

Here O
, O
we O
describe O
the O
design O
and O
development O
of O
multicolor O
narrow O
emissive O
Pdots O
based O
on O
different O
boron O
dipyrromethene O
( O
BODIPY B
) O
units O
. O

BODIPY B
- O
containing O
semiconducting O
polymers O
emitting O
at O
multiple O
wavelengths O
were O
synthesized O
and O
used O
as O
precursors O
for O
preparing O
the O
Pdots O
, O
where O
intraparticle O
energy O
transfer O
led O
to O
highly O
bright O
, O
narrow O
emissions O
. O

BODIPY B
520 O
Pdots O
were O
about O
an O
order O
of O
magnitude O
brighter O
than O
commercial O
Qdot O
525 O
under O
identical O
laser O
excitation O
conditions O
. O

Characterization O
of O
arsenic B
induced O
cytotoxicity O
in O
liver O
with O
stress O
in O
erythrocytes O
and O
its O
reversibility O
with O
Pleurotus O
florida O
lectin O
. O

Arsenic B
is O
one O
of O
the O
most O
hazardous O
substances O
in O
the O
environment O
known O
to O
cause O
toxicity O
in O
multiple O
organs O
. O

Cell O
adhesion O
, O
morphological O
alterations O
, O
cell O
proliferation O
, O
terminal O
deoxyuridine B
triphosphate I
nick O
- O
end O
labeling O
( O
TUNEL O
) O
and O
caspase O
- O
3 O
/ O
CPP32 O
fluorometric O
protease O
assay O
were O
important O
biomarkers O
to O
assess O
apoptosis O
in O
cells O
. O

This O
study O
aimed O
to O
evaluate O
arsenic B
- O
induced O
apoptosis O
in O
the O
hepatocytes O
of O
rat O
and O
its O
protective O
efficacy O
with O
coadministration O
of O
ascorbic B
acid I
( O
AA O
) O
and O
Pleurotus O
florida O
lectin O
( O
PFL O
) O
individually O
. O

Results O
of O
the O
present O
study O
also O
showed O
that O
arsenic B
caused O
cytotoxicity O
by O
elevating O
morphological O
alterations O
, O
TUNEL O
- O
positive O
nuclei O
, O
caspase O
- O
3 O
activity O
and O
DNA O
damage O
and O
reducing O
cell O
adhesion O
and O
cell O
proliferation O
in O
a O
time O
- O
dependent O
manner O
. O

The O
apoptosis O
in O
hepatocytes O
was O
reverted O
to O
normal O
value O
after O
coadministration O
of O
mushroom O
lectin O
in O
arsenic B
- O
exposed O
rat O
. O

The O
study O
provided O
significant O
evidence O
that O
PFL O
has O
antiapoptotic O
property O
against O
arsenic B
- O
induced O
toxicity O
. O

Retard O
activities O
of O
superoxide B
dismutase O
and O
catalase O
, O
enhanced O
lipid O
peroxidation O
as O
well O
as O
protein O
carbonyl B
in O
erythrocytes O
caused O
by O
arsenic B
could O
also O
be O
maintained O
toward O
normalcy O
by O
supplementation O
of O
AA O
and O
PFL O
. O

In O
rat O
, O
treatment O
with O
AA O
and O
PFL O
prevented O
alteration O
of O
plasma O
enzyme O
activities O
caused O
by O
arsenic B
. O

The O
results O
concluded O
that O
treatment O
with O
PFL O
has O
significant O
role O
in O
protecting O
animals O
from O
arsenic B
- O
induced O
erythrocytic O
damage O
. O

This O
finding O
might O
be O
of O
therapeutic O
benefit O
in O
people O
suffering O
from O
chronic O
exposure O
to O
arsenic B
from O
natural O
sources O
, O
a O
global O
problem O
especially O
relevant O
to O
millions O
of O
people O
on O
the O
Indian O
subcontinent O
. O

Precise O
transcription O
by O
cellular O
RNA O
polymerase O
requires O
the O
efficient O
removal O
of O
noncognate O
nucleotide B
residues O
that O
are O
occasionally O
incorporated O
. O

Mis O
- O
incorporation O
causes O
the O
transcription O
elongation O
complex O
to O
backtrack O
, O
releasing O
a O
single O
strand O
3 O
' O
- O
RNA O
segment O
bearing O
a O
noncognate O
residue O
, O
which O
is O
hydrolyzed O
by O
the O
active O
center O
that O
carries O
two O
Mg B
( I
2 I
+ I
) I
ions O
. O

However O
, O
in O
most O
x O
- O
ray O
structures O
only O
one O
Mg B
( I
2 I
+ I
) I
is O
present O
. O

This O
Mg B
( I
2 I
+ I
) I
is O
tightly O
bound O
to O
the O
active O
center O
aspartates B
, O
creating O
an O
inactive O
stable O
state O
. O

The O
first O
residue O
of O
the O
single O
strand O
RNA O
segment O
in O
the O
backtracked O
transcription O
elongation O
complex O
strongly O
promotes O
transcript O
hydrolytic O
cleavage O
by O
establishing O
a O
network O
of O
interactions O
that O
force O
a O
shift O
of O
stably O
bound O
Mg B
( I
2 I
+ I
) I
to O
release O
some O
of O
its O
aspartate B
coordination O
valences O
for O
binding O
to O
the O
second O
Mg B
( I
2 I
+ I
) I
thus O
enabling O
catalysis O
. O

Transcription O
factor O
Gre O
builds O
on O
the O
ACT O
mechanism O
in O
the O
same O
reaction O
by O
increasing O
the O
retention O
of O
the O
second O
Mg B
( I
2 I
+ I
) I
and O
by O
activating O
the O
attacking O
water O
, O
causing O
3000 O
- O
4000 O
- O
fold O
reaction O
acceleration O
and O
strongly O
reinforcing O
proofreading O
. O

The O
inhibition O
was O
shown O
to O
be O
noncompetitive O
for O
both O
natural O
enzyme O
substrates O
( O
d O
- O
luciferin O
and O
ATP B
) O
and O
selective O
to O
FLuc O
and O
proven O
to O
arise O
from O
a O
direct O
interaction O
between O
the O
enzyme O
and O
the O
inhibitor O
. O

Of O
the O
63 O
evaluated O
compounds O
, O
28 O
showed O
significantly O
better O
inhibition O
potency O
than O
the O
well O
- O
known O
inhibitor O
resveratrol B
( O
IC O
( O
50 O
) O
= O
59 O
nM O
) O
, O
with O
five O
compounds O
having O
distinctly O
subnanomolar O
IC O
( O
50 O
) O
values O
. O

The O
most O
efficient O
compounds O
inhibited O
the O
luminescence O
at O
concentrations O
lower O
than O
( O
1 O
) O
/ O
( O
100 O
) O
in O
comparison O
to O
resveratrol B
( O
lowest O
IC O
( O
50 O
) O
= O
0 O
. O
26 O
nM O
) O
and O
can O
thus O
be O
considered O
to O
belong O
to O
the O
most O
potent O
FLuc O
inhibitors O
reported O
thus O
far O
. O

A O
two O
- O
dimensional O
model O
of O
a O
solid O
- O
supported O
enzyme O
catalyst O
bead O
is O
fabricated O
on O
a O
quartz B
crystal O
microbalance O
with O
dissipation O
monitoring O
( O
QCM O
- O
D O
) O
sensor O
to O
measure O
in O
situ O
interfacial O
stability O
and O
mechanical O
properties O
of O
Candida O
antarctica O
Lipase O
B O
( O
CAL O
B O
) O
under O
varied O
conditions O
relating O
to O
ring O
- O
opening O
polymerization O
. O

The O
model O
was O
fabricated O
using O
a O
dual O
photochemical O
approach O
, O
where O
poly B
( I
methyl I
methacrylate I
) I
( O
PMMA B
) O
thin O
films O
were O
cross O
- O
linked O
by O
a O
photoactive O
benzophenone B
monolayer O
and O
blended O
cross O
- O
linking O
agent O
. O

This O
process O
produces O
two O
- O
dimensional O
, O
homogeneous O
, O
rigid O
PMMA B
layers O
, O
which O
mimic O
commercial O
acrylic B
resins O
in O
a O
QCM O
- O
D O
experiment O
. O

Adsorption O
of O
CAL O
B O
to O
PMMA B
in O
QCM O
- O
D O
under O
varied O
buffer O
ionic O
strengths O
produces O
a O
viscoelastic O
enzyme O
surface O
that O
becomes O
more O
rigid O
as O
ionic O
strength O
increases O
. O

The O
rigid O
CAL O
B O
/ O
PMMA B
interface O
demonstrates O
up O
to O
20 O
% O
desorption O
of O
enzyme O
with O
increasing O
trace O
water O
content O
. O

Increased O
polycaprolactone B
( O
PCL B
) O
binding O
at O
the O
enzyme O
surface O
was O
also O
observed O
, O
indicating O
greater O
PCL B
affinity O
for O
a O
more O
hydrated O
enzyme O
surface O
. O

Effects O
of O
the O
benzimidazole B
anthelmintic O
drug O
flubendazole O
on O
rat O
embryos O
in O
vitro O
. O

The O
antidyslipidemic O
activity O
of O
pigeon O
pea O
were O
evaluated O
by O
high O
- O
fat O
diet O
( O
HFD O
) O
hamsters O
model O
, O
in O
which O
the O
level O
of O
high O
- O
density O
lipoprotein O
- O
cholesterol B
( O
HDL O
- O
C O
) O
, O
low O
- O
density O
lipoprotein O
- O
cholesterol B
( O
LDL O
- O
C O
) O
, O
total O
cholesterol B
( O
TC O
) O
, O
and O
total O
triglyceride B
( O
TG O
) O
were O
examined O
. O

We O
found O
that O
pigeon O
pea O
administration O
promoted O
cholesterol B
converting O
to O
bile B
acid I
in O
HFD O
- O
induced O
hamsters O
, O
thereby O
exerting O
hypolipidemic O
activity O
. O

In O
the O
statistical O
results O
, O
pigeon O
pea O
significantly O
increased O
hepatic O
carnitine B
palmitoyltransferase O
- O
1 O
( O
CPT O
- O
1 O
) O
, O
LDL O
receptor O
, O
and O
cholesterol B
7 O
alpha O
- O
hydroxylase O
( O
also O
known O
as O
cytochrome O
P450 O
7A1 O
, O
CYP7A1 O
) O
expression O
to O
attenuate O
dyslipidemia O
in O
HFD O
- O
fed O
hamsters O
; O
and O
markedly O
elevated O
antioxidant O
enzymes O
in O
the O
liver O
of O
HFD O
- O
induced O
hamsters O
, O
further O
alleviating O
lipid O
peroxidation O
. O

These O
effects O
may O
attribute O
to O
pigeon O
pea O
contained O
large O
of O
unsaturated B
fatty I
acids I
( O
UFA B
; O
C18 O
: O
2 O
) O
and O
phytosterol O
( O
beta B
- I
sitosterol I
, O
campesterol B
, O
and O
stigmasterol B
) O
. O

Moreover O
, O
the O
effects O
of O
pigeon O
pea O
on O
dyslipidemia O
were O
greater O
than O
beta B
- I
sitosterol I
administration O
( O
4 O
% O
) O
, O
suggesting O
that O
phytosterone O
in O
pigeon O
pea O
could O
prevent O
metabolic O
syndrome O
. O

Pharmacological O
studies O
suggest O
that O
perampanel O
acts O
with O
a O
new O
mechanism O
of O
action O
via O
non O
- O
competitive O
antagonism O
of O
the O
ionotropic O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazoleproprionic I
acid I
( O
AMPA B
) O
receptor O
of O
glutamate B
, O
the O
main O
mediator O
of O
excitatory O
neurotransmission O
in O
the O
central O
nervous O
system O
. O

Evaluation O
of O
iodide B
deficiency O
in O
the O
lactating O
rat O
and O
pup O
using O
a O
biologically O
based O
dose O
- O
response O
model O
. O

A O
biologically O
based O
dose O
- O
response O
( O
BBDR O
) O
model O
for O
the O
hypothalamic O
- O
pituitary O
thyroid O
( O
HPT O
) O
axis O
in O
the O
lactating O
rat O
and O
nursing O
pup O
was O
developed O
to O
describe O
the O
perturbations O
caused O
by O
iodide B
deficiency O
on O
the O
HPT O
axis O
. O

Model O
calibrations O
, O
carried O
out O
by O
adjusting O
key O
model O
parameters O
, O
were O
used O
as O
a O
technique O
to O
evaluate O
HPT O
axis O
adaptations O
to O
dietary O
iodide B
intake O
in O
euthyroid O
( O
4 O
. O
1 O
- O
39 O
micro O
g O
iodide B
/ O
day O
) O
and O
iodide B
- O
deficient O
( O
0 O
. O
31 O
and O
1 O
. O
2 O
micro O
g O
iodide B
/ O
day O
) O
conditions O
. O

Iodide B
- O
deficient O
conditions O
in O
both O
the O
dam O
and O
the O
pup O
were O
described O
with O
increased O
blood O
flow O
to O
the O
thyroid O
gland O
, O
TSH O
- O
mediated O
increase O
in O
thyroidal O
uptake O
of O
iodide B
and O
binding O
of O
iodide B
in O
the O
thyroid O
gland O
( O
organification O
) O
, O
and O
, O
in O
general O
, O
reduced O
thyroid B
hormone I
production O
and O
metabolism O
. O

Alterations O
in O
thyroxine B
( O
T4 O
) O
homeostasis O
were O
more O
apparent O
than O
for O
triiodothyronine B
( O
T3 O
) O
. O

Model O
- O
predicted O
average O
daily O
area O
- O
under O
- O
the O
- O
serum O
- O
concentration O
- O
curve O
( O
nM O
- O
day O
) O
values O
for O
T4 O
at O
steady O
state O
in O
the O
dam O
and O
pup O
decreased O
by O
14 O
- O
15 O
% O
for O
the O
1 O
. O
2 O
micro O
g O
iodide B
/ O
day O
iodide B
- O
deficient O
diet O
and O
42 O
- O
52 O
% O
for O
the O
0 O
. O
31 O
micro O
g O
iodide B
/ O
day O
iodide B
- O
deficient O
diet O
. O

In O
rat O
pups O
that O
were O
iodide B
deficient O
during O
gestation O
and O
lactation O
, O
these O
decreases O
in O
serum O
T4 O
levels O
were O
associated O
with O
declines O
in O
thyroid B
hormone I
in O
the O
fetal O
brain O
and O
a O
suppression O
of O
synaptic O
responses O
in O
the O
hippocampal O
region O
of O
the O
brain O
of O
the O
adult O
offspring O
( O
Gilbert O
et O
al O
. O
, O
2013 O
) O
. O

Inhibition O
of O
matrix O
metalloproteinase O
- O
9 O
expression O
by O
docosahexaenoic B
acid I
mediated O
by O
heme B
oxygenase O
1 O
in O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
- O
induced O
MCF O
- O
7 O
human O
breast O
cancer O
cells O
. O

Previous O
studies O
showed O
that O
polyunsaturated B
fatty I
acids I
exhibit O
an O
anti O
- O
cancer O
effect O
in O
various O
human O
carcinoma O
cells O
, O
but O
the O
effect O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
linoleic B
acid I
( O
LA O
) O
on O
metastasis O
of O
breast O
cancer O
cells O
is O
not O
fully O
clarified O
. O

We O
studied O
the O
anti O
- O
metastasis O
potential O
of O
DHA B
and O
LA O
in O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
( O
TPA B
) O
- O
induced O
MCF O
- O
7 O
cells O
. O

We O
found O
that O
TPA B
( O
100 O
ng O
/ O
ml O
) O
induced O
MMP O
- O
9 O
enzyme O
activity O
both O
dose O
- O
and O
time O
- O
dependently O
, O
and O
200 O
mu O
M O
DHA B
and O
LA O
significantly O
inhibited O
MMP O
- O
9 O
mRNA O
and O
protein O
expression O
, O
enzyme O
activity O
, O
cell O
migration O
, O
and O
invasion O
. O

Treatment O
with O
PD98059 B
( O
10 O
mu O
M O
) O
, O
wortmannin B
( O
10 O
mu O
M O
) O
, O
and O
GF109203X B
( O
0 O
. O
5 O
mu O
M O
) O
decreased O
TPA B
- O
induced O
MMP O
- O
9 O
protein O
expression O
and O
enzyme O
activity O
. O

TPA B
- O
induced O
activation O
of O
ERK1 O
, O
Akt O
, O
and O
PKC O
delta O
was O
attenuated O
by O
DHA B
, O
whereas O
LA O
attenuated O
only O
ERK1 O
activation O
. O

GF109203X B
also O
suppressed O
ERK1 O
activation O
. O

EMSA O
showed O
that O
DHA B
, O
LA O
, O
PD98059 B
, O
and O
wortmannin B
decreased O
TPA B
- O
induced O
NF O
- O
kappa O
B O
and O
AP O
- O
1 O
DNA O
- O
binding O
activity O
. O

Furthermore O
, O
DHA B
rather O
than O
LA O
dose O
- O
dependently O
increased O
HO O
- O
1 O
expression O
. O

HO O
- O
1 O
siRNA O
alleviated O
the O
inhibition O
by O
DHA B
of O
TPA B
- O
induced O
MMP O
- O
9 O
protein O
expression O
and O
enzyme O
activity O
in O
MCF O
- O
7 O
cells O
, O
and O
HO O
- O
1 O
knockdown O
reversed O
the O
DHA B
inhibition O
of O
cell O
migration O
. O

These O
results O
suggest O
that O
DHA B
and O
LA O
have O
both O
similar O
and O
divergent O
signaling O
pathways O
in O
the O
suppression O
of O
TPA B
- O
induced O
MCF O
- O
7 O
metastasis O
. O

This O
article O
reviews O
the O
recent O
progress O
on O
ternary O
organic O
photovoltaic O
systems O
, O
including O
polymer O
/ O
small O
molecule O
/ O
functional O
fullerene B
, O
polymer O
/ O
polymer O
/ O
functional O
fullerene B
, O
small O
molecule O
/ O
small O
molecule O
/ O
functional O
fullerene B
, O
polymer O
/ O
functional O
fullerene B
I O
/ O
functional O
fullerene B
II O
, O
and O
polymer O
/ O
quantum O
dot O
or O
metal O
/ O
functional O
fullerene B
systems O
. O

Pretreatment O
with O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
, O
previously O
shown O
to O
increase O
PLD1 O
expression O
and O
activity O
, O
had O
no O
effect O
on O
, O
and O
a O
PLD2 O
- O
selective O
( O
but O
not O
a O
PLD1 O
- O
selective O
) O
inhibitor O
decreased O
, O
cell O
lifting O
- O
induced O
PLD O
activation O
, O
suggesting O
PLD2 O
as O
the O
isoform O
activated O
. O

PLD2 O
interacts O
functionally O
with O
the O
glycerol B
channel O
aquaporin O
- O
3 O
( O
AQP3 O
) O
to O
produce O
phosphatidylglycerol O
( O
PG O
) O
; O
however O
, O
wounding O
resulted O
in O
decreased O
PG O
production O
, O
suggesting O
a O
potential O
PG O
deficiency O
in O
wounded O
cells O
. O

Transplantation O
of O
wild O
- O
type O
, O
Nur77 O
- O
/ O
- O
, O
or O
Nor1 O
- O
/ O
- O
null O
hematopoetic O
precursors O
into O
LDL O
receptor O
( O
LDLR O
) O
- O
/ O
- O
recipient O
mice O
led O
to O
comparable O
development O
of O
atherosclerotic O
lesions O
after O
high O
- O
cholesterol B
diet O
. O

On O
the O
azo B
/ O
hydrazo O
equilibrium O
in O
Sudan O
I O
azo B
dye O
derivatives O
. O

In O
this O
study O
, O
Raman O
, O
infrared O
, O
UV O
/ O
vis O
, O
NMR O
, O
and O
single O
crystal O
X O
- O
ray O
diffraction O
spectroscopies O
are O
used O
to O
elucidate O
the O
tautomeric O
equilibrium O
of O
azo B
dyes O
derived O
from O
1 O
- O
phenyl O
- O
azo O
- O
2 O
- O
naphthol O
( O
Sudan O
I O
) O
. O

A O
new O
crystallographic O
structure O
is O
described O
for O
Sudan O
I O
, O
revealing O
the O
presence O
of O
intramolecular O
hydrogen B
bonds O
and O
supramolecular O
interactions O
, O
such O
as O
the O
unconventional O
C B
- I
H I
. O
. O
. O
O B
hydrogen B
bond O
type O
, O
pi O
- O
stacking O
, O
and O
charge O
- O
dipole O
interactions O
. O

The O
predicted O
spectra O
are O
in O
accordance O
with O
the O
experiments O
carried O
out O
in O
the O
solid O
state O
and O
in O
solution O
of O
dichloromethane B
, O
carbon B
tetrachloride I
, O
and O
chloroform B
, O
suggesting O
the O
hydrazo O
form O
as O
the O
preferable O
tautomer O
in O
gas O
and O
condensate O
phases O
for O
Sudan O
I O
and O
its O
derivatives O
. O

Stereoselective O
Rh2 O
( O
S O
- O
IBAZ O
) O
4 O
- O
catalyzed O
cyclopropanation O
of O
alkenes B
, O
alkynes O
, O
and O
allenes O
: O
asymmetric O
synthesis O
of O
diacceptor O
cyclopropylphosphona O
and O
alkylidenecyclopropa O
. O

A O
mild O
and O
highly O
stereoselective O
rhodium O
( O
II O
) O
- O
catalyzed O
cyclopropanation O
of O
alkenes B
, O
alkynes O
, O
and O
allenes O
with O
diacceptor O
diazo O
compounds O
is O
reported O
. O

Using O
the O
phosphonate B
moiety O
as O
an O
efficient O
trans O
- O
directing O
group O
, O
the O
first O
catalytic O
asymmetric O
route O
to O
diacceptor O
cycloprop O
( O
en O
) O
ylphosphonates O
was O
developed O
by O
employing O
an O
alpha O
- O
cyano O
diazophosphonate O
and O
Rh O
( O
2 O
) O
( O
S O
- O
IBAZ O
) O
( O
4 O
) O
as O
chiral O
catalyst O
. O

Discovery O
of O
thiazolidine B
- I
2 I
, I
4 I
- I
dione I
/ O
biphenylcarbonitrile O
hybrid O
as O
dual O
PPAR O
alpha O
/ O
gamma O
modulator O
with O
antidiabetic O
effect O
: O
in O
vitro O
, O
in O
silico O
and O
in O
vivo O
approaches O
. O

A O
small O
series O
of O
thiazolidine B
- I
2 I
, I
4 I
- I
dione I
and O
barbituric O
acid O
derivatives O
1 O
- O
4 O
was O
prepared O
using O
a O
short O
synthetic O
route O
, O
and O
all O
compounds O
were O
characterized O
by O
elemental O
analysis O
, O
mass O
spectrometry O
, O
and O
NMR O
( O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
) O
spectroscopy O
. O

The O
results O
indicated O
a O
significant O
decrease O
in O
plasma O
glucose B
levels O
. O

In O
these O
binding O
models O
, O
compound O
1 O
may O
bind O
into O
the O
active O
site O
of O
both O
isoforms O
showing O
important O
short O
contacts O
with O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
residues O
: O
Tyr B
473 O
, O
His B
449 O
, O
Ser B
289 O
, O
His B
323 O
; O
and O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
residues O
: O
Tyr B
464 O
, O
His B
440 O
, O
Ser B
280 O
and O
Tyr B
314 O
. O

Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose B
transporter O
- O
4 O
( O
Glut O
- O
4 O
) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5 O
- O
and O
4 O
- O
fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine B
, O
respectively O
. O

Next O
to O
Glut O
- O
4 O
, O
the O
predominant O
protein O
influencing O
glucose B
metabolism O
is O
PPAR O
alpha O
and O
gamma O
whose O
expressions O
were O
also O
positively O
modulated O
. O

Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose B
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine B
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

The O
core O
of O
the O
delayed O
release O
tablets O
consisted O
of O
hydroxypropyl B
methylcellulose O
( O
HPMC O
) O
and O
caffeine B
. O

The O
shell O
consisted O
of O
microcrystalline O
cellulose O
( O
MCC O
) O
and O
glucose B
. O

The O
core O
of O
the O
pH O
resistant O
formulations O
was O
an O
ibuprofen B
and O
PEG B
melt O
and O
the O
shell O
was O
constructed O
from O
HPMC O
and O
a O
basic O
buffer O
. O

The O
pH O
resistant O
formulations O
prevented O
crystallization O
of O
the O
ibuprofen B
in O
the O
core O
during O
dissolution O
despite O
an O
acidic O
dissolution O
medium O
. O

Substituted O
phenyl B
groups O
improve O
the O
pharmacokinetic O
profile O
and O
anti O
- O
inflammatory O
effect O
of O
urea B
- O
based O
soluble O
epoxide B
hydrolase O
inhibitors O
in O
murine O
models O
. O

Soluble O
epoxide B
hydrolase O
inhibitors O
( O
sEHIs O
) O
are O
anti O
- O
inflammatory O
, O
analgesic O
, O
anti O
- O
hypertensive O
, O
cardio O
- O
and O
renal O
- O
protective O
in O
multiple O
animal O
models O
. O

However O
, O
the O
earlier O
adamantyl O
- O
containing O
urea B
- O
based O
inhibitors O
are O
rapidly O
metabolized O
. O

Therefore O
, O
new O
potent O
inhibitors O
with O
the O
adamantyl O
group O
replaced O
by O
a O
substituted O
phenyl B
group O
were O
synthesized O
to O
presumptively O
offer O
better O
pharmacokinetic O
( O
PK O
) O
properties O
. O

Compared O
with O
the O
earlier O
adamantyl O
- O
containing O
urea B
- O
based O
inhibitors O
, O
substituted O
phenyl B
- O
containing O
urea B
- O
based O
inhibitors O
afford O
more O
favorable O
PK O
properties O
, O
such O
as O
higher O
Cmaxs O
, O
larger O
AUCs O
and O
longer O
t1 O
/ O
2s O
, O
which O
, O
as O
expected O
, O
show O
more O
stable O
metabolic O
stability O
. O

The O
substituted O
phenyl B
- O
containing O
sEHIs O
are O
more O
metabolically O
stable O
than O
those O
with O
adamantyl O
group O
, O
resulting O
in O
more O
potent O
efficacy O
in O
vivo O
. O

The O
structures O
of O
thiosemicarbazones O
were O
confirmed O
by O
spectroscopic O
( O
IR O
, O
( B
1 I
) I
H I
NMR O
, O
( B
13 I
) I
C I
NMR O
and O
ESI O
- O
MS O
) O
method O
. O

Amongst O
the O
compounds O
screened O
for O
antioxidant O
activity O
, O
thiosemicarbazones O
4a O
, O
4b O
and O
4c O
showed O
good O
antioxidant O
activity O
on O
DPPH B
. O

The O
compounds O
4g O
, O
4i O
, O
4l O
caused O
significant O
elevation O
of O
SOD O
activity O
and O
4e O
, O
4g O
, O
4i O
, O
4l O
had O
higher O
catalase O
activity O
, O
and O
only O
compounds O
4c O
and O
4f O
expressed O
the O
GSH B
- O
Px O
activity O
. O

Cerebral O
and O
extracerebral O
cholesterol B
metabolism O
and O
CSF O
markers O
of O
Alzheimer O
' O
s O
disease O
. O

The O
disturbances O
of O
the O
cholesterol B
synthesis O
and O
metabolism O
described O
in O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
may O
be O
both O
a O
consequence O
of O
the O
neurodegenerative O
process O
and O
a O
contributor O
to O
the O
pathogenesis O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relationship O
between O
the O
cerebral O
and O
extracerebral O
cholesterol B
synthesis O
and O
metabolism O
, O
and O
the O
AD O
pathology O
as O
reflected O
by O
CSF O
markers O
in O
humans O
. O

We O
evaluated O
the O
relationships O
between O
the O
plasma O
and O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
of O
cholesterol B
, O
the O
cholesterol B
precursors O
lanosterol B
, O
lathosterol O
and O
desmosterol O
, O
and O
the O
cholesterol B
elimination O
products O
24S O
- O
hydroxycholesterol O
and O
27 B
- I
hydroxycholesterol I
, O
and O
the O
CSF O
markers O
for O
AD O
pathology O
A O
beta O
1 O
- O
42 O
and O
p O
- O
tau181 O
in O
86 O
subjects O
with O
normal O
cognition O
and O
in O
107 O
AD O
patients O
. O

CSF O
desmosterol O
, O
cholesterol B
and O
24S O
- O
hydroxycholesterol O
in O
the O
AD O
group O
, O
and O
CSF O
24S O
- O
hydroxycholesterol O
in O
the O
control O
group O
correlated O
with O
the O
p O
- O
tau181 O
levels O
. O

In O
multivariate O
regression O
tests O
including O
age O
, O
gender O
, O
albumin O
ratio O
, O
number O
of O
the O
APOE O
epsilon O
4 O
alleles O
, O
and O
diagnosis O
, O
p O
- O
tau181 O
levels O
independently O
predicted O
the O
CSF O
desmosterol O
, O
cholesterol B
and O
24S O
- O
hydroxycholesterol O
concentrations O
. O

The O
associations O
remained O
significant O
for O
CSF O
cholesterol B
and O
24S O
- O
hydroxycholesterol O
when O
analyses O
were O
separately O
performed O
in O
the O
AD O
group O
. O

The O
results O
suggest O
that O
alterations O
of O
CNS O
cholesterol B
de O
novo O
genesis O
and O
metabolism O
are O
related O
to O
neurodegeneration O
and O
in O
particular O
to O
the O
cerebral O
accumulation O
of O
phosphorylated O
tau O
. O

Lead O
( O
Pb B
) O
is O
considered O
to O
be O
a O
multi O
- O
target O
toxicant O
. O

The O
Pb O
- O
acetate O
( O
5mg O
/ O
kg O
body O
weight O
) O
treated O
rats O
exhibited O
a O
significant O
inhibition O
of O
co O
- O
enzymes O
Q O
, O
antioxidant O
enzymes O
and O
reduced O
glutathione B
levels O
in O
the O
tissues O
. O

Simultaneous O
administration O
of O
test O
extract O
( O
25 O
, O
50 O
and O
100mg O
/ O
kg O
body O
weight O
) O
, O
could O
significantly O
restore O
the O
biochemical O
and O
haematological O
parameters O
near O
to O
the O
normal O
status O
through O
antioxidant O
activity O
and O
/ O
or O
by O
preventing O
bioaccumulation O
of O
Pb B
within O
the O
tissues O
of O
experimental O
rats O
. O

Presence O
of O
substantial O
quantity O
of O
phenolics B
and O
flavonoids B
in O
the O
extract O
may O
be O
responsible O
for O
the O
observed O
protective O
role O
against O
Pb B
- O
intoxication O
. O

Results O
show O
that O
the O
main O
components O
were O
alpha O
- O
thujone O
, O
camphor B
, O
borneol B
, O
gamma O
- O
muurolene O
and O
sclareol O
for O
all O
the O
samples O
, O
but O
the O
percentages O
of O
these O
compounds O
varied O
depending O
on O
environmental O
factors O
such O
as O
altitude O
, O
water O
availability O
and O
pedo O
- O
climatic O
conditions O
. O

Alkyl B
esters I
of O
gallic B
acid I
as O
anticancer O
agents O
: O
a O
review O
. O

The O
current O
review O
presents O
the O
antitumoral O
properties O
of O
gallic B
acid I
and O
its O
ester B
derivatives O
. O

Numerous O
studies O
have O
indicated O
that O
the O
alkyl B
esters I
are O
more O
effective O
against O
tumor O
cell O
lines O
than O
gallic B
acid I
, O
and O
that O
this O
activity O
is O
related O
to O
their O
hydrophobic O
moiety O
. O

Chlamydophila O
pneumoniae O
endonuclease O
IV O
prefers O
to O
remove O
mismatched O
3 O
' O
ribonucleotides O
: O
implication O
in O
proofreading O
mismatched O
3 O
' O
- O
terminal O
nucleotides B
in O
short O
- O
patch O
repair O
synthesis O
. O

DNA O
polymerase O
I O
( O
DNApolI O
) O
catalyzes O
DNA O
synthesis O
during O
Okazaki O
fragment O
maturation O
, O
base O
excision O
repair O
, O
and O
nucleotide B
excision O
repair O
. O

Some O
bacterial O
DNApolIs O
are O
deficient O
in O
3 O
' O
- O
5 O
' O
exonuclease O
, O
which O
is O
required O
for O
removing O
an O
incorrectly O
incorporated O
3 O
' O
- O
terminal O
nucleotide B
during O
DNA O
elongation O
by O
DNA O
polymerase O
activity O
. O

The O
key O
amino B
acid I
residues O
in O
the O
exonuclease O
center O
of O
Chlamydophila O
pneumoniae O
DNApolI O
( O
CpDNApolI O
) O
are O
naturally O
mutated O
, O
resulting O
in O
the O
loss O
of O
3 O
' O
- O
5 O
' O
exonuclease O
. O

Hence O
, O
the O
manner O
by O
which O
CpDNApolI O
proofreads O
the O
incorrectly O
incorporated O
nucleotide B
during O
DNA O
synthesis O
warrants O
clarification O
. O

Among O
them O
, O
C O
. O
pneumoniae O
endonuclease O
IV O
( O
CpendoIV O
) O
possesses O
3 O
' O
- O
5 O
' O
exonuclease O
activity O
that O
prefers O
to O
remove O
mismatched O
3 O
' O
- O
terminal O
nucleotides B
in O
the O
nick O
, O
gap O
, O
and O
3 O
' O
recess O
of O
a O
double O
- O
stranded O
DNA O
( O
dsDNA O
) O
. O

Finally O
, O
we O
reconstituted O
the O
proofreading O
reaction O
of O
the O
mismatched O
3 O
' O
- O
terminal O
nucleotide B
using O
the O
dsDNA O
with O
a O
nick O
or O
3 O
' O
recess O
as O
substrate O
. O

Upon O
proofreading O
of O
the O
mismatched O
3 O
' O
- O
terminal O
nucleotide B
by O
CpendoIV O
, O
CpDNApolI O
can O
correctly O
reincorporate O
the O
matched O
nucleotide B
and O
the O
nick O
is O
further O
sealed O
by O
DNA O
ligase O
. O

Nuclear O
receptor O
CAR O
specifically O
activates O
the O
two O
- O
pore O
K B
+ I
channel O
Kcnk1 O
gene O
in O
male O
mouse O
livers O
, O
which O
attenuates O
phenobarbital B
- O
induced O
hepatic O
hyperplasia O
. O

KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two O
- O
pore O
K B
( I
+ I
) I
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital B
treatment O
. O

Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male O
- O
specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital B
- O
inducible O
antihyperplasia O
factor O
. O

Upon O
activation O
by O
phenobarbital B
, O
nuclear O
receptor O
CAR O
binds O
the O
97 O
- O
bp O
response O
element O
( O
- O
2441 O
/ O
- O
2345 O
) O
within O
the O
Kcnk1 O
promoter O
. O

Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O
- O
/ O
- O
) O
male O
mice O
compared O
with O
those O
of O
Kcnk1 O
( O
+ O
/ O
+ O
) O
males O
after O
phenobarbital B
treatment O
. O

Thus O
, O
KCNK1 O
suppresses O
phenobarbital B
- O
induced O
hyperplasia O
. O

These O
results O
indicate O
that O
phenobarbital B
treatment O
induces O
KCNK1 O
to O
elicit O
a O
male O
- O
specific O
and O
growth O
- O
suppressing O
signal O
. O

Postweaning O
exposure O
to O
dietary O
zearalenone B
, O
a O
mycotoxin O
, O
promotes O
premature O
onset O
of O
puberty O
and O
disrupts O
early O
pregnancy O
events O
in O
female O
mice O
. O

Zearalenone B
( O
ZEA B
) O
is O
a O
mycotoxin O
commonly O
found O
in O
contaminated O
livestock O
feed O
and O
human O
food O
with O
levels O
in O
the O
range O
of O
ppb O
and O
low O
ppm O
. O

It O
was O
hypothesized O
that O
ZEA B
, O
an O
endocrine O
disruptor O
, O
could O
affect O
puberty O
and O
early O
pregnancy O
. O

To O
test O
this O
hypothesis O
, O
newly O
weaned O
( O
3 O
weeks O
old O
) O
C57BL O
/ O
6J O
female O
mice O
were O
exposed O
to O
0 O
, O
0 O
. O
002 O
, O
4 O
, O
10 O
, O
and O
40 O
ppm O
ZEA B
and O
0 O
. O
05 O
ppm O
diethylstilbestrol B
( O
positive O
control O
) O
in O
phytoestrogen O
- O
free O
AIN O
- O
93G O
diet O
. O

Females O
exposed O
to O
10 O
and O
40 O
ppm O
ZEA B
diets O
showed O
earlier O
onset O
of O
vaginal O
opening O
. O

Those O
treated O
with O
40 O
ppm O
ZEA B
diet O
also O
had O
earlier O
first O
copulation O
plug O
and O
irregular O
estrous O
cyclicity O
. O

Exposure O
to O
40 O
ppm O
ZEA B
diet O
resulted O
in O
reduced O
percentage O
of O
plugged O
mice O
with O
implantation O
sites O
, O
distended O
uterine O
appearance O
, O
and O
retained O
expression O
of O
progesterone B
receptor O
in O
D4 O
. O
5 O
uterine O
epithelium O
. O

To O
determine O
the O
exposure O
timing O
and O
mechanisms O
of O
disrupted O
embryo O
implantation O
, O
four O
groups O
of O
females O
were O
fed O
with O
0 O
or O
40 O
ppm O
ZEA B
diets O
during O
premating O
( O
weaning O
to O
mating O
) O
and O
postmating O
( O
D0 O
. O
5 O
- O
D4 O
. O
5 O
) O
, O
respectively O
. O

Premating O
exposure O
to O
40 O
ppm O
ZEA B
diet O
reduced O
fertilization O
rate O
, O
whereas O
postmating O
exposure O
to O
40 O
ppm O
ZEA B
diet O
delayed O
embryo O
transport O
and O
preimplantation O
embryo O
development O
, O
which O
subsequently O
affected O
embryo O
implantation O
. O

These O
data O
demonstrate O
that O
postweaning O
exposure O
to O
dietary O
ZEA B
can O
promote O
premature O
onset O
of O
puberty O
and O
disrupt O
early O
pregnancy O
events O
. O

Multiple O
clinical O
trials O
are O
currently O
in O
progress O
to O
evaluate O
the O
antimalarial O
agent O
chloroquine B
( O
generally O
in O
its O
clinical O
formulation O
as O
hydroxychloroquine B
) O
and O
its O
impact O
on O
various O
forms O
of O
cancer O
therapy O
. O

In O
this O
commentary O
/ O
review O
, O
we O
focus O
on O
the O
relatively O
limited O
number O
of O
studies O
in O
the O
literature O
where O
chloroquine B
has O
been O
tested O
in O
combination O
with O
chemotherapy O
or O
radiation O
in O
experimental O
tumor O
- O
bearing O
animal O
models O
. O

We O
also O
present O
recent O
data O
from O
our O
own O
laboratories O
, O
in O
cell O
culture O
experiments O
as O
well O
as O
in O
vivo O
studies O
, O
which O
demonstrate O
that O
neither O
chloroquine B
nor O
silencing O
of O
an O
autophagy O
regulatory O
gene O
was O
effective O
in O
conferring O
radiation O
sensitivity O
in O
an O
experimental O
model O
of O
breast O
cancer O
. O

The O
capacity O
for O
sensitization O
by O
chloroquine B
appears O
to O
be O
quite O
wide O
- O
ranging O
, O
with O
dramatic O
effects O
for O
some O
drugs O
/ O
tumor O
models O
and O
modest O
or O
minimal O
effects O
in O
others O
. O

The O
results O
of O
thermogravimetric O
analysis O
( O
TGA O
) O
, O
elemental O
analysis O
( O
EA O
) O
, O
and O
( B
1 I
) I
H I
/ O
( B
13 I
) I
C I
NMR O
spectroscopy O
confirmed O
the O
cluster O
composition O
. O

The O
physico O
- O
chemical O
" O
anatomy O
" O
of O
the O
tautomerization O
through O
the O
DPT O
of O
the O
biologically O
important O
pairs O
of O
hypoxanthine B
with O
DNA O
bases O
: O
QM O
and O
QTAIM O
perspectives O
. O

The O
biologically O
important O
tautomerization O
of O
the O
Hyp B
. O
Cyt O
, O
Hyp B
* O
. O
Thy O
and O
Hyp B
. O
Hyp B
base O
pairs O
to O
the O
Hyp B
* O
. O
Cyt O
* O
, O
Hyp B
. O
Thy O
* O
and O
Hyp B
* O
. O
Hyp B
* O
base O
pairs O
, O
respectively O
, O
by O
the O
double O
proton O
transfer O
( O
DPT O
) O
was O
comprehensively O
studied O
in O
vacuo O
and O
in O
the O
continuum O
with O
a O
low O
dielectric O
constant O
( O
epsilon O
= O
4 O
) O
corresponding O
to O
hydrophobic O
interfaces O
of O
protein O
- O
nucleic O
acid O
interactions O
by O
combining O
theoretical O
investigations O
at O
the O

Based O
on O
the O
sweeps O
of O
the O
energetic O
, O
electron O
- O
topological O
, O
geometric O
and O
polar O
parameters O
, O
which O
describe O
the O
course O
of O
the O
tautomerization O
along O
the O
intrinsic O
reaction O
coordinate O
( O
IRC O
) O
, O
it O
was O
proved O
that O
the O
tautomerization O
through O
the O
DPT O
is O
concerted O
and O
asynchronous O
process O
for O
the O
Hyp B
. O
Cyt O
and O
Hyp B
* O
. O
Thy O
base O
pairs O
, O
while O
concerted O
and O
synchronous O
for O
the O
Hyp B
. O
Hyp B
homodimer O
. O

The O
nine O
key O
points O
along O
the O
IRC O
of O
the O
Hyp B
. O
Cyt O
< O
- O
- O
> O
Hyp B
* O
. O
Cyt O
* O
and O
Hyp B
* O
. O
Thy O
< O
- O
- O
> O
Hyp B
. O
Thy O
* O
tautomerizations O
and O
the O
six O
key O
points O
of O
the O
Hyp B
. O
Hyp B
< O
- O
- O
> O
Hyp B
* O
. O
Hyp B
* O
tautomerization O
have O
been O
identified O
and O
fully O
characterized O
. O

These O
key O
points O
could O
be O
considered O
as O
electron O
- O
topological O
" O
fingerprints O
" O
of O
concerted O
asynchronous O
( O
for O
Hyp B
. O
Cyt O
and O
Hyp B
* O
. O
Thy O
) O
or O
synchronous O
( O
for O
Hyp B
. O
Hyp B
) O
tautomerization O
process O
via O
the O
DPT O
. O

It O
was O
found O
, O
that O
in O
the O
Hyp B
* O
. O
Cyt O
* O
, O
Hyp B
. O
Thy O
* O
, O
Hyp B
. O
Hyp B
and O
Hyp B
* O
. O
Hyp B
* O
base O
pairs O
all O
H B
- O
bonds O
are O
significantly O
cooperative O
and O
mutually O
reinforce O
each O
other O
, O
while O
the O
C2H O
. O
. O
. O
O2 O
H O
- O
bond O
in O
the O
Hyp B
. O
Cyt O
base O
pair O
and O
the O
O6H O
. O
. O
. O
O4 O
H B
- O
bond O
in O
the O
Hyp B
* O
. O
Thy O
base O
pair O
behave O
anti O
- O
cooperatively O
, O
i O
. O
e O
. O
, O
they O
become O
weakened O
, O
while O
two O
others O
become O
strengthened O
. O

Zinc B
deficiency O
induced O
in O
Swiss O
3T3 O
cells O
by O
a O
low O
- O
zinc B
medium O
impairs O
calcium B
entry O
and O
two O
mechanisms O
of O
entry O
are O
involved O
. O

Zinc B
deficiency O
in O
3T3 O
cells O
induced O
by O
the O
use O
of O
diethylenetriaminepe O
( O
DTPA B
) O
has O
been O
shown O
to O
impair O
calcium B
entry O
associated O
with O
failure O
of O
proliferation O
when O
the O
cells O
are O
stimulated O
with O
polypeptide O
growth O
factors O
( O
GF O
) O
. O

These O
functions O
of O
zinc B
have O
been O
evaluated O
here O
in O
the O
same O
clone O
of O
cells O
by O
simple O
depletion O
using O
a O
low O
- O
zinc B
medium O
( O
0 O
. O
05 O
mu O
mol O
/ O
L O
zinc B
) O
without O
chelator O
. O

Confluent O
cells O
were O
maintained O
for O
1 O
day O
in O
the O
low O
- O
zinc B
medium O
without O
GF O
, O
then O
loaded O
with O
Fluo B
- I
4 I
, O
and O
stimulated O
with O
GF O
. O

Calcium B
entry O
was O
measured O
by O
the O
increase O
in O
sustained O
fluorescence O
. O

It O
was O
preceded O
by O
the O
release O
of O
stored O
calcium B
as O
observed O
in O
the O
previous O
study O
using O
DTPA B
. O

Zinc B
deprivation O
decreased O
calcium B
entry O
when O
calcium B
was O
added O
at O
0 O
or O
0 O
. O
05 O
mmol O
/ O
L O
but O
not O
when O
0 O
. O
1 O
mmol O
/ O
L O
or O
higher O
. O

Cell O
proliferation O
reflected O
similar O
effects O
of O
zinc B
and O
calcium B
concentrations O
. O

In O
a O
newly O
acquired O
clone O
of O
3T3 O
cells O
, O
GF O
did O
not O
induce O
internal O
calcium B
release O
but O
thapsigargin B
( O
TG O
) O
did O
. O

When O
added O
in O
a O
low O
- O
calcium B
medium O
, O
both O
agonists O
stimulated O
calcium B
entry O
when O
external O
calcium B
was O
added O
, O
suggesting O
that O
two O
different O
mechanisms O
of O
entry O
were O
impaired O
by O
zinc B
deficiency O
. O

Zinc B
deficiency O
produced O
by O
DTPA B
in O
the O
newer O
clones O
gave O
similar O
results O
, O
decreasing O
calcium B
entry O
induced O
by O
both O
agonists O
. O

The O
results O
confirm O
the O
earlier O
observation O
that O
zinc B
deficiency O
impairs O
calcium B
entry O
into O
3T3 O
cells O
when O
stimulated O
by O
GF O
and O
show O
that O
the O
cells O
can O
take O
up O
calcium B
by O
either O
store O
- O
operated O
or O
receptor O
- O
operated O
mechanisms O
. O

Polyethylene B
Glycol I
and O
Polyethylenimine B
Dual O
- O
Functionalized O
Nano O
- O
Graphene B
Oxide I
for O
Photothermally O
Enhanced O
Gene O
Delivery O
. O

Graphene B
oxide I
( O
GO O
) O
has O
been O
extensively O
explored O
in O
nanomedicine O
for O
its O
excellent O
physiochemical O
, O
electrical O
, O
and O
optical O
properties O
. O

Here O
, O
polyethylene B
glycol I
( O
PEG B
) O
and O
polyethylenimine B
( O
PEI B
) O
are O
covalently O
conjugated O
to O
GO O
via O
amide B
bonds O
, O
obtaining O
a O
physiologically O
stable O
dual O
- O
polymer O
- O
functionalized O
nano O
- O
GO O
conjugate O
( O
NGO O
- O
PEG B
- O
PEI B
) O
with O
ultra O
- O
small O
size O
. O

Compared O
with O
free O
PEI B
and O
the O
GO O
- O
PEI B
conjugate O
without O
PEGylation O
, O
NGO O
- O
PEG B
- O
PEI B
shows O
superior O
gene O
transfection O
efficiency O
without O
serum O
interference O
, O
as O
well O
as O
reduced O
cytotoxicity O
. O

Utilizing O
the O
NIR O
optical O
absorbance O
of O
NGO O
, O
the O
cellular O
uptake O
of O
NGO O
- O
PEG B
- O
PEI B
is O
shown O
to O
be O
enhanced O
under O
a O
low O
power O
NIR O
laser O
irradiation O
, O
owing O
to O
the O
mild O
photothermal O
heating O
that O
increases O
the O
cell O
membrane O
permeability O
without O
significantly O
damaging O
cells O
. O

As O
the O
results O
, O
remarkably O
enhanced O
plasmid O
DNA O
transfection O
efficiencies O
induced O
by O
the O
NIR O
laser O
are O
achieved O
using O
NGO O
- O
PEG B
- O
PEI B
as O
the O
light O
- O
responsive O
gene O
carrier O
. O

More O
importantly O
, O
it O
is O
shown O
that O
our O
NGO O
- O
PEG B
- O
PEI B
is O
able O
to O
deliver O
small O
interfering O
RNA O
( O
siRNA O
) O
into O
cells O
under O
the O
control O
of O
NIR O
light O
, O
resulting O
in O
obvious O
down O
- O
regulation O
of O
the O
target O
gene O
, O
Polo O
- O
like O
kinase O
1 O
( O
Plk1 O
) O
, O
in O
the O
presence O
of O
laser O
irradiation O
. O

Results O
revealed O
that O
cholesterol B
, O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
and O
glutathion O
peroxidase O
( O
GPx O
) O
enzyme O
were O
significantly O
higher O
in O
the O
38 O
smoker O
sprayers O
than O
in O
the O
42 O
nonsmoker O
sprayers O
. O

Cholesterol B
and O
LDL O
were O
correlated O
with O
smoking O
index O
and O
high O
- O
density O
lipoprotein O
( O
HDL O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
enzyme O
and O
zinc B
( O
Zn B
) O
were O
inversely O
correlated O
with O
duration O
of O
pesticides O
' O
exposure O
. O

In O
nonsmokers O
, O
LDL O
and O
cholesterol B
were O
negatively O
correlated O
with O
SOD O
and O
correlated O
with O
malondialdehyde B
( O
MDA B
) O
, O
and O
cholesterol B
was O
negatively O
correlated O
with O
Zn B
. O

HDL O
was O
negatively O
correlated O
with O
MDA B
in O
all O
the O
sprayers O
, O
but O
was O
correlated O
with O
GPx O
in O
smokers O
and O
with O
Zn B
in O
nonsmokers O
. O

In O
smokers O
, O
LDL O
was O
negatively O
correlated O
with O
GPx O
, O
HDL O
was O
negatively O
correlated O
with O
MDA B
and O
triglycerides B
and O
very O
- O
low O
- O
density O
lipoprotein O
were O
negatively O
correlated O
with O
Zn B
. O

MDA B
was O
negatively O
correlated O
with O
SOD O
, O
GPx O
and O
Zn B
. O

Although O
it O
has O
been O
suggested O
that O
high O
- O
resolution O
computed O
tomography O
( O
HRCT O
) O
scans O
can O
be O
obtained O
when O
plain O
radiographs O
are O
equivocal O
for O
the O
presence O
of O
interstitial O
lung O
fibrosis O
( O
ILF O
) O
caused O
by O
inhalation O
of O
dust O
, O
such O
as O
silica B
, O
asbestos O
fibres O
, O
etc O
. O
, O
the O
specificity O
of O
the O
findings O
remains O
in O
question O
. O

The O
levels O
of O
zinc B
( O
Zn B
) O
, O
copper B
( O
Cu B
) O
, O
iron B
( O
Fe B
) O
, O
magnesium B
( O
Mg B
) O
, O
calcium B
( O
Ca B
) O
, O
potassium B
( O
K B
) O
, O
chlorine B
( O
Cl B
) O
, O
sodium B
( O
Na B
) O
and O
phosphorus B
( O
P B
) O
were O
measured O
by O
autoanalyzer O
using O
commercial O
kits O
. O

Although O
there O
was O
no O
statistical O
difference O
( O
p O
> O
0 O
. O
05 O
) O
between O
the O
groups O
regarding O
the O
levels O
of O
K B
, O
P B
, O
Mg B
, O
Na B
, O
Cl B
, O
Zn B
, O
Fe B
, O
Ca B
and O
Cu B
, O
some O
positive O
correlations O
were O
observed O
in O
controls O
but O
not O
in O
smokers O
. O

From O
the O
perspective O
of O
prevention O
, O
the O
spread O
and O
prediction O
of O
hydrochloric O
acid O
( O
HCl B
) O
that O
escaped O
from O
the O
metal O
- O
etching O
chamber O
during O
maintenance O
were O
studied O
in O
this O
article O
. O

The O
computational O
fluid O
dynamics O
technology O
was O
used O
for O
a O
three O
- O
dimensional O
numerical O
simulation O
of O
the O
indoor O
air O
velocity O
field O
and O
the O
HCl B
concentration O
field O
, O
and O
the O
simulation O
results O
were O
then O
compared O
with O
the O
on O
- O
site O
monitoring O
data O
to O
verify O
the O
correctness O
and O
feasibility O
. O

Plasmon O
dynamics O
in O
colloidal O
Au O
2 O
Cd O
alloy O
- O
CdSe B
core O
/ O
shell O
nanocrystals O
. O

Here O
we O
report O
the O
synthesis O
of O
colloidal O
Au O
2 O
Cd O
( O
core O
) O
/ O
CdSe B
( O
shell O
) O
nanocrystal O
heterostructures O
, O
which O
were O
characterized O
extensively O
with O
several O
structural O
and O
optical O
techniques O
, O
including O
time O
- O
resolved O
fluorescence O
and O
broad O
- O
band O
transient O
absorption O
spectroscopy O
( O
both O
below O
and O
above O
the O
CdSe B
band O
gap O
) O
. O

Thermodynamic O
studies O
of O
ionic O
hydration O
and O
interactions O
for O
amino B
acid I
ionic O
liquids O
in O
aqueous O
solutions O
at O
298 O
. O
15 O
K O
. O

Amino B
acid I
ionic O
liquids O
are O
a O
special O
class O
of O
ionic O
liquids O
due O
to O
their O
unique O
acid O
- O
base O
behavior O
, O
biological O
significance O
, O
and O
applications O
in O
different O
fields O
such O
as O
templates O
in O
synthetic O
chemistry O
, O
stabilizers O
for O
biological O
macromolecules O
, O
etc O
. O

The O
physicochemical O
properties O
of O
these O
ionic O
liquids O
can O
easily O
be O
altered O
by O
making O
the O
different O
combinations O
of O
amino B
acids I
as O
anion O
along O
with O
possible O
cation O
modification O
which O
makes O
amino B
acid I
ionic O
liquids O
more O
suitable O
to O
understand O
the O
different O
kinds O
of O
molecular O
and O
ionic O
interactions O
with O
sufficient O
depth O
so O
that O
they O
can O
provide O
fruitful O
information O
for O
a O
molecular O
level O
understanding O
of O
more O
complicated O
biological O
processes O
. O

In O
this O
context O
, O
volumetric O
and O
osmotic O
coefficient O
measurements O
for O
aqueous O
solutions O
containing O
1 O
- O
ethyl O
- O
3 O
- O
methylimidazolium O
( O
[ O
Emim O
] O
) O
based O
amino B
acid I
ionic O
liquids O
of O
glycine B
, O
alanine B
, O
valine B
, O
leucine B
, O
and O
isoleucine B
are O
reported O
at O
298 O
. O
15 O
K O
. O

The O
enthalpy O
- O
entropy O
compensation O
effect O
, O
explained O
using O
the O
Starikov O
- O
Nord O
e O
n O
model O
of O
enthalpy O
- O
entropy O
compensation O
, O
and O
partial O
molar O
entropy O
analysis O
for O
aqueous O
[ O
Emim O
] O
[ O
Gly B
] O
solutions O
are O
made O
by O
using O
experimental O
Gibb O
' O
s O
free O
energy O
data O
and O
literature O
enthalpy O
data O
. O

Analysis O
of O
the O
results O
further O
shows O
that O
the O
hydration O
of O
amino B
acid I
ionic O
liquids O
occurs O
through O
the O
cooperative O
H B
- O
bond O
formation O
with O
the O
kosmotropic O
effect O
in O
contrast O
to O
the O
usual O
inorganic O
salts O
or O
hydrophobic O
salts O
like O
tetraalkylammonium O
halides O
. O

Spiroketal O
formation O
and O
modification O
in O
avermectin B
biosynthesis O
involves O
a O
dual O
activity O
of O
AveC O
. O

Avermectins B
( O
AVEs O
) O
, O
which O
are O
widely O
used O
for O
the O
treatment O
of O
agricultural O
parasitic O
diseases O
, O
belong O
to O
a O
family O
of O
6 O
, O
6 O
- O
spiroketal O
moiety O
- O
containing O
, O
macrolide B
natural O
products O
. O

AVE O
biosynthesis O
is O
known O
to O
employ O
a O
type O
I O
polyketide B
synthase O
( O
PKS O
) O
system O
to O
assemble O
the O
molecular O
skeleton O
for O
further O
functionalization O
. O

These O
reactions O
take O
place O
between O
the O
closures O
of O
the O
hexene O
ring O
and O
16 O
- O
membered O
macrolide B
and O
the O
formation O
of O
the O
hexahydrobenzofuran O
unit O
. O

The O
trypsin O
- O
like O
serine B
protease O
plasmin O
is O
a O
target O
for O
the O
development O
of O
antifibrinolytic O
drugs O
for O
use O
in O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
or O
organ O
transplantations O
to O
reduce O
excessive O
blood O
loss O
. O

The O
most O
potent O
inhibitor O
8 O
binds O
to O
plasmin O
with O
an O
inhibition O
constant O
of O
0 O
. O
2 O
nM O
, O
whereas O
K O
( O
i O
) O
values O
> O
1 O
mu O
M O
were O
determined O
for O
nearly O
all O
other O
tested O
trypsin O
- O
like O
serine B
proteases O
, O
with O
the O
exception O
of O
trypsin O
, O
which O
is O
also O
inhibited O
in O
the O
nanomolar O
range O
. O

The O
dialkylated O
piperazine B
- O
linker O
segment O
contributes O
to O
an O
excellent O
solubility O
of O
all O
analogues O
. O

The O
free O
fatty O
acid O
receptor O
1 O
( O
FFA1 O
, O
also O
known O
as O
GPR40 O
) O
mediates O
enhancement O
of O
glucose B
- O
stimulated O
insulin O
secretion O
and O
is O
emerging O
as O
a O
new O
target O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O

We O
here O
describe O
the O
continued O
structure O
- O
activity O
exploration O
and O
optimization O
of O
this O
compound O
series O
, O
leading O
to O
the O
discovery O
of O
the O
more O
potent O
agonist O
40 O
, O
a O
compound O
with O
low O
lipophilicity O
, O
excellent O
in O
vitro O
metabolic O
stability O
and O
permeability O
, O
complete O
oral O
bioavailability O
, O
and O
appreciable O
efficacy O
on O
glucose B
tolerance O
in O
mice O
. O

A O
safety O
study O
on O
single O
intravenous O
dose O
of O
tetrachloro O
- O
diphenyl O
glycoluril O
[ O
iodogen O
] O
dissolved O
in O
dimethyl O
sulphoxide O
( O
DMSO B
) O
. O

Iodogen O
( O
tetrachloro O
- O
diphenyl O
glycoluril O
) O
dissolved O
in O
DMSO B
( O
dimethyl O
sulphoxide O
) O
appears O
indispensable O
in O
radioiodination O
of O
hypericin O
for O
a O
new O
anticancer O
strategy O
. O

We O
studied O
the O
safety O
of O
intravenously O
administered O
iodogen O
/ O
DMSO B
in O
mice O
( O
n O
= O
132 O
) O
. O

Median O
lethal O
dose O
( O
LD O
( O
50 O
) O
) O
of O
iodogen O
/ O
DMSO B
was O
determined O
with O
doses O
of O
40 O
. O
0 O
, O
50 O
. O
0 O
, O
55 O
. O
0 O
, O
60 O
. O
0 O
, O
65 O
. O
0 O
and O
70 O
. O
0 O
mg O
/ O
kg O
. O

Next O
, O
toxicity O
of O
iodogen O
/ O
DMSO B
at O
30 O
. O
0 O
mg O
/ O
kg O
was O
evaluated O
using O
saline O
and O
DMSO B
as O
controls O
. O

LD O
( O
50 O
) O
values O
of O
iodogen O
/ O
DMSO B
were O
59 O
. O
5 O
mg O
/ O
kg O
( O
95 O
% O
confidence O
limits O
( O
CI O
) O
: O
54 O
. O
1 O
- O
65 O
. O
4 O
mg O
/ O
kg O
) O
and O
61 O
. O
0 O
mg O
/ O
kg O
( O
95 O
% O
CI O
: O
56 O
. O
2 O
- O
66 O
. O
2 O
mg O
/ O
kg O
) O
for O
female O
and O
male O
mice O
, O
respectively O
. O

Similar O
to O
that O
of O
control O
groups O
, O
no O
animal O
deaths O
were O
encountered O
after O
iodogen O
/ O
DMSO B
administration O
at O
30 O
. O
0 O
mg O
/ O
kg O
. O

Body O
weights O
over O
24 O
h O
were O
not O
altered O
in O
all O
groups O
, O
but O
significantly O
higher O
in O
iodogen O
/ O
DMSO B
and O
DMSO B
groups O
( O
p O
< O
0 O
. O
05 O
) O
14 O
d O
post O
- O
injection O
. O

Blood O
urea B
nitrogen B
and O
alkaline O
phosphatase O
increased O
( O
p O
< O
0 O
. O
05 O
) O
in O
iodogen O
/ O
DMSO B
group O
without O
clinical O
symptoms O
. O

A O
single O
dose O
of O
iodogen O
/ O
DMSO B
up O
to O
30 O
. O
0 O
mg O
/ O
kg O
, O
over O
3000 O
times O
the O
dose O
in O
potential O
human O
applications O
, O
appears O
safe O
, O
with O
an O
LD O
( O
50 O
) O
doubling O
that O
dose O
in O
mice O
. O

The O
discovered O
synthetic O
route O
to O
introduce O
three O
different O
substituents O
independently O
paves O
the O
way O
for O
versatile O
applications O
of O
the O
7 B
- I
azaindole I
core O
. O

Paracetamol B
release O
from O
granulates O
was O
very O
rapid O
, O
but O
after O
compression O
of O
the O
granules O
into O
tablets O
, O
drug O
release O
was O
considerably O
slower O
. O

The O
mechanism O
of O
discrimination O
between O
oxidized O
and O
reduced O
coenzyme O
in O
the O
aldehyde B
dehydrogenase O
domain O
of O
Aldh1l1 O
. O

Aldh1l1 O
, O
also O
known O
as O
10 O
- O
formyltetrahydrofola O
dehydrogenase O
( O
FDH O
) O
, O
contains O
the O
carboxy B
- O
terminal O
domain O
( O
Ct O
- O
FDH O
) O
, O
which O
is O
a O
structural O
and O
functional O
homolog O
of O
aldehyde B
dehydrogenases O
( O
ALDHs O
) O
. O

This O
domain O
is O
capable O
of O
catalyzing O
the O
NADP B
( I
+ I
) I
- O
dependent O
oxidation O
of O
short O
chain O
aldehydes B
to O
their O
corresponding O
acids O
, O
and O
similar O
to O
most O
ALDHs O
it O
has O
two O
conserved O
catalytic O
residues O
, O
Cys707 O
and O
Glu673 O
. O

Specifically O
, O
the O
replacement O
of O
Cys707 O
with O
an O
alanine B
resulted O
in O
the O
enzyme O
lacking O
the O
ability O
to O
differentiate O
between O
the O
oxidized O
and O
reduced O
coenzyme O
. O

We O
suggested O
that O
this O
was O
due O
to O
the O
loss O
of O
a O
covalent O
bond O
between O
the O
cysteine B
and O
the O
C4N O
atom O
of O
nicotinamide B
ring O
of O
NADP B
( I
+ I
) I
formed O
during O
Ct O
- O
FDH O
catalysis O
. O

To O
obtain O
further O
insight O
into O
the O
functional O
significance O
of O
the O
covalent O
bond O
between O
Cys707 O
and O
the O
coenzyme O
, O
and O
the O
overall O
role O
of O
the O
two O
catalytic O
residues O
in O
the O
coenzyme O
binding O
and O
positioning O
, O
we O
have O
now O
solved O
crystal O
structures O
of O
Ct O
- O
FDH O
in O
the O
complex O
with O
thio O
- O
NADP O
( O
+ O
) O
and O
the O
complexes O
of O
the O
C707S O
mutant O
with O
NADP B
( I
+ I
) I
and O
NADPH B
. O

X O
- O
ray O
structure O
of O
the O
V301L O
aldo O
- O
keto O
reductase O
1B10 O
complexed O
with O
NADP B
( I
+ I
) I
and O
the O
potent O
aldose B
reductase O
inhibitor O
fidarestat O
: O
implications O
for O
inhibitor O
binding O
and O
selectivity O
. O

Only O
one O
crystal O
structure O
is O
currently O
available O
for O
tumor O
marker O
AKR1B10 O
, O
complexed O
with O
NADP B
( I
+ I
) I
and O
tolrestat O
, O
which O
is O
an O
aldose B
reductase O
inhibitor O
( O
ARI O
) O
of O
the O
carboxylic B
acid I
type O
. O

Previously O
, O
fidarestat O
was O
found O
to O
be O
safe O
in O
phase O
III O
trials O
for O
diabetic O
neuropathy O
and O
, O
consistent O
with O
its O
low O
in O
vivo O
side O
effects O
, O
was O
highly O
selective O
for O
aldose B
reductase O
( O
AR O
or O
AKR1B1 O
) O
versus O
aldehyde B
reductase O
( O
AKR1A1 O
) O
. O

Now O
, O
inhibition O
studies O
showed O
that O
fidarestat O
was O
indeed O
1300 O
- O
fold O
more O
selective O
for O
AR O
as O
compared O
to O
AKR1B10 O
, O
while O
the O
change O
of O
Val B
to O
Leu B
( O
found O
in O
AR O
) O
caused O
a O
20 O
- O
fold O
decrease O
in O
the O
IC50 O
value O
with O
fidarestat O
. O

In O
the O
crystal O
structure O
, O
a O
significant O
motion O
of O
loop O
A O
was O
observed O
between O
AR O
and O
V301L O
AKR1B10 O
, O
linked O
to O
a O
Phe B
- O
122 O
/ O
Phe B
- O
123 O
side O
chain O
displacement O
. O

This O
was O
due O
to O
the O
presence O
of O
the O
more O
voluminous O
Gln B
- O
303 O
side O
chain O
( O
Ser B
- O
302 O
in O
AR O
) O
and O
of O
a O
water O
molecule O
buried O
in O
a O
subpocket O
located O
at O
the O
base O
of O
flexible O
loop O
A O
. O

In O
the O
wild O
- O
type O
AKR1B10 O
model O
, O
a O
short O
contact O
was O
predicted O
between O
the O
Val B
- O
301 O
side O
chain O
and O
fidarestat O
, O
but O
would O
not O
be O
present O
in O
AR O
or O
in O
V301L O
AKR1B10 O
. O

Potential O
monovalent O
cation O
- O
binding O
sites O
in O
aldehyde B
dehydrogenases O
. O

Potassium B
ions O
are O
non O
- O
essential O
activators O
of O
several O
aldehyde B
dehydrogenases O
( O
ALDHs O
) O
, O
whereas O
a O
few O
others O
require O
the O
cation O
for O
activity O
. O

Also O
, O
by O
performing O
multiple O
alignments O
of O
855 O
non O
- O
redundant O
amino B
acid I
sequences O
, O
we O
assessed O
the O
degree O
of O
conservation O
in O
their O
respective O
families O
of O
the O
amino B
acid I
residues O
putatively O
relevant O
for O
cation O
binding O
. O

Because O
potassium B
is O
the O
most O
abundant O
intracellular O
cation O
, O
we O
propose O
that O
these O
are O
potassium B
- O
binding O
sites O
, O
but O
the O
specific O
structural O
and O
/ O
or O
functional O
roles O
of O
the O
cation O
bound O
to O
these O
different O
sites O
remain O
to O
be O
investigated O
. O

Specific O
surface O
area O
of O
titanium B
dioxide I
( O
TiO2 B
) O
particles O
influences O
cyto O
- O
and O
photo O
- O
toxicity O
. O

The O
aim O
of O
this O
study O
is O
to O
examine O
how O
different O
specific O
surface O
areas O
of O
similar O
- O
sized O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
particles O
could O
influence O
both O
cytotoxicity O
and O
phototoxicity O
. O

TiO B
( I
2 I
) I
particles O
of O
different O
specific O
surface O
areas O
were O
compared O
for O
their O
toxic O
effects O
on O
RAW264 O
. O
7 O
cells O
in O
the O
absence O
and O
presence O
of O
UV O
light O
. O

From O
the O
results O
, O
TiO B
( I
2 I
) I
particles O
with O
larger O
specific O
surface O
area O
were O
found O
to O
induce O
higher O
cyto O
- O
( O
UV O
absent O
) O
and O
photo O
- O
toxicity O
( O
UV O
activated O
) O
to O
cells O
after O
24h O
incubation O
. O

The O
observed O
cytotoxicity O
from O
TiO B
( I
2 I
) I
particles O
with O
larger O
surface O
area O
could O
be O
explained O
from O
their O
interactions O
with O
biomolecules O
. O

Upon O
photoactivation O
, O
a O
larger O
number O
of O
hydroxyl B
radicals O
were O
detected O
from O
TiO B
( I
2 I
) I
particles O
with O
larger O
surface O
area O
, O
again O
suggesting O
a O
surface O
area O
dependent O
phototoxic O
effect O
. O

On O
the O
other O
hand O
, O
pre O
- O
adsorbing O
TiO B
( I
2 I
) I
particles O
with O
extracellular O
proteins O
were O
found O
to O
decrease O
toxicity O
effects O
. O

Lack O
of O
transient O
receptor O
potential O
melastatin O
8 O
activation O
by O
phthalate B
esters I
that O
enhance O
contact O
hypersensitivity O
in O
mice O
. O

Skin O
sensitization O
to O
fluorescein B
isothiocyanate I
( O
FITC B
) O
has O
been O
shown O
to O
be O
enhanced O
by O
several O
phthalate B
esters I
, O
including O
dibutyl B
phthalate I
( O
DBP O
) O
. O

For O
different O
types O
of O
phthalate B
esters I
, O
we O
found O
a O
correlation O
between O
the O
ability O
of O
transient O
receptor O
potential O
( O
TRP O
) O
A1 O
activation O
and O
that O
of O
enhancing O
skin O
sensitization O
. O

A O
TRPA1 O
- O
specific O
antagonist O
, O
HC B
- I
030031 I
, O
was O
shown O
to O
suppress O
skin O
sensitization O
in O
the O
presence O
of O
DBP O
. O

However O
, O
since O
phthalate B
esters I
also O
activate O
TRPV1 O
, O
phthalate B
esters I
could O
activate O
other O
types O
of O
TRP O
channels O
non O
- O
selectively O
. O

Furthermore O
, O
sensitization O
to O
FITC B
is O
also O
enhanced O
by O
menthol B
, O
which O
activates O
TRPA1 O
and O
TRPM8 O
. O

The O
selectivity O
for O
TRPM8 O
was O
established O
by O
the O
fact O
that O
two O
TRPM8 O
agonists O
( O
menthol B
and O
icilin B
) O
induced O
calcium B
mobilization O
, O
whereas O
agonists O
of O
TRPA1 O
and O
TRPV1 O
did O
not O
. O

We O
demonstrated O
that O
phthalate B
esters I
do O
not O
activate O
TRPM8 O
. O

TRPA1 O
- O
antagonist O
HC B
- I
030031 I
did O
not O
inhibit O
TRPM8 O
activation O
induced O
by O
menthol B
or O
icilin B
. O

These O
results O
show O
that O
phthalate B
esters I
activate O
TRPA1 O
and O
TRPV1 O
with O
selectivity O
. O

TRPM8 O
activation O
is O
not O
likely O
to O
be O
involved O
in O
the O
sensitization O
to O
FITC B
. O

The O
genotoxicity O
of O
PEI B
- O
based O
nanoparticles O
is O
reduced O
by O
acetylation O
of O
polyethylenimine O
amines O
in O
human O
primary O
cells O
. O

Polyethylenimine B
( O
PEI B
) O
is O
a O
highly O
positive O
charged O
polymer O
and O
is O
known O
to O
have O
varying O
degree O
of O
toxic O
effect O
to O
cells O
based O
on O
its O
chemical O
structure O
( O
i O
. O
e O
. O
, O
amount O
of O
primary O
and O
secondary O
amine O
) O
. O

Herein O
, O
drug O
delivery O
carriers O
such O
as O
PEI B
- O
PLGA B
nanoparticles O
( O
PEI B
- O
NPs O
) O
and O
acetylated O
PEI O
- O
PLGA B
nanoparticles O
( O
AcPEI O
- O
NPs O
) O
were O
utilized O
to O
examine O
the O
effect O
of O
acetylation O
on O
NPs O
biocompatibility O
and O
genotoxicity O
, O
using O
human O
primary O
cells O
as O
in O
vitro O
model O
. O

This O
phenomenon O
was O
significantly O
reduced O
by O
PEI B
acetylation O
. O

Endocytosed O
PEI B
- O
NPs O
trigger O
an O
oxidative O
stress O
on O
cells O
by O
inducing O
the O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
which O
cause O
DNA O
damage O
without O
apparently O
affecting O
cell O
viability O
. O

Graphene B
oxide I
for O
effective O
radionuclide O
removal O
. O

Here O
we O
show O
the O
efficacy O
of O
graphene B
oxide I
( O
GO O
) O
for O
rapid O
removal O
of O
some O
of O
the O
most O
toxic O
and O
radioactive O
long O
- O
lived O
human O
- O
made O
radionuclides O
from O
contaminated O
water O
, O
even O
from O
acidic O
solutions O
( O
pH O
< O
2 O
) O
. O

The O
interaction O
of O
GO O
with O
actinides O
including O
Am O
( O
III O
) O
, O
Th O
( O
IV O
) O
, O
Pu O
( O
IV O
) O
, O
Np O
( O
V O
) O
, O
U O
( O
VI O
) O
and O
typical O
fission O
products O
Sr O
( O
II O
) O
, O
Eu B
( I
III I
) I
and O
Tc O
( O
VII O
) O
were O
studied O
, O
along O
with O
their O
sorption O
kinetics O
. O

GO O
is O
far O
more O
effective O
in O
removal O
of O
transuranium O
elements O
from O
simulated O
nuclear O
waste O
solutions O
than O
other O
routinely O
used O
sorbents O
such O
as O
bentonite O
clays O
and O
activated O
carbon B
. O

Ebullition O
rates O
and O
mercury B
concentrations O
in O
St O
. O

Ebullition O
, O
the O
release O
of O
gas O
from O
anaerobic O
decomposition O
in O
sediments O
, O
was O
recorded O
in O
a O
mercury B
- O
contaminated O
depositional O
zone O
( O
Zone O
1 O
) O
of O
the O
St O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
test O
if O
this O
disturbance O
affected O
the O
bioavailability O
of O
total O
mercury B
( O
THg O
) O
and O
methylmercury B
( O
MeHg B
) O
in O
surficial O
sediments O
to O
a O
benthic O
invertebrate O
( O
Echinogammarus O
ischnus O
) O
. O

Ebullition O
rates O
ranged O
from O
< O
1 O
to O
2 O
, O
800 O
ml O
/ O
m O
( O
2 O
) O
daily O
, O
with O
methane B
gas O
comprising O
29 O
to O
84 O
% O
of O
the O
total O
. O

No O
direct O
effects O
of O
ebullition O
were O
found O
on O
either O
abiotic O
( O
sediment O
or O
pore O
water O
THg O
or O
MeHg B
concentrations O
) O
or O
biotic O
( O
amphipod O
THg O
or O
MeHg B
concentrations O
) O
variables O
measured O
. O

Instead O
, O
amphipod O
MeHg B
concentrations O
were O
best O
predicted O
by O
pore O
water O
THg O
and O
MeHg B
concentrations O
, O
organic O
matter O
of O
surficial O
sediments O
, O
and O
water O
depth O
and O
location O
. O

Trend O
surface O
analyses O
demonstrated O
that O
a O
shallow O
, O
southwestern O
part O
of O
Zone O
1 O
was O
most O
contaminated O
with O
pore O
water O
mercury B
, O
which O
decreased O
in O
a O
gradient O
toward O
the O
northeast O
. O

Further O
study O
is O
needed O
to O
determine O
if O
the O
amount O
of O
sediment O
resuspended O
by O
ebullition O
affects O
the O
spatial O
distribution O
of O
mercury B
. O

Ab O
initio O
molecular O
dynamics O
simulation O
on O
the O
formation O
process O
of O
He B
@ O
C O
6 O
0 O
synthesized O
by O
explosion O
. O

The O
applications O
of O
endohedral O
non O
- O
metallic O
fullerenes B
are O
limited O
by O
their O
low O
production O
rate O
. O

Recently O
, O
an O
explosive O
method O
developed O
in O
our O
group O
shows O
promise O
to O
prepare O
He B
@ O
C O
6 O
0 O
at O
fairly O
high O
yield O
, O
but O
the O
mechanism O
of O
He B
inserting O
into O
C O
6 O
0 O
cage O
at O
explosive O
conditions O
was O
not O
clear O
. O

The O
results O
show O
that O
defects O
formed O
on O
the O
fullerene B
cage O
by O
collidsion O
can O
effectively O
decrease O
the O
reaction O
barrier O
for O
the O
insertion O
of O
He B
into O
C O
6 O
0 O
, O
and O
the O
self O
- O
healing O
capability O
of O
the O
defects O
was O
also O
observed O
. O

Three O
cynomolgus O
monkey O
OATPs O
( O
cOATPs O
) O
, O
with O
a O
high O
degree O
of O
amino B
acid I
sequence O
identity O
( O
91 O
. O
9 O
, O
93 O
. O
5 O
, O
and O
96 O
. O
6 O
% O
for O
OATP1B1 O
, O
1B3 O
, O
and O
2B1 O
, O
respectively O
) O
to O
their O
human O
counterparts O
, O
were O
cloned O
, O
expressed O
, O
and O
characterized O
. O

To O
further O
evaluate O
the O
appropriateness O
of O
the O
cynomolgus O
monkey O
as O
a O
model O
, O
a O
known O
hOATP O
substrate O
[ O
rosuvastatin B
( O
RSV O
) O
] O
- O
inhibitor O
[ O
rifampicin B
( O
RIF O
) O
] O
pair O
was O
examined O
in O
vitro O
; O
the O
monkey O
- O
derived O
parameters O
( O
RSV O
K O
( O
m O
) O
and O
RIF O
IC O
( O
50 O
) O
) O
were O
similar O
( O
within O
3 O
. O
5 O
- O
fold O
) O
to O
those O
obtained O
with O
hOATPs O
and O
human O
primary O
hepatocytes O
. O

Resveratrol B
improves O
cardiomyopathy O
in O
dystrophin O
- O
deficient O
mice O
through O
SIRT1 O
protein O
- O
mediated O
modulation O
of O
p300 O
protein O
. O

Here O
, O
we O
show O
that O
oral O
administration O
of O
resveratrol B
, O
which O
leads O
to O
activation O
of O
an O
NAD B
( I
+ I
) I
- O
dependent O
protein O
deacetylase O
SIRT1 O
, O
suppresses O
cardiac O
hypertrophy O
and O
fibrosis O
and O
restores O
cardiac O
diastolic O
function O
in O
dystrophin O
- O
deficient O
mdx O
mice O
. O

The O
pro O
- O
hypertrophic O
co O
- O
activator O
p300 O
protein O
but O
not O
p300 O
mRNA O
was O
up O
- O
regulated O
in O
the O
mdx O
heart O
, O
and O
resveratrol B
administration O
down O
- O
regulated O
the O
p300 O
protein O
level O
. O

In O
cultured O
cardiomyocytes O
, O
cardiomyocyte O
hypertrophy O
induced O
by O
the O
alpha O
( O
1 O
) O
- O
agonist O
phenylephrine B
was O
inhibited O
by O
the O
overexpression O
of O
SIRT1 O
as O
well O
as O
resveratrol B
, O
both O
of O
which O
down O
- O
regulated O
p300 O
protein O
levels O
but O
not O
p300 O
mRNA O
levels O
. O

We O
found O
that O
SIRT1 O
induced O
p300 O
down O
- O
regulation O
via O
the O
ubiquitin O
- O
proteasome O
pathway O
by O
deacetylation O
of O
lysine B
residues O
for O
ubiquitination O
. O

Herein O
we O
report O
a O
NMR O
relaxation O
study O
[ O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
T O
( O
1 O
) O
, O
T O
( O
2 O
) O
; O
( B
13 I
) I
C I
{ O
( B
1 I
) I
H I
} O
NOE O
; O
various O
fields O
and O
temperatures O
] O
which O
reveals O
profound O
differences O
between O
the O
relaxation O
behavior O
of O
dendrimers O
and O
linear O
polymers O
. O

All B
- I
trans I
retinoic I
acid I
protects O
hepatocellular O
carcinoma O
cells O
against O
serum O
- O
starvation O
- O
induced O
cell O
death O
by O
upregulating O
collagen O
8A2 O
. O

As O
a O
therapeutic O
or O
chemopreventative O
agent O
for O
various O
cancers O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
has O
been O
reported O
to O
inhibit O
growth O
, O
induce O
apoptosis O
or O
cause O
differentiation O
. O

It O
was O
found O
that O
atRA B
could O
protect O
hepatocellular O
carcinoma O
( O
HCC O
) O
cells O
against O
cell O
death O
induced O
by O
serum O
starvation O
. O

Furthermore O
, O
it O
was O
found O
that O
atRA B
could O
enhance O
cell O
adhesion O
, O
but O
had O
no O
effect O
on O
the O
cell O
cycle O
and O
apoptosis O
. O

Using O
an O
Illumina O
Human O
HT O
- O
12 O
v4 O
expression O
microarray O
, O
207 O
upregulated O
and O
173 O
downregulated O
genes O
were O
identified O
in O
HepG2 O
cells O
treated O
with O
atRA B
. O

The O
most O
upregulated O
genes O
are O
cytochrome O
P450 O
family O
26 O
subfamily O
A O
polypeptide O
1 O
( O
CYP26A1 O
) O
, O
histidine B
triad O
nucleotide O
binding O
protein O
3 O
( O
HINT3 O
) O
, O
miR O
- O
1282 O
and O
cytochrome O
P450 O
family O
26 O
subfamily O
B O
polypeptide O
1 O
( O
CYP26B1 O
) O
, O
which O
showed O
more O
than O
fivefold O
greater O
expression O
. O

Knockdown O
of O
COL8A2 O
blocked O
enhancement O
in O
the O
early O
stage O
of O
cell O
adhesion O
by O
atRA B
treatment O
. O

Thus O
, O
COL8A2 O
was O
identified O
as O
the O
key O
protein O
involved O
in O
the O
enhancement O
of O
cell O
adhesion O
of O
atRA B
under O
serum O
- O
free O
conditions O
. O

In O
conclusion O
, O
atRA B
protects O
HCC O
cells O
against O
serum O
- O
starvation O
- O
induced O
cell O
death O
by O
enhancing O
cell O
adhesion O
, O
and O
COL8A2 O
plays O
an O
important O
role O
in O
HCC O
cell O
migration O
and O
invasion O
. O

Systemic O
leptin O
increases O
the O
electrical O
activity O
of O
supraoptic O
nucleus O
oxytocin B
neurones O
in O
virgin O
and O
late O
pregnant O
rats O
. O

In O
the O
rat O
hypothalamus O
, O
fasting O
attenuates O
the O
expression O
of O
oxytocin B
and O
this O
can O
be O
reversed O
by O
exogenous O
leptin O
administration O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effects O
of O
systemically O
administered O
leptin O
on O
the O
electrical O
activity O
of O
magnocellular O
neurones O
in O
the O
supraoptic O
nucleus O
of O
urethane B
- O
anaesthetised O
rats O
. O

In O
virgin O
female O
rats O
, O
systemic O
leptin O
significantly O
excited O
identified O
oxytocin B
neurones O
with O
no O
detected O
effects O
on O
the O
patterning O
of O
activity O
, O
as O
reflected O
by O
hazard O
function O
analyses O
. O

In O
virgin O
rats O
fasted O
overnight O
, O
the O
spontaneous O
firing O
rate O
of O
oxytocin B
neurones O
was O
significantly O
lower O
than O
in O
unfasted O
rats O
, O
although O
leptin O
had O
a O
similar O
excitatory O
effect O
as O
in O
unfasted O
rats O
. O

In O
late O
pregnant O
rats O
( O
days O
19 O
- O
21 O
of O
pregnancy O
) O
, O
spontaneous O
firing O
rates O
of O
oxytocin B
neurones O
were O
higher O
than O
in O
virgins O
, O
and O
the O
initial O
response O
to O
leptin O
was O
similar O
to O
that O
in O
virgin O
rats O
, O
although O
the O
increase O
in O
activity O
was O
more O
persistent O
. O

In O
fasted O
pregnant O
rats O
, O
the O
mean O
spontaneous O
firing O
rate O
of O
oxytocin B
neurones O
was O
again O
lower O
than O
in O
unfasted O
rats O
, O
although O
leptin O
had O
no O
significant O
effect O
even O
at O
the O
higher O
dose O
of O
1 O
mg O
/ O
rat O
. O

Thus O
, O
fasting O
reduced O
the O
spontaneous O
firing O
rates O
of O
oxytocin B
neurones O
in O
nonpregnant O
rats O
, O
and O
this O
effect O
could O
be O
reversed O
by O
the O
excitatory O
effects O
of O
leptin O
. O

Design O
and O
synthesis O
of O
potent O
inhibitor O
of O
apoptosis O
( O
IAP O
) O
proteins O
antagonists O
bearing O
an O
octahydropyrrolo O
[ O
1 O
, O
2 O
- O
a O
] O
pyrazine O
scaffold O
as O
a O
novel O
proline B
mimetic O
. O

To O
develop O
novel O
inhibitor O
of O
apoptosis O
( O
IAP O
) O
proteins O
antagonists O
, O
we O
designed O
a O
bicyclic O
octahydropyrrolo O
[ O
1 O
, O
2 O
- O
a O
] O
pyrazine O
scaffold O
as O
a O
novel O
proline B
bioisostere O
. O

This O
design O
was O
based O
on O
the O
X O
- O
ray O
co O
- O
crystal O
structure O
of O
four O
N B
- O
terminal O
amino B
acid I
residues O
( O
AVPI O
) O
of O
the O
second O
mitochondria O
- O
derived O
activator O
of O
caspase O
( O
Smac O
) O
with O
the O
X O
- O
chromosome O
- O
linked O
IAP O
( O
XIAP O
) O
protein O
. O

Smart O
mesoporous O
SiO2 B
nanoparticles O
for O
the O
DNAzyme O
- O
induced O
multiplexed O
release O
of O
substrates O
. O

The O
fluorescent O
dyes O
methylene B
blue I
, O
MB O
( O
+ O
) O
, O
and O
thionine O
, O
Th O
( O
+ O
) O
, O
can O
be O
trapped O
in O
the O
pores O
of O
mesoporous O
silica B
, O
MP O
- O
SiO B
( I
2 I
) I
, O
by O
means O
of O
functional O
nanostructures O
consisting O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
. O

In O
the O
presence O
of O
Mg B
( I
2 I
+ I
) I
or O
Zn B
( I
2 I
+ I
) I
ions O
the O
respective O
DNAzymes O
are O
activated O
, O
leading O
to O
the O
specific O
cleavage O
of O
the O
respective O
caps O
, O
and O
the O
selective O
release O
of O
MB O
( O
+ O
) O
or O
Th O
( O
+ O
) O
. O

The O
enlargement O
of O
the O
conserved O
loop O
domains O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
sequences O
with O
foreign O
nucleotides B
prohibits O
the O
formation O
of O
active O
DNAzymes O
and O
eliminates O
the O
release O
of O
the O
respective O
dyes O
. O

The O
insertion O
of O
aptamer O
sequences O
( O
e O
. O
g O
. O
, O
the O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
aptamer O
) O
or O
ion O
- O
binding O
sequences O
( O
e O
. O
g O
. O
, O
T O
- O
rich O
Hg B
( I
2 I
+ I
) I
ion O
- O
binding O
domains O
) O
as O
foreign O
components O
to O
the O
loop O
regions O
allows O
the O
formation O
of O
active O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
structures O
through O
the O
cooperative O
formation O
of O
aptamer O
- O
ATP B
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
. O

These O
aptamer O
- O
substrate O
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
allosterically O
stabilize O
and O
activate O
the O
DNAzymes O
, O
thus O
allowing O
the O
selective O
release O
of O
the O
fluorescent O
substrates O
MB O
( O
+ O
) O
or O
Th O
( O
+ O
) O
. O

The O
metal O
ion O
- O
driven O
DNAzyme O
release O
of O
substrates O
from O
the O
pores O
of O
MP O
- O
SiO B
( I
2 I
) I
, O
and O
particularly O
the O
allosteric O
activation O
of O
the O
DNAzymes O
through O
cooperative O
aptamer O
- O
substrate O
complexes O
or O
metal O
- O
ion O
bridges O
, O
has O
important O
future O
nanomedical O
implications O
for O
targeted O
release O
of O
drugs O
. O

This O
is O
demonstrated O
with O
the O
triggered O
release O
of O
the O
anticancer O
drug O
, O
doxorubicin B
, O
by O
the O
Mg B
( I
2 I
+ I
) I
- O
DNAzyme O
- O
locked O
pores O
or O
by O
the O
aptamer O
- O
ATP B
complex O
- O
triggered O
activation O
of O
the O
Mg B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
. O

Application O
of O
implantable O
glucose B
biosensors O
for O
" O
real O
- O
time O
" O
monitoring O
is O
reliant O
on O
controlling O
the O
negative O
tissue O
reaction O
at O
the O
sensor O
tissue O
interphase O
. O

A O
novel O
polymer O
coating O
consisting O
of O
poly B
( I
lactic I
- I
co I
- I
glycolic I
) I
acid I
( O
PLGA B
) O
microsphere O
dispersed O
in O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
hydrogels O
was O
evaluated O
in O
combination O
with O
dummy O
sensors O
as O
a O
" O
smart O
" O
drug O
eluting O
biocompatible O
coating O
for O
implantable O
biosensors O
to O
prevent O
the O
foreign O
body O
response O
, O
and O
thus O
enhance O
sensor O
performance O
in O
vivo O
. O

Dummy O
sensors O
with O
identical O
dimensions O
to O
that O
of O
the O
functional O
glucose B
sensors O
( O
0 O
. O
5 O
x O
0 O
. O
5 O
x O
5mm O
) O
were O
coated O
with O
the O
PLGA B
/ O
PVA B
composites O
using O
a O
mold O
fabrication O
process O
. O

It O
was O
evident O
that O
the O
PLGA B
/ O
PVA B
hydrogel O
composite O
was O
able O
to O
form O
a O
uniform O
coating O
around O
the O
dummy O
sensor O
and O
stayed O
intact O
throughout O
the O
course O
of O
the O
study O
( O
one O
month O
) O
. O

Tissue O
samples O
containing O
dummy O
sensors O
that O
were O
coated O
with O
dexamethasone B
free O
composites O
exhibited O
acute O
and O
chronic O
inflammation O
as O
well O
as O
fibrous O
encapsulation O
in O
both O
normal O
and O
diabetic O
rats O
. O

On O
the O
other O
hand O
, O
tissues O
containing O
dummy O
sensors O
that O
were O
coated O
with O
dexamethasone B
containing O
composites O
remained O
normal O
( O
i O
. O
e O
. O
similar O
to O
untreated O
tissues O
) O
, O
with O
no O
inflammatory O
reaction O
or O
fibrous O
encapsulation O
occurring O
over O
the O
one O
- O
month O
period O
in O
both O
the O
normal O
and O
diabetic O
rats O
. O

The O
feasibility O
of O
utilizing O
PLGA B
microsphere O
/ O
PVA B
hydrogel O
composites O
as O
coatings O
for O
implantable O
biosensors O
was O
demonstrated O
. O

Claisen O
- O
Schmidt O
condensation O
reaction O
of O
4 O
- O
acetamidoacetophenon O
with O
aromatic B
aldehydes I
under O
ultrasonic O
irradiation O
affords O
acetylaminochalcones O
( O
yields O
: O
71 O
- O
90 O
% O
) O
which O
also O
under O
ultrasonic O
irradiation O
and O
in O
the O
presence O
of O
sodium O
acetate O
and O
acetic B
acid I
aqueous O
undergo O
facile O
and O
clean O
cyclocondensation O
with O
hydrazine B
to O
afford O
3 O
- O
( O
4 O
- O
acetamidophenyl O
) O
- O
5 O
- O
( O
aryl O
) O
- O
1 O
- O
H O
- O
pyrazolines O
. O

This O
is O
currently O
well O
documented O
in O
the O
AKR6A O
subfamily O
which O
contains O
the O
beta O
- O
subunits O
of O
the O
voltage O
- O
gated O
potassium B
ion O
channels O
. O

Protective O
effects O
of O
alpha B
lipoic I
acid I
versus O
N B
- I
acetylcysteine I
on O
ifosfamide B
- O
induced O
nephrotoxicity O
. O

Ifosfamide B
( O
IFO O
) O
is O
a O
highly O
effective O
chemotherapeutic O
agent O
for O
treating O
a O
variety O
of O
pediatric O
solid O
tumors O
. O

Therefore O
, O
this O
study O
was O
carried O
out O
to O
investigate O
the O
possible O
underlying O
mechanisms O
that O
may O
be O
involved O
in O
IFO O
- O
induced O
nephrotoxicity O
, O
including O
free O
radical O
generation O
and O
the O
possible O
role O
of O
alpha B
lipoic I
acid I
( O
ALA B
) O
versus O
N B
- I
acetylcysteine I
( O
NAC B
) O
in O
protection O
against O
this O
toxicity O
. O

Male O
albino O
rats O
were O
injected O
intraperitoneally O
with O
saline O
, O
IFO O
( O
50 O
mg O
/ O
kg O
daily O
for O
5 O
days O
) O
, O
IFO O
+ O
ALA B
( O
100 O
mg O
/ O
kg O
daily O
for O
8 O
days O
) O
and O
IFO O
+ O
NAC B
( O
200 O
mg O
/ O
kg O
daily O
for O
8 O
days O
) O
. O

Kidney O
malondialdehyde B
, O
nitric B
oxide I
and O
glutathione B
contents O
and O
serum O
biochemical O
parameters O
and O
histopathological O
analysis O
were O
determined O
. O

Both O
ALA B
and O
NAC B
markedly O
reduced O
the O
severity O
of O
renal O
dysfunction O
induced O
by O
IFO O
. O

NAC B
was O
more O
nephroprotective O
than O
ALA B
. O

The O
study O
also O
suggests O
the O
potential O
therapeutic O
role O
for O
ALA B
and O
NAC B
against O
IFO O
- O
induced O
nephrotoxicity O
. O

Antioxidative O
, O
antiapoptotic O
, O
and O
proliferative O
effect O
of O
curcumin B
on O
liver O
regeneration O
after O
partial O
hepatectomy O
in O
rats O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
influence O
of O
curcumin B
on O
liver O
regeneration O
after O
partial O
hepatectomy O
( O
PH O
) O
in O
rats O
. O

A O
total O
of O
24 O
male O
Sprague O
Dawley O
rats O
were O
divided O
into O
three O
groups O
: O
sham O
- O
operated O
( O
SH O
) O
, O
PH O
, O
and O
PH O
+ O
curcumin B
; O
each O
group O
contains O
eight O
animals O
. O

The O
rats O
in O
curcumin B
- O
treated O
groups O
were O
given O
curcumin B
( O
in O
a O
dose O
of O
100 O
mg O
/ O
kg O
body O
weight O
) O
once O
a O
day O
orally O
for O
7 O
days O
, O
starting O
3 O
days O
prior O
to O
hepatectomy O
operation O
. O

The O
malondialdehyde B
( O
MDA B
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
and O
glutathione B
( O
GSH B
) O
levels O
were O
estimated O
in O
liver O
homogenates O
. O

Moreover O
, O
histopathological O
examination O
, O
mitotic O
index O
( O
MI O
) O
, O
proliferating O
cell O
nuclear O
antigen O
labeling O
, O
proliferation O
index O
( O
PI O
) O
, O
transferase O
- O
mediated O
2 B
' I
- I
deoxyuridine I
, O
5 O
' O
- O
triphosphate O
nick O
end O
- O
labeling O
assay O
, O
and O
apoptotic O
index O
( O
AI O
) O
were O
evaluated O
at O
7 O
days O
after O
hepatectomy O
. O

As O
a O
result O
, O
curcumin B
significantly O
increased O
MI O
and O
PI O
and O
significantly O
decreased O
AI O
in O
PH O
rats O
. O

Additionally O
, O
curcumin B
remarkably O
inhibited O
MDA B
elevation O
, O
restored O
impaired O
antioxidant O
SOD O
activity O
and O
GSH B
level O
and O
also O
attenuated O
hepatic O
vacuolar O
degeneration O
and O
sinusoidal O
congestion O
. O

These O
results O
suggested O
that O
curcumin B
treatment O
had O
a O
beneficial O
effect O
on O
liver O
regenerative O
capacity O
of O
the O
remnant O
liver O
tissue O
after O
hepatectomy O
, O
probably O
due O
to O
its O
antioxidative O
, O
antiapoptotic O
, O
and O
proliferative O
properties O
. O

Simultaneous O
determination O
and O
characterization O
of O
tannins B
and O
triterpene O
saponins O
from O
the O
fruits O
of O
various O
species O
of O
Terminalia O
and O
Phyllantus O
emblica O
using O
a O
UHPLC O
- O
UV O
- O
MS O
method O
: O
application O
to O
triphala O
. O

Terminalia O
species O
are O
a O
rich O
source O
of O
tannins B
. O

A O
simple O
UHPLC O
method O
was O
developed O
for O
the O
simultaneous O
analysis O
of O
such O
hydrolysable O
tannins B
and O
triterpene O
saponins O
from O
the O
fruit O
rinds O
of O
different O
species O
of O
Terminalia O
( O
T O
. O
chebula O
, O
T O
. O
arjuna O
, O
T O
. O
bellirica O
) O
and O
Phyllantus O
emblica O
. O

A O
separation O
by O
LC O
was O
achieved O
using O
a O
reversed O
- O
phase O
column O
and O
a O
water O
/ O
acetonitrile B
mobile O
phase O
, O
both O
containing O
formic B
acid I
, O
using O
a O
gradient O
system O
and O
a O
temperature O
of O
40 O
degrees O
C O
. O

Eight O
hydrolysable O
tannins B
( O
gallic B
acid I
, O
gallic O
acid O
methyl O
ester O
, O
corilagin O
, O
chebulagic O
acid O
, O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetra O
- O
O O
- O
galloyl O
- O
beta O
- O
D O
- O
glucose O
, O
ellagic B
acid I
, O
chebulinic B
acid I
, O
and O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
- I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
D I
- I
glucose I
) O
and O
six O
triterpene O
saponins O
( O
arjunglucoside O
- O
I O
, O
arjunglucoside O
- O
III O
, O

The O
wavelength O
used O
for O
detection O
with O
the O
diode O
array O
detector O
was O
254 O
and O
275 O
nm O
for O
tannins B
and O
205 O
nm O
for O
triterpene O
saponins O
. O

The O
developed O
method O
is O
economical O
, O
fast O
, O
and O
especially O
suitable O
for O
quality O
control O
analysis O
of O
tannins B
and O
triterpene O
saponins O
in O
various O
plant O
samples O
and O
commercial O
products O
of O
Terminalia O
. O

After O
addition O
of O
fluorescein B
isothiocyanate I
- O
conjugated O
secondary O
antibodies O
, O
the O
sections O
were O
analyzed O
by O
confocal O
laser O
scanning O
microscopy O
. O

An O
in O
vitro O
model O
of O
human O
acute O
ethanol B
exposure O
that O
incorporates O
CXCR3 O
- O
and O
CXCR4 O
- O
dependent O
recruitment O
of O
immune O
cells O
. O

We O
developed O
a O
human O
tissue O
- O
based O
system O
to O
study O
lymphocyte O
recruitment O
in O
response O
to O
ethanol B
challenge O
. O

Precision O
- O
cut O
liver O
slices O
( O
PCLS O
) O
from O
human O
livers O
were O
incubated O
in O
culture O
, O
and O
hepatic O
function O
was O
determined O
by O
albumin O
production O
, O
3 O
- O
( O
4 O
, O
5 O
- O
dimethylthiazol O
) O
- O
2 O
, O
5 O
- O
diphenyl O
tetrazolium O
bromide O
assay O
, O
glucose B
uptake O
responses O
, O
and O
morphometric O
assessment O
. O

Responses O
of O
tissue O
and O
lymphocytes O
to O
ethanol B
exposure O
were O
determined O
by O
PCR O
, O
flow O
cytometry O
, O
histology O
, O
and O
lymphocyte O
infiltration O
assays O
. O

Human O
PCLS O
demonstrated O
appropriate O
upregulation O
of O
CYP2E1 O
, O
ADH1 O
alpha O
, O
and O
ADH3 O
in O
response O
to O
ethanol B
treatment O
. O

Ethanol B
also O
induced O
expression O
of O
endothelial O
VCAM O
- O
1 O
and O
ICAM O
- O
1 O
, O
production O
of O
sICAM O
- O
1 O
and O
CXCL8 O
, O
and O
the O
chemokine O
receptors O
CXCR3 O
and O
CXCR4 O
on O
CD4 O
and O
CD8 O
lymphocytes O
. O

CXCR3 O
- O
and O
CXCR4 O
- O
dependent O
migration O
of O
lymphocytes O
into O
the O
tissue O
increased O
significantly O
in O
response O
to O
treatment O
with O
ethanol B
. O

We O
have O
demonstrated O
that O
ethanol B
increases O
chemokine O
receptor O
expression O
and O
lymphocyte O
recruitment O
into O
human O
liver O
tissue O
, O
suggesting O
that O
it O
may O
operate O
directly O
to O
promote O
hepatitis O
in O
ALD O
. O

The O
physiological O
and O
pathophysiological O
responses O
of O
the O
PCLS O
to O
ethanol B
in O
vitro O
highlight O
the O
potential O
of O
this O
assay O
for O
dissecting O
the O
molecular O
mechanisms O
underlying O
human O
liver O
inflammation O
and O
as O
a O
screening O
tool O
for O
novel O
therapeutics O
. O

Identification O
of O
propofol B
binding O
sites O
in O
a O
nicotinic O
acetylcholine B
receptor O
with O
a O
photoreactive O
propofol B
analog O
. O

Propofol B
, O
a O
widely O
used O
intravenous O
general O
anesthetic O
, O
acts O
at O
anesthetic O
concentrations O
as O
a O
positive O
allosteric O
modulator O
of O
gamma B
- I
aminobutyric I
acid I
type O
A O
receptors O
and O
at O
higher O
concentration O
as O
an O
inhibitor O
of O
nicotinic O
acetylcholine B
receptors O
( O
nAChRs O
) O
. O

Here O
, O
we O
characterize O
propofol B
binding O
sites O
in O
a O
muscle O
- O
type O
nAChR O
by O
use O
of O
a O
photoreactive O
analog O
of O
propofol B
, O
2 O
- O
isopropyl O
- O
5 O
- O
[ O
3 O
- O
( O
trifluoromethyl O
) O
- O
3H O
- O
diazirin O
- O
3 O
- O
yl O
] O
phenol O
( O
AziPm O
) O
. O

Based O
upon O
radioligand O
binding O
assays O
, O
AziPm O
stabilized O
the O
Torpedo O
nAChR O
in O
the O
resting O
state O
, O
whereas O
propofol B
stabilized O
the O
desensitized O
state O
. O

nAChR O
- O
rich O
membranes O
were O
photolabeled O
with O
[ O
( O
3 O
) O
H O
] O
AziPm O
, O
and O
labeled O
amino B
acids I
were O
identified O
by O
Edman O
degradation O
. O

[ O
( O
3 O
) O
H O
] O
AziPm O
binds O
at O
three O
sites O
within O
the O
nAChR O
transmembrane O
domain O
: O
( O
i O
) O
an O
intrasubunit O
site O
in O
the O
delta O
subunit O
helix O
bundle O
, O
photolabeling O
in O
the O
nAChR O
desensitized O
state O
( O
+ O
agonist O
) O
delta O
M2 O
- O
18 O
' O
and O
two O
residues O
in O
delta O
M1 O
( O
delta O
Phe O
- O
232 O
and O
delta O
Cys O
- O
236 O
) O
; O
( O
ii O
) O
in O
the O
ion O
channel O
, O
photolabeling O
in O
the O
nAChR O
resting O
, O
closed O
channel O
state O
( O
- O
agonist O
) O
amino B
acids I
in O
the O
M2 O

Propofol B
enhanced O
[ O
( O
3 O
) O
H O
] O
AziPm O
photolabeling O
at O
alpha O
M2 O
- O
10 O
' O
. O

Propofol B
inhibited O
[ O
( O
3 O
) O
H O
] O
AziPm O
photolabeling O
within O
the O
delta O
subunit O
helix O
bundle O
at O
lower O
concentrations O
( O
IC50 O
= O
40 O
mu O
m O
) O
than O
it O
inhibited O
ion O
channel O
photolabeling O
( O
IC50 O
= O
125 O
mu O
m O
) O
. O

These O
results O
identify O
for O
the O
first O
time O
a O
single O
intrasubunit O
propofol B
binding O
site O
in O
the O
nAChR O
transmembrane O
domain O
and O
suggest O
that O
this O
is O
the O
functionally O
relevant O
inhibitory O
binding O
site O
. O

However O
, O
neither O
the O
complex O
multistep O
process O
that O
leads O
to O
activation O
of O
Akt1 O
through O
phosphorylation O
at O
Thr B
( O
3 O
) O
0 O
8 O
and O
Ser B
4 O
7 O
( O
3 O
) O
nor O
the O
mechanism O
by O
which O
Akt1 O
stimulates O
adipogenesis O
is O
fully O
understood O
. O

We O
found O
that O
the O
BSD O
domain O
- O
containing O
signal O
transducer O
and O
Akt O
interactor O
( O
BSTA O
) O
promoted O
phosphorylation O
of O
Akt1 O
at O
Ser B
4 O
7 O
( O
3 O
) O
in O
various O
human O
and O
murine O
cells O
, O
and O
we O
uncovered O
a O
function O
for O
the O
BSD O
domain O
in O
BSTA O
- O
Akt1 O
complex O
formation O
. O

The O
mammalian O
target O
of O
rapamycin O
complex O
2 O
( O
mTORC2 O
) O
facilitated O
the O
phosphorylation O
of O
BSTA O
and O
its O
association O
with O
Akt1 O
, O
and O
the O
BSTA O
- O
Akt1 O
interaction O
promoted O
the O
association O
of O
mTORC2 O
with O
Akt1 O
and O
phosphorylation O
of O
Akt1 O
at O
Ser B
4 O
7 O
( O
3 O
) O
in O
response O
to O
growth O
factor O
stimulation O
. O

Furthermore O
, O
analyses O
of O
bsta O
gene O
- O
trap O
murine O
embryonic O
stem O
cells O
revealed O
an O
essential O
function O
for O
BSTA O
and O
phosphorylation O
of O
Akt1 O
at O
Ser B
4 O
7 O
( O
3 O
) O
in O
promoting O
adipocyte O
differentiation O
, O
which O
required O
suppression O
of O
the O
expression O
of O
the O
gene O
encoding O
the O
transcription O
factor O
FoxC2 O
. O

These O
findings O
indicate O
that O
BSTA O
is O
a O
molecular O
switch O
that O
promotes O
phosphorylation O
of O
Akt1 O
at O
Ser B
4 O
7 O
( O
3 O
) O
and O
reveal O
an O
mTORC2 O
- O
BSTA O
- O
Akt1 O
- O
FoxC2 O
- O
mediated O
signaling O
mechanism O
that O
is O
critical O
for O
adipocyte O
differentiation O
. O

Amino B
acid I
grafted O
chitosan O
for O
high O
performance O
gene O
delivery O
: O
comparison O
of O
amino B
acid I
hydrophobicity O
on O
vector O
and O
polyplex O
characteristics O
. O

To O
develop O
a O
safe O
, O
effective O
, O
and O
biocompatible O
gene O
delivery O
vector O
, O
a O
series O
of O
hydrophobic O
amino B
acid I
grafted O
chitosan O
( O
AGC O
) O
derivatives O
were O
synthesized O
by O
carbodiimide O
mediated O
coupling O
reaction O
. O

AGC O
polymers O
demonstrated O
excellent O
blood O
compatibility O
and O
cell O
viability O
, O
as O
evaluated O
by O
hemolysis O
and O
MTT B
assay O
, O
respectively O
. O

Moreover O
, O
both O
cellular O
uptake O
and O
transfection O
efficiency O
improved O
with O
the O
increasing O
amino B
acid I
hydrophobicity O
. O

Hydrophobic O
amino B
acid I
substitution O
contributed O
to O
the O
enhance O
pDNA O
release O
at O
cytosolic O
pH O
. O

Improved O
self O
- O
healing O
of O
polyethylene B
/ O
carbon B
black I
nanocomposites O
by O
their O
shape O
memory O
effect O
. O

In O
this O
work O
, O
the O
improved O
self O
- O
healing O
of O
cross O
- O
linked O
polyethylene B
( O
PE O
) O
( O
cPE O
) O
/ O
carbon B
black I
( O
CB O
) O
nanocomposites O
by O
their O
shape O
memory O
effect O
( O
SME O
) O
is O
investigated O
. O

Formulation O
study O
of O
a O
patch O
containing O
propranolol B
by O
design O
of O
experiments O
. O

Abstract O
Objective O
: O
To O
evaluate O
the O
feasibility O
of O
a O
transdermal O
patch O
containing O
propranolol B
( O
PR O
) O
. O

Results O
: O
N O
- O
methyl O
pyrrolidone O
( O
NMP B
) O
resulted O
as O
the O
best O
SPE O
: O
in O
addition O
, O
the O
critical O
factors O
influencing O
the O
PR O
diffusion O
through O
the O
human O
epidermis O
when O
loaded O
in O
the O
patch O
resulted O
in O
the O
matrix O
thickness O
( O
X O
( O
1 O
) O
, O
p O
= O
0 O
. O
0957 O
) O
and O
PR O
content O
( O
X O
( O
3 O
) O
, O
p O
= O
0 O
. O
0004 O
) O
which O
improved O
the O
flux O
; O
conversely O
, O
NMP B
lacked O
its O
enhancement O
effect O
when O
loaded O
in O
the O
patch O
and O
the O
increase O
in O
its O
concentration O
( O
X O
( O
4 O
) O
, O
p O
= O
0 O
. O
006 O
) O
affected O
the O
drug O

In O
particular O
, O
the O
use O
of O
a O
50 O
mu O
m O
thick O
methacrylic O
matrix O
containing O
8 O
% O
( O
S O
) O
- O
PR O
and O
15 O
% O
NMP B
can O
allow O
to O
develop O
a O
patch O
non O
- O
irritating O
to O
the O
skin O
, O
in O
order O
to O
ensure O
a O
constant O
permeation O
flux O
of O
PR O
over O
48 O
h O
. O

Nanoscale O
Dynamics O
and O
Protein O
Adhesivity O
of O
Alkylamine O
Self O
- O
Assembled O
Monolayers O
on O
Graphene B
. O

Atomic O
- O
scale O
molecular O
dynamics O
computer O
simulations O
are O
used O
to O
probe O
the O
structure O
, O
dynamics O
, O
and O
energetics O
of O
alkylamine O
self O
- O
assembled O
monolayer O
( O
SAM O
) O
films O
on O
graphene B
and O
to O
model O
the O
formation O
of O
molecular O
bilayers O
and O
protein O
complexes O
on O
the O
films O
. O

Routes O
toward O
the O
development O
and O
exploitation O
of O
functionalized O
graphene B
structures O
are O
detailed O
here O
, O
and O
we O
show O
that O
the O
SAM O
architecture O
can O
be O
tailored O
for O
use O
in O
emerging O
applications O
( O
e O
. O
g O
. O
, O
electrically O
stimulated O
nerve O
fiber O
growth O
via O
the O
targeted O
binding O
of O
specific O
cell O
surface O
peptide O
sequences O
on O
the O
functionalized O
graphene B
scaffold O
) O
. O

The O
simulations O
quantify O
the O
changes O
in O
film O
physisorption O
on O
graphene B
and O
the O
alkyl B
chain O
packing O
efficiency O
as O
the O
film O
surface O
is O
made O
more O
polar O
by O
changing O
the O
terminal O
groups O
from O
methyl B
( O
- O
CH B
( I
3 I
) I
) O
to O
amine B
( O
- O
NH B
( I
2 I
) I
) O
to O
hydroxyl B
( O
- O
OH B
) O
. O

The O
simulations O
show O
the O
formation O
of O
ordered O
, O
stable O
assemblies O
of O
monolayers O
and O
bilayers O
of O
decylamine O
- O
based O
molecules O
on O
graphene B
. O

These O
films O
can O
serve O
as O
protein O
adsorption O
platforms O
, O
with O
a O
hydrophobin O
protein O
showing O
strong O
and O
selective O
adsorption O
by O
binding O
via O
its O
hydrophobic O
patch O
to O
methyl B
- O
terminated O
films O
and O
binding O
to O
amine B
- O
terminated O
films O
using O
its O
more O
hydrophilic O
surface O
regions O
. O

Abstract O
Bombesin B
and O
its O
derivatives O
exhibit O
a O
high O
affinity O
for O
gastrin O
- O
releasing O
peptide O
receptor O
( O
GRPr O
) O
, O
which O
is O
over O
- O
expressed O
in O
a O
variety O
of O
human O
cancers O
( O
prostate O
, O
pancreatic O
, O
lung O
, O
etc O
. O
) O
. O

( B
99m I
) I
Tc I
labeling O
was O
performed O
by O
using O
different O
co O
- O
ligands O
: O
tricine O
and O
ethylenediamine O
diacetic O
acid O
( O
EDDA O
) O
. O

The O
radiochemical O
stability O
of O
radiolabeled O
peptide O
conjugates O
was O
checked O
at O
room O
temperature O
and O
in O
cysteine B
solution O
up O
to O
24 O
h O
. O

Single O
- O
walled O
carbon B
nanotube O
surface O
control O
of O
complement O
recognition O
and O
activation O
. O

Carbon B
nanotubes O
( O
CNTs O
) O
are O
receiving O
considerable O
attention O
in O
site O
- O
specific O
drug O
and O
nucleic O
acid O
delivery O
, O
photodynamic O
therapy O
, O
and O
photoacoustic O
molecular O
imaging O
. O

CNTs O
with O
linear O
poly B
( I
ethylene I
glycol I
) I
amphiphiles O
trigger O
the O
lectin O
pathway O
of O
the O
complement O
through O
both O
L O
- O
ficolin O
and O
mannan O
- O
binding O
lectin O
recognition O
. O

An O
amphiphile O
with O
branched O
poly B
( I
ethylene I
glycol I
) I
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L O
- O
ficolin O
recognition O
. O

Synthesis O
of O
novel O
phosphorylated O
guanidine O
derivatives O
from O
cyanamide B
and O
their O
anti O
- O
inflammatory O
activity O
. O

A O
series O
of O
novel O
guanidine B
derivatives O
were O
synthesized O
in O
three O
steps O
and O
their O
anti O
- O
inflammatory O
activities O
in O
vitro O
and O
in O
vivo O
evaluated O
. O

It O
was O
further O
reacted O
with O
cyanamide B
to O
afford O
the O
corresponding O
cyanamine O
( O
4 O
) O
, O
which O
was O
subsequently O
reacted O
with O
different O
heterocyclic B
amines I
to O
form O
the O
title O
compounds O
( O
5a O
- O
l O
) O
. O

The O
substituent O
in O
the O
guanidine B
function O
affected O
the O
potency O
of O
anti O
- O
inflammatory O
activity O
. O

The O
compounds O
having O
benzothiazole B
, O
fluorophenyl O
, O
and O
piperazinyl O
moieties O
enhanced O
the O
anti O
- O
inflammatory O
activity O
. O

Discovering O
some O
novel O
7 O
- O
chloroquinolines O
carrying O
a O
biologically O
active O
benzenesulfonamide B
moiety O
as O
a O
new O
class O
of O
anticancer O
agents O
. O

Based O
on O
the O
reported O
anticancer O
activity O
of O
quinolines B
, O
a O
new O
series O
of O
7 O
- O
chloroquinoline O
derivatives O
bearing O
the O
biologically O
active O
benzenesulfonamide B
moiety O
2 O
- O
17 O
and O
19 O
- O
25 O
were O
synthesized O
starting O
with O
4 O
, O
7 O
- O
dichloroquinolne O
1 O
. O

Compound O
17 O
was O
the O
most O
active O
compound O
with O
IC O
( O
50 O
) O
value O
64 O
. O
41 O
, O
75 O
. O
05 O
and O
30 O
. O
71 O
micro O
M O
compared O
with O
Doxorubicin B
as O
reference O
drug O
with O
IC O
( O
50 O
) O
values O
82 O
. O
53 O
, O
88 O
. O
32 O
and O
73 O
. O
72 O
micro O
M O
on O
breast O
cancer O
cells O
, O
skin O
cancer O
cells O
and O
neuroblastoma O
, O
respectively O
. O

In O
order O
to O
suggest O
the O
mechanism O
of O
action O
for O
their O
cytotoxic O
activity O
, O
molecular O
docking O
for O
all O
synthesized O
compounds O
was O
done O
on O
the O
active O
site O
of O
phosphoinositide B
kinase O
( O
PI3K O
) O
and O
good O
results O
were O
obtained O
. O

Two O
new O
triterpenoid B
saponins I
from O
the O
root O
of O
Platycodon O
grandiflorum O
. O

Two O
new O
triterpenoid B
saponins I
, O
named O
platycodon O
A O
( O
3 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O
16 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O
2 O
beta O
, O
3 O
beta O
, O
16 O
beta O
, O
21 O
beta O
- O
tetrahydroxyolean O
- O
12 O
- O
en O
- O
28 O
- O
oic O
acid O
) O
and O
platycodon O
B O
( O
3 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranosyl O
- O
16 O
- O
O O
- O
beta O
- O
D O
- O
xylopyranosyl O
- O
2 O
beta O
, O
3 O
beta O
, O
16 O
beta O

Two O
freshwater O
fish O
, O
Rasbora O
sumatrana O
( O
Cyprinidae O
) O
and O
Poecilia O
reticulata O
( O
guppy O
; O
Poeciliidae O
) O
, O
were O
exposed O
to O
a O
range O
of O
eight O
heavy O
metals O
( O
copper O
( O
Cu B
) O
, O
cadmium B
( O
Cd B
) O
, O
zinc B
( O
Zn B
) O
, O
lead O
( O
Pb B
) O
, O
nickel B
( O
Ni B
) O
, O
iron B
( O
Fe B
) O
, O
aluminium B
( O
Al B
) O
, O
and O
manganese B
( O
Mn B
) O
) O
at O
varied O
concentrations O
for O
96 O
h O
in O
the O
laboratory O
. O

The O
96 O
- O
h O
LC O
( O
50 O
) O
values O
for O
Cu B
, O
Cd B
, O
Zn B
, O
Pb B
, O
Ni B
, O
Fe B
, O
Al B
, O
and O
Mn B
were O
0 O
. O
006 O
, O
0 O
. O
10 O
, O
0 O
. O
46 O
, O
0 O
. O
63 O
, O
0 O
. O
83 O
, O
1 O
. O
71 O
, O
1 O
. O
53 O
, O
and O
5 O
. O
71 O
mg O
/ O
L O
for O
R O
. O
sumatrana O
and O
0 O
. O
038 O
, O
0 O
. O
17 O
, O
1 O
. O
06 O
, O
1 O
. O
99 O
, O
15 O
. O
62 O
, O
1 O
. O
46 O
, O
6 O
. O
76 O
, O
and O
23 O
. O
91 O
mg O
/ O
L O
for O
P O
. O
reticulata O
, O
respectively O
. O

The O
metal O
toxicity O
trend O
for O
R O
. O
sumatrana O
and O
P O
. O
reticulata O
from O
most O
to O
least O
toxic O
was O
Cu B
> O
Cd B
> O
Zn B
> O
Pb B
> O
Ni B
> O
Al B
> O
Fe B
> O
Mn B
and O
Cu B
> O
Cd B
> O
Zn B
> O
Fe B
> O
Pb B
> O
Al B
> O
Ni B
> O
Mn B
, O
respectively O
. O

Results O
indicated O
that O
Cu B
was O
the O
most O
toxic O
metal O
on O
both O
fish O
, O
and O
R O
. O
sumatrana O
was O
more O
sensitive O
than O
P O
. O
reticulata O
to O
all O
the O
eight O
metals O
. O

Synthesis O
and O
characterization O
of O
an O
MRI O
Gd B
- O
based O
probe O
designed O
to O
target O
the O
translocator O
protein O
. O

The O
Gd O
- O
DOTA O
monoamide O
cage O
( O
DOTA B
= O
1 O
, O
4 O
, O
7 O
, O
10 O
- O
tetraazacyclododecan O
- O
1 O
, O
4 O
, O
7 O
, O
10 O
- O
tetraacetic O
acid O
) O
represents O
the O
magnetic O
resonance O
imaging O
reporter O
, O
which O
is O
spaced O
from O
the O
phenylpyrazolo O
[ O
1 O
, O
5 O
- O
a O
] O
pyrimidineacetamide O
moiety O
( O
DPA O
- O
713 O
motif O
) O
by O
a O
six O
carbon B
- O
atom O
chain O
. O

The O
stability O
of O
the O
supramolecular O
adduct O
formed O
by O
the O
Gd B
- O
complex O
and O
liposomes O
was O
assessed O
by O
a O
competition O
test O
with O
albumin O
. O

As O
carbaboranes O
represent O
interesting O
pharmacophores O
as O
phenyl B
mimetics O
in O
drug O
development O
, O
this O
paper O
presents O
the O
synthesis O
of O
carbaboranyl O
derivatives O
of O
COX O
- O
2 O
- O
selective O
2 O
, O
3 O
- O
disubstituted O
indoles O
. O

Despite O
the O
lability O
of O
carbaboranes O
under O
reducing O
conditions O
, O
2 O
- O
carbaborane O
- O
3 O
- O
phenyl O
- O
1H O
- O
indoles O
could O
be O
synthesized O
by O
McMurry O
cyclization O
of O
the O
corresponding O
amides B
. O

Unwinding O
of O
primer O
- O
templates O
by O
archaeal O
family O
- O
B O
DNA O
polymerases O
in O
response O
to O
template O
- O
strand O
uracil B
. O

Archaeal O
family O
- O
B O
DNA O
polymerases O
bind O
tightly O
to O
deaminated O
bases O
and O
stall O
replication O
on O
encountering O
uracil B
in O
template O
strands O
, O
four O
bases O
ahead O
of O
the O
primer O
- O
template O
junction O
. O

Should O
the O
polymerase O
progress O
further O
towards O
the O
uracil B
, O
for O
example O
, O
to O
position O
uracil B
only O
two O
bases O
in O
front O
of O
the O
junction O
, O
3 O
' O
- O
5 O
' O
proof O
- O
reading O
exonuclease O
activity O
becomes O
stimulated O
, O
trimming O
the O
primer O
and O
re O
- O
setting O
uracil B
to O
the O
+ O
4 O
position O
. O

Uracil B
sensing O
prevents O
copying O
of O
the O
deaminated O
base O
and O
permanent O
mutation O
in O
50 O
% O
of O
the O
progeny O
. O

This O
publication O
uses O
both O
steady O
- O
state O
and O
time O
- O
resolved O
2 O
- O
aminopurine O
fluorescence O
to O
show O
pronounced O
unwinding O
of O
primer O
- O
templates O
with O
Pyrococcus O
furiosus O
( O
Pfu O
) O
polymerase O
- O
DNA O
complexes O
containing O
uracil B
at O
+ O
2 O
; O
much O
less O
strand O
separation O
is O
seen O
with O
uracil B
at O
+ O
4 O
. O

The O
roles O
of O
M247 O
and O
Y261 O
, O
amino B
acids I
suggested O
by O
structural O
studies O
to O
play O
a O
role O
in O
primer O
- O
template O
unwinding O
, O
have O
been O
probed O
. O

The O
drugs O
clinically O
used O
for O
the O
treatment O
of O
this O
disease O
, O
such O
as O
acetylcholinesterase O
inhibitors O
( O
AChEIs O
) O
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
antagonist O
, O
can O
only O
provide O
a O
limited O
therapeutic O
effect O
. O

This O
review O
will O
give O
an O
update O
demonstration O
on O
the O
novel O
anti O
- O
AD O
natural O
products O
and O
their O
derivatives O
/ O
analogues O
, O
which O
have O
been O
divided O
into O
five O
subgroups O
according O
to O
their O
different O
action O
mechanisms O
: O
AChEIs O
, O
antioxidants O
, O
neuroprotective O
agents O
, O
monoamine B
oxidase O
( O
MAO O
) O
inhibitors O
, O
and O
tau O
hyperphosphorylation O
inhibitors O
. O

Comparison O
of O
antiproliferative O
effects O
of O
metformine O
and O
progesterone B
on O
estrogen B
- O
induced O
endometrial O
hyperplasia O
in O
rats O
. O

Metformin B
has O
been O
shown O
to O
inhibit O
the O
growth O
of O
endometriotic O
implants O
, O
and O
reverse O
endometrial O
hyperplasia O
when O
combined O
with O
oral O
contraceptive O
in O
a O
case O
report O
. O

The O
aim O
of O
this O
study O
is O
to O
compare O
the O
antiproliferative O
effects O
of O
medroxyprogesterone B
acetate I
( O
MPA B
) O
, O
and O
metformin B
in O
oopherectomized O
rat O
endometrium O
. O

Forty O
oopherectomized O
Wistar O
- O
Albino O
rats O
were O
used O
, O
and O
assigned O
to O
receive O
saline O
, O
17 O
beta O
Estradiol O
hemihydrate O
( O
4 O
mg O
/ O
kg O
) O
, O
17 O
beta O
Estradiol O
hemihydrate O
( O
4 O
mg O
/ O
kg O
) O
and O
metformin B
( O
50 O
mg O
/ O
kg O
) O
, O
17 O
beta O
Estradiol O
hemihydrate O
( O
4 O
mg O
/ O
kg O
) O
and O
MPA B
( O
1 O
mg O
/ O
day O
) O
for O
14 O
days O
. O

Rats O
treated O
with O
estradiol B
had O
significantly O
increased O
in O
endometrial O
height O
, O
endomerial O
luminal O
epithelial O
height O
and O
endometrial O
gland O
densitiy O
than O
the O
other O
groups O
. O

Metformin B
and O
MPA O
acetate O
significantly O
reduced O
all O
parameters O
indicating O
endometrial O
hyperplasia O
, O
and O
uterotrophy O
with O
respect O
to O
the O
control O
group O
. O

Antiproliferative O
effects O
of O
metformin B
, O
and O
MPA B
was O
found O
to O
be O
comparable O
for O
all O
three O
parameters O
. O

In O
conclusion O
, O
metformin B
attenuates O
estrogen B
- O
induced O
endometrial O
hyperplasia O
in O
ooferectomized O
rats O
to O
the O
same O
degree O
as O
progesterone B
. O

However O
, O
at O
high O
concentrations O
( O
= O
~ O
0 O
. O
2 O
mg O
/ O
mL O
) O
, O
( B
1 I
) I
H I
NMR O
and O
DOSY O
measurements O
confirmed O
that O
irradiating O
BBS O
at O
350 O
nm O
induced O
a O
conversion O
from O
the O
trans O
- O
BBS O
into O
its O
cis O
isomer O
by O
photoisomerization O
. O

It O
was O
further O
found O
that O
the O
stilbene B
moiety O
of O
both O
isomers O
was O
photocleaved O
. O

The O
resulting O
photoproduct O
was O
an O
aldehyde B
that O
was O
oxidized O
under O
ambient O
conditions O
to O
its O
corresponding O
carboxylic B
acid I
, O
i O
. O
e O
. O
, O
4 O
- O
( O
1 O
, O
3 O
- O
benzoxazol O
- O
2 O
- O
yl O
) O
benzoic O
acid O
. O

We O
previously O
reported O
that O
caffeoyl O
- O
amino O
acidyl O
- O
hydroxamic O
acid O
( O
CA O
- O
Xaa O
- O
NHOH O
) O
acted O
as O
both O
a O
good O
antioxidant O
and O
tyrosinase O
inhibitor O
, O
in O
particular O
when O
caffeic B
acid I
was O
conjugated O
with O
proline B
or O
amino B
acids I
having O
aromatic O
ring O
like O
phenylalanine B
. O

Here O
, O
various O
hydroxycinnamic B
acid I
( O
HCA B
) O
derivatives O
were O
further O
conjugated O
with O
phenylalanyl O
hydroxamic O
acid O
and O
prolyl O
hydroxamic O
acid O
( O
HCA O
- O
Phe O
- O
NHOH O
and O
HCA O
- O
Pro O
- O
NHOH O
) O
to O
study O
the O
structure O
and O
activity O
relationship O
as O
both O
antioxidants O
and O
tyrosinase O
inhibitors O
. O

When O
their O
biological O
activities O
were O
evaluated O
, O
all O
HCA O
- O
Phe O
- O
NHOH O
and O
HCA O
- O
Pro O
- O
NHOH O
exhibited O
enhanced O
antioxidant O
activity O
compared O
to O
HCA B
alone O
. O

Moreover O
, O
derivatives O
of O
caffeic B
acid I
, O
ferulic B
acid I
, O
and O
sinapic B
acid I
inhibited O
lipid O
peroxidation O
more O
efficiently O
than O
vitamin B
E I
analogue O
( O
Trolox B
) O
. O

In O
addition O
, O
derivatives O
of O
caffeic B
acid I
and O
sinapic B
acid I
efficiently O
inhibited O
tyrosinase O
activity O
and O
reduced O
melanin O
content O
in O
melanocytes O
Mel O
- O
Ab O
cell O
. O

The O
role O
of O
individual O
gastric O
emptying O
of O
pellets O
in O
the O
prediction O
of O
diclofenac B
in O
vivo O
dissolution O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
check O
for O
the O
possibility O
to O
successfully O
predict O
individual O
in O
vivo O
dissolution O
/ O
absorption O
profiles O
resulting O
from O
fasted O
administration O
of O
a O
diclofenac B
extended O
release O
pellet O
formulation O
. O

Additionally O
, O
obtained O
results O
indicated O
that O
a O
substantial O
part O
of O
variability O
of O
diclofenac B
absorption O
profiles O
can O
be O
explained O
by O
the O
variability O
of O
pellet O
gastric O
emptying O
kinetics O
. O

The O
colon O
carcinogen O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
is O
actively O
secreted O
in O
the O
distal O
colon O
of O
the O
rat O
: O
an O
integrated O
view O
on O
the O
role O
of O
PhIP B
transport O
and O
metabolism O
in O
PhIP B
- O
induced O
colon O
carcinogenesis O
. O

In O
this O
context O
, O
it O
has O
been O
postulated O
that O
the O
uptake O
of O
toxic O
substances O
formed O
during O
meat O
and O
fish O
processing O
such O
as O
heterocyclic O
aromatic O
amines O
( O
HCAs B
) O
may O
be O
causally O
related O
to O
colon O
carcinogenesis O
. O

In O
a O
previous O
study O
, O
we O
have O
shown O
that O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
, O
the O
most O
abundantly O
formed O
HCA B
in O
the O
above O
- O
mentioned O
food O
items O
, O
is O
mainly O
absorbed O
in O
the O
small O
intestine O
( O
i O
. O
e O
. O
proximal O
jejunum O
) O
of O
the O
rat O
. O

In O
the O
present O
study O
, O
we O
analysed O
whether O
PhIP B
can O
actively O
be O
secreted O
by O
enterocytes O
in O
the O
rat O
proximal O
jejunum O
and O
distal O
colon O
. O

Unidirectional O
PhIP B
flux O
rates O
from O
the O
mucosal O
- O
to O
- O
the O
serosal O
compartment O
( O
J O
ms O
) O
and O
in O
the O
opposite O
direction O
( O
J O
sm O
) O
were O
examined O
in O
Ussing O
chambers O
with O
( O
14 O
) O
C O
- O
PhIP O
as O
radiotracer O
and O
in O
the O
absence O
of O
electrochemical O
gradients O
. O

Under O
these O
experimental O
conditions O
, O
significant O
negative O
net O
flux O
rates O
( O
J O
net O
= O
J O
ms O
- O
J O
sm O
) O
can O
only O
be O
explained O
by O
an O
active O
secretion O
of O
PhIP B
into O
the O
luminal O
compartment O
, O
and O
such O
an O
effect O
was O
observed O
in O
the O
rat O
distal O
colon O
, O
but O
not O
in O
the O
proximal O
jejunum O
. O

Moreover O
, O
the O
data O
obtained O
suggest O
that O
the O
breast O
cancer O
resistance O
protein O
, O
the O
multidrug O
resistance O
protein O
4 O
and O
P O
- O
glycoprotein O
are O
not O
involved O
in O
the O
active O
secretion O
of O
PhIP B
in O
the O
rat O
distal O
colon O
. O

The O
potential O
role O
of O
PhIP B
transport O
in O
colon O
carcinogenesis O
is O
discussed O
. O

Warfarin B
dose O
prediction O
in O
children O
using O
pharmacometric O
bridging O
- O
comparison O
with O
published O
pharmacogenetic O
dosing O
algorithms O
. O

PURPOSE O
: O
Numerous O
studies O
have O
investigated O
causes O
of O
warfarin B
dose O
variability O
in O
adults O
, O
whereas O
studies O
in O
children O
are O
limited O
both O
in O
numbers O
and O
size O
. O

The O
main O
objectives O
with O
this O
study O
were O
to O
evaluate O
the O
predictive O
performance O
of O
a O
theoretically O
bridged O
adult O
warfarin B
model O
in O
children O
, O
and O
to O
compare O
accuracy O
in O
dose O
prediction O
relative O
to O
published O
warfarin B
algorithms O
for O
children O
. O

METHOD O
: O
An O
adult O
population O
pharmacokinetic O
/ O
pharmacodynamic O
( O
PK O
/ O
PD O
) O
model O
for O
warfarin B
, O
with O
CYP2C9 O
and O
VKORC1 O
genotype O
, O
age O
and O
target O
international O
normalized O
ratio O
( O
INR O
) O
as O
dose O
predictors O
, O
was O
bridged O
to O
children O
using O
allometric O
scaling O
methods O
. O

RESULTS O
: O
Overall O
, O
the O
bridged O
model O
predicted O
INR O
response O
well O
in O
64 O
warfarin B
- O
treated O
Swedish O
children O
( O
median O
age O
4 O
. O
3 O
years O
) O
, O
but O
with O
a O
tendency O
to O
overpredict O
INR O
in O
children O
< O
= O
2 O
years O
old O
. O

CONCLUSION O
: O
A O
mechanism O
- O
based O
population O
model O
developed O
on O
adult O
data O
provides O
a O
promising O
first O
step O
towards O
more O
individualized O
warfarin B
therapy O
in O
children O
. O

Post O
- O
translational O
modifications O
of O
TRF2 O
such O
as O
phosphorylation O
, O
ubiquitination O
, O
SUMOylation O
, O
methylation O
and O
poly O
( O
ADP B
- O
ribosyl O
) O
ation O
have O
been O
shown O
to O
play O
important O
roles O
in O
telomere O
function O
. O

Here O
we O
show O
that O
TRF2 O
specifically O
interacts O
with O
the O
histone O
acetyltransferase O
p300 O
, O
and O
that O
p300 O
acetylates O
the O
lysine B
residue O
at O
position O
293 O
of O
TRF2 O
. O

These O
GCMA O
inhibitors O
have O
a O
better O
selectivity O
profile O
than O
the O
previously O
described O
agmatine O
analogues O
, O
and O
possess O
negligible O
affinity O
for O
the O
trypsin O
- O
like O
serine B
proteases O
thrombin O
, O
factor O
Xa O
, O
and O
matriptase O
. O

The O
inhibitor O
adopts O
a O
horseshoe O
- O
like O
conformation O
, O
most O
likely O
due O
to O
a O
hydrophobic O
contact O
between O
the O
P4 O
phenyl B
ring O
and O
the O
P1 O
cyclohexyl O
group O
, O
which O
is O
further O
stabilized O
by O
an O
intramolecular O
hydrogen B
bond O
between O
the O
P1 O
guanidino B
group O
and O
the O
P4 O
carbonyl O
oxygen O
atom O
. O

Several O
lines O
of O
evidence O
, O
including O
the O
recent O
discovery O
of O
novel O
susceptibility O
genes O
, O
point O
out O
an O
important O
role O
for O
the O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
signaling O
pathway O
in O
the O
development O
of O
pheochromocytoma O
. O

Using O
selective O
ATP B
- O
competitive O
inhibitors O
targeting O
both O
mTORC1 O
and O
mTORC2 O
, O
we O
significantly O
arrested O
the O
in O
vitro O
cell O
proliferation O
and O
blocked O
migration O
of O
pheochromocytoma O
cells O
as O
a O
result O
of O
the O
pharmacological O
suppression O
of O
the O
Akt O
/ O
mTOR O
signaling O
pathway O
. O

Moreover O
, O
AZD8055 O
, O
a O
selective O
ATP B
- O
competitive O
dual O
mTORC1 O
/ O
2 O
small O
molecular O
inhibitor O
, O
significantly O
reduced O
the O
tumor O
burden O
in O
a O
model O
of O
metastatic O
pheochromocytoma O
using O
female O
athymic O
nude O
mice O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
- O
induced O
hypertension O
: O
The O
beneficial O
effects O
of O
melatonin B
. O

Objective O
: O
The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
effects O
of O
melatonin B
on O
biochemical O
and O
cardiovascular O
changes O
resulting O
from O
exposure O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
a O
polychlorinated O
dibenzo O
- O
para O
- O
dioxin O
. O
Methods O
: O
A O
total O
of O
24 O
Sprague O
- O
Dawley O
rats O
were O
divided O
equally O
into O
the O
following O
four O
groups O
: O
( O
1 O
) O
control O
group O
was O
administered O
with O
0 O
. O
5 O
mL O
corn O
oil O
by O
gavage O
and O
0 O
. O
5 O
cc O
vehicle O
of O

melatonin B
( O
proportionally O
nine O
parts O
physiological O
serum O
+ O
one O
part O
ethyl O
alcohol O
) O
intraperitoneally O
for O
4 O
weeks O
, O
( O
2 O
) O
the O
melatonin B
group O
was O
given O
5 O
mg O
/ O
kg O
/ O
day O
melatonin B
intraperitoneally O
for O
4 O
weeks O
, O
( O
3 O
) O
the O
TCDD B
group O
was O
given O
500 O
ng O
/ O
kg O
/ O
day O
TCDD B
by O
gavage O
for O
4 O
weeks O
and O
( O
4 O
) O
the O
TCDD B
+ O
melatonin B
group O
was O
given O
TCDD B
( O
500 O
ng O
/ O
kg O
/ O
day O
) O
by O
gavage O
and O
melatonin B
( O
5 O
mg O
/ O
kg O

Vascular O
responses O
to O
phenylephrine B
and O
acetylcholine B
were O
evaluated O
in O
the O
isolated O
thoracic O
aortas O
. O
Results O
: O
TCDD B
not O
only O
augmented O
the O
systolic O
blood O
pressure O
but O
also O
increased O
the O
contractile O
responses O
to O
phenylephrine B
in O
aorta O
. O

Melatonin B
reversed O
the O
blood O
pressure O
augmented O
by O
TCDD B
and O
decreased O
the O
contractile O
responses O
to O
phenylephrine B
in O
aorta O
. O

TCDD B
induced O
an O
increase O
in O
the O
malondialdehyde B
levels O
in O
kidney O
tissue O
and O
melatonin B
did O
not O
change O
it O
. O

Therefore O
, O
TCDD B
caused O
a O
decrease O
in O
glutathione B
levels O
in O
kidney O
tissues O
and O
melatonin B
reversed O
it O
. O
Conclusion O
: O
Present O
data O
demonstrated O
that O
TCDD B
may O
lead O
to O
an O
increase O
in O
blood O
pressure O
via O
increased O
renal O
oxidative O
stress O
and O
vascular O
reactivity O
. O

However O
, O
melatonin B
might O
ameliorate O
the O
blood O
pressure O
disturbed O
by O
TCDD B
in O
part O
by O
decreasing O
the O
oxidant O
activity O
induced O
by O
TCDD B
. O

Diels O
- O
Alder O
mediated O
controlled O
release O
from O
a O
poly B
( I
ethylene I
glycol I
) I
based O
hydrogel O
. O

A O
synthetic O
amino B
acid I
bearing O
a O
furan B
functionality O
was O
developed O
and O
incorporated O
into O
peptide O
sequences O
using O
solid O
phase O
synthesis O
. O

Peptides O
expressing O
the O
furan B
moiety O
were O
attached O
to O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
hydrogels O
through O
a O
thermally O
reversible O
covalent O
bond O
formed O
by O
a O
Diels O
- O
Alder O
reaction O
. O

Reactions O
of O
thiol B
and O
maleimide O
PEG O
macromers O
in O
an O
off O
- O
stoichiometric O
Michael O
addition O
were O
performed O
, O
such O
that O
the O
maleimide B
moiety O
was O
in O
excess O
, O
to O
create O
hydrogel O
networks O
with O
pendant O
Diels O
- O
Alder O
compatible O
tethering O
sites O
, O
that O
is O
, O
the O
maleimide B
. O

This O
concept O
was O
demonstrated O
by O
incorporating O
a O
fluorescently O
labeled O
furan B
- O
RGDS O
sequence O
into O
a O
hydrogel O
possessing O
excess O
maleimide B
functionalities O
and O
monitoring O
the O
subsequent O
liberation O
of O
RGDS O
at O
various O
temperatures O
, O
illustrating O
a O
Diels O
- O
Alder O
mediated O
release O
mechanism O
. O

Increasing O
the O
amount O
of O
free O
maleimide B
and O
, O
therefore O
, O
the O
number O
of O
potential O
Diels O
- O
Alder O
reaction O
sites O
, O
effectively O
slowed O
the O
release O
of O
peptide O
from O
the O
polymer O
. O

For O
instance O
, O
doubling O
the O
amount O
of O
maleimide B
sites O
present O
in O
the O
hydrogel O
system O
decreased O
the O
amount O
of O
peptide O
released O
from O
approximately O
60 O
% O
to O
about O
40 O
% O
in O
the O
same O
span O
of O
time O
. O

Bottom O
- O
up O
approach O
to O
creating O
three O
- O
dimensional O
nanoring O
arrays O
composed O
of O
Au B
nanoparticles O
. O

A O
bottom O
- O
up O
approach O
to O
creating O
3D O
assemblies O
of O
Au B
nanorings O
by O
drying O
aqueous O
dispersions O
of O
PS O
colloidal O
particles O
and O
Au B
NPs O
is O
shown O
. O

The O
evaporation O
of O
water O
from O
the O
dispersion O
allowed O
for O
the O
formation O
of O
hexagonally O
assembled O
colloidal O
crystals O
and O
nanorings O
composed O
of O
Au B
nanoparticles O
among O
the O
PS O
colloidal O
particles O
. O

After O
sintering O
, O
the O
Au B
NPs O
formed O
Au B
nanorings O
. O

Poly O
( O
ferrocenyl O
( O
3 O
- O
bromopropyl O
) O
methylsilane O
) O
and O
poly O
( O
ethylene O
imine O
) O
are O
employed O
in O
a O
layer O
- O
by O
- O
layer O
deposition O
process O
to O
form O
covalently O
connected O
, O
redox O
- O
active O
multilayer O
thin O
films O
by O
means O
of O
an O
amine B
alkylation O
reaction O
. O

The O
stepwise O
buildup O
of O
these O
multilayers O
on O
silicon B
, O
ITO B
, O
and O
quartz B
substrates O
was O
monitored O
by O
UV O
- O
vis O
absorption O
spectroscopy O
, O
Fourier O
transform O
infrared O
spectroscopy O
( O
FTIR O
) O
, O
static O
contact O
angle O
measurements O
, O
surface O
plasmon O
resonance O
( O
SPR O
) O
, O
atomic O
force O
microscopy O
, O
ellipsometry O
, O
and O
cyclic O
voltammetry O
, O
which O
provide O
evidence O
for O
a O
linear O
increase O
in O
multilayer O
thickness O
with O
the O
number O
of O
deposited O
bilayers O
. O

Upon O
oxidation O
and O
reduction O
, O
these O
covalently O
interconnected O
layers O
do O
not O
disassemble O
, O
in O
contrast O
to O
poly O
( O
ferrocenylsilane O
) O
( O
PFS B
) O
layers O
featuring O
similar O
backbone O
structures O
that O
are O
held O
together O
by O
electrostatic O
forces O
. O

The O
PFS B
/ O
PEI B
multilayers O
are O
effective O
for O
the O
electrochemical O
sensing O
of O
ascorbic B
acid I
and O
hydrogen B
peroxide I
and O
show O
improved O
sensing O
performance O
at O
higher O
bilayer O
numbers O
. O

Stenesen O
and O
colleagues O
( O
2012 O
) O
activate O
AMPK O
both O
directly O
and O
indirectly O
by O
altering O
AMP B
biosynthesis O
to O
slow O
aging O
in O
Drosophila O
, O
highlighting O
AMPK O
as O
a O
conserved O
life O
span O
modulator O
that O
links O
energy O
sensing O
to O
longevity O
. O

In O
the O
work O
described O
here O
, O
we O
developed O
three O
cyclic O
peptides O
, O
VP O
mimic1 O
, O
VP O
mimic2 O
and O
OT O
mimic1 O
, O
which O
mimic O
endocrine O
hormones O
vasopressin O
and O
oxytocin B
. O

Vasopressin O
and O
oxytocin B
contain O
a O
disulfide B
linkage O
leaving O
them O
particularly O
vulnerable O
to O
deactivation O
from O
the O
reducing O
environment O
inside O
the O
cell O
. O

Thus O
, O
we O
increased O
the O
complexity O
of O
our O
assays O
by O
adding O
reducing O
agent O
glutathione B
to O
each O
mixture O
. O

The O
design O
concept O
involved O
the O
replacement O
of O
the O
3 O
- O
carboxylic O
acid O
in O
ciprofloxacin B
with O
an O
oxaborole O
- O
fused O
ring O
as O
an O
acid O
- O
mimicking O
group O
. O

The O
synthetic O
method O
employed O
in O
this O
work O
provides O
a O
good O
example O
of O
incorporating O
boron B
atom O
in O
complex O
molecules O
with O
multiple O
functional O
groups O
. O

Vinclozolin B
- O
- O
no O
transgenerational O
inheritance O
of O
anti O
- O
androgenic O
effects O
after O
maternal O
exposure O
during O
organogenesis O
via O
the O
intraperitoneal O
route O
. O

The O
goal O
of O
this O
study O
was O
to O
examine O
the O
potential O
transgenerational O
inheritance O
of O
anti O
- O
androgenic O
effects O
induced O
by O
Vinclozolin B
administered O
intraperitoneally O
to O
pregnant O
Wistar O
rats O
( O
Crl O
: O
WI O
[ O
Han O
] O
) O
. O

Dams O
were O
dosed O
with O
Vinclozolin B
at O
0 O
, O
4 O
or O
100mg O
/ O
kg O
bw O
/ O
d O
on O
gestation O
days O
6 O
- O
15 O
. O

In O
conclusion O
, O
transgenerational O
inheritance O
of O
Vinclozolin B
' O
s O
anti O
- O
androgenic O
effects O
was O
not O
evident O
in O
outbred O
Wistar O
rats O
. O

Enhancing O
nicotine B
vaccine O
immunogenicity O
with O
liposomes O
. O

A O
major O
liability O
of O
existing O
nicotine B
vaccine O
candidates O
is O
the O
wide O
variation O
in O
anti O
- O
nicotine B
immune O
responses O
among O
clinical O
trial O
participants O
. O

In O
order O
to O
address O
this O
liability O
, O
significant O
emphasis O
has O
been O
directed O
at O
evaluating O
adjuvants O
and O
delivery O
systems O
that O
confer O
more O
robust O
potentiation O
of O
the O
anti O
- O
nicotine B
immune O
response O
. O

The O
results O
of O
the O
murine O
immunization O
study O
described O
herein O
support O
the O
hypothesis O
that O
a O
liposomal O
nicotine B
vaccine O
formulation O
may O
provide O
a O
means O
for O
addressing O
the O
immunogenicity O
challenge O
. O

Triglyceride B
accumulation O
inhibitory O
effects O
of O
phenylpropanoid O
glycosides O
from O
Boschniakia O
rossica O
Fedtsch O
et O
Flerov O
. O

Anti O
- O
apoptotic O
activity O
of O
hydroxytyrosol B
and O
hydroxytyrosyl O
laurate O
. O

Hydroxytyrosol B
( O
HyT O
) O
is O
a O
polyphenol B
primarily O
released O
in O
olive O
mill O
wastewater O
and O
in O
olive O
oil O
. O

Differently O
, O
many O
researchers O
reported O
that O
HyT O
down O
- O
regulates O
tumor O
cell O
viability O
and O
cell O
cycle O
progression O
, O
and O
induces O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
apoptosis O
. O

H2O2 B
, O
at O
the O
concentrations O
known O
to O
induce O
apoptosis O
, O
was O
utilized O
as O
cell O
death O
trigger O
. O

The O
results O
obtained O
show O
that O
laur O
- O
HyT O
has O
a O
protective O
antioxidant O
effect O
against O
H2O2 B
treatment O
, O
greater O
than O
HyT O
, O
so O
having O
a O
role O
in O
the O
prevention O
of O
apoptotic O
death O
in O
normal O
and O
tumor O
cells O
. O

Zinc B
protection O
against O
aluminium B
induced O
altered O
lipid O
profile O
and O
membrane O
integrity O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
Zinc B
( O
Zn B
) O
supplementation O
on O
lipid O
profile O
and O
fluidity O
of O
cerebrum O
and O
cerebellum O
membranes O
of O
rats O
treated O
with O
aluminium B
( O
Al B
) O
. O

Sprague O
dawley O
male O
rats O
were O
divided O
into O
four O
different O
treatment O
groups O
viz O
: O
Control O
, O
aluminium B
treated O
, O
zinc B
treated O
and O
aluminium B
+ O
zinc B
treated O
. O

Aluminium B
( O
AlCl3 B
) O
was O
administered O
orally O
at O
a O
dose O
of O
100mg O
/ O
kgb O
. O
wt O
. O
/ O
day O
( O
dissolved O
in O
drinking O
water O
) O
. O

Zinc B
as O
zinc B
sulphate I
was O
supplemented O
to O
rats O
at O
a O
dose O
of O
227mg O
/ O
l O
in O
drinking O
water O
. O

A O
significant O
decrease O
in O
the O
levels O
of O
total O
lipids O
, O
glycolipids O
, O
phospholipids O
, O
cholesterol B
and O
gangliosides O
contents O
were O
observed O
in O
both O
the O
cerebrum O
and O
cerebellum O
following O
Al B
exposure O
, O
which O
were O
found O
to O
be O
significantly O
increased O
following O
Zn B
supplementation O
. O

On O
the O
contrary O
, O
Al B
treatment O
caused O
a O
significant O
increase O
in O
the O
formation O
of O
conjugated O
dienes B
, O
which O
were O
observed O
to O
be O
reduced O
on O
Zn B
co O
- O
treatment O
. O

Further O
, O
Al B
treatment O
significantly O
elevated O
the O
fluorescence O
polarization O
, O
anisotropy O
and O
order O
parameter O
, O
which O
however O
were O
normalized O
upon O
Zn B
co O
- O
administration O
. O

Hence O
, O
the O
present O
study O
depicts O
the O
potential O
of O
Zn B
in O
moderating O
the O
changes O
caused O
by O
Al B
on O
membrane O
composition O
and O
fluidity O
in O
rat O
brain O
. O

FXR O
- O
dependent O
and O
- O
independent O
interaction O
of O
glucocorticoids O
with O
the O
regulatory O
pathways O
involved O
in O
the O
control O
of O
bile B
acid I
handling O
by O
the O
liver O
. O

The O
ability O
of O
dexamethasone B
, O
prednisolone B
and O
budesonide B
to O
affect O
the O
liver O
handling O
of O
bile B
acids I
( O
BAs O
) O
has O
been O
investigated O
. O

Enhanced O
chemopreventive O
activity O
of O
hydroxytyrosol B
on O
HL60 O
and O
HL60R O
cells O
by O
chemical O
conversion O
into O
thio O
derivatives O
. O

Thio O
derivatives O
of O
hydroxytyrosol B
containing O
thiol B
, O
thioacetate O
and O
disulfide B
functionalities O
were O
synthesized O
from O
natural O
hydroxytyrosol B
( O
3 O
, O
4 O
- O
DHPEA O
) O
via O
3 O
, O
4 O
- O
dihydroxyphenethyl O
halides O
. O

These O
compounds O
, O
containing O
the O
combination O
of O
catechol B
moiety O
and O
divalent O
sulfur B
functions O
, O
were O
tested O
for O
the O
pro O
- O
apoptotic O
and O
anti O
- O
proliferative O
activities O
on O
both O
parental O
HL60 O
and O
multi O
- O
drug O
resistant O
HL60R O
cells O
. O

It O
was O
found O
that O
all O
synthesized O
compounds O
were O
more O
effective O
than O
3 O
, O
4 O
- O
DHPEA O
in O
inducing O
apoptosis O
on O
HL60R O
cells O
, O
and O
that O
the O
hydroxytyrosol B
disulfide B
was O
the O
most O
active O
pro O
- O
apoptotic O
and O
anti O
- O
proliferative O
compound O
on O
both O
HL60 O
and O
HL60R O
cells O
. O

Different O
from O
3 O
, O
4 O
- O
DHPEA O
, O
all O
thio O
derivatives O
of O
hydroxytyrosol B
induced O
apoptosis O
by O
a O
mechanism O
not O
involving O
the O
release O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
in O
the O
culture O
medium O
. O

Tablets O
consisting O
of O
acetaminophen B
( O
20 O
- O
30 O
% O
) O
, O
lactose B
( O
69 O
. O
07 O
- O
78 O
. O
93 O
% O
) O
and O
magnesium O
stearate O
( O
0 O
. O
93 O
- O
1 O
. O
07 O
% O
) O
were O
prepared O
in O
a O
continuous O
direct O
compression O
line O
that O
consisted O
of O
two O
loss O
- O
in O
- O
weight O
feeders O
, O
one O
for O
acetaminophen B
and O
one O
for O
premixed O
lactose B
and O
magnesium O
stearate O
, O
and O
a O
continuous O
mixer O
followed O
by O
a O
rotary O
tablet O
press O
. O

The O
UV O
- O
spectrophotometric O
method O
was O
used O
as O
an O
off O
- O
line O
reference O
method O
to O
determine O
the O
acetaminophen B
content O
in O
the O
samples O
. O

OAT1 O
and O
OAT3 O
: O
targets O
of O
drug O
- O
drug O
interaction O
between O
entecavir O
and O
JBP485 B
. O

Entecavir O
and O
JBP485 B
( O
a O
dipeptide B
) O
exhibit O
the O
antihepatitis O
activities O
and O
it O
is O
possible O
for O
the O
two O
drugs O
to O
be O
coadministered O
in O
the O
treatment O
of O
hepatitis O
. O

We O
aimed O
to O
elucidate O
whether O
entecavir O
was O
a O
substrate O
of O
OAT1 O
, O
OAT3 O
, O
OCT O
, O
and O
PEPT1 O
and O
to O
investigate O
the O
targets O
of O
drug O
- O
drug O
interactions O
between O
entecavir O
and O
JBP485 B
. O

Following O
intravenous O
co O
- O
administration O
of O
entecavir O
and O
JBP485 B
in O
rats O
, O
entecavir O
AUC O
increased O
1 O
. O
93 O
- O
fold O
, O
t1 O
/ O
2 O
beta O
was O
prolonged O
2 O
. O
08 O
- O
fold O
, O
CLP O
decreased O
49 O
% O
, O
CLR O
decreased O
73 O
% O
, O
and O
accumulated O
urinary O
excretion O
decreased O
54 O
% O
. O

In O
rat O
kidney O
slices O
, O
uptake O
of O
entecavir O
was O
markedly O
inhibited O
by O
p O
- O
aminohippurate O
, O
benzylpenicillin O
, O
JBP485 B
, O
and O
tetraethyl O
ammonium O
. O

In O
hOAT1 O
- O
and O
hOAT3 O
- O
HEK293 O
cells O
, O
uptake O
of O
entecavir O
was O
significantly O
higher O
compared O
to O
vector O
- O
HEK293 O
cells O
and O
was O
markedly O
inhibited O
by O
p O
- O
aminohippurate O
, O
benzylpenicillin O
, O
and O
JBP485 B
. O

Moreover O
, O
OAT1 O
and O
OAT3 O
are O
the O
targets O
of O
DDI O
between O
entecavir O
and O
JBP485 B
. O

Bioactive O
barrigenol O
type O
triterpenoids B
from O
the O
leaves O
of O
Xanthoceras O
sorbifolia O
Bunge O
. O

In O
order O
to O
find O
out O
new O
natural O
barrigenol O
type O
triterpenenoids O
as O
antitumor O
agent O
and O
reveal O
the O
difference O
on O
material O
basis O
of O
different O
parts O
of O
Xanthoceras O
sorbifolia O
Bunge O
, O
the O
bioassay O
- O
directed O
separation O
of O
the O
saponin B
fraction O
from O
leaves O
of O
X O
. O
sorbifolia O
Bunge O
was O
carried O
out O
to O
afford O
5 O
new O
barrigenol O
type O
triterpenoids B
( O
1 O
- O
5 O
) O
, O
together O
with O
2 O
known O
ones O
. O

Synthesis O
of O
quinoline B
derivatives O
: O
discovery O
of O
a O
potent O
and O
selective O
phosphodiesterase O
5 O
inhibitor O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

Phosphodiesterase O
type O
5 O
( O
PDE5 O
) O
mediates O
the O
degradation O
of O
cGMP B
in O
a O
variety O
of O
tissues O
including O
brain O
. O

Recent O
studies O
have O
demonstrated O
the O
importance O
of O
the O
nitric B
oxide I
/ O
cGMP B
/ O
cAMP B
- O
responsive O
element O
- O
binding O
protein O
( O
CREB O
) O
pathway O
to O
the O
process O
of O
learning O
and O
memory O
. O

To O
explore O
this O
possibility O
, O
a O
series O
of O
quinoline B
derivatives O
were O
synthesized O
and O
evaluated O
. O

Quinoline B
- O
based O
, O
CNS O
- O
permeant O
PDE5Is O
have O
potential O
for O
AD O
therapeutic O
development O
. O

The O
present O
study O
employs O
an O
in O
vivo O
MMR O
assay O
developed O
in O
our O
laboratory O
to O
assess O
how O
prevalent O
environmental O
carcinogens O
such O
as O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
affect O
MMR O
activity O
in O
human O
breast O
carcinoma O
cells O
. O

Specifically O
, O
we O
quantitatively O
measured O
MMR O
activity O
in O
ZR75 O
- O
1 O
cells O
after O
they O
were O
exposed O
to O
benzo O
[ O
alpha O
] O
pyrene O
( O
BaP B
) O
, O
a O
prototypical O
PAH B
, O
at O
various O
concentrations O
. O

Our O
findings O
revealed O
that O
BaP B
exposure O
at O
high O
concentrations O
of O
1 O
and O
5 O
mu O
M O
induced O
significant O
inhibition O
of O
MMR O
activity O
in O
ZR75 O
- O
1 O
cells O
. O

Further O
, O
we O
also O
identified O
that O
MMR O
repression O
induced O
by O
5 O
mu O
M O
BaP B
was O
mediated O
through O
one O
of O
the O
MMR O
key O
proteins O
MSH6 O
as O
significant O
reduction O
in O
protein O
level O
was O
detected O
by O
western O
blot O
. O

More O
importantly O
, O
ectopic O
expression O
of O
hMSH6 O
restored O
MMR O
activity O
in O
the O
BaP B
treated O
cells O
to O
the O
same O
level O
as O
in O
the O
control O
cells O
. O

Our O
findings O
suggest O
that O
BaP B
induced O
repression O
of O
MMR O
activity O
may O
also O
contribute O
to O
the O
progression O
of O
mutagenesis O
event O
. O

Detoxification O
of O
aldehydes B
by O
histidine B
- O
containing O
dipeptides O
: O
from O
chemistry O
to O
clinical O
implications O
. O

Aldehydes B
are O
generated O
by O
oxidized O
lipids O
and O
carbohydrates B
at O
increased O
levels O
under O
conditions O
of O
metabolic O
imbalance O
and O
oxidative O
stress O
during O
atherosclerosis O
, O
myocardial O
and O
cerebral O
ischemia O
, O
diabetes O
, O
neurodegenerative O
diseases O
and O
trauma O
. O

In O
most O
tissues O
, O
aldehydes B
are O
detoxified O
by O
oxidoreductases O
that O
catalyze O
the O
oxidation O
or O
the O
reduction O
of O
aldehydes B
or O
enzymatic O
and O
nonenzymatic O
conjugation O
with O
low O
molecular O
weight O
thiols B
and O
amines B
, O
such O
as O
glutathione B
and O
histidine B
dipeptides O
. O

Histidine B
dipeptides O
are O
present O
in O
micromolar O
to O
millimolar O
range O
in O
the O
tissues O
of O
vertebrates O
, O
where O
they O
are O
involved O
in O
a O
variety O
of O
physiological O
functions O
such O
as O
pH O
buffering O
, O
metal O
chelation O
, O
oxidant O
and O
aldehyde B
scavenging O
. O

Histidine B
dipeptides O
such O
as O
carnosine B
form O
Michael O
adducts O
with O
lipid O
- O
derived O
unsaturated O
aldehydes O
, O
and O
react O
with O
carbohydrate B
- O
derived O
oxo O
- O
and O
hydroxy O
- O
aldehydes O
forming O
products O
of O
unknown O
structure O
. O

Although O
these O
peptides O
react O
with O
electrophilic O
molecules O
at O
lower O
rate O
than O
glutathione B
, O
they O
can O
protect O
glutathione B
from O
modification O
by O
oxidant O
and O
they O
may O
be O
important O
for O
aldehyde B
quenching O
in O
glutathione B
- O
depleted O
cells O
or O
extracellular O
space O
where O
glutathione B
is O
scarce O
. O

Consistent O
with O
in O
vitro O
findings O
, O
treatment O
with O
carnosine B
has O
been O
shown O
to O
diminish O
ischemic O
injury O
, O
improve O
glucose B
control O
, O
ameliorate O
the O
development O
of O
complications O
in O
animal O
models O
of O
diabetes O
and O
obesity O
, O
promote O
wound O
healing O
and O
decrease O
atherosclerosis O
. O

The O
protective O
effects O
of O
carnosine B
have O
been O
linked O
to O
its O
anti O
- O
oxidant O
properties O
, O
its O
ability O
to O
promote O
glycolysis O
, O
detoxify O
reactive O
aldehydes B
and O
enhance O
histamine B
levels O
. O

Thus O
, O
treatment O
with O
carnosine B
and O
related O
histidine B
dipeptides O
may O
be O
a O
promising O
strategy O
for O
the O
prevention O
and O
treatment O
of O
diseases O
associated O
with O
high O
carbonyl B
load O
. O

The O
effect O
of O
manganese B
on O
dopamine B
toxicity O
and O
dopamine B
transporter O
( O
DAT O
) O
in O
control O
and O
DAT O
transfected O
HEK O
cells O
. O

Chronic O
exposure O
to O
Mn B
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O

Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn B
- O
induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine B
- O
induced O
DA O
release O
and O
loss O
of O
the O
dopamine B
transporter O
( O
DAT O
) O
. O

Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn B
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT O
- O
transfected O
HEK O
cells O
reveal O
that O
Mn B
is O
equally O
toxic O
to O
both O
cell O
lines O
whereas O
DA O
was O
only O
toxic O
to O
cells O
containing O
DAT O
. O

When O
Mn B
and O
DA O
were O
added O
simultaneously O
to O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn B
alone O
suggesting O
that O
Mn B
may O
suppress O
DA O
uptake O
in O
the O
DAT O
containing O
cells O
. O

Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn B
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O

Mn B
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine B
- O
induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O

Time O
- O
lapsed O
confocal O
microscopy O
indicates O
that O
Mn B
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O

Mn B
- O
induced O
internalization O
of O
DAT O
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

Flavonoids B
profiles O
, O
antioxidant O
, O
acetylcholinesterase O
inhibition O
activities O
of O
extract O
from O
Dryoathyrium O
boryanum O
( O
Willd O
. O
) O
Ching O
. O

The O
profiles O
and O
bioactivities O
of O
flavonoids B
extracted O
from O
Dryoathyrium O
boryanum O
( O
Willd O
. O
) O
Ching O
were O
investigated O
. O

The O
total O
flavonoids B
content O
in O
extract O
from O
D O
. O
boryanum O
is O
about O
145 O
. O
8mg O
/ O
g O
. O

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids B
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 O
- O
hydroxyphloretin O
6 O
' O
- O
O O
- O
hexoside O
, O
quercetin O
- O
7 O
- O
hexoside O
, O
apigenin7 O
- O
O O
- O
glucoside O
, O
luteolin B
7 I
- I
O I
- I
glucoside I
, O
apigenin O
7 O
- O
O O
- O
galactoside O
, O
acacetin O
7 O
- O
O O
- O
( O
alpha O
- O
D O
- O
apio O
- O
furanosyl O
) O
( O
1 O
- O
- O
> O
6 O

0 O
. O
21mg O
/ O
ml O
flavonoids B
extract O
from O
D O
. O
boryanum O
showed O
very O
strong O
superoxide B
anion O
radical O
scavenging O
potential O
, O
which O
is O
higher O
than O
that O
of O
rutin B
( O
0 O
. O
25mg O
/ O
ml O
) O
. O

The O
extract O
( O
0 O
. O
21mg O
/ O
ml O
of O
flavonoids B
) O
from O
D O
. O
boryanum O
exhibited O
similar O
DPPH B
scavenging O
potential O
with O
that O
of O
rutin B
( O
0 O
. O
25mg O
/ O
ml O
) O
. O

However O
, O
rutin B
( O
0 O
. O
25mg O
/ O
ml O
) O
showed O
a O
significantly O
higher O
reducing O
power O
and O
ABTS B
scavenging O
potential O
than O
that O
of O
0 O
. O
21mg O
/ O
ml O
flavonoids B
extract O
from O
D O
. O
boryanum O
. O

D O
. O
boryanum O
can O
be O
considered O
as O
a O
medicinal O
plant O
and O
the O
flavonoids B
from O
D O
. O
boryanum O
are O
excellent O
antioxidants O
. O

Profiling O
of O
neuraminidase O
inhibitory O
polyphenols B
from O
the O
seeds O
of O
Paeonia O
lactiflora O
. O

All O
these O
active O
species O
( O
1 O
- O
4 O
) O
contained O
a O
resveratrol B
chemotype O
, O
however O
resveratrol B
itself O
was O
inactive O
( O
IC50 O
> O
100 O
mu O
M O
) O
. O

1 O
- O
4 O
were O
isolated O
from O
the O
60 O
% O
aqueous O
ethanol B
extract O
of O
seeds O
of O
Paeonia O
lactiflora O
, O
which O
exhibited O
potent O
neuraminidase O
inhibition O
. O

Purification O
of O
the O
extracts O
yielded O
four O
chiral O
polyphenols B
, O
suffruticosol O
A O
( O
1 O
) O
, O
suffruticosol O
B O
( O
2 O
) O
, O
trans O
- O
epsilon O
- O
viniferin O
( O
3 O
) O
, O
and O
trans O
- O
gnetin O
H O
( O
4 O
) O
. O

We O
found O
that O
only O
the O
presence O
of O
a O
polyphenolic B
moiety O
anchored O
to O
the O
beta B
- I
lactam I
ring O
ensured O
an O
adequate O
antioxidant O
potency O
. O

By O
using O
reversible O
hydrogenation O
of O
graphene B
and O
binding O
of O
streptavidin O
- O
biotin B
, O
we O
demonstrate O
an O
areal O
mass O
sensitivity O
at O
a O
level O
of O
fg O
mm O
( O
- O
2 O
) O
and O
detection O
of O
individual O
biomolecules O
, O
respectively O
. O

A O
physiologically O
based O
pharmacokinetic O
model O
for O
the O
oxime B
TMB B
- I
4 I
: O
simulation O
of O
rodent O
and O
human O
data O
. O

Multiple O
oximes B
have O
been O
synthesized O
and O
evaluated O
for O
use O
as O
countermeasures O
against O
chemical O
warfare O
nerve O
agents O
. O

The O
current O
U O
. O
S O
. O
military O
and O
civilian O
oxime B
countermeasure O
, O
2 O
- O
[ O
( O
hydroxyimino O
) O
methyl O
] O
- O
1 O
- O
methylpyridin O
- O
1 O
- O
ium O
chloride O
( O
2 B
- I
PAM I
) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase O
reactivator O
, O
1 O
, O
1 O
' O
- O
methylenebis O
{ O
4 O
- O
hydroxyiminomethyl O
} O
pyridinium O
dimethanesulfonate O
( O
MMB O
- O
4 O
) O
. O

Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB O
- O
4 O
are O
limited O
; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime B
, O
1 O
, O
1 O
' O
- O
trimethylenebis O
{ O
4 O
- O
hydroximinomethyl O
} O
pyridinium O
dibromide O
. O

Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate B
diisopropylfluoropho O
, O
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase O
inhibition O
( O
brain O
and O
diaphragm O
) O
, O
as O
well O
as O
fat O
, O
kidney O
, O
liver O
, O
rapidly O
perfused O
tissues O
and O
slowly O
perfused O
tissues O
. O

The O
PBPK O
model O
can O
be O
used O
to O
optimize O
the O
dosing O
regimen O
to O
improve O
oxime B
therapeutic O
efficacy O
in O
a O
human O
population O
. O

Detonation O
nanodiamond O
( O
ND O
) O
is O
a O
suitable O
source O
material O
to O
produce O
unique O
samples O
consisting O
of O
almost O
uniform O
diamond B
nanocrystals O
( O
d O
= O
3 O
- O
5 O
nm O
) O
. O

Such O
samples O
exist O
in O
the O
form O
of O
long O
stable O
aqueous O
dispersions O
with O
narrow O
size O
distribution O
of O
diamond B
particles O
. O

The O
major O
problem O
in O
producing O
monodispersed O
diamond B
colloids O
lies O
in O
the O
necessity O
of O
deagglomeration O
of O
detonation O
soot O
and O
/ O
or O
removing O
of O
clusters O
formed O
by O
already O
isolated O
core O
particles O
in O
dry O
powders O
. O

Although O
there O
are O
reports O
that O
oxidative O
injury O
may O
play O
a O
role O
in O
the O
pathophysiology O
of O
some O
neurologic O
disorders O
, O
such O
as O
migraine O
and O
epilepsy O
, O
by O
disrupting O
or O
destroying O
cell O
membranes O
through O
the O
formation O
of O
free O
radical O
and O
reactive O
oxygen B
species O
, O
the O
pathophysiology O
of O
headache O
is O
not O
clearly O
established O
. O

Activities O
of O
erythrocyte O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
glutathione B
peroxidase O
( O
GPx O
) O
as O
well O
as O
malondialdehyde B
( O
MDA B
) O
levels O
in O
all O
the O
children O
of O
both O
the O
groups O
were O
measured O
. O

Mean O
activities O
of O
erythrocyte O
SOD O
, O
CAT O
, O
and O
GPx O
as O
well O
as O
MDA B
levels O
were O
significantly O
higher O
in O
the O
study O
group O
than O
in O
the O
control O
group O
( O
p O
< O
0 O
. O
001 O
) O
. O

Study O
of O
intracellular O
delivery O
of O
doxorubicin B
from O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
nanoparticles O
by O
means O
of O
fluorescence O
lifetime O
imaging O
and O
confocal O
Raman O
microscopy O
. O

The O
intracellular O
delivery O
of O
Doxorubicin B
( O
Dox B
) O
from O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
nanoparticles O
stabilised O
with O
bovine O
serum O
albumin O
, O
in O
HepG2 O
cells O
, O
is O
studied O
via O
flow O
cytometry O
, O
fluorescence O
lifetime O
imaging O
microscopy O
( O
FLIM O
) O
, O
confocal O
Raman O
microscopy O
( O
CRM O
) O
and O
cell O
viability O
studies O
. O

Flow O
cytometry O
shows O
that O
the O
initial O
uptake O
of O
PLGA B
and O
Dox B
follow O
the O
same O
kinetics O
. O

However O
, O
following O
8 O
h O
of O
incubation O
, O
the O
fluorescence O
intensity O
and O
cellular O
uptake O
of O
Dox B
decreases O
, O
while O
in O
the O
case O
of O
PLGA B
both O
parameters O
remain O
constant O
. O

Cell O
viability O
decreases O
by O
approximately O
20 O
% O
when O
incubated O
for O
24 O
h O
with O
PLGA B
loaded O
with O
Dox B
, O
with O
a O
particle O
concentration O
of O
100 O
micro O
g O
. O
mL O
( O
- O
1 O
) O
. O

At O
the O
single O
- O
cell O
level O
, O
CRM O
shows O
changes O
in O
the O
bands O
from O
DNA O
and O
proteins O
in O
the O
cell O
nucleus O
when O
incubated O
with O
PLGA B
loaded O
with O
Dox B
. O

The O
mechanisms O
leading O
to O
the O
deposition O
of O
colloidal O
particles O
in O
a O
copper B
- O
gold O
galvanic O
microreactor O
are O
investigated O
. O

Ionic O
transport O
phenomena O
are O
responsible O
for O
the O
occurrence O
of O
strongly O
localized O
high O
current O
density O
at O
the O
edges O
and O
corners O
of O
the O
copper B
electrodes O
at O
large O
electrode O
separation O
, O
leading O
to O
a O
preferential O
aggregation O
of O
colloidal O
particles O
at O
the O
electrode O
edges O
. O

We O
demonstrate O
that O
electrolyte O
flow O
is O
most O
likely O
driven O
by O
electrochemical O
potential O
gradients O
of O
reaction O
products O
formed O
during O
the O
inhomogeneous O
copper B
dissolution O
. O

New O
prospects O
for O
vinblastine B
analogues O
as O
anticancer O
agents O
. O

Boger O
et O
al O
. O
synthesized O
a O
series O
of O
C20 O
' O
urea B
derivatives O
of O
vinblastine B
that O
matched O
or O
exceeded O
the O
potency O
of O
vinblastine B
in O
cell O
growth O
inhibition O
assays O
. O

The O
studies O
demonstrated O
the O
importance O
of O
the O
H B
- O
bond O
donor O
on O
the O
C20 O
' O
position O
and O
revealed O
the O
presence O
of O
a O
space O
surrounding O
the O
C20 O
' O
substituent O
that O
tolerates O
a O
wide O
variety O
of O
substituents O
, O
remarkably O
enhancing O
potency O
of O
vinblastine B
analogues O
. O

Rheological O
study O
of O
mutarotation O
of O
fructose B
in O
anhydrous O
state O
. O

This O
work O
demonstrates O
that O
, O
in O
addition O
to O
the O
routine O
techniques O
such O
polarimetry O
and O
gas O
- O
liquid O
chromatography O
, O
rheological O
measurement O
can O
be O
used O
as O
an O
alternative O
method O
to O
continuously O
monitor O
the O
mutarotation O
of O
sugars B
. O

One O
- O
pot O
synthesis O
of O
tin O
- O
embedded O
carbon B
/ O
silica B
nanocomposites O
for O
anode O
materials O
in O
lithium B
- O
ion O
batteries O
. O

We O
report O
a O
facile O
" O
one O
- O
pot O
" O
method O
for O
the O
synthesis O
of O
Sn B
- O
embedded O
carbon B
- O
silica B
( O
CS O
) O
mesostructured O
( O
nanostructured O
) O
composites O
through O
the O
selective O
interaction O
of O
resol O
( O
carbon B
precursor O
) O
, O
tetraethylorthosilic O
( O
TEOS O
) O
, O
and O
tributylphenyltin O
( O
Sn B
precursor O
) O
with O
an O
amphiphilic O
diblock O
copolymer O
, O
poly O
( O
ethylene O
oxide O
- O
b O
- O
styrene O
) O
, O
PEO O
- O
b O
- O
PS O
. O

A O
unique O
morphology O
transition O
from O
Sn B
nanowires O
to O
spherical O
Sn B
nanoparticles O
embedded O
in O
CS O
framework O
has O
been O
obtained O
. O

Metallic O
Sn B
species O
are O
homogeneously O
embedded O
in O
a O
rigid O
CS O
framework O
and O
are O
effectively O
confined O
within O
the O
nanostructures O
. O

The O
resulting O
composites O
are O
used O
as O
anode O
materials O
for O
lithium B
- O
ion O
batteries O
and O
exhibit O
high O
specific O
capacities O
( O
600 O
mA O
h O
g O
- O
( O
1 O
) O
at O
a O
current O
density O
of O
45 O
mA O
g O
- O
( O
1 O
) O
, O
and O
440 O
mA O
h O
g O
- O
( O
1 O
) O
at O
a O
current O
density O
of O
300 O
mA O
g O
- O
( O
1 O
) O
) O
and O
an O
excellent O
cyclability O
of O
over O
100 O
cycles O
with O
high O
Coulombic O
efficiency O
. O

Among O
them O
, O
the O
cardiac O
M O
( O
3 O
) O
muscarinic O
acetylcholine B
receptor O
( O
M O
( O
3 O
) O
- O
mAChR O
) O
has O
been O
studied O
for O
more O
than O
2 O
decades O
since O
its O
first O
discovery O
in O
mammalian O
heart O
in O
1990s O
. O

Growth O
of O
Pt B
nanowires O
by O
atomic O
layer O
deposition O
on O
highly O
ordered O
pyrolytic O
graphite B
. O

The O
formation O
of O
Pt B
nanowires O
( O
NWs O
) O
by O
atomic O
layer O
deposition O
on O
highly O
ordered O
pyrolytic O
graphite B
( O
HOPG O
) O
is O
investigated O
. O

Pt B
is O
deposited O
only O
at O
the O
step O
edges O
of O
HOPG O
and O
not O
on O
the O
basal O
planes O
, O
leading O
to O
the O
formation O
of O
laterally O
aligned O
Pt B
NWs O
. O

This O
asymmetry O
is O
ascribed O
to O
the O
wetting O
properties O
of O
Pt B
on O
HOPG O
as O
influenced O
by O
the O
formation O
of O
graphene B
oxide I
. O

A O
difference O
in O
Pt B
growth O
kinetics O
based O
on O
crystallographic O
orientation O
may O
also O
contribute O
. O

The O
key O
challenges O
in O
transplanted O
islets O
are O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
associated O
oxidative O
stress O
, O
pro O
- O
inflammatory O
cytokine O
- O
( O
TNF O
alpha O
) O
mediated O
apoptotic O
induction O
, O
attack O
by O
immune O
cells O
, O
and O
achieving O
revascularization O
with O
minimal O
hypoxic O
microenvironment O
. O

Currently O
, O
very O
few O
techniques O
have O
been O
routinely O
used O
to O
qualitatively O
and O
quantitatively O
assess O
the O
survival O
and O
function O
of O
islet O
grafts O
, O
especially O
to O
confirm O
the O
success O
of O
treatment O
, O
which O
includes O
metabolic O
parameters O
such O
as O
blood O
glucose B
, O
insulin O
and O
C O
- O
peptide O
levels O
. O

After O
pharmacokinetic O
studies O
, O
the O
neuroprotective O
efficacy O
of O
C O
- O
DIM5 O
, O
C O
- O
DIM8 O
, O
and O
C O
- O
DIM12 O
( O
50 O
mg O
/ O
Kg O
per O
oral O
) O
was O
examined O
in O
mice O
exposed O
to O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
MPTP B
) O
and O
probenecid O
for O
14 O
days O
, O
a O
model O
of O
progressive O
neurodegeneration O
with O
a O
strong O
neuroinflammatory O
component O
. O

C O
- O
DIM5 O
and O
C O
- O
DIM12 O
given O
orally O
once O
daily O
after O
one O
week O
of O
exposure O
to O
MPTP B
and O
probenecid O
prevented O
further O
loss O
of O
dopaminergic O
neurons O
in O
the O
substantia O
nigra O
pars O
compacta O
and O
striatal O
dopamine B
terminals O
, O
indicating O
that O
these O
compounds O
could O
be O
effective O
therapeutic O
agents O
to O
prevent O
neurodegeneration O
. O

Peroxynitrite B
mediates O
testosterone B
- O
induced O
vasodilation O
of O
microvascular O
resistance O
vessels O
. O

Our O
knowledge O
of O
how O
androgens B
influence O
the O
cardiovascular O
system O
is O
far O
from O
complete O
, O
and O
this O
lack O
of O
understanding O
is O
especially O
true O
of O
how O
androgens B
affect O
resistance O
vessels O
. O

Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone B
( O
TES O
) O
in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES O
- O
induced O
vasodilation O
. O

Tension O
studies O
demonstrated O
a O
rapid O
, O
concentration O
- O
dependent O
, O
vasodilatory O
response O
to O
TES O
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17 B
beta I
- I
estradiol I
. O

Dichlorofluorescein B
fluorescence O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite B
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES O
- O
induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite B
. O

As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite B
precursors O
( O
i O
. O
e O
. O
, O
superoxide B
and O
nitic O
oxide O
) O
, O
and O
xanthine B
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES O
- O
stimulated O
superoxide B
production O
. O

Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide B
3 O
( O
PI3 O
) O
kinase O
- O
protein O
kinase O
B O
( O
Akt O
) O
cascade O
initiated O
by O
activation O
of O
the O
androgen B
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP B
and O
microvascular O
vasodilation O
. O

These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen B
action O
in O
the O
microvasculature O
: O
TES O
- O
stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite B
formed O
from O
xanthine B
oxidase O
- O
generated O
superoxide B
and O
NO B
. O

This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase O
- O
Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen B
receptor O
. O

We O
propose O
this O
mechanism O
could O
account O
for O
TES O
- O
stimulated O
cGMP B
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

Ordered O
mesoporous O
boron O
- O
doped O
carbons O
as O
metal O
- O
free O
electrocatalysts O
for O
the O
oxygen B
reduction O
reaction O
in O
alkaline O
solution O
. O

Ordered O
mesoporous O
boron O
- O
doped O
carbons O
( O
BOMCs O
) O
were O
prepared O
by O
co O
- O
impregnation O
and O
carbonization O
of O
sucrose B
and O
4 O
- O
hydroxyphenylboronic O
acid O
into O
SBA B
- I
15 I
silica B
template O
. O

Nitrogen B
sorption O
, O
small O
angle O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
and O
transmission O
electron O
microscopy O
( O
TEM O
) O
reveals O
that O
BOMCs O
possess O
highly O
ordered O
mesoporous O
structure O
, O
uniform O
pore O
size O
distribution O
, O
and O
high O
surface O
area O
. O

X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
analysis O
demonstrates O
that O
B B
atoms O
can O
be O
successfully O
doped O
into O
the O
framework O
of O
OMCs O
. O

Due O
to O
the O
desirable O
characteristics O
of O
BOMCs O
, O
BOMCs O
are O
highly O
active O
, O
cheap O
, O
and O
selective O
metal O
- O
free O
electrocatalysts O
for O
the O
oxygen B
reduction O
reaction O
( O
ORR O
) O
in O
alkaline O
solution O
. O

Although O
B B
content O
is O
a O
key O
factor O
in O
determining O
ORR O
activity O
, O
the O
ORR O
activity O
of O
BOMCs O
is O
also O
dependent O
on O
the O
surface O
area O
. O

A O
multiple O
logistic O
regression O
analysis O
showed O
that O
systolic O
blood O
pressure O
( O
SBP O
) O
, O
total O
cholesterol B
( O
TC O
) O
, O
alanine B
aminotransferase O
( O
ALT O
) O
, O
homeostasis O
model O
assessment O
of O
insulin O
resistance O
( O
HOMA O
- O
IR O
) O
, O
leptin O
, O
and O
vaspin O
were O
associated O
with O
an O
increased O
risk O
of O
being O
overweight O
, O
whereas O
high O
- O
density O
lipoprotein O
( O
HDL O
) O
cholesterol B
was O
associated O
with O
a O
decreased O
risk O
of O
being O
overweight O
. O

Peginesatide O
, O
a O
polyethylene B
glycol I
( O
PEG B
) O
ylated O
peptide O
- O
based O
erythropoiesis O
- O
stimulating O
agent O
, O
stimulates O
the O
erythropoietin O
receptor O
dimer O
that O
governs O
erythropoiesis O
. O

Effects O
of O
nicotine B
, O
its O
metabolites O
and O
tobacco O
extracts O
on O
human O
platelet O
function O
in O
vitro O
. O

Previous O
reports O
investigating O
the O
effects O
of O
nicotine B
and O
tobacco O
on O
platelet O
function O
are O
inconsistent O
. O

The O
present O
study O
investigated O
in O
vitro O
effects O
of O
nicotine B
, O
its O
major O
metabolites O
, O
tobacco O
extracts O
and O
extract O
of O
tobacco O
- O
free O
snuff O
on O
human O
platelets O
. O

None O
of O
the O
metabolites O
cotinine B
, O
cotinine O
- O
N O
- O
oxide O
, O
nicotine O
- O
1 O
' O
- O
N O
- O
oxide O
or O
trans O
- O
3 O
' O
- O
hydroxycotinine O
( O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
affected O
platelet O
aggregation O
or O
P O
- O
selectin O
expression O
. O

Nicotine B
( O
10 O
mu O
M O
) O
weakly O
increased O
platelet O
aggregation O
, O
whereas O
trans O
- O
3 O
' O
- O
hydroxycotinine O
( O
0 O
. O
1 O
mu O
M O
) O
and O
nicotine O
- O
1 O
' O
- O
N O
- O
oxide O
( O
1 O
- O
10 O
mu O
M O
) O
weakly O
inhibited O
adhesion O
to O
fibrinogen O
. O

The O
inhibitory O
effects O
of O
tobacco O
extracts O
on O
platelet O
adhesion O
were O
independent O
of O
nicotine B
content O
and O
the O
nitric B
- I
oxide I
- O
pathway O
and O
not O
mediated O
through O
a O
platelet O
- O
nicotine B
- O
receptor O
. O

As O
only O
limited O
effects O
of O
nicotine B
and O
nicotine B
metabolites O
were O
seen O
, O
the O
tobacco O
- O
induced O
platelet O
inhibition O
are O
likely O
induced O
by O
other O
compounds O
present O
in O
tobacco O
and O
tobacco O
free O
snuff O
. O

Re O
- O
print O
of O
" O
Intestinal O
luminal O
nitrogen B
metabolism O
: O
role O
of O
the O
gut O
microbiota O
and O
consequences O
for O
the O
host O
" O
. O

Although O
experimental O
evidences O
suggest O
that O
the O
intestinal O
microbiota O
is O
able O
to O
incorporate O
and O
degrade O
some O
of O
the O
available O
amino B
acids I
, O
it O
appears O
that O
the O
microbiota O
is O
also O
able O
to O
synthesize O
amino B
acids I
raising O
the O
view O
that O
amino B
acid I
exchange O
between O
the O
microbiota O
and O
host O
can O
proceed O
in O
both O
directions O
. O

Although O
the O
net O
result O
of O
such O
exchanges O
remains O
to O
be O
determined O
, O
it O
is O
likely O
that O
a O
significant O
part O
of O
the O
amino B
acids I
recovered O
from O
the O
alimentary O
proteins O
are O
used O
by O
the O
microbiota O
. O

In O
the O
large O
intestine O
, O
where O
the O
density O
of O
bacteria O
is O
much O
higher O
than O
in O
the O
small O
intestine O
and O
the O
transit O
time O
much O
longer O
, O
the O
residual O
undigested O
luminal O
proteins O
and O
peptides O
can O
be O
degraded O
in O
amino B
acids I
by O
the O
microbiota O
. O

These O
amino B
acids I
cannot O
be O
absorbed O
to O
a O
significant O
extent O
by O
the O
colonic O
epithelium O
, O
but O
are O
precursors O
for O
the O
synthesis O
of O
numerous O
metabolic O
end O
products O
in O
reactions O
made O
by O
the O
microbiota O
. O

Among O
these O
products O
, O
some O
like O
short O
- O
chain O
fatty B
acids I
and O
organic O
acids O
are O
energy O
substrates O
for O
the O
colonic O
mucosa O
and O
several O
peripheral O
tissues O
while O
others O
like O
sulfide B
and O
ammonia B
can O
affect O
the O
energy O
metabolism O
of O
colonic O
epithelial O
cells O
. O

ICA O
- O
105574 O
interacts O
with O
a O
common O
binding O
site O
to O
elicit O
opposite O
effects O
on O
inactivation O
gating O
of O
EAG O
and O
ERG O
potassium B
channels O
. O

Rapid O
and O
voltage O
- O
dependent O
inactivation O
greatly O
attenuates O
outward O
currents O
in O
ether B
- O
a O
- O
go O
- O
go O
- O
related O
gene O
( O
ERG O
) O
K B
( I
+ I
) I
channels O
. O

In O
contrast O
, O
inactivation O
of O
related O
ether B
- O
a O
- O
go O
- O
go O
( O
EAG O
) O
K B
( I
+ I
) I
channels O
is O
very O
slow O
and O
minimally O
reduces O
outward O
currents O
. O

ICA O
- O
105574 O
( O
ICA B
, O
or O
3 O
- O
nitro O
- O
N O
- O
[ O
4 O
- O
phenoxyphenyl O
] O
- O
benzamide O
) O
has O
opposite O
effects O
on O
inactivation O
of O
these O
two O
channel O
types O
. O

Although O
ICA B
greatly O
attenuates O
ERG O
inactivation O
by O
shifting O
its O
voltage O
dependence O
to O
more O
positive O
potentials O
, O
it O
enhances O
the O
rate O
and O
extent O
of O
EAG O
inactivation O
without O
altering O
its O
voltage O
dependence O
. O

Here O
, O
we O
investigate O
whether O
the O
inverse O
functional O
response O
to O
ICA B
in O
EAG O
and O
ERG O
channels O
is O
related O
to O
differences O
in O
ICA B
binding O
site O
or O
to O
intrinsic O
mechanisms O
of O
inactivation O
. O

Molecular O
modeling O
coupled O
with O
site O
- O
directed O
mutagenesis O
suggests O
that O
ICA B
binds O
in O
a O
channel O
- O
specific O
orientation O
to O
a O
hydrophobic O
pocket O
bounded O
by O
the O
S5 O
/ O
pore O
helix O
/ O
S6 O
of O
one O
subunit O
and O
S6 O
of O
an O
adjacent O
subunit O
. O

ICA B
is O
a O
mixed O
agonist O
of O
mutant O
EAG O
and O
EAG O
/ O
ERG O
chimera O
channels O
that O
inactivate O
by O
a O
combination O
of O
slow O
and O
fast O
mechanisms O
. O

With O
the O
exception O
of O
three O
residues O
, O
the O
specific O
amino B
acids I
that O
form O
the O
putative O
binding O
pocket O
for O
ICA B
in O
ERG O
are O
conserved O
in O
EAG O
. O

Mutations O
introduced O
into O
EAG O
to O
replicate O
the O
ICA B
binding O
site O
in O
ERG O
did O
not O
alter O
the O
functional O
response O
to O
ICA B
. O

Together O
these O
findings O
suggest O
that O
ICA B
binds O
to O
the O
same O
site O
in O
EAG O
and O
ERG O
channels O
to O
elicit O
opposite O
functional O
effects O
. O

L B
- I
3 I
, I
4 I
- I
Dihydroxyphenylalani I
( O
L O
- O
DOPA O
) O
remains O
the O
most O
effective O
symptomatic O
treatment O
of O
Parkinson O
' O
s O
disease O
( O
PD O
) O
. O

Specifically O
, O
we O
review O
evidence O
gathered O
from O
postmortem O
and O
pharmacological O
studies O
, O
both O
preclinical O
and O
clinical O
, O
and O
discuss O
the O
involvement O
of O
dopaminergic O
and O
nondopaminergic O
systems O
, O
including O
glutamatergic O
, O
opioid O
, O
serotonergic O
, O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
- O
ergic O
, O
adenosine B
, O
cannabinoid O
, O
adrenergic O
, O
histaminergic O
, O
and O
cholinergic O
systems O
. O

This O
was O
accomplished O
by O
incorporating O
controlled O
amounts O
of O
an O
azide B
- O
containing O
monomer O
into O
a O
shape O
memory O
polymeric O
material O
. O

Using O
copper B
- O
assisted O
click O
chemistry O
, O
they O
can O
be O
functionalized O
with O
a O
variety O
of O
molecules O
to O
yield O
different O
surfaces O
. O

Development O
of O
a O
novel O
bioerodible O
dexamethasone B
implant O
for O
uveitis O
and O
postoperative O
cataract O
inflammation O
. O

Delivery O
of O
anti O
- O
inflammatory O
steroids B
concurrently O
to O
both O
anterior O
and O
posterior O
segments O
of O
the O
eye O
is O
a O
challenge O
. O

We O
developed O
a O
novel O
implant O
that O
can O
compensate O
for O
the O
limited O
conveyance O
of O
topical O
medicine O
and O
reduce O
the O
repetitive O
invasiveness O
of O
injection O
from O
the O
capsular O
bag O
allowing O
dexamethasone B
( O
DXM B
) O
delivery O
to O
both O
the O
anterior O
and O
posterior O
chambers O
. O

To O
establish O
proof O
of O
concept O
, O
microparticles O
were O
prepared O
with O
PLGA B
[ O
poly O
( O
d O
, O
l O
- O
lactide O
- O
co O
- O
glycolide O
) O
, O
50 O
: O
50 O
, O
MW O
. O
7000 O
- O
17000 O
] O
, O
hydroxypropyl B
methyl I
cellulose O
( O
HPMC O
) O
, O
and O
DXM B
by O
oil O
- O
in O
- O
water O
emulsion O
/ O
solvent O
evaporation O
technique O
. O

The O
target O
load O
of O
DXM B
in O
the O
microparticles O
was O
~ O
20 O
. O
0 O
% O
with O
a O
% O
recovery O
of O
99 O
. O
9 O
% O
( O
w O
/ O
w O
) O
. O

DXM B
flow O
was O
bidirectional O
from O
the O
endocapsular O
space O
and O
significant O
concentrations O
were O
found O
in O
the O
anterior O
and O
posterior O
chambers O
after O
up O
to O
6 O
weeks O
. O

Caffeine B
has O
greater O
potency O
and O
efficacy O
than O
theophylline B
to O
reverse O
the O
motor O
impairment O
caused O
by O
chronic O
but O
not O
acute O
interruption O
of O
striatal O
dopaminergic O
transmission O
in O
rats O
. O

In O
order O
to O
assess O
whether O
caffeine B
and O
theophylline B
have O
the O
same O
potency O
and O
efficacy O
to O
reverse O
the O
impairment O
of O
motor O
function O
caused O
by O
acute O
or O
chronic O
interruption O
of O
striatal O
dopamine B
transmission O
, O
a O
comparison O
of O
their O
dose O
- O
response O
relationship O
was O
made O
in O
the O
acute O
model O
of O
haloperidol B
- O
induced O
catalepsy O
, O
and O
the O
chronic O
model O
of O
unilateral O
lesion O
of O
the O
dopamine B
nigrostriatal O
pathway O
with O
6 B
- I
hydroxydopamine I
. O

Catalepsy O
intensity O
: O
caffeine B
ED50 O
= O
24 O
. O
1 O
mu O
mol O
/ O
kg O
[ O
95 O
% O
CI O
, O
18 O
. O
4 O
- O
31 O
. O
5 O
] O
; O
theophylline B
ED50 O
= O
22 O
. O
0 O
mu O
mol O
/ O
kg O
[ O
95 O
% O
CI O
, O
17 O
. O
0 O
- O
28 O
. O
4 O
] O
. O

Catalepsy O
latency O
: O
caffeine B
ED50 O
= O
27 O
. O
0 O
mu O
mol O
/ O
kg O
[ O
95 O
% O
CI O
, O
21 O
. O
1 O
- O
34 O
. O
6 O
] O
; O
theophylline B
ED50 O
= O
28 O
. O
8 O
mu O
mol O
/ O
kg O
[ O
95 O
% O
CI O
, O
22 O
. O
5 O
- O
36 O
. O
7 O
] O
. O

In O
one O
group O
of O
hemiparkinsonian O
rats O
( O
n O
= O
5 O
) O
, O
caffeine B
caused O
a O
dose O
- O
dependent O
recovery O
of O
the O
contralateral O
forepaw O
stepping O
: O
ED50 O
= O
2 O
. O
4 O
mu O
mol O
/ O
kg O
/ O
day O
[ O
95 O
% O
CI O
, O
1 O
. O
9 O
- O
3 O
. O
1 O
] O
) O
, O
reaching O
its O
maximum O
at O
the O
dose O
of O
5 O
. O
15 O
mu O
mol O
/ O
kg O
/ O
day O
. O

When O
the O
treatment O
of O
these O
same O
rats O
was O
switched O
to O
5 O
. O
15 O
mu O
mol O
/ O
kg O
/ O
day O
of O
theophylline B
, O
the O
stepping O
recovery O
was O
only O
51 O
+ O
/ O
- O
12 O
% O
of O
that O
induced O
by O
caffeine B
. O

Assessing O
the O
dose O
- O
response O
relationship O
of O
theophylline B
in O
another O
group O
of O
hemiparkinsonian O
rats O
( O
n O
= O
7 O
) O
revealed O
that O
it O
caused O
stepping O
recovery O
in O
an O
all O
- O
or O
- O
none O
fashion O
. O

Thus O
, O
the O
three O
lower O
doses O
had O
no O
effect O
, O
but O
at O
the O
dose O
of O
5 O
. O
15 O
mu O
mol O
/ O
kg O
/ O
day O
theophylline B
suddenly O
increased O
the O
stepping O
to O
56 O
+ O
/ O
- O
5 O
% O
of O
the O
maximal O
effect O
observed O
when O
the O
treatment O
of O
these O
same O
rats O
was O
switched O
to O
an O
equimolar O
dose O
of O
caffeine B
. O

Increasing O
the O
dose O
of O
theophylline B
up O
to O
15 O
. O
45 O
mu O
mol O
/ O
kg O
/ O
day O
caused O
no O
further O
stepping O
improvement O
since O
it O
was O
only O
41 O
+ O
/ O
- O
6 O
% O
of O
the O
maximal O
effect O
produced O
by O
caffeine B
at O
the O
dose O
of O
5 O
. O
15 O
mu O
mol O
/ O
kg O
/ O
day O
. O

Given O
that O
theophylline B
showed O
less O
potency O
and O
efficacy O
than O
caffeine B
to O
reverse O
the O
motor O
impairment O
caused O
by O
chronic O
, O
but O
not O
acute O
, O
interruption O
of O
striatal O
dopaminergic O
transmission O
in O
rats O
, O
it O
is O
suggested O
that O
caffeine B
would O
provide O
more O
benefits O
than O
theophylline B
to O
improve O
the O
motor O
function O
in O
patients O
with O
Parkinson O
' O
s O
disease O
. O

Arsenic B
present O
in O
the O
soil O
- O
vine O
- O
wine O
chain O
in O
vineyards O
situated O
in O
an O
old O
mining O
area O
in O
Trentino O
, O
Italy O
. O

The O
present O
study O
follows O
arsenic B
( O
As B
) O
transfer O
through O
the O
chain O
of O
soil O
- O
vine O
- O
leaves O
- O
grapes O
- O
wine O
to O
assess O
the O
possible O
risk O
of O
arsenic B
intake O
related O
to O
consuming O
grapes O
and O
wines O
produced O
in O
10 O
vineyards O
located O
in O
a O
mining O
area O
rich O
in O
this O
element O
. O

In O
the O
soil O
, O
the O
content O
of O
As B
extracted O
with O
acqua O
regia O
and O
that O
extracted O
with O
ammonium B
acetate I
, O
were O
analyzed O
. O

The O
aqua O
regia O
extractable O
As B
concentration O
in O
soil O
ranged O
from O
3 O
. O
7 O
to O
283 O
mg O
/ O
kg O
, O
whereas O
available O
As B
varied O
from O
18 O
to O
639 O
micro O
g O
/ O
kg O
, O
and O
As B
total O
concentration O
ranged O
from O
16 O
. O
3 O
to O
579 O
micro O
g O
/ O
kg O
dry O
weight O
in O
leaves O
and O
from O
< O
0 O
. O
1 O
to O
36 O
. O
8 O
micro O
g O
/ O
kg O
dry O
weight O
in O
grapes O
. O

Arsenic B
levels O
in O
wines O
were O
always O
below O
1 O
. O
62 O
micro O
g O
/ O
L O
, O
with O
higher O
concentration O
in O
red O
wines O
than O
in O
white O
wines O
. O

Significant O
and O
positive O
correlations O
between O
the O
As B
concentrations O
in O
soils O
, O
leaves O
, O
and O
berries O
are O
highlighted O
, O
with O
the O
samples O
collected O
near O
the O
mining O
area O
having O
significantly O
higher O
values O
. O

Nevertheless O
, O
As B
levels O
in O
wines O
were O
always O
well O
below O
the O
limit O
( O
200 O
micro O
g O
/ O
L O
) O
suggested O
by O
the O
International O
Organization O
of O
Vine O
and O
Wine O
. O

The O
cytoplasmic O
receptor O
NOD2 O
( O
nucleotide B
- O
binding O
oligomerization O
domain O
2 O
) O
senses O
peptidoglycan O
fragments O
and O
triggers O
host O
defense O
pathways O
, O
including O
activation O
of O
nuclear O
factor O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
signaling O
, O
which O
lead O
to O
inflammatory O
immune O
responses O
. O

Folic B
acid I
modified O
cationic O
gamma O
- O
cyclodextrin O
- O
oligoethylenimine O
star O
polymer O
with O
bioreducible O
disulfide B
linker O
for O
efficient O
targeted O
gene O
delivery O
. O

For O
an O
efficient O
folate B
- O
targeted O
delivery O
, O
while O
the O
interaction O
between O
the O
folate B
on O
the O
carriers O
and O
the O
folate B
receptor O
( O
FR O
) O
on O
the O
cells O
is O
necessary O
, O
the O
recovering O
and O
recycling O
of O
FR O
to O
maintain O
a O
high O
density O
level O
of O
FR O
on O
the O
cellular O
membrane O
is O
also O
important O
. O

Herein O
, O
we O
demonstrate O
a O
design O
and O
synthesis O
of O
a O
new O
star O
- O
shaped O
cationic O
polymer O
containing O
a O
gamma O
- O
cyclodextrin O
( O
gamma O
- O
CD O
) O
core O
and O
multiple O
oligoethylenimine O
( O
OEI O
) O
arms O
with O
folic B
acid I
( O
FA O
) O
linked O
by O
a O
bioreducible O
disulfide B
bond O
for O
efficient O
targeted O
gene O
delivery O
. O

The O
gamma O
- O
CD O
- O
OEI O
- O
SS O
- O
FA O
polymer O
was O
well O
- O
characterized O
and O
studied O
in O
terms O
of O
its O
gene O
delivery O
properties O
in O
FR O
- O
positive O
KB O
cells O
and O
FR O
- O
negative O
A549 O
cells O
under O
various O
conditions O
, O
in O
comparison O
with O
cationic O
polymers O
such O
as O
high O
molecular O
weight O
branched O
polyethylenimine B
( O
PEI B
) O
, O
gamma O
- O
CD O
- O
OEI O
star O
- O
shaped O
cationic O
polymer O
, O
gamma O
- O
CD O
- O
OEI O
- O
FA O
polymer O
where O
FA O
was O
directed O
linked O
to O
the O
star O
polymer O
without O
disulfide B
linker O
. O

A O
new O
2 O
, O
5 O
- O
diketopiperazine O
, O
( O
R O
) O
- O
2 O
- O
( O
2 O
- O
( O
furan O
- O
2 O
- O
yl O
) O
- O
oxoethyl O
) O
- O
octahydropyrrolo O
[ O
1 O
, O
2 O
- O
a O
] O
pyrazine O
- O
1 O
, O
4 O
- O
dione O
, O
and O
seven O
known O
compounds O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
liquid O
fermentation O
broth O
of O
Armillaria O
mellea O
. O

Dissecting O
single O
- O
molecule O
signal O
transduction O
in O
carbon B
nanotube O
circuits O
with O
protein O
engineering O
. O

A O
novel O
, O
nonfluorescent O
single O
- O
molecule O
technique O
involves O
attaching O
single O
molecules O
to O
single O
- O
walled O
carbon B
nanotube O
field O
- O
effective O
transistors O
( O
SWNT O
FETs O
) O
. O

The O
data O
prove O
that O
effective O
signal O
generation O
can O
be O
accomplished O
using O
a O
single O
charged O
amino B
acid I
, O
when O
appropriately O
located O
, O
providing O
a O
foundation O
to O
widely O
apply O
SWNT O
FET O
sensitivity O
to O
other O
biomolecular O
systems O
. O

Two O
new O
compounds O
lyciumtetraterpenic O
hexaarabinoside O
( O
1 O
) O
and O
tetraterpenyl O
hexaarabinoside O
( O
2 O
) O
, O
along O
with O
two O
known O
compounds O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
fruits O
of O
Lycium O
chinense O
Miller O
( O
Solanaceae O
) O
, O
and O
their O
structures O
have O
been O
elucidated O
as O
6 O
- O
( O
1 O
, O
1 O
, O
5 O
- O
trimethyl O
- O
5 O
alpha O
- O
hydroxycyclohexanyl O
) O
- O
6 O
' O
- O
( O
1 O
' O
, O
1 O
' O
, O
5 O
' O
- O
trimethyl O
- O
2 O
' O
beta O
- O

The O
first O
is O
a O
population O
of O
1 O
, O
228 O
Danish O
men O
( O
702 O
aged O
20 O
- O
29 O
years O
; O
532 O
aged O
60 O
- O
74 O
years O
) O
from O
the O
Odense O
Androgen B
Study O
( O
OAS O
) O
, O
which O
was O
designed O
as O
a O
cross O
- O
sectional O
, O
population O
- O
based O
study O
. O

A O
significant O
but O
moderate O
increase O
in O
plasma O
cortisol B
after O
SPST O
occurred O
, O
independent O
of O
treatment O
. O

Because O
sumatriptan O
decreases O
5 B
- I
HT I
release O
into O
the O
extracellular O
space O
, O
the O
potentiation O
of O
SPST O
- O
induced O
fear O
caused O
by O
the O
drug O
supports O
the O
hypothesis O
that O
5 B
- I
HT I
attenuates O
this O
emotional O
state O
. O

As O
acute O
administration O
of O
antidepressants O
has O
also O
been O
shown O
to O
enhance O
speaking O
fear O
and O
increase O
plasma O
prolactin O
, O
in O
contrast O
to O
sumatriptan O
, O
the O
5 B
- I
HT I
regulation O
of O
stress O
- O
hormone O
release O
is O
likely O
to O
be O
different O
from O
that O
of O
emotion O
. O

Increases O
in O
triglyceride B
levels O
are O
associated O
with O
clinical O
response O
to O
clozapine B
treatment O
. O

Increases O
in O
serum O
triglyceride B
( O
TG O
) O
levels O
are O
associated O
with O
clinical O
response O
to O
clozapine B
treatment O
. O

Clozapine B
is O
the O
most O
efficacious O
therapy O
for O
treatment O
of O
refractory O
schizophrenia O
, O
although O
its O
use O
is O
well O
recognised O
to O
be O
associated O
with O
substantial O
metabolic O
dysfunction O
. O

Interestingly O
, O
there O
is O
some O
evidence O
that O
the O
therapeutic O
benefit O
of O
clozapine B
is O
associated O
with O
treatment O
- O
emergent O
weight O
gain O
and O
dyslipidaemia O
, O
specifically O
hypertriglyceridaemi O
. O

In O
this O
prospective O
observational O
study O
, O
we O
examine O
associations O
between O
therapeutic O
response O
to O
clozapine B
in O
49 O
patients O
with O
treatment O
- O
resistant O
schizophrenia O
and O
lipid O
dysregulation O
. O

antipsychotic O
polypharmacy O
and O
serum O
clozapine B
levels O
. O

This O
finding O
suggests O
that O
clozapine B
' O
s O
therapeutic O
efficacy O
is O
linked O
to O
serum O
lipid O
changes O
. O

Hypertriglyceridaemi O
as O
a O
predictor O
of O
clinical O
response O
in O
patients O
treated O
with O
clozapine B
merits O
further O
investigation O
in O
order O
to O
better O
elucidate O
its O
effect O
on O
the O
pharmacological O
activity O
of O
clozapine B
. O

The O
whole O
brain O
GABA B
estimation O
of O
brain O
homogenate O
indicated O
that O
the O
anticonvulsant O
activity O
of O
above O
mentioned O
quinazolinone O
derivatives O
might O
be O
due O
to O
an O
increased O
GABA B
concentration O
. O

Here O
, O
the O
film O
formation O
processes O
of O
three O
methyl O
methacrylate O
/ O
butyl B
acrylate I
copolymer O
latexes O
with O
high O
glass O
transition O
temperatures O
( O
T O
( O
g O
) O
) O
, O
ranging O
from O
45 O
to O
64 O
degrees O
C O
, O
have O
been O
studied O
when O
heated O
by O
infrared O
radiation O
. O

Dynamic O
Domains O
in O
Polymersomes O
: O
Mixtures O
of O
Polyanionic O
and O
Neutral O
Diblocks O
Respond O
More O
Rapidly O
to O
Changes O
in O
Calcium B
than O
to O
pH O
. O

Here O
we O
describe O
the O
morphodynamics O
and O
remixing O
kinetics O
of O
spotted O
polymersomes O
made O
with O
mixtures O
of O
polyanionic O
and O
neutral O
amphiphiles O
plus O
calcium B
. O

Addition O
of O
the O
calcium B
chelator O
EDTA B
to O
vesicle O
dispersions O
produced O
a O
decrease O
in O
domain O
size O
within O
minutes O
, O
whereas O
increasing O
the O
pH O
with O
NaOH B
led O
to O
the O
viscous O
fingering O
of O
domains O
and O
decreased O
domain O
size O
over O
hours O
. O

Domain O
roughening O
at O
high O
pH O
is O
also O
accelerated O
by O
EDTA B
, O
which O
highlights O
the O
dominance O
of O
cross O
- O
bridging O
. O

An O
isomerization O
- O
roaming O
pathway O
to O
the O
CH O
( O
3 O
) O
ONO O
isomer O
and O
then O
to O
the O
CH O
( O
3 O
) O
O O
+ O
NO B
products O
is O
found O
. O

For O
example O
, O
Trx O
activates O
extracellular O
transglutaminase O
2 O
( O
TG2 O
) O
via O
reduction O
of O
an O
intramolecular O
disulfide B
bond O
. O

Starting O
from O
a O
clinical O
- O
stage O
asymmetric O
disulfide B
lead O
, O
we O
have O
identified O
analogs O
with O
> O
100 O
- O
fold O
specificity O
for O
Trx O
. O

Acutely O
administered O
antipsychotic O
drugs O
are O
highly O
selective O
for O
dopamine B
D2 O
over O
D3 O
receptors O
. O

We O
showed O
previously O
, O
using O
[ O
( O
3 O
) O
H O
] O
- O
( O
+ O
) O
- O
4 O
- O
propyl O
- O
9 O
- O
hydroxynaphthoxazine O
( O
[ O
( O
3 O
) O
H O
] O
- O
( O
+ O
) O
- O
PHNO O
) O
autoradiography O
, O
that O
several O
antipsychotic O
drugs O
do O
not O
occupy O
dopamine B
D3 O
receptors O
at O
clinically O
- O
relevant O
doses O
in O
rat O
. O

At O
clinically O
- O
relevant O
levels O
of O
D2 O
occupancy O
( O
57 O
- O
82 O
% O
inhibition O
of O
striatal O
binding O
) O
, O
neither O
olanzapine B
nor O
haloperidol B
occupied O
D3 O
receptors O
, O
while O
clozapine B
occupied O
D3 O
receptors O
at O
levels O
similar O
to O
our O
previous O
report O
( O
33 O
% O
) O
. O

Risperidone B
moderately O
occupied O
D3 O
receptors O
( O
40 O
% O
) O
, O
but O
at O
a O
dose O
occupying O
> O
90 O
% O
of O
D2 O
receptors O
and O
therefore O
of O
questionable O
clinical O
relevance O
. O

Logistic O
regression O
analysis O
revealed O
that O
bone O
fracture O
was O
closely O
associated O
with O
not O
only O
low O
bone O
mass O
but O
also O
age O
, O
fall O
, O
family O
histories O
of O
kyphosis O
and O
hip O
fracture O
, O
DM O
, O
kidney O
disease O
, O
menopause O
, O
and O
lifestyle O
factors O
of O
dieting O
, O
exercise O
, O
and O
alcohol B
. O

Women O
' O
s O
health O
care O
focusing O
on O
lifestyle O
- O
related O
fracture O
risks O
such O
as O
dieting O
, O
exercise O
, O
and O
alcohol B
appears O
necessary O
to O
prevent O
bone O
fracture O
in O
postmenopausal O
osteoporosis O
. O

Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3 O
- O
O O
- O
gallate O
and O
several O
quercetin B
derivatives O
. O

Flavonoids B
such O
as O
green O
tea O
catechins B
and O
quercetin B
glycosides I
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O

In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin B
derivatives O
( O
1 O
- O
6 O
) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O

Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17 O
beta O
- O
glucuronide O
, O
estrone O
3 O
- O
sulfate O
, O
and O
dehydroepiandrostero B
sulfate I
( O
DHEAS O
) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1 O
- O
6 O
using O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O

Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3 O
- O
O O
- O
gallate O
( O
EGCG B
) O
and O
most O
of O
compounds O
1 O
- O
6 O
killed O
preferentially O
OATP O
- O
expressing O
CHO O
cells O
. O

EGCG B
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG B
and O
3 O
selectively O
killing O
OATP1B3 O
- O
expressing O
cells O
. O

Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG B
and O
some O
of O
the O
quercetin B
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

Labdane O
- O
type O
diterpenoids B
from O
the O
fruits O
of O
Vitex O
trifolia O
. O

Seven O
new O
labdane O
- O
type O
diterpenoids B
, O
vitextrifolins O
A O
- O
G O
( O
1 O
- O
7 O
) O
, O
along O
with O
eight O
previously O
reported O
analogues O
, O
were O
isolated O
from O
the O
fruits O
of O
Vitex O
trifolia O
. O

Injectable O
hyaluronic O
acid O
- O
tyramine B
hydrogels O
incorporating O
interferon O
- O
alpha O
2a O
for O
liver O
cancer O
therapy O
. O

IFN O
- O
alpha O
2a O
was O
incorporated O
in O
hydrogels O
composed O
of O
hyaluronic O
acid O
- O
tyramine B
( O
HA O
- O
Tyr B
) O
conjugates O
through O
the O
oxidative O
coupling O
of O
Tyr B
moieties O
with O
hydrogen B
peroxide I
( O
H2O2 B
) O
and O
horseradish O
peroxidase O
( O
HRP O
) O
. O

IFN O
- O
alpha O
2a O
- O
incorporated O
HA O
- O
Tyr B
hydrogels O
of O
varying O
stiffness O
were O
formed O
by O
changing O
the O
H2O2 B
concentration O
. O

Through O
the O
caspase O
- O
3 O
/ O
7 O
pathway O
in O
vitro O
, O
IFN O
- O
alpha O
2a O
released O
from O
HA O
- O
Tyr B
hydrogels O
inhibited O
the O
proliferation O
of O
liver O
cancer O
cells O
and O
induced O
apoptosis O
. O

The O
tumor O
regression O
study O
revealed O
that O
IFN O
- O
alpha O
2a O
- O
incorporated O
HA O
- O
Tyr B
hydrogels O
effectively O
inhibited O
tumor O
growth O
, O
while O
the O
injection O
of O
an O
IFN O
- O
alpha O
2a O
solution O
did O
not O
demonstrate O
antitumor O
efficacy O
. O

Histological O
studies O
confirmed O
that O
tumor O
tissues O
in O
mice O
treated O
with O
IFN O
- O
alpha O
2a O
- O
incorporated O
HA O
- O
Tyr B
hydrogels O
showed O
lower O
cell O
density O
, O
with O
more O
apoptotic O
and O
less O
proliferating O
cells O
compared O
with O
tissues O
treated O
with O
an O
IFN O
- O
alpha O
2a O
solution O
. O

A O
complete O
medical O
history O
is O
important O
to O
rule O
out O
other O
causes O
of O
fatty O
liver O
disease O
( O
alcohol B
abuse O
, O
medications O
, O
other O
) O
. O

Although O
there O
is O
no O
pharmacological O
agent O
approved O
for O
the O
treatment O
of O
NAFLD O
, O
vitamin B
E I
( O
in O
patients O
without O
T2DM O
) O
and O
the O
thiazolidinedione O
pioglitazone B
( O
in O
patients O
with O
and O
without O
T2DM O
) O
have O
shown O
the O
most O
consistent O
results O
in O
randomized O
controlled O
trials O
. O

Extended O
- O
release O
ranolazine O
( O
ranolazine O
ER O
) O
[ O
Ranexa O
( O
( O
R O
) O
) O
] O
is O
an O
antianginal O
agent O
that O
achieves O
its O
effects O
via O
a O
novel O
mechanism O
of O
action O
( O
inhibition O
of O
the O
late O
phase O
of O
the O
inward O
sodium B
current O
) O
, O
without O
affecting O
heart O
rate O
or O
blood O
pressure O
( O
BP O
) O
. O

PKR O
consists O
of O
tandem O
dsRNA O
binding O
motifs O
( O
dsRBMs O
) O
connected O
via O
a O
flexible O
linker O
to O
a O
Ser B
/ O
Thr B
kinase O
domain O
. O

Nuclear O
receptors O
in O
bile B
acid I
metabolism O
. O

Bile B
acids I
are O
signaling O
molecules O
that O
activate O
nuclear O
receptors O
, O
such O
as O
farnesoid O
X O
receptor O
, O
pregnane B
X O
receptor O
, O
constitutive O
androstane B
receptor O
, O
and O
vitamin B
D I
receptor O
, O
and O
play O
a O
critical O
role O
in O
the O
regulation O
of O
lipid O
, O
glucose B
, O
energy O
, O
and O
drug O
metabolism O
. O

These O
xenobiotic O
/ O
endobiotic O
- O
sensing O
nuclear O
receptors O
regulate O
phase O
I O
oxidation O
, O
phase O
II O
conjugation O
, O
and O
phase O
III O
transport O
in O
bile B
acid I
and O
drug O
metabolism O
in O
the O
digestive O
system O
. O

Integration O
of O
bile B
acid I
metabolism O
with O
drug O
metabolism O
controls O
absorption O
, O
transport O
, O
and O
metabolism O
of O
nutrients O
and O
drugs O
to O
maintain O
metabolic O
homeostasis O
and O
also O
protects O
against O
liver O
injury O
, O
inflammation O
, O
and O
related O
metabolic O
diseases O
, O
such O
as O
nonalcoholic O
fatty O
liver O
disease O
, O
diabetes O
, O
and O
obesity O
. O

Bile B
- I
acid I
- O
based O
drugs O
targeting O
nuclear O
receptors O
are O
in O
clinical O
trials O
for O
treating O
cholestatic O
liver O
diseases O
and O
fatty O
liver O
disease O
. O

Electrokinetic O
charging O
of O
aqueous O
microjets O
was O
characterized O
by O
measuring O
streaming O
currents O
as O
a O
function O
of O
sodium B
iodide I
salt O
concentration O
. O

Liquified O
capsules O
featuring O
( O
i O
) O
an O
external O
shell O
by O
layer O
- O
by O
- O
layer O
assembly O
of O
poly B
( I
l I
- I
lysine I
) I
, O
alginate O
, O
and O
chitosan O
, O
and O
encapsulating O
( O
ii O
) O
surface O
functionalized O
poly B
( I
l I
- I
lactic I
acid I
) I
( O
PLLA B
) O
microparticles O
were O
developed O
. O

The O
influence O
of O
the O
incorporation O
of O
PLL B
on O
the O
regime O
growth O
, O
thickness O
, O
and O
stability O
was O
analyzed O
. O

Density O
functional O
theory O
was O
applied O
to O
study O
the O
interaction O
of O
group O
IIb O
transition O
- O
metal O
cations O
( O
Zn B
( I
2 I
+ I
) I
, O
Cd B
( I
2 I
+ I
) I
, O
and O
Hg B
( I
2 I
+ I
) I
) O
with O
one O
and O
two O
fully O
or O
partially O
deprotonated O
3 O
- O
mercaptopropionic O
acid O
ligands O
. O

From O
our O
chemical O
bonding O
analysis O
, O
we O
concluded O
that O
the O
2D O
- O
3D O
transition O
occurs O
at O
B O
( O
6 O
) O
H O
( O
4 O
) O
( O
- O
) O
because O
the O
addition O
of O
one O
extra O
hydrogen B
atom O
further O
destroys O
the O
network O
of O
the O
peripheral O
2c O
- O
2e O
B O
- O
B O
sigma O
- O
bonding O
, O
making O
planar O
structures O
less O
stable O
, O
and O
because O
the O
distorted O
octahedral O
structure O
provides O
some O
occupation O
of O
all O
s O
- O
and O
p O
- O
AOs O
of O
boron B
, O
avoiding O
the O
presence O
of O
any O
empty O
atomic O
orbitals O
. O

In O
aphakia O
mice O
, O
virtually O
all O
surviving O
mDA O
neurons O
in O
the O
substantia O
nigra O
( O
SN O
) O
and O
the O
majority O
of O
neurons O
in O
the O
adjacent O
ventral O
tegmental O
area O
( O
VTA O
) O
also O
express O
calbindin O
- O
D28k O
, O
a O
calcium B
- O
binding O
protein O
previously O
associated O
with O
resistance O
to O
injury O
in O
PD O
and O
in O
animal O
models O
. O

Cell O
- O
mapping O
studies O
in O
wild O
- O
type O
mice O
revealed O
that O
Pitx3 O
is O
primarily O
expressed O
in O
the O
ventral O
SN O
, O
a O
region O
particularly O
susceptible O
to O
MPTP B
and O
other O
dopaminergic O
neurotoxins O
. O

Furthermore O
, O
Pitx3 O
- O
expressing O
SN O
cells O
are O
preferentially O
lost O
following O
MPTP B
treatment O
. O

Finally O
, O
SN O
mDA O
neurons O
in O
Pitx3 O
hemizygous O
mice O
show O
increased O
sensitivity O
when O
exposed O
to O
MPTP B
. O

Thus O
, O
SN O
mDA O
neurons O
are O
represented O
by O
at O
least O
two O
distinct O
subpopulations O
including O
MPTP B
- O
resistant O
Pitx3 O
- O
autonomous O
, O
calbindin O
- O
positive O
neurons O
, O
and O
calbindin O
- O
negative O
Pitx O
- O
3 O
- O
dependent O
cells O
that O
display O
elevated O
vulnerability O
to O
toxic O
injury O
, O
and O
probably O
correspond O
to O
the O
subpopulation O
that O
degenerates O
in O
PD O
. O

At O
pH O
4 O
, O
surface O
layer O
formations O
consisting O
of O
metal O
- O
deficient O
sulfide B
and O
elemental O
sulfur B
were O
identified O
, O
associated O
with O
a O
limited O
increase O
in O
root O
- O
mean O
- O
square O
( O
rms O
) O
roughness O
( O
1 O
. O
228 O
to O
3 O
. O
143 O
nm O
) O
and O
apparent O
heterogeneous O
distribution O
of O
surface O
products O
as O
demonstrated O
by O
AFM O
imaging O
. O

A O
mechanism O
of O
initial O
rapid O
dissolution O
of O
Cu B
followed O
by O
diffusion O
- O
limited O
surface O
layer O
deposition O
was O
identified O
. O

Surface O
species O
were O
identified O
as O
copper B
sulfate I
and O
copper B
hydroxide I
. O

Competing O
effects O
of O
hydrophilic O
( O
copper O
oxides O
and O
hydroxides O
) O
and O
hydrophobic O
( O
elemental O
sulfur B
) O
species O
on O
the O
mineral O
surface O
under O
oxidizing O
conditions O
at O
pH O
4 O
and O
the O
change O
in O
surface O
roughness O
at O
pH O
10 O
may O
contribute O
to O
the O
observed O
effects O
of O
electrochemically O
controlled O
oxidation O
on O
enargite O
hydrophobicity O
. O

Specific O
- O
heat O
measurements O
demonstrated O
that O
a O
large O
portion O
of O
the O
magnetic O
entropy O
, O
> O
60 O
% O
, O
has O
been O
removed O
above O
T O
( O
N O
) O
as O
a O
result O
of O
strong O
spin O
correlations O
within O
the O
quasi O
- O
one O
- O
dimensional O
Mn B
( I
3 I
+ I
) I
- O
spin O
chains O
. O

The O
Reitveld O
refinement O
of O
neutron O
powder O
diffraction O
data O
gives O
a O
commensurate O
magnetic O
structure O
defined O
by O
k O
= O
[ O
0 O
0 O
0 O
. O
5 O
] O
with O
Mn B
moments O
aligned O
mainly O
along O
the O
c O
- O
axis O
with O
a O
small O
component O
along O
both O
a O
- O
and O
b O
- O
axes O
. O

The O
crystal O
structure O
of O
NF O
- O
Y O
bound O
to O
a O
25 O
bp O
CCAAT O
oligonucleotide O
shows O
that O
the O
HFD O
dimer O
binds O
to O
the O
DNA O
sugar B
- O
phosphate B
backbone O
, O
mimicking O
the O
nucleosome O
H2A O
/ O
H2B O
- O
DNA O
assembly O
. O

Exercise O
training O
leads O
to O
an O
improved O
bioavailability O
of O
the O
endothelial O
nitric B
oxide I
and O
partially O
attenuates O
endothelial O
dysfunction O
. O

The O
extract O
of O
this O
plant O
showed O
, O
using O
different O
antioxidant O
assays O
( O
DPPH B
, O
ABTS B
and O
AAPH B
/ O
linoleic B
acid I
methods O
) O
and O
an O
IFN O
- O
gamma O
/ O
LPS O
induced O
RAW O
264 O
. O
7 O
murine O
macrophages O
' O
assay O
, O
the O
highest O
antioxidant O
( O
IC50 O
( O
DPPH B
assay O
) O
20 O
. O
64 O
+ O
/ O
- O
0 O
. O
84mg O
/ O
L O
) O
and O
anti O
- O
inflammatory O
( O
72 O
% O
inhibition O
at O
150mg O
/ O
L O
) O
activities O
, O
respectively O
. O

Areca O
nut O
procyanidins B
ameliorate O
streptozocin O
- O
induced O
hyperglycemia O
by O
regulating O
gluconeogenesis O
. O

Hepatic O
gluconeogenesis O
is O
a O
major O
contributor O
to O
blood O
glucose B
in O
diabetes O
mellitus O
. O

Our O
previous O
study O
indicated O
that O
areca O
nut O
extract O
enriched O
with O
catechin B
- O
based O
procyanidins B
from O
oligomers O
to O
polymers O
gave O
rise O
to O
anti O
- O
inflammatory O
effects O
in O
vitro O
and O
in O
vivo O
. O

Here O
we O
have O
surveyed O
the O
molecular O
features O
of O
areca O
nut O
procyanidins B
( O
ANPs O
) O
using O
quadrupole O
time O
- O
of O
- O
flight O
liquid O
chromatography O
/ O
mass O
spectrometry O
( O
Q O
- O
TOF O
LC O
/ O
MS O
) O
and O
the O
resulting O
mass O
spectrum O
accurately O
described O
ANP O
from O
monomer O
to O
hexadecamer O
. O

Furthermore O
, O
the O
potential O
of O
ANP O
in O
terms O
of O
blood O
glucose B
homeostasis O
was O
explored O
using O
cyclic O
adenosine O
monophosphate O
( O
cAMP B
) O
/ O
dexamethasone B
stimulated O
primary O
mouse O
hepatocytes O
and O
multiple O
low O
dose O
streptozocin O
( O
MLD O
- O
STZ B
) O
treated O
mice O
. O

With O
the O
primary O
hepatocytes O
, O
ANP O
dose O
- O
dependently O
inhibited O
gluconeogenesis O
and O
reduced O
the O
mRNA O
expression O
of O
two O
gluconeogenic O
key O
enzymes O
, O
phosphoenol B
- I
pyruvate I
carboxykinase O
( O
PEPCK O
) O
and O
glucose B
- O
6 O
- O
phosphatase O
( O
G6Pase O
) O
. O

Intragastrically O
feeding O
of O
10mg O
/ O
kg O
ANP O
for O
4weeks O
reduced O
the O
levels O
of O
fasting O
blood O
glucose B
, O
PEPCK O
and O
G6Pase O
in O
MLD O
- O
STZ B
mice O
. O

In O
additional O
, O
the O
level O
of O
5 B
' I
- I
AMP I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
expression O
showed O
a O
trend O
towards O
being O
restored O
in O
the O
ANP O
treated O
MLD O
- O
STZ B
- O
mice O
. O

This O
study O
indicated O
that O
ANP O
has O
the O
potential O
to O
improve O
hyperglycemia O
by O
regulating O
gluconeogenic O
related O
kinases O
in O
MLD O
- O
STZ B
- O
mice O
. O

Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
( O
FAK O
) O
/ O
c O
- O
Src O
/ O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
signaling O
, O
and O
phosphoinositide B
3 O
- O
kinase O
( O
PI3K O
) O
/ O
Akt O
/ O
glycogen O
synthase O
kinase O
3 O
beta O
( O
GSK O
- O
3 O
beta O
) O
signaling O
pathway O
. O

Spray O
- O
drying O
had O
less O
impact O
on O
the O
antimicrobial O
activities O
and O
polyphenolic B
contents O
than O
did O
evaporation O
followed O
by O
freeze O
- O
drying O
. O

The O
analysis O
of O
the O
composition O
of O
the O
extracts O
revealed O
that O
the O
inhibitory O
activity O
against O
E O
. O
coli O
may O
be O
related O
to O
the O
presence O
of O
galloylated O
flavanols O
and O
specific O
flavonols B
, O
whereas O
the O
inhibitory O
capacity O
against O
S O
. O
aureus O
may O
be O
related O
primarily O
to O
polar O
compounds O
and O
to O
other O
flavonols B
. O

Potential O
synergistic O
effects O
among O
polyphenols B
may O
deserve O
further O
studies O
. O

Genotoxic O
and O
inflammatory O
effects O
of O
organic O
extracts O
from O
traffic O
- O
related O
particulate O
matter O
in O
human O
lung O
epithelial O
A549 O
cells O
: O
the O
role O
of O
quinones B
. O

Quinones B
present O
in O
the O
traffic O
- O
related O
PM O
are O
hypothesized O
to O
contribute O
to O
these O
harmful O
effects O
through O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
. O

However O
, O
the O
impacts O
of O
the O
traffic O
- O
related O
PM O
and O
quinones B
on O
inflammatory O
processes O
and O
genotoxic O
damages O
are O
less O
well O
known O
. O

In O
present O
study O
we O
aimed O
to O
examine O
the O
genotoxic O
and O
inflammatory O
impacts O
of O
organic O
extracts O
from O
traffic O
- O
related O
PM O
( O
oTRP O
) O
in O
human O
lung O
epithelial O
A549 O
cells O
, O
and O
reveal O
the O
contributions O
from O
quinones B
. O

Second O
, O
the O
effects O
from O
two O
typical O
airborne O
quinones B
, O
9 O
, O
10 O
- O
anthraquinone O
( O
AQ O
) O
and O
1 O
, O
4 O
- O
naphthroquinone O
( O
NQ O
) O
were O
compared O
. O

Silica B
nanoparticles O
were O
prepared O
by O
St O
o O
ber O
synthesis O
and O
characterized O
by O
dynamic O
light O
scattering O
and O
scanning O
electron O
microscopy O
. O

Actin O
polymerization O
was O
measured O
by O
phalloidin B
- O
TRITC O
staining O
, O
and O
cell O
activation O
was O
determined O
by O
reverse O
transcription O
quantitative O
PCR O
analysis O
, O
L929 O
cytotoxicity O
assay O
( O
cytokine O
induction O
) O
, O
and O
pull O
- O
down O
assays O
( O
Rho O
GTPases O
) O
. O

RESULTS O
: O
In O
contrast O
to O
immune O
stimulatory O
sequence O
ISS O
1018 O
, O
BCG O
DNA O
spontaneously O
formed O
nanoparticulate O
structures O
and O
induced O
actin O
polymerization O
as O
did O
synthetic O
silica B
nanoparticles O
. O

Co O
- O
incubation O
with O
silica B
nanoparticles O
amplified O
the O
responsiveness O
of O
macrophages O
toward O
the O
TLR9 O
ligand O
ISS O
1018 O
. O

The O
activation O
of O
Rac1 O
was O
induced O
by O
silica B
nanoparticles O
as O
well O
as O
BCG O
DNA O
and O
is O
suggested O
as O
the O
critical O
signaling O
event O
inducing O
both O
cytoskeleton O
changes O
as O
well O
as O
inflammatory O
cell O
activation O
. O

Administration O
of O
the O
optimized O
beta O
- O
Lapachone O
- O
poloxamer B
- O
cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model O
. O

beta O
- O
Lapachone O
( O
beta O
- O
Lap O
) O
is O
a O
1 O
, O
2 O
- O
orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
- O
1 O
( O
NQO1 O
) O
. O

We O
formulated O
beta O
- O
Lap O
in O
an O
optimal O
random O
methylated O
- O
beta O
- O
cyclodextrin O
/ O
poloxamer B
407 I
mixture O
( O
i O
. O
e O
. O
, O
beta O
- O
Lap O
ternary O
system O
) O
and O
, O
using O
human O
breast O
adenocarcinoma O
MCF O
- O
7 O
cells O
and O
immunodeficient O
mice O
, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti O
- O
tumor O
effects O
on O
proliferation O
, O
cell O
cycle O
, O
apoptosis O
, O
DNA O
damage O
, O
and O
tumor O
growth O
. O

Hydrophobicity O
of O
rare O
- O
earth O
oxide B
ceramics O
. O

We O
attribute O
their O
hydrophobicity O
to O
their O
unique O
electronic O
structure O
, O
which O
inhibits O
hydrogen B
bonding O
with O
interfacial O
water O
molecules O
. O

Rare O
- O
earth O
oxide B
ceramics O
should O
find O
widespread O
applicability O
as O
robust O
hydrophobic O
surfaces O
. O

Two O
species O
of O
mammary O
microcalcifications O
have O
been O
identified O
; O
calcium O
oxalate O
and O
hydroxyapatite B
. O

Calcium O
oxalate O
is O
mostly O
associated O
with O
benign O
lesions O
of O
the O
breast O
, O
whereas O
hydroxyapatite B
is O
associated O
with O
both O
benign O
and O
malignant O
tumors O
. O

The O
way O
in O
which O
hydroxyapatite B
forms O
within O
mammary O
tissue O
remains O
largely O
unexplored O
, O
however O
lessons O
can O
be O
learned O
from O
the O
process O
of O
physiological O
mineralization O
. O

Normal O
physiological O
mineralization O
by O
osteoblasts O
results O
in O
hydroxyapatite B
deposition O
in O
bone O
. O

Self O
- O
assembly O
of O
double O
helical O
nanostructures O
inside O
carbon B
nanotubes O
. O

We O
use O
molecular O
dynamics O
( O
MD O
) O
simulations O
to O
show O
that O
a O
DNA O
- O
like O
double O
helix O
of O
two O
poly O
( O
acetylene O
) O
( O
PA O
) O
chains O
can O
form O
inside O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
. O

Almorexant O
effects O
on O
CYP3A4 O
activity O
studied O
by O
its O
simultaneous O
and O
time O
- O
separated O
administration O
with O
simvastatin B
and O
atorvastatin B
. O

METHODS O
: O
Pharmacokinetic O
interactions O
were O
investigated O
( O
n O
= O
14 O
healthy O
male O
subjects O
in O
two O
treatment O
groups O
) O
between O
almorexant O
at O
steady O
- O
state O
when O
administered O
either O
concomitantly O
or O
2 O
h O
after O
administration O
of O
single O
doses O
of O
simvastatin B
( O
40 O
mg O
) O
or O
atorvastatin B
( O
40 O
mg O
) O
. O

RESULTS O
: O
Almorexant O
dose O
- O
dependently O
increased O
simvastatin B
exposure O
( O
AUC O
( O
0 O
- O
infinity O
) O
) O
when O
administered O
concomitantly O
[ O
geometric O
mean O
ratios O
( O
90 O
% O
CI O
) O
: O
2 O
. O
5 O
( O
2 O
. O
1 O
, O
2 O
. O
9 O
) O
( O
100 O
mg O
) O
, O
3 O
. O
9 O
( O
3 O
. O
3 O
, O
4 O
. O
6 O
) O
( O
200 O
mg O
) O
] O
, O
but O
not O
C O
( O
max O
) O
[ O
3 O
. O
7 O
( O
3 O
. O
0 O
, O
4 O
. O
5 O
) O
for O
both O
doses O
] O
. O

Independent O
of O
almorexant O
dose O
and O
relative O
time O
of O
administration O
, O
AUC O
( O
0 O
- O
infinity O
) O
and O
C O
( O
max O
) O
of O
atorvastatin B
increased O
( O
ratios O
ranged O
from O
1 O
. O
1 O
to O
1 O
. O
5 O
) O
. O

AUC O
( O
0 O
- O
infinity O
) O
and O
C O
( O
max O
) O
of O
o O
- O
hydroxy O
atorvastatin O
decreased O
dose O
- O
independently O
[ O
AUC O
( O
0 O
- O
infinity O
) O
: O
0 O
. O
8 O
( O
0 O
. O
8 O
, O
0 O
. O
9 O
) O
( O
100 O
mg O
) O
, O
0 O
. O
6 O
( O
0 O
. O
5 O
, O
0 O
. O
6 O
) O
( O
200 O
mg O
) O
; O
C O
( O
max O
) O
: O
0 O
. O
3 O
( O
0 O
. O
3 O
, O
0 O
. O
4 O
) O
( O
100 O
mg O
) O
, O
0 O
. O
2 O
( O
0 O
. O
2 O
, O
0 O
. O
3 O
) O
( O
200 O
mg O
) O
] O
when O
atorvastatin B
was O
concomitantly O
administered O
. O

CONCLUSIONS O
: O
Whereas O
almorexant O
increased O
simvastatin B
exposure O
dose O
- O
and O
relative O
time O
of O
administration O
- O
dependently O
, O
atorvastatin B
exposure O
increased O
to O
a O
smaller O
extent O
and O
irrespective O
of O
dose O
and O
time O
. O

This O
suggests O
that O
the O
observed O
interaction O
of O
almorexant O
with O
simvastatin B
is O
mainly O
caused O
by O
intestinal O
CYP3A4 O
inhibition O
, O
whereas O
the O
interaction O
with O
atorvastatin B
is O
more O
due O
to O
hepatic O
CYP3A4 O
inhibition O
. O

Our O
test O
bed O
is O
a O
device O
- O
ready O
electrode O
architecture O
in O
which O
scalable O
, O
manufacturable O
carbon B
nanofoam O
papers O
with O
tunable O
pore O
sizes O
( O
5 O
- O
200 O
nm O
) O
and O
thickness O
( O
100 O
- O
300 O
mu O
m O
) O
are O
painted O
with O
~ O
10 O
nm O
coatings O
of O
manganese O
oxide O
( O
MnOx O
) O
. O

The O
quantity O
of O
capacitance O
and O
the O
rate O
at O
which O
it O
is O
delivered O
for O
four O
different O
MnOx O
- O
C B
variants O
was O
assessed O
by O
fabricating O
symmetric O
electrochemical O
capacitors O
using O
a O
concentrated O
aqueous O
electrolyte O
. O

Carbon B
nanofoam O
papers O
containing O
primarily O
10 O
- O
20 O
nm O
mesopores O
support O
high O
MnOx O
loadings O
( O
60 O
wt O
% O
) O
and O
device O
- O
level O
capacitance O
( O
30 O
F O
g O
( O
- O
1 O
) O
) O
, O
but O
the O
small O
mesoporous O
network O
hinders O
electrolyte O
transport O
and O
the O
low O
void O
volume O
restricts O
the O
quantity O
of O
charge O
- O
compensating O
ions O
within O
the O
electrode O
, O
making O
the O
full O
capacitance O
only O
accessible O
at O
slow O
rates O
( O
5 O
mV O
s O
( O
- O
1 O
) O
) O
. O

Carbon B
nanofoam O
papers O
with O
macropores O
( O
100 O
- O
200 O
nm O
) O
facilitate O
high O
rate O
operation O
( O
50 O
mV O
s O
( O
- O
1 O
) O
) O
, O
but O
deliver O
significantly O
lower O
device O
capacitance O
( O
13 O
F O
g O
( O
- O
1 O
) O
) O
as O
a O
result O
of O
lower O
MnOx O
loadings O
( O
41 O
wt O
% O
) O
. O

Devices O
comprising O
MnOx O
- O
carbon B
nanofoams O
with O
interconnecting O
networks O
of O
meso O
- O
and O
macropores O
balance O
capacitance O
and O
rate O
performance O
, O
delivering O
33 O
F O
g O
( O
- O
1 O
) O
at O
5 O
mV O
s O
( O
- O
1 O
) O
and O
23 O
F O
g O
( O
- O
1 O
) O
at O
50 O
mV O
s O
( O
- O
1 O
) O
. O

The O
use O
of O
carbon B
nanofoam O
papers O
with O
size O
- O
tunable O
pore O
structures O
and O
thickness O
provides O
the O
opportunity O
to O
engineer O
the O
electrode O
architecture O
to O
deliver O
scalable O
quantities O
of O
capacitance O
( O
F O
cm O
( O
- O
2 O
) O
) O
in O
tens O
of O
seconds O
with O
a O
single O
device O
. O

Fluocinolone O
acetonide O
intravitreal O
implant O
( O
Iluvien O
( O
R O
) O
) O
is O
an O
injectable O
, O
non O
- O
erodible O
, O
corticosteroid B
implant O
that O
is O
approved O
in O
several O
European O
countries O
for O
the O
treatment O
of O
chronic O
diabetic O
macular O
oedema O
( O
DMO O
) O
. O

Group O
I O
mGluRs O
evoke O
K B
- O
ATP B
current O
by O
intracellular O
Ca2 B
+ I
mobilization O
in O
rat O
subthalamus O
neurons O
. O

We O
reported O
previously O
that O
Ca B
( I
2 I
+ I
) I
influx O
through O
N O
- O
methly O
- O
d O
- O
aspartate O
- O
gated O
channels O
evokes O
ATP B
- O
sensitive O
K B
( I
+ I
) I
( O
K B
- O
ATP B
) O
currents O
in O
rat O
subthalamic O
nucleus O
( O
STN O
) O
neurons O
. O

By O
using O
whole O
- O
cell O
patch O
clamp O
recordings O
in O
brain O
slices O
, O
we O
investigated O
the O
ability O
of O
( O
RS O
) O
- O
3 O
, O
5 O
- O
dihydroxyphenylglyci O
( O
DHPG B
) O
, O
a O
group O
I O
metabotropic O
glutamate B
receptor O
( O
mGluR O
) O
agonist O
, O
to O
evoke O
K B
- O
ATP B
currents O
. O

DHPG B
( O
20 O
micro O
M O
) O
evoked O
outward O
current O
at O
- O
70 O
mV O
and O
was O
associated O
with O
a O
positive O
slope O
conductance O
of O
2 O
. O
7 O
nS O
. O

The O
sulfonylurea B
agent O
tolbutamide B
( O
100 O
micro O
M O
) O
converted O
the O
positive O
slope O
to O
negative O
slope O
conductance O
, O
indicating O
mediation O
by O
K B
- O
ATP B
channels O
( O
ATP B
- O
sensitive O
K B
+ I
channels O
) O
. O

Currents O
evoked O
by O
DHPG B
were O
significantly O
reduced O
by O
a O
combination O
of O
mGluR1 O
and O
mGluR5 O
negative O
allosteric O
modulators O
. O

DHPG B
- O
evoked O
outward O
current O
was O
blocked O
by O
cyclopiazonic B
acid I
and O
thapsigargin B
and O
mimicked O
by O
caffeine B
, O
suggesting O
mediation O
by O
release O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
. O

DHPG B
outward O
current O
was O
also O
blocked O
by O
ryanodine B
and O
2 B
- I
aminoethoxydiphenylb I
, O
suggesting O
mediation O
by O
ryanodine B
- O
and O
inositol O
1 O
, O
4 O
, O
5 O
- O
triphosphate O
- O
sensitive O
Ca B
( I
2 I
+ I
) I
release O
. O

The O
nitric B
oxide I
synthase O
inhibitor O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
and O
inhibitors O
of O
protein O
kinase O
G O
activity O
also O
suppressed O
DHPG B
- O
induced O
outward O
current O
. O

Voltage O
recordings O
showed O
that O
tolbutamide B
prolonged O
depolarizing O
plateau O
potentials O
and O
increased O
the O
spontaneous O
firing O
rate O
of O
STN O
neurons O
recorded O
in O
the O
presence O
of O
DHPG B
. O

These O
results O
show O
that O
group O
I O
mGluR O
stimulation O
generates O
K B
- O
ATP B
current O
by O
a O
nitric B
oxide I
- O
and O
protein O
kinase O
G O
- O
dependent O
process O
that O
is O
mediated O
by O
release O
of O
Ca B
( I
2 I
+ I
) I
from O
intracellular O
stores O
. O

Because O
burst O
firing O
is O
linked O
to O
symptoms O
of O
Parkinson O
' O
s O
disease O
, O
we O
suggest O
that O
K B
- O
ATP B
channels O
might O
provide O
a O
physiologically O
important O
inhibitory O
influence O
on O
STN O
neuronal O
activity O
. O

Internalization O
Pathways O
of O
Anisotropic O
Disc O
- O
Shaped O
Zeolite B
L I
Nanocrystals O
with O
Different O
Surface O
Properties O
in O
HeLa O
Cancer O
Cells O
. O

Here O
the O
uptake O
and O
intracellular O
delivery O
of O
disc O
- O
shaped O
zeolite B
L I
nanocrystals O
as O
porous O
aminosilicates O
with O
well O
- O
defined O
crystal O
structure O
, O
uncoated O
as O
well O
as O
with O
COOH B
- I
, O
NH B
( I
2 I
) I
- I
, O
polyethyleneglycol B
( O
PEG B
) O
- O
and O
polyallylamine O
hydrochloride O
( O
PAH B
) O
surface O
coatings O
are O
reported O
. O

Hypoxia O
stress O
test O
reveals O
exaggerated O
cardiovascular O
effects O
in O
hypertensive O
rats O
after O
exposure O
to O
the O
air O
pollutant O
acrolein B
. O

We O
hypothesized O
that O
exposure O
to O
acrolein B
, O
an O
unsaturated O
aldehyde B
and O
mucosal O
irritant O
found O
in O
cigarette O
smoke O
, O
diesel O
exhaust O
, O
and O
power O
plant O
emissions O
, O
would O
increase O
cardiopulmonary O
sensitivity O
to O
hypoxia O
, O
particularly O
in O
hypertensive O
rats O
. O

Spontaneously O
hypertensive O
and O
Wistar O
Kyoto O
( O
normotensive O
) O
rats O
, O
implanted O
with O
radiotelemeters O
, O
were O
exposed O
once O
for O
3h O
to O
3 O
ppm O
acrolein B
gas O
or O
filtered O
air O
in O
whole O
- O
body O
plethysmograph O
chambers O
and O
challenged O
with O
a O
10 O
% O
oxygen B
atmosphere O
( O
10min O
) O
24h O
later O
. O

Acrolein B
exposure O
increased O
heart O
rate O
, O
blood O
pressure O
, O
breathing O
frequency O
, O
and O
minute O
volume O
in O
hypertensive O
rats O
and O
also O
increased O
the O
heart O
rate O
variability O
parameter O
LF O
, O
suggesting O
a O
potential O
role O
for O
increased O
sympathetic O
tone O
. O

Normotensive O
rats O
only O
had O
increased O
blood O
pressure O
during O
acrolein B
exposure O
. O

The O
hypoxia O
stress O
test O
after O
acrolein B
exposure O
revealed O
increased O
diastolic O
blood O
pressure O
only O
in O
hypertensive O
rats O
and O
increased O
minute O
volume O
and O
expiratory O
time O
only O
in O
normotensive O
rats O
. O

In O
order O
to O
elucidate O
the O
mode O
of O
action O
of O
some O
of O
these O
compounds O
, O
molecular O
modeling O
was O
employed O
to O
dock O
a O
suite O
of O
molecules O
into O
the O
ATP B
- O
binding O
domain O
of O
several O
histidine B
kinases O
. O

Furthermore O
, O
generation O
of O
several O
simplified O
scaffolds O
derived O
from O
a O
reported O
inhibitor O
and O
characterization O
of O
these O
compounds O
using O
activity O
assays O
, O
protein O
aggregation O
studies O
and O
saturation O
transfer O
differential O
( O
STD O
) O
NMR O
suggests O
that O
targeting O
of O
this O
protein O
feature O
may O
provide O
a O
basis O
for O
the O
design O
of O
ATP B
- O
competitive O
compounds O
. O

5 B
- I
Hydroxytryptamine I
type O
7 O
receptor O
neuroprotection O
against O
NMDA B
- O
induced O
excitotoxicity O
is O
PDGF O
beta O
receptor O
dependent O
. O

The O
serotonin B
( O
5 B
- I
HT I
) O
type O
7 O
receptor O
is O
expressed O
throughout O
the O
CNS O
including O
the O
hippocampus O
. O

Direct O
activation O
of O
PDGF O
beta O
receptors O
in O
primary O
hippocampal O
and O
cortical O
neurons O
inhibits O
NMDA B
receptor O
activity O
and O
attenuates O
NMDA B
receptor O
- O
induced O
neurotoxicity O
. O

We O
demonstrate O
that O
5 O
- O
HT7 O
receptor O
agonist O
treatment O
in O
primary O
hippocampal O
neurons O
also O
increases O
the O
expression O
of O
phospholipase O
C O
( O
PLC O
) O
gamma O
, O
a O
downstream O
effector O
of O
PDGF O
beta O
receptors O
associated O
with O
the O
inhibition O
of O
NMDA B
receptor O
activity O
. O

Indeed O
, O
LP O
12 O
treatment O
prevented O
NMDA B
- O
induced O
neurotoxicity O
and O
this O
effect O
was O
dependent O
on O
PDGF O
beta O
receptor O
kinase O
activity O
. O

Treatment O
of O
primary O
neurons O
with O
LP O
12 O
also O
differentially O
altered O
NMDA B
receptor O
subunit O
expression O
, O
reducing O
the O
expression O
of O
NR1 O
and O
NR2B O
, O
but O
not O
NR2A O
. O

Mixed O
valency O
in O
hydrogen B
bonded O
' O
dimers O
of O
dimers O
' O
. O

Dimolybdenum O
quadruply O
bonded O
compounds O
containing O
a O
pendant O
lactam B
functional O
group O
form O
self O
- O
complementary O
hydrogen B
bonded O
' O
dimers O
of O
dimers O
' O
in O
the O
solid O
- O
state O
and O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
solutions O
. O

Electrochemical O
studies O
in O
CH B
( I
2 I
) I
Cl I
( I
2 I
) I
show O
two O
consecutive O
one O
- O
electron O
redox O
processes O
corresponding O
to O
oxidation O
of O
the O
Mo O
( O
2 O
) O
( O
4 O
+ O
) O
cores O
. O

Treatment O
with O
anagliptin O
for O
16 O
wk O
significantly O
reduced O
accumulation O
of O
monocytes O
and O
macrophages O
in O
the O
vascular O
wall O
, O
SMC O
content O
in O
plaque O
areas O
, O
and O
oil O
red O
O O
- O
stained O
area O
around O
the O
aortic O
valve O
without O
affecting O
glucose B
tolerance O
or O
body O
weight O
. O

Prenatal O
exposure O
to O
bisphenol B
A I
impacts O
midbrain O
dopamine B
neurons O
and O
hippocampal O
spine O
synapses O
in O
non O
- O
human O
primates O
. O

Prevalent O
use O
of O
bisphenol B
- I
A I
( O
BPA B
) O
in O
the O
manufacture O
of O
resins O
, O
plastics O
and O
paper O
products O
has O
led O
to O
frequent O
exposure O
of O
most O
people O
to O
this O
endocrine O
disruptor O
. O

Some O
rodent O
studies O
have O
suggested O
that O
BPA B
can O
exert O
detrimental O
effects O
on O
brain O
development O
. O

However O
as O
rodent O
models O
cannot O
be O
relied O
on O
to O
predict O
consequences O
of O
human O
exposure O
to O
BPA B
during O
development O
, O
it O
is O
important O
to O
investigate O
the O
effects O
of O
BPA B
on O
non O
- O
human O
primate O
brain O
development O
. O

Previous O
research O
suggests O
that O
BPA B
preferentially O
targets O
dopamine B
neurons O
in O
ventral O
mesencephalon O
and O
glutamatergic O
neurons O
in O
hippocampus O
, O
so O
the O
present O
work O
examined O
the O
susceptibility O
of O
these O
systems O
to O
low O
dose O
BPA B
exposure O
at O
the O
fetal O
and O
juvenile O
stages O
of O
development O
in O
non O
- O
human O
primates O
. O

Exposure O
of O
pregnant O
rhesus O
monkeys O
to O
relatively O
low O
levels O
of O
BPA B
during O
the O
final O
2 O
months O
of O
gestation O
, O
induced O
abnormalities O
in O
fetal O
ventral O
mesencephalon O
and O
hippocampus O
. O

Specifically O
, O
light O
microscopy O
revealed O
a O
decrease O
in O
tyrosine B
hydroxylase O
- O
expressing O
( O
dopamine B
) O
neurons O
in O
the O
midbrain O
of O
BPA B
- O
exposed O
fetuses O
and O
electron O
microscopy O
identified O
a O
reduction O
in O
spine O
synapses O
in O
the O
CA1 O
region O
of O
hippocampus O
. O

In O
contrast O
, O
administration O
of O
BPA B
to O
juvenile O
vervet O
monkeys O
( O
14 O
- O
18 O
months O
of O
age O
) O
was O
without O
effect O
on O
these O
indices O
, O
or O
on O
dopamine B
and O
serotonin B
concentrations O
in O
striatum O
and O
prefrontal O
cortex O
, O
or O
on O
performance O
of O
a O
cognitive O
task O
that O
tests O
working O
memory O
capacity O
. O

These O
data O
indicate O
that O
BPA B
exerts O
an O
age O
- O
dependent O
detrimental O
impact O
on O
primate O
brain O
development O
, O
at O
blood O
levels O
within O
the O
range O
measured O
in O
humans O
having O
only O
environmental O
contact O
with O
BPA B
. O

Although O
alanine B
aminotransferase O
( O
ALT O
) O
remains O
the O
gold O
standard O
biomarker O
of O
liver O
injury O
, O
alternative O
biomarker O
strategies O
to O
better O
predict O
the O
potential O
for O
severe O
drug O
- O
induced O
liver O
injury O
( O
DILI O
) O
are O
essential O
. O

In O
this O
study O
, O
we O
evaluated O
the O
utility O
of O
glutamate B
dehydrogenase O
( O
GLDH O
) O
, O
purine O
nucleoside O
phosphorylase O
( O
PNP O
) O
, O
malate B
dehydrogenase O
( O
MDH O
) O
, O
and O
paraxonase O
1 O
( O
PON1 O
) O
as O
indicators O
of O
liver O
injury O
in O
cohorts O
of O
human O
subjects O
, O
including O
healthy O
subjects O
across O
age O
and O
gender O
, O
subjects O
with O
a O
variety O
of O
liver O
impairments O
, O
and O
several O
cases O
of O
acetaminophen B
poisoning O
. O

Finally O
, O
evaluation O
of O
patients O
with O
acetaminophen B
- O
induced O
liver O
injury O
provided O
evidence O
that O
both O
GLDH O
and O
MDH O
might O
have O
utility O
as O
biomarkers O
of O
DILI O
in O
humans O
. O

Graphene B
nanoribbons O
as O
an O
advanced O
precursor O
for O
making O
carbon B
fiber O
. O

Graphene B
oxide I
nanoribbons O
( O
GONRs O
) O
and O
chemically O
reduced O
graphene O
nanoribbons O
( O
crGNRs O
) O
were O
dispersed O
at O
high O
concentrations O
in O
chlorosulfonic O
acid O
to O
form O
anisotropic O
liquid O
crystal O
phases O
. O

Heat O
treatment O
of O
the O
as O
- O
spun O
GONR O
fibers O
at O
1500 O
degrees O
C O
produced O
thermally O
reduced O
graphene O
nanoribbon O
( O
trGNR O
) O
fibers O
with O
a O
tensile O
strength O
of O
378 O
MPa O
, O
Young O
' O
s O
modulus O
of O
36 O
. O
2 O
GPa O
, O
and O
electrical O
conductivity O
of O
285 O
S O
/ O
cm O
, O
which O
is O
considerably O
higher O
than O
that O
in O
other O
reported O
graphene B
- O
derived O
fibers O
. O

The O
specific O
modulus O
of O
trGNR O
fibers O
is O
higher O
than O
that O
of O
the O
commercial O
general O
purpose O
carbon B
fibers O
and O
commonly O
used O
metals O
such O
as O
Al B
, O
Cu B
, O
and O
steel B
. O

This O
technique O
is O
a O
new O
high O
- O
carbon B
- O
yield O
approach O
to O
make O
the O
next O
generation O
carbon B
fibers O
based O
on O
solution O
- O
based O
liquid O
crystal O
phase O
spinning O
. O

Time O
- O
dependent O
changes O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone B
to O
rats O
. O

Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
( O
CYP3A O
) O
in O
rats O
using O
dexamethasone O
21 O
- O
phosphate O
( O
DEX O
- O
P O
) O
and O
midazolam B
( O
MDZ B
) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O

Following O
light O
absorption O
, O
localization O
of O
the O
excitation O
on O
a O
single O
thymine B
leads O
to O
fast O
singlet O
- O
triplet O
crossing O
that O
populates O
the O
triplet O
( O
3 O
) O
( O
n O
pi O
* O
) O
state O
of O
thymine B
. O

This O
state O
, O
displaying O
an O
elongated O
C O
( O
4 O
) O
= O
O O
bond O
, O
triggers O
( O
6 O
- O
4 O
) O
dimer O
formation O
by O
reaction O
with O
the O
C O
( O
5 O
) O
= O
C O
( O
6 O
) O
double O
bond O
of O
the O
adjacent O
thymine B
, O
followed O
by O
a O
second O
intersystem O
crossing O
, O
which O
acts O
as O
a O
gate O
between O
the O
excited O
state O
of O
the O
reactant O
and O
the O
ground O
state O
of O
the O
photoproduct O
. O

The O
requirement O
of O
localized O
excitation O
on O
just O
one O
thymine B
, O
whose O
main O
decay O
channel O
( O
by O
radiationless O
repopulation O
of O
its O
ground O
state O
) O
is O
nonphotochemical O
, O
can O
rationalize O
the O
experimentally O
observed O
low O
quantum O
yield O
of O
formation O
for O
the O
thymine O
- O
thymine O
( O
6 O
- O
4 O
) O
adduct O
. O

Methods O
: O
Cocktail O
approach O
was O
used O
to O
evaluate O
the O
influence O
of O
IR O
and O
IPC O
on O
the O
activities O
of O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2E1 O
, O
CYP2D6 O
and O
CYP3A4 O
, O
which O
were O
reflected O
by O
the O
changes O
of O
pharmacokinetic O
parameters O
of O
five O
specific O
probe O
drugs O
: O
caffeine B
, O
chlorzoxazone B
, O
tolbutamide B
, O
metoprolol O
and O
midazolam B
, O
respectively O
. O

Category O
B O
has O
lower O
toxicity O
with O
wider O
range O
, O
including O
Staphylococcal O
Entrotoxin O
type O
B O
( O
SEB O
) O
, O
Epsilon O
toxin O
of O
Clostridium O
perfringens O
, O
Ricin O
, O
Saxotoxins O
, O
Abrin O
and O
Trichothecene B
mycotoxins O
. O

Sonochemical O
effects O
on O
free O
phenolic B
acids I
under O
ultrasound O
treatment O
in O
a O
model O
system O
. O

Sonochemical O
effects O
on O
seven O
free O
phenolic B
acids I
under O
ultrasound O
treatment O
in O
a O
model O
system O
have O
been O
investigated O
. O

Five O
phenolic B
acids I
( O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
vanillic B
acid I
, O
p B
- I
coumaric I
acid I
, O
and O
ferulic B
acid I
) O
proved O
to O
be O
stable O
, O
while O
two O
others O
( O
caffeic B
acid I
and O
sinapic B
acid I
) O
were O
degraded O
under O
ultrasound O
treatment O
. O

The O
degradation O
rates O
of O
caffeic B
acid I
and O
sinapic B
acid I
decreased O
with O
increasing O
temperature O
. O

Both O
decomposition O
and O
polymerization O
reactions O
occurred O
when O
caffeic B
acid I
and O
sinapic B
acid I
were O
subjected O
to O
ultrasound O
. O

Characterization O
of O
a O
key O
aminoglycoside O
phosphotransferase O
in O
gentamicin B
biosynthesis O
. O

Gentamicin B
is O
an O
aminoglycoside O
antibiotic O
obtained O
from O
cultures O
of O
Micromonospora O
as O
the O
important O
anti O
- O
infective O
agents O
. O

Gentamicin B
which O
lacks O
3 B
' I
- I
hydroxyl I
group O
can O
avoid O
the O
attack O
from O
the O
modification O
enzymes O
of O
antibiotic O
- O
resistant O
bacteria O
in O
clinic O
. O

The O
gentamicin B
biosynthetic O
gene O
gntI O
, O
encoding O
an O
aminoglycoside O
phosphotransferase O
, O
was O
cloned O
from O
Micromonospora O
echinospora O
ATCC15835 O
and O
overexpressed O
in O
Escherichia O
coli O
. O

Elucidation O
of O
NMR O
data O
of O
phosphorylated O
kanamycin O
B O
has O
unambiguously O
demonstrated O
a O
regiospecific O
phosphorylation O
of O
3 B
' I
- I
hydroxyl I
of O
the O
6 O
- O
aminohexose O
ring O
. O

FSH O
and O
IGF O
- O
I O
synergistically O
stimulate O
gonadal O
steroid B
production O
; O
conversely O
, O
silencing O
the O
FSH O
or O
the O
IGF O
- O
I O
genes O
leads O
to O
infertility O
and O
hypogonadism O
. O

In O
human O
and O
rodent O
granulosa O
cells O
( O
GCs O
) O
, O
IGF O
- O
I O
potentiated O
the O
stimulatory O
effects O
of O
FSH O
and O
cAMP B
on O
the O
expression O
of O
steroidogenic O
genes O
. O

In O
contrast O
, O
inhibition O
of O
IGF O
- O
I O
receptor O
( O
IGF O
- O
IR O
) O
activity O
or O
expression O
using O
pharmacological O
, O
genetic O
, O
or O
biochemical O
approaches O
prevented O
the O
FSH O
- O
and O
cAMP B
- O
induced O
expression O
of O
steroidogenic O
genes O
and O
estradiol B
production O
. O

Palladium B
nanoparticles O
supported O
on O
nitrogen B
- O
doped O
HOPG O
: O
a O
surface O
science O
and O
electrochemical O
study O
. O

We O
have O
investigated O
by O
photoemission O
spectroscopy O
and O
scanning O
tunnelling O
microscopy O
what O
are O
the O
chemical O
and O
structural O
changes O
induced O
by O
nitrogen B
ion O
implantation O
( O
500 O
eV O
) O
on O
highly O
oriented O
pyrolytic O
graphite B
and O
how O
the O
defects O
induced O
by O
this O
process O
modify O
the O
growth O
and O
thermal O
stability O
of O
palladium B
nanoparticles O
, O
deposited O
in O
situ O
by O
physical O
vapour O
deposition O
. O

Since O
nitrogen B
derived O
defects O
are O
mostly O
buried O
below O
the O
surface O
, O
they O
are O
not O
accessible O
for O
a O
chemical O
interaction O
with O
metal O
nanoparticles O
; O
however O
, O
the O
amorphization O
induced O
by O
the O
ion O
beam O
in O
the O
outermost O
layers O
of O
the O
substrate O
beneficially O
affects O
the O
metal O
morphology O
, O
limiting O
the O
size O
of O
the O
nanoparticles O
and O
improving O
their O
thermal O
stability O
. O

The O
supported O
nanoparticles O
have O
been O
tested O
towards O
the O
oxygen B
reduction O
reaction O
indicating O
that O
the O
electrochemical O
activity O
does O
not O
depend O
significantly O
on O
the O
ion O
implantation O
, O
but O
mostly O
on O
the O
amount O
of O
palladium B
. O

A O
significant O
correlation O
between O
microscopically O
visible O
lipid O
droplets O
estimated O
by O
Nile B
Red I
staining O
and O
MR O
visible O
lipid O
signals O
was O
observed O
in O
metastatic O
lung O
carcinomas O
( O
p O
= O
0 O
. O
01 O
) O
, O
indicating O
that O
the O
proton O
MR O
visible O
lipid O
signals O
arise O
from O
cytoplasmic O
lipid O
droplets O
. O

Low O
oxygen B
tension O
maintains O
multipotency O
, O
whereas O
normoxia O
increases O
differentiation O
of O
mouse O
bone O
marrow O
stromal O
cells O
. O

O B
( I
2 I
) I
regulates O
various O
aspects O
of O
cellular O
biology O
and O
, O
in O
vivo O
, O
MSC O
are O
exposed O
to O
different O
O B
( I
2 I
) I
concentrations O
spanning O
from O
very O
low O
tension O
in O
the O
bone O
marrow O
niche O
, O
to O
higher O
amounts O
in O
wounds O
. O

In O
order O
to O
establish O
the O
effect O
of O
low O
O B
( I
2 I
) I
on O
cellular O
properties O
, O
we O
examined O
BSMC O
cultured O
under O
hypoxic O
( O
3 O
% O
O B
( I
2 I
) I
) O
conditions O
. O

Our O
results O
demonstrate O
that O
3 O
% O
O B
( I
2 I
) I
augmented O
proliferation O
of O
BMSC O
, O
as O
well O
as O
the O
formation O
of O
colonies O
in O
the O
colony O
- O
forming O
unit O
assay O
( O
CFU O
- O
A O
) O
, O
the O
percentage O
of O
quiescent O
cells O
, O
and O
the O
expression O
of O
stemness O
markers O
Rex O
- O
1 O
and O
Oct O
- O
4 O
, O
thereby O
suggesting O
an O
increase O
in O
the O
stemness O
of O
culture O
when O
exposed O
to O
hypoxia O
. O

In O
contrast O
, O
intrinsic O
differentiation O
processes O
were O
inhibited O
by O
3 O
% O
O B
( I
2 I
) I
. O

Overall O
yield O
of O
differentiation O
was O
dependent O
on O
the O
adjustment O
of O
O B
( I
2 I
) I
tension O
to O
the O
specific O
stage O
of O
BMSC O
culture O
. O

Thus O
, O
we O
established O
a O
strategy O
for O
efficient O
BMSC O
in O
vitro O
differentiation O
using O
an O
initial O
phase O
of O
cell O
propagation O
at O
3 O
% O
O B
( I
2 I
) I
, O
followed O
by O
differentiation O
stage O
at O
21 O
% O
O B
( I
2 I
) I
. O

We O
also O
demonstrated O
that O
3 O
% O
O B
( I
2 I
) I
affected O
BMSC O
differentiation O
in O
p53 O
and O
reactive O
oxygen B
species O
( O
ROS O
) O
independent O
pathways O
. O

The O
first O
dehydration O
and O
the O
competing O
reaction O
pathways O
of O
glucose B
homogeneously O
and O
heterogeneously O
catalyzed O
by O
acids O
. O

The O
dehydration O
mechanisms O
for O
glucose B
in O
beta O
- O
pyranose O
( O
BP O
) O
and O
in O
open O
- O
chain O
( O
OC O
) O
forms O
, O
catalyzed O
by O
acids O
homogeneously O
and O
heterogeneously O
, O
were O
investigated O
using O
density O
functional O
and O
two O
- O
layer O
ONIOM O
calculations O
. O

No O
dehydration O
pathway O
of O
OC O
glucose B
is O
favored O
over O
its O
isomerization O
to O
BP O
or O
to O
fructose B
. O

These O
mechanistic O
insights O
provide O
an O
important O
guide O
for O
the O
catalyst O
design O
/ O
selection O
of O
the O
reaction O
media O
for O
glucose B
dehydration O
. O

We O
examined O
the O
30 O
- O
year O
cardiovascular O
disease O
( O
CVD O
) O
risk O
factor O
burden O
that O
participants O
have O
up O
to O
the O
time O
of O
diabetes O
diagnosis O
. O
RESEARCH O
DESIGN O
AND O
METHODSAmong O
participants O
free O
of O
CVD O
, O
incident O
diabetes O
cases O
( O
fasting O
plasma O
glucose B
> O
= O
126 O
mg O
/ O
dL O
or O
treatment O
) O
occurring O
at O
examinations O
2 O
through O
8 O
( O
1979 O
- O
2008 O
) O
of O
the O
Framingham O
Heart O
Study O
Offspring O
cohort O
were O
age O
- O
and O
sex O
- O
matched O
1 O
: O
2 O
to O
controls O
. O

CVD O
risk O
factors O
( O
hypertension O
, O
high O
LDL O
cholesterol B
, O
low O
HDL O
cholesterol B
, O
high O
triglycerides B
, O
obesity O
) O
were O
measured O
at O
the O
time O
of O
diabetes O
diagnosis O
and O
at O
time O
points O
10 O
, O
20 O
, O
and O
30 O
years O
prior O
. O

Compared O
with O
those O
without O
diabetes O
, O
individuals O
who O
eventually O
developed O
diabetes O
had O
higher O
levels O
of O
hypertension O
( O
odds O
ratio O
[ O
OR O
] O
, O
2 O
. O
2 O
; O
P O
= O
0 O
. O
003 O
) O
, O
high O
LDL O
( O
OR O
, O
1 O
. O
5 O
; O
P O
= O
0 O
. O
04 O
) O
, O
low O
HDL O
( O
OR O
, O
2 O
. O
1 O
; O
P O
= O
0 O
. O
0001 O
) O
, O
high O
triglycerides B
( O
OR O
, O
1 O
. O
7 O
; O
P O
= O
0 O
. O
04 O
) O
, O
and O
obesity O
( O
OR O
, O
3 O
. O
3 O
; O
P O
< O
0 O
. O
0001 O
) O
at O
time O
points O
30 O
years O
before O
diabetes O
diagnosis O
. O

TV O
viewing O
at O
age O
16 O
years O
was O
associated O
with O
central O
obesity O
, O
low O
HDL O
cholesterol B
, O
and O
hypertension O
at O
age O
43 O
years O
, O
whereas O
low O
leisure O
- O
time O
physical O
activity O
at O
age O
16 O
years O
was O
associated O
with O
central O
obesity O
and O
triglycerides B
at O
age O
43 O
years O
. O
CONCLUSIONSBoth O
TV O
viewing O
and O
low O
leisure O
- O
time O
physical O
activity O
in O
adolescence O
independently O
predicted O
the O
metabolic O
syndrome O
and O
several O
of O
the O
metabolic O
syndrome O
components O
in O
mid O
- O
adulthood O
. O

25 B
- I
Hydroxyvitamin I
D I
in O
Obese O
Youth O
Across O
the O
Spectrum O
of O
Glucose B
Tolerance O
From O
Normal O
to O
Prediabetes O
to O
Type O
2 O
Diabetes O
. O

OBJECTIVETo O
1 O
) O
determine O
if O
plasma O
25 B
- I
hydroxyvitamin I
D I
( O
25 O
[ O
OH O
] O
D O
) O
concentrations O
differ O
among O
obese O
youth O
with O
normal O
glucose B
tolerance O
( O
NGT O
) O
versus O
prediabetes O
versus O
type O
2 O
diabetes O
, O
and O
2 O
) O
assess O
the O
relationships O
between O
25 O
( O
OH O
) O
D O
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
in O
this O
cohort O
. O
RESEARCH O
DESIGN O
AND O
METHODSPlasma O
25 O
( O
OH O
) O
D O
concentrations O
were O
examined O
in O
banked O
specimens O
in O
9 O
- O
to O
20 O
- O
year O
- O
old O
obese O
youth O
( O

n O
= O
175 O
; O
male O
42 O
. O
3 O
% O
, O
black O
46 O
. O
3 O
% O
) O
( O
NGT O
, O
n O
= O
105 O
; O
impaired O
glucose B
tolerance O
[ O
IGT O
] O
, O
n O
= O
43 O
; O
type O
2 O
diabetes O
, O
n O
= O
27 O
) O
who O
had O
in O
vivo O
insulin O
sensitivity O
and O
secretion O
measured O
by O
hyperinsulinemic O
- O
euglycemic O
and O
hyperglycemic O
clamp O
techniques O
and O
had O
an O
assessment O
of O
total O
body O
composition O
and O
abdominal O
adiposity O
. O
RESULTSThe O
mean O
age O
and O
BMI O
of O
the O
subjects O
were O
14 O
. O
3 O
+ O
/ O
- O
2 O
. O
1 O
years O
and O
35 O
. O
7 O
+ O
/ O
- O

BMI O
, O
plasma O
25 O
( O
OH O
) O
D O
, O
and O
the O
proportion O
of O
vitamin B
D I
- O
deficient O
and O
- O
insufficient O
children O
did O
not O
differ O
across O
the O
three O
groups O
. O

Furthermore O
, O
there O
was O
no O
association O
between O
25 O
( O
OH O
) O
D O
and O
in O
vivo O
insulin O
sensitivity O
or O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
( O
disposition O
index O
) O
in O
all O
groups O
combined O
or O
in O
each O
group O
separately O
. O
CONCLUSIONSOur O
data O
in O
obese O
youth O
show O
1 O
) O
no O
differences O
in O
plasma O
25 O
( O
OH O
) O
D O
concentrations O
across O
the O
glucose B
tolerance O
groups O
, O
and O
2 O
) O
no O
relationship O
between O
25 O
( O
OH O
) O
D O
and O
in O
vivo O
insulin O
sensitivity O
and O
beta O
- O
cell O
function O
relative O
to O
insulin O
sensitivity O
in O
any O
of O
the O
groups O
. O

It O
remains O
uncertain O
if O
enhancement O
of O
the O
vitamin B
D I
status O
could O
improve O
pathophysiological O
mechanisms O
of O
prediabetes O
and O
type O
2 O
diabetes O
in O
obese O
youth O
. O

Serum O
25 B
- I
hydroxyvitamin I
D I
, O
parathyroid O
hormone O
, O
and O
their O
association O
with O
metabolic O
syndrome O
in O
Chinese O
. O

Increasing O
evidence O
suggests O
that O
25 B
- I
hydroxyvitamin I
D I
[ O
25 O
( O
OH O
) O
D O
] O
and O
parathyroid O
hormone O
( O
PTH O
) O
levels O
are O
associated O
with O
metabolic O
syndrome O
( O
MetS O
) O
. O

The O
prevalence O
of O
vitamin B
D I
deficiency O
( O
< O
50 O
nmol O
/ O
l O
) O
was O
39 O
. O
9 O
% O
, O
with O
34 O
. O
5 O
% O
in O
men O
and O
47 O
. O
8 O
% O
in O
women O
. O

Furthermore O
, O
participants O
with O
vitamin B
D I
sufficiency O
had O
a O
35 O
% O
lower O
risk O
of O
MetS O
than O
those O
with O
vitamin B
D I
deficiency O
( O
OR O
= O
0 O
. O
65 O
, O
95 O
% O
CI O
0 O
. O
51 O
- O
0 O
. O
84 O
, O
P O
= O
0 O
. O
0009 O
) O
. O

Thus O
in O
this O
cohort O
of O
Chinese O
individuals O
, O
vitamin B
D I
deficiency O
is O
common O
and O
optimal O
vitamin B
D I
level O
is O
inversely O
associated O
with O
MetS O
, O
independent O
of O
several O
confounders O
and O
PTH O
level O
. O

Novel O
type O
II O
fatty B
acid I
biosynthesis O
( O
FAS O
II O
) O
inhibitors O
as O
multistage O
antimalarial O
agents O
. O

P O
. O
falciparum O
( O
Pf O
) O
enoyl O
acyl O
carrier O
protein O
( O
ACP O
) O
reductase O
( O
ENR O
) O
is O
a O
key O
enzyme O
of O
plasmodial O
type O
II O
fatty B
acid I
biosynthesis O
( O
FAS O
II O
) O
. O

Solid O
- O
state O
NMR O
study O
reveals O
collagen O
I O
structural O
modifications O
of O
amino B
acid I
side O
chains O
upon O
fibrillogenesis O
. O

In O
the O
present O
work O
, O
we O
study O
a O
high O
concentrated O
collagen O
sample O
in O
its O
soluble O
, O
fibrillar O
, O
and O
denatured O
states O
using O
one O
and O
two O
dimensional O
{ O
( B
1 I
) I
H I
} O
- O
( B
13 I
) I
C I
solid O
- O
state O
NMR O
spectroscopy O
. O

We O
interpret O
( B
13 I
) I
C I
chemical O
shift O
variations O
in O
terms O
of O
dihedral O
angle O
conformation O
changes O
. O

Nevertheless O
, O
only O
three O
to O
five O
rotameric O
equilibria O
are O
found O
for O
each O
amino B
acid I
residue O
, O
indicating O
a O
relatively O
low O
structural O
heterogeneity O
of O
collagen O
upon O
fibrillogenesis O
. O

Using O
side O
chain O
statistical O
data O
, O
we O
calculate O
equilibrium O
constants O
for O
a O
great O
number O
of O
amino B
acid I
residues O
. O

Moreover O
, O
based O
on O
a O
( B
13 I
) I
C I
quantitative O
spectrum O
, O
we O
estimate O
the O
percentage O
of O
residues O
implicated O
in O
each O
equilibrium O
. O

Our O
data O
indicate O
that O
fibril O
formation O
greatly O
affects O
hydroxyproline B
and O
proline O
prolyl O
pucker O
ring O
conformation O
. O

Finally O
, O
we O
discuss O
the O
implication O
of O
these O
structural O
data O
and O
propose O
a O
model O
in O
which O
the O
attractive O
force O
of O
fibrillogenesis O
comes O
from O
a O
structural O
reorganization O
of O
10 O
to O
15 O
% O
of O
the O
amino B
acids I
. O

A O
total O
of O
775 O
fragments O
were O
grouped O
into O
143 O
cocktails O
, O
which O
were O
soaked O
into O
crystals O
of O
RT O
in O
complex O
with O
the O
non O
- O
nucleoside B
drug O
rilpivirine O
( O
TMC278 O
) O
. O

Seven O
new O
sites O
were O
discovered O
, O
including O
the O
Incoming O
Nucleotide B
Binding O
, O
Knuckles O
, O
NNRTI O
Adjacent O
, O
and O
399 O
sites O
, O
located O
in O
the O
polymerase O
region O
of O
RT O
, O
and O
the O
428 O
, O
RNase O
H O
Primer O
Grip O
Adjacent O
, O
and O
507 O
sites O
, O
located O
in O
the O
RNase O
H O
region O
. O

Three O
of O
these O
sites O
( O
Knuckles O
, O
NNRTI O
Adjacent O
, O
and O
Incoming O
Nucleotide B
Binding O
) O
are O
inhibitory O
and O
provide O
opportunities O
for O
discovery O
of O
new O
anti O
- O
AIDS O
drugs O
. O

An O
aqueous O
self O
- O
assembled O
micellar O
system O
( O
sodium B
dodecyl I
sulfate I
, O
SDS B
, O
decorated O
with O
various O
adhesive O
sites O
, O
cryptand O
Kryptofix O
222 O
and O
crown B
ether I
18 O
- O
Crown O
- O
6 O
molecules O
) O
has O
been O
investigated O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
and O
small O
angle O
x O
- O
ray O
scattering O
( O
SAXS O
) O
to O
have O
insights O
into O
the O
micellar O
structure O
, O
the O
micellar O
interactions O
, O
and O
the O
aggregation O
properties O
of O
the O
system O
. O

Considering O
that O
SDS B
micelles O
in O
water O
do O
not O
aggregate O
at O
low O
concentration O
, O
it O
is O
shown O
that O
macrocyclic O
ligands O
induce O
the O
SDS B
micelle O
aggregation O
as O
a O
function O
of O
the O
concentration O
( O
i O
. O
e O
. O
, O
investigated O
ligand O
/ O
SDS B
molar O
ratios O
are O
5 O
. O
0 O
, O
1 O
. O
5 O
, O
1 O
. O
0 O
, O
and O
0 O
. O
5 O
) O
and O
hydrophobicity O
of O
the O
adhesive O
sites O
. O

Personality O
and O
the O
acute O
subjective O
effects O
of O
d B
- I
amphetamine I
in O
humans O
. O

Here O
, O
we O
extend O
previous O
findings O
by O
examining O
personality O
measures O
in O
relation O
to O
acute O
responses O
to O
d B
- I
amphetamine I
( O
AMPH O
) O
in O
a O
large O
sample O
of O
healthy O
volunteers O
. O

High O
trait O
physical O
fearlessness O
was O
significantly O
associated O
with O
greater O
amphetamine B
- O
related O
Arousal O
, O
and O
high O
trait O
reward O
sensitivity O
was O
significantly O
associated O
with O
greater O
Euphoria O
. O

The O
structure O
, O
formation O
mechanism O
, O
and O
stability O
of O
the O
hybrid O
nanosheets O
were O
investigated O
in O
detail O
by O
taking O
the O
Co O
9 O
S O
8 O
- O
oleylamine B
( O
Co O
9 O
S O
8 O
- O
OA O
) O
hybrid O
nanosheets O
as O
an O
example O
. O

Both O
experimental O
data O
and O
theoretical O
simulations O
demonstrate O
that O
the O
hybrid O
nanosheets O
were O
formed O
by O
in O
- O
plane O
connection O
of O
small O
two O
- O
dimensional O
( O
2D O
) O
Co O
9 O
S O
8 O
nanoplates O
via O
oleylamine B
molecules O
adsorbed O
at O
the O
side O
surface O
and O
corner O
sites O
of O
the O
nanoplates O
. O

Such O
targets O
include O
the O
organic O
anion O
- O
transporting O
polypeptides O
( O
OATPs O
in O
humans O
; O
Oatps O
in O
rodents O
) O
, O
a O
family O
of O
sodium B
- O
independent O
transporters O
that O
are O
endogenously O
expressed O
in O
the O
brain O
and O
are O
involved O
in O
drug O
uptake O
. O

Catalytic O
transformation O
of O
alcohols B
to O
carboxylic B
acid I
salts O
and O
H2 B
using O
water O
as O
the O
oxygen B
atom O
source O
. O

The O
oxidation O
of O
alcohols B
to O
carboxylic B
acids I
is O
an O
important O
industrial O
reaction O
used O
in O
the O
synthesis O
of O
bulk O
and O
fine O
chemicals O
. O

Most O
current O
processes O
are O
performed O
by O
making O
use O
of O
either O
stoichiometric O
amounts O
of O
toxic O
oxidizing O
agents O
or O
the O
use O
of O
pressurized O
dioxygen B
. O

Here O
, O
we O
describe O
an O
alternative O
dehydrogenative O
pathway O
effected O
by O
water O
and O
base O
with O
the O
concomitant O
generation O
of O
hydrogen B
gas O
. O

A O
homogeneous O
ruthenium B
complex O
catalyses O
the O
transformation O
of O
primary O
alcohols B
to O
carboxylic B
acid I
salts O
at O
low O
catalyst O
loadings O
( O
0 O
. O
2 O
mol O
% O
) O
in O
basic O
aqueous O
solution O
. O

A O
consequence O
of O
this O
finding O
could O
be O
a O
safer O
and O
cleaner O
process O
for O
the O
synthesis O
of O
carboxylic B
acids I
and O
their O
derivatives O
at O
both O
laboratory O
and O
industrial O
scales O
. O

Increased O
impulsive O
choice O
for O
saccharin B
during O
PCP B
withdrawal O
in O
female O
monkeys O
: O
influence O
of O
menstrual O
cycle O
phase O
. O

BACKGROUND O
: O
In O
previous O
studies O
with O
male O
and O
female O
rhesus O
monkeys O
, O
withdrawal O
of O
access O
to O
oral O
phencyclidine B
( O
PCP B
) O
self O
- O
administration O
reduced O
responding O
for O
food O
under O
a O
high O
fixed O
- O
ratio O
( O
FR O
) O
schedule O
more O
in O
males O
than O
females O
, O
and O
with O
a O
delay O
discounting O
( O
DD O
) O
task O
with O
saccharin B
( O
SACC O
) O
as O
the O
reinforcer O
impulsive O
choice O
for O
SACC O
increased O
during O
PCP B
withdrawal O
more O
in O
males O
than O
females O
. O

OBJECTIVES O
: O
The O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
effect O
of O
PCP B
( O
0 O
. O
25 O
or O
0 O
. O
5 O
mg O
/ O
ml O
) O
withdrawal O
on O
impulsive O
choice O
for O
SACC O
in O
females O
during O
the O
follicular O
and O
luteal O
phases O
of O
the O
menstrual O
cycle O
. O

MATERIALS O
AND O
METHODS O
: O
In O
component O
1 O
, O
PCP B
and O
water O
were O
available O
from O
two O
drinking O
spouts O
for O
1 O
. O
5 O
h O
sessions O
under O
concurrent O
FR O
16 O
schedules O
. O

There O
was O
then O
a O
10 O
- O
day O
water O
substitution O
phase O
, O
or O
PCP B
withdrawal O
, O
that O
occurred O
during O
the O
mid O
- O
follicular O
phase O
( O
days O
7 O
- O
11 O
) O
or O
the O
late O
luteal O
phase O
( O
days O
24 O
- O
28 O
) O
of O
the O
menstrual O
cycle O
. O

Access O
to O
PCP B
and O
concurrent O
water O
was O
then O
restored O
, O
and O
the O
PCP B
withdrawal O
procedure O
was O
repeated O
over O
several O
follicular O
and O
luteal O
menstrual O
phases O
. O

RESULTS O
: O
PCP B
deliveries O
were O
higher O
during O
the O
luteal O
( O
vs O
follicular O
) O
phase O
. O

Impulsive O
choice O
was O
greater O
during O
the O
luteal O
( O
vs O
follicular O
) O
phase O
during O
withdrawal O
of O
the O
higher O
PCP B
concentration O
. O

CONCLUSIONS O
: O
PCP B
withdrawal O
was O
associated O
with O
elevated O
impulsive O
choice O
for O
SACC O
, O
especially O
in O
the O
luteal O
( O
vs O
follicular O
) O
phase O
of O
the O
menstrual O
cycle O
in O
female O
monkeys O
. O

Although O
the O
excited O
state O
of O
the O
quinoidal O
thiophene O
dye O
is O
deactivated O
within O
several O
picoseconds O
even O
in O
solution O
, O
the O
DSSCs O
using O
the O
quinoidal O
thiophene O
dye O
showed O
incident O
photon O
to O
current O
conversion O
efficiency O
( O
IPCE O
) O
values O
of O
more O
than O
90 O
% O
, O
demonstrating O
the O
fast O
and O
efficient O
electron O
injection O
from O
the O
excited O
dye O
to O
TiO B
( I
2 I
) I
. O

Oxidative O
stress O
and O
alteration O
of O
biochemical O
markers O
in O
liver O
and O
kidney O
by O
malathion B
in O
rat O
pups O
. O

The O
present O
study O
was O
undertaken O
to O
determine O
the O
effects O
of O
malathion B
exposure O
through O
maternal O
milk O
on O
oxidative O
stress O
, O
functional O
an O
metabolic O
parameters O
in O
kidney O
and O
liver O
of O
rat O
pups O
. O

We O
found O
that O
lactational O
exposure O
to O
malation O
( O
200 O
mg O
/ O
kg O
, O
body O
weight O
( O
bw O
) O
) O
induced O
an O
oxidative O
stress O
status O
assessed O
by O
an O
increase O
in O
malondialdhyde O
( O
MDA B
) O
content O
, O
reflecting O
lipoperoxidation O
, O
a O
decrease O
in O
thiol B
groups O
' O
content O
as O
well O
as O
depletion O
of O
enzyme O
activities O
as O
a O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
on O
postnatal O
days O
( O
Pnds O
) O
21 O
and O
51 O
. O

Moreover O
, O
the O
current O
study O
showed O
that O
malathion B
induced O
liver O
and O
kidney O
dysfunctions O
demonstrated O
by O
considerable O
increase O
in O
phosphatase O
alkaline O
( O
PAL O
) O
, O
aspartate B
aminotransferase O
( O
AST O
) O
and O
alanine B
aminotransferase O
( O
ALT O
) O
activities O
as O
well O
as O
total O
and O
direct O
bilirubin B
, O
creatinine B
urea B
and O
acid O
uric O
contents O
. O

We O
also O
observed O
an O
increase O
in O
triglyceride B
( O
TG O
) O
, O
total O
cholesterol B
( O
TC O
) O
, O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
and O
a O
decrease O
in O
high O
- O
density O
lipoprotein O
cholesterol B
( O
HDL O
- O
C O
) O
in O
the O
plasma O
of O
treated O
rat O
pups O
. O

These O
findings O
evidenced O
that O
malathion B
exposure O
during O
lactation O
through O
maternal O
milk O
of O
rats O
pups O
induced O
kidney O
and O
liver O
oxidative O
stress O
as O
well O
as O
functional O
and O
metabolic O
disorders O
that O
play O
a O
role O
in O
the O
development O
of O
others O
pathologies O
as O
cardiovascular O
diseases O
and O
cancers O
. O

Interleukin O
- O
10 O
involvement O
in O
exposure O
to O
low O
dose O
of O
benzene B
. O

OBJECTIVE O
: O
To O
establish O
if O
serum O
levels O
of O
interleukin O
- O
10 O
( O
IL O
- O
10 O
) O
in O
subjects O
exposed O
to O
benzene B
are O
connected O
with O
age O
, O
working O
years O
, O
and O
employment O
age O
. O

CONCLUSIONS O
: O
The O
role O
played O
by O
IL O
- O
10 O
in O
benzene B
immune O
suppression O
may O
be O
relevant O
and O
attention O
should O
be O
directed O
toward O
assessment O
of O
age O
, O
working O
years O
, O
and O
employment O
age O
in O
benzene B
- O
exposed O
populations O
. O

Regulation O
of O
sodium B
and O
calcium B
in O
Daphnia O
magna O
exposed O
to O
silver B
nanoparticles O
. O

The O
toxicity O
of O
manufactured O
silver B
nanoparticles O
( O
AgNPs O
) O
has O
been O
widely O
studied O
, O
but O
the O
influence O
of O
AgNPs O
on O
the O
major O
ions O
( O
such O
as O
sodium B
[ O
Na B
] O
and O
calcium B
[ O
Ca B
] O
) O
regulations O
are O
unknown O
. O

In O
the O
present O
study O
, O
a O
freshwater O
cladoceran O
Daphnia O
magna O
was O
exposed O
to O
commercial O
AgNPs O
coated O
with O
polyvinylpyrrolidone B
. O

After O
48 O
h O
, O
the O
Na B
body O
content O
was O
significantly O
reduced O
by O
AgNO3 B
exposure O
, O
but O
the O
Ca B
body O
content O
was O
significantly O
increased O
under O
AgNO3 B
and O
AgNP O
exposures O
, O
respectively O
. O

No O
effect O
was O
observed O
on O
the O
body O
concentrations O
of O
Na B
and O
Ca B
at O
50 O
to O
500 O
micro O
g O
/ O
L O
AgNPs O
with O
1 O
- O
micro O
M O
cysteine B
addition O
. O

Exposure O
of O
AgNO3 B
and O
AgNPs O
inhibited O
the O
Na B
influx O
and O
elevated O
the O
Na B
efflux O
. O

In O
contrast O
, O
their O
exposure O
increased O
the O
Ca B
influx O
, O
but O
did O
not O
affect O
the O
Ca B
efflux O
. O

The O
results O
of O
the O
present O
study O
demonstrated O
the O
significant O
influences O
of O
AgNO3 B
and O
AgNPs O
( O
without O
cysteine B
) O
on O
Na B
and O
Ca B
regulations O
. O

Such O
effect O
of O
AgNPs O
on O
Na B
and O
Ca B
regulation O
disappeared O
after O
cysteine B
addition O
, O
indicating O
that O
the O
soluble O
Ag B
released O
from O
AgNPs O
played O
a O
major O
role O
in O
the O
ionoregulatory O
dysfunction O
. O

Similar O
changes O
are O
also O
observed O
in O
cells O
expressing O
another O
disease O
- O
causing O
gene O
that O
triggers O
ER O
stress O
, O
as O
well O
as O
in O
cells O
treated O
with O
brefeldin B
A I
, O
which O
induces O
ER O
stress O
and O
GA O
fragmentation O
by O
inhibiting O
GA O
to O
ER O
trafficking O
. O

Topoisomerase O
II O
beta O
deficiency O
enhances O
camptothecin B
- O
induced O
apoptosis O
. O

Camptothecin B
( O
CPT B
) O
, O
a O
topoisomerase O
( O
Top O
) O
I O
- O
targeting O
drug O
that O
stabilizes O
Top1 O
- O
DNA O
covalent O
adducts O
, O
can O
induce O
S O
- O
phase O
- O
specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O

However O
, O
CPT B
- O
induced O
non O
- O
S O
- O
phase O
cytotoxicity O
is O
less O
well O
characterized O
. O

In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
II O
beta O
( O
Top2 O
beta O
) O
as O
a O
specific O
determinant O
for O
CPT B
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non O
- O
S O
- O
phase O
cells O
. O

First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
( O
MEFs O
) O
lacking O
Top2 O
beta O
were O
shown O
to O
be O
hypersensitive O
to O
CPT B
with O
prominent O
induction O
of O
apoptosis O
. O

Second O
, O
ICRF O
- O
187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2 O
beta O
, O
specifically O
sensitized O
MEFs O
to O
CPT B
. O

To O
explore O
the O
molecular O
basis O
for O
CPT B
hypersensitivity O
in O
Top2 O
beta O
- O
deficient O
cells O
, O
we O
found O
that O
upon O
CPT B
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
( O
RNAP O
LS O
) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O
in O
wild O
- O
type O
MEFs O
, O
whereas O
RNAP O
LS O
remained O
depleted O
without O
recovery O
in O
Top2 O
beta O
- O
deficient O
cells O
. O

Altogether O
, O
our O
findings O
support O
a O
model O
in O
which O
Top2 O
beta O
deficiency O
promotes O
CPT B
- O
induced O
apoptosis O
in O
quiescent O
non O
- O
S O
- O
phase O
cells O
, O
possibly O
due O
to O
RNAP O
LS O
depletion O
and O
p53 O
accumulation O
. O

Moreover O
, O
some O
isolated O
compounds O
were O
examined O
for O
their O
inhibitory O
activity O
towards O
superoxide B
anion O
generation O
and O
elastase O
release O
in O
human O
neutrophils O
. O

Among O
the O
tested O
compounds O
, O
1 O
, O
3 O
, O
and O
5 O
exhibited O
strong O
inhibition O
of O
superoxide B
anion O
generation O
with O
IC50 O
values O
ranging O
from O
5 O
. O
25 O
to O
8 O
. O
65 O
micro O
M O
. O

Bauhinia O
seeds O
contain O
relatively O
large O
quantities O
of O
peptidase O
inhibitors O
, O
and O
two O
Bauhinia O
inhibitors O
were O
obtained O
in O
a O
recombinant O
form O
from O
the O
Bauhinia O
bauhinioides O
species O
, O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
, O
which O
is O
a O
cysteine B
and O
serine B
peptidase O
inhibitor O
, O
and O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
, O
which O
is O
a O
serine B
peptidase O
inhibitor O
. O

While O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
inhibits O
human O
neutrophil O
elastase O
cathepsin O
G O
and O
the O
cysteine B
proteinase O
cathepsin O
L O
, O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
inhibits O
plasma O
kallikrein O
and O
plasmin O
. O

The O
effects O
of O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
and O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
on O
the O
viability O
of O
tumor O
cell O
lines O
with O
a O
distinct O
potential O
of O
growth O
from O
the O
same O
tissue O
were O
compared O
to O
those O
of O
the O
clinical O
cytotoxic O
drug O
5 B
- I
fluorouracil I
. O

At O
12 O
. O
5 O
micro O
M O
concentration O
, O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
and O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
were O
more O
efficient O
than O
5 B
- I
fluorouracil I
in O
inhibiting O
MKN O
- O
28 O
and O
Hs746T O
( O
gastric O
) O
, O
HCT116 O
and O
HT29 O
( O
colorectal O
) O
, O
SkBr O
- O
3 O
and O
MCF O
- O
7 O
( O
breast O
) O
, O
and O
THP O
- O
1 O
and O
K562 O
( O
leukemia O
) O
cell O
lines O
. O

Recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
and O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
, O
even O
at O
high O
doses O
, O
did O
not O
affect O
hMSC O
proliferation O
while O
5 B
- I
fluorouracil I
greatly O
reduced O
the O
proliferation O
rates O
of O
hMSCs O
. O

Therefore O
, O
both O
recombinant O
B O
. O
bauhinoides O
cruzipain O
inhibitor O
and O
recombinant O
B O
. O
bauhinioides O
kallikrein O
inhibitor O
might O
be O
considered O
for O
further O
studies O
to O
block O
peptidase O
activities O
in O
order O
to O
target O
specific O
peptidase O
- O
mediated O
growth O
and O
invasion O
characteristics O
of O
individual O
tumors O
, O
mainly O
in O
patients O
resistant O
to O
5 B
- I
fluorouracil I
chemotherapy O
. O

The O
phosphoramidate B
nerve O
agent O
tabun B
inhibits O
butyrylcholinesteras O
( O
BChE O
) O
and O
acetylcholinesterase O
by O
making O
a O
covalent O
bond O
on O
the O
active O
site O
serine B
. O

The O
adduct O
loses O
an O
alkyl B
group O
in O
a O
process O
called O
aging O
. O

The O
mechanism O
of O
aging O
of O
the O
tabun B
adduct O
is O
controversial O
. O

Some O
studies O
claim O
that O
aging O
proceeds O
through O
deamination O
, O
whereas O
crystal O
structure O
studies O
show O
aging O
by O
O B
- O
dealkylation O
. O

Our O
goal O
was O
to O
develop O
a O
method O
that O
clearly O
distinguishes O
between O
deamination O
and O
O B
- O
dealkylation O
. O

We O
began O
by O
studying O
the O
tetraisopropyl B
pyrophosphoramide I
adduct O
of O
BChE O
because O
this O
adduct O
has O
two O
P O
- O
N O
bonds O
. O

The O
P O
- O
N O
bond O
in O
tabun B
was O
also O
acid O
labile O
, O
whereas O
the O
P B
- I
O I
bond O
was O
stable O
. O

A O
scheme O
to O
distinguish O
aging O
by O
deamination O
from O
aging O
by O
O B
- O
dealkylation O
was O
based O
on O
the O
acid O
labile O
P O
- O
N O
bond O
. O

BChE O
was O
inhibited O
with O
Sp O
- O
and O
Rp O
- O
tabun O
thiocholine O
nerve O
agent O
model O
compounds O
to O
make O
adducts O
identical O
to O
those O
of O
tabun B
with O
known O
stereochemistry O
. O

After O
aging O
and O
digestion O
with O
pepsin O
at O
pH O
2 O
, O
peptide O
FGES198AGAAS O
from O
Sp O
- O
tabun O
thiocholine O
had O
a O
mass O
of O
902 O
. O
2 O
m O
/ O
z O
in O
negative O
mode O
, O
indicating O
that O
it O
had O
aged O
by O
deamination O
, O
whereas O
peptide O
FGES198AGAAS O
from O
Rp O
- O
tabun O
thiocholine O
had O
a O
mass O
of O
874 O
. O
2 O
m O
/ O
z O
in O
negative O
mode O
, O
indicating O
that O
it O
had O
aged O
by O
O B
- O
dealkylation O
. O

Inhibitors O
of O
A2E O
photooxidation O
were O
prepared O
by O
Mannich O
reaction O
of O
the O
antioxidant O
quercetin B
. O

These O
compounds O
contain O
water O
- O
solubilizing O
amine B
groups O
, O
and O
several O
were O
more O
potent O
inhibitors O
of O
A2E O
photooxidation O
than O
quercetin B
. O

The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P O
/ O
IGF2R O
in O
SCC O
- O
VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P O
- O
binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non O
- O
redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate B
- O
binding O
domains O
of O
the O
receptor O
. O

Catalytic O
DNAs O
that O
harness O
violet O
light O
to O
repair O
thymine B
dimers O
in O
a O
DNA O
substrate O
. O

UV1C O
is O
an O
in O
vitro O
selected O
catalytic O
DNA O
that O
shows O
efficient O
photolyase O
activity O
, O
using O
light O
of O
< O
310 O
nm O
wavelength O
to O
photo O
- O
reactivate O
CPD O
thymine B
dimers O
within O
a O
substrate O
DNA O
. O

We O
show O
here O
that O
a O
minimal O
mutational O
strategy O
of O
substituting O
a O
guanine B
analogue O
, O
6MI O
, O
for O
single O
guanine B
residues O
within O
UV1C O
extends O
the O
DNAzyme O
' O
s O
activity O
into O
the O
violet O
region O
of O
the O
spectrum O
. O

These O
6MI O
point O
mutant O
DNAzymes O
fall O
into O
three O
distinct O
functional O
classes O
, O
which O
photo O
- O
reactivate O
the O
thymine B
dimer O
along O
different O
pathways O
. O

When O
grafted O
beta B
- I
cyclodextrin I
is O
used O
as O
targeting O
sites O
, O
Pluronic O
polymers O
have O
been O
introduced O
on O
the O
surface O
of O
cellulose O
nanocrystals O
by O
means O
of O
inclusion O
interaction O
between O
beta B
- I
cyclodextrin I
and O
hydrophobic O
segment O
of O
the O
polymer O
. O

Because O
of O
the O
steric O
stabilization O
effect O
, O
surface O
poly B
( I
ethylene I
glycol I
) I
chains O
facilitate O
the O
dispersion O
and O
compatibility O
of O
nanocrystals O
, O
which O
also O
enhance O
the O
loading O
levels O
of O
nanocrystals O
in O
the O
hydrogel O
system O
. O

Meanwhile O
, O
uncovered O
poly B
( I
ethylene I
glycol I
) I
segments O
render O
the O
participating O
inclusion O
of O
alpha B
- I
cyclodextrin I
for O
the O
architecture O
of O
in O
situ O
hydrogels O
. O

Surface O
grafting O
and O
inclusion O
reactions O
were O
proved O
by O
solid O
( B
13 I
) I
C I
NMR O
and O
FTIR O
. O

Grafting O
efficiency O
of O
beta B
- I
cyclodextrin I
and O
inclusion O
efficiency O
of O
Pluronic O
on O
the O
surface O
of O
nanocrystals O
were O
confirmed O
by O
UV O
spectroscopy O
and O
elemental O
analysis O
. O

Finally O
, O
in O
situ O
hydrogels O
were O
used O
as O
drug O
carrier O
for O
in O
vitro O
release O
of O
doxorubicin B
and O
exhibit O
the O
behavior O
of O
prolonged O
drug O
release O
with O
special O
release O
kinetics O
. O

Nanocomposites O
derived O
from O
montmorillonite B
and O
metallosupramolecula O
polyelectrolytes O
: O
modular O
compounds O
for O
electrorheological O
fluids O
. O

Nanocomposites O
made O
from O
Na B
- O
montmorillonite B
and O
metallo O
- O
supramolecular O
polyelectrolytes O
( O
MEPE O
) O
based O
on O
nickel B
and O
ditopic O
bis O
- O
terpyridine O
ligands O
are O
prepared O
by O
an O
aqueous O
synthesis O
. O

Adsorption O
and O
dilational O
rheology O
of O
mixed O
beta O
- O
casein O
/ O
DoTAB O
layers O
formed O
by O
sequential O
and O
simultaneous O
adsorption O
at O
the O
water O
/ O
hexane B
interface O
. O

The O
interfacial O
behavior O
of O
beta O
- O
casein O
( O
beta O
CS O
) O
has O
been O
investigated O
in O
presence O
of O
the O
cationic O
surfactant O
dodecyl O
trimethyl O
ammonium O
bromide O
( O
DoTAB O
) O
at O
the O
water O
/ O
hexane B
interface O
and O
compared O
to O
that O
obtained O
for O
the O
water O
/ O
air O
interface O
. O

5 O
- O
Iodo O
- O
2 O
- O
aminoindan O
( O
5 O
- O
IAI O
) O
: O
chemistry O
, O
pharmacology O
, O
and O
toxicology O
of O
a O
research O
chemical O
producing O
MDMA B
- O
like O
effects O
. O

5 O
- O
IAI O
is O
a O
rigid O
analogue O
of O
p O
- O
iodoamphetamine O
producing O
MDMA B
- O
like O
effects O
. O

Morphine B
withdrawal O
produces O
ERK O
- O
dependent O
and O
ERK O
- O
independent O
epigenetic O
marks O
in O
neurons O
of O
the O
nucleus O
accumbens O
and O
lateral O
septum O
. O

In O
this O
study O
we O
show O
that O
new O
gene O
expression O
induced O
in O
vivo O
by O
morphine B
withdrawal O
occurs O
with O
concomitant O
epigenetic O
modifications O
in O
brain O
regions O
critically O
involved O
in O
drug O
- O
dependent O
behaviors O
. O

We O
found O
that O
naloxone B
- O
precipitated O
withdrawal O
, O
but O
not O
chronic O
morphine B
administration O
, O
caused O
a O
strong O
induction O
of O
phospho B
- O
histone O
H3 O
immunoreactivity O
in O
the O
nucleus O
accumbens O
( O
NAc O
) O
shell O
/ O
core O
and O
in O
the O
lateral O
septum O
( O
LS O
) O
, O
a O
change O
that O
was O
accompanied O
by O
augmented O
H3 O
acetylation O
( O
lys14 O
) O
in O
neurons O
of O
the O
NAc O
shell O
. O

Morphine B
withdrawal O
induced O
the O
phosphorylation O
of O
the O
epigenetic O
factor O
methyl B
- O
CpG B
- O
binding O
protein O
2 O
( O
MeCP2 O
) O
in O
Ser421 O
both O
in O
the O
LS O
and O
the O
NAc O
shell O
. O

Motivational O
properties O
of O
D2 O
and O
D3 O
dopamine B
receptors O
agonists O
and O
cocaine B
, O
but O
not O
with O
D1 O
dopamine B
receptors O
agonist O
and O
l O
- O
dopa O
, O
in O
bilateral O
6 B
- I
OHDA I
- O
lesioned O
rat O
. O

Dopamine B
dysregulation O
syndrome O
in O
Parkinson O
' O
s O
disease O
( O
PD O
) O
has O
been O
attributed O
to O
dopamine B
replacement O
therapy O
( O
DRT O
) O
. O

Using O
the O
conditioned O
place O
preference O
( O
CPP O
) O
paradigm O
, O
we O
investigated O
the O
motivational O
effects O
of O
l O
- O
dopa O
, O
dopamine B
receptor O
agonists O
( O
DRAs O
) O
, O
and O
cocaine B
in O
rat O
with O
a O
bilateral O
6 B
- I
OHDA I
lesion O
of O
the O
nigrostriatal O
dopaminergic O
pathway O
. O

In O
6 B
- I
OHDA I
animals O
, O
D1 O
receptors O
agonist O
( O
SKF81297 O
) O
revealed O
significantly O
a O
conditioned O
place O
aversion O
( O
CPA O
) O
at O
3 O
mg O
/ O
kg O
and O
9 O
mg O
/ O
kg O
doses O
. O

D3 O
receptors O
agonist O
( O
PD128907 O
) O
induced O
a O
CPP O
only O
at O
1 O
mg O
/ O
kg O
, O
comparable O
to O
that O
of O
cocaine B
. O

However O
, O
l O
- O
dopa O
induced O
no O
significant O
effect O
while O
cocaine B
induced O
CPP O
in O
both O
lesioned O
and O
sham O
animals O
. O

New O
insight O
into O
the O
discharge O
mechanism O
of O
silicon B
- O
air O
batteries O
using O
electrochemical O
impedance O
spectroscopy O
. O

The O
mechanism O
of O
discharge O
termination O
in O
silicon B
- O
air O
batteries O
, O
employing O
a O
silicon B
wafer O
anode O
, O
a O
room O
- O
temperature O
fluorohydrogenate O
ionic O
liquid O
electrolyte O
and O
an O
air O
cathode O
membrane O
, O
is O
investigated O
using O
a O
wide O
range O
of O
tools O
. O

EIS O
studies O
indicate O
that O
the O
interfacial O
impedance O
between O
the O
electrolyte O
and O
the O
silicon B
wafer O
increases O
upon O
continuous O
discharge O
. O

Equivalent O
circuit O
fitting O
parameters O
indicate O
the O
difference O
in O
the O
anode O
- O
electrolyte O
interface O
characteristics O
for O
different O
types O
of O
silicon B
wafers O
. O

Evolution O
of O
porous O
silicon B
surfaces O
at O
the O
anode O
and O
their O
properties O
, O
by O
means O
of O
estimated O
circuit O
parameters O
, O
is O
also O
presented O
. O

Moreover O
, O
it O
is O
found O
that O
the O
silicon B
anode O
potential O
has O
the O
highest O
negative O
impact O
on O
the O
battery O
discharge O
voltage O
, O
while O
the O
air O
cathode O
potential O
is O
actually O
stable O
and O
invariable O
along O
the O
whole O
discharge O
period O
. O

The O
discharge O
capacity O
of O
the O
battery O
can O
be O
increased O
significantly O
by O
mechanically O
replacing O
the O
silicon B
anode O
. O

The O
effect O
of O
apricots O
on O
the O
experimental O
cataract O
model O
formed O
by O
sodium B
selenite I
. O

This O
study O
was O
designed O
in O
order O
to O
investigate O
whether O
sun O
dried O
apricots O
have O
a O
preventive O
effect O
on O
the O
experimental O
cataract O
model O
formed O
by O
sodium B
selenite I
in O
rats O
. O

Subcutaneous O
( O
30nmol O
/ O
gr O
) O
sodium B
selenite I
injection O
was O
applied O
to O
all O
the O
newborn O
rats O
except O
the O
control O
group O
( O
Group O
1 O
) O
on O
postpartum O
day O
10 O
. O

Encapsulated O
lenses O
were O
analyzed O
for O
reduced O
glutathione B
( O
GSH B
) O
and O
malondialdehyde B
( O
MDA B
) O
, O
a O
marker O
of O
lipid O
per O
oxidation O
. O

Lenses O
were O
also O
analyzed O
for O
total O
nitrite B
( O
TN O
) O
. O

Gout O
, O
a O
common O
form O
of O
inflammatory O
arthritis O
, O
is O
strongly O
associated O
with O
elevated O
uric B
acid I
concentrations O
in O
the O
blood O
( O
hyperuricemia O
) O
. O

A O
recent O
study O
in O
Icelanders O
identified O
a O
rare O
missense O
single O
nucleotide B
polymorphism O
( O
SNP O
) O
in O
the O
ALDH16A1 O
gene O
, O
ALDH16A1 O
* O
2 O
, O
to O
be O
associated O
with O
gout O
and O
serum O
uric B
acid I
levels O
. O

The O
active O
site O
of O
ALDH16 O
proteins O
from O
bacterial O
, O
frog O
and O
lower O
animals O
contain O
the O
catalytically O
important O
cysteine B
residue O
( O
Cys B
- O
302 O
) O
; O
this O
residue O
is O
absent O
from O
the O
mammalian O
and O
fish O
orthologs O
. O

Molecular O
modeling O
predicts O
that O
both O
the O
short O
and O
long O
forms O
of O
human O
ALDH16A1 O
protein O
would O
lack O
catalytic O
activity O
but O
may O
interact O
with O
the O
hypoxanthine B
- O
guanine B
phosphoribosyltransf O
( O
HPRT1 O
) O
protein O
, O
a O
key O
enzyme O
involved O
in O
uric B
acid I
metabolism O
and O
gout O
. O

Evaluation O
of O
suppressive O
and O
pro O
- O
resolving O
effects O
of O
EPA B
and O
DHA B
in O
human O
primary O
monocytes O
and O
T O
- O
helper O
cells O
. O

Despite O
their O
beneficial O
anti O
- O
inflammatory O
properties O
, O
eicosapentaenoic B
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
may O
increase O
the O
infection O
risk O
at O
high O
doses O
, O
likely O
by O
generating O
an O
immune O
- O
depressed O
state O
. O

To O
assess O
the O
contribution O
of O
different O
immune O
cell O
populations O
to O
the O
immunomodulatory O
fatty B
acid I
effect O
, O
we O
comparatively O
investigated O
several O
aspects O
of O
inflammation O
in O
human O
T O
- O
helper O
( O
Th O
) O
cells O
and O
monocytes O
. O

Both O
fatty B
acids I
, O
but O
DHA B
to O
a O
lesser O
extent O
compared O
with O
EPA B
, O
selectively O
and O
dose O
- O
dependently O
reduced O
the O
percentage O
of O
cytokine O
- O
expressing O
Th O
cells O
in O
a O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
gamma O
- O
dependent O
fashion O
, O
whereas O
the O
expression O
of O
the O
cell O
surface O
marker O
CD69 O
was O
unaltered O
on O
activated O
T O
cells O
. O

In O
monocytes O
, O
both O
EPA B
and O
DHA B
increased O
interleukin O
( O
IL O
) O
- O
10 O
without O
affecting O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
and O
IL O
- O
6 O
. O

Cellular O
incorporation O
of O
EPA B
and O
DHA B
occurred O
mainly O
at O
the O
expense O
of O
arachidonic B
acid I
. O

Concomitantly O
, O
thromboxane O
B O
( B
TXB I
) I
2 I
and O
leukotriene O
B O
( O
LTB O
) O
4 O
in O
supernatants O
decreased O
, O
while O
levels O
of O
TXB3 O
and O
LTB5 O
increased O
. O

Moreover O
, O
EPA B
and O
DHA B
gave O
rise O
to O
a O
variety O
of O
mono O
- O
and O
trihydroxy O
derivatives O
of O
highly O
anti O
- O
inflammatory O
potential O
, O
such O
as O
resolvins B
and O
their O
precursors O
. O

Our O
results O
suggest O
that O
EPA B
and O
DHA B
do O
not O
generally O
affect O
immune O
cell O
functions O
in O
an O
inhibitory O
manner O
but O
rather O
promote O
pro O
- O
resolving O
responses O
. O

Reduction O
of O
reactive O
oxygen B
species O
ameliorates O
metabolism O
- O
secretion O
coupling O
in O
islets O
of O
diabetic O
GK O
rats O
by O
suppressing O
lactate B
overproduction O
. O

We O
previously O
demonstrated O
that O
impaired O
glucose B
- O
induced O
insulin O
secretion O
( O
IS O
) O
and O
ATP B
elevation O
in O
islets O
of O
Goto O
- O
Kakizaki O
( O
GK O
) O
rats O
, O
a O
non O
- O
obese O
model O
of O
diabetes O
, O
were O
significantly O
restored O
by O
30 O
~ O
60 O
min O
suppression O
of O
endogenous O
reactive O
oxygen B
species O
( O
ROS O
) O
overproduction O
. O

In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
longer O
( O
12 O
h O
) O
suppression O
of O
ROS O
on O
metabolism O
- O
secretion O
coupling O
in O
beta O
- O
cells O
by O
exposure O
to O
tempol O
, O
a O
superoxide B
dismutase O
mimic O
, O
plus O
ebselen B
, O
a O
glutathione B
peroxidase O
mimic O
( O
TE O
- O
treatment O
) O
. O

In O
GK O
islets O
, O
both O
H B
( I
2 I
) I
O I
( I
2 I
) I
and O
superoxide B
were O
sufficiently O
reduced O
and O
glucose B
- O
induced O
IS O
and O
ATP B
elevation O
were O
improved O
by O
TE O
- O
treatment O
. O

Glucose B
oxidation O
, O
an O
indicator O
of O
Krebs O
cycle O
velocity O
, O
also O
was O
improved O
by O
TE O
- O
treatment O
at O
high O
glucose B
, O
whereas O
glucokinase O
activity O
, O
which O
determines O
glycolytic O
velocity O
, O
was O
not O
affected O
. O

Lactate B
production O
was O
markedly O
increased O
in O
GK O
islets O
and O
TE O
- O
treatment O
reduced O
lactate B
production O
and O
protein O
expression O
of O
lactate B
dehydrogenase O
and O
hypoxia O
- O
inducible O
factor O
1 O
alpha O
( O
HIF1 O
alpha O
) O
. O

These O
results O
indicate O
that O
the O
Warburg O
- O
like O
effect O
, O
which O
is O
characteristic O
of O
aerobic O
metabolism O
in O
cancer O
cells O
by O
which O
lactate B
is O
overproduced O
with O
reduced O
linking O
to O
mitochondria O
metabolism O
, O
plays O
an O
important O
role O
in O
impaired O
metabolism O
- O
secretion O
coupling O
in O
diabetic O
beta O
- O
cells O
and O
suggest O
that O
ROS O
reduction O
can O
improve O
mitochondrial O
metabolism O
by O
suppressinglactate O
overproduction O
through O
inhibition O
of O
HIF1 O
alpha O
stabilization O
. O

The O
HHEX O
/ O
IDE O
T2D O
locus O
is O
associated O
with O
decreased O
insulin O
secretion O
in O
response O
to O
oral O
glucose B
stimulation O
in O
humans O
. O

We O
find O
that O
glucose B
stimulated O
insulin O
secretion O
( O
GSIS O
) O
is O
decreased O
in O
Ide O
KO O
mice O
due O
to O
impaired O
replenishment O
of O
the O
releasable O
pool O
of O
granules O
and O
that O
the O
Ide O
gene O
is O
haploinsufficient O
. O

The O
NF O
kappa O
B O
inhibition O
did O
not O
affect O
blood O
glucose B
level O
and O
body O
weight O
. O

Intracellular O
drug O
release O
from O
curcumin B
- O
loaded O
PLGA B
nanoparticles O
induces O
G2 O
/ O
M O
block O
in O
breast O
cancer O
cells O
. O

PLGA B
nanoparticles O
are O
among O
the O
most O
studied O
polymer O
nanoformulations O
for O
several O
drugs O
against O
different O
kinds O
of O
malignant O
diseases O
, O
thanks O
to O
their O
in O
vivo O
stability O
and O
tumor O
localization O
exploiting O
the O
well O
- O
documented O
" O
enhanced O
permeation O
and O
retention O
" O
( O
EPR O
) O
effect O
. O

In O
this O
paper O
, O
we O
have O
developed O
uniform O
curcumin B
- O
bearing O
PLGA B
nanoparticles O
by O
a O
single O
- O
emulsion O
process O
, O
which O
exhibited O
a O
curcumin B
release O
following O
a O
Fickian O
- O
law O
diffusion O
over O
10 O
days O
in O
vitro O
. O

PLGA B
nanoparticles O
were O
about O
120 O
nm O
in O
size O
, O
as O
determined O
by O
dynamic O
light O
scattering O
, O
with O
a O
surface O
negative O
charge O
of O
- O
30 O
mV O
. O

The O
loading O
ratio O
of O
encapsulated O
drug O
in O
our O
PLGA B
nanoformulation O
was O
8 O
wt O
% O
. O

PLGA B
encapsulation O
provided O
efficient O
protection O
of O
curcumin B
from O
environment O
, O
as O
determined O
by O
fluorescence O
emission O
experiments O
. O

Next O
, O
we O
have O
investigated O
the O
possibility O
to O
study O
the O
intracellular O
degradation O
of O
nanoparticles O
associated O
with O
a O
specific O
G2 O
/ O
M O
blocking O
effect O
on O
MCF7 O
breast O
cancer O
cells O
caused O
by O
curcumin B
release O
in O
the O
cytoplasm O
, O
which O
provided O
direct O
evidence O
on O
the O
mechanism O
of O
action O
of O
our O
nanocomplex O
. O

This O
study O
was O
carried O
out O
using O
Annexin O
V O
- O
based O
cell O
death O
analysis O
, O
MTT B
assessment O
of O
proliferation O
, O
flow O
cytometry O
, O
and O
confocal O
laser O
scanning O
microscopy O
. O

PLGA B
nanoparticles O
proved O
to O
be O
completely O
safe O
, O
suggesting O
a O
potential O
utilization O
of O
this O
nanocomplex O
to O
improve O
the O
intrinsically O
poor O
bioavailability O
of O
curcumin B
for O
the O
treatment O
of O
severe O
malignant O
breast O
cancer O
. O

Thus O
, O
using O
computational O
molecular O
docking O
, O
a O
virtual O
screen O
of O
a O
library O
of O
small O
molecules O
, O
including O
xanthones B
and O
flavonoids B
( O
described O
with O
potential O
for O
antiviral O
activity O
against O
EBV O
) O
, O
was O
carried O
out O
targeting O
EBV O
proteins O
. O

Chemoselective O
Dieckmann O
cyclization O
reactions O
may O
be O
used O
on O
oxazolidine O
and O
thiazolidine B
templates O
derived O
from O
various O
aldehydes B
to O
access O
bicyclic O
tetramates O
, O
which O
have O
potential O
as O
templates O
for O
chemical O
library O
construction O
. O

Pyrrolopyrazines O
as O
Selective O
Spleen O
Tyrosine B
Kinase O
Inhibitors O
. O

Termini O
of O
bottom O
- O
up O
fabricated O
graphene B
nanoribbons O
. O

Atomically O
precise O
graphene B
nanoribbons O
( O
GNRs O
) O
can O
be O
obtained O
via O
thermally O
induced O
polymerization O
of O
suitable O
precursor O
molecules O
on O
a O
metal O
surface O
. O

By O
combining O
STM O
experiments O
with O
large O
- O
scale O
density O
functional O
theory O
calculations O
, O
we O
demonstrate O
that O
the O
termini O
are O
passivated O
by O
hydrogen B
. O

Our O
results O
suggest O
that O
the O
length O
of O
nanoribbons O
grown O
by O
this O
protocol O
may O
be O
limited O
by O
hydrogen B
passivation O
during O
the O
polymerization O
step O
. O

Copper B
( I
I I
) I
- O
catalyzed O
borylative O
exo O
- O
cyclization O
of O
alkenyl O
halides O
containing O
unactivated O
double O
bond O
. O

The O
reaction O
includes O
the O
regioselective O
addition O
of O
a O
borylcopper O
( O
I O
) O
intermediate O
to O
unactivated O
terminal O
alkenes B
, O
followed O
by O
the O
intramolecular O
substitution O
of O
the O
resulting O
alkylcopper O
( O
I O
) O
moiety O
for O
the O
halide B
leaving O
groups O
. O

In O
particular O
, O
compounds O
from O
the O
' O
tonifying O
and O
replenishing O
medicinal O
' O
class O
from O
TCM O
exhibit O
a O
hypoglycemic O
effect O
which O
can O
be O
related O
to O
activity O
of O
the O
ingredients O
against O
the O
Sodium B
- O
Glucose B
Transporters O
( O
SGLT O
) O
1 O
and O
2 O
as O
well O
as O
Protein O
Tyrosine B
Phosphatase O
( O
PTP O
) O
. O

Here O
, O
both O
primary O
anticancer O
targets O
( O
those O
directly O
involved O
in O
cancer O
pathogenesis O
) O
such O
as O
steroid B
- O
5 O
- O
alpha O
- O
reductase O
1 O
and O
2 O
were O
predicted O
as O
well O
as O
targets O
which O
act O
synergistically O
with O
the O
primary O
target O
, O
such O
as O
the O
efflux O
pump O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
. O

Pharmacokinetics O
, O
tissue O
distribution O
and O
excretion O
study O
of O
resveratrol B
and O
its O
prodrug O
3 O
, O
5 O
, O
4 O
' O
- O
tri O
- O
O O
- O
acetylresveratrol O
in O
rats O
. O

3 O
, O
5 O
, O
4 O
' O
- O
Tri O
- O
O O
- O
acetylresveratrol O
( O
TARES O
) O
synthesized O
by O
acetylating O
three O
hydroxyl B
groups O
of O
resveratrol B
( O
RES B
) O
is O
a O
prodrug O
of O
RES B
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
and O
compare O
the O
pharmacokinetics O
, O
tissue O
distribution O
and O
excretion O
of O
TARES O
and O
RES B
in O
rats O
following O
a O
single O
intragastric O
gavage O
( O
i O
. O
g O
. O
) O
administration O
. O

After O
RES B
is O
transformed O
into O
TARES O
, O
its O
pharmacokinetic O
properties O
are O
improved O
, O
such O
as O
the O
t1 O
/ O
2 O
has O
been O
prolonged O
and O
the O
AUC O
has O
been O
enhanced O
. O

The O
major O
distribution O
tissues O
of O
TARES O
or O
RES B
in O
rats O
were O
liver O
, O
spleen O
, O
heart O
and O
lung O
. O

TARES O
can O
increase O
the O
content O
of O
RES B
in O
lung O
significantly O
. O

There O
was O
no O
long O
- O
term O
accumulation O
of O
RES B
in O
rat O
tissues O
. O

Whether O
we O
administrated O
to O
rats O
of O
equimolar O
TARES O
or O
RES B
, O
total O
recoveries O
of O
RES B
in O
urine O
and O
feces O
within O
36h O
were O
low O
( O
0 O
. O
99 O
% O
or O
0 O
. O
07 O
% O
in O
urine O
and O
1 O
. O
69 O
% O
or O
0 O
. O
15 O
% O
in O
feces O
) O
. O

Development O
of O
amino O
- O
pyrimidine O
inhibitors O
of O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
: O
kinase O
profiling O
guided O
optimization O
of O
a O
1 O
, O
2 O
, O
3 O
- O
benzotriazole O
lead O
. O

A O
beta O
11 O
- O
42 O
and O
[ O
Pyr O
( O
11 O
) O
] O
A O
beta O
11 O
- O
42 O
showed O
comparable O
aggregation O
capability O
and O
cytotoxicity O
, O
suggesting O
that O
the O
pyroglutamate O
modification O
at O
Glu B
( O
11 O
) O
does O
not O
have O
a O
crucial O
role O
in O
these O
events O
. O

However O
, O
given O
that O
A O
beta O
11 O
- O
42 O
is O
converted O
to O
[ O
Pyr O
( O
11 O
) O
] O
A O
beta O
11 O
- O
42 O
by O
a O
glutamyl B
cyclase O
in O
vivo O
, O
the O
potential O
aggregative O
and O
cytotoxic O
nature O
of O
[ O
Pyr O
( O
11 O
) O
] O
A O
beta O
11 O
- O
42 O
that O
was O
observed O
in O
the O
present O
study O
provides O
valuable O
insights O
into O
the O
pathological O
functions O
of O
pyroglutamate O
- O
modified O
A O
beta O
species O
in O
Alzheimer O
' O
s O
disease O
. O

Cohort O
studies O
suggest O
that O
women O
with O
oophorectomy O
are O
at O
greater O
risk O
for O
CHD O
than O
intact O
women O
, O
pointing O
to O
a O
greater O
risk O
from O
testosterone B
deficiency O
than O
from O
estradiol B
levels O
. O

Perfluorocarbon O
- O
loaded O
lipid O
nanocapsules O
as O
oxygen B
sensors O
for O
tumor O
tissue O
pO O
( O
2 O
) O
assessment O
. O

The O
assessment O
of O
tumor O
oxygenation O
is O
a O
crucial O
factor O
in O
cancer O
therapy O
and O
may O
be O
carried O
out O
using O
fluorine B
MRI O
once O
fluorine B
probes O
have O
been O
distributed O
within O
the O
tumor O
. O

In O
this O
study O
, O
perfluoropentane O
( O
PFC5 O
) O
emulsions O
were O
encapsulated O
inside O
folated O
eLiposomes O
carrying O
a O
model O
drug O
( O
calcein B
) O
or O
a O
model O
GFP O
plasmid O
to O
examine O
the O
effects O
of O
a O
folate B
ligand O
, O
PFC5 O
emulsion O
and O
various O
ultrasonic O
acoustic O
parameters O
in O
drug O
delivery O
and O
gene O
transfection O
into O
HeLa O
cells O
. O

The O
results O
showed O
that O
drug O
delivery O
or O
transfection O
was O
minimal O
without O
incorporation O
of O
internal O
PFC5 O
emulsions O
and O
folate B
ligand O
on O
the O
eLiposome O
surface O
. O

One O
of O
the O
most O
popular O
models O
to O
evaluate O
the O
hepatoprotective O
potential O
of O
natural O
products O
is O
acetaminophen B
( O
APAP B
) O
- O
induced O
liver O
injury O
, O
although O
other O
hepatotoxicity O
models O
such O
as O
carbon B
tetrachloride I
, O
thioacetamide O
, O
ethanol B
and O
endotoxin O
are O
occasionally O
used O
. O

APAP B
overdose O
is O
a O
clinically O
relevant O
model O
of O
drug O
- O
induced O
liver O
injury O
. O

Although O
there O
is O
increasing O
understanding O
of O
the O
pathophysiology O
of O
APAP B
- O
induced O
liver O
injury O
, O
the O
mechanism O
is O
complex O
and O
prone O
to O
misinterpretation O
, O
especially O
when O
unknown O
chemicals O
such O
as O
plant O
extracts O
are O
tested O
. O

The O
phages O
were O
dried O
in O
the O
presence O
of O
lactose B
, O
trehalose O
or O
dextran O
35 O
, O
serving O
as O
an O
excipient O
to O
give O
the O
resulting O
powder O
the O
necessary O
bulk O
mass O
and O
offer O
protection O
to O
the O
delicate O
phage O
structure O
. O

Sonhafouonic O
acid O
, O
a O
new O
cytotoxic O
and O
antifungal O
hopene O
- O
triterpenoid B
from O
Zehneria O
scabra O
camerunensis O
. O

A O
new O
hopene O
- O
type O
triterpenoid B
, O
namely O
sonhafouonic O
acid O
1a O
was O
isolated O
from O
Zehneria O
scabra O
camerunensis O
, O
together O
with O
eight O
known O
compounds O
. O

Two O
new O
isoprenylated O
chromone O
derivatives O
, O
pestaloficiols O
Q O
( O
1 O
) O
and O
R O
( O
2 O
) O
, O
and O
one O
new O
benzofuran B
derivative O
, O
pestaloficiol O
S O
( O
3 O
) O
, O
along O
with O
three O
known O
metabolites O
, O
anofinic O
acid O
( O
4 O
) O
, O
siccayne O
( O
5 O
) O
, O
and O
pyrenophorol O
( O
6 O
) O
were O
isolated O
from O
solid O
cultures O
of O
the O
plant O
endophytic O
fungus O
Pestalotiopsis O
fici O
. O

Anti O
- O
hepatitis O
B O
virus O
and O
anti O
- O
cancer O
activities O
of O
novel O
isoflavone B
analogs O
. O

We O
have O
synthesized O
a O
series O
of O
novel O
isoflavone B
analogs O
and O
evaluated O
their O
anti O
- O
HBV O
and O
anti O
- O
cancer O
activities O
in O
vitro O
. O

Design O
, O
synthesis O
and O
SAR O
of O
piperidyl O
- O
oxadiazoles O
as O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
1 O
inhibitors O
. O

To O
find O
potent O
compounds O
with O
good O
pharmacokinetics O
, O
we O
used O
the O
bioisosterism O
approach O
, O
and O
designed O
the O
compound O
2 O
and O
3 O
bearing O
an O
1 O
, O
2 O
, O
4 O
- O
oxadiazole O
ring O
to O
replace O
the O
amide B
group O
in O
compound O
1 O
. O

Guided O
by O
docking O
study O
, O
we O
then O
transformed O
compound O
3 O
into O
a O
potent O
lead O
compound O
4a O
by O
changing O
sulfonamide B
group O
to O
amide B
. O

The O
most O
active O
derivatives O
toward O
all O
the O
cell O
lines O
tested O
bear O
alkyl B
substituents O
on O
the O
aroyl O
moiety O
of O
the O
molecules O
. O

Design O
, O
synthesis O
and O
biological O
evaluation O
of O
novel O
hybrid O
compounds O
of O
imidazole B
scaffold O
- O
based O
2 O
- O
benzylbenzofuran O
as O
potent O
anticancer O
agents O
. O

A O
series O
of O
novel O
hybrid O
compounds O
between O
2 O
- O
benzylbenzofuran O
and O
imidazole B
has O
been O
prepared O
and O
evaluated O
in O
vitro O
against O
a O
panel O
of O
human O
tumor O
cell O
lines O
. O

The O
results O
suggest O
that O
the O
existence O
of O
benzimidazole B
ring O
and O
substitution O
of O
the O
imidazolyl O
- O
3 O
- O
position O
with O
a O
naphthylacyl O
or O
4 O
- O
methoxyphenacyl O
group O
were O
vital O
for O
modulating O
cytotoxic O
activity O
. O

In O
particular O
, O
hybrid O
compounds O
46 O
and O
47 O
were O
found O
to O
be O
the O
most O
potent O
derivatives O
against O
5 O
strains O
human O
tumor O
cell O
lines O
and O
more O
active O
than O
cisplatin B
( O
DDP O
) O
, O
and O
exhibited O
cytotoxic O
activities O
selectively O
against O
breast O
carcinoma O
( O
MCF O
- O
7 O
) O
and O
myeloid O
liver O
carcinoma O
( O
SMMC O
- O
7721 O
) O
, O
respectively O
. O

Herein O
we O
report O
the O
investigation O
of O
terpolymeric O
contrast O
agent O
for O
magnetic O
resonance O
imaging O
and O
doxorubicin B
( O
Dox B
) O
delivery O
. O

The O
polymer O
was O
synthesized O
by O
graft O
polymerization O
of O
methacrylic B
acid I
( O
MAA O
) O
and O
polysorbate O
80 O
( O
PS O
80 O
) O
onto O
starch O
with O
multiple O
, O
chemically O
bound O
diethylenetriaminepe O
acetic O
acid O
( O
DTPA B
) O
groups O
for O
gadolinium B
chelating O
. O

The O
terpolymer O
self O
- O
assembled O
to O
form O
nanoparticles O
upon O
addition O
of O
doxorubicin B
which O
binds O
with O
the O
PMAA O
chain O
. O

The O
polymer O
was O
able O
to O
load O
gadolinium B
with O
high O
thermodynamic O
stability O
and O
exhibited O
low O
cytotoxicity O
. O

The O
Gd B
- O
loaded O
polymer O
( O
PolyGd O
) O
, O
and O
Gd B
- O
Dox B
co O
- O
loaded O
nanoparticles O
( O
PolyGd O
- O
Dox O
) O
significantly O
enhanced O
MR O
signals O
, O
with O
ionic O
T1 O
relaxivities O
3 O
- O
5 O
times O
higher O
than O
those O
from O
Omniscan O
( O
R O
) O
, O
a O
small O
molecule O
contrast O
agent O
. O

The O
PolyGd O
and O
PolyGd O
- O
Dox B
accumulated O
in O
the O
tumor O
and O
painted O
the O
tumor O
boundaries O
clearly O
for O
at O
least O
48h O
. O

Seven O
days O
after O
intravenous O
administration O
, O
only O
relatively O
small O
amounts O
of O
gadolinium B
could O
be O
detected O
in O
the O
major O
organs O
of O
the O
mice O
( O
supplementary O
materials O
) O
. O

These O
results O
suggest O
that O
the O
new O
terpolymeric O
system O
is O
useful O
as O
a O
theranostic O
platform O
for O
contrast O
enhanced O
MR O
imaging O
of O
vasculature O
and O
tumor O
as O
well O
as O
Dox B
delivery O
. O

Silica B
- O
lipid O
hybrid O
( O
SLH O
) O
formulations O
enhance O
the O
oral O
bioavailability O
and O
efficacy O
of O
celecoxib B
: O
An O
in O
vivo O
evaluation O
. O

This O
study O
is O
the O
first O
to O
demonstrate O
in O
canines O
the O
ability O
of O
silica B
- O
lipid O
hybrid O
( O
SLH O
) O
microparticles O
to O
enhance O
the O
bioavailability O
and O
efficacy O
of O
a O
poorly O
water O
- O
soluble O
drug O
after O
oral O
administration O
. O

Spray O
- O
dried O
SLH O
microparticles O
comprising O
Capmul O
MCM O
( O
mono O
- O
diglycerides O
of O
C8 O
/ O
C12 O
fatty B
acids I
) O
and O
silica B
nanoparticles O
( O
Aerosil B
( O
R O
) O
380 O
) O
were O
shown O
to O
significantly O
enhance O
the O
fasted O
state O
oral O
bioavailability O
of O
celecoxib B
( O
CEL O
) O
( O
6 O
. O
5 O
fold O
, O
relative O
to O
an O
aqueous O
suspension O
and O
more O
than O
2 O
- O
fold O
higher O
relative O
to O
the O
fed O
state O
) O
after O
oral O
administration O
to O
beagle O
dogs O
. O

We O
hypothesise O
that O
the O
presence O
of O
silica B
in O
the O
formulation O
may O
have O
contributed O
to O
the O
prevention O
of O
drug O
precipitation O
in O
the O
intestinal O
lumen O
by O
providing O
an O
alternative O
binding O
site O
for O
CEL O
to O
adsorb O
to O
prior O
to O
re O
- O
solubilisation O
and O
absorption O
. O

Gender O
- O
specific O
effects O
of O
fluoxetine B
on O
hippocampal O
glucocorticoid O
receptor O
phosphorylation O
and O
behavior O
in O
chronically O
stressed O
rats O
. O

The O
current O
study O
investigated O
potential O
gender O
specificities O
regarding O
the O
effect O
of O
chronic O
therapy O
by O
an O
antidepressant O
fluoxetine B
( O
FLU O
) O
on O
GR O
signaling O
in O
HIPPO O
and O
depressive O
- O
like O
behavior O
in O
CPSI O
animals O
. O

FLU O
was O
administrated O
to O
female O
and O
male O
na O
i O
ve O
or O
CPSI O
rats O
for O
21 O
days O
and O
GR O
protein O
, O
its O
phosphorylation O
status O
and O
upstream O
kinases O
, O
as O
well O
as O
GR O
and O
BDNF O
mRNA O
were O
followed O
in O
HIPPO O
together O
with O
animal O
serum O
corticosterone B
( O
CORT B
) O
and O
depressive O
- O
like O
behavior O
. O

In O
contrast O
, O
in O
both O
genders O
CPSI O
increased O
the O
nuclear O
levels O
of O
GR O
and O
pGR246 O
but O
decreased O
CORT B
and O
mRNA O
levels O
of O
GR O
and O
BDNF O
. O

In O
both O
females O
and O
males O
, O
FLU O
reversed O
the O
nuclear O
levels O
of O
GR O
and O
pGR246 O
without O
affecting O
CORT B
and O
GR O
mRNA O
levels O
. O

Improved O
pharmaceutical O
stability O
of O
a O
boronphenylalanine O
mannitol O
formulation O
for O
boron B
neutron O
capture O
therapy O
. O

Boron B
neutron O
capture O
therapy O
( O
BNCT O
) O
is O
a O
radiotherapy O
based O
cancer O
treatment O
requiring O
the O
availability O
of O
a O
low O
energy O
thermal O
neutron O
beam O
and O
a O
boron B
containing O
drug O
. O

These O
requirements O
limit O
BNCT O
availability O
with O
the O
latter O
pharmaceutical O
issue O
related O
to O
the O
extremely O
short O
shelf O
- O
life O
and O
clinical O
acceptability O
of O
the O
current O
fructose B
based O
L O
- O
boronphenylalanine O
( O
BPA B
) O
formulation O
. O

After O
suitable O
periods O
the O
formulation O
was O
analysed O
by O
HPLC O
for O
BPA B
and O
degradation O
products O
. O

Lyophilised O
and O
solution O
mannitol O
BPA O
formulations O
exhibited O
a O
temperature O
and O
time O
dependent O
loss O
of O
BPA B
with O
concomitant O
increases O
in O
degradation O
products O
. O

A O
solution O
or O
lyophilised O
mannitol O
BPA O
formulation O
has O
a O
shelf O
- O
life O
of O
between O
1 O
and O
4 O
years O
respectively O
, O
a O
marked O
improvement O
over O
the O
current O
fructose B
formulation O
. O

The O
enhanced O
stability O
of O
the O
mannitol B
formulation O
removes O
the O
requirement O
for O
extemporaneous O
aseptic O
preparation O
of O
BPA B
just O
prior O
to O
treatment O
and O
eliminates O
one O
of O
the O
issues O
complicating O
the O
delivery O
of O
BNCT O
. O

CIT O
can O
co O
- O
occur O
with O
ochratoxin B
A I
( O
OTA O
) O
, O
a O
mycotoxin O
also O
known O
for O
its O
nephrotoxicity O
, O
and O
this O
raises O
concern O
regarding O
possible O
combined O
effects O
. O

Crude O
composition O
, O
fatty B
acids I
, O
sterols B
, O
total O
phenolic O
content O
( O
TPC O
) O
, O
individual O
polyphenols B
and O
terpenic O
acids O
were O
determined O
in O
five O
wild O
edible O
mushrooms O
species O
( O
Lactarius O
deliciosus O
, O
Lactarius O
sanguifluus O
, O
Lactarius O
semisanguifluus O
, O
Russula O
delica O
, O
Suillus O
bellinii O
) O
from O
Lesvos O
Island O
, O
Greece O
. O

In O
addition O
, O
the O
DPPH B
scavenging O
capacity O
, O
the O
ferric B
ion O
reducing O
power O
( O
FRAP O
) O
and O
the O
ferrous B
ion O
chelating O
activity O
of O
mushroom O
methanolic O
extracts O
were O
assessed O
. O

Among O
sterols B
, O
ergosterol B
predominated O
at O
concentrations O
9 O
. O
2 O
- O
18 O
. O
0mg O
/ O
100g O
fw O
. O

Up O
to O
19 O
simple O
polyphenols B
were O
determined O
in O
mushrooms O
extracts O
, O
the O
more O
abundant O
being O
p O
- O
OH O
- O
benzoic O
acid O
, O
p O
- O
OH O
- O
phenylacetic O
acid O
, O
o O
- O
coumaric O
acid O
, O
ferulic B
acid I
and O
chrysin B
. O

All O
species O
exerted O
antioxidant O
activity O
and O
ferrous B
ion O
chelating O
capacity O
. O

Principal O
component O
analysis O
revealed O
good O
correlations O
between O
TPC O
, O
DPPH B
and O
FRAP O
but O
not O
with O
metal O
chelating O
activity O
. O

It O
seems O
that O
mushrooms O
polyphenols B
exert O
antiradical O
and O
reducing O
activities O
, O
but O
they O
are O
not O
strong O
metal O
chelators O
, O
the O
observed O
chelating O
ability O
being O
probably O
due O
to O
other O
classes O
of O
compounds O
. O

Subchronic O
memantine B
induced O
concurrent O
functional O
disconnectivity O
and O
altered O
ultra O
- O
structural O
tissue O
integrity O
in O
the O
rodent O
brain O
: O
revealed O
by O
multimodal O
MRI O
. O

BACKGROUND O
: O
An O
effective O
NMDA B
antagonist O
imaging O
model O
may O
find O
key O
utility O
in O
advancing O
schizophrenia O
drug O
discovery O
research O
. O

We O
investigated O
effects O
of O
subchronic O
treatment O
with O
the O
NMDA B
antagonist O
memantine B
by O
using O
behavioural O
observation O
and O
multimodal O
MRI O
. O

METHODS O
: O
Pharmacological O
MRI O
( O
phMRI O
) O
was O
used O
to O
map O
the O
neuroanatomical O
binding O
sites O
of O
memantine B
after O
acute O
and O
subchronic O
treatment O
. O

Resting O
state O
fMRI O
( O
rs O
- O
fMRI O
) O
and O
diffusion O
MRI O
were O
used O
to O
study O
the O
changes O
in O
functional O
connectivity O
( O
FC O
) O
and O
ultra O
- O
structural O
tissue O
integrity O
before O
and O
after O
subchronic O
memantine B
treatment O
. O

RESULTS O
: O
Dose O
- O
dependent O
phMRI O
activation O
was O
observed O
in O
the O
prelimbic O
cortex O
following O
acute O
doses O
of O
memantine B
. O

Limited O
behavioural O
assessment O
suggested O
that O
memantine B
induced O
behavioural O
effects O
comparable O
to O
other O
NMDA B
antagonists O
as O
measured O
by O
locomotor O
hyperactivity O
and O
that O
the O
effects O
could O
be O
reversed O
by O
antipsychotic O
drugs O
. O

CONCLUSION O
: O
Our O
findings O
substantiate O
the O
hypothesis O
that O
repeated O
NMDA B
receptor O
blockade O
with O
nonspecific O
, O
noncompetitive O
NMDA B
antagonists O
may O
lead O
to O
functional O
and O
ultra O
- O
structural O
alterations O
, O
particularly O
in O
the O
hippocampus O
and O
cingulate O
cortex O
. O

Furthermore O
, O
the O
present O
findings O
underscore O
the O
utility O
and O
the O
translational O
potential O
of O
multimodal O
MR O
imaging O
and O
acute O
/ O
subchronic O
memantine B
model O
in O
the O
search O
for O
novel O
disease O
- O
modifying O
treatments O
for O
schizophrenia O
. O

A O
prospective O
study O
of O
selenium B
concentration O
and O
risk O
of O
preeclampsia O
in O
pregnant O
Iranian O
women O
: O
a O
nested O
case O
- O
control O
study O
. O

Some O
studies O
implicate O
poor O
maternal O
selenium B
status O
predisposing O
the O
mother O
to O
preeclampsia O
. O

This O
study O
was O
designed O
to O
determine O
changes O
in O
plasma O
selenium B
levels O
in O
women O
having O
preeclampsia O
as O
compared O
with O
those O
with O
normal O
pregnancy O
. O

After O
3 O
months O
of O
follow O
- O
up O
of O
all O
subjects O
, O
blood O
selenium B
levels O
were O
measured O
in O
38 O
women O
presenting O
consecutively O
with O
preeclampsia O
and O
in O
38 O
women O
having O
a O
normal O
pregnancy O
by O
atomic O
absorption O
spectrophotometry O
. O

The O
selenium B
concentrations O
in O
plasma O
in O
women O
with O
preeclampsia O
were O
significantly O
lower O
as O
compared O
with O
those O
in O
women O
with O
normal O
pregnancy O
( O
70 O
. O
63 O
+ O
/ O
- O
21 O
. O
41 O
versus O
82 O
. O
03 O
+ O
/ O
- O
15 O
. O
54 O
mu O
g O
/ O
L O
, O
p O
< O
0 O
. O
05 O
) O
. O

Being O
in O
the O
bottom O
tertile O
of O
selenium B
concentration O
( O
less O
than O
62 O
. O
2 O
mu O
g O
/ O
L O
) O
was O
associated O
with O
greater O
risk O
of O
preeclampsia O
in O
pregnant O
women O
. O

The O
reduced O
selenium B
in O
the O
maternal O
circulations O
observed O
in O
the O
preeclamptic O
mothers O
support O
the O
hypothesis O
that O
insufficient O
selenium B
concentration O
may O
be O
a O
contributing O
factor O
to O
the O
pathophysiological O
mechanisms O
associated O
with O
preeclampsia O
, O
and O
optimizing O
the O
dietary O
selenium B
intake O
through O
supplementation O
could O
produce O
demonstrable O
clinical O
benefits O
. O

Environmental O
concentrations O
and O
bioaccumulations O
of O
cadmium B
and O
zinc B
in O
coastal O
watersheds O
along O
the O
Chinese O
Northern O
Bohai O
and O
Yellow O
Seas O
. O

Cadmium B
( O
Cd B
) O
and O
zinc B
( O
Zn B
) O
in O
surface O
water O
, O
sediment O
, O
carp O
, O
and O
crab O
samples O
collected O
from O
upstream O
and O
downstream O
regions O
of O
coastal O
watersheds O
along O
the O
Chinese O
Northern O
Bohai O
and O
Yellow O
Seas O
were O
analyzed O
to O
provide O
a O
comprehensive O
understanding O
and O
assessment O
of O
their O
environmental O
concentrations O
and O
bioaccumulations O
. O

The O
results O
showed O
that O
downstream O
waters O
contaminated O
with O
Zn B
would O
have O
adverse O
effects O
on O
aquatic O
organisms O
. O

Although O
nearly O
all O
sediments O
were O
contaminated O
with O
Cd B
due O
to O
human O
activities O
, O
little O
potential O
existed O
for O
Cd B
toxicity O
in O
sediment O
- O
dwelling O
fauna O
. O

Concentrations O
of O
Cd B
and O
Zn B
in O
most O
water O
, O
sediment O
, O
carp O
, O
and O
crab O
were O
less O
than O
published O
values O
. O

The O
downstream O
carp O
and O
crabs O
had O
higher O
mean O
bioaccumulation O
factors O
and O
biota O
- O
sediment O
accumulation O
factors O
for O
Cd B
but O
lower O
mean O
biota O
- O
sediment O
accumulation O
factors O
for O
Zn B
than O
the O
upstream O
carp O
and O
crabs O
. O

Based O
on O
the O
relationships O
among O
Cd B
and O
Zn B
concentrations O
in O
water O
, O
sediment O
, O
and O
biota O
, O
the O
authors O
conclude O
that O
Cd B
and O
Zn B
in O
crabs O
primarily O
derived O
from O
sediment O
exposure O
. O

Although O
Cd B
and O
Zn B
in O
water O
and O
sediment O
originated O
from O
some O
of O
the O
same O
sources O
, O
the O
sources O
of O
Cd B
or O
Zn B
in O
water O
were O
likely O
different O
from O
those O
in O
sediment O
. O

3 B
- I
Methylglutaconic I
aciduria O
- O
lessons O
from O
50 O
genes O
and O
977 O
patients O
. O

Elevated O
urinary O
excretion O
of O
3 B
- I
methylglutaconic I
acid I
is O
considered O
rare O
in O
patients O
suspected O
of O
a O
metabolic O
disorder O
. O

In O
3 B
- I
methylglutaconyl I
- I
CoA I
hydratase O
deficiency O
( O
mutations O
in O
AUH O
) O
, O
it O
derives O
from O
leucine B
degradation O
. O

In O
all O
other O
disorders O
with O
3 B
- I
methylglutaconic I
aciduria O
the O
origin O
is O
unknown O
, O
yet O
mitochondrial O
dysfunction O
is O
thought O
to O
be O
the O
common O
denominator O
. O

We O
investigate O
the O
biochemical O
, O
clinical O
and O
genetic O
data O
of O
388 O
patients O
referred O
to O
our O
centre O
under O
suspicion O
of O
a O
metabolic O
disorder O
showing O
3 B
- I
methylglutaconic I
aciduria O
in O
routine O
metabolic O
screening O
. O

Furthermore O
, O
we O
investigate O
591 O
patients O
with O
50 O
different O
, O
genetically O
proven O
, O
mitochondrial O
disorders O
for O
the O
presence O
of O
3 B
- I
methylglutaconic I
aciduria O
. O

Three O
percent O
of O
all O
urine O
samples O
of O
the O
patients O
referred O
showed O
3 B
- I
methylglutaconic I
aciduria O
, O
often O
in O
correlation O
with O
disorders O
not O
reported O
earlier O
in O
association O
with O
3 B
- I
methylglutaconic I
aciduria O
( O
e O
. O
g O
. O
organic O
acidurias O
, O
urea B
cycle O
disorders O
, O
haematological O
and O
neuromuscular O
disorders O
) O
. O

In O
the O
patient O
cohort O
with O
genetically O
proven O
mitochondrial O
disorders O
11 O
% O
presented O
3 B
- I
methylglutaconic I
aciduria O
. O

3 B
- I
methylglutaconic I
aciduria O
is O
found O
quite O
frequently O
in O
patients O
suspected O
of O
a O
metabolic O
disorder O
, O
and O
mitochondrial O
dysfunction O
is O
indeed O
a O
common O
denominator O
. O

These O
conditions O
should O
therefore O
be O
referred O
to O
as O
inborn O
errors O
of O
metabolism O
with O
3 B
- I
methylglutaconic I
aciduria O
as O
discriminative O
feature O
. O

Gas O
Dielectric O
Transistor O
of O
CuPc O
Single O
Crystalline O
Nanowire O
for O
SO2 B
Detection O
Down O
to O
Sub O
- O
ppm O
Levels O
at O
Room O
Temperature O
. O

A O
room O
- O
temperature O
highly O
- O
sensitive O
SO2 B
sensor O
with O
fast O
response O
and O
complete O
recovery O
is O
constructed O
based O
on O
gas O
dielectric O
field O
- O
effect O
transistor O
( O
FET O
) O
of O
CuPc O
single O
crystalline O
nanowire O
. O

The O
exposed O
conductive O
channel O
by O
gas O
dielectric O
is O
responsible O
for O
the O
high O
sensitivity O
to O
SO2 B
and O
the O
adsorption O
of O
the O
SO2 B
molecules O
dramatically O
enhances O
the O
field O
- O
effect O
mobility O
. O

These O
results O
not O
only O
open O
up O
new O
opportunities O
to O
develop O
new O
SO2 B
sensors O
, O
but O
also O
provide O
an O
efficient O
way O
to O
improve O
the O
performance O
of O
organic O
FETs O
. O

Efficient O
stacking O
on O
protein O
amide B
fragments O
. O

The O
less O
polar O
pi O
- O
surface O
of O
protein O
amide B
groups O
is O
exposed O
in O
many O
receptor O
binding O
sites O
, O
either O
as O
part O
of O
the O
backbone O
or O
in O
Gln B
/ O
Asn B
side O
chains O
. O

Using O
quantum O
chemical O
calculations O
and O
Protein O
Data O
Bank O
( O
PDB O
) O
searches O
on O
model O
systems O
, O
we O
investigate O
the O
energetics O
and O
geometric O
preferences O
for O
the O
stacking O
on O
amide B
groups O
of O
a O
large O
number O
of O
heteroarenes B
that O
are O
relevant O
to O
medicinal O
chemistry O
. O

From O
this O
study O
, O
we O
discern O
that O
the O
stacking O
energy O
of O
an O
aromatic O
ligand O
substituent O
can O
be O
improved O
by O
: O
1 O
) O
orienting O
the O
fragment O
dipole O
vector O
such O
that O
it O
is O
aligned O
in O
an O
antiparallel O
fashion O
with O
the O
dipole O
of O
the O
interacting O
protein O
amide B
group O
, O
2 O
) O
increasing O
its O
dipole O
moment O
, O
and O
3 O
) O
decreasing O
its O
pi O
- O
electron O
density O
. O

Lapatinib B
- O
mediated O
cyclooxygenase O
- O
2 O
expression O
via O
epidermal O
growth O
factor O
receptor O
/ O
HuR O
interaction O
enhances O
the O
aggressiveness O
of O
triple O
- O
negative O
breast O
cancer O
cells O
. O

Lapatinib B
, O
a O
dual O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
/ O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
kinase O
inhibitor O
, O
showed O
clinical O
benefits O
in O
advanced O
HER2 O
- O
positive O
breast O
cancer O
patients O
. O

Because O
some O
triple O
- O
negative O
breast O
cancers O
( O
TNBCs O
) O
frequently O
overexpress O
EGFR O
, O
the O
antitumor O
activity O
of O
lapatinib B
in O
such O
diseases O
was O
also O
tested O
. O

It O
remains O
unknown O
whether O
and O
how O
lapatinib B
elicits O
the O
aggressiveness O
of O
such O
cancer O
cells O
. O

In O
this O
study O
, O
our O
results O
demonstrated O
that O
lapatinib B
facilitated O
axillary O
and O
lung O
metastases O
of O
triple O
- O
negative O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
without O
affecting O
their O
viability O
, O
leading O
to O
worse O
survival O
in O
orthotopic O
xenograft O
mice O
. O

The O
lapatinib B
- O
increased O
motility O
was O
attributed O
by O
the O
elevation O
of O
EGFR O
through O
the O
downregulation O
of O
microRNA O
- O
7 O
and O
by O
the O
subsequent O
overexpression O
of O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
. O

Our O
results O
suggest O
that O
lapatinib B
may O
increase O
the O
migration O
and O
invasion O
of O
MDA O
- O
MB O
- O
231 O
cells O
by O
upregulating O
EGFR O
and O
COX O
- O
2 O
through O
the O
downregulation O
of O
microRNA O
- O
7 O
, O
providing O
a O
potential O
explanation O
for O
the O
worse O
clinical O
outcome O
of O
TNBC O
patients O
who O
receive O
lapatinib B
- O
based O
treatment O
. O

Dispersion O
and O
Filtration O
of O
Carbon B
Nanotubes O
( O
CNTs O
) O
and O
Measurement O
of O
Nanoparticle O
Agglomerates O
in O
Diesel O
Exhaust O
. O

Carbon B
nanotubes O
( O
CNTs O
) O
tend O
to O
form O
bundles O
due O
to O
their O
geometry O
and O
van O
der O
Walls O
forces O
, O
which O
usually O
complicates O
studies O
of O
the O
CNT O
properties O
. O

Moreover O
, O
compound O
8c4 O
was O
also O
equally O
potent O
against O
paclitaxel B
resistant O
cancer O
cells O
. O

A O
new O
iridoid O
glycoside O
, O
rotunduside O
( O
1 O
) O
, O
along O
with O
four O
known O
iridoid O
glycosides O
, O
10 O
- O
O O
- O
p O
- O
hydroxybenzoylthevir O
( O
2 O
) O
, O
10 O
- O
O O
- O
vanilloyltheviridosi O
( O
3 O
) O
, O
6 O
' O
' O
- O
O O
- O
( O
trans O
- O
p O
- O
coumaroyl O
) O
- O
procumbide O
( O
4 O
) O
and O
loganic B
acid I
( O
5 O
) O
, O
was O
isolated O
from O
the O
rhizomes O
of O
Cyperus O
rotundus O
L O
. O

Identification O
of O
alpha B
- I
tocopherol I
and O
alpha O
- O
tocopheryl O
acetate O
from O
the O
cuticle O
of O
soybean O
pods O
armyworm O
( O
Spodoptera O
cosmioides O
) O
. O

Among O
the O
usual O
lipids O
found O
in O
the O
insect O
cuticle O
, O
alpha B
- I
tocopherol I
and O
alpha O
- O
tocopheryl O
acetate O
were O
also O
isolated O
from O
S O
. O
cosmioides O
. O

On O
the O
other O
hand O
, O
no O
vitamin B
E I
derivative O
was O
found O
in O
A O
. O
gemmatalis O
exuvia O
. O

This O
is O
the O
first O
report O
of O
vitamin B
E I
occurrence O
in O
the O
insect O
' O
s O
cuticle O
. O

An O
in O
- O
depth O
analytical O
investigation O
from O
2008 O
to O
2010 O
showed O
how O
this O
innovative O
olive O
extraction O
process O
led O
to O
an O
excellent O
peculiar O
final O
product O
, O
mainly O
attributable O
to O
the O
improved O
biophenol O
and O
volatile O
composition O
, O
as O
well O
as O
higher O
concentrations O
of O
the O
lipophilic O
and O
vitamin O
antioxidants O
( O
tocopherols B
and O
tocotrienols O
) O
. O

Its O
head O
- O
space O
aroma O
displayed O
new O
volatile O
phytomolecules O
and O
also O
had O
higher O
levels O
of O
green O
volatiles O
from O
the O
lipoxygenase O
( O
LOX O
) O
- O
pathway O
( O
one O
having O
as O
precursors O
the O
polyunsaturated B
fatty I
acids I
containing O
a O
cis O
- O
cis O
- O
1 O
, O
4 O
- O
pentadiene O
system O
) O
. O

Among O
the O
other O
bioactives O
, O
we O
highlight O
its O
significant O
levels O
of O
trans O
- O
beta O
- O
carotene O
and O
xanthophylls O
( O
lutein B
, O
violaxanthin O
, O
neoxanthin O
and O
other O
carotenoids O
) O
. O

Improvement O
of O
p O
- O
cymene O
antinociceptive O
and O
anti O
- O
inflammatory O
effects O
by O
inclusion O
in O
beta B
- I
cyclodextrin I
. O

Here O
, O
we O
used O
p O
- O
cymene O
/ O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
complex O
and O
p O
- O
cymene O
( O
PC O
) O
isolated O
to O
evaluated O
whether O
the O
complex O
formulation O
is O
able O
to O
improve O
the O
antinociceptive O
activity O
of O
this O
monoterpene B
. O

Male O
mice O
( O
26 O
- O
30g O
) O
were O
pretreated O
with O
PC O
/ O
beta B
- I
CD I
( O
20 O
or O
40mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
, O
PC O
( O
20 O
or O
40mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
or O
vehicle O
( O
distilled O
water O
) O
, O
0 O
. O
5h O
before O
painful O
tests O
and O
antinociceptive O
effect O
was O
evaluated O
at O
times O
: O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
, O
8 O
, O
and O
16h O
after O
treatment O
. O

We O
evaluated O
the O
analgesic O
- O
like O
effect O
of O
PC O
/ O
beta B
- I
CD I
and O
PC O
in O
acetic B
acid I
- O
induced O
abdominal O
writhes O
, O
hot O
- O
plate O
, O
carrageenan O
- O
induced O
paw O
edema O
and O
in O
rota O
- O
rod O
apparatus O
. O

Our O
results O
demonstrated O
that O
acute O
treatment O
with O
complex O
PC O
/ O
beta B
- I
CD I
produced O
an O
antinocicepitve O
effect O
( O
p O
< O
0 O
. O
01 O
or O
p O
< O
0 O
. O
001 O
) O
for O
8h O
followed O
whereas O
isolated O
PC O
produced O
the O
same O
effect O
for O
2h O
. O

Similar O
results O
were O
obtained O
in O
hot O
- O
plate O
test O
, O
PC O
/ O
beta B
- I
CD I
, O
in O
all O
doses O
, O
significantly O
reduces O
( O
p O
< O
0 O
. O
01 O
or O
p O
< O
0 O
. O
001 O
) O
nociceptive O
behavior O
for O
8h O
while O
isolated O
PC O
for O
1h O
, O
did O
so O
only O
in O
higher O
dose O
. O

Systemic O
pretreatment O
with O
PC O
/ O
beta B
- I
CD I
and O
PC O
inhibited O
the O
development O
paw O
edema O
by O
carrageenan O
1 O
% O
, O
but O
PC O
/ O
beta B
- I
CD I
did O
so O
during O
a O
longer O
period O
when O
compared O
with O
isolated O
monoterpene B
alone O
. O

Our O
results O
provide O
evidence O
to O
propose O
that O
the O
complex O
with O
beta B
- I
CD I
improved O
analgesic O
and O
anti O
- O
inflammatory O
effects O
of O
p O
- O
cymene O
. O

Dichloro O
- O
dihydro O
- O
fluorescein O
diacetate O
( O
DCFH B
- I
DA I
) O
assay O
: O
a O
quantitative O
method O
for O
oxidative O
stress O
assessment O
of O
nanoparticle O
- O
treated O
cells O
. O

No O
consensus O
exists O
on O
how O
to O
address O
possible O
toxicity O
of O
nanomaterials O
as O
they O
interfere O
with O
most O
in O
vitro O
screening O
tests O
based O
on O
colorimetric O
and O
fluorimetric O
probes O
such O
as O
the O
dichloro O
- O
dihydro O
- O
fluorescein O
diacetate O
( O
DCFH B
- I
DA I
) O
assay O
for O
detection O
of O
oxidative O
species O
. O

In O
the O
present O
research O
, O
nanomaterial O
interaction O
with O
DCFH B
- I
DA I
was O
studied O
in O
relation O
to O
its O
nature O
and O
/ O
or O
assay O
conditions O
( O
cell O
- O
based O
and O
time O
exposure O
) O
by O
incubating O
Rhodamine B
( O
Rhd O
) O
- O
labeled O
25nm O
and O
50nm O
silica B
( O
SiO2 B
) O
, O
naked O
and O
oleic O
acid O
coated O
magnetite O
, O
( O
Fe3O4 B
) O
and O
maghemite B
( O
Fe2O3 B
) O
iron B
oxide I
, O
titanium B
dioxide I
( O
TiO2 B
) O
and O
poly O
( O
ethylene O
oxide O
) O
- O
poly O
( O
lactide O
/ O

Overall O
data O
indicate O
that O
despite O
the O
quenching O
effect O
of O
nanoparticles O
on O
DCFH B
- I
DA I
assay O
, O
it O
can O
be O
considered O
as O
a O
useful O
tool O
for O
quantitative O
measurement O
of O
NPs O
- O
induced O
oxidative O
stress O
by O
minor O
modifications O
of O
standardized O
protocols O
. O

The O
WHO O
TobReg O
proposed O
mandating O
ceilings O
on O
selected O
smoke O
constituents O
determined O
from O
the O
market O
- O
specific O
median O
of O
nicotine B
- O
normalized O
yield O
distributions O
. O

In O
the O
present O
study O
, O
18 O
priority O
WHO O
smoke O
constituent O
yields O
( O
nicotine B
- O
normalized O
) O
were O
determined O
( O
using O
two O
smoking O
regimens O
) O
from O
262 O
commercial O
brands O
including O
American O
, O
Virginia O
and O
local O
blends O
from O
13 O
countries O
. O

PC2 O
and O
PC3 O
cluster O
American O
- O
and O
Virginia O
- O
blends O
, O
revealing O
inverse O
correlations O
: O
Nitrogen O
oxides O
and O
amino B
- O
or O
nitroso B
- O
aromatic O
compounds O
inversely O
correlate O
to O
either O
formaldehyde B
and O
acrolein B
, O
or O
benzo B
( I
a I
) I
pyrene I
and O
di O
- O
hydroxybenzenes O
. O

The O
association O
between O
daily O
calcium B
intake O
and O
sarcopenia O
in O
older O
, O
non O
- O
obese O
Korean O
adults O
: O
the O
fourth O
Korea O
national O
health O
and O
nutrition O
examination O
survey O
( O
KNHANES O
IV O
) O
2009 O
. O

Recent O
data O
suggest O
that O
variations O
in O
calcium B
intake O
may O
influence O
body O
weight O
and O
composition O
; O
however O
, O
the O
relationship O
between O
daily O
calcium B
intake O
and O
muscle O
mass O
has O
not O
been O
well O
established O
. O

The O
objective O
of O
this O
study O
was O
to O
assess O
the O
relationship O
between O
daily O
calcium B
intake O
and O
sarcopenia O
. O

Daily O
calcium B
intake O
based O
on O
the O
consumption O
of O
each O
food O
item O
was O
calculated O
. O

We O
found O
that O
daily O
calcium B
intake O
was O
negatively O
correlated O
with O
total O
body O
fat O
percentage O
and O
positively O
correlated O
with O
appendicular O
skeletal O
mass O
( O
p O
< O
0 O
. O
001 O
) O
. O

Participants O
with O
sarcopenia O
appear O
to O
have O
significantly O
lower O
daily O
calcium B
intakes O
than O
participants O
without O
sarcopenia O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
unadjusted O
prevalence O
of O
sarcopenia O
according O
to O
daily O
calcium B
intake O
tertiles O
were O
6 O
. O
3 O
% O
, O
4 O
. O
3 O
% O
, O
and O
2 O
. O
7 O
% O
in O
tertiles O
1 O
, O
2 O
, O
and O
3 O
, O
respectively O
. O

After O
adjustment O
for O
age O
, O
sex O
, O
BMI O
, O
total O
energy O
intake O
, O
and O
lifestyle O
factors O
, O
compared O
with O
those O
in O
the O
lowest O
tertile O
of O
daily O
calcium B
intake O
, O
participants O
in O
the O
highest O
tertile O
had O
an O
odds O
ratio O
for O
sarcopenia O
of O
0 O
. O
295 O
( O
95 O
% O
confidence O
interval O
, O
0 O
. O
087 O
- O
0 O
. O
768 O
; O
p O
for O
trend O
= O
0 O
. O
014 O
) O
. O

We O
found O
that O
daily O
calcium B
intake O
, O
corrected O
for O
total O
energy O
intake O
and O
serum O
25 O
( O
OH O
) O
D O
status O
, O
was O
significantly O
lower O
in O
subjects O
with O
sarcopenia O
than O
in O
those O
without O
. O

Our O
results O
suggest O
a O
strong O
inverse O
association O
between O
daily O
calcium B
intake O
and O
sarcopenia O
in O
non O
- O
obese O
, O
older O
Korean O
adults O
. O

Functional O
profiling O
discovers O
the O
dieldrin B
organochlorinated O
pesticide O
affects O
leucine B
availability O
in O
yeast O
. O

Exposure O
to O
organochlorinated O
pesticides O
such O
as O
dieldrin B
has O
been O
linked O
to O
Parkinson O
' O
s O
and O
Alzheimer O
' O
s O
diseases O
, O
endocrine O
disruption O
, O
and O
cancer O
, O
but O
the O
cellular O
and O
molecular O
mechanisms O
of O
toxicity O
behind O
these O
effects O
remain O
largely O
unknown O
. O

Here O
we O
demonstrate O
, O
using O
a O
functional O
genomics O
approach O
in O
the O
model O
eukaryote O
Saccharomyces O
cerevisiae O
, O
that O
dieldrin B
alters O
leucine B
availability O
. O

This O
model O
is O
supported O
by O
multiple O
lines O
of O
congruent O
evidence O
: O
( O
1 O
) O
mutants O
defective O
in O
amino B
acid I
signaling O
or O
transport O
are O
sensitive O
to O
dieldrin B
, O
which O
is O
reversed O
by O
the O
addition O
of O
exogenous O
leucine B
; O
( O
2 O
) O
dieldrin B
sensitivity O
of O
wild O
- O
type O
or O
mutant O
strains O
is O
dependent O
upon O
leucine B
concentration O
in O
the O
media O
; O
( O
3 O
) O
overexpression O
of O
proteins O
that O
increase O
intracellular O
leucine B
confer O
resistance O
to O
dieldrin B
; O
( O
4 O
) O
leucine B
uptake O
is O
inhibited O
in O
the O
presence O
of O
dieldrin B
; O
and O
( O
5 O
) O
dieldrin O

Additionally O
, O
we O
demonstrate O
that O
appropriate O
negative O
regulation O
of O
the O
Ras O
/ O
protein O
kinase O
A O
pathway O
, O
along O
with O
an O
intact O
pyruvate B
dehydrogenase O
complex O
, O
is O
required O
for O
dieldrin B
tolerance O
. O

Many O
yeast O
genes O
described O
in O
this O
study O
have O
human O
orthologs O
that O
may O
modulate O
dieldrin B
toxicity O
in O
humans O
. O

Both O
low O
- O
level O
lead O
( O
Pb B
) O
exposure O
and O
prenatal O
stress O
( O
PS O
) O
have O
been O
associated O
with O
mesocorticolimbic O
system O
- O
mediated O
executive O
- O
function O
cognitive O
and O
attention O
deficits O
. O

This O
study O
examined O
laterality O
of O
mesocorticolimbic O
monoamines B
( O
frontal O
cortex O
, O
nucleus O
accumbens O
, O
striatum O
, O
midbrain O
) O
and O
amino B
acids I
( O
frontal O
cortex O
) O
in O
male O
and O
female O
rats O
subjected O
to O
lifetime O
Pb B
exposure O
( O
0 O
or O
50 O
ppm O
in O
drinking O
water O
) O
, O
PS O
( O
restraint O
stress O
on O
gestational O
days O
16 O
- O
17 O
) O
, O
or O
the O
combination O
with O
and O
without O
repeated O
learning O
behavioral O
experience O
. O

Lateralized O
Pb B
+ O
/ O
- O
PS O
induced O
neurotransmitter O
changes O
were O
assessed O
only O
in O
males O
because O
of O
limited O
sample O
sizes O
of O
Pb B
+ O
PS O
females O
. O

In O
males O
, O
Pb B
+ O
/ O
- O
PS O
changes O
occurred O
in O
left O
hemisphere O
of O
frontal O
cortex O
and O
right O
hemisphere O
of O
midbrain O
. O

Behavioral O
experience O
modified O
the O
laterality O
of O
Pb B
+ O
/ O
- O
PS O
- O
induced O
neurotransmitter O
changes O
in O
a O
region O
- O
dependent O
manner O
. O

Notably O
, O
behavioral O
experience O
eliminated O
Pb B
+ O
/ O
- O
PS O
neurotransmitter O
changes O
in O
males O
. O

Transcriptome O
alterations O
following O
developmental O
atrazine B
exposure O
in O
zebrafish O
are O
associated O
with O
disruption O
of O
neuroendocrine O
and O
reproductive O
system O
function O
, O
cell O
cycle O
, O
and O
carcinogenesis O
. O

Atrazine B
, O
a O
herbicide O
commonly O
applied O
to O
agricultural O
areas O
and O
a O
common O
contaminant O
of O
potable O
water O
supplies O
, O
is O
implicated O
as O
an O
endocrine O
- O
disrupting O
chemical O
( O
EDC O
) O
and O
potential O
carcinogen O
. O

Environmental O
Protection O
Agency O
considers O
an O
atrazine B
concentration O
of O
< O
= O
3 O
ppb O
in O
drinking O
water O
safe O
for O
consumption O
. O

The O
specific O
adverse O
human O
health O
effects O
associated O
with O
a O
developmental O
atrazine B
exposure O
and O
the O
underlying O
genetic O
mechanisms O
of O
these O
effects O
are O
not O
well O
defined O
. O

In O
this O
study O
, O
zebrafish O
embryos O
were O
exposed O
to O
a O
range O
of O
atrazine B
concentrations O
to O
establish O
toxicity O
. O

Morphological O
, O
transcriptomic O
, O
and O
protein O
alterations O
were O
then O
assessed O
at O
72h O
postfertilization O
following O
developmental O
atrazine B
exposure O
at O
0 O
, O
0 O
. O
3 O
, O
3 O
, O
or O
30 O
ppb O
. O

A O
significant O
increase O
in O
head O
length O
was O
observed O
in O
all O
three O
atrazine B
treatments O
. O

Transcriptomic O
profiles O
revealed O
21 O
, O
62 O
, O
and O
64 O
genes O
with O
altered O
expression O
in O
the O
0 O
. O
3 O
, O
3 O
, O
and O
30 O
ppb O
atrazine B
treatments O
, O
respectively O
. O

There O
was O
a O
significant O
overlap O
( O
42 O
genes O
) O
between O
the O
3 O
and O
30 O
ppb O
differentially O
expressed O
gene O
lists O
, O
with O
two O
of O
these O
genes O
( O
CYP17A1 O
and O
SAMHD1 O
) O
present O
in O
all O
three O
atrazine B
treatments O
. O

Overall O
, O
this O
study O
identifies O
genetic O
and O
molecular O
targets O
altered O
in O
response O
to O
a O
developmental O
atrazine B
exposure O
to O
further O
define O
the O
biological O
pathways O
and O
mechanisms O
of O
toxicity O
. O

GLP O
- O
1 O
Action O
and O
Glucose B
Tolerance O
in O
Subjects O
With O
Remission O
of O
Type O
2 O
Diabetes O
Mellitus O
After O
Gastric O
Bypass O
Surgery O
. O

OBJECTIVEGlucagon O
like O
peptide O
- O
1 O
( O
GLP O
- O
1 O
) O
has O
been O
suggested O
as O
a O
major O
factor O
for O
the O
improved O
glucose B
tolerance O
ensuing O
after O
Roux O
- O
en O
- O
Y O
Gastric O
Bypass O
( O
RYGBP O
) O
surgery O
. O

We O
examined O
the O
effect O
of O
blocking O
endogenous O
GLP O
- O
1 O
action O
on O
glucose B
tolerance O
in O
subjects O
with O
sustained O
remission O
of O
type O
2 O
diabetes O
( O
T2DM O
) O
present O
before O
RYGBP O
. O
RESEARCH O
DESIGN O
AND O
METHODSBlood O
glucose B
, O
insulin O
, O
C O
- O
peptide O
, O
glucagon O
, O
GLP O
- O
1 O
, O
and O
glucose B
- O
dependent O
insulinotropic O
peptide O
levels O
were O
measured O
after O
a O
meal O
challenge O
with O
either O
exendin O
- O
( O
9 O
- O
39 O
) O
( O
a O
GLP O
- O
1r O
antagonist O
) O
or O
saline O
infusion O
in O
eight O
subjects O
with O
sustained O
remission O
of O
T2DM O

after O
RYGBP O
and O
seven O
healthy O
controls O
. O
RESULTSInfusion O
of O
exendin O
- O
( O
9 O
- O
39 O
) O
resulted O
in O
marginal O
deterioration O
of O
the O
2 O
- O
h O
plasma O
glucose B
after O
meal O
intake O
in O
RYGBP O
subjects O
( O
saline O
78 O
. O
4 O
+ O
/ O
- O
15 O
. O
1 O
mg O
/ O
dL O
compared O
with O
exendin O
- O
( O
9 O
- O
39 O
) O
116 O
. O
5 O
+ O
/ O
- O
22 O
. O
3 O
mg O
/ O
dL O
; O
P O
< O
0 O
. O
001 O
) O
. O

Furthermore O
, O
glucose B
response O
to O
meal O
intake O
was O
similarly O
enlarged O
in O
the O
two O
study O
groups O
( O
percent O
change O
in O
the O
area O
under O
the O
curve O
of O
glucose B
exendin O
- O
( O
9 O
- O
39 O
) O
- O
infusion O
versus O
saline O
- O
infusion O
: O
controls O
10 O
. O
84 O
+ O
/ O
- O
8 O
. O
8 O
% O
versus O
RYGBP O
9 O
. O
94 O
+ O
/ O
- O
8 O
. O
4 O
% O
; O
P O
= O
0 O
. O
884 O
) O
. O

In O
the O
RYGBP O
group O
, O
the O
blockade O
of O
the O
enlarged O
GLP O
- O
1 O
response O
to O
meal O
intake O
resulted O
in O
reduced O
insulin O
( O
P O
= O
0 O
. O
001 O
) O
and O
C O
- O
peptide O
( O
P O
< O
0 O
. O
001 O
) O
, O
but O
no O
change O
in O
glucagon O
( O
P O
= O
0 O
. O
258 O
) O
responses O
. O
CONCLUSIONThe O
limited O
deterioration O
of O
glucose B
tolerance O
on O
blockade O
of O
GLP O
- O
1 O
action O
in O
our O
study O
suggests O
the O
resolution O
of O
T2DM O
after O
RYGBP O
may O
be O
explained O
by O
mechanisms O
beyond O
enhancement O
of O
GLP O
- O
1 O
action O
. O

We O
investigated O
the O
potential O
modulation O
of O
xenobiotic O
- O
metabolizing O
CYPs O
in O
liver O
, O
heart O
and O
duodenum O
of O
pigs O
subjected O
to O
a O
high O
- O
fat O
/ O
high O
- O
cholesterol B
diet O
for O
2 O
months O
continuously O
( O
C O
- O
HFD O
) O
or O
on O
alternate O
weeks O
( O
A O
- O
HFD O
) O
. O

The O
administration O
of O
the O
high O
- O
fat O
diet O
resulted O
in O
considerably O
increased O
plasma O
cholesterol B
levels O
although O
the O
animals O
were O
still O
able O
to O
manage O
the O
lipid O
overload O
efficiently O
, O
and O
no O
sign O
of O
effective O
tissue O
inflammation O
occurred O
in O
livers O
. O

Therapeutic O
potential O
of O
targeting O
lipid O
aldehydes B
and O
lipoxidation O
end O
- O
products O
in O
the O
treatment O
of O
ocular O
disease O
. O

Here O
, O
we O
begin O
by O
outlining O
some O
of O
the O
major O
lipid O
aldehydes B
produced O
through O
lipoxidation O
reactions O
, O
the O
ALEs O
formed O
upon O
their O
reaction O
with O
proteins O
, O
and O
the O
endogenous O
aldehyde B
metabolizing O
enzymes O
involved O
in O
protecting O
cells O
against O
lipoxidation O
mediated O
damage O
. O

Discussions O
are O
subsequently O
focused O
on O
the O
clinical O
and O
experimental O
evidence O
supporting O
the O
contribution O
of O
lipid O
aldehydes B
and O
ALEs O
in O
the O
development O
of O
ocular O
diseases O
. O

Current O
and O
emerging O
pharmacological O
strategies O
to O
prevent O
or O
neutralize O
the O
effects O
of O
lipid O
aldehydes B
and O
ALEs O
are O
therefore O
considered O
, O
with O
particular O
emphasis O
on O
the O
potential O
of O
these O
drugs O
for O
treatment O
of O
diseases O
of O
the O
eye O
. O

We O
demonstrate O
, O
using O
mass O
spectrometry O
and O
X O
- O
ray O
crystallography O
, O
that O
the O
selective O
inhibitor O
covalently O
modifies O
PI3K O
alpha O
on O
cysteine B
862 O
( O
C862 O
) O
, O
an O
amino B
acid I
unique O
to O
the O
alpha O
isoform O
, O
and O
that O
PI3K O
beta O
, O
- O
gamma O
, O
and O
- O
delta O
are O
not O
covalently O
modified O
. O

In O
addition O
to O
vascular O
disrupting O
activity O
verified O
by O
in O
vitro O
assays O
, O
compounds O
21 O
and O
31 O
displayed O
much O
higher O
selectivity O
for O
activated O
HUVECs O
versus O
quiescent O
HUVECs O
than O
those O
of O
colchicine B
and O
combretastatinA O
- O
4 O
. O

Bisphenol B
A I
activates O
the O
Nrf1 O
/ O
2 O
- O
antioxidant O
response O
element O
pathway O
in O
HEK O
293 O
cells O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
used O
in O
the O
production O
of O
polycarbonate B
plastics O
and O
epoxy O
resins O
for O
baby O
bottles O
, O
liners O
of O
canned O
food O
, O
and O
many O
other O
consumer O
products O
. O

Previously O
, O
BPA B
has O
been O
shown O
to O
reduce O
the O
activity O
of O
several O
antioxidant O
enzymes O
, O
which O
may O
contribute O
to O
oxidative O
stress O
. O

However O
, O
the O
underlying O
mechanism O
of O
the O
BPA B
- O
mediated O
effect O
upon O
antioxidant O
enzyme O
activity O
is O
unknown O
. O

In O
this O
work O
, O
we O
have O
assessed O
the O
effect O
of O
BPA B
on O
the O
Nrf1 O
/ O
2 O
- O
ARE O
pathway O
in O
cultured O
human O
embryonic O
kidney O
( O
HEK O
) O
293 O
cells O
. O

Surprisingly O
, O
glutathione B
and O
reactive O
oxygen B
species O
( O
ROS O
) O
assays O
revealed O
that O
BPA B
application O
created O
a O
more O
reduced O
intracellular O
environment O
in O
cultured O
HEK O
293 O
cells O
. O

Furthermore O
, O
BPA B
increased O
the O
transactivation O
activity O
of O
ectopic O
Nrf1 O
and O
Nrf2 O
and O
increased O
the O
expression O
of O
ARE O
- O
target O
genes O
ho O
- O
1 O
and O
nqo1 O
at O
high O
( O
100 O
- O
200 O
mu O
M O
) O
BPA B
concentrations O
only O
. O

Our O
study O
suggests O
that O
BPA B
activates O
the O
Nrf1 O
/ O
2 O
- O
ARE O
pathway O
at O
high O
( O
> O
10 O
mu O
M O
) O
micromolar O
concentrations O
. O

Organoselenium O
compounds O
modulate O
extracellular O
redox O
by O
induction O
of O
extracellular O
cysteine B
and O
cell O
surface O
thioredoxin O
reductase O
. O

The O
effect O
of O
selenium B
compounds O
on O
extracellular O
redox O
modulating O
capacity O
was O
studied O
in O
murine O
macrophage O
RAW O
264 O
. O
7 O
cells O
and O
differentiated O
human O
THP O
- O
1 O
monocytes O
. O

The O
arylselenium O
compounds O
benzeneselenol O
( O
PhSeH O
) O
, O
dibenzyl O
diselenide O
( O
DBDSe O
) O
, O
diphenyl B
diselenide I
( O
DPDSe O
) O
, O
and O
ebselen B
were O
capable O
of O
inducing O
extracellular O
cysteine B
accumulation O
via O
a O
cystine B
- O
and O
glucose B
- O
dependent O
process O
. O

Extracellular O
cysteine B
production O
was O
dose O
- O
dependently O
inhibited O
by O
glutamate B
, O
an O
inhibitor O
of O
cystine B
/ O
glutamate B
antiporter O
( O
Xc O
( O
- O
) O
transporter O
) O
, O
supporting O
the O
involvement O
of O
Xc O
( O
- O
) O
transporter O
for O
cystine B
uptake O
in O
the O
above O
process O
. O

TrxR1 O
knockdown O
using O
small O
interfering O
RNA O
attenuated O
TrxR O
increases O
and O
cysteine B
efflux O
induced O
in O
cells O
by O
DPDSe O
. O

Sodium B
selenite I
( O
Na2SeO3 O
) O
, O
selenomethionine B
( O
SeMet B
) O
, O
seleno O
- O
l O
- O
cystine O
( O
SeCySS O
) O
, O
and O
Se O
- O
methylselenocysteine O
( O
MeSeCys O
) O
did O
not O
have O
these O
effects O
on O
macrophages O
under O
the O
same O
treatment O
conditions O
. O

The O
effects O
of O
organoselenium O
compounds O
on O
extracellular O
redox O
may O
contribute O
to O
the O
known O
, O
but O
inadequately O
understood O
, O
biological O
effects O
of O
selenium B
compounds O
. O

Based O
on O
microarray O
analysis O
followed O
by O
comparative O
metabolomics O
of O
overexpression O
/ O
knockout O
mutants O
, O
we O
identified O
a O
tryptophan B
- O
derived O
iron O
( O
III O
) O
- O
complex O
, O
hexadehydro O
- O
astechrome O
( O
HAS O
) O
, O
as O
the O
major O
product O
of O
the O
cryptic O
has O
nonribosomal O
peptide O
synthetase O
( O
NRPS O
) O
gene O
cluster O
in O
the O
human O
pathogen O
Aspergillus O
fumigatus O
. O

Identification O
of O
a O
small O
- O
molecule O
inhibitor O
of O
HIV O
- O
1 O
assembly O
that O
targets O
the O
phosphatidylinositol B
( I
4 I
, I
5 I
) I
- I
bisphosphate I
binding O
site O
of O
the O
HIV O
- O
1 O
matrix O
protein O
. O

We O
previously O
reported O
on O
a O
novel O
anti O
- O
HIV O
- O
1 O
compound O
, O
N O
( O
2 O
) O
- O
( O
phenoxyacetyl O
) O
- O
N O
- O
[ O
4 O
- O
( O
1 O
- O
piperidinylcarbonyl O
) O
benzyl O
] O
glycinamide O
( O
14 O
) O
, O
that O
binds O
to O
the O
highly O
conserved O
phosphatidylinositol B
( I
4 I
, I
5 I
) I
- I
bisphosphate I
( O
PI O
( O
4 O
, O
5 O
) O
P O
( O
2 O
) O
) O
binding O
pocket O
of O
the O
HIV O
- O
1 O
matrix O
( O
MA O
) O
protein O
. O

CrbpI O
regulates O
mammary O
retinoic B
acid I
homeostasis O
and O
the O
mammary O
microenvironment O
. O

Cellular O
retinol B
- O
binding O
protein O
, O
type O
I O
( O
CrbpI O
) O
, O
encoded O
by O
retinol B
- O
binding O
protein O
, O
type O
1 O
( O
Rbp1 O
) O
, O
is O
a O
chaperone O
of O
vitamin B
A I
( O
retinol B
) O
that O
is O
epigenetically O
silenced O
in O
~ O
25 O
% O
of O
human O
breast O
cancers O
. O

CrbpI O
delivers O
vitamin B
A I
to O
enzymes O
for O
metabolism O
into O
an O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
where O
atRA B
is O
essential O
to O
cell O
proliferation O
, O
apoptosis O
, O
differentiation O
, O
and O
migration O
. O

Here O
, O
we O
show O
the O
effect O
of O
CrbpI O
loss O
on O
mammary O
atRA B
homeostasis O
using O
the O
Rbp1 O
( O
- O
/ O
- O
) O
mouse O
model O
. O

Rbp1 O
( O
- O
/ O
- O
) O
mouse O
mammary O
tissue O
has O
disrupted O
retinoid B
homeostasis O
that O
results O
in O
40 O
% O
depleted O
endogenous O
atRA B
. O

CrbpI O
loss O
and O
atRA B
depletion O
precede O
defects O
in O
atRA B
biosynthesis O
enzyme O
expression O
. O

Compensation O
by O
CrbpIII O
as O
a O
retinoid B
chaperone O
does O
not O
functionally O
replace O
CrbpI O
. O

Mammary O
subcellular O
fractions O
isolated O
from O
Rbp1 O
( O
- O
/ O
- O
) O
mice O
have O
altered O
retinol B
dehydrogenase O
/ O
reductase O
( O
Rdh O
) O
enzyme O
activity O
that O
results O
in O
24 O
- O
42 O
% O
less O
atRA B
production O
. O

Rbp1 O
( O
- O
/ O
- O
) O
mammary O
tissue O
has O
epithelial O
hyperplasia O
, O
stromal O
hypercellularity O
, O
increased O
collagen O
, O
and O
increased O
oxidative O
stress O
characteristic O
of O
atRA B
deficiency O
and O
early O
tissue O
dysfunction O
that O
precedes O
tumor O
formation O
. O

Consistent O
with O
the O
findings O
from O
the O
Rbp1 O
( O
- O
/ O
- O
) O
mouse O
, O
tumorigenic O
epithelial O
cells O
lacking O
CrbpI O
expression O
produce O
51 O
% O
less O
atRA B
. O

Together O
, O
these O
data O
show O
that O
CrbpI O
loss O
disrupts O
atRA B
homeostasis O
in O
mammary O
tissue O
, O
resulting O
in O
microenvironmental O
defects O
similar O
to O
those O
observed O
at O
the O
early O
stages O
of O
tumorigenesis O
. O
- O
Pierzchalski O
, O
K O
. O
, O
Yu O
, O
J O
. O
, O
Norman O
, O
V O
. O
, O
Kane O
, O
M O
. O

CrbpI O
regulates O
mammary O
retinoic B
acid I
homeostasis O
and O
the O
mammary O
microenvironment O
. O

Influenza O
uses O
many O
individually O
weak O
ligand O
binding O
interactions O
for O
a O
high O
avidity O
multivalent O
attachment O
to O
sialic B
acid I
- O
bearing O
cells O
. O

Polymerized O
sialic B
acid I
analogs O
can O
form O
multivalent O
interactions O
with O
influenza O
but O
are O
not O
ideal O
therapeutics O
due O
to O
solubility O
and O
toxicity O
issues O
. O

Secondary O
interactions O
are O
demonstrated O
to O
direct O
the O
stability O
of O
well O
- O
defined O
Ru O
- O
NHC O
- O
based O
heterogeneous O
alkene B
metathesis O
catalysts O
. O

Specifically O
, O
they O
can O
be O
described O
as O
interactions O
between O
the O
metal O
center O
( O
active O
site O
) O
and O
the O
surface O
functionality O
of O
the O
support O
, O
and O
they O
have O
been O
detected O
by O
surface O
- O
enhanced O
( B
1 I
) I
H I
- O
( B
29 I
) I
Si I
NMR O
spectroscopy O
of O
the O
ligand O
and O
( B
31 I
) I
P I
solid O
- O
state O
NMR O
of O
the O
catalyst O
precursor O
. O

They O
are O
present O
only O
when O
the O
metal O
center O
is O
attached O
to O
the O
surface O
via O
a O
flexible O
linker O
( O
a O
propyl B
group O
) O
, O
which O
allows O
the O
active O
site O
to O
either O
react O
with O
the O
substrate O
or O
relax O
, O
reversibly O
, O
to O
the O
surface O
, O
thus O
providing O
stability O
. O

Intercalation O
pathway O
in O
many O
- O
particle O
LiFePO4 B
electrode O
revealed O
by O
nanoscale O
state O
- O
of O
- O
charge O
mapping O
. O

The O
intercalation O
pathway O
of O
lithium B
iron I
phosphate I
( O
LFP O
) O
in O
the O
positive O
electrode O
of O
a O
lithium B
- O
ion O
battery O
was O
probed O
at O
the O
~ O
40 O
nm O
length O
scale O
using O
oxidation O
- O
state O
- O
sensitive O
X O
- O
ray O
microscopy O
. O

The O
S O
stereoisomer O
was O
shown O
to O
be O
in O
excellent O
agreement O
with O
the O
NOE O
- O
derived O
distance O
constraints O
and O
hydrogen B
- O
bonding O
stability O
studies O
. O

Gas O
hydrates O
represent O
an O
unconventional O
methane B
resource O
and O
a O
production O
/ O
safety O
risk O
to O
traditional O
oil O
and O
gas O
flowlines O
. O

In O
both O
systems O
, O
hydrate O
may O
share O
interfaces O
with O
both O
aqueous O
and O
hydrocarbon B
fluids O
. O

This O
work O
presents O
hydrate O
cohesive O
force O
results O
measured O
on O
a O
micromechanical O
force O
apparatus O
, O
and O
complementary O
water O
- O
hydrocarbon B
interfacial O
tension O
data O
. O

By O
combining O
a O
revised O
cohesive O
force O
model O
with O
experimental O
data O
, O
two O
interfacial O
properties O
of O
cyclopentane O
hydrate O
were O
estimated O
: O
hydrate O
- O
water O
and O
hydrate O
- O
cyclopentane B
interfacial O
tension O
values O
at O
0 O
. O
32 O
+ O
/ O
- O
0 O
. O
05 O
mN O
/ O
m O
and O
47 O
+ O
/ O
- O
5 O
mN O
/ O
m O
, O
respectively O
. O

The O
addition O
of O
surfactants O
in O
the O
cyclopentane B
phase O
significantly O
reduced O
the O
cyclopentane O
hydrate O
cohesive O
force O
; O
we O
hypothesize O
this O
behavior O
to O
be O
the O
result O
of O
surfactant O
adsorption O
on O
the O
hydrate O
- O
oil O
interface O
. O

The O
trichothecene B
mycotoxin O
T O
- O
2 O
toxin O
, O
which O
is O
produced O
by O
fungi O
of O
the O
Fusarium O
species O
, O
is O
a O
worldwide O
occurring O
contaminant O
of O
cereal O
based O
food O
and O
feed O
. O

However O
, O
only O
few O
data O
on O
neurotoxic O
properties O
of O
T O
- O
2 O
toxin O
are O
reported O
so O
far O
, O
but O
in O
vivo O
studies O
showed O
different O
effects O
of O
T O
- O
2 O
toxin O
on O
behavior O
as O
well O
as O
on O
levels O
of O
brain O
amines B
in O
animals O
. O

Central O
to O
this O
method O
is O
a O
thermally O
activated O
chemical O
reaction O
occurring O
across O
multiple O
interfaces O
between O
alternately O
layered O
elemental O
zinc B
- O
( O
Zn B
- O
) O
and O
selenium B
- O
( O
Se B
- O
) O
rich O
films O
embedded O
in O
a O
preform O
and O
drawn O
into O
meters O
of O
fiber O
at O
a O
temperature O
well O
below O
the O
melting O
temperature O
of O
either O
Zn B
or O
ZnSe O
. O

By O
depositing O
50 O
nm O
thick O
layers O
of O
Zn B
interleaved O
between O
1 O
mu O
m O
thick O
Se B
layers O
, O
a O
controlled O
breakup O
of O
the O
Zn B
sheet O
is O
achieved O
, O
thereby O
enabling O
a O
complete O
and O
controlled O
chemical O
reaction O
. O

Zinc B
- O
dependent O
lysosomal O
enlargement O
in O
TRPML1 O
- O
deficient O
cells O
involves O
MTF O
- O
1 O
transcription O
factor O
and O
ZnT4 O
( O
Slc30a4 O
) O
transporter O
. O

Zinc B
is O
critical O
for O
a O
multitude O
of O
cellular O
processes O
, O
including O
gene O
expression O
, O
secretion O
and O
enzymatic O
activities O
. O

Cellular O
zinc B
is O
controlled O
by O
zinc B
- O
chelating O
proteins O
and O
by O
zinc B
transporters O
. O

The O
recent O
identification O
of O
zinc B
permeability O
of O
the O
lysosomal O
ion O
channel O
TRPML1 O
( O
transient O
receptor O
potential O
mucolipin O
1 O
) O
, O
and O
the O
evidence O
of O
abnormal O
zinc B
levels O
in O
cells O
deficient O
in O
TRPML1 O
, O
suggested O
a O
role O
for O
TRPML1 O
in O
zinc B
transport O
. O

In O
agreement O
with O
the O
previously O
published O
data O
, O
an O
acute O
siRNA O
( O
small O
interfering O
RNA O
) O
- O
driven O
TRPML1 O
KD O
( O
knockdown O
) O
leads O
to O
the O
build O
- O
up O
of O
large O
cytoplasmic O
vesicles O
positive O
for O
LysoTracker O
( O
TM O
) O
and O
zinc B
staining O
, O
when O
cells O
are O
exposed O
to O
high O
concentrations O
of O
zinc B
. O

We O
now O
show O
that O
lysosomal O
enlargement O
and O
zinc B
build O
- O
up O
in O
TRPML1 O
- O
KD O
cells O
exposed O
to O
zinc B
are O
ameliorated O
by O
KD O
of O
the O
zinc B
- O
sensitive O
transcription O
factor O
MTF O
- O
1 O
( O
metal O
- O
regulatory O
- O
element O
- O
binding O
transcription O
factor O
- O
1 O
) O
or O
the O
zinc B
transporter O
ZnT4 O
. O

TRPML1 O
KD O
is O
associated O
with O
a O
build O
- O
up O
of O
cytoplasmic O
zinc B
and O
with O
enhanced O
transcriptional O
response O
of O
mRNA O
for O
MT2a O
( O
metallothionein O
2a O
) O
. O

TRPML1 O
KD O
did O
not O
suppress O
lysosomal O
secretion O
, O
but O
it O
did O
delay O
zinc B
leak O
from O
the O
lysosomes O
into O
the O
cytoplasm O
. O

These O
results O
underscore O
a O
role O
for O
TRPML1 O
in O
zinc B
metabolism O
. O

Furthermore O
, O
they O
suggest O
that O
TRPML1 O
works O
in O
concert O
with O
ZnT4 O
to O
regulate O
zinc B
translocation O
between O
the O
cytoplasm O
and O
lysosomes O
. O

Hydrogenated O
ZnO B
core O
- O
shell O
nanocables O
for O
flexible O
supercapacitors O
and O
self O
- O
powered O
systems O
. O

Although O
MnO2 B
is O
a O
promising O
material O
for O
supercapacitors O
( O
SCs O
) O
due O
to O
its O
excellent O
electrochemical O
performance O
and O
natural O
abundance O
, O
its O
wide O
application O
is O
limited O
by O
poor O
electrical O
conductivity O
. O

Inspired O
by O
our O
results O
that O
the O
electrochemical O
activity O
and O
electrical O
conductivity O
of O
ZnO B
nanowires O
were O
greatly O
improved O
after O
hydrogenation O
, O
we O
designed O
and O
fabricated O
hydrogenated O
single O
- O
crystal O
ZnO B
@ O
amorphous O
ZnO O
- O
doped O
MnO2 O
core O
- O
shell O
nanocables O
( O
HZM O
) O
on O
carbon B
cloth O
as O
SC O
electrodes O
, O
showing O
excellent O
performance O
such O
as O
areal O
capacitance O
of O
138 O
. O
7 O
mF O
/ O
cm O
( O
2 O
) O
and O
specific O
capacitance O
of O
1260 O
. O
9 O
F O
/ O
g O
. O

Highly O
flexible O
all O
- O
solid O
- O
state O
SCs O
were O
subsequently O
assembled O
with O
these O
novel O
HZM O
electrodes O
using O
polyvinyl B
alcohol I
/ O
LiCl B
electrolyte O
. O

In O
preceding O
studies O
, O
we O
demonstrated O
that O
choline O
carboxylates O
ChC O
( O
m O
) O
with O
alkyl B
chain O
lengths O
of O
m O
= O
12 O
- O
18 O
are O
highly O
water O
- O
soluble O
( O
for O
m O
= O
12 O
, O
soluble O
up O
to O
93 O
wt O
% O
soap O
and O
0 O
degrees O
C O
) O
. O

In O
addition O
, O
choline B
soaps O
are O
featured O
by O
an O
extraordinary O
lyotropic O
phase O
behavior O
. O

The O
present O
work O
is O
also O
focused O
on O
the O
lyotropic O
phase O
behavior O
of O
choline B
soaps O
but O
with O
shorter O
alkyl B
chains O
or O
different O
alkyl B
chain O
properties O
. O

We O
have O
investigated O
the O
aqueous O
phase O
behavior O
of O
choline B
soaps O
with O
C O
( O
8 O
) O
and O
C O
( O
10 O
) O
chain O
- O
lengths O
( O
choline O
octanoate O
and O
choline O
decanoate O
) O
and O
with O
a O
C O
( O
18 O
) O
chain O
- O
length O
with O
a O
cis O
- O
double O
bond O
( O
choline O
oleate O
) O
. O

Preparation O
, O
characterization O
, O
in O
vivo O
biodistribution O
and O
pharmacokinetic O
studies O
of O
donepezil B
- O
loaded O
PLGA B
nanoparticles O
for O
brain O
targeting O
. O

Donepezil B
is O
a O
reversible O
cholinesterase O
inhibitor O
used O
for O
the O
treatment O
of O
AD O
. O

The O
purpose O
of O
this O
work O
is O
to O
prepare O
a O
nanoparticulate O
drug O
delivery O
system O
of O
donepezil B
using O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
for O
sustained O
release O
and O
efficient O
brain O
targeting O
. O

Materials O
and O
methods O
: O
PLGA B
nanoparticles O
( O
NPs O
) O
were O
prepared O
by O
the O
solvent O
emulsification O
diffusion O
- O
evaporation O
technique O
and O
characterized O
for O
particle O
size O
, O
particle O
- O
size O
distribution O
, O
zeta O
potential O
, O
entrapment O
efficiency O
, O
drug O
loading O
and O
interaction O
studies O
and O
in O
vivo O
studies O
using O
gamma O
scintigraphy O
techniques O
. O

The O
TEM O
and O
SEM O
images O
of O
the O
formulation O
suggested O
that O
particle O
size O
was O
within O
20 O
- O
100 O
nm O
and O
spherical O
in O
shape O
, O
smooth O
morphology O
and O
coating O
of O
Tween B
- I
80 I
on O
the O
NPs O
was O
clearly O
observed O
. O

The O
release O
behavior O
of O
donepezil B
exhibited O
a O
biphasic O
pattern O
characterized O
by O
an O
initial O
burst O
release O
followed O
by O
a O
slower O
and O
continuous O
sustained O
release O
. O

The O
biodistribution O
studies O
of O
donepezil B
- O
loaded O
PLGA B
NPs O
and O
drug O
solution O
via O
intravenous O
route O
revealed O
higher O
percentage O
of O
radioactivity O
per O
gram O
in O
the O
brain O
for O
the O
nanoparticulate O
formulation O
as O
compared O
with O
the O
drug O
solution O
( O
p O
< O
0 O
. O
05 O
) O
. O

Conclusion O
: O
The O
high O
concentrations O
of O
donepezil B
uptake O
in O
brain O
due O
to O
coated O
NPs O
may O
help O
in O
a O
significant O
improvement O
for O
treating O
AD O
. O

Synthesis O
and O
biological O
evaluation O
of O
nucleoside B
analogues O
than O
contain O
silatrane O
on O
the O
basis O
of O
the O
structure O
of O
acyclovir B
( O
ACV B
) O
as O
novel O
inhibitors O
of O
hepatitis O
B O
virus O
( O
HBV O
) O
. O

Acyclovir B
( O
ACV B
) O
is O
mainly O
used O
to O
inhibit O
herpes O
simplex O
virus O
( O
HSV O
) O
rather O
than O
HBV O
. O

In O
this O
study O
, O
we O
used O
the O
combination O
principle O
to O
design O
and O
synthesize O
nucleoside B
analogues O
that O
contain O
silatrane O
on O
the O
basis O
of O
the O
structure O
of O
ACV B
. O

Ritodrine O
significantly O
altered O
the O
expression O
of O
genes O
related O
to O
steroid B
and O
lipid O
metabolism O
, O
as O
well O
as O
the O
metabolism O
of O
ritodrine O
itself O
. O

This O
large O
increase O
in O
blood O
SAA O
levels O
serves O
as O
a O
more O
sensitive O
biomarker O
than O
conventional O
liver O
enzymes O
, O
such O
as O
aspartate B
aminotransferase O
and O
alanine B
aminotransferase O
. O

The O
increase O
in O
SAA O
expression O
is O
specific O
to O
ritodrine O
- O
induced O
liver O
damage O
, O
because O
SAA O
expression O
was O
not O
induced O
by O
other O
hepatotoxic O
drugs O
such O
as O
acetaminophen B
, O
valproic B
acid I
, O
or O
metformin B
. O

Our O
in O
vitro O
studies O
showed O
that O
cyclic O
adenosine O
3 O
' O
, O
5 O
' O
- O
monophosphate O
( O
cAMP B
) O
accumulation O
was O
not O
a O
primary O
cause O
of O
the O
ritodrine O
- O
induced O
SAA O
increase O
. O

L O
- O
type O
voltage O
- O
dependent O
calcium B
channel O
is O
involved O
in O
the O
snake O
venom O
group O
IA O
secretory O
phospholipase O
A2 O
- O
induced O
neuronal O
apoptosis O
. O

Snake O
venom O
sPLA2s O
are O
neurotoxic O
in O
vivo O
and O
in O
vitro O
, O
causing O
synergistic O
neurotoxicity O
to O
cortical O
cultures O
when O
applied O
with O
toxic O
concentrations O
of O
glutamate B
. O

NMDA B
receptor O
blockers O
suppressed O
the O
neurotoxicity O
of O
sPLA2 O
- O
IA O
, O
but O
an O
AMPA B
receptor O
blocker O
did O
not O
. O

Interestingly O
, O
L O
- O
type O
voltage O
- O
dependent O
Ca B
( I
2 I
+ I
) I
channel O
( O
L O
- O
VDCC O
) O
blocker O
significantly O
protected O
neurons O
from O
the O
sPLA2 O
- O
IA O
- O
induced O
apoptosis O
. O

Furthermore O
, O
the O
present O
study O
suggests O
that O
not O
only O
NMDA B
receptor O
but O
also O
L O
- O
VDCC O
contributed O
to O
the O
neurotoxicity O
of O
snake O
venom O
sPLA2 O
- O
IA O
. O

Methotrexate B
, O
the O
standard O
disease O
- O
modifying O
anti O
- O
rheumatic O
drug O
( O
DMARD O
) O
, O
has O
shown O
a O
gradual O
loss O
of O
efficacy O
in O
a O
significant O
proportion O
of O
patients O
, O
probably O
due O
to O
the O
onset O
of O
drug O
resistance O
, O
and O
thus O
it O
was O
hoped O
that O
the O
development O
of O
biologics O
would O
revolutionise O
RA O
management O
. O

The O
light O
delivered O
by O
artificial O
illumination O
systems O
, O
and O
in O
particular O
by O
halogen B
quartz B
bulbs O
, O
contains O
UVA O
, O
UVB O
, O
and O
UVC O
radiation O
, O
is O
genotoxic O
to O
both O
bacterial O
and O
human O
cells O
and O
is O
potently O
carcinogenic O
to O
hairless O
mice O
. O

RATIONALE O
AND O
OBJECTIVES O
: O
To O
evaluate O
direct O
exposure O
to O
sodium O
valproate O
( O
VPA B
) O
during O
embryogenesis O
, O
we O
administered O
VPA B
to O
chick O
embryos O
and O
examined O
their O
social O
behaviors O
after O
hatching O
. O

METHODS O
AND O
RESULTS O
: O
Embryos O
treated O
with O
VPA B
( O
35 O
mu O
mol O
/ O
egg O
) O
on O
day O
14 O
were O
similar O
to O
controls O
for O
hatching O
date O
( O
day O
21 O
) O
and O
hatchlings O
' O
abilities O
, O
such O
as O
motor O
, O
imprinting O
, O
and O
surface O
righting O
. O

However O
, O
these O
VPA B
chicks O
on O
posthatching O
day O
3 O
scored O
significantly O
low O
in O
the O
chick O
' O
s O
social O
separation O
stress O
( O
SSS O
) O
test O
as O
follows O
. O

The O
results O
demonstrated O
that O
compared O
with O
controls O
, O
VPA B
chicks O
were O
significantly O
slow O
in O
aggregation O
( O
12 O
. O
7 O
+ O
/ O
- O
2 O
. O
5 O
s O
vs O
. O
2 O
. O
9 O
+ O
/ O
- O
0 O
. O
9 O
s O
, O
p O
= O
0 O
. O
006 O
) O
and O
belongingness O
( O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
28 O
s O
/ O
40 O
cm O
vs O
. O
2 O
. O
6 O
+ O
/ O
- O
0 O
. O
14 O
s O
/ O
40 O
cm O
, O
P O
= O
0 O
. O
003 O
) O
and O
weak O
in O
vocalization O
( O
13 O
. O
4 O
+ O
/ O
- O
2 O
. O
8 O
dB O
/ O
30 O
s O
vs O
. O
26 O
. O
7 O
+ O
/ O
- O
1 O
. O
3 O
dB O
/ O
30 O
s O

CONCLUSIONS O
: O
Chick O
embryos O
exposed O
to O
VPA B
during O
the O
last O
week O
of O
embryogenesis O
had O
impaired O
social O
behaviors O
in O
spite O
of O
normal O
mortar O
and O
imprinting O
ability O
. O

Abstinence O
from O
repeated O
amphetamine B
treatment O
induces O
depressive O
- O
like O
behaviors O
and O
oxidative O
damage O
in O
rat O
brain O
. O

RATIONALE O
: O
Amphetamine B
has O
a O
significant O
potential O
for O
abuse O
and O
addiction O
. O

Among O
prolonged O
abusers O
, O
amphetamine B
withdrawal O
- O
induced O
depressive O
symptoms O
are O
common O
; O
however O
, O
their O
pathophysiological O
mechanism O
is O
not O
fully O
understood O
. O

Previously O
, O
we O
found O
that O
repeated O
treatment O
with O
amphetamine B
for O
2 O
weeks O
induced O
oxidative O
stress O
in O
rat O
brain O
. O

OBJECTIVES O
: O
The O
purpose O
of O
the O
current O
study O
is O
to O
analyze O
whether O
abstinence O
from O
repeated O
amphetamine B
treatment O
in O
rats O
induces O
depressive O
- O
like O
behaviors O
and O
if O
oxidative O
damage O
in O
the O
brain O
continues O
during O
abstinence O
. O

METHODS O
: O
Rats O
were O
given O
repeated O
treatment O
with O
amphetamine B
once O
daily O
at O
1 O
, O
2 O
, O
or O
4 O
mg O
/ O
kg O
for O
14 O
days O
. O

From O
10 O
to O
14 O
days O
after O
final O
amphetamine B
treatment O
, O
behavioral O
changes O
were O
monitored O
using O
open O
field O
test O
, O
novel O
object O
recognition O
test O
, O
and O
forced O
swim O
test O
. O

RESULTS O
: O
We O
found O
that O
drug O
abstinence O
after O
repeated O
amphetamine B
stimulation O
decreased O
locomotor O
activity O
and O
exploratory O
behavior O
in O
the O
open O
field O
test O
, O
increased O
immobility O
in O
the O
forced O
swim O
test O
, O
and O
had O
no O
significant O
effect O
on O
the O
recognition O
index O
in O
the O
novel O
object O
recognition O
test O
. O

We O
also O
found O
that O
amphetamine B
abstinence O
increased O
levels O
of O
4 B
- I
hydroxynonenal I
- O
protein O
adducts O
and O
8 B
- I
hydroxyguanosine I
in O
rat O
medial O
frontal O
cortex O
and O
in O
CA3 O
and O
dentate O
gyrus O
regions O
of O
the O
hippocampus O
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
amphetamine B
abstinence O
displays O
depressive O
- O
like O
behaviors O
in O
rats O
and O
induces O
oxidative O
damage O
to O
lipids O
and O
RNA O
in O
rat O
brain O
. O

Our O
findings O
indicate O
that O
the O
process O
of O
oxidative O
stress O
may O
play O
a O
role O
in O
pathophysiological O
changes O
during O
drug O
abstinence O
from O
repeated O
amphetamine B
stimulation O
. O

Oroxylin O
A O
improves O
attention O
deficit O
hyperactivity O
disorder O
- O
like O
behaviors O
in O
the O
spontaneously O
hypertensive O
rat O
and O
inhibits O
reuptake O
of O
dopamine B
in O
vitro O
. O

In O
previous O
studies O
we O
have O
demonstrated O
that O
the O
gamma O
- O
aminobutryic O
acid O
- O
A O
( O
GABA B
- O
A O
) O
receptor O
antagonist O
oroxylin O
A O
has O
an O
awakening O
effect O
and O
it O
also O
represses O
ADHD O
- O
like O
behaviors O
( O
hyperactivity O
, O
impulsivity O
and O
inattention O
) O
in O
the O
spontaneously O
hypertensive O
rat O
( O
SHR O
) O
model O
of O
attention O
- O
deficit O
hyperactivity O
disorder O
( O
ADHD O
) O
. O

We O
hypothesized O
that O
the O
effects O
of O
oroxylin O
A O
were O
exerted O
via O
the O
GABA B
- O
A O
receptor O
given O
the O
important O
role O
of O
the O
GABAergic O
system O
in O
ADHD O
. O

To O
test O
this O
hypothesis O
, O
we O
evaluated O
the O
effects O
of O
GABA B
agonist O
, O
or O
dopamine B
( O
DA O
) O
antagonist O
in O
oroxylin O
A O
- O
induced O
alleviation O
of O
ADHD O
- O
like O
behaviors O
in O
SHR O
. O

Oroxylin O
A O
significantly O
improved O
these O
behaviors O
, O
furthermore O
, O
its O
effect O
on O
SHR O
impulsivity O
was O
attenuated O
by O
haloperidol B
, O
a O
DA O
antagonist O
, O
but O
not O
by O
baicalein B
, O
an O
agonist O
of O
the O
GABA B
- O
A O
receptor O
. O

In O
vitro O
studies O
showed O
that O
oroxylin O
A O
inhibited O
DA O
uptake O
similar O
to O
methylphenidate B
, O
a O
dopamine B
transporter O
blocker O
, O
but O
did O
not O
influence O
norepinephrine B
uptake O
unlike O
atomoxetine B
, O
a O
selective O
NE O
reuptake O
inhibitor O
. O

Collectively O
, O
the O
present O
findings O
suggest O
that O
oroxylin O
A O
improves O
ADHD O
- O
like O
behaviors O
in O
SHR O
via O
enhancement O
of O
DA O
neurotransmission O
and O
not O
modulation O
of O
GABA B
pathway O
as O
previously O
reported O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
toxicity O
of O
a O
mixture O
containing O
the O
biocides O
picoxystrobin O
, O
esfenvalerate B
, O
and O
triclosan B
to O
the O
reproduction O
and O
adult O
survival O
of O
two O
consecutive O
generations O
of O
Eisenia O
fetida O
( O
Savigny O
, O
1826 O
) O
. O

Inadequate O
levothyroxine B
replacement O
for O
primary O
hypothyroidism O
is O
associated O
with O
poor O
health O
- O
related O
quality O
of O
life O
- O
a O
Brazilian O
multicentre O
study O
. O

This O
study O
aimed O
to O
verify O
the O
impact O
of O
levothyroxine B
replacement O
on O
health O
- O
related O
quality O
of O
life O
( O
HRQoL O
) O
in O
a O
Brazilian O
sample O
of O
primary O
hypothyroidism O
patients O
. O

A O
cross O
- O
sectional O
study O
was O
performed O
with O
2 O
, O
057 O
consecutive O
primary O
hypothyroidism O
patients O
on O
levothyroxine B
( O
LT4 B
) O
replacement O
at O
four O
referral O
centers O
in O
Brazil O
( O
median O
age O
= O
53 O
; O
25th O
percentile O
= O
43 O
; O
75th O
percentile O
= O
61 O
years O
) O
. O

Therefore O
, O
adequate O
LT4 B
therapy O
should O
be O
given O
to O
maintain O
serum O
TSH O
within O
the O
reference O
range O
. O

Dietary O
intake O
of O
macronutrients O
( O
carbohydrate B
, O
protein O
, O
and O
fat O
) O
has O
been O
associated O
with O
risk O
of O
chronic O
conditions O
such O
as O
obesity O
and O
diabetes O
. O

carbohydrate B
. O

Herein O
, O
we O
show O
that O
, O
although O
all O
studied O
nanodiscs O
align O
with O
their O
lipid O
bilayer O
parallel O
to O
the O
interface O
, O
gel O
- O
phase O
DMPC B
nanodiscs O
form O
the O
most O
suitable O
film O
for O
future O
membrane O
protein O
studies O
since O
they O
yield O
a O
dense O
irreversibly O
adsorbed O
film O
with O
low O
roughness O
and O
high O
stability O
over O
time O
. O

This O
may O
be O
explained O
by O
the O
appropriate O
matching O
between O
the O
thickness O
of O
the O
hydrophobic O
lipid O
core O
of O
gel O
phase O
DMPC B
and O
the O
height O
of O
the O
belt O
protein O
. O

Moreover O
, O
once O
formed O
the O
gel O
- O
phase O
DMPC B
nanodiscs O
film O
can O
be O
heated O
up O
to O
melt O
the O
lipid O
bilayer O
, O
thus O
providing O
a O
more O
biologically O
friendly O
environment O
for O
membrane O
proteins O
. O

The O
GABA B
A O
receptor O
subunits O
heterologously O
expressed O
in O
Xenopus O
oocytes O
. O

The O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
A O
receptor O
is O
composed O
of O
a O
variety O
of O
subunits O
and O
combinations O
and O
shows O
a O
characteristic O
distribution O
in O
the O
CNS O
. O

To O
date O
, O
20 O
subunits O
of O
the O
GABA B
A O
receptor O
have O
been O
cloned O
: O
alpha O
1 O
- O
6 O
, O
beta O
1 O
- O
4 O
, O
gamma O
1 O
- O
3 O
, O
delta O
, O
pi O
, O
epsilon O
, O
Theta O
, O
and O
rho O
1 O
- O
3 O
. O

Oocyte O
of O
Xenopus O
laevis O
is O
one O
of O
the O
most O
frequently O
used O
heterologous O
expression O
systems O
, O
which O
are O
used O
to O
design O
and O
analyze O
specific O
combinations O
of O
GABA B
A O
receptor O
subunits O
. O

In O
oocytes O
, O
a O
certain O
GABA B
A O
receptor O
function O
is O
studied O
only O
by O
comparing O
the O
amplitude O
of O
the O
response O
to O
GABA B
and O
other O
drugs O
by O
physiological O
and O
pharmacological O
methods O
. O

The O
results O
of O
studies O
on O
oocytes O
show O
that O
PKA O
, O
NKCC1 O
, O
P2X3 O
receptors O
, O
and O
GABA B
A O
receptor O
- O
associated O
protein O
, O
etc O
. O
, O
are O
existing O
systems O
that O
show O
different O
reactivity O
to O
the O
GABA B
A O
receptors O
. O

The O
GABA B
A O
receptor O
subunits O
contain O
distinct O
binding O
sites O
for O
BZDs O
, O
neurosteroids B
, O
general O
anesthetics O
, O
etc O
. O
, O
which O
are O
responsible O
for O
the O
numerous O
functions O
of O
the O
GABA B
A O
receptor O
. O

A O
variety O
of O
other O
drugs O
, O
such O
as O
topiramate B
, O
TG41 O
, O
( O
+ O
) O
- O
and O
( O
- O
) O
- O
borneol O
, O
apigenin B
, O
and O
6 O
- O
methylflavone O
could O
also O
have O
modulatory O
effects O
on O
the O
GABA B
A O
receptors O
. O

Some O
of O
the O
different O
models O
and O
hypotheses O
on O
GABA B
A O
receptor O
structure O
and O
function O
have O
been O
achieved O
by O
using O
the O
two O
- O
electrode O
voltage O
clamp O
method O
in O
oocytes O
. O

Taxol B
: O
efficacy O
against O
oral O
squamous O
cell O
carcinoma O
. O

In O
medicinal O
chemistry O
, O
one O
of O
the O
most O
studied O
molecules O
in O
recent O
history O
is O
taxol B
. O

Taxol B
is O
a O
versatile O
natural O
product O
that O
is O
used O
in O
various O
cancer O
treatment O
regimens O
. O

Taxol B
has O
been O
tested O
in O
a O
number O
of O
research O
and O
clinical O
phase O
trials O
to O
determine O
feasibility O
, O
toxicity O
, O
and O
cytotoxicity O
against O
oral O
squamous O
cell O
carcinoma O
as O
a O
single O
drug O
regimen O
and O
as O
a O
contributing O
drug O
component O
in O
treatment O
plans O
. O

This O
paper O
reviews O
over O
forty O
articles O
that O
examine O
cell O
lines O
, O
murine O
models O
, O
and O
human O
results O
for O
the O
response O
of O
taxol B
against O
squamous O
cell O
carcinoma O
( O
SCC O
) O
of O
the O
oral O
cavity O
and O
the O
tongue O
. O

Unfortunatelly O
there O
is O
a O
single O
drug O
for O
the O
treatment O
of O
all O
forms O
of O
schistosomiasis O
, O
praziquantel B
, O
which O
was O
introduced O
in O
therapy O
in O
1980 O
. O

The O
article O
goes O
by O
antimony O
compounds O
, O
emetine O
, O
hydantoin O
, O
nitrofurans O
, O
lucanthone O
, O
hycanthone O
, O
oxamniquine O
derivatives O
and O
organophosphates B
until O
it O
finally O
gets O
to O
praziquantel B
derivatives O
. O

This O
ECL O
platform O
was O
presented O
by O
covalently O
coupling O
the O
18 O
- O
mer O
amino O
- O
substituted O
oligonucleotide O
( O
ODN O
) O
probes O
with O
aldehyde B
groups O
that O
are O
strongly O
reactive O
toward O
a O
variety O
of O
nucleophiles O
on O
the O
surface O
of O
solid O
substrates O
. O

How O
the O
quantum O
efficiency O
of O
a O
highly O
emissive O
binuclear O
copper B
complex O
is O
enhanced O
by O
changing O
the O
processing O
solvent O
. O

The O
influence O
of O
these O
effects O
on O
a O
binuclear O
, O
strongly O
luminescent O
copper B
( I
I I
) I
complex O
was O
investigated O
. O

The O
existence O
of O
similar O
effects O
on O
aluminum B
and O
iridium O
compounds O
has O
been O
confirmed O
by O
application O
of O
different O
processing O
solvents O
on O
Alq3 O
and O
Ir O
( O
ppy O
) O
3 O
. O

Heavy O
- O
enzyme O
kinetic O
isotope O
effects O
on O
proton O
transfer O
in O
alanine B
racemase O
. O

The O
catalytic O
effects O
of O
perdeuterating O
the O
pyridoxal O
phosphate O
- O
dependent O
enzyme O
alanine B
racemase O
from O
Geobacillus O
stearothermophilus O
are O
reported O
. O

These O
data O
implicate O
a O
direct O
role O
for O
protein O
vibrational O
motions O
in O
barrier O
crossing O
for O
proton O
- O
transfer O
steps O
in O
alanine B
racemase O
. O

NMR O
and O
functional O
data O
indicate O
that O
activation O
requires O
an O
N B
- O
terminal O
interaction O
between O
the O
transmembrane O
helices O
, O
which O
promotes O
an O
antiparallel O
interaction O
between O
juxtamembrane O
segments O
and O
release O
of O
inhibition O
by O
the O
membrane O
. O

We O
conclude O
that O
EGF O
binding O
removes O
steric O
constraints O
in O
the O
extracellular O
module O
, O
promoting O
activation O
through O
N B
- O
terminal O
association O
of O
the O
transmembrane O
helices O
. O

Vitamin B
D I
metabolism O
in O
human O
bone O
marrow O
stromal O
( O
mesenchymal O
stem O
) O
cells O
. O

Their O
in O
vitro O
differentiation O
to O
osteoblasts O
is O
stimulated O
by O
1 O
alpha O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
, O
and O
recent O
evidence O
indicates O
that O
they O
have O
the O
capacity O
to O
metabolize O
vitamin B
D I
in O
a O
regulated O
manner O
. O

Human O
MSCs O
express O
the O
vitamin B
D I
receptor O
, O
25 O
- O
hydroxylases O
, O
1 O
alpha O
- O
hydroxylase O
, O
and O
24 O
- O
hydroxylase O
; O
stimulation O
of O
in O
vitro O
osteoblastogenesis O
by O
25 O
( O
OH O
) O
D O
depends O
on O
the O
activity O
of O
CYP27B1 O
/ O
1 O
alpha O
- O
hydroxylase O
. O

The O
finding O
that O
hMSCs O
are O
a O
both O
a O
producer O
and O
target O
of O
1 O
alpha O
, O
25 O
( O
OH O
) O
( O
2 O
) O
D O
suggests O
a O
potential O
autocrine O
/ O
paracrine O
role O
of O
vitamin B
D I
metabolism O
in O
osteoblast O
differentiation O
. O

Branched O
chain O
amino B
acids I
are O
novel O
biomarkers O
for O
discrimination O
of O
metabolic O
wellness O
. O

Cardiometabolic O
abnormalities O
were O
defined O
as O
: O
( O
1 O
) O
impaired O
fasting O
glucose B
( O
> O
= O
100mg O
/ O
dL O
and O
< O
= O
126mg O
/ O
dL O
) O
; O
( O
2 O
) O
hypertension O
; O
( O
3 O
) O
triglycerides B
> O
= O
150mg O
/ O
dL O
; O
( O
4 O
) O
HDL O
- O
C O
< O
40mg O
/ O
dL O
in O
men O
, O
< O
50mg O
/ O
dL O
in O
women O
; O
and O
( O
5 O
) O
insulin O
resistance O
( O
calculated O
Homeostatic O
Model O
Assessment O
( O
HOMA O
- O
IR O
) O
index O
of O
> O
5 O
. O
13 O
) O
. O

PCA O
- O
derived O
factors O
with O
levels O
that O
differed O
the O
most O
between O
MW O
and O
MUW O
groups O
were O
factors O
4 O
( O
branched O
chain O
amino B
acids I
[ O
BCAA O
] O
) O
[ O
p O
< O
. O
0001 O
] O
, O
8 O
( O
various O
metabolites O
) O
[ O
p O
< O
. O
0001 O
] O
, O
9 O
( O
C4 O
/ O
Ci4 O
, O
C3 O
, O
C5 O
acylcarnitines O
) O
[ O
p O
< O
. O
0001 O
] O
and O
10 O
( O
amino B
acids I
) O
[ O
p O
< O
. O
0002 O
] O
. O

Critical O
role O
of O
a O
methyl B
group O
on O
the O
gamma B
- I
lactone I
ring O
of O
annonaceous O
acetogenins O
in O
the O
potent O
inhibition O
of O
mitochondrial O
complex O
I O
. O

Their O
inhibitory O
activity O
, O
along O
with O
previously O
synthesized O
analogues O
( O
C35 O
- O
fluoro O
, O
C35 O
- O
difluoro O
, O
and O
C35 O
- O
trifluorosolamins O
) O
, O
against O
bovine O
mitochondrial O
NADH B
- O
ubiquinone O
oxidoreductase O
( O
complex O
I O
) O
was O
determined O
. O

The O
present O
study O
revealed O
that O
the O
methyl B
group O
on O
the O
gamma B
- I
lactone I
moiety O
is O
critical O
to O
the O
potent O
inhibition O
of O
complex O
I O
by O
natural O
acetogenins O
. O

Synthesis O
and O
antibacterial O
activity O
of O
9 O
- O
oxime O
ether B
non O
- O
ketolides O
, O
and O
novel O
binding O
mode O
of O
alkylides O
with O
bacterial O
rRNA O
. O

We O
report O
a O
series O
of O
new O
9 O
- O
oxime O
ether B
non O
- O
ketolides O
, O
including O
3 O
- O
hydroxyl O
, O
3 O
- O
O O
- O
acyl O
and O
3 O
- O
O O
- O
alkyl O
clarithromycin O
derivatives O
, O
and O
thiophene B
- O
containing O
ketolides O
1b O
- O
1d O
. O

The O
3 O
- O
O B
- O
sidechains O
of O
19 O
and O
20 O
point O
to O
the O
so O
- O
called O
hydrophilic O
side O
of O
the O
macrolide B
ring O
, O
as O
seen O
in O
clarithromycin B
. O

In O
contrast O
, O
the O
3 O
- O
O B
- O
sidechains O
of O
17 O
and O
18 O
bend O
to O
the O
backside O
, O
the O
so O
- O
called O
hydrophobic O
side O
of O
the O
macrolide O
ring O
. O

The O
results O
clearly O
indicated O
the O
alkylides O
with O
improved O
antibacterial O
activity O
might O
possess O
a O
novel O
binding O
mode O
, O
which O
is O
different O
from O
clarithromycin B
and O
the O
alkylides O
with O
poor O
activity O
. O

Influence O
of O
GluN2 O
subunit O
identity O
on O
NMDA B
receptor O
function O
. O

N B
- I
methyl I
- I
d I
- I
aspartate I
receptors O
( O
NMDARs O
) O
are O
ligand O
- O
gated O
ion O
channels O
( O
' O
ionotropic O
' O
receptors O
) O
activated O
by O
the O
major O
excitatory O
neurotransmitter O
, O
l O
- O
glutamate O
. O

Arsenic B
induced O
neuronal O
apoptosis O
in O
guinea O
pigs O
is O
Ca2 B
+ I
dependent O
and O
abrogated O
by O
chelation O
therapy O
: O
role O
of O
voltage O
gated O
calcium B
channels O
. O

Arsenic B
contaminated O
drinking O
water O
has O
affected O
more O
than O
200 O
million O
people O
globally O
. O

One O
of O
the O
prime O
mechanisms O
postulated O
for O
arsenic B
toxicity O
is O
reactive O
oxygen B
species O
( O
ROS O
) O
mediated O
oxidative O
stress O
. O

In O
this O
study O
, O
we O
explored O
the O
kinetic O
relationship O
of O
ROS O
with O
calcium B
and O
attempted O
to O
dissect O
the O
calcium B
ion O
channels O
responsible O
for O
calcium B
imbalance O
after O
arsenic B
exposure O
. O

We O
also O
explored O
if O
mono O
- O
or O
combinational O
chelation O
therapy O
prevents O
arsenic B
- O
induced O
( O
25ppm O
in O
drinking O
water O
for O
4 O
months O
) O
neuronal O
apoptosis O
in O
a O
guinea O
pig O
animal O
model O
. O

Results O
indicate O
that O
chronic O
arsenic B
exposure O
caused O
a O
significant O
increase O
in O
ROS O
followed O
by O
NO B
and O
calcium B
influx O
. O

This O
calcium B
influx O
is O
mainly O
dependent O
on O
L O
- O
type O
voltage O
gated O
channels O
that O
disrupt O
mitochondrial O
membrane O
potential O
, O
increase O
bax O
/ O
bcl2 O
levels O
and O
caspase O
3 O
activity O
leading O
to O
apoptosis O
. O

Interestingly O
, O
blocking O
of O
ROS O
could O
completely O
reduce O
calcium B
influx O
whereas O
calcium B
blockage O
partially O
reduced O
ROS O
increase O
. O

While O
in O
general O
mono O
- O
and O
combinational O
chelation O
therapies O
were O
effective O
in O
reversing O
arsenic B
induced O
alteration O
, O
combinational O
therapy O
of O
DMSA O
and O
MiADMSA O
was O
most O
effective O
. O

Our O
results O
provide O
evidence O
for O
the O
role O
of O
L O
- O
type O
calcium B
channels O
in O
regulating O
arsenic B
- O
induced O
calcium B
influx O
and O
DMSA O
+ O
MiADMSA O
combinational O
therapy O
may O
be O
a O
better O
protocol O
than O
monotherapy O
in O
mitigating O
chronic O
arsenicosis O
. O

Gastrodin O
attenuation O
of O
the O
inflammatory O
response O
in O
H9c2 O
cardiomyocytes O
involves O
inhibition O
of O
NF O
- O
kappa O
B O
and O
MAPKs O
activation O
via O
the O
phosphatidylinositol B
3 O
- O
kinase O
signaling O
. O

Our O
results O
showed O
that O
gastrodin O
treatment O
strongly O
suppressed O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
family O
activation O
and O
upregulation O
of O
the O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
stimulated O
H9c2 O
cardiomyocytes O
. O

Simultaneously O
, O
gastrodin O
obviously O
upregulated O
the O
phosphatidylinositol B
3 O
- O
kinase O
( O
PI3 O
- O
K O
) O
/ O
Akt O
signaling O
in O
a O
dose O
- O
dependent O
manner O
. O

However O
, O
wortmannin B
, O
a O
specific O
PI3 O
- O
K O
inhibitor O
, O
blocked O
the O
inhibitory O
effects O
of O
gastrodin O
on O
LPS O
- O
stimulated O
H9c2 O
cardiomyocytes O
. O

Furthermore O
, O
PI3 O
- O
K O
/ O
Akt O
inhibition O
partially O
abolished O
the O
inhibitory O
effects O
of O
gastrodin O
on O
the O
phosphorylation O
of O
inhibitor O
kappa O
B O
- O
alpha O
( O
I O
kappa O
B O
- O
alpha O
) O
, O
extracellular O
signal O
- O
regulated O
kinase O
1 O
/ O
2 O
( O
ERK1 O
/ O
2 O
) O
, O
c O
- O
Jun O
N B
- O
terminal O
protein O
kinase O
( O
JNK O
) O
, O
and O
p38 O
mitogen O
- O
activated O
protein O
kinase O
( O
p38 O
MAPK O
) O
, O
and O
activity O
of O
NF O
- O
kappa O
B O
. O

Catalytic O
- O
site O
conformational O
equilibrium O
in O
nerve O
- O
agent O
adducts O
of O
acetylcholinesterase O
: O
Possible O
implications O
for O
the O
HI B
- I
6 I
antidote O
substrate O
specificity O
. O

Nerve O
agents O
such O
as O
tabun B
, O
cyclosarin B
and O
Russian O
VX O
inhibit O
the O
essential O
enzyme O
acetylcholinesterase O
( O
AChE O
) O
by O
organophosphorylatin O
the O
catalytic O
serine B
residue O
. O

Nucleophiles O
, O
such O
as O
oximes B
, O
are O
used O
as O
antidotes O
as O
they O
can O
reactivate O
and O
restore O
the O
function O
of O
the O
inhibited O
enzyme O
. O

The O
oxime B
HI B
- I
6 I
shows O
a O
notably O
low O
activity O
on O
tabun B
adducts O
but O
can O
effectively O
reactivate O
adducts O
of O
cyclosarin B
and O
Russian O
VX O
. O

To O
examine O
the O
structural O
basis O
for O
the O
pronounced O
substrate O
specificity O
of O
HI B
- I
6 I
, O
we O
determined O
the O
binary O
crystal O
structures O
of O
Mus O
musculus O
AChE O
( O
mAChE O
) O
conjugated O
by O
cyclosarin B
and O
Russian O
VX O
and O
found O
a O
conformational O
mobility O
of O
the O
side O
chains O
of O
Phe338 O
and O
His447 O
. O

The O
interaction O
between O
HI B
- I
6 I
and O
tabun B
- O
adducts O
of O
AChE O
were O
subsequently O
investigated O
using O
a O
combination O
of O
time O
resolved O
fluorescence O
spectroscopy O
and O
X O
- O
ray O
crystallography O
. O

Our O
findings O
show O
that O
HI B
- I
6 I
binds O
to O
tabun B
inhibited O
Homo O
sapiens O
AChE O
( O
hAChE O
) O
with O
an O
IC50 O
value O
of O
300 O
mu O
M O
and O
suggest O
that O
the O
reactive O
nucleophilic O
moiety O
of O
HI B
- I
6 I
is O
excluded O
from O
the O
phosphorus B
atom O
of O
tabun B
. O

We O
also O
suggest O
that O
the O
conformational O
mobility O
allow O
HI B
- I
6 I
to O
reactivate O
conjugates O
of O
cyclosarin B
and O
Russian O
VX O
while O
a O
reduced O
mobility O
in O
tabun B
conjugated O
AChE O
results O
in O
steric O
hindrance O
that O
prevents O
efficient O
reactivation O
. O

Hepatocytes O
display O
a O
compensatory O
survival O
response O
against O
cadmium B
toxicity O
by O
a O
mechanism O
mediated O
by O
EGFR O
and O
Src O
. O

Although O
the O
liver O
is O
a O
cadmium B
- O
target O
organ O
, O
hepatocyte O
response O
involved O
in O
its O
toxicity O
is O
not O
yet O
elucidated O
. O

We O
provided O
evidence O
of O
a O
novel O
link O
among O
NADPH B
oxidase O
and O
Stat3 O
signaling O
, O
mediated O
by O
Src O
, O
EGFR O
, O
and O
Erk1 O
/ O
2 O
. O

Cadmium B
activates O
NADPH B
oxidase O
. O

ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine B
, O
allowing O
its O
dimerization O
. O

Also O
, O
ROS O
from O
NADPH B
oxidase O
favors O
ERK1 O
/ O
2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine B
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein O
- O
II O
in O
short O
Cd B
exposure O
times O
. O

However O
, O
after O
12h O
CdCl2 B
treatment O
, O
cell O
viability O
diminished O
in O
50 O
% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein O
- O
II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro O
- O
apoptotic O
protein O
Bax O
. O

Catalpol O
suppresses O
advanced O
glycation O
end O
- O
products O
- O
induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen B
species O
in O
human O
monocytic O
THP O
- O
1 O
cells O
. O

Catalpol O
reduced O
the O
expression O
of O
pro O
- O
inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
inducible O
NO B
synthase O
( O
iNOS O
) O
, O
and O
receptor O
for O
AGE O
( O
RAGE O
) O
. O

Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH B
oxidase O
activity O
. O

Excessive O
ethanol B
consumption O
under O
exposure O
to O
lead O
intensifies O
disorders O
in O
bone O
metabolism O
: O
A O
study O
in O
a O
rat O
model O
. O

It O
was O
investigated O
whether O
ethanol B
( O
Et O
) O
modifies O
the O
damaging O
impact O
of O
lead O
( O
Pb B
) O
on O
bone O
metabolism O
in O
a O
rat O
model O
reflecting O
excessive O
alcohol B
consumption O
by O
humans O
exposed O
to O
relatively O
high O
levels O
of O
this O
metal O
. O

For O
this O
purpose O
, O
markers O
of O
bone O
formation O
( O
osteocalcin O
, O
procollagen O
I O
, O
osteoprotegerin O
, O
alkaline O
phosphatase O
) O
and O
resorption O
( O
telopeptides O
of O
collagen O
I O
, O
soluble O
receptor O
activator O
of O
nuclear O
factor O
- O
kappa O
B O
ligand O
) O
, O
calciotropic O
hormones O
( O
parathormone O
, O
calcitonin O
, O
25 B
- I
hydroxyvitamin I
D I
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
) O
in O
the O
serum O
, O
and O
the O
femur O
content O
of O
mineral O
( O
including O
calcium B
- O

Ca B
and O
inorganic O
phosphorus B
- O
Pi O
) O
and O
organic O
components O
were O
estimated O
in O
the O
rats O
exposed O
to O
500mg O
Pb B
/ O
l O
( O
in O
drinking O
water O
) O
or O
/ O
and O
Et O
( O
5g O
/ O
kg O
b O
. O
wt O
. O
/ O
24h O
, O
by O
oral O
gavage O
) O
for O
12weeks O
. O

Moreover O
, O
Ca B
and O
Pi O
in O
the O
serum O
and O
urine O
, O
alkaline O
phosphatase O
in O
the O
bone O
tissue O
and O
Pb B
in O
the O
blood O
and O
femur O
were O
determined O
. O

The O
exposure O
to O
Pb B
or O
/ O
and O
Et O
decreased O
bone O
formation O
and O
increased O
its O
resorption O
resulting O
in O
the O
bone O
demineralization O
. O

These O
effects O
were O
accompanied O
by O
destroying O
the O
hormonal O
regulation O
of O
mineral O
metabolism O
, O
and O
Ca B
and O
Pi O
imbalance O
. O

The O
co O
- O
exposure O
to O
Pb B
and O
Et O
- O
induced O
disorders O
in O
bone O
metabolism O
were O
more O
advanced O
than O
those O
caused O
by O
Pb B
alone O
. O

Et O
co O
- O
administration O
increased O
Pb B
concentration O
in O
the O
blood O
and O
decreased O
its O
accumulation O
in O
the O
bone O
. O

This O
paper O
is O
the O
first O
report O
providing O
evidence O
that O
consumption O
of O
Et O
under O
exposure O
to O
Pb B
intensifies O
disorders O
in O
bone O
metabolism O
and O
that O
destroying O
of O
the O
receptor O
activator O
nuclear O
factor O
- O
kappa O
B O
( O
RANK O
) O
/ O
RANK O
ligand O
/ O
osteoprotegerin O
system O
is O
involved O
in O
the O
mechanisms O
of O
interactive O
action O
of O
these O
xenobiotics O
on O
the O
skeleton O
. O

The O
modifying O
impact O
of O
Et O
may O
be O
an O
effect O
of O
its O
independent O
osteotropic O
action O
and O
interaction O
with O
Pb B
. O

Based O
on O
the O
results O
it O
can O
be O
concluded O
that O
alcohol B
abuse O
by O
subjects O
excessively O
exposed O
to O
Pb B
considerably O
increases O
the O
risk O
of O
bone O
damage O
. O

Cellular O
mechanisms O
of O
the O
cytotoxic O
effects O
of O
the O
zearalenone B
metabolites O
alpha O
- O
zearalenol O
and O
beta O
- O
zearalenol O
on O
RAW264 O
. O
7 O
macrophages O
. O

Zearalenone B
( O
ZEN O
) O
and O
its O
metabolites O
are O
commonly O
found O
in O
many O
food O
commodities O
and O
are O
known O
to O
cause O
reproductive O
disorders O
and O
genotoxic O
effects O
. O

Use O
of O
an O
inhibitor O
specific O
to O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
, O
p38 O
kinase O
or O
p53 O
, O
but O
not O
pan O
- O
caspase O
or O
caspase O
- O
8 O
, O
decreased O
the O
toxin O
- O
induced O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
also O
attenuated O
the O
alpha O
- O
ZOL O
- O
or O
beta O
- O
ZOL O
- O
induced O
decrease O
of O
cell O
viability O
. O

Sodium B
arsenite I
induces O
cyclooxygenase O
- O
2 O
expression O
in O
human O
uroepithelial O
cells O
through O
MAPK O
pathway O
activation O
and O
reactive O
oxygen B
species O
induction O
. O

Arsenic B
can O
induce O
reactive O
oxygen B
species O
( O
ROS O
) O
leading O
to O
oxidative O
stress O
and O
carcinogenesis O
. O

Bladder O
is O
one O
of O
the O
major O
target O
organs O
of O
arsenic B
, O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
may O
play O
an O
important O
role O
in O
arsenic B
- O
induced O
bladder O
cancer O
. O

However O
, O
the O
mechanism O
by O
which O
arsenic B
induces O
COX O
- O
2 O
in O
bladder O
cells O
remains O
unclear O
. O

This O
study O
aimed O
at O
investigating O
arsenic B
- O
mediated O
intracellular O
redox O
status O
and O
signaling O
cascades O
leading O
to O
COX O
- O
2 O
induction O
in O
human O
uroepithelial O
cells O
( O
SV O
- O
HUC O
- O
1 O
) O
. O

SV O
- O
HUC O
- O
1 O
cells O
were O
exposed O
to O
sodium B
arsenite I
and O
COX O
- O
2 O
expression O
, O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
phosphorylation O
, O
glutathione B
( O
GSH B
) O
levels O
, O
ROS O
induction O
and O
Nrf2 O
expression O
were O
quantified O
. O

Our O
results O
demonstrate O
that O
arsenite B
( O
1 O
- O
10 O
mu O
M O
) O
elevates O
COX O
- O
2 O
expression O
, O
GSH B
levels O
, O
ROS O
and O
Nrf2 O
expression O
. O

Arsenite B
treatment O
for O
24h O
stimulates O
phosphorylation O
of O
ERK O
and O
p38 O
, O
but O
not O
JNK O
in O
SV O
- O
HUC O
- O
1 O
cells O
. O

Induction O
of O
Cox O
- O
2 O
mRNA O
levels O
by O
arsenite B
was O
attenuated O
by O
inhibitors O
of O
ERK O
, O
p38 O
and O
JNK O
. O

Arsenite B
- O
induced O
ROS O
generation O
and O
COX O
- O
2 O
expression O
were O
significantly O
attenuated O
by O
treatment O
with O
melatonin B
( O
a O
ROS O
scavenger O
) O
, O
but O
enhanced O
by O
DL O
- O
buthionine O
- O
( O
S O
, O
R O
) O
- O
sulfoximine O
( O
BSO B
, O
an O
inhibitor O
of O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
resulting O
in O
lower O
GSH B
and O
increased O
ROS O
levels O
) O
. O

These O
data O
indicate O
that O
arsenite B
promotes O
an O
induction O
of O
ROS O
, O
which O
results O
in O
an O
induction O
of O
COX O
- O
2 O
expression O
through O
activation O
of O
the O
MAPK O
pathway O
. O

8 B
- I
Oxoguanine I
DNA O
glycosylase O
1 O
( O
OGG1 O
) O
plays O
an O
important O
role O
in O
repairing O
oxidative O
DNA O
damage O
induced O
by O
chemical O
agents O
, O
such O
as O
tobacco O
. O

Sperm O
8 O
- O
hydroxydeoxyguanine O
( O
8 B
- I
OHdG I
) O
was O
measured O
by O
immunofluorescent O
assay O
using O
flow O
cytometry O
and O
genotypes O
were O
determined O
by O
OpenArray O
platform O
with O
a O
chip O
- O
based O
Taq O
- O
Man O
genotyping O
technology O
. O

Our O
results O
demonstrated O
that O
both O
cigarette O
smoking O
and O
OGG1 O
polymorphism O
can O
affect O
the O
sperm O
8 B
- I
OHdG I
levels O
. O

Individuals O
with O
variant O
Cys B
/ O
Cys B
homozygote O
showed O
higher O
levels O
of O
sperm O
8 B
- I
OHdG I
than O
wide O
- O
type O
homozygote O
carriers O
( O
Ser B
/ O
Ser B
) O
. O

Stratified O
analysis O
found O
that O
the O
association O
between O
OGG1 O
polymorphism O
and O
sperm O
8 B
- I
OHdG I
levels O
was O
only O
observed O
among O
smokers O
with O
pack O
- O
years O
> O
= O
5 O
but O
not O
among O
those O
subjects O
with O
pack O
- O
years O
< O
5 O
( O
pack O
- O
years O
= O
packs O
smoked O
per O
day O
x O
years O
as O
a O
smoker O
) O
. O

Further O
analysis O
based O
on O
the O
case O
- O
control O
study O
revealed O
that O
variant O
allele O
( O
Cys B
) O
of O
OGG1 O
was O
significantly O
associated O
with O
male O
infertility O
risk O
in O
a O
dominant O
model O
( O
OR O
= O
1 O
. O
35 O
, O
95 O
% O
CI O
: O
1 O
. O
01 O
- O
1 O
. O
82 O
; O
trend O
P O
< O
0 O
. O
001 O
) O
. O

Catechins B
are O
not O
major O
components O
responsible O
for O
the O
beneficial O
effect O
of O
Camellia O
sinensis O
on O
the O
ovarian O
delta B
- I
ALA I
- O
D O
activity O
inhibited O
by O
cadmium B
. O

Cadmium B
has O
been O
associated O
with O
a O
wide O
spectrum O
of O
deleterious O
effects O
on O
the O
reproductive O
tissues O
, O
including O
ovary O
. O

This O
investigation O
evaluated O
the O
protective O
role O
of O
Camellia O
sinensis O
( O
green O
, O
white O
and O
red O
teas O
) O
in O
the O
cadmium B
- O
induced O
inhibition O
of O
ovarian O
delta O
- O
aminolevulinate O
dehydratase O
( O
delta B
- I
ALA I
- O
D O
) O
activity O
in O
vitro O
and O
ex O
vivo O
. O

This O
study O
demonstrated O
that O
green O
and O
white O
teas O
restored O
the O
cow O
ovary O
delta B
- I
ALA I
- O
D O
activity O
inhibited O
by O
cadmium B
whereas O
red O
tea O
had O
no O
effect O
in O
vitro O
. O

In O
addition O
, O
green O
tea O
was O
able O
to O
restore O
enzyme O
activity O
inhibited O
after O
acute O
cadmium B
exposure O
in O
mice O
ovary O
. O

Teas O
infusions O
composition O
was O
assessed O
by O
HPLC O
in O
a O
quantitative O
assay O
for O
catechins B
, O
purine O
alkaloids O
and O
gallic B
acid I
as O
well O
as O
total O
polyphenol B
content O
. O

The O
greatest O
effect O
of O
green O
tea O
observed O
in O
vitro O
as O
well O
as O
the O
protective O
role O
presented O
in O
the O
ex O
vivo O
study O
could O
be O
attributed O
to O
the O
major O
content O
of O
phenols B
, O
but O
not O
catechins B
. O

In O
fact O
, O
catechins B
were O
not O
able O
to O
restore O
enzyme O
activity O
inhibited O
by O
cadmium B
, O
demonstrating O
that O
these O
compounds O
are O
not O
major O
components O
responsible O
for O
the O
beneficial O
effect O
of O
green O
tea O
observed O
in O
this O
study O
. O

This O
study O
demonstrated O
the O
helpful O
effect O
of O
green O
tea O
infusion O
in O
ameliorating O
a O
marker O
protein O
of O
cadmium B
intoxication O
in O
ovarian O
tissue O
. O

Compound O
5 O
showed O
, O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
and O
beta B
- I
carotene I
systems O
, O
similar O
antioxidant O
activity O
when O
compared O
to O
compound O
( O
1 O
) O
. O

Isolation O
of O
a O
flavonoid B
, O
apigenin B
7 I
- I
O I
- I
glucoside I
, O
from O
Mentha O
longifolia O
( O
L O
. O
) O
Hudson O
subspecies O
longifolia O
and O
its O
genotoxic O
potency O
. O

Recently O
, O
it O
has O
been O
found O
that O
the O
use O
of O
Mentha O
as O
a O
pharmaceutical O
source O
is O
based O
on O
its O
phytochemical O
constituents O
that O
have O
far O
been O
identified O
as O
tannins B
, O
saponins B
, O
phenolic B
acids I
and O
flavonoids B
. O

This O
study O
was O
designed O
to O
evaluate O
the O
mutagenic O
and O
antimutagenic O
activities O
of O
apigenin B
7 I
- I
O I
- I
glucoside I
( O
A7G O
) O
, O
a O
flavonoid B
isolated O
from O
Mentha O
longifolia O
( O
L O
. O
) O
Hudson O
subspecies O
longifolia O
( O
ML O
) O
. O

The O
possible O
antimutagenic O
potential O
of O
A7G O
was O
examined O
against O
mutagens O
ethyl O
methanesulfonate O
and O
acridine B
in O
an O
eukaryotic O
cell O
system O
Saccharomyces O
cerevisiae O
and O
sodium B
azide I
in O
Salmonella O
typhimurium O
TA1535 O
and O
9 O
- O
aminoacridine O
in O
S O
. O
typhimurium O
TA1537 O
. O

This O
genotoxicological O
study O
suggests O
that O
a O
flavonoid B
from O
ML O
owing O
to O
antimutagenic O
properties O
is O
of O
great O
pharmacological O
importance O
and O
might O
be O
beneficial O
to O
industries O
producing O
food O
additives O
, O
cosmetics O
and O
pharmaceuticals O
products O
. O

Moreover O
, O
the O
in O
vitro O
effects O
of O
some O
commonly O
used O
pesticides O
including O
chlorpyrifos B
, O
cypermethrin B
, O
dichlorvos B
, O
glyphosate O
isopropylamine O
and O
lambda O
cyhalomethrin O
on O
the O
enzyme O
activity O
were O
investigated O
. O

Of O
these O
compounds O
, O
glyphosate O
isopropylamine O
and O
dichlorvos B
showed O
an O
inhibition O
on O
CA O
- O
II O
esterase O
activity O
. O

Both O
glyphosate O
isopropylamine O
and O
dichlorvos B
inhibited O
CA O
- O
II O
isoenzyme O
in O
a O
noncompetitive O
manner O
. O

Here O
we O
show O
that O
Trim24 O
and O
Trim33 O
cooperatively O
repress O
retinoic B
acid I
receptor O
- O
dependent O
activity O
of O
VL30 O
- O
class O
endogenous O
retroviruses O
( O
ERVs O
) O
in O
liver O
. O

Association O
between O
bisphenol B
A I
and O
abnormal O
free O
thyroxine B
level O
in O
men O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
a O
chemical O
that O
is O
used O
in O
a O
variety O
of O
consumer O
products O
, O
and O
exposure O
to O
BPA B
is O
widespread O
among O
the O
general O
population O
. O

Recent O
studies O
have O
suggested O
that O
BPA B
may O
affect O
the O
thyroid O
and O
related O
pathways O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
relationship O
between O
BPA B
exposure O
and O
thyroid O
function O
. O

Serum O
BPA B
, O
TSH O
, O
FT O
( O
4 O
) O
, O
and O
related O
covariates O
were O
measured O
. O

BPA B
was O
log O
- O
transformed O
prior O
to O
analysis O
. O

BPA B
was O
detected O
in O
52 O
. O
8 O
% O
of O
serum O
samples O
with O
a O
median O
concentration O
of O
0 O
. O
33 O
( O
range O
0 O
- O
66 O
. O
91 O
) O
ng O
/ O
mL O
. O

We O
excluded O
subjects O
who O
tested O
positive O
for O
thyroid O
autoantibody O
and O
then O
stratified O
the O
remaining O
subjects O
by O
gender O
; O
the O
analysis O
showed O
a O
significantly O
negative O
correlation O
between O
serum O
BPA B
and O
FT O
( O
4 O
) O
levels O
in O
males O
( O
r O
= O
- O
0 O
. O
14 O
, O
P O
< O
0 O
. O
001 O
) O
. O

BPA B
was O
not O
associated O
with O
TSH O
in O
either O
gender O
. O

This O
gender O
- O
related O
discrepancy O
is O
possibly O
related O
to O
androgen B
- O
related O
differences O
in O
the O
metabolism O
of O
BPA B
. O

Our O
preliminary O
results O
provide O
evidence O
of O
a O
negative O
association O
between O
BPA B
and O
FT O
( O
4 O
) O
levels O
. O

Antiviral O
treatment O
is O
available O
chiefly O
for O
infections O
caused O
by O
herpesviruses O
, O
and O
acyclovir B
( O
aciclovir O
) O
is O
the O
drug O
of O
choice O
for O
empirical O
therapy O
in O
suspected O
viral O
encephalitis O
. O

Although O
the O
brain O
damage O
is O
believed O
to O
depend O
, O
to O
a O
varying O
degree O
, O
on O
the O
intrathecal O
host O
immune O
response O
, O
the O
use O
of O
corticosteroids B
in O
viral O
CNS O
infections O
is O
scarcely O
studied O
, O
as O
is O
specific O
treatment O
for O
neuroinflammation O
. O

Sediment O
- O
associated O
legacy O
organochlorine B
pesticides O
and O
CUPs O
- O
including O
organophosphates B
, O
pyrethroids B
, O
fipronil B
, O
and O
abamectin O
- O
were O
analyzed O
. O

Abamectin O
, O
fipronil B
, O
and O
pyrethroids B
( O
mainly O
cypermethrin B
) O
were O
identified O
as O
the O
principal O
contributors O
to O
the O
noted O
toxicity O
in O
the O
midges O
, O
with O
median O
predicted O
toxic O
units O
of O
1 O
. O
63 O
, O
1 O
. O
63 O
, O
and O
1 O
. O
03 O
, O
respectively O
. O

The O
present O
study O
is O
the O
first O
of O
its O
kind O
to O
link O
sediment O
CUPs O
, O
fipronil B
, O
and O
abamectin O
concentrations O
with O
toxicity O
in O
urban O
streams O
in O
China O
with O
a O
focus O
on O
shifting O
pesticide O
usage O
patterns O
. O

This O
was O
independent O
of O
age O
, O
sex O
, O
calcineurine O
inhibitors O
, O
prednisolone B
use O
, O
components O
of O
the O
metabolic O
syndrome O
, O
or O
homeostasis O
model O
assessment O
. O
CONCLUSIONSIn O
conclusion O
, O
fasting O
proinsulin O
is O
strongly O
associated O
with O
NODAT O
development O
in O
RTR O
. O

OBJECTIVEWe O
investigated O
whether O
glycation O
gap O
( O
G O
- O
Gap O
) O
, O
an O
index O
of O
intracellular O
glycation O
of O
proteins O
, O
was O
associated O
with O
diabetes O
complications O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
concomitantly O
HbA O
( O
1c O
) O
and O
fructosamine B
in O
925 O
patients O
with O
type O
2 O
diabetes O
to O
calculate O
the O
G O
- O
Gap O
, O
defined O
as O
the O
difference O
between O
measured O
HbA O
( O
1c O
) O
, O
and O
fructosamine B
- O
based O
predicted O
HbA O
( O
1c O
) O
. O

Because O
macroproteinuria O
was O
associated O
with O
lower O
serum O
albumin O
and O
fructosamine B
levels O
, O
which O
might O
account O
for O
higher O
G O
- O
Gap O
, O
we O
calculated O
in O
this O
subpopulation O
albumin O
- O
indexed O
fructosamine B
and O
G O
- O
Gap O
; O
macroproteinuria O
was O
independently O
associated O
with O
male O
gender O
( O
odds O
ratio O
[ O
OR O
] O
, O
3 O
. O
2 O
; O
95 O
% O
CI O
, O
1 O
. O
5 O
- O
6 O
. O
7 O
; O
P O
< O
0 O
. O
01 O
) O
, O
hypertension O
( O
2 O
. O
9 O
; O
[ O
1 O
. O
1 O
- O
7 O
. O
5 O
] O
; O
P O
< O
0 O
. O
05 O
) O
, O
and O
the O
third O
tertile O

Upamostat O
( O
Mesupron O
( O
R O
) O
) O
is O
a O
new O
small O
molecule O
serine B
protease O
inhibitor O
. O

The O
recently O
discovered O
molybdenum O
enzyme O
" O
mitochondrial O
Amidoxime O
Reducing O
Component O
" O
( O
mARC O
) O
catalyses O
together O
with O
its O
electron O
transport O
proteins O
cytochrome O
b O
( O
5 O
) O
and O
NADH B
cytochrome O
b O
( O
5 O
) O
reductase O
the O
reduction O
of O
N B
- O
hydroxylated O
prodrugs O
. O

In O
vitro O
biotransformation O
assays O
with O
porcine O
subcellular O
fractions O
and O
the O
reconstituted O
human O
enzymes O
demonstrate O
an O
mARC O
- O
dependent O
N B
- O
reduction O
of O
upamostat O
. O

Multifunctional O
conducting O
fibres O
with O
electrically O
controlled O
release O
of O
ciprofloxacin B
. O

The O
method O
involves O
wet O
- O
spinning O
of O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
poly O
( O
styrenesulfonate O
) O
( O
PEDOT B
: O
PSS O
) O
fibre O
, O
which O
served O
as O
the O
inner O
core O
to O
the O
electropolymerised O
outer O
shell O
layer O
of O
polypyrrole B
( O
Ppy O
) O
. O

Ciprofloxacin B
hydrochloride B
( O
Cipro O
) O
was O
selected O
as O
the O
model O
drug O
and O
as O
the O
dopant O
in O
the O
Ppy O
synthesis O
. O

The O
release O
of O
Cipro O
in O
phosphate B
buffered O
saline O
( O
PBS O
) O
from O
the O
fibres O
was O
controlled O
by O
switching O
the O
redox O
state O
of O
Ppy O
. O
Cipro O
layer O
. O

PEI B
and O
polylysine O
are O
among O
the O
most O
investigated O
synthetic O
polymeric O
carriers O
for O
DNA O
delivery O
. O

Hyperbranched O
polylysine O
can O
be O
produced O
at O
low O
costs O
and O
in O
large O
quantities O
, O
is O
partially O
biodegradable O
, O
which O
may O
help O
to O
prevent O
cumulative O
cytotoxicity O
, O
and O
possesses O
transfection O
properties O
that O
can O
approach O
those O
of O
PEI B
. O

Titanium B
dioxide I
nanoparticles O
increase O
inflammatory O
responses O
in O
vascular O
endothelial O
cells O
. O

Recently O
, O
engineered O
nanoparticles O
( O
NPs O
) O
such O
as O
titanium O
( O
TiO2 B
) O
NPs O
have O
attracted O
much O
attention O
due O
to O
their O
wide O
range O
of O
applications O
. O

Although O
TiO2 B
NPs O
are O
known O
to O
induce O
oxidative O
stress O
and O
inflammation O
, O
the O
associated O
signaling O
pathways O
have O
not O
been O
well O
studied O
. O

The O
focus O
of O
this O
work O
, O
therefore O
, O
deals O
with O
examination O
of O
the O
cellular O
signaling O
pathways O
responsible O
for O
TiO2 B
NP O
- O
induced O
endothelial O
oxidative O
stress O
and O
inflammation O
. O

In O
this O
study O
, O
primary O
vascular O
endothelial O
cells O
were O
treated O
with O
TiO2 B
NPs O
for O
2 O
- O
16h O
at O
concentrations O
of O
0 O
- O
50 O
mu O
g O
/ O
mL O
. O

TiO2 B
NP O
exposure O
increased O
cellular O
oxidative O
stress O
and O
DNA O
binding O
of O
NF O
- O
kappa O
B O
. O

Further O
, O
phosphorylation O
of O
Akt O
, O
ERK O
, O
JNK O
and O
p38 O
was O
increased O
in O
cells O
exposed O
to O
TiO2 B
NPs O
. O

TiO2 B
NPs O
also O
significantly O
increased O
induction O
of O
mRNA O
and O
protein O
levels O
of O
vascular O
cell O
adhesion O
molecule O
- O
1 O
( O
VCAM O
- O
1 O
) O
and O
mRNA O
levels O
of O
monocyte O
chemoattractant O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
. O

Pretreatment O
with O
inhibitors O
for O
NF O
- O
kappa O
B O
( O
pyrrolidine B
dithiocarbamate I
) O
, O
oxidative O
stress O
( O
epigallocatechin B
gallate I
and O
apocynin B
) O
, O
Akt O
( O
LY294002 B
) O
, O
ERK O
( O
PD98059 B
) O
, O
JNK O
( O
SP600125 B
) O
and O
p38 O
( O
SB203580 B
) O
significantly O
attenuated O
TiO2 B
NP O
- O
induced O
MCP O
- O
1 O
and O
VCAM O
- O
1 O
gene O
expression O
. O

These O
data O
indicate O
that O
TiO2 B
NPs O
can O
induce O
endothelial O
inflammatory O
responses O
via O
redox O
- O
sensitive O
cellular O
signaling O
pathways O
. O

Cinnamic B
acid I
derivatives O
as O
inhibitors O
for O
chorismatases O
and O
isochorismatases O
. O

Based O
on O
simplification O
of O
the O
physiological O
substrates O
, O
two O
cinnamic B
acid I
- O
derived O
compounds O
, O
differing O
in O
the O
saturation O
of O
the O
side O
chain O
, O
were O
developed O
. O

Carbon B
monoxide I
protects O
against O
ovariectomy O
- O
induced O
bone O
loss O
by O
inhibiting O
osteoclastogenesis O
. O

Carbon B
monoxide I
( O
CO B
) O
has O
been O
shown O
to O
have O
remarkable O
therapeutic O
value O
at O
low O
dosage O
by O
suppressing O
inflammation O
via O
inhibitory O
effects O
on O
macrophages O
, O
which O
are O
also O
precursors O
of O
osteoclasts O
( O
OC O
) O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
determine O
whether O
CO B
limits O
bone O
loss O
through O
its O
effects O
on O
osteoclastogenesis O
. O

Intraperitoneal O
injection O
of O
CO B
- O
releasing O
molecule O
2 O
( O
CORM2 O
) O
into O
mice O
with O
reduced O
bone O
mass O
due O
to O
ovariectomy O
( O
OVX O
) O
resulted O
in O
significantly O
elevated O
bone O
mass O
. O

Increased O
serum O
levels O
of O
collagen O
- O
type O
I O
fragments O
, O
tartrate B
- O
resistant O
acid O
phosphatase O
5b O
, O
and O
reactive O
oxygen B
species O
( O
ROS O
) O
due O
to O
OVX O
were O
also O
decreased O
when O
treated O
with O
CORM2 O
. O

Inhibition O
of O
NADPH B
oxidase O
partially O
reduced O
the O
inhibitory O
effect O
of O
CO B
. O

CO B
induced O
increase O
of O
peroxiredoxin O
1 O
( O
PRX1 O
) O
in O
BMM O
. O

Down O
- O
regulation O
of O
PRX1 O
reduced O
the O
inhibitory O
effect O
of O
CO B
on O
OC O
formation O
and O
sustained O
the O
ROS O
levels O
induced O
by O
RANKL O
, O
suggesting O
that O
CO B
reduces O
generation O
of O
ROS O
and O
scavenges O
ROS O
to O
inhibit O
osteoclastogenesis O
. O

These O
data O
suggest O
that O
the O
inhibitory O
effect O
of O
CO B
on O
osteoclastogenesis O
is O
caused O
by O
impaired O
RANKL O
signaling O
through O
defective O
NF O
- O
kappa O
B O
activation O
and O
reduced O
levels O
of O
long O
- O
lasting O
ROS O
. O

Our O
data O
highlight O
the O
potential O
utility O
of O
CO B
for O
ameliorating O
bone O
loss O
induced O
by O
loss O
of O
ovarian O
function O
. O

Kocurin B
, O
the O
true O
structure O
of O
PM181104 O
, O
an O
anti O
- O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
thiazolyl B
peptide O
from O
the O
marine O
- O
derived O
bacterium O
Kocuria O
palustris O
. O

A O
new O
thiazolyl B
peptide O
, O
kocurin B
( O
1 O
) O
, O
was O
isolated O
from O
culture O
broths O
of O
a O
marine O
- O
derived O
Kocuria O
palustris O
. O

Its O
structural O
elucidation O
was O
accomplished O
using O
a O
combination O
of O
spectroscopic O
and O
chemical O
methods O
, O
including O
HRMS O
, O
extensive O
1D O
and O
2D O
NMR O
analysis O
, O
MS O
/ O
MS O
fragmentation O
, O
and O
chemical O
degradation O
and O
Marfey O
' O
s O
analysis O
of O
the O
resulting O
amino B
acid I
residues O
. O

Kocurin B
displayed O
activity O
against O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
, O
with O
MIC O
values O
in O
the O
submicromolar O
range O
. O

We O
investigated O
the O
hydrolysis O
of O
anisole O
to O
phenol B
in O
high O
- O
temperature O
water O
with O
and O
without O
water O
- O
tolerant O
Lewis B
acid I
catalysis O
. O

With O
no O
catalyst O
present O
, O
anisole O
hydrolyzes O
to O
phenol B
in O
97 O
% O
yield O
after O
24 O
hours O
at O
365 O
degrees O
C O
, O
our O
experimentally O
determined O
optimal O
temperature O
and O
time O
. O

Of O
the O
water O
- O
tolerant O
Lewis B
acid I
catalysts O
studied O
, O
In O
( O
OTf O
) O
( O
3 O
) O
offered O
the O
best O
phenol B
yield O
. O

In O
the O
presence O
of O
5 O
mol O
% O
In O
( O
OTf O
) O
( O
3 O
) O
catalyst O
, O
anisole O
hydrolyzes O
to O
phenol B
in O
97 O
% O
yield O
after O
90 O
minutes O
at O
300 O
degrees O
C O
. O

Results O
revealed O
that O
the O
electronic O
transitions O
of O
La B
@ O
C O
( O
2v O
) O
- O
C O
( O
82 O
) O
, O
La O
( O
2 O
) O
@ O
I O
( O
h O
) O
- O
C O
( O
80 O
) O
, O
and O
Sc O
( O
3 O
) O
N O
@ O
I O
( O
h O
) O
- O
C O
( O
80 O
) O
can O
be O
assigned O
using O
these O
techniques O
. O

Relationships O
between O
plasma O
pazopanib O
concentrations O
and O
the O
probability O
of O
elevations O
in O
blood O
pressure O
, O
a O
marker O
of O
vascular O
endothelial O
growth O
factor O
receptor O
inhibition O
, O
and O
alanine B
aminotransferase O
( O
ALT O
) O
were O
investigated O
with O
logistic O
regression O
models O
. O

Clopidogrel B
, O
CYP2C19 O
, O
and O
a O
Black O
Box O
. O

It O
has O
been O
presumed O
that O
CYP2C19 O
has O
a O
major O
role O
in O
the O
metabolism O
of O
clopidogrel B
. O

If O
clopidogrel B
were O
primarily O
a O
CYP2C19 O
substrate O
, O
a O
drug O
/ O
drug O
interaction O
with O
CYP2C19 O
inhibitors O
, O
such O
as O
proton O
pump O
inhibitors O
( O
PPIs O
) O
, O
for O
example O
, O
omeprazole B
and O
lansoprazole O
would O
be O
anticipated O
. O

Several O
ex O
vivo O
studies O
, O
using O
ADP B
stimulated O
platelet O
aggregation O
, O
suggested O
that O
there O
was O
such O
an O
interaction O
. O

The O
data O
from O
these O
studies O
served O
as O
a O
basis O
for O
FDA O
to O
provide O
a O
" O
Black O
Box O
" O
warning O
for O
the O
clopidogrel B
label O
in O
March O
of O
2010 O
. O

However O
, O
a O
prospective O
clinical O
study O
, O
COGENT O
, O
and O
several O
large O
meta O
- O
analyses O
have O
failed O
to O
demonstrate O
a O
negative O
effect O
on O
major O
adverse O
cardiovascular O
events O
( O
MACE O
) O
, O
with O
concomitant O
administration O
of O
clopidogrel B
and O
PPIs O
. O

In O
vitro O
metabolism O
using O
hepatosomes O
, O
which O
resemble O
the O
native O
cytochrome O
P O
- O
450 O
enzyme O
expression O
, O
has O
confirmed O
the O
earlier O
work O
that O
clopidogrel B
is O
primarily O
a O
CYP3A O
substrate O
. O

The O
absence O
of O
an O
increase O
in O
MACE O
by O
concomitant O
administration O
of O
PPIs O
, O
which O
are O
CYP2C19 O
inhibitors O
, O
to O
a O
regimen O
including O
clopidogrel B
, O
is O
therefore O
not O
surprising O
. O

Ultralow O
reflection O
from O
a O
- O
Si B
nanograss O
/ O
Si B
nanofrustum O
double O
layers O
. O

A O
double O
- O
layer O
nanostructure O
comprising O
amorphous O
Si B
nanograss O
on O
top O
of O
Si B
nanofrustums O
( O
NFs O
) O
with O
a O
total O
height O
of O
680 O
nm O
exhibits O
ultralow O
reflection O
. O

Almost O
near O
- O
unity O
absorption O
and O
near O
- O
zero O
reflectance O
result O
in O
this O
layered O
nanostructure O
, O
over O
a O
broad O
range O
of O
wavelengths O
and O
a O
wide O
range O
of O
angles O
of O
incidence O
, O
due O
to O
the O
low O
packing O
density O
of O
a O
- O
Si B
and O
the O
smooth O
transition O
of O
the O
refractive O
index O
from O
the O
air O
to O
the O
Si B
substrate O
across O
both O
the O
nanograss O
and O
NF O
layers O
. O

Moreover O
, O
we O
show O
that O
USP22 O
is O
acetylated O
on O
multiple O
lysine B
residues O
and O
that O
alteration O
of O
a O
single O
lysine B
( O
K129 O
) O
within O
the O
ZnF O
- O
UBP O
domain O
is O
sufficient O
to O
alter O
interaction O
of O
the O
DUBm O
with O
the O
core O
SAGA O
complex O
. O

The O
myosin O
- O
18A O
alpha O
isoform O
, O
additionally O
, O
has O
an O
N B
- O
terminal O
PDZ O
domain O
. O

Actin O
binding O
was O
unchanged O
by O
presence O
of O
nucleotide B
. O

Both O
myosin O
- O
18A O
isoforms O
bound O
N O
- O
methylanthraniloyl O
- O
nucleotides O
, O
but O
the O
rate O
of O
ATP B
hydrolysis O
was O
very O
slow O
( O
< O
0 O
. O
002 O
s O
( O
- O
1 O
) O
) O
and O
not O
significantly O
enhanced O
by O
actin O
. O

Phosphorylation O
of O
the O
regulatory O
light O
chain O
had O
no O
effect O
on O
ATP B
hydrolysis O
, O
and O
neither O
did O
the O
addition O
of O
tropomyosin O
or O
of O
GOLPH3 O
, O
a O
myosin O
- O
18A O
binding O
partner O
. O

Electron O
microscopy O
of O
myosin O
- O
18A O
- O
S1 O
showed O
that O
the O
lever O
is O
strongly O
angled O
with O
respect O
to O
the O
long O
axis O
of O
the O
motor O
domain O
, O
suggesting O
a O
pre O
- O
power O
stroke O
conformation O
regardless O
of O
the O
presence O
of O
ATP B
. O

Cellular O
responses O
to O
DNA O
damage O
induced O
by O
etoposide B
or O
doxorubicin B
include O
down O
- O
regulation O
of O
endogenous O
supervillin O
coincident O
with O
increases O
in O
p53 O
. O

USP7 O
binds O
directly O
to O
the O
supervillin O
N B
terminus O
and O
can O
deubiquitinate O
and O
stabilize O
supervillin O
. O

Menopause O
, O
estrogens B
and O
frailty O
. O

However O
, O
these O
results O
have O
been O
vehemently O
contested O
and O
several O
lines O
of O
evidence O
suggest O
that O
in O
perimenopausal O
and O
non O
- O
obese O
women O
, O
estrogen B
therapy O
may O
indeed O
be O
of O
benefit O
. O

Besides O
the O
independent O
, O
direct O
effects O
on O
the O
musculoskeletal O
tissues O
, O
estrogen B
deficiency O
also O
reduces O
the O
ability O
to O
adequately O
respond O
and O
adapt O
to O
external O
mechanical O
and O
metabolic O
stressors O
, O
e O
. O
g O
. O
exercise O
, O
which O
are O
otherwise O
the O
main O
stimuli O
that O
should O
maintain O
musculoskeletal O
integrity O
and O
metabolic O
function O
. O

Thus O
, O
normophysiological O
estrogen B
levels O
appear O
to O
exert O
a O
permissive O
effect O
on O
musculoskeletal O
adaptations O
to O
loading O
, O
thereby O
likely O
improving O
the O
outcome O
of O
rehabilitation O
following O
critical O
illness O
, O
musculoskeletal O
trauma O
or O
orthopedic O
surgical O
therapy O
. O

These O
effects O
add O
to O
the O
evidence O
supporting O
the O
use O
of O
estrogen B
therapy O
, O
particularly O
accelerated O
gain O
of O
functional O
capacity O
and O
independence O
following O
musculoskeletal O
disuse O
. O

Isolation O
of O
a O
mixed O
valence O
diiron O
hydride O
: O
evidence O
for O
a O
spectator O
hydride B
in O
hydrogen B
evolution O
catalysis O
. O

The O
mixed O
- O
valence O
diiron O
hydrido O
complex O
( O
mu O
- O
H O
) O
Fe2 O
( O
pdt O
) O
( O
CO O
) O
2 O
( O
dppv O
) O
2 O
( O
[ O
H1 O
] O
( O
0 O
) O
, O
where O
pdt B
= O
1 O
, O
3 O
- O
propanedithiolate O
and O
dppv O
= O
cis O
- O
1 O
, O
2 O
- O
C2H2 O
( O
PPh2 O
) O
2 O
) O
, O
was O
generated O
by O
reduction O
of O
the O
differous O
hydride B
[ O
H1 O
] O
( O
+ O
) O
using O
decamethylcobaltocen B
. O

The O
unsymmetrical O
( O
unsym O
) O
arrangement O
of O
the O
dppv O
ligands O
is O
reflected O
in O
the O
values O
of O
A O
( O
( B
31 I
) I
P I
) O
, O
which O
range O
from O
31 O
MHz O
for O
the O
basal O
phosphines B
to O
284 O
MHz O
for O
the O
apical O
phosphine O
. O

Density O
functional O
theory O
calculations O
were O
employed O
to O
rationalize O
the O
electronic O
structure O
of O
[ O
H1 O
] O
( O
0 O
) O
and O
to O
facilitate O
spectral O
simulation O
and O
assignment O
of O
EPR O
parameters O
including O
( B
1 I
) I
H I
and O
( B
31 I
) I
P I
hyperfine O
couplings O
. O

The O
EPR O
spectra O
of O
[ O
H1 O
] O
( O
0 O
) O
and O
[ O
D1 O
] O
( O
0 O
) O
demonstrate O
that O
the O
singly O
occupied O
molecular O
orbital O
is O
primarily O
localized O
on O
the O
Fe B
center O
with O
the O
longer O
bond O
to O
H B
, O
that O
is O
, O
Fe O
( O
II O
) O
- O
H O
. O
. O
. O
Fe O
( O
I O
) O
. O

The O
coupling O
to O
the O
hydride B
is O
A O
( O
( B
1 I
) I
H I
) O
= O
55 O
and O
74 O
MHz O
for O
unsym O
- O
amd O
sym O
- O
[ O
H1 O
] O
( O
0 O
) O
, O
respectively O
. O

Treatment O
of O
[ O
H1 O
] O
( O
0 O
) O
with O
H B
( I
+ I
) I
gives O
0 O
. O
5 O
equiv O
of O
H2 B
and O
[ O
H1 O
] O
( O
+ O
) O
. O

Reduction O
of O
D B
( I
+ I
) I
affords O
D2 B
, O
leaving O
the O
hydride B
ligand O
intact O
. O

These O
experiments O
demonstrate O
that O
the O
bridging O
hydride B
ligand O
in O
this O
complex O
is O
a O
spectator O
in O
the O
hydrogen B
evolution O
reaction O
. O

Femtosecond O
Dynamics O
of O
Excitons O
and O
Hole O
- O
Polarons O
in O
Composite O
P3HT B
/ O
PCBM B
Nanoparticles O
. O

The O
dynamics O
of O
charge O
separation O
in O
aqueous O
suspensions O
of O
regioregular O
P3HT B
nanoparticles O
containing O
PCBM B
were O
investigated O
for O
the O
first O
time O
using O
femtosecond O
transient O
absorption O
spectroscopy O
. O

This O
investigation O
is O
supported O
by O
the O
recently O
reported O
use O
of O
regioregular O
P3HT B
/ O
PCBM B
nanoparticles O
as O
charge O
trapping O
and O
storage O
devices O
. O

In O
this O
study O
, O
the O
presence O
of O
excited O
- O
state O
and O
charge O
- O
separated O
species O
, O
including O
singlet O
excitons O
, O
polymer O
polarons O
and O
free O
charges O
, O
generated O
in O
rr O
- O
P3HT B
/ O
PCBM B
nanoparticles O
was O
identified O
through O
visible O
pump O
and O
visible O
/ O
near O
- O
infrared O
probe O
femtosecond O
transient O
absorption O
spectroscopy O
at O
a O
range O
of O
electron O
acceptor O
concentrations O
. O

The O
decrease O
of O
the O
singlet O
exciton O
lifetime O
by O
charge O
transfer O
to O
PCBM B
is O
well O
described O
by O
a O
one O
- O
dimensional O
diffusion O
model O
with O
a O
P3HT B
domain O
size O
of O
approximately O
5 O
nm O
for O
5 O
- O
50 O
wt O
% O
PCBM B
. O

This O
model O
also O
indicates O
that O
bimolecular O
recombination O
is O
the O
dominant O
charge O
recombination O
mechanism O
at O
20 O
wt O
% O
PCBM B
and O
above O
. O

Based O
on O
multivariate O
pattern O
recognition O
methods O
( O
PLS O
- O
DA O
or O
soft O
independent O
modelling O
of O
class O
analogy O
[ O
SIMCA O
] O
) O
, O
these O
models O
allowed O
prediction O
of O
N B
- O
acetylation O
and O
subsequent O
N O
- O
oxanilic O
acid O
formation O
. O

Modelling O
the O
physicochemical O
properties O
of O
the O
N B
- O
acetylated O
compounds O
was O
considered O
as O
an O
addition O
to O
the O
stepwise O
model O
. O

Inclusion O
of O
parameters O
describing O
the O
N B
- I
acetyl I
moiety O
had O
little O
effect O
on O
the O
predictive O
ability O
of O
a O
stepwise O
parent O
to O
N B
- I
acetyl I
to O
N O
- O
oxanilic O
acid O
PLS O
- O
DA O
model O
, O
and O
had O
a O
negative O
impact O
on O
that O
of O
SIMCA O
models O
. O

This O
was O
attributed O
to O
the O
relatively O
small O
contribution O
to O
the O
total O
parameter O
variance O
caused O
by O
differences O
arising O
as O
a O
result O
of O
N B
- O
acetylation O
compared O
to O
the O
contribution O
made O
by O
the O
substituent O
effects O
. O

An O
aluminum B
film O
was O
placed O
between O
two O
polydimethylsiloxane B
( O
PDMS B
) O
membranes O
to O
realize O
frequency O
multiplication O
by O
twice O
contact O
electrifications O
within O
one O
cycle O
of O
external O
force O
. O

Additionally O
, O
the O
well O
- O
designed O
micro O
/ O
nano O
dual O
- O
scale O
structures O
( O
i O
. O
e O
. O
, O
pyramids O
and O
V O
- O
shape O
grooves O
) O
fabricated O
atop O
PDMS B
surface O
was O
employed O
to O
enhance O
the O
device O
performance O
. O

The O
salicylate B
1 O
, O
2 O
- O
dioxygenase O
as O
a O
model O
for O
a O
conventional O
gentisate O
1 O
, O
2 O
- O
dioxygenase O
: O
crystal O
structures O
of O
the O
G106A O
mutant O
and O
its O
adducts O
with O
gentisate O
and O
salicylate B
. O

The O
salicylate B
1 O
, O
2 O
- O
dioxygenase O
( O
SDO O
) O
from O
the O
bacterium O
Pseudaminobacter O
salicylatoxidans O
BN12 O
is O
a O
versatile O
gentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
GDO O
) O
that O
converts O
both O
gentisate O
( O
2 O
, O
5 O
- O
dihydroxybenzoate O
) O
and O
various O
monohydroxylated O
substrates O
. O

SDO O
variants O
M103L O
, O
G106A O
, O
G111A O
, O
R113G O
, O
S147R O
and O
F159Y O
were O
constructed O
and O
it O
was O
found O
that O
G106A O
oxidized O
only O
gentisate O
; O
1 O
- O
hydroxy O
- O
2 O
- O
naphthoate O
and O
salicylate B
were O
not O
converted O
. O

Crystals O
of O
the O
G106A O
SDO O
variant O
and O
its O
complexes O
with O
salicylate B
and O
gentisate O
were O
obtained O
under O
anaerobic O
conditions O
, O
and O
the O
structures O
were O
solved O
and O
analyzed O
. O

The O
amino B
acid I
residue O
Gly106 O
is O
located O
inside O
the O
SDO O
active O
site O
cavity O
but O
does O
not O
directly O
interact O
with O
the O
substrates O
. O

Crystal O
structures O
of O
G106A O
SDO O
complexes O
with O
gentisate O
and O
salicylate B
showed O
a O
different O
binding O
mode O
for O
salicylate B
when O
compared O
with O
the O
wild O
- O
type O
enzyme O
. O

Thus O
, O
salicylate B
coordinated O
in O
the O
G106A O
variant O
with O
the O
catalytically O
active O
Fe B
( I
II I
) I
ion O
in O
an O
unusual O
and O
unproductive O
manner O
because O
of O
the O
inability O
of O
salicylate B
to O
displace O
a O
hydrogen B
bond O
that O
was O
formed O
between O
Trp104 O
and O
Asp174 O
in O
the O
G106A O
variant O
. O

Although O
shedding O
of O
the O
human O
transferrin O
receptor O
- O
1 O
( O
TfR1 O
) O
has O
been O
known O
for O
> O
30 O
years O
and O
soluble O
TfR1 O
is O
an O
accepted O
diagnostic O
marker O
, O
the O
fate O
of O
the O
remaining O
N B
- O
terminal O
fragment O
( O
NTF O
) O
remains O
unknown O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
for O
the O
first O
time O
that O
TfR1 O
- O
NTF O
is O
subject O
to O
regulated O
intramembrane O
proteolysis O
and O
, O
using O
MALDI O
- O
TOF O
- O
TOF O
- O
MS O
, O
we O
have O
identified O
the O
cleavage O
site O
as O
being O
located O
C B
- O
terminal O
from O
Gly B
- O
84 O
. O

We O
showed O
that O
the O
resulting O
C B
- O
terminal O
peptide O
is O
extracellularly O
released O
after O
regulated O
intramembrane O
proteolysis O
and O
it O
was O
detected O
as O
a O
monomer O
with O
an O
internal O
disulfide B
bridge O
. O

Northern O
contaminant O
mixtures O
induced O
morphological O
and O
functional O
changes O
in O
human O
coronary O
artery O
endothelial O
cells O
under O
culture O
conditions O
typifying O
high O
fat O
/ O
sugar B
diet O
and O
ethanol B
exposure O
. O

To O
determine O
if O
these O
contaminants O
may O
contribute O
to O
a O
cardiovascular O
health O
risk O
, O
especially O
when O
combined O
with O
a O
high O
fat O
and O
sugar B
diet O
and O
ethanol B
exposure O
, O
we O
treated O
human O
coronary O
artery O
endothelial O
cells O
( O
HCAEC O
) O
with O
two O
mixtures O
of O
4 O
organic O
( O
NCM1 O
) O
or O
22 O
organic O
and O
inorganic O
( O
NCM2 O
) O
chemicals O
detected O
in O
Northerners O
' O
blood O
during O
2004 O
- O
2005 O
in O
the O
presence O
or O
absence O
of O
low O
- O
density O
lipoprotein O
( O
1 O
. O
5mg O
/ O
ml O
) O
, O
very O
- O
low O
- O
density O
lipoprotein O
( O
1 O
. O
0mg O
/ O
ml O

) O
and O
glucose B
( O
10mmol O
/ O
L O
) O
( O
LVG O
) O
, O
and O
in O
the O
absence O
or O
presence O
of O
0 O
. O
1 O
% O
ethanol B
. O

NCM1 O
treatment O
did O
not O
affect O
cell O
viability O
, O
but O
increased O
cell O
size O
, O
disrupted O
cell O
membrane O
integrity O
, O
and O
decreased O
cell O
density O
, O
uptake O
of O
small O
peptides O
, O
release O
of O
endothelin O
- O
1 O
( O
ET O
- O
1 O
) O
and O
plasminogen O
activator O
inhibitor O
( O
PAI O
) O
, O
while O
causing O
no O
changes O
in O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
protein O
expression O
and O
nitric B
oxide I
( O
NO B
) O
release O
. O

In O
contrast O
, O
NCM2 O
decreased O
cell O
viability O
, O
total O
protein O
yield O
, O
uptake O
of O
small O
peptides O
, O
eNOS O
protein O
expression O
, O
and O
NO B
release O
and O
caused O
membrane O
damage O
, O
but O
caused O
no O
changes O
in O
the O
secretion O
of O
ET O
- O
1 O
, O
prostacyclin B
and O
PAI O
. O

The O
presence O
of O
LVG O
and O
/ O
or O
alcohol B
did O
or O
did O
not O
influence O
the O
effects O
of O
NCM1 O
or O
NCM2 O
depending O
on O
the O
endpoint O
and O
the O
mixture O
examined O
. O

These O
results O
suggested O
that O
the O
effects O
of O
one O
or O
one O
group O
of O
contaminants O
may O
be O
altered O
by O
the O
presence O
of O
other O
contaminants O
, O
and O
that O
with O
or O
without O
the O
interaction O
of O
high O
fat O
and O
sugar B
diet O
and O
/ O
or O
ethanol B
exposure O
, O
NCMs O
at O
the O
concentrations O
used O
caused O
endothelial O
dysfunction O
in O
vitro O
. O

The O
main O
antitumoral O
drugs O
used O
in O
ECT O
are O
nonpermeant O
bleomycin B
and O
low O
permeant O
cisplatin B
. O

We O
used O
bleomycin B
and O
cisplatin B
to O
confirm O
its O
relevance O
and O
doxorubicin B
to O
show O
its O
potential O
to O
screen O
new O
antitumor O
drug O
candidates O
for O
ECT O
. O

New O
pyrazole B
derivatives O
containing O
1 O
, O
2 O
, O
4 O
- O
triazoles O
and O
benzoxazoles B
as O
potent O
antimicrobial O
and O
analgesic O
agents O
. O

Azole B
class O
of O
compounds O
are O
well O
known O
for O
their O
excellent O
therapeutic O
properties O
. O

Present O
paper O
describes O
about O
the O
synthesis O
of O
three O
series O
of O
new O
1 O
, O
2 O
, O
4 O
- O
triazole O
and O
benzoxazole B
derivatives O
containing O
substituted O
pyrazole B
moiety O
( O
11a O
- O
d O
, O
12a O
- O
d O
and O
13a O
- O
d O
) O
. O

The O
newly O
synthesized O
compounds O
were O
characterized O
by O
spectral O
studies O
and O
also O
by O
C B
, O
H B
, O
N B
analyses O
. O

The O
results O
revealed O
that O
the O
compound O
11c O
having O
2 O
, O
5 O
- O
dichlorothiophene O
substituent O
on O
pyrazole B
moiety O
and O
a O
triazole B
ring O
showed O
significant O
analgesic O
and O
antimicrobial O
activity O
. O

Staphylococcus O
aureus O
CstR O
( O
CsoR O
- O
like O
sulfur B
transferase O
repressor O
) O
is O
a O
member O
of O
the O
CsoR O
family O
of O
transition B
metal I
sensing O
metalloregulatory O
proteins O
. O

Unlike O
CsoR O
, O
CstR O
does O
not O
form O
a O
stable O
complex O
with O
transition O
metals O
but O
instead O
reacts O
with O
sulfite B
to O
form O
a O
mixture O
of O
di O
- O
and O
trisulfide O
species O
, O
CstR2 O
( O
RS O
- O
SR O
' O
) O
and O
CstR2 O
( O
RS O
- O
S O
- O
SR O
' O
) O
n O
) O
n O
= O
1 O
or O
2 O
, O
respectively O
. O

We O
show O
that O
Cys31 O
initiates O
the O
reaction O
with O
sulfite B
through O
the O
formation O
of O
S O
- O
sulfocysteine O
( O
RS O
- O
SO3 O
( O
2 O
- O
) O
) O
and O
Cys60 O
is O
required O
to O
fully O
derivatize O
CstR O
to O
CstR2 O
( O
RS O
- O
SR O
' O
) O
and O
CstR2 O
( O
RS O
- O
S O
- O
SR O
' O
) O
. O

These O
results O
highlight O
the O
differences O
between O
CstRs O
and O
CsoRs O
in O
chemical O
reactivity O
and O
metal O
ion O
selectivity O
and O
establish O
Cys31 O
as O
the O
functionally O
important O
cysteine B
residue O
in O
CstRs O
. O

Manganese B
- O
exposed O
developing O
rats O
display O
motor O
deficits O
and O
striatal O
oxidative O
stress O
that O
are O
reversed O
by O
Trolox B
. O

While O
manganese B
( O
Mn B
) O
is O
essential O
for O
proper O
central O
nervous O
system O
( O
CNS O
) O
development O
, O
excessive O
Mn B
exposure O
may O
lead O
to O
neurotoxicity O
. O

Mn B
preferentially O
accumulates O
in O
the O
basal O
ganglia O
, O
and O
in O
adults O
it O
may O
cause O
Parkinson O
' O
s O
disease O
- O
like O
disorder O
. O

Compared O
to O
adults O
, O
younger O
individuals O
accumulate O
greater O
Mn B
levels O
in O
the O
CNS O
and O
are O
more O
vulnerable O
to O
its O
toxicity O
. O

Moreover O
, O
the O
mechanisms O
mediating O
developmental O
Mn B
- O
induced O
neurotoxicity O
are O
not O
completely O
understood O
. O

The O
present O
study O
investigated O
the O
developmental O
neurotoxicity O
elicited O
by O
Mn B
exposure O
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
; O
i O
. O
p O
. O
) O
from O
postnatal O
day O
8 O
to O
PN27 O
in O
rats O
. O

Mn B
exposure O
( O
20 O
mg O
/ O
kg O
) O
increased O
p38 O
( O
MAPK O
) O
and O
Akt O
phosphorylation O
, O
but O
decreased O
DARPP O
- O
32 O
- O
Thr O
- O
34 O
phosphorylation O
. O

Mn B
( O
10 O
and O
20 O
mg O
/ O
kg O
) O
increased O
caspase O
activity O
and O
F O
( O
2 O
) O
- O
isoprostane O
production O
( O
a O
biological O
marker O
of O
lipid O
peroxidation O
) O
. O

Paralleling O
the O
changes O
in O
striatal O
biochemical O
parameters O
, O
Mn B
( O
20 O
mg O
/ O
kg O
) O
also O
caused O
motor O
impairment O
, O
evidenced O
by O
increased O
falling O
latency O
in O
the O
rotarod O
test O
, O
decreased O
distance O
traveled O
and O
motor O
speed O
in O
the O
open O
- O
field O
test O
. O

Notably O
, O
the O
antioxidant O
Trolox B
( O
TM O
) O
reversed O
the O
Mn B
( O
20 O
mg O
/ O
kg O
) O
- O
dependent O
augmentation O
in O
p38 O
( O
MAPK O
) O
phosphorylation O
and O
reduced O
the O
Mn B
( O
20 O
mg O
/ O
kg O
) O
- O
induced O
caspase O
activity O
and O
F O
( O
2 O
) O
- O
isoprostane O
production O
. O

Trolox B
( O
TM O
) O
also O
reversed O
the O
Mn B
- O
induced O
motor O
coordination O
deficits O
. O

These O
findings O
are O
the O
first O
to O
show O
that O
long O
- O
term O
exposure O
to O
Mn B
during O
a O
critical O
period O
of O
neurodevelopment O
causes O
motor O
coordination O
dysfunction O
with O
parallel O
increment O
in O
oxidative O
stress O
markers O
, O
p38 O
( O
MAPK O
) O
phosphorylation O
and O
caspase O
activity O
in O
the O
striatum O
. O

Moreover O
, O
we O
establish O
Trolox B
( O
TM O
) O
as O
a O
potential O
neuroprotective O
agent O
given O
its O
efficacy O
in O
reversing O
the O
Mn B
- O
induced O
neurodevelopmental O
effects O
. O

Refining O
the O
UGT1A O
haplotype O
associated O
with O
irinotecan B
- O
induced O
hematological O
toxicity O
in O
metastatic O
colorectal O
cancer O
patients O
treated O
with O
5 B
- I
fluorouracil I
/ O
irinotecan B
- O
based O
regimens O
. O

Despite O
the O
importance O
of O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
1A1 O
* O
28 O
in O
irinotecan B
pharmacogenetics O
, O
our O
capability O
to O
predict O
drug O
- O
induced O
severe O
toxicity O
remains O
limited O
. O

We O
aimed O
at O
identifying O
novel O
genetic O
markers O
that O
would O
improve O
prediction O
of O
irinotecan B
toxicity O
and O
response O
in O
advanced O
colorectal O
cancer O
patients O
treated O
with O
folic B
acid I
( O
leucovorin O
) O
, O
fluorouracil O
( O
5 B
- I
FU I
) O
, O
and O
irinotecan B
( O
camptosar O
) O
- O
based O
regimens O
. O

Our O
results O
suggest O
that O
specific O
SNPs O
in O
UGT1A O
, O
other O
than O
UGT1A1 O
* O
28 O
, O
may O
influence O
irinotecan B
toxicity O
and O
should O
be O
considered O
to O
refine O
pharmacogenetic O
testing O
. O

Androgen B
Receptor O
mRNA O
Measured O
by O
Quantitative O
Real O
Time O
PCR O
is O
Decreased O
in O
the O
Urethral O
Mucosa O
of O
Patients O
with O
Middle O
Idiopathic O
Hypospadias O
. O

Androgen B
action O
is O
exerted O
through O
the O
androgen B
receptor O
. O

The O
normal O
46 O
, O
XY O
genital O
virilization O
depends O
on O
androgen B
receptor O
gene O
expression O
, O
which O
is O
tissue O
specific O
, O
and O
requires O
normal O
androgen B
receptor O
mRNA O
levels O
in O
androgen B
sensitive O
tissues O
. O

Hypospadias O
is O
a O
frequent O
male O
genital O
abnormality O
, O
potentially O
related O
to O
reduced O
androgen B
sensitivity O
in O
genital O
tissues O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
, O
by O
quantitative O
real O
time O
PCR O
, O
the O
amount O
of O
androgen B
receptor O
mRNA O
in O
cells O
obtained O
from O
the O
urethral O
mucosa O
of O
patients O
with O
middle O
idiopathic O
hypospadias O
with O
the O
androgen B
receptor O
mRNA O
levels O
observed O
in O
control O
phimosis O
subjects O
with O
eutopic O
urethral O
opening O
. O

We O
observed O
significantly O
less O
androgen B
receptor O
mRNA O
in O
the O
urethral O
mucosa O
of O
patients O
with O
hypospadias O
than O
in O
the O
controls O
( O
p O
= O
0 O
. O
002 O
) O
. O

The O
correlation O
between O
the O
level O
of O
androgen B
receptor O
mRNA O
expression O
and O
the O
penile O
size O
was O
almost O
statistically O
significant O
only O
in O
hypospadias O
patients O
( O
r O
= O
0 O
. O
47 O
; O
p O
= O
0 O
. O
053 O
) O
. O

We O
also O
established O
the O
number O
of O
CAG O
repeats O
in O
exon O
1 O
of O
the O
androgen B
receptor O
gene O
by O
GeneScan O
analysis O
. O

Our O
data O
suggest O
that O
a O
critical O
lower O
level O
of O
androgen B
receptor O
mRNA O
expression O
could O
be O
a O
determining O
factor O
in O
the O
development O
of O
middle O
hypospadias O
. O

Identification O
and O
characterization O
of O
bacterial O
diterpene B
cyclases O
that O
synthesize O
the O
cembrane O
skeleton O
. O

Digging O
up O
skeletons O
: O
We O
report O
the O
identification O
and O
the O
functional O
characterization O
of O
two O
terpene B
cyclases O
( O
DtcycA O
and O
DtcycB O
) O
that O
were O
mined O
from O
the O
genome O
of O
Streptomyces O
sp O
. O

DtcycA O
and O
DtcycB O
are O
novel O
bacterial O
diterpene B
cyclases O
for O
the O
synthesis O
of O
the O
cembrane O
skeleton O
. O

A O
case O
- O
based O
approach O
to O
the O
practical O
application O
of O
dexmedetomidine B
in O
critically O
ill O
adults O
. O

Dexmedetomidine B
is O
a O
selective O
alpha O
( O
2 O
) O
- O
adrenoceptor O
agonist O
that O
offers O
unique O
sedation O
because O
patients O
are O
readily O
awakened O
while O
administration O
continues O
and O
the O
drug O
does O
not O
suppress O
the O
respiratory O
center O
. O

Using O
a O
case O
- O
based O
approach O
, O
the O
purpose O
of O
this O
review O
was O
to O
qualitatively O
assess O
the O
role O
of O
dexmedetomidine B
in O
the O
care O
of O
the O
critically O
ill O
and O
in O
the O
management O
of O
alcohol B
withdrawal O
, O
and O
to O
formulate O
recommendations O
regarding O
its O
clinical O
application O
. O

Sixty O
- O
six O
studies O
were O
identified O
that O
investigated O
dexmedetomidine B
for O
the O
provision O
of O
sedation O
. O

These O
studies O
were O
heterogeneous O
in O
design O
and O
patient O
populations O
; O
most O
investigated O
patients O
did O
not O
require O
heavy O
sedation O
, O
and O
few O
used O
propofol B
as O
the O
comparator O
. O

In O
general O
, O
though O
, O
the O
aggregate O
results O
of O
all O
studies O
demonstrate O
that O
dexmedetomidine B
provides O
comfort O
, O
possibly O
shortens O
the O
duration O
of O
mechanical O
ventilation O
to O
facilitate O
extubation O
, O
reduces O
the O
occurrence O
of O
acute O
brain O
dysfunction O
, O
and O
facilitates O
communication O
, O
but O
the O
drug O
is O
associated O
with O
hemodynamic O
instability O
and O
requires O
the O
supplemental O
use O
of O
traditional O
sedative O
and O
analgesic O
agents O
. O

Dexmedetomidine B
should O
be O
considered O
when O
patients O
require O
mild O
to O
moderate O
levels O
of O
sedation O
of O
short O
to O
intermediate O
time O
frames O
, O
and O
they O
qualify O
for O
daily O
awakenings O
with O
traditional O
sedative O
therapies O
. O

The O
data O
for O
dexmedetomidine B
in O
relation O
to O
alcohol B
withdrawal O
are O
limited O
to O
12 O
retrospective O
reports O
representing O
a O
total O
of O
127 O
patients O
. O

Its O
role O
for O
this O
indication O
requires O
further O
study O
, O
but O
it O
may O
be O
considered O
as O
adjunctive O
therapy O
when O
clinicians O
are O
concerned O
about O
respiratory O
suppression O
associated O
with O
escalating O
doses O
of O
gamma B
- I
aminobutyric I
acid I
agonists O
. O

Regardless O
of O
the O
indication O
for O
dexmedetomidine B
, O
the O
practitioner O
must O
closely O
monitor O
patient O
comfort O
and O
the O
occurrence O
of O
hemodynamic O
deviations O
with O
the O
realization O
that O
as O
- O
needed O
administration O
of O
traditional O
sedatives O
and O
analgesics O
will O
be O
required O
and O
some O
degree O
of O
bradycardia O
and O
hypotension O
expected O
but O
intervention O
rarely O
required O
. O

The O
Sec7 O
Guanine B
Nucleotide B
Exchange O
Factor O
GBF1 O
Regulates O
Membrane O
Recruitment O
of O
BIG1 O
and O
BIG2 O
Guanine B
Nucleotide B
Exchange O
Factors O
to O
the O
Trans O
- O
Golgi O
Network O
( O
TGN O
) O
. O

Three O
Sec7 O
guanine B
nucleotide B
exchange O
factors O
( O
GEFs O
) O
activate O
ADP B
- O
ribosylation O
factors O
( O
ARFs O
) O
to O
facilitate O
coating O
of O
transport O
vesicles O
within O
the O
secretory O
and O
endosomal O
pathways O
. O

Investigating O
the O
enteroenteric O
recirculation O
of O
apixaban B
, O
a O
factor O
Xa O
inhibitor O
: O
administration O
of O
activated O
charcoal O
to O
bile O
duct O
- O
cannulated O
rats O
and O
dogs O
receiving O
an O
intravenous O
dose O
and O
use O
of O
drug O
transporter O
knockout O
rats O
. O

The O
study O
described O
here O
investigated O
the O
impact O
of O
intestinal O
excretion O
( O
IE O
; O
excretion O
of O
drug O
directly O
from O
circulation O
to O
intestinal O
lumen O
) O
, O
enteroenteric O
recirculation O
( O
EER O
) O
, O
and O
renal O
tubule O
recirculation O
( O
RTR O
) O
on O
apixaban B
pharmacokinetics O
and O
disposition O
. O

The O
experimental O
approaches O
involve O
integrating O
apixaban B
elimination O
pathways O
with O
pharmacokinetic O
profiles O
obtained O
from O
bile O
duct O
- O
cannulated O
( O
BDC O
) O
rats O
and O
dogs O
receiving O
i O
. O
v O
. O
doses O
together O
with O
oral O
administration O
of O
activated O
charcoal O
( O
AC O
) O
. O

Additionally O
, O
the O
role O
of O
P O
- O
gp O
( O
P O
- O
glycoprotein O
; O
abcb1 O
) O
and O
BCRP O
( O
breast O
cancer O
resistance O
protein O
; O
abcg2 O
) O
in O
apixaban B
disposition O
was O
evaluated O
in O
experiments O
using O
transporter O
inhibitors O
and O
transporter O
knockout O
( O
KO O
) O
rats O
. O

Approximately O
20 O
- O
50 O
% O
of O
an O
apixaban B
i O
. O
v O
. O
dose O
was O
found O
in O
feces O
of O
BDC O
rats O
and O
dogs O
, O
suggesting O
IE O
leading O
to O
fecal O
elimination O
and O
intestinal O
clearance O
( O
IC O
) O
. O

The O
fecal O
elimination O
, O
IC O
, O
and O
systemic O
clearance O
of O
apixaban B
were O
increased O
upon O
AC O
administration O
in O
both O
BDC O
rats O
and O
dogs O
and O
were O
decreased O
in O
BDC O
rats O
dosed O
with O
GF O
- O
120918 O
, O
a O
dual O
BCRP O
and O
P O
- O
gp O
inhibitor O
) O
. O

BCRP O
appeared O
to O
play O
a O
more O
important O
role O
for O
absorption O
and O
intestinal O
and O
renal O
elimination O
of O
apixaban B
than O
P O
- O
gp O
in O
transporter O
- O
KO O
rats O
after O
oral O
and O
i O
. O
v O
. O
dosing O
, O
which O
led O
to O
a O
higher O
level O
of O
active O
renal O
excretion O
in O
rat O
than O
other O
species O
. O

These O
data O
demonstrate O
that O
apixaban B
undergoes O
IE O
, O
EER O
, O
and O
RTR O
that O
are O
facilitated O
by O
efflux O
transporters O
. O

Intestinal O
reabsorption O
of O
apixaban B
could O
be O
interrupted O
by O
AC O
even O
at O
3 O
hours O
post O
- O
drug O
dose O
in O
dogs O
( O
late O
charcoal O
effect O
) O
. O

This O
study O
demonstrates O
that O
the O
intestine O
is O
an O
organ O
for O
direct O
clearance O
and O
redistribution O
of O
apixaban B
. O

The O
IE O
, O
EER O
, O
and O
RTR O
contribute O
to O
overall O
pharmacokinetic O
profiles O
of O
apixaban B
. O

IE O
as O
a O
clearance O
pathway O
, O
balanced O
with O
metabolism O
and O
renal O
excretion O
, O
helps O
decrease O
the O
impacts O
of O
intrinsic O
( O
renal O
or O
hepatic O
impairment O
) O
and O
extrinsic O
( O
drug O
- O
drug O
interactions O
) O
factors O
on O
apixaban B
disposition O
. O

Removal O
of O
molecular O
adsorbates O
on O
gold O
nanoparticles O
using O
sodium B
borohydride I
in O
water O
. O

The O
mechanism O
of O
sodium B
borohydride I
removal O
of O
organothiols O
from O
gold O
nanoparticles O
( O
AuNPs O
) O
was O
studied O
using O
an O
experimental O
investigation O
and O
computational O
modeling O
. O

Organothiols O
and O
other O
AuNP O
surface O
adsorbates O
such O
as O
thiophene B
, O
adenine B
, O
rhodamine B
, O
small O
anions O
( O
Br B
( I
- I
) I
and O
I B
( I
- I
) I
) O
, O
and O
a O
polymer O
( O
PVP B
, O
poly B
( I
N I
- I
vinylpyrrolidone I
) I
) O
can O
all O
be O
rapidly O
and O
completely O
removed O
from O
the O
AuNP O
surfaces O
. O

A O
computational O
study O
showed O
that O
hydride B
derived O
from O
sodium B
borohydride I
has O
a O
higher O
binding O
affinity O
to O
AuNPs O
than O
organothiols O
. O

Sodium B
borohydride I
may O
be O
used O
as O
a O
hazard O
- O
free O
, O
general O
- O
purpose O
detergent O
that O
should O
find O
utility O
in O
a O
variety O
of O
AuNP O
applications O
including O
catalysis O
, O
biosensing O
, O
surface O
enhanced O
Raman O
spectroscopy O
, O
and O
AuNP O
recycle O
and O
reuse O
. O

Synthesis O
of O
MoS2 B
and O
MoSe2 O
films O
with O
vertically O
aligned O
layers O
. O

They O
often O
crystallize O
to O
form O
atomically O
smooth O
thin O
films O
, O
nanotubes O
, O
and O
platelet O
or O
fullerene B
- O
like O
nanoparticles O
due O
to O
the O
anisotropic O
bonding O
. O

In O
this O
communication O
, O
we O
present O
a O
synthesis O
process O
to O
grow O
MoS2 B
and O
MoSe2 O
thin O
films O
with O
vertically O
aligned O
layers O
, O
thereby O
maximally O
exposing O
the O
edges O
on O
the O
film O
surface O
. O

Such O
edge O
- O
terminated O
films O
are O
metastable O
structures O
of O
MoS2 B
and O
MoSe2 O
, O
which O
may O
find O
applications O
in O
diverse O
catalytic O
reactions O
. O

We O
have O
confirmed O
their O
catalytic O
activity O
in O
a O
hydrogen B
evolution O
reaction O
( O
HER O
) O
, O
in O
which O
the O
exchange O
current O
density O
correlates O
directly O
with O
the O
density O
of O
the O
exposed O
edge O
sites O
. O

Nevirapine B
bioactivation O
and O
covalent O
binding O
in O
the O
skin O
. O

Nevirapine B
( O
NVP B
) O
treatment O
is O
associated O
with O
serious O
skin O
rashes O
that O
appear O
to O
be O
immune O
- O
mediated O
. O

Treatment O
of O
rats O
with O
the O
major O
NVP B
metabolite O
, O
12 O
- O
OH O
- O
NVP O
, O
also O
caused O
the O
rash O
. O

Most O
idiosyncratic O
drug O
reactions O
are O
caused O
by O
reactive O
metabolites O
; O
12 O
- O
OH O
- O
NVP O
forms O
a O
benzylic O
sulfate O
, O
which O
was O
detected O
in O
the O
blood O
of O
animals O
treated O
with O
NVP B
or O
12 O
- O
OH O
- O
NVP O
. O

This O
sulfate B
is O
presumably O
formed O
in O
the O
liver O
; O
however O
, O
the O
skin O
also O
has O
significant O
sulfotransferase O
activity O
. O

In O
this O
study O
, O
we O
used O
a O
serum O
against O
NVP B
to O
detect O
covalent O
binding O
in O
the O
skin O
of O
rats O
. O

In O
contrast O
to O
rats O
, O
treatment O
of O
mice O
with O
NVP B
did O
not O
result O
in O
covalent O
binding O
in O
the O
skin O
or O
skin O
rash O
. O

Although O
the O
reaction O
of O
12 O
- O
OH O
- O
NVP O
sulfate O
with O
nucleophiles O
such O
as O
glutathione B
is O
slow O
, O
incubation O
of O
this O
sulfate B
with O
homogenized O
human O
and O
rat O
skin O
led O
to O
extensive O
covalent O
binding O
. O

Incubations O
of O
12 O
- O
OH O
- O
NVP O
with O
the O
soluble O
fraction O
from O
a O
9 O
, O
000g O
centrifugation O
( O
S9 O
) O
of O
rat O
or O
human O
skin O
homogenate O
in O
the O
presence O
of O
3 B
' I
- I
phosphoadenosine I
- I
5 I
' I
- I
phosphosulfate I
( O
PAPS O
) O
produced O
extensive O
covalent O
binding O
, O
but O
no O
covalent O
binding O
was O
detected O
with O
mouse O
skin O
S9 O
, O
which O
suggests O
that O
the O
reason O
mice O
do O
not O
develop O
a O
rash O
is O
that O
they O
lack O
the O
required O
sulfotransferase O
. O

This O
is O
the O
first O
study O
to O
report O
covalent O
binding O
of O
NVP B
to O
rat O
and O
human O
skin O
. O

These O
data O
provide O
strong O
evidence O
that O
covalent O
binding O
of O
NVP B
in O
the O
skin O
is O
due O
to O
12 O
- O
OH O
- O
NVP O
sulfate O
, O
which O
is O
likely O
responsible O
for O
NVP B
- O
induced O
skin O
rash O
. O

We O
designed O
and O
screened O
minimal O
peptide O
motifs O
whose O
conjugates O
with O
polyethylene B
glycol I
interact O
with O
heparin O
to O
form O
non O
- O
covalent O
hydrogels O
. O

We O
characterized O
the O
oxidative O
stress O
( O
OS O
) O
status O
by O
the O
levels O
of O
reduced O
/ O
oxidized O
glutathione O
( O
GSH B
/ O
GSSG B
) O
, O
malondialdehyde B
( O
MDA B
) O
and O
the O
mutagenic O
base O
8 O
- O
oxo O
- O
7 O
' O
8 O
- O
dihydro O
- O
2 O
' O
- O
deoxyguanosine O
( O
8 O
- O
oxo O
- O
dG O
) O
in O
human O
gastric O
carcinoma O
( O
HGC O
) O
samples O
and O
compared O
the O
results O
with O
normal O
tissue O
from O
the O
same O
patients O
. O

Tumor O
specimens O
exhibited O
increased O
levels O
of O
MDA B
and O
8 O
- O
oxo O
- O
dG O
compared O
with O
normal O
gastric O
tissue O
. O

GSH B
levels O
were O
also O
increased O
, O
while O
GSSG B
levels O
remained O
stable O
. O

To O
elucidate O
the O
biosynthetic O
machinery O
associated O
with O
ICZs O
production O
in O
S O
. O
sanyensis O
FMA O
, O
PCR O
using O
degenerate O
primers O
was O
carried O
out O
to O
clone O
the O
FAD B
- O
dependent O
monooxygenase O
gene O
fragment O
for O
ICZ O
ring O
formation O
, O
which O
was O
used O
as O
a O
probe O
to O
isolate O
the O
34 O
. O
6 O
- O
kb O
DNA O
region O
containing O
the O
spc O
gene O
cluster O
. O

Sequence O
analysis O
revealed O
genes O
for O
ICZ O
ring O
formation O
( O
spcO O
, O
D O
, O
P O
, O
C O
) O
, O
sugar B
unit O
formation O
( O
spcA O
, O
B O
, O
E O
, O
K O
, O
J O
, O
I O
) O
, O
glycosylation O
( O
spcN O
, O
G O
) O
, O
methylation O
( O
spcMA O
, O
MB O
) O
, O
as O
well O
as O
regulation O
( O
spcR O
) O
. O

Identification O
and O
characterization O
of O
the O
formation O
of O
the O
N O
- O
halamine O
bonds O
( O
> O
N B
- O
X O
with O
X O
= O
Cl B
or O
Br B
or O
I B
) O
by O
physical O
techniques O
such O
as O
Fourier O
transform O
infrared O
spectroscopy O
( O
FTIR O
) O
, O
nuclear O
magnetic O
resonance O
spectroscopy O
( O
NMR O
) O
, O
energy O
- O
dispersive O
X O
- O
ray O
spectroscopy O
( O
EDX O
) O
, O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
, O
and O
by O
chemical O
reactions O
are O
described O
. O

The O
porous O
structure O
of O
PSM O
was O
characterized O
by O
scanning O
electron O
microscopy O
( O
SEM O
) O
and O
nitrogen B
adsorption O
/ O
desorption O
analysis O
. O

3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
was O
used O
to O
evaluate O
carrier O
cytotoxicity O
. O

MTT B
assay O
shows O
PSM O
has O
no O
toxicity O
for O
Caco O
- O
2 O
cell O
. O

Different O
pharmacokinetics O
of O
the O
two O
structurally O
similar O
dammarane O
sapogenins O
, O
protopanaxatriol B
and O
protopanaxadiol B
, O
in O
rats O
. O

Dammarane O
Sapogenins O
( O
DS O
) O
, O
with O
main O
ingredients O
of O
protopanaxatriol B
( O
PPT B
, O
33 O
% O
) O
and O
protopanaxadiol B
( O
PPD B
, O
16 O
% O
) O
, O
is O
an O
alkaline O
hydrolyzed O
product O
of O
ginsenosides B
and O
had O
significant O
activities O
in O
improving O
learning O
and O
memory O
and O
decreasing O
chemotherapy O
- O
induced O
myelosuppression O
. O

In O
the O
present O
study O
, O
the O
pharmacokinetics O
and O
oral O
bioavailabilities O
of O
PPT B
and O
PPD B
were O
investigated O
when O
a O
single O
dose O
of O
DS O
was O
administrated O
orally O
( O
75mg O
/ O
kg O
) O
and O
intravenously O
( O
i O
. O
v O
. O
, O
30mg O
/ O
kg O
) O
to O
rats O
. O

PPT B
and O
PPD B
concentrations O
were O
measured O
by O
LC O
- O
MS O
. O

The O
results O
showed O
that O
PPT B
was O
eliminated O
rapidly O
from O
the O
body O
with O
an O
average O
t1 O
/ O
2 O
, O
lambda O
z O
value O
of O
0 O
. O
80h O
and O
CL O
of O
4 O
. O
27l O
/ O
h O
/ O
kg O
after O
i O
. O
v O
. O
administration O
, O
while O
PPD B
was O
eliminated O
relatively O
slowly O
with O
a O
t1 O
/ O
2 O
, O
lambda O
z O
of O
6 O
. O
25h O
and O
CL O
of O
0 O
. O
98l O
/ O
h O
/ O
kg O
. O

After O
oral O
administration O
, O
both O
PPD B
and O
PPT B
could O
be O
absorbed O
into O
the O
body O
, O
but O
their O
systemic O
exposures O
were O
quite O
different O
. O

PPT B
was O
absorbed O
into O
the O
body O
quickly O
, O
with O
a O
Tmax O
of O
0 O
. O
58h O
and O
a O
Cmax O
of O
0 O
. O
13 O
mu O
g O
/ O
ml O
, O
while O
PPD B
was O
absorbed O
relatively O
slowly O
with O
a O
Tmax O
of O
1 O
. O
82h O
and O
a O
Cmax O
of O
1 O
. O
04 O
mu O
g O
/ O
ml O
. O

The O
absolute O
bioavailabilities O
of O
PPT B
and O
PPD B
were O
estimated O
as O
3 O
. O
69 O
% O
and O
48 O
. O
12 O
% O
, O
respectively O
. O

The O
stability O
test O
found O
that O
PPT B
was O
instable O
in O
the O
stomach O
with O
40 O
% O
degradation O
after O
4h O
incubation O
at O
37 O
degrees O
C O
, O
both O
in O
pH1 O
. O
2 O
buffer O
and O
in O
the O
stomach O
content O
solution O
. O

The O
instability O
in O
the O
stomach O
might O
be O
one O
of O
the O
reasons O
for O
PPT B
' O
s O
poor O
bioavailability O
. O

In O
some O
of O
these O
cases O
radioiodine O
treatment O
may O
not O
be O
effective O
in O
eradicating O
nodal O
metastases O
due O
to O
scant O
131 B
- I
I I
uptake O
. O

The O
lipid O
nanoparticles O
were O
polymerized O
on O
the O
external O
leaflet O
using O
a O
disulfide B
cross O
- O
linker O
. O

In O
the O
presence O
of O
cytosolic O
concentrations O
of O
glutathione B
, O
the O
lipid O
nanoparticles O
released O
76 O
% O
of O
encapsulated O
contents O
. O

Plasma O
concentrations O
of O
glutathione B
failed O
to O
release O
the O
encapsulated O
contents O
. O

Folic B
acid I
conjugated O
, O
doxorubicin B
- O
loaded O
nanoparticles O
showed O
enhanced O
uptake O
and O
higher O
cytotoxicity O
in O
cancer O
cells O
overexpressing O
the O
folate B
receptor O
( O
compared O
to O
the O
control O
) O
. O

Surface O
structures O
of O
PDMS B
incorporated O
with O
quaternary O
ammonium O
salts O
designed O
for O
antibiofouling O
and O
fouling O
release O
applications O
. O

Poly B
( I
dimethylsiloxane I
) I
( O
PDMS B
) O
materials O
have O
been O
extensively O
shown O
to O
function O
as O
excellent O
fouling O
- O
release O
( O
FR O
) O
coatings O
in O
the O
marine O
environment O
. O

The O
incorporation O
of O
biocide O
moieties O
, O
such O
as O
quaternary O
ammonium O
salts O
( O
QAS O
) O
, O
can O
impart O
additional O
antibiofouling O
properties O
to O
PDMS B
- O
based O
FR O
coating O
systems O
. O

In O
this O
study O
, O
the O
molecular O
surface O
structures O
of O
two O
different O
types O
of O
QAS O
- O
incorporated O
PDMS B
systems O
were O
investigated O
in O
different O
chemical O
environments O
using O
sum O
frequency O
generation O
vibrational O
spectroscopy O
( O
SFG O
) O
. O

Specifically O
, O
a O
series O
of O
PDMS B
coatings O
containing O
either O
a O
QAS O
with O
a O
single O
ammonium O
salt O
group O
per O
molecule O
or O
a O
quaternary O
ammonium O
- O
functionalized O
polyhedral B
oligomeric I
silsesquioxane I
( O
Q O
- O
POSS B
) O
were O
measured O
with O
SFG O
in O
air O
, O
water O
, O
and O
artificial O
seawater O
( O
ASW O
) O
to O
investigate O
the O
relationships O
between O
the O
interfacial O
surface O
structures O
of O
these O
materials O
and O
their O
antifouling O
properties O
. O

Indeed O
, O
the O
SFG O
results O
presented O
here O
indicated O
that O
the O
surface O
structures O
of O
these O
materials O
depend O
on O
several O
factors O
, O
such O
as O
the O
extent O
of O
quaternization O
, O
the O
molecular O
weight O
of O
the O
PDMS B
component O
, O
and O
the O
functional O
groups O
of O
the O
QAS O
used O
for O
incorporation O
into O
the O
PDMS B
matrix O
. O

It O
was O
concluded O
that O
in O
aqueous O
environments O
a O
lower O
extent O
of O
Q O
- O
POSS B
quaternization O
and O
the O
use O
of O
ethoxy O
( O
instead O
of O
methoxy B
) O
functional O
groups O
for O
QAS O
incorporation O
facilitated O
the O
extension O
of O
the O
alkyl O
chains O
away O
from O
the O
nitrogen B
atom O
of O
the O
QAS O
on O
the O
surface O
. O

The O
first O
step O
is O
the O
adsorption O
of O
the O
bacteria O
on O
the O
surface O
as O
a O
result O
of O
the O
electrostatic O
attraction O
between O
the O
negatively O
charged O
microorganisms O
and O
the O
positively O
charged O
QAS O
nitrogen B
atoms O
on O
the O
surface O
. O

Personalized O
medicine O
for O
targeted O
and O
platinum B
- O
based O
chemotherapy O
of O
lung O
and O
bladder O
cancer O
. O

This O
review O
covers O
the O
molecular O
basis O
for O
biomarkers O
of O
response O
to O
targeted O
and O
cytotoxic O
lung O
and O
bladder O
cancer O
treatment O
with O
an O
emphasis O
on O
platinum B
- O
based O
chemotherapy O
. O

Platinum B
derivatives O
are O
a O
class O
of O
drugs O
commonly O
employed O
against O
solid O
tumors O
that O
kill O
cells O
by O
covalent O
attachment O
to O
DNA O
. O

Platinum B
- O
DNA O
adduct O
levels O
in O
patient O
tissues O
have O
been O
correlated O
to O
response O
and O
survival O
. O

Fbxl10 O
/ O
Kdm2b O
recruits O
polycomb O
repressive O
complex O
1 O
to O
CpG B
islands O
and O
regulates O
H2A O
ubiquitylation O
. O

Polycomb O
repressive O
complex O
1 O
( O
PRC1 O
) O
catalyzes O
lysine B
119 O
monoubiquitylation O
on O
H2A O
( O
H2AK119ub1 O
) O
and O
regulates O
pluripotency O
in O
embryonic O
stem O
cells O
( O
ESCs O
) O
. O

Genome O
- O
wide O
analyses O
reveal O
that O
Fbxl10 O
preferentially O
binds O
to O
CpG B
islands O
and O
colocalizes O
with O
Ring1B O
on O
Polycomb O
target O
genes O
. O

Uncoupling O
of O
endothelial O
NO B
synthase O
in O
atherosclerosis O
and O
vascular O
disease O
. O

Nitric B
oxide I
( O
NO B
) O
produced O
by O
the O
endothelial O
NO B
synthase O
( O
eNOS O
) O
is O
an O
antihypertensive O
, O
antithrombotic O
and O
anti O
- O
atherosclerotic O
molecule O
. O

Hypercholesterolemia O
leads O
to O
a O
reduction O
in O
vascular O
NO B
bioavailability O
. O

NADPH B
oxidase O
- O
mediated O
oxidative O
stress O
leads O
to O
oxidation O
of O
tetrahydrobiopterin O
( O
BH4 O
) O
, O
the O
essential O
cofactor O
of O
eNOS O
. O

In O
BH4 O
deficiency O
, O
oxygen B
reduction O
uncouples O
from O
NO B
synthesis O
, O
thereby O
converting O
eNOS O
to O
a O
superoxide B
- O
producing O
enzyme O
. O

As O
a O
consequence O
of O
eNOS O
uncoupling O
, O
NO B
production O
is O
reduced O
and O
the O
pre O
- O
existing O
oxidative O
stress O
is O
enhanced O
, O
which O
contribute O
significantly O
to O
atherogenesis O
. O

Angiotensin O
- O
converting O
enzyme O
inhibitors O
, O
AT1 O
receptor O
blockers O
, O
statins O
, O
nebivolol O
and O
resveratrol B
have O
been O
shown O
to O
reverse O
eNOS O
uncoupling O
and O
to O
stimulate O
eNOS O
activity O
concurrently O
. O

How O
sugar B
tunes O
your O
clock O
. O

Two O
papers O
in O
this O
issue O
of O
Cell O
Metabolism O
reveal O
that O
O B
- O
GlcNAcylation O
of O
clock O
proteins O
, O
which O
is O
dependent O
on O
nutrients O
, O
adjusts O
our O
circadian O
clock O
( O
Kaasik O
et O
al O
. O
, O
2013 O
; O
Li O
et O
al O
. O
, O
2013 O
) O
. O

Synthesis O
and O
characterization O
of O
novel O
quick O
- O
release O
propofol B
prodrug O
via O
lactonization O
. O

The O
water O
- O
soluble O
derivatives O
of O
propofol B
have O
gained O
attention O
as O
a O
method O
to O
increase O
solubility O
of O
propofol B
. O

According O
to O
the O
principle O
of O
lactonization O
, O
the O
lead O
compound O
HX0969 O
was O
synthesized O
first O
and O
then O
the O
pharmacological O
features O
of O
HX0969 O
were O
evaluated O
in O
a O
comparison O
with O
those O
of O
propofol B
in O
the O
SD O
rats O
. O

Then O
, O
HX0969 O
disodium O
phosphate O
monoester O
( O
HX0969W O
) O
and O
glycine O
ester O
trifluoroacetic O
acid O
salt O
( O
HX101230 O
) O
were O
synthesized O
, O
and O
their O
pharmacological O
features O
were O
compared O
with O
those O
of O
Lusedra O
( O
R O
) O
, O
which O
has O
been O
recognized O
and O
marketed O
as O
a O
water O
- O
soluble O
prodrug O
of O
propofol B
since O
2008 O
. O

Therefore O
, O
our O
study O
has O
indicated O
that O
HX0969 O
is O
a O
potentially O
useful O
lead O
compound O
of O
propofol B
derivative O
. O

Chemical O
probes O
of O
a O
trisubstituted O
pyrrole B
to O
identify O
its O
protein O
target O
( O
s O
) O
in O
Plasmodium O
sporozoites O
. O

A O
trisubstituted O
pyrrole B
was O
recently O
found O
to O
inhibit O
infection O
of O
mammalian O
hepatocytes O
by O
Plasmodium O
sporozoites O
, O
but O
the O
target O
of O
this O
agent O
is O
not O
known O
. O

In O
this O
study O
trisubstituted O
pyrrole B
derivatives O
with O
different O
substituents O
on O
a O
piperidinyl O
nitrogen O
were O
prepared O
. O

We O
determined O
if O
modifications O
of O
the O
piperidinyl O
nitrogen O
would O
accommodate O
a O
drug O
- O
biotin B
linking O
strategy O
for O
affinity O
purification O
of O
the O
trisubstituted O
pyrrole B
' O
s O
target O
protein O
( O
s O
) O
. O

Viscoelastic O
, O
injectable O
aggregates O
of O
micrometer O
- O
sized O
hydrogel O
particles O
made O
of O
multiarmed O
polyethylene B
glycol I
( O
starPEG O
) O
and O
heparin O
were O
prepared O
and O
tested O
for O
site O
- O
specific O
paracrine O
stimulation O
of O
tissue O
regeneration O
. O

To O
investigate O
GF O
delivery O
in O
vivo O
, O
a O
hydrogel O
loaded O
with O
murine O
EGF O
or O
bFGF O
was O
injected O
subcapsularly O
into O
the O
left O
kidney O
of O
mice O
with O
experimental O
acute O
kidney O
injury O
caused O
by O
glycerol B
induced O
rhabdomyolysis O
. O

Ozonolysis O
efficiency O
and O
safety O
evaluation O
of O
aflatoxin B
B1 I
in O
peanuts O
. O

Ozonolysis O
efficiency O
of O
aflatoxin B
- O
contaminated O
peanuts O
( O
ACPs O
) O
was O
investigated O
, O
and O
the O
safety O
of O
ACPs O
untreated O
/ O
treated O
by O
ozone B
was O
evaluated O
after O
28 O
- O
day O
intragastrically O
administration O
in O
male O
and O
female O
Wistar O
rats O
. O

89 O
. O
40 O
% O
of O
aflatoxin B
B1 I
( O
AFB1 O
) O
in O
peanuts O
was O
decomposed O
by O
ozone B
with O
a O
concentration O
of O
50mg O
/ O
L O
, O
flow O
rate O
of O
5L O
/ O
min O
for O
60h O
. O

Rats O
fed O
on O
ACPs O
treated O
by O
ozone B
showed O
significant O
beneficial O
health O
effects O
. O

All O
the O
results O
suggested O
that O
the O
deleterious O
effects O
of O
AFB1 O
could O
be O
highly O
reduced O
by O
ozone B
, O
and O
ozone B
itself O
did O
not O
show O
any O
toxic O
effects O
on O
animals O
in O
this O
processing O
. O

Elevation O
of O
4 B
- I
hydroxynonenal I
and O
malondialdehyde B
modified O
protein O
levels O
in O
cerebral O
cortex O
with O
cognitive O
dysfunction O
in O
rats O
exposed O
to O
1 O
- O
bromopropane O
. O

1 O
- O
Bromopropane O
( O
1 O
- O
BP O
) O
, O
an O
alternative O
to O
ozone B
- O
depleting O
solvents O
( O
ODS O
) O
, O
exhibits O
central O
nervous O
system O
( O
CNS O
) O
toxicity O
in O
animals O
and O
humans O
. O

Glutathione B
( O
GSH B
) O
, O
oxidized B
glutathione I
( O
GSSG B
) O
and O
total O
thiol B
( O
total O
- O
SH B
) O
content O
, O
GSH B
reductase O
( O
GR O
) O
and O
GSH B
peroxidase O
( O
GSH B
- O
Px O
) O
activities O
, O
malondialdehyde B
( O
MDA B
) O
level O
, O
as O
well O
as O
4 B
- I
hydroxynonenal I
( O
4 O
- O
HNE O
) O
and O
MDA B
modified O
proteins O
in O
homogenates O
of O
cerebral O
cortex O
were O
measured O
. O

GSH B
and O
total O
- O
SH B
content O
, O
GSH B
/ O
GSSG B
ratio O
, O
GR O
activity O
significantly O
decreased O
in O
cerebral O
cortex O
of O
rats O
, O
coupling O
with O
the O
increase O
of O
MDA B
level O
. O

4 O
- O
HNE O
and O
MDA B
modified O
protein O
levels O
obviously O
elevated O
after O
1 O
- O
BP O
exposure O
. O

GSH B
- O
Px O
activities O
in O
cerebral O
cortex O
of O
rats O
also O
increased O
. O

Treatment O
of O
cells O
with O
alpha O
- O
amanitin O
or O
actinomycin B
D I
revealed O
that O
extension O
of O
B2 O
RNA O
by O
Pol O
II O
destabilizes O
the O
RNA O
. O

To O
test O
whether O
the O
reduction O
in O
exposure O
was O
due O
to O
Pgp O
- O
mediated O
efflux O
, O
verapamil B
, O
a O
known O
Pgp O
inhibitor O
, O
was O
dosed O
to O
the O
rifampin O
pre O
- O
treated O
mice O
which O
led O
to O
an O
increase O
in O
exposure O
to O
that O
obtained O
after O
a O
single O
dose O
of O
rifampin O
, O
suggesting O
the O
role O
of O
Pgp O
induction O
in O
reducing O
exposure O
to O
rifampin O
. O

Mini O
- O
review O
: O
Foldosome O
regulation O
of O
androgen B
receptor O
action O
in O
prostate O
cancer O
. O

This O
review O
summarises O
current O
knowledge O
of O
how O
the O
foldosome O
impacts O
upon O
androgen B
receptor O
signalling O
, O
which O
is O
the O
key O
therapeutic O
target O
on O
prostate O
cancer O
, O
and O
how O
foldosome O
components O
may O
be O
used O
as O
biomarkers O
or O
therapeutic O
targets O
in O
this O
disease O
. O

The O
HC O
can O
be O
further O
subdivided O
into O
two O
halves O
: O
the O
N B
- O
terminal O
translocation O
domain O
( O
TD O
) O
and O
the O
C B
- O
terminal O
Receptor O
Binding O
Domain O
( O
RBD O
) O
. O

Optovin O
activates O
human O
TRPA1 O
via O
structure O
- O
dependent O
photochemical O
reactions O
with O
redox O
- O
sensitive O
cysteine B
residues O
. O

Overcoming O
chemotherapy O
resistance O
of O
ovarian O
cancer O
cells O
by O
liposomal O
cisplatin B
: O
molecular O
mechanisms O
unveiled O
by O
gene O
expression O
profiling O
. O

Previously O
we O
reported O
that O
liposomal O
cisplatin B
( O
CDDP B
) O
overcomes O
CDDP B
resistance O
of O
ovarian O
A2780cis O
cancer O
cells O
( O
Krieger O
et O
al O
. O
, O
Int O
. O
J O
. O
Pharm O
. O
389 O
, O
2010 O
, O
10 O
- O
17 O
) O
. O

Here O
we O
find O
that O
the O
cytotoxic O
activity O
of O
liposomal O
CDDP B
is O
not O
associated O
with O
detectable O
DNA O
platination O
in O
resistant O
ovarian O
cancer O
cells O
. O

This O
suggests O
that O
the O
mode O
of O
action O
of O
liposomal O
CDDP B
is O
different O
from O
the O
free O
drug O
. O

To O
gain O
insight O
into O
mechanisms O
of O
liposomal O
CDDP B
activity O
, O
we O
performed O
a O
transcriptome O
analysis O
of O
untreated O
A2780cis O
cells O
, O
and O
A2780cis O
cells O
in O
response O
to O
exposure O
with O
IC50 O
values O
of O
free O
or O
liposomal O
CDDP B
. O

A O
process O
network O
analysis O
of O
upregulated O
genes O
showed O
that O
liposomal O
CDDP B
induced O
a O
highly O
different O
gene O
expression O
profile O
in O
comparison O
to O
the O
free O
drug O
. O

p53 O
was O
identified O
as O
a O
key O
player O
directing O
transcriptional O
responses O
to O
free O
or O
liposomal O
CDDP B
. O

In O
contrast O
, O
liposomal O
CDDP B
induced O
expression O
of O
genes O
from O
DNA O
damage O
pathways O
and O
several O
genes O
of O
the O
extrinsic O
pathway O
of O
apoptosis O
( O
TNFRSF10B O
- O
DR5 O
, O
CD70 O
- O
TNFSF7 O
) O
. O

It O
thus O
appears O
that O
liposomal O
CDDP B
overcomes O
CDDP B
resistance O
by O
inducing O
DNA O
damage O
and O
in O
consequence O
programmed O
cell O
death O
by O
the O
extrinsic O
pathway O
. O

This O
sheds O
new O
light O
on O
liposomal O
drug O
carrier O
approaches O
in O
cancer O
and O
suggests O
liposomal O
CDDP B
as O
promising O
strategy O
for O
the O
treatment O
of O
CDDP B
resistant O
ovarian O
carcinomas O
. O

In O
HaCaT O
cells O
, O
buthanol O
and O
ethylacetate B
fractions O
of O
80 O
% O
methanol B
C O
. O
fragile O
extract O
( O
CFB O
or O
CFE O
) O
and O
a O
single O
compound O
, O
clerosterol O
( O
CLS O
) O
isolated O
from O
CFE O
attenuated O
UVB O
( O
60mJ O
/ O
cm O
( O
2 O
) O
) O
- O
induced O
cytotoxicity O
and O
reduced O
expression O
of O
pro O
- O
inflammatory O
proteins O
including O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
and O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O

Moreover O
, O
CFB O
, O
CFE O
and O
CLS O
effectively O
suppressed O
UVB O
- O
induced O
production O
of O
pro O
- O
inflammatory O
mediators O
such O
as O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
nitric B
oxide I
( O
NO B
) O
. O

Uptake O
of O
dioscin O
by O
rat O
liver O
slices O
and O
isolated O
rat O
hepatocytes O
was O
inhibited O
significantly O
by O
Oatp O
modulators O
, O
such O
as O
ibuprofen B
( O
Oatp1a1 O
inhibitor O
) O
, O
digoxin O
( O
Oatp1a4 O
substrate O
) O
, O
and O
glycyrrhizic O
acid O
( O
Oatp1b2 O
inhibitor O
) O
, O
but O
not O
by O
TEA B
or O
p O
- O
aminohippurate O
. O

( B
- I
) I
- I
Epigallocatechin I
gallate I
, O
cyclosporin O
A O
, O
rifampicin B
, O
and O
telmisartan B
inhibited O
transport O
of O
dioscin O
in O
OATP1B3 O
- O
HEK293 O
cells O
. O

In O
in O
vitro O
assays O
, O
protocatechuate O
and O
other O
phenolic B
compounds O
disrupt O
the O
PcaV O
- O
DNA O
complex O
. O

We O
identify O
an O
arginine B
residue O
that O
is O
critical O
for O
ligand O
coordination O
and O
demonstrate O
that O
it O
is O
also O
required O
for O
binding O
DNA O
. O

We O
propose O
that O
interaction O
of O
ligand O
with O
this O
arginine B
residue O
dictates O
conformational O
changes O
that O
modulate O
DNA O
binding O
. O

In O
the O
early O
stages O
, O
the O
efficiency O
of O
DSCs O
with O
arylamine O
organic O
dyes O
with O
D O
- O
pi O
- O
A O
character O
was O
far O
behind O
that O
of O
DSCs O
with O
ruthenium B
( I
II I
) I
complexes O
partly O
due O
to O
the O
lack O
of O
information O
about O
the O
relationship O
between O
the O
chemical O
structures O
and O
the O
photovoltaic O
performance O
. O

It O
is O
thus O
that O
the O
recent O
research O
and O
development O
in O
the O
field O
of O
arylamine O
organic O
dyes O
employing O
an O
iodide B
/ O
triiodide B
redox O
couple O
or O
polypyridyl O
cobalt O
redox O
shuttles O
as O
the O
electrolytes O
for O
either O
DSCs O
or O
solid O
- O
state O
DSCs O
has O
been O
summarized O
. O

Impaired O
cliff O
avoidance O
reaction O
in O
dopamine B
transporter O
knockout O
mice O
. O

Dopamine B
transporter O
knockout O
( O
DAT O
- O
KO O
) O
mice O
display O
features O
of O
ADHD O
and O
are O
candidates O
in O
which O
to O
test O
other O
impulsive O
phenotypes O
. O

Treatment O
with O
methylphenidate B
or O
nisoxetine O
ameliorated O
CAR O
impairments O
in O
DAT O
- O
KO O
mice O
. O

Blockade O
of O
monoamine B
transporters O
, O
especially O
the O
norepinephrine B
transporter O
( O
NET O
) O
in O
the O
prefrontal O
cortex O
( O
PFC O
) O
, O
may O
contribute O
to O
pharmacological O
improvement O
of O
impulsivity O
in O
these O
mice O
. O

The O
atypical O
antipsychotic O
risperidone B
reverses O
the O
recognition O
memory O
deficits O
induced O
by O
post O
- O
weaning O
social O
isolation O
in O
rats O
. O

OBJECTIVE O
: O
This O
study O
evaluated O
the O
ability O
of O
the O
atypical O
antipsychotic O
risperidone B
to O
reverse O
behavioural O
deficits O
induced O
by O
post O
- O
weaning O
social O
isolation O
of O
rat O
pups O
and O
to O
further O
characterise O
the O
predictive O
validity O
of O
this O
model O
. O

On O
PNDs O
58 O
, O
59 O
, O
65 O
and O
72 O
, O
rats O
received O
either O
vehicle O
( O
1 O
ml O
/ O
kg O
; O
i O
. O
p O
. O
) O
or O
risperidone B
( O
0 O
. O
2 O
or O
0 O
. O
5 O
mg O
/ O
kg O
; O
i O
. O
p O
. O
) O
30 O
min O
prior O
to O
testing O
in O
LMA O
, O
novel O
object O
discrimination O
( O
NOD O
) O
, O
prepulse O
inhibition O
( O
PPI O
) O
of O
acoustic O
startle O
and O
conditioned O
emotional O
response O
( O
CER O
) O
learning O
paradigms O
, O
respectively O
. O

Risperidone B
caused O
a O
dose O
- O
dependent O
reduction O
in O
LMA O
, O
irrespective O
of O
rearing O
condition O
, O
but O
selectively O
reversed O
the O
NOD O
deficit O
in O
isolation O
- O
reared O
rats O
. O

Risperidone B
did O
not O
reverse O
the O
isolation O
rearing O
- O
induced O
CER O
deficit O
. O

CONCLUSIONS O
: O
Similar O
to O
its O
clinical O
profile O
, O
risperidone B
only O
partially O
reverses O
the O
schizophrenic O
symptomology O
; O
since O
it O
reversed O
some O
, O
but O
not O
all O
, O
of O
the O
learning O
and O
memory O
deficits O
induced O
by O
post O
- O
weaning O
isolation O
, O
the O
isolation O
rearing O
model O
may O
be O
useful O
to O
predict O
antipsychotic O
activity O
of O
novel O
therapeutic O
agents O
. O

Impaired O
function O
of O
prejunctional O
adenosine B
A1 O
receptors O
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA O
- O
salt O
hypertensive O
rats O
. O

ATP B
and O
norepinephrine B
( O
NE O
) O
are O
coreleased O
from O
perivascular O
sympathetic O
nerves O
. O

Adenosine B
, O
an O
enzymatic O
ATP B
degradation O
product O
, O
acts O
at O
prejunctional O
A1 O
adenosine B
receptors O
( O
A1Rs O
) O
to O
inhibit O
NE O
release O
. O

Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine B
hydroxylase O
( O
TH O
) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O

Adenosine B
and O
N O
( O
6 O
) O
- O
cyclopentyl O
- O
adenosine O
( O
CPA B
, O
A1R O
agonist O
) O
constricted O
MVs O
but O
not O
MAs O
. O

Adenosine B
and O
CPA B
( O
0 O
. O
001 O
- O
10 O
micro O
M O
) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O

DOCA O
- O
salt O
arteries O
were O
resistant O
to O
adenosine B
and O
CPA B
- O
mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O

The O
A2A O
adenosine B
receptor O
agonist O
CGS21680 O
( O
C23H29N7O6 O
. O
HCl O
. O
xH2O O
) O
( O
0 O
. O
001 O
- O
0 O
. O
1 O
mu O
M O
) O
did O
not O
alter O
NE O
oxidation O
currents O
. O

We O
conclude O
that O
there O
are O
prejunctional O
A1Rs O
in O
arteries O
and O
both O
pre O
- O
and O
postjunctional O
A1Rs O
in O
veins O
; O
thus O
, O
adenosine B
selectively O
constricts O
the O
veins O
. O

Time O
- O
of O
- O
flight O
secondary O
ion O
mass O
spectrometry O
( O
TOF O
- O
SIMS O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
are O
employed O
to O
characterize O
a O
wedge O
- O
shaped O
crater O
eroded O
by O
a O
40 O
keV O
C B
( I
60 I
) I
( I
+ I
) I
cluster O
ion O
beam O
on O
an O
organic O
thin O
film O
of O
402 O
nm O
of O
barium O
arachidate O
( O
AA O
) O
multilayers O
prepared O
by O
the O
Langmuir O
- O
Blodgett O
( O
LB O
) O
technique O
. O

Antitumoural O
alkylphospholipid O
( O
APL O
) O
analogues O
alter O
cholesterol B
homoeostasis O
in O
HepG2 O
cells O
by O
interfering O
with O
cholesterol B
transport O
from O
the O
plasma O
membrane O
to O
the O
endoplasmic O
reticulum O
( O
ER O
) O
and O
at O
the O
same O
time O
stimulating O
the O
release O
of O
considerable O
quantities O
of O
membrane O
cholesterol B
. O

The O
capacity O
of O
APLs O
to O
stimulate O
cholesterol B
efflux O
is O
suppressed O
when O
cells O
are O
incubated O
simultaneously O
with O
APLs O
and O
serum O
whilst O
the O
inhibition O
of O
cholesterol B
transport O
to O
the O
ER O
( O
measured O
in O
terms O
of O
the O
synthesis O
of O
esterified O
cholesterol O
) O
persists O
, O
indicating O
that O
both O
effects O
are O
independent O
of O
each O
other O
. O

Interestingly O
, O
our O
results O
suggest O
that O
both O
raft O
and O
non O
- O
raft O
membrane O
domains O
contribute O
to O
the O
cholesterol B
released O
to O
APLs O
. O

In O
addition O
, O
a O
marked O
efflux O
of O
choline B
- O
bearing O
phospholipids O
( O
phosphatidylcholine B
( O
PC O
) O
and O
sphingomyelins O
( O
SM O
) O
) O
was O
found O
to O
be O
related O
to O
this O
release O
of O
cholesterol B
. O

Finally O
, O
we O
observed O
that O
APL O
micelles O
composed O
of O
cholesterol B
might O
act O
as O
donor O
/ O
acceptor O
cholesterol B
systems O
. O

Thus O
, O
the O
findings O
of O
this O
study O
clearly O
demonstrate O
that O
antitumoural O
APLs O
act O
as O
extracellular O
acceptors O
, O
stimulating O
cholesterol B
and O
phospholipid O
efflux O
, O
although O
they O
may O
also O
play O
a O
role O
as O
cholesterol B
donors O
. O

Prolactin O
and O
sex O
steroids B
levels O
in O
congenital O
lifetime O
isolated O
GH O
deficiency O
. O

Because O
they O
are O
able O
to O
breast O
feed O
, O
we O
hypothesized O
that O
this O
prolactin O
reduction O
is O
limited O
to O
climacteric O
, O
as O
result O
of O
lower O
estradiol B
exposure O
of O
the O
lactotrophs O
. O

The O
purposes O
of O
this O
work O
were O
to O
assess O
prolactin O
levels O
in O
broader O
age O
adults O
homozygous O
and O
heterozygous O
( O
MUT O
/ O
N O
) O
for O
the O
mutation O
and O
in O
normal O
controls O
( O
N O
/ O
N O
) O
, O
and O
to O
correlate O
them O
to O
sex O
steroids B
levels O
. O

Anthropometric O
data O
and O
serum O
prolactin O
, O
estradiol B
, O
total O
testosterone B
, O
and O
sex O
hormone O
binding O
globulin O
( O
SHBG O
) O
were O
measured O
. O

Free O
testosterone B
was O
calculated O
. O

In O
males O
, O
testosterone B
and O
SHBG O
levels O
were O
higher O
in O
MUT O
/ O
MUT O
in O
comparison O
to O
N O
/ O
N O
. O

There O
was O
no O
difference O
in O
free O
testosterone B
among O
groups O
. O

In O
all O
74 O
individuals O
, O
prolactin O
correlated O
inversely O
with O
age O
( O
p O
< O
0 O
. O
0001 O
) O
and O
directly O
with O
serum O
estradiol B
( O
p O
= O
0 O
. O
018 O
) O
. O

Prolactin O
levels O
in O
subjects O
with O
IGHD O
due O
to O
a O
homozygous O
GHRHR O
mutation O
are O
similar O
to O
heterozygous O
and O
normal O
homozygous O
, O
but O
total O
testosterone B
and O
SHBG O
are O
higher O
in O
male O
MUT O
/ O
MUT O
, O
with O
no O
difference O
in O
free O
testosterone B
. O

The O
reduced O
prolactin O
level O
is O
limited O
to O
climacteric O
period O
, O
possibly O
due O
to O
reduced O
estrogen B
exposure O
. O

Lithium B
/ O
sulfur B
batteries O
with O
high O
specific O
energy O
: O
old O
challenges O
and O
new O
opportunities O
. O

In O
this O
review O
, O
we O
begin O
with O
a O
brief O
discussion O
of O
the O
operating O
principles O
and O
scientific O
/ O
technical O
challenges O
faced O
by O
the O
development O
of O
lithium B
/ O
sulfur B
cells O
. O

We O
then O
introduce O
some O
recent O
progress O
in O
exploring O
cathodes O
, O
anodes O
, O
and O
electrolytes O
for O
lithium B
/ O
sulfur B
cells O
. O

Iodothyronine O
deiodinase O
types O
I O
, O
II O
, O
and O
III O
( O
D1 O
, O
D2 O
, O
and O
D3 O
, O
respectively O
) O
, O
which O
constitute O
a O
family O
of O
selenoenzymes O
, O
activate O
and O
inactivate O
thyroid O
hormones O
through O
the O
removal O
of O
specific O
iodine B
moieties O
from O
thyroxine B
and O
its O
derivatives O
. O

The O
expression O
levels O
of O
10 O
of O
these O
genes O
( O
ID2 O
, O
ID3 O
, O
CCL2 O
, O
TBX3 O
, O
TGOLN2 O
, O
C1orf71 O
, O
ZNF676 O
, O
GULP1 O
, O
KLF9 O
, O
and O
ITGB5 O
) O
were O
altered O
by O
deiodinase O
- O
disrupting O
chemicals O
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
, O
polychlorinated B
biphenyls I
, O
propylthiouracil O
, O
iodoacetic O
acid O
, O
methylmercury B
, O
beta O
- O
estradiol O

, O
methimazole O
, O
3 B
- I
methylcholanthrene I
, O
aminotriazole O
, O
amiodarone B
, O
cadmium B
chloride I
, O
dimethoate O
, O
fenvalerate O
, O
octylmethoxycinnamat O
, O
iopanoic O
acid O
, O
methoxychlor B
, O
and O
4 O
- O
methylbenzylidene O
- O
camphor O
) O
. O

In O
addition O
to O
topical O
treatment O
with O
steroid B
ointments O
, O
there O
have O
been O
previous O
reports O
of O
subcutaneous O
injections O
of O
steroids B
. O

In O
the O
present O
study O
, O
we O
have O
tried O
a O
novel O
modality O
of O
treatment O
of O
PTM O
by O
injecting O
a O
solution O
of O
dexamethasone B
in O
the O
subcutaneous O
tissue O
using O
needles O
employed O
for O
mesotherapy O
. O

We O
utilized O
multiple O
injections O
of O
a O
solution O
of O
dexamethasone B
, O
lidocaine B
, O
and O
saline O
in O
the O
PTM O
plaque O
and O
in O
the O
pretibial O
area O
, O
both O
in O
the O
PTM O
plaque O
and O
in O
the O
area O
surrounding O
the O
lesions O
, O
once O
a O
week O
for O
three O
consecutive O
weeks O
. O

The O
present O
study O
, O
although O
preliminary O
, O
shows O
that O
intralesion O
steroid B
injection O
with O
mesotherapy O
needles O
in O
PTM O
is O
effective O
and O
well O
tolerated O
, O
and O
does O
not O
cause O
undesired O
long O
- O
term O
modifications O
of O
the O
skin O
. O

This O
modification O
improves O
the O
COSMO O
- O
RS O
estimate O
of O
ambient O
vapor O
pressure O
by O
more O
than O
1 O
order O
of O
magnitude O
for O
a O
range O
of O
nitrogen B
- O
rich O
explosives O
and O
their O
derivatives O
, O
bringing O
the O
theoretical O
predictions O
to O
within O
typical O
experimental O
error O
bars O
for O
vapor O
pressure O
measurements O
. O

Inductive O
tuning O
of O
Fano O
- O
resonant O
metasurfaces O
using O
plasmonic O
response O
of O
graphene B
in O
the O
mid O
- O
infrared O
. O

Graphene B
is O
widely O
known O
for O
its O
anomalously O
strong O
broadband O
optical O
absorptivity O
of O
2 O
. O
3 O
% O
that O
enables O
seeing O
its O
single O
- O
atom O
layer O
with O
the O
naked O
eye O
. O

However O
, O
in O
the O
mid O
- O
infrared O
part O
of O
the O
spectrum O
graphene B
represents O
a O
quintessential O
lossless O
zero O
- O
volume O
plasmonic O
material O
. O

We O
experimentally O
demonstrate O
that O
, O
when O
integrated O
with O
Fano O
- O
resonant O
plasmonic O
metasurfaces O
, O
single O
- O
layer O
graphene B
( O
SLG O
) O
can O
be O
used O
to O
tune O
their O
mid O
- O
infrared O
optical O
response O
. O

SiO2 B
@ O
Au B
core O
- O
shell O
nanospheres O
self O
- O
assemble O
to O
form O
colloidal O
crystals O
that O
can O
be O
sintered O
and O
surface O
modified O
to O
produce O
pH O
- O
controlled O
membranes O
. O

We O
prepared O
colloidal O
crystals O
by O
self O
- O
assembly O
of O
gold O
- O
coated O
silica B
nanospheres O
, O
and O
free O
- O
standing O
nanoporous O
membranes O
by O
sintering O
these O
colloidal O
crystals O
. O

We O
modified O
the O
nanopore O
surface O
with O
ionizable O
functional O
groups O
, O
by O
forming O
a O
monolayer O
of O
L O
- O
cysteine O
or O
by O
surface O
- O
initiated O
polymerization O
of O
methacrylic B
acid I
. O

Diffusion O
experiments O
for O
the O
cationic O
dye O
Rhodamine B
B I
through O
L O
- O
cysteine O
- O
modified O
membranes O
showed O
a O
decrease O
in O
flux O
upon O
addition O
of O
an O
acid O
due O
to O
the O
nanopore O
surface O
becoming O
positively O
charged O
. O

Our O
results O
demonstrate O
that O
SiO2 B
@ O
Au B
core O
- O
shell O
nanospheres O
can O
self O
- O
assemble O
into O
colloidal O
crystals O
and O
that O
transport O
through O
the O
corresponding O
surface O
- O
modified O
Au B
- O
coated O
colloidal O
membranes O
can O
be O
controlled O
by O
pH O
. O

Medicinal O
plants O
are O
prized O
sources O
of O
alpha O
- O
glucosidase O
inhibitors O
, O
which O
delay O
the O
liberation O
of O
glucose B
from O
complex O
carbohydrates B
, O
retarding O
glucose B
absorption O
, O
and O
thus O
controlling O
the O
characteristic O
hyperglycemia O
of O
TII O
- O
DM O
. O

Here O
we O
demonstrate O
electric O
- O
field O
induced O
magnetic O
anisotropy O
in O
a O
multiferroic O
composite O
containing O
nickel B
nanocrystals O
strain O
coupled O
to O
a O
piezoelectric O
substrate O
. O

Synthesis O
and O
biological O
evaluation O
of O
guanidino B
analogues O
of O
roscovitine B
. O

A O
series O
of O
2 O
, O
9 O
- O
substituted O
6 O
- O
guanidinopurines O
, O
structurally O
related O
to O
the O
cyclin O
- O
dependent O
kinase O
( O
CDK O
) O
inhibitors O
olomoucine O
and O
roscovitine B
, O
has O
been O
synthesized O
and O
characterized O
. O

A O
new O
copper B
- O
catalyzed O
method O
for O
the O
synthesis O
of O
2 O
- O
substituted O
6 O
- O
guanidino O
- O
9 O
- O
isopropylpurines O
under O
mild O
reaction O
conditions O
has O
been O
developed O
. O

The O
most O
active O
derivative O
16g O
possessed O
an O
identical O
side O
chain O
in O
the O
C2 O
position O
to O
roscovitine B
; O
this O
compound O
displayed O
approximately O
five O
fold O
higher O
inhibitory O
activity O
towards O
CDK2 O
/ O
cyclin O
E O
and O
more O
than O
ten O
fold O
increase O
in O
cytotoxicity O
in O
MCF7 O
cells O
. O

Kinase O
selectivity O
profiling O
of O
( O
R O
) O
- O
and O
( O
S O
) O
- O
enantiomers O
16e O
and O
16g O
, O
respectively O
, O
revealed O
that O
introduction O
of O
a O
guanidino B
group O
at O
the O
C6 O
position O
of O
the O
purine B
moiety O
decreased O
selectivity O
towards O
protein O
kinases O
compared O
to O
roscovitine B
. O

Agmatine O
attenuates O
acquisition O
but O
not O
the O
expression O
of O
ethanol B
conditioned O
place O
preference O
in O
mice O
: O
a O
role O
for O
imidazoline O
receptors O
. O

The O
present O
study O
investigated O
the O
effect O
of O
agmatine O
on O
acquisition O
and O
expression O
of O
ethanol B
conditioned O
place O
preference O
( O
CPP O
) O
and O
its O
modulation O
by O
imidazoline O
agents O
. O

Swiss O
albino O
mice O
were O
treated O
intraperitoneally O
with O
saline O
or O
agmatine O
( O
20 O
- O
40 O
mg O
/ O
kg O
) O
before O
injection O
of O
ethanol B
( O
1 O
. O
25 O
mg O
/ O
kg O
) O
during O
conditioning O
days O
or O
on O
a O
test O
day O
( O
20 O
- O
120 O
mg O
/ O
kg O
) O
, O
to O
observe O
the O
effect O
on O
acquisition O
or O
expression O
of O
CPP O
, O
respectively O
. O

Agmatine O
inhibited O
the O
acquisition O
but O
not O
the O
expression O
of O
ethanol B
CPP O
. O

Furthermore O
, O
both O
the O
I O
( O
1 O
) O
receptor O
antagonist O
, O
efaroxan O
( O
9 O
mg O
/ O
kg O
) O
and O
the O
I O
( O
2 O
) O
receptor O
antagonist O
, O
BU224 O
( O
5 O
mg O
/ O
kg O
) O
attenuated O
the O
agmatine O
- O
induced O
inhibition O
of O
the O
ethanol B
CPP O
acquisition O
. O

In O
contrast O
, O
the O
I O
( O
2 O
) O
receptor O
agonist O
, O
2 O
- O
BFI O
( O
5 O
mg O
/ O
kg O
) O
and O
I O
( O
1 O
) O
receptor O
agonist O
, O
moxonidine O
( O
0 O
. O
4 O
mg O
/ O
kg O
) O
alone O
, O
or O
a O
combination O
of O
their O
subeffective O
doses O
, O
significantly O
attenuated O
the O
effect O
of O
agmatine O
( O
20 O
mg O
/ O
kg O
) O
on O
acquisition O
of O
ethanol B
CPP O
. O

Thus O
, O
agmatine O
attenuates O
the O
acquisition O
of O
ethanol B
CPP O
at O
least O
in O
part O
by O
imidazoline O
( O
I O
( O
1 O
) O
or O
I O
( O
2 O
) O
) O
receptors O
. O

In O
future O
studies O
, O
agmatine O
or O
agents O
acting O
at O
the O
imidazoline O
receptors O
could O
be O
explored O
for O
their O
therapeutic O
potential O
in O
ethanol B
dependence O
. O

The O
critical O
effect O
of O
polarization O
on O
the O
dynamical O
structure O
of O
guanine B
quadruplex O
DNA O
. O

Guanine B
quadruplex O
DNA O
( O
G O
- O
DNA O
) O
, O
found O
in O
eukaryotic O
telomeres O
and O
recently O
in O
non O
- O
telomeric O
genomic O
DNA O
, O
plays O
important O
biological O
roles O
and O
their O
structures O
are O
being O
explored O
as O
potential O
targets O
for O
therapeutic O
intervention O
. O

In O
current O
work O
, O
MD O
simulation O
was O
carried O
out O
to O
study O
the O
dynamical O
structure O
of O
a O
special O
G O
- O
DNA O
( O
with O
sequence O
d O
( O
G O
( O
4 O
) O
T O
( O
4 O
) O
G O
( O
4 O
) O
) O
) O
complexed O
with O
five O
K B
( I
+ I
) I
ions O
. O

Our O
study O
showed O
that O
polarization O
of O
the O
nucleobases B
by O
K B
( I
+ I
) I
enhanced O
electrostatic O
attraction O
between O
the O
base O
and O
ions O
. O

The O
gold O
clusters O
were O
washed O
with O
toluene B
at O
100 O
degrees O
C O
or O
calcined O
at O
200 O
degrees O
C O
to O
remove O
the O
organic O
ligand O
. O

From O
the O
position O
of O
the O
Au B
4f O
( O
7 O
/ O
2 O
) O
peak O
it O
is O
concluded O
that O
cluster O
size O
is O
not O
altered O
through O
the O
deposition O
. O

From O
the O
analysis O
of O
the O
phosphorous B
spectra O
, O
it O
can O
be O
concluded O
that O
the O
applied O
heat O
treatment O
removes O
the O
organic O
ligands O
. O

Oxidation O
of O
the O
clusters O
is O
most O
likely O
due O
to O
the O
interaction O
of O
the O
cluster O
core O
with O
the O
oxygen B
of O
the O
titania O
surface O
after O
removal O
of O
ligands O
. O

The O
position O
of O
the O
Au B
4f O
( O
7 O
/ O
2 O
) O
peak O
indicates O
that O
the O
size O
of O
the O
agglomerated O
clusters O
is O
still O
smaller O
than O
that O
of O
Au O
( O
101 O
) O
. O

They O
authors O
conclude O
that O
AML O
possesses O
an O
enhancement O
effect O
in O
beta B
- I
lactam I
antibiotic O
bioavailability O
( O
in O
this O
case O
, O
LEX O
) O
, O
and O
this O
interaction O
may O
be O
specific O
to O
the O
peptidomimetic O
beta B
- I
lactam I
antibiotics O
. O

Correlation O
between O
carbapenem B
consumption O
and O
antimicrobial O
resistance O
rates O
of O
Acinetobacter O
baumannii O
in O
a O
university O
- O
affiliated O
hospital O
in O
China O
. O

To O
investigate O
the O
correlation O
between O
carbapenem B
consumption O
and O
rates O
of O
antimicrobial O
resistance O
in O
Acinetobacter O
baumannii O
, O
carbapenem B
consumption O
was O
expressed O
as O
defined O
daily O
dose O
based O
on O
the O
World O
Health O
Organization O
( O
WHO O
) O
anatomical O
therapeutic O
chemical O
classification O
index O
. O

Results O
show O
that O
the O
consumption O
of O
imipenem O
/ O
cilastatin O
, O
meropenem O
, O
and O
total O
carbapenem B
is O
significantly O
correlated O
with O
imipenem O
resistance O
in O
A O
baumannii O
( O
r O
= O
0 O
. O
818 O
, O
P O
= O
. O
007 O
; O
r O
= O
0 O
. O
817 O
, O
P O
= O
. O
007 O
; O
r O
= O
0 O
. O
827 O
, O
P O
= O
. O
006 O
) O
. O

Furthermore O
, O
total O
carbapenem B
consumption O
is O
significantly O
correlated O
with O
meropenem O
resistance O
in O
A O
baumannii O
( O
r O
= O
0 O
. O
900 O
, O
P O
= O
. O
037 O
) O
. O

In O
addition O
, O
consumption O
of O
imipenem O
/ O
cilastatin O
, O
meropenem O
, O
and O
total O
carbapenem B
is O
associated O
with O
A O
baumannii O
resistance O
to O
piperacillin O
- O
tazobactam O
, O
ceftazidime B
, O
cefepime O
, O
amikacin O
, O
and O
levofloxacin O
. O

These O
drugs O
are O
mainly O
beta B
- I
lactams I
, O
aminoglycosides O
, O
and O
fluoroquinolones O
. O

The O
imipenem O
and O
meropenem O
resistance O
rates O
are O
significantly O
correlated O
with O
resistance O
rates O
to O
numerous O
antimicrobial O
drugs O
( O
eg O
, O
beta B
- I
lactams I
, O
aminoglycosides O
, O
and O
fluoroquinolones O
) O
in O
A O
baumannii O
. O

Therefore O
, O
increased O
consumption O
of O
carbapenem B
may O
contribute O
to O
the O
development O
of O
resistance O
in O
A O
baumannii O
to O
imipenem O
, O
meropenem O
, O
and O
other O
antimicrobial O
drugs O
. O

Cross O
- O
resistance O
possibly O
occurs O
among O
imipenem O
/ O
cilastatin O
and O
meropenem O
, O
as O
well O
as O
with O
beta B
- I
lactams I
, O
aminoglycosides O
, O
and O
fluoroquinolones O
. O

The O
authors O
conducted O
an O
aquatic O
mesocosm O
experiment O
to O
assess O
the O
behavior O
of O
three O
NBFRs O
: O
bis O
( O
tribromophenoxy O
) O
ethane O
( O
BTBPE O
) O
, O
tetrabromobisphenol O
A O
bis O
( O
2 O
, O
3 O
- O
dibromopropyl O
ether O
; O
TBBPA B
- O
DBPE O
) O
, O
and O
Firemaster O
BZ O
- O
54 O
, O
a O
commercial O
mixture O
containing O
bis O
( O
2 O
- O
ethylhexyl O
) O
tetrabromophthalate O
( O
BEHTBP O
) O
and O
2 O
- O
ethylhexyl O
- O
2 O
, O
3 O
, O
4 O

Analysis O
by O
gas O
chromatography O
- O
mass O
spectrometry O
, O
operated O
in O
the O
electron O
capture O
negative O
ionization O
mode O
, O
revealed O
partitioning O
between O
the O
particulate O
and O
sediment O
phases O
, O
with O
BTBPE O
, O
TBBPA B
- O
DBPE O
, O
and O
BEHTBP O
identified O
as O
being O
environmentally O
persistent O
in O
both O
the O
particulate O
and O
the O
sediment O
compartments O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
cause O
neurobehavioral O
toxicity O
, O
but O
their O
effects O
on O
visual O
behavior O
remain O
unknown O
. O

In O
the O
present O
study O
, O
the O
impact O
of O
PBDEs B
on O
visual O
behavior O
was O
examined O
using O
optokinetic O
responses O
and O
phototaxis O
in O
zebrafish O
larvae O
. O

Rash O
associated O
with O
dabigatran B
etexilate I
. O

Dabigatran B
etexilate I
was O
approved O
by O
the O
Food O
and O
Drug O
Administration O
in O
2010 O
as O
anticoagulant O
prophylaxis O
for O
patients O
with O
nonvalvular O
atrial O
fibrillation O
. O

The O
frequency O
of O
dermatologic O
reactions O
to O
dabigatran B
etexilate I
is O
estimated O
in O
the O
product O
labeling O
to O
be O
less O
than O
0 O
. O
1 O
% O
. O

To O
date O
, O
five O
cases O
of O
dabigatran B
etexilate I
- O
associated O
rash O
have O
reported O
, O
including O
three O
published O
cases O
. O

We O
describe O
the O
sixth O
reported O
case O
of O
dabigatran B
etexilate I
- O
associated O
rash O
, O
in O
a O
59 O
- O
year O
- O
old O
man O
with O
a O
history O
of O
atrial O
fibrillation O
who O
received O
dabigatran B
etexilate I
150 O
mg O
twice O
/ O
day O
for O
atrial O
flutter O
before O
cardioversion O
. O

The O
patient O
had O
taken O
dabigatran B
etexilate I
for O
5 O
days O
before O
the O
rash O
was O
noted O
on O
hospital O
admission O
. O

He O
had O
no O
known O
previous O
drug O
allergies O
, O
and O
his O
platelet O
count O
, O
serum O
creatinine B
concentration O
, O
and O
hepatic O
function O
were O
normal O
. O

The O
rash O
resolved O
7 O
days O
after O
the O
discontinuation O
of O
dabigatran B
etexilate I
, O
and O
the O
patient O
was O
stabilized O
on O
warfarin B
therapy O
. O

Use O
of O
the O
Naranjo O
Adverse O
Drug O
Reaction O
Probability O
Scale O
indicated O
a O
probable O
relationship O
( O
score O
of O
5 O
) O
between O
the O
patient O
' O
s O
development O
of O
the O
rash O
and O
dabigatran B
etexilate I
therapy O
. O

Clinicians O
should O
be O
aware O
of O
this O
adverse O
effect O
of O
dabigatran B
etexilate I
and O
monitor O
for O
dermatologic O
reactions O
during O
follow O
- O
up O
visits O
. O

Joining O
Copper B
Oxide I
Nanotube O
Arrays O
Driven O
by O
the O
Nanoscale O
Kirkendall O
effect O
. O

Various O
annealing O
conditions O
( O
environment O
, O
temperature O
, O
and O
duration O
) O
are O
applied O
to O
study O
the O
nanoscale O
Kirkendall O
effect O
of O
copper B
( O
Cu B
) O
nanowire O
( O
NW O
) O
arrays O
on O
a O
Si B
substrate O
. O

The O
results O
show O
that O
an O
appropriate O
amount O
of O
oxygen B
supply O
is O
crucial O
for O
uniform O
transformation O
from O
Cu B
NWs O
( O
average O
diameter O
~ O
50 O
nm O
) O
into O
Cu O
oxide O
nanotube O
arrays O
. O

An O
annealing O
duration O
of O
30 O
min O
at O
200 O
degrees O
C O
in O
a O
low O
vacuum O
environment O
reveals O
that O
the O
voids O
are O
not O
uniformly O
distributed O
at O
the O
Cu B
/ O
Cu O
oxide O
interface O
. O

This O
suggests O
that O
void O
growth O
is O
due O
to O
surface O
diffusion O
of O
Cu B
along O
void O
surfaces O
. O

Annealing O
above O
200 O
degrees O
C O
for O
60 O
min O
resulted O
in O
complete O
transformation O
from O
Cu B
NWs O
into O
Cu O
oxide O
nanotubes O
. O

X O
- O
ray O
photoelectron O
spectroscopy O
characterization O
indicates O
that O
the O
Cu O
oxides O
formed O
at O
200 O
degrees O
C O
and O
300 O
degrees O
C O
are O
Cu O
( O
2 O
) O
O O
and O
CuO B
, O
respectively O
. O

It O
is O
demonstrated O
that O
the O
transformation O
from O
Cu B
NW O
arrays O
into O
Cu O
oxide O
nanotube O
arrays O
can O
be O
combined O
with O
the O
joining O
of O
stacked O
Si B
chips O
in O
a O
single O
- O
process O
step O
with O
reasonable O
joint O
shear O
strength O
. O

The O
outward O
diffusion O
of O
Cu B
driven O
by O
the O
nanoscale O
Kirkendall O
effect O
is O
believed O
to O
enhance O
the O
joining O
process O
. O

By O
controlling O
the O
environment O
, O
temperature O
, O
and O
duration O
, O
joined O
Cu O
( O
2 O
) O
O O
or O
CuO B
nanotube O
stacked O
chips O
can O
be O
achieved O
, O
which O
serve O
as O
a O
platform O
for O
the O
further O
development O
of O
nanostructured O
, O
stacked O
devices O
. O

Protein O
- O
Carbohydrate B
Complex O
Reveals O
Circulating O
Metastatic O
Cells O
in O
a O
Microfluidic O
Assay O
. O

Advances O
in O
carbohydrate B
sequencing O
technologies O
reveal O
the O
tremendous O
complexity O
of O
the O
glycome O
and O
the O
role O
that O
glycomics O
might O
have O
to O
bring O
insight O
into O
the O
biological O
functions O
. O

Carbohydrate B
- O
protein O
interactions O
, O
in O
particular O
, O
are O
known O
to O
be O
crucial O
to O
most O
mammalian O
physiological O
processes O
as O
mediators O
of O
cell O
adhesion O
and O
metastasis O
, O
signal O
transducers O
, O
and O
organizers O
of O
protein O
interactions O
. O

An O
assay O
is O
developed O
here O
to O
mimic O
the O
multivalency O
of O
biological O
complexes O
that O
selectively O
and O
sensitively O
detect O
carbohydrate B
- O
protein O
interactions O
. O

Modulation O
of O
photophysics O
and O
pKa O
shift O
of O
the O
anti O
- O
cancer O
drug O
camptothecin B
in O
the O
nanocavities O
of O
supramolecular O
hosts O
. O

This O
article O
reports O
the O
pK O
( O
a O
) O
shift O
of O
an O
anti O
- O
cancer O
drug O
, O
20 O
( O
S O
) O
- O
camptothecin O
( O
CPT B
) O
, O
upon O
encapsulation O
into O
the O
nanocavity O
of O
a O
cucurbit O
[ O
7 O
] O
uril O
( O
CB7 O
) O
macrocycle O
. O

Steady O
- O
state O
, O
time O
- O
resolved O
fluorescence O
and O
electrospray O
ionisation O
mass O
spectrometry O
( O
ESI O
- O
MS O
) O
studies O
provide O
evidence O
for O
the O
formation O
of O
both O
1 O
: O
1 O
and O
2 O
: O
1 O
( O
CB7 O
. O
CPT B
) O
stoichiometries O
. O

Astonishingly O
, O
we O
have O
found O
that O
protonation O
of O
CPT B
takes O
place O
at O
a O
higher O
concentration O
of O
macrocycle O
( O
> O
= O
50 O
mu O
M O
) O
when O
the O
2 O
: O
1 O
stoichiometric O
complex O
develops O
. O

However O
, O
we O
did O
not O
find O
any O
proof O
for O
protonation O
of O
CPT B
when O
it O
is O
encased O
by O
a O
beta B
- I
cyclodextrin I
cavity O
, O
which O
has O
a O
cavity O
size O
almost O
the O
same O
as O
that O
of O
CB7 O
. O

Hence O
, O
we O
conclude O
that O
electron O
- O
rich O
carbonyl B
portals O
of O
CB7 O
have O
an O
important O
role O
in O
protonation O
of O
the O
drug O
in O
the O
2 O
: O
1 O
inclusion O
complex O
. O

Docking O
and O
semi O
- O
empirical O
quantum O
chemical O
calculations O
have O
been O
employed O
to O
gain O
an O
insight O
into O
the O
molecular O
picture O
of O
orientation O
of O
CPT B
in O
the O
inclusion O
complexes O
. O

It O
is O
clearly O
seen O
from O
the O
optimised O
structure O
of O
the O
2 O
: O
1 O
( O
CB7 O
. O
CPT B
) O
inclusion O
complex O
that O
the O
quinoline O
nitrogen O
of O
CPT B
does O
not O
reside O
within O
either O
of O
the O
CB7 O
cavities O
, O
rather O
it O
is O
almost O
sandwiched O
between O
two O
CB7 O
rings O
, O
and O
therefore O
, O
it O
experiences O
huge O
electron O
density O
exerted O
by O
both O
carbonyl B
portals O
of O
the O
macrocycles O
. O

As O
a O
result O
, O
the O
pK O
( O
a O
) O
of O
CPT B
shifts O
from O
1 O
. O
2 O
to O
6 O
. O
2 O
. O

Finally O
, O
controlled O
release O
of O
the O
drug O
has O
been O
achieved O
through O
the O
introduction O
of O
NaCl B
, O
which O
is O
rich O
in O
cells O
, O
as O
an O
external O
stimulus O
. O

Species O
difference O
in O
the O
mechanism O
of O
nonlinear O
pharmacokinetics O
of O
e2074 O
, O
a O
novel O
sodium B
channel O
inhibitor O
, O
in O
rats O
, O
dogs O
, O
and O
monkeys O
. O

Intestinal O
metabolism O
was O
observed O
in O
monkey O
intestinal O
microsomes O
but O
not O
in O
rats O
and O
dogs O
, O
and O
the O
nonlinear O
PK O
in O
monkeys O
was O
diminished O
by O
inhibition O
of O
intestinal O
metabolism O
with O
a O
concomitant O
oral O
dose O
of O
ketoconazole B
. O

Furthermore O
, O
silymarin O
, O
silybin O
A O
, O
and O
silybin O
B O
( O
100 O
micro O
M O
) O
significantly O
inhibited O
OATP O
- O
mediated O
estradiol O
- O
17 O
beta O
- O
glucuronide O
and O
rosuvastatin B
uptake O
into O
human O
hepatocytes O
. O

Thiolates B
chemically O
induce O
redox O
activation O
of O
BTZ043 O
and O
related O
potent O
nitroaromatic O
anti O
- O
tuberculosis O
agents O
. O

Nitroaromatic O
compounds O
, O
including O
1 O
, O
3 O
- O
benzothiazin O
- O
4 O
- O
ones O
( O
BTZs B
) O
and O
related O
agents O
, O
are O
a O
promising O
new O
class O
for O
the O
treatment O
of O
TB O
. O

Research O
has O
shown O
that O
the O
nitroso B
intermediates O
of O
BTZs B
that O
are O
generated O
in O
vivo O
cause O
suicide O
inhibition O
of O
decaprenylphosphoryl O
- O
beta O
- O
D O
- O
ribose O
2 O
' O
oxidase O
( O
DprE1 O
) O
, O
which O
is O
responsible O
for O
cell O
wall O
arabinogalactan O
biosynthesis O
. O

We O
have O
designed O
and O
synthesized O
novel O
anti O
- O
TB O
agents O
inspired O
from O
BTZs B
and O
other O
nitroaromatic O
compounds O
. O

Computational O
studies O
indicated O
that O
the O
unsubstituted O
aromatic O
carbons B
of O
BTZ043 O
and O
related O
nitroaromatic O
compounds O
are O
the O
most O
electron O
- O
deficient O
and O
might O
be O
prone O
to O
nucleophilic O
attack O
. O

The O
results O
indicate O
that O
nucleophiles O
such O
as O
thiolates B
, O
cyanide B
, O
and O
hydride B
induce O
nonenzymatic O
reduction O
of O
the O
nitro B
groups O
present O
in O
these O
compounds O
to O
the O
corresponding O
nitroso B
intermediates O
by O
addition O
at O
the O
unsubstituted O
electron O
- O
deficient O
aromatic O
carbon B
present O
in O
these O
compounds O
. O

These O
chemical O
studies O
offer O
an O
alternate O
hypothesis O
for O
the O
mechanism O
of O
action O
of O
nitroaromatic O
anti O
- O
TB O
agents O
, O
in O
that O
the O
cysteine O
thiol O
( O
ate O
) O
or O
a O
hydride B
source O
at O
the O
active O
site O
of O
DprE1 O
may O
trigger O
the O
reduction O
of O
the O
nitro B
groups O
in O
a O
manner O
similar O
to O
the O
von O
Richter O
reaction O
to O
the O
nitroso B
intermediates O
, O
to O
initiate O
the O
inhibition O
of O
DprE1 O
. O

A O
low O
- O
overpotential O
potassium B
- O
oxygen B
battery O
based O
on O
potassium O
superoxide O
. O

The O
parasitic O
reactions O
of O
electrolyte O
and O
carbon B
electrode O
induced O
by O
the O
high O
charging O
potential O
cause O
the O
decay O
of O
capacity O
and O
limit O
the O
battery O
life O
. O

Here O
, O
a O
K O
- O
O O
( O
2 O
) O
battery O
is O
report O
that O
uses O
K B
( I
+ I
) I
ions O
to O
capture O
O B
( I
2 I
) I
( I
- I
) I
to O
form O
the O
thermodynamically O
stable O
KO O
( O
2 O
) O
product O
. O

This O
allows O
for O
the O
battery O
to O
operate O
through O
the O
one O
- O
electron O
redox O
process O
of O
O B
( I
2 I
) I
/ O
O B
( I
2 I
) I
( I
- I
) I
. O

In O
vitro O
MRP2 O
activity O
was O
determined O
by O
measuring O
the O
ATP B
- O
dependent O
uptake O
of O
5 O
( O
6 O
) O
- O
carboxy O
- O
2 O
' O
, O
7 O
' O
- O
dichlorofluorescein O
( O
CDCF O
) O
in O
inside O
- O
out O
membrane O
vesicles O
isolated O
from O
MDCK O
- O
ABCC2 O
cells O
. O

CDCF O
uptake O
was O
time O
- O
and O
concentration O
- O
dependent O
( O
K O
( O
m O
) O
of O
4 O
. O
0 O
+ O
/ O
- O
1 O
. O
2 O
micro O
M O
and O
a O
V O
( O
max O
) O
of O
7 O
. O
8 O
+ O
/ O
- O
0 O
. O
9 O
pmol O
/ O
mg O
/ O
min O
) O
and O
inhibited O
by O
benzbromarone B
and O
MK O
- O
571 O
with O
IC O
( O
50 O
) O
values O
of O
1 O
. O
2 O
and O
7 O
. O
6 O
micro O
M O
, O
respectively O
. O

Effects O
of O
hydrogen B
bonding O
on O
internal O
conversion O
of O
GFP O
- O
like O
chromophores O
. O

To O
rationalize O
the O
efficient O
quenching O
of O
the O
fluorescence O
and O
the O
Z O
- O
- O
> O
E O
photoisomerization O
of O
m O
- O
ABDI O
, O
the O
meta O
- O
amino O
analogue O
of O
the O
green O
fluorescent O
protein O
( O
GFP O
) O
chromophore O
, O
in O
protic O
solvents O
, O
the O
femtosecond O
time O
- O
resolved O
fluorescence O
and O
transient O
infrared O
( O
TRIR O
) O
spectra O
of O
m O
- O
ABDI O
in O
CD3CN O
, O
CH3OH B
, O
and O
CD3OD O
are O
determined O
. O

For O
solutions O
in O
CH3OH B
, O
the O
fluorescence O
decay O
is O
double O
exponential O
with O
time O
constants O
of O
~ O
16 O
and O
62 O
ps O
. O

We O
conclude O
that O
the O
torsion O
of O
the O
exocyclic O
C B
= I
C I
bond O
( O
the O
tau O
torsion O
) O
is O
responsible O
for O
the O
nonradiative O
decay O
of O
electronically O
excited O
m O
- O
ABDI O
in O
CD3CN O
. O

However O
, O
in O
CH3OH B
and O
CD3OD O
, O
the O
solute O
- O
solvent O
hydrogen B
bonding O
( O
SSHB O
) O
interactions O
diminish O
significantly O
the O
barrier O
of O
the O
tau O
torsion O
and O
induce O
a O
new O
pathway O
that O
competes O
successfully O
with O
the O
tau O
torsion O
, O
consistent O
with O
the O
efficient O
fluorescence O
quenching O
and O
the O
diminished O
yield O
for O
Z O
- O
- O
> O
E O
photoisomerization O
. O

The O
new O
pathway O
is O
likely O
associated O
with O
excited O
- O
state O
proton O
transfer O
( O
ESPT O
) O
from O
the O
solvent O
to O
m O
- O
ABDI O
, O
particularly O
the O
carbonyl B
group O
, O
and O
generates O
an O
intermediate O
( O
ESPT O
* O
) O
that O
is O
weakly O
fluorescent O
. O

Selective O
oxidation O
of O
omega O
- O
tertiary O
amine O
self O
- O
assembled O
thiol B
monolayers O
to O
tertiary O
amine O
N O
- O
oxides O
is O
shown O
to O
transform O
the O
adhesion O
of O
model O
proteins O
lysozyme O
and O
fibrinogen O
upon O
them O
. O

Efficient O
preparation O
of O
both O
secondary O
and O
tertiary O
linker O
amides O
as O
judged O
by O
X O
- O
ray O
photoelectron O
spectroscopy O
( O
XPS O
) O
and O
water O
droplet O
contact O
angle O
was O
achieved O
with O
an O
improved O
amide B
bond O
formation O
on O
gold O
quartz B
crystal O
microbalance O
( O
QCM O
) O
sensors O
using O
2 O
- O
( O
1H O
- O
7 O
- O
azabenzotriazol O
- O
1 O
- O
yl O
) O
- O
1 O
, O
1 O
, O
3 O
, O
3 O
- O
tetramethyl O
hexafluorophosphate O
methanaminium O
uronium O
( O
HATU O
) O
. O

Oxidation O
with O
hydrogen B
peroxide I
was O
similarly O
assessed O
, O
and O
adhesion O
of O
lysozyme O
and O
fibrinogen O
from O
phosphate B
buffered O
saline O
was O
then O
assayed O
by O
QCM O
and O
imaged O
by O
AFM O
. O

Sexually O
dimorphic O
behavior O
after O
developmental O
exposure O
to O
characterize O
endocrine O
- O
mediated O
effects O
of O
different O
non O
- O
dioxin B
- O
like O
PCBs B
in O
rats O
. O

We O
previously O
demonstrated O
that O
developmental O
exposure O
to O
a O
mixture O
of O
polychlorinated B
biphenyls I
( O
PCBs B
) O
which O
was O
reconstituted O
according O
to O
the O
congener O
pattern O
found O
in O
human O
breast O
milk O
caused O
feminization O
of O
sweet O
preference O
as O
a O
sexually O
dimorphic O
behavior O
in O
adult O
male O
rats O
, O
following O
decreases O
in O
aromatase O
activity O
in O
the O
brain O
of O
newborn O
male O
pups O
. O

This O
result O
may O
be O
due O
to O
dioxin B
- O
like O
or O
non O
- O
dioxin B
- O
like O
( O
NDL O
) O
PCBs B
and O
their O
respective O
effects O
on O
steroid B
hormones O
. O

The O
aim O
of O
the O
present O
experiments O
was O
to O
determine O
if O
exposure O
to O
highly O
purified O
NDL O
- O
PCBs B
( O
to O
remove O
Ah O
receptor O
active O
contaminants O
) O
also O
results O
in O
alteration O
of O
sweet O
preference O
. O

Adult O
male O
and O
female O
offspring O
were O
given O
a O
choice O
between O
a O
bottle O
of O
saccharin B
solution O
( O
0 O
. O
25 O
% O
) O
and O
a O
bottle O
of O
tap O
water O
on O
five O
consecutive O
days O
. O

Female O
offspring O
exposed O
to O
PCB180 O
exhibited O
signs O
of O
supernormal O
behavior O
as O
illustrated O
by O
increased O
saccharin B
consumption O
at O
intermediate O
dose O
levels O
. O

Only O
PCB95 O
increased O
saccharin B
consumption O
in O
exposed O
males O
, O
leading O
to O
decreased O
sexual O
dimorphism O
of O
this O
behavior O
and O
behavioral O
feminization O
. O

The O
results O
demonstrate O
that O
different O
NDL O
- O
PCBs B
exhibit O
differential O
effects O
on O
sexually O
dimorphic O
behavior O
and O
that O
feminization O
occurs O
after O
removal O
of O
Ah O
receptor O
active O
contaminants O
. O

Comparison O
with O
data O
from O
the O
literature O
reveals O
little O
evidence O
for O
a O
relation O
to O
anti O
- O
androgenic O
activity O
of O
the O
studied O
NDL O
- O
PCBs B
. O

Combined O
effects O
of O
organochlorine B
pesticides O
heptachlor O
and O
hexachlorobenzene O
on O
the O
promotion O
stage O
of O
hepatocarcinogenesis O
in O
rats O
. O

We O
aimed O
to O
investigate O
the O
combined O
effect O
of O
organochlorine B
pesticides O
heptachlor O
( O
HEP O
) O
and O
hexachlorobenzene O
( O
HCB O
) O
by O
using O
a O
medium O
- O
term O
rat O
liver O
bioassay O
. O

Male O
F344 O
rats O
were O
initially O
administered O
diethylnitrosamine B
( O
DEN B
, O
200mg O
/ O
kgi O
. O
p O
. O
) O
; O
after O
a O
2 O
- O
week O
non O
- O
dosing O
period O
, O
they O
were O
given O
diets O
containing O
HEP O
( O
5 O
or O
25ppm O
) O
, O
HCB O
( O
70 O
or O
350ppm O
) O
, O
or O
their O
mixtures O
( O
5 O
and O
70ppm O
or O
25 O
and O
350ppm O
) O
for O
6weeks O
. O

Number O
and O
area O
of O
preneoplastic O
foci O
positive O
for O
glutathione B
S B
- O
transferase O
placental O
form O
( O
GST O
- O
P O
) O
were O
consistently O
higher O
in O
these O
groups O
than O
the O
sum O
of O
individual O
values O
in O
the O
groups O
treated O
with O
HEP O
or O
HCB O
alone O
. O

On O
the O
basis O
of O
these O
findings O
, O
we O
conclude O
that O
HEP O
and O
HCB O
have O
additive O
and O
synergistic O
effects O
on O
the O
development O
of O
GST O
- O
P O
- O
positive O
foci O
and O
that O
higher O
risks O
are O
associated O
with O
a O
combination O
of O
residual O
organochlorine B
pesticides O
in O
foods O
than O
with O
individual O
residual O
organochlorine B
pesticides O
. O

Monitoring O
of O
arsenic B
levels O
in O
some O
ready O
- O
to O
- O
use O
anti O
- O
malaria O
herbal O
products O
from O
drug O
sales O
outlets O
in O
the O
Madina O
area O
of O
Accra O
, O
Ghana O
. O

In O
this O
study O
, O
four O
common O
aqueous O
based O
anti O
- O
malaria O
herbal O
products O
( O
coded O
HEB O
, O
KFE O
, O
MDM O
and O
NIB O
) O
which O
are O
used O
by O
Ghanaian O
population O
from O
pharmacy O
/ O
herbal O
stores O
in O
the O
Madina O
area O
, O
Accra O
were O
blindly O
and O
randomly O
sampled O
for O
cadmium B
( O
Cd B
) O
, O
arsenic B
( O
As B
) O
and O
Lead O
( O
Pb B
) O
analysis O
using O
Atomic O
Absorption O
Spectrophotometry O
technique O
. O

Arsenic B
concentrations O
were O
1 O
. O
087 O
mu O
g O
/ O
mL O
( O
108 O
. O
7 O
% O
) O
, O
1 O
. O
027 O
mu O
g O
/ O
mL O
( O
102 O
. O
7 O
% O
) O
, O
0 O
. O
330 O
mu O
g O
/ O
mL O
( O
33 O
. O
0 O
% O
) O
and O
0 O
. O
274 O
mu O
g O
/ O
mL O
( O
27 O
. O
4 O
% O
) O
in O
MDM O
, O
KFE O
, O
NIB O
and O
HEB O
respectively O
. O

Arsenic B
concentration O
determined O
in O
MDM O
and O
KFE O
were O
above O
the O
maximum O
permissible O
limit O
of O
1 O
. O
0ppm O
determined O
by O
WHO O
/ O
FAO O
. O

Cadmium B
concentration O
in O
each O
of O
the O
four O
products O
as O
well O
as O
lead O
concentration O
in O
KFE O
, O
NIB O
and O
HEB O
were O
below O
the O
detection O
limit O
of O
< O
0 O
. O
002mg O
/ O
mL O
( O
Cd B
) O
and O
< O
0 O
. O
005mg O
/ O
mL O
( O
Pb B
) O
respectively O
. O

The O
maximum O
permissible O
limits O
for O
Pb B
and O
Cd B
determined O
by O
WHO O
/ O
FAO O
are O
10 O
. O
0ppm O
and O
0 O
. O
3ppm O
respectively O
. O

Although O
lead O
and O
cadmium B
concentration O
in O
the O
anti O
- O
malaria O
herbal O
products O
were O
below O
the O
maximum O
permissible O
limits O
, O
their O
cumulative O
effect O
on O
the O
health O
of O
an O
individual O
which O
consume O
recommended O
volume O
of O
not O
less O
than O
1000 O
mL O
for O
effective O
malaria O
parasite O
clearance O
cannot O
be O
ignored O
. O

Enzymatic O
catalyzed O
palm O
oil O
hydrolysis O
under O
ultrasound O
irradiation O
: O
diacylglycerol B
synthesis O
. O

Diacylglycerol B
( O
DAG O
) O
rich O
oils O
have O
an O
organoleptic O
property O
like O
that O
of O
regular O
edible O
oils O
, O
but O
these O
oils O
do O
not O
tend O
to O
be O
accumulated O
as O
fat O
. O

The O
aim O
of O
this O
study O
was O
to O
propose O
a O
new O
methodology O
to O
produce O
diacylglycerol B
by O
hydrolysis O
of O
palm O
oil O
using O
Lipozyme O
RM O
IM O
commercial O
lipase O
as O
a O
catalyst O
under O
ultrasound O
irradiation O
. O

In O
these O
conditions O
diacylglycerol B
yield O
was O
34 O
. O
17 O
wt O
. O
% O
. O

Spray O
- O
dried O
casein O
- O
based O
micelles O
as O
a O
vehicle O
for O
solubilization O
and O
controlled O
delivery O
of O
flutamide B
: O
Formulation O
, O
characterization O
, O
and O
in O
vivo O
pharmacokinetics O
. O

Novel O
casein O
( O
CAS O
) O
- O
based O
micelles O
loaded O
with O
the O
poorly O
soluble O
anti O
- O
cancer O
drug O
, O
flutamide B
( O
FLT O
) O
, O
were O
successfully O
developed O
in O
a O
powdered O
form O
via O
spray O
- O
drying O
technique O
. O

Genipin B
( O
GNP O
) O
was O
used O
to O
crosslink O
CAS O
micelles O
as O
demonstrated O
by O
color O
variation O
of O
the O
micelles O
. O

Neuroprotective O
effects O
of O
mercaptoethylleonuri O
and O
mercaptoethylguanidi O
analogs O
on O
hydrogen B
peroxide I
- O
induced O
apoptosis O
in O
human O
neuronal O
SH O
- O
SY5Y O
cells O
. O

Their O
neuroprotective O
effects O
toward O
H2O2 B
- O
induced O
apoptosis O
were O
investigated O
in O
human O
SH O
- O
SY5Y O
cells O
. O

Further O
investigation O
demonstrated O
that O
8k O
reduced O
H2O2 B
- O
induced O
activation O
of O
mitochondrial O
apoptosis O
by O
inhibiting O
the O
expression O
of O
Bax O
and O
elevating O
the O
expression O
of O
Bcl O
- O
2 O
. O

Paeoniflorin B
protects O
human O
EA O
. O
hy926 O
endothelial O
cells O
against O
gamma O
- O
radiation O
induced O
oxidative O
injury O
by O
activating O
the O
NF O
- O
E2 O
- O
related O
factor O
2 O
/ O
heme B
oxygenase O
- O
1 O
pathway O
. O

Our O
preliminary O
experiments O
indicated O
that O
Paeoniflorin B
protected O
human O
EA O
. O
hy926 O
endothelial O
cells O
from O
radiation O
- O
induced O
oxidative O
injury O
. O

This O
study O
was O
designed O
to O
confirm O
the O
protective O
effect O
of O
Paeoniflorin B
against O
radiation O
- O
induced O
endothelial O
cellular O
damage O
and O
to O
elucidate O
the O
underlying O
mechanisms O
. O

Preincubation O
of O
EA O
. O
hy926 O
cells O
with O
Paeoniflorin B
before O
gamma O
- O
radiation O
resulted O
in O
significant O
inhibition O
of O
apoptosis O
, O
a O
decrease O
in O
mitochondrial O
membrane O
potential O
and O
enhanced O
cell O
viability O
. O

In O
particular O
, O
we O
showed O
that O
Paeoniflorin B
significantly O
reduced O
the O
formation O
of O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
the O
level O
of O
malondialdehyde B
( O
MDA B
) O
and O
lactate B
dehydrogenase O
( O
LDH O
) O
leakage O
, O
and O
enhanced O
production O
of O
the O
endogenous O
antioxidants O
, O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
in O
EA O
. O
hy926 O
cells O
. O

Treatment O
of O
these O
cells O
with O
Paeoniflorin B
significantly O
induced O
HO O
- O
1 O
expression O
. O

Moreover O
, O
Paeoniflorin B
promoted O
the O
nuclear O
translocation O
of O
nuclear O
factor O
erythroid O
2 O
related O
factor O
- O
2 O
( O
Nrf O
- O
2 O
) O
. O

The O
Paeoniflorin B
- O
induced O
HO O
- O
1 O
expression O
was O
abrogated O
by O
Nrf2 O
siRNA O
. O

Furthermore O
, O
inhibition O
of O
HO O
- O
1 O
with O
zinc O
protoporphyrin O
IX O
( O
ZNPP B
) O
significantly O
reversed O
the O
protective O
effect O
of O
Paeoniflorin B
against O
radiation O
- O
induced O
damage O
in O
EA O
. O
hy926 O
cells O
. O

Our O
findings O
confirmed O
that O
Paeoniflorin B
protected O
EA O
. O
hy926 O
cells O
against O
radiation O
- O
induced O
injury O
through O
the O
Nrf2 O
/ O
HO O
- O
1 O
pathway O
. O

The O
responsiveness O
of O
polymer O
solution O
assemblies O
and O
surfaces O
to O
biological O
stimuli O
( O
e O
. O
g O
. O
pH O
, O
reduction O
- O
oxidation O
, O
enzymes O
, O
glucose B
) O
and O
externally O
applied O
triggers O
( O
e O
. O
g O
. O
temperature O
, O
light O
, O
solvent O
quality O
) O
shows O
particular O
promise O
for O
various O
biomedical O
applications O
including O
drug O
delivery O
, O
tissue O
engineering O
, O
medical O
diagnostics O
, O
and O
bioseparations O
. O

RATIONALE O
: O
The O
neurotransmitter O
dopamine B
plays O
a O
key O
role O
in O
cognitive O
functions O
that O
are O
associated O
with O
fronto O
- O
striatal O
circuitry O
and O
has O
been O
implicated O
in O
many O
neuropsychiatric O
disorders O
. O

METHODS O
: O
The O
effects O
of O
the O
dopamine B
receptor O
agonist O
bromocriptine O
were O
assessed O
using O
functional O
magnetic O
resonance O
imaging O
in O
22 O
healthy O
volunteers O
in O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
within O
- O
subject O
design O
. O

CONCLUSIONS O
: O
These O
data O
reinforce O
the O
link O
between O
dopamine B
, O
cognition O
and O
the O
basal O
ganglia O
and O
have O
implications O
for O
the O
individual O
tailoring O
of O
dopaminergic O
drug O
therapy O
based O
on O
anatomical O
fronto O
- O
striatal O
connection O
strength O
. O

The O
use O
of O
a O
combination O
of O
a O
serotonin B
5 O
- O
HT3 O
receptor O
antagonist O
, O
dexamethasone B
and O
a O
neurokinin O
1 O
( O
NK1 O
) O
receptor O
antagonist O
has O
significantly O
improved O
the O
control O
of O
acute O
and O
delayed O
emesis O
in O
single O
- O
day O
chemotherapy O
. O

Aprepitant O
, O
the O
first O
and O
only O
agent O
clinically O
available O
in O
the O
NK1 O
receptor O
antagonist O
drug O
class O
has O
been O
used O
effectively O
as O
an O
additive O
agent O
to O
the O
5 O
- O
HT3 O
receptor O
antagonists O
and O
dexamethasone B
to O
control O
CINV O
. O

Olanzapine B
, O
a O
US O
- O
FDA O
approved O
antipsychotic O
, O
has O
emerged O
in O
recent O
trials O
as O
an O
effective O
preventative O
agent O
for O
CINV O
, O
as O
well O
as O
a O
very O
effective O
agent O
for O
the O
treatment O
of O
breakthrough O
emesis O
and O
nausea O
. O

Clinical O
trials O
using O
gabapentin B
, O
cannabinoids O
and O
ginger O
have O
not O
been O
definitive O
regarding O
their O
efficacy O
in O
the O
prevention O
of O
CINV O
. O

Metabolism O
- O
Dependent O
Inhibition O
of O
CYP3A4 O
by O
Lapatinib B
: O
Evidence O
for O
Formation O
of O
a O
Metabolic O
Intermediate O
Complex O
with O
a O
Nitroso B
/ O
Oxime B
Metabolite O
Formed O
via O
a O
Nitrone O
Intermediate O
. O

In O
the O
case O
of O
several O
alkylamine O
drugs O
, O
MDI O
of O
P450 O
involves O
formation O
of O
a O
metabolite O
that O
binds O
quasi O
- O
irreversibly O
to O
the O
ferrous B
heme B
iron B
to O
form O
a O
metabolic O
intermediate O
( O
MI O
) O
complex O
. O

The O
specific O
metabolites O
coordinately O
bound O
to O
ferrous B
iron B
and O
the O
pathways O
leading O
to O
MI O
complex O
formation O
are O
the O
subject O
of O
debate O
. O

We O
describe O
an O
approach O
combining O
heme B
iron B
oxidation O
with O
potassium O
ferricyanide O
and O
metabolite O
profiling O
to O
probe O
the O
mechanism O
of O
MI O
complex O
- O
based O
CYP3A4 O
inactivation O
by O
the O
secondary O
alkylamine O
drug O
lapatinib B
. O

Ten O
metabolites O
formed O
from O
lapatinib B
by O
CYP3A4 O
- O
mediated O
heteroatom O
dealkylation O
, O
C B
- O
hydroxylation O
, O
N B
- O
oxygenation O
with O
or O
without O
further O
oxidation O
, O
or O
a O
combination O
thereof O
, O
were O
detected O
by O
accurate O
mass O
spectrometry O
. O

The O
abundance O
of O
one O
metabolite O
, O
the O
N B
- O
dealkylated O
nitroso B
/ O
oxime B
lapatinib B
metabolite O
( O
M9 O
) O
, O
correlated O
directly O
with O
the O
prevalence O
or O
the O
disruption O
of O
the O
MI O
complex O
with O
CYP3A4 O
. O

Nitroso B
/ O
oxime B
metabolite O
formation O
from O
secondary O
alkylamines O
has O
been O
proposed O
to O
occur O
through O
two O
possible O
pathways O
: O
( O
1 O
) O
sequential O
N B
- O
dealkylation O
, O
N B
- O
hydroxylation O
, O
and O
dehydrogenation O
( O
primary O
hydroxylamine O
pathway O
) O
or O
( O
2 O
) O
N B
- O
hydroxylation O
with O
dehydrogenation O
to O
yield O
a O
nitrone O
followed O
by O
N B
- O
dealkylation O
( O
secondary O
hydroxylamine O
pathway O
) O
. O

All O
intermediates O
for O
the O
secondary O
hydroxylamine O
pathway O
were O
detected O
but O
the O
primary O
N B
- O
hydroxylamine B
intermediate O
of O
the O
primary O
hydroxylamine O
pathway O
was O
not O
. O

Our O
findings O
support O
the O
mechanism O
of O
lapatinib B
CYP3A4 O
inactivation O
as O
MI O
complex O
formation O
with O
the O
nitroso B
metabolite O
formed O
through O
the O
secondary O
hydroxylamine O
and O
nitrone O
pathway O
, O
rather O
than O
by O
N B
- O
dealkylation O
to O
the O
primary B
amine I
followed O
by O
N B
- O
hydroxylation O
and O
dehydrogenation O
as O
is O
usually O
assumed O
. O

Functional O
UDP B
- O
glucuronyltransferas O
2B15 O
polymorphism O
and O
bisphenol B
A I
concentrations O
in O
blood O
: O
results O
from O
physiologically O
based O
kinetic O
modelling O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
a O
chemical O
in O
widespread O
use O
that O
is O
under O
scientific O
discussion O
due O
to O
its O
endocrine O
activity O
. O

Moreover O
, O
in O
controlled O
situations O
, O
BPA B
did O
not O
exceed O
the O
level O
of O
detection O
( O
< O
0 O
. O
3 O
ng O
/ O
ml O
) O
in O
human O
blood O
or O
urine O
. O

Using O
a O
validated O
human O
PBK O
model O
, O
this O
study O
investigated O
the O
influence O
of O
functionally O
relevant O
polymorphic O
UGT2B15 O
, O
the O
enzyme O
mediating O
BPA B
metabolism O
, O
on O
the O
BPA B
concentration O
- O
time O
profile O
in O
human O
blood O
. O

Low O
metabolisers O
excreted O
a O
greater O
proportion O
of O
BPA B
via O
the O
sulphate B
pathway O
compared O
to O
high O
metabolisers O
. O

From O
the O
risk O
assessment O
perspective O
, O
our O
results O
indicate O
that O
the O
traditional O
uncertainty O
factor O
is O
sufficient O
to O
account O
for O
the O
variability O
in O
the O
polymorphic O
glucuronidation O
of O
BPA B
. O

At O
two O
sites O
that O
received O
high O
aqueous O
- O
phase O
entries O
of O
the O
pyrethroid O
lambda B
- I
cyhalothrin I
( O
logTUMax O
> O
- O
0 O
. O
6 O
) O
, O
the O
abundance O
and O
number O
of O
sensitive O
species O
in O
terms O
of O
the O
species O
at O
risk O
index O
decreased O
during O
the O
pesticide O
application O
period O
. O

Transphosphorylation O
of O
tyrosine B
residues O
in O
the O
kinase O
domain O
of O
FGFRs O
leads O
to O
activation O
of O
intracellular O
signaling O
cascades O
, O
including O
those O
mediated O
by O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
. O

FGFRs O
also O
contain O
a O
serine B
- O
rich O
C B
- O
terminal O
tail O
. O

We O
identified O
a O
regulatory O
mechanism O
of O
FGFR O
signaling O
involving O
phosphorylation O
of O
Ser B
( O
777 O
) O
in O
the O
C B
- O
terminal O
region O
of O
FGFR1 O
by O
the O
MAPKs O
extracellular O
signal O
- O
regulated O
kinase O
1 O
( O
ERK1 O
) O
and O
ERK2 O
. O

Prevention O
of O
the O
phosphorylation O
of O
Ser B
( O
777 O
) O
in O
FGFR1 O
or O
mutation O
of O
Ser B
( O
777 O
) O
to O
alanine B
enhanced O
FGF O
- O
stimulated O
receptor O
tyrosine B
phosphorylation O
and O
increased O
cell O
proliferation O
, O
cell O
migration O
, O
and O
axonal O
growth O
. O

A O
form O
of O
FGFR1 O
with O
a O
phosphomimetic O
mutation O
at O
Ser B
( O
777 O
) O
exhibited O
reduced O
signaling O
. O

Activation O
of O
MAPKs O
by O
other O
receptor O
tyrosine B
kinases O
also O
resulted O
in O
phosphorylation O
of O
Ser B
( O
777 O
) O
in O
FGFR1 O
, O
thereby O
enabling O
crosstalk O
regulation O
of O
FGFR O
activity O
by O
other O
signaling O
pathways O
. O

In O
a O
previous O
study O
, O
a O
disulfide B
constrained O
cyclic O
peptide O
cyclo O
S O
( O
1 O
) O
, O
S O
( O
9 O
) O
Cys O
- O
Glu O
- O
Thr O
- O
Gly O
- O
Ala O
- O
Lys O
- O
Pro O
- O
His O
- O
Cys O
( O
S O
( O
1 O
) O
, O
S O
( O
9 O
) O
- O
cyclo O
- O
CETGAKPHC O
) O
was O
isolated O
from O
a O
phage O
displayed O
cyclic O
peptide O
library O
using O
an O
affinity O
selection O
method O
against O
HBV O
surface O
antigen O
( O
HBsAg O
) O
. O

The O
solution O
structure O
of O
this O
cyclic O
peptide O
was O
solved O
using O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
and O
( B
15 I
) I
N I
NMR O
spectroscopy O
and O
molecular O
dynamics O
( O
MD O
) O
simulations O
with O
NMR O
- O
derived O
distance O
and O
torsion O
angle O
restraints O
. O

The O
cyclic O
peptide O
adopted O
two O
distinct O
conformations O
due O
to O
the O
isomerization O
of O
the O
Pro B
residue O
with O
one O
structured O
region O
in O
the O
ETGA O
sequence O
. O

The O
adsorption O
of O
the O
model O
perfumes O
phenyl O
ethanol O
, O
PE O
, O
and O
linalool B
, O
LL O
, O
at O
the O
air O
- O
solution O
interface O
by O
coadsorption O
with O
the O
anionic O
surfactant O
sodium O
dodecyl O
6 O
- O
benezene O
sulfonate O
, O
LAS B
- I
6 I
, O
has O
been O
studied O
primarily O
by O
neutron O
reflectivity O
, O
NR O
. O

At O
a O
LAS B
- I
6 I
concentration O
of O
0 O
. O
5 O
mM O
the O
adsorption O
of O
PE O
and O
LL O
is O
broadly O
similar O
but O
with O
the O
LL O
systematically O
more O
surface O
active O
, O
and O
at O
2 O
mM O
the O
LL O
completes O
more O
effectively O
for O
the O
surface O
than O
the O
PE O
. O

Changing O
the O
geometry O
of O
the O
LAS O
isomer O
, O
from O
the O
symmetrical O
LAS B
- I
6 I
geometry O
to O
the O
more O
asymmetrical O
LAS O
- O
4 O
, O
results O
in O
the O
LL O
competing O
more O
effectively O
for O
the O
surface O
due O
to O
changes O
in O
the O
packing O
constraints O
associated O
with O
the O
hydrophobic O
region O
. O

In O
vitro O
polyphenolics O
erythrocyte O
model O
and O
in O
vivo O
chicken O
embryo O
model O
revealed O
gallic B
acid I
to O
be O
a O
potential O
hemorrhage O
inducer O
: O
physicochemical O
action O
mechanisms O
. O

The O
in O
vivo O
chicken O
embryo O
model O
( O
CEM O
) O
demonstrated O
that O
gallic B
acid I
( O
GA O
) O
induced O
dysvascularization O
and O
hypoxia O
. O

We O
hypothesized O
that O
GA O
could O
deplete O
the O
dissolved O
oxygen B
( O
DO O
) O
at O
the O
expense O
of O
semiquinone O
and O
quinone B
formation O
, O
favoring O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
to O
induce O
RBC O
disruption O
and O
Fe B
( I
2 I
+ I
) I
ion O
release O
. O

PEM O
revealed O
that O
the O
DO O
was O
rapidly O
depleted O
, O
leading O
to O
the O
release O
of O
a O
huge O
amount O
of O
Fe B
( I
II I
) I
ions O
and O
hydrogen B
peroxide I
( O
HPO O
) O
in O
a O
two O
- O
phase O
kinetic O
pattern O
. O

The O
kinetic O
coefficients O
for O
Fe B
( I
II I
) I
ion O
release O
ranged O
from O
0 O
. O
347 O
h O
( O
- O
1 O
) O
to O
0 O
. O
774 O
h O
( O
- O
1 O
) O
; O
and O
those O
for O
Fe B
( I
III I
) I
ion O
production O
were O
from O
6 O
. O
66 O
x O
10 O
( O
- O
3 O
) O
h O
( O
- O
1 O
) O
to O
8 O
. O
93 O
x O
10 O
( O
- O
3 O
) O
h O
( O
- O
1 O
) O
. O

The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl O
- O
tRNA O
synthetase O
( O
MetRS O
) O
that O
charges O
the O
Met B
surrogate O
azidonorleucine O
( O
Anl O
) O
to O
tRNA O
( O
Met B
) O
. O

Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N B
- O
and O
C B
- O
terminal O
fragments O
of O
the O
bisected O
MetRS O
. O

Anl O
- O
labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper B
- O
catalyzed O
or O
strain O
- O
promoted O
azide O
- O
alkyne O
cycloaddition O
. O

The O
approach O
is O
demonstrated O
by O
selective O
labeling O
of O
proteins O
in O
bacterial O
cells O
immobilized O
in O
the O
center O
of O
a O
laminar O
- O
flow O
microfluidic O
channel O
, O
where O
they O
are O
exposed O
to O
overlapping O
, O
opposed O
gradients O
of O
inducers O
of O
the O
N B
- O
and O
C B
- O
terminal O
MetRS O
fragments O
. O

With O
this O
combined O
method O
, O
SHV O
- O
1 O
, O
a O
class O
A O
beta O
- O
lactamase O
, O
and O
tazobactam O
, O
a O
commercially O
available O
beta O
- O
lactamase O
inhibitor O
, O
were O
rapidly O
mixed O
on O
the O
millisecond O
time O
scale O
and O
then O
were O
flash O
- O
frozen O
by O
injection O
into O
an O
isopentane O
solution O
surrounded O
by O
liquid O
nitrogen B
. O

Between O
25 O
and O
500 O
ms O
, O
minor O
populations O
of O
protonated O
imine B
are O
detected O
that O
have O
previously O
been O
postulated O
to O
precede O
enamine B
intermediates O
. O

However O
, O
within O
1 O
s O
, O
the O
imines B
are O
converted O
entirely O
to O
enamines B
. O

Second O
, O
the O
surface O
amino B
acids I
of O
lipase O
can O
be O
tailored O
to O
suit O
biomolecule O
conjugation O
. O

This O
approach O
has O
been O
demonstrated O
by O
amino B
- O
epoxy B
activation O
of O
lipase O
, O
enabling O
the O
conjugation O
of O
different O
biomolecules O
to O
the O
magnetic O
particle O
' O
s O
surface O
. O

Exposure O
to O
lambda B
- I
cyhalothrin I
, O
a O
synthetic O
pyrethroid B
, O
increases O
reactive O
oxygen B
species O
production O
and O
induces O
genotoxicity O
in O
rat O
peripheral O
blood O
. O

Lambda B
- I
cyhalothrin I
( O
LTC O
) O
is O
a O
synthetic O
pyrethroid B
with O
a O
broad O
spectrum O
of O
insecticidal O
and O
acaricidal O
activities O
used O
to O
control O
a O
wide O
range O
of O
insect O
pests O
in O
a O
variety O
of O
applications O
. O

To O
elucidate O
the O
genotoxicity O
mechanisms O
of O
LTC O
, O
the O
micronuclei O
( O
MN O
) O
frequencies O
, O
the O
levels O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
erythrocyte O
osmotic O
fragility O
, O
nitrite B
( O
NO B
) O
formation O
, O
protein O
carbonyl B
( O
PCO O
) O
levels O
and O
malondialdehyde B
( O
MDA B
) O
production O
were O
evaluated O
for O
a O
period O
of O
7 O
, O
14 O
and O
21 O
days O
. O

Further O
, O
a O
significant O
( O
p O
< O
0 O
. O
01 O
) O
increase O
in O
ROS O
contents O
, O
NO B
formation O
, O
PCO O
levels O
and O
lipid O
peroxidation O
in O
erythrocytes O
were O
observed O
at O
different O
times O
of O
treatments O
, O
suggesting O
the O
implication O
of O
oxidative O
stress O
in O
its O
toxicity O
. O

Protective O
role O
of O
L B
- I
carnitine I
and O
vitamin B
E I
on O
the O
testis O
of O
atherosclerotic O
rats O
. O

Vitamin B
E I
and O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
have O
well O
- O
known O
lipid O
- O
lowering O
and O
antioxidative O
activities O
. O

The O
present O
study O
evaluates O
the O
protective O
role O
of O
vitamin B
E I
and O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
on O
the O
testis O
in O
atherosclerosis O
and O
detects O
the O
most O
effective O
choice O
for O
protection O
against O
atherosclerosis O
; O
vitamin B
E I
, O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
or O
a O
combination O
of O
both O
. O

A O
total O
of O
80 O
albino O
male O
rats O
were O
divided O
into O
eight O
groups O
( O
10 O
rats O
for O
each O
group O
) O
: O
control O
( O
G O
( O
1 O
) O
) O
, O
triton O
( O
G O
( O
2 O
) O
) O
, O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
( O
G O
( O
3 O
) O
) O
, O
triton O
+ O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
( O
G O
( O
4 O
) O
) O
, O
vitamin B
E I
( O
G O
( O
5 O
) O
) O
, O
triton O
+ O
vitamin B
E I
( O
G O
( O
6 O
) O
) O
, O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
+ O
vitamin B
E I
( O
G O

( O
7 O
) O
) O
and O
triton O
+ O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
+ O
vitamin B
E I
( O
G O
( O
8 O
) O
) O
. O

Data O
showed O
a O
significant O
increase O
in O
the O
levels O
of O
total O
cholesterol B
( O
TC O
) O
, O
triglycerides B
( O
TGs O
) O
, O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
, O
17 B
beta I
hydroxysteroid I
dehydrogenase O
( O
17 O
beta O
HSD O
) O
, O
testicular O
catalase O
and O
malondialdehyde B
( O
MDA B
) O
in O
G O
( O
2 O
) O
when O
compared O
with O
G O
( O
1 O
) O
, O
whereas O
high O
- O
density O
lipoprotein O
cholesterol B
( O
HDL O
- O
C O
) O
, O
serum O
testosterone B
, O
testicular O
17 O

ketosteroid B
reductase O
( O
17 O
KSR O
) O
, O
total O
thiol B
and O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
data O
showed O
a O
significant O
decrease O
in O
G O
( O
2 O
) O
when O
compared O
with O
G O
( O
1 O
) O
. O

Treatment O
with O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
or O
/ O
and O
vitamin B
E I
helps O
in O
improving O
the O
adverse O
effect O
of O
triton O
; O
also O
the O
histological O
changes O
confirm O
this O
finding O
. O

So O
the O
present O
study O
recommends O
all O
people O
to O
include O
< O
sc O
> O
l O
< O
/ O
sc O
> O
- O
carnitine O
and O
vitamin B
E I
in O
their O
diet O
to O
be O
protected O
against O
atherosclerosis O
. O

Critical O
parameters O
in O
exfoliating O
graphite B
into O
graphene B
. O

Dispersing O
graphite B
into O
few O
- O
layers O
graphene B
sheets O
( O
GS O
) O
in O
water O
is O
very O
appealing O
as O
an O
environmental O
- O
friendly O
, O
low O
- O
cost O
, O
low O
- O
energy O
method O
of O
obtaining O
graphene B
. O

Raman O
and O
transmission O
electron O
microscopy O
indicate O
few O
- O
layers O
graphene B
patches O
with O
typical O
size O
of O
~ O
0 O
. O
65 O
mu O
m O
in O
one O
dimension O
and O
~ O
0 O
. O
35 O
mu O
m O
in O
the O
other O
. O

The O
CRF O
( O
1 O
) O
receptor O
antagonist O
SSR125543 O
prevents O
stress O
- O
induced O
cognitive O
deficit O
associated O
with O
hippocampal O
dysfunction O
: O
Comparison O
with O
paroxetine B
and O
D O
- O
cycloserine O
. O

Effects O
of O
SSR125543 O
were O
compared O
to O
those O
of O
the O
5 B
- I
HT I
reuptake O
inhibitor O
, O
paroxetine B
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
and O
the O
partial O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
receptor O
agonist O
, O
D O
- O
cycloserine O
( O
10 O
mg O
/ O
kg O
/ O
day O
) O
, O
two O
compounds O
which O
have O
demonstrated O
clinical O
efficacy O
against O
PTSD O
. O

Both O
stress O
- O
induced O
effects O
were O
prevented O
by O
repeated O
administration O
of O
SSR125543 O
, O
paroxetine B
and O
D O
- O
cycloserine O
. O

Lupenone B
from O
Erica O
multiflora O
leaf O
extract O
stimulates O
melanogenesis O
in O
B16 O
murine O
melanoma O
cells O
through O
the O
inhibition O
of O
ERK1 O
/ O
2 O
activation O
. O

B16 O
murine O
melanoma O
cells O
were O
treated O
with O
E O
. O
multiflora O
extracts O
or O
its O
active O
component O
lupenone B
to O
evaluate O
their O
effects O
on O
melanin O
biosynthesis O
. O

Bioactivity O
- O
guided O
fractionation O
of O
fifteen O
ethyl B
acetate I
fractions O
identified O
fraction O
2 O
to O
have O
melanogenesis O
stimulatory O
effects O
due O
to O
its O
ability O
to O
decrease O
mitogen O
- O
activated O
protein O
kinase O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
activation O
. O

Preparative O
TLC O
of O
ethyl B
acetate I
fraction O
2 O
revealed O
the O
presence O
of O
lup O
- O
20 O
( O
29 O
) O
- O
en O
- O
3 O
- O
one O
as O
the O
major O
bioactive O
component O
. O

We O
report O
for O
the O
first O
time O
that O
E O
. O
multiflora O
ethyl B
acetate I
extract O
and O
its O
active O
compound O
lup O
- O
20 O
( O
29 O
) O
- O
en O
- O
3 O
- O
one O
stimulate O
melanogenesis O
by O
increasing O
the O
tyrosinase O
enzyme O
expression O
via O
mitogen O
- O
activated O
protein O
kinase O
phosphorylated O
extracellular O
signal O
- O
regulated O
kinases O
1 O
and O
2 O
phosphorylation O
inhibition O
, O
making O
it O
a O
possible O
treatment O
for O
hypopigmentation O
diseases O
. O

Histone O
deacetylases O
have O
been O
found O
to O
influence O
cellular O
function O
by O
catalyzing O
the O
removal O
of O
acetyl B
groups O
from O
epsilon O
- O
N O
- O
acetylated O
lysine O
residues O
of O
several O
protein O
substrates O
including O
histones O
, O
transcription O
factors O
, O
alpha O
- O
tubulin O
, O
and O
nuclear O
importers O
. O

Each O
subtype O
of O
the O
Histone O
Deacetylase O
( O
HDAC O
) O
family O
perform O
a O
distinct O
role O
in O
the O
gene O
expression O
and O
cyclic O
peptides O
with O
their O
plentiful O
set O
of O
surface O
contacts O
, O
zinc B
binding O
group O
and O
macrocyclic O
cap O
, O
can O
target O
enzyme O
precisely O
through O
adequate O
modulation O
of O
the O
amino B
acid I
configurational O
and O
structural O
assortment O
. O

Membrane O
transporters O
, O
including O
two O
members O
: O
ATP B
- O
binding O
cassette O
( O
ABC O
) O
transporters O
and O
solute O
carrier O
( O
SLC O
) O
transporters O
are O
proteins O
that O
play O
important O
roles O
to O
facilitate O
molecules O
into O
and O
out O
of O
cells O
. O

Uridine B
provided O
options O
to O
overcome O
any O
toxicity O
in O
the O
host O
but O
still O
suppressing O
the O
parasite O
load O
when O
treated O
with O
15 O
. O

In O
drug O
combination O
studies O
, O
compound O
15 O
showed O
good O
efficacy O
in O
vivo O
with O
artemisinin B
and O
azithromycin B
. O

Solution O
effect O
on O
diazonium B
- O
modified O
Au B
( I
111 I
) I
: O
reactions O
and O
structures O
. O

Surface O
modifications O
of O
a O
Au B
( I
111 I
) I
electrode O
with O
4 O
- O
bromobenzenediazoniu O
tetrafluoroborate O
( O
BBD O
) O
in O
acetonitrile B
( O
ACN B
) O
and O
0 O
. O
1 O
M O
HClO4 O
have O
been O
characterized O
by O
scanning O
tunneling O
microscopy O
( O
STM O
) O
. O

In O
ACN B
, O
STM O
results O
reveal O
the O
formation O
of O
disordered O
thin O
organic O
films O
. O

The O
biphenyl B
compound O
is O
considered O
to O
be O
generated O
by O
a O
radical O
- O
radical O
coupling O
reaction O
. O

Genome O
- O
wide O
integrated O
analyses O
of O
androgen B
receptor O
signaling O
in O
prostate O
cancer O
based O
on O
high O
- O
throughput O
technology O
. O

The O
androgen B
receptor O
( O
AR O
) O
is O
a O
steroid B
hormone O
receptor O
that O
functions O
as O
a O
ligand O
- O
dependent O
transcriptional O
factor O
, O
which O
plays O
a O
key O
role O
in O
the O
development O
and O
progression O
of O
prostate O
cancer O
. O

Recent O
advancement O
in O
high O
throughput O
technologies O
including O
microarrays O
and O
deep O
- O
sequencing O
provides O
unbiased O
genome O
- O
wide O
knowledge O
on O
the O
AR O
signaling O
including O
datasets O
for O
androgen B
- O
regulated O
gene O
expression O
and O
genomic O
binding O
sites O
for O
AR O
. O

Cap O
analysis O
gene O
expression O
( O
CAGE O
) O
is O
also O
featured O
as O
a O
unique O
transcriptome O
method O
, O
which O
particularly O
determines O
the O
androgen B
- O
dependent O
transcription O
start O
points O
in O
prostate O
cancer O
. O

Interestingly O
, O
the O
androgen B
receptor O
( O
AR O
) O
, O
already O
known O
to O
play O
a O
significant O
role O
in O
prostate O
cancer O
tumorigenesis O
, O
has O
recently O
been O
implicated O
in O
the O
processes O
resulting O
in O
gene O
fusions O
by O
inducing O
the O
spatial O
proximity O
of O
genes O
involved O
in O
rearrangements O
, O
promoting O
the O
formation O
of O
double O
- O
strand O
DNA O
breaks O
( O
DSB O
) O
, O
and O
facilitating O
the O
recruitment O
of O
proteins O
for O
non O
- O
homologous O
end O
- O
joining O
( O
NHEJ O
) O
. O

Among O
them O
, O
the O
PI3K O
- O
Akt O
- O
mTOR O
axis O
, O
in O
particular O
the O
serine B
/ O
threonine B
kinase O
Akt O
, O
is O
recognized O
as O
a O
key O
player O
. O

The O
kinase O
is O
hyperactivated O
due O
to O
a O
variety O
of O
mechanisms O
including O
loss O
of O
PTEN O
, O
mutations O
in O
the O
PI3K O
catalytic O
subunit O
, O
receptor O
tyrosine B
kinase O
and O
Ras O
activation O
. O

This O
serine B
/ O
threonine B
kinase O
may O
therefore O
represent O
an O
amenable O
target O
for O
modulation O
of O
sensitivity O
to O
compounds O
with O
different O
molecular O
features O
due O
to O
its O
pleiotropic O
role O
in O
cell O
survival O
. O

Different O
types O
of O
Akt O
inhibitors O
[ O
i O
. O
e O
. O
, O
ATP B
mimetics O
and O
pleckstrin O
- O
homology O
( O
PH O
) O
domain O
binders O
] O
have O
been O
generated O
and O
some O
of O
them O
have O
reached O
the O
clinical O
setting O
. O

Notably O
, O
synthetic O
polycyclic O
cage O
compounds O
have O
served O
as O
scaffolds O
for O
novel O
voltage O
- O
gated O
calcium B
channel O
blockers O
, O
NMDA B
receptor O
antagonists O
, O
and O
sigma O
- O
receptor O
ligands O
- O
attractive O
targets O
in O
neurodegeneration O
. O

In O
an O
entirely O
different O
approach O
, O
compounds O
containing O
the O
thiazolidinedione B
moiety O
( O
referred O
to O
as O
glitazones B
) O
alter O
mitochondrial O
function O
through O
the O
mitochondrial O
protein O
mitoNEET O
, O
an O
attractive O
new O
drug O
target O
for O
the O
treatment O
of O
neurodegenerative O
diseases O
. O

The O
design O
strategy O
for O
yet O
another O
agent O
, O
ladostigil O
, O
employed O
the O
amalgamation O
of O
active O
chemical O
moieties O
of O
the O
AChE O
inhibitor O
rivastigmine B
, O
and O
the O
monoamine B
oxidase O
- O
B O
( O
MAO O
- O
B O
) O
inhibitor O
rasagiline B
, O
leading O
to O
a O
single O
compound O
that O
targets O
both O
enzymes O
simultaneously O
. O

In O
particular O
, O
the O
stilbene B
scaffold O
has O
become O
popular O
in O
particular O
due O
to O
the O
neuroprotective O
effects O
of O
the O
non O
- O
flavonoid B
natural O
product O
resveratrol B
. O

Recently O
, O
stilbene B
scaffold O
- O
based O
compounds O
were O
developed O
to O
reduce O
- O
through O
chelation O
with O
metal O
ions O
that O
interact O
with O
beta O
- O
amyloid O
- O
both O
metal O
- O
induced O
beta O
- O
amyloid O
protein O
aggregation O
, O
and O
ROS O
generated O
from O
this O
aggregate O
. O

Other O
subtle O
modifications O
of O
the O
stilbene B
motif O
led O
to O
the O
creation O
of O
reversible O
, O
non O
- O
competitive O
MAO O
inhibitors O
. O

Finally O
, O
compounds O
derived O
from O
the O
xanthine B
scaffold O
afford O
neuroprotection O
in O
Parkinson O
' O
s O
disease O
through O
mechanisms O
that O
include O
dual O
adenosine B
A2A O
receptor O
antagonism O
and O
MAO O
- O
B O
inhibition O
. O

Photothermal O
tautomerization O
of O
a O
UV O
sunscreen O
( O
4 O
- O
tert O
- O
butyl O
- O
4 O
' O
- O
methoxydibenzoylmeth O
) O
in O
acetonitrile B
studied O
by O
steady O
- O
state O
and O
laser O
flash O
photolysis O
. O

The O
photothermal O
tautomerization O
processes O
between O
enol B
and O
keto B
forms O
of O
4 O
- O
tert O
- O
butyl O
- O
4 O
' O
- O
methoxydibenzoylmeth O
( O
trade O
name O
, O
Avobenzone O
) O
in O
acetonitrile B
have O
been O
studied O
by O
steady O
- O
state O
and O
laser O
flash O
photolysis O
. O

The O
keto B
form O
is O
produced O
upon O
photolysis O
of O
the O
enol B
in O
only O
acetonitrile B
with O
a O
quantum O
yield O
of O
0 O
. O
014 O
. O

The O
molar O
absorptivity O
of O
the O
keto B
form O
was O
determined O
. O

Phototautomerization O
from O
the O
keto B
to O
the O
enol B
form O
was O
not O
seen O
. O

Laser O
flash O
photolysis O
of O
the O
keto B
form O
recognized O
the O
formation O
of O
the O
triplet O
state O
. O

In O
the O
dark O
, O
the O
keto B
form O
underwent O
thermal O
tautomerization O
to O
the O
enol B
with O
a O
lifetime O
of O
5 O
. O
1 O
h O
at O
295 O
K O
. O

The O
enolization O
rate O
in O
acetonitrile B
was O
not O
accelerated O
by O
the O
presence O
of O
alcohols B
and O
/ O
or O
water O
but O
increased O
with O
increasing O
temperature O
and O
followed O
the O
Arrhenius O
expression O
. O

The O
activation O
energy O
and O
the O
frequency O
factor O
were O
determined O
for O
the O
enolization O
process O
from O
the O
keto B
to O
the O
enol B
form O
. O

On O
the O
basis O
of O
the O
energy O
states O
of O
the O
tautomers O
and O
isomers O
as O
estimated O
by O
DFT O
calculations O
, O
a O
schematic O
energy O
diagram O
was O
determined O
for O
the O
photothermal O
tautomerization O
processes O
in O
acetonitrile B
. O

The O
plant O
growth O
regulator O
ethephon O
( O
2 O
- O
chloroethylphosphoni O
acid O
) O
inhibits O
human O
butyrylcholinesteras O
( O
BChE O
) O
by O
making O
a O
covalent O
adduct O
on O
the O
active O
site O
serine B
198 O
. O

Mass O
spectral O
analysis O
of O
the O
active O
site O
peptide O
from O
inhibited O
BChE O
showed O
that O
the O
inhibitor O
added O
a O
mass O
of O
108 O
Da O
to O
the O
active O
site O
serine B
on O
peptide O
FGES198AGAAS O
. O

To O
accommodate O
these O
observations O
, O
we O
propose O
that O
in O
aqueous O
media O
at O
neutral O
to O
slightly O
alkaline O
pH O
about O
3 O
% O
of O
the O
ethephon O
is O
converted O
( O
t1 O
/ O
2 O
= O
9 O
. O
9 O
h O
at O
pH O
7 O
. O
0 O
) O
into O
a O
cyclic O
oxaphosphetane O
which O
is O
the O
actual O
BChE O
inhibitor O
forming O
the O
2 O
- O
hydroxyethylphosphon O
adduct O
on O
BChE O
at O
Ser198 O
while O
about O
97 O
% O
of O
the O
ethephon O
breaks O
down O
to O
ethylene B
( O
t1 O
/ O
2 O
= O
11 O
- O
48 O
h O
at O
pH O
7 O
. O
0 O
) O
which O
is O
responsible O
for O
plant O
growth O

Maintenance O
of O
NSPC O
multipotency O
is O
promoted O
by O
low O
oxygen B
tension O
, O
although O
the O
metabolic O
underpinnings O
of O
this O
trait O
have O
not O
been O
described O
. O

NSPCs O
were O
also O
more O
resistant O
than O
neurons O
to O
mitochondrial O
cyanide B
toxicity O
, O
less O
capable O
of O
utilizing O
galactose B
as O
an O
alternative O
substrate O
to O
glucose B
, O
and O
more O
susceptible O
to O
pharmacological O
inhibition O
of O
the O
pentose B
phosphate I
pathway O
by O
6 O
- O
aminonicotinamide O
. O

Inducible O
deletion O
of O
exon O
1 O
of O
the O
Hif1a O
gene O
improved O
the O
ability O
of O
NSPCs O
to O
utilize O
pyruvate B
during O
glycolytic O
inhibition O
, O
but O
did O
not O
alter O
other O
parameters O
of O
metabolism O
, O
including O
their O
ability O
to O
withstand O
prolonged O
hypoxia O
. O

The O
in O
vitro O
and O
in O
vivo O
effects O
of O
nicotine B
on O
bone O
, O
bone O
cells O
and O
fracture O
repair O
. O

However O
, O
no O
study O
has O
reviewed O
effects O
of O
nicotine B
on O
bone O
and O
fracture O
repair O
independent O
of O
other O
constituents O
of O
cigarette O
smoke O
. O

The O
authors O
review O
the O
existing O
evidence O
of O
the O
effect O
of O
nicotine B
on O
' O
bone O
' O
and O
' O
bone O
cells O
' O
and O
fracture O
repair O
, O
drawing O
conclusions O
relevant O
to O
clinical O
practice O
and O
future O
research O
. O

Articles O
were O
included O
if O
they O
specifically O
investigated O
the O
effects O
of O
nicotine B
on O
' O
bone O
' O
or O
fracture O
repair O
in O
animal O
or O
human O
models O
or O
in O
vitro O
effects O
on O
' O
bone O
cells O
' O
. O

In O
vivo O
studies O
of O
the O
effects O
of O
nicotine B
in O
animals O
demonstrated O
widespread O
effects O
on O
bone O
including O
osteoneogenesis O
, O
osseointegration O
, O
steady O
- O
state O
skeletal O
bone O
and O
genes O
and O
cytokines O
relevant O
to O
bone O
cell O
physiology O
and O
bone O
homeostasis O
. O

In O
these O
studies O
, O
nicotine B
' O
s O
effects O
are O
predominately O
negative O
, O
inhibiting O
bone O
cell O
metabolism O
and O
fracture O
repair O
, O
whereas O
most O
in O
vitro O
studies O
reported O
biphasic O
responses O
in O
all O
bone O
cells O
except O
osteoclastic O
cells O
. O

EXPERT O
OPINION O
: O
The O
review O
suggests O
that O
nicotine B
has O
effects O
on O
osteoneogenesis O
, O
osseointegration O
and O
steady O
- O
state O
skeletal O
bone O
in O
animal O
in O
vivo O
models O
, O
as O
well O
as O
effects O
on O
all O
' O
bone O
cells O
' O
, O
via O
several O
mechanisms O
in O
both O
animal O
and O
human O
cell O
in O
vitro O
studies O
. O

The O
effect O
of O
nicotine B
is O
dose O
- O
dependent O
, O
with O
higher O
concentrations O
having O
predominantly O
negative O
effects O
, O
whereas O
at O
low O
concentrations O
a O
stimulatory O
effect O
is O
seen O
. O

Stimulatory O
effects O
on O
certain O
cells O
may O
indicate O
a O
possible O
, O
limited O
therapeutic O
role O
; O
advice O
regarding O
smoking O
cessation O
perioperatively O
should O
remain O
due O
to O
the O
other O
harmful O
components O
of O
cigarette O
smoke O
, O
but O
there O
may O
be O
scope O
for O
allowing O
the O
use O
of O
nicotine B
patches O
instead O
of O
complete O
abstention O
. O

Further O
research O
into O
clinical O
outcomes O
is O
required O
before O
the O
exact O
response O
of O
bone O
and O
fracture O
repair O
in O
humans O
to O
nicotine B
is O
known O
. O

Benchmark O
dose O
for O
estimation O
of O
cadmium B
reference O
level O
for O
osteoporosis O
in O
a O
Chinese O
female O
population O
. O

In O
this O
study O
, O
the O
reference O
level O
of O
cadmium B
in O
urine O
and O
blood O
related O
with O
bone O
damage O
was O
assessed O
using O
benchmark O
dose O
in O
a O
Chinese O
female O
population O
. O

Total O
of O
338 O
women O
was O
recruited O
, O
and O
urine O
and O
blood O
samples O
were O
collected O
from O
each O
individual O
for O
determination O
of O
cadmium B
in O
urine O
( O
UCd O
) O
and O
blood O
( O
BCd O
) O
. O

DNA O
damage O
and O
oxidative O
stress O
in O
human O
B O
lymphoblastoid O
cells O
after O
combined O
exposure O
to O
hexavalent B
chromium I
and O
nickel B
compounds O
. O

In O
the O
present O
study O
, O
human O
B O
lymphoblastoid O
cells O
were O
exposed O
to O
potassium B
dichromate I
and O
/ O
or O
nickel B
chloride I
for O
24h O
or O
48h O
. O

In O
addition O
, O
the O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
the O
levels O
of O
malondialdehyde B
( O
MDA B
) O
were O
measured O
using O
commercially O
available O
kits O
. O

Our O
results O
indicated O
that O
potassium B
dichromate I
could O
decrease O
cell O
viability O
and O
induce O
DNA O
damage O
in O
human O
B O
lymphoblastoid O
cells O
in O
a O
time O
- O
and O
concentration O
- O
dependent O
manner O
, O
but O
the O
toxicity O
of O
nickel B
chloride I
was O
not O
so O
obvious O
at O
concentrations O
used O
in O
our O
study O
. O

The O
results O
of O
ROS O
showed O
that O
both O
two O
compounds O
could O
only O
induce O
weak O
elevation O
of O
ROS O
level O
, O
but O
MDA B
levels O
were O
significantly O
enhanced O
. O

Antagonistic O
effects O
of O
cytotoxicity O
were O
mainly O
found O
between O
Cr B
( I
VI I
) I
and O
Ni B
( I
II I
) I
, O
and O
synergistic O
effects O
of O
DNA O
damage O
and O
oxidative O
stress O
were O
partially O
found O
between O
these O
two O
compounds O
. O

It O
is O
suggested O
that O
synergistic O
DNA O
damage O
induced O
by O
simultaneously O
exposure O
of O
hexavalent B
chromium I
and O
nickel B
compounds O
is O
possibly O
related O
to O
oxidative O
stress O
. O

Spiro O
heterocycles O
as O
potential O
inhibitors O
of O
SIRT1 O
: O
Pd B
/ O
C B
- O
mediated O
synthesis O
of O
novel O
N O
- O
indolylmethyl O
spiroindoline O
- O
3 O
, O
2 O
' O
- O
quinazolines O
. O

These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd B
/ O
C O
- O
Cu O
mediated O
coupling O
- O
cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1 O
- O
( O
prop O
- O
2 O
- O
ynyl O
) O
- O
1 O
' O
H O
- O
spiro O
[ O
indoline O
- O
3 O
, O
2 O
' O
- O
quinazoline O
] O
- O
2 O
, O
4 O
' O
( O
3 O
' O
H O
) O
- O
dione O
with O
2 O
- O
iodoanilides O
. O

The O
docking O
results O
suggested O
that O
the O
benzene B
ring O
of O
1 O
, O
2 O
, O
3 O
, O
4 O
- O
tetrahydroquinazolin O
ring O
system O
of O
these O
molecules O
occupied O
the O
deep O
hydrophobic O
pocket O
of O
the O
protein O
and O
one O
of O
the O
NH B
along O
with O
the O
sulfonyl O
group O
participated O
in O
strong O
H B
- O
bonding O
interaction O
with O
the O
amino B
acid I
residues O
. O

Cytotoxic O
effects O
of O
salinomycin O
were O
monitored O
by O
the O
[ O
3 O
- O
( O
4 O
, O
5 O
- O
dimethylthiazol O
- O
2 O
- O
yl O
) O
- O
2 O
, O
5 O
- O
diphenyl O
tetrazolium O
bromide O
] O
( O
MTT B
) O
assay O
. O

The O
anti O
- O
inflammatory O
effects O
of O
WOE O
were O
closely O
attributed O
to O
decreased O
levels O
of O
tissue O
NO B
and O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
. O

Further O
evidence O
for O
WOE O
' O
s O
protection O
is O
shown O
in O
the O
reduction O
of O
lipid O
oxidation O
and O
the O
increase O
of O
antioxidant O
enzyme O
activities O
, O
including O
catalase O
( O
CAT O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
and O
glutathione B
peroxidase O
( O
GPX O
) O
in O
vivo O
. O

Further O
, O
WOE O
also O
decreased O
the O
number O
of O
acetic B
acid I
- O
induced O
writhing O
responses O
and O
formalin B
- O
induced O
pain O
in O
the O
late O
phase O
in O
mice O
. O

Apple O
polyphenols B
suppress O
antigen O
presentation O
of O
ovalbumin O
by O
THP O
- O
1 O
- O
derived O
dendritic O
cells O
. O

Apple O
polyphenol B
extract O
( O
AP O
) O
and O
procyanidin B
contained O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP O
- O
1 O
- O
derived O
human O
dendritic O
cells O
( O
TDDCs O
) O
. O

A O
significant O
decrease O
in O
HLA O
- O
DR O
expression O
was O
observed O
in O
the O
AP O
and O
fractionated O
procyanidin B
- O
treated O
cells O
in O
the O
presence O
of O
ovalbumin O
( O
OVA O
) O
, O
but O
no O
effect O
on O
CD86 O
expression O
was O
observed O
. O

Furthermore O
, O
the O
up O
- O
regulation O
of O
IL O
- O
12 O
and O
TNF O
- O
alpha O
was O
found O
in O
the O
procyanidin B
trimers O
- O
treated O
cells O
in O
the O
presence O
of O
OVA O
. O

These O
results O
suggest O
that O
apple O
polyphenols B
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

The O
content O
of O
elements O
( O
Cd B
, O
Cr B
, O
Cu B
, O
Fe B
, O
Mn B
, O
Ni B
, O
Pb B
and O
Zn B
) O
in O
edible O
oils O
( O
sunflower O
, O
hazelnut O
, O
canola O
, O
corn O
and O
olive O
oils O
) O
from O
Turkey O
was O
determined O
using O
inductively O
coupled O
plasma O
optical O
emission O
spectrometry O
( O
ICP O
- O
OES O
) O
after O
ultrasonic O
extraction O
, O
wet O
digestion O
, O
and O
extraction O
induced O
by O
emulsion O
breaking O
procedures O
( O
EIEB O
) O
. O

The O
results O
in O
the O
samples O
( O
minimum O
- O
maximum O
in O
mgkg O
( O
- O
1 O
) O
) O
were O
: O
0 O
. O
022 O
- O
0 O
. O
058 O
, O
Cr B
0 O
. O
126 O
- O
7 O
. O
106 O
, O
Cu B
0 O
. O
570 O
- O
4 O
. O
504 O
, O
Fe B
8 O
. O
004 O
- O
12 O
. O
588 O
, O
Mn B
0 O
. O
035 O
- O
0 O
. O
054 O
, O
Ni B
0 O
. O
908 O
- O
2 O
. O
182 O
, O
Pb B
0 O
. O
099 O
- O
0 O
. O
134 O
and O
Zn B
2 O
. O
206 O
- O
8 O
. O
982 O
. O

Reduction O
of O
abdominal O
fat O
accumulation O
in O
rats O
by O
8 O
- O
week O
ingestion O
of O
a O
newly O
developed O
sweetener O
made O
from O
high O
fructose B
corn O
syrup O
. O

Many O
studies O
have O
shown O
that O
ingestion O
of O
high O
- O
fructose B
corn O
syrup O
( O
HFCS O
) O
may O
cause O
an O
increase O
in O
body O
weight O
and O
abdominal O
fat O
. O

We O
recently O
developed O
a O
new O
sweetener O
containing O
rare O
sugars B
( O
rare O
sugar B
syrup O
; O
RSS O
) O
by O
slight O
isomerization O
of O
HFCS O
. O

Fasting O
serum O
insulin O
in O
the O
RSS O
group O
was O
significantly O
lower O
than O
in O
the O
Starch O
and O
HFCS O
groups O
, O
although O
serum O
glucose B
in O
the O
HFCS O
and O
RSS O
groups O
was O
significantly O
lower O
than O
that O
in O
the O
Starch O
group O
. O

This O
paper O
investigates O
polyphenol B
oxidase O
( O
PPO O
) O
activity O
, O
reduced O
weight O
percentage O
after O
sun O
drying O
, O
and O
the O
changes O
in O
colour O
and O
appearance O
of O
green O
pepper O
( O
Piper O
nigrum O
Linnaeus O
) O
berries O
after O
blanching O
and O
sun O
drying O
. O

Thus O
, O
the O
PPO O
enzymatic O
oxidation O
of O
polyphenols B
might O
not O
be O
the O
only O
reason O
for O
the O
browning O
of O
green O
pepper O
berries O
. O

The O
results O
showed O
that O
heather O
, O
polyfloral O
, O
blackberry O
, O
and O
eucalyptus O
honeys O
had O
the O
highest O
carbohydrate B
contents O
, O
whereas O
honeydew O
and O
chestnut O
honeys O
had O
the O
lowest O
. O

Related O
to O
the O
presence O
of O
several O
antioxidant O
compounds O
, O
heather O
honey O
had O
the O
highest O
phenolic O
content O
, O
whereas O
honeydew O
and O
chestnut O
honeys O
had O
the O
highest O
flavonoid B
contents O
. O

Multivariate O
analysis O
showed O
that O
some O
variables O
, O
such O
as O
the O
amounts O
of O
flavonoids B
, O
minerals O
, O
proteins O
, O
and O
phenols B
, O
were O
significantly O
correlated O
with O
antioxidant O
activity O
. O

The O
regression O
analysis O
produced O
a O
significant O
model O
( O
R O
( O
2 O
) O
= O
0 O
. O
716 O
; O
F O
= O
154 O
. O
680 O
; O
P O
< O
0 O
. O
001 O
) O
that O
related O
the O
antioxidant O
activity O
and O
the O
flavonoids B
, O
K B
, O
and O
P B
contents O
. O

LC O
- O
DAD O
- O
MS O
data O
revealed O
the O
presence O
of O
pseudohypericin O
( O
0 O
. O
135 O
- O
3 O
. O
280 O
mu O
g O
/ O
g O
) O
and O
hypericin O
( O
0 O
. O
277 O
- O
6 O
. O
634 O
mu O
g O
/ O
g O
) O
in O
all O
the O
oils O
, O
whereas O
chlorogenic B
acid I
( O
1 O
. O
063 O
mu O
g O
/ O
g O
) O
was O
detected O
only O
in O
one O
oil O
sample O
. O

Hypericin O
and O
pseudohypericin O
were O
common O
in O
the O
active O
oils O
, O
whereas O
hyperforin O
, O
adhyperforin O
, O
and O
chlorogenic B
acid I
were O
absent O
in O
these O
samples O
. O

Five O
fractions O
including O
crude O
phenolic O
extracts O
( O
using O
80 O
per O
cent O
aqueous O
acetone B
) O
of O
whole O
plant O
, O
leaf O
, O
stem O
, O
washed O
leaf O
( O
WL O
) O
and O
dried O
water O
washing O
material O
( O
WW O
) O
were O
used O
in O
this O
study O
. O

Linoleic B
acid I
autoxidation O
inhibitions O
on O
all O
fractions O
were O
higher O
than O
that O
on O
alpha B
- I
tocopherol I
. O

Except O
for O
WL O
and O
WW O
, O
other O
fractions O
also O
showed O
DPPH B
radical O
scavenging O
efficiency O
. O

All O
fractions O
diminished O
LPS O
- O
induced O
protein O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
2 O
( O
COX O
- O
2 O
) O
. O

Nitric B
oxide I
( O
NO B
) O
and O
prostaglandin B
E2 I
( O
PGE B
( I
2 I
) I
) O
, O
downstream O
products O
, O
were O
also O
suppressed O
in O
dose O
- O
dependent O
manners O
, O
except O
for O
WL O
and O
WW O
. O

Oxidative O
modification O
and O
loss O
of O
leaf O
phenolics B
after O
kneading O
and O
washing O
greatly O
affected O
DPPH B
radical O
scavenging O
and O
inflammatory O
responses O
. O

The O
amount O
of O
free O
amino B
groups O
decreased O
, O
with O
an O
increase O
in O
rate O
of O
loss O
, O
as O
temperature O
increased O
in O
the O
100 O
% O
HEW O
+ O
0 O
% O
DEW O
model O
. O

When O
DEW O
was O
substituted O
for O
some O
HEW O
, O
the O
regeneration O
of O
the O
free O
amino B
groups O
after O
loss O
was O
observed O
as O
a O
function O
of O
time O
. O

Samples O
were O
then O
analysed O
in O
SRM O
mode O
to O
detect O
nicotinic B
acid I
and O
nicotinic O
acid O
- O
d O
( O
4 O
) O
at O
m O
/ O
z O
124 O
- O
- O
> O
80 O
and O
127 O
- O
- O
> O
84 O
, O
respectively O
. O

In O
the O
case O
of O
multivitamin O
sample O
that O
contains O
mainly O
free O
nicotinamide B
, O
LC O
/ O
MS O
monitored O
nicotinamide B
and O
nicotinamide O
- O
d O
( O
4 O
) O
at O
their O
SRM O
channels O
of O
m O
/ O
z O
123 O
- O
- O
> O
80 O
and O
m O
/ O
z O
127 O
- O
- O
> O
84 O
, O
respectively O
, O
after O
simple O
extraction O
. O

Hypolipidemic O
and O
antioxidant O
activities O
of O
thymoquinone O
and O
limonene B
in O
atherogenic O
suspension O
fed O
rats O
. O

The O
hypolipidemic O
and O
antioxidant O
actions O
of O
thymoquinone O
( O
TQ O
) O
and O
limonene B
( O
LMN O
) O
were O
investigated O
by O
giving O
1 O
ml O
of O
10mg O
TQ O
or O
200mg O
LMN O
suspension O
, O
by O
gavage O
in O
two O
equal O
doses O
( O
morning O
and O
evening O
) O
of O
0 O
. O
5 O
ml O
each O
for O
30 O
days O
, O
in O
rats O
, O
fed O
an O
atherogenic O
suspension O
. O

These O
compounds O
effectively O
ameliorated O
all O
the O
altered O
cardiovascular O
risk O
parameters O
via O
a O
reduction O
in O
HMG B
- I
CoA I
reductase O
activity O
, O
along O
with O
an O
increase O
in O
arylesterase O
activity O
. O

These O
compounds O
also O
blocked O
basal O
and O
maximal O
formation O
of O
CD O
and O
malondialdehyde B
, O
and O
lengthened O
the O
lag O
times O
of O
LDL O
, O
sd O
- O
LDL O
and O
lb O
- O
LDL O
in O
the O
order O
TQ O
> O
LMN O
. O

Effects O
of O
sodium B
caseinate O
concentration O
and O
storage O
conditions O
on O
the O
oxidative O
stability O
of O
oil O
- O
in O
- O
water O
emulsions O
. O

The O
mean O
particle O
size O
decreased O
from O
1179 O
to O
325 O
nm O
as O
sodium B
caseinate O
( O
emulsifier O
) O
concentration O
was O
increased O
from O
0 O
. O
25 O
% O
to O
3 O
% O
in O
O O
/ O
W O
emulsions O
( O
P O
< O
0 O
. O
05 O
) O
. O

Emulsified O
oils O
had O
lower O
detectable O
lipid O
hydroperoxide B
and O
p B
- I
Anisidine I
values O
than O
their O
corresponding O
bulk O
oils O
( O
P O
< O
0 O
. O
05 O
) O
. O

The O
lipid O
hydroperoxide B
and O
p B
- I
Anisidine I
values O
of O
emulsions O
generally O
decreased O
as O
sodium B
caseinate O
concentration O
increased O
, O
and O
similarly O
decreased O
as O
microfluidisation O
pressure O
increased O
( O
P O
< O
0 O
. O
05 O
) O
. O

Antioxidant O
activity O
and O
nutritional O
quality O
of O
traditional O
red O
- O
grained O
rice O
varieties O
containing O
proanthocyanidins B
. O

Proanthocyanidin B
- O
containing O
rice O
varieties O
have O
been O
rarely O
reported O
. O

Antioxidant O
capacity O
, O
major O
antioxidant O
components O
, O
and O
nutritional O
parameters O
of O
eight O
traditional O
red O
- O
grained O
rice O
varieties O
containing O
proanthocyanidins B
grown O
in O
Sri O
Lanka O
were O
investigated O
. O

Major O
antioxidant O
phenolic B
compounds O
identified O
in O
this O
study O
included O
proanthocyanidins B
, O
phenolic B
acids I
and O
gamma O
- O
oryzanols O
( O
ferulic B
acid I
derivatives O
) O
. O

Proanthocyanidins B
were O
detected O
only O
in O
the O
traditional O
red O
varieties O
, O
but O
not O
found O
in O
new O
- O
improved O
ones O
. O

Most O
traditional O
red O
varieties O
also O
contained O
significantly O
higher O
levels O
of O
protein O
with O
well O
balanced O
amino B
acids I
and O
higher O
contents O
of O
fat O
, O
fibre O
and O
vitamin B
E I
( O
tocopherols B
and O
tocotrienols O
) O
than O
the O
new O
- O
improved O
ones O
. O

Great O
variations O
in O
antioxidant O
capacity O
, O
major O
phenolics B
, O
and O
nutritional O
parameters O
were O
observed O
among O
different O
rice O
varieties O
. O

These O
Sri O
Lankan O
traditional O
red O
- O
grained O
rice O
varieties O
containing O
proanthocyanidins B
may O
be O
used O
as O
important O
genetic O
sources O
for O
rice O
breeding O
. O

Hydroxytyrosyl O
ethyl O
ether O
exhibits O
stronger O
intestinal O
anticarcinogenic O
potency O
and O
effects O
on O
transcript O
profiles O
compared O
to O
hydroxytyrosol B
. O

The O
anticarcinogenic O
activity O
of O
hydroxytyrosyl O
ethyl O
ether O
( O
HTy O
- O
Et O
) O
compared O
to O
its O
precursor O
hydroxytyrosol B
( O
HTy O
) O
has O
been O
studied O
in O
human O
Caco O
- O
2 O
colon O
adenocarcinoma O
cells O
. O

Moreover O
, O
these O
polyphenols B
up O
- O
regulated O
xenobiotic O
metabolizing O
enzymes O
UGT1A10 O
and O
CYP1A1 O
, O
enhancing O
carcinogen O
detoxification O
. O

Determination O
of O
ethyl O
carbamate O
in O
cacha O
c O
a O
produced O
from O
copper B
stills O
by O
HPLC O
. O

We O
focus O
especially O
on O
mixtures O
of O
glucose B
homopolymers O
and O
water O
. O

Using O
literature O
data O
obtained O
for O
the O
whole O
class O
of O
glucose B
homopolymer O
, O
we O
show O
that O
these O
theories O
predict O
the O
moisture O
diffusivity O
for O
the O
whole O
range O
of O
volume O
fractions O
, O
from O
zero O
to O
one O
, O
and O
a O
broad O
range O
of O
temperatures O
. O

This O
universal O
behaviour O
arises O
because O
these O
biopolymers O
form O
a O
hydrogen B
bonded O
network O
, O
where O
water O
molecules O
move O
via O
rearrangement O
of O
the O
free O
volume O
. O

Investigation O
of O
the O
effect O
of O
gelatine O
, O
egg O
albumin O
and O
cross O
- O
flow O
microfiltration O
on O
the O
phenolic B
composition O
of O
Pinotage O
wine O
. O

The O
effect O
of O
fining O
and O
cross O
- O
flow O
microfiltration O
on O
the O
phenolic B
composition O
of O
red O
wine O
was O
investigated O
. O

Thus O
, O
the O
fining O
agents O
and O
cross O
- O
flow O
microfiltration O
selectively O
removed O
the O
highly O
polymerised O
phenols B
. O

CF O
had O
the O
most O
significant O
effect O
on O
the O
flavan B
- I
3 I
- I
ol I
and O
polymeric O
phenol O
( O
tannin O
) O
content O
of O
the O
wines O
compared O
to O
the O
control O
followed O
by O
G O
fining O
. O

Iron B
and O
zinc B
bioavailability O
in O
Caco O
- O
2 O
cells O
: O
influence O
of O
caseinophosphopeptid O
. O

A O
study O
has O
been O
made O
of O
the O
influence O
of O
two O
pools O
of O
caseinophosphopeptid O
( O
CPPs O
) O
obtained O
from O
alpha O
( O
s O
) O
- O
and O
beta O
- O
casein O
( O
CN O
) O
fractions O
, O
and O
of O
three O
specific O
CPPs O
( O
beta O
- O
CN O
( O
1 O
- O
25 O
) O
4P O
, O
alpha O
( O
s1 O
) O
- O
CN O
( O
64 O
- O
74 O
) O
4P O
and O
alpha O
( O
s2 O
) O
- O
CN O
( O
1 O
- O
19 O
) O
4P O
) O
, O
on O
iron B
bioavailability O
( O
ferritin O
synthesis O
) O
and O
zinc B
bioavailability O
( O
retention O
, O
transport O
and O
uptake O
of O
zinc B
) O
in O

In O
relation O
to O
zinc B
bioavailability O
, O
alpha O
- O
CPPs O
, O
beta O
- O
CPPs O
, O
alpha O
( O
s1 O
) O
- O
CN O
( O
64 O
- O
74 O
) O
4P O
and O
beta O
- O
CN O
( O
1 O
- O
25 O
) O
4P O
increased O
zinc B
uptake O
. O

However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc B
sulphate I
. O

Urea B
- O
polyacrylamide B
gel O
electrophoresis O
( O
PAGE O
) O
of O
partially O
dephosphorylated O
beta O
- O
casein O
showed O
a O
number O
of O
bands O
, O
depending O
on O
the O
final O
level O
of O
phosphorylation O
. O

Use O
of O
partially O
dephosphorylated O
beta O
- O
casein O
to O
stabilise O
oil O
- O
in O
- O
water O
emulsions O
resulted O
in O
larger O
fat O
globules O
compared O
to O
control O
beta O
- O
casein O
, O
but O
such O
globules O
were O
less O
susceptible O
to O
aggregation O
in O
the O
presence O
of O
15 O
or O
30 O
mM O
CaCl B
( I
2 I
) I
. O

Overall O
, O
the O
dephosphorylation O
of O
beta O
- O
casein O
resulted O
in O
a O
protein O
similar O
to O
human O
beta O
- O
casein O
in O
terms O
of O
physicochemical O
functionality O
, O
with O
increased O
stability O
against O
calcium B
- O
induced O
aggregation O
. O

A O
rapid O
determination O
method O
for O
ethylenethiourea B
in O
potato O
and O
cucumber O
by O
modified O
QuEChERS O
- O
high O
performance O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

A O
rapid O
and O
sensitive O
analytical O
method O
for O
the O
determination O
of O
ethylenethiourea B
( O
ETU B
) O
in O
potatoes O
and O
cucumbers O
is O
developed O
. O

ETU B
was O
extracted O
by O
alkaline O
acetonitrile B
( O
containing O
1 O
% O
NH O
( O
3 O
) O
. O
H O
( O
2 O
) O
0 O
) O
, O
separated O
on O
a O
ZIC O
- O
pHILIC O
column O
, O
confirmed O
by O
multiple O
reaction O
monitoring O
( O
MRM O
) O
mode O
with O
electrospray O
ionisation O
source O
. O

The O
method O
was O
finally O
applied O
to O
detect O
ETU B
in O
potato O
and O
cucumber O
samples O
collected O
at O
harvest O
period O
. O

Residues O
of O
ETU B
were O
detected O
in O
four O
cucumber O
samples O
with O
the O
level O
lower O
than O
LOQ O
. O

Multiple O
mutations O
of O
the O
critical O
amino B
acid I
residues O
for O
the O
sweetness O
of O
the O
sweet O
- O
tasting O
protein O
, O
brazzein O
. O

The O
aim O
of O
this O
research O
was O
to O
characterise O
the O
dialdehydic O
form O
of O
decarboxymethyl O
elenolic O
acid O
linked O
to O
hydroxytyrosol B
( O
3 O
, O
4 O
- O
DHPEA O
- O
EDA O
) O
oxidation O
products O
to O
find O
analytical O
indicators O
that O
could O
be O
used O
as O
early O
evaluation O
index O
of O
the O
VOO O
autoxidation O
state O
. O

Terpenic O
structure O
oxidation O
products O
accumulated O
in O
VOO O
during O
the O
autoxidation O
process O
, O
thus O
they O
may O
be O
used O
as O
early O
evaluation O
index O
of O
the O
VOO O
autoxidation O
state O
before O
fatty B
acids I
oxidation O
. O

Effects O
of O
Azocompost O
and O
urea B
on O
the O
herbage O
yield O
and O
contents O
and O
compositions O
of O
essential O
oils O
from O
two O
genotypes O
of O
dragonhead O
( O
Dracocephalum O
moldavica O
L O
. O
) O
in O
two O
regions O
of O
Iran O
. O

We O
examined O
effects O
of O
different O
sources O
of O
nitrogen B
on O
the O
content O
and O
composition O
of O
essential O
oils O
in O
two O
genotypes O
of O
dragonhead O
in O
two O
regions O
of O
Iran O
. O

The O
sources O
of O
nitrogen B
used O
were O
100 O
% O
urea B
( O
70 O
kg O
N O
ha O
( O
- O
1 O
) O
) O
, O
75 O
% O
urea B
( O
52 O
. O
5 O
kg O
N O
ha O
( O
- O
1 O
) O
) O
+ O
25 O
% O
Azocompost O
( O
3 O
. O
85 O
tonha O
( O
- O
1 O
) O
) O
, O
50 O
% O
urea B
( O
35 O
kg O
N O
ha O
( O
- O
1 O
) O
) O
+ O
50 O
% O
Azocompost O
( O
7 O
. O
77 O
tonha O
( O
- O
1 O
) O
) O
, O
25 O
% O
urea B
( O
17 O
. O
5 O
kg O
N O
ha O
( O
- O
1 O
) O
) O
+ O
75 O
% O
Azocompost O
( O
11 O
. O
55 O
tonha O
( O
- O
1 O
) O
) O
, O
and O
100 O

Optimal O
yield O
and O
content O
of O
essential O
oil O
at O
both O
locations O
for O
both O
genotypes O
were O
obtained O
by O
applying O
50 O
% O
urea B
+ O
50 O
% O
Azocompost O
. O

Geraniol B
, O
geranial O
, O
and O
geranyl O
acetate O
were O
the O
most O
abundant O
compounds O
. O

For O
both O
genotypes O
and O
both O
locations O
, O
application O
of O
50 O
% O
urea B
+ O
50 O
% O
Azocompost O
increased O
levels O
of O
geraniol B
and O
geranial O
, O
and O
application O
of O
Azocompost O
alone O
increased O
levels O
of O
geranyl O
acetate O
. O

Overall O
, O
we O
conclude O
that O
the O
application O
of O
50 O
% O
urea B
with O
50 O
% O
Azocompost O
is O
recommended O
for O
optimising O
the O
content O
and O
composition O
of O
essential O
oils O
in O
dragonhead O
. O

After O
elicitation O
, O
the O
highest O
TS O
content O
was O
determined O
in O
3 O
- O
day O
- O
old O
control O
sprouts O
( O
100 O
. O
9 O
mg O
/ O
gf O
. O
m O
. O
) O
, O
whereas O
the O
lowest O
was O
in O
4 O
- O
day O
- O
old O
sprouts O
induced O
with O
300 O
mM O
NaCl B
( O
57 O
. O
8 O
mg O
/ O
gf O
. O
m O
. O
) O
. O

Resistant O
starch O
( O
RS O
) O
content O
was O
most O
effectively O
increased O
by O
induction O
with O
600 O
mM O
mannitol B
. O

The O
highest O
eGI O
values O
were O
determined O
for O
3 O
- O
day O
- O
old O
sprouts O
induced O
with O
300 O
mM O
NaCl B
, O
whereas O
the O
lowest O
were O
for O
6 O
- O
day O
- O
old O
sprouts O
induced O
with O
100mM O
NaCl B
. O

Gelatins O
extracted O
from O
the O
skin O
of O
unicorn O
leatherjacket O
at O
different O
temperatures O
( O
45 O
, O
55 O
, O
65 O
and O
75 O
degrees O
C O
) O
in O
the O
presence O
and O
the O
absence O
of O
soybean O
trypsin B
inhibitor O
( O
SBTI O
; O
100 O
units O
/ O
g O
pretreated O
skin O
) O
for O
12h O
were O
characterised O
. O

The O
highest O
alpha B
- I
amino I
group O
content O
was O
observed O
in O
gelatin O
extracted O
at O
55 O
degrees O
C O
without O
SBTI O
incorporated O
. O

Glycerol B
release O
was O
employed O
as O
a O
marker O
for O
lipolysis O
in O
3T3 O
- O
L1 O
adipocytes O
. O

A O
higher O
glycerol B
release O
represents O
a O
better O
lipolysis O
- O
stimulating O
activity O
. O

The O
peptide O
fraction O
with O
highest O
glycerol B
release O
obtained O
from O
F O
- O
SPIH O
fractionated O
by O
sequential O
ultrafiltration O
membranes O
was O
further O
purified O
using O
gel O
filtration O
chromatography O
and O
two O
steps O
of O
reverse O
- O
phase O
high O
- O
performance O
liquid O
chromatography O
. O

Three O
lipolysis O
- O
stimulating O
peptides O
were O
obtained O
, O
and O
the O
amino B
acid I
sequences O
were O
ILL O
, O
LLL O
and O
VHVV O
, O
respectively O
. O

Vitexin O
- O
2 O
- O
O O
- O
xyloside O
, O
raphasatin O
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
synergistically O
affect O
cell O
growth O
and O
apoptosis O
of O
colon O
cancer O
cells O
. O

Cytotoxic O
effects O
of O
the O
combination O
of O
the O
food O
components O
vitexin O
- O
2 O
- O
O O
- O
xyloside O
( O
X O
) O
, O
raphasatin O
( O
4 O
- O
methylsulphanyl O
- O
3 O
- O
butenyl O
isothiocyanates O
; O
G O
) O
and O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
( O
E O
) O
were O
investigated O
in O
colon O
( O
LoVo O
and O
CaCo O
- O
2 O
) O
and O
breast O
( O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
) O
cancer O
cells O
. O

Further O
analysis O
revealed O
a O
G0 O
/ O
G1 O
arrest O
of O
the O
phase O
cell O
progression O
and O
apoptosis O
, O
linked O
to O
modulation O
of O
Bax O
, O
Bcl2 O
, O
caspase O
- O
9 O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
as O
well O
as O
Reactive O
Oxygen B
Species O
( O
ROS O
) O
generation O
in O
both O
colon O
cancer O
cells O
, O
whereas O
apoptosis O
and O
ROS O
were O
not O
significantly O
detected O
in O
normal O
human O
lymphocytes O
. O

Intervention O
studies O
with O
A O
- O
type O
oligomeric O
procyanidins B
from O
litchi O
( O
Litchi O
chinensis O
) O
pericarp O
( O
LPOPC O
) O
suggested O
its O
protective O
effect O
against O
cardiovascular O
diseases O
. O

It O
was O
demonstrated O
that O
the O
main O
components O
in O
LPOPC O
were O
( B
- I
) I
- I
epicatechin I
, O
A O
- O
type O
procyanidin O
dimers O
, O
trimers O
and O
tetramers O
. O

Rats O
were O
orally O
administered O
different O
levels O
of O
LPOPC O
( O
150 O
and O
300 O
mg O
/ O
kgbw O
) O
, O
the O
procyanidins B
and O
their O
microbial O
metabolites O
in O
urine O
were O
identified O
by O
HPLC O
- O
MS O
/ O
MS O
analysis O
18 O
h O
post O
- O
administration O
. O

However O
, O
only O
( B
- I
) I
- I
epicatechin I
and O
its O
methylated O
derivatives O
were O
detected O
in O
rat O
plasma O
1h O
after O
300 O
mg O
/ O
kgbw O
of O
LPOPC O
administration O
. O

The O
total O
EC O
content O
absorbed O
in O
plasma O
was O
only O
2 O
. O
54 O
+ O
/ O
- O
0 O
. O
53 O
mu O
mol O
/ O
L O
, O
indicating O
that O
the O
biological O
properties O
of O
LPOPC O
should O
be O
probably O
explained O
by O
its O
microbial O
degraded O
phenolic B
acids I
. O

Phenolics B
content O
and O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
of O
legume O
fractions O
. O

These O
fractions O
, O
together O
with O
their O
corresponding O
whole O
seeds O
, O
were O
extracted O
with O
two O
solvents O
, O
aqueous O
( O
70 O
% O
) O
acetone B
and O
( O
80 O
% O
) O
ethanol B
, O
and O
evaluated O
for O
antioxidant O
activity O
in O
relation O
to O
their O
phenolic B
contents O
. O

Acetone B
selectively O
extracted O
tannins B
from O
faba O
beans O
. O

The O
hulls O
always O
exhibited O
high O
antioxidant O
activity O
, O
measured O
using O
the O
reducing O
power O
( O
RP O
) O
, O
antiradical O
activity O
( O
DPPH B
) O
or O
oxygen B
radical O
absorbance O
capacity O
( O
ORAC O
) O
assays O
. O

Aqueous O
ethanol B
( O
80 O
% O
) O
extract O
of O
lentil O
hulls O
exhibited O
high O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
preferentially O
inhibiting O
15 O
- O
LOX O
( O
IC O
( O
50 O
) O
, O
55 O
mu O
g O
/ O
ml O
) O
, O
with O
moderate O
COX O
- O
1 O
( O
IC O
( O
50 O
) O
, O
66 O
mu O
g O
/ O
ml O
) O
and O
COX O
- O
2 O
( O
IC O
( O
50 O
) O
, O
119 O
mu O
g O
/ O
ml O
) O
inhibitory O
effects O
on O
the O
COX O
pathway O
, O
whereas O
faba O
bean O
hull O
extracts O
exerted O
relatively O
mild O
LOX O
inhibitory O
activity O
. O

Microbial O
metabolites O
, O
but O
not O
other O
phenolics B
derived O
from O
grape O
seed O
phenolic O
extract O
, O
are O
transported O
through O
differentiated O
Caco O
- O
2 O
cell O
monolayers O
. O

In O
addition O
, O
all O
forms O
of O
phenolic B
compounds O
decreased O
following O
pancreatic O
digestion O
. O

However O
, O
none O
of O
the O
original O
GSE O
phenolic B
compounds O
passed O
the O
Caco O
- O
2 O
cell O
monolayer O
, O
since O
all O
were O
recovered O
in O
the O
apical O
compartment O
. O

Galacto O
- O
oligosaccharides O
( O
GOS O
) O
, O
an O
important O
class O
of O
functional O
food O
, O
are O
commonly O
produced O
from O
lactose B
using O
beta O
- O
galactosidase O
. O

Detection O
of O
adulteration O
in O
honey O
samples O
added O
various O
sugar B
syrups O
with O
13C B
/ O
12C O
isotope O
ratio O
analysis O
method O
. O

One O
of O
the O
adulteration O
methods O
is O
the O
addition O
of O
different O
sugar B
syrups O
during O
or O
after O
honey O
production O
. O

Starch O
- O
based O
sugar B
syrups O
, O
high O
fructose B
corn O
syrup O
( O
HFCS O
) O
, O
glucose B
syrup O
( O
GS O
) O
and O
saccharose O
syrups O
( O
SS O
) O
, O
which O
are O
produced O
from O
beet O
or O
canes O
, O
can O
be O
used O
for O
adulterating O
honey O
. O

In O
this O
study O
, O
adulterated O
honey O
samples O
were O
prepared O
with O
the O
addition O
of O
HFCS O
, O
GS O
and O
SS O
( O
beet O
sugar B
) O
at O
a O
ratio O
of O
0 O
% O
, O
10 O
% O
, O
20 O
% O
, O
40 O
% O
and O
50 O
% O
by O
weight O
. O

( B
13 I
) I
C I
/ O
( O
12 O
) O
C O
analysis O
was O
conducted O
on O
these O
adulterated O
honey O
samples O
using O
an O
isotope O
ratio O
mass O
spectrometer O
in O
combination O
with O
an O
elemental O
analyser O
( O
EA O
- O
IRMS O
) O
. O

As O
a O
result O
, O
adulteration O
using O
C O
( O
4 O
) O
sugar B
syrups O
( O
HFCS O
and O
GS O
) O
could O
be O
detected O
to O
a O
certain O
extent O
while O
adulteration O
of O
honey O
using O
C O
( O
3 O
) O
sugar B
syrups O
( O
beet O
sugar B
) O
could O
not O
be O
detected O
. O

Adulteration O
by O
using O
SS O
( O
beet O
sugar B
) O
still O
has O
a O
serious O
detection O
problem O
, O
especially O
in O
countries O
in O
which O
beet O
is O
used O
in O
manufacturing O
sugar B
. O

Effect O
of O
TiO2 B
photocatalytic O
activity O
in O
a O
HDPE O
- O
based O
food O
packaging O
on O
the O
structural O
and O
microbiological O
stability O
of O
a O
short O
- O
ripened O
cheese O
. O

A O
high O
density O
polyethylene B
( O
HDPE O
) O
/ O
calcium B
carbonate I
( O
CaCO B
( I
3 I
) I
) O
film O
containing O
TiO B
( I
2 I
) I
was O
prepared O
via O
blown O
film O
extrusion O
process O
. O

The O
photocatalytic O
properties O
of O
this O
film O
were O
evaluated O
by O
voltammetric O
, O
UV O
- O
Vis O
spectrophotometric O
and O
gas O
chromatographic O
measurements O
following O
the O
decomposition O
rate O
of O
suitably O
selected O
molecular O
probes O
, O
such O
as O
4 B
- I
hydroxybenzoic I
acid I
and O
methylene B
blue I
. O

The O
film O
containing O
1 O
% O
w O
/ O
w O
of O
TiO B
( I
2 I
) I
displayed O
a O
profitable O
and O
reproducible O
photoinduced O
degradation O
activity O
towards O
target O
organic O
compounds O
. O

A O
container O
consisting O
of O
a O
multilayer O
material O
, O
where O
the O
layer O
brought O
in O
contact O
with O
the O
food O
, O
made O
from O
the O
HDPE O
+ O
CaCO B
( I
3 I
) I
+ O
TiO B
( I
2 I
) I
composite O
matrix O
, O
was O
able O
to O
provide O
a O
greater O
maintenance O
of O
the O
original O
cheese O
structure O
than O
a O
rigid O
container O
currently O
used O
, O
mainly O
due O
to O
the O
inhibition O
of O
lactic B
acid I
bacteria O
and O
coliforms O
. O

Prediction O
of O
fatty B
acid I
composition O
in O
Camellia O
oleifera O
oil O
by O
near O
infrared O
transmittance O
spectroscopy O
( O
NITS O
) O
. O

UV O
- O
C O
treatment O
at O
high O
doses O
( O
from O
32 O
, O
181 O
J O
L O
( O
- O
1 O
) O
, O
about O
2 O
times O
higher O
than O
that O
needed O
to O
inactivate O
5 O
log O
of O
relevant O
microorganisms O
) O
showed O
an O
increased O
lipid O
oxidation O
in O
egg O
yolk O
and O
slight O
effects O
in O
liquid O
whole O
eggs O
; O
this O
was O
confirmed O
by O
slightly O
but O
not O
statistically O
significant O
increased O
peroxide B
values O
. O

UV O
- O
C O
induced O
also O
slight O
protein O
damage O
, O
characterised O
by O
the O
total O
sulfhydryl B
group O
reduction O
. O

Protein O
derived O
from O
blue O
mussel O
( O
Mytilus O
edulis O
) O
was O
hydrolysed O
using O
four O
kinds O
of O
proteases O
( O
pepsin O
, O
papain O
, O
neutrase O
and O
alcalase O
) O
, O
and O
the O
neutrase O
hydrolysate O
( O
BNH O
) O
obtained O
by O
3 O
- O
h O
hydrolysis O
exhibited O
the O
highest O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
) O
radical O
scavenging O
activity O
compared O
to O
other O
hydrolysates O
. O

By O
using O
ultrafiltration O
, O
gel O
filtration O
chromatography O
and O
reversed O
phase O
high O
performance O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
, O
a O
novel O
antioxidant O
peptide O
( O
BNH O
- O
P7 O
) O
was O
isolated O
from O
BNH O
, O
and O
its O
amino B
acid I
sequence O
was O
identified O
as O
YPPAK O
( O
Tyr O
- O
Pro O
- O
Pro O
- O
Ala O
- O
Lys O
) O
with O
molecular O
weight O
of O
574 O
Da O
. O

BNH O
- O
P7 O
exhibited O
good O
scavenging O
activity O
on O
DPPH B
radical O
, O
hydroxyl B
radical O
, O
and O
superoxide B
anion O
radical O
with O
EC O
( O
50 O
) O
of O
2 O
. O
62 O
, O
0 O
. O
228 O
, O
and O
0 O
. O
072 O
mg O
/ O
ml O
, O
respectively O
. O

BNH O
- O
P7 O
was O
also O
effectively O
against O
lipid O
peroxidation O
in O
a O
linoleic B
acid I
model O
system O
. O

The O
high O
activity O
of O
BNH O
- O
P7 O
was O
due O
to O
the O
small O
size O
and O
the O
presence O
of O
antioxidant O
and O
hydrophobic O
amino B
acid I
residues O
( O
Tyr B
and O
Pro B
) O
within O
its O
sequence O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 O
- O
methylfurfural O
, O
1 O
( O
H O
) O
- O
pyrrole O
, O
furfuryl B
alcohol I
, O
1 O
( O
H O
) O
- O
pyrrole O
- O
2 O
- O
carboxaldehyde O
, O
1 O
- O
hydroxy O
- O
2 O
- O
propanone O
, O
dihydro O
- O
2 O
( O
3H O
) O
- O
furanone O
, O
5 O
- O
methyl O
- O
( O
E O
) O
- O
2 O
- O
hepten O
- O
4 O
- O
one O
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

pyrazine B
, O
and O
several O
alkyl O
- O
pyrazines O
) O
; O
and O
, O
( O
b O
) O
the O
reliability O
of O
proposed O
chemical O
indices O
: O
5 O
- O
methylfurfural O
/ O
2 O
, O
5 O
- O
dimethylpyrazine O
, O
5 O
- O
methylfurfural O
/ O
2 O
- O
methylpyrazine O
, O
2 O
, O
5 O
- O
dimethylpyrazine O
/ O
2 O
, O
3 O
- O
dimethylpyrazine O
; O
these O
maintained O
a O
consistent O
trend O
versus O
harvest O
and O
sampling O
/ O
analysis O
technology O
. O

Concentrations O
of O
PCDD O
/ O
Fs O
, O
dioxin O
- O
like O
PCBs O
, O
PBDEs B
, O
and O
hexachlorobenzene O
in O
fat O
samples O
from O
cattle O
of O
different O
ages O
and O
gender O
in O
Korea O
. O

Polychlorinated O
dibenzo O
- O
p O
- O
dioxins O
and O
dibenzofurans O
( O
PCDD O
/ O
Fs O
) O
, O
dioxin O
- O
like O
polychlorinated O
biphenyls O
( O
DL O
- O
PCBs O
) O
, O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
and O
hexachlorobenzene O
( O
HCB O
) O
concentrations O
were O
determined O
in O
abdominal O
fat O
samples O
from O
30 O
cattle O
. O

The O
concentration O
of O
PCDD O
/ O
Fs O
ranged O
from O
0 O
. O
01 O
to O
1 O
. O
36 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
DL O
- O
PCBs O
ranged O
from O
0 O
. O
17 O
to O
1 O
. O
64 O
pg O
TEQ O
g O
( O
- O
1 O
) O
fat O
, O
PBDEs B
ranged O
from O
135 O
to O
725 O
pgg O
( O
- O
1 O
) O
fat O
, O
and O
HCB O
ranged O
from O
25 O
. O
5 O
to O
2061 O
pgg O
( O
- O
1 O
) O
fat O
. O

Moreover O
, O
the O
concentrations O
of O
PBDEs B
in O
cattle O
fat O
did O
not O
correspond O
with O
the O
age O
of O
cattle O
. O

Effects O
of O
various O
pressing O
programs O
and O
yields O
on O
the O
antioxidant O
activity O
, O
antimicrobial O
activity O
, O
phenolic B
content O
and O
colour O
of O
pomegranate O
juices O
. O

Effects O
of O
pressing O
pressure O
- O
time O
and O
yield O
on O
total O
phenolic B
( O
TP O
) O
content O
, O
condensed O
tannin O
( O
CT O
) O
content O
, O
monomeric O
anthocyanin B
( O
MA O
) O
content O
, O
antioxidant O
activity O
( O
AOA O
) O
and O
antimicrobial O
activity O
( O
AMA O
) O
of O
the O
samples O
were O
determined O
. O

Evolution O
of O
flavonoids B
in O
Mourat O
o O
n O
berries O
taken O
from O
both O
bunch O
halves O
. O

In O
this O
work O
, O
anthocyanin B
and O
flavonol B
evolution O
was O
followed O
in O
red O
berries O
from O
V O
. O
vinifera O
L O
. O

The O
novelty O
of O
this O
study O
is O
that O
grapes O
were O
separately O
collected O
from O
two O
different O
positions O
( O
tips O
and O
shoulders O
) O
within O
the O
cluster O
, O
over O
ripening O
to O
examine O
the O
effects O
of O
berry O
position O
within O
the O
fruit O
cluster O
on O
the O
flavonoid B
compounds O
. O

Derivatives O
of O
five O
anthocyanins B
( O
malvidin B
, O
peonidin B
, O
petunidin B
, O
delphinidin B
and O
cyanidin B
) O
and O
derivatives O
of O
six O
flavonols B
( O
quercetin B
, O
myricetin B
, O
kaempherol O
, O
laricitrin O
isorhamnetin B
and O
syringetin O
) O
were O
detected O
in O
both O
positions O
within O
the O
cluster O
. O

Dynamic O
of O
anthocyanins B
( O
from O
819 O
mg O
/ O
kg O
to O
1206 O
mg O
/ O
kg O
in O
tips O
; O
and O
from O
786 O
mg O
/ O
kg O
to O
1077 O
mg O
/ O
kg O
in O
shoulders O
) O
and O
dynamic O
of O
flavonols B
( O
from O
25mg O
/ O
kg O
to O
41 O
mg O
/ O
kg O
in O
tips O
; O
and O
from O
18 O
mg O
/ O
kg O
to O
21 O
mg O
/ O
kg O
in O
shoulders O
) O
confirmed O
their O
upward O
trends O
over O
ripening O
. O

Purification O
, O
properties O
and O
cDNA O
cloning O
of O
glutamate B
decarboxylase O
in O
germinated O
faba O
bean O
( O
Vicia O
faba O
L O
. O
) O
. O

Gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
is O
a O
non O
- O
protein O
amino B
acid I
with O
bioactive O
functions O
in O
humans O
. O

In O
this O
work O
, O
glutamate B
decarboxylase O
( O
EC O
4 O
. O
1 O
. O
1 O
. O
15 O
, O
GAD O
) O
which O
is O
key O
in O
the O
GABA B
bioformation O
was O
purified O
from O
5 O
- O
day O
germinated O
faba O
beans O
and O
characterized O
. O

A O
single O
band O
was O
observed O
at O
58 O
kDa O
using O
sodium B
dodecyl I
sulphate I
gel O
electrophoresis O
. O

GAD O
optimal O
activity O
was O
at O
pH O
6 O
. O
0 O
at O
40 O
degrees O
C O
with O
a O
K O
( O
m O
) O
value O
for O
glutamic B
acid I
( O
Glu B
) O
of O
2 O
. O
63 O
mM O
. O

The O
enzyme O
was O
inhibited O
significantly O
by O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
aminoxyacetate O
, O
EGTA B
, O
Na O
( O
2 O
) O
EDTA O
, O
l O
- O
cysteine O
and O
beta O
- O
mercaptoethanol O
; O
and O
activated O
at O
low O
Ca B
( I
2 I
+ I
) I
0 O
. O
2mM O
. O

Using O
RT O
- O
PCR O
, O
the O
GAD O
cDNA O
was O
sequenced O
which O
indicated O
1787 O
bp O
long O
, O
containing O
a O
1527 O
bp O
open O
reading O
frame O
( O
ORF O
) O
that O
encoded O
509 O
amino B
- I
acid I
peptides O
with O
a O
calculated O
molecular O
weight O
of O
57 O
. O
74 O
kDa O
and O
a O
pI O
of O
5 O
. O
41 O
( O
GenBank O
accession O
number O
: O
JX444699 O
) O
. O

The O
properties O
of O
natural O
actomyosin O
( O
NAM O
) O
containing O
2 O
% O
or O
8 O
% O
fish O
protein O
hydrolysate O
( O
FPH O
- O
2 O
, O
FPH O
- O
8 O
) O
or O
8 O
% O
sucrose B
- O
sorbitol B
blend O
( O
SuSo O
) O
were O
compared O
to O
control O
NAM O
before O
and O
after O
freeze O
- O
thaw O
treatment O
. O

Ten O
organophosphorus B
pesticides O
( O
OPs O
) O
were O
found O
in O
concentrations O
ranging O
from O
0 O
. O
004 O
to O
0 O
. O
257 O
mg O
/ O
kg O
. O

The O
mean O
levels O
of O
omethoate O
, O
phorate O
, O
chlorpyrifos B
, O
methidathion O
, O
ethoprophos O
in O
vegetables O
exceeded O
the O
maximum O
residue O
limits O
( O
MRLs O
) O
allowed O
by O
the O
Ministry O
of O
Health O
, O
of O
China O
. O

Five O
pyrethroid B
pesticides O
( O
PYRs O
) O
were O
detectable O
in O
vegetable O
samples O
respectively O
. O

Liquid O
model O
systems O
were O
composed O
of O
different O
types O
of O
Citrus O
pectins O
, O
juices O
( O
J O
) O
and O
the O
respective O
phenolic O
extracts O
( O
E O
) O
from O
elderberry O
( O
EB O
) O
, O
black O
currant O
( O
BC O
) O
, O
red O
cabbage O
( O
RC O
) O
and O
purple O
carrot O
( O
PC O
) O
in O
the O
presence O
of O
ferric B
ions O
. O

Colour O
and O
its O
stability O
strongly O
depended O
on O
the O
amount O
of O
ferric B
ions O
and O
the O
plant O
source O
; O
however O
, O
colour O
decay O
could O
generally O
be O
described O
as O
a O
pseudo O
- O
first O
- O
order O
kinetics O
. O

Highest O
colour O
intensities O
and O
best O
stabilities O
were O
observed O
for O
model O
systems O
containing O
PC O
- O
E O
at O
a O
molar O
anthocyanin B
: O
ferric B
ion O
ratio O
of O
1 O
: O
2 O
. O

Ascorbic O
and O
lactic O
acids O
interfered O
with O
ferric B
ions O
, O
thus O
significantly O
affecting O
blue O
colour O
evolution O
and O
stability O
. O

Combined O
effect O
of O
starter O
culture O
and O
temperature O
on O
phenolic B
compounds O
during O
fermentation O
of O
Taggiasca O
black O
olives O
. O

pH O
and O
phenolic B
compounds O
were O
monitored O
in O
the O
brine O
and O
olive O
flesh O
during O
the O
fermentation O
. O

Higher O
temperatures O
( O
37 O
degrees O
C O
) O
enhanced O
notably O
the O
release O
of O
phenolic B
compounds O
in O
the O
brine O
. O

The O
antioxidant O
power O
of O
the O
extracts O
was O
linearly O
correlated O
to O
their O
polyphenol B
contents O
. O

Phenolic B
compounds O
in O
the O
brines O
can O
be O
then O
extracted O
and O
used O
in O
food O
, O
cosmetic O
and O
pharmaceutical O
industries O
. O

To O
clarify O
the O
regulatory O
molecular O
mechanisms O
behind O
cell O
cycle O
aberrations O
related O
to O
the O
early O
stages O
of O
hepatocarcinogenesis O
, O
we O
performed O
gene O
expression O
analysis O
using O
microarrays O
and O
real O
- O
time O
reverse O
transcription O
polymerase O
chain O
reaction O
followed O
by O
immunohistochemical O
analysis O
in O
the O
livers O
of O
rats O
treated O
with O
the O
cytomegaly O
inducing O
hepatocarcinogens O
thioacetamide O
( O
TAA O
) O
, O
fenbendazole O
, O
and O
methyleugenol B
, O
the O
cytomegaly O
non O
- O
inducing O
hepatocarcinogen O
piperonyl B
butoxide I
( O

PBO O
) O
, O
or O
the O
non O
- O
carcinogenic O
hepatotoxicants O
acetaminophen B
and O
alpha O
- O
naphthyl O
isothiocyanate O
, O
for O
28 O
days O
. O

Experimental O
verification O
of O
the O
simulation O
approach O
is O
demonstrated O
using O
polystyrene B
microspheres O
and O
leukemia O
cells O
. O

Adenosine B
2A O
receptor O
modulates O
inflammation O
and O
phenotype O
in O
experimental O
abdominal O
aortic O
aneurysms O
. O

Activation O
of O
the O
adenosine B
2A O
receptor O
( O
A O
( O
2A O
) O
R O
) O
reduces O
inflammation O
in O
models O
of O
acute O
injury O
but O
contribution O
in O
development O
of O
chronic O
abdominal O
aortic O
aneurysms O
( O
AAAs O
) O
is O
unknown O
. O

Adenosine B
2A O
receptor O
modulates O
inflammation O
and O
phenotype O
in O
experimental O
abdominal O
aortic O
aneurysms O
. O

Chlorocarbonylthio O
- O
and O
isothiocyanate O
( O
ClC O
( O
O O
) O
SCN O
and O
ClC O
( O
O O
) O
NCS O
) O
have O
been O
isolated O
and O
characterized O
by O
IR O
( O
Ar B
matrix O
, O
gas O
) O
, O
Raman O
( O
liquid O
) O
, O
( B
13 I
) I
C I
NMR O
and O
UV O
- O
visible O
spectroscopies O
. O

Vibrational O
and O
quantum O
chemical O
studies O
suggest O
the O
presence O
of O
the O
syn O
and O
anti O
conformers O
( O
SCN O
group O
with O
respect O
to O
the O
C B
= I
O I
bond O
) O
in O
the O
gas O
phase O
for O
both O
constitutional O
isomers O
. O

The O
photochemistry O
of O
both O
constitutional O
isomers O
isolated O
in O
solid O
argon B
at O
15 O
K O
was O
studied O
. O

Rearrangement O
of O
ClC O
( O
O O
) O
SCN O
to O
ClC O
( O
O O
) O
NCS O
was O
observed O
in O
the O
neat O
liquid O
and O
under O
UV O
- O
vis O
irradiation O
of O
ClC O
( O
O O
) O
SCN O
isolated O
in O
solid O
argon B
. O

Potential O
- O
dependent O
interaction O
of O
DOPC B
liposomes O
with O
an O
octadecanol O
- O
covered O
Au B
( I
111 I
) I
surface O
investigated O
using O
electrochemical O
methods O
coupled O
with O
in O
situ O
fluorescence O
microscopy O
. O

The O
potential O
- O
controlled O
incorporation O
of O
DOPC B
liposomes O
( O
100 O
nm O
diameter O
) O
into O
an O
adsorbed O
octadecanol O
layer O
on O
Au B
( I
111 I
) I
was O
studied O
using O
electrochemical O
and O
in O
situ O
fluorescence O
microscopy O
. O

The O
adsorbed O
layer O
of O
octadecanol O
included O
a O
small O
amount O
of O
a O
lipophilic O
fluorophore O
- O
octadecanol O
modified O
with O
BODIPY B
- O
to O
enable O
fluorescence O
imaging O
. O

Thioredoxin O
protects O
cells O
against O
oxidative O
damage O
by O
reducing O
disulfide B
bonds O
in O
improperly O
oxidized O
proteins O
. O

Cross O
- O
linking O
of O
Trx2 O
and O
Tsa1 O
to O
other O
proteins O
by O
DVSF O
and O
DAD O
is O
dependent O
on O
modification O
of O
the O
active O
site O
Cys B
residues O
within O
these O
proteins O
. O

Bioanalytical O
LC O
separation O
techniques O
for O
quantitative O
analysis O
of O
free O
amino B
acids I
in O
human O
plasma O
. O

The O
quantitative O
analysis O
of O
free O
amino B
acids I
in O
human O
plasma O
has O
become O
an O
important O
and O
essential O
analysis O
parameter O
in O
different O
areas O
of O
life O
sciences O
. O

Free O
amino B
acid I
concentrations O
in O
human O
plasma O
samples O
are O
generally O
determined O
by O
means O
of O
GC O
or O
LC O
after O
chemical O
derivatization O
followed O
by O
UV O
, O
fluorescent O
or O
MS O
detection O
of O
the O
amino B
acid I
derivatives O
. O

Derivatization O
of O
free O
amino B
acids I
is O
done O
either O
pre O
- O
or O
post O
- O
column O
, O
and O
the O
amino B
acid I
derivatives O
obtained O
posess O
improved O
chromatographic O
behavior O
, O
increased O
detection O
sensitivity O
and O
selectivity O
compared O
with O
non O
- O
derivatized O
free O
amino B
acids I
. O

This O
work O
gives O
an O
overview O
of O
different O
chemical O
derivatization O
methods O
applied O
and O
their O
liquid O
separation O
techniques O
in O
bioanalytical O
assays O
for O
quantitative O
free O
amino B
acid I
analysis O
in O
human O
plasma O
samples O
. O

Ester B
hydrolysis O
by O
a O
histidine B
- O
containing O
cavitein O
. O

We O
have O
used O
a O
template O
- O
assembled O
synthetic O
protein O
( O
TASP O
) O
to O
investigate O
catalytic O
function O
in O
ester B
hydrolysis O
. O

A O
histidine B
- O
containing O
cavitein O
has O
been O
found O
to O
catalyze O
ester B
hydrolysis O
with O
a O
rate O
increase O
of O
18 O
times O
that O
of O
background O
. O

Triazolo O
and O
imidazo O
dihydropyrazolopyrim O
potassium B
channel O
antagonists O
. O

Discovery O
of O
a O
novel O
series O
of O
quinolone B
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
agonists O
. O

High O
throughput O
screening O
led O
to O
the O
identification O
of O
a O
novel O
series O
of O
quinolone B
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
agonists O
. O

This O
effect O
requires O
cold O
- O
induced O
, O
TRPA O
- O
1 O
- O
mediated O
calcium B
influx O
and O
a O
calcium B
- O
sensitive O
PKC O
that O
signals O
to O
the O
transcription O
factor O
DAF O
- O
16 O
/ O
FOXO O
. O

Our O
results O
reveal O
a O
previously O
unrecognized O
function O
for O
TRP O
channels O
, O
link O
calcium B
signaling O
to O
longevity O
, O
and O
, O
importantly O
, O
demonstrate O
that O
genetic O
programs O
contribute O
to O
lifespan O
extension O
at O
cold O
temperatures O
. O

Inflammation O
was O
assessed O
by O
evaluating O
inflammatory O
markers O
/ O
parameters O
( O
colon O
weight O
/ O
colon O
length O
ratio O
and O
myeloperoxidase O
activity O
) O
, O
by O
histological O
analysis O
and O
immunohistochemistry O
; O
interleukin O
- O
1 O
beta O
, O
interleukin O
- O
10 O
and O
interferon O
- O
gamma O
levels O
by O
ELISA O
, O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
by O
western O
blot O
and O
RT O
- O
PCR O
; O
CuZn O
- O
superoxide B
dismutase O
( O

Murine O
macrophages O
and O
intestinal O
epithelial O
cells O
were O
used O
to O
evaluate O
the O
effect O
of O
CBG O
on O
nitric B
oxide I
production O
and O
oxidative O
stress O
, O
respectively O
. O

In O
macrophages O
, O
CBG O
reduced O
nitric B
oxide I
production O
and O
iNOS O
protein O
( O
but O
not O
mRNA O
) O
expression O
. O

Rimonabant B
( O
a O
CB1 O
receptor O
antagonist O
) O
did O
not O
change O
the O
effect O
of O
CBG O
on O
nitric B
oxide I
production O
, O
while O
SR144528 O
( O
a O
CB2 O
receptor O
antagonist O
) O
further O
increased O
the O
inhibitory O
effect O
of O
CBG O
on O
nitric B
oxide I
production O
. O

In O
conclusion O
, O
CBG O
attenuated O
murine O
colitis O
, O
reduced O
nitric B
oxide I
production O
in O
macrophages O
( O
effect O
being O
modulated O
by O
the O
CB2 O
receptor O
) O
and O
reduced O
ROS O
formation O
in O
intestinal O
epithelial O
cells O
. O

11 B
beta I
- I
Hydroxysteroid I
dehydrogenase O
type O
1 O
contributes O
to O
the O
balance O
between O
7 O
- O
keto O
- O
and O
7 O
- O
hydroxy O
- O
oxysterols O
in O
vivo O
. O

11 B
beta I
- I
Hydroxysteroid I
dehydrogenase O
1 O
( O
11 O
beta O
HSD1 O
; O
EC O
1 O
. O
1 O
. O
1 O
. O
146 O
) O
generates O
active O
glucocorticoids O
from O
inert O
11 O
- O
keto O
metabolites O
. O

However O
, O
it O
can O
also O
metabolize O
alternative O
substrates O
, O
including O
7 O
beta O
- O
hydroxy O
- O
and O
7 O
- O
keto O
- O
cholesterol O
( O
7 B
beta I
OHC I
, O
7KC B
) O
. O

We O
used O
genetically O
modified O
mice O
to O
investigate O
the O
contribution O
of O
11 O
beta O
HSD1 O
to O
the O
balance O
of O
circulating O
levels O
of O
7KC B
and O
7 B
beta I
OHC I
in O
vivo O
, O
and O
dissected O
in O
vitro O
the O
kinetics O
of O
the O
interactions O
between O
oxysterols B
and O
glucocorticoids O
for O
metabolism O
by O
the O
mouse O
enzyme O
. O

Circulating O
levels O
of O
7KC B
and O
7 B
beta I
OHC I
in O
mice O
were O
91 O
. O
3 O
+ O
/ O
- O
22 O
. O
3 O
and O
22 O
. O
6 O
+ O
/ O
- O
5 O
. O
7nM O
respectively O
, O
increasing O
to O
1240 O
+ O
/ O
- O
220 O
and O
406 O
+ O
/ O
- O
39nM O
in O
ApoE O
( O
- O
/ O
- O
) O
mice O
receiving O
atherogenic O
western O
diet O
. O

Disruption O
of O
11 O
beta O
HSD1 O
in O
mice O
increased O
( O
p O
< O
0 O
. O
05 O
) O
the O
7KC B
/ O
7 B
beta I
OHC I
ratio O
in O
plasma O
( O
by O
20 O
% O
) O
and O
also O
in O
isolated O
microsomes O
( O
2 O
fold O
) O
. O

The O
7KC B
/ O
7 B
beta I
OHC I
ratio O
was O
similarly O
increased O
when O
NADPH B
generation O
was O
restricted O
by O
disruption O
of O
hexose O
- O
6 O
- O
phosphate O
dehydrogenase O
. O

Reduction O
and O
oxidation O
of O
7 O
- O
oxysterols O
by O
murine O
11 O
beta O
HSD1 O
proceeded O
more O
slowly O
and O
substrate O
affinity O
was O
lower O
than O
for O
glucocorticoids O
. O
in O
vitro O
7 B
beta I
OHC I
was O
a O
competitive O
inhibitor O
of O
oxidation O
of O
corticosterone B
( O
Ki O
= O
0 O
. O
9 O
mu O
M O
) O
, O
whereas O
7KC B
only O
weakly O
inhibited O
reduction O
of O
11 B
- I
dehydrocorticosteron I
. O

However O
, O
supplementation O
of O
7 O
- O
oxysterols O
in O
cultured O
cells O
, O
secondary O
to O
cholesterol B
loading O
, O
preferentially O
slowed O
reduction O
of O
glucocorticoids O
, O
rather O
than O
oxidation O
. O

Thus O
, O
in O
mouse O
, O
11 O
beta O
HSD1 O
influenced O
the O
abundance O
and O
balance O
of O
circulating O
and O
tissue O
levels O
of O
7 B
beta I
OHC I
and O
7KC B
, O
promoting O
reduction O
of O
7KC B
. O

However O
, O
in O
hyperlipidaemia O
, O
7 O
- O
oxysterols O
may O
inhibit O
glucocorticoid O
metabolism O
and O
modulate O
signaling O
through O
corticosteroid B
receptors O
. O

Amino B
acid I
derived O
quinazolines O
as O
Rock O
/ O
PKA O
inhibitors O
. O

SAR O
and O
lead O
optimization O
studies O
for O
Rock O
inhibitors O
based O
on O
amino B
acid I
- O
derived O
quinazolines O
are O
described O
. O

Studies O
demonstrated O
that O
these O
amino B
acid I
derived O
quinazolinones O
were O
mainly O
pan O
- O
Rock O
( O
I O
& O
II O
) O
inhibitors O
. O

This O
is O
distinct O
from O
Rock O
inhibitors O
based O
on O
non O
- O
amino B
acid I
derived O
quinazolinones O
, O
where O
high O
selectivity O
against O
PKA O
could O
be O
obtained O
. O
( O
22 O
) O
The O
inhibitors O
presented O
here O
in O
some O
cases O
possessed O
sub O
- O
nanomolar O
inhibition O
of O
Rock O
, O
nanomolar O
potency O
in O
ppMLC O
cell O
based O
assays O
, O
low O
to O
fair O
cytochrome O
P O
- O
450 O
inhibition O
, O
and O
good O
human O
microsomal O
stability O
. O

These O
results O
indicate O
that O
aza O
- O
BODIPY O
could O
serve O
as O
a O
near O
- O
IR O
probe O
for O
detecting O
conformational O
changes O
of O
A O
beta O
1 O
- O
42 O
soluble O
oligomers O
in O
vitro O
, O
and O
it O
should O
eliminate O
false O
- O
positive O
effects O
that O
are O
associated O
with O
currently O
utilized O
thioflavin B
T I
- O
based O
dyes O
. O

Recent O
studies O
have O
positioned O
the O
serotonin B
5 O
- O
HT7 O
receptor O
as O
a O
new O
target O
for O
the O
treatment O
of O
depression O
. O

In O
the O
repeated O
open O
- O
space O
swim O
test O
lurasidone O
was O
able O
to O
reverse O
the O
despair O
induced O
by O
repeated O
swims O
in O
a O
manner O
similar O
to O
the O
commonly O
used O
antidepressant O
citalopram B
. O

Dexamethasone B
alters O
epithelium O
proliferation O
and O
survival O
and O
suppresses O
Wnt O
/ O
beta O
- O
catenin O
signaling O
in O
developing O
cleft O
palate O
. O

Dexamethasone B
( O
Dex B
) O
contributes O
to O
a O
cleft O
palate O
, O
but O
the O
cellular O
and O
molecular O
mechanisms O
responsible O
for O
the O
deleterious O
effect O
on O
the O
developing O
palate O
are O
unclear O
. O

Wnt O
signaling O
is O
a O
causal O
mechanism O
of O
Dex B
- O
induced O
osteoporosis O
, O
so O
this O
study O
was O
conducted O
to O
determine O
whether O
Dex B
- O
induced O
cleft O
palate O
may O
result O
from O
altered O
Wnt O
signaling O
. O

Administration O
of O
Dex B
to O
mice O
completely O
inhibited O
canonical O
Wnt O
/ O
beta O
- O
catenin O
signaling O
and O
altered O
cell O
proliferation O
and O
apoptosis O
of O
the O
craniofacial O
epithelium O
in O
developing O
embryos O
. O

Thus O
, O
downregulated O
Wnt O
/ O
beta O
- O
catenin O
signaling O
was O
associated O
with O
Dex B
- O
induced O
cleft O
palate O
. O

Moreover O
, O
altered O
cell O
fate O
by O
Dex B
responsible O
for O
small O
palates O
, O
delaying O
shelf O
elevation O
and O
unfused O
palates O
was O
a O
crucial O
mechanism O
in O
cleft O
palate O
. O

Our O
findings O
help O
in O
elucidating O
the O
mechanisms O
of O
Dex B
- O
induced O
cleft O
palate O
. O

Cysteamine B
: O
an O
old O
drug O
with O
new O
potential O
. O

Cysteamine B
is O
an O
amino O
thiol O
with O
the O
chemical O
formula O
HSCH2CH2NH2 O
. O

Endogenously O
, O
cysteamine B
is O
derived O
from O
coenzyme O
A O
degradation O
, O
although O
its O
plasma O
concentrations O
are O
low O
. O

Most O
experience O
with O
cysteamine B
as O
a O
drug O
originates O
from O
the O
field O
of O
the O
orphan O
disease O
cystinosis O
, O
in O
which O
cysteamine B
is O
prescribed O
to O
decrease O
intralysosomal O
cystine B
accumulation O
. O

In O
this O
article O
, O
we O
review O
the O
different O
applications O
of O
cysteamine B
, O
ending O
with O
an O
overview O
of O
ongoing O
clinical O
trials O
for O
new O
indications O
, O
such O
as O
neurodegenerative O
disorders O
and O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
. O

The O
recent O
development O
of O
an O
enteric O
- O
coated O
cysteamine B
formulation O
makes O
cysteamine B
more O
patient O
friendly O
and O
will O
extend O
its O
applicability O
for O
both O
old O
and O
new O
indications O
. O

To O
study O
the O
antioxidant O
defense O
system O
in O
melanocytes O
, O
the O
activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
and O
glutathione B
peroxidase O
( O
GPx O
) O
in O
cells O
exposed O
to O
amikacin O
were O
determined O
. O

The O
highest O
bioaccessibility O
was O
observed O
for O
As B
, O
Cu B
, O
Ni B
and O
Se B
, O
and O
the O
lowest O
for O
Fe B
, O
Co B
and O
Pb B
. O

Compared O
with O
the O
high O
- O
fat O
control O
( O
HFC O
) O
group O
GMP O
supplementation O
significantly O
decreased O
adipose O
tissue O
weight O
, O
activity O
of O
fatty B
acid I
synthase O
( O
FAS O
) O
and O
glycerol O
- O
3 O
- O
phosphate O
dehydrogenase O
( O
GPDH O
) O
. O

Moreover O
, O
GMP O
reduces O
plasma O
total O
cholesterol B
and O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
cholesterol B
as O
well O
as O
hepatic O
- O
cholesterol B
and O
triglycerides B
. O

In O
addition O
, O
GMP O
significantly O
diminished O
mitochondrial O
and O
liver O
malondialdehyde B
( O
MDA B
) O
production O
, O
and O
obviously O
elevated O
the O
activities O
of O
mitochondrial O
and O
hepatic O
superoxidase O
dismutase O
( O
SOD O
) O
and O
glutathione B
peroxidase O
( O
GSH B
- O
Px O
) O
. O

Central O
administration O
of O
angiotensin B
IV I
rapidly O
enhances O
novel O
object O
recognition O
among O
mice O
. O

Angiotensin B
IV I
( O
Val O
( O
1 O
) O
- O
Tyr O
( O
2 O
) O
- O
Ile O
( O
3 O
) O
- O
His O
( O
4 O
) O
- O
Pro O
( O
5 O
) O
- O
Phe O
( O
6 O
) O
) O
has O
demonstrated O
potential O
cognitive O
- O
enhancing O
effects O
. O

The O
present O
investigation O
assessed O
and O
characterized O
: O
( O
1 O
) O
dose O
- O
dependency O
of O
angiotensin B
IV I
' O
s O
cognitive O
enhancement O
in O
a O
C57BL O
/ O
6J O
mouse O
model O
of O
novel O
object O
recognition O
, O
( O
2 O
) O
the O
time O
- O
course O
for O
these O
effects O
, O
( O
3 O
) O
the O
identity O
of O
residues O
in O
the O
hexapeptide O
important O
to O
these O
effects O
and O
( O
4 O
) O
the O
necessity O
of O
actions O
at O
angiotensin B
IV I
receptors O
for O
procognitive O
activity O
. O

Assessment O
of O
C57BL O
/ O
6J O
mice O
in O
a O
novel O
object O
recognition O
task O
demonstrated O
that O
prior O
administration O
of O
angiotensin B
IV I
( O
0 O
. O
1 O
, O
1 O
. O
0 O
, O
or O
10 O
. O
0 O
, O
but O
not O
0 O
. O
01 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
significantly O
enhanced O
novel O
object O
recognition O
in O
a O
dose O
- O
dependent O
manner O
. O

These O
effects O
were O
time O
dependent O
, O
with O
improved O
novel O
object O
recognition O
observed O
when O
angiotensin B
IV I
( O
0 O
. O
1 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
was O
administered O
10 O
or O
20 O
, O
but O
not O
30 O
min O
prior O
to O
the O
onset O
of O
the O
novel O
object O
recognition O
testing O
. O

An O
alanine B
scan O
of O
the O
angiotensin B
IV I
peptide O
revealed O
that O
replacement O
of O
the O
Val B
( O
1 O
) O
, O
Ile B
( O
3 O
) O
, O
His B
( O
4 O
) O
, O
or O
Phe B
( O
6 O
) O
residues O
with O
Ala B
attenuated O
peptide O
- O
induced O
improvements O
in O
novel O
object O
recognition O
, O
whereas O
Tyr B
( O
2 O
) O
or O
Pro B
( O
5 O
) O
replacement O
did O
not O
significantly O
affect O
performance O
. O

Administration O
of O
the O
angiotensin B
IV I
receptor O
antagonist O
, O
divalinal O
- O
Ang O
IV O
( O
20 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
, O
reduced O
( O
but O
did O
not O
abolish O
) O
novel O
object O
recognition O
; O
however O
, O
this O
antagonist O
completely O
blocked O
the O
procognitive O
effects O
of O
angiotensin B
IV I
( O
0 O
. O
1 O
nmol O
, O
i O
. O
c O
. O
v O
. O
) O
in O
this O
task O
. O

Rotorod O
testing O
demonstrated O
no O
locomotor O
effects O
with O
any O
angiotensin B
IV I
or O
divalinal O
- O
Ang O
IV O
dose O
tested O
. O

These O
data O
demonstrate O
that O
angiotensin B
IV I
produces O
a O
rapid O
enhancement O
of O
associative O
learning O
and O
memory O
performance O
in O
a O
mouse O
model O
that O
was O
dependent O
on O
the O
angiotensin B
IV I
receptor O
. O

Pregnant O
female O
ICR O
mice O
were O
intralaryngopharynge O
administered O
with O
30 O
mu O
l O
of O
phosphate B
buffered O
solution O
( O
the O
control O
group O
) O
or O
resuspended O
PM O
of O
Standard O
Reference O
Material O
1649a O
at O
0 O
. O
09 O
( O
low O
) O
, O
0 O
. O
28 O
( O
medium O
) O
, O
1 O
. O
85 O
( O
high O
) O
or O
6 O
. O
92 O
( O
overdose O
) O
mu O
g O
/ O
mu O
l O
once O
every O
three O
days O
from O
day O
0 O
to O
18 O
of O
pregnancy O
( O
n O
= O
8 O
- O
10 O
) O
. O

Dexamethasone B
antagonizes O
the O
in O
vivo O
myotoxic O
and O
inflammatory O
effects O
of O
Bothrops O
venoms O
. O

In O
the O
present O
work O
we O
investigated O
the O
toxic O
activities O
of O
two O
Bothrops O
snake O
venoms O
using O
in O
vivo O
and O
in O
vitro O
experimental O
protocols O
in O
mice O
and O
tested O
the O
protective O
effect O
of O
dexamethasone B
( O
DEXA O
) O
in O
different O
conditions O
, O
comparing O
it O
with O
the O
polyvalent O
antivenom O
. O

The O
administration O
of O
Bothrops O
jararaca O
and O
Bothrops O
jararacussu O
snake O
venoms O
induced O
muscle O
damage O
demonstrated O
in O
vivo O
by O
the O
elevation O
on O
plasma O
creatine B
kinase O
( O
CK O
) O
activity O
in O
mice O
and O
by O
the O
decrease O
in O
CK O
content O
in O
the O
extensor O
digitorum O
longus O
( O
EDL O
) O
muscle O
of O
these O
animals O
, O
and O
in O
vitro O
by O
the O
increase O
in O
the O
rate O
of O
CK O
release O
from O
the O
isolated O
EDL O
muscle O
. O

Altogether O
our O
results O
show O
that O
inflammation O
is O
at O
least O
in O
part O
responsible O
for O
the O
tissue O
damage O
induced O
by O
Bothrops O
snake O
venoms O
, O
once O
the O
steroidal O
anti O
- O
inflammatory O
drug O
dexamethasone B
was O
able O
to O
decrease O
the O
myotoxic O
effects O
of O
these O
venoms O
, O
by O
reducing O
the O
inflammatory O
response O
to O
the O
venom O
injection O
. O

Additional O
studies O
determined O
that O
the O
hemorrhage O
- O
induced O
decrease O
in O
receptor O
size O
was O
not O
due O
to O
changes O
in O
GHR O
N B
- O
linked O
glycosylation O
. O

The O
effects O
of O
an O
environmentally O
relevant O
58 O
- O
congener O
polychlorinated B
biphenyl I
( O
PCB B
) O
mixture O
on O
cardiac O
development O
in O
the O
chick O
embryo O
. O

Chicken O
( O
Gallus O
domesticus O
) O
embryonic O
exposure O
in O
ovo O
to O
a O
58 O
- O
congener O
polychlorinated B
biphenyl I
( O
PCB B
) O
mixture O
resulted O
in O
teratogenic O
heart O
defects O
in O
chick O
embryos O
at O
critical O
heart O
developmental O
stages O
Hamburger O
- O
Hamilton O
( O
HH O
) O
stages O
10 O
, O
16 O
, O
and O
20 O
. O

Embryos O
were O
injected O
with O
0 O
. O
08 O
micro O
g O
PCBs B
/ O
g O
egg O
weight O
and O
0 O
. O
50 O
micro O
g O
PCBs B
/ O
g O
egg O
weight O
( O
0 O
. O
01 O
and O
0 O
. O
064 O
ng O
toxic O
equivalent O
/ O
g O
, O
respectively O
) O
at O
embryonic O
day O
0 O
, O
prior O
to O
incubation O
. O

Histology O
was O
conducted O
on O
2 O
cardiac O
proteins O
critical O
to O
embryonic O
heart O
development O
, O
ventricular O
myosin O
heavy O
chain O
and O
titin O
, O
to O
investigate O
potential O
mechanistic O
effects O
of O
PCBs B
on O
heart O
development O
, O
but O
no O
difference O
was O
observed O
in O
spatiotemporal O
expression O
. O

Similarly O
, O
cellular O
apoptosis O
in O
the O
developing O
heart O
was O
not O
affected O
by O
exposure O
to O
the O
PCB B
mixture O
. O

Conversely O
, O
cardiomyocyte O
proliferation O
rates O
dramatically O
declined O
( O
p O
< O
0 O
. O
01 O
) O
at O
HH16 O
and O
HH20 O
as O
PCB B
exposure O
concentrations O
increased O
. O

Therefore O
, O
in O
ovo O
exposure O
to O
this O
58 O
- O
congener O
PCB B
mixture O
at O
critical O
stages O
adversely O
affects O
embryonic O
heart O
development O
. O

The O
electrostatic O
interaction O
and O
hydrogen B
bonding O
under O
weak O
- O
acid O
conditions O
between O
aliphatic O
PUA O
and O
PSS O
contribute O
to O
the O
formation O
of O
multilayer O
microcapsules O
. O

Drug O
- O
release O
behaviors O
using O
DOX B
as O
a O
model O
drug O
demonstrate O
that O
the O
drug O
release O
increases O
on O
decreasing O
the O
pH O
value O
because O
of O
the O
interaction O
weakness O
between O
aliphatic O
PUA O
and O
PSS O
in O
acidic O
conditions O
. O

BaSnO3 O
perovskite B
nanoparticles O
for O
high O
efficiency O
dye O
- O
sensitized O
solar O
cells O
. O

The O
synthesis O
of O
highly O
crystalline O
perovskite B
BaSnO3 O
nanoparticles O
for O
use O
as O
photoanode O
materials O
in O
dye O
- O
sensitized O
solar O
cells O
( O
DSSCs O
) O
is O
reported O
, O
and O
the O
photovoltaic O
properties O
of O
DSSCs O
based O
on O
BaSnO3 O
nanoparticles O
( O
BaSnO3 O
cells O
) O
are O
demonstrated O
. O

More O
importantly O
, O
the O
BaSnO3 O
cells O
show O
superior O
charge O
collection O
in O
nanoparticle O
films O
compared O
to O
TiO2 B
cells O
and O
could O
offer O
a O
breakthrough O
in O
the O
efficiencies O
of O
DSSCs O
. O

Incorporating O
Graphene B
Oxide I
and O
Gold O
Nanoclusters O
: O
A O
Synergistic O
Catalyst O
with O
Surprisingly O
High O
Peroxidase O
- O
Like O
Activity O
Over O
a O
Broad O
pH O
Range O
and O
its O
Application O
for O
Cancer O
Cell O
Detection O
. O

A O
synergistic O
graphene B
oxide I
- O
gold O
nanocluster O
( O
GO O
- O
AuNC O
) O
hybrid O
has O
been O
constructed O
as O
an O
enzyme O
mimic O
that O
is O
able O
to O
show O
high O
catalytic O
activity O
over O
a O
broad O
pH O
range O
, O
especially O
at O
neutral O
pH O
. O

Synthesis O
of O
heterocyclic O
terpenoids O
by O
promiscuous O
squalene B
- O
hopene O
cyclases O
. O

PROMISCUOUS O
ENZYMES O
: O
The O
substrate O
promiscuity O
of O
squalene B
- O
hopene O
cyclases O
has O
been O
explored O
and O
applied O
in O
the O
enzyme O
- O
catalyzed O
synthesis O
of O
heterocyclic O
terpenoids O
. O

Features O
of O
this O
work O
include O
cyclization O
reactions O
without O
pyrophosphate B
activation O
, O
and O
stereospecific O
ring O
closure O
of O
substrates O
of O
varying O
chain O
length O
and O
terminal O
nucleophile O
. O

Five O
nanomaterials O
( O
nano O
- O
Ag B
, O
nano O
- O
TiO2 B
, O
nano O
- O
ZnO B
, O
carbon B
nanotubes O
[ O
CNTs O
] O
, O
and O
fullerenes B
) O
and O
4 O
environmental O
compartments O
( O
surface O
water O
, O
sewage O
treatment O
plant O
effluents O
, O
soils O
, O
and O
sludge O
- O
treated O
soils O
) O
were O
considered O
. O

From O
60 O
ecotoxicological O
studies O
, O
the O
authors O
extracted O
112 O
single O
values O
to O
work O
with O
( O
25 O
values O
in O
13 O
studies O
for O
nano O
- O
Ag B
, O
17 O
values O
in O
10 O
studies O
for O
CNTs O
, O
7 O
values O
in O
7 O
studies O
for O
fullerenes B
, O
34 O
values O
in O
23 O
studies O
for O
nano O
- O
TiO2 B
, O
and O
29 O
values O
in O
17 O
studies O
for O
nano O
- O
ZnO B
) O
. O

The O
results O
indicate O
there O
is O
only O
a O
marginal O
risk O
for O
these O
metal O
- O
based O
nanomaterials O
in O
surface O
water O
( O
0 O
. O
7 O
% O
risk O
for O
nano O
- O
Ag B
and O
< O
0 O
. O
1 O
% O
for O
nano O
- O
TiO2 B
) O
and O
some O
risk O
in O
sewage O
treatment O
plant O
effluents O
( O
nano O
- O
Ag B
39 O
. O
7 O
% O
, O
nano O
- O
TiO2 B
18 O
. O
7 O
% O
, O
and O
nano O
- O
ZnO B
1 O
. O
1 O
% O
) O
. O

Apart O
from O
a O
marginal O
value O
of O
< O
0 O
. O
1 O
% O
for O
nano O
- O
TiO2 B
in O
sludge O
- O
treated O
soils O
, O
no O
risk O
from O
the O
other O
evaluated O
ENMs O
in O
terrestrial O
compartments O
is O
currently O
predicted O
. O

OBJECTIVETo O
determine O
the O
prevalence O
of O
people O
with O
diabetes O
who O
meet O
hemoglobin O
A O
( O
1c O
) O
( O
A1C O
) O
, O
blood O
pressure O
( O
BP O
) O
, O
and O
LDL O
cholesterol B
( O
ABC O
) O
recommendations O
, O
and O
their O
current O
statin O
use O
, O
factors O
associated O
with O
goal O
achievement O
, O
and O
changes O
in O
the O
proportion O
achieving O
goals O
between O
1988 O
and O
2010 O
. O
RESEARCH O
AND O
DESIGN O
METHODSData O
were O
cross O
- O
sectional O
from O
the O
National O
Health O
and O
Nutrition O
Examination O
Surveys O
( O
NHANES O
) O
from O
1988 O
- O
1994 O
, O
1999 O
- O
2002 O
, O
2003 O
- O
2006 O
, O
and O
2007 O

Main O
outcome O
measures O
were O
A1C O
, O
BP O
, O
and O
LDL O
cholesterol B
, O
in O
accordance O
with O
the O
American O
Diabetes O
Association O
recommendations O
, O
and O
current O
use O
of O
statins O
. O
RESULTSIn O
2007 O
- O
2010 O
, O
52 O
. O
5 O
% O
of O
people O
with O
diabetes O
achieved O
A1C O
< O
7 O
. O
0 O
% O
( O
< O
53 O
mmol O
/ O
mol O
) O
, O
51 O
. O
1 O
% O
achieved O
BP O
< O
130 O
/ O
80 O
mmHg O
, O
56 O
. O
2 O
% O
achieved O
LDL O
< O
100 O
mg O
/ O
dL O
, O
and O
18 O
. O
8 O
% O
achieved O
all O
three O
ABCs O
. O

Simultaneous O
determination O
of O
evodiamine B
and O
evodine O
in O
Beagle O
dog O
plasma O
using O
liquid O
chromatography O
tandem O
mass O
spectrometry O
. O

A O
sensitive O
, O
rapid O
, O
and O
specific O
liquid O
chromatography O
/ O
tandem O
mass O
spectrometry O
assay O
has O
been O
established O
and O
validated O
for O
the O
quantitation O
of O
evodiamine B
and O
evodine O
in O
Beagle O
dog O
plasma O
. O

Plasma O
samples O
of O
0 O
. O
2 O
ml O
were O
processed O
by O
liquid O
- O
liquid O
extraction O
with O
n B
- I
hexane I
/ O
ethyl B
acetate I
( O
2 O
: O
1 O
, O
v O
/ O
v O
) O
. O

Chromatographic O
separations O
were O
done O
on O
a O
Symmetry O
C O
( O
18 O
) O
column O
( O
100 O
mm O
x O
4 O
. O
6 O
mm O
, O
ID O
, O
5 O
mu O
m O
) O
at O
35 O
degrees O
C O
with O
a O
linear O
gradient O
of O
methanol B
and O
20 O
mM O
ammonium O
formate O
containing O
0 O
. O
2 O
% O
formic B
acid I
. O

Evodiamine B
, O
evodine O
, O
and O
glibenclamide B
[ O
internal O
standard O
( O
IS O
) O
] O
were O
ionized O
with O
an O
electrospray O
ionization O
source O
operated O
in O
positive O
ion O
mode O
. O

The O
MS O
/ O
MS O
transitions O
were O
m O
/ O
z O
304 O
. O
1 O
- O
- O
> O
161 O
. O
1 O
for O
evodiamine B
, O
m O
/ O
z O
471 O
. O
2 O
- O
- O
> O
425 O
. O
1 O
for O
evodine O
, O
and O
m O
/ O
z O
494 O
. O
1 O
- O
- O
> O
369 O
. O
1 O
for O
IS O
. O

Calibration O
curves O
were O
linear O
over O
the O
concentration O
range O
of O
0 O
. O
1 O
- O
100 O
ng O
/ O
ml O
for O
evodiamine B
and O
0 O
. O
5 O
- O
500 O
ng O
/ O
ml O
for O
evodine O
. O

The O
mean O
extraction O
recoveries O
were O
88 O
. O
10 O
+ O
/ O
- O
3 O
. O
21 O
% O
for O
evodiamine B
and O
81 O
. O
24 O
+ O
/ O
- O
4 O
. O
07 O
% O
for O
evodine O
. O

Evodiamine B
and O
evodine O
were O
stable O
during O
storage O
and O
analytical O
periods O
. O

The O
validated O
method O
has O
been O
successfully O
applied O
to O
a O
pharmacokinetic O
study O
of O
evodiamine B
and O
evodine O
in O
beagle O
dogs O
after O
oral O
administration O
. O

A O
new O
alkaloid O
was O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
the O
culture O
of O
a O
termite O
- O
associated O
Streptomyces O
koyangensis O
BY O
- O
4 O
. O

Two O
new O
triterpenoids B
from O
the O
fungus O
Perenniporia O
maackiae O
. O

Two O
new O
triterpenoids B
, O
3 O
beta O
- O
( O
2 O
- O
methoxy O
- O
oxalyloxy O
) O
- O
24 O
- O
methylene O
- O
lanost O
- O
8 O
- O
en O
- O
21 O
- O
oic O
acid O
( O
1 O
) O
and O
3 O
beta O
- O
( O
2 O
- O
methoxy O
- O
oxalyloxy O
) O
- O
15 O
alpha O
- O
hydroxy O
- O
24 O
- O
methylene O
- O
lanost O
- O
8 O
- O
en O
- O
21 O
- O
oic O
acid O
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Perenniporia O
maackiae O
, O
together O
with O
two O
previously O
known O
triterpenoids B
( O
3 O
and O
4 O
) O

Three O
new O
norlignans O
, O
glechomols O
A O
- O
C O
( O
1 O
- O
3 O
, O
respectively O
) O
, O
together O
with O
a O
known O
compound O
, O
4 O
- O
ethylcatechol O
( O
4 O
) O
, O
were O
isolated O
from O
the O
ethyl B
acetate I
extract O
of O
Glechoma O
longituba O
( O
NaKai O
) O
Kupr O
. O

Intracellular O
antioxidant O
assays O
showed O
that O
compounds O
1 O
- O
4 O
displayed O
significant O
protective O
effects O
on O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
induced O
cardiac O
cell O
injury O
. O

The O
aggregation O
and O
interfacial O
behavior O
of O
mixtures O
of O
anionic O
( O
sodium O
dodecylsulfate O
, O
SDS B
) O
and O
cationic O
( O
dodecylammonium O
bromide O
, O
DTAB O
) O
surfactants O
were O
investigated O
. O

A O
room O
- O
temperature O
ionic O
liquid O
( O
IL O
) O
was O
explored O
as O
a O
solvent O
for O
the O
SDS B
/ O
DTAB O
system O
and O
compared O
to O
water O
. O

Our O
experiments O
showed O
nearly O
ideal O
mixing O
of O
SDS B
/ O
DTAB O
over O
the O
entire O
composition O
range O
and O
suggest O
that O
charge O
screening O
is O
prominent O
in O
ILs O
. O

It O
was O
found O
that O
the O
addition O
of O
gelatin O
methacrylate B
( O
GelMA O
) O
into O
HA O
methacrylate B
( O
HAMA O
) O
promoted O
cell O
spreading O
in O
the O
hybrid O
hydogels O
. O

Laponite O
nanodisks O
as O
an O
efficient O
platform O
for O
Doxorubicin B
delivery O
to O
cancer O
cells O
. O

We O
report O
a O
facile O
approach O
to O
using O
laponite O
( O
LAP O
) O
nanodisks O
as O
a O
platform O
for O
efficient O
delivery O
of O
doxorubicin B
( O
DOX B
) O
to O
cancer O
cells O
. O

In O
this O
study O
, O
DOX B
was O
encapsulated O
into O
the O
interlayer O
space O
of O
LAP O
through O
an O
ionic O
exchange O
process O
with O
an O
exceptionally O
high O
loading O
efficiency O
of O
98 O
. O
3 O
+ O
/ O
- O
0 O
. O
77 O
% O
. O

The O
successful O
DOX B
loading O
was O
extensively O
characterized O
via O
different O
methods O
. O

In O
vitro O
drug O
release O
study O
shows O
that O
the O
release O
of O
DOX B
from O
LAP O
/ O
DOX B
nanodisks O
is O
pH O
- O
dependent O
, O
and O
DOX B
is O
released O
at O
a O
quicker O
rate O
at O
acidic O
pH O
condition O
( O
pH O
= O
5 O
. O
4 O
) O
than O
at O
physiological O
pH O
condition O
. O

Importantly O
, O
cell O
viability O
assay O
results O
reveal O
that O
LAP O
/ O
DOX B
nanodisks O
display O
a O
much O
higher O
therapeutic O
efficacy O
in O
inhibiting O
the O
growth O
of O
a O
model O
cancer O
cell O
line O
( O
human O
epithelial O
carcinoma O
cells O
, O
KB O
cells O
) O
than O
free O
DOX B
drug O
at O
the O
same O
DOX B
concentration O
. O

The O
enhanced O
antitumor O
efficacy O
is O
primarily O
due O
to O
the O
much O
more O
cellular O
uptake O
of O
the O
LAP O
/ O
DOX B
nanodisks O
than O
that O
of O
free O
DOX B
, O
which O
has O
been O
confirmed O
by O
confocal O
laser O
scanning O
microscope O
and O
flow O
cytometry O
analysis O
. O

The O
high O
DOX B
payload O
and O
enhanced O
antitumor O
efficacy O
render O
LAP O
nanodisks O
as O
a O
robust O
carrier O
system O
for O
different O
biomedical O
applications O
. O

Danshen O
mediates O
through O
estrogen B
receptors O
to O
activate O
Akt O
and O
inhibit O
apoptosis O
effect O
of O
Leu27IGF O
- O
II O
- O
induced O
IGF O
- O
II O
receptor O
signaling O
activation O
in O
cardiomyoblasts O
. O

Danshen O
possesses O
lipid O
- O
soluble O
biologically O
active O
components O
with O
a O
structure O
similar O
to O
17 B
beta I
- I
estrodiol I
( O
E2 O
) O
. O

Cardiomyoblast O
cells O
pretreated O
with O
Fulvestrant B
( O
ICI B
182 I
, I
780 I
) O
, O
an O
estrogen B
receptor O
antagonist O
was O
applied O
to O
investigate O
the O
estrogenic O
activity O
of O
Danshen O
. O

We O
found O
that O
Danshen O
extract O
treatments O
significantly O
enhanced O
phosphorylated O
Akt O
through O
estrogen B
receptor O
activation O
to O
inhibit O
Leu27IGF O
- O
II O
- O
induced O
calcineurin O
activation O
and O
block O
H9c2 O
cell O
apoptosis O
. O

However O
, O
the O
cardioprotective O
properties O
of O
Danshen O
to O
inhibit O
Leu27IGF O
- O
II O
- O
induced O
cell O
apoptosis O
and O
promote O
cell O
survival O
were O
attenuated O
by O
applying O
ICI O
, O
which O
suggests O
that O
the O
Danshen O
cardioprotective O
effect O
is O
mediated O
through O
estrogen B
receptors O
. O

All O
our O
data O
indicated O
that O
Danshen O
exerts O
strong O
estrogenic O
activity O
which O
can O
be O
considered O
a O
novel O
selective O
estrogen B
receptor O
modulator O
( O
SERM O
) O
against O
IGF2R O
signaling O
that O
blocks O
cardiac O
apoptosis O
. O

Approach O
to O
distribution O
and O
accumulation O
of O
dibutyl B
phthalate I
in O
rats O
by O
immunoassay O
. O

Dibutyl B
phthalate I
( O
DBP O
) O
is O
mainly O
taken O
up O
by O
the O
general O
population O
from O
food O
intake O
. O

To O
estimate O
intake O
of O
phthalates B
, O
determining O
distribution O
and O
accumulation O
of O
DBP O
in O
biological O
materials O
was O
a O
critical O
need O
. O

Integrating O
clinical O
pharmacology O
concepts O
in O
individualized O
therapy O
with O
tyrosine B
kinase O
inhibitors O
. O

Tyrosine B
kinases O
have O
emerged O
as O
important O
tumor O
targets O
for O
the O
design O
of O
potent O
and O
selective O
inhibitors O
. O

Eighteen O
of O
these O
tyrosine B
kinase O
inhibitors O
( O
TKIs O
) O
have O
already O
been O
approved O
for O
the O
treatment O
of O
diseases O
that O
were O
previously O
essentially O
resistant O
to O
standard O
chemotherapy O
. O

Uncharged O
( O
polyethylene B
glycol I
; O
PEG B
) O
, O
positively O
charged O
( O
amino B
- O
terminated O
: O
NH2 B
) O
and O
negatively O
charged O
( O
carboxyl B
- O
modified O
; O
COOH B
) O
cadmium O
selenide O
/ O
zinc O
sulfide O
quantum O
dots O
were O
used O
to O
monitor O
ingestion O
, O
uptake O
and O
depuration O
of O
nanometals O
in O
Daphnia O
magna O
and O
Ceriodaphnia O
dubia O
over O
24h O
of O
exposure O
. O

These O
studies O
demonstrated O
that O
particles O
with O
higher O
negative O
charge O
( O
COOH B
quantum O
dots O
) O
were O
taken O
up O
to O
a O
greater O
extent O
by O
Daphnia O
( O
259 O
. O
17 O
+ O
/ O
- O
17 O
. O
70 O
RFU O
/ O
20 O
Daphnia O
) O
than O
either O
the O
NH2 B
( O
150 O
. O
01 O
+ O
/ O
- O
18 O
. O
91 O
) O
or O
PEG B
quantum O
dots O
( O
95 O
. O
17 O
+ O
/ O
- O
9 O
. O
78 O
) O
, O
however O
this O
is O
likely O
related O
to O
the O
functional O
groups O
attached O
to O
the O
nanoparticles O
as O
there O
were O
no O
real O
differences O
in O
zeta O
potential O
. O

A O
kavalactone O
derivative O
inhibits O
lipopolysaccharide O
- O
stimulated O
iNOS O
induction O
and O
NO B
production O
through O
activation O
of O
Nrf2 O
signaling O
in O
BV2 O
microglial O
cells O
. O

In O
BV2 O
microglial O
cells O
, O
compound O
1 O
strongly O
inhibited O
LPS O
- O
stimulated O
iNOS O
induction O
and O
NO B
production O
, O
but O
did O
not O
affect O
LPS O
- O
stimulated O
induction O
of O
COX2 O
. O

At O
6h O
after O
LPS O
challenge O
, O
when O
iNOS O
induction O
was O
not O
clearly O
seen O
, O
treatment O
with O
LPS O
or O
compound O
1 O
alone O
increased O
expression O
of O
heme B
oxygenase O
1 O
( O
HO O
- O
1 O
) O
whose O
transcription O
is O
regulated O
by O
Nrf2 O
. O

The O
mechanism O
by O
which O
compound O
1 O
activated O
Nrf2 O
signaling O
was O
supposed O
to O
be O
a O
covalent O
modification O
of O
the O
sulfhydryl B
groups O
of O
Keap1 O
by O
an O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
group O
present O
in O
the O
compound O
1 O
. O

Treatment O
with O
hemin O
, O
a O
HO O
- O
1 O
inducer O
, O
and O
with O
[ O
Ru O
( O
CO O
) O
3Cl2 O
] O
2 O
, O
a O
CO B
donor O
, O
decreased O
LPS O
- O
stimulated O
iNOS O
induction O
and O
NO B
production O
. O

In O
contrast O
, O
siRNA O
- O
mediated O
knockdown O
of O
HO O
- O
1 O
expression O
reduced O
the O
inhibitory O
effect O
of O
compound O
1 O
on O
LPS O
- O
stimulated O
iNOS O
induction O
and O
NO B
production O
. O

Finally O
, O
compound O
1 O
suppressed O
LPS O
/ O
IFN O
- O
gamma O
- O
stimulated O
NO B
production O
in O
primary O
microglial O
cells O
. O

These O
results O
suggest O
that O
compound O
1 O
is O
capable O
of O
inhibiting O
LPS O
- O
stimulated O
iNOS O
induction O
and O
NO B
production O
via O
activation O
of O
Nrf2 O
signaling O
and O
HO O
- O
1 O
induction O
in O
microglial O
cells O
. O

Effects O
of O
phosphate B
buffer O
in O
parenteral O
drugs O
on O
particle O
formation O
from O
glass O
vials O
. O

The O
characteristics O
of O
inorganic O
particles O
generated O
in O
glass O
vials O
filled O
with O
phosphate B
buffer O
solutions O
were O
investigated O
. O

During O
storage O
, O
particles O
were O
visually O
detected O
in O
the O
phosphate B
buffer O
solution O
in O
particular O
glass O
vials O
which O
pass O
compendial O
tests O
of O
containers O
for O
injectable O
drugs O
. O

These O
particles O
were O
considered O
to O
be O
different O
from O
ordinal O
glass O
delamination O
, O
which O
has O
been O
reported O
in O
a O
number O
of O
papers O
because O
the O
particles O
were O
mainly O
composed O
of O
Al B
, O
P B
and O
O B
, O
but O
not O
Si B
. O

Among O
the O
surface O
treatments O
tested O
for O
the O
glass O
vials O
, O
sulfur B
treatment O
showed O
a O
protective O
effect O
on O
the O
particle O
formation O
in O
the O
vials O
, O
whereas O
the O
SiO2 B
coating O
did O
not O
have O
any O
protective O
effects O
. O

It O
was O
found O
that O
the O
elution O
ratio O
of O
Al B
and O
Si B
in O
the O
solution O
stored O
in O
the O
glass O
vials O
after O
the O
heating O
was O
similar O
to O
the O
ratio O
of O
Al B
and O
Si B
in O
borosilicate B
glass O
. O

However O
, O
the O
Al B
concentration O
decreased O
during O
storage O
( O
5 O
degrees O
C O
, O
6 O
months O
) O
, O
and O
consequently O
, O
particle O
formation O
was O
observed O
in O
the O
solution O
. O

Adding O
citrate B
, O
which O
is O
a O
chelating O
agent O
for O
Al B
, O
effectively O
suppressed O
the O
particle O
formation O
in O
the O
heated O
solution O
. O

When O
50 O
ppb O
and O
higher O
concentrations O
of O
Al B
ion O
were O
added O
to O
the O
phosphate B
buffer O
solution O
, O
the O
formation O
of O
white O
particles O
containing O
Al B
, O
P B
and O
O B
was O
detected O
. O

It O
is O
suggested O
that O
a O
phosphate B
buffer O
solution O
in O
a O
borosilicate B
glass O
vial O
has O
the O
ability O
to O
form O
particles O
due O
to O
interactions O
with O
the O
Al B
that O
is O
eluted O
from O
the O
glass O
during O
storage O
. O

Microengineered O
PEG B
Hydrogels O
: O
3D O
Scaffolds O
for O
Guided O
Cell O
Growth O
. O

Co O
- O
delivery O
of O
10 O
- O
Hydroxycamptothecin O
with O
Doxorubicin B
Conjugated O
Prodrugs O
for O
Enhanced O
Anticancer O
Efficacy O
. O

Well O
- O
defined O
amphiphilic O
linear O
- O
dendritic O
prodrugs O
( O
MPEG O
- O
b O
- O
PAMAM O
- O
DOX O
) O
are O
synthesized O
by O
conjugating O
doxorubicin B
( O
DOX B
) O
, O
to O
MPEG O
- O
b O
- O
PAMAM O
through O
the O
acid O
- O
labile O
hydrazone B
bond O
. O

In O
vitro O
methyl O
thiazolyl O
tetrazolium O
( O
MTT B
) O
assays O
and O
drug O
- O
induced O
apoptosis O
tests O
demonstrate O
the O
HCPT O
- O
loaded O
nanoparticles O
suppress O
cancer O
cell O
growth O
more O
efficiently O
than O
the O
MPEG O
- O
b O
- O
PAMAM O
- O
DOX O
prodrugs O
, O
free O
HCPT O
, O
and O
physical O
mixtures O
of O
MPEG O
- O
b O
- O
PAMAM O
- O
DOX O
and O
HCPT O
at O
equivalent O
DOX B
or O
HCPT O
doses O
. O

Virtual O
screening O
was O
performed O
involving O
a O
total O
of O
13 O
, O
341 O
small O
compounds O
, O
with O
the O
backbone O
structures O
of O
chalcone B
, O
flavanone O
and O
flavone B
, O
available O
from O
the O
ZINC O
database O
. O

Periodate O
oxidation O
of O
NCC O
can O
augment O
reactive O
carbonyl B
groups O
on O
NCC O
and O
facilitate O
its O
cross O
- O
linking O
with O
fibrin O
. O

The O
pharmacokinetics O
and O
conversion O
of O
the O
lactone B
to O
the O
carboxylate B
forms O
of O
ginkgolide O
B O
in O
rat O
plasma O
. O

Ginkgolide O
B O
consists O
of O
three O
lactone B
groups O
, O
which O
may O
undergo O
hydrolysis O
, O
and O
lead O
to O
the O
rings O
opening O
in O
aqueous O
solution O
with O
different O
pHs O
. O

From O
mechanisms O
of O
pharmacological O
activity O
in O
vivo O
, O
the O
lactone B
appears O
to O
be O
the O
active O
form O
of O
the O
drug O
. O

Pharmacokinetics O
of O
lactone B
form O
( O
GB O
- O
lac O
) O
and O
the O
total O
of O
the O
lactone B
and O
carboxylate B
form O
( O
GB O
- O
tot O
) O
of O
ginkgolide O
B O
were O
investigated O
after O
intravenous O
administration O
of O
a O
dose O
of O
4 O
mg O
/ O
kg O
ginkgolide O
B O
. O

The O
rate O
of O
lactone B
hydrolysis O
was O
also O
studied O
in O
plasma O
in O
vitro O
. O

After O
intravenous O
administration O
, O
ginkgolide O
B O
in O
the O
original O
form O
was O
converted O
to O
its O
carboxylate B
form O
under O
simulated O
physiological O
conditions O
. O

The O
ratio O
of O
average O
cumulation O
of O
excretion O
of O
lactone B
to O
carboxylate B
reached O
approximately O
1 O
to O
1 O
in O
urine O
. O

From O
the O
equilibrium O
of O
lactone B
hydrolysis O
in O
rat O
plasma O
in O
vitro O
, O
the O
k O
obs O
was O
- O
0 O
. O
0176 O
min O
( O
- O
1 O
) O
and O
t O
1 O
/ O
2 O
was O
39 O
. O
38 O
min O
. O

In O
conclusion O
, O
the O
equilibrium O
existed O
between O
lactone B
of O
ginkgolide O
B O
and O
its O
carboxylate B
form O
in O
vivo O
at O
physiological O
pH O
, O
which O
suggested O
that O
more O
attention O
should O
be O
focused O
on O
the O
original O
and O
the O
ionization O
forms O
of O
ginkgolide O
B O
and O
the O
conversion O
of O
the O
lactone B
into O
carboxylate B
in O
vivo O
. O

The O
molecular O
orientation O
and O
dynamics O
of O
di O
- O
t O
- O
butylnitroxide O
( O
DTBN O
) O
and O
4 O
- O
oxo O
- O
2 O
, O
2 O
, O
6 O
, O
6 O
- O
tetramethyl O
- O
1 O
- O
piperidinyl O
- O
1 O
- O
oxyl O
( O
TEMPONE O
) O
radicals O
in O
the O
organic O
1D O
nanochannels O
of O
tris O
( O
o O
- O
phenylenedioxy O
) O
cyclotriphosphazene O
( O
TPP B
) O
were O
investigated O
by O
examining O
inclusion O
compounds O
( O
ICs O
) O
diluted O
by O
the O
co O
- O
inclusion O
of O
nonradicals O
using O
electron O
spin O
resonance O
( O

Spectral O
simulation O
showed O
that O
the O
axial O
rotation O
of O
DTBN O
or O
TEMPONE O
molecules O
is O
excited O
in O
TPP B
nanochannels O
with O
activation O
energies O
of O
3 O
and O
10 O
kJ O
mol O
( O
- O
1 O
) O
, O
respectively O
. O

The O
rotation O
axes O
for O
both O
DTBN O
and O
TEMPONE O
were O
determined O
to O
be O
almost O
parallel O
to O
the O
principal O
y O
- O
axis O
of O
the O
g O
tensor O
, O
which O
agrees O
with O
the O
result O
reported O
for O
2 O
, O
2 O
, O
6 O
, O
6 O
- O
tetramethyl O
- O
1 O
- O
piperidinyl O
- O
1 O
- O
oxyl O
( O
TEMPO B
) O
in O
TPP B
nanochannels O
, O
which O
has O
the O
activation O
energy O
of O
5 O
kJ O
mol O
( O
- O
1 O
) O
. O

These O
results O
indicate O
that O
the O
molecular O
orientations O
of O
guest O
nitroxide B
radicals O
are O
almost O
independent O
of O
the O
molecular O
sizes O
of O
the O
guest O
radicals O
in O
TPP B
nanochannels O
, O
although O
the O
molecular O
dynamics O
are O
dependent O
on O
the O
molecular O
sizes O
. O

We O
demonstrated O
previously O
that O
monocytes O
and O
macrophages O
are O
target O
cells O
for O
the O
Rho O
- O
modifying O
Clostridium O
botulinum O
C3 O
ADP B
- O
ribosyltransferase O
. O

Here O
, O
we O
report O
the O
construction O
, O
expression O
and O
characterization O
of O
a O
recombinant O
streptavidin O
- O
C3 O
fusion O
protein O
which O
allows O
for O
delivery O
of O
biotin B
- O
labelled O
molecules O
into O
the O
cytosol O
of O
macrophages O
via O
enzymatically O
inactive O
C3bot1E174Q O
. O

Exposure O
of O
cardiac O
cells O
to O
palmitate O
increased O
apoptosis O
by O
activating O
NADPH B
oxidase O
- O
associated O
nitrosative O
stress O
and O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
, O
which O
abolished O
by O
pretreatment O
with O
SDF O
- O
1 O
beta O
via O
up O
- O
regulation O
of O
AMPK O
- O
mediated O
p38 O
MAPK O
phosphorylation O
and O
IL O
- O
6 O
production O
. O

Administration O
of O
SDF O
- O
1 O
beta O
to O
diabetic O
rats O
, O
induced O
by O
high O
- O
fat O
- O
diet O
feeding O
with O
a O
small O
dose O
of O
streptozotocin B
, O
could O
significantly O
reduce O
cardiac O
apoptosis O
and O
increase O
in O
AMPK O
phosphorylation O
along O
with O
a O
prevention O
of O
diabetes O
- O
induced O
cardiac O
oxidative O
damage O
, O
inflammation O
, O
hypertrophy O
and O
remodeling O
. O

These O
results O
showed O
that O
SDF O
- O
1 O
beta O
protects O
palmitate O
- O
induced O
cardiac O
apoptosis O
, O
which O
is O
mediated O
by O
NADPH B
oxidase O
- O
activated O
nitrosative O
damage O
and O
ER O
stress O
, O
via O
CXCR7 O
to O
activate O
AMPK O
/ O
p38 O
MAPK O
- O
mediated O
IL O
- O
6 O
generation O
. O

Modulation O
of O
cytochrome O
P450 O
1 O
( O
Cyp1 O
) O
by O
vanadium B
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL O
/ O
6 O
mice O
. O

The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium B
( O
V O
( O
5 O
+ O
) O
) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL O
/ O
6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O

For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V O
( O
5 O
+ O
) O
( O
5 O
mg O
/ O
kg O
) O
in O
the O
absence O
and O
presence O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
( O
15 O
mu O
g O
/ O
kg O
) O
for O
6 O
and O
24 O
h O
. O

Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V O
( O
5 O
+ O
) O
( O
5 O
, O
10 O
, O
and O
20 O
mu O
M O
) O
in O
the O
absence O
and O
presence O
of O
TCDD B
( O
1 O
nM O
) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O

Upon O
co O
- O
exposure O
to O
V O
( O
5 O
+ O
) O
and O
TCDD B
, O
V O
( O
5 O
+ O
) O
significantly O
potentiated O
the O
TCDD B
- O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O

In O
vitro O
, O
V O
( O
5 O
+ O
) O
decreased O
the O
TCDD B
- O
mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O

Furthermore O
, O
V O
( O
5 O
+ O
) O
significantly O
inhibited O
the O
TCDD B
- O
induced O
AhR O
- O
dependent O
luciferase O
activity O
. O

Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD B
, O
there O
was O
an O
increase O
in O
the O
AhR O
- O
dependent O
luciferase O
activity O
. O

When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V O
( O
5 O
+ O
) O
in O
the O
presence O
of O
TCDD B
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD B
- O
mediated O
effect O
. O

Since O
haemoglobin O
adducts O
are O
formed O
by O
the O
same O
pathway O
( O
N B
- O
hydroxylation O
) O
as O
the O
ultimate O
carcinogens O
from O
2NA O
, O
the O
comparison O
of O
adduct O
concentrations O
after O
2NA O
and O
P2NA O
dosage O
permits O
a O
quantitative O
estimate O
of O
the O
carcinogenicity O
of O
P2NA O
. O

Effect O
of O
bisphenol B
- I
A I
on O
insulin O
signal O
transduction O
and O
glucose B
oxidation O
in O
skeletal O
muscle O
of O
adult O
male O
albino O
rat O
. O

The O
estrogenic O
monomer O
bisphenol B
- I
A I
( O
BPA B
) O
is O
an O
endocrine O
- O
disrupting O
chemical O
used O
in O
the O
production O
of O
epoxy B
resins O
, O
plastic O
food O
and O
beverage O
containers O
, O
leading O
to O
ubiquitous O
human O
exposure O
. O

Environmentally O
relevant O
doses O
of O
BPA B
have O
profound O
effects O
on O
mice O
endocrine O
pancreas O
. O

Skeletal O
muscle O
plays O
a O
crucial O
role O
in O
maintaining O
systemic O
glucose B
metabolism O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
possible O
effects O
of O
BPA B
on O
insulin O
- O
signaling O
molecules O
and O
glucose B
oxidation O
in O
skeletal O
muscle O
of O
male O
rat O
. O

Group O
I O
: O
control O
( O
vehicle O
treated O
) O
and O
groups O
II O
and O
III O
were O
administered O
with O
BPA B
orally O
( O
20 O
and O
200 O
mg O
/ O
kg O
bw O
/ O
day O
, O
respectively O
) O
. O

Although O
there O
was O
no O
change O
in O
the O
levels O
of O
insulin O
receptor O
( O
IR O
) O
, O
Akt O
( O
protein O
kinase O
B O
) O
and O
glucose B
transporter O
- O
4 O
( O
GLUT4 O
) O
messenger O
RNA O
, O
BPA B
significantly O
decreased O
the O
IR O
, O
Akt O
and O
GLUT4 O
protein O
levels O
( O
both O
plasma O
membrane O
and O
cytosolic O
fraction O
) O
of O
the O
gastrocnemius O
muscle O
. O

There O
was O
an O
increase O
in O
serum O
insulin O
and O
decrease O
in O
serum O
testosterone B
levels O
but O
fasting O
blood O
glucose B
level O
remained O
unaltered O
. O

In O
conclusion O
, O
BPA B
has O
adverse O
effects O
on O
phosphorylation O
of O
Akt O
, O
GLUT4 O
translocation O
and O
( B
14 I
) I
C I
- I
glucose I
oxidation O
. O

Artemisinins B
combination O
therapy O
( O
ACT O
) O
is O
the O
first O
choice O
therapy O
for O
falciparum O
malaria O
. O

Rutin B
has O
been O
enzymatically O
oligomerized O
by O
laccase O
from O
Trametes O
versicolor O
. O

Five O
fractions O
of O
oligomers O
were O
obtained O
from O
the O
monomers O
having O
high O
solubility O
in O
water O
, O
which O
can O
reach O
351 O
- O
times O
that O
of O
rutin B
. O

Cytotoxicity O
of O
rutin B
and O
oligorutin O
fractions O
was O
evaluated O
towards O
K562 O
cells O
. O

The O
genotoxic O
potential O
of O
rutin B
and O
oligorutin O
fractions O
was O
assessed O
, O
at O
the O
limit O
of O
the O
solubility O
of O
each O
molecule O
, O
using O
the O
comet O
test O
. O

None O
of O
the O
tested O
concentrations O
of O
either O
rutin B
or O
oligorutin O
fractions O
has O
showed O
a O
genotoxic O
effect O
. O

Similarly O
, O
the O
antigenotoxic O
effect O
of O
these O
flavonoids B
was O
tested O
using O
the O
same O
assay O
. O

The O
obtained O
results O
showed O
a O
higher O
ability O
of O
oligorutin O
fractions O
to O
reduce O
the O
genotoxicity O
induced O
by O
hydrogen B
peroxide I
compared O
with O
monomeric O
rutin B
. O

In O
this O
work O
we O
report O
on O
the O
preparation O
, O
characterization O
, O
and O
properties O
of O
a O
thermally O
treated O
lignin O
- O
derived O
, O
phenolic O
- O
rich O
fraction O
( O
PRF O
) O
of O
wood O
pyrolysis O
bio O
- O
oil O
obtained O
by O
ethyl B
acetate I
extraction O
. O

These O
rotational O
constants O
along O
with O
those O
of O
the O
( B
13 I
) I
C I
, O
( B
15 I
) I
N I
, O
and O
D1 O
species O
were O
used O
together O
with O
vibration O
- O
rotation O
constants O
calculated O
from O
a O
cubic O
force O
field O
calculated O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
( O
3df O
, O
2pd O
) O
level O
of O
theory O
to O
derive O
a O
semiexperimental O
equilibrium O
structure O
. O

In O
this O
study O
, O
we O
investigated O
the O
antinociceptive O
effect O
of O
7 O
- O
methoxyflavone O
( O
7MF O
) O
in O
mice O
using O
the O
following O
tests O
: O
acetic B
acid I
- O
induced O
writhing O
, O
glutamate B
- O
and O
formalin B
- O
induced O
nociception O
and O
hotplate O
. O

7MF O
treatment O
( O
100 O
mu O
mol O
/ O
kg O
, O
i O
. O
p O
. O
) O
inhibited O
paw O
- O
licking O
time O
in O
the O
neurogenic O
phase O
of O
the O
formalin B
pain O
response O
( O
65 O
. O
6 O
% O
) O
and O
did O
not O
decrease O
the O
nociceptive O
response O
in O
the O
inflammatory O
phase O
. O

In O
addition O
, O
in O
glutamate B
- O
induced O
nociception O
, O
7MF O
inhibited O
26 O
% O
of O
the O
nociceptive O
answer O
. O

Tetraarylmethane O
compounds O
consisting O
of O
two O
pyrogallol O
and O
two O
aniline B
units O
, O
namely O
, O
Ar2CAr O
' O
2 O
{ O
Ar O
= O
3 O
, O
4 O
, O
5 O
- O
C6H2 O
( O
OH O
) O
3 O
and O
Ar O
' O
= O
3 O
, O
5 O
- O
R2 O
- O
4 O
- O
C6H2NH2 O
[ O
R O
= O
Me O
( O
1 O
) O
, O
iPr O
( O
2 O
) O
] O
} O
exhibit O
excellent O
self O
- O
assembly O
behavior O
. O

Compound O
1 O
yields O
size O
- O
tunable O
hollow O
nanospheres O
( O
HNSs O
) O
with O
a O
narrow O
size O
distribution O
, O
and O
2 O
yields O
various O
morphologies O
ranging O
from O
microtubules O
to O
microrods O
via O
self O
- O
assembly O
induced O
by O
hydrogen B
bonding O
and O
pi O
- O
pi O
stacking O
interactions O
. O

As O
a O
means O
of O
utilizing O
the O
self O
- O
assembled O
HNSs O
for O
targeting O
controlled O
drug O
delivery O
, O
folic B
acid I
( O
FA O
) O
and O
rhodamine B
6G I
( O
Rh6G B
) O
were O
grafted O
onto O
compound O
1 O
to O
yield O
the O
FA O
- O
Rh6G O
- O
1 O
complex O
. O

The O
HNSs O
fabricated O
with O
FA O
- O
Rh6G O
- O
1 O
showed O
low O
cytotoxicity O
against O
human O
embryonic O
kidney O
293T O
cells O
and O
CT26 O
colon O
carcinoma O
cells O
and O
good O
doxorubicin B
( O
DOX B
) O
loading O
capacity O
( O
9 O
. O
6 O
wt O
% O
) O
. O

In O
vitro O
drug O
delivery O
tests O
showed O
that O
the O
DOX B
molecules O
were O
released O
from O
the O
resulting O
HNSs O
in O
a O
sustainable O
and O
pH O
- O
dependent O
manner O
, O
demonstrating O
a O
potential O
application O
for O
HNSs O
in O
targeted O
drug O
delivery O
for O
cancer O
therapy O
. O

Chemical O
synthesis O
of O
Nd2Fe14B O
nanoparticles O
is O
challenging O
due O
to O
the O
large O
reduction O
potential O
of O
Nd B
( I
3 I
+ I
) I
and O
the O
high O
tendency O
for O
Nd2Fe14B O
oxidation O
. O

The O
process O
consisted O
of O
Nd O
- O
Fe O
- O
B O
mixed O
oxide B
preparation O
by O
microwave O
assisted O
combustion O
, O
followed O
by O
the O
reduction O
of O
the O
mixed O
oxide B
by O
CaH2 O
. O

After O
removal O
of O
CaO B
by O
washing O
, O
saturation O
magnetization O
increased O
and O
an O
energy O
product O
of O
3 O
. O
57 O
MGOe O
was O
obtained O
. O

A O
range O
of O
magnetic O
properties O
was O
obtained O
by O
varying O
the O
microwave O
power O
, O
reduction O
temperature O
and O
Nd B
to O
Fe B
ratio O
. O

Acyl B
- I
CoA I
Synthetase O
1 O
Is O
Induced O
by O
Gram O
- O
negative O
Bacteria O
and O
Lipopolysaccharide O
and O
Is O
Required O
for O
Phospholipid O
Turnover O
in O
Stimulated O
Macrophages O
. O

The O
enzyme O
acyl B
- I
CoA I
synthetase O
1 O
( O
ACSL1 O
) O
is O
induced O
by O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
( O
PPAR O
alpha O
) O
and O
PPAR O
gamma O
in O
insulin O
target O
tissues O
, O
such O
as O
skeletal O
muscle O
and O
adipose O
tissue O
, O
and O
plays O
an O
important O
role O
in O
beta O
- O
oxidation O
in O
these O
tissues O
. O

Epoxieicosatrienoic O
acids O
( O
EETs B
) O
play O
a O
protective O
role O
against O
damaging O
processes O
in O
the O
kidney O
. O

We O
have O
assessed O
the O
effect O
of O
polymorphisms O
in O
EETs B
- O
producing O
enzymes O
( O
CYP2C8 O
and O
CYP2J2 O
) O
and O
other O
proteins O
involved O
in O
calcineurin O
inhibitors O
( O
CNIs O
) O
disposition O
( O
CYP3A4 O
, O
CYP3A5 O
, O
and O
ABCB1 O
) O
on O
graft O
function O
and O
clinical O
outcome O
in O
166 O
renal O
transplant O
recipients O
treated O
with O
CNIs O
. O

Both O
CYP2C8 O
* O
3 O
and O
donor O
age O
greater O
than O
48 O
years O
were O
associated O
to O
a O
higher O
incidence O
of O
delayed O
graft O
function O
( O
DGF O
) O
[ O
OR O
= O
2 O
. O
01 O
( O
1 O
. O
1 O
- O
4 O
. O
1 O
) O
, O
P O
= O
. O
04 O
and O
5 O
. O
14 O
( O
2 O
. O
4 O
- O
10 O
. O
9 O
) O
, O
P O
< O
. O
0001 O
; O
respectively O
] O
and O
worse O
creatinine B
clearance O
1 O
year O
after O
grafting O
( O
P O
< O
. O
05 O
and O
P O
< O
. O
001 O
, O
respectively O
) O
. O

Carrying O
the O
2C8 O
* O
3 O
allele O
and O
having O
a O
donor O
older O
than O
48 O
years O
was O
defined O
as O
a O
high O
- O
risk O
status O
and O
observed O
to O
be O
highly O
related O
to O
DGF O
[ O
OR O
= O
3 O
. O
91 O
( O
1 O
. O
46 O
- O
10 O
. O
48 O
) O
, O
P O
< O
. O
01 O
] O
and O
worse O
creatinine B
clearance O
( O
P O
= O
. O
033 O
) O
. O

Dissecting O
the O
roles O
of O
the O
N B
- O
and O
C B
- O
flanking O
residues O
of O
acetyllysine O
substrates O
for O
SIRT1 O
activity O
. O

Kinetic O
analysis O
of O
SIRT1 O
with O
a O
panel O
of O
peptide O
substrates O
shows O
the O
high O
importance O
of O
the O
region O
N B
- O
flanking O
the O
target O
acetyllysine O
and O
its O
high O
conservation O
through O
evolution O
. O

Chromatin O
Remodeling O
by O
Rosuvastatin B
Normalizes O
TSC2 O
- O
/ O
meth O
Cell O
Phenotype O
through O
the O
Expression O
of O
Tuberin O
. O

Statins O
inhibit O
3 O
- O
hydroxy O
- O
3 O
- O
methylglutaryl O
coenzyme O
A O
reductase O
and O
block O
the O
synthesis O
of O
isoprenoid B
lipids O
with O
inhibition O
of O
Rheb O
farnesylation O
and O
RhoA O
geranylgeranylation O
. O

The O
effects O
of O
rosuvastatin B
on O
the O
function O
of O
human O
TSC2 O
( O
- O
/ O
- O
) O
and O
TSC2 O
( O
- O
/ O
meth O
) O
alpha O
- O
actin O
smooth O
muscle O
( O
ASM O
) O
cells O
have O
been O
investigated O
. O

Exposure O
to O
rosuvastatin B
affected O
TSC2 O
( O
- O
/ O
meth O
) O
ASM O
cell O
growth O
and O
promoted O
tuberin O
expression O
by O
acting O
as O
a O
demethylating O
agent O
. O

Rosuvastatin B
also O
reduced O
RhoA O
activation O
in O
TSC2 O
( O
- O
/ O
meth O
) O
ASM O
cells O
, O
and O
it O
required O
coadministration O
with O
the O
specific O
mTOR O
( O
mammalian O
target O
of O
rapamycin B
) O
inhibitor O
rapamycin B
to O
be O
effective O
in O
TSC2 O
( O
- O
/ O
- O
) O
ASM O
cells O
. O

Rapamycin B
enhanced O
rosuvastatin B
effect O
in O
inhibiting O
cell O
proliferation O
in O
TSC2 O
( O
- O
/ O
- O
) O
and O
TSC2 O
( O
- O
/ O
meth O
) O
ASM O
cells O
. O

Rosuvastatin B
alone O
did O
not O
alter O
phosphorylation O
of O
S6 O
and O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
, O
and O
at O
the O
higher O
concentration O
, O
rosuvastatin B
and O
rapamycin B
slightly O
decreased O
ERK O
phosphorylation O
. O

These O
results O
suggest O
that O
rosuvastatin B
may O
potentially O
represent O
a O
treatment O
adjunct O
to O
the O
therapy O
with O
mTOR O
inhibitors O
now O
in O
clinical O
development O
for O
TSC O
. O

In O
particular O
, O
rosuvastatin B
appears O
useful O
when O
the O
disease O
is O
originated O
by O
epigenetic O
defects O
. O

On O
the O
move O
: O
A O
novel O
PtCl2 O
- O
catalyzed O
tandem O
1 O
, O
6 O
- O
enyne O
cyclization O
/ O
1 B
, I
2 I
- I
acyloxy I
migration O
reaction O
was O
developed O
, O
which O
was O
shown O
to O
be O
controlled O
by O
substitution O
effects O
. O

A O
single O
gold O
microshell O
, O
which O
was O
elaborately O
fabricated O
to O
carry O
numerous O
hot O
spots O
on O
its O
own O
surface O
, O
enabled O
the O
acquisition O
of O
the O
SERS O
spectra O
from O
the O
molecules O
on O
non O
- O
SERS O
active O
substrates O
such O
as O
Si B
/ O
SiO2 B
, O
ITO B
, O
and O
glass O
. O

A O
self O
- O
assembled O
monolayer O
of O
11 O
- O
mercaptoundecanols O
on O
the O
gold O
microshell O
offered O
an O
easy O
and O
reliable O
way O
to O
electrically O
insulate O
from O
the O
underlying O
flat O
Pt B
electrode O
and O
accomplish O
in O
situ O
monitoring O
the O
electrochemical O
reaction O
with O
minimal O
interference O
. O

Acute O
waterborne O
copper B
toxicity O
to O
the O
euryhaline O
copepod O
Acartia O
tonsa O
at O
different O
salinities O
: O
Influence O
of O
natural O
freshwater O
and O
marine O
dissolved O
organic O
matter O
. O

The O
influence O
of O
natural O
dissolved O
organic O
matter O
( O
DOM O
) O
on O
acute O
waterborne O
Cu B
toxicity O
was O
evaluated O
in O
the O
euryhaline O
copepod O
Acartia O
tonsa O
at O
3 O
different O
water O
salinities O
. O

Different O
combinations O
of O
Cu B
concentrations O
and O
DOM O
sources O
and O
concentrations O
were O
tested O
at O
salinities O
of O
5 O
, O
15 O
, O
and O
30 O
ppt O
. O

Toxicity O
data O
( O
48 O
- O
h O
median O
lethal O
concentration O
[ O
LC50 O
] O
values O
) O
were O
calculated O
based O
on O
dissolved O
Cu B
concentrations O
. O

In O
a O
broad O
view O
, O
data O
showed O
that O
increasing O
salinity O
was O
protective O
against O
the O
acute O
waterborne O
Cu B
toxicity O
. O

In O
general O
, O
Cu B
toxicity O
was O
also O
lower O
in O
the O
presence O
than O
in O
the O
absence O
of O
DOM O
. O

Toxicity O
( O
48 O
- O
h O
LC50 O
) O
values O
from O
all O
treatments O
at O
the O
same O
salinity O
showed O
a O
positive O
linear O
relationship O
with O
the O
dissolved O
organic O
carbon B
( O
DOC O
) O
. O

Thus O
, O
the O
protective O
effect O
of O
DOM O
against O
the O
acute O
Cu B
toxicity O
seems O
to O
be O
dependent O
mainly O
on O
the O
DOM O
concentration O
. O

Crosslinking O
with O
glutaraldehyde B
results O
in O
stable O
gelatine O
nanoparticles O
. O

Furthermore O
, O
methanol B
and O
ethanol B
are O
good O
nonsolvents O
, O
whereas O
other O
nonsolvents O
such O
as O
acetone B
, O
isopropyl O
alcohol O
, O
and O
acetonitrile B
, O
result O
in O
phase O
separation O
and O
visible O
precipitates O
. O

The O
entrapment O
efficiency O
of O
fluorescein B
- I
isothiocyanate I
( O
FITC B
) O
- O
dextran O
as O
model O
drug O
was O
determined O
to O
50 O
% O
with O
no O
substantial O
effect O
on O
particle O
size O
. O

Since O
the O
discovery O
of O
electroluminescence O
in O
the O
phenyl B
- O
based O
conjugated O
polymers O
in O
1990 O
, O
the O
field O
of O
polymer O
optoelectronics O
has O
matured O
to O
the O
extent O
that O
presently O
a O
wide O
class O
of O
devices O
have O
been O
commercialized O
. O

The O
Adult O
Treatment O
Panel O
III O
criteria O
of O
the O
National O
Cholesterol B
Education O
Program O
were O
used O
for O
the O
definition O
of O
MetS O
. O

Particularly O
hypertriglyceridaemi O
, O
hypertension O
and O
fasting O
plasma O
glucose B
( O
FPG O
) O
seem O
to O
carry O
this O
association O
. O

Atorvastatin B
withdrawal O
elicits O
oxidative O
/ O
nitrosative O
damage O
in O
the O
rat O
cerebral O
cortex O
. O

Statins O
are O
inhibitors O
of O
the O
enzyme O
3 O
- O
hydroxy O
- O
3 O
- O
methylglutaryl O
coenzyme O
A O
reductase O
, O
the O
rate O
- O
limiting O
step O
in O
cholesterol B
biosynthesis O
. O

Statins O
effectively O
prevent O
and O
reduce O
the O
risk O
of O
coronary O
artery O
disease O
through O
lowering O
serum O
cholesterol B
, O
and O
also O
exert O
anti O
- O
thrombotic O
, O
anti O
- O
inflammatory O
and O
antioxidant O
effects O
independently O
of O
changes O
in O
cholesterol B
levels O
. O

In O
the O
present O
study O
adult O
male O
Wistar O
rats O
were O
treated O
with O
atorvastatin B
for O
seven O
days O
( O
10mg O
/ O
kg O
/ O
day O
) O
and O
neurochemical O
assays O
were O
performed O
in O
the O
cerebral O
cortex O
30min O
( O
atorvastatin B
treatment O
) O
or O
24h O
( O
atorvastatin B
withdrawal O
) O
after O
the O
last O
atorvastatin B
administration O
. O

We O
found O
that O
atorvastatin B
withdrawal O
decreased O
levels O
of O
nitric B
oxide I
and O
mitochondrial O
superoxide B
dismutase O
activity O
, O
whereas O
increased O
NADPH B
oxidase O
activity O
and O
immunoreactivity O
for O
the O
protein O
nitration O
marker O
3 B
- I
nitrotyrosine I
in O
the O
cerebral O
cortex O
. O

Catalase O
, O
glutathione B
- O
S B
- O
transferase O
and O
xanthine B
oxidase O
activities O
were O
not O
altered O
by O
atorvastatin B
treatment O
or O
withdrawal O
, O
as O
well O
as O
protein O
carbonyl B
and O
4 O
- O
hydroxy O
- O
2 O
- O
nonenal O
immunoreactivity O
. O

Immunoprecipitation O
of O
mitochondrial O
SOD O
followed O
by O
analysis O
of O
3 B
- I
nitrotyrosine I
revealed O
increased O
levels O
of O
nitrated O
mitochondrial O
SOD O
, O
suggesting O
the O
mechanism O
underlying O
the O
atorvastatin B
withdrawal O
- O
induced O
decrease O
in O
enzyme O
activity O
. O

Altogether O
, O
our O
results O
indicate O
the O
atorvastatin B
withdrawal O
elicits O
oxidative O
/ O
nitrosative O
damage O
in O
the O
rat O
cerebral O
cortex O
, O
and O
that O
changes O
in O
NADPH B
oxidase O
activity O
and O
mitochondrial O
superoxide B
dismutase O
activities O
may O
underlie O
such O
harmful O
effects O
. O

The O
mainstay O
of O
stent O
thrombosis O
prevention O
remains O
dual O
anti O
- O
platelet O
therapy O
with O
acetylsalicylic B
acid I
and O
a O
platelet O
ADP B
- O
receptor O
blocker O
, O
traditionally O
clopidogrel B
. O

Two O
new O
drugs O
, O
prasugrel O
and O
ticagrelor O
, O
provide O
faster O
, O
greater O
, O
and O
more O
consistent O
platelet O
inhibition O
than O
clopidogrel B
, O
and O
have O
been O
shown O
to O
be O
more O
efficacious O
in O
preventing O
ischemic O
events O
after O
PCI O
in O
acute O
coronary O
syndrome O
patients O
. O

Oxysterol B
- O
binding O
proteins O
: O
Functions O
in O
cell O
regulation O
beyond O
lipid O
metabolism O
. O

Oxysterol B
- O
binding O
( O
OSBP O
) O
- O
related O
proteins O
( O
ORPs O
) O
constitute O
a O
family O
of O
sterol B
and O
phosphoinositide B
binding O
/ O
transfer O
proteins O
in O
eukaryotes O
from O
yeast O
to O
man O
. O

While O
their O
functions O
have O
mainly O
been O
addressed O
in O
cellular O
lipid O
metabolism O
or O
sterol B
transport O
, O
increasing O
evidence O
points O
to O
more O
versatile O
regulatory O
roles O
in O
a O
spectrum O
of O
cellular O
regimes O
. O

Further O
functions O
assigned O
for O
ORPs O
include O
regulation O
of O
extracellular O
signal O
regulated O
kinase O
( O
ERK O
) O
activity O
( O
OSBP O
) O
, O
control O
of O
ER O
- O
late O
endosome O
MCS O
and O
late O
endosome O
motility O
( O
ORP1L O
) O
, O
regulation O
of O
beta O
1 O
- O
integrin O
activity O
( O
ORP3 O
) O
, O
modulation O
of O
hepatocyte O
insulin O
signaling O
and O
macrophage O
migration O
( O
ORP8 O
) O
, O
as O
well O
as O
post O
- O
Golgi O
vesicle O
transport O
, O
phosphatidylinositol B
- I
4 I
- I
phosphate I
and O
target O
of O
rapamycin B
complex O
1 O
signaling O
and O
nitrogen O

Inhibitory O
effect O
of O
dihydroartemisinin O
against O
phorbol B
ester I
- O
induced O
cyclooxygenase O
- O
2 O
expression O
in O
macrophages O
. O

Dihydroartemisinin O
( O
DHA B
) O
, O
a O
semi O
- O
synthetic O
derivative O
of O
artemisinin B
isolated O
from O
the O
traditional O
Chinese O
herb O
Artemisia O
annua O
L O
. O
, O
has O
recently O
been O
shown O
to O
possess O
antitumor O
activity O
in O
various O
cancer O
cells O
. O

However O
, O
the O
effect O
of O
anti O
- O
inflammatory O
potentials O
of O
DHA B
in O
murine O
macrophage O
RAW O
264 O
. O
7 O
cells O
has O
not O
been O
studied O
. O

The O
present O
study O
investigated O
the O
effect O
of O
COX O
- O
2 O
and O
molecular O
mechanisms O
by O
DHA B
in O
PMA B
stimulated O
RAW O
264 O
. O
7 O
cells O
. O

DHA B
dose O
- O
dependently O
decreased O
PMA B
- O
induced O
COX O
- O
2 O
expression O
and O
PGE2 B
production O
, O
as O
well O
as O
COX O
- O
2 O
promoter O
- O
driven O
luciferase O
activity O
. O

Additionally O
, O
DHA B
decreased O
luciferase O
activity O
of O
COX O
- O
2 O
regulation O
- O
related O
transcription O
factors O
including O
NF O
- O
kappa O
B O
, O
AP O
- O
1 O
, O
C O
/ O
EBP O
and O
CREB O
. O

DHA B
also O
remarkably O
reduced O
PMA B
- O
induced O
p65 O
, O
C O
/ O
EBP O
beta O
, O
c O
- O
jun O
and O
CREB O
nuclear O
translocation O
. O

Furthermore O
, O
DHA B
evidently O
inhibited O
PMA B
- O
induced O
phosphorylation O
of O
AKT O
and O
the O
MAP O
Kinases O
, O
such O
as O
ERK O
, O
JNK O
and O
p38 O
. O

Taken O
together O
, O
our O
data O
indicated O
that O
DHA B
effectively O
attenuates O
COX O
- O
2 O
production O
via O
down O
- O
regulation O
of O
AKT O
and O
MAPK O
pathway O
, O
revealing O
partial O
molecular O
basis O
for O
the O
anti O
- O
inflammatory O
properties O
of O
DHA B
. O

Low O
- O
dose O
bisphenol B
A I
and O
estrogen B
increase O
ventricular O
arrhythmias O
following O
ischemia O
- O
reperfusion O
in O
female O
rat O
hearts O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
environmental O
estrogenic O
endocrine O
disruptor O
that O
may O
have O
adverse O
health O
impacts O
on O
a O
range O
of O
tissue O
/ O
systems O
. O

In O
previous O
studies O
, O
we O
reported O
that O
BPA B
rapidly O
promoted O
arrhythmias O
in O
female O
rodent O
hearts O
through O
alteration O
of O
myocyte O
calcium B
handling O
. O

In O
the O
present O
study O
we O
investigated O
the O
acute O
effects O
of O
BPA B
on O
ventricular O
arrhythmias O
and O
infarction O
following O
ischemia O
- O
reperfusion O
in O
rat O
hearts O
. O

In O
female O
, O
but O
not O
male O
hearts O
, O
acute O
exposure O
to O
1nM O
BPA B
, O
either O
alone O
or O
combined O
with O
1nM O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
, O
during O
reperfusion O
resulted O
in O
a O
marked O
increase O
in O
the O
duration O
of O
sustained O
ventricular O
arrhythmias O
. O

BPA B
plus O
E2 O
increased O
the O
duration O
ventricular O
fibrillation O
, O
and O
the O
duration O
of O
VF O
as O
a O
fraction O
of O
total O
duration O
of O
sustained O
ventricular O
arrhythmia O
. O

The O
pro O
- O
arrhythmic O
effects O
of O
estrogens B
were O
abolished O
by O
MPP B
combined O
with O
PHTPP O
, O
suggesting O
the O
involvements O
of O
both O
ER O
alpha O
and O
ER O
beta O
signaling O
. O

In O
contrast O
to O
their O
pro O
- O
arrhythmic O
effects O
, O
BPA B
and O
E2 O
reduced O
infarction O
size O
, O
agreeing O
with O
previously O
described O
protective O
effect O
of O
estrogen B
against O
cardiac O
infarction O
. O

In O
conclusion O
, O
rapid O
exposure O
to O
low O
dose O
BPA B
, O
particularly O
when O
combined O
with O
E2 O
, O
exacerbates O
ventricular O
arrhythmia O
following O
IR O
injury O
in O
female O
rat O
hearts O
. O

N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
( O
NMDARs O
) O
and O
nicotinic O
acetylcholine B
receptors O
( O
nACHRs O
) O
are O
thought O
to O
be O
effective O
in O
the O
learning O
and O
memory O
- O
generating O
process O
. O

We O
administered O
a O
mixture O
of O
AFCAs O
( O
Eritrosin O
, O
Ponceau O
4R O
, O
Allura B
Red I
AC I
, O
Sunset O
Yellow O
FCF O
, O
Tartrazin O
, O
Amaranth O
, O
Brilliant B
Blue I
, O
Azorubin O
and O
Indigotin O
) O
to O
female O
rats O
before O
and O
during O
gestation O
. O

Metallothionein O
1A O
polymorphisms O
may O
influence O
urine O
uric B
acid I
and O
N B
- I
acetyl I
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
) O
excretion O
in O
chronic O
lead O
- O
exposed O
workers O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
association O
of O
blood O
lead O
levels O
, O
urinary O
uric B
acid I
( O
UA O
) O
and O
N B
- I
acetyl I
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
) O
in O
chronic O
occupational O
lead O
- O
exposed O
workers O
, O
and O
to O
study O
whether O
the O
association O
was O
influenced O
by O
MT1A O
gene O
polymorphisms O
. O

There O
was O
a O
significant O
inverted O
relationship O
of O
creatinine B
- O
adjusted O
urine O
UA O
concentrations O
and O
the O
time O
- O
weighted O
index O
of O
cumulative O
blood O
lead O
levels O
( O
TWICL O
) O
that O
may O
be O
significantly O
influenced O
by O
the O
AC O
genotypes O
of O
rs11640851 O
in O
exon O
2 O
and O
rs8052394 O
in O
exon O
3 O
. O

After O
controlling O
for O
potential O
confounding O
factors O
, O
the O
creatinine B
- O
adjusted O
urine O
NAG O
concentrations O
were O
shown O
to O
be O
influenced O
by O
the O
GG O
genotype O
of O
rs8052394 O
in O
exon O
3 O
, O
and O
were O
weakly O
increased O
with O
TWICL O
. O

Therefore O
, O
we O
concluded O
that O
the O
variations O
of O
MT1A O
SNPs O
may O
influence O
urine O
UA O
and O
NAG O
excretion O
in O
chronic O
lead O
- O
exposed O
workers O
, O
and O
urine O
creatinine B
- O
adjusted O
urine O
UA O
as O
a O
biomarker O
of O
lead O
toxicity O
should O
be O
considered O
. O

Reduced O
Acute O
Recovery O
from O
Alcohol B
Impairment O
in O
Adults O
with O
ADHD O
. O

RATIONALE O
: O
Prior O
research O
has O
found O
that O
adults O
with O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
( O
ADHD O
) O
show O
increased O
sensitivity O
to O
the O
impairing O
effects O
of O
alcohol B
( O
Weafer O
et O
al O
. O
, O
Exp O
Clin O
Psychopharmacol O
17 O
: O
113 O
- O
121 O
, O
2009 O
) O
. O

However O
, O
these O
studies O
have O
focused O
exclusively O
on O
the O
ascending O
limb O
of O
the O
blood O
alcohol B
concentration O
( O
BAC O
) O
curve O
, O
and O
it O
is O
unclear O
whether O
these O
adults O
continue O
to O
show O
increased O
sensitivity O
during O
the O
later O
phase O
of O
the O
dose O
as O
BAC O
is O
declining O
. O

OBJECTIVE O
: O
This O
study O
tested O
the O
hypothesis O
that O
those O
with O
ADHD O
would O
display O
increased O
response O
to O
alcohol B
during O
the O
ascending O
limb O
of O
the O
BAC O
curve O
and O
less O
recovery O
from O
the O
impairing O
effects O
during O
the O
descending O
limb O
. O

METHODS O
: O
Adult O
social O
drinkers O
with O
ADHD O
and O
control O
adults O
completed O
measures O
of O
motor O
coordination O
, O
reaction O
time O
( O
RT O
) O
, O
and O
subjective O
intoxication O
twice O
following O
0 O
. O
64 O
g O
/ O
kg O
alcohol B
and O
placebo O
. O

RESULTS O
: O
During O
the O
ascending O
limb O
, O
alcohol B
reduced O
motor O
coordination O
, O
slowed O
RT O
, O
and O
increased O
self O
- O
reports O
of O
subjective O
intoxication O
. O

During O
the O
descending O
limb O
, O
controls O
reported O
diminished O
subjective O
intoxication O
and O
showed O
recovery O
from O
the O
impairing O
effects O
of O
alcohol B
on O
both O
their O
motor O
coordination O
and O
their O
RT O
. O

Effect O
of O
chronic O
ethanol B
treatment O
on O
mu O
- O
opioid O
receptor O
function O
, O
interacting O
proteins O
and O
morphine B
- O
induced O
place O
preference O
. O

RATIONALE O
: O
Both O
the O
acute O
and O
chronic O
consumption O
of O
ethanol B
have O
been O
reported O
to O
modify O
several O
molecular O
events O
in O
the O
central O
nervous O
system O
, O
and O
the O
endogenous O
mu O
- O
opioid O
receptor O
system O
is O
involved O
in O
the O
reinforcing O
/ O
rewarding O
effects O
of O
ethanol B
. O

OBJECTIVES O
: O
The O
present O
study O
was O
designed O
to O
clarify O
the O
effects O
of O
chronic O
ethanol B
treatment O
on O
cellular O
processes O
involving O
mu O
- O
opioid O
receptor O
and O
the O
development O
of O
morphine B
- O
induced O
rewarding O
effects O
. O

METHODS O
: O
Male O
C57BL O
/ O
6J O
mice O
were O
continuously O
treated O
with O
a O
liquid O
diet O
containing O
3 O
. O
0 O
w O
/ O
v O
ethanol B
. O

The O
direct O
involvement O
of O
mu O
- O
opioid O
receptor O
functions O
in O
the O
activation O
of O
G O
- O
proteins O
and O
changes O
in O
protein O
levels O
in O
the O
lower O
midbrain O
of O
mice O
after O
chronic O
treatment O
with O
ethanol B
were O
investigated O
by O
a O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
assay O
and O
Western O
blotting O
, O
respectively O
. O

The O
rewarding O
effects O
of O
morphine B
( O
5 O
mg O
/ O
kg O
) O
under O
treatment O
with O
ethanol B
were O
measured O
by O
the O
conditioned O
place O
preference O
paradigm O
. O

RESULTS O
: O
The O
function O
of O
mu O
- O
opioid O
receptor O
was O
increased O
by O
treatment O
with O
ethanol B
in O
the O
lower O
midbrain O
using O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
assay O
. O

Furthermore O
, O
the O
GRK2 O
protein O
level O
was O
significantly O
increased O
by O
treatment O
with O
ethanol B
. O

Chronic O
treatment O
with O
ethanol B
enhanced O
the O
rewarding O
effects O
of O
morphine B
. O

On O
the O
other O
hand O
, O
this O
enhancement O
of O
the O
rewarding O
effects O
of O
morphine B
by O
ethanol B
treatment O
was O
significantly O
inhibited O
by O
the O
GRK2 O
inhibitor O
beta O
- O
adrenergic O
receptor O
kinase O
1 O
inhibitor O
. O

CONCLUSIONS O
: O
The O
present O
study O
demonstrated O
that O
chronic O
treatment O
with O
ethanol B
enhanced O
the O
rewarding O
effects O
of O
morphine B
by O
up O
- O
regulating O
functional O
changes O
in O
mu O
- O
opioid O
receptor O
, O
mediated O
by O
GRK2 O
. O

Effect O
of O
Ketoconazole B
on O
the O
Pharmacokinetics O
of O
the O
11 B
beta I
- I
Hydroxysteroid I
Dehydrogenase O
Type O
1 O
Inhibitor O
ABT O
- O
384 O
and O
Its O
Two O
Active O
Metabolites O
in O
Healthy O
Volunteers O
: O
Population O
Analysis O
of O
Data O
from O
a O
Drug O
- O
Drug O
Interaction O
Study O
. O

ABT O
- O
384 O
[ O
1 O
- O
piperazineacetamide O
, O
N O
- O
[ O
5 O
- O
( O
aminocarbonyl O
) O
tricyclo O
[ O
3 O
. O
3 O
. O
1 O
. O
13 O
, O
7 O
] O
dec O
- O
2 O
- O
yl O
] O
- O
alpha O
, O
alpha O
- O
dimethyl O
- O
4 O
- O
[ O
5 O
- O
( O
trifluoromethyl O
) O
- O
2 O
- O
pyridinyl O
] O
- O
, O
stereoisomer O
] O
is O
a O
potent O
and O
selective O
inhibitor O
of O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
( O
HSD O
- O
1 O
) O
. O

The O
effect O
of O
ketoconazole B
on O
the O
pharmacokinetics O
of O
ABT O
- O
384 O
and O
its O
two O
active O
metabolites O
, O
A O
- O
1331480 O
and O
A O
- O
847082 O
, O
was O
investigated O
in O
healthy O
volunteers O
. O

When O
10 O
mg O
of O
ABT O
- O
384 O
was O
coadministered O
with O
ketoconazole B
, O
ABT O
- O
384 O
exposures O
increased O
18 O
- O
fold O
for O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
from O
time O
0 O
to O
infinity O
and O
3 O
. O
5 O
- O
fold O
for O
Cmax O
. O

After O
ketoconazole B
coadministration O
, O
exposures O
of O
A O
- O
1331480 O
and O
A O
- O
847082 O
were O
also O
greatly O
increased O
. O

The O
model O
predicted O
a O
69 O
. O
3 O
% O
decrease O
in O
ABT O
- O
384 O
clearance O
and O
91 O
. O
1 O
% O
increase O
in O
the O
volume O
of O
distribution O
of O
ABT O
- O
384 O
in O
the O
presence O
of O
ketoconazole B
. O

Overall O
the O
model O
adequately O
captured O
the O
concentration O
- O
time O
profiles O
of O
ABT O
- O
384 O
, O
A O
- O
1331480 O
, O
and O
A O
- O
847082 O
in O
both O
ABT O
- O
384 O
- O
alone O
and O
ketoconazole B
- O
coadministration O
conditions O
. O

Although O
ABT O
- O
384 O
exposures O
were O
greatly O
increased O
in O
the O
presence O
of O
ketoconazole B
, O
coadministration O
of O
ABT O
- O
384 O
with O
ketoconazole B
or O
other O
strong O
/ O
moderate O
CYP3A O
inhibitors O
is O
not O
expected O
to O
contribute O
to O
any O
major O
clinical O
safety O
issues O
considering O
the O
favorable O
safety O
profile O
of O
ABT O
- O
384 O
. O

Two O
new O
sesquiterpenoids B
from O
the O
rhizomes O
of O
Nardostachys O
jatamansi O
. O

Phytochemical O
investigation O
of O
CHCl B
( I
3 I
) I
: O
MeOH B
( O
1 O
: O
1 O
) O
extract O
from O
the O
rhizomes O
of O
Nardostachys O
jatamansi O
led O
to O
the O
isolation O
of O
two O
new O
sesquiterpenoids B
( O
5 O
and O
6 O
) O
, O
along O
with O
six O
known O
compounds O
( O
1 O
- O
4 O
, O
7 O
, O
and O
8 O
) O
. O

It O
was O
demonstrated O
for O
collinear O
H B
+ O
H2 B
reactive O
scattering O
on O
the O
BKMP2 O
potential O
energy O
surface O
that O
reaction O
probabilities O
computed O
via O
the O
SQC O
methodology O
using O
a O
Gaussian O
window O
function O
of O
1 O
/ O
2 O
unit O
width O
produces O
good O
agreement O
with O
quantum O
mechanical O
results O
over O
the O
0 O
. O
4 O
- O
0 O
. O
6 O
eV O
energy O
range O
relevant O
to O
the O
ground O
vibrational O
state O
to O
the O
ground O
vibrational O
state O
reactive O
transition O
. O

A O
total O
of O
68 O
chemicals O
including O
derivatives O
of O
naphthalene B
, O
phenanthrene B
, O
fluoranthene B
, O
pyrene B
, O
biphenyl B
, O
and O
flavone B
were O
examined O
for O
their O
abilities O
to O
interact O
with O
human O
P450s O
2A13 O
and O
2A6 O
. O

Fifty O
- O
one O
of O
these O
68 O
chemicals O
induced O
stronger O
Type O
I O
binding O
spectra O
( O
iron B
low O
- O
to O
high O
- O
spin O
state O
shift O
) O
with O
P450 O
2A13 O
than O
those O
seen O
with O
P450 O
2A6 O
, O
i O
. O
e O
. O
, O
the O
spectral O
binding O
intensities O
( O
Delta O
Amax O
/ O
Ks O
ratio O
) O
determined O
with O
these O
chemicals O
were O
always O
higher O
for O
P450 O
2A13 O
. O

In O
addition O
, O
benzo O
[ O
c O
] O
phenanthrene O
, O
fluoranthene B
, O
2 O
, O
3 O
- O
dihydroxy O
- O
2 O
, O
3 O
- O
dihydrofluoranthene O
, O
pyrene B
, O
1 B
- I
hydroxypyrene I
, O
1 O
- O
nitropyrene O
, O
1 O
- O
acetylpyrene O
, O
2 O
- O
acetylpyrene O
, O
2 O
, O
5 O
, O
2 O
' O
, O
5 O
' O
- O
tetrachlorobiphenyl O
, O
7 O
- O
hydroxyflavone O
, O
chrysin B
, O
and O
galangin B
were O
found O
to O
induce O
a O
Type O
I O
spectral O
change O
only O
with O
P450 O

Coumarin B
7 O
- O
hydroxylation O
, O
catalyzed O
by O
P450 O
2A13 O
, O
was O
strongly O
inhibited O
by O
2 O
' O
- O
methoxy O
- O
5 O
, O
7 O
- O
dihydroxyflavone O
, O
2 O
- O
ethynylnaphthalene O
, O
2 O
' O
- O
methoxyflavone O
, O
2 O
- O
naphththalene O
propargyl O
ether O
, O
acenaphthene O
, O
acenaphthylene O
, O
naphthalene B
, O
1 O
- O
acetylpyrene O
, O
flavanone O
, O
chrysin B
, O
3 O
- O
ethynylphenanthrene O
, O

flavone B
, O
and O
7 O
- O
hydroxyflavone O
; O
these O
chemicals O
induced O
Type O
I O
spectral O
changes O
with O
low O
Ks O
values O
. O

ATP B
synthase O
: O
a O
molecular O
therapeutic O
drug O
target O
for O
antimicrobial O
and O
antitumor O
peptides O
. O

In O
this O
review O
we O
discuss O
the O
role O
of O
ATP B
synthase O
as O
a O
molecular O
drug O
target O
for O
natural O
and O
synthetic O
antimicrobial O
/ O
antitumor O
peptides O
. O

We O
start O
with O
an O
introduction O
of O
the O
universal O
nature O
of O
the O
ATP B
synthase O
enzyme O
and O
its O
role O
as O
a O
biological O
nanomotor O
. O

Significant O
structural O
features O
required O
for O
catalytic O
activity O
and O
motor O
functions O
of O
ATP B
synthase O
are O
described O
. O

Relevant O
details O
regarding O
the O
presence O
of O
ATP B
synthase O
on O
the O
surface O
of O
several O
animal O
cell O
types O
, O
where O
it O
is O
associated O
with O
multiple O
cellular O
processes O
making O
it O
a O
potential O
drug O
target O
with O
respect O
to O
antimicrobial O
peptides O
and O
other O
inhibitors O
such O
as O
dietary O
polyphenols B
, O
is O
also O
reviewed O
. O

ATP B
synthase O
is O
known O
to O
have O
about O
twelve O
discrete O
inhibitor O
binding O
sites O
including O
peptides O
and O
other O
inhibitors O
located O
at O
the O
interface O
of O
alpha O
/ O
beta O
subunits O
on O
the O
F1 O
sector O
of O
the O
enzyme O
. O

Molecular O
interaction O
of O
peptides O
at O
the O
beta O
DEELSEED O
site O
on O
ATP B
synthase O
is O
discussed O
with O
specific O
examples O
. O

An O
inhibitory O
effect O
of O
other O
natural O
/ O
synthetic O
inhibitors O
on O
ATP B
is O
highlighted O
to O
explore O
the O
therapeutic O
roles O
played O
by O
peptides O
and O
other O
inhibitors O
. O

Lastly O
, O
the O
effect O
of O
peptides O
on O
the O
inhibition O
of O
the O
Escherichia O
coli O
model O
system O
through O
their O
action O
on O
ATP B
synthase O
is O
presented O
. O

Interlayer O
breathing O
and O
shear O
modes O
in O
few O
- O
trilayer O
MoS2 B
and O
WSe2 O
. O

Here O
we O
uncover O
the O
ultralow O
frequency O
interlayer O
breathing O
and O
shear O
modes O
in O
few O
- O
layer O
MoS2 B
and O
WSe2 O
, O
prototypical O
layered O
TMDs O
, O
using O
both O
Raman O
spectroscopy O
and O
first O
principles O
calculations O
. O

Checkpoint O
protein O
Rad9 O
plays O
an O
important O
role O
in O
nucleotide B
excision O
repair O
. O

However O
, O
whether O
Rad9 O
has O
an O
impact O
on O
nucleotide B
excision O
repair O
remains O
unknown O
. O

Here O
we O
demonstrated O
that O
Rad9 O
was O
involved O
in O
nucleotide B
excision O
repair O
and O
loss O
of O
Rad9 O
led O
to O
defective O
removal O
of O
the O
UV O
- O
derived O
photoproduct O
6 O
- O
4PP O
( O
6 O
, O
4 O
pyrimidine O
- O
pyrimidone O
) O
and O
the O
BPDE O
( O
anti O
- O
benzo O
( O
a O
) O
pyrene O
- O
trans O
- O
7 O
, O
8 O
- O
dihydrodiol O
- O
9 O
, O
10 O
- O
epoxide O
) O
- O
DNA O
adducts O
in O
mammalian O
cells O
. O

However O
, O
our O
data O
showed O
that O
Rad9 O
was O
not O
required O
for O
the O
photoproducts O
recognition O
step O
of O
nucleotide B
excision O
repair O
. O

Further O
investigation O
revealed O
that O
reduction O
of O
Rad9 O
reduced O
the O
UV O
- O
induced O
transcription O
of O
the O
genes O
of O
the O
nucleotide B
excision O
repair O
factors O
DDB2 O
, O
XPC O
, O
DDB1 O
and O
XPB O
and O
DDB2 O
protein O
levels O
in O
human O
cells O
. O

Based O
on O
these O
results O
, O
we O
suggest O
that O
Rad9 O
plays O
an O
important O
role O
in O
nucleotide B
excision O
repair O
through O
mechanisms O
including O
maintaining O
DDB2 O
protein O
level O
in O
human O
cells O
. O

Microwave O
assisted O
nano O
( O
ZnO B
- O
TiO2 B
) O
catalyzed O
synthesis O
of O
some O
new O
4 O
, O
5 O
, O
6 O
, O
7 O
- O
tetrahydro O
- O
6 O
- O
( O
( O
5 O
- O
substituted O
- O
1 O
, O
3 O
, O
4 O
- O
oxadiazol O
- O
2 O
- O
yl O
) O
methyl O
) O
thieno O
[ O
2 O
, O
3 O
- O
c O
] O
pyridine O
as O
antimicrobial O
agents O
. O

Combined O
nano O
zinc B
oxide I
and O
titanium B
dioxide I
[ O
nano O
( O
ZnO B
- O
TiO B
( I
2 I
) I
) O
] O
has O
been O
reported O
first O
time O
for O
the O
synthesis O
of O
novel O
series O
of O
4 O
, O
5 O
, O
6 O
, O
7 O
- O
tetrahydro O
- O
6 O
- O
( O
( O
5 O
- O
substituted O
- O
1 O
, O
3 O
, O
4 O
- O
oxadiazol O
- O
2 O
- O
yl O
) O
methyl O
) O
thieno O
[ O
2 O
, O
3 O
- O
c O
] O
pyridine O
. O

SAR O
for O
the O
newly O
synthesised O
derivatives O
has O
been O
developed O
by O
comparing O
their O
MIC O
values O
with O
ampicillin B
, O
ciprofloxacin B
and O
miconazole O
for O
antibacterial O
and O
antifungal O
activities O
, O
respectively O
. O

Among O
the O
synthesized O
compounds O
, O
2 O
, O
6 O
dichlorophenyl O
analogue O
( O
7f O
) O
, O
4 O
fluorophenyl O
analogue O
( O
7k O
) O
and O
2 O
, O
6 O
dichlorophenyl O
analogue O
( O
7l O
) O
shows O
promising O
antibacterial O
as O
well O
as O
antifungal O
activity O
whereas O
thiophene B
substituted O
compound O
( O
7j O
) O
shows O
promising O
antibacterial O
activity O
. O

Subsequently O
, O
crystal O
structures O
of O
CXCR4 O
were O
used O
to O
dock O
a O
series O
of O
naphthylguanide O
derivatives O
of O
the O
polyamines B
spermidine B
and O
spermine B
. O

A O
number O
of O
linezolid B
- O
like O
oxazolidino O
- O
sulfonamides O
( O
7a O
- O
y O
and O
8a O
- O
b O
) O
were O
designed O
and O
synthesized O
with O
a O
view O
to O
develop O
antimicrobial O
agents O
with O
improved O
properties O
. O

The O
migration O
ability O
and O
cytoskeleton O
rearrangement O
of O
ovarian O
cancer O
cells O
were O
determined O
by O
Transwell O
migration O
assay O
and O
phalloidin B
staining O
. O

Food O
- O
borne O
pathogen O
Cronobacter O
sakazakii O
synthesizes O
two O
lipid O
A O
species O
, O
differing O
by O
the O
length O
of O
the O
secondary O
acyl B
chain O
. O

C O
. O
sakazakii O
LpxL O
and O
LpxM O
transfer O
a O
C14 O
: O
0 O
secondary O
acyl B
chain O
to O
the O
2 O
' O
- O
and O
3 O
' O
- O
position O
of O
lipid O
A O
, O
respectively O
. O

C O
. O
sakazakii O
LpxP O
can O
transfer O
either O
a O
C16 O
: O
1 O
or O
a O
C14 O
: O
0 O
secondary O
acyl B
chains O
to O
the O
2 O
' O
- O
position O
of O
lipid O
A O
. O

A O
35kD O
Phyllanthus O
niruri O
protein O
modulates O
iron B
mediated O
oxidative O
impairment O
to O
hepatocytes O
via O
the O
inhibition O
of O
ERKs O
, O
p38 O
MAPKs O
and O
activation O
of O
PI3k O
/ O
Akt O
pathway O
. O

The O
goal O
of O
our O
present O
study O
was O
to O
evaluate O
the O
protective O
role O
of O
a O
35kD O
protein O
( O
PNP O
) O
isolated O
from O
this O
herb O
against O
iron B
- O
induced O
cytotoxicity O
in O
murine O
hepatocytes O
. O

Exposure O
of O
hepatocytes O
to O
iron B
( O
FeSO4 B
) O
caused O
elevation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
, O
enhanced O
lipid O
peroxidation O
and O
protein O
carbonylation O
, O
depleted O
glutathione B
levels O
, O
decreased O
the O
antioxidant O
power O
( O
FRAP O
) O
of O
the O
cells O
and O
reduced O
cell O
viability O
. O

Iron B
mediated O
cytotoxicity O
disrupted O
mitochondrial O
membrane O
potential O
( O
Delta O
psi O
m O
) O
and O
thereby O
caused O
apoptosis O
mainly O
by O
the O
intrinsic O
pathway O
via O
the O
down O
- O
regulation O
of O
I O
kappa O
B O
alpha O
with O
a O
concomitant O
up O
- O
regulation O
of O
NF O
- O
kB O
as O
well O
as O
the O
phosphorylation O
of O
ERKs O
and O
p38 O
MAP O
kinases O
. O

In O
addition O
, O
iron B
- O
induced O
cytotoxicity O
disrupted O
the O
normal O
balance O
of O
Bcl O
- O
2 O
family O
proteins O
in O
hepatocytes O
. O

Combining O
all O
, O
results O
suggest O
that O
simultaneous O
treatment O
with O
PNP O
might O
suppress O
the O
iron B
- O
induced O
cytotoxicity O
in O
hepatocytes O
. O

Hepatic O
and O
renal O
Bcrp O
transporter O
expression O
in O
mice O
treated O
with O
perfluorooctanoic B
acid I
. O

The O
current O
study O
investigated O
the O
regulation O
of O
hepatic O
and O
renal O
Bcrp O
mRNA O
and O
protein O
in O
mice O
treated O
with O
the O
PPAR O
alpha O
agonist O
perfluorooctanoic B
acid I
( O
PFOA B
) O
and O
the O
ability O
of O
PFOA B
to O
alter O
human O
BCRP O
function O
in O
vitro O
. O

Bcrp O
mRNA O
and O
protein O
expression O
were O
quantified O
in O
the O
livers O
and O
kidneys O
of O
male O
C57BL O
/ O
6 O
mice O
treated O
with O
vehicle O
or O
PFOA B
( O
1 O
or O
3mg O
/ O
kg O
/ O
day O
oral O
gavage O
) O
for O
7 O
days O
. O

PFOA B
treatment O
increased O
liver O
weights O
as O
well O
as O
the O
hepatic O
mRNA O
and O
protein O
expression O
of O
the O
PPAR O
alpha O
target O
gene O
, O
cytochrome O
P450 O
4a14 O
. O

Compared O
to O
vehicle O
- O
treated O
control O
mice O
, O
PFOA B
increased O
hepatic O
Bcrp O
mRNA O
and O
protein O
between O
1 O
. O
5 O
- O
and O
3 O
- O
fold O
. O

Immunofluorescent O
staining O
confirmed O
enhanced O
canalicular O
Bcrp O
staining O
in O
liver O
sections O
from O
PFOA B
- O
treated O
mice O
. O

The O
kidney O
expression O
of O
cytochrome O
P450 O
4a14 O
mRNA O
, O
but O
not O
Bcrp O
, O
was O
increased O
in O
mice O
treated O
with O
PFOA B
. O

Micromolar O
concentrations O
of O
PFOA B
decreased O
human O
BCRP O
ATPase O
activity O
and O
inhibited O
BCRP O
- O
mediated O
transport O
in O
inverted O
membrane O
vesicles O
. O

Together O
, O
these O
studies O
demonstrate O
that O
PFOA B
induces O
hepatic O
Bcrp O
expression O
in O
mice O
and O
may O
inhibit O
human O
BCRP O
transporter O
function O
at O
concentrations O
that O
exceed O
levels O
observed O
in O
humans O
. O

Modulation O
of O
A O
- O
type O
K B
( I
+ I
) I
channels O
by O
the O
short O
- O
chain O
cobrotoxin O
through O
the O
protein O
kinase O
C O
- O
delta O
isoform O
decreases O
membrane O
excitability O
in O
dorsal O
root O
ganglion O
neurons O
. O

A O
- O
type O
K B
( I
+ I
) I
channels O
are O
crucial O
in O
controlling O
neuronal O
excitability O
, O
and O
their O
regulation O
in O
sensory O
neurons O
may O
alter O
pain O
sensation O
. O

In O
this O
study O
, O
we O
identified O
the O
functional O
role O
of O
cobrotoxin O
, O
the O
short O
- O
chain O
alpha O
- O
neurotoxin O
isolated O
from O
Naja O
atra O
venom O
, O
which O
acts O
in O
the O
regulation O
of O
the O
transient O
A O
- O
type O
K B
( I
+ I
) I
currents O
( O
IA O
) O
and O
membrane O
excitability O
in O
dorsal O
root O
ganglion O
( O
DRG O
) O
neurons O
via O
the O
activation O
of O
the O
muscarinic O
M3 O
receptor O
( O
M3R O
) O
. O

Our O
results O
showed O
that O
cobrotoxin O
increased O
IA O
in O
a O
concentration O
- O
dependent O
manner O
, O
whereas O
the O
sustained O
delayed O
rectifier O
K B
( I
+ I
) I
currents O
( O
IDR O
) O
were O
not O
affected O
. O

Moreover O
, O
specific O
changes O
in O
the O
target O
bring O
resistance O
to O
specific O
drugs O
like O
modification O
in O
nucleotide B
synthesis O
enzymes O
upon O
anti O
- O
metabolite O
exposure O
, O
in O
microtubule O
composition O
upon O
spindle O
poison O
treatment O
, O
in O
topoisomerase O
activity O
upon O
topoisomerase O
inhibitor O
incubation O
or O
in O
intracellular O
signaling O
pathways O
when O
targeting O
tyrosine B
kinase O
receptors O
. O

Fluorescence O
spectroscopy O
of O
PTCDA B
molecules O
on O
the O
KCl B
( O
100 O
) O
surface O
in O
the O
limit O
of O
low O
coverages O
: O
site O
selection O
and O
diffusion O
. O

We O
performed O
fluorescence O
( O
FL O
) O
and O
fluorescence O
excitation O
( O
FLE O
) O
spectroscopy O
on O
the O
model O
molecule O
perylene O
- O
3 O
, O
4 O
, O
9 O
, O
10 O
- O
tetracarboxyl O
acid O
dianhydride O
( O
PTCDA B
) O
for O
very O
low O
coverages O
( O
below O
1 O
% O
of O
a O
monolayer O
) O
on O
thin O
( O
100 O
) O
oriented O
KCl B
films O
. O

Two O
different O
states O
of O
PTCDA B
molecules O
can O
be O
distinguished O
in O
the O
spectra O
: O
an O
initial O
state O
, O
which O
is O
observed O
directly O
after O
deposition O
of O
the O
molecules O
onto O
the O
cold O
sample O
at O
20 O
K O
, O
and O
a O
final O
state O
, O
which O
is O
found O
after O
intensive O
optical O
excitation O
or O
thermal O
annealing O
of O
the O
sample O
. O

Polarization O
dependent O
spectroscopy O
reveals O
the O
same O
azimuthal O
orientation O
of O
the O
molecules O
on O
both O
adsorption O
sites O
and O
leads O
to O
a O
model O
of O
the O
adsorption O
geometry O
of O
PTCDA B
at O
the O
KCl B
step O
sites O
. O

Avoidance O
behaviour O
response O
and O
esterase O
inhibition O
in O
the O
earthworm O
, O
Lumbricus O
terrestris O
, O
after O
exposure O
to O
chlorpyrifos B
. O

In O
this O
study O
, O
the O
avoidance O
response O
of O
Lumbricus O
terrestris O
was O
quantified O
in O
chlorpyrifos B
- O
spiked O
soils O
, O
depending O
on O
the O
pesticide O
concentration O
and O
exposure O
duration O
. O

The O
effects O
of O
different O
chlorpyrifos B
concentrations O
were O
examined O
in O
a O
standardised O
test O
( O
two O
- O
chamber O
system O
) O
with O
0 O
. O
6 O
, O
3 O
and O
15 O
mg O
/ O
kg O
chlorpyrifos B
. O

However O
, O
the O
esterase O
activities O
showed O
that O
all O
earthworms O
were O
exposed O
to O
chlorpyrifos B
. O

In O
the O
modified O
test O
, O
earthworms O
had O
greatly O
inhibited O
AChE O
activity O
( O
0 O
. O
088 O
+ O
/ O
- O
0 O
. O
034 O
U O
/ O
mg O
protein O
, O
n O
= O
72 O
) O
, O
which O
was O
supported O
by O
reactivation O
of O
the O
inhibited O
enzyme O
activity O
in O
the O
presence O
of O
pralidoxime O
( O
2 B
- I
PAM I
) O
. O

This O
study O
suggests O
that O
the O
avoidance O
behaviour O
test O
for O
organophosphorus B
- O
contaminated O
soils O
could O
be O
supported O
by O
specific O
biomarkers O
to O
facilitate O
a O
better O
understanding O
of O
pesticide O
exposure O
and O
toxicity O
during O
this O
test O
. O

Induction O
of O
heme B
oxygenase O
- O
1 O
protects O
mouse O
liver O
from O
apoptotic O
ischemia O
/ O
reperfusion O
injury O
. O

Cobalt B
- I
protoporphyrin I
( O
CoPP B
) O
- O
dependent O
induction O
of O
heme B
oxygenase O
( O
HO O
) O
- O
1 O
has O
been O
shown O
to O
protect O
the O
liver O
from O
I O
/ O
R O
injury O
. O

HO O
- O
1 O
induction O
was O
achieved O
by O
the O
administration O
of O
CoPP B
( O
1 O
. O
5 O
mg O
/ O
kg O
body O
weight O
i O
. O
p O
. O
) O
. O

( O
2 O
) O
Similar O
to O
group O
1 O
but O
with O
the O
administration O
of O
CoPP B
72 O
h O
before O
the O
operation O
. O

( O
4 O
) O
Similar O
to O
group O
3 O
but O
with O
the O
administration O
of O
CoPP B
72 O
h O
before O
ischemia O
induction O
. O

When O
compared O
with O
the O
I O
/ O
R O
mice O
group O
, O
in O
the O
I O
/ O
R O
+ O
CoPP B
mice O
group O
, O
the O
increased O
hepatic O
expression O
of O
HO O
- O
1 O
was O
associated O
with O
a O
significant O
reduction O
in O
liver O
enzyme O
levels O
, O
fewer O
apoptotic O
hepatocytes O
cells O
were O
identified O
by O
morphological O
criteria O
and O
by O
immunohistochemistry O
for O
caspase O
- O
3 O
, O
there O
was O
a O
decreased O
mean O
number O
of O
proliferating O
cells O
( O
positively O
stained O
for O
Ki67 O
) O
, O
and O
a O
reduced O
hepatic O
expression O
of O
: O
C O
/ O
EBP O
homologous O
protein O
( O
an O
index O
of O
endoplasmic O
reticulum O

Microporous O
carbon B
nanoplates O
from O
regenerated O
silk O
proteins O
for O
supercapacitors O
. O

Novel O
carbon B
- O
based O
microporous O
nanoplates O
containing O
numerous O
heteroatoms O
( O
H O
- O
CMNs O
) O
are O
fabricated O
from O
regenerated O
silk O
fibroin O
by O
the O
carbonization O
and O
activation O
of O
KOH B
. O

Oseltamivir O
is O
a O
prodrug O
for O
the O
active O
carboxylate B
metabolite O
. O

The O
H275Y O
mutation O
in O
NA O
confers O
high O
- O
level O
oseltamivir O
resistance O
and O
intermediate O
peramivir B
resistance O
but O
does O
not O
alter O
zanamivir B
susceptibility O
. O

Zanamivir B
is O
available O
as O
a O
powder O
for O
inhalation O
, O
and O
a O
parenteral O
form O
is O
under O
development O
. O

Zanamivir B
distributes O
in O
an O
apparent O
volume O
of O
distribution O
approximating O
that O
of O
extracellular O
water O
and O
is O
rapidly O
eliminated O
( O
t O
( O
1 O
/ O
2 O
) O
beta O
of O
approximately O
3 O
. O
0 O
hours O
) O
. O

Peramivir B
is O
slowly O
eliminated O
( O
t O
( O
1 O
/ O
2 O
) O
beta O
of O
7 O
. O
7 O
- O
20 O
. O
8 O
hours O
) O
and O
is O
prescribed O
as O
either O
a O
once O
- O
daily O
injection O
or O
as O
a O
single O
infusion O
. O

Laninamivir B
is O
a O
recently O
developed O
slowly O
eliminated O
compound O
for O
administration O
by O
inhalation O
. O

Inhibitory O
effect O
of O
ketoconazole B
on O
the O
pharmacokinetics O
of O
a O
multireceptor O
tyrosine B
kinase O
inhibitor O
BMS B
- I
690514 I
in O
healthy O
participants O
: O
assessing O
the O
mechanism O
of O
the O
interaction O
with O
physiologically O
- O
based O
pharmacokinetic O
simulations O
. O

BMS B
- I
690514 I
, O
a O
selective O
inhibitor O
of O
the O
ErbB O
and O
vascular O
endothelial O
growth O
factor O
receptors O
, O
has O
shown O
antitumor O
activity O
in O
early O
clinical O
development O
. O

To O
assess O
the O
effect O
of O
ketoconazole B
on O
BMS B
- I
690514 I
pharmacokinetics O
, O
17 O
healthy O
volunteers O
received O
200 O
mg O
BMS B
- I
690514 I
alone O
followed O
by O
100 O
mg O
BMS B
- I
690514 I
with O
ketoconazole B
( O
400 O
mg O
once O
daily O
for O
4 O
days O
) O
. O

The O
AUC O
( O
infinity O
) O
of O
100 O
mg O
BMS B
- I
690514 I
concomitantly O
administered O
with O
ketoconazole B
was O
similar O
to O
that O
of O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

The O
dose O
- O
normalized O
C O
( O
max O
) O
and O
AUC O
( O
infinity O
) O
of O
BMS B
- I
690514 I
from O
the O
100 O
- O
mg O
BMS B
- I
690514 I
/ O
400 O
- O
mg O
ketoconazole B
treatment O
increased O
by O
55 O
% O
and O
127 O
% O
, O
respectively O
, O
relative O
to O
those O
from O
200 O
mg O
BMS B
- I
690514 I
alone O
. O

Prediction O
of O
the O
drug O
- O
drug O
interaction O
( O
DDI O
) O
using O
a O
population O
- O
based O
simulator O
( O
Simcyp O
) O
indicated O
that O
, O
in O
addition O
to O
CYP3A4 O
inhibition O
, O
the O
inhibition O
of O
P O
- O
gp O
by O
ketoconazole B
in O
the O
intestine O
, O
liver O
, O
and O
kidneys O
must O
be O
invoked O
to O
fully O
account O
for O
the O
DDI O
observed O
. O

This O
finding O
suggests O
that O
the O
inhibition O
of O
P O
- O
gp O
by O
ketoconazole B
, O
along O
with O
its O
effect O
on O
CYP3A4 O
, O
needs O
to O
be O
considered O
when O
designing O
a O
DDI O
study O
of O
ketoconazole B
with O
a O
victim O
drug O
that O
is O
a O
dual O
substrate O
. O

Construction O
of O
robust O
enzyme O
nanocapsules O
for O
effective O
organophosphate B
decontamination O
, O
detoxification O
, O
and O
protection O
. O

Nanocapsules O
of O
organophosphorous O
hydrolase O
with O
enhanced O
enzyme O
activity O
and O
stability O
are O
prepared O
via O
in O
situ O
polymerization O
, O
providing O
a O
novel O
class O
of O
nanoparticles O
for O
the O
decontamination O
and O
detoxification O
of O
organophosphates B
such O
as O
chemical O
warfare O
agents O
and O
pesticides O
. O

Using O
the O
nanocapsules O
as O
building O
blocks O
, O
bioactive O
nanocomposites O
are O
also O
fabricated O
, O
enabling O
their O
use O
for O
organophosphate B
protection O
. O

Bioactive O
formulations O
with O
sugar B
- O
derived O
surfactants O
: O
a O
new O
approach O
for O
photoprotection O
and O
controlled O
release O
of O
promethazine O
. O

A O
simple O
method O
for O
fabricating O
patterned O
curvilinear O
microstructures O
in O
poly B
( I
dimethylsiloxane I
) I
by O
selective O
wetting O
. O

The O
fabrication O
of O
patterned O
microstructures O
in O
poly B
( I
dimethylsiloxane I
) I
( O
PDMS B
) O
is O
a O
prerequisite O
for O
soft O
lithography O
. O

Herein O
, O
curvilinear O
surface O
relief O
microstructures O
in O
PDMS B
are O
fabricated O
through O
a O
simple O
three O
- O
stage O
approach O
combining O
microcontact O
printing O
( O
mu O
CP O
) O
, O
selective O
surface O
wetting O
/ O
dewetting O
and O
replica O
molding O
( O
REM O
) O
. O

First O
, O
using O
an O
original O
PDMS B
stamp O
( O
first O
- O
generation O
stamp O
) O
with O
linear O
relief O
features O
, O
a O
chemical O
pattern O
on O
gold O
substrate O
is O
generated O
by O
mu O
CP O
using O
hexadecanethiol O
( O
HDT O
) O
as O
an O
ink O
. O

Then O
, O
by O
a O
dip O
- O
coating O
process O
, O
an O
ordered O
polyethylene B
glycol I
( O
PEG B
) O
polymer O
- O
dot O
array O
forms O
on O
the O
HDT O
- O
patterned O
gold O
substrate O
. O

Finally O
, O
based O
on O
a O
REM O
process O
, O
the O
PEG B
- O
dot O
array O
on O
gold O
substrate O
is O
used O
to O
fabricate O
a O
second O
- O
generation O
PDMS B
stamp O
with O
microcavity O
array O
, O
and O
the O
second O
- O
generation O
PDMS B
stamp O
is O
used O
to O
generate O
third O
- O
generation O
PDMS B
stamp O
with O
microbump O
array O
. O

These O
fabricated O
new O
- O
generation O
stamps O
are O
utilized O
in O
mu O
CP O
and O
in O
micromolding O
in O
capillaries O
( O
MIMIC O
) O
, O
allowing O
the O
generation O
of O
surface O
micropatterns O
which O
cannot O
be O
obtained O
using O
the O
original O
PDMS B
stamp O
. O

The O
method O
will O
be O
useful O
in O
producing O
new O
- O
generation O
PDMS B
stamps O
, O
especially O
for O
those O
who O
want O
to O
use O
soft O
lithography O
in O
their O
studies O
but O
have O
no O
access O
to O
the O
microfabrication O
facilities O
. O

The O
discovery O
of O
novel O
human O
androgen B
receptor O
antagonist O
chemotypes O
using O
a O
combined O
pharmacophore O
screening O
procedure O
. O

Unraveling O
the O
mechanisms O
involved O
in O
castration O
- O
and O
therapy O
- O
resistant O
prostate O
cancer O
has O
led O
to O
a O
renewed O
interest O
in O
androgen B
receptor O
( O
AR O
) O
- O
targeted O
therapeutics O
. O

Anti O
- O
androgens B
that O
block O
the O
activity O
of O
the O
AR O
therefore O
remain O
a O
valid O
therapeutic O
option O
. O

However O
, O
they O
must O
be O
more O
effective O
than O
, O
or O
display O
a O
distinct O
mechanism O
of O
action O
or O
binding O
mode O
from O
those O
of O
bicalutamide B
and O
hydroxyflutamide O
, O
which O
are O
currently O
in O
clinical O
use O
. O

For O
that O
reason O
, O
the O
second O
- O
generation O
anti O
- O
androgen B
MDV3100 O
was O
developed O
. O

MDV3100 O
, O
however O
, O
shares O
its O
4 O
- O
cyano O
- O
3 O
- O
( O
trifluoromethyl O
) O
phenyl O
group O
with O
bicalutamide B
and O
hydroxyflutamide O
required O
for O
binding O
to O
the O
AR O
. O

We O
found O
two O
novel O
chemotypes O
with O
AR O
- O
antagonistic O
activity O
( O
IC O
( O
50 O
) O
: O
3 O
- O
6 O
mu O
M O
) O
by O
virtual O
screening O
and O
confirmed O
their O
biological O
activity O
in O
an O
androgen B
- O
responsive O
reporter O
assay O
. O

The O
Overexpression O
of O
Hypomethylated O
miR O
- O
663 O
Induces O
Chemotherapy O
Resistance O
in O
Human O
Breast O
Cancer O
Cells O
by O
Targeting O
Heparin O
Sulfate B
Proteoglycan O
2 O
( O
HSPG2 O
) O
. O

Cell O
apoptosis O
was O
evaluated O
by O
annexin O
V O
/ O
propidium B
iodide I
staining O
, O
TUNEL O
, O
and O
reactive O
oxygen B
species O
generation O
analysis O
. O

Bisulfite B
sequencing O
PCR O
was O
used O
to O
analyze O
the O
methylation O
status O
. O

We O
found O
that O
miR O
- O
663 O
was O
significantly O
elevated O
in O
MDA O
- O
MB O
- O
231 O
/ O
ADM O
cells O
, O
and O
the O
down O
- O
regulation O
of O
miR O
- O
663 O
sensitized O
MDA O
- O
MB O
- O
231 O
/ O
ADM O
cells O
to O
both O
cyclophosphamide B
and O
docetaxel B
. O

MDA O
- O
MB O
- O
231 O
/ O
ADM O
contained O
fewer O
methylated O
CpG B
sites O
than O
its O
parental O
cell O
line O
, O
and O
miR O
- O
663 O
expression O
in O
MDA O
- O
MB O
- O
231 O
cells O
was O
reactivated O
by O
5 O
- O
aza O
- O
29 O
- O
deoxycytidine O
treatment O
, O
indicating O
that O
DNA O
methylation O
may O
play O
a O
functional O
role O
in O
the O
expression O
of O
miR O
- O
663 O
. O

A O
concise O
synthesis O
of O
pyrazole B
analogues O
of O
combretastatin O
A1 O
as O
potent O
anti O
- O
tubulin O
agents O
. O

Combretastatin O
A1 O
( O
CA1 O
) O
binds O
to O
the O
beta O
- O
subunit O
at O
the O
colchicine B
binding O
site O
of O
tubulin O
and O
inhibits O
polymerization O
. O

Metabolism O
experiments O
demonstrate O
that O
27 O
retains O
the O
ability O
to O
form O
ortho O
- O
quinone O
species O
, O
while O
the O
pyrazole B
ring O
shows O
high O
metabolic O
stability O
, O
suggesting O
that O
this O
compound O
might O
result O
in O
better O
pharmacokinetic O
profiles O
than O
CA1 O
, O
with O
similar O
pharmacodynamic O
properties O
and O
clinical O
potential O
. O

In O
the O
present O
study O
, O
QSPR O
- O
induced O
uncertainty O
in O
overall O
persistence O
( O
POV O
) O
and O
long O
- O
range O
transport O
potential O
( O
LRTP O
) O
was O
studied O
by O
integrating O
QSPRs O
into O
probabilistic O
assessments O
of O
five O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
, O
using O
the O
multimedia O
fate O
model O
Simplebox O
. O

The O
uncertainty O
analysis O
considered O
QSPR O
predictions O
of O
the O
fate O
input O
parameters O
' O
melting O
point O
, O
water O
solubility O
, O
vapor O
pressure O
, O
organic O
carbon B
- O
water O
partition O
coefficient O
, O
hydroxyl B
radical O
degradation O
, O
biodegradation O
, O
and O
photolytic O
degradation O
. O

However O
, O
the O
QSPRs O
developed O
specifically O
for O
PBDEs B
had O
a O
relatively O
low O
contribution O
to O
uncertainty O
. O

These O
findings O
suggest O
that O
the O
reliability O
of O
the O
ranking O
of O
PBDEs B
on O
the O
basis O
of O
POV O
and O
LRTP O
can O
be O
substantially O
improved O
by O
developing O
better O
QSPRs O
to O
estimate O
degradation O
properties O
. O

This O
study O
investigated O
the O
effect O
of O
M O
( O
n O
+ O
) O
ions O
( O
Zn B
( I
2 I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Ba B
( I
2 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
La B
( I
3 I
+ I
) I
, O
Eu O
( O
3 O
+ O
) O
, O
and O
Tb O
( O
3 O
+ O
) O
) O
and O
hydrophobic O
chains O
( O
hydrocarbon B
and O
fluorocarbon O
) O
on O
the O
formation O
of O
metal O
- O
coordinated O
bilayers O
. O

We O
found O
that O
fluorocarbon O
chains O
and O
branched O
hydrocarbon B
chains O
are O
preferable O
to O
the O
corresponding O
linear O
hydrocarbon B
chains O
for O
the O
formation O
of O
an O
L O
alpha O
phase O
. O

Moreover O
, O
L O
alpha O
phases O
formed O
by O
fluorocarbon O
chains O
exhibited O
higher O
viscoelasticity O
than O
ones O
formed O
by O
the O
hydrocarbons B
, O
and O
the O
bilayers O
formed O
by O
branched O
chains O
were O
rather O
flexible O
, O
revealing O
obvious O
undulation O
. O

Well O
- O
established O
examples O
are O
diamond B
, O
one O
of O
the O
hardest O
known O
materials O
, O
or O
graphite B
as O
a O
suitable O
precursor O
of O
graphene B
. O

Robust O
ordered O
cubic O
mesostructured O
polymer O
/ O
silica B
composite O
films O
grown O
at O
the O
air O
/ O
water O
interface O
. O

Polymer O
/ O
silica B
composite O
films O
, O
stable O
to O
calcination O
, O
were O
produced O
using O
catanionic O
surfactant O
mixtures O
( O
hexadecyltrimethylam B
bromide I
( O
CTAB B
) O
and O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
) O
and O
polymers O
( O
polyethylenimine B
( O
PEI B
) O
or O
polyacrylamide B
( O
PAAm O
) O
) O
at O
the O
air O
/ O
water O
interface O
. O

These O
films O
can O
be O
easily O
removed O
from O
the O
interface O
and O
mesoporous O
silica B
films O
which O
retain O
the O
film O
geometry O
can O
be O
obtained O
after O
calcination O
; O
moreover O
, O
this O
film O
preparation O
method O
provides O
a O
simple O
way O
to O
impart O
polymer O
functionality O
into O
the O
mesostructured O
silica B
wall O
, O
which O
means O
these O
films O
have O
potential O
applications O
in O
a O
variety O
of O
fields O
such O
as O
catalysis O
, O
molecular O
separation O
, O
and O
drug O
delivery O
. O

A O
critical O
role O
in O
organismal O
homeostatic O
functions O
is O
played O
by O
the O
aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
complex O
, O
which O
senses O
environmental O
and O
endogenous O
compounds O
, O
influences O
metabolic O
responses O
controlling O
phase O
I O
/ O
II O
gene O
expression O
, O
and O
modulates O
vital O
phenomena O
such O
as O
development O
, O
inflammation O
and O
adaptive O
immunity O
. O

Deficient O
fear O
recognition O
in O
regular O
cocaine B
users O
is O
not O
attributable O
to O
elevated O
impulsivity O
or O
conduct O
disorder O
prior O
to O
cocaine B
use O
. O

We O
previously O
reported O
that O
regular O
recreational O
intranasal O
cocaine B
users O
exhibit O
impaired O
recognition O
of O
facial O
expressions O
of O
fear O
compared O
to O
occasional O
cocaine B
users O
and O
cocaine B
- O
na O
i O
ve O
controls O
. O

We O
employed O
a O
cross O
- O
sectional O
design O
to O
compare O
31 O
cocaine B
- O
na O
i O
ve O
participants O
, O
35 O
occasional O
cocaine B
users O
and O
20 O
regular O
recreational O
cocaine B
users O
. O

After O
treating O
impulsiveness O
and O
CD O
as O
covariates O
we O
again O
observed O
a O
group O
difference O
in O
fear O
recognition O
ability O
attributable O
to O
the O
particularly O
impaired O
performance O
of O
regular O
cocaine B
users O
. O

This O
suggests O
that O
, O
although O
elevated O
impulsiveness O
and O
CD O
before O
the O
age O
of O
15 O
years O
, O
may O
predispose O
a O
relative O
inability O
to O
recognize O
facial O
expressions O
of O
fear O
in O
adulthood O
, O
subsequent O
regular O
recreational O
use O
of O
cocaine B
represents O
an O
additional O
factor O
that O
is O
specifically O
associated O
with O
a O
selective O
deficit O
in O
fear O
recognition O
. O

What O
is O
required O
is O
NMDA B
receptor O
activation O
followed O
by O
CaMKII O
activation O
. O

The O
consequence O
of O
CaMKII O
activation O
is O
the O
rapid O
recruitment O
of O
AMPA B
receptors O
to O
the O
synapse O
. O

This O
recruitment O
is O
independent O
of O
AMPA B
receptor O
subunit O
type O
, O
but O
absolutely O
requires O
an O
adequate O
pool O
of O
surface O
receptors O
. O

Disposition O
and O
Metabolism O
of O
GSK2251052 O
in O
Humans O
: O
A O
Novel O
Boron B
- O
Containing O
Antibiotic O
. O

( O
S O
) O
- O
3 O
- O
( O
Aminomethyl O
) O
- O
7 O
- O
( O
3 O
- O
hydroxypropoxy O
) O
- O
1 O
- O
hydroxy O
- O
1 O
, O
3 O
- O
dihydro O
- O
2 O
, O
1 O
- O
benzoxaborole O
( O
GSK2251052 O
) O
is O
a O
novel O
boron B
- O
containing O
antibiotic O
that O
inhibits O
bacterial O
leucyl O
tRNA O
synthetase O
, O
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram O
- O
negative O
infections O
. O

GSK2251052 O
and O
its O
major O
metabolite O
M3 O
, O
which O
resulted O
from O
oxidation O
of O
the O
propanol O
side O
chain O
to O
the O
corresponding O
carboxylic B
acid I
, O
comprised O
the O
majority O
of O
the O
plasma O
radioactivity O
, O
37 O
and O
53 O
% O
of O
the O
area O
under O
the O
plasma O
versus O
time O
concentration O
curve O
from O
time O
zero O
to O
infinity O
, O
respectively O
. O

A O
combination O
of O
in O
vitro O
metabolism O
experiments O
and O
a O
pharmacokinetic O
study O
in O
monkeys O
with O
the O
inhibitor O
4 O
- O
methylpyrazole O
provided O
strong O
evidence O
that O
alcohol B
dehydrogenase O
, O
potentially O
in O
association O
with O
aldehyde B
dehydrogenase O
, O
is O
the O
primary O
enzyme O
involved O
in O
the O
formation O
of O
the O
M3 O
metabolite O
. O

Strain O
- O
dependent O
dysregulation O
of O
one O
- O
carbon B
metabolism O
in O
male O
mice O
is O
associated O
with O
choline B
- O
and O
folate B
- O
deficient O
diet O
- O
induced O
liver O
injury O
. O

Dysregulation O
of O
one O
- O
carbon B
metabolism O
- O
related O
metabolic O
processes O
is O
a O
major O
contributor O
to O
the O
pathogenesis O
of O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
. O

It O
is O
well O
established O
that O
genetic O
and O
gender O
- O
specific O
variations O
in O
one O
- O
carbon B
metabolism O
contribute O
to O
the O
vulnerability O
to O
NAFLD O
in O
humans O
. O

To O
examine O
the O
role O
of O
one O
- O
carbon B
metabolism O
dysregulation O
in O
the O
pathogenesis O
and O
individual O
susceptibility O
to O
NAFLD O
, O
we O
used O
a O
" O
population O
- O
based O
" O
mouse O
model O
where O
male O
mice O
from O
7 O
inbred O
were O
fed O
a O
choline B
- O
and O
folate B
- O
deficient O
( O
CFD O
) O
diet O
for O
12 O
wk O
. O

Strain O
- O
dependent O
down O
- O
regulation O
of O
several O
key O
one O
- O
carbon B
metabolism O
genes O
, O
including O
methionine B
adenosyltransferase O
1 O
alpha O
( O
Mat1a O
) O
, O
cystathionine B
- O
beta O
- O
synthase O
( O
Cbs O
) O
, O
methylenetetrahydrof O
reductase O
( O
Mthfr O
) O
, O
adenosyl O
- O
homocysteinase O
( O
Ahcy O
) O
, O
and O
methylenetetrahydrof O
dehydrogenase O
1 O
( O
Mthfd1 O
) O
, O
was O
observed O
. O

The O
strain O
specificity O
of O
diet O
- O
induced O
dysregulation O
of O
one O
- O
carbon B
metabolism O
suggests O
that O
interstrain O
variation O
in O
the O
regulation O
of O
one O
- O
carbon B
metabolism O
may O
contribute O
to O
the O
differential O
vulnerability O
to O
NFLD O
and O
that O
correcting O
the O
imbalance O
may O
be O
considered O
as O
preventive O
and O
treatment O
strategies O
for O
NAFLD O
. O
- O
Pogribny O
, O
I O
. O

Strain O
- O
dependent O
dysregulation O
of O
one O
- O
carbon B
metabolism O
in O
male O
mice O
is O
associated O
with O
choline B
- O
and O
folate B
- O
deficient O
diet O
- O
induced O
liver O
injury O
. O

Post O
- O
synthesis O
, O
characterization O
and O
catalytic O
properties O
of O
fluorine B
- O
planted O
MWW O
- O
type O
titanosilicate O
. O

F O
- O
Ti O
- O
MWW O
was O
post O
- O
synthesized O
by O
implanting O
fluorine B
species O
into O
a O
Ti B
- O
MWW O
framework O
through O
an O
acid O
treatment O
process O
in O
the O
presence O
of O
ammonium O
fluoride O
. O

The O
effects O
of O
NH4F O
addition O
amount O
, O
acid O
treatment O
temperature O
and O
precursor O
Ti B
content O
were O
investigated O
on O
the O
incorporation O
of O
F B
species O
, O
the O
zeolite B
structure O
and O
the O
coordination O
sites O
of O
Ti B
. O

Fluorine B
- O
implanting O
improved O
the O
surface O
hydrophobicity O
of O
the O
zeolite B
and O
altered O
the O
electropositivity O
nearby O
the O
tetrahedral O
Ti B
sites O
through O
forming O
the O
SiO3 O
/ O
2F O
and O
SiO4 O
/ O
2F O
( O
- O
) O
units O
. O

F O
- O
Ti O
- O
MWW O
containing O
the O
SiO3 O
/ O
2F O
units O
possessed O
better O
catalytic O
activity O
and O
reusability O
, O
and O
a O
longer O
catalyst O
lifetime O
than O
conventional O
Ti B
- O
MWW O
. O

Annealing O
of O
the O
films O
at O
temperatures O
close O
to O
or O
higher O
than O
the O
softening O
temperature O
of O
the O
glass O
substrate O
induces O
morphological O
transformation O
to O
discrete O
Au B
islands O
and O
gradual O
embedding O
of O
the O
formed O
islands O
in O
the O
glass O
. O

It O
is O
shown O
that O
the O
morphological O
transformation O
of O
just O
- O
percolated O
, O
10 O
nm O
( O
nominal O
thickness O
) O
Au B
films O
evaporated O
on O
glass O
and O
annealed O
at O
600 O
degrees O
C O
, O
i O
. O
e O
. O
, O
in O
the O
vicinity O
of O
the O
substrate O
glass O
transition O
temperature O
( O
Tg O
= O
557 O
degrees O
C O
) O
, O
proceeds O
via O
three O
processes O
exhibiting O
different O
time O
scales O
: O
( O
i O
) O
fast O
recrystallization O
and O
dewetting O
, O
leading O
to O
formation O
of O
single O
- O
crystalline O
islands O
( O
minutes O
) O
; O
the O
initial O
spectrum O
characteristic O
of O
a O
continuous O
Au B
film O
is O
transformed O
to O
that O
of O
an O
island O
film O
, O
displaying O
a O
surface O
plasmon O
( O
SP O
) O

The O
first O
method O
analyzed O
seven O
marker O
compounds O
simultaneously O
on O
a O
reversed O
- O
phase O
column O
, O
while O
the O
second O
method O
analyzed O
a O
single O
marker O
compound O
, O
conduritol O
F O
, O
which O
exists O
only O
in O
C O
. O
wilfordii O
, O
on O
a O
Si B
- O
column O
. O

Targeted O
agents O
currently O
approved O
or O
under O
investigation O
for O
SCCHN O
include O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
monoclonal O
antibodies O
( O
cetuximab O
, O
panitumumab O
, O
zalutumumab O
, O
nimotuzumab O
) O
, O
EGFR O
tyrosine B
kinase O
inhibitors O
( O
gefitinib B
, O
erlotinib B
, O
lapatinib B
, O
afatanib O
, O
dacomitinib B
) O
, O
vascular O
endothelial O
growth O
factor O
receptor O
( O
VEGFR O
) O
inhibitors O
( O
bevacizumab O
, O
sorafenib O

, O
sunitinib O
, O
vandetanib B
) O
and O
various O
inhibitors O
of O
other O
pathways O
and O
targets O
, O
including O
phosphatidylinositol B
3 O
' O
kinase O
( O
PI3K O
) O
/ O
AKT O
/ O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
, O
MET O
and O
insulin O
- O
like O
growth O
factor O
receptor O
( O
IGF O
- O
1R O
) O
. O

The O
C B
- O
terminal O
extended O
serine B
residue O
is O
absolutely O
required O
in O
nosiheptide O
maturation O
. O

Serine B
qua O
non O
: O
Substitution O
of O
the O
extended O
Ser13 O
in O
the O
core O
peptide O
of O
nosiheptide O
by O
analogous O
amino B
acids I
prevented O
enamide O
dealkylation O
of O
the O
terminal O
residue O
for O
nosiheptide O
maturation O
. O

Carnosine B
inhibits O
A O
beta O
( O
42 O
) O
aggregation O
by O
perturbing O
the O
H B
- O
bond O
network O
in O
and O
around O
the O
central O
hydrophobic O
cluster O
. O

Here O
, O
we O
used O
experimental O
techniques O
and O
atomistic O
simulations O
to O
investigate O
the O
influence O
of O
carnosine B
, O
a O
dipeptide B
naturally O
occurring O
in O
the O
brain O
, O
on O
A O
beta O
aggregation O
. O

Scanning O
force O
microscopy O
, O
circular O
dichroism O
and O
thioflavin B
T I
fluorescence O
experiments O
showed O
that O
carnosine B
does O
not O
modify O
the O
conformational O
features O
of O
A O
beta O
42 O
but O
nonetheless O
inhibits O
amyloid O
growth O
. O

Molecular O
dynamics O
( O
MD O
) O
simulations O
indicated O
that O
carnosine B
interacts O
transiently O
with O
monomeric O
A O
beta O
42 O
by O
salt O
bridges O
with O
charged O
side O
chains O
, O
and O
van O
der O
Waals O
contacts O
with O
residues O
in O
and O
around O
the O
central O
hydrophobic O
cluster O
( O
( O
17 O
) O
LVFFA O
( O
21 O
) O
) O
. O

NMR O
experiments O
on O
the O
nonaggregative O
fragment O
A O
beta O
12 O
- O
28 O
did O
not O
evidence O
specific O
intermolecular O
interactions O
between O
the O
peptide O
and O
carnosine B
, O
in O
agreement O
with O
MD O
simulations O
. O

However O
, O
a O
close O
inspection O
of O
the O
spectra O
revealed O
that O
carnosine B
interferes O
with O
the O
local O
propensity O
of O
the O
peptide O
to O
form O
backbone O
hydrogen B
bonds O
close O
to O
the O
central O
hydrophobic O
cluster O
( O
residues O
E22 O
, O
S26 O
and O
N27 O
) O
. O

Finally O
, O
MD O
simulations O
of O
aggregation O
- O
prone O
A O
beta O
heptapeptide O
segments O
show O
that O
carnosine B
reduces O
the O
propensity O
to O
form O
intermolecular O
backbone O
hydrogen B
bonds O
in O
the O
region O
18 O
- O
24 O
. O

Taken O
together O
, O
the O
experimental O
and O
simulation O
results O
( O
cumulative O
MD O
sampling O
of O
0 O
. O
2 O
ms O
) O
suggest O
that O
, O
despite O
the O
inability O
of O
carnosine B
to O
form O
stable O
contacts O
with O
A O
beta O
, O
it O
might O
block O
the O
pathway O
toward O
toxic O
aggregates O
by O
perturbing O
the O
hydrogen B
bond O
network O
near O
residues O
with O
key O
roles O
in O
fibrillogenesis O
. O

Highly O
Ordered O
Hollow O
Oxide B
Nanostructures O
: O
The O
Kirkendall O
Effect O
at O
the O
Nanoscale O
. O

Highly O
ordered O
ultra O
- O
long O
oxide B
nanotubes O
are O
fabricated O
by O
a O
simple O
two O
- O
step O
strategy O
involving O
the O
growth O
of O
copper B
nanowires O
on O
nanopatterned O
template O
substrates O
by O
magnetron O
sputtering O
, O
followed O
by O
thermal O
annealing O
in O
air O
. O

Solvatochromic O
Effect O
on O
the O
Photoluminescence O
of O
MoS2 B
Monolayers O
. O

The O
effect O
of O
surrounding O
solvents O
on O
the O
photoluminescence O
( O
PL O
) O
of O
MoS2 B
monolayers O
on O
Si B
/ O
SiO2 B
substrates O
is O
studied O
. O

A O
redshift O
( O
up O
to O
- O
60 O
meV O
) O
is O
observed O
for O
MoS2 B
monolayers O
with O
nonhalogenated O
solvent O
surroundings O
. O

It O
has O
been O
known O
that O
the O
addition O
of O
bile B
salts I
to O
lecithin O
organosols O
induces O
the O
formation O
of O
reverse O
wormlike O
micelles O
and O
that O
the O
worms O
are O
similar O
to O
long O
polymer O
chains O
that O
entangle O
each O
other O
to O
form O
viscoelastic O
solutions O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
effects O
of O
different O
bile B
salts I
and O
bile B
acids I
on O
the O
growth O
of O
lecithin O
reverse O
worms O
in O
cyclohexane B
and O
n O
- O
decane O
. O

All O
of O
the O
bile B
salts I
can O
transform O
the O
originally O
spherical O
lecithin O
reverse O
micelles O
into O
wormlike O
micelles O
and O
their O
rheological O
behaviors O
can O
be O
described O
by O
the O
single O
- O
relaxation O
- O
time O
Maxwell O
model O
. O

In O
contrast O
, O
before O
phase O
separation O
, O
bile B
acids I
can O
induce O
only O
short O
cylindrical O
micelles O
that O
are O
not O
long O
enough O
to O
impart O
viscoelasticity O
. O

We O
used O
Fourier O
transform O
infrared O
spectroscopy O
to O
investigate O
the O
interactions O
between O
lecithin O
and O
bile O
salts O
/ O
acids O
and O
found O
that O
different O
bile O
salts O
/ O
acids O
employ O
different O
functional O
groups O
to O
form O
hydrogen B
bonds O
with O
lecithin O
. O

Control O
of O
10 O
nm O
scale O
cylinder O
orientation O
in O
self O
- O
organized O
sugar B
- O
based O
block O
copolymer O
thin O
films O
. O

The O
present O
paper O
describes O
the O
orientational O
control O
of O
10 O
nm O
scale O
cylinders O
in O
sugar B
- O
based O
block O
copolymer O
thin O
films O
by O
simply O
varying O
the O
composition O
of O
the O
annealing O
co O
- O
solvent O
. O

Multiphase O
chemistry O
of O
atmospheric O
amines B
. O

Heterogeneous O
reactions O
of O
amines B
have O
been O
recently O
shown O
to O
play O
an O
important O
role O
in O
the O
formation O
and O
transformation O
of O
atmospheric O
aerosols O
. O

This O
perspective O
summarizes O
the O
latest O
laboratory O
progress O
in O
the O
multiphase O
chemistry O
of O
amines B
. O

Particular O
emphasis O
is O
given O
to O
the O
contributions O
of O
amines B
to O
new O
particle O
formation O
, O
growth O
of O
submicron O
particles O
, O
and O
alteration O
in O
the O
physiochemical O
properties O
of O
pre O
- O
existing O
particles O
, O
including O
hygroscopicity O
, O
thermostability O
, O
density O
, O
phase O
, O
and O
optical O
properties O
, O
from O
exposure O
to O
gaseous O
amines B
. O

The O
atmospheric O
implications O
of O
the O
multiphase O
reactions O
of O
amines B
, O
including O
the O
potential O
impact O
on O
direct O
and O
indirect O
climate O
forcing O
of O
aerosols O
, O
and O
future O
research O
directions O
are O
discussed O
. O

Interestingly O
, O
miR O
- O
21 O
expression O
positively O
correlated O
with O
urine O
albumin O
creatine B
ratio O
( O
ACR O
) O
, O
TIMP1 O
, O
collagen O
IV O
( O
ColIV O
) O
, O
and O
fibronectin O
( O
FN O
) O
; O
while O
negatively O
correlated O
with O
creatine B
clearance O
ratio O
( O
Ccr O
) O
and O
MMP O
- O
9 O
protein O
. O

Probing O
the O
Metabotropic O
Glutamate B
Receptor O
5 O
( O
mGlu5 O
) O
Positive O
Allosteric O
Modulator O
( O
PAM O
) O
Binding O
Pocket O
: O
Discovery O
of O
Point O
Mutations O
That O
Engender O
a O
" O
Molecular O
Switch O
" O
in O
PAM O
Pharmacology O
. O

Positive O
allosteric O
modulation O
of O
metabotropic O
glutamate B
receptor O
subtype O
5 O
( O
mGlu5 O
) O
is O
a O
promising O
novel O
approach O
for O
the O
treatment O
of O
schizophrenia O
and O
cognitive O
disorders O
. O

Focusing O
on O
the O
modulators O
based O
on O
the O
acetylene B
scaffold O
, O
we O
sought O
to O
determine O
the O
molecular O
interactions O
that O
contribute O
to O
PAM O
versus O
NAM O
pharmacology O
. O

Novel O
mutations O
within O
the O
transmembrane O
domain O
( O
TM O
) O
regions O
were O
identified O
that O
had O
differential O
effects O
on O
acetylene B
PAMs O
versus O
2 O
- O
methyl O
- O
6 O
- O
( O
phenylethynyl O
) O
- O
pyridine O
, O
a O
prototypical O
NAM O
. O

Three O
conserved O
amino B
acids I
( O
Y658 O
, O
T780 O
, O
and O
S808 O
) O
and O
two O
nonconserved O
residues O
( O
P654 O
and O
A809 O
) O
were O
identified O
as O
key O
determinants O
of O
PAM O
activity O
. O

Coactivators O
enable O
glucocorticoid O
receptor O
recruitment O
to O
fine O
- O
tune O
estrogen B
receptor O
transcriptional O
responses O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
and O
how O
steroid B
NRs O
can O
influence O
each O
other O
' O
s O
activity O
under O
co O
- O
agonist O
treatment O
. O

We O
used O
a O
unique O
system O
consisting O
of O
a O
multicopy O
integration O
of O
an O
estrogen B
receptor O
responsive O
unit O
that O
allows O
direct O
visualization O
and O
quantification O
of O
estrogen B
receptor O
alpha O
( O
ER O
alpha O
) O
DNA O
binding O
, O
co O
- O
regulator O
recruitment O
and O
transcriptional O
readout O
. O

We O
focused O
on O
ER O
alpha O
/ O
glucocorticoid O
receptor O
interplay O
and O
demonstrated O
that O
it O
requires O
steroid B
receptor O
coactivators O
( O
SRC O
- O
2 O
, O
SRC O
- O
3 O
) O
and O
the O
mediator O
component O
MED14 O
. O

Comparing O
the O
pharmacokinetics O
of O
doxylamine O
/ O
pyridoxine B
delayed O
- O
release O
combination O
in O
nonpregnant O
women O
of O
reproductive O
age O
and O
women O
in O
the O
first O
trimester O
of O
pregnancy O
. O

Although O
Diclectin O
( O
doxylamine O
/ O
pyridoxine B
delayed O
- O
released O
combination O
) O
is O
widely O
used O
in O
Canada O
, O
its O
pharmacokinetics O
( O
PK O
) O
during O
pregnancy O
has O
never O
been O
described O
. O

The O
objective O
of O
this O
study O
was O
to O
compare O
the O
PK O
of O
doxylamine O
/ O
pyridoxine B
delayed O
- O
released O
combination O
in O
pregnant O
versus O
nonpregnant O
women O
. O

The O
apparent O
clearances O
( O
CL O
) O
of O
doxylamine O
and O
pyridoxal B
5 I
' I
- I
phosphate I
( O
PLP B
; O
the O
active O
metabolite O
of O
vitamin O
B O
( O
6 O
) O
) O
during O
the O
first O
- O
trimester O
pregnancy O
in O
women O
who O
participated O
in O
a O
Diclectin O
randomized O
trial O
were O
compared O
with O
those O
of O
healthy O
, O
adult O
, O
nonpregnant O
women O
who O
participated O
in O
a O
voluntary O
PK O
trial O
. O

There O
was O
no O
pregnancy O
- O
induced O
effect O
in O
the O
apparent O
CL O
of O
either O
doxylamine O
or O
PLP B
in O
women O
during O
the O
first O
trimester O
of O
pregnancy O
despite O
the O
existence O
of O
morning O
sickness O
. O

An O
assembly O
consisting O
of O
three O
units O
, O
that O
is O
, O
a O
meso O
- O
substituted O
corrole O
( O
) O
, O
1 O
, O
8 O
naphthaleneimide O
( O
) O
, O
and O
a O
Zn B
porphyrin B
( O
) O
, O
has O
been O
synthesized O
. O

NIE O
is O
connected O
to O
C3 O
through O
a O
1 O
, O
3 O
- O
phenylene O
bridge O
and O
to O
the O
ZnP O
unit O
through O
a O
direct O
C B
< I
F8FF I
> I
C I
bond O
. O

The O
light O
energy O
transferred O
from O
NIE O
to O
Zn B
porphyrin B
unit O
is O
ultimately O
funneled O
to O
the O
corrole O
component O
, O
which O
is O
the O
final O
recipient O
of O
the O
excitation O
energy O
absorbed O
by O
the O
different O
components O
of O
the O
array O
. O

Protective O
effect O
of O
butylated B
hydroxytoluene I
on O
ferric O
nitrilotriacetate O
induced O
hepatotoxicity O
and O
oxidative O
stress O
in O
mice O
. O

The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated O
hydroxyl O
toluene O
( O
BHT B
) O
, O
associated O
with O
ferric O
nitrilotriacetate O
( O
Fe O
- O
NTA O
) O
- O
induced O
oxidative O
stress O
and O
liver O
injury O
in O
mice O
. O

The O
treatment O
of O
mice O
with O
Fe O
- O
NTA O
alone O
enhances O
ornithine B
decarboxylase O
activity O
to O
4 O
. O
6 O
folds O
, O
protein O
carbonyl B
formation O
increased O
up O
to O
2 O
. O
9 O
folds O
and O
DNA O
synthesis O
expressed O
in O
terms O
of O
[ B
( I
3 I
) I
H I
] I
thymidine I
incorporation O
increased O
to O
3 O
. O
2 O
folds O
, O
and O
antioxidants O
and O
antioxidant O
enzymes O
decreased O
to O
1 O
. O
8 O
- O
2 O
. O
5 O
folds O
, O
compared O
with O
the O
corresponding O
saline O
- O
treated O
controls O
. O

These O
changes O
were O
reversed O
significantly O
( O
p O
< O
0 O
. O
001 O
) O
in O
animals O
receiving O
a O
pretreatment O
of O
BHT B
. O

Our O
data O
show O
that O
BHT B
can O
reciprocate O
the O
toxic O
effects O
of O
Fe O
- O
NTA O
and O
can O
serve O
as O
a O
potent O
chemopreventive O
agent O
. O

Archaeon O
Aeropyrum O
pernix O
K1 O
is O
an O
obligate O
aerobic O
hyperthermophilic O
organism O
with O
C O
( O
25 O
, O
25 O
) O
- O
archeol O
membrane O
lipids O
with O
head O
groups O
containing O
inositol B
. O

The O
uptake O
of O
archaeosomes O
and O
the O
release O
of O
loaded O
calcein B
are O
more O
prominent O
in O
EA O
. O
hy926 O
cells O
, O
which O
is O
in O
line O
with O
high O
toxicity O
toward O
these O
cells O
. O

Simultaneous O
high O
- O
performance O
liquid O
chromatographic O
determination O
of O
a O
rhein O
- O
diclofenac B
prodrug O
and O
its O
active O
compounds O
. O

The O
mobile O
phase O
was O
methanol B
- O
0 O
. O
1 O
% O
phosphoric B
acid I
solution O
( O
adjusted O
pH O
to O
2 O
. O
3 O
) O
( O
80 O
: O
20 O
, O
v O
/ O
v O
) O
; O
wavelength O
of O
257nm O
and O
mobile O
phase O
flow O
rate O
of O
1 O
. O
0 O
mL O
/ O
min O
was O
utilized O
for O
the O
quantitative O
analysis O
. O

Rapid O
identification O
of O
sibutramine B
in O
dietary O
supplements O
using O
a O
stepwise O
approach O
. O

The O
present O
study O
aimed O
at O
the O
development O
of O
a O
multistep O
analytical O
method O
for O
the O
quick O
and O
reliable O
determination O
of O
sibutramine B
, O
one O
of O
the O
most O
common O
adulterants O
among O
botanical O
food O
supplements O
. O

The O
extract O
of O
a O
sibutramine B
- O
containing O
slimming O
formula O
was O
analysed O
by O
colour O
tests O
, O
TLC O
, O
HPLC O
- O
DAD O
, O
MS O
and O
NMR O
. O

The O
multistep O
method O
proposed O
by O
the O
authors O
allows O
the O
quick O
identification O
of O
sibutramine B
in O
counterfeit O
samples O
in O
laboratories O
with O
different O
instrumentation O
. O

Development O
and O
validation O
of O
a O
simple O
LC O
method O
for O
the O
determination O
of O
phenacetin B
, O
coumarin B
, O
tolbutamide B
, O
chlorzoxazone B
, O
testosterone B
and O
their O
metabolites O
as O
markers O
of O
cytochromes O
1A2 O
, O
2A6 O
, O
2C11 O
, O
2E1 O
and O
3A2 O
in O
rat O
microsomal O
medium O
. O

Phenacetin B
, O
coumarin B
, O
tolbutamide B
, O
chlorzoxazone B
and O
testosterone B
are O
commonly O
used O
as O
probe O
substrates O
to O
evaluate O
cytochrome O
P450 O
function O
. O

A O
C18 O
analytical O
column O
and O
mobile O
phase O
composed O
of O
acetonitrile B
and O
0 O
. O
02 O
% O
aqueous O
phosphoric B
acid I
were O
used O
for O
the O
chromatographic O
separation O
with O
DAD O
detection O
. O

Devices O
were O
fabricated O
using O
flat O
and O
nanostructured O
TiO2 B
and O
compared O
to O
systems O
using O
nanostructured O
ZrO2 O
to O
differentiate O
between O
the O
transport O
processes O
within O
the O
different O
components O
of O
the O
ssDSC O
. O

Using O
this O
approach O
the O
activation O
energy O
of O
the O
hole O
hopping O
transport O
within O
the O
undoped O
spiro O
- O
MeOTAD O
film O
was O
determined O
to O
be O
0 O
. O
34 O
+ O
/ O
- O
0 O
. O
02 O
and O
0 O
. O
40 O
+ O
/ O
- O
0 O
. O
02 O
eV O
for O
the O
mesoporous O
TiO2 B
and O
ZrO2 O
systems O
, O
respectively O
. O

In O
this O
study O
, O
the O
ethanolic O
extract O
obtained O
from O
piqui O
a O
pulp O
was O
assessed O
for O
genotoxicity O
and O
oxidative O
stress O
by O
employing O
the O
micronucleus O
test O
in O
bone O
marrow O
and O
peripheral O
blood O
cells O
in O
addition O
to O
comet O
, O
thiobarbituric B
- I
acid I
- O
reactive O
substances O
( O
TBARS O
) O
, O
and O
reduced B
glutathione I
assays O
in O
the O
liver O
, O
kidney O
, O
and O
heart O
. O

Wistar O
rats O
were O
treated O
by O
gavage O
with O
an O
ethanolic O
extract O
from O
piqui O
a O
pulp O
( O
75 O
mg O
/ O
kg O
body O
weight O
) O
for O
14 O
days O
, O
and O
24 O
h O
prior O
to O
euthanasia O
, O
they O
received O
an O
injection O
of O
saline O
or O
doxorubicin B
( O
15 O
mg O
/ O
kg O
body O
weight O
, O
intraperoneally O
) O
. O

Abstract O
Vegetable O
- O
based O
diets O
have O
generally O
focused O
on O
their O
health O
benefits O
including O
negative O
associations O
with O
the O
serum O
cholesterol B
concentrations O
. O

Concentrations O
of O
fasting O
blood O
glucose B
( O
FBG O
) O
, O
total O
glucose B
, O
total O
cholesterol B
and O
low O
density O
lipoprotein O
( O
LDL O
) O
- O
C O
significantly O
decreased O
in O
both O
groups O
after O
7 O
days O
of O
kimchi O
intake O
, O
but O
the O
effects O
were O
dose O
dependent O
. O

Lipid O
lowering O
effects O
of O
kimchi O
were O
more O
profound O
in O
the O
subjects O
with O
total O
cholesterol B
and O
LDL O
- O
C O
level O
over O
190 O
and O
130 O
mg O
/ O
dL O
, O
respectively O
, O
in O
both O
groups O
. O

In O
conclusion O
, O
greater O
consumption O
of O
kimchi O
improved O
FBG O
and O
serum O
total O
cholesterol B
in O
young O
healthy O
adults O
. O

In O
comparison O
to O
extracts O
from O
other O
Salvia O
species O
, O
S O
. O
sclarea O
oil O
contains O
twice O
as O
much O
omega B
- I
3 I
fatty I
acids I
, O
which O
are O
involved O
in O
eicosanoid B
synthesis O
pathways O
, O
and O
has O
been O
found O
to O
contain O
significant O
levels O
of O
the O
psychoactive O
monoterpane O
linalool B
. O

S O
. O
sclarea O
oil O
- O
treated O
submissive O
animals O
exhibited O
a O
similar O
tendency O
, O
and O
showed O
a O
significant O
reduction O
in O
blood O
corticosterone B
levels O
. O

Here O
, O
we O
report O
four O
women O
with O
POI O
who O
achieved O
pregnancies O
resulting O
from O
timed O
intercourse O
or O
intrauterine O
insemination O
in O
combination O
with O
cyclic O
estrogen B
/ O
progesterone B
therapy O
and O
close O
monitoring O
of O
follicle O
development O
. O

Artificial O
leaf O
structures O
as O
a O
UV O
detector O
formed O
by O
the O
self O
- O
assembly O
of O
ZnO B
nanoparticles O
. O

Artificial O
leaf O
structures O
have O
been O
fabricated O
by O
the O
self O
- O
assembly O
of O
ZnO B
nanoparticles O
. O

Glutathione B
dimerization O
- O
based O
plasmonic O
nanoswitch O
for O
biodetection O
of O
reactive O
oxygen B
and O
nitrogen B
species O
. O

Reactive O
oxygen B
and O
nitrogen B
species O
( O
ROS O
and O
RNS O
) O
are O
continuously O
produced O
in O
the O
cellular O
systems O
and O
are O
controlled O
by O
several O
antioxidant O
mechanisms O
. O

Here O
, O
we O
developed O
a O
straightforward O
, O
sensitive O
, O
and O
quantitative O
assay O
for O
the O
colorimetric O
and O
spectroscopic O
detection O
of O
various O
ROS O
and O
RNS O
such O
as O
H2O2 B
, O
. B
OH I
, O
( O
- O
) O
OCl O
, O
NO B
. I
, O
and O
O2 B
( I
- I
) I
using O
glutathione B
- O
modified O
gold O
nanoparticles O
( O
GSH B
- O
AuNPs O
) O
. O

For O
nonradical O
species O
such O
as O
H2O2 B
, O
this O
process O
can O
be O
more O
efficiently O
achieved O
by O
converting O
them O
into O
radical O
species O
via O
the O
Fenton O
reaction O
. O

Twisting O
bilayer O
graphene B
superlattices O
. O

Bilayer O
graphene B
is O
an O
intriguing O
material O
in O
that O
its O
electronic O
structure O
can O
be O
altered O
by O
changing O
the O
stacking O
order O
or O
the O
relative O
twist O
angle O
, O
yielding O
a O
new O
class O
of O
low O
- O
dimensional O
carbon B
system O
. O

Twisted O
bilayer O
graphene B
can O
be O
obtained O
by O
( O
i O
) O
thermal O
decomposition O
of O
SiC B
; O
( O
ii O
) O
chemical O
vapor O
deposition O
( O
CVD O
) O
on O
metal O
catalysts O
; O
( O
iii O
) O
folding O
graphene B
; O
or O
( O
iv O
) O
stacking O
graphene B
layers O
one O
atop O
the O
other O
, O
the O
latter O
of O
which O
suffers O
from O
interlayer O
contamination O
. O

Existing O
synthesis O
protocols O
, O
however O
, O
usually O
result O
in O
graphene B
with O
polycrystalline O
structures O
. O

The O
present O
study O
investigates O
bilayer O
graphene B
grown O
by O
ambient O
pressure O
CVD O
on O
polycrystalline O
Cu B
. O

The O
successful O
growth O
of O
single O
- O
crystal O
bilayer O
graphene B
provides O
an O
attractive O
jumping O
- O
off O
point O
for O
systematic O
studies O
of O
interlayer O
coupling O
in O
misoriented O
few O
- O
layer O
graphene B
systems O
with O
well O
- O
defined O
geometry O
. O

Acyclic O
nucleoside O
phosphonates O
containing O
a O
second O
phosphonate B
group O
are O
potent O
inhibitors O
of O
6 O
- O
oxopurine O
phosphoribosyltransf O
and O
have O
antimalarial O
activity O
. O

These O
novel O
compounds O
contain O
a O
second O
phosphonate B
group O
attached O
to O
the O
ANP O
scaffold O
. O

The O
crystal O
structure O
of O
this O
compound O
in O
complex O
with O
human O
HGPRT O
shows O
that O
it O
fills O
or O
partially O
fills O
three O
critical O
locations O
in O
the O
active O
site O
: O
the O
binding O
sites O
of O
the O
purine B
base O
, O
the O
5 B
' I
- I
phosphate I
group O
, O
and O
pyrophosphate B
. O

Synthesis O
of O
novel O
estrogen B
receptor O
antagonists O
using O
metal O
- O
catalyzed O
coupling O
reactions O
and O
characterization O
of O
their O
biological O
activity O
. O

Estrogen B
receptor O
( O
ER O
) O
antagonists O
are O
valuable O
in O
the O
treatment O
of O
ER O
- O
positive O
human O
breast O
cancer O
. O

In O
this O
study O
, O
we O
designed O
and O
synthesized O
nine O
new O
derivatives O
of O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
with O
a O
bulky O
side O
chain O
attached O
to O
its O
C O
- O
7 O
alpha O
position O
, O
and O
determined O
their O
ER O
antagonistic O
activity O
using O
in O
vitro O
bioassays O
. O

Computational O
docking O
analysis O
was O
conducted O
to O
model O
the O
interaction O
of O
these O
antagonists O
with O
the O
human O
ER O
alpha O
and O
showed O
that O
they O
could O
tightly O
bind O
to O
the O
ER O
alpha O
in O
a O
manner O
similar O
to O
that O
of O
ICI B
- I
182 I
, I
780 I
, O
a O
pure O
ER O
antagonist O
. O

These O
results O
provide O
an O
example O
that O
attachment O
of O
a O
bulky O
side O
chain O
to O
the O
C O
- O
7 O
alpha O
position O
of O
E2 O
can O
produce O
ER O
antagonists O
with O
ER O
affinity O
comparable O
to O
that O
of O
ICI B
- I
182 I
, I
780 I
. O

Three O
pharmaceutical O
compounds O
, O
acetaminophen B
, O
indomethacin B
, O
and O
tri O
- O
O O
- O
methyl O
- O
beta O
- O
cyclodextrin O
were O
used O
as O
model O
compounds O
. O

Ca2 B
+ I
- O
dependent O
protein O
kinase11 O
and O
24 O
modulate O
the O
activity O
of O
the O
inward O
rectifying O
K B
+ I
channels O
in O
Arabidopsis O
pollen O
tubes O
. O

Potassium B
( O
K B
( I
+ I
) I
) O
influx O
into O
pollen O
tubes O
via O
K B
( I
+ I
) I
transporters O
is O
essential O
for O
pollen O
tube O
growth O
; O
however O
, O
the O
mechanism O
by O
which O
K B
( I
+ I
) I
transporters O
are O
regulated O
in O
pollen O
tubes O
remains O
unknown O
. O

Here O
, O
we O
report O
that O
Arabidopsis O
thaliana O
Ca B
( I
2 I
+ I
) I
- O
dependent O
protein O
kinase11 O
( O
CPK11 O
) O
and O
CPK24 O
are O
involved O
in O
Ca B
( I
2 I
+ I
) I
- O
dependent O
regulation O
of O
the O
inward O
K B
( I
+ I
) I
( O
K B
( I
+ I
) I
in O
) O
channels O
in O
pollen O
tubes O
. O

Using O
patch O
- O
clamp O
analysis O
, O
we O
demonstrated O
that O
K B
( I
+ I
) I
in O
currents O
of O
pollen O
tube O
protoplasts O
were O
inhibited O
by O
elevated O
[ O
Ca B
( I
2 I
+ I
) I
] O
cyt O
. O

However O
, O
disruption O
of O
CPK11 O
or O
CPK24 O
completely O
impaired O
the O
Ca B
( I
2 I
+ I
) I
- O
dependent O
inhibition O
of O
K B
( I
+ I
) I
in O
currents O
and O
enhanced O
pollen O
tube O
growth O
. O

Furthermore O
, O
CPK11 O
phosphorylated O
the O
N B
terminus O
of O
CPK24 O
in O
vitro O
, O
suggesting O
that O
these O
two O
CDPKs O
work O
together O
as O
part O
of O
a O
kinase O
cascade O
. O

Electrophysiological O
assays O
demonstrated O
that O
the O
Shaker O
pollen O
K B
( I
+ I
) I
in O
channel O
is O
the O
main O
contributor O
to O
pollen O
tube O
K B
( I
+ I
) I
in O
currents O
and O
acts O
as O
the O
downstream O
target O
of O
the O
CPK11 O
- O
CPK24 O
pathway O
. O

We O
conclude O
that O
CPK11 O
and O
CPK24 O
together O
mediate O
the O
Ca B
( I
2 I
+ I
) I
- O
dependent O
inhibition O
of O
K B
( I
+ I
) I
in O
channels O
and O
participate O
in O
the O
regulation O
of O
pollen O
tube O
growth O
in O
Arabidopsis O
. O

LCOs O
having O
a O
conjugated O
backbone O
of O
at O
least O
five O
thiophene B
units O
emitted O
strong O
fluorescence O
upon O
binding O
, O
and O
showed O
co O
- O
localization O
with O
proteins O
reported O
to O
accumulate O
in O
s O
- O
IBM O
protein O
inclusion O
bodies O
. O

When O
the O
conjugated O
thiophene B
backbone O
was O
extended O
with O
terminal O
carboxyl B
groups O
, O
the O
LCO O
revealed O
striking O
spectral O
differences O
between O
distinct O
protein O
inclusion O
bodies O
. O

These O
studies O
quantify O
the O
importance O
of O
the O
hydrogen B
bonding O
interactions O
between O
the O
ligands O
and O
the O
water O
molecule O
involved O
in O
the O
DHQ2 O
reaction O
mechanism O
. O

Selective O
functionalization O
of O
the O
internal O
and O
the O
external O
surfaces O
of O
mesoporous O
silicon B
by O
liquid O
masking O
. O

A O
general O
approach O
for O
selective O
, O
differential O
functionalization O
of O
the O
interior O
and O
exterior O
surfaces O
of O
mesoporous O
Si B
is O
reported O
. O

The O
method O
employs O
two O
immiscible O
liquids O
, O
one O
inert O
and O
the O
other O
chemically O
reactive O
with O
the O
porous O
Si B
nanostructure O
. O

First O
, O
a O
porous O
Si B
sample O
is O
prepared O
by O
electrochemical O
etch O
and O
then O
it O
is O
mildly O
oxidized O
, O
which O
places O
a O
thin O
layer O
of O
silicon O
oxide O
at O
the O
surface O
. O

The O
inner O
pore O
walls O
of O
the O
partially O
oxidized O
porous O
Si B
film O
are O
then O
infiltrated O
with O
an O
inert O
liquid O
( O
octane B
) O
. O

The O
sample O
is O
then O
immersed O
in O
aqueous O
solution O
containing O
hydrogen O
fluoride O
( O
HF B
) O
, O
which O
serves O
as O
the O
reactive O
liquid O
. O

The O
hydrophobic O
phase O
is O
retained O
in O
the O
interior O
of O
the O
porous O
nanostructure O
, O
and O
HF B
( O
aq O
) O
attacks O
only O
the O
exposed O
surfaces O
of O
the O
oxidized O
porous O
Si B
sample O
, O
generating O
a O
hydrophobic O
, O
hydrogen B
- O
terminated O
( O
Si B
- I
H I
) O
outer O
layer O
. O

The O
reaction O
is O
self O
- O
limiting O
due O
to O
the O
immiscibility O
of O
octane B
and O
water O
, O
and O
the O
extent O
of O
penetration O
of O
the O
Si B
- I
H I
surface O
into O
the O
porous O
layer O
is O
dependent O
on O
the O
time O
of O
exposure O
to O
HF B
( O
aq O
) O
. O

The O
Si B
- I
H I
surface O
can O
then O
be O
modified O
by O
thermal O
hydrosilylation O
( O
1 O
- O
dodecene O
or O
10 O
- O
bromo O
- O
1 O
- O
decene O
) O
in O
a O
subsequent O
step O
, O
resulting O
in O
a O
bifunctional O
porous O
Si B
film O
containing O
hydrophobic O
pore O
entrances O
to O
hydrophilic O
inner O
pores O
. O

The O
hydrophobic O
dodecyl B
species O
at O
the O
mouths O
of O
the O
pores O
is O
found O
to O
form O
a O
barrier O
for O
molecular O
transport O
; O
it O
decreases O
the O
rate O
of O
leaching O
( O
into O
water O
) O
of O
a O
rhodamine B
test O
molecule O
that O
is O
preloaded O
into O
the O
sample O
by O
> O
8 O
fold O
. O

In O
earlier O
work O
[ O
Gruzman O
, O
D O
. O
; O
Karton O
, O
A O
. O
; O
Martin O
, O
J O
. O
M O
. O
L O
. O
J O
. O
Phys O
. O
Chem O
. O
A O
2009 O
, O
113 O
, O
11974 O
] O
, O
we O
showed O
that O
conformer O
energies O
in O
alkanes B
( O
and O
other O
systems O
) O
are O
highly O
dispersion O
- O
driven O
and O
that O
uncorrected O
DFT O
functionals O
fail O
badly O
at O
reproducing O
them O
, O
while O
simple O
empirical O
dispersion O
corrections O
tend O
to O
overcorrect O
. O

Adhesion O
of O
Mussel O
Foot O
Protein O
- O
3 O
to O
TiO2 B
Surfaces O
: O
the O
Effect O
of O
pH O
. O

The O
underwater O
adhesion O
of O
marine O
mussels O
relies O
on O
mussel O
foot O
proteins O
( O
mfps O
) O
rich O
in O
the O
catecholic O
amino O
acid O
3 O
, O
4 O
- O
dihydroxyphenylalani O
( O
Dopa B
) O
. O

As O
a O
side O
chain O
, O
Dopa B
is O
capable O
of O
strong O
bidentate O
interactions O
with O
a O
variety O
of O
surfaces O
, O
including O
many O
minerals O
and O
metal B
oxides I
. O

Titanium O
is O
among O
the O
most O
widely O
used O
medical O
implant O
material O
and O
quickly O
forms O
a O
TiO2 B
passivation O
layer O
under O
physiological O
conditions O
. O

Understanding O
the O
binding O
mechanism O
of O
Dopa B
to O
TiO2 B
surfaces O
is O
therefore O
of O
considerable O
theoretical O
and O
practical O
interest O
. O

Using O
a O
surface O
forces O
apparatus O
, O
we O
explored O
the O
force O
- O
distance O
profiles O
and O
adhesion O
energies O
of O
mussel O
foot O
protein O
3 O
( O
mfp O
- O
3 O
) O
to O
TiO2 B
surfaces O
at O
three O
different O
pHs O
( O
pH O
3 O
, O
5 O
. O
5 O
and O
7 O
. O
5 O
) O
. O

At O
pH O
3 O
, O
mfp O
- O
3 O
showed O
the O
strongest O
adhesion O
force O
on O
TiO2 B
, O
with O
an O
adhesion O
energy O
of O
~ O
- O
7 O
. O
0 O
mJ O
/ O
m O
( O
2 O
) O
. O

Increasing O
the O
pH O
gives O
rise O
to O
two O
opposing O
effects O
: O
( O
1 O
) O
increased O
oxidation O
of O
Dopa B
, O
thus O
, O
decreasing O
availability O
for O
the O
Dopa B
- O
mediated O
adhesion O
, O
and O
( O
2 O
) O
increased O
bidentate O
Dopa B
- O
Ti B
coordination O
, O
leading O
to O
the O
further O
stabilization O
of O
the O
Dopa B
group O
and O
, O
thus O
, O
an O
increase O
in O
adhesion O
force O
. O

The O
two O
competing O
effects O
give O
rise O
to O
a O
higher O
adhesion O
force O
of O
mfp O
- O
3 O
on O
the O
TiO2 B
surface O
at O
pH O
7 O
. O
5 O
than O
at O
pH O
5 O
. O
5 O
. O

Our O
results O
suggest O
that O
Dopa B
- O
containing O
proteins O
and O
synthetic O
polymers O
have O
great O
potential O
as O
coating O
materials O
for O
medical O
implant O
materials O
, O
particularly O
if O
redox O
activity O
can O
be O
controlled O
. O

Synthetic O
Approaches O
to O
RBC O
Mimicry O
and O
Oxygen B
Carrier O
Systems O
. O

Consequently O
, O
there O
is O
a O
significant O
interest O
in O
synthetic O
RBC O
analogues O
that O
can O
mimic O
its O
oxygen B
- O
transport O
properties O
while O
allowing O
convenient O
manufacture O
, O
reproducibility O
, O
long O
shelf O
life O
, O
and O
reduced O
biological O
risks O
. O

To O
this O
end O
, O
the O
current O
Review O
provides O
a O
comprehensive O
description O
and O
discussion O
of O
the O
various O
research O
approaches O
and O
current O
state O
- O
of O
- O
the O
- O
art O
in O
synthetically O
mimicking O
RBC O
' O
s O
oxygen B
- O
carrying O
biochemical O
properties O
, O
as O
well O
as O
the O
biophysical O
parameters O
( O
shape O
, O
size O
and O
mechanical O
modulus O
) O
that O
influence O
RBCs O
' O
hemodynamic O
transport O
properties O
in O
blood O
flow O
. O

In O
the O
type O
2 O
diabetic O
heart O
, O
substrate O
metabolism O
is O
shifted O
from O
glucose B
utilisation O
to O
fatty B
acid I
oxidation O
, O
resulting O
in O
metabolic O
inflexibility O
and O
cardiac O
dysfunction O
. O

The O
ischaemic O
heart O
also O
loses O
its O
metabolic O
flexibility O
and O
can O
switch O
to O
glucose B
or O
fatty B
acid I
oxidation O
as O
its O
preferential O
state O
, O
which O
may O
deteriorate O
cardiac O
function O
even O
further O
in O
case O
of O
type O
2 O
diabetes O
mellitus O
. O
Recent O
experimental O
studies O
suggest O
that O
the O
cardioprotective O
properties O
of O
volatile O
anaesthetics O
partly O
rely O
on O
changing O
myocardial O
substrate O
metabolism O
. O

Groups O
of O
rats O
were O
treated O
orally O
with O
different O
doses O
of O
ectoine O
( O
30 O
- O
300mg O
/ O
kg O
) O
or O
sulfasalazine B
( O
reference O
drug O
) O
daily O
for O
11 O
days O
. O

Induction O
of O
colitis O
led O
to O
marked O
weight O
loss O
, O
significant O
histopathological O
changes O
of O
the O
colon O
, O
and O
variable O
changes O
in O
levels O
of O
myeloperoxidase O
, O
reduced O
glutathione B
, O
malondialdehyde B
, O
and O
all O
inflammatory O
markers O
tested O
. O

Followed O
by O
GC O
- O
MS O
analysis O
, O
its O
composition O
was O
characterized O
by O
the O
presence O
of O
thymol B
( O
55 O
. O
50 O
% O
) O
, O
as O
major O
constituent O
. O

EO O
and O
its O
constituents O
( O
thymol B
, O
p O
- O
cymene O
, O
gamma B
- I
terpinene I
and O
myrcene O
) O
displayed O
cytotoxicity O
to O
different O
tumor O
cell O
lines O
. O

In O
conclusion O
, O
the O
tested O
essential O
oil O
of O
L O
. O
gracilis O
leaves O
, O
which O
has O
thymol B
as O
its O
major O
constituent O
, O
possesses O
significant O
in O
vitro O
and O
in O
vivo O
antitumor O
activity O
. O

The O
goal O
of O
this O
study O
was O
to O
re O
- O
assess O
monogyny O
in O
wild O
golden O
lion O
tamarin O
groups O
based O
upon O
pregnancy O
diagnoses O
that O
used O
non O
- O
invasive O
enzyme O
immunoassay O
for O
progesterone B
and O
cortisol B
, O
combined O
with O
weekly O
data O
on O
individual O
weight O
gain O
, O
bi O
- O
annual O
physical O
examinations O
noting O
pregnancy O
and O
lactation O
status O
and O
daily O
behavioral O
observations O
. O

As O
a O
part O
of O
systematic O
investigation O
of O
synthesis O
and O
biological O
activities O
of O
indole B
analogues O
linked O
to O
various O
heterocyclic O
systems O
, O
we O
have O
synthesized O
new O
compounds O
viz O
. O
, O
2 O
- O
amino O
- O
4 O
- O
( O
5 O
' O
- O
substituted O
2 O
' O
- O
phenyl O
- O
1H O
- O
indol O
- O
3 O
' O
- O
yl O
) O
- O
6 O
- O
aryl O
- O
4H O
- O
pyran O
- O
3 O
- O
carbonitriles O
( O
2a O
- O
i O
) O
, O
4 O
, O
5 O
- O
diamino O
- O
6 O
- O
( O
5 O
' O
- O
substituted O
2 O
' O
- O
phenyl O
- O
1H O
- O
indol O
- O
3 O
' O
- O

In O
case O
of O
antioxidant O
activity O
, O
compound O
4a O
showed O
promising O
radical O
scavenging O
activity O
, O
ferric B
ions O
( O
Fe B
( I
3 I
+ I
) I
) O
reducing O
antioxidant O
power O
( O
FRAP O
) O
and O
metal O
chelating O
activity O
. O

Selective O
COX O
- O
2 O
inhibitors O
( O
COXib O
) O
belonging O
to O
the O
class O
of O
diaryl O
heterocycles O
( O
e O
. O
g O
. O
, O
celecoxib B
, O
rofecoxib O
, O
etc O
. O
) O
, O
are O
devoid O
of O
the O
undesirable O
effects O
due O
to O
their O
capacity O
to O
inhibit O
selectively O
inducible O
( O
COX O
- O
2 O
) O
, O
responsible O
for O
inflammatory O
effects O
but O
not O
constitutive O
cyclooxygenase O
- O
1 O
( O
COX O
- O
1 O
) O
( O
COX O
) O
; O
responsible O
for O
cytoprotective O
effects O
on O
gastric O
mucosa O
. O

To O
evaluate O
the O
effect O
of O
two O
1 O
, O
5 O
- O
diarylpyrrole O
- O
3 O
- O
alkoxyethyl O
ethers O
, O
VA441 O
and O
VA428 O
( O
up O
to O
100 O
mu O
M O
) O
, O
respectively O
, O
in O
comparison O
with O
two O
well O
known O
COXib O
, O
celecoxib B
and O
rofecoxib O
, O
on O
HaCaT O
cell O
( O
keratinocytes O
) O
proliferation O
and O
toxicity O
. O

Reactive O
oxygen B
species O
( O
ROS O
) O
can O
serve O
as O
essential O
second O
messengers O
mediating O
cellular O
responses O
resulting O
in O
immune O
cells O
activation O
. O

Relative O
expression O
of O
cholesterol B
transport O
- O
related O
proteins O
and O
inflammation O
markers O
through O
the O
induction O
of O
7 O
- O
ketosterol O
- O
mediated O
stress O
in O
Caco O
- O
2 O
cells O
. O

Human O
diets O
contain O
sterol B
oxidation O
products O
that O
can O
induce O
cytotoxic O
effects O
, O
mainly O
caused O
by O
cholesterol B
oxides I
. O

This O
study O
evaluates O
the O
production O
of O
inflammatory O
biomarkers O
( O
IL O
- O
1 O
beta O
, O
IL O
- O
8 O
, O
IL O
- O
10 O
, O
TNF O
alpha O
) O
and O
the O
influence O
of O
gene O
expression O
transporters O
and O
enzymes O
related O
to O
cholesterol B
absorption O
and O
metabolism O
( O
NPC1L1 O
, O
ABCG5 O
/ O
8 O
, O
HMGCoA O
, O
ACAT O
) O
produced O
by O
7 O
- O
ketosterols O
( O
stigmasterol B
/ O
cholesterol B
) O
in O
Caco O
- O
2 O
cells O
. O

Results O
showed O
7 O
- O
ketostigmasterol O
to O
have O
a O
greater O
proinflammatory O
potential O
than O
7 B
- I
ketocholesterol I
. O

Cell O
- O
pre O
- O
incubation O
with O
bradykinin O
induced O
changes O
in O
ABCG O
expression O
levels O
after O
7 O
- O
ketostigmasterol O
- O
incubation O
; O
however O
, O
the O
energetic O
metabolism O
inhibition O
reduced O
NPC1L1 O
expression O
only O
in O
7 B
- I
ketocholesterol I
- O
incubated O
cells O
. O

In O
non O
- O
pre O
- O
treated O
cells O
, O
HMG B
- I
CoA I
was O
up O
- O
regulated O
by O
both O
7 O
- O
ketosterols O
. O

However O
, O
exposure O
to O
inhibitors O
down O
- O
regulated O
the O
expression O
levels O
, O
mainly O
in O
7 B
- I
ketocholesterol I
- O
incubated O
cells O
. O

These O
results O
suggest O
that O
internalization O
and O
excretion O
of O
7 O
- O
ketostigmasterol O
is O
probably O
influenced O
by O
[ O
Ca B
] O
i O
, O
which O
also O
could O
mediate O
HMGCoA O
activity O
in O
POPs O
metabolism O
. O

Neuroprotective O
effects O
of O
neolignans B
isolated O
from O
Magnoliae O
Cortex O
against O
glutamate B
- O
induced O
apoptotic O
stimuli O
in O
HT22 O
cells O
. O

Obovatol B
, O
honokiol B
, O
and O
magnolol B
were O
isolated O
from O
the O
ethanolic O
extract O
of O
Magnoliae O
Cortex O
. O

Isolated O
compounds O
obovatol B
, O
honokiol B
, O
and O
magnolol B
were O
protective O
against O
5mM O
glutamate B
- O
induced O
cell O
death O
. O

When O
cells O
were O
stressed O
using O
glutamate B
, O
cell O
viability O
decreased O
to O
16 O
. O
98 O
+ O
/ O
- O
4 O
. O
58 O
% O
over O
the O
control O
( O
100 O
. O
00 O
+ O
/ O
- O
10 O
. O
15 O
% O
) O
. O

In O
contrast O
, O
10 O
mu O
M O
obovatol B
, O
10 O
mu O
M O
honokiol B
, O
and O
50 O
mu O
M O
magnolol B
increased O
cell O
viability O
to O
91 O
. O
80 O
+ O
/ O
- O
1 O
. O
70 O
% O
, O
93 O
. O
59 O
+ O
/ O
- O
1 O
. O
93 O
% O
, O
and O
85 O
. O
36 O
+ O
/ O
- O
7 O
. O
40 O
% O
, O
respectively O
. O

The O
neuroprotective O
effects O
of O
obovatol B
and O
honokiol B
were O
attributable O
to O
the O
inhibition O
of O
intracellular O
reactive O
oxygen B
species O
production O
, O
followed O
by O
protection O
of O
the O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
, O
recovery O
of O
Bcl O
- O
2 O
and O
Bid O
levels O
, O
inhibition O
of O
apoptosis O
- O
inducing O
factor O
expression O
, O
and O
phosphorylation O
of O
mitogen O
- O
activated O
protein O
kinases O
such O
as O
p38 O
kinases O
, O
extracellular O
signal O
- O
regulated O
kinases O
, O
and O
c O
- O
Jun O
N B
- O
terminal O
kinases O
. O

On O
the O
contrary O
, O
magnolol B
did O
not O
show O
any O
significant O
effect O
on O
the O
Delta O
Psi O
m O
and O
apoptotic O
factors O
. O

Among O
three O
compounds O
, O
obovatol B
most O
strongly O
scavenged O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radicals O
and O
inhibited O
the O
elevation O
of O
intracellular O
reactive O
oxygen B
species O
levels O
in O
glutamate B
- O
stressed O
HT22 O
cells O
. O

These O
data O
suggest O
that O
obovatol B
and O
honokiol B
may O
have O
clinical O
applications O
for O
preventing O
neurodegenerative O
disorders O
. O

MTT B
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O

Curcumin B
loaded O
solid O
lipid O
nanoparticles O
: O
An O
efficient O
formulation O
approach O
for O
cerebral O
ischemic O
reperfusion O
injury O
in O
rats O
. O

SCOPE O
: O
To O
evaluate O
curcumin B
loaded O
solid O
lipid O
nanoparticles O
( O
C O
- O
SLNs O
) O
in O
the O
experimental O
paradigm O
of O
cerebral O
ischemia O
( O
BCCAO O
model O
) O
in O
rats O
. O

METHODS O
AND O
RESULTS O
: O
Oral O
administration O
of O
free O
curcumin B
and O
C O
- O
SLNs O
( O
25 O
and O
50mg O
/ O
kg O
) O
was O
started O
5days O
prior O
and O
continued O
for O
3days O
after O
BCCAO O
. O

Levels O
of O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
, O
and O
mitochondrial O
complex O
enzyme O
activities O
were O
significantly O
increased O
, O
while O
lipid O
peroxidation O
, O
nitrite B
, O
and O
acetylcholinesterase O
levels O
decreased O
( O
p O
< O
0 O
. O
05 O
) O
after O
C O
- O
SLNs O
administration O
. O

It O
is O
noteworthy O
to O
report O
the O
restoration O
of O
SOD O
, O
GSH B
, O
catalase O
, O
and O
mitochondrial O
complex O
enzyme O
levels O
equivalent O
to O
sham O
control O
values O
. O

Gamma O
- O
scintigraphic O
studies O
show O
16 O
. O
4 O
and O
30 O
times O
improvement O
in O
brain O
bioavailability O
( O
AUC O
) O
upon O
oral O
and O
i O
. O
v O
administration O
of O
C O
- O
SLNs O
versus O
solubilized O
curcumin B
( O
C O
- O
S O
) O
. O

CONCLUSIONS O
: O
Study O
indicates O
protective O
role O
of O
curcumin B
against O
cerebral O
ischemic O
insult O
; O
provided O
it O
is O
packaged O
suitably O
for O
improved O
brain O
delivery O
. O

Steroids B
excreted O
in O
urine O
by O
neonates O
with O
21 O
- O
hydroxylase O
deficiency O
. O

In O
21 O
- O
hydroxylase O
deficiency O
, O
urinary O
metabolites O
of O
21 O
- O
deoxycortisol O
, O
mainly O
derived O
from O
its O
11oxo O
form O
21 O
- O
deoxycortisone O
, O
are O
indicators O
of O
intra O
- O
adrenal O
overproduction O
of O
17 B
- I
hydroxyprogesterone I
. O

This O
work O
forms O
the O
concluding O
part O
of O
a O
comprehensive O
study O
of O
urinary O
steroids B
, O
aiming O
to O
enhance O
the O
diagnosis O
of O
this O
disorder O
and O
to O
further O
elucidate O
steroid B
metabolism O
in O
neonates O
. O

Cortisol B
metabolites O
found O
in O
untreated O
patients O
, O
similarly O
almost O
exclusively O
present O
in O
their O
11oxo O
form O
in O
neonates O
, O
have O
been O
included O
for O
completeness O
. O

Steroids B
were O
analyzed O
, O
after O
extraction O
and O
enzymatic O
conjugate O
hydrolysis O
, O
as O
methyloxime O
- O
trimethylsilyl O
ether O
derivatives O
on O
gas O
- O
chromatographs O
coupled O
to O
quadrupole O
and O
ion O
- O
trap O
mass O
- O
spectrometers O
. O

GC O
- O
MS O
/ O
MS O
contributed O
only O
to O
the O
characterization O
of O
structures O
outside O
the O
C B
- O
ring O
, O
as O
described O
in O
the O
preceding O
parts O
of O
this O
study O
. O

Parallels O
were O
found O
between O
the O
metabolism O
of O
21 O
- O
deoxycortisone O
and O
cortisone B
. O

Protein O
nitration O
promotes O
inducible O
nitric B
oxide I
synthase O
transcription O
mediated O
by O
NF O
- O
kappa O
B O
in O
high O
glucose B
- O
stimulated O
human O
lens O
epithelial O
cells O
. O

Although O
an O
important O
event O
in O
hyperglycaemia O
- O
induced O
oxidative O
stress O
is O
the O
nuclear O
factor O
- O
kappa O
b O
( O
NF O
- O
kappa O
B O
) O
- O
activated O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
expression O
, O
the O
underlying O
mechanism O
is O
not O
fully O
characterized O
. O

Peroxynitrite B
, O
formed O
from O
NO B
and O
superoxide B
, O
can O
induce O
multiple O
proteins O
nitration O
, O
even O
including O
NF O
- O
kappa O
B O
and O
iNOS O
, O
to O
alter O
their O
functions O
. O

In O
this O
study O
, O
we O
found O
high O
glucose B
caused O
conspicuous O
nitration O
of O
nuclear O
NF O
- O
kappa O
B O
p65 O
and O
its O
co O
- O
activator O
p300 O
in O
human O
lens O
epithelial O
cells O
. O

Moreover O
, O
nearly O
all O
predicted O
NF O
- O
kappa O
B O
binding O
sites O
in O
the O
human O
iNOS O
gene O
promoter O
were O
responsive O
to O
high O
glucose B
stimulation O
, O
might O
for O
a O
synergistic O
role O
. O

While O
, O
only O
the O
NF O
- O
kappa O
B O
binding O
site O
- O
5212 O
showed O
significant O
alterations O
by O
high O
glucose B
and O
peroxynitrite B
stimulations O
, O
indicating O
it O
a O
more O
important O
role O
in O
the O
protein O
nitration O
promoted O
iNOS O
gene O
transcription O
. O

Our O
results O
demonstrated O
that O
protein O
nitration O
can O
promote O
the O
NF O
- O
kappa O
B O
- O
activated O
iNOS O
gene O
transcription O
in O
human O
lens O
epithelial O
cells O
by O
high O
glucose B
stimulation O
. O

N B
- I
acetylcysteine I
( O
NAC B
, O
33 O
mM O
) O
and O
the O
c O
- O
jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
inhibitor O
( O
SP600125 B
, O
33 O
mu O
M O
) O
further O
decreased O
the O
viability O
in O
the O
presence O
of O
DEP O
( O
200 O
mu O
g O
/ O
ml O
) O
and O
3 O
. O
3 O
% O
FCS O
. O

Neuropeptide O
S O
enhances O
memory O
and O
mitigates O
memory O
impairment O
induced O
by O
MK801 O
, O
scopolamine B
or O
A O
beta O
1 O
- O
42 O
in O
mice O
novel O
object O
and O
object O
location O
recognition O
tasks O
. O

Here O
, O
we O
investigated O
the O
role O
of O
NPS O
in O
memory O
formation O
, O
and O
determined O
whether O
NPS O
could O
mitigate O
memory O
impairment O
induced O
by O
selective O
N B
- I
methyl I
- I
d I
- I
aspartate I
receptor O
antagonist O
MK801 O
, O
muscarinic O
cholinergic O
receptor O
antagonist O
scopolamine B
or O
A O
beta O
1 O
- O
42 O
in O
mice O
, O
using O
novel O
object O
and O
object O
location O
recognition O
tasks O
. O

Then O
, O
we O
found O
that O
i O
. O
c O
. O
v O
. O
injection O
of O
NPS O
reversed O
memory O
disruption O
induced O
by O
MK801 O
, O
scopolamine B
or O
A O
beta O
1 O
- O
42 O
in O
both O
tasks O
. O

Recently O
, O
it O
has O
been O
proposed O
to O
couple O
an O
enzymatic O
activation O
step O
based O
on O
horseradish O
peroxidase O
( O
HRP O
) O
/ O
hydrogen B
peroxide I
to O
such O
peptide O
reactivity O
assays O
. O

To O
evaluate O
this O
approach O
, O
the O
behavior O
of O
2 B
- I
methoxy I
- I
4 I
- I
methylphenol I
( O
2M4MP O
) O
, O
reported O
as O
a O
moderate O
sensitizer O
according O
to O
the O
Local O
Lymph O
Node O
Assay O
( O
LLNA O
) O
, O
has O
been O
investigated O
in O
this O
assay O
. O

To O
follow O
the O
reaction O
with O
the O
peptides O
and O
characterize O
more O
easily O
intermediates O
and O
adducts O
, O
the O
molecule O
was O
first O
( B
13 I
) I
C I
isotopically O
substituted O
at O
the O
most O
probable O
reactive O
position O
. O

When O
2M4MP O
was O
incubated O
with O
HRP O
/ O
H2O2 B
in O
a O
mixture O
PBS O
( O
pH O
7 O
. O
4 O
, O
0 O
. O
1M O
) O
/ O
acetonitrile B
2 O
: O
1 O
, O
two O
main O
products O
were O
formed O
deriving O
from O
the O
formation O
of O
a O
quinone O
methide O
2M4MQ O
subsequently O
trapped O
by O
either O
H2O2 B
or O
H2O B
to O
form O
a O
benzylic O
hydroperoxide O
or O
alcohol B
, O
respectively O
. O

When O
nucleophiles O
such O
as O
GSH B
or O
a O
peptide O
containing O
a O
cysteine B
residue O
( O
Pep O
- O
Cys B
) O
were O
present O
in O
the O
reaction O
medium O
, O
the O
quinone O
methide O
2M4MQ O
was O
trapped O
by O
the O
more O
nucleophilic O
thiol B
function O
to O
form O
thio O
- O
adducts O
. O

Amino B
nucleophiles O
were O
shown O
to O
be O
far O
less O
reactive O
towards O
the O
quinone O
methide O
2M4MQ O
with O
only O
tiny O
formation O
of O
adducts O
with O
lysine B
or O
arginine B
side O
chains O
. O

In O
addition O
we O
demonstrated O
that O
the O
same O
enzymatic O
activation O
could O
also O
take O
place O
in O
a O
microemulsion O
based O
on O
sodium B
dodecyl I
sulfate I
/ O
tert O
- O
butanol O
/ O
chloroform B
/ O
buffer O
. O

Our O
analysis O
suggests O
that O
fm O
is O
the O
major O
determinant O
of O
total O
drug O
M O
/ O
P O
ratio O
for O
amine B
, O
alcohol B
, O
N O
- O
and O
S O
- O
oxide O
, O
and O
carboxylic B
acid I
metabolites O
. O

In O
some O
cases O
, O
active O
transport O
plays O
an O
important O
role O
in O
this O
process O
( O
e O
. O
g O
. O
, O
carboxylic B
acid I
metabolites O
) O
. O

For O
these O
metabolites O
, O
a O
more O
thorough O
understanding O
of O
the O
elimination O
clearance O
of O
the O
metabolite O
is O
critical O
to O
discern O
the O
likelihood O
of O
whether O
the O
phenol B
will O
constitute O
a O
major O
circulating O
metabolite O
. O

Alternariol B
induces O
abnormal O
nuclear O
morphology O
and O
cell O
cycle O
arrest O
in O
murine O
RAW O
264 O
. O
7 O
macrophages O
. O

The O
mycotoxin O
alternariol B
( O
AOH B
) O
, O
a O
frequent O
contaminant O
in O
fruit O
and O
cereal O
products O
, O
is O
known O
to O
induce O
DNA O
damage O
with O
subsequent O
cell O
cycle O
arrest O
. O

Here O
we O
elucidated O
the O
effects O
of O
AOH B
on O
stages O
of O
cell O
cycle O
progression O
using O
the O
RAW O
264 O
. O
7 O
macrophage O
model O
. O

AOH B
resulted O
in O
an O
accumulation O
of O
cells O
in O
the O
G2 O
/ O
M O
- O
phase O
( O
4N O
) O
. O

Remarkably O
, O
after O
exposure O
to O
AOH B
for O
24h O
, O
most O
of O
the O
cells O
exhibited O
abnormally O
shaped O
nuclei O
, O
as O
evidenced O
by O
partly O
divided O
nuclei O
, O
nuclear O
blebs O
, O
polyploidy O
and O
micronuclei O
( O
MN O
) O
. O

AOH B
treatment O
also O
induced O
abnormal O
Aurora O
B O
bridges O
, O
suggesting O
that O
cytokinesis O
was O
interfered O
within O
cells O
undergoing O
karyokinesis O
. O

pH O
- O
sensitive O
nanocargo O
based O
on O
smart O
polymer O
functionalized O
graphene B
oxide I
for O
site O
- O
specific O
drug O
delivery O
. O

Graphene B
oxide I
( O
GO O
) O
was O
functionalized O
covalently O
with O
pH O
- O
sensitive O
poly O
( O
2 O
- O
( O
diethylamino O
) O
ethyl O
methacrylate O
) O
( O
PDEA O
) O
by O
surface O
- O
initiated O
in O
situ O
atom O
transfer O
radical O
polymerization O
. O

Simple O
physisorption O
by O
pi O
- O
pi O
stacking O
and O
hydrophobic O
interactions O
on O
GO O
- O
PDEA O
can O
be O
used O
to O
load O
camptothecin B
( O
CPT B
) O
, O
a O
widely O
used O
water O
- O
insoluble O
cancer O
drug O
. O

The O
loaded O
CPT B
was O
released O
only O
at O
the O
lower O
( O
acidic O
) O
pH O
normally O
found O
in O
a O
tumor O
environment O
but O
not O
in O
basic O
and O
neutral O
pH O
. O

Revised O
conformational O
assignments O
and O
conformational O
evolution O
of O
tyrosine B
by O
laser O
desorption O
supersonic O
jet O
laser O
spectroscopy O
. O

The O
number O
of O
conformers O
and O
their O
structures O
of O
tyrosine B
are O
reassigned O
on O
the O
basis O
of O
resonance O
enhanced O
multiphoton O
ionization O
( O
REMPI O
) O
, O
ultraviolet O
- O
ultraviolet O
hole O
burning O
( O
UV O
- O
UV O
HB O
) O
, O
infrared O
( O
IR O
) O
dip O
spectra O
, O
and O
quantum O
chemical O
calculations O
. O

The O
importance O
of O
dipole O
- O
dipole O
interaction O
between O
an O
amino B
- I
acid I
chain O
and O
hydroxyl B
group O
at O
the O
benzene B
ring O
was O
also O
discussed O
. O

We O
demonstrate O
that O
activation O
of O
STAT3 O
serine B
- O
727 O
and O
tyrosine B
- O
705 O
phosphorylations O
is O
promoted O
by O
B O
- O
RAF O
( O
V600E O
) O
activity O
and O
that O
the O
Mcl O
- O
1 O
promoter O
is O
dependent O
on O
a O
STAT O
consensus O
- O
site O
for O
B O
- O
RAF O
- O
mediated O
activation O
. O

Active O
silver B
nanoparticles O
for O
wound O
healing O
. O

In O
this O
preliminary O
study O
, O
the O
silver B
nanoparticle O
( O
Ag B
NP O
) O
- O
based O
dressing O
, O
Acticoat O
( O
TM O
) O
Flex O
3 O
, O
has O
been O
applied O
to O
a O
3D O
fibroblast O
cell O
culture O
in O
vitro O
and O
to O
a O
real O
partial O
thickness O
burn O
patient O
. O

The O
in O
vitro O
results O
show O
that O
Ag B
NPs O
greatly O
reduce O
mitochondrial O
activity O
, O
while O
cellular O
staining O
techniques O
show O
that O
nuclear O
integrity O
is O
maintained O
, O
with O
no O
signs O
of O
cell O
death O
. O

The O
results O
show O
that O
Ag B
NPs O
are O
released O
as O
aggregates O
and O
are O
localized O
in O
the O
cytoplasm O
of O
fibroblasts O
. O

Depth O
profiles O
of O
the O
Ag B
concentrations O
were O
determined O
along O
the O
skin O
biopsies O
. O

In O
the O
healed O
sample O
, O
most O
of O
the O
silver B
remained O
in O
the O
surface O
layers O
, O
whereas O
in O
the O
unhealed O
sample O
, O
the O
silver B
penetrated O
more O
deeply O
. O

The O
Ag B
concentrations O
in O
the O
cell O
cultures O
were O
also O
determined O
. O

Clinical O
observations O
and O
experimental O
data O
collected O
here O
are O
consistent O
with O
previously O
published O
articles O
and O
support O
the O
safety O
of O
Ag B
NP O
- O
based O
dressing O
in O
wound O
treatment O
. O

Assessment O
of O
the O
abuse O
liability O
of O
ABT O
- O
288 O
, O
a O
novel O
histamine B
H3 O
receptor O
antagonist O
. O

RATIONALE O
: O
Histamine B
H3 O
receptor O
antagonists O
, O
such O
as O
ABT O
- O
288 O
, O
have O
been O
shown O
to O
possess O
cognitive O
- O
enhancing O
and O
wakefulness O
- O
promoting O
effects O
. O

Drug O
discrimination O
was O
used O
to O
assess O
amphetamine B
- O
like O
stimulus O
properties O
, O
and O
drug O
self O
- O
administration O
was O
used O
to O
evaluate O
reinforcing O
effects O
of O
ABT O
- O
288 O
. O

Repeated O
administration O
of O
ABT O
- O
288 O
did O
not O
result O
in O
cross O
- O
sensitization O
to O
the O
stimulant O
effects O
of O
d B
- I
amphetamine I
in O
mice O
, O
suggesting O
that O
there O
is O
little O
overlap O
in O
circuitries O
upon O
which O
the O
two O
drugs O
interact O
for O
motor O
activity O
. O

ABT O
- O
288 O
did O
not O
produce O
amphetamine B
- O
like O
discriminative O
stimulus O
effects O
in O
drug O
discrimination O
studies O
nor O
was O
it O
self O
- O
administered O
by O
rats O
trained O
to O
self O
- O
administer O
cocaine B
. O

We O
have O
used O
this O
approach O
to O
generate O
high O
- O
performance O
chip O
- O
based O
biosensors O
using O
silicon B
as O
a O
platform O
for O
the O
generation O
of O
sensor O
arrays O
. O

Current O
self O
- O
complianced O
and O
self O
- O
rectifying O
resistive O
switching O
in O
Ag B
- O
electroded O
single O
Na B
- O
doped O
ZnO B
nanowires O
. O

We O
demonstrate O
current O
self O
- O
complianced O
and O
self O
- O
rectifying O
bipolar O
resistive O
switching O
in O
an O
Ag B
- O
electroded O
Na B
- O
doped O
ZnO B
nanowire O
device O
. O

The O
resistive O
switching O
is O
controlled O
by O
the O
formation O
and O
rupture O
of O
an O
Ag B
nanoisland O
chain O
on O
the O
surface O
along O
the O
Na B
- O
doped O
ZnO B
nanowire O
. O

Na B
- O
doping O
plays O
important O
roles O
in O
both O
the O
self O
- O
compliance O
and O
self O
- O
rectifying O
properties O
. O

Unusual O
amino B
acids I
and O
monofluoroacetate O
from O
Dichapetalum O
michelsonii O
( O
Umutambasha O
) O
, O
a O
toxic O
plant O
from O
Rwanda O
. O

Three O
free O
unusual O
amino B
acids I
, O
named O
N O
- O
methyl O
- O
alpha O
- O
alanine O
, O
N O
- O
methyl O
- O
beta O
- O
alanine O
, O
and O
2 O
, O
7 O
- O
diaminooctan O
- O
1 O
, O
8 O
- O
dioic O
acid O
, O
described O
for O
the O
first O
time O
in O
a O
plant O
, O
and O
known O
trigonelline B
were O
also O
isolated O
from O
the O
stem O
bark O
of O
D O
. O
michelsonii O
. O

Structure O
elucidations O
were O
mainly O
achieved O
by O
spectroscopic O
methods O
( O
1H B
- O
NMR O
, O
2D O
- O
NMR O
, O
MS O
) O
and O
by O
comparison O
with O
authentic O
references O
. O

These O
unusual O
amino B
acids I
were O
detected O
by O
a O
fast O
, O
reliable O
TLC O
analysis O
in O
all O
our O
batches O
of O
Umutambasha O
, O
suggesting O
that O
they O
could O
be O
used O
for O
identification O
purposes O
in O
case O
of O
human O
or O
livestock O
intoxications O
. O

Robust O
Synthesis O
of O
Gold O
Cubic O
Nanoframes O
through O
a O
Combination O
of O
Galvanic O
Replacement O
, O
Gold O
Deposition O
, O
and O
Silver B
Dealloying O
. O

A O
facile O
, O
robust O
approach O
to O
the O
synthesis O
of O
Au B
cubic O
nanoframes O
is O
described O
. O

The O
synthesis O
involves O
three O
major O
steps O
: O
1 O
) O
preparation O
of O
Au O
- O
Ag O
alloyed O
nanocages O
using O
a O
galvanic O
replacement O
reaction O
between O
Ag B
nanocubes O
and O
HAuCl4 O
; O
2 O
) O
deposition O
of O
thin O
layers O
of O
pure O
Au B
onto O
the O
surfaces O
of O
the O
nanocages O
by O
reducing O
HAuCl4 O
with O
ascorbic B
acid I
, O
and O
; O
3 O
) O
formation O
of O
Au B
cubic O
nanoframes O
through O
a O
dealloying O
process O
with O
HAuCl4 O
. O

The O
key O
to O
the O
formation O
of O
Au B
cubic O
nanoframes O
is O
to O
coat O
the O
surfaces O
of O
the O
Au O
- O
Ag O
nanocages O
with O
sufficiently O
thick O
layers O
of O
Au B
before O
they O
are O
dealloyed O
. O

The O
Au B
layer O
could O
prevent O
the O
skeleton O
of O
a O
nanocage O
from O
being O
fragmented O
during O
the O
dealloying O
step O
. O

The O
as O
- O
prepared O
Au B
cubic O
nanoframes O
exhibit O
tunable O
localized O
surface O
plasmon O
resonance O
peaks O
in O
the O
near O
- O
infrared O
region O
, O
but O
with O
much O
lower O
Ag B
content O
as O
compared O
with O
the O
initial O
Au O
- O
Ag O
nanocages O
. O

Prenatal O
bisphenol B
a I
exposure O
alters O
sex O
- O
specific O
estrogen B
receptor O
expression O
in O
the O
neonatal O
rat O
hypothalamus O
and O
amygdala O
. O

Bisphenol B
A I
( O
BPA B
) O
exposure O
is O
ubiquitous O
, O
and O
in O
laboratory O
animals O
, O
early O
- O
life O
BPA B
exposure O
has O
been O
shown O
to O
alter O
sex O
- O
specific O
neural O
organization O
, O
neuroendocrine O
physiology O
, O
and O
behavior O
. O

In O
the O
perinatal O
rat O
brain O
, O
estrogen B
is O
masculinizing O
, O
suggesting O
that O
BPA B
- O
induced O
perturbation O
of O
estrogen B
receptor O
( O
ESR O
) O
expression O
may O
underpin O
later O
in O
- O
life O
neuroendocrine O
effects O
. O

We O
hypothesized O
that O
prenatal O
BPA B
exposure O
alters O
sex O
- O
specific O
ESR1 O
( O
ER O
alpha O
) O
and O
ESR2 O
( O
ER O
beta O
) O
expression O
in O
postnatal O
limbic O
nuclei O
. O

Sprague O
Dawley O
rats O
were O
mated O
and O
gavaged O
on O
gestational O
days O
( O
GDs O
) O
6 O
- O
21 O
with O
vehicle O
, O
2 O
. O
5 O
or O
25 O
mu O
g O
/ O
kg O
bw O
/ O
day O
BPA B
, O
or O
5 O
or O
10 O
mu O
g O
/ O
kg O
bw O
/ O
day O
ethinyl B
estradiol I
. O

Relative O
to O
the O
vehicle O
group O
, O
significant O
effects O
of O
BPA B
were O
observed O
on O
ESR1 O
and O
ESR2 O
expression O
throughout O
the O
mediobasal O
hypothalamus O
and O
amygdala O
in O
both O
sexes O
. O

These O
results O
indicate O
that O
ESR O
expression O
in O
the O
neonatal O
brain O
of O
both O
sexes O
can O
be O
altered O
by O
low O
- O
dose O
prenatal O
BPA B
exposure O
. O

Cellulose O
- O
ethylenediaminetetra B
Acid I
conjugates O
protect O
Mammalian O
cells O
from O
bacterial O
cells O
. O

Cellulose O
- O
ethylenediaminetetra B
acid I
( O
EDTA B
) O
conjugates O
were O
synthesized O
by O
the O
esterification O
of O
cellulose O
with O
ethylenediaminetetra O
dianhydride O
( O
EDTAD O
) O
. O

The O
biocompatibility O
of O
the O
new O
cellulose O
- O
EDTA B
conjugates O
was O
evaluated O
with O
mouse O
skin O
fibroblasts O
for O
up O
to O
14 O
days O
. O

Moreover O
, O
in O
mouse O
skin O
fibroblast O
- O
bacteria O
co O
- O
culture O
systems O
, O
the O
new O
cellulose O
- O
EDTA B
conjugates O
prevented O
bacterial O
biofilm O
formation O
and O
protected O
the O
mammalian O
cells O
from O
the O
bacterial O
cells O
for O
at O
least O
one O
day O
. O

The O
quantum O
yield O
( O
QY O
) O
was O
~ O
50 O
% O
when O
the O
feed O
ratio O
of O
Cd B
( I
2 I
+ I
) I
to O
Hg B
( I
2 I
+ I
) I
was O
equal O
to O
1 O
. O

The O
results O
showed O
that O
, O
for O
Cd0 O
. O
21Hg0 O
. O
79Te O
NCs O
, O
its O
quasi O
core O
/ O
shell O
structure O
was O
very O
stable O
and O
little O
cadmium B
ions O
were O
released O
. O

Isolation O
of O
thermally O
stable O
cellulose O
nanocrystals O
by O
phosphoric B
Acid I
hydrolysis O
. O

Due O
to O
hydrogen B
bonding O
between O
their O
surface O
hydroxyl B
groups O
, O
unmodified O
CNCs O
( O
H O
- O
CNCs O
) O
aggregate O
easily O
and O
are O
often O
difficult O
to O
disperse O
. O

It O
is O
shown O
here O
that O
on O
account O
of O
ionic O
repulsion O
between O
charged O
surface O
groups O
, O
slightly O
phosphorylated O
CNCs O
( O
P O
- O
CNCs O
, O
average O
dimensions O
31 O
+ O
/ O
- O
14 O
x O
316 O
+ O
/ O
- O
127 O
nm O
, O
surface O
charge O
density O
= O
10 O
. O
8 O
+ O
/ O
- O
2 O
. O
7 O
mmol O
/ O
kg O
cellulose O
) O
, O
prepared O
by O
controlled O
hydrolysis O
of O
cotton O
with O
phosphoric B
acid I
, O
are O
readily O
dispersible O
and O
form O
stable O
dispersions O
in O
polar O
solvents O
such O
as O
water O
, O
dimethyl B
sulfoxide I
, O
and O
dimethylformamide O
. O

Nanocomposites O
of O
an O
ethylene B
oxide I
- O
epichlorohydrin B
copolymer O
and O
H O
- O
CNCs O
, O
S O
- O
CNCs O
, O
and O
P O
- O
CNCs O
were O
prepared O
, O
and O
their O
mechanical O
properties O
were O
studied O
by O
dynamic O
mechanical O
thermal O
analysis O
. O

Electronic O
transitions O
of O
protonated O
and O
deprotonated O
amino B
acids I
in O
aqueous O
solution O
in O
the O
region O
145 O
- O
300 O
nm O
studied O
by O
attenuated O
total O
reflection O
far O
- O
ultraviolet O
spectroscopy O
. O

The O
electronic O
transitions O
of O
20 O
naturally O
occurring O
amino B
acids I
in O
aqueous O
solution O
were O
studied O
with O
attenuated O
total O
reflection O
far O
- O
ultraviolet O
( O
ATR O
- O
FUV O
) O
spectroscopy O
in O
the O
region O
from O
145 O
to O
300 O
nm O
. O

From O
the O
measured O
ATR O
spectra O
of O
sample O
solutions O
, O
the O
FUV O
absorption O
spectra O
attributed O
to O
the O
amino B
acids I
were O
separated O
from O
the O
intense O
solvent O
absorption O
by O
using O
a O
modified O
Kramers O
- O
Kronig O
transformation O
method O
. O

The O
FUV O
absorption O
spectra O
of O
the O
amino B
acids I
reflect O
the O
protonation O
states O
of O
the O
backbone O
and O
side O
- O
chain O
structures O
. O

The O
contributions O
of O
the O
side O
chains O
to O
the O
spectra O
were O
also O
examined O
from O
the O
difference O
spectra O
subtracting O
the O
corresponding O
Gly B
spectrum O
from O
each O
spectrum O
. O

The O
observed O
spectra O
were O
compared O
mostly O
with O
the O
electronic O
transition O
studies O
of O
the O
molecular O
fragments O
of O
the O
amino B
acids I
in O
gas O
phase O
. O

The O
FUV O
spectra O
of O
the O
amino B
acids I
exhibited O
the O
intra O
- O
and O
intermolecular O
electronic O
interactions O
of O
the O
solute O
- O
solute O
as O
well O
as O
the O
solute O
- O
solvent O
, O
and O
those O
are O
essential O
factors O
to O
elucidate O
UV O
photochemical O
processes O
of O
the O
amino B
acids I
in O
aqueous O
solution O
. O

Next O
, O
we O
assessed O
the O
mutual O
correlations O
among O
maximum O
amount O
of O
change O
of O
cell O
- O
surface O
thiols B
( O
MAC O
value O
) O
in O
the O
SH O
test O
, O
CV75 O
value O
( O
concentration O
giving O
75 O
% O
cell O
viability O
) O
in O
a O
cytotoxicity O
assay O
, O
EC150 O
and O
EC200 O
values O
( O
thresholds O
concentrations O
of O
CD86 O
and O
CD54 O
expression O
, O
respectively O
) O
in O
h O
- O
CLAT O
and O
published O
LLNA O
thresholds O
of O
64 O
chemicals O
. O

Synthesis O
of O
a O
paraffin B
phase O
change O
material O
microencapsulated O
in O
a O
siloxane O
polymer O
. O

This O
method O
allows O
to O
synthesize O
core O
- O
shell O
microcapsules O
of O
paraffin B
which O
have O
the O
shape O
of O
spheres O
or O
distorted O
spheres O
and O
are O
designed O
for O
the O
use O
as O
phase O
change O
materials O
. O

The O
polysiloxane O
is O
modified O
by O
the O
attachment O
of O
silylvinyl O
and O
alkoxy B
functions O
before O
coemulsification O
with O
the O
paraffin B
. O

The O
shell O
is O
additionally O
modified O
by O
the O
in O
situ O
generation O
of O
silanol B
groups O
which O
provide O
colloidal O
stabilization O
of O
microspheres O
in O
aqueous O
phase O
. O

Differential O
surface O
properties O
of O
commercial O
crystalline O
telmisartan B
samples O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
differences O
in O
surface O
chemistry O
of O
commercially O
available O
telmisartan B
( O
TMS B
) O
samples O
in O
Indian O
market O
and O
to O
correlate O
them O
to O
the O
surface O
molecular O
environment O
. O

Comprehensive O
characterization O
of O
material O
properties O
of O
four O
TMS B
samples O
from O
different O
sources O
showed O
that O
all O
samples O
exhibited O
same O
polymorphic O
form O
, O
but O
different O
particle O
shape O
, O
particle O
size O
distribution O
, O
surface O
energetics O
and O
surface O
chemistry O
. O

TMS B
samples O
exhibited O
significant O
variations O
in O
their O
wetting O
behavior O
. O

The O
role O
of O
crystal O
shape O
, O
particle O
size O
distribution O
, O
surface O
energetics O
and O
surface O
chemistry O
in O
controlling O
TMS B
powder O
wettability O
was O
collectively O
explored O
by O
contact O
angle O
experiments O
. O

The O
surface O
polarity O
index O
was O
determined O
by O
XPS O
and O
expressed O
as O
( O
oxygen B
+ O
nitrogen B
) O
- O
to O
- O
( O
carbon B
) O
atomic O
concentration O
ratio O
. O

It O
was O
found O
to O
be O
different O
for O
all O
four O
TMS B
samples O
. O

Crystal O
morphology O
of O
TMS B
polymorph O
A O
was O
predicted O
using O
Bravais O
- O
Friedel O
Donnay O
- O
Harker O
( O
BFDH O
) O
method O
. O

Molecular O
lipophilic O
surface O
potential O
( O
MLSP O
) O
data O
for O
TMS B
showed O
the O
varied O
surface O
lipophilic O
environment O
throughout O
the O
molecule O
. O

Hence O
it O
can O
be O
concluded O
that O
the O
differential O
abundance O
of O
surface O
elements O
play O
an O
important O
role O
in O
controlling O
the O
biopharmaceutical O
performance O
of O
TMS B
powder O
samples O
. O

Analytical O
chemistry O
, O
toxicology O
, O
epidemiology O
and O
health O
impact O
assessment O
of O
melamine B
in O
infant O
formula O
: O
Recent O
progress O
and O
developments O
. O

This O
review O
summarizes O
the O
most O
recent O
scientific O
literature O
and O
regulations O
regarding O
analytical O
chemistry O
, O
toxicology O
, O
epidemiology O
, O
exposure O
, O
and O
risk O
assessment O
of O
melamine B
in O
infant O
formula O
. O

Organization O
of O
proficiency O
test O
programs O
provided O
good O
evidence O
to O
facilitate O
granting O
laboratories O
accreditation O
and O
to O
ascertain O
the O
measurement O
reliability O
of O
melamine B
methods O
. O

Metabolic O
studies O
demonstrated O
that O
melamine B
is O
predominantly O
restricted O
to O
blood O
or O
extracellular O
fluid O
and O
is O
not O
extensively O
distributed O
to O
organs O
and O
tissues O
. O

Studies O
of O
human O
renal O
histopathology O
and O
clinical O
diagnoses O
indicated O
that O
melamine B
- O
related O
obstructive O
nephropathy O
derives O
from O
melamine B
precipitation O
in O
the O
lower O
urinary O
tract O
, O
with O
stones O
that O
are O
thought O
to O
be O
melamine B
- O
uric B
acid I
complexes O
. O

Epidemiologic O
studies O
showed O
that O
the O
occurrence O
of O
melamine B
- O
related O
urolithiasis O
is O
related O
to O
both O
the O
concentration O
of O
melamine B
in O
ingested O
milk O
products O
and O
the O
duration O
of O
ingestion O
. O

Long O
- O
term O
follow O
- O
up O
cohort O
studies O
should O
be O
continued O
to O
further O
investigate O
the O
epidemic O
and O
chronic O
hazard O
of O
melamine B
- O
induced O
nephrotoxicity O
. O

Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin O
knockout O
and O
midkine O
knockout O
mice O
treated O
with O
amphetamine B
: O
Correlations O
with O
amphetamine B
- O
induced O
neurotoxicity O
. O

The O
neurotrophic O
factors O
pleiotrophin O
( O
PTN O
) O
and O
midkine O
( O
MK O
) O
have O
been O
shown O
to O
modulate O
amphetamine B
- O
induced O
neurotoxicity O
. O

Accordingly O
, O
PTN O
- O
/ O
- O
and O
MK O
- O
/ O
- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine B
- O
induced O
neurotoxic O
effects O
. O

In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine B
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O
chromatography O
( O
IMAC O
) O
, O
with O
two O
- O
dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry O
, O
in O
order O
to O
identify O
the O
phosphoproteins O
regulated O
in O
the O
striatum O
of O
PTN O
- O
/ O
- O
, O
MK O
- O
/ O
- O
and O
wild O
type O
( O
WT O
) O

mice O
treated O
with O
amphetamine B
. O

We O
identified O
13 O
differentially O
expressed O
phosphoproteins O
that O
are O
judged O
to O
be O
relevant O
in O
the O
neuroprotective O
roles O
of O
PTN O
and O
MK O
against O
amphetamine B
- O
induced O
neurotoxicity O
. O

It O
is O
very O
interesting O
to O
note O
that O
4 O
of O
these O
phosphoproteins O
, O
annexin O
A7 O
( O
ANXA7 O
) O
, O
COP9 O
signalosome O
subunit O
5 O
( O
COPS5 O
) O
, O
aldehyde B
dehydrogenase O
family O
1 O
member O
A1 O
( O
ALDH1A1 O
) O
and O
creatine B
kinase O
U O
- O
type O
( O
CKMT1 O
) O
, O
are O
known O
to O
be O
involved O
in O
Parkinson O
' O
s O
disease O
, O
a O
result O
of O
significant O
importance O
since O
PTN O
and O
MK O
have O
been O
also O
demonstrated O
to O
limit O
Parkinson O
' O
s O
disease O
( O
PD O
) O
progress O
and O
have O
been O
suggested O
to O
be O
among O
the O
important O
genetic O
factors O
possibly O

preventing O
the O
development O
of O
PD O
in O
methamphetamine B
abusers O
. O

The O
data O
identify O
phosphoproteins O
differentially O
regulated O
by O
amphetamine B
treatment O
and O
/ O
or O
the O
presence O
of O
endogenous O
PTN O
/ O
MK O
which O
may O
be O
relevant O
mediators O
of O
PTN O
/ O
MK O
neuroprotective O
effects O
against O
amphetamine B
- O
induced O
neurotoxicity O
. O

The O
data O
support O
further O
studies O
to O
validate O
the O
phosphoproteins O
here O
identified O
as O
possible O
new O
pharmacological O
targets O
to O
prevent O
amphetamine B
neurotoxic O
effects O
. O

COMT O
Val158Met O
modulates O
subjective O
responses O
to O
intravenous O
nicotine B
and O
cognitive O
performance O
in O
abstinent O
smokers O
. O

The O
catechol B
- O
O B
- O
methyltransferase O
( O
COMT O
) O
Val158Met O
polymorphism O
may O
be O
a O
risk O
factor O
for O
nicotine B
addiction O
. O

This O
study O
examined O
the O
influence O
of O
the O
COMT O
Val158Met O
polymorphism O
on O
subjective O
, O
physiological O
and O
cognitive O
effects O
of O
intravenous O
( O
IV O
) O
nicotine B
use O
in O
African O
Americans O
( O
AAs O
; O
n O
= O
56 O
) O
and O
European O
Americans O
( O
EAs O
; O
n O
= O
68 O
) O
smokers O
. O

Overnight O
abstinent O
smokers O
received O
saline O
followed O
by O
0 O
. O
5 O
and O
1 O
. O
0 O
mg O
per O
70 O
kg O
doses O
of O
nicotine B
, O
administered O
30 O
min O
apart O
. O

Smokers O
with O
valine B
( O
Val B
) O
/ O
Val B
genotype O
, O
compared O
with O
methionine B
( O
Met B
) O
carriers O
, O
had O
greater O
negative O
subjective O
effects O
from O
IV O
nicotine B
and O
had O
more O
severe O
withdrawal O
severity O
following O
overnight O
abstinence O
from O
smoking O
. O

Women O
with O
Val B
/ O
Val B
genotype O
reported O
greater O
difficulty O
concentrating O
and O
irritability O
than O
men O
with O
Val B
/ O
Val B
or O
Met B
carrier O
genotypes O
. O

The O
Val B
/ O
Val B
genotype O
was O
associated O
with O
better O
performance O
on O
the O
math O
task O
and O
in O
AA O
smokers O
it O
was O
associated O
with O
greater O
systolic O
blood O
pressure O
. O

These O
results O
support O
the O
rationale O
of O
pharmacologically O
inhibiting O
COMT O
to O
aid O
with O
smoking O
cessation O
among O
Val B
/ O
Val B
genotype O
smokers O
. O
The O
Pharmacogenomics O
Journal O
advance O
online O
publication O
, O
5 O
March O
2013 O
; O
doi O
: O
10 O
. O
1038 O
/ O
tpj O
. O
2013 O
. O
1 O
. O

An O
arginine B
- O
leucine B
block O
copolypeptide O
( O
R60 O
L20 O
) O
is O
synthesized O
, O
which O
is O
capable O
of O
forming O
vesicles O
with O
controllable O
sizes O
, O
able O
to O
transport O
hydrophilic O
cargo O
across O
the O
cell O
membrane O
, O
and O
exhibit O
relatively O
low O
cytotoxicity O
. O

Preliminary O
in O
vitro O
studies O
are O
carried O
out O
to O
evaluate O
targeted O
uptake O
efficiency O
of O
folate B
conjugated O
HNPs O
. O

In O
our O
study O
, O
biocompatible O
Ni O
( O
II O
) O
- O
nitrilo O
( O
triacetic O
acid O
) O
- O
modified O
poly O
( O
ethylene O
imine O
) O
- O
maltose O
( O
Ni O
- O
NTA O
- O
DG O
) O
is O
realized O
and O
evaluated O
as O
complexation O
agent O
against O
His B
- O
tagged O
peptides O
using O
fluorescence O
polarization O
and O
dynamic O
light O
scattering O
. O

The O
polyplexes O
are O
stable O
until O
a O
pH O
of O
6 O
. O
5 O
- O
6 O
. O
0 O
, O
and O
also O
up O
to O
50 O
mM O
of O
imidazole B
. O

Supramolecular O
cl B
. O
. O
. O
h B
and O
o B
. O
. O
. O
h B
interactions O
in O
self O
- O
assembled O
1 O
, O
5 O
- O
dichloroanthraquinon O
layers O
on O
au B
( I
111 I
) I
. O

The O
role O
of O
halogen B
bonds O
in O
self O
- O
assembled O
networks O
for O
systems O
with O
Br B
and O
I B
ligands O
has O
recently O
been O
studied O
with O
scanning O
tunneling O
microscopy O
( O
STM O
) O
, O
which O
provides O
physical O
insight O
at O
the O
atomic O
scale O
. O

Here O
, O
we O
study O
the O
supramolecular O
interactions O
of O
1 O
, O
5 O
- O
dichloroanthraquinon O
molecules O
on O
Au B
( I
111 I
) I
, O
including O
Cl B
ligands O
, O
by O
using O
STM O
. O

Both O
molecular O
structures O
are O
stabilized O
by O
intermolecular O
Cl B
. O
. O
. O
H B
and O
O B
. O
. O
. O
H B
hydrogen B
bonds O
with O
marginal O
contributions O
from O
Cl B
- O
related O
halogen B
bonds O
, O
as O
revealed O
by O
density O
functional O
theory O
calculations O
. O

Our O
study O
shows O
that O
, O
in O
contrast O
to O
Br B
- O
and O
I B
- O
related O
halogen B
bonds O
, O
Cl B
- O
related O
halogen B
bonds O
weakly O
contribute O
to O
the O
molecular O
structure O
due O
to O
a O
modest O
positive O
potential O
( O
sigma O
hole O
) O
of O
the O
Cl B
ligands O
. O

This O
methodology O
was O
subsequently O
used O
to O
assess O
the O
relative O
contribution O
of O
OATP1B1 O
uptake O
in O
human O
hepatocytes O
for O
olmesartan B
( O
42 O
% O
- O
62 O
% O
) O
, O
valsartan O
( O
28 O
% O
- O
81 O
% O
) O
, O
rosuvastatin B
( O
64 O
% O
- O
72 O
% O
) O
, O
pitavastatin O
( O
84 O
% O
- O
98 O
% O
) O
and O
lopinavir O
( O
64 O
% O
- O
89 O
% O
) O
. O

We O
report O
on O
the O
synthesis O
of O
tuned O
energy O
band O
gap O
Mg O
( O
x O
) O
Zn O
( O
1 O
- O
x O
) O
O O
nanofibers O
( O
NFs O
) O
with O
different O
Mg B
( I
2 I
+ I
) I
content O
via O
the O
sol O
- O
gel O
electrospinning O
( O
ES O
) O
technique O
wherein O
the O
addition O
of O
the O
doping O
material O
affects O
not O
only O
the O
morphologies O
of O
as O
- O
spun O
ZnAc O
/ O
PVA B
and O
MgAc O
/ O
ZnAc O
/ O
PVA B
nanofibers O
but O
also O
the O
crystal O
microstructure O
and O
optical O
properties O
of O
calcined O
ZnO B
and O
Mg O
( O
x O
) O
Zn O
( O

Following O
an O
appropriate O
aqueous O
solution O
preparation O
of O
magnesium O
acetate O
( O
MgAc O
) O
and O
zinc O
acetate O
( O
ZnAc O
) O
with O
poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
, O
electrospinning O
is O
performed O
and O
then O
as O
- O
spun O
nanofibers O
are O
calcined O
in O
an O
air O
atmosphere O
at O
600 O
degrees O
C O
for O
3 O
h O
. O

As O
- O
spun O
and O
calcined O
nanofiber O
diameters O
and O
morphologies O
are O
evaluated O
with O
scanning O
( O
SEM O
) O
and O
transmission O
( O
TEM O
) O
electron O
microscopies O
, O
whereas O
crystalline O
microstructural O
interpretations O
of O
ZnO B
and O
Mg O
( O
x O
) O
Zn O
( O
1 O
- O
x O
) O
O O
are O
conducted O
with O
wide O
- O
angle O
X O
- O
ray O
diffraction O
spectra O
( O
XRD O
) O
. O

Because O
Zn B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
have O
similar O
ionicity O
and O
atomic O
radii O
, O
some O
Zn B
( I
2 I
+ I
) I
atoms O
are O
replaced O
by O
Mg B
( I
2 I
+ I
) I
atoms O
in O
the O
crystals O
, O
leading O
to O
a O
change O
in O
the O
properties O
of O
crystal O
lattices O
. O

The O
band O
gap O
energy O
of O
the O
calcined O
fibers O
increases O
significantly O
with O
addition O
of O
Mg B
( I
2 I
+ I
) I
along O
with O
an O
increase O
in O
the O
ultraviolet O
( O
UV O
) O
photoluminescence O
emission O
of O
the O
fibers O
. O

The O
active O
compounds O
were O
purified O
by O
solid O
- O
phase O
extraction O
and O
HPLC O
, O
and O
their O
primary O
structures O
determined O
using O
mass O
spectrometry O
and O
amino B
acid I
analysis O
. O

A O
new O
fengycin O
isoform O
, O
fengycin O
C O
, O
with O
the O
amino B
acid I
sequence O
Glu O
- O
Orn O
- O
Tyr O
- O
Thr O
- O
Glu O
- O
Val O
- O
Pro O
- O
Gln O
- O
Thr O
- O
Ile O
was O
isolated O
. O

The O
beta O
- O
hydroxy O
fatty O
acyl O
chain O
is O
connected O
to O
the O
N B
- O
terminal O
of O
the O
decapeptide O
and O
can O
be O
saturated O
or O
unsaturated O
, O
ranging O
from O
14 O
to O
18 O
carbons B
. O

The O
C B
- O
terminal O
residue O
of O
the O
peptidic O
moiety O
is O
linked O
to O
the O
tyrosine B
residue O
at O
position O
3 O
, O
forming O
the O
branching O
point O
of O
the O
acyl B
peptide O
and O
the O
eight O
- O
membered O
cyclic O
lactone O
. O

Reactive O
oxygen B
species O
( O
ROS O
) O
have O
been O
long O
regarded O
as O
by O
- O
products O
of O
a O
cascade O
of O
reactions O
stemming O
from O
cellular O
oxygen B
metabolism O
, O
which O
, O
if O
they O
accumulate O
to O
toxic O
levels O
, O
can O
have O
detrimental O
effects O
on O
cellular O
biomolecules O
. O

The O
prototypic O
redox O
- O
regulated O
targets O
downstream O
of O
ROS O
are O
the O
protein O
tyrosine B
phosphatases O
, O
and O
the O
wealth O
of O
research O
that O
has O
focused O
on O
this O
area O
has O
come O
to O
shape O
our O
understanding O
of O
how O
redox O
- O
signalling O
contributes O
to O
and O
facilitates O
protein O
tyrosine B
phosphorylation O
signalling O
cascades O
. O

However O
, O
it O
is O
becoming O
increasingly O
apparent O
that O
there O
is O
more O
to O
this O
system O
than O
simply O
the O
negative O
regulation O
of O
protein O
tyrosine B
phosphatases O
. O

Identification O
of O
redox O
- O
sensitive O
kinases O
such O
as O
Src O
led O
to O
the O
slow O
emergence O
of O
a O
role O
for O
redox O
regulation O
of O
tyrosine B
kinases O
. O

A O
flow O
of O
evidence O
, O
which O
has O
increased O
exponentially O
in O
recent O
times O
as O
a O
result O
of O
the O
development O
of O
new O
methods O
for O
the O
detection O
of O
oxidative O
modifications O
, O
demonstrates O
that O
, O
by O
concurrent O
oxidative O
activation O
of O
tyrosine B
kinases O
, O
ROS O
fine O
tune O
the O
duration O
and O
amplification O
of O
the O
phosphorylation O
signal O
. O

Antitubercular O
diterpenoids B
from O
Vitex O
trifolia O
. O

A O
new O
halimane O
diterpenoid O
, O
13 O
- O
hydroxy O
- O
5 O
( O
10 O
) O
, O
14 O
- O
halimadien O
- O
6 O
- O
one O
( O
1 O
) O
and O
two O
new O
labdane O
diterpenoids O
, O
6 O
alpha O
, O
7 O
alpha O
- O
diacetoxy O
- O
13 O
- O
hydroxy O
- O
8 O
( O
9 O
) O
, O
14 O
- O
labdadien O
( O
2 O
) O
and O
9 O
- O
hydroxy O
- O
13 O
( O
14 O
) O
- O
labden O
- O
15 O
, O
16 O
- O
olide O
( O
3 O
) O
, O
were O
isolated O
for O
the O
first O
time O
, O
along O
with O
fifteen O
known O
compounds O
, O
from O
the O
hexane B
soluble O
fraction O
of O
methanolic O
extract O
of O

The O
structures O
of O
these O
new O
diterpenoids B
were O
elucidated O
by O
spectral O
analysis O
. O

Their O
relative O
configurations O
were O
established O
using O
analysis O
of O
NOESY O
correlations O
and O
coupling O
constants O
observed O
in O
( B
1 I
) I
H I
NMR O
. O

Compounds O
2 O
, O
3 O
and O
another O
known O
diterpenoid B
, O
isoambreinolide O
( O
4 O
) O
were O
evaluated O
for O
antitubercular O
activity O
. O

Aldehyde B
oxidase O
importance O
in O
vivo O
in O
xenobiotic O
metabolism O
: O
imidacloprid B
nitroreduction O
in O
mice O
. O

Aldehyde B
oxidase O
( O
AOX O
) O
metabolizes O
many O
xenobiotics O
in O
vitro O
, O
but O
its O
importance O
in O
vivo O
is O
usually O
unknown O
relative O
to O
cytochrome O
P450s O
( O
CYPs O
) O
and O
other O
detoxification O
systems O
. O

The O
procedure O
was O
to O
reduce O
liver O
AOX O
activity O
by O
providing O
tungsten B
or O
hydralazine B
in O
the O
drinking O
water O
or O
to O
use O
the O
AOX O
- O
deficient O
DBA O
/ O
2 O
mouse O
strain O
. O

Liver O
AOX O
activity O
was O
reduced O
by O
45 O
% O
with O
tungsten B
and O
61 O
% O
with O
hydralazine B
and O
81 O
% O
in O
AOX O
- O
deficient O
mice O
relative O
to O
controls O
. O

When O
mice O
were O
treated O
ip O
with O
the O
major O
neonicotinoid O
imidacloprid B
( O
IMI O
) O
, O
metabolism O
by O
CYP O
oxidation O
reactions O
was O
not O
appreciably O
affected O
, O
whereas O
the O
AOX O
- O
generated O
nitrosoguanidine O
metabolite O
was O
decreased O
by O
30 O
% O
with O
tungsten B
and O
56 O
% O
with O
hydralazine B
and O
86 O
% O
in O
the O
AOX O
- O
deficient O
mice O
. O

The O
other O
IMI O
nitroreduction O
metabolite O
, O
desnitro O
- O
IMI O
, O
was O
decreased O
by O
55 O
% O
, O
65 O
% O
, O
and O
81 O
% O
with O
tungsten B
, O
hydralazine B
, O
and O
in O
the O
AOX O
- O
deficient O
mice O
, O
respectively O
. O

Modulation O
of O
membrane O
phospholipids O
, O
the O
cytosolic O
calcium B
influx O
and O
cell O
proliferation O
following O
treatment O
of O
B16 O
- O
F10 O
cells O
with O
recombinant O
phospholipase O
- O
D O
from O
Loxosceles O
intermedia O
( O
brown O
spider O
) O
venom O
. O

Using O
a O
recombinant O
phospholipase O
- O
D O
from O
the O
venom O
gland O
of O
L O
. O
intermedia O
( O
LiRecDT1 O
) O
in O
phospholipid O
- O
degrading O
kinetic O
experiments O
, O
we O
determined O
that O
this O
phospholipase O
- O
D O
mainly O
hydrolyzes O
synthetic O
sphingomyelin B
in O
a O
time O
- O
dependent O
manner O
, O
generating O
ceramide O
1 O
- O
phosphate O
plus O
choline B
, O
as O
well O
as O
lysophosphatidylchol B
, O
generating O
lysophosphatidic B
acid I
plus O
choline B
, O
but O
exhibits O
little O
activity O
against O

phosphatidylcholine B
. O

We O
determined O
that O
LiRecDT1 O
hydrolyzes O
phospholipids O
in O
detergent O
extracts O
and O
from O
ghosts O
of O
B16 O
- O
F10 O
cells O
, O
generating O
choline B
, O
indicating O
that O
the O
enzyme O
can O
access O
and O
modulate O
and O
has O
activity O
against O
membrane O
phospholipids O
. O

Additionally O
, O
using O
Fluo B
- I
4 I
, O
a O
calcium B
- O
sensitive O
fluorophore O
, O
it O
was O
shown O
that O
treatment O
of O
cells O
with O
phospholipase O
- O
D O
induced O
an O
increase O
in O
the O
calcium B
concentration O
in O
the O
cytoplasm O
, O
but O
without O
altering O
viability O
or O
causing O
damage O
to O
cells O
. O

Treatment O
of O
the O
cells O
was O
effective O
in O
increasing O
their O
proliferation O
in O
a O
time O
- O
and O
concentration O
- O
dependent O
manner O
, O
especially O
in O
the O
presence O
of O
synthetic O
sphingomyelin B
in O
the O
medium O
. O

The O
results O
described O
herein O
indicate O
the O
ability O
of O
brown O
spider O
phospholipase O
- O
D O
to O
induce O
the O
generation O
of O
bioactive O
phospholipids O
, O
calcium B
influx O
into O
the O
cytoplasm O
and O
cell O
proliferation O
, O
suggesting O
that O
this O
molecule O
can O
be O
used O
as O
a O
bioactive O
tool O
for O
experimental O
protocols O
in O
cell O
biology O
. O

Identification O
of O
functionally O
relevant O
lysine B
residues O
that O
modulate O
human O
farnesoid O
x O
receptor O
activation O
. O

Base O
amino B
acid I
lysine B
residues O
play O
an O
important O
role O
in O
regulation O
of O
nuclear O
receptors O
[ O
e O
. O
g O
. O
, O
farnesyl O
X O
receptor O
( O
FXR O
) O
] O
, O
leading O
to O
enhanced O
or O
suppressed O
biologic O
activity O
. O

To O
understand O
the O
molecular O
mechanisms O
and O
the O
subsequent O
effects O
in O
modulating O
FXR O
functions O
in O
diverse O
biologic O
processes O
, O
we O
individually O
replaced O
eight O
highly O
conserved O
lysine B
residues O
of O
human O
FXR O
( O
hFXR O
) O
with O
arginine B
. O

Results O
demonstrated O
that O
K122R O
, O
K210R O
, O
K339R O
, O
and O
K460R O
mutants O
of O
hFXR O
significantly O
impaired O
target O
gene O
[ O
organic O
solute O
transporter O
alpha O
/ O
beta O
and O
bile B
salt I
export O
pump O
( O
BSEP O
) O
] O
promoter O
reporter O
activity O
in O
a O
ligand O
- O
dependent O
fashion O
. O

Protein O
interaction O
studies O
show O
that O
K210R O
slightly O
but O
significantly O
decreased O
FXR O
/ O
retinoid B
X O
receptor O
( O
RXR O
) O
binding O
affinity O
but O
enhanced O
the O
interaction O
of O
FXR O
with O
lysine B
methyltransferase O
Set7 O
/ O
9 O
by O
~ O
21 O
% O
. O

In O
conclusion O
, O
four O
highly O
conserved O
lysine B
residues O
of O
hFXR O
, O
K122 O
, O
K210 O
, O
K339 O
, O
and O
K460 O
, O
have O
been O
identified O
that O
play O
a O
critical O
role O
in O
FXR O
target O
gene O
regulation O
and O
molecular O
interaction O
( O
protein O
- O
protein O
and O
protein O
- O
DNA O
) O
. O

NMR O
- O
based O
metabonomic O
in O
hippocampus O
, O
nucleus O
accumbens O
and O
prefrontal O
cortex O
of O
methamphetamine B
- O
sensitized O
rats O
. O

( B
1 I
) I
H I
NMR O
spectroscopy O
was O
applied O
to O
investigate O
the O
changes O
of O
cerebral O
metabolites O
in O
brain O
hippocampus O
, O
nucleus O
accumbens O
( O
NAC O
) O
and O
prefrontal O
cortex O
( O
PFC O
) O
of O
the O
rats O
subjected O
to O
subcutaneous O
twice O
- O
daily O
injections O
of O
2 O
. O
5mg O
/ O
kg O
methamphetamine B
( O
MAP B
) O
for O
7 O
days O
. O

The O
results O
indicated O
that O
MAP B
exposure O
induced O
significant O
behavioral O
sensitization O
and O
altered O
cerebral O
metabolites O
in O
rats O
. O

The O
neurotransmitters O
glutamate B
, O
glutamine B
and O
GABA B
significantly O
decreased O
in O
hippocampus O
, O
NAC O
and O
PFC O
. O

Specifically O
, O
increased O
succinic O
acid O
semialdehyde O
, O
a O
metabolism O
product O
of O
GABA B
, O
was O
observed O
in O
hippocampus O
. O

Additionally O
, O
decreased O
serotonin B
was O
observed O
in O
both O
NAC O
and O
PFC O
, O
whereas O
decreased O
dopamine B
was O
only O
observed O
in O
NAC O
after O
repeated O
MAP B
treatment O
. O

Glutathione B
obviously O
decreased O
in O
above O
brain O
regions O
, O
whereas O
acetylcysteine B
declined O
in O
hippocampus O
and O
NAC O
, O
and O
taurine B
declined O
in O
NAC O
and O
PFC O
. O

Homocysteic O
acid O
was O
elevated O
in O
hippocampus O
and O
NAC O
by O
repeated O
MAP B
administration O
. O

Membrane O
ingredients O
like O
phosphocholine O
elevated O
in O
response O
to O
MAP B
administration O
in O
NAC O
and O
PFC O
. O

N O
- O
Acetyl O
- O
aspartate O
, O
a O
marker O
of O
neuronal O
viability O
, O
decreased O
in O
the O
three O
regions O
; O
however O
, O
myo B
- I
inositol I
, O
a O
glial O
cell O
marker O
, O
increased O
in O
hippocampus O
and O
PFC O
. O

Tricarboxylic B
acid I
cycle O
intermediate O
products O
, O
such O
as O
alpha B
- I
ketoglutarate I
, O
succinate B
, O
citrate B
and O
the O
methionine B
significantly O
decreased O
in O
above O
three O
brain O
regions O
after O
MAP B
administration O
; O
however O
, O
ADP B
decreased O
in O
hippocampus O
. O

These O
results O
indicate O
that O
repeated O
MAP B
treatment O
causes O
neurotransmitters O
disturbance O
, O
imbalance O
between O
oxidative O
stress O
and O
antioxidants O
, O
and O
gliosis O
in O
hippocampus O
, O
NAC O
and O
PFC O
. O

Profound O
metabolic O
changes O
detected O
across O
brain O
regions O
provide O
the O
first O
evidence O
of O
metabonomic O
changes O
in O
MAP B
- O
induced O
sensitized O
rats O
. O

Alcohol B
cirrhosis O
alters O
nuclear O
receptor O
and O
drug O
transporter O
expression O
in O
human O
liver O
. O

Unsafe O
use O
of O
alcohol B
results O
in O
approximately O
2 O
. O
5 O
million O
deaths O
worldwide O
, O
with O
cirrhosis O
contributing O
to O
16 O
. O
6 O
% O
of O
reported O
deaths O
. O

Cirrhosis O
increased O
nuclear O
factor O
E2 O
- O
related O
factor O
2 O
mRNA O
expression O
, O
whereas O
it O
decreased O
pregnane B
- O
X O
- O
receptor O
and O
farnesoid O
- O
X O
- O
receptor O
mRNA O
expression O
in O
comparison O
with O
normal O
livers O
. O

Octahedral O
Co3O4 B
particles O
threaded O
by O
carbon B
nanotube O
arrays O
as O
integrated O
structure O
anodes O
for O
lithium B
ion O
batteries O
. O

Octahedral O
Co3O4 B
particles O
threaded O
by O
ultra O
- O
long O
multi O
- O
walled O
carbon B
nanotube O
( O
MWCNT O
) O
arrays O
were O
prepared O
by O
a O
hydrothermal O
process O
and O
subsequent O
calcination O
. O

The O
Co3O4 B
octahedron O
with O
the O
( O
111 O
) O
facets O
attaches O
to O
MWCNTs O
uniformly O
and O
closely O
. O

The O
composite O
can O
be O
used O
as O
an O
integrated O
anode O
for O
lithium B
ion O
batteries O
( O
LIBs O
) O
without O
any O
other O
additives O
( O
such O
as O
conductive O
additives O
and O
polymer O
binder O
) O
, O
which O
exhibits O
a O
high O
reversible O
capacity O
of O
725 O
mA O
h O
g O
( O
- O
1 O
) O
at O
a O
current O
density O
of O
100 O
mA O
g O
( O
- O
1 O
) O
, O
and O
excellent O
cyclic O
stability O
without O
capacity O
degradation O
over O
100 O
cycles O
at O
a O
current O
density O
of O
500 O
mA O
g O
( O
- O
1 O
) O
. O

The O
high O
performance O
can O
be O
attributed O
to O
the O
unique O
structure O
: O
( O
i O
) O
the O
ultra O
- O
long O
MWCNT O
array O
facilitates O
fast O
electron O
transfer O
; O
( O
ii O
) O
the O
tight O
adhesion O
between O
Co3O4 B
and O
MWCNTs O
prevents O
particle O
drifting O
and O
agglomeration O
; O
( O
iii O
) O
the O
free O
space O
between O
MWCNTs O
promotes O
fast O
ion O
transport O
and O
alleviates O
the O
large O
volume O
variation O
during O
discharge O
- O
charge O
process O
. O

It O
may O
be O
possible O
to O
achieve O
insulin O
sensitivity O
through O
the O
recently O
identified O
mitochondrial O
target O
of O
thiazolidinediones B
( O
mTOT O
) O
, O
thereby O
avoiding O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
( O
PPAR O
- O
gamma O
) O
- O
dependent O
side O
effects O
. O

The O
two O
active O
treatments O
lowered O
fasting O
glucose B
levels O
to O
the O
same O
extent O
. O

The O
decreases O
in O
glycated O
hemoglobin O
( O
HbA1c O
) O
observed O
with O
the O
two O
higher O
doses O
of O
MSDC O
- O
0160 O
were O
not O
different O
from O
those O
associated O
with O
pioglitazone B
. O

There O
was O
also O
a O
smaller O
increase O
in O
high O
- O
molecular O
- O
weight O
( O
HMW O
) O
adiponectin O
with O
MSDC O
- O
0160 O
than O
with O
pioglitazone B
( O
P O
< O
0 O
. O
0001 O
) O
, O
suggesting O
that O
MSDC O
- O
0160 O
produces O
less O
expansion O
of O
white O
adipose O
tissue O
. O

Thus O
, O
mTOT O
modulators O
may O
have O
glucose B
- O
lowering O
effects O
similar O
to O
those O
of O
pioglitazone B
but O
without O
the O
adverse O
effects O
associated O
with O
PPAR O
- O
gamma O
agonists O
. O

Gram O
- O
scale O
synthesis O
of O
graphene B
sheets O
by O
a O
catalytic O
arc O
- O
discharge O
method O
. O

Flake O
graphite B
is O
used O
as O
carbon B
source O
and O
ZnO B
or O
ZnS B
as O
catalyst O
in O
the O
synthesis O
of O
high O
- O
quality O
graphene B
sheets O
. O

A O
catalytic O
growth O
mechanism O
for O
cathode O
- O
part O
graphene B
synthesis O
in O
the O
arc O
- O
discharge O
apparatus O
and O
an O
exfoliation O
mechanism O
for O
wall O
- O
part O
graphene B
synthesis O
are O
introduced O
. O

N B
- O
doped O
cathode O
- O
part O
graphene B
and O
undoped O
wall O
- O
part O
graphene B
are O
formed O
simultaneously O
. O

Furthermore O
, O
photodetection O
in O
InAsSb O
nanowire O
arrays O
integrated O
on O
Si B
substrates O
is O
also O
demonstrated O
. O

The O
results O
show O
that O
on O
glass O
, O
graphite B
, O
and O
mica O
surfaces O
the O
slip O
lengths O
are O
98 O
, O
234 O
, O
and O
110 O
nm O
, O
respectively O
. O

Templating O
Sub O
- O
10 O
nm O
Atomic O
Layer O
Deposited O
Oxide B
Nanostructures O
on O
Graphene B
via O
One O
- O
Dimensional O
Organic O
Self O
- O
Assembled O
Monolayers O
. O

Molecular O
- O
scale O
control O
over O
the O
integration O
of O
disparate O
materials O
on O
graphene B
is O
a O
critical O
step O
in O
the O
development O
of O
graphene B
- O
based O
electronics O
and O
sensors O
. O

Here O
, O
we O
report O
that O
self O
- O
assembled O
monolayers O
of O
10 O
, O
12 O
- O
pentacosadiynoic O
acid O
( O
PCDA O
) O
on O
epitaxial O
graphene B
can O
be O
used O
to O
template O
the O
reaction O
and O
directed O
growth O
of O
atomic O
layer O
deposited O
( O
ALD O
) O
oxide B
nanostructures O
with O
sub O
- O
10 O
nm O
lateral O
resolution O
. O

PCDA O
spontaneously O
assembles O
into O
well O
- O
ordered O
domains O
consisting O
of O
one O
- O
dimensional O
molecular O
chains O
that O
coat O
the O
entire O
graphene B
surface O
in O
a O
manner O
consistent O
with O
the O
symmetry O
of O
the O
underlying O
graphene B
lattice O
. O

Subsequently O
, O
zinc B
oxide I
and O
alumina B
ALD O
precursors O
are O
shown O
to O
preferentially O
react O
with O
the O
functional O
moieties O
of O
PCDA O
, O
resulting O
in O
templated O
oxide B
nanostructures O
. O

Marfey O
' O
s O
analysis O
of O
the O
acid O
hydrolysate O
of O
1 O
demonstrated O
that O
the O
two O
constituent O
amino B
acids I
were O
both O
in O
the O
l O
- O
form O
. O

We O
demonstrated O
radiolytic O
ligation O
of O
oligodeoxynucleotide O
( O
ODNs O
) O
possessing O
disulfide B
bond O
and O
its O
application O
to O
regulation O
of O
DNA O
quadruplex O
formation O
. O

G O
- O
rich O
hexamer O
ODNs O
had O
poor O
ability O
to O
form O
quadruplex O
, O
while O
X O
- O
irradiation O
of O
the O
ODNs O
induced O
interstrand O
exchange O
reaction O
at O
disulfide B
bond O
to O
form O
ligated O
12 O
mer O
ODNs O
, O
leading O
to O
the O
ready O
formation O
of O
quadruplex O
due O
to O
the O
entropic O
effect O
. O

Since O
complexation O
of O
the O
ligated O
ODNs O
with O
hemin O
in O
the O
presence O
of O
K B
( I
+ I
) I
showed O
strong O
soret O
band O
absorption O
and O
also O
catalyzed O
the O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
mediated O
oxidation O
of O
luminol O
, O
it O
appears O
that O
the O
quadruplex O
formed O
from O
ligated O
ODNs O
showed O
a O
function O
similar O
to O
native O
DNA O
quadruplex O
. O

A O
new O
diarylheptanoid O
, O
( O
5S O
) O
- O
hydroxy O
- O
1 O
- O
( O
3 O
, O
4 O
- O
dihydroxyphenyl O
) O
- O
7 O
- O
( O
4 O
- O
hydroxyphenyl O
) O
- O
hepta O
- O
1E O
- O
en O
- O
3 O
- O
one O
( O
1 O
) O
, O
was O
isolated O
along O
with O
seventeen O
known O
diarylheptanoids O
( O
2 O
- O
18 O
) O
from O
the O
methanol B
extract O
of O
Alnus O
hirsuta O
f O
. O
sibirica O
leaves O
using O
bioactivity O
- O
guided O
fractionation O
. O

Of O
the O
compounds O
active O
in O
the O
present O
assay O
system O
, O
the O
most O
potent O
compound O
7 O
, O
platyphyllonol O
- O
5 O
- O
O O
- O
beta O
- O
d O
- O
xylopyranoside O
, O
significantly O
suppressed O
the O
induction O
of O
peroxisome O
proliferator O
activated O
receptor O
gamma O
( O
PPAR O
gamma O
and O
CCAAT O
/ O
enhancer O
binding O
protein O
alpha O
( O
C O
/ O
EBP O
alpha O
) O
protein O
expression O
, O
and O
inhibited O
adipocyte O
differentiation O
induced O
by O
troglitazone B
, O
a O
PPAR O
gamma O
agonist O
. O

Gimatecan O
and O
other O
camptothecin B
derivatives O
poison O
Leishmania O
DNA O
- O
topoisomerase O
IB O
leading O
to O
a O
strong O
leishmanicidal O
effect O
. O

The O
aim O
of O
this O
work O
is O
the O
in O
vitro O
and O
ex O
vivo O
assessment O
of O
the O
leishmanicidal O
activity O
of O
camptothecin B
and O
three O
analogues O
used O
in O
cancer O
therapy O
: O
topotecan B
( O
Hycantim O
( O
( O
R O
) O
) O
) O
, O
gimatecan O
( O
ST1481 O
) O
and O
the O
pro O
- O
drug O
irinotecan B
( O
Camptosar O
( O
( O
R O
) O
) O
) O
as O
well O
as O
its O
active O
metabolite O
SN B
- I
38 I
against O
Leishmania O
infantum O
. O

The O
activity O
of O
camptothecin B
and O
its O
derivatives O
was O
studied O
on O
extracellular O
L O
. O
infantum O
infrared O
- O
emitting O
promastigotes O
and O
on O
an O
ex O
vivo O
murine O
model O
of O
infected O
splenocytes O
with O
L O
. O
infantum O
fluorescent O
amastigotes O
. O

The O
inhibitory O
potency O
of O
camptothecin B
derivatives O
on O
recombinant O
L O
. O
infantum O
topoisomerase O
IB O
was O
assessed O
in O
vitro O
showing O
that O
gimatecan O
is O
the O
most O
active O
compound O
preventing O
the O
relaxation O
of O
supercoiled O
DNA O
at O
submicromolar O
concentrations O
. O

Cleavage O
equilibrium O
assays O
in O
Leishmania O
topoisomerase O
IB O
show O
that O
gimatecan O
changes O
the O
equilibrium O
towards O
cleavage O
at O
much O
lower O
concentrations O
than O
the O
other O
camptothecin B
derivatives O
and O
that O
this O
effect O
persists O
over O
time O
. O

Gimatecan O
and O
camptothecin B
were O
the O
most O
powerful O
compounds O
preventing O
cell O
growth O
of O
free O
- O
living O
L O
. O
infantum O
promastigotes O
within O
the O
same O
concentration O
range O
. O

Camptothecin B
derivatives O
are O
suitable O
for O
reducing O
the O
parasitic O
burden O
of O
ex O
vivo O
infected O
splenocytes O
. O

Hydrogen B
- O
bond O
reinforced O
vanadia O
nanofiber O
paper O
of O
high O
stiffness O
. O

Its O
excellent O
mechanical O
performance O
results O
from O
a O
brick O
- O
and O
- O
mortar O
like O
architecture O
, O
which O
combines O
strong O
covalent O
bonding O
within O
the O
single O
- O
crystalline O
nanofibers O
with O
an O
intricate O
hydrogen B
bonding O
network O
between O
them O
. O

Porphyrin B
photosensitizers O
tend O
to O
aggregate O
in O
aqueous O
solutions O
even O
in O
the O
micromolar O
concentration O
range O
. O

Substituents O
, O
overall O
charge O
and O
charge O
distribution O
influenced O
the O
pKa O
- O
values O
and O
interaction O
of O
the O
porphyrins B
with O
different O
solvents O
, O
excipients O
and O
impurities O
. O

Modification O
of O
medium O
polarity O
and O
solubilization O
by O
the O
nonionic O
surfactant O
Tween B
80 I
adjusted O
the O
acid O
- O
base O
equilibria O
and O
increased O
the O
solubility O
by O
reduction O
of O
porphyrin B
aggregation O
. O

The O
selected O
porphyrins B
were O
sensitive O
towards O
ionic O
strength O
, O
temperature O
and O
inorganic O
impurities O
to O
various O
extents O
. O

The O
results O
will O
be O
further O
used O
during O
development O
of O
parenteral O
and O
topical O
formulations O
of O
porphyrin B
photosensitizers O
for O
use O
in O
photodynamic O
therapy O
of O
cancer O
and O
bacterial O
infections O
. O

Folate B
Conjugation O
to O
Polymeric O
Micelles O
via O
Boronic O
Acid O
Ester O
to O
Deliver O
Platinum B
Drugs O
to O
Ovarian O
Cancer O
Cell O
Lines O
. O

In O
this O
study O
, O
a O
novel O
technique O
was O
used O
for O
the O
reversible O
attachment O
of O
folic B
acid I
on O
the O
surface O
of O
polymeric O
micelles O
for O
a O
tumor O
- O
specific O
drug O
delivery O
system O
. O

The O
reversible O
conjugation O
is O
based O
on O
the O
interaction O
between O
phenylboronic O
acid O
( O
PBA O
) O
and O
dopamine B
to O
form O
a O
borate O
ester O
. O

The O
platinum B
drug O
, O
oxoplatin O
, O
was O
then O
subsequently O
attached O
to O
the O
polymer O
via O
ester O
formation O
leading O
to O
platinum B
loading O
of O
12 O
wt O
% O
as O
determined O
by O
TGA O
. O

The O
platinum B
- O
induced O
amphiphilic O
block O
copolymers O
that O
consequently O
led O
to O
the O
formation O
of O
micelles O
of O
sizes O
150 O
and O
20 O
nm O
in O
an O
aqueous O
environment O
with O
the O
longer O
PMAA O
block O
forming O
larger O
micelles O
. O

The O
targeting O
ability O
of O
folate B
conjugated O
polymeric O
micelles O
was O
investigated O
against O
two O
types O
of O
tumor O
cell O
lines O
: O
A549 O
( O
- O
FR O
) O
and O
OVCAR O
- O
3 O
( O
+ O
FR O
) O
. O

The O
results O
revealed O
that O
folate B
conjugated O
micelles O
showed O
higher O
activity O
in O
FR O
+ O
OVCAR O
- O
3 O
cells O
but O
not O
in O
FR O
- O
A549 O
cells O
. O

Similar O
results O
were O
obtained O
for O
both O
small O
and O
large O
micelles O
without O
the O
conjugation O
of O
folate B
. O

Synthesis O
and O
relaxometric O
characterization O
of O
a O
MRI O
Gd B
- O
based O
probe O
responsive O
to O
glutamic B
acid I
decarboxylase O
enzymatic O
activity O
. O

We O
report O
here O
the O
synthesis O
and O
in O
vitro O
validation O
of O
a O
Gd B
( I
III I
) I
- O
based O
contrast O
agent O
designed O
to O
act O
as O
an O
MRI O
responsive O
probe O
for O
imaging O
the O
activity O
of O
the O
enzyme O
glutamic B
acid I
decarboxylase O
( O
GAD O
) O
present O
in O
neurons O
. O

Upon O
the O
action O
of O
the O
enzyme O
, O
the O
Gd B
( I
III I
) I
complex O
increases O
its O
hydration O
sphere O
and O
takes O
on O
a O
residual O
positive O
charge O
that O
promotes O
its O
binding O
to O
endogenous O
macromolecules O
. O

A O
new O
sesquiterpene B
lactone I
from O
Salvia O
plebeia O
. O

A O
new O
eudesmanolide O
, O
1 O
alpha O
- O
acetoxy O
- O
8 O
alpha O
, O
9 O
beta O
- O
dihydroxy O
- O
2 O
- O
oxo O
- O
eudesman O
- O
3 O
, O
7 O
( O
11 O
) O
- O
dien O
- O
8 O
, O
12 O
- O
olide O
( O
2 O
) O
, O
together O
with O
a O
known O
eudesmanolide O
, O
1 O
alpha O
- O
acetoxy O
- O
8 O
alpha O
- O
hydroxy O
- O
2 O
- O
oxo O
- O
eudesman O
- O
3 O
, O
7 O
( O
11 O
) O
- O
dien O
- O
8 O
, O
12 O
- O
olide O
( O
1 O
) O
, O
and O
a O
known O
flavone B
, O
4 O
' O
, O
5 O
, O
7 O
- O

Asymmetric O
Dimethylarginine O
( O
ADMA O
) O
is O
an O
endogenous O
inhibitor O
of O
nitric B
oxide I
( O
NO B
) O
production O
. O

ADMA O
is O
generated O
from O
methylation O
of O
arginine B
residues O
by O
protein O
arginine B
methyltransferases O
( O
PRMTs O
) O
and O
subsequent O
proteolysis O
, O
while O
its O
elimination O
is O
achieved O
mainly O
by O
degradation O
with O
dimethylarginine B
dimethylaminohydrola O
( O
DDAH O
) O
. O

Oxidative O
stress O
, O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
inhibition O
, O
eNOS O
uncoupling O
, O
inflammation O
and O
shear O
stress O
play O
a O
pivotal O
role O
in O
ADMA O
pathophysiology O
by O
managing O
PRMT O
/ O
DDAH O
expression O
and O
NO B
synthesis O
and O
leading O
to O
a O
common O
result O
- O
endothelial O
dysfunction O
. O

Use O
of O
fluorescein B
isothiocyanate I
( O
FITC B
) O
- O
labeled O
chitosan O
derivates O
in O
confocal O
microscopy O
showed O
that O
LMW O
- O
TGA O
attaches O
to O
microbial O
cell O
walls O
, O
while O
transmission O
electron O
microscopy O
indicated O
that O
this O
derivative O
severely O
affects O
cell O
wall O
integrity O
and O
intracellular O
ultrastructure O
in O
all O
species O
tested O
. O

New O
surface O
- O
enhanced O
Raman O
scattering O
platforms O
: O
composite O
calcium B
carbonate I
microspheres O
coated O
with O
astralen O
and O
silver B
nanoparticles O
. O

Here O
, O
we O
prepare O
a O
new O
type O
of O
micrometer O
- O
sized O
SERS O
substrate O
, O
core O
- O
shell O
microparticles O
composed O
of O
solid O
carbonate B
core O
coated O
with O
silver B
nanoparticles O
and O
polyhedral O
multishell O
fullerene B
- O
like O
structure O
, O
astralen O
. O

Astralen O
has O
been O
assembled O
with O
polyallylamine O
hydrochloride O
( O
PAH B
) O
by O
the O
layer O
- O
by O
- O
layer O
manner O
followed O
by O
Ag B
nanoparticle O
formation O
by O
means O
of O
a O
silver B
mirror O
reaction O
, O
giving O
the O
final O
structure O
of O
composite O
particles O
CaCO3 O
( O
PAH B
/ O
astralen O
) O
x O
/ O
Ag B
, O
where O
x O
= O
1 O
- O
3 O
. O

The O
components O
of O
the O
microparticle O
carry O
multiple O
functionalities O
: O
( O
i O
) O
an O
easy O
identification O
by O
Raman O
imaging O
( O
photostable O
astralen O
) O
and O
( O
ii O
) O
SERS O
due O
to O
a O
rough O
surface O
of O
Ag B
nanoparticles O
. O

A O
combination O
of O
Ag B
and O
astralen O
nanoparticles O
provides O
an O
enhancement O
of O
astralen O
Raman O
signal O
by O
more O
than O
1 O
order O
of O
magnitude O
. O

Raman O
signals O
of O
commonly O
used O
scaffold O
components O
such O
as O
polylactide B
and O
polyvinyl B
alcohol I
as O
well O
as O
ECM O
component O
( O
hyaluronic O
acid O
) O
are O
significantly O
enhanced O
. O

Apoaequorin O
, O
a O
calcium B
- O
binding O
protein O
originally O
isolated O
from O
jellyfish O
is O
available O
commercially O
as O
a O
dietary O
supplement O
. O

Environmental O
stress O
, O
oxytocin B
receptor O
gene O
( O
OXTR O
) O
polymorphism O
, O
and O
mental O
health O
following O
collective O
stress O
. O

We O
examined O
whether O
the O
oxytocin B
receptor O
gene O
( O
OXTR O
) O
single O
nucleotide B
polymorphism O
( O
SNP O
) O
rs53576 O
genotype O
buffers O
the O
combined O
impact O
of O
negative O
social O
environments O
( O
e O
. O
g O
. O
, O
interpersonal O
conflict O
/ O
constraint O
) O
and O
economic O
stress O
on O
post O
- O
traumatic O
stress O
( O
PTS O
) O
symptoms O
and O
impaired O
daily O
functioning O
following O
collective O
stress O
( O
September O
11th O
terrorist O
attacks O
) O
. O

Neurotrophin O
3 O
genotype O
and O
emotional O
adverse O
effects O
of O
osmotic O
- O
release O
oral O
system O
methylphenidate B
( O
OROS O
- O
MPH O
) O
in O
children O
with O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

We O
hypothesized O
that O
the O
risk O
of O
an O
emotional O
side O
effect O
to O
methylphenidate B
( O
MPH O
) O
treatment O
may O
be O
associated O
with O
NTF3 O
genotypes O
. O

Resveratrol B
protects O
against O
arsenic B
trioxide I
- O
induced O
nephrotoxicity O
by O
facilitating O
arsenic B
metabolism O
and O
decreasing O
oxidative O
stress O
. O

Arsenic B
trioxide I
( O
As2O3 O
) O
is O
an O
environmental O
toxicant O
and O
a O
potent O
antineoplastic O
agent O
. O

Exposure O
to O
arsenic B
causes O
renal O
cancer O
. O

Resveratrol B
is O
a O
well O
- O
known O
polyphenolic B
compound O
that O
is O
reported O
to O
reduce O
As2O3 O
- O
induced O
cardiotoxicity O
. O

The O
present O
study O
aimed O
to O
investigate O
the O
effect O
of O
resveratrol B
on O
As2O3 O
- O
induced O
nephrotoxicity O
and O
arsenic B
metabolism O
. O

Chinese O
Dragon O
- O
Li O
cats O
were O
injected O
with O
1 O
mg O
/ O
kg O
As2O3 O
on O
alternate O
days O
; O
resveratrol B
( O
3 O
mg O
/ O
kg O
) O
was O
administered O
via O
the O
forearm O
vein O
1 O
h O
before O
the O
As2O3 O
treatment O
. O

On O
the O
sixth O
day O
, O
the O
cats O
were O
killed O
to O
determine O
the O
histological O
renal O
damage O
, O
renal O
function O
, O
the O
accumulation O
of O
arsenic B
, O
and O
antioxidant O
activities O
in O
the O
kidney O
. O

Urine O
samples O
were O
taken O
for O
arsenic B
speciation O
. O

In O
the O
resveratrol B
+ O
As2O3 O
- O
treated O
group O
, O
activities O
of O
glutathione B
peroxidase O
, O
catalase O
, O
and O
superoxide B
dismutase O
, O
the O
ratio O
of O
reduced O
glutathione B
to O
oxidized B
glutathione I
, O
the O
total O
arsenic B
concentrations O
, O
and O
the O
percentage O
of O
methylated O
arsenic O
in O
urine O
were O
significantly O
increased O
. O

The O
concentrations O
of O
renal O
malondialdehyde B
, O
reactive O
oxygen B
species O
, O
8 B
- I
hydroxydeoxyguanosin I
, O
serum O
creatinine B
, O
blood O
urea B
nitrogen B
, O
and O
renal O
arsenic B
accumulation O
were O
significantly O
decreased O
and O
reduced O
renal O
morphologic O
injury O
was O
observed O
compared O
with O
the O
As2O3 O
- O
treated O
group O
. O

These O
results O
demonstrate O
that O
resveratrol B
could O
significantly O
scavenge O
reactive O
oxygen B
species O
, O
inhibit O
As2O3 O
- O
induced O
oxidative O
damage O
, O
and O
significantly O
attenuate O
the O
accumulation O
of O
arsenic B
in O
renal O
tissues O
by O
facilitating O
As2O3 O
metabolism O
. O

These O
data O
suggest O
that O
use O
of O
resveratrol B
as O
postremission O
therapy O
for O
acute O
promyelocytic O
leukemia O
as O
well O
as O
adjunctive O
therapy O
in O
patients O
with O
exposure O
to O
arsenic B
may O
decrease O
arsenic B
nephrotoxicity O
. O

Global O
analysis O
of O
Drosophila O
Cys2 O
- O
His2 O
zinc B
finger O
proteins O
reveals O
a O
multitude O
of O
novel O
recognition O
motifs O
and O
binding O
determinants O
. O

Cys2 O
- O
His2 O
zinc B
finger O
proteins O
( O
ZFPs O
) O
are O
the O
largest O
group O
of O
transcription O
factors O
in O
higher O
metazoans O
. O

As O
a O
first O
step O
in O
this O
process O
, O
we O
have O
characterized O
the O
DNA O
- O
binding O
specificities O
of O
129 O
zinc B
finger O
sets O
from O
Drosophila O
using O
a O
bacterial O
one O
- O
hybrid O
system O
. O

To O
confirm O
the O
utility O
of O
our O
finger O
recognition O
models O
, O
we O
employed O
subsets O
of O
Drosophila O
fingers O
in O
combination O
with O
an O
existing O
archive O
of O
artificial O
zinc B
finger O
modules O
to O
create O
ZFPs O
with O
novel O
DNA O
- O
binding O
specificity O
. O

These O
hybrids O
of O
natural O
and O
artificial O
fingers O
can O
be O
used O
to O
create O
functional O
zinc B
finger O
nucleases O
for O
editing O
vertebrate O
genomes O
. O

Ritonavir B
is O
commonly O
used O
as O
a O
pharmacokinetic O
booster O
for O
antiretroviral O
regimens O
in O
the O
management O
of O
human O
immunodeficiency O
virus O
infections O
. O

Limitations O
to O
ritonavir B
boosting O
include O
increased O
pill O
burden O
, O
adverse O
effects O
, O
and O
a O
wide O
range O
of O
clinically O
significant O
drug O
- O
drug O
interactions O
. O

Based O
on O
successful O
clinical O
trials O
, O
a O
new O
single O
- O
tablet O
regimen O
of O
elvitegravir O
, O
cobicistat O
, O
emtricitabine B
, O
and O
tenofovir B
has O
been O
approved O
for O
the O
management O
of O
treatment O
- O
na O
i O
ve O
patients O
. O

Tumor O
- O
suppressive O
Maspin O
Functions O
as O
a O
Reactive O
Oxygen B
Species O
Scavenger O
: O
IMPORTANCE O
OF O
CYSTEINE B
RESIDUES O
. O

Here O
, O
we O
provide O
evidence O
that O
maspin O
acts O
as O
a O
reactive O
oxygen B
species O
( O
ROS O
) O
scavenger O
through O
oxidation O
of O
three O
structurally O
exposed O
cysteine O
thiols O
to O
sulfenic O
acid O
. O

Ablation O
of O
these O
cysteine B
residues O
in O
maspin O
resulted O
in O
a O
significant O
increase O
in O
total O
ROS O
production O
in O
mouse O
mammary O
TM40D O
cells O
. O

Also O
, O
cells O
containing O
a O
triple O
- O
cysteine B
mutant O
of O
maspin O
showed O
elevated O
ERK1 O
/ O
2 O
activity O
, O
a O
downstream O
target O
of O
ROS O
, O
and O
enhanced O
proliferation O
and O
colony O
formation O
. O

Global O
iodine B
nutrition O
: O
where O
do O
we O
stand O
in O
2013 O
? O

Background O
: O
Dietary O
iodine B
intake O
is O
required O
for O
the O
production O
of O
thyroid B
hormone I
. O

Consequences O
of O
iodine B
deficiency O
include O
goiter O
, O
intellectual O
impairments O
, O
growth O
retardation O
, O
neonatal O
hypothyroidism O
, O
and O
increased O
pregnancy O
loss O
and O
infant O
mortality O
. O

Summary O
: O
In O
1990 O
, O
the O
United O
Nations O
World O
Summit O
for O
Children O
established O
the O
goal O
of O
eliminating O
iodine B
deficiency O
worldwide O
. O

In O
2013 O
, O
as O
defined O
by O
a O
national O
or O
subnational O
median O
urinary O
iodine B
concentration O
of O
100 O
- O
299 O
mu O
g O
/ O
L O
in O
school O
- O
aged O
children O
, O
111 O
countries O
have O
sufficient O
iodine B
intake O
. O

Thirty O
countries O
remain O
iodine B
- O
deficient O
; O
9 O
are O
moderately O
deficient O
, O
21 O
are O
mildly O
deficient O
, O
and O
none O
are O
currently O
considered O
severely O
iodine B
- O
deficient O
. O

Ten O
countries O
have O
excessive O
iodine B
intake O
. O

In O
North O
America O
, O
both O
the O
United O
States O
and O
Canada O
are O
generally O
iodine B
- O
sufficient O
, O
although O
recent O
data O
suggest O
pregnant O
U O
. O
S O
. O
women O
are O
mildly O
iodine B
- O
deficient O
. O

Emerging O
issues O
include O
discrepancies O
between O
urinary O
iodine B
status O
in O
pregnant O
women O
compared O
to O
school O
- O
aged O
children O
in O
some O
populations O
, O
the O
problem O
of O
re O
- O
emerging O
iodine B
deficiency O
in O
parts O
of O
the O
developed O
world O
, O
the O
importance O
of O
food O
industry O
use O
of O
iodized O
salt O
, O
regions O
of O
iodine B
excess O
, O
and O
the O
potential O
effects O
of O
initiatives O
to O
lower O
population O
sodium B
consumption O
on O
iodine B
intake O
. O

Conclusions O
: O
Although O
substantial O
progress O
has O
been O
made O
over O
the O
last O
several O
decades O
, O
iodine B
deficiency O
remains O
a O
significant O
health O
problem O
worldwide O
and O
affects O
both O
industrialized O
and O
developing O
nations O
. O

The O
ongoing O
monitoring O
of O
population O
iodine B
status O
remains O
crucially O
important O
, O
and O
particular O
attention O
may O
need O
to O
be O
paid O
to O
monitoring O
the O
status O
of O
vulnerable O
populations O
, O
such O
as O
pregnant O
women O
and O
infants O
. O

There O
is O
also O
need O
for O
ongoing O
monitoring O
of O
iodized O
salt O
and O
other O
dietary O
iodine B
sources O
in O
order O
to O
prevent O
excess O
as O
well O
as O
insufficient O
iodine B
nutrition O
. O

Finally O
, O
it O
will O
be O
essential O
to O
coordinate O
interventions O
designed O
to O
reduce O
population O
sodium B
intake O
with O
salt O
iodization O
programs O
in O
order O
to O
maintain O
adequate O
levels O
of O
iodine B
nutrition O
as O
salt O
intake O
declines O
. O

In O
vivo O
HIF O
- O
mediated O
reductive O
carboxylation O
is O
regulated O
by O
citrate B
levels O
and O
sensitizes O
VHL O
- O
deficient O
cells O
to O
glutamine B
deprivation O
. O

Hypoxic O
and O
VHL O
- O
deficient O
cells O
use O
glutamine B
to O
generate O
citrate B
and O
lipids O
through O
reductive O
carboxylation O
( O
RC O
) O
of O
alpha B
- I
ketoglutarate I
. O

HIF O
expression O
drastically O
reduced O
intracellular O
citrate B
levels O
. O

Feeding O
VHL O
- O
deficient O
RCC O
cells O
with O
acetate B
or O
citrate B
or O
knocking O
down O
PDK O
- O
1 O
and O
ACLY O
restored O
citrate B
levels O
and O
suppressed O
RC O
. O

These O
data O
suggest O
that O
HIF O
- O
induced O
low O
intracellular O
citrate B
levels O
promote O
the O
reductive O
flux O
by O
mass O
action O
to O
maintain O
lipogenesis O
. O

Lastly O
, O
HIF O
rendered O
VHL O
- O
deficient O
cells O
sensitive O
to O
glutamine B
deprivation O
in O
vitro O
, O
and O
systemic O
administration O
of O
glutaminase O
inhibitors O
suppressed O
the O
growth O
of O
RCC O
cells O
as O
mice O
xenografts O
. O

When O
expressed O
at O
elevated O
levels O
in O
brown O
fat O
, O
TLE3 O
counters O
Prdm16 O
, O
suppressing O
brown O
- O
selective O
genes O
and O
inducing O
white O
- O
selective O
genes O
, O
resulting O
in O
impaired O
fatty B
acid I
oxidation O
and O
thermogenesis O
. O

In O
the O
present O
study O
, O
we O
focused O
on O
[ O
TBP O
] O
/ O
[ O
Au B
( I
III I
) I
] O
ratios O
of O
1 O
- O
5 O
( O
= O
~ O
1 O
mM O
HAuCl4 O
) O
and O
seed O
sizes O
~ O
20 O
nm O
. O

Molecular O
interactions O
in O
1 B
- I
butanol I
+ O
IL O
solutions O
by O
measuring O
and O
modeling O
activity O
coefficients O
. O

Molecular O
interactions O
in O
1 B
- I
butanol I
+ O
ionic O
liquid O
( O
IL O
) O
solutions O
have O
been O
investigated O
by O
measuring O
and O
modeling O
activity O
- O
coefficient O
data O
. O

The O
activity O
coefficients O
in O
binary O
solutions O
containing O
1 B
- I
butanol I
and O
an O
IL O
were O
determined O
experimentally O
: O
the O
ILs O
studied O
were O
1 O
- O
decyl O
- O
3 O
- O
methyl O
- O
imidazolium O
tetracyanoborate O
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
) O
, O
4 O
- O
decyl O
- O
4 O
- O
methyl O
- O
morpholinium O
tetracyanoborate O
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
) O
, O
1 O
- O
decyl O
- O
3 O
- O
methyl O
- O
imidazolium O
bis O

( O
trifluoromethylsulfo O
) O
imide O
( O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 O
] O
( O
- O
) O
) O
, O
and O
4 O
- O
decyl O
- O
4 O
- O
methyl O
- O
morpholinium O
bis O
( O
trifluoromethylsulfo O
) O
imide O
( O
[ O
Mo10 O
. O
1 O
] O
( O
+ O
) O
[ O
ntf2 B
] O
( O
- O
) O
) O
. O

The O
results O
from O
all O
of O
these O
techniques O
were O
combined O
to O
obtain O
activity O
- O
coefficient O
data O
over O
the O
entire O
IL O
concentration O
range O
, O
and O
the O
ion O
- O
specific O
interactions O
of O
the O
ILs O
investigated O
were O
identified O
with O
1 B
- I
butanol I
. O

The O
highest O
( O
1 B
- I
butanol I
) O
- O
IL O
interactions O
of O
the O
ILs O
considered O
in O
this O
work O
were O
found O
for O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
; O
thus O
, O
[ O
Im10 O
. O
1 O
] O
( O
+ O
) O
[ O
tcb O
] O
( O
- O
) O
showed O
the O
highest O
affinity O
for O
1 B
- I
butanol I
in O
a O
binary O
mixture O
. O

PC O
- O
SAFT O
was O
able O
to O
accurately O
describe O
the O
pure O
IL O
and O
( O
1 B
- I
butanol I
) O
- O
IL O
data O
. O

Chemical O
informatics O
uncovers O
a O
new O
role O
for O
moexipril O
as O
a O
novel O
inhibitor O
of O
cAMP B
phosphodiesterase O
- O
4 O
( O
PDE4 O
) O
. O

PDE4 O
is O
one O
of O
eleven O
known O
cyclic O
nucleotide O
phosphodiesterase O
families O
and O
plays O
a O
pivotal O
role O
in O
mediating O
hydrolytic O
degradation O
of O
the O
important O
cyclic O
nucleotide O
second O
messenger O
, O
cyclic O
3 O
' O
5 O
' O
adenosine O
monophosphate O
( O
cAMP B
) O
. O

Employing O
a O
FRET O
- O
based O
biosensor O
constructed O
from O
the O
nucleotide B
binding O
domain O
of O
the O
type O
1 O
exchange O
protein O
activated O
by O
cAMP B
, O
EPAC1 O
, O
we O
demonstrated O
that O
moexipril O
markedly O
potentiated O
the O
ability O
of O
forskolin B
to O
increase O
intracellular O
cAMP B
levels O
. O

Finally O
, O
we O
demonstrated O
that O
the O
PDE4 O
inhibitory O
effect O
of O
moexipril O
is O
functionally O
able O
to O
induce O
phosphorylation O
of O
the O
small O
heat O
shock O
protein O
, O
Hsp20 O
, O
by O
cAMP B
dependent O
protein O
kinase O
A O
. O

The O
membrane O
transporter O
MDR O
- O
1 O
( O
P O
- O
gp O
, O
ABCB1 O
) O
, O
a O
member O
of O
the O
ATP B
- O
binding O
cassette O
( O
ABC O
) O
transporter O
family O
, O
effluxes O
anti O
- O
cancer O
drugs O
from O
cancer O
cells O
. O

MDR O
- O
1 O
is O
known O
to O
be O
localized O
in O
the O
cholesterol B
- O
and O
sphingolipid B
- O
enriched O
plasma O
membrane O
microdomains O
, O
known O
as O
lipid O
rafts O
. O

Disruption O
of O
lipid O
rafts O
by O
cholesterol B
depletion O
alters O
lipid O
raft O
functions O
, O
indicating O
that O
cholesterol B
is O
critical O
for O
raft O
function O
. O

Because O
ginsenosides B
are O
structurally O
similar O
to O
cholesterol B
, O
in O
this O
study O
, O
we O
investigated O
the O
effect O
of O
Rp1 O
, O
a O
novel O
ginsenoside B
derivative O
, O
on O
drug O
resistance O
using O
drug O
- O
sensitive O
OVCAR O
- O
8 O
and O
drug O
- O
resistant O
NCI O
/ O
ADR O
- O
RES O
and O
DXR O
cells O
. O

Rp1 O
treatment O
resulted O
in O
an O
accumulation O
of O
doxorubicin B
or O
rhodamine O
123 O
by O
decreasing O
MDR O
- O
1 O
activity O
in O
doxorubicin B
- O
resistant O
cells O
. O

Rp1 O
synergistically O
induced O
cell O
death O
with O
actinomycin B
D I
in O
DXR O
cells O
. O

Moreover O
, O
Rp1 O
reversed O
resistance O
to O
actinomycin B
D I
by O
decreasing O
MDR O
- O
1 O
protein O
levels O
and O
Src O
phosphorylation O
with O
modulation O
of O
lipid O
rafts O
. O

Addition O
of O
cholesterol B
attenuated O
Rp1 O
- O
induced O
raft O
aggregation O
and O
MDR O
- O
1 O
redistribution O
. O

Rp1 O
and O
actinomycin B
D I
reduced O
Src O
activity O
, O
and O
overexpression O
of O
active O
Src O
decreased O
the O
synergistic O
effect O
of O
Rp1 O
with O
actinomycin B
D I
. O

Rp1 O
- O
induced O
drug O
sensitization O
was O
also O
observed O
with O
several O
anti O
- O
cancer O
drugs O
, O
including O
doxorubicin B
. O

Robust O
PEGylated O
hyaluronic O
acid O
nanoparticles O
as O
the O
carrier O
of O
doxorubicin B
: O
Mineralization O
and O
its O
effect O
on O
tumor O
targetability O
in O
vivo O
. O

In O
this O
study O
, O
to O
develop O
biostable O
nanoparticles O
with O
high O
tumor O
targetability O
, O
poly B
( I
ethylene I
glycol I
) I
- O
conjugated O
hyaluronic O
acid O
nanoparticles O
( O
PEG B
- O
HANPs O
) O
were O
mineralized O
through O
controlled O
deposition O
of O
inorganic O
calcium B
and O
phosphate B
ions O
on O
the O
nanoparticular O
shell O
via O
a O
sequential O
addition O
method O
. O

The O
resulting O
nanoparticles O
( O
M O
- O
PEG B
- O
HANPs O
) O
had O
a O
smaller O
size O
( O
153 O
. O
7 O
+ O
/ O
- O
4 O
. O
5nm O
) O
than O
bare O
PEG B
- O
HANPs O
( O
265 O
. O
1 O
+ O
/ O
- O
9 O
. O
5nm O
) O
, O
implying O
that O
mineralization O
allows O
the O
formation O
of O
compact O
nanoparticles O
. O

The O
role O
of O
DNA O
methylation O
and O
histone O
acetylation O
in O
the O
regulation O
of O
progesterone B
receptor O
isoforms O
expression O
in O
human O
astrocytoma O
cell O
lines O
. O

Many O
progesterone B
( O
P4 O
) O
effects O
are O
mediated O
by O
its O
intracellular O
receptor O
( O
PR O
) O
, O
which O
has O
two O
isoforms O
, O
PR O
- O
A O
and O
PR O
- O
B O
, O
each O
of O
them O
with O
different O
function O
and O
regulation O
. O

We O
evaluated O
the O
effect O
of O
the O
demethylating O
agent O
5 B
- I
aza I
- I
2 I
' I
- I
deoxycytidine I
( O
5AzadC O
) O
and O
the O
histone O
deacetylase O
inhibitor O
trichostatin B
A I
( O
TSA B
) O
on O
PR O
expression O
in O
human O
astrocytoma O
cell O
lines O
U373 O
( O
grade O
III O
) O
and O
D54 O
( O
grade O
IV O
) O
by O
RT O
- O
PCR O
and O
Western O
blot O
. O

PR O
- O
B O
expression O
was O
not O
modified O
by O
the O
TSA B
concentrations O
that O
were O
used O
, O
and O
the O
combination O
with O
5AzadC O
did O
not O
change O
the O
effects O
of O
the O
latter O
. O

Neutralization O
of O
Apis O
mellifera O
bee O
venom O
activities O
by O
suramin B
. O

In O
this O
work O
we O
evaluated O
the O
ability O
of O
suramin B
, O
a O
polysulfonated B
naphthylurea I
derivative O
, O
to O
antagonize O
the O
cytotoxic O
and O
enzymatic O
effects O
of O
the O
crude O
venom O
of O
Apis O
mellifera O
. O

Suramin B
was O
efficient O
to O
decrease O
the O
lethality O
in O
a O
dose O
- O
dependent O
way O
. O

The O
hemoconcentration O
caused O
by O
lethal O
dose O
injection O
of O
bee O
venom O
was O
abolished O
by O
suramin B
( O
30 O
mu O
g O
/ O
g O
) O
. O

The O
edematogenic O
activity O
of O
the O
venom O
( O
0 O
. O
3 O
mu O
g O
/ O
g O
) O
was O
antagonized O
by O
suramin B
( O
10 O
mu O
g O
/ O
g O
) O
in O
all O
treatment O
protocols O
. O

The O
changes O
in O
the O
vascular O
permeability O
caused O
by O
A O
. O
mellifera O
( O
1 O
mu O
g O
/ O
g O
) O
venom O
were O
inhibited O
by O
suramin B
( O
30 O
mu O
g O
/ O
g O
) O
in O
the O
pre O
- O
and O
posttreatment O
as O
well O
as O
when O
the O
venom O
was O
preincubated O
with O
suramin B
. O

In O
addition O
, O
suramin B
also O
inhibited O
cultured O
endothelial O
cell O
lesion O
, O
as O
well O
as O
in O
vitro O
myotoxicity O
, O
evaluated O
in O
mouse O
extensor O
digitorumlongus O
muscle O
, O
which O
was O
inhibited O
by O
suramin B
( O
10 O
and O
25 O
mu O
M O
) O
, O
decreasing O
the O
rate O
of O
CK O
release O
, O
showing O
that O
suramin B
protected O
the O
sarcolemma O
against O
damage O
induced O
by O
components O
of O
bee O
venom O
( O
2 O
. O
5 O
mu O
g O
/ O
mL O
) O
. O

Moreover O
, O
suramin B
inhibited O
the O
in O
vivo O
myotoxicity O
induced O
by O
i O
. O
m O
. O
injection O
of O
A O
. O
mellifera O
venom O
in O
mice O
( O
0 O
. O
5 O
mu O
g O
/ O
g O
) O
. O

The O
analysis O
of O
the O
area O
under O
the O
plasma O
CK O
vs O
. O
time O
curve O
showed O
that O
preincubation O
, O
pre O
- O
and O
posttreatment O
with O
suramin B
( O
30 O
mu O
g O
/ O
g O
) O
inhibited O
bee O
venom O
myotoxic O
activity O
in O
mice O
by O
about O
89 O
% O
, O
45 O
% O
and O
40 O
% O
, O
respectively O
. O

Suramin B
markedly O
inhibited O
the O
PLA2 O
activity O
in O
a O
concentration O
- O
dependent O
way O
( O
1 O
- O
30 O
mu O
M O
) O
. O

Being O
suramin B
a O
polyanion O
molecule O
, O
the O
effects O
observed O
may O
be O
due O
to O
the O
interaction O
of O
its O
charges O
with O
the O
polycation O
components O
present O
in O
A O
. O
mellifera O
bee O
venom O
. O

Effects O
of O
perinatal O
exposure O
to O
waterborne O
fluoxetine B
on O
memory O
processing O
in O
the O
cuttlefish O
Sepia O
officinalis O
. O

Amongst O
them O
is O
the O
antidepressant O
fluoxetine B
( O
FLX B
) O
, O
a O
selective O
serotonin B
reuptake O
inhibitor O
, O
primarily O
indicated O
for O
treatment O
of O
depression O
. O

The O
effect O
of O
chronic O
exposure O
to O
FLX B
on O
memory O
processing O
in O
1 O
- O
month O
- O
old O
cuttlefish O
Sepia O
officinalis O
was O
evaluated O
. O

Three O
groups O
of O
new O
- O
borns O
were O
reared O
in O
different O
conditions O
: O
one O
control O
group O
( O
no O
FLX B
) O
and O
two O
groups O
exposed O
to O
environmental O
concentrations O
of O
FLX B
( O
1 O
and O
100ng O
/ O
L O
) O
from O
15 O
days O
pre O
- O
hatching O
to O
1 O
month O
post O
- O
hatching O
. O

Perinatal O
exposure O
to O
fluoxetine B
led O
to O
significant O
changes O
in O
memory O
processing O
of O
the O
animals O
. O

Cuttlefish O
exposed O
at O
low O
FLX B
concentration O
had O
impaired O
acquisition O
capabilities O
and O
animals O
exposed O
at O
high O
FLX B
concentration O
displayed O
a O
deficit O
of O
memory O
retention O
compared O
to O
the O
control O
group O
that O
had O
nonimpaired O
initial O
acquisition O
and O
retention O
performances O
. O

The O
results O
subsequently O
suggested O
that O
FLX B
- O
induced O
changes O
in O
cognitive O
capacities O
could O
potentially O
lead O
to O
inappropriate O
predatory O
behaviors O
in O
the O
natural O
environment O
. O

We O
studied O
in O
Enallagma O
cyathigerum O
damselfly O
larvae O
potential O
synergistic O
effects O
between O
exposure O
to O
the O
pesticide O
glyphosate B
and O
predator O
cues O
on O
a O
key O
life O
history O
trait O
, O
growth O
rate O
, O
its O
associated O
behavioural O
trait O
, O
food O
intake O
, O
and O
three O
types O
of O
physiological O
traits O
known O
to O
be O
affected O
by O
both O
stressors O
in O
isolation O
: O
the O
stress O
protein O
Hsp70 O
, O
energy O
storage O
and O
variables O
related O
to O
oxidative O
stress O
and O
damage O
. O

One O
potential O
physiological O
mechanism O
was O
that O
both O
stressors O
additively O
increased O
Hsp70 O
levels O
, O
this O
may O
also O
have O
contributed O
to O
the O
reduced O
levels O
of O
total O
carbohydrates B
when O
exposed O
to O
predator O
cues O
. O

Chronic O
exposure O
to O
predator O
cues O
reduced O
oxygen B
consumption O
, O
possibly O
to O
avoid O
too O
high O
costs O
of O
an O
increased O
metabolic O
rate O
. O

When O
both O
stressors O
were O
combined O
, O
there O
was O
a O
reduction O
of O
the O
antioxidant O
enzyme O
superoxide B
dismutase O
activity O
( O
SOD O
) O
and O
an O
associated O
increase O
of O
oxidative O
damage O
in O
lipids O
. O

Can O
acetylcholinesterase O
activity O
be O
considered O
as O
a O
reliable O
biomarker O
for O
the O
assessment O
of O
cadmium B
- O
induced O
neurotoxicity O
? O

( O
2012 O
) O
recently O
reported O
the O
findings O
of O
a O
long O
- O
awaited O
study O
on O
the O
effects O
of O
long O
- O
term O
dietary O
- O
induced O
exposure O
to O
cadmium B
( O
Cd B
) O
on O
the O
acetylcholinesterase O
( O
AChE O
) O
activity O
of O
adult O
rodents O
' O
brain O
regions O
. O

Their O
study O
can O
be O
regarded O
as O
a O
significant O
contribution O
to O
the O
field O
, O
as O
there O
is O
paucity O
of O
information O
on O
the O
AChE O
activity O
in O
brain O
regions O
following O
exposure O
to O
Cd B
. O

However O
, O
the O
Cd B
- O
induced O
modulation O
of O
AChE O
activity O
is O
an O
issue O
surrounded O
by O
controversy O
. O

We O
, O
herein O
, O
discuss O
and O
summarize O
the O
relative O
in O
vivo O
and O
in O
vitro O
experimental O
data O
, O
and O
set O
out O
to O
answer O
the O
straightforward O
question O
: O
can O
AChE O
activity O
be O
considered O
as O
a O
reliable O
biomarker O
for O
the O
assessment O
of O
Cd B
- O
induced O
neurotoxicity O
? O

Cd B
modifies O
AChE O
activity O
. O

OBJECTIVETo O
investigate O
changes O
in O
body O
composition O
after O
12 O
months O
of O
high O
- O
intensity O
progressive O
resistance O
training O
( O
PRT O
) O
in O
relation O
to O
changes O
in O
insulin O
resistance O
( O
IR O
) O
or O
glucose B
homeostasis O
in O
older O
adults O
with O
type O
2 O
diabetes O
. O
RESEARCH O
DESIGN O
AND O
METHODSOne O
- O
hundred O
three O
participants O
were O
randomized O
to O
receive O
either O
PRT O
or O
sham O
exercise O
3 O
days O
per O
week O
for O
12 O
months O
. O

Homeostatic O
model O
of O
assessment O
2 O
( O
HOMA2 O
- O
IR O
) O
and O
glycosylated O
hemoglobin O
( O
HbA1c O
) O
were O
used O
as O
indices O
of O
IR O
and O
glucose B
homeostasis O
. O

Mn B
@ O
Si14 O
+ O
: O
a O
singlet O
fullerene B
- I
like O
endohedrally O
doped O
silicon B
cluster O
. O

The O
electronic O
structure O
of O
Mn B
@ O
Si14 O
( O
+ O
) O
is O
determined O
using O
DFT O
and O
CASPT2 O
/ O
CASSCF O
( O
14 O
, O
15 O
) O
computations O
with O
large O
basis O
sets O
. O

The O
endohedrally O
Mn O
- O
doped O
Si O
cationic O
cluster O
has O
a O
D3h O
fullerene B
- I
like O
structure O
featuring O
a O
closed O
- O
shell O
singlet O
ground O
state O
with O
a O
singlet O
- O
triplet O
gap O
of O
~ O
1 O
eV O
. O

A O
strong O
stabilizing O
interaction O
occurs O
between O
the O
3d O
( O
Mn B
) O
and O
the O
2D O
- O
shell O
( O
Si14 O
) O
orbitals O
, O
and O
a O
large O
amount O
of O
charge O
is O
transferred O
from O
the O
Si14 O
cage O
to O
the O
Mn B
dopant O
. O

The O
3d O
( O
Mn B
) O
orbitals O
are O
filled O
by O
encapsulation O
, O
and O
the O
magnetic O
moment O
of O
Mn B
is O
completely O
quenched O
. O

Full O
occupation O
of O
[ O
2S O
, O
2P O
, O
2D O
] O
shell O
orbitals O
by O
18 O
delocalized O
electrons O
confers O
the O
doped O
Mn B
@ O
Si14 O
( O
+ O
) O
cluster O
a O
spherically O
aromatic O
character O
. O

Influence O
of O
the O
novel O
histamine B
H3 O
receptor O
antagonist O
ST1283 O
on O
voluntary O
alcohol B
consumption O
and O
ethanol B
- O
induced O
place O
preference O
in O
mice O
. O

RATIONALE O
: O
Growing O
evidence O
supports O
a O
role O
for O
the O
central O
histaminergic O
system O
to O
have O
a O
modulatory O
influence O
on O
drug O
addiction O
in O
general O
and O
alcohol B
- O
use O
disorders O
in O
particular O
through O
histamine B
H3 O
receptors O
( O
H3R O
) O
. O

OBJECTIVE O
: O
In O
the O
present O
study O
, O
the O
effects O
of O
systemic O
injection O
of O
the O
newly O
synthesized O
H3R O
antagonist O
ST1283 O
on O
ethanol B
( O
EtOH B
) O
voluntary O
intake O
and O
EtOH B
- O
conditioned O
reward O
in O
mice O
have O
been O
investigated O
. O

METHODS O
: O
Oral O
EtOH B
, O
saccharin B
, O
and O
quinine B
intake O
was O
assessed O
in O
a O
two O
- O
bottle O
choice O
paradigm O
using O
escalating O
concentrations O
of O
alcohol B
or O
tastant O
solutions O
. O

EtOH B
- O
induced O
place O
preference O
( O
CPP O
) O
, O
EtOH B
- O
induced O
locomotor O
activity O
, O
and O
blood O
ethanol B
concentration O
( O
BEC O
) O
were O
also O
measured O
. O

RESULTS O
: O
Following O
administration O
of O
the O
H3R O
antagonist O
( O
2 O
. O
5 O
, O
5 O
, O
and O
10 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
there O
was O
a O
significant O
dose O
- O
dependent O
decrease O
in O
alcohol B
consumption O
and O
preference O
. O

More O
interestingly O
, O
systemic O
administration O
of O
ST1283 O
inhibited O
EtOH B
- O
CPP O
and O
EtOH B
- O
enhanced O
locomotion O
. O

CONCLUSION O
: O
Our O
results O
show O
that O
ST1283 O
may O
decrease O
voluntary O
EtOH B
consumption O
and O
EtOH B
- O
CPP O
by O
altering O
its O
reinforcing O
effects O
, O
suggesting O
a O
novel O
role O
for O
histamine B
signaling O
in O
regulation O
of O
alcoholism O
. O

Lastly O
, O
the O
results O
add O
to O
the O
growing O
literature O
on O
H3R O
modulation O
in O
the O
pharmacotherapy O
of O
EtOH B
addiction O
. O

Selenium B
Attenuates O
Adriamycin B
- O
Induced O
Cardiac O
Dysfunction O
via O
Restoring O
Expression O
of O
ATP B
- O
Sensitive O
Potassium B
Channels O
in O
Rats O
. O

The O
possible O
mechanism O
of O
adriamycin B
( O
ADR O
) O
and O
/ O
or O
selenium B
( O
Se B
) O
deficiency O
- O
induced O
cardiac O
dysfunction O
, O
and O
cardioprotective O
effects O
of O
Se B
against O
ADR O
- O
induced O
cardiac O
toxicity O
were O
investigated O
in O
this O
study O
. O

Cardiac O
glutathione B
peroxidase O
( O
GPx O
) O
activity O
was O
assessed O
spectrophotometrical O
. O

Expression O
of O
ATP B
- O
sensitive O
potassium B
channels O
( O
KATP O
) O
subunits O
- O
SUR2A O
and O
Kir6 O
. O
2 O
- O
were O
examined O
by O
real O
- O
time O
PCR O
and O
Western O
blotting O
. O

The O
results O
showed O
that O
cardiac O
function O
and O
cardiac O
GPx O
activity O
decreased O
remarkably O
after O
administration O
of O
ADR O
or O
Se B
deficiency O
; O
more O
dramatic O
impairment O
of O
cardiac O
function O
and O
cardiac O
GPx O
activity O
were O
observed O
after O
co O
- O
administration O
of O
ADR O
and O
Se B
deficiency O
. O

Mechanically O
, O
it O
is O
novel O
for O
us O
to O
find O
down O
- O
regulation O
of O
KATP O
subunits O
gene O
expression O
in O
cardiac O
tissue O
after O
administration O
of O
ADR O
or O
Se B
deficiency O
, O
and O
more O
significant O
inhibition O
of O
cardiac O
KATP O
gene O
expression O
was O
identified O
after O
co O
- O
administration O
of O
ADR O
and O
Se B
deficiency O
. O

Furthermore O
, O
cardiac O
toxicity O
of O
ADR O
was O
found O
alleviated O
by O
Se B
supplementation O
, O
accompanied O
by O
restoring O
of O
cardiac O
GPx O
activity O
and O
cardiac O
KATP O
gene O
expression O
. O

These O
results O
indicate O
that O
decreased O
expression O
of O
cardiac O
KATP O
is O
involved O
in O
adriamycin B
and O
/ O
or O
Se B
deficiency O
- O
induced O
cardiac O
dysfunction O
; O
Se B
deficiency O
exacerbates O
adriamycin B
- O
induced O
cardiac O
dysfunction O
by O
future O
inhibition O
of O
KATP O
expression O
; O
Se B
supplementation O
seems O
to O
protect O
against O
adriamycin B
- O
induced O
cardiac O
dysfunction O
via O
restoring O
KATP O
expression O
, O
showing O
potential O
clinical O
application O
in O
cancer O
chemotherapy O
. O

Of O
the O
patients O
aged O
60 O
years O
and O
above O
( O
7 O
. O
2 O
% O
) O
, O
the O
majority O
( O
95 O
. O
3 O
% O
) O
suffered O
unintentional O
poisoning O
with O
pharmaceuticals O
; O
56 O
% O
with O
warfarin B
, O
12 O
% O
with O
digoxin O
and O
7 O
% O
with O
insulin O
. O

We O
investigated O
the O
structural O
shape O
transitions O
induced O
in O
the O
QII O
( O
G O
) O
phase O
upon O
complexation O
with O
a O
series O
of O
sDNAs O
( O
5 O
, O
11 O
, O
24 O
, O
and O
48 O
bp O
) O
with O
three O
types O
of O
end O
structure O
( O
" O
sticky O
" O
adenine B
( O
A O
) O
- O
thymine B
( O
T O
) O
( O
dAdT O
) O
overhangs O
, O
no O
overhang O
( O
blunt O
) O
, O
and O
" O
nonsticky O
" O
dTdT O
overhangs O
) O
using O
synchrotron O
small O
- O
angle O
X O
- O
ray O
scattering O
. O

Sensing O
of O
biologically O
important O
cations O
such O
as O
na B
( I
+ I
) I
, O
k B
( I
+ I
) I
, O
ca B
( I
2 I
+ I
) I
, O
cu B
( I
2 I
+ I
) I
, O
and O
fe B
( I
3 I
+ I
) I
using O
magnetic O
nanoemulsions O
. O

The O
nanoemulsion O
used O
in O
our O
study O
was O
an O
oil O
- O
in O
- O
water O
emulsion O
droplet O
of O
average O
size O
~ O
190 O
nm O
containing O
ferrimagnetic O
iron B
oxide I
nanoparticles O
of O
average O
size O
~ O
10 O
nm O
. O

The O
sensor O
shows O
good O
selectivity O
to O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
and O
Fe B
( I
3 I
+ I
) I
ions O
and O
offers O
a O
rapid O
response O
compared O
to O
conventional O
techniques O
. O

Steroids B
Glycosylated O
with O
Both O
d O
- O
and O
l O
- O
Arabinoses O
from O
the O
South O
China O
Sea O
Gorgonian O
Dichotella O
gemmacea O
. O

These O
glycosides O
are O
found O
to O
have O
sugar B
moieties O
of O
both O
beta O
- O
l O
- O
and O
beta O
- O
d O
- O
arabinopyranoses O
by O
HPLC O
analysis O
of O
their O
thiocarbamoyl O
- O
thiazolidine O
derivatives O
and O
those O
of O
authentic O
d O
- O
and O
l O
- O
arabinoses O
, O
leading O
to O
the O
structure O
revision O
of O
junceelloside O
C O
( O
1 O
) O
. O

These O
copolymers O
were O
freely O
soluble O
in O
phosphate B
buffer O
but O
formed O
disulfide B
- O
cross O
- O
linked O
nanogels O
with O
defined O
sizes O
ranging O
from O
72 O
. O
5 O
to O
124 O
. O
1 O
nm O
in O
the O
presence O
of O
cystamine O
via O
ring O
- O
opening O
reaction O
with O
cyclic O
carbonate O
groups O
. O

Dynamic O
light O
scattering O
studies O
showed O
that O
these O
nanogels O
though O
stable O
at O
physiological O
conditions O
were O
rapidly O
dissociated O
in O
response O
to O
10 O
mM O
dithiothreitol B
( O
DTT O
) O
. O

Interestingly O
, O
FITC B
- O
labeled O
cytochrome O
C O
( O
FITC B
- O
CC O
) O
could O
be O
readily O
loaded O
into O
nanogels O
with O
remarkable O
loading O
efficiencies O
( O
up O
to O
98 O
. O
2 O
% O
) O
and O
loading O
contents O
( O
up O
to O
48 O
. O
2 O
wt O
. O
% O
) O
. O

The O
in O
vitro O
release O
studies O
showed O
that O
release O
of O
FITC B
- O
CC O
was O
minimal O
under O
physiological O
conditions O
but O
significantly O
enhanced O
under O
reductive O
conditions O
in O
the O
presence O
of O
10 O
mM O
DTT O
with O
about O
96 O
. O
8 O
% O
of O
FITC B
- O
CC O
released O
in O
22 O
h O
from O
nanogel O
1 O
. O

MTT B
assays O
showed O
that O
these O
nanogels O
were O
nontoxic O
to O
HeLa O
cells O
up O
to O
a O
tested O
concentration O
of O
2 O
mg O
/ O
mL O
. O

Confocal O
microscopy O
results O
showed O
that O
nanogel O
1 O
delivered O
and O
released O
FITC B
- O
CC O
into O
the O
perinuclei O
region O
of O
HeLa O
cells O
following O
8 O
h O
incubation O
. O

Synonymous O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
within O
a O
transcript O
' O
s O
coding O
region O
produce O
no O
change O
in O
the O
amino B
acid I
sequence O
of O
the O
protein O
product O
and O
are O
therefore O
intuitively O
assumed O
to O
have O
a O
neutral O
effect O
on O
protein O
function O
. O

The O
NAD B
+ I
- O
dependent O
deacetylases O
Sirt1 O
and O
Sirt2 O
mediate O
cellular O
stress O
responses O
and O
are O
highly O
expressed O
in O
vascular O
endothelial O
cells O
. O

We O
found O
that O
Sirt2 O
knock O
down O
changed O
expression O
of O
340 O
genes O
, O
which O
are O
mainly O
involved O
in O
cellular O
processes O
including O
actin O
binding O
, O
cellular O
amino B
acid I
metabolic O
process O
, O
transmembrane O
receptor O
protein O
serine B
/ O
threonine B
kinase O
signaling O
, O
ferrous O
iron O
transport O
, O
protein O
transport O
and O
localization O
, O
cell O
morphogenesis O
, O
and O
functions O
associated O
with O
endosome O
membrane O
and O
the O
trans O
- O
Golgi O
network O
. O

Selective O
poisoning O
of O
Ctnnb1 O
- O
mutated O
hepatoma O
cells O
in O
mouse O
liver O
tumors O
by O
a O
single O
application O
of O
acetaminophen B
. O

Acetaminophen B
( O
AAP O
) O
is O
metabolized O
in O
hepatocytes O
by O
these O
CYPs O
to O
the O
reactive O
intermediate O
N O
- O
acetyl O
- O
p O
- O
benzoquinone O
- O
imine O
, O
which O
is O
toxic O
to O
hepatocytes O
at O
high O
doses O
where O
depletion O
of O
glutathione B
occurs O
. O

We O
have O
induced O
liver O
tumors O
in O
mice O
by O
treatment O
with O
the O
liver O
carcinogen O
N O
- O
nitrosodiethylamine O
followed O
by O
chronic O
treatment O
with O
the O
tumor O
promoter O
phenobarbital B
. O

Theoretical O
study O
of O
the O
thermodynamic O
and O
burning O
properties O
of O
oxygen B
- O
rich O
hydrazine B
derivatives O
- O
green O
and O
powerful O
oxidants O
for O
energetic O
materials O
. O

A O
series O
of O
no O
- O
chlorine B
and O
oxygen B
- O
rich O
hydrazine B
derivatives O
( O
hydrazine B
modified O
with O
- O
NO2 B
and O
NO3 B
( I
- I
) I
groups O
) O
was O
designed O
and O
optimized O
to O
obtain O
molecular O
geometries O
and O
electronic O
structures O
at O
density O
functional O
theory O
- O
B3PW91 O
/ O
6 O
- O
311 O
+ O
+ O
G O
( O
3df O
, O
3pd O
) O
level O
. O

Flavonoids B
and O
3 O
- O
Arylcoumarin O
from O
Pterocarpus O
soyauxii O
. O

Phytochemical O
study O
on O
the O
constituents O
of O
the O
heartwood O
of O
Pterocarpus O
soyauxii O
led O
to O
the O
isolation O
of O
five O
new O
isoflavonoids B
and O
one O
new O
3 O
- O
arylcoumarin O
, O
pterosonins O
A O
- O
F O
( O
1 O
- O
6 O
) O
, O
together O
with O
17 O
known O
analogues O
, O
among O
which O
8 O
, O
9 O
, O
and O
18 O
were O
reported O
as O
natural O
products O
for O
the O
first O
time O
. O

Despite O
the O
mounting O
clinical O
trial O
data O
, O
the O
management O
of O
dyslipidemia O
other O
than O
lowering O
the O
low O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
c O
) O
continues O
to O
be O
controversial O
. O

The O
characteristic O
features O
of O
diabetic O
dyslipidemia O
are O
high O
plasma O
triglyceride B
concentration O
, O
reduced O
high O
density O
lipoprotein O
cholesterol B
( O
HDL O
- O
c O
) O
concentration O
, O
and O
increased O
concentration O
of O
small O
dense O
LDL O
particles O
. O

These O
changes O
are O
caused O
by O
increased O
free O
fatty B
acid I
flux O
secondary O
to O
insulin O
resistance O
and O
aggravated O
by O
increased O
inflammatory O
adipokines O
. O

Although O
the O
evidence O
for O
clinical O
utility O
of O
combination O
of O
statins O
with O
fibrates O
or O
nicotinic B
acid I
in O
reducing O
cardiovascular O
events O
remains O
inconclusive O
, O
the O
preponderance O
of O
evidence O
suggests O
that O
a O
subgroup O
who O
have O
high O
triglycerides B
and O
low O
HDL O
- O
c O
levels O
may O
benefit O
from O
combination O
therapy O
of O
statins O
and O
fibrates O
. O

Crystal O
Structures O
of O
a O
Glycoside O
Hydrolase O
Family O
20 O
Lacto O
- O
N B
- O
biosidase O
from O
Bifidobacterium O
bifidum O
. O

Several O
strains O
of O
infant O
gut O
- O
associated O
bifidobacteria O
possess O
lacto O
- O
N B
- O
biosidase O
, O
a O
membrane O
- O
anchored O
extracellular O
enzyme O
, O
that O
liberates O
LNB O
from O
the O
nonreducing O
end O
of O
human O
milk O
oligosaccharides O
and O
plays O
a O
key O
role O
in O
the O
metabolic O
pathway O
of O
these O
compounds O
. O

Lacto O
- O
N B
- O
biosidase O
belongs O
to O
the O
glycoside O
hydrolase O
family O
20 O
, O
and O
its O
reaction O
proceeds O
via O
a O
substrate O
- O
assisted O
catalytic O
mechanism O
. O

Several O
crystal O
structures O
of O
GH20 O
beta O
- O
N B
- O
acetylhexosaminidase O
, O
which O
release O
monosaccharide B
GlcNAc B
from O
its O
substrate O
, O
have O
been O
determined O
, O
but O
to O
date O
, O
a O
structure O
of O
lacto O
- O
N B
- O
biosidase O
is O
unknown O
. O

Here O
, O
we O
have O
determined O
the O
first O
three O
- O
dimensional O
structures O
of O
lacto O
- O
N B
- O
biosidase O
from O
Bifidobacterium O
bifidum O
JCM1254 O
in O
complex O
with O
LNB O
and O
LNB O
- O
thiazoline O
( O
Gal O
- O
beta O
1 O
, O
3 O
- O
GlcNAc O
- O
thiazoline O
) O
at O
1 O
. O
8 O
- O
A O
resolution O
. O

Lacto O
- O
N B
- O
biosidase O
consists O
of O
three O
domains O
, O
and O
the O
C B
- O
terminal O
domain O
has O
a O
unique O
beta O
- O
trefoil O
- O
like O
fold O
. O

Compared O
with O
other O
beta O
- O
N B
- O
acetylhexosaminidase O
, O
lacto O
- O
N B
- O
biosidase O
has O
a O
wide O
substrate O
- O
binding O
pocket O
with O
a O
- O
2 O
subsite O
specific O
for O
beta O
- O
1 O
, O
3 O
- O
linked O
Gal B
, O
and O
the O
residues O
responsible O
for O
Gal B
recognition O
were O
identified O
. O

The O
bound O
ligands O
are O
recognized O
by O
extensive O
hydrogen B
bonds O
at O
all O
of O
their O
hydroxyls B
consistent O
with O
the O
enzyme O
' O
s O
strict O
substrate O
specificity O
for O
the O
LNB O
moiety O
. O

The O
GlcNAc B
sugar B
ring O
of O
LNB O
is O
in O
a O
distorted O
conformation O
near O
( O
4 O
) O
E O
, O
whereas O
that O
of O
LNB O
- O
thiazoline O
is O
in O
a O
( O
4 O
) O
C1 O
conformation O
. O

A O
possible O
conformational O
pathway O
for O
the O
lacto O
- O
N B
- O
biosidase O
reaction O
is O
discussed O
. O

Degradation O
and O
Rearrangement O
of O
a O
Lung O
Surfactant O
Lipid O
at O
the O
Air O
- O
Water O
Interface O
during O
Exposure O
to O
the O
Pollutant O
Gas O
Ozone B
. O

In O
this O
work O
, O
we O
have O
used O
neutron O
reflection O
and O
surface O
pressure O
measurements O
to O
study O
the O
reaction O
of O
the O
ubiquitous O
pollutant O
gas O
- O
phase O
ozone B
, O
O3 O
, O
with O
pure O
and O
mixed O
phospholipid O
monolayers O
at O
the O
air O
- O
water O
interface O
. O

The O
results O
reveal O
that O
the O
reaction O
of O
the O
unsaturated O
lipid O
1 O
- O
palmitoyl O
- O
2 O
- O
oleoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
, O
POPC B
, O
with O
ozone B
leads O
to O
the O
rapid O
loss O
of O
the O
terminal O
C9 O
portion O
of O
the O
oleoyl O
strand O
of O
POPC B
from O
the O
air O
- O
water O
interface O
. O

The O
reaction O
of O
POPC B
with O
ozone B
also O
leads O
to O
a O
loss O
of O
material O
from O
the O
palmitoyl B
strand O
, O
but O
the O
loss O
of O
palmitoyl B
material O
occurs O
after O
the O
loss O
of O
the O
terminal O
C9 O
portion O
from O
the O
oleoyl O
strand O
of O
the O
molecule O
, O
suggesting O
that O
the O
palmitoyl B
material O
is O
lost O
in O
a O
secondary O
reaction O
step O
. O

Further O
experiments O
studying O
the O
reaction O
of O
mixed O
monolayers O
composed O
of O
unsaturated O
lipid O
POPC B
and O
saturated O
lipid O
dipalmitoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
, O
DPPC B
, O
revealed O
that O
no O
loss O
of O
DPPC B
from O
the O
air O
- O
water O
interface O
occurs O
, O
eliminating O
the O
possibility O
that O
a O
reactive O
species O
such O
as O
an O
OH B
radical O
is O
formed O
and O
is O
able O
to O
attack O
nearby O
lipid O
chains O
. O

The O
reaction O
of O
ozone B
with O
the O
mixed O
films O
does O
cause O
a O
significant O
change O
in O
the O
surface O
pressure O
of O
the O
air O
- O
water O
interface O
. O

MD O
simulations O
of O
the O
formation O
of O
stable O
clusters O
in O
mixtures O
of O
alkaline O
salts O
and O
imidazolium B
- O
based O
ionic O
liquids O
. O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ O
BMIM O
] O
( O
+ O
) O
) O
and O
three O
different O
anions O
( O
hexafluorophosphate O
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate O
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis O
( O
trifluoromethylsulfo O
) O
imide O
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

Lithium B
/ O
sodium B
solvation O
and O
ionic O
mobilities O
were O
analyzed O
via O
the O
study O
of O
radial O
distribution O
functions O
, O
coordination O
numbers O
, O
cage O
autocorrelation O
functions O
, O
mean O
- O
square O
displacements O
( O
including O
the O
analysis O
of O
both O
ballistic O
and O
diffusive O
regimes O
) O
, O
self O
- O
diffusion O
coefficients O
of O
all O
the O
ionic O
species O
, O
velocity O
and O
current O
autocorrelation O
functions O
, O
and O
ionic O
conductivity O
in O
all O
the O
ionic O
liquid O
/ O
salt O
systems O
. O

We O
found O
that O
lithium B
and O
sodium B
cations O
are O
strongly O
coordinated O
in O
two O
different O
positions O
with O
the O
anion O
present O
in O
the O
mixture O
. O

Moreover O
, O
[ B
Li I
] I
( I
+ I
) I
and O
[ B
Na I
] I
( I
+ I
) I
cations O
were O
found O
to O
form O
bonded O
- O
like O
, O
long O
- O
lived O
aggregates O
with O
the O
anions O
in O
their O
first O
solvation O
shell O
, O
which O
act O
as O
very O
stable O
kinetic O
entities O
within O
which O
a O
marked O
rattling O
motion O
of O
salt O
ions O
takes O
place O
. O

The O
Emerging O
Use O
of O
Ketamine B
for O
Anesthesia O
and O
Sedation O
in O
Traumatic O
Brain O
Injuries O
. O

BACKGROUND O
: O
Traditionally O
, O
the O
use O
of O
ketamine B
for O
patients O
with O
traumatic O
brain O
injuries O
is O
contraindicated O
due O
to O
the O
concern O
of O
increasing O
intracranial O
pressure O
( O
ICP O
) O
. O

Recently O
, O
the O
concern O
of O
using O
ketamine B
in O
these O
patients O
has O
been O
challenged O
by O
a O
number O
of O
published O
studies O
demonstrating O
that O
the O
use O
of O
ketamine B
was O
safe O
in O
these O
patients O
. O

AIMS O
: O
The O
purpose O
of O
this O
article O
was O
to O
review O
the O
current O
literature O
in O
regards O
to O
using O
ketamine B
in O
patients O
with O
traumatic O
brain O
injuries O
in O
different O
clinical O
settings O
associated O
with O
anesthesia O
, O
as O
well O
as O
review O
the O
potential O
mechanisms O
underlying O
the O
neuroprotective O
effects O
of O
ketamine B
. O

RESULTS O
: O
Studies O
examining O
the O
use O
of O
ketamine B
for O
induction O
, O
maintenance O
, O
and O
sedation O
in O
patients O
with O
TBI O
have O
had O
promising O
results O
. O

The O
use O
of O
ketamine B
in O
a O
controlled O
ventilation O
setting O
and O
in O
combination O
with O
other O
sedative O
agents O
has O
demonstrated O
no O
increase O
in O
ICP O
. O

CONCLUSIONS O
: O
The O
role O
of O
ketamine B
as O
a O
neuroprotective O
agent O
in O
humans O
remains O
inconclusive O
and O
adequately O
powered O
; O
randomized O
controlled O
trials O
performed O
in O
patients O
undergoing O
surgery O
for O
traumatic O
brain O
injury O
are O
necessary O
. O

When O
bound O
with O
biotinylated O
cetuximab O
these O
spores O
could O
specifically O
target O
to O
the O
epidermal O
growth O
factor O
receptor O
on O
HT O
29 O
colon O
cancer O
cells O
, O
thereby O
delivered O
paclitaxel B
to O
the O
cells O
with O
4 O
- O
fold O
higher O
efficiency O
, O
as O
indicated O
by O
fluorescent O
intensity O
of O
paclitaxel B
Oregon O
Green O
488 O
bound O
to O
HT29 O
cells O
. O

Based O
on O
real O
- O
time O
monitoring O
of O
cell O
index O
, O
the O
IC50 O
of O
growth O
of O
HT29 O
cells O
by O
paclitaxel B
- O
SA1 O
- O
cetuximab O
was O
estimated O
to O
be O
2 O
. O
9 O
nM O
approximately O
5 O
- O
fold O
lower O
than O
water O
- O
soluble O
paclitaxel B
( O
14 O
. O
5 O
nM O
) O
. O

Instability O
of O
DNA O
content O
was O
observed O
when O
cells O
were O
treated O
with O
16 O
nM O
paclitaxel B
- O
SA1 O
- O
cetuximab O
, O
resulting O
in O
a O
2 O
- O
fold O
enhancement O
in O
polyploidy O
cells O
. O

Thus O
, O
by O
targeting O
the O
release O
of O
paclitaxel B
to O
HT29 O
cells O
, O
spore O
- O
associated O
cetuximab O
augmented O
the O
inhibitory O
effect O
of O
paclitaxel B
on O
cell O
division O
and O
proliferation O
. O

Preclinical O
Activity O
of O
Simvastatin B
Induces O
Cell O
Cycle O
Arrest O
in O
G1 O
via O
Blockade O
of O
Cyclin O
D O
- O
Cdk4 O
Expression O
in O
Non O
- O
Small O
Cell O
Lung O
Cancer O
( O
NSCLC O
) O
. O

In O
recent O
studies O
, O
Simvastatin B
( O
SIM O
) O
has O
demonstrated O
anti O
- O
tumor O
activity O
, O
as O
well O
as O
potent O
chemopreventive O
action O
. O

As O
an O
inhibitor O
of O
3 O
- O
hydroxy O
- O
3 O
- O
methylglutaryl O
- O
coenzyme O
A O
reductase O
( O
HMG O
- O
CoA B
) O
, O
SIM O
has O
been O
shown O
to O
stimulate O
apoptotic O
cell O
death O
. O

In O
this O
study O
, O
an O
MTT B
assay O
revealed O
the O
cytotoxic O
activity O
of O
SIM O
against O
human O
large O
cell O
lung O
cancer O
( O
Non O
- O
small O
cell O
lung O
cancer O
; O
NSCLC O
) O
cells O
( O
NCI O
- O
H460 O
) O
; O
however O
, O
induced O
apoptosis O
was O
not O
observed O
in O
NCI O
- O
H460 O
cells O
. O

Characterization O
of O
the O
5 B
- I
hydroxymethylcytosin I
- O
specific O
DNA O
restriction O
endonucleases O
. O

In O
T4 O
bacteriophage O
, O
5 B
- I
hydroxymethylcytosin I
( O
5hmC O
) O
is O
incorporated O
into O
DNA O
during O
replication O
. O

PvuRts1I O
was O
the O
first O
identified O
restriction O
enzyme O
to O
exhibit O
specificity O
toward O
hmC B
over O
5 B
- I
methylcytosine I
( O
5mC O
) O
and O
cytosine B
. O

Most O
enzymes O
exhibited O
similar O
cutting O
properties O
to O
PvuRts1I O
, O
creating O
a O
double O
- O
stranded O
cleavage O
on O
the O
3 O
' O
side O
of O
the O
modified O
cytosine B
. O

In O
addition O
, O
for O
efficient O
cutting O
, O
the O
enzymes O
require O
two O
cytosines B
21 O
- O
22 O
- O
nt O
apart O
and O
on O
opposite O
strands O
where O
one O
cytosine B
must O
be O
modified O
. O

These O
observations O
indicate O
that O
the O
position O
of O
the O
sugar B
ring O
relative O
to O
the O
base O
is O
a O
determining O
factor O
in O
the O
substrate O
specificity O
of O
the O
PvuRts1I O
homologues O
. O

The O
induction O
of O
mitochondria O
- O
mediated O
apoptosis O
in O
cancer O
cells O
by O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
. O

Four O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
, O
[ O
Ru O
( O
bpy O
) O
2 O
( O
PAIDH O
) O
] O
( O
2 O
+ O
) O
( O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
PAIDH O
= O
2 O
- O
pyridyl O
- O
1H O
- O
anthra O
[ O
1 O
, O
2 O
- O
d O
] O
imidazole O
- O
6 O
, O
11 O
- O
dione O
, O
) O
, O
[ O
Ru O
( O
phen O
) O
2 O
( O
PAIDH O
) O
] O
( O
2 O
+ O
) O
( O
phen O
= O
1 B
, I
10 I
- I
phenanthroline I
, O
) O
, O
[ O
Ru O
( O
dmp O
) O
2 O
( O

PAIDH O
) O
] O
( O
2 O
+ O
) O
( O
dmp O
= O
4 O
, O
7 O
- O
dimethyl O
- O
1 O
, O
10 O
- O
phenanthroline O
, O
) O
and O
[ O
Ru O
( O
dip O
) O
2 O
( O
PAIDH O
) O
] O
( O
2 O
+ O
) O
( O
dip B
= O
4 O
, O
7 O
- O
diphenyl O
- O
1 O
, O
10 O
- O
phenanthroline O
, O
) O
, O
have O
been O
synthesized O
and O
characterized O
. O

Overall O
, O
shared O
structure O
- O
activity O
traits O
are O
emerging O
, O
as O
well O
as O
specific O
binding O
modes O
related O
to O
their O
ability O
to O
engage O
in O
hydrogen B
bonding O
. O

Adsorption O
of O
Primary O
Substituted O
Hydrocarbons B
onto O
Solid O
Gallium B
Substrates O
. O

Adsorption O
of O
a O
series O
of O
primary O
substituted O
hydrocarbons B
( O
RX O
; O
C18H37PO O
( O
OH O
) O
2 O
( O
ODPA O
) O
, O
C17H35COOH O
, O
C18H37OH O
, O
C18H37NH2 O
, O
and O
C18H37SH O
) O
onto O
solid O
gallium B
substrates O
with O
and O
without O
UV O
/ O
ozone B
treatment O
was O
studied O
using O
contact O
angle O
goniometry O
, O
spectroscopic O
ellipsometry O
, O
and O
cyclic O
voltammetry O
( O
CV O
) O
. O

UV O
/ O
ozone B
treatment O
offered O
a O
hydrophilic O
surface O
( O
water O
contact O
angle O
( O
theta O
( O
water O
) O
) O
less O
than O
10 O
degrees O
) O
, O
reflecting O
the O
formation O
of O
a O
surface O
oxide B
layer O
with O
the O
maximum O
thickness O
of O
ca O
. O

Upon O
immersion O
in O
a O
toluene B
solution O
of O
a O
RX O
, O
theta O
( O
water O
) O
increased O
due O
to O
adsorption O
of O
the O
RX O
onto O
gallium B
substrates O
. O

In O
particular O
, O
UV O
/ O
ozone B
- O
treated O
gallium B
substrates O
( O
UV O
- O
Ga B
) O
immersed O
in O
an O
ODPA O
solution O
exhibited O
theta O
( O
water O
) O
close O
to O
105 O
degrees O
. O

2 O
. O
4 O
nm O
, O
and O
CV O
data O
measured O
in O
an O
acetonitrile B
solution O
showed O
significant O
inhibition O
of O
redox O
reaction O
on O
the O
substrate O
surface O
. O

These O
results O
indicate O
the O
formation O
of O
a O
densely O
packed O
ODPA O
monolayer O
on O
UV O
- O
Ga B
. O

The O
coverage O
of O
a O
C17H35COOH O
layer O
adsorbed O
onto O
UV O
- O
Ga B
was O
lower O
, O
as O
shown O
by O
smaller O
theta O
( O
water O
) O
( O
ca O
. O
99 O
degrees O
) O
, O
smaller O
ellipsometric O
thickness O
( O
ca O
. O
1 O
. O
3 O
nm O
) O
, O
and O
smaller O
electrode O
reaction O
inhibition O
. O

Adsorption O
of O
the O
other O
RX O
onto O
UV O
- O
Ga B
was O
weaker O
, O
as O
indicated O
by O
smaller O
theta O
( O
water O
) O
( O
82 O
degrees O
- O
92 O
degrees O
) O
. O

ODPA O
did O
not O
strongly O
adsorb O
onto O
UV O
- O
untreated O
gallium B
substrates O
, O
suggesting O
that O
the O
ODPA O
adsorption O
mainly O
originates O
from O
hydrogen B
bond O
interaction O
of O
a O
phosphonate B
group O
with O
surface O
oxide B
. O

These O
results O
will O
provide O
a O
means O
for O
controlling O
the O
surface O
properties O
of O
oxide B
- O
coated O
gallium B
that O
play O
an O
essential O
role O
in O
monolayer O
conductivity O
measurements O
and O
electroanalytical O
applications O
. O

Diarylheptanoids O
and O
Flavonoids B
from O
Viscum O
album O
Inhibit O
LPS O
- O
Stimulated O
Production O
of O
Pro O
- O
inflammatory O
Cytokines O
in O
Bone O
Marrow O
- O
Derived O
Dendritic O
Cells O
. O

Layers O
of O
a O
two O
- O
dimensional O
( O
2D O
) O
zinc B
coordination O
polymer O
are O
self O
- O
assembled O
in O
the O
interlamellar O
space O
of O
a O
reverse O
microemulsion O
mesophase O
into O
stacks O
of O
nanosheets O
interleaved O
with O
cethyltrimethylammon O
bromide O
( O
CTAB B
) O
at O
regular O
intervals O
, O
thus O
giving O
rise O
to O
a O
lamellar O
hybrid O
mesostructure O
with O
a O
lattice O
period O
of O
~ O
8 O
nm O
and O
an O
underlying O
highly O
crystalline O
substructure O
. O

The O
basic O
structural O
motif O
is O
composed O
of O
2D O
acetato O
- O
benzimidazolato O
- O
zinc O
layers O
of O
tetrahedrally O
coordinated O
zinc B
joined O
together O
by O
anionic O
acetate B
and O
benzimidazolate O
ligands O
. O

Exfoliation O
of O
the O
hybrid O
material O
in O
organic O
solvents O
such O
as O
THF B
and O
chloroform B
yields O
sheet O
- O
and O
belt O
- O
like O
nanostructures O
with O
lateral O
sizes O
between O
10 O
' O
s O
and O
100 O
' O
s O
of O
nanometers O
and O
a O
height O
of O
about O
10 O
nm O
measured O
by O
AFM O
, O
which O
precisely O
maps O
the O
basal O
spacing O
of O
the O
lamellar O
mesostructure O
; O
further O
exfoliation O
results O
in O
nanobelts O
with O
minimum O
sizes O
around O
4 O
nm O
. O

Computational O
study O
of O
the O
coordination O
of O
methane B
to O
first O
row O
transition O
metal O
dication O
complexes O
. O

The O
coordination O
of O
methane B
, O
the O
first O
step O
in O
methane B
activation O
, O
to O
coordinately O
unsaturated O
first O
row O
transition O
metal O
dication O
complexes O
has O
been O
studied O
computationally O
to O
determine O
the O
most O
stable O
metal O
- O
methane B
interaction O
. O

The O
periodic O
trend O
in O
methane B
binding O
energies O
in O
the O
[ O
M O
( O
pyridine O
) O
2 O
( O
CH4 O
) O
] O
( O
2 O
+ O
) O
complexes O
follows O
the O
trend O
in O
electron O
affinity O
until O
the O
Mn B
complex O
but O
then O
exhibits O
decreasing O
energies O
from O
Fe B
to O
Zn B
. O

Synergistic O
interactions O
of O
epigallocatechin B
gallate I
and O
oxytetracycline B
against O
various O
drug O
resistant O
Staphylococcus O
aureus O
strains O
in O
vitro O
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
, O
the O
major O
catechin B
contained O
in O
tea O
leaves O
, O
is O
known O
to O
possess O
the O
synergistic O
anti O
- O
staphylococcal O
activity O
in O
combination O
with O
various O
beta B
- I
lactam I
antibiotics O
and O
tetracycline B
. O

In O
the O
present O
study O
, O
we O
explored O
the O
in O
vitro O
combinatory O
effect O
of O
EGCG B
in O
combination O
with O
oxytetracycline B
against O
eight O
standard O
strains O
and O
clinical O
isolates O
of O
Staphylococcus O
aureus O
, O
including O
erythromycin B
, O
methicillin B
and O
tetracycline B
resistant O
strains O
. O

According O
to O
our O
best O
knowledge O
, O
it O
is O
the O
first O
report O
on O
the O
EGCG B
synergy O
with O
oxytetracycline B
. O

Considering O
its O
significant O
synergistic O
antimicrobial O
effect O
and O
low O
toxicity O
, O
we O
suggest O
EGCG B
as O
a O
promising O
compound O
for O
the O
development O
of O
new O
anti O
- O
staphylococcal O
formulations O
. O

Orally O
bioavailable O
and O
brain O
- O
penetrant O
pyridazine O
and O
pyridine B
- O
derived O
gamma O
- O
secretase O
modulators O
reduced O
amyloidogenic O
A O
beta O
peptides O
in O
vivo O
. O

Here O
, O
we O
report O
in O
vivo O
A O
beta O
- O
lowering O
profiles O
of O
a O
pyridazine O
and O
a O
pyridine B
- O
derived O
GSM O
: O
GSM O
- O
C O
( O
Wan O
et O
al O
. O
, O
2011a O
) O
and O
GSM O
- O
D O
( O
Wan O
et O
al O
. O
, O
2011b O
) O
. O

Protective O
effect O
of O
bark O
and O
empty O
pod O
extracts O
from O
Acacia O
auriculiformis O
against O
paracetamol B
intoxicated O
liver O
injury O
and O
alloxan B
induced O
type O
II O
diabetes O
. O

Animal O
models O
with O
paracetamol B
intoxicated O
liver O
injury O
and O
alloxan B
induced O
diabetes O
were O
used O
in O
a O
7 O
and O
14days O
trial O
respectively O
. O

Both O
interventions O
restored O
the O
liver O
function O
markers O
( O
alanine B
transaminase O
: O
ALT O
, O
aspartate B
transaminase O
: O
AST O
, O
alkaline O
phosphatase O
: O
ALP O
, O
total O
bilirubin B
and O
total O
protein O
) O
and O
hepatic O
antioxidants O
( O
superoxide B
dismutase O
: O
SOD O
, O
catalase O
: O
CAT O
, O
reduced O
glutathione B
: O
GSH B
and O
glutathione B
peroxidase O
: O
GPx O
) O
to O
the O
normal O
levels O
than O
elevated O
levels O
noticed O
on O
paracetamol B
control O
at O
P O
< O
0 O
. O
001 O
. O

Reversal O
of O
hepatoarchitecture O
has O
also O
been O
registered O
and O
the O
hepatoprotection O
is O
comparable O
to O
the O
reference O
drug O
silymarin B
. O

Similarly O
, O
substantial O
elevations O
of O
blood O
glucose B
, O
distorted O
lipid O
profile O
( O
total O
cholesterol B
: O
TC O
, O
triglycerides B
: O
TGs O
, O
high O
density O
lipoprotein O
cholesterol B
: O
HDL O
- O
C O
and O
low O
density O
lipoprotein O
cholesterol B
: O
LDL O
- O
C O
) O
and O
kidney O
function O
signs O
( O
creatinine B
and O
urea B
) O
have O
been O
refurbished O
to O
the O
desirable O
levels O
on O
par O
with O
the O
standard O
antidiabetic O
glibenclamide B
. O

The O
influence O
of O
study O
design O
and O
sex O
- O
differences O
on O
results O
from O
developmental O
neurotoxicity O
studies O
of O
bisphenol B
A I
, O
implications O
for O
toxicity O
testing O
. O

Developmental O
neurotoxicity O
( O
DNT O
) O
of O
bisphenol B
A I
( O
BPA B
) O
has O
been O
investigated O
in O
a O
large O
number O
of O
studies O
. O

Forty O
- O
four O
DNT O
studies O
of O
BPA B
were O
identified O
from O
the O
open O
literature O
. O

In O
conclusion O
, O
this O
analysis O
suggests O
that O
DNT O
- O
studies O
conducted O
according O
to O
the O
standardized O
OECD O
TG O
426 O
may O
overlook O
sensitive O
effects O
of O
BPA B
, O
and O
possibly O
other O
potential O
endocrine O
disruptors O
, O
especially O
in O
female O
offspring O
. O

Synthesis O
and O
application O
of O
FePt B
/ O
CNTs O
nanocomposite O
as O
a O
sensor O
and O
novel O
amide B
ligand O
as O
a O
mediator O
for O
simultaneous O
determination O
of O
glutathione B
, O
nicotinamide O
adenine O
dinucleotide O
and O
tryptophan B
. O

In O
this O
study O
, O
we O
report O
the O
synthesis O
and O
application O
of O
a O
FePt B
/ O
CNTs O
nanocomposite O
as O
a O
highly O
sensitive O
sensor O
and O
novel O
amide B
ligand O
( O
9 O
, O
10 O
- O
dihydro O
- O
9 O
, O
10 O
- O
ethanoanthracene O
- O
11 O
, O
12 O
- O
dicarboximido O
) O
- O
4 O
- O
ethylbenzene O
- O
1 O
, O
2 O
- O
diol O
as O
a O
mediator O
for O
the O
determination O
of O
glutathione B
( O
GSH B
) O
, O
nicotinamide O
adenine O
dinucleotide O
( O
NADH B
) O
and O
tryptophan B
( O
Trp B
) O

The O
modified O
electrode O
exhibited O
a O
potent O
and O
persistent O
electron O
mediating O
behavior O
followed O
by O
well O
- O
separated O
oxidation O
peaks O
of O
GSH B
, O
NADH B
and O
Trp B
. O

The O
peak O
currents O
were O
linearly O
dependent O
on O
GSH B
, O
NADH B
and O
Trp B
concentrations O
in O
the O
range O
of O
0 O
. O
08 O
- O
220 O
, O
1 O
. O
0 O
- O
400 O
and O
5 O
. O
0 O
- O
500 O
mu O
mol O
L O
( O
- O
1 O
) O
, O
with O
detection O
limits O
of O
0 O
. O
05 O
, O
0 O
. O
8 O
and O
1 O
. O
0 O
mu O
mol O
L O
( O
- O
1 O
) O
, O
respectively O
. O

Iodine B
Status O
in O
Pregnant O
Women O
in O
the O
United O
States O
: O
National O
Children O
' O
s O
Study O
and O
National O
Health O
and O
Nutrition O
Examination O
Survey O
. O

Background O
: O
This O
report O
presents O
iodine B
data O
from O
NHANES O
and O
from O
a O
sample O
of O
pregnant O
women O
in O
the O
National O
Children O
' O
s O
Study O
( O
NCS O
) O
Vanguard O
Study O
. O

Third O
trimester O
women O
participating O
in O
the O
NCS O
study O
similarly O
had O
an O
adequate O
level O
of O
iodine B
intake O
, O
with O
a O
median O
UI O
concentration O
of O
167 O
micro O
g O
/ O
L O
. O

A O
head O
- O
to O
- O
head O
comparison O
between O
insulin O
detemir O
and O
NPH O
insulin O
in O
women O
with O
type O
1 O
diabetes O
showed O
that O
while O
foetal O
outcomes O
did O
not O
differ O
, O
fasting O
plasma O
glucose B
improved O
with O
insulin O
detemir O
without O
an O
increased O
incidence O
of O
hypoglycaemia O
. O

To O
rationalize O
this O
result O
, O
a O
mechanism O
which O
involves O
initial O
acylation O
at O
the O
more O
active O
amidine B
- O
function O
followed O
by O
intramolecular O
acyl B
- O
group O
transfer O
to O
beta O
- O
phenylamino O
- O
group O
was O
suggested O
. O

The O
in O
vitro O
antiviral O
potency O
of O
4d O
, O
e O
is O
6 O
- O
20 O
times O
greater O
than O
that O
of O
commercial O
rimantadine B
with O
lower O
EC50 O
values O
and O
higher O
therapeutic O
index O
. O

N B
- O
terminal O
sequencing O
confirmed O
the O
principal O
antigen O
detected O
by O
the O
anti O
- O
CYP3A4 O
antibody O
in O
cortical O
microsomes O
to O
be O
CYP3A4 O
. O

Finally O
, O
analysis O
of O
the O
frontal O
cortex O
of O
chronic O
alcohol B
abusers O
revealed O
elevated O
expression O
of O
CYP3A4 O
in O
microsomal O
but O
not O
mitochondrial O
fractions O
; O
CYP3A5 O
expression O
was O
unchanged O
. O

Polybrominated O
Dibenzo O
- O
p O
- O
dioxins O
( O
PBDDs O
) O
, O
Dibenzofurans O
( O
PBDFs O
) O
and O
Biphenyls O
( O
PBBs O
) O
- O
Inclusion O
in O
the O
Toxicity O
Equivalency O
Factor O
Concept O
for O
Dioxin B
- O
like O
Compounds O
- O

In O
2011 O
a O
joint O
World O
Health O
Organization O
( O
WHO O
) O
and O
United O
Nations O
Environment O
Programme O
( O
UNEP O
) O
expert O
consultation O
took O
place O
, O
during O
which O
the O
possible O
inclusion O
of O
brominated O
analogues O
of O
the O
dioxin B
- O
like O
compounds O
in O
the O
WHO O
Toxicity O
Equivalency O
Factor O
( O
TEF O
) O
scheme O
were O
evaluated O
. O

The O
expert O
panel O
concluded O
that O
polybrominated O
dibenzo O
- O
p O
- O
dioxins O
( O
PBDDs O
) O
, O
dibenzofurans O
( O
PBDFs O
) O
, O
and O
some O
dioxin B
- O
like O
biphenyls O
( O
dl O
- O
PBBs O
) O
may O
contribute O
significantly O
in O
daily O
human O
background O
exposure O
to O
the O
total O
dioxin B
toxic O
equivalencies O
( O
TEQs O
) O
. O

Both O
have O
retained O
many O
duplicated O
genes O
associated O
with O
glucose B
fermentation O
and O
are O
characterized O
by O
the O
ability O
to O
achieve O
grape O
must O
fermentation O
. O

Dexamethasone B
- O
mediated O
changes O
in O
adipose O
triacylglycerol B
metabolism O
are O
exaggerated O
, O
not O
diminished O
, O
in O
the O
absence O
of O
a O
functional O
GR O
dimerization O
domain O
. O

To O
understand O
the O
role O
of O
GR O
dimerization O
- O
dependent O
targets O
in O
multiple O
tissues O
, O
we O
measured O
metabolic O
fluxes O
through O
several O
disease O
- O
relevant O
GC O
target O
pathways O
using O
heavy O
water O
labeling O
and O
mass O
spectrometry O
in O
wild O
- O
type O
and O
GR O
( O
dim O
/ O
dim O
) O
mice O
administered O
the O
potent O
GC O
dexamethasone B
( O
DEX B
) O
. O

Absolute O
triglyceride B
synthesis O
was O
increased O
in O
both O
wild O
- O
type O
and O
GR O
( O
dim O
/ O
dim O
) O
mice O
by O
DEX B
in O
the O
inguinal O
and O
epididymal O
fat O
depots O
. O

GR O
( O
dim O
/ O
dim O
) O
mice O
showed O
an O
exaggerated O
response O
to O
DEX B
in O
both O
depots O
. O

De O
novo O
lipogenesis O
was O
also O
greatly O
increased O
in O
both O
depots O
in O
response O
to O
DEX B
in O
GR O
( O
dim O
/ O
dim O
) O
, O
but O
not O
wild O
- O
type O
mice O
. O

In O
contrast O
, O
the O
inhibitory O
effect O
of O
DEX B
on O
bone O
and O
skin O
collagen O
synthesis O
rates O
was O
greater O
in O
wild O
- O
type O
compared O
with O
GR O
( O
dim O
/ O
dim O
) O
mice O
. O

Wild O
- O
type O
mice O
were O
more O
sensitive O
to O
DEX B
- O
dependent O
decreases O
in O
insulin O
sensitivity O
than O
GR O
( O
dim O
/ O
dim O
) O
mice O
. O

Wild O
- O
type O
and O
GR O
( O
dim O
/ O
dim O
) O
mice O
were O
equally O
sensitive O
to O
DEX B
- O
dependent O
decreases O
in O
muscle O
protein O
synthesis O
. O

X O
- O
box O
binding O
protein O
1 O
( O
XBP1 O
) O
is O
a O
transcription O
factor O
that O
plays O
a O
crucial O
role O
in O
the O
unfolded O
protein O
response O
( O
UPR O
) O
and O
its O
deficiency O
in O
beta O
- O
cells O
has O
been O
reported O
to O
impair O
insulin O
secretion O
leading O
to O
glucose B
intolerance O
. O

alpha O
XBPKO O
mice O
exhibited O
glucose B
intolerance O
, O
mild O
insulin O
resistance O
and O
an O
inability O
to O
suppress O
glucagon O
secretion O
following O
glucose B
stimulation O
. O

Interestingly O
, O
insulin O
treatment O
of O
alpha O
XBPKD O
cells O
reduced O
tyrosine B
phosphorylation O
of O
IRS O
- O
1 O
( O
pY O
( O
896 O
) O
) O
, O
and O
phosphorylation O
of O
Akt O
, O
while O
enhancing O
serine B
phosphorylation O
( O
pS O
( O
307 O
) O
) O
of O
IRS O
- O
1 O
. O

Consequently O
the O
alpha O
XBPKD O
cells O
exhibited O
blunted O
suppression O
of O
glucagon O
secretion O
following O
insulin O
treatment O
in O
the O
presence O
of O
high O
glucose B
. O

LDL O
Cholesterol B
Goals O
in O
High O
- O
Risk O
Patients O
: O
How O
Low O
Do O
We O
Go O
and O
How O
Do O
We O
Get O
There O
? O

It O
is O
widely O
recognised O
that O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
is O
one O
of O
the O
most O
important O
and O
modifiable O
risk O
factors O
for O
cardiovascular O
disease O
( O
CVD O
) O
. O

Statins O
( O
HMG B
- I
CoA I
reductase O
inhibitors O
) O
have O
consistently O
been O
shown O
to O
decrease O
both O
LDL O
- O
C O
and O
CVD O
risk O
in O
almost O
all O
patient O
categories O
, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis O
. O

In O
patients O
who O
do O
not O
reach O
the O
LDL O
- O
C O
target O
, O
combination O
therapy O
with O
additional O
LDL O
- O
C O
lowering O
drugs O
( O
e O
. O
g O
. O
ezetimibe O
, O
bile B
acid I
sequestrants O
or O
fibrates O
) O
should O
be O
considered O
. O

Neuroprotection O
against O
neuroblastoma O
cell O
death O
induced O
by O
depletion O
of O
mitochondrial O
glutathione B
. O

Mitochondrial O
glutathione B
pool O
is O
vital O
in O
protecting O
cells O
against O
oxidative O
stress O
as O
the O
majority O
of O
the O
cellular O
reactive O
oxygen B
species O
are O
generated O
in O
mitochondria O
. O

We O
hypothesized O
that O
depletion O
of O
mitochondrial O
glutathione B
leads O
to O
mitochondrial O
dysfunction O
and O
apoptotic O
death O
of O
SK O
- O
N O
- O
SH O
( O
human O
neuroblastoma O
) O
cells O
and O
investigated O
the O
neuroprotective O
strategies O
against O
GSH B
depletion O
. O

SK O
- O
N O
- O
SH O
cells O
were O
treated O
with O
two O
distinct O
inhibitors O
of O
glutathione B
metabolism O
: O
L B
- I
buthionine I
- I
( I
S I
, I
R I
) I
- I
sulfoximine I
( O
BSO B
) O
and O
ethacrynic O
acid O
( O
EA O
) O
. O

EA O
treatment O
caused O
depletion O
of O
both O
the O
total O
and O
mitochondrial O
glutathione B
( O
while O
BSO B
had O
no O
effect O
on O
mitochondrial O
glutathione B
) O
, O
enhanced O
rotenone B
- O
induced O
ROS O
production O
, O
and O
reduced O
the O
viability O
of O
SK O
- O
N O
- O
SH O
cells O
. O

Glutathione B
depletion O
by O
BSO B
or O
EA O
demonstrated O
positive O
features O
of O
mitochondria O
- O
mediated O
apoptosis O
in O
neuroblastoma O
cell O
death O
. O

Prevention O
of O
apoptosis O
by O
Bcl2 O
overexpression O
or O
use O
of O
antioxidant O
ebselen B
did O
not O
confer O
neuroprotection O
. O

Our O
data O
suggest O
that O
depletion O
of O
mitochondrial O
glutathione B
leads O
to O
mitochondrial O
dysfunction O
and O
apoptosis O
. O

The O
study O
indicates O
that O
preventing O
mitochondrial O
glutathione B
depletion O
could O
become O
a O
novel O
strategy O
for O
the O
development O
of O
neuroprotective O
therapeutics O
in O
neurodegenerative O
disorders O
. O

Structure O
of O
dipeptides B
having O
N B
- O
terminal O
selenocysteine B
residues O
: O
a O
DFT O
study O
in O
gas O
and O
aqueous O
phase O
. O

Over O
the O
last O
few O
decades O
, O
dipeptides B
as O
well O
as O
their O
analogues O
have O
served O
as O
important O
model O
systems O
for O
the O
computational O
studies O
concerning O
the O
structure O
of O
protein O
and O
energetics O
of O
protein O
folding O
. O

Here O
, O
we O
present O
a O
density O
functional O
structural O
study O
on O
a O
set O
of O
seven O
dipeptides B
having O
N B
- O
terminal O
selenocysteine B
residues O
( O
the O
component O
in O
the O
C B
- O
terminus O
is O
varied O
with O
seven O
different O
combinations O
viz O
. O
Ala B
, O
Phe B
, O
Glu B
, O
Thr B
, O
Asn B
, O
Arg O
and O
Sec B
) O
in O
gas O
and O
simulated O
aqueous O
phase O
using O
a O
polarizable O
continuum O
model O
( O
PCM O
) O
. O

The O
molecular O
geometries O
of O
the O
dipeptides B
are O
fully O
optimized O
at O
B3LYP O
/ O
6 O
- O
311 O
+ O
+ O
G O
( O
d O
, O
p O
) O
level O
and O
subsequent O
frequency O
calculations O
confirm O
them O
as O
true O
minima O
. O

The O
effects O
of O
solvation O
and O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
on O
the O
energetics O
, O
structural O
features O
of O
the O
peptide O
planes O
, O
values O
of O
the O
psi O
and O
phi O
dihedrals O
, O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
and O
theoretically O
predicted O
vibrational O
spectra O
of O
the O
dipeptides B
are O
investigated O
. O

Two O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
N B
. O
. O
. O
H O
- O
N O
and O
O B
. O
. O
. O
H O
- O
C O
, O
are O
found O
to O
play O
important O
roles O
in O
influencing O
the O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
of O
the O
dipeptides B
. O

The O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
influences O
the O
values O
of O
phi O
, O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
C7 O
alpha B
- I
carbon I
atoms O
while O
the O
solvation O
effects O
are O
evident O
on O
the O
values O
of O
bond O
lengths O
and O
bond O
angles O
of O
the O
amide B
planes O
. O

Nickel O
sulfide O
/ O
nitrogen O
- O
doped O
graphene O
composites O
: O
phase O
- O
controlled O
synthesis O
and O
high O
performance O
anode O
materials O
for O
lithium B
ion O
batteries O
. O

The O
composites O
show O
ultrahigh O
capacity O
retentions O
of O
98 O
. O
87 O
% O
and O
95 O
. O
94 O
% O
for O
Ni3 O
S4 O
/ O
NG O
and O
NiS1 O
. O
03 O
/ O
NG O
electrodes O
, O
respectively O
, O
as O
anode O
materials O
for O
lithium B
ion O
batteries O
. O

( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
analysis O
of O
2 O
- O
acetamido O
- O
3 O
- O
mercapto O
- O
3 O
- O
methyl O
- O
N O
- O
aryl O
- O
butanamides O
and O
2 O
- O
acetamido O
- O
3 O
- O
methyl O
- O
3 O
- O
nitrososulfanyl O
- O
N O
- O
aryl O
- O
butanamide O
derivatives O
. O

The O
complete O
assignment O
of O
the O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
spectra O
of O
various O
2 O
- O
acetamido O
- O
3 O
- O
mercapto O
- O
3 O
- O
methyl O
- O
N O
- O
aryl O
- O
butanamides O
and O
2 O
- O
acetamide O
- O
3 O
- O
methyl O
- O
3 O
- O
nitrososulfanyl O
- O
N O
- O
aryl O
- O
butanamides O
with O
p B
- I
methoxy I
, O
o O
- O
chloro O
and O
m O
- O
chloro O
substituents O
is O
reported O
. O

Targeting O
protein O
- O
protein O
interactions O
within O
the O
cyclic B
AMP I
signaling O
system O
as O
a O
therapeutic O
strategy O
for O
cardiovascular O
disease O
. O

The O
cAMP B
signaling O
system O
can O
trigger O
precise O
physiological O
cellular O
responses O
that O
depend O
on O
the O
fidelity O
of O
many O
protein O
- O
protein O
interactions O
, O
which O
act O
to O
bring O
together O
signaling O
intermediates O
at O
defined O
locations O
within O
cells O
. O

In O
the O
heart O
, O
cAMP B
participates O
in O
the O
fine O
control O
of O
excitation O
- O
contraction O
coupling O
, O
hence O
, O
any O
disregulation O
of O
this O
signaling O
cascade O
can O
lead O
to O
cardiac O
disease O
. O

Due O
to O
the O
ubiquitous O
nature O
of O
the O
cAMP B
pathway O
, O
general O
inhibitors O
of O
cAMP B
signaling O
proteins O
such O
as O
PKA O
, O
EPAC O
and O
PDEs O
would O
act O
non O
- O
specifically O
and O
universally O
, O
increasing O
the O
likelihood O
of O
serious O
' O
off O
target O
' O
effects O
. O

Recent O
advances O
in O
the O
discovery O
of O
peptides O
and O
small O
molecules O
that O
disrupt O
the O
protein O
- O
protein O
interactions O
that O
underpin O
cellular O
targeting O
of O
cAMP B
signaling O
proteins O
are O
described O
and O
discussed O
. O

Determination O
of O
substrates O
was O
performed O
by O
transglutaminase O
- O
mediated O
incorporation O
of O
biotinylated O
probes O
displaying O
several O
glutamine B
and O
lysine B
donor O
proteins O
. O

One O
of O
the O
modulating O
proteins O
was O
serotransferrin O
, O
a O
lysine B
donor O
substrate O
of O
bacterial O
transglutaminase O
. O

An O
additional O
substrate O
was O
the O
carboxy B
- O
terminal O
propeptide O
of O
type O
II O
collagen O
, O
chondrocalcin O
. O

By O
modulating O
expression O
levels O
of O
endogenous O
APP O
in O
primary O
cortical O
neurons O
, O
the O
frequency O
and O
amplitude O
of O
calcium B
oscillations O
is O
modified O
, O
implying O
a O
key O
role O
for O
APP O
in O
maintaining O
neuronal O
calcium B
homeostasis O
essential O
for O
synaptic O
transmission O
. O

Pyridone O
Alkaloids O
from O
a O
Marine O
- O
Derived O
Fungus O
, O
Stagonosporopsis O
cucurbitacearum O
, O
and O
Their O
Activities O
against O
Azole B
- O
Resistant O
Candida O
albicans O
. O

Didymellamide O
A O
( O
1 O
) O
exhibited O
antifungal O
activity O
against O
azole B
- O
resistant O
Candida O
albicans O
. O

Powder O
formulations O
of O
both O
species O
revealed O
the O
presence O
of O
essential O
nutrients O
, O
such O
as O
proteins O
, O
carbohydrates B
and O
unsaturated B
fatty I
acids I
. O

APF O
showed O
higher O
antioxidant O
activity O
and O
higher O
content O
of O
tocopherols B
and O
phenolic B
compounds O
( O
124 O
and O
770 O
mu O
g O
/ O
100g O
, O
respectively O
) O
than O
LPF O
( O
32 O
and O
690 O
mu O
g O
/ O
100g O
) O
. O

The O
intake O
of O
SFO O
- O
breakfast O
reduced O
plasma O
GSH B
levels O
and O
the O
GSH B
/ O
GSSG B
ratio O
, O
increased O
protein O
carbonyl B
levels O
, O
and O
induced O
a O
higher O
gene O
expression O
of O
the O
different O
NADPH B
- O
oxidase O
subunits O
, O
Nrf2 O
- O
Keap1 O
activation O
, O
gene O
expression O
of O
the O
antioxidant O
enzymes O
in O
peripheral O
blood O
mononuclear O
cells O
and O
antioxidant O
plasma O
activities O
than O
the O
intake O
of O
the O
breakfasts O
prepared O
with O
VOO O
, O
SOP O
and O
SOX O
. O

Oils O
with O
phenolic B
compounds O
, O
whether O
natural O
( O
VOO O
) O
or O
artificially O
added O
( O
SOP O
) O
, O
or O
with O
artificial O
antioxidant O
( O
SOX O
) O
, O
could O
reduce O
postprandial O
oxidative O
stress O
compared O
with O
sunflower O
oil O
. O

This O
novel O
instrumental O
approach O
enabled O
rapid O
fingerprinting O
of O
examined O
samples O
and O
detection O
of O
numerous O
sample O
components O
, O
such O
as O
triacylglycerols B
( O
TAGs B
) O
, O
phytosterols O
, O
free O
fatty O
acids O
( O
FFA O
) O
, O
and O
their O
respective O
oxidation O
products O
. O

Good O
correlation O
was O
observed O
between O
the O
normalized O
intensities O
of O
the O
pre O
- O
selected O
ion O
corresponding O
to O
mono O
- O
oxidized O
TAG B
and O
' O
classic O
' O
criterion O
represented O
by O
the O
levels O
of O
TAG B
polymers O
determined O
by O
high O
performance O
- O
size O
exclusion O
chromatography O
with O
refractometric O
detection O
( O
HP O
- O
SEC O
- O
RID O
) O
. O

Calcium O
hydroxy O
palmitate O
: O
possible O
precursor O
phase O
in O
calcium B
precipitation O
by O
palmitate O
. O

Calcium O
( O
II O
) O
precipitates O
with O
palmitate O
( O
Pal O
( O
- O
) O
) O
, O
a O
process O
affecting O
calcium B
absorption O
in O
the O
gut O
, O
in O
a O
first O
- O
order O
reaction O
, O
as O
followed O
by O
a O
calcium B
electrode O
in O
neutral O
aqueous O
solution O
for O
excess O
of O
calcium O
( O
II O
) O
, O
with O
a O
rate O
constant O
showing O
a O
minimum O
at O
physiological O
ionic O
strength O
of O
0 O
. O
32 O
+ O
/ O
- O
0 O
. O
09 O
d O
( O
- O
1 O
) O
at O
25 O
degrees O
C O
with O
a O
stoichiometry O
of O
1 O
. O
79 O
+ O
/ O
- O
0 O
. O
03 O
, O
lower O
than O
the O
expected O
1 O
: O
2 O
. O

X O
- O
ray O
diffraction O
showed O
a O
d O
- O
spacing O
of O
44 O
. O
15 O
A O
( O
different O
from O
45 O
. O
2 O
A O
reported O
for O
Ca O
( O
Pal O
) O
2 O
) O
, O
and O
infrared O
spectroscopy O
confirmed O
the O
presence O
of O
a O
hydroxy B
group O
. O

Enzymatic O
processing O
increased O
the O
juice O
yield O
by O
10 O
- O
22 O
% O
and O
the O
content O
of O
various O
phenolic B
compounds O
in O
juice O
by O
4 O
- O
10 O
- O
fold O
as O
compared O
to O
the O
non O
- O
enzymatic O
process O
. O

In O
enzyme O
- O
aided O
juices O
, O
the O
contents O
of O
flavonol O
glycosides O
and O
hydroxycinnamic B
acids I
were O
associated O
with O
mouth O
- O
drying O
astringency O
, O
and O
sugar B
/ O
acid O
ratio O
correlated O
with O
sweetness O
. O

These O
correlations O
were O
less O
clear O
in O
non O
- O
enzyme O
juices O
possibly O
due O
to O
lower O
content O
of O
phenolic B
compounds O
and O
the O
high O
content O
of O
pectin O
. O

Molecular O
modeling O
experiments O
were O
also O
performed O
to O
study O
the O
binding O
mode O
of O
these O
compounds O
in O
Pim O
- O
3 O
ATP B
- O
binding O
pocket O
. O

The O
bizarre O
pharmacology O
of O
the O
ATP B
release O
channel O
pannexin1 O
. O

However O
, O
it O
is O
now O
evident O
that O
pannexins O
function O
as O
unapposed O
membrane O
channels O
and O
the O
major O
role O
of O
Panx1 O
is O
that O
of O
an O
ATP B
release O
channel O
. O

Most O
gap O
junction O
blockers O
also O
attenuate O
the O
function O
of O
Panx1 O
, O
including O
carbenoxolone O
, O
mefloquine O
and O
flufenamic B
acid I
. O

The O
drugs O
affecting O
Panx1 O
channels O
include O
several O
transport O
inhibitors O
, O
chloride B
channel O
blockers O
, O
mitochondrial O
inhibitors O
, O
P2X7 O
receptor O
ligands O
, O
inflammasome O
inhibitors O
and O
malaria O
drugs O
. O

Steroidal B
glycosides I
from O
the O
bulbs O
of O
Fritillaria O
meleagris O
and O
their O
cytotoxic O
activities O
. O

Steroidal B
glycosides I
( O
1 O
- O
18 O
) O
, O
including O
10 O
new O
compounds O
( O
1 O
- O
10 O
) O
, O
were O
isolated O
from O
the O
bulbs O
of O
Fritillaria O
meleagris O
( O
Liliaceae O
) O
. O

It O
is O
also O
acknowledged O
that O
currents O
through O
Erg1 O
K B
( I
+ I
) I
channels O
in O
cardiac O
myocytes O
are O
important O
for O
electrical O
stability O
of O
the O
heart O
and O
alterations O
in O
its O
activity O
has O
been O
linked O
to O
the O
onset O
of O
a O
potentially O
life O
- O
threatening O
heart O
condition O
named O
long O
QT O
syndrome O
type O
2 O
. O

Using O
MPs O
loaded O
with O
simvastatin B
( O
pro O
or O
active O
drug O
) O
or O
BMP O
- O
2 O
, O
we O
have O
demonstrated O
osteogenic O
differentiation O
within O
the O
3D O
aggregates O
, O
maintained O
in O
culture O
for O
up O
to O
21days O
, O
and O
quantified O
by O
real O
time O
QPCR O
for O
osteocalcin O
. O

Immunostaining O
for O
RUNX2 O
and O
osteocalcin O
, O
and O
also O
histochemical O
staining O
with O
picrosirius O
red O
to O
demonstrate O
collage O
type O
1 O
and O
Alizarin B
red I
to O
demonstrate O
calcium B
/ O
mineralisation O
further O
demonstrated O
osteogenic O
differentiation O
and O
revealed O
regional O
staining O
associated O
with O
the O
locations O
of O
MPs O
within O
the O
aggregates O
. O

Analysis O
of O
the O
enhanced O
oral O
bioavailability O
of O
fenofibrate B
lipid O
formulations O
in O
fasted O
humans O
using O
an O
in O
vitro O
- O
in O
silico O
- O
in O
vivo O
approach O
. O

In O
order O
to O
better O
understand O
their O
potential O
advantages O
over O
solid O
oral O
dosage O
forms O
, O
we O
studied O
the O
solubility O
and O
dissolution O
/ O
precipitation O
characteristics O
of O
three O
self O
- O
microemulsifying O
drug O
delivery O
system O
( O
SMEDDS O
) O
formulations O
and O
one O
suspension O
of O
micronized O
fenofibrate B
in O
lipid O
excipients O
, O
for O
which O
pharmacokinetic O
studies O
had O
already O
been O
reported O
in O
the O
open O
literature O
. O

These O
were O
followed O
up O
by O
in O
silico O
simulations O
using O
STELLA O
( O
R O
) O
software O
, O
in O
which O
not O
only O
dispersion O
/ O
dissolution O
, O
but O
also O
the O
precipitation O
and O
re O
- O
dissolution O
of O
fenofibrate B
was O
taken O
into O
account O
. O

While O
unformulated O
drug O
exhibited O
poor O
solubility O
( O
0 O
. O
22 O
mu O
g O
/ O
mL O
in O
FaSSGF O
and O
4 O
. O
31 O
mu O
g O
/ O
mL O
in O
FaSSIF O
- O
V2 O
( O
PO4 O
) O
) O
and O
dissolved O
less O
than O
2 O
% O
in O
dissolution O
tests O
, O
the O
solubility O
of O
fenofibrate B
in O
the O
presence O
of O
the O
lipid O
excipients O
increased O
dramatically O
( O
e O
. O
g O
. O
, O
to O
65 O
. O
44 O
mu O
g O
/ O
mL O
in O
the O
presence O
of O
the O
Myritol O
318 O
/ O
TPGS B
/ O
Tween B
80 I
SMEDDS O
) O
and O
there O
was O
an O

attendant O
increase O
in O
the O
dissolution O
( O
over O
80 O
% O
from O
capsules O
containing O
the O
Myritol O
318 O
/ O
TPGS B
/ O
Tween B
80 I
SMEDDS O
and O
about O
20 O
% O
from O
the O
dispersion O
of O
fenofibrate B
in O
lipid O
excipients O
) O
. O

For O
the O
four O
lipid O
- O
based O
fenofibrate B
formulations O
studied O
, O
combining O
in O
vitro O
data O
in O
biorelevant O
media O
with O
in O
silico O
simulation O
resulted O
in O
accurate O
prediction O
of O
the O
in O
vivo O
human O
plasma O
profiles O
. O

Evaluation O
of O
the O
pharmacodynamics O
and O
pharmacokinetics O
of O
brucine B
following O
transdermal O
administration O
. O

Before O
the O
design O
of O
brucine B
- O
containing O
transdermal O
formulations O
, O
the O
pharmacodynamics O
and O
pharmacokinetics O
of O
brucine B
following O
transdermal O
administration O
should O
be O
evaluated O
. O

In O
this O
study O
, O
the O
effect O
of O
addition O
of O
ethanol B
on O
solubility O
of O
bruicne O
was O
investigated O
and O
20 O
% O
ethanol B
was O
added O
into O
PBS O
to O
obtain O
10mg O
/ O
mL O
brucine B
solution O
. O

It O
had O
been O
demonstrated O
that O
brucine B
possessed O
analgesic O
and O
anti O
- O
inflammatory O
activity O
in O
a O
dose O
- O
dependent O
manner O
. O

Cytotoxicities O
of O
brucine B
against O
various O
tumor O
cells O
including O
skin O
tumor O
cell O
were O
also O
compared O
in O
vitro O
. O

Brucine B
was O
found O
to O
possess O
antitumor O
activity O
in O
a O
concentration O
and O
time O
- O
dependent O
manner O
and O
gastrointestinal O
tumor O
cells O
seemed O
to O
be O
more O
sensitive O
to O
brucine B
. O

The O
cumulative O
amounts O
of O
brucine B
across O
mouse O
skin O
in O
vitro O
were O
found O
to O
be O
higher O
than O
90 O
% O
. O

The O
absolute O
bioavailability O
of O
brucine B
was O
determined O
to O
be O
40 O
. O
83 O
% O
. O

Finally O
, O
no O
dermal O
toxicity O
of O
brucine B
was O
observed O
. O

The O
results O
of O
this O
study O
indicated O
that O
transdermal O
administration O
might O
be O
beneficial O
for O
the O
sustained O
efficacy O
and O
reduced O
toxicity O
of O
brucine B
. O

The O
vascular O
protective O
properties O
of O
kinsenoside O
isolated O
from O
Anoectochilus O
roxburghii O
under O
high O
glucose B
condition O
. O

The O
vascular O
protective O
effect O
of O
its O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose B
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O

In O
in O
vivo O
tests O
, O
kinsenoside O
( O
50 O
and O
100mg O
/ O
kg O
) O
efficiently O
lowered O
blood O
glucose B
and O
cholesterol B
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin B
. O

In O
the O
in O
vitro O
assay O
, O
kinsenoside O
( O
20 O
and O
50 O
mu O
g O
/ O
mL O
) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
( O
nitric B
oxide I
( O
NO B
) O
, O
lactic O
dehydrogenase O
( O
LDH O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
and O
catalase O
( O
CAT O
) O
) O
in O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
damaged O
by O
high O
glucose B
( O
35mM O
) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases O
- O
the O
tissue O
inhibitors O
of O
matrix O

The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
mRNA O
expression O
levels O
in O
high O
glucose B
conditions O
. O

Moreover O
, O
histological O
examination O
, O
including O
hematoxylin B
- O
eosin B
( O
H O
& O
E O
) O
staining O
, O
masson O
trichrome O
( O
Masson O
) O
staining O
, O
and O
periodic O
Schiff O
- O
methenamine O
( O
PASM O
) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O
diabetes O
- O
related O
changes O
in O
mice O
aortas O
after O
kinsenoside O
( O
20 O
and O
50 O
mu O
g O
/ O
mL O
) O
treatment O
. O

Compounds O
4 O
, O
6 O
, O
16 O
, O
and O
17 O
( O
10 O
mu O
M O
) O
had O
moderate O
hepatoprotective O
activities O
against O
d B
- I
galactosamine I
- O
induced O
HL O
- O
7702 O
cell O
damage O
. O

Curcumin B
attenuates O
allergic O
airway O
inflammation O
by O
regulation O
of O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
regulatory O
T O
cells O
( O
Tregs O
) O
/ O
Th17 O
balance O
in O
ovalbumin O
- O
sensitized O
mice O
. O

The O
present O
study O
aimed O
to O
determine O
the O
protective O
effects O
and O
the O
underlying O
mechanisms O
of O
curcumin B
on O
ovalbumin O
( O
OVA O
) O
- O
induced O
allergic O
inflammation O
in O
a O
mouse O
model O
of O
allergic O
asthma O
. O

A O
total O
of O
60 O
mice O
were O
randomly O
assigned O
to O
six O
experimental O
groups O
: O
control O
, O
model O
, O
dexamethasone B
( O
2mg O
/ O
kg O
) O
, O
and O
curcumin B
( O
50mg O
/ O
kg O
, O
100mg O
/ O
kg O
, O
200mg O
/ O
kg O
) O
. O

Airway O
resistance O
( O
Raw O
) O
was O
measured O
by O
the O
forced O
oscillation O
technique O
, O
differential O
cell O
count O
in O
BAL O
fluid O
( O
BALF O
) O
was O
measured O
by O
Wright O
- O
Giemsa O
staining O
, O
histological O
assessment O
was O
measured O
by O
hematoxylin B
and O
eosin B
( O
HE O
) O
staining O
, O
BALF O
levels O
of O
Treg O
/ O
Th17 O
cytokines O
were O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
, O
Treg O
cells O
and O
Th17 O
cells O
were O
evaluated O
by O
flow O
cytometry O
( O
FCM O
) O
. O

Our O
study O
demonstrated O
that O
curcumin B
inhibited O
OVA O
- O
induced O
increases O
in O
eosinophil O
count O
; O
interleukin O
( O
IL O
) O
- O
17A O
level O
were O
recovered O
in O
bronchoalveolar O
lavage O
fluid O
increased O
IL O
- O
10 O
level O
in O
bronchoalveolar O
lavage O
fluid O
. O

Histological O
studies O
demonstrated O
that O
curcumin B
substantially O
inhibited O
OVA O
- O
induced O
eosinophilia O
in O
lung O
tissue O
. O

Flow O
cytometry O
( O
FCM O
) O
studies O
demonstrated O
that O
curcumin B
remarkably O
inhibited O
Th17 O
cells O
and O
significantly O
increased O
Treg O
cells O
. O

The O
results O
in O
vivo O
show O
ovalbumin O
- O
induced O
significantly O
broke O
Treg O
/ O
Th17 O
balance O
; O
curcumin B
treatments O
markedly O
attenuated O
the O
inflammatory O
in O
asthma O
model O
by O
regulating O
Treg O
/ O
Th17 O
balance O
. O

Our O
findings O
support O
the O
possible O
use O
of O
curcumin B
as O
a O
therapeutic O
drug O
for O
patients O
with O
allergic O
asthma O
. O

The O
C B
- O
Terminal O
Region O
of O
Cytoplasmic O
Polyadenylation O
Element O
Binding O
Protein O
Is O
a O
ZZ O
Domain O
with O
Potential O
for O
Protein O
- O
Protein O
Interactions O
. O

Two O
RNA O
recognition O
motif O
domains O
and O
a O
C B
- O
terminal O
binuclear O
zinc B
- O
binding O
domain O
are O
required O
for O
mRNA O
binding O
, O
but O
the O
zinc B
- O
binding O
domain O
is O
not O
required O
for O
sequence O
- O
specific O
recognition O
of O
the O
targeted O
mRNA O
transcript O
. O

The O
structure O
and O
function O
of O
the O
zinc B
- O
binding O
domain O
of O
CPEB O
are O
unknown O
. O

The O
C B
- O
terminal O
region O
of O
CPEB O
may O
participate O
in O
assembly O
of O
the O
ribonucleoprotein O
complex O
that O
includes O
the O
scaffold O
protein O
, O
Symplekin O
, O
and O
the O
cleavage O
and O
polyadenylation O
specificity O
factor O
. O

While O
zinc B
- O
binding O
domains O
are O
renowned O
for O
nucleic O
acid O
recognition O
, O
binuclear O
zinc B
- O
binding O
structural O
motifs O
, O
such O
as O
LIM O
( O
Lin O
- O
11 O
, O
Isl O
- O
1 O
, O
Mec O
- O
3 O
) O
, O
RING O
( O
really O
interesting O
new O
gene O
) O
, O
PHD O
( O
plant O
homeodomain O
) O
and O
ZZ O
( O
ZZ O
- O
type O
zinc B
finger O
) O
domains O
, O
participate O
in O
protein O
- O
protein O
interactions O
. O

Here O
, O
we O
report O
the O
solution O
structure O
of O
the O
C B
- O
terminal O
zinc B
- O
binding O
domain O
of O
CPEB1 O
( O
CPEB1 O
- O
ZZ O
) O
, O
which O
has O
a O
cross O
- O
braced O
zinc B
binding O
topology O
. O

All O
SPANs O
inhibited O
nerve O
- O
evoked O
twitch O
contractions O
at O
the O
neuromuscular O
junction O
without O
inhibiting O
contractile O
responses O
to O
cholinergic O
agonists O
or O
KCl B
. O

Several O
other O
coagulopathic O
and O
myotoxic O
high O
mass O
proteins O
including O
a O
class O
PIII O
snake O
venom O
metalloproteinase O
, O
C O
- O
type O
lectin O
, O
l B
- I
amino I
acid I
oxidase O
, O
acetylcholinesterase O
and O
phospholipase O
B O
were O
also O
identified O
that O
may O
contribute O
to O
the O
overall O
toxicity O
of O
A O
. O
superbus O
venom O
. O

Analysis O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
of O
sterols B
and O
oxysterols B
in O
brain O
of O
the O
newborn O
Dhcr7 O
( O
Delta O
3 O
- O
5 O
/ O
T93M O
) O
mouse O
: O
A O
model O
of O
Smith O
- O
Lemli O
- O
Opitz O
syndrome O
. O

In O
this O
study O
the O
sterol B
and O
oxysterol B
profile O
of O
newborn O
brain O
from O
the O
Dhcr7 O
( O
Delta O
3 O
- O
5 O
/ O
T93M O
) O
mouse O
model O
of O
Smith O
- O
Lemli O
- O
Opitz O
syndrome O
( O
SLOS O
) O
has O
been O
investigated O
. O

We O
find O
the O
SLOS O
mouse O
has O
reduced O
levels O
of O
cholesterol B
and O
desmosterol O
and O
increased O
levels O
of O
7 O
- O
and O
8 O
- O
dehydrocholesterol O
and O
of O
7 O
- O
and O
8 O
- O
dehydrodesmosterol O
in O
brain O
compared O
to O
the O
wild O
type O
. O

The O
profile O
of O
enzymatically O
formed O
oxysterols B
in O
the O
SLOS O
mouse O
resembles O
that O
in O
the O
wild O
type O
but O
the O
level O
of O
24S O
- O
hydroxycholesterol O
, O
the O
dominating O
cholesterol B
metabolite O
, O
is O
reduced O
in O
a O
similar O
proportion O
to O
that O
of O
cholesterol B
. O

A O
number O
of O
oxysterols B
abundant O
in O
the O
SLOS O
mouse O
are O
probably O
derived O
from O
7 B
- I
dehydrocholesterol I
, O
however O
, O
the O
mechanism O
of O
their O
formation O
is O
unclear O
. O

Interrelationship O
between O
ATP B
- O
binding O
cassette O
transporters O
and O
oxysterols B
. O

ATP B
- O
binding O
cassette O
( O
ABC O
) O
transporters O
constitute O
a O
ubiquitous O
superfamily O
of O
membrane O
proteins O
responsible O
for O
the O
translocation O
of O
several O
substances O
across O
membranes O
using O
the O
chemical O
energy O
provided O
by O
ATP B
hydrolysis O
. O

ABC O
transporters O
participate O
in O
many O
physiological O
and O
pathophysiological O
processes O
, O
including O
cholesterol B
and O
lipid O
transportation O
and O
multidrug O
resistance O
. O

Oxysterols B
are O
the O
products O
of O
cholesterol B
oxidation O
, O
formed O
by O
both O
enzymatic O
and O
non O
- O
enzymatic O
mechanisms O
. O

The O
role O
of O
oxysterols B
in O
cholesterol B
metabolism O
and O
several O
diseases O
has O
been O
widely O
investigated O
, O
but O
many O
questions O
remain O
to O
be O
answered O
. O

Several O
lines O
of O
evidence O
link O
ABC O
transporter O
functions O
with O
cholesterol B
and O
oxysterol B
metabolism O
. O

This O
review O
discusses O
ABC O
transporters O
, O
oxysterols B
, O
and O
how O
they O
interact O
with O
each O
other O
. O

The O
enzyme O
gamma O
- O
glutamyltransferase O
( O
GGT O
) O
catalyzes O
the O
hydrolysis O
of O
the O
gamma O
- O
glutamyl O
isopeptide O
bond O
of O
glutathione B
conjugates O
( O
donor O
substrates O
) O
, O
releasing O
glutamic B
acid I
, O
or O
the O
transfer O
of O
the O
donor O
' O
s O
gamma O
- O
glutamyl O
group O
to O
an O
acceptor O
substrate O
, O
such O
as O
a O
dipeptide B
. O

The O
transpeptidation O
activity O
of O
bovine O
kidney O
GGT O
was O
measured O
with O
glycylglycine O
as O
the O
acceptor O
substrate O
and O
several O
glutathione B
conjugate O
donor O
substrates O
, O
representative O
of O
detoxication O
products O
of O
polycyclic O
aromatic O
xenobiotics O
. O

Anti O
- O
fibrotic O
effects O
of O
puerarin B
on O
CCl4 B
- O
induced O
hepatic O
fibrosis O
in O
rats O
possibly O
through O
the O
regulation O
of O
PPAR O
- O
gamma O
expression O
and O
inhibition O
of O
PI3K O
/ O
Akt O
pathway O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
therapeutic O
effects O
of O
puerarin B
( O
PR O
) O
, O
an O
active O
ingredient O
from O
kudzu O
root O
, O
on O
CCl4 B
- O
induced O
HF O
rats O
. O

PR O
effectively O
ameliorated O
the O
liver O
metabolic O
function O
, O
resulting O
in O
reduced O
serum O
enzymatic O
activities O
of O
alanine B
aminotransferase O
( O
ALT O
) O
, O
aspartate B
aminotransferase O
( O
AST O
) O
, O
total O
- O
bilirubin B
( O
T O
- O
bilirubin B
) O
, O
extracellular O
matrix O
( O
ECM O
) O
contents O
and O
increased O
levels O
of O
albumin O
, O
total O
- O
protein O
( O
T O
- O
protein O
) O
in O
HF O
rats O
. O

Similarly O
, O
pathological O
examination O
showed O
that O
the O
CCl4 B
- O
lesioned O
liver O
was O
mitigated O
by O
PR O
treatments O
. O

Meanwhile O
, O
we O
also O
detected O
significantly O
reduced O
levels O
of O
hydroxyproline B
( O
Hyp B
) O
, O
type O
III O
precollagen O
( O
PCIII O
) O
and O
collagen O
I O
( O
Col O
I O
) O
in O
the O
liver O
tissue O
of O
HF O
rats O
, O
whereas O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
( O
PPAR O
- O
gamma O
) O
expression O
was O
effectively O
increased O
. O

Taken O
together O
, O
PR O
could O
attenuate O
the O
CCl4 B
- O
induced O
toxicity O
in O
the O
hepatocytes O
of O
HF O
rats O
. O

Dietary O
exposure O
of O
juvenile O
female O
mice O
to O
polyhalogenated O
seafood O
contaminants O
( O
HBCD O
, O
BDE B
- I
47 I
, O
PCB O
- O
153 O
, O
TCDD B
) O
: O
Comparative O
assessment O
of O
effects O
in O
potential O
target O
tissues O
. O

The O
study O
compared O
the O
effects O
of O
two O
legacy O
and O
two O
emerging O
fish O
pollutants O
( O
Hexabromocyclododeca B
HBCD O
; O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
ether I
BDE B
- I
47 I
; O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
, O
5 O
' O
- O
Hexachlorobiphenyl O
PCB O
- O
153 O
; O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
Tetrachlorodibenzo O
- O
p O
- O
doxin O
TCDD B
) O
in O
juvenile O
female O
mice O
exposed O
through O
a O
salmon O
based O
rodent O
diet O
for O
28days O
( O

dietary O
doses O
: O
HBCD O
199mg O
/ O
kg O
bw O
/ O
day O
; O
BDE B
- I
47 I
450 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
PCB O
- O
153 O
195 O
mu O
g O
/ O
kg O
bw O
/ O
day O
; O
TCDD B
90ng O
/ O
kg O
bw O
/ O
day O
) O
. O

All O
compounds O
caused O
changes O
in O
liver O
, O
thymus O
and O
thyroid O
; O
spleen O
was O
affected O
by O
BDE B
- I
47 I
and O
PCB O
- O
153 O
; O
no O
effects O
were O
seen O
in O
uterus O
and O
adrenals O
. O

Strongest O
effects O
in O
thyroid O
follicles O
were O
elicited O
by O
PCB O
- O
153 O
, O
in O
thymus O
and O
liver O
by O
BDE B
- I
47 I
. O

HBCD O
and O
BDE B
- I
47 I
induced O
liver O
fatty O
changes O
, O
but O
appeared O
to O
be O
less O
potent O
in O
the O
other O
tissues O
. O

HBCD O
, O
BDE B
- I
47 I
and O
TCDD B
increased O
serum O
testosterone B
levels O
and O
the O
testosterone B
/ O
estradiol B
ratio O
, O
suggesting O
a O
potential O
involvement O
of O
pathways O
related O
to O
sex O
steroid B
biosynthesis O
and O
/ O
or O
metabolism O
. O

HIF O
prolyl B
hydroxylases O
( O
PHD O
enzymes O
) O
act O
as O
oxygen B
sensors O
regulating O
HIF O
, O
and O
hence O
angiogenesis O
. O

Coumarins B
hinged O
directly O
on O
benzimidazoles O
and O
their O
ribofuranosides O
to O
inhibit O
hepatitis O
C O
virus O
. O

A O
new O
compound O
library O
that O
contained O
20 O
hinged O
benzimidazole B
- O
coumarin B
hybrids O
and O
their O
beta O
- O
d O
- O
ribofuranosides O
was O
established O
. O

The O
anti O
- O
hepatitis O
C O
virus O
( O
HCV O
) O
activity O
of O
all O
novel O
coumarin B
derivatives O
, O
which O
were O
obtained O
by O
use O
of O
organic O
synthetic O
methods O
, O
was O
tested O
. O

The O
incorporation O
of O
a O
d O
- O
ribofuranose O
into O
the O
hinged O
hybrids O
provided O
the O
corresponding O
nucleosides B
with O
the O
beta O
configuration O
, O
one O
of O
which O
inhibited O
HCV O
replication O
with O
an O
EC50 O
value O
of O
20 O
mu O
M O
. O

Additionally O
, O
the O
structure O
- O
activity O
relationship O
is O
elucidated O
on O
the O
basis O
of O
the O
functional O
groups O
that O
were O
attached O
to O
the O
nuclei O
of O
benzimidazole B
, O
coumarin B
, O
and O
ribofuranose O
of O
the O
hybrids O
. O

The O
protective O
role O
of O
l B
- I
carnitine I
against O
cylindrospermopsin O
- O
induced O
oxidative O
stress O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
. O

The O
principal O
mechanisms O
of O
action O
of O
CYN O
involve O
inhibition O
of O
protein O
and O
glutathione B
synthesis O
. O

We O
investigated O
the O
protective O
effects O
of O
l B
- I
carnitine I
( O
LC O
) O
pre O
- O
treatment O
on O
A O
. O
ovalisporum O
- O
induced O
oxidative O
stress O
in O
cells O
containing O
CYN O
and O
deoxy O
- O
CYN O
, O
or O
pure O
standard O
CYN O
, O
in O
tilapia O
( O
Oreochromis O
niloticus O
) O
that O
had O
been O
acutely O
exposed O
via O
oral O
administration O
. O

Various O
oxidative O
stress O
markers O
, O
including O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
oxidation O
, O
DNA O
oxidation O
, O
and O
the O
ratio O
of O
reduced B
glutathione I
to O
oxidised O
glutathione O
( O
GSH B
/ O
GSSG B
) O
, O
and O
the O
activities O
of O
NADPH B
oxidase O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
and O
gamma O
- O
glutamyl O
- O
cysteine O
synthetase O
( O
gamma O
- O
GCS O
) O
, O
were O
evaluated O
in O
the O
livers O
and O
kidneys O
of O
fish O
in O
the O
absence O
and O
presence O
of O

A O
child O
exposed O
to O
primidone B
not O
prescribed O
for O
her O
. O

A O
7 O
. O
5 O
- O
year O
- O
old O
girl O
who O
was O
treated O
with O
phenobarbital B
( O
PHB B
) O
for O
epilepsy O
was O
admitted O
with O
decreased O
levels O
of O
consciousness O
. O

She O
had O
been O
known O
to O
have O
high O
PHB B
levels O
of O
unknown O
cause O
, O
without O
symptoms O
. O

Her O
PHB B
levels O
were O
very O
high O
, O
as O
expected O
, O
but O
primidone B
levels O
were O
also O
detected O
although O
she O
and O
her O
parents O
denied O
history O
of O
primidone B
administration O
. O

We O
wished O
to O
rule O
out O
intentional O
unprescribed O
use O
of O
primidone B
. O

Our O
retrospective O
review O
showed O
3 O
other O
children O
with O
high O
PHB B
concentrations O
where O
primidone B
was O
also O
detected O
when O
PHB B
levels O
were O
over O
130 O
mu O
mol O
/ O
L O
. O

Complementary O
studies O
confirmed O
that O
high O
- O
dose O
PHB B
can O
convert O
to O
its O
prodrug O
primidone B
, O
which O
has O
not O
been O
reported O
previously O
. O

Systematic O
review O
of O
population O
pharmacokinetic O
analyses O
of O
imatinib B
and O
relationships O
with O
treatment O
outcomes O
. O

Several O
population O
pharmacokinetic O
( O
PPK O
) O
analyses O
of O
the O
anticancer O
drug O
imatinib B
have O
been O
performed O
to O
investigate O
different O
patient O
populations O
and O
covariate O
effects O
. O

Its O
primary O
objective O
was O
to O
provide O
useful O
information O
for O
evaluating O
the O
expectedness O
of O
imatinib B
plasma O
concentration O
measurements O
in O
the O
frame O
of O
therapeutic O
drug O
monitoring O
. O

Nine O
PPK O
models O
describing O
total O
imatinib B
plasma O
concentration O
were O
identified O
. O

Therapeutic O
drug O
monitoring O
- O
guided O
dosage O
adjustment O
seems O
justified O
for O
imatinib B
, O
but O
a O
formal O
predictive O
therapeutic O
range O
remains O
difficult O
to O
propose O
in O
the O
absence O
of O
prospective O
target O
concentration O
intervention O
trials O
. O

Loss O
of O
phosphatases O
such O
as O
PTEN O
( O
phosphatase O
and O
tensin O
homologue O
deleted O
on O
chromosome O
10 O
) O
, O
a O
known O
tumour O
suppressor O
, O
across O
tumour O
types O
lends O
credence O
to O
the O
development O
of O
phosphatidylinositol B
3 O
- O
- O
kinase O
inhibitors O
alongside O
the O
use O
of O
phosphatase O
expression O
as O
a O
biomarker O
, O
though O
phase O
3 O
trial O
data O
are O
lacking O
. O

Sol O
- O
gel O
nanoglues O
for O
an O
organic O
binder O
- O
free O
TiO2 B
nanofiber O
anode O
for O
lithium B
ion O
batteries O
. O

A O
TiO2 B
nanofiber O
anode O
is O
glued O
using O
a O
sol O
- O
gel O
reaction O
to O
improve O
cycle O
performance O
and O
Coulombic O
efficiencies O
. O

The O
hydrolysis O
- O
condensation O
process O
produces O
TiO2 B
nanoglues O
consisting O
of O
TiO2 B
nanoparticles O
, O
providing O
strong O
adhesion O
between O
nanofibers O
and O
the O
current O
collector O
as O
well O
as O
between O
nanofibers O
, O
rendering O
favourable O
transporting O
properties O
of O
electrons O
and O
Li B
ions O
in O
the O
TiO2 B
nanofiber O
electrode O
, O
and O
eventually O
leading O
to O
the O
excellent O
performance O
of O
Li B
ion O
batteries O
exhibiting O
an O
excellent O
initial O
Coulombic O
efficiency O
( O
~ O
85 O
% O
) O
, O
cycle O
performance O
up O
to O
100 O
cycles O
, O
and O
high O
rate O
capability O
( O
60 O
% O
at O
5 O
C O
) O
. O

Consequently O
, O
accurate O
determination O
of O
released O
or O
secreted O
proteins O
such O
as O
lactate B
dehydrogenase O
and O
cytokines O
adsorbed O
to O
nanoparticles O
is O
affected O
. O

Gas O
- O
phase O
structures O
and O
thermochemistry O
of O
neutral O
histidine B
and O
its O
conjugated O
acid O
and O
base O
. O

Extensive O
exploration O
of O
the O
conformational O
space O
of O
neutral O
, O
protonated O
and O
deprotonated O
histidine B
has O
been O
conducted O
at O
the O
G4MP2 O
level O
. O

Theoretical O
protonation O
and O
deprotonation O
thermochemistry O
as O
well O
as O
heats O
of O
formation O
of O
gaseous O
histidine B
and O
its O
ionized O
forms O
have O
been O
calculated O
at O
the O
G4 O
level O
considering O
either O
the O
most O
stable O
conformers O
or O
an O
equilibrium O
population O
of O
conformers O
at O
298 O
K O
. O

Recommended O
proton O
affinity O
and O
protonation O
entropy O
deduced O
from O
these O
comparisons O
are O
PA O
( O
His B
) O
= O
980 O
kJ O
mol O
( O
- O
1 O
) O
and O
Delta O
pS O
( O
His B
) O
~ O
0 O
J O
mol O
( O
- O
1 O
) O
K O
( O
- O
1 O
) O
, O
thus O
leading O
to O
a O
gas O
- O
phase O
basicity O
value O
of O
GB O
( O
His B
) O
= O
947 O
. O
5 O
kJ O
mol O
( O
- O
1 O
) O
. O

Similarly O
, O
gas O
phase O
acidity O
parameters O
are O
Delta O
acidH O
( O
o O
) O
( O
His B
) O
= O
1373 O
kJ O
mol O
( O
- O
1 O
) O
, O
Delta O
acidS O
( O
His B
) O
~ O
10 O
J O
mol O
( O
- O
1 O
) O
K O
( O
- O
1 O
) O
and O
Delta O
acidG O
( O
o O
) O
( O
His B
) O
= O
1343 O
kJ O
mol O
( O
- O
1 O
) O
. O

Computed O
G4 O
heats O
of O
formation O
values O
are O
equal O
to O
- O
290 O
, O
265 O
and O
- O
451 O
kJ O
mol O
( O
- O
1 O
) O
for O
gaseous O
neutral O
histidine B
and O
its O
protonated O
and O
deprotonated O
forms O
, O
respectively O
. O

Outcomes O
at O
14 O
and O
26 O
weeks O
of O
age O
included O
body O
mass O
, O
body O
composition O
, O
whole O
- O
body O
bone O
mineral O
content O
( O
WBBMC O
) O
via O
peripheral O
dual O
- O
energy O
X O
- O
ray O
absorptiometry O
, O
femoral O
cortical O
and O
trabecular O
architecture O
via O
microcomputed O
tomography O
, O
and O
glucose B
tolerance O
. O

Female O
HF O
- O
N O
had O
normal O
body O
mass O
and O
glucose B
tolerance O
, O
with O
lower O
body O
fat O
( O
% O
) O
but O
higher O
serum O
leptin O
at O
14 O
weeks O
vs O
. O
N O
- O
N O
( O
P O
< O
0 O
. O
05 O
for O
both O
) O
. O

Male O
HF O
- O
N O
had O
normal O
body O
mass O
and O
mildly O
impaired O
glucose B
tolerance O
, O
with O
lower O
body O
fat O
( O
% O
) O
at O
14 O
weeks O
and O
lower O
serum O
leptin O
at O
26 O
weeks O
vs O
. O
N O
- O
N O
( O
P O
< O
0 O
. O
05 O
for O
both O
) O
. O

In O
addition O
to O
the O
well O
known O
regulating O
effects O
of O
leptin O
on O
energy O
balance O
and O
glucose B
homeostasis O
through O
the O
central O
nervous O
system O
, O
circulating O
leptin O
has O
a O
direct O
effect O
on O
pancreatic O
islet O
and O
insulin O
secretion O
through O
its O
receptor O
( O
OBRb O
) O
. O

The O
resulting O
phase O
arises O
via O
suppression O
of O
polarization O
by O
a O
structural O
order O
parameter O
and O
can O
thus O
be O
identified O
as O
anti O
- O
ferroelectric O
( O
Fe B
displacements O
- O
bottom O
panel O
) O
. O

Cobalt B
chloride I
speciation O
, O
mechanisms O
of O
cytotoxicity O
on O
human O
pulmonary O
cells O
, O
and O
synergistic O
toxicity O
with O
zinc B
. O

Cobalt B
is O
used O
in O
numerous O
industrial O
sectors O
, O
leading O
to O
occupational O
diseases O
, O
particularly O
by O
inhalation O
. O

Cobalt B
- O
associated O
mechanisms O
of O
toxicity O
are O
far O
from O
being O
understood O
and O
information O
that O
could O
improve O
knowledge O
in O
this O
area O
is O
required O
. O

We O
investigated O
the O
impact O
of O
a O
soluble O
cobalt B
compound O
, O
CoCl O
( O
2 O
) O
. O
6H O
( O
2 O
) O
O O
, O
on O
the O
BEAS O
- O
2B O
lung O
epithelial O
cell O
line O
, O
as O
well O
as O
its O
impact O
on O
metal O
homeostasis O
. O

Cobalt B
speciation O
in O
different O
culture O
media O
, O
in O
particular O
soluble O
and O
precipitated O
cobalt B
species O
, O
was O
investigated O
via O
theoretical O
and O
analytical O
approaches O
. O

The O
cytotoxic O
effects O
of O
cobalt B
on O
the O
cells O
were O
assessed O
. O

Upon O
exposure O
of O
BEAS O
- O
2B O
cells O
to O
cobalt B
, O
intracellular O
accumulation O
of O
cobalt B
and O
zinc B
was O
demonstrated O
using O
direct O
in O
situ O
microchemical O
analysis O
based O
on O
ion O
micro O
- O
beam O
techniques O
and O
analysis O
after O
cell O
lysis O
by O
inductively O
coupled O
plasma O
mass O
spectrometry O
( O
ICP O
- O
MS O
) O
. O

Microchemical O
imaging O
revealed O
that O
cobalt B
was O
rather O
homogeneously O
distributed O
in O
the O
nucleus O
and O
in O
the O
cytoplasm O
whereas O
zinc B
was O
more O
abundant O
in O
the O
nucleus O
. O

The O
modulation O
of O
zinc B
homeostasis O
led O
to O
the O
evaluation O
of O
the O
effect O
of O
combined O
cobalt B
and O
zinc B
exposure O
. O

In O
this O
case O
, O
a O
clear O
synergistic O
increase O
in O
toxicity O
was O
observed O
as O
well O
as O
a O
substantial O
increase O
in O
zinc B
content O
within O
cells O
. O

Western O
blots O
performed O
under O
the O
same O
coexposure O
conditions O
revealed O
a O
decrease O
in O
ZnT1 O
expression O
, O
suggesting O
that O
cobalt B
could O
inhibit O
zinc B
release O
through O
the O
modulation O
of O
ZnT1 O
. O

Overall O
, O
this O
study O
highlights O
the O
potential O
hazard O
to O
lung O
function O
, O
of O
combined O
exposure O
to O
cobalt B
and O
zinc B
. O

Boosting O
Immunity O
to O
Small O
Tumor O
- O
Associated O
Carbohydrates B
with O
Bacteriophage O
Q O
beta O
Capsids O
. O

Tumor O
associated O
carbohydrate B
antigens O
( O
TACAs O
) O
are O
overexpressed O
on O
a O
variety O
of O
cancer O
cell O
surfaces O
, O
which O
present O
tempting O
targets O
for O
anticancer O
vaccine O
development O
. O

However O
, O
such O
carbohydrates B
are O
often O
poorly O
immunogenic O
. O

To O
overcome O
this O
challenge O
, O
we O
show O
here O
that O
the O
display O
of O
a O
very O
weak O
TACA O
, O
the O
monomeric O
Tn O
antigen O
, O
on O
bacteriophage O
Q O
beta O
virus O
- O
like O
particles O
elicits O
powerful O
humoral O
responses O
to O
the O
carbohydrate B
. O

Thus O
, O
Q O
beta O
presents O
a O
highly O
attractive O
platform O
for O
the O
development O
of O
carbohydrate B
- O
based O
anticancer O
vaccines O
. O

The O
PEMUs O
were O
built O
layer O
- O
by O
- O
layer O
with O
the O
polycation O
poly B
( I
allylamine I
hydrochloride I
) I
( O
PAH B
) O
and O
a O
polyanion O
poly B
( I
acrylic I
acid I
) I
( O
PAA B
) O
that O
was O
modified O
with O
photoreactive O
4 O
- O
( O
2 O
- O
hydroxyethoxy O
) O
benzophenone O
( O
PAABp O
) O
. O

One O
possible O
mechanism O
linking O
inflammation O
with O
cancer O
involves O
the O
generation O
of O
reactive O
oxygen B
, O
nitrogen B
, O
and O
halogen B
species O
by O
activated O
macrophages O
and O
neutrophils O
infiltrating O
sites O
of O
infection O
or O
tissue O
damage O
, O
with O
these O
chemical O
mediators O
causing O
damage O
that O
ultimately O
leads O
to O
cell O
death O
and O
mutation O
. O

To O
determine O
the O
most O
biologically O
deleterious O
chemistries O
of O
inflammation O
, O
we O
previously O
assessed O
products O
across O
the O
spectrum O
of O
DNA O
damage O
arising O
in O
inflamed O
tissues O
in O
the O
SJL O
mouse O
model O
nitric B
oxide I
overproduction O
( O
Pang O
et O
al O
. O
( O
2007 O
) O
Carcinogenesis O
28 O
, O
1807 O
- O
1813 O
) O
. O

We O
have O
now O
developed O
an O
isotope O
- O
dilution O
, O
liquid O
chromatography O
- O
coupled O
, O
tandem O
quadrupole O
mass O
spectrometric O
method O
to O
quantify O
representative O
species O
across O
the O
spectrum O
of O
RNA O
damage O
products O
predicted O
to O
arise O
at O
sites O
of O
inflammation O
, O
including O
nucleobase B
deamination O
( O
xanthosine O
and O
inosine O
) O
, O
oxidation O
( O
8 O
- O
oxoguanosine O
) O
, O
and O
alkylation O
( O
1 O
, O
N O
( O
6 O
) O
- O
ethenoadenosine O
) O
. O

However O
, O
compared O
to O
control O
mice O
, O
RcsX O
treatment O
to O
induce O
nitric B
oxide I
overproduction O
resulted O
in O
significant O
increases O
only O
in O
inosine O
and O
only O
in O
the O
spleen O
. O

Further O
, O
the O
nitric B
oxide I
synthase O
inhibitor O
, O
N O
- O
methylarginine O
, O
did O
not O
significantly O
affect O
the O
levels O
of O
inosine O
in O
control O
and O
RcsX O
- O
treated O
mice O
. O

The O
differences O
between O
DNA O
and O
RNA O
damage O
in O
the O
same O
animal O
model O
of O
inflammation O
point O
to O
possible O
influences O
from O
DNA O
repair O
, O
RcsX O
- O
induced O
alterations O
in O
adenosine B
deaminase O
activity O
, O
and O
differential O
accessibility O
of O
DNA O
and O
RNA O
to O
reactive O
oxygen B
and O
nitrogen B
species O
as O
determinants O
of O
nucleic O
acid O
damage O
during O
inflammation O
. O

The O
present O
short O
review O
ends O
with O
landmark O
studies O
by O
Max O
Harry O
Weil O
, O
demonstrating O
the O
importance O
of O
venous O
pooling O
, O
and O
John O
H O
. O
Siegel O
, O
which O
introduced O
the O
concept O
of O
deficient O
peripheral O
utilization O
of O
oxygen B
, O
inspiring O
later O
work O
on O
the O
microvascular O
disturbances O
of O
septic O
shock O
. O

We O
have O
recently O
shown O
that O
thermolysine O
, O
a O
protease O
enzyme O
obtained O
from O
Bacillus O
thermoproteolyticus O
rokko O
, O
can O
be O
used O
to O
trigger O
the O
gelation O
of O
FEFK O
( O
F O
, O
phenylalanine B
; O
E O
, O
glutamic B
acid I
; O
K O
, O
lysine B
) O
tetrapeptides O
through O
reverse O
hydrolysis O
and O
formation O
of O
longer O
peptide O
sequences O
, O
mainly O
octapeptides O
, O
that O
self O
- O
assemble O
readily O
. O

Subsequently O
' O
bacoside O
A O
' O
was O
identified O
as O
a O
mixture O
of O
four O
saponins B
[ O
bacoside O
A3 O
( O
1 O
) O
, O
bacopaside O
II O
( O
2 O
) O
, O
bacopasaponin O
C O
( O
3 O
) O
and O
the O
jujobogenin O
isomer O
of O
the O
latter O
( O
4 O
) O
] O
and O
was O
considered O
as O
part O
of O
major O
constituents O
of O
the O
herb O
along O
with O
bacopaside O
I O
( O
5 O
) O
. O

These O
major O
saponins B
now O
form O
part O
of O
analytical O
monographs O
in O
many O
Pharmacopoeia O
. O

Compared O
to O
control O
HDLs O
, O
ABLP O
HDLs O
showed O
a O
40 O
% O
decrease O
of O
alpha B
- I
tocopherol I
and O
an O
11 O
- O
fold O
increased O
malondialdehyde B
concentration O
. O

In O
a O
genome O
- O
wide O
association O
study O
of O
acute O
bronchodilator O
response O
( O
BDR O
) O
to O
inhaled O
albuterol O
, O
534 O
290 O
single O
- O
nucleotide B
polymorphisms O
( O
SNPs O
) O
were O
tested O
in O
403 O
white O
trios O
from O
the O
Childhood O
Asthma O
Management O
Program O
using O
five O
statistical O
models O
to O
determine O
the O
most O
robust O
genetic O
associations O
. O

Differential O
tolerance O
to O
copper B
, O
but O
no O
evidence O
of O
population O
- O
level O
genetic O
differences O
in O
a O
widely O
- O
dispersing O
native O
barnacle O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
whether O
populations O
of O
A O
. O
variegatus O
from O
metal O
- O
impacted O
sites O
, O
displayed O
a O
greater O
tolerance O
to O
a O
toxicant O
( O
copper B
) O
than O
reference O
populations O
. O

Within O
24 O
h O
, O
adults O
were O
induced O
to O
spawn O
and O
the O
offspring O
were O
exposed O
to O
copper B
in O
a O
laboratory O
assay O
. O

Larvae O
collected O
from O
the O
metal O
- O
impacted O
estuaries O
demonstrated O
a O
greater O
tolerance O
to O
copper B
compared O
to O
those O
from O
reference O
sites O
. O

Diurnal O
pituitary O
- O
adrenal O
activity O
during O
schedule O
- O
induced O
polydipsia O
of O
water O
and O
ethanol B
in O
cynomolgus O
monkeys O
( O
Macaca O
fascicularis O
) O
. O

OBJECTIVES O
: O
This O
study O
characterized O
the O
endocrine O
correlates O
during O
schedule O
- O
induced O
polydipsia O
of O
water O
and O
ethanol B
using O
a O
longitudinal O
approach O
in O
non O
- O
human O
primates O
. O

METHODS O
: O
Plasma O
adrenocorticotropic O
hormone O
( O
ACTH O
) O
and O
cortisol B
were O
measured O
in O
samples O
from O
awake O
cynomolgus O
monkeys O
( O
Macaca O
fascicularis O
, O
11 O
adult O
males O
) O
obtained O
at O
the O
onset O
, O
mid O
- O
day O
, O
and O
offset O
of O
their O
12 O
- O
h O
light O
cycle O
. O

The O
monkeys O
were O
induced O
to O
drink O
water O
and O
ethanol B
( O
4 O
% O
w O
/ O
v O
, O
in O
water O
) O
using O
a O
fixed O
time O
( O
FT O
) O
300 O
- O
s O
interval O
schedule O
of O
pellet O
delivery O
. O

The O
induction O
fluid O
changed O
every O
30 O
sessions O
in O
the O
following O
order O
: O
water O
, O
0 O
. O
5 O
g O
/ O
kg O
ethanol B
, O
1 O
. O
0 O
g O
/ O
kg O
ethanol B
, O
and O
1 O
. O
5 O
g O
/ O
kg O
ethanol B
. O

Following O
induction O
, O
ethanol B
and O
water O
were O
concurrently O
available O
for O
22 O
h O
/ O
day O
. O

RESULTS O
: O
The O
FT O
300 O
- O
s O
schedule O
gradually O
increased O
ACTH O
, O
but O
not O
cortisol B
, O
during O
water O
induction O
to O
a O
plateau O
sustained O
throughout O
ethanol B
induction O
in O
every O
monkey O
. O

Upon O
termination O
of O
the O
schedule O
, O
ACTH O
decreased O
to O
baseline O
and O
cortisol B
below O
baseline O
. O

Diurnal O
ACTH O
and O
cortisol B
were O
unrelated O
to O
the O
dose O
of O
ethanol B
, O
but O
ACTH O
rhythm O
flattened O
at O
0 O
. O
5 O
g O
/ O
kg O
/ O
day O
and O
remained O
flattened O
. O

Serotonin B
5 O
- O
HT2A O
and O
metabotropic O
glutamate B
2 O
( O
mGlu2 O
) O
are O
G O
protein O
- O
coupled O
receptors O
suspected O
in O
the O
pathophysiology O
of O
psychiatric O
disorders O
such O
as O
schizophrenia O
, O
depression O
and O
suicide O
. O

Disruption O
of O
5 O
- O
HT2A O
receptor O
- O
dependent O
signaling O
in O
mice O
was O
associated O
with O
decreased O
acetylation O
of O
histone O
H3 O
( O
H3ac O
) O
and O
H4 O
( O
H4ac O
) O
, O
and O
increased O
tri O
- O
methylation O
of O
histone O
H3 O
at O
lysine B
27 O
( O
H3K27me3 O
) O
at O
the O
mGlu2 O
promoter O
- O
epigenetic O
changes O
that O
correlate O
with O
transcriptional O
repression O
. O

Neither O
methylation O
of O
histone O
H3 O
at O
lysine B
4 O
( O
H3K4me1 O
/ O
2 O
/ O
3 O
) O
nor O
tri O
- O
methylation O
of O
histone O
H3 O
at O
lysine B
9 O
( O
H3K9me3 O
) O
was O
affected O
. O

Relationship O
of O
Dehydroepiandrostero B
Sulfate I
with O
Overweight O
and O
Insulin O
Sensitivity O
in O
12 O
- O
16 O
- O
Year O
- O
old O
Spanish O
Children O
. O

DHEA B
- I
S I
is O
the O
most O
abundant O
steroid B
hormone O
in O
human O
circulation O
. O

Although O
a O
relationship O
of O
DHEA B
- I
S I
with O
obesity O
- O
related O
diseases O
has O
been O
reported O
, O
the O
metabolic O
role O
of O
this O
hormone O
remains O
unclear O
, O
particularly O
in O
children O
. O

In O
our O
study O
, O
we O
have O
investigated O
the O
relationship O
of O
DHEA B
- I
S I
levels O
with O
anthropometric O
variables O
, O
insulin O
, O
HOMA O
, O
and O
free O
fatty O
acids O
in O
adolescents O
. O

Plasma O
DHEA B
- I
S I
was O
determined O
by O
RIA O
, O
insulin O
concentrations O
by O
IRMA O
, O
and O
free O
fatty O
acids O
by O
using O
a O
commercial O
kit O
. O

No O
significant O
differences O
in O
plasma O
DHEA B
- I
S I
levels O
were O
found O
between O
sexes O
. O

DHEA B
- I
S I
levels O
in O
overweight O
children O
were O
significantly O
higher O
than O
in O
normal O
- O
weight O
children O
. O

DHEA B
- I
S I
levels O
were O
significantly O
correlated O
with O
weight O
and O
BMI O
after O
adjusting O
for O
age O
. O

Significant O
positive O
correlations O
between O
DHEA B
- I
S I
and O
free O
fatty O
acids O
levels O
were O
found O
after O
adjusting O
for O
age O
and O
BMI O
, O
particularly O
in O
boys O
, O
but O
not O
between O
DHEA B
- I
S I
levels O
and O
insulin O
or O
HOMA O
in O
either O
gender O
. O

DHEA B
- I
S I
levels O
in O
12 O
- O
16 O
- O
year O
- O
old O
children O
are O
correlated O
with O
weight O
and O
BMI O
independently O
of O
age O
. O

We O
failed O
to O
find O
any O
association O
between O
DHEA B
- I
S I
and O
insulin O
levels O
, O
but O
we O
did O
find O
a O
- O
significant O
correlation O
between O
DHEA B
- I
S I
and O
free O
fatty O
acids O
levels O
, O
suggesting O
that O
its O
association O
with O
free O
fatty O
acids O
may O
be O
related O
to O
the O
onset O
of O
the O
association O
of O
DHEA B
- I
S I
with O
insulin O
resi O
- O
stance O
. O

Dammarane B
- O
type O
saponins B
from O
heat O
- O
processed O
Gynostemma O
pentaphyllum O
show O
fortified O
activity O
against O
A549 O
cells O
. O

An O
ethanol B
extract O
from O
heat O
- O
processed O
Gynostemma O
pentaphyllum O
showed O
more O
potent O
cytotoxic O
activity O
against O
human O
lung O
adenocarcinoma O
A549 O
cells O
than O
that O
of O
raw O
G O
. O
pentaphyllum O
. O

Four O
constituents O
were O
isolated O
from O
heat O
- O
processed O
G O
. O
pentaphyllum O
using O
resin O
HP O
- O
20 O
, O
silica B
gel I
and O
reversed O
ODS O
column O
chromatography O
. O

To O
evaluate O
the O
efficacy O
of O
these O
four O
constituents O
, O
the O
MTT B
cytotoxicity O
assay O
was O
performed O
using O
A549 O
cells O
. O

Based O
on O
the O
structure O
of O
these O
four O
constituents O
, O
the O
results O
indicate O
that O
the O
hydroxyl B
group O
in O
C O
- O
2 O
and O
double O
bond O
in O
C20 O
( O
21 O
) O
and O
C20 O
( O
22 O
) O
positions O
are O
of O
importance O
in O
inhibition O
of O
A549 O
cell O
proliferation O
. O

The O
known O
compounds O
, O
ursolic B
acid I
( O
7 O
) O
and O
5 O
, O
7 O
, O
4 O
' O
- O
trimethoxyflavone O
( O
14 O
) O
, O
exhibited O
weak O
cytotoxic O
activity O
against O
some O
cells O
. O

Free O
radical O
reactions O
in O
two O
dimensions O
: O
a O
case O
study O
on O
photochlorination O
of O
graphene B
. O

Graphene B
, O
a O
two O
- O
dimensional O
giant O
- O
molecule O
of O
sp O
( O
2 O
) O
- O
bonded O
carbon B
atoms O
, O
provides O
a O
perfect O
platform O
for O
studying O
free O
radical O
reaction O
chemistry O
in O
two O
- O
dimensions O
, O
which O
holds O
promise O
to O
control O
the O
chemical O
functionality O
of O
graphene B
. O

Free O
- O
radical O
photochlorination O
of O
graphene B
is O
used O
as O
an O
example O
to O
investigate O
the O
thickness O
, O
stacking O
order O
, O
and O
single O
- O
and O
double O
- O
side O
dependent O
reactivity O
in O
graphene B
. O

Anomalously O
low O
reactivity O
is O
observed O
in O
the O
photochlorination O
of O
AB O
- O
stacked O
bilayer O
graphene B
in O
comparison O
with O
that O
of O
few O
- O
layer O
graphene B
. O

Double O
- O
sided O
chlorination O
of O
graphene B
shows O
higher O
reactivity O
and O
chlorine B
coverage O
than O
single O
- O
sided O
reaction O
. O

It O
is O
also O
experimentally O
and O
theoretically O
demonstrated O
that O
chlorine B
free O
radicals O
at O
low O
coverage O
prefer O
to O
form O
a O
stable O
charge O
- O
transfer O
complex O
with O
graphene B
, O
which O
highly O
enhances O
graphene B
' O
s O
conductivity O
and O
simultaneously O
generates O
a O
pseudo O
- O
bandgap O
through O
noninvasive O
doping O
. O

Moreover O
, O
the O
initial O
accumulation O
of O
chlorine B
radicals O
is O
considered O
as O
the O
rate O
- O
determining O
step O
of O
photochlorination O
of O
graphene B
. O

In O
the O
presence O
of O
substrate O
analogs O
, O
the O
E O
. O
coli O
IspF O
- O
MEP B
complex O
shows O
activities O
distinct O
from O
IspF O
, O
and O
bisphosphonates B
( O
BP O
) O
behave O
differently O
than O
their O
diphosphate O
( O
DP O
) O
counterparts O
. O

Bisphosphonate B
analogs O
activate O
and O
/ O
or O
stabilize O
IspF O
, O
and O
only O
the O
closest O
structural O
substrate O
analog O
weakly O
inhibits O
the O
IspF O
- O
MEP B
complex O
. O

Scopoletin B
and O
Scopolin B
Isolated O
from O
Artemisia O
iwayomogi O
Suppress O
Differentiation O
of O
Osteoclastic O
Macrophage O
RAW O
264 O
. O
7 O
Cells O
by O
Scavenging O
Reactive O
Oxygen B
Species O
. O

Scopoletin B
( O
1 O
) O
and O
scopolin B
( O
2 O
) O
were O
isolated O
from O
this O
species O
. O

Scopoletin B
( O
1 O
) O
showed O
more O
potent O
peroxyl B
radical O
- O
scavenging O
capacity O
, O
reducing O
capacity O
, O
and O
cellular O
antioxidant O
capacity O
compared O
to O
scopolin B
( O
2 O
) O
. O

The O
production O
of O
general O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
superoxide B
anions O
during O
differentiation O
of O
preosteoclastic O
RAW O
264 O
. O
7 O
cells O
into O
osteoclasts O
was O
attenuated O
by O
compounds O
1 O
and O
2 O
. O

Acoustic O
properties O
of O
three O
( O
1 O
- O
ethyl O
- O
, O
1 B
- I
butyl I
- O
, O
and O
1 O
- O
octyl O
- O
) O
1 O
- O
alkyl O
- O
3 O
- O
methylimidazolium O
bis O
[ O
( O
trifluoromethyl O
) O
sulfonyl O
] O
imide O
room O
- O
temperature O
ionic O
liquids O
are O
reported O
and O
discussed O
. O

The O
ETTAG O
was O
histologically O
indistinguishable O
from O
normal O
orthotopic O
thyroid O
tissue O
, O
and O
its O
follicular O
nature O
was O
confirmed O
by O
immunohistochemical O
positivity O
for O
thyroglobulin O
, O
thyroperoxidase O
, O
thyroid O
transcription O
factor O
- O
1 O
( O
TTF O
- O
1 O
/ O
Titf O
- O
1 O
/ O
Nkx2 O
. O
1 O
) O
, O
cytokeratin O
( O
CK O
) O
AE1 O
/ O
AE3 O
, O
CK O
7 O
, O
pendrin O
, O
human O
sodium B
iodide I
symporter O
( O
hNIS O
) O
, O
paired O
box O
gene O

Dendrimer O
Driven O
Self O
- O
Assembly O
of O
SPR O
Active O
Silver B
- O
Gold O
Nanohybrids O
. O

A O
fourth O
generation O
PAMAM B
dendrimer O
has O
been O
successfully O
employed O
for O
the O
development O
of O
a O
single O
step O
synthesis O
strategy O
for O
self O
- O
assembled O
Ag B
- O
Au B
nanohybrid O
structures O
. O

Insight O
into O
the O
Aqua O
- O
Hydroxo O
< O
- O
- O
> O
Hydroxyl B
Equilibrium O
: O
A O
Combined O
Experimental O
and O
Theoretical O
Study O
. O

A O
metal O
- O
organic O
framework O
( O
MOF O
) O
bearing O
the O
aqua O
- O
hydroxo O
species O
( O
O2H3 O
) O
( O
- O
) O
in O
the O
framework O
, O
as O
well O
as O
the O
processes O
that O
govern O
the O
equilibrium O
aqua O
- O
hydroxo O
( O
O2H3 O
) O
( O
- O
) O
< O
- O
- O
> O
hydroxyl B
( O
OH B
) O
in O
Sc O
- O
MOFs O
, O
are O
studied O
experimentally O
and O
theoretically O
. O

Additionally O
, O
a O
third O
compound O
that O
appears O
at O
pH O
between O
3 O
. O
5 O
and O
4 O
, O
[ O
Sc3 O
( O
3 O
, O
5 O
- O
DSB O
) O
( O
mu O
- O
OH O
) O
6 O
( O
H2O O
) O
] O
and O
a O
fourth O
, O
[ O
Sc O
( O
3 O
, O
5 O
- O
DSB O
) O
( O
Phen O
) O
( O
H2O O
) O
] O
( O
H2O O
) O
, O
in O
whose O
formula O
neither O
OH B
groups O
nor O
H3O2 O
( O
- O
) O
anions O
appear O
, O
are O
reported O
for O
comparative O
purposes O
. O

A O
study O
of O
the O
( O
O2H3 O
) O
Sc O
- O
MOF O
electronic O
structure O
, O
and O
some O
heterogeneous O
catalytic O
tests O
in O
cyanosilylation O
of O
aldehydes B
reactions O
, O
are O
also O
reported O
. O

Identification O
of O
benzofurano O
[ O
3 O
, O
2 O
- O
d O
] O
pyrimidin O
- O
2 O
- O
ones O
, O
a O
new O
series O
of O
HIV O
- O
1 O
nucleotide B
- O
competing O
reverse O
transcriptase O
inhibitors O
. O

Screening O
of O
our O
sample O
collection O
led O
to O
the O
identification O
of O
a O
set O
of O
benzofurano O
[ O
3 O
, O
2 O
- O
d O
] O
pyrimidine O
- O
2 O
- O
one O
hits O
acting O
as O
nucleotide B
- O
competing O
HIV O
- O
1 O
reverse O
transcriptase O
inhibitiors O
( O
NcRTI O
) O
. O

High O
density O
lipoprotein O
as O
a O
source O
of O
cholesterol B
for O
adrenal O
steroidogenesis O
: O
a O
study O
in O
individuals O
with O
low O
plasma O
HDL O
- O
C O
. O

Few O
studies O
have O
addressed O
the O
delivery O
of O
lipoprotein O
- O
derived O
cholesterol B
to O
the O
adrenals O
for O
steroid B
production O
in O
humans O
. O

To O
study O
this O
, O
steroid O
hormone O
profiles O
in O
urine O
were O
assessed O
in O
male O
subjects O
suffering O
from O
functional O
mutations O
in O
ATP B
binding O
cassette O
transporter O
A1 O
( O
ABCA1 O
) O
( O
n O
= O
24 O
) O
, O
lecithin O
: O
cholesterol B
acyltransferase O
( O
LCAT O
) O
( O
n O
= O
40 O
) O
, O
as O
well O
as O
in O
11 O
subjects O
with O
low O
HDL O
cholesterol B
( O
HDL O
- O
C O
) O
without O
ABCA1 O
/ O
LCAT O
mutations O
. O

These O
findings O
lend O
support O
to O
a O
role O
for O
HDL O
as O
a O
cholesterol B
donor O
for O
basal O
adrenal O
steroidogenesis O
in O
humans O
. O

Redox O
- O
and O
pH O
- O
Responsive O
Cysteamine B
- O
Modified O
Poly B
( I
aspartic I
acid I
) I
Showing O
a O
Reversible O
Sol O
- O
Gel O
Transition O
. O

Synthesis O
and O
characterization O
of O
a O
pH O
- O
and O
redox O
- O
sensitive O
hydrogel O
of O
poly B
( I
aspartic I
acid I
) I
are O
reported O
. O

Reduction O
- O
facilitated O
release O
of O
an O
entrapped O
drug O
from O
disulphide B
cross O
- O
linked O
hydrogels O
is O
studied O
. O

A O
study O
of O
secondary O
metabolites O
from O
the O
bark O
of O
Alnus O
glutinosa O
led O
to O
the O
isolation O
of O
fourteen O
diarylheptanoids O
: O
oregonin O
( O
1 O
) O
, O
platyphylloside O
( O
2 O
) O
, O
rubranoside O
A O
( O
3 O
) O
, O
rubranoside O
B O
( O
4 O
) O
, O
hirsutanonol O
( O
5 O
) O
, O
hirsutenone B
( O
6 O
) O
, O
hirsutanonol O
- O
5 O
- O
O O
- O
beta O
- O
D O
- O
glucopyranoside O
( O
7 O
) O
, O
platyphyllonol O
- O
5 O
- O
O O
- O
beta O
- O
D O
- O
xylopyranoside O
( O
8 O

Edge O
- O
to O
- O
Edge O
Assembled O
Graphene B
Oxide I
Aerogels O
with O
Outstanding O
Mechanical O
Performance O
and O
Superhigh O
Chemical O
Activity O
. O

Herein O
, O
chemically O
crosslinked O
graphene B
oxide I
( O
GO O
) O
3D O
aerogels O
with O
large O
specific O
surface O
areas O
( O
up O
to O
850 O
m O
( O
2 O
) O
g O
( O
- O
1 O
) O
) O
, O
outstanding O
mechanical O
performance O
( O
up O
to O
20 O
MPa O
Young O
' O
s O
modulus O
, O
1 O
MPa O
yield O
strength O
and O
45 O
J O
g O
( O
- O
1 O
) O
specific O
energy O
adsorption O
) O
, O
and O
superhigh O
chemical O
activity O
( O
toward O
some O
reducing O
gases O
such O
as O
H2 O
S O
, O
HI O
, O
and O
SO2 B
) O
, O
are O
fabricated O
by O
assembling O
2D O
GO O
sheets O
edge O
- O
to O
- O
edge O
into O
uniform O
, O
3D O
hydrogel O
networks O
with O
subsequent O

These O
aerogels O
are O
superior O
to O
other O
3D O
frameworks O
( O
e O
. O
g O
. O
graphene B
aerogels O
) O
assembled O
via O
partial O
overlapping O
of O
the O
basal O
planes O
of O
the O
2D O
building O
blocks O
. O

Mastoid O
Obliteration O
Using O
Three O
- O
Dimensional O
Composite O
Scaffolds O
Consisting O
of O
Polycaprolactone B
/ O
beta O
- O
Tricalcium O
Phosphate O
/ O
Collagen O
Nanofibers O
: O
An O
In O
Vitro O
and O
In O
Vivo O
Study O
. O

Two O
different O
composite O
scaffolds O
, O
solid O
- O
freeform O
- O
fabricated O
PCL B
/ O
beta O
- O
TCP O
supplemented O
with O
and O
without O
collagen O
nanofibers O
are O
fabricated O
. O

These O
scaffolds O
are O
evaluated O
whether O
a O
combination O
of O
collagen O
nanofibers O
with O
PCL B
/ O
beta O
- O
TCP O
can O
promote O
osteogenesis O
in O
a O
mastoid O
obliteration O
. O

To O
assess O
the O
effects O
of O
the O
cellular O
activities O
of O
osteoblast O
- O
like O
- O
cells O
( O
MG63 O
) O
, O
SEM O
images O
and O
MTT B
assays O
are O
conducted O
. O

Experimental O
mastoid O
obliteration O
is O
performed O
using O
guinea O
pigs O
that O
are O
divided O
group O
A O
( O
PCL B
/ O
beta O
- O
TCP O
/ O
collagen O
- O
nanofiber O
scaffold O
) O
and O
group O
B O
( O
PCL B
/ O
beta O
- O
TCP O
scaffold O
) O
. O

The O
results O
reveal O
that O
PCL B
/ O
beta O
- O
TCP O
/ O
collagen O
scaffold O
provide O
much O
broader O
cell O
attachment O
sites O
than O
PCL B
/ O
beta O
- O
TCP O
scaffold O
. O

In O
addition O
, O
based O
on O
the O
results O
of O
the O
histological O
and O
micro O
- O
CT O
at O
12 O
weeks O
post O
- O
surgery O
, O
the O
effective O
regeneration O
of O
bone O
in O
the O
PCL B
/ O
beta O
- O
TCP O
/ O
collagen O
scaffold O
is O
appeared O
. O

One O
indirect O
pathway O
for O
the O
treatment O
of O
epilepsy O
includes O
the O
inhibition O
of O
carbonic O
anhydrase O
( O
CA O
) O
, O
thereby O
increasing O
CO2 B
levels O
in O
the O
brain O
. O

Areas O
covered O
: O
Carbonic O
anhydrases O
( O
EC O
4 O
. O
2 O
. O
1 O
. O
1 O
) O
are O
ubiquitous O
metalloenzymes O
that O
catalyze O
the O
reversible O
hydration O
/ O
dehydration O
of O
CO2 B
/ O
HCO3 O
( O
- O
) O
, O
respectively O
. O

CA O
inhibitors O
( O
CAIs O
) O
such O
as O
acetazolamide O
, O
methazolamide O
, O
topiramate B
, O
zonisamide B
, O
and O
sulthiame O
can O
reduce O
seizures O
through O
perturbation O
of O
the O
CO2 B
equilibrium O
and O
/ O
or O
the O
inhibition O
of O
ion O
channels O
. O

Serotonin B
- O
kynurenine O
hypothesis O
of O
depression O
: O
historical O
overview O
and O
recent O
developments O
. O

IP O
Lapin O
( O
1903 O
- O
2012 O
) O
and O
his O
research O
team O
on O
the O
role O
of O
methoxyindole O
and O
kynurenine O
( O
KYN O
) O
pathways O
of O
tryptophan B
( O
TRP B
) O
metabolism O
in O
the O
pathogenesis O
of O
depression O
and O
action O
mechanisms O
of O
antidepressant O
effect O
. O

The O
cause O
of O
serotonin B
deficiency O
in O
depression O
was O
attributed O
to O
the O
shunt O
of O
TRP B
" O
metabolism O
away O
from O
serotonin B
production O
towards O
KYN O
production O
" O
due O
to O
cortisol B
- O
induced O
activation O
of O
liver O
enzyme O
, O
tryptophan B
2 O
, O
3 O
- O
dioxygenase O
, O
the O
rate O
- O
limiting O
enzyme O
of O
TRP B
- O
KYN O
pathway O
. O

Further O
research O
suggested O
the O
antidepressant O
and O
cognition O
- O
enhancing O
effects O
of O
post O
- O
serotonin B
metabolite O
, O
N O
- O
acetylserotonin O
( O
NAS O
) O
, O
an O
agonist O
to O
tyrosine B
kinase O
B O
( O
TrkB O
) O
receptor O
; O
and O
link O
between O
depression O
and O
chronic O
inflammation O
- O
associated O
disorders O
( O
e O
. O
g O
. O
, O
insulin O
resistance O
, O
hepatitis O
C O
virus O
) O
via O
inflammation O
- O
induced O
activation O
of O
indoleamine B
2 O
, O
3 O
- O
dioxygenase O
, O
brain O
located O
rate O
- O
limiting O
enzyme O
of O
TRY O
- O
KYN O
metabolism O
. O

Insulin O
- O
Like O
Growth O
Factor O
Binding O
Protein O
2 O
( O
IGFBP O
- O
2 O
) O
Promotes O
Growth O
and O
Survival O
of O
Breast O
Epithelial O
Cells O
: O
Novel O
Regulation O
of O
the O
Estrogen B
Receptor O
. O

This O
was O
dependent O
on O
a O
functional O
estrogen B
receptor O
( O
ER O
) O
- O
alpha O
because O
silencing O
ER O
- O
alpha O
blocked O
the O
ability O
of O
IGFBP O
- O
2 O
to O
confer O
cell O
survival O
. O

Silencing O
IGFBP O
- O
2 O
had O
no O
effect O
on O
the O
response O
to O
IGF O
- O
II O
, O
but O
responses O
to O
estrogen B
and O
tamoxifen B
were O
no O
longer O
observed O
due O
to O
loss O
of O
ER O
- O
alpha O
, O
which O
could O
be O
prevented O
by O
the O
inhibition O
of O
PTEN O
. O

These O
actions O
of O
IGFBP O
- O
2 O
on O
ER O
- O
alpha O
involved O
the O
IGF O
- O
I O
receptor O
and O
activation O
of O
phosphatidylinositol B
3 O
- O
kinase O
in O
the O
cancer O
cells O
but O
were O
independent O
of O
this O
in O
normal O
breast O
cells O
. O

Involvement O
of O
serotonin B
mechanism O
in O
methamphetamine B
- O
induced O
chronic O
pulmonary O
toxicity O
in O
rats O
. O

The O
widest O
distribution O
and O
the O
highest O
uptake O
of O
methamphetamine B
( O
MA O
) O
in O
the O
human O
body O
occurred O
in O
the O
lungs O
, O
so O
that O
more O
and O
more O
attention O
should O
be O
paid O
to O
MA O
- O
induced O
pulmonary O
toxicity O
. O

MA O
induces O
the O
release O
of O
serotonin B
, O
which O
is O
an O
important O
mediator O
in O
pulmonary O
disease O
. O

In O
addition O
, O
MA O
resulted O
in O
a O
significant O
increase O
in O
the O
lung O
serotonin B
concentration O
and O
the O
marked O
upregulation O
of O
tryptophan B
hydroxylase O
1 O
, O
vesicular O
monoamine O
transporter O
2 O
, O
serotonin B
transporter O
, O
and O
downregulation O
of O
monoamine B
oxidase O
- O
A O
. O

These O
findings O
suggest O
that O
MA O
induced O
chronic O
pulmonary O
toxicity O
, O
which O
is O
concerned O
with O
the O
elevated O
serotonin B
concentration O
in O
rat O
lungs O
by O
increased O
synthesis O
, O
reduced O
metabolism O
, O
augmented O
accumulation O
, O
and O
promoted O
release O
of O
serotonin B
. O

We O
aimed O
to O
find O
the O
relationship O
between O
serum O
transforming O
growth O
factor O
beta O
1 O
( O
TGF O
- O
beta O
1 O
) O
and O
urinary O
monocyte O
chemoattractant O
protein O
- O
1 O
( O
MCP O
- O
1 O
) O
throughout O
the O
course O
of O
diabetic O
nephropathy O
( O
DN O
) O
and O
to O
assess O
the O
relationship O
between O
both O
levels O
and O
other O
parameters O
of O
renal O
injury O
such O
as O
albumin O
/ O
creatinine B
ratio O
and O
estimated O
glomerular O
filtration O
rate O
( O
eGFR O
) O
. O

Both O
the O
levels O
of O
serum O
TGF O
- O
beta O
1 O
and O
urinary O
MCP O
- O
1 O
were O
significantly O
higher O
in O
patients O
with O
micro O
- O
and O
macroalbuminuria O
( O
137 O
. O
8 O
+ O
/ O
- O
69 O
. O
5 O
and O
329 O
. O
25 O
+ O
/ O
- O
41 O
. O
46 O
ng O
/ O
dl O
, O
respectively O
, O
for O
TGF O
- O
beta O
1 O
and O
167 O
. O
41 O
+ O
/ O
- O
50 O
. O
23 O
and O
630 O
. O
87 O
+ O
/ O
- O
318 O
. O
10 O
ng O
/ O
g O
creatinine B
, O
respectively O
, O
for O
MCP O
- O
1 O
) O
compared O
with O
normoalbuminuric O
patients O
and O
healthy O
controls O
( O
33 O
. O
25 O
+ O
/ O
- O

17 O
. O
5 O
and O
29 O
. O
64 O
+ O
/ O
- O
10 O
. O
57 O
ng O
/ O
dl O
, O
respectively O
, O
for O
TGF O
- O
beta O
1 O
and O
63 O
. O
85 O
+ O
/ O
- O
21 O
. O
15 O
and O
61 O
. O
50 O
+ O
/ O
- O
24 O
. O
81 O
ng O
/ O
g O
creatinine B
, O
respectively O
, O
for O
MCP O
- O
1 O
; O
p O
< O
0 O
. O
001 O
) O
. O

Efficacy O
of O
D O
- O
penicillamine O
, O
a O
sequestering O
acetaldehyde B
agent O
, O
in O
the O
prevention O
of O
alcohol B
relapse O
- O
like O
drinking O
in O
rats O
. O

An O
exciting O
rationale O
drug O
development O
opportunity O
for O
the O
treatment O
of O
chronic O
alcoholism O
is O
the O
use O
of O
acetaldehyde B
sequestering O
agents O
. O

Although O
these O
compounds O
are O
able O
to O
attenuate O
or O
prevent O
most O
of O
the O
behavioral O
and O
neurochemical O
effects O
of O
ethanol B
, O
the O
efficacy O
of O
acetaldehyde B
sequestration O
, O
by O
using O
agents O
such O
as O
D O
- O
penicillamine O
( O
DP O
) O
, O
in O
relapse O
prevention O
has O
not O
been O
studied O
yet O
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
effects O
of O
DP O
treatment O
on O
the O
alcohol B
deprivation O
effect O
( O
ADE O
) O
in O
long O
- O
term O
ethanol B
- O
experienced O
rats O
as O
a O
model O
of O
relapse O
behavior O
and O
measure O
drug O
plasma O
and O
brain O
levels O
during O
treatment O
. O

RESULTS O
: O
One O
milligram O
per O
hour O
, O
but O
not O
0 O
. O
25 O
mg O
/ O
h O
, O
DP O
infusion O
prevented O
ADE O
and O
reduced O
the O
total O
ethanol B
preference O
in O
animals O
. O

CONCLUSION O
: O
DP O
is O
able O
to O
prevent O
alcohol B
- O
relapse O
- O
like O
drinking O
in O
rats O
suggesting O
that O
this O
drug O
may O
be O
a O
useful O
new O
tool O
in O
the O
management O
of O
relapse O
in O
alcohol B
- O
dependent O
patients O
. O

Sublethal O
silver B
and O
NaCl B
toxicity O
in O
Daphnia O
magna O
: O
a O
comparative O
study O
of O
standardized O
chronic O
endpoints O
and O
progeny O
phototaxis O
. O

D O
. O
magna O
21 O
day O
studies O
were O
conducted O
with O
model O
stressors O
of O
sodium B
chloride I
and O
dissolved O
silver B
. O

Significant O
differences O
in O
neonate O
phototactic O
behavior O
were O
observed O
among O
treatment O
level O
broods O
, O
suggesting O
that O
maternal O
exposure O
to O
sublethal O
levels O
of O
NaCl B
and O
Ag B
+ I
impacted O
offspring O
. O

In O
fact O
, O
progeny O
phototactic O
response O
was O
significantly O
affected O
at O
or O
below O
21 O
- O
day O
LOEC O
thresholds O
for O
fecundity O
in O
broods O
2 O
, O
3 O
, O
5 O
and O
6 O
of O
the O
NaCl B
experiment O
and O
in O
broods O
2 O
, O
4 O
, O
5 O
and O
6 O
of O
the O
dissolved O
Ag B
+ I
study O
. O

Activation O
of O
PTH1R O
promotes O
regulation O
of O
multiple O
signaling O
pathways O
, O
including O
Gs O
/ O
cAMP B
/ O
PKA O
, O
Gq O
/ O
calcium B
/ O
PKC O
, O
beta O
- O
arrestin O
recruitment O
and O
ERK1 O
/ O
2 O
phosphorylation O
as O
well O
as O
receptor O
internalization O
but O
their O
role O
in O
promoting O
anabolic O
and O
catabolic O
actions O
of O
PTH O
( O
1 O
- O
34 O
) O
are O
unclear O
. O

Results O
indicate O
that O
both O
N B
- O
and O
C B
- O
terminal O
domains O
are O
critical O
for O
activation O
of O
signaling O
pathways O
. O

The O
substantial O
contribution O
of O
the O
peptide O
C B
- O
terminal O
domain O
in O
activation O
of O
hPTH1R O
- O
signaling O
suggests O
a O
role O
in O
positioning O
of O
the O
peptide O
N B
- O
terminal O
region O
into O
the O
receptor O
J O
- O
domain O
. O

The O
structure O
- O
activity O
relationships O
showed O
that O
a O
leucinol O
moiety O
attached O
to O
the O
core O
- O
structure O
in O
the O
7 O
- O
position O
together O
with O
alpha O
- O
methyl O
branched O
benzyl B
derivatives O
in O
the O
5 O
- O
position O
displayed O
promising O
affinity O
, O
and O
selectivity O
as O
well O
as O
physicochemical O
properties O
, O
as O
exemplified O
by O
compounds O
18a O
and O
24h O
. O

Ultrafast O
Spectroscopy O
of O
Quantum O
Confined O
States O
in O
a O
Single O
CdSe B
Nanowire O
. O

We O
measure O
for O
the O
first O
time O
transient O
absorption O
spectra O
of O
individual O
CdSe B
nanowires O
with O
about O
10 O
nm O
diameter O
. O

These O
findings O
might O
explain O
the O
low O
overall O
quantum O
efficiency O
of O
CdSe B
nanowires O
. O

1 O
, O
4 O
, O
2 O
- O
Benzo O
/ O
pyridodithiazine O
1 O
, O
1 O
- O
Dioxides O
Structurally O
Related O
to O
the O
ATP B
- O
Sensitive O
Potassium B
Channel O
Openers O
1 O
, O
2 O
, O
4 O
- O
Benzo O
/ O
pyridothiadiazine O
1 O
, O
1 O
- O
Dioxides O
Exert O
a O
Myorelaxant O
Activity O
Linked O
to O
a O
Distinct O
Mechanism O
of O
Action O
. O

Their O
biological O
activities O
on O
pancreatic O
beta O
- O
cells O
and O
on O
smooth O
muscle O
cells O
were O
compared O
to O
those O
of O
the O
reference O
ATP B
- O
sensitive O
potassium B
channel O
( O
KATP O
channel O
) O
openers O
diazoxide B
and O
7 O
- O
chloro O
- O
3 O
- O
isopropylamino O
- O
4H O
- O
1 O
, O
2 O
, O
4 O
- O
benzothiadiazine O
1 O
, O
1 O
- O
dioxide O
. O

Such O
an O
effect O
did O
not O
appear O
to O
be O
related O
to O
the O
opening O
of O
KATP O
channels O
but O
rather O
reflected O
a O
mechanism O
of O
action O
similar O
to O
that O
of O
calcium B
channel O
blockers O
. O

Tightly O
related O
3 O
- O
( O
1 O
- O
phenylethyl O
) O
sulfanyl O
- O
4H O
- O
1 O
, O
2 O
, O
4 O
- O
benzothiadiazine O
1 O
, O
1 O
- O
dioxides O
were O
also O
found O
to O
exert O
a O
pronounced O
myorelaxant O
activity O
, O
resulting O
from O
both O
a O
KATP O
channel O
activation O
and O
a O
calcium B
channel O
blocker O
mechanism O
. O

The O
present O
work O
highlights O
the O
critical O
importance O
of O
an O
intracyclic O
NH B
group O
at O
the O
4 O
- O
position O
, O
as O
well O
as O
an O
exocyclic O
NH B
group O
linked O
to O
the O
3 O
- O
position O
of O
the O
benzo O
- O
and O
pyridothiadiazine O
dioxides O
, O
for O
activity O
on O
KATP O
channels O
. O

An O
efficient O
protocol O
for O
synthesis O
of O
3 O
, O
3 O
' O
- O
diindolylmethanes O
using O
recyclable O
Fe B
- O
pillared O
interlayered O
clay O
( O
Fe B
- O
PILC O
) O
catalyst O
under O
aqueous O
medium O
has O
been O
developed O
. O

A O
new O
type O
of O
azaphenothiazines O
- O
tetracyclic O
quino O
[ O
3 O
, O
2 O
- O
b O
] O
benzo O
[ O
1 O
, O
4 O
] O
thiazines O
, O
possessing O
common O
substituents O
( O
H B
, O
CH3 B
, O
Cl B
, O
Br B
, O
F B
, O
CF3 B
, O
SCH3 O
) O
in O
positions O
8 O
- O
10 O
and O
pharmacophoric O
aminoalkyl O
substituents O
in O
position O
6 O
, O
were O
obtained O
from O
diquinodithiin O
and O
2 O
, O
2 O
' O
- O
dichloro O
- O
3 O
, O
3 O
' O
- O
diquinolinyl O
disulfide O
in O

The O
most O
active O
compounds O
exhibited O
anticancer O
activity O
against O
these O
cell O
lines O
comparable O
to O
that O
of O
cisplatin B
. O

Fisetin B
regulates O
obesity O
by O
targeting O
mTORC1 O
signaling O
. O

Fisetin B
, O
a O
flavonol B
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti O
- O
inflammatory O
properties O
. O

In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin B
prevents O
diet O
- O
induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin B
complex O
1 O
( O
mTORC1 O
) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O

To O
evaluate O
whether O
fisetin B
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70 O
- O
kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
( O
S6K1 O
) O
and O
mTORC1 O
in O
3T3 O
- O
L1 O
preadipocytes O
. O

Fisetin B
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time O
- O
and O
concentration O
- O
dependent O
manner O
. O

To O
further O
our O
understanding O
of O
how O
fisetin B
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin B
- O
treated O
TSC2 O
- O
knockdown O
cells O
. O

The O
results O
suggested O
that O
fisetin B
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt O
- O
dependent O
manner O
. O

Fisetin B
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin B
on O
mTOR O
. O

The O
inhibitory O
effect O
of O
fisetin B
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin B
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides B
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O

Fisetin B
supplementation O
in O
mice O
fed O
a O
high O
- O
fat O
diet O
( O
HFD O
) O
significantly O
attenuated O
HFD O
- O
induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O

We O
also O
observed O
that O
fisetin B
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O

Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin B
prevents O
adipocyte O
differentiation O
of O
3T3 O
- O
L1 O
preadipocytes O
and O
obesity O
in O
HFD O
- O
fed O
mice O
. O

Therefore O
, O
fisetin B
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet O
- O
induced O
obesity O
. O

Structural O
elucidation O
of O
possible O
lutein B
oxidation O
products O
mediated O
through O
peroxyl B
radical O
inducer O
2 O
, O
2 O
' O
- O
Azobis O
( O
2 O
- O
methylpropionamidine O
) O
dihydrochloride O
: O
Antioxidant O
and O
cytotoxic O
influence O
of O
oxidized O
lutein B
in O
HeLa O
cells O
. O

Aim O
of O
this O
study O
was O
to O
elucidate O
lutein B
oxidation O
products O
mediated O
through O
peroxyl B
radical O
inducer O
2 O
, O
2 O
' O
- O
Azobis O
( O
2 O
- O
methylpropionamidine O
) O
dihydrochloride O
( O
AAPH B
) O
and O
to O
study O
antioxidant O
and O
cytotoxic O
effects O
of O
oxidized O
lutein O
using O
liposome O
and O
HeLa O
cells O
. O

Lutein B
( O
20 O
mu O
mol O
) O
with O
AAPH B
( O
5mM O
) O
in O
liposome O
' O
s O
was O
incubated O
at O
37 O
degrees O
C O
in O
dark O
for O
3h O
, O
oxidized O
lutein O
products O
were O
characterized O
by O
LC O
- O
MS O
( O
APCI O
( O
+ O
) O
) O
and O
studied O
for O
their O
free O
radical O
scavenging O
activity O
and O
cytotoxic O
effects O
in O
terms O
of O
cell O
viability O
, O
cellular O
glutathione B
, O
and O
malondialdehyde B
levels O
. O

AAPH B
mediated O
lutein B
fragmented O
ions O
were O
identified O
as O
551 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
- O
H2O B
) O
, O
391 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 O
- O
C22H32O O
) O
and O
276 O
( O
M O
( O
+ O
) O
+ O
H B
( I
+ I
) I
+ O
O2 O
- O
C12H20O O
) O
and O
its O
isomers O
as O
13 O
- O
Z O
lutein O
, O
13 O
- O
Z O
zeaxanthin O
, O
13 O
' O
- O
Z O
zeaxanthin O
and O
all O
- O
E O
zeaxanthin O
. O

Free O
radical O
scavenging O
activity O
of O
oxidized O
lutein O
was O
higher O
by O
32 O
. O
7 O
% O
( O
IC50 O
, O
2 O
. O
64 O
mu O
g O
) O
than O
lutein B
( O
IC50 O
, O
5 O
. O
28 O
mu O
g O
) O
. O

Oxidized O
lutein O
lowered O
the O
lipid O
peroxidation O
( O
21 O
% O
) O
, O
HeLa O
cells O
viability O
( O
22 O
% O
) O
and O
glutathione B
levels O
( O
32 O
% O
) O
than O
lutein B
. O

To O
conclude O
, O
the O
oxidized O
lutein O
may O
be O
highly O
reactive O
, O
since O
oxidation O
by O
AAPH B
results O
in O
peroxyl B
radical O
ions O
, O
which O
can O
react O
with O
conjugated O
polyene B
chain O
of O
lutein B
that O
could O
lead O
to O
higher O
antioxidant O
and O
cytotoxic O
effects O
on O
HeLa O
cells O
. O

Neuroprotective O
effect O
of O
sulforaphane B
in O
6 B
- I
hydroxydopamine I
- O
lesioned O
mouse O
model O
of O
Parkinson O
' O
s O
disease O
. O

Sulforaphane B
( O
SFN B
) O
, O
found O
in O
cruciferous O
vegetables O
, O
is O
a O
potent O
indirect O
antioxidant O
and O
recent O
advances O
have O
shown O
its O
neuroprotective O
activity O
in O
various O
experimental O
models O
of O
neurodegeneration O
. O

This O
study O
was O
undertaken O
to O
examine O
the O
effects O
of O
SFN B
on O
behavioral O
changes O
and O
dopaminergic O
neurotoxicity O
in O
mice O
exposed O
to O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
. O

For O
this O
purpose O
, O
mice O
were O
treated O
with O
SFN B
( O
5mg O
/ O
kg O
twice O
a O
week O
) O
for O
four O
weeks O
after O
the O
unilateral O
intrastriatal O
injection O
of O
6 B
- I
OHDA I
. O

The O
increase O
in O
6 B
- I
OHDA I
- O
induced O
rotations O
and O
deficits O
in O
motor O
coordination O
were O
ameliorated O
significantly O
by O
SFN B
treatment O
. O

In O
addition O
, O
SFN B
protected O
6 B
- I
OHDA I
- O
induced O
apoptosis O
via O
blocking O
DNA O
fragmentation O
and O
caspase O
- O
3 O
activation O
. O

These O
results O
were O
further O
supported O
by O
immunohistochemical O
findings O
in O
the O
substantia O
nigra O
that O
showed O
that O
SFN B
protected O
neurons O
from O
neurotoxic O
effects O
of O
6 B
- I
OHDA I
. O

The O
neuroprotective O
effect O
of O
SFN B
may O
be O
attributed O
to O
its O
ability O
to O
enhance O
glutathione B
levels O
and O
its O
dependent O
enzymes O
( O
glutathione B
- O
S B
- O
transferase O
and O
glutathione B
reductase O
) O
and O
to O
modulate O
neuronal O
survival O
pathways O
, O
such O
as O
ERK1 O
/ O
2 O
, O
in O
the O
brain O
of O
mice O
. O

These O
results O
suggest O
that O
SFN B
may O
potentially O
be O
effective O
in O
slowing O
down O
the O
progression O
of O
idiopathic O
PD O
by O
the O
modulation O
of O
oxidative O
stress O
and O
apoptotic O
machinery O
. O

Oxidative O
DNA O
damage O
corresponds O
to O
the O
long O
term O
survival O
of O
human O
cells O
treated O
with O
silver B
nanoparticles O
. O

We O
examined O
the O
relation O
between O
DNA O
damage O
and O
the O
clonogenic O
potential O
of O
3 O
human O
cell O
lines O
, O
HepG2 O
, O
HT29 O
and O
A549 O
, O
treated O
with O
bare O
20nm O
or O
200nm O
silver B
nanoparticles O
( O
AgNPs O
) O
. O

The O
overall O
pattern O
of O
DNA O
breakage O
and O
base O
damage O
induction O
corresponded O
to O
the O
intracellular O
generation O
of O
reactive O
oxygen B
species O
. O

A O
total O
of O
42 O
pre O
- O
migrating O
( O
silver O
) O
female O
eels O
from O
lowly O
, O
highly O
and O
extremely O
polluted O
environments O
in O
Belgium O
and O
, O
for O
comparative O
purposes O
, O
a O
lowly O
polluted O
habitat O
in O
Italy O
were O
measured O
for O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
organochlorine B
pesticides O
( O
OCPs O
) O
and O
brominated O
flame O
retardants O
( O
BFRs O
) O
. O

First O
, O
an O
altered O
pattern O
of O
transcription O
of O
genes O
was O
associated O
with O
detoxification O
, O
with O
a O
novel O
European O
eel O
CYP3A O
gene O
and O
gluthatione O
S B
- O
transferase O
transcriptionally O
up O
- O
regulated O
. O

Second O
, O
an O
altered O
pattern O
of O
transcription O
of O
genes O
associated O
with O
the O
oxidative O
phosphorylation O
pathway O
, O
with O
the O
following O
genes O
involved O
in O
the O
generation O
of O
ATP B
being O
transcriptionally O
down O
- O
regulated O
in O
individuals O
from O
the O
highly O
polluted O
site O
: O
NADH B
dehydrogenase O
, O
succinate B
dehydrogenase O
, O
ubiquinol O
- O
cytochrome O
c O
reductase O
, O
cytochrome O
c O
oxidase O
and O
ATP B
synthase O
. O

Large O
- O
scale O
synthesis O
of O
Zn3P2 O
and O
Zn4Sb3 O
nanowire O
powders O
was O
accomplished O
using O
a O
hot O
- O
walled O
chemical O
vapor O
deposition O
chamber O
by O
transporting O
phosphorus B
and O
antimony O
, O
respectively O
, O
via O
the O
vapor O
phase O
onto O
heated O
zinc B
foils O
. O

The O
zinc B
foils O
were O
rolled O
concentrically O
into O
coils O
to O
maximize O
the O
substrate O
surface O
area O
, O
and O
consequently O
, O
the O
nanowire O
yield O
. O

Using O
this O
method O
, O
250 O
mg O
of O
Zn3P2 O
nanowires O
were O
obtained O
on O
480 O
cm O
( O
2 O
) O
of O
zinc B
foil O
in O
a O
span O
of O
45 O
minutes O
. O

Furthermore O
, O
the O
loss O
of O
survivin O
in O
regenerating O
hepatocytes O
was O
associated O
with O
reduced O
levels O
of O
phosphorylated O
Histone O
H3 O
at O
serine B
28 O
and O
abolished O
phosphorylation O
of O
CENP O
- O
A O
and O
Hec1 O
at O
serine B
55 O
, O
which O
is O
a O
consequence O
of O
decreased O
Aurora O
B O
kinase O
activity O
. O

Combinations O
of O
elisidepsin O
with O
lapatinib B
and O
several O
chemotherapies O
including O
5 B
- I
FU I
and O
oxaliplatin O
resulted O
in O
synergistic O
effects O
that O
offer O
the O
potential O
of O
clinical O
use O
of O
elisidepsin O
in O
combination O
settings O
. O

Gold O
nanoparticle O
- O
enhanced O
luminescence O
of O
silicon B
quantum O
dots O
co O
- O
encapsulated O
in O
polymer O
nanoparticles O
. O

The O
preparation O
of O
two O
- O
component O
polymer O
composite O
nanoparticles O
encapsulating O
both O
Si B
quantum O
dots O
( O
SiQDs O
) O
and O
Au B
nanoparticles O
( O
AuNPs O
) O
by O
a O
single O
step O
miniemulsion O
polymerization O
of O
divinylbenzene O
is O
described O
. O

Novel O
Phosphorylation O
and O
Ubiquitination O
Sites O
Regulate O
Reactive O
Oxygen B
Species O
- O
dependent O
Degradation O
of O
Anti O
- O
apoptotic O
c O
- O
FLIP O
Protein O
. O

The O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
has O
been O
implicated O
in O
c O
- O
FLIP O
protein O
degradation O
. O

We O
show O
here O
that O
treatment O
of O
prostate O
cancer O
PPC O
- O
1 O
cells O
with O
the O
superoxide B
generators O
menadione B
, O
paraquat B
, O
or O
buthionine B
sulfoximine I
down O
- O
regulates O
c O
- O
FLIP O
long O
( O
c O
- O
FLIPL O
) O
protein O
levels O
, O
which O
is O
prevented O
by O
the O
proteasome O
inhibitor O
MG132 B
. O

Furthermore O
, O
pretreatment O
of O
PPC O
- O
1 O
cells O
with O
a O
ROS O
scavenger O
prevented O
ubiquitination O
and O
loss O
of O
c O
- O
FLIPL O
protein O
induced O
by O
menadione B
or O
paraquat B
. O

We O
identified O
lysine B
167 O
as O
a O
novel O
ubiquitination O
site O
of O
c O
- O
FLIPL O
important O
for O
ROS O
- O
dependent O
degradation O
. O

We O
also O
identified O
threonine B
166 O
as O
a O
novel O
phosphorylation O
site O
and O
demonstrate O
that O
Thr B
- O
166 O
phosphorylation O
is O
required O
for O
ROS O
- O
induced O
Lys B
- O
167 O
ubiquitination O
. O

The O
mutation O
of O
either O
Thr B
- O
166 O
or O
Lys B
- O
167 O
was O
sufficient O
to O
stabilize O
c O
- O
FLIP O
protein O
levels O
in O
PPC O
- O
1 O
, O
HEK293T O
, O
and O
HeLa O
cancer O
cells O
treated O
with O
menadione B
or O
paraquat B
. O

Nicotine B
- O
, O
tobacco O
particulate O
matter O
- O
and O
methamphetamine B
- O
produced O
locomotor O
sensitisation O
in O
rats O
. O

RATIONALE O
: O
Repeated O
nicotine B
exposure O
produces O
a O
weak O
and O
transient O
sensitised O
locomotor O
response O
in O
rats O
. O

Since O
tobacco O
smoke O
contains O
thousands O
of O
non O
- O
nicotine B
chemical O
constituents O
, O
these O
could O
alter O
the O
sensitised O
response O
. O

OBJECTIVES O
: O
This O
study O
aims O
to O
compare O
the O
magnitude O
, O
persistence O
and O
spatial O
distribution O
of O
locomotor O
sensitisation O
produced O
by O
repeated O
doses O
of O
nicotine B
, O
aqueous O
tobacco O
particulate O
matter O
( O
TPM O
) O
and O
a O
positive O
methamphetamine B
control O
. O

METHODS O
: O
Male O
Sprague O
- O
Dawley O
rats O
received O
five O
nicotine B
( O
0 O
. O
0 O
, O
0 O
. O
2 O
or O
0 O
. O
4 O
mg O
/ O
kg O
) O
, O
TPM O
( O
containing O
0 O
. O
2 O
or O
0 O
. O
4 O
mg O
/ O
kg O
nicotine B
) O
or O
methamphetamine B
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
injections O
every O
second O
day O
, O
followed O
by O
a O
4 O
- O
day O
withdrawal O
before O
the O
first O
challenge O
( O
Challenge O
1 O
, O
C1 O
) O
. O

RESULTS O
: O
There O
were O
no O
major O
differences O
in O
sensitisation O
profile O
between O
nicotine B
and O
TPM O
. O

At O
the O
lowest O
0 O
. O
2 O
mg O
/ O
kg O
nicotine B
/ O
TPM O
dose O
, O
however O
, O
small O
differences O
emerged O
on O
select O
test O
days O
. O

CONCLUSIONS O
: O
The O
results O
indicated O
that O
the O
non O
- O
nicotinic O
agents O
in O
TPM O
did O
not O
greatly O
impact O
the O
nicotine B
- O
produced O
locomotor O
- O
sensitised O
response O
. O

Secondary O
outcome O
measures O
included O
blood O
pressure O
, O
estimated O
glomerular O
filtration O
rate O
, O
erythrocyturia O
, O
serum O
alanine B
aminotransferase O
, O
aspartate B
transaminase O
and O
electrolytes O
. O

6 B
- I
Gingerol I
Inhibits O
Rosiglitazone B
- O
Induced O
Adipogenesis O
in O
3T3 O
- O
L1 O
Adipocytes O
. O

We O
investigated O
the O
effects O
of O
6 B
- I
gingerol I
( O
( O
S O
) O
- O
5 O
- O
hydroxy O
- O
1 O
- O
( O
4 O
- O
hydroxy O
- O
3 O
- O
methoxyphenyl O
) O
- O
3 O
- O
decanone O
) O
on O
the O
inhibition O
of O
rosiglitazone B
( O
RGZ O
) O
- O
induced O
adipogenesis O
in O
3T3 O
- O
L1 O
cells O
. O

The O
morphological O
changes O
were O
photographed O
based O
on O
staining O
lipid O
accumulation O
by O
Oil O
- O
Red O
O O
in O
RGZ O
( O
1 O
micro O
mol O
/ O
l O
) O
- O
treated O
3T3 O
- O
L1 O
cells O
without O
or O
with O
various O
concentrations O
of O
6 B
- I
gingerol I
on O
differentiation O
day O
8 O
. O

Quantitation O
of O
triglycerides B
content O
was O
performed O
in O
cells O
on O
day O
8 O
after O
differentiation O
induction O
. O

6 B
- I
gingerol I
( O
50 O
micro O
mol O
/ O
l O
) O
effectively O
suppressed O
oil O
droplet O
accumulation O
and O
reduced O
the O
sizes O
of O
the O
droplets O
in O
RGZ O
- O
induced O
adipocyte O
differentiation O
in O
3T3 O
- O
L1 O
cells O
. O

The O
triglyceride B
accumulation O
induced O
by O
RGZ O
in O
differentiated O
3T3 O
- O
L1 O
cells O
was O
also O
reduced O
by O
6 B
- I
gingerol I
( O
50 O
micro O
mol O
/ O
l O
) O
. O

Treatment O
of O
differentiated O
3T3 O
- O
L1 O
cells O
with O
6 B
- I
gingerol I
( O
50 O
micro O
mol O
/ O
l O
) O
antagonized O
RGZ O
- O
induced O
gene O
expression O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
gamma O
and O
CCAAT O
/ O
enhancer O
- O
binding O
protein O
alpha O
. O

Additionally O
, O
the O
increased O
levels O
of O
mRNA O
and O
protein O
in O
adipocyte O
- O
specific O
fatty B
acid I
binding O
protein O
4 O
and O
fatty B
acid I
synthase O
induced O
by O
RGZ O
in O
3T3 O
- O
L1 O
cells O
were O
decreased O
upon O
treatment O
with O
6 B
- I
gingerol I
. O

Our O
data O
suggests O
that O
6 B
- I
gingerol I
may O
be O
beneficial O
in O
obesity O
, O
by O
reducing O
adipogenesis O
partly O
through O
the O
down O
- O
regulating O
PPAR O
gamma O
activity O
. O

Two O
survival O
analyses O
were O
completed O
for O
each O
site O
- O
a O
univariate O
analysis O
and O
an O
adjusted O
multivariate O
analysis O
controlling O
for O
age O
, O
anti O
- O
resorptive O
use O
, O
femoral O
neck O
bone O
mineral O
density O
, O
number O
of O
diseases O
, O
previous O
fractures O
, O
BMI O
, O
parental O
history O
of O
hip O
fracture O
, O
current O
smoking O
, O
current O
alcoholic B
drinks O
> O
3 O
per O
day O
, O
current O
using O
glucocorticoids O
, O
and O
rheumatoid O
arthritis O
diagnosis O
( O
variables O
from O
the O
FRAX O
10 O
- O
year O
fracture O
risk O
assessment O
tool O
) O
. O

Library O
construction O
and O
biological O
evaluation O
of O
enmein O
- O
type O
diterpenoid B
analogues O
as O
potential O
anticancer O
agents O
. O

The O
IC50 O
values O
are O
similar O
to O
or O
improved O
over O
those O
of O
the O
parent O
molecule O
and O
paclitaxel B
, O
the O
latter O
of O
which O
was O
used O
as O
a O
positive O
control O
. O

These O
results O
warrant O
further O
preclinical O
investigations O
of O
these O
diterpenoid B
- O
based O
analogues O
as O
potential O
novel O
anticancer O
chemotherapeutics O
. O

PHARMACODYNAMIC O
EFFECTS O
OF O
A O
D B
- I
AMINO I
ACID I
OXIDASE O
INHIBITOR O
INDICATE O
A O
SPINAL O
SITE O
OF O
ACTION O
IN O
RAT O
MODELS O
OF O
NEUROPATHIC O
PAIN O
. O

Inhibition O
of O
D B
- I
amino I
acid I
oxidase O
( O
DAAO O
) O
activity O
is O
a O
potential O
target O
for O
the O
treatment O
of O
chronic O
pain O
. O

In O
these O
models O
, O
maximal O
reversal O
of O
pain O
- O
related O
behaviors O
corresponded O
with O
maximum O
rates O
- O
of O
- O
increase O
in O
brain O
and O
plasma O
D B
- I
serine I
concentrations O
, O
indicative O
of O
full O
inhibition O
of O
DAAO O
activity O
. O

Radiolabeling O
with O
fluorine O
- O
18 O
( O
( B
18 I
) I
F I
) O
facilitated O
production O
of O
2 O
- O
( O
5 O
, O
7 O
- O
diethyl O
- O
2 O
- O
( O
4 O
- O
( O
2 O
- O
[ O
( O
18 O
) O
F O
] O
fluoroethoxy O
) O
phenyl O
) O
pyrazolo O
[ O
1 O
, O
5 O
- O
a O
] O
pyrimidin O
- O
3 O
- O
yl O
) O
- O
N O
, O
N O
- O
diethylacetamide O
( O
( B
18 I
) I
F I
- O
6b O
) O
in O
high O
radiochemical O
yield O
and O
specific O
activity O
. O

In O
vivo O
studies O
of O
( B
18 I
) I
F I
- O
6b O
were O
performed O
which O
illuminated O
this O
agent O
as O
an O
improved O
probe O
for O
molecular O
imaging O
of O
TSPO O
- O
expressing O
cancers O
. O

A O
new O
sesquiterpene B
from O
the O
mangrove O
endophytic O
fungus O
Aspergillus O
terreus O
( O
No O
. O
GX7 O
- O
3B O
) O
. O

The O
hypothetical O
biogenic O
relationship O
of O
four O
sesquiterpene B
analogues O
was O
also O
described O
in O
this O
paper O
. O

A O
phytochemical O
study O
of O
Baeckea O
frutescens O
afforded O
a O
new O
biflavonoid B
named O
as O
baeckein O
E O
( O
1 O
) O
, O
along O
with O
four O
known O
C O
- O
methylated O
flavonols O
, O
baeckeins O
A O
( O
2 O
) O
and O
B O
( O
3 O
) O
, O
6 O
- O
methylquercetin O
( O
6 O
) O
and O
6 O
- O
methylquercetin O
- O
4 O
' O
- O
O O
- O
beta O
- O
d O
- O
glucopyranoside O
( O
7 O
) O
, O
and O
two O
known O
biflavonoids O
baeckeins O
C O
( O
4 O
) O
and O
D O
( O
5 O
) O
. O

Discovery O
of O
oxysterol B
- O
derived O
pharmacological O
chaperones O
for O
NPC1 O
: O
implication O
for O
the O
existence O
of O
second O
sterol B
- O
binding O
site O
. O

Niemann O
- O
Pick O
type O
C1 O
( O
NPC1 O
) O
is O
a O
polytopic O
endosomal O
membrane O
protein O
required O
for O
efflux O
of O
LDL O
- O
derived O
cholesterol B
from O
endosomes O
, O
and O
mutations O
of O
this O
protein O
are O
associated O
with O
Niemann O
- O
Pick O
disease O
type O
C O
, O
a O
fatal O
neurodegenerative O
disease O
. O

Here O
, O
we O
show O
that O
several O
oxysterols B
and O
their O
derivatives O
act O
as O
pharmacological O
chaperones O
; O
binding O
of O
these O
compounds O
to O
I1061T O
NPC1 O
corrects O
the O
localization O
/ O
maturation O
defect O
of O
the O
mutant O
protein O
. O

Further O
, O
these O
compounds O
alleviate O
intracellular O
cholesterol B
accumulation O
in O
patient O
- O
derived O
fibroblasts O
, O
suggesting O
that O
they O
may O
have O
therapeutic O
potential O
. O

These O
oxysterol B
derivatives O
bind O
to O
a O
domain O
of O
NPC1 O
that O
is O
different O
from O
the O
known O
N B
- O
terminal O
sterol B
- O
binding O
domain O
; O
i O
. O
e O
. O
, O
there O
is O
an O
additional O
sterol B
- O
binding O
site O
on O
NPC1 O
. O

The O
recruitment O
was O
mediated O
through O
Pol O
kappa O
C B
- O
terminus O
which O
contains O
the O
PCNA O
- O
interacting O
peptide O
, O
ubiquitin O
zinc B
finger O
motif O
2 O
and O
nuclear O
localization O
signal O
. O

We O
further O
observed O
that O
Pol O
kappa O
- O
deficient O
mouse O
embryo O
fibroblasts O
were O
abnormally O
sensitive O
to O
H2O2 B
treatment O
and O
displayed O
defects O
in O
both O
single O
- O
strand O
break O
repair O
and O
double O
- O
strand O
break O
repair O
. O

In O
silico O
identification O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
- O
1 O
inhibitors O
and O
their O
chemosensitizing O
effects O
against O
cisplatin B
- O
resistant O
human O
gastric O
cancer O
cells O
. O

Poly B
( I
ADP I
- I
ribose I
) I
polymerase O
- O
1 O
( O
PARP O
- O
1 O
) O
enzyme O
is O
involved O
in O
the O
repair O
of O
DNA O
damages O
made O
by O
certain O
anticancer O
agents O
. O

It O
is O
suggested O
that O
PARP O
- O
1 O
inhibitors O
potentiate O
the O
cytotoxic O
effects O
and O
circumvent O
the O
resistance O
of O
DNA O
- O
modifying O
anticancer O
agents O
such O
as O
cisplatin B
. O

We O
then O
examined O
the O
chemosensitization O
of O
cisplatin B
by O
pre O
- O
treatment O
of O
PARP O
- O
1 O
inhibitors O
in O
cisplatin B
- O
resistant O
human O
gastric O
cancer O
cells O
. O

Our O
results O
show O
that O
PARP O
- O
1 O
inhibitors O
suppress O
the O
formation O
of O
poly B
( I
ADP I
- I
ribose I
) I
and O
enhance O
the O
cytotoxicity O
of O
cisplatin B
. O

Activation O
of O
PPAR O
gamma O
is O
required O
for O
hydroxysafflor B
yellow I
A I
of O
Carthamus O
tinctorius O
to O
attenuate O
hepatic O
fibrosis O
induced O
by O
oxidative O
stress O
. O

Hydroxysafflor B
yellow I
A I
( O
HSYA B
) O
as O
a O
nature O
active O
ingredient O
with O
antioxidant O
capacity O
was O
able O
to O
effectively O
attenuate O
oxidative O
stress O
mediated O
injury O
. O

So O
it O
will O
be O
very O
interesting O
to O
study O
effect O
of O
HSYA B
on O
HSCs O
activation O
and O
liver O
fibrosis O
, O
and O
reveal O
the O
role O
of O
PPAR O
gamma O
. O
CCl4 B
and O
H2O2 B
were O
used O
to O
mimic O
oxidative O
stress O
mediated O
hepatic O
injury O
in O
vitro O
and O
in O
vivo O
respectively O
. O

The O
anti O
- O
fibrosis O
effects O
of O
HSYA B
were O
evaluated O
and O
its O
mechanisms O
were O
disclosed O
by O
applying O
western O
blot O
, O
histopathological O
analysis O
, O
flow O
cytometry O
, O
RT O
- O
PCR O
and O
ELISA O
. O

HSYA B
was O
able O
to O
effectively O
inhibit O
oxidative O
stress O
mediated O
hepatic O
injury O
by O
increasing O
the O
activities O
of O
antioxidant O
enzymes O
, O
up O
regulating O
the O
expression O
of O
PPAR O
gamma O
and O
MMP O
- O
2 O
, O
and O
down O
regulating O
the O
expression O
of O
TGF O
- O
beta O
1 O
and O
TIMP O
- O
1 O
, O
and O
reducing O
alpha O
- O
SMA O
level O
. O

The O
protective O
effect O
of O
HSYA B
can O
be O
significantly O
attenuated O
by O
GW9662 B
via O
blocking O
PPAR O
gamma O
( O
p O
< O
0 O
. O
05 O
or O
p O
< O
0 O
. O
01 O
) O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
HSYA B
is O
able O
to O
significantly O
protect O
the O
liver O
from O
oxidative O
stress O
, O
which O
requires O
for O
HSYA B
to O
stimulate O
PPAR O
gamma O
activity O
, O
reduce O
cell O
proliferation O
and O
suppress O
ECM O
synthesis O
. O

Characterization O
of O
the O
first O
K B
( I
+ I
) I
channel O
blockers O
from O
the O
venom O
of O
the O
Moroccan O
scorpion O
Buthus O
occitanus O
Paris O
. O

The O
availability O
of O
a O
large O
variety O
of O
specific O
blockers O
, O
which O
inhibit O
different O
K B
( I
+ I
) I
currents O
, O
would O
help O
to O
elucidate O
their O
differences O
in O
physiological O
function O
. O

Short O
peptide O
toxins O
isolated O
from O
scorpion O
venoms O
are O
able O
to O
block O
voltage O
- O
dependent O
or O
Ca B
( I
2 I
+ I
) I
- O
activated O
K B
( I
+ I
) I
channels O
. O

They O
were O
further O
pharmacologically O
characterized O
by O
competition O
using O
( B
125 I
) I
I I
- O
KTX O
bound O
to O
its O
specific O
binding O
sites O
on O
rat O
brain O
synaptosomes O
. O

A O
single O
component O
( O
4161 O
Da O
) O
inhibited O
totally O
the O
( B
125 I
) I
I I
- O
KTX O
binding O
and O
with O
high O
- O
affinity O
( O
IC50 O
= O
0 O
. O
1 O
nM O
) O
, O
while O
the O
two O
other O
components O
poorly O
competed O
with O
( O
IC50 O
> O
100 O
nM O
) O
. O

The O
two O
others O
peptides O
( O
BoP1 O
and O
BoP2 O
, O
4093 O
Da O
and O
4121 O
Da O
, O
respectively O
) O
only O
differ O
by O
a O
Lys B
/ O
Arg O
mutation O
. O

Their O
amino B
acid I
sequences O
were O
related O
to O
Martentoxin O
, O
which O
has O
been O
characterized O
from O
the O
Chinese O
scorpion O
Buthus O
martenzi O
Karch O
and O
described O
as O
both O
a O
BKCa O
and O
Kv1 O
. O
3 O
blocker O
. O

Towards O
the O
bioequivalence O
of O
pressurised O
metered O
dose O
inhalers O
1 O
: O
Design O
and O
characterisation O
of O
aerodynamically O
equivalent O
beclomethasone O
dipropionate O
inhalers O
with O
and O
without O
glycerol B
as O
a O
non O
- O
volatile O
excipient O
. O

Both O
inhaler O
formulations O
contained O
the O
drug O
, O
beclomethasone O
dipropionate O
( O
BDP O
) O
, O
a O
volatile O
mixture O
of O
ethanol B
co O
- O
solvent O
and O
propellant O
( O
hydrofluoroalkane O
- O
HFA B
) O
. O

However O
, O
one O
formulation O
was O
designed O
such O
that O
the O
emitted O
aerosol O
particles O
contained O
BDP O
and O
glycerol B
, O
a O
common O
inhalation O
particle O
modifying O
excipient O
, O
in O
a O
1 O
: O
1 O
mass O
ratio O
. O

By O
modifying O
the O
formulation O
parameters O
, O
including O
actuator O
orifice O
, O
HFA B
and O
metering O
volumes O
, O
it O
was O
possible O
to O
produce O
two O
formulations O
( O
glycerol B
- O
free O
and O
glycerol B
- O
containing O
) O
which O
had O
identical O
mass O
median O
aerodynamic O
diameters O
( O
2 O
. O
4 O
mu O
m O
+ O
/ O
- O
0 O
. O
1 O
and O
2 O
. O
5 O
mu O
m O
+ O
/ O
- O
0 O
. O
2 O
) O
, O
fine O
particle O
dose O
( O
> O
= O
5 O
mu O
m O
; O
66 O
mu O
g O
+ O
/ O
- O
6 O
and O
68 O
mu O
g O
+ O
/ O
- O
2 O
) O
and O
fine O
particle O
fractions O
( O
28 O
% O
+ O
/ O
- O
2 O
% O
and O
30 O

The O
particles O
produced O
from O
both O
formulations O
were O
amorphous O
; O
however O
, O
the O
formulation O
containing O
glycerol B
generated O
particles O
with O
a O
porous O
structure O
, O
while O
the O
glycerol B
- O
free O
formulation O
generated O
particles O
with O
a O
primarily O
spherical O
morphology O
. O

Furthermore O
, O
the O
glycerol B
- O
containing O
particles O
had O
a O
significantly O
lower O
dissolution O
rate O
( O
7 O
. O
8 O
% O
+ O
/ O
- O
2 O
. O
1 O
% O
, O
over O
180min O
) O
compared O
to O
the O
glycerol B
- O
free O
particles O
( O
58 O
. O
0 O
% O
+ O
/ O
- O
2 O
. O
9 O
% O
, O
over O
60min O
) O
when O
measured O
using O
a O
Franz O
diffusion O
cell O
. O

It O
is O
hypothesised O
that O
the O
presence O
of O
glycerol B
in O
the O
emitted O
aerosol O
particles O
altered O
solubility O
and O
drug O
transport O
, O
which O
may O
have O
implications O
for O
BDP O
pharmacokinetics O
after O
deposition O
in O
the O
respiratory O
tract O
. O

Baicalein B
attenuates O
bleomycin B
- O
induced O
pulmonary O
fibrosis O
in O
rats O
through O
inhibition O
of O
miR O
- O
21 O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
baicalein B
on O
bleomycin B
- O
induced O
pulmonary O
fibrosis O
, O
and O
the O
novel O
mechanisms O
involved O
in O
the O
anti O
- O
fibrosis O
effects O
. O

Pulmonary O
fibrosis O
was O
induced O
by O
a O
single O
intratracheal O
instillation O
of O
5 O
mg O
/ O
kg O
bleomycin B
. O

Two O
bleomycin B
- O
treated O
groups O
were O
orally O
administered O
daily O
with O
50 O
and O
100 O
mg O
/ O
kg O
of O
baicalein B
from O
day O
1 O
to O
28 O
. O

The O
results O
showed O
baicalein B
decreased O
hydroxyproline B
content O
and O
alpha O
- O
SMA O
levels O
and O
increased O
lung O
index O
. O

Histopathological O
examinations O
demonstrated O
baicalein B
could O
obviously O
lower O
the O
degree O
of O
alveolitis O
and O
lung O
fibrosis O
. O

The O
total O
antioxidant O
capacity O
in O
bleomycin B
- O
treated O
rats O
with O
baicalein B
was O
also O
remarkably O
higher O
than O
in O
those O
without O
baicalein B
. O

Baicalein B
remarkably O
decreased O
miR O
- O
21 O
levels O
and O
inhibited O
the O
increased O
expression O
of O
TGF O
- O
beta O
1 O
and O
p O
- O
Smad O
- O
2 O
/ O
3 O
in O
bleomycin B
- O
treated O
rats O
. O

Baicalein B
can O
attenuate O
bleomycin B
- O
induced O
pulmonary O
fibrosis O
. O

Quercetin B
and O
epigallocatechin B
- I
3 I
- I
gallate I
effect O
on O
the O
anisotropy O
of O
model O
membranes O
with O
cholesterol B
. O

Flavonoids B
are O
among O
the O
most O
studied O
food O
substances O
that O
prevent O
and O
/ O
or O
reduce O
oxidative O
stress O
, O
but O
their O
action O
mechanisms O
are O
far O
from O
being O
understood O
. O

We O
performed O
a O
study O
on O
the O
effect O
of O
quercetin B
and O
epigallocatechin B
- I
3 I
- I
gallate I
on O
2 O
- O
Dimyristoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
small O
unilamellar O
vesicles O
( O
SUVs O
) O
with O
different O
amounts O
of O
cholesterol B
, O
using O
Laurdan B
as O
a O
fluorescent O
probe O
, O
to O
put O
into O
evidence O
the O
perturbations O
of O
the O
phospholipid O
membrane O
fluidity O
and O
local O
lipid O
order O
in O
an O
attempt O
to O
decipher O
the O
action O
mechanism O
of O
the O
flavonoids B
at O
the O
cell O
membrane O
level O
. O

Results O
indicate O
that O
polyphenols B
modulate O
the O
transition O
from O
the O
gel O
phase O
to O
the O
liquid O
crystalline O
phase O
of O
SUVs O
in O
all O
studied O
membranes O
. O

SUVs O
with O
cholesterol B
have O
by O
themselves O
higher O
phase O
transition O
temperature O
and O
the O
presence O
of O
polyphenols B
stabilizes O
further O
the O
membrane O
. O

Quercetin B
has O
a O
dose O
- O
dependent O
effect O
on O
the O
fluidity O
and O
local O
order O
of O
the O
lipid O
membranes O
, O
whilst O
epigallocatechin B
- I
3 I
- I
gallate I
action O
is O
not O
dose O
- O
dependent O
, O
the O
differences O
being O
attributable O
to O
the O
hydrophobic O
/ O
hydrophilic O
character O
of O
the O
substances O
. O

The O
findings O
are O
discussed O
within O
the O
frame O
of O
earlier O
reports O
on O
the O
effect O
of O
polyphenols B
on O
artificial O
membranes O
. O

In O
the O
absence O
of O
superoxide B
dismutase O
( O
in O
sod1 O
Delta O
mutant O
strain O
) O
sensitivity O
to O
the O
essential O
oil O
and O
nerolidol O
increased O
indicating O
that O
this O
oil O
and O
nerolidol O
are O
generating O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

Differential O
effects O
of O
acute O
and O
chronic O
zinc B
( O
Zn B
) O
exposure O
on O
hepatic O
lipid O
deposition O
and O
metabolism O
in O
yellow O
catfish O
Pelteobagrus O
fulvidraco O
. O

The O
present O
study O
is O
conducted O
to O
determine O
the O
potential O
mechanisms O
of O
Zn B
on O
hepatic O
lipid O
deposition O
and O
metabolism O
for O
yellow O
catfish O
Pelteobagrus O
fulvidraco O
with O
8 O
- O
week O
chronic O
exposure O
to O
low O
Zn B
levels O
( O
Zn B
levels O
: O
0 O
. O
05 O
, O
0 O
. O
35 O
and O
0 O
. O
86mg O
/ O
l O
Zn B
, O
respectively O
) O
and O
96 O
- O
h O
acute O
exposure O
to O
a O
high O
Zn B
level O
( O
Zn B
level O
: O
4 O
. O
71mg O
/ O
l O
Zn B
, O
respectively O
) O
. O

For O
that O
purpose O
, O
hepatic O
lipid O
deposition O
and O
Zn B
accumulation O
, O
hepatic O
carnitine B
palmitoyltransferase O
I O
( O
CPT O
I O
) O
and O
lipoprotein O
lipase O
( O
LPL O
) O
activities O
, O
and O
the O
hepatic O
mRNA O
expression O
of O
ten O
genes O
involved O
in O
lipid O
metabolism O
are O
determined O
. O

Chronic O
( O
8 O
weeks O
) O
exposure O
to O
low O
Zn B
levels O
apparently O
increases O
hepatic O
lipid O
content O
, O
hepatosomatic O
index O
( O
HSI O
) O
( O
P O
< O
0 O
. O
05 O
) O
and O
LPL O
activity O
, O
and O
reduces O
hepatic O
CPT O
I O
activity O
. O

In O
contrast O
, O
the O
acute O
( O
96h O
) O
exposure O
to O
high O
Zn B
level O
reduces O
hepatic O
lipid O
content O
, O
HSI O
and O
LPL O
activity O
, O
and O
increases O
CPT O
I O
activity O
. O

The O
change O
of O
mRNA O
levels O
of O
genes O
related O
to O
lipid O
metabolism O
is O
Zn B
concentration O
- O
dependent O
. O

Pearson O
correlations O
among O
mRNA O
expression O
levels O
, O
lipid O
content O
, O
CPT O
I O
and O
LPL O
activities O
in O
liver O
are O
also O
observed O
in O
yellow O
catfish O
with O
the O
8 O
- O
week O
chronic O
Zn B
exposure O
. O

For O
the O
first O
time O
, O
our O
study O
demonstrates O
the O
effect O
of O
waterborne O
Zn B
exposure O
on O
lipid O
metabolism O
at O
the O
molecular O
levels O
in O
fish O
, O
which O
may O
contribute O
to O
understanding O
the O
mechanism O
of O
Zn B
- O
induced O
hepatic O
toxicity O
in O
fish O
. O

The O
force O
of O
the O
spontaneously O
contracting O
zebrafish O
heart O
, O
in O
the O
assessment O
of O
cardiovascular O
toxicity O
: O
Application O
on O
adriamycin B
. O

The O
advantage O
of O
prolonged O
vitality O
in O
the O
assessment O
of O
cardiovascular O
toxicity O
was O
shown O
using O
the O
well O
- O
known O
anticancer O
drug O
adriamycin B
, O
which O
has O
severe O
cardiotoxic O
side O
effects O
. O

These O
contradictory O
positive O
chronotropic O
and O
negative O
inotropic O
responses O
indicate O
the O
strong O
inhibitory O
effect O
of O
adriamycin B
on O
ventricular O
cardiomyocytes O
and O
its O
excitatory O
effects O
on O
auto O
- O
rhythmical O
pacemaker O
cells O
. O

If O
heart O
frequency O
was O
the O
only O
parameter O
used O
to O
assess O
the O
cardiotoxic O
effect O
of O
adriamycin B
, O
at O
the O
above O
range O
of O
concentrations O
, O
this O
compound O
would O
have O
been O
classified O
as O
non O
- O
cardiotoxic O
. O

Potentiation O
of O
morphine B
- O
induced O
mechanical O
antinociception O
by O
sigma O
1 O
receptor O
inhibition O
: O
Role O
of O
peripheral O
sigma O
1 O
receptors O
. O

We O
studied O
the O
modulation O
of O
morphine B
- O
induced O
mechanical O
antinociception O
and O
side O
effects O
by O
sigma O
1 O
receptor O
inhibition O
. O

However O
, O
sigma O
1 O
- O
KO O
mice O
exhibited O
an O
enhanced O
mechanical O
antinociception O
in O
response O
to O
systemic O
morphine B
( O
1 O
- O
16 O
mg O
/ O
kg O
) O
. O

Similarly O
, O
systemic O
treatment O
of O
WT O
mice O
with O
sigma O
1 O
antagonists O
markedly O
potentiated O
morphine B
- O
induced O
antinociception O
, O
and O
its O
effects O
were O
reversed O
by O
the O
selective O
sigma O
1 O
agonist O
PRE O
- O
084 O
. O

Although O
the O
local O
administration O
of O
morphine B
( O
50 O
- O
200 O
mu O
g O
) O
was O
devoid O
of O
antinociceptive O
effects O
in O
WT O
mice O
, O
it O
induced O
dose O
- O
dependent O
antinociception O
in O
sigma O
1 O
- O
KO O
mice O
. O

Enhancement O
of O
peripheral O
morphine B
antinociception O
was O
replicated O
in O
WT O
mice O
locally O
co O
- O
administered O
with O
sigma O
1 O
antagonists O
and O
the O
opioid O
. O

None O
of O
the O
sigma O
1 O
antagonists O
tested O
enhanced O
morphine B
- O
antinociception O
in O
sigma O
1 O
- O
KO O
mice O
, O
confirming O
a O
sigma O
1 O
- O
mediated O
action O
. O

Morphine B
- O
induced O
side O
- O
effects O
( O
hyperlocomotion O
and O
inhibition O
of O
gastrointestinal O
transit O
) O
were O
unaltered O
in O
sigma O
1 O
- O
KO O
mice O
. O

These O
results O
show O
that O
sigma O
1 O
receptor O
inhibition O
potentiates O
morphine B
- O
induced O
mechanical O
analgesia O
but O
not O
its O
acute O
side O
effects O
, O
and O
that O
this O
enhanced O
analgesia O
can O
be O
induced O
at O
peripheral O
level O
. O

Accumulation O
of O
phenolic B
compounds O
in O
in O
vitro O
cultures O
and O
wild O
plants O
of O
Lavandula O
viridis O
L O
' O
H O
e O
r O
and O
their O
antioxidant O
and O
anti O
- O
cholinesterase O
potential O
. O

The O
HPLC O
- O
DAD O
analysis O
allowed O
the O
identification O
and O
quantification O
of O
3 O
- O
O O
- O
caffeoylquinic O
, O
4 O
- O
O O
- O
caffeoylquinic O
, O
5 O
- O
O O
- O
caffeoylquinic O
and O
rosmarinic O
acids O
, O
and O
luteolin B
and O
pinocembrin B
. O

Water O
/ O
ethanol B
extract O
from O
in O
vitro O
cultures O
contained O
the O
highest O
amount O
of O
the O
identified O
phenolic B
compounds O
( O
51652 O
. O
92mg O
/ O
kg O
) O
. O

To O
investigate O
the O
antioxidant O
activity O
we O
used O
Trolox B
equivalent O
antioxidant O
capacity O
, O
oxygen B
radical O
absorbance O
capacity O
, O
Fe B
( I
2 I
+ I
) I
chelation O
activity O
and O
the O
inhibition O
of O
Fe B
( I
2 I
+ I
) I
- O
induced O
lipid O
peroxidation O
in O
mouse O
brain O
homogenates O
( O
in O
vitro O
) O
. O

Overall O
, O
all O
the O
extracts O
from O
both O
wild O
plants O
and O
in O
vitro O
cultures O
exhibited O
ability O
to O
scavenge O
free O
radicals O
, O
to O
chelate O
Fe B
( I
2 I
+ I
) I
and O
to O
protect O
against O
lipid O
peroxidation O
. O

Hypocholesterolemic O
effect O
of O
daily O
fisetin B
supplementation O
in O
high O
fat O
fed O
Sprague O
- O
Dawley O
rats O
. O

We O
aimed O
to O
test O
whether O
fisetin B
could O
modulate O
cholesterol B
homeostasis O
in O
rats O
with O
diet O
- O
induced O
hypercholesterolemia O
, O
and O
further O
investigated O
the O
underlying O
mechanisms O
by O
which O
fisetin B
exerts O
its O
cholesterol B
lowering O
effect O
. O

Blood O
lipid O
profile O
, O
hepatic O
cholesterol B
content O
, O
as O
well O
as O
gene O
expressions O
in O
cholesterol B
metabolism O
were O
examined O
. O

Elevated O
levels O
of O
total O
cholesterol B
and O
LDL O
- O
cholesterol B
, O
along O
with O
hepatic O
cholesterol B
content O
in O
a O
high O
fat O
group O
were O
found O
to O
be O
significantly O
reduced O
by O
fisetin B
. O

The O
high O
fat O
diet O
significantly O
decreased O
hepatic O
mRNA O
levels O
of O
LDLR O
, O
SREBP2 O
, O
HMGCR O
and O
PCSK9 O
in O
comparison O
to O
the O
control O
diet O
, O
however O
, O
fisetin B
did O
not O
further O
elicit O
any O
changes O
in O
mRNA O
levels O
of O
the O
same O
genes O
. O

The O
high O
fat O
diet O
dramatically O
increased O
the O
transcript O
levels O
of O
CYP7A1 O
, O
which O
was O
subsequently O
reversed O
by O
the O
fisetin B
. O

In O
HepG2 O
cells O
, O
fisetin B
was O
found O
to O
increase O
the O
levels O
of O
a O
nuclear O
form O
of O
SREBP2 O
and O
LDLR O
. O

In O
conclusion O
, O
fisetin B
supplementation O
displayed O
hypocholesterolemic O
effects O
by O
modulating O
the O
expression O
of O
genes O
associated O
with O
cholesterol B
and O
bile B
acid I
metabolism O
. O

Phenolic B
compounds O
from O
Jacaranda O
caroba O
( O
Vell O
. O
) O
A O
. O

The O
present O
study O
describes O
, O
for O
the O
first O
time O
, O
the O
phenolic B
composition O
and O
bioactivity O
of O
Jacaranda O
caroba O
( O
Vell O
. O
) O
A O
. O

The O
HPLC O
- O
DAD O
- O
ESI O
/ O
MS O
( O
n O
) O
analysis O
revealed O
the O
presence O
of O
four O
dicaffeoyl O
acid O
derivatives O
and O
nine O
flavonoids B
, O
comprising O
quercetin B
, O
kaempferol B
and O
isorhamnetin B
derivatives O
. O

Both O
extracts O
proved O
to O
be O
strong O
radicals O
' O
scavengers O
and O
effective O
monoamine B
- O
oxidase O
A O
inhibitors O
, O
but O
showed O
weak O
protection O
against O
cholinesterases O
' O
activity O
. O

Metabolism O
Studies O
of O
Unformulated O
Internally O
[ O
3H B
] O
- O
labeled O
siRNAs O
in O
Mice O
. O

Absorption O
, O
distribution O
, O
metabolism O
, O
and O
excretion O
properties O
of O
two O
unformulated O
model O
siRNAs O
were O
determined O
using O
a O
single O
internal O
[ O
( B
3 I
) I
H I
] O
- O
radiolabeling O
procedure O
, O
where O
the O
full O
- O
length O
oligonucleotides O
were O
radiolabeled O
by O
Br B
/ O
( B
3 I
) I
H I
- O
exchange O
. O

Tissue O
distribution O
, O
excretion O
, O
and O
mass O
balance O
of O
radioactivity O
were O
investigated O
in O
male O
CD O
- O
1 O
mice O
, O
following O
a O
single O
intravenous O
administration O
of O
the O
[ O
( B
3 I
) I
H I
] O
- O
siRNAs O
, O
at O
a O
target O
dose O
level O
of O
5 O
mg O
/ O
kg O
. O

In O
general O
, O
there O
was O
little O
difference O
in O
the O
distribution O
of O
total O
radiolabeled O
components O
after O
administration O
of O
the O
two O
unformulated O
[ O
( B
3 I
) I
H I
] O
- O
siRNAs O
. O

The O
radioactivity O
was O
rapidly O
and O
widely O
distributed O
throughout O
the O
body O
, O
and O
remained O
detectable O
in O
all O
tissues O
investigated O
at O
later O
time O
points O
( O
24 O
and O
48 O
hours O
for O
[ O
( B
3 I
) I
H I
] O
- O
MRP4 O
and O
[ O
( B
3 I
) I
H I
] O
- O
SSB O
siRNA O
, O
respectively O
) O
. O

A O
nearly O
complete O
mass O
balance O
was O
obtained O
for O
the O
[ O
( B
3 I
) I
H I
] O
- O
SSB O
siRNA O
and O
renal O
excretion O
was O
the O
main O
route O
of O
elimination O
( O
38 O
% O
) O
. O

Instead O
, O
radiolabeled O
nucleosides B
resulting O
from O
nuclease O
hydrolysis O
were O
observed O
. O

In O
the O
metabolism O
profiles O
obtained O
from O
various O
tissues O
only O
radiolabeled O
nucleosides B
were O
found O
, O
suggesting O
that O
siRNAs O
are O
rapidly O
metabolized O
and O
that O
the O
distribution O
pattern O
of O
total O
radiolabeled O
components O
can O
be O
ascribed O
to O
small O
molecular O
weight O
metabolites O
. O

Enhanced O
broadband O
and O
omnidirectional O
performance O
of O
Cu O
( O
In O
, O
Ga O
) O
Se2 O
solar O
cells O
with O
ZnO B
functional O
nanotree O
arrays O
. O

An O
effective O
approach O
is O
demonstrated O
for O
enhancing O
photoelectric O
conversion O
of O
Cu O
( O
In O
, O
Ga O
) O
Se2 O
( O
CIGS O
) O
solar O
cells O
with O
three O
- O
dimensional O
ZnO B
nanotree O
arrays O
. O

Under O
a O
simulated O
one O
- O
sun O
condition O
, O
cells O
with O
ZnO B
nanotree O
arrays O
enhance O
the O
short O
- O
circuit O
current O
density O
by O
10 O
. O
62 O
% O
. O

The O
omnidirectional O
anti O
- O
reflection O
of O
CIGS O
solar O
cells O
with O
various O
ZnO B
nanostructures O
is O
also O
investigated O
. O

This O
enhancement O
in O
light O
harvesting O
is O
attributable O
to O
the O
gradual O
refractive O
index O
profile O
between O
the O
ZnO B
nanostructures O
and O
air O
. O

Psychoactive O
compounds O
, O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
( O
NMDAR O
) O
antagonists O
, O
modify O
gamma O
( O
40 O
- O
90 O
) O
and O
high O
frequency O
oscillations O
( O
HFO O
, O
130 O
- O
180 O
Hz O
) O
in O
local O
field O
potentials O
( O
LFPs O
) O
recorded O
in O
the O
NAc O
. O

Lysergic O
acid O
diethylamide O
( O
LSD O
) O
and O
2 O
, O
5 O
- O
dimethoxy O
- O
4 O
- O
iodoamphetamine O
( O
DOI B
) O
are O
serotonergic O
hallucinogens O
and O
activation O
of O
5HT2A O
receptors O
likely O
underlies O
their O
hallucinogenic O
effects O
. O

RESULTS O
: O
LSD O
( O
0 O
. O
03 O
- O
0 O
. O
3 O
mg O
/ O
kg O
) O
and O
DOI B
( O
0 O
. O
5 O
- O
2 O
. O
0 O
mg O
/ O
kg O
) O
increased O
the O
power O
and O
reduced O
the O
frequency O
of O
HFO O
. O

MDL O
11939 O
( O
1 O
. O
0 O
mg O
/ O
kg O
) O
, O
a O
5HT2A O
receptor O
antagonist O
, O
fully O
reversed O
the O
changes O
induced O
by O
DOI B
on O
HFO O
but O
only O
partially O
for O
the O
low O
gamma O
band O
. O

Notably O
, O
hallucinogen O
- O
induced O
increases O
in O
HFO O
power O
were O
smaller O
than O
those O
produced O
by O
ketamine B
( O
25 O
mg O
/ O
kg O
) O
. O

A O
high O
throughput O
screen O
identified O
adamantane B
dipeptide O
1 O
as O
an O
inhibitor O
of O
Ebola O
virus O
( O
EboV O
) O
infection O
. O

AGAP2 O
is O
a O
multidomain O
Arf O
GAP O
( O
ADP B
ribosylation O
factor O
- O
directed O
GTPase O
- O
activating O
protein O
) O
that O
was O
shown O
to O
promote O
the O
fast O
- O
recycling O
of O
transferrin O
receptors O
. O

Identification O
of O
the O
first O
synthetic O
inhibitors O
of O
the O
type O
II O
transmembrane O
serine B
protease O
TMPRSS2 O
suitable O
for O
inhibition O
of O
influenza O
virus O
activation O
. O

TMPRSS2 O
is O
a O
multidomain O
type O
II O
transmembrane O
serine B
protease O
that O
cleaves O
the O
surface O
glycoprotein O
hemagglutinin O
( O
HA O
) O
of O
influenza O
viruses O
with O
monobasic O
cleavage O
site O
, O
which O
is O
a O
prerequisite O
for O
virus O
fusion O
and O
propagation O
. O

The O
catalytic O
domain O
of O
TMPRSS2 O
was O
expressed O
in O
E O
. O
coli O
and O
used O
for O
an O
inhibitor O
screen O
with O
previously O
synthesized O
inhibitors O
of O
various O
trypsin O
- O
like O
serine B
proteases O
. O

Broken O
Symmetry O
Quantum O
Hall O
States O
in O
Dual O
- O
Gated O
ABA O
Trilayer O
Graphene B
. O

ABA O
- O
stacked O
trilayer O
graphene B
is O
a O
unique O
2D O
electron O
system O
with O
mirror O
reflection O
symmetry O
and O
unconventional O
quantum O
Hall O
effect O
. O

We O
present O
low O
- O
temperature O
transport O
measurements O
on O
dual O
- O
gated O
suspended O
trilayer O
graphene B
in O
the O
quantum O
Hall O
( O
QH O
) O
regime O
. O

Our O
results O
underscore O
the O
rich O
interaction O
- O
induced O
phenomena O
in O
trilayer O
graphene B
. O

The O
model O
includes O
stacking O
, O
hydrogen B
bond O
, O
and O
electrostatic O
interactions O
as O
fundamental O
components O
in O
describing O
the O
stability O
of O
RNA O
structures O
. O

The O
stacking O
interactions O
are O
parametrized O
using O
a O
set O
of O
nucleotide B
- O
specific O
parameters O
, O
which O
were O
calibrated O
against O
the O
thermodynamic O
measurements O
for O
single O
- O
base O
stacks O
and O
base O
- O
pair O
stacks O
. O

All O
hydrogen B
bonds O
are O
assumed O
to O
have O
the O
same O
strength O
, O
regardless O
of O
their O
context O
in O
the O
RNA O
structure O
. O

The O
aggregation O
behavior O
of O
cationic O
5 O
, O
5 O
' O
, O
6 O
, O
6 O
' O
- O
tetrachloro O
- O
1 O
, O
1 O
' O
, O
3 O
, O
3 O
' O
- O
tetraethylbenzimidac O
with O
chloride B
( O
TTBC O
- O
Cl O
) O
or O
iodide B
counterions O
( O
TTBC O
- O
I O
) O
in O
aqueous O
solution O
is O
investigated O
by O
absorption O
, O
linear O
dichroism O
, O
and O
fluorescence O
spectroscopies O
, O
as O
well O
as O
cryogenic O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

Unlike O
the O
chloride B
salt O
, O
the O
iodide B
salt O
TTBC O
- O
I O
forms O
two O
different O
types O
of O
J O
- O
aggregates O
depending O
on O
the O
pH O
of O
the O
aqueous O
solution O
. O

Synthesis O
of O
indolyl O
- O
3 O
- O
acetonitrile O
derivatives O
and O
their O
inhibitory O
effects O
on O
nitric B
oxide I
and O
PGE2 B
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

Several O
indolyl O
- O
3 O
- O
acetonitrile O
derivatives O
were O
synthesized O
as O
arvelexin O
analogs O
and O
evaluated O
for O
their O
abilities O
to O
inhibit O
NO B
and O
PGE2 B
productions O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
cells O
. O

Of O
the O
indolyl O
- O
3 O
- O
acetonitriles O
synthesized O
, O
compound O
2k O
, O
which O
possesses O
a O
hydroxyl B
group O
at O
C O
- O
7 O
position O
of O
the O
indole B
ring O
and O
an O
N B
- I
methyl I
substituent O
, O
more O
potently O
inhibited O
NO B
and O
PGE2 B
productions O
and O
was O
less O
cytotoxic O
than O
arvelexin O
on O
macrophage O
cells O
. O

MATERIALS O
AND O
METHODS O
: O
We O
investigated O
the O
inhibitory O
action O
of O
ethanolic O
extract O
of O
Atropa O
acuminata O
( O
AAEE O
) O
on O
production O
of O
NO B
, O
TNF O
- O
alpha O
and O
IL O
- O
1 O
beta O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
RAW264 O
. O
7 O
cells O
and O
also O
assayed O
it O
for O
COX O
1 O
/ O
2 O
and O
5 O
- O
LOX O
inhibitory O
activities O
. O

Next O
AAEE O
was O
tested O
in O
acute O
inflammatory O
animal O
models O
. O
, O
carragenean O
induced O
rat O
paw O
edema O
, O
carragenean O
induce O
pleurisy O
in O
rats O
and O
vascular O
permeability O
in O
mice O
and O
the O
effects O
on O
NO B
, O
PGE2 B
and O
LTB4 O
production O
in O
the O
pleural O
fluid O
and O
paw O
exudates O
were O
evaluated O
. O

RESULTS O
: O
Our O
findings O
summarized O
novel O
anti O
- O
inflammatory O
mechanisms O
for O
Atropa O
acuminata O
based O
on O
dual O
in O
vitro O
cyclooxygenase O
1 O
/ O
2 O
/ O
and O
5 O
- O
Lipoxygenase O
inhibitory O
activities O
and O
also O
significant O
downregulation O
of O
nitric B
oxide I
( O
NO B
) O
and O
pro O
- O
inflammatory O
cytokin O
( O
TNF O
- O
alpha O
and O
Il O
- O
1 O
beta O
) O
release O
in O
LPS O
- O
stimulated O
RAW O
246 O
. O
7 O
macrophage O
cell O
line O
. O

This O
was O
indicated O
on O
the O
basis O
of O
dose O
dependent O
suppression O
of O
multi O
targeted O
inflammatory O
mediators O
. O
, O
NO B
, O
TNF O
- O
alpha O
and O
IL O
- O
1 O
beta O
, O
eicosanoids O
. O
, O
PGE2 B
and O
leukotrienes O
. O
, O
LTB4 O
along O
with O
significantly O
decreased O
leucocyte O
migration O
, O
exudation O
and O
decreased O
vascular O
permeability O
. O

AAEE O
was O
found O
to O
be O
safe O
for O
long O
term O
administration O
, O
as O
confirmed O
by O
the O
results O
of O
acute O
toxicity O
studies O
and O
MTT B
assay O
. O

The O
complex O
mode O
of O
action O
of O
the O
herbs O
was O
attributed O
possibly O
due O
to O
the O
high O
polyphenolic B
, O
flavanol O
and O
flavonoid B
content O
present O
in O
the O
extracts O
as O
observed O
by O
means O
of O
quantitative O
screening O
for O
phytochemicals O
. O

Reversal O
of O
Morphine B
Analgesic O
Tolerance O
by O
Ethanol B
in O
the O
Mouse O
. O

It O
has O
been O
observed O
that O
the O
blood O
level O
of O
opioids O
in O
postmortem O
analyses O
of O
addicts O
, O
who O
consumed O
ethanol B
along O
with O
the O
opioid O
, O
was O
much O
less O
than O
that O
observed O
in O
individuals O
that O
died O
from O
opioids O
alone O
. O

This O
relationship O
between O
ethanol B
and O
opioids O
led O
us O
to O
investigate O
the O
hypothesis O
that O
ethanol B
alters O
tolerance O
to O
opioids O
. O

In O
the O
present O
study O
, O
we O
report O
that O
ethanol B
significantly O
and O
dose O
- O
dependently O
reduced O
the O
antinociceptive O
tolerance O
produced O
by O
morphine B
and O
the O
cross O
tolerance O
between O
DAMGO O
and O
morphine B
in O
the O
mouse O
tail O
- O
flick O
test O
. O

The O
reversal O
of O
morphine B
tolerance O
was O
partially O
blocked O
by O
both O
the O
GABAA O
receptor O
blocker O
bicuculline B
and O
by O
the O
GABAB O
receptor O
blocker O
phaclofen O
and O
the O
administration O
of O
both O
inhibitors O
completely O
reversed O
the O
effects O
of O
ethanol B
on O
morphine B
tolerance O
. O

Diazepam B
, O
like O
ethanol B
, O
decreased O
morphine B
tolerance O
. O

However O
, O
this O
inhibition O
was O
reversed O
by O
the O
GABAA O
antagonist O
bicuculline B
but O
not O
by O
the O
GABAB O
antagonist O
phaclofen O
. O

These O
findings O
have O
important O
implications O
for O
individuals O
who O
abuse O
opioids O
and O
ethanol B
as O
well O
as O
suggest O
a O
mechanism O
to O
reduce O
the O
amount O
of O
opioid O
needed O
in O
chronic O
pain O
treatment O
. O

Here O
we O
determined O
if O
shifts O
in O
parental O
care O
and O
corticosterone B
had O
carry O
- O
over O
effects O
on O
future O
reproductive O
effort O
in O
the O
rufous O
- O
and O
- O
white O
wren O
( O
Thryophilus O
rufalbus O
) O
, O
a O
host O
of O
the O
Central O
American O
striped O
cuckoo O
( O
Tapera O
naevia O
) O
. O

We O
found O
that O
parasitized O
parents O
had O
significantly O
higher O
stress O
- O
induced O
, O
but O
not O
baseline O
, O
corticosterone B
than O
natural O
parents O
during O
the O
fledgling O
stage O
, O
which O
was O
associated O
with O
changes O
in O
parental O
care O
. O

Although O
a O
reduction O
in O
future O
reproductive O
effort O
can O
result O
from O
a O
combination O
of O
factors O
, O
this O
work O
suggests O
that O
fitness O
costs O
of O
brood O
parasitism O
are O
mediated O
by O
changes O
in O
corticosterone B
and O
parental O
care O
behavior O
that O
carry O
over O
into O
subsequent O
breeding O
seasons O
. O

Two O
novel O
saponins B
of O
20 O
, O
26 O
- O
epoxy O
derivatives O
of O
pseudojujubogenin O
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

Two O
new O
saponins B
of O
20 O
, O
26 O
- O
epoxy O
derivatives O
of O
pseudojujubogenin O
, O
hoduloside O
XI O
( O
1 O
) O
and O
hoduloside O
XII O
( O
2 O
) O
were O
isolated O
from O
the O
seeds O
of O
Hovenia O
trichocarpa O
. O

HYDP O
also O
showed O
gastroprotective O
activity O
in O
the O
model O
of O
ethanol B
- O
induced O
gastric O
lesion O
, O
with O
a O
75 O
. O
59 O
% O
maximum O
inhibition O
of O
ulcers O
at O
a O
dose O
of O
100mg O
/ O
kg O
. O

This O
gastroprotective O
effect O
was O
attenuated O
by O
N B
( I
G I
) I
- I
nitro I
- I
l I
- I
arginine I
methyl I
ester I
, O
indomethacin B
and O
N B
- I
ethylmaleimide I
, O
indicating O
that O
NO B
, O
prostaglandins B
and O
sulfhydryl B
groups O
are O
involved O
in O
the O
mechanisms O
of O
action O
. O

The O
effect O
of O
sodium B
selenite I
on O
lead O
induced O
cognitive O
dysfunction O
. O

The O
effect O
of O
lead O
( O
Pb B
) O
on O
spatial O
memory O
and O
hippocampal O
long O
- O
term O
potentiation O
( O
LTP O
) O
as O
a O
key O
risk O
factor O
has O
been O
widely O
recognized O
and O
the O
oxidative O
damage O
has O
been O
proposed O
as O
a O
possible O
mechanism O
of O
lead O
neurotoxicity O
. O

Selenium B
( O
Se B
) O
is O
a O
nutritionally O
essential O
trace O
element O
with O
known O
antioxidant O
potential O
. O

In O
this O
study O
we O
investigated O
the O
effect O
and O
the O
underlying O
mechanisms O
of O
Se B
supplementary O
on O
Pb B
induced O
cognition O
and O
synaptic O
plasticity O
impairment O
. O

Lactating O
Sprague O
- O
Dawley O
rats O
( O
SD O
rats O
) O
were O
randomly O
divided O
to O
four O
groups O
: O
0ppm O
lead O
acetate O
( O
Pb B
) O
; O
0ppm O
Pb B
and O
0 O
. O
2ppm O
sodium B
selenite I
( O
Se B
) O
; O
100ppm O
Pb B
; O
100ppm O
Pb B
and O
0 O
. O
2ppm O
Se B
. O

Lactating O
rats O
were O
treated O
with O
or O
without O
Pb B
and O
/ O
or O
Se B
throughout O
lactation O
until O
weaning O
. O

The O
levels O
of O
hippocampal O
LTP O
, O
the O
spatial O
memory O
, O
the O
apoptosis O
of O
hippocampal O
neurons O
, O
the O
levels O
of O
lactate B
dehydrogenase O
( O
LDH O
) O
release O
, O
and O
the O
serum O
level O
of O
superoxide B
dismutase O
( O
SOD O
) O
and O
malondialdehyde B
( O
MDA B
) O
were O
assayed O
. O

It O
had O
been O
observed O
that O
in O
Pb B
group O
the O
spatial O
memory O
, O
the O
induce O
level O
of O
LTP O
, O
the O
serum O
SOD O
level O
decreased O
, O
the O
LDH O
release O
level O
, O
the O
neurons O
apoptosis O
level O
, O
the O
serum O
MDA B
level O
increased O
, O
while O
in O
the O
Se B
supplements O
groups O
, O
the O
spatial O
memory O
, O
the O
induce O
level O
of O
LTP O
increased O
significantly O
. O

Compared O
with O
the O
Pb B
group O
, O
Se B
supplements O
shown O
down O
regulated O
the O
level O
of O
LDH O
, O
the O
neurons O
apoptosis O
and O
the O
serum O
MDA B
, O
and O
up O
regulated O
the O
level O
of O
serum O
SOD O
. O

We O
could O
draw O
the O
conclusion O
that O
Se B
supplements O
could O
alleviate O
toxic O
effect O
of O
lead O
on O
hippocampal O
LTP O
and O
spatial O
memory O
. O

The O
treated O
with O
selenium B
around O
0 O
. O
2ppm O
may O
protect O
against O
spatial O
memory O
dysfunction O
induced O
by O
lead O
exposure O
. O

METHODS O
: O
Experiment O
1 O
examined O
the O
effects O
of O
nicotine B
and O
methylphenidate B
on O
delayed O
matching O
- O
to O
- O
sample O
( O
DMTS O
) O
and O
self O
- O
ordered O
spatial O
search O
( O
SOSS O
) O
performances O
in O
rhesus O
monkeys O
( O
DMTS O
: O
n O
= O
7 O
; O
SOSS O
: O
n O
= O
6 O
) O
to O
determine O
the O
validity O
and O
reliability O
of O
best O
dose O
effects O
. O

The O
doses O
identified O
as O
best O
doses O
from O
two O
nicotine B
dose O
- O
response O
curve O
determinations O
were O
unrelated O
, O
and O
the O
improvement O
associated O
with O
the O
best O
dose O
observed O
during O
the O
first O
dose O
- O
response O
curve O
determination O
was O
not O
reliable O
when O
the O
dose O
was O
administered O
repeatedly O
. O

Exposure O
of O
Bacillus O
subtilis O
to O
mercury B
induces O
accumulation O
of O
shorter O
tRNA O
Cys B
species O
. O

In O
this O
work O
, O
Bacillus O
subtilis O
was O
used O
to O
understand O
the O
effects O
of O
mercury B
on O
the O
mechanism O
of O
tRNA O
metabolism O
. O

The O
CVAAS O
( O
cold O
vapor O
atomic O
absorption O
spectroscopy O
) O
method O
revealed O
that O
from O
the O
addition O
of O
HgCl2 B
( O
0 O
. O
75 O
mu O
g O
ml O
( O
- O
1 O
) O
) O
during O
the O
bacterial O
exponential O
phase O
, O
ca O
. O

48 O
% O
of O
the O
added O
mercury B
was O
taken O
up O
by O
the O
cells O
. O

During O
this O
response O
, O
we O
observed O
accumulation O
of O
species O
shorter O
than O
mature O
tRNA O
( O
Cys B
) O
over O
a O
10 O
h O
period O
. O

Thus O
, O
when O
the O
exonuclease O
PNPase O
was O
absent O
, O
we O
found O
that O
the O
shorter O
tRNA O
( O
Cys B
) O
species O
increased O
and O
mature O
tRNA O
( O
Cys B
) O
decreased O
after O
mercury B
addition O
, O
but O
this O
proportion O
changed O
during O
the O
time O
analyzed O
. O

However O
, O
in O
the O
absence O
of O
RNase O
R O
and O
PNPase O
the O
accumulation O
of O
the O
shorter O
tRNA O
( O
Cys B
) O
was O
more O
pronounced O
and O
the O
mature O
form O
was O
not O
recovered O
. O

In O
the O
single O
rnr O
mutant O
strain O
the O
shorter O
tRNA O
( O
Cys B
) O
was O
not O
observed O
. O

All O
together O
, O
we O
provide O
in O
vivo O
evidence O
that O
PNPase O
and O
RNase O
R O
are O
indispensable O
in O
controlling O
tRNA O
( O
Cys B
) O
quality O
in O
the O
presence O
of O
mercury B
. O

Insights O
into O
the O
adsorption O
and O
energy O
transfer O
of O
Ag B
clusters O
on O
the O
AgCl B
( O
100 O
) O
surface O
. O

It O
is O
fundamental O
to O
uncover O
the O
real O
adsorption O
properties O
of O
Ag B
clusters O
on O
an O
AgCl B
surface O
and O
the O
energy O
transfer O
mechanisms O
at O
the O
interface O
to O
understand O
the O
highly O
active O
photocatalytic O
performance O
and O
the O
stability O
of O
the O
plasmonic O
photocatalyst O
Ag B
@ O
AgCl B
. O

Based O
on O
density O
functional O
theory O
calculations O
we O
provide O
valuable O
insights O
into O
the O
binding O
nature O
of O
Ag B
clusters O
on O
AgCl B
surface O
, O
where O
the O
binding O
between O
Ag B
atoms O
in O
the O
cluster O
and O
on O
the O
surface O
plays O
a O
decisive O
role O
in O
determining O
the O
most O
stable O
adsorption O
configurations O
. O

The O
hot O
holes O
excited O
by O
the O
decay O
of O
surface O
plasmon O
resonance O
on O
the O
metals O
can O
diffuse O
into O
the O
Cl B
ions O
in O
the O
outermost O
two O
layers O
of O
the O
surface O
producing O
highly O
oxidative O
Cl B
atoms O
. O

The O
dipole O
- O
dipole O
interaction O
between O
the O
plasmonic O
metal O
clusters O
and O
substrate O
Cl B
ions O
can O
also O
generate O
electron O
- O
hole O
pairs O
in O
the O
surface O
layers O
. O

It O
is O
deduced O
that O
the O
positively O
charged O
nature O
of O
adsorbed O
clusters O
acting O
as O
electron O
trapping O
centers O
and O
reduction O
sites O
plays O
a O
crucial O
role O
in O
keeping O
the O
stability O
of O
the O
Ag B
@ O
AgCl B
system O
during O
the O
photocatalytic O
process O
. O

Finally O
, O
the O
validity O
of O
the O
cluster O
adsorption O
model O
for O
energy O
transfer O
is O
verified O
with O
respect O
to O
the O
nucleation O
and O
aggregation O
process O
of O
Ag B
atoms O
on O
the O
AgCl B
surface O
and O
a O
detailed O
description O
of O
the O
formation O
and O
evolution O
of O
Ag B
nanoparticles O
on O
an O
AgCl B
surface O
is O
provided O
. O

Pooled O
sensitivity O
and O
specificity O
of O
( O
99m O
) O
Tc O
- O
MIBI O
scan O
in O
detecting O
malignant O
thyroid O
nodules O
were O
85 O
. O
1 O
% O
[ O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
: O
81 O
. O
1 O
- O
88 O
. O
5 O
% O
] O
and O
45 O
. O
7 O
% O
( O
95 O
% O
CI O
: O
42 O
. O
7 O
- O
48 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
, O
irrespective O
of O
eventual O
results O
of O
previous O
technetium O
pertechnetate O
( O
( O
99m O
) O
TcO4 O
) O
or O
iodine O
- O
123 O
( O
( B
123 I
) I
I I
) O
scan O
. O

A O
sub O
- O
analysis O
restricted O
to O
data O
on O
hypofunctioning O
nodules O
on O
( O
99m O
) O
TcO4 O
or O
( B
123 I
) I
I I
scans O
was O
performed O
: O
pooled O
sensitivity O
and O
specificity O
of O
( O
99m O
) O
Tc O
- O
MIBI O
scan O
in O
these O
nodules O
were O
82 O
. O
1 O
% O
( O
95 O
% O
CI O
: O
77 O
. O
2 O
- O
86 O
. O
3 O
% O
) O
and O
62 O
. O
8 O
% O
( O
95 O
% O
CI O
: O
58 O
. O
9 O
- O
66 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
. O

Synthesis O
, O
antimicrobial O
evaluation O
and O
molecular O
modelling O
of O
novel O
sulfonamides B
carrying O
a O
biologically O
active O
quinazoline B
nucleus O
. O

A O
novel O
series O
of O
quinazolines O
5 O
- O
10 O
, O
triazoloquinazolines O
11 O
- O
17 O
and O
triazinoquinazoline O
19 O
bearing O
a O
biologically O
active O
sulfonamide B
moiety O
were O
synthesized O
, O
utilizing O
methyl O
2 O
- O
isothiocyanato O
benzoate O
2 O
. O

Some O
of O
the O
newly O
synthesized O
compounds O
revealed O
promising O
bacterial O
growth O
inhibition O
, O
compared O
with O
the O
ampicillin B
, O
as O
the O
reference O
drug O
. O

INTERVENTION O
: O
Completion O
of O
a O
survey O
containing O
10 O
hypothetical O
ICU O
cases O
in O
which O
patients O
had O
agitated O
delirium O
for O
which O
a O
psychiatrist O
recommended O
intravenous O
haloperidol B
5 O
mg O
every O
6 O
hours O
. O

A O
group O
of O
five O
EP O
cardiologists O
agreed O
that O
haloperidol B
use O
was O
safe O
in O
five O
cases O
and O
not O
safe O
in O
five O
cases O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
For O
each O
case O
, O
participants O
were O
asked O
to O
document O
whether O
they O
would O
administer O
haloperidol B
, O
to O
provide O
a O
rationale O
for O
their O
decision O
, O
and O
to O
state O
their O
level O
of O
confidence O
in O
that O
decision O
. O

Among O
the O
five O
cases O
where O
EP O
cardiologists O
agreed O
that O
haloperidol B
was O
not O
safe O
, O
29 O
% O
of O
respondents O
felt O
that O
haloperidol B
was O
safe O
. O

Conversely O
, O
in O
the O
five O
cases O
where O
EP O
cardiologists O
felt O
haloperidol B
was O
safe O
, O
21 O
% O
of O
respondents O
believed O
that O
it O
was O
not O
safe O
. O

Overall O
respondent O
- O
EP O
cardiologist O
agreement O
for O
haloperidol B
use O
across O
the O
10 O
cases O
was O
moderate O
( O
kappa O
= O
0 O
. O
51 O
) O
. O

We O
evaluated O
the O
contribution O
of O
caloric O
restriction O
versus O
surgically O
induced O
changes O
to O
glucose B
homeostasis O
in O
the O
immediate O
postoperative O
period O
. O
RESEARCH O
DESIGN O
AND O
METHODSPatients O
with O
type O
2 O
diabetes O
planning O
to O
undergo O
RYGB O
participated O
in O
a O
prospective O
two O
- O
period O
study O
( O
each O
period O
involved O
a O
10 O
- O
day O
inpatient O
stay O
and O
periods O
were O
separated O
by O
a O
minimum O
of O
6 O
weeks O
of O
wash O
- O
out O
) O
in O
which O
patients O
served O
as O
their O
own O
controls O
. O

Glucose B
measurements O
were O
performed O
every O
4 O
h O
throughout O
the O
study O
. O

The O
improvements O
in O
the O
fasting O
and O
maximum O
poststimulation O
glucose B
and O
6 O
- O
h O
glucose B
area O
under O
the O
curve O
( O
primary O
outcome O
) O
were O
similar O
during O
both O
periods O
. O
CONCLUSIONSGlucose O
homeostasis O
improved O
in O
response O
to O
a O
reduced O
caloric O
diet O
, O
with O
a O
greater O
effect O
observed O
in O
the O
absence O
of O
surgery O
as O
compared O
with O
after O
RYGB O
. O

Serial O
activation O
of O
the O
tyrosine B
kinases O
Lck O
and O
ZAP O
- O
70 O
initiates O
signaling O
downstream O
of O
the O
T O
- O
cell O
receptor O
. O

We O
had O
previously O
reported O
the O
structure O
of O
an O
autoinhibited O
ZAP O
- O
70 O
variant O
in O
which O
two O
regulatory O
tyrosine B
residues O
( O
315 O
and O
319 O
) O
in O
the O
SH2 O
- O
kinase O
linker O
were O
replaced O
by O
phenylalanine B
. O

We O
now O
present O
the O
crystal O
structure O
of O
ZAP O
- O
70 O
in O
which O
Tyr B
315 O
and O
Tyr B
319 O
are O
not O
mutated O
, O
leading O
to O
the O
recognition O
of O
a O
five O
- O
residue O
sequence O
register O
error O
in O
the O
SH2 O
- O
kinase O
linker O
of O
the O
original O
crystallographic O
model O
. O

As O
seen O
in O
a O
recently O
reported O
structure O
of O
the O
related O
tyrosine B
kinase O
Syk O
, O
Tyr B
315 O
of O
ZAP O
- O
70 O
is O
part O
of O
a O
hydrophobic O
interface O
between O
the O
regulatory O
apparatus O
and O
the O
kinase O
domain O
, O
and O
the O
integrity O
of O
this O
interface O
would O
be O
lost O
upon O
engagement O
of O
doubly O
- O
phosphorylated O
peptides O
by O
the O
SH2 O
domains O
. O

Tyr B
319 O
is O
not O
necessarily O
dislodged O
by O
SH2 O
engagement O
, O
which O
activates O
ZAP O
- O
70 O
by O
only O
~ O
5 O
- O
fold O
in O
vitro O
. O

This O
difference O
is O
due O
to O
the O
ability O
of O
Tyr B
319 O
to O
suppress O
ZAP O
- O
70 O
activity O
even O
when O
the O
SH2 O
domains O
are O
dislodged O
from O
the O
kinase O
domain O
, O
providing O
stringent O
control O
of O
ZAP O
- O
70 O
activity O
downstream O
of O
Lck O
. O

In O
this O
study O
, O
we O
utilized O
tunicate O
cellulose O
nanocrystals O
as O
the O
nanofiller O
that O
are O
functionalized O
with O
allyl B
moieties O
. O

Using O
photoinduced O
thiol B
- O
ene O
chemistry O
, O
we O
have O
been O
able O
to O
cross O
- O
link O
the O
CNC O
nanofiller O
. O

Multitarget O
Global O
Sensitivity O
Analysis O
of O
n B
- I
Butanol I
Combustion O
. O

A O
model O
for O
the O
combustion O
of O
butanol B
is O
studied O
using O
a O
recently O
developed O
theoretical O
method O
for O
the O
systematic O
improvement O
of O
the O
kinetic O
mechanism O
. O

The O
butanol B
mechanism O
includes O
1446 O
reactions O
, O
and O
we O
demonstrate O
that O
it O
is O
straightforward O
and O
computationally O
feasible O
to O
implement O
a O
full O
global O
sensitivity O
analysis O
incorporating O
all O
the O
reactions O
. O

HISTONE O
DEACETYLASE O
INHIBITION O
AFFECTS O
SODIUM B
IODIDE I
SYMPORTER O
( O
NIS O
) O
EXPRESSION O
AND O
INDUCES O
( O
1 O
) O
( O
3 O
) O
( O
1 O
) O
I O
CYTOTOXICITY O
IN O
ANAPLASTIC O
THYROID O
CANCER O
CELLS O
. O

The O
resistance O
of O
anaplastic O
thyroid O
cancer O
to O
radioiodine O
treatment O
is O
principally O
due O
to O
the O
absence O
of O
expression O
of O
the O
sodium B
iodide I
symporter O
( O
NIS O
) O
, O
mainly O
due O
to O
epigenetic O
silencing O
. O

Moreover O
, O
125I O
uptake O
and O
efflux O
experiments O
show O
the O
correct O
protein O
function O
and O
iodine B
retention O
, O
that O
translate O
into O
cytotoxicity O
effects O
, O
as O
demonstrated O
by O
a O
clonogenic O
assay O
with O
131I O
. O

Using O
whole O
mount O
in O
situ O
hybridization O
to O
examine O
thyroid B
hormone I
deiodinase O
expression O
in O
embryonic O
and O
larval O
zebrafish O
: O
A O
tool O
for O
examining O
OH O
- O
BDE O
toxicity O
to O
early O
life O
stages O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
and O
their O
oxidative O
metabolites O
( O
hydroxylated O
PBDEs O
; O
OH O
- O
BDEs O
) O
are O
known O
endocrine O
disrupting O
contaminants O
that O
have O
been O
shown O
to O
disrupt O
thyroid B
hormone I
regulation O
both O
in O
mammals O
and O
in O
fish O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
precise O
organ O
and O
tissue O
locations O
that O
express O
genes O
critical O
to O
thyroid B
hormone I
regulation O
in O
developing O
zebrafish O
( O
Danio O
rerio O
) O
, O
and O
to O
determine O
the O
effects O
of O
an O
OH O
- O
BDE O
on O
their O
expression O
. O

While O
PBDEs B
and O
OH O
- O
BDEs O
have O
been O
shown O
to O
inhibit O
the O
activity O
and O
expression O
of O
deiodionases O
, O
a O
family O
of O
enzymes O
that O
regulate O
thyroid B
hormone I
concentrations O
intracellularly O
, O
it O
is O
unclear O
whether O
or O
not O
they O
can O
affect O
regional O
expression O
of O
the O
different O
isoforms O
during O
early O
development O
. O

These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
( O
OATP2B1 O
- O
FL O
) O
or O
shortened O
protein O
lacking O
22 O
N B
- O
terminus O
amino B
acids I
( O
OATP2B O
- O
Short O
) O
. O

Little O
is O
known O
regarding O
the O
transport O
activity O
and O
regulation O
of O
OATP2B1 O
variants O
with O
N B
- O
terminus O
truncation O
. O

Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short O
OATP2B1 O
variant O
towards O
substrates O
estrone O
sulfate O
and O
rosuvastatin B
are O
similar O
to O
the O
well O
- O
characterized O
full O
length O
variant O
. O

The O
rs10229583 O
risk O
variant O
was O
associated O
with O
elevated O
fasting O
plasma O
glucose B
, O
impaired O
beta O
cell O
function O
in O
controls O
, O
and O
an O
earlier O
age O
at O
diagnosis O
for O
the O
cases O
. O

Existing O
FAK O
- O
based O
therapeutics O
focus O
on O
inhibiting O
the O
kinase O
' O
s O
catalytic O
function O
and O
not O
the O
large O
scaffold O
it O
creates O
that O
includes O
many O
oncogenic O
receptor O
tyrosine B
kinases O
and O
tumor O
suppressor O
proteins O
. O

ERP O
evidence O
suggests O
executive O
dysfunction O
in O
ecstasy B
polydrug O
users O
. O

BACKGROUND O
: O
Deficits O
in O
executive O
functions O
such O
as O
access O
to O
semantic O
/ O
long O
- O
term O
memory O
have O
been O
shown O
in O
ecstasy B
users O
in O
previous O
research O
. O

The O
current O
study O
sought O
to O
further O
investigate O
behavioural O
and O
electro O
- O
physiological O
measures O
of O
this O
executive O
function O
in O
ecstasy B
users O
. O

METHOD O
: O
Twenty O
ecstasy B
- O
polydrug O
users O
, O
20 O
non O
- O
ecstasy B
- O
polydrug O
users O
and O
20 O
drug O
- O
na O
i O
ve O
controls O
were O
recruited O
. O

Subsequent O
exploratory O
univariate O
ANOVAs O
on O
the O
N2 O
component O
revealed O
marginally O
significant O
between O
- O
group O
differences O
, O
generally O
showing O
greater O
negativity O
at O
occipito O
- O
parietal O
electrodes O
in O
ecstasy B
users O
compared O
to O
drug O
- O
na O
i O
ve O
controls O
. O

Despite O
absence O
of O
behavioural O
differences O
, O
differences O
in O
N2 O
magnitude O
are O
evidence O
of O
abnormal O
executive O
functioning O
in O
ecstasy B
- O
polydrug O
users O
. O

In O
vitro O
read O
- O
through O
of O
phenylalanine B
hydroxylase O
( O
PAH O
) O
nonsense O
mutations O
using O
aminoglycosides O
: O
a O
potential O
therapy O
for O
phenylketonuria O
. O

Phenylketonuria O
( O
PKU O
, O
OMIM O
261600 O
) O
is O
an O
autosomal O
recessive O
inborn O
error O
of O
phenylalanine B
metabolism O
, O
predominantly O
caused O
by O
mutations O
in O
the O
phenylalanine B
hydroxylase O
( O
PAH O
) O
gene O
. O

In O
some O
genetic O
disorders O
, O
including O
cystic O
fibrosis O
and O
Duchenne O
muscular O
dystrophy O
, O
restoration O
of O
full O
- O
length O
protein O
has O
been O
achieved O
by O
aminoglycoside O
antibiotics O
, O
such O
as O
gentamicin B
and O
G O
- O
418 O
( O
Geneticin O
) O
. O

The O
efficacy O
of O
read O
- O
through O
induced O
by O
three O
compounds O
, O
aminoglycosides O
G418 O
and O
gentamicin B
, O
and O
PTC124 O
were O
evaluated O
for O
four O
nonsense O
mutations O
of O
PAH O
in O
an O
in O
vitro O
expression O
system O
in O
two O
mammalian O
cell O
lines O
( O
COS O
- O
7 O
and O
HEK293 O
) O
. O

Gentamicin B
and O
G O
- O
418 O
induced O
read O
- O
through O
of O
nonsense O
PAH O
mutations O
in O
HEK293 O
cells O
. O

In O
vitro O
studies O
with O
new O
non O
- O
toxic O
read O
- O
through O
agents O
as O
well O
as O
in O
vivo O
studies O
would O
also O
be O
essential O
to O
determine O
the O
extent O
of O
read O
- O
through O
required O
to O
restore O
normal O
phenylalanine B
levels O
. O

In O
the O
current O
study O
, O
we O
crossed O
mdr1a O
. O
fLUC O
mice O
into O
the O
pxr O
knockout O
( O
pxr O
( O
- O
/ O
- O
) O
) O
genetic O
background O
and O
injected O
mice O
with O
pregnenolone O
- O
16 O
alpha O
- O
carbonitrile O
( O
PCN O
) O
, O
a O
strong O
PXR O
ligand O
, O
and O
two O
therapeutically O
relevant O
taxanes B
, O
paclitaxel B
and O
docetaxel B
. O

All O
three O
agents O
induced O
mdr1a O
. O
fLUC O
expression O
( O
bioluminescence O
) O
, O
but O
only O
PCN O
and O
docetaxel B
appeared O
to O
act O
primarily O
via O
PXR O
. O

Three O
new O
polyketides O
( O
( O
- O
) O
- O
1 O
, O
( O
+ O
) O
- O
1 O
, O
and O
2 O
) O
were O
isolated O
from O
the O
EtOAc B
extract O
of O
the O
fungus O
Embellisia O
eureka O
, O
an O
endophyte O
of O
the O
Moroccan O
plant O
Cladanthus O
arabicus O
( O
Asteraceae O
) O
. O

Both O
FSTL3KO O
and O
FST288 O
- O
only O
mice O
had O
extensive O
hepatic O
steatosis O
and O
elevated O
hepatic O
triglyceride B
( O
TG O
) O
content O
. O

Gene O
expression O
analysis O
suggests O
that O
increased O
lipid O
uptake O
, O
enhanced O
de O
novo O
lipid O
synthesis O
, O
decreased O
lipolysis O
and O
/ O
or O
enhanced O
glucose B
uptake O
contribute O
to O
increased O
hepatic O
TG O
content O
in O
these O
models O
. O

Effect O
of O
surface O
charge O
density O
on O
the O
affinity O
of O
oxide B
nanoparticles O
for O
the O
vapor O
- O
water O
interface O
. O

Using O
in O
- O
situ O
X O
- O
ray O
photoelectron O
spectroscopy O
at O
the O
vapor O
- O
water O
interface O
, O
the O
affinity O
of O
nanometer O
- O
sized O
silica B
colloids O
to O
adsorb O
at O
the O
interface O
is O
shown O
to O
depend O
on O
colloid O
surface O
charge O
density O
. O

In O
aqueous O
suspensions O
at O
pH O
10 O
corrected O
Debye O
- O
H O
u O
ckel O
theory O
for O
surface O
complexation O
calculations O
predict O
that O
smaller O
silica B
colloids O
have O
increased O
negative O
surface O
charge O
density O
that O
originates O
from O
enhanced O
screening O
of O
deprotonated O
silanol B
groups O
( O
= O
Si O
- O
O O
( O
- O
) O
) O
by O
counterions O
in O
the O
condensed O
ion O
layer O
. O

In O
order O
to O
investigate O
outer O
valence O
ionic O
states O
of O
open O
- O
shell O
metallocenes O
, O
we O
have O
applied O
two O
- O
dimensional O
collision O
- O
energy O
/ O
electron O
- O
energy O
- O
resolved O
Penning O
ionization O
electron O
spectroscopy O
( O
2D O
- O
PIES O
) O
upon O
collision O
with O
metastable O
He B
* O
( O
2 O
( O
3 O
) O
S O
) O
excited O
atoms O
as O
well O
as O
a O
high O
level O
ab O
initio O
molecular O
orbital O
calculation O
( O
the O
partial O
third O
- O
order O
quasiparticle O
theory O
of O
the O
electron O
propagator O
( O
P3 O
) O
) O
to O
ionization O
from O
neutral O
ground O
states O
of O
vanadocene O
( O
( O
4 O
) O
A2g O
) O
and O
nickelocene O
( O
( O

Assignments O
of O
observed O
Penning O
ionization O
electron O
/ O
He B
I O
ultraviolet O
photoelectron O
spectra O
were O
consistent O
with O
the O
P3 O
calculation O
results O
for O
ionization O
of O
alpha O
and O
beta O
spin O
electrons O
except O
for O
electron O
correlation O
bands O
observed O
by O
PIES O
. O

Negative O
collision O
energy O
dependence O
of O
partial O
Penning O
ionization O
cross O
- O
sections O
( O
CEDPICS O
) O
indicate O
attractive O
interaction O
with O
He B
* O
( O
2 O
( O
3 O
) O
S O
) O
around O
the O
molecule O
. O

Results O
by O
model O
potential O
calculation O
utilizing O
Li B
( O
2 O
( O
2 O
) O
S O
) O
instead O
of O
He B
* O
( O
2 O
( O
3 O
) O
S O
) O
for O
interaction O
between O
He B
* O
( O
2 O
( O
3 O
) O
S O
) O
and O
open O
- O
shell O
metallocenes O
do O
not O
explain O
the O
strong O
negative O
CEDPICS O
of O
the O
bands O
observed O
in O
PIES O
. O

Antifreeze O
( O
Glyco O
) O
protein O
Mimetic O
Behavior O
of O
Poly B
( I
vinyl I
alcohol I
) I
: O
Detailed O
Structure O
Ice O
Recrystallization O
Inhibition O
Activity O
Study O
. O

This O
manuscript O
reports O
a O
detailed O
study O
on O
the O
ability O
of O
poly B
( I
vinyl I
alcohol I
) I
to O
act O
as O
a O
biomimetic O
surrogate O
for O
antifreeze O
( O
glyco O
) O
proteins O
, O
with O
a O
focus O
on O
the O
specific O
property O
of O
ice O
- O
recrystallization O
inhibition O
( O
IRI O
) O
. O

Poly B
( I
vinyl I
alcohol I
) I
( O
PVA B
) O
has O
been O
shown O
to O
display O
remarkable O
ice O
recrystallization O
inhibition O
activity O
despite O
its O
major O
structural O
differences O
to O
native O
antifreeze O
proteins O
. O

Here O
, O
controlled O
radical O
polymerization O
is O
used O
to O
synthesize O
well O
- O
defined O
PVA B
, O
which O
has O
enabled O
us O
to O
obtain O
the O
first O
quantitative O
structure O
- O
activity O
relationships O
, O
to O
probe O
the O
role O
of O
molecular O
weight O
and O
comonomers O
on O
IRI O
activity O
. O

Hydrophobic O
modifications O
to O
the O
backbone O
were O
slightly O
more O
tolerated O
than O
side O
chain O
modifications O
, O
which O
implies O
an O
unbroken O
sequence O
of O
hydroxyl B
units O
is O
necessary O
for O
activity O
. O

In O
compounds O
possessing O
a O
structural O
alert O
( O
aldehyde B
) O
and O
an O
activation O
alert O
( O
double O
bond O
) O
, O
it O
is O
important O
to O
consider O
bioactivation O
/ O
autoxidation O
( O
e O
. O
g O
. O
, O
epoxidation O
) O
. O

In O
the O
present O
study O
, O
we O
have O
explored O
a O
series O
of O
aldehydes B
with O
regard O
to O
contact O
allergy O
. O

The O
chemical O
reactivity O
of O
these O
6 O
aldehydes B
toward O
a O
model O
hexapeptide O
was O
investigated O
, O
and O
their O
skin O
sensitization O
potencies O
were O
evaluated O
using O
the O
local O
lymph O
node O
assay O
( O
LLNA O
) O
. O

The O
highly O
reactive O
conjugated O
aldehydes B
( O
alpha O
, O
beta O
- O
unsaturated O
aldehydes O
and O
2 O
, O
3 O
- O
epoxyaldehydes O
) O
are O
sensitizing O
moieties O
, O
while O
nonconjugated O
aldehydes B
and O
nonterminal O
aliphatic O
epoxides O
show O
low O
reactivity O
and O
low O
sensitization O
potency O
. O

Our O
data O
show O
the O
importance O
of O
not O
only O
double O
bond O
conjugation O
to O
aldehyde B
but O
also O
epoxide B
- O
aldehyde B
conjugation O
. O

The O
analyses O
have O
been O
performed O
in O
comparison O
to O
acetylsalicylic B
acid I
( O
ASA B
) O
and O
diclofenac B
( O
Diclo O
) O
, O
which O
are O
well O
- O
known O
to O
reduce O
colon O
carcinoma O
risk O
. O

In O
contrast O
to O
NSAIDs O
, O
STW O
5 O
induced O
COX O
- O
1 O
/ O
COX O
- O
2 O
, O
caspase O
- O
3 O
and O
Bax O
mRNA O
expressions O
in O
HT O
- O
29 O
and O
blocked O
LPS O
mediated O
translocation O
of O
the O
NF O
- O
kappa O
B O
p65 O
from O
the O
cytoplasm O
into O
the O
nucleus O
in O
PMA B
- O
differentiated O
THP O
- O
1 O
macrophages O
. O

Active O
concentrations O
of O
STW O
5 O
are O
, O
in O
relation O
to O
therapeutic O
doses O
, O
comparable O
to O
those O
of O
ASA B
and O
Diclo O
, O
suggesting O
a O
similar O
favorable O
effect O
on O
colon O
carcinoma O
risk O
. O

The O
generation O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
upon O
H2O2 B
and O
CSA O
treatment O
was O
lower O
than O
that O
of O
H2O2 B
alone O
. O

Our O
study O
indicated O
that O
treatment O
of O
HepG2 O
cells O
with O
CSA O
induces O
Nrf2 O
- O
dependent O
ARE O
activity O
and O
gene O
expression O
of O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
NAD B
( I
P I
) I
H I
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
, O
and O
glutamate B
- O
cysteine B
ligase O
modifier O
subunits O
by O
activation O
of O
PI3K O
/ O
AKT O
, O
ERK O
and O
JNK O
signaling O
pathways O
. O

Use O
of O
asenapine B
in O
clinical O
practice O
for O
the O
management O
of O
bipolar O
mania O
. O

Asenapine B
is O
a O
second O
- O
generation O
antipsychotic O
with O
a O
unique O
receptor O
binding O
profile O
, O
licensed O
for O
the O
treatment O
of O
manic O
episodes O
in O
adults O
with O
bipolar O
I O
disorder O
. O

Evidence O
from O
real O
- O
world O
case O
reports O
demonstrates O
that O
- O
as O
in O
clinical O
trials O
- O
asenapine B
is O
effective O
in O
treating O
mania O
and O
mixed O
episodes O
associated O
with O
bipolar O
I O
disorder O
, O
whether O
used O
as O
monotherapy O
or O
in O
combination O
with O
a O
mood O
stabiliser O
. O

Asenapine B
also O
shows O
promise O
in O
controlling O
depressive O
symptoms O
and O
clinically O
challenging O
mixed O
states O
. O

Asenapine B
has O
a O
favourable O
tolerability O
profile O
, O
compared O
with O
other O
first O
- O
line O
agents O
, O
having O
a O
minimal O
impact O
on O
weight O
and O
metabolic O
parameters O
. O

Asenapine B
should O
be O
considered O
a O
first O
- O
line O
treatment O
option O
for O
adults O
with O
bipolar O
I O
disorder O
. O

For O
this O
purpose O
, O
the O
right O
ventricular O
pressures O
( O
RVPs O
) O
and O
right O
ventricular O
/ O
heart O
weight O
( O
HW O
) O
ratios O
were O
compared O
between O
groups O
and O
the O
glutathione B
( O
GSH B
) O
level O
and O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
and O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
activities O
were O
determined O
in O
lung O
and O
liver O
tissue O
samples O
of O
rats O
. O

MCT O
- O
induced O
pulmonary O
hypertension O
resulted O
in O
decreased O
GSH B
level O
, O
decreased O
GST O
and O
SOD O
activities O
and O
increased O
CAT O
activity O
in O
lung O
and O
liver O
tissues O
of O
both O
male O
and O
female O
rats O
. O

In O
addition O
, O
the O
lung O
and O
liver O
GSH B
level O
and O
GST O
and O
SOD O
levels O
were O
higher O
in O
female O
control O
rats O
compared O
to O
male O
control O
rats O
. O

Rats O
received O
three O
injections O
( O
90 O
- O
min O
intervals O
, O
0 O
. O
2 O
mL O
/ O
kg O
) O
of O
0 O
. O
9 O
% O
NaCl B
, O
0 O
. O
5 O
% O
ropivacaine O
or O
1 O
. O
0 O
% O
ropivacaine O
via O
an O
implanted O
intrathecal O
catheter O
. O

Furthermore O
, O
in O
the O
rat O
spinal O
cord O
1 O
. O
0 O
% O
ropivacaine O
induced O
the O
down O
- O
regulation O
of O
voltage O
- O
dependent O
anion O
channel O
2 O
( O
VDAC2 O
) O
and O
mitochondrial O
pyruvate B
dehydrogenase O
subunit O
alpha O
( O
ODPA O
) O
, O
the O
upregulation O
of O
myelin O
basic O
protein O
( O
MBP O
) O
, O
the O
disappearance O
of O
myelin O
transcription O
factor O
1 O
( O
MYT1 O
) O
and O
the O
appearance O
of O
heat O
shock O
protein O
25 O
( O
HSP25 O
) O
. O

We O
investigate O
temperature O
- O
dependence O
of O
free O
energetics O
with O
two O
single O
halide B
anions O
, O
I B
- O
and O
Cl B
- O
, O
crossing O
the O
aqueous O
liquid O
- O
vapor O
interface O
through O
molecular O
dynamics O
simulations O
. O

The O
result O
shows O
that O
I B
- O
has O
a O
modest O
surface O
stability O
of O
0 O
. O
5 O
kcal O
/ O
mol O
at O
300 O
K O
and O
the O
stability O
decreases O
as O
the O
temperature O
increases O
, O
indicating O
the O
surface O
adsorption O
process O
for O
the O
anion O
is O
entropically O
disfavored O
. O

In O
contrast O
, O
Cl B
- O
shows O
no O
such O
surface O
state O
at O
all O
temperatures O
. O

Calculations O
of O
surface O
fluctuations O
demonstrate O
that O
I B
- O
generates O
significantly O
greater O
interfacial O
fluctuations O
compared O
to O
Cl B
- O
. O

The O
fluctuation O
is O
attributed O
to O
the O
malleability O
of O
the O
solvation O
shells O
, O
which O
allows O
for O
more O
long O
- O
ranged O
perturbations O
and O
solvent O
density O
redistribution O
induced O
by O
I B
- O
as O
the O
anion O
approaches O
the O
liquid O
- O
vapor O
interface O
. O

The O
increase O
in O
temperature O
of O
the O
solvent O
enhances O
the O
inherent O
thermally O
- O
excited O
fluctuations O
and O
consequently O
reduces O
the O
relative O
contribution O
from O
anion O
to O
surface O
fluctuations O
, O
which O
is O
consistent O
with O
the O
decrease O
in O
surface O
- O
stability O
of O
I B
- O
. O

Molecular O
Mechanism O
of O
the O
Inhibition O
of O
EGCG B
on O
the O
Alzheimer O
A O
beta O
1 O
- O
42 O
Dimer O
. O

The O
polyphenol B
( B
- I
) I
- I
epigallocatechin I
gallate I
( O
EGCG B
) O
was O
recently O
reported O
to O
inhibit O
A O
beta O
fibrillization O
and O
redirect O
A O
beta O
aggregation O
into O
unstructured O
, O
off O
- O
pathway O
oligomers O
. O

Given O
the O
experimental O
challenge O
to O
characterize O
the O
structures O
of O
A O
beta O
/ O
EGCG B
complexes O
, O
we O
performed O
extensive O
atomistic O
replica O
exchange O
molecular O
dynamics O
simulations O
of O
A O
beta O
1 O
- O
42 O
dimer O
in O
the O
present O
and O
absence O
of O
EGCG B
in O
explicit O
solvent O
. O

Our O
equilibrium O
A O
beta O
dimeric O
structures O
free O
of O
EGCG B
are O
consistent O
with O
the O
collision O
cross O
section O
from O
ion O
- O
mobility O
mass O
spectrometry O
and O
the O
secondary O
structure O
composition O
from O
circular O
dichroism O
experiment O
. O

In O
the O
presence O
of O
EGCG B
, O
the O
A O
beta O
structures O
are O
characterized O
by O
increased O
inter O
- O
center O
- O
of O
- O
mass O
distances O
, O
reduced O
interchain O
and O
intrachain O
contacts O
, O
reduced O
beta O
- O
sheet O
content O
, O
and O
increased O
coil O
and O
alpha O
- O
helix O
contents O
. O

Analysis O
of O
the O
free O
energy O
surfaces O
reveals O
that O
the O
A O
beta O
dimer O
with O
EGCG B
adopts O
new O
conformations O
, O
affecting O
therefore O
its O
propensity O
to O
adopt O
fibril O
- O
prone O
states O
. O

Overall O
, O
this O
study O
provides O
, O
for O
the O
first O
time O
, O
insights O
on O
the O
equilibrium O
structures O
of O
A O
beta O
1 O
- O
42 O
dimer O
in O
explicit O
aqueous O
solution O
and O
an O
atomic O
picture O
of O
the O
EGCG B
- O
mediated O
conformational O
change O
on O
A O
beta O
dimer O
. O

Lipopolysaccharide O
Interactions O
of O
C B
- O
Terminal O
Peptides O
from O
Human O
Thrombin O
. O

Interactions O
with O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
, O
both O
in O
aqueous O
solution O
and O
in O
lipid O
membranes O
, O
were O
investigated O
for O
a O
series O
of O
amphiphilic O
peptides O
derived O
from O
the O
C B
- O
terminal O
region O
of O
human O
thrombin O
, O
using O
ellipsometry O
, O
dual O
polarization O
interferometry O
, O
fluorescence O
spectroscopy O
, O
circular O
dichroism O
( O
CD O
) O
, O
dynamic O
light O
scattering O
, O
and O
z O
- O
potential O
measurements O
. O

The O
ability O
of O
these O
peptides O
to O
block O
endotoxic O
effects O
caused O
by O
LPS O
, O
monitored O
through O
NO B
production O
in O
macrophages O
, O
was O
compared O
to O
peptide O
binding O
to O
LPS O
and O
its O
endotoxic O
component O
lipid O
A O
, O
and O
to O
size O
, O
charge O
, O
and O
secondary O
structure O
of O
peptide O
/ O
LPS O
complexes O
. O

While O
the O
antiendotoxic O
peptide O
GKY25 O
( O
GKYGFYTHVFRLKKWIQKVI O
) O
displayed O
significant O
binding O
to O
both O
LPS O
and O
lipid O
A O
, O
so O
did O
two O
control O
peptides O
with O
either O
selected O
D B
- I
amino I
acid I
substitutions O
or O
with O
maintained O
composition O
but O
scrambled O
sequence O
, O
both O
displaying O
strongly O
attenuated O
antiendotoxic O
effects O
. O

Structural O
Changes O
in O
Cytochrome O
c O
Oxidase O
Induced O
by O
Binding O
of O
Sodium B
and O
Calcium B
Ions O
: O
An O
ATR O
- O
FTIR O
Study O
. O

Attenuated O
total O
reflection O
Fourier O
transform O
infrared O
( O
ATR O
- O
FTIR O
) O
spectroscopy O
was O
used O
to O
investigate O
the O
binding O
of O
Na B
( I
+ I
) I
and O
Ca B
( I
2 I
+ I
) I
cations O
to O
bovine O
cytochrome O
c O
oxidase O
in O
its O
fully O
oxidized O
and O
partially O
reduced O
, O
cyanide B
- O
ligated O
( O
a O
( O
2 O
+ O
) O
a3 O
( O
3 O
+ O
) O
- O
CN O
) O
( O
mixed O
valence O
) O
forms O
. O

Dissociation O
constants O
for O
Na B
( I
+ I
) I
and O
Ca B
( I
2 I
+ I
) I
with O
the O
oxidized O
enzyme O
were O
1 O
. O
2 O
mM O
and O
11 O
mu O
M O
, O
respectively O
and O
Na B
( I
+ I
) I
binding O
appeared O
to O
involve O
cooperative O
binding O
of O
two O
Na B
( I
+ I
) I
. O

Ca B
( I
2 I
+ I
) I
binding O
induced O
a O
large O
IR O
spectrum O
, O
with O
prominent O
amide B
I O
/ O
II O
polypeptide O
changes O
, O
bandshifts O
assigned O
to O
carboxylate B
and O
an O
arginine B
, O
and O
a O
number O
of O
bandshifts O
of O
heme O
a O
. O

The O
Na B
( I
+ I
) I
- O
induced O
binding O
spectrum O
showed O
much O
weaker O
amide B
I O
/ O
II O
and O
heme O
a O
changes O
but O
had O
similar O
shifts O
assignable O
to O
carboxylate B
and O
arginine B
residues O
. O

Yeast O
CcO O
also O
displayed O
a O
calcium B
- O
induced O
IR O
and O
UV O
/ O
visible O
binding O
spectra O
, O
though O
of O
lower O
intensities O
. O

This O
was O
attributed O
to O
the O
difficulty O
in O
fully O
depleting O
Ca B
( I
2 I
+ I
) I
from O
its O
binding O
site O
, O
as O
has O
been O
found O
with O
bacterial O
CcOs O
. O

The O
implications O
of O
Ca B
( I
2 I
+ I
) I
/ O
Na B
( I
+ I
) I
ion O
binding O
are O
discussed O
in O
terms O
of O
structure O
and O
possible O
modulation O
of O
core O
catalytic O
function O
. O

NMDA B
receptor O
- O
dependent O
function O
and O
plasticity O
in O
inhibitory O
circuits O
. O

NMDA B
receptors O
have O
been O
known O
to O
play O
a O
central O
role O
in O
long O
- O
term O
potentiation O
at O
glutamatergic O
synapses O
in O
principal O
cells O
for O
thirty O
years O
. O

This O
review O
summarizes O
recent O
evidence O
on O
the O
role O
of O
NMDA B
receptors O
in O
the O
development O
and O
plasticity O
of O
GABAergic O
synapses O
on O
principal O
cells O
and O
of O
glutamatergic O
synapses O
on O
identified O
interneurons O
. O

A O
major O
challenge O
is O
to O
understand O
how O
NMDA B
receptors O
affect O
the O
routing O
of O
information O
in O
healthy O
inhibitory O
circuits O
, O
and O
how O
changes O
in O
NMDA B
receptor O
function O
may O
contribute O
to O
altered O
circuit O
function O
in O
disorders O
such O
as O
schizophrenia O
. O

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
" O
Glutamate B
receptor O
- O
dependent O
synaptic O
plasticity O
" O
. O

Amino B
acids I
as O
co O
- O
amorphous O
stabilizers O
for O
poorly O
water O
soluble O
drugs O
- O
Part O
1 O
: O
Preparation O
, O
stability O
and O
dissolution O
enhancement O
. O

In O
this O
study O
, O
we O
investigated O
a O
fundamentally O
different O
approach O
to O
stabilize O
the O
amorphous O
form O
of O
drugs O
, O
namely O
the O
use O
of O
amino B
acids I
as O
small O
molecular O
weight O
excipients O
that O
form O
specific O
molecular O
interactions O
with O
the O
drug O
resulting O
in O
co O
- O
amorphous O
forms O
. O

The O
two O
poorly O
water O
soluble O
drugs O
carbamazepine B
and O
indomethacin B
were O
combined O
with O
amino B
acids I
from O
the O
binding O
sites O
of O
the O
biological O
receptors O
of O
these O
drugs O
. O

Mixtures O
of O
drug O
and O
the O
amino B
acids I
arginine B
, O
phenylalanine B
, O
tryptophan B
and O
tyrosine B
were O
prepared O
by O
vibrational O
ball O
milling O
. O

The O
dissolution O
rate O
of O
all O
co O
- O
amorphous O
drug O
- O
amino B
acid I
mixtures O
was O
significantly O
increased O
over O
that O
of O
the O
respective O
crystalline O
and O
amorphous O
pure O
drugs O
. O

Amino B
acids I
thus O
appear O
as O
promising O
excipients O
to O
solve O
challenges O
connected O
with O
the O
stability O
and O
dissolution O
of O
amorphous O
drugs O
. O

Dysfunctions O
of O
the O
translational O
machinery O
in O
digestive O
glands O
of O
mussels O
exposed O
to O
mercury B
ions O
. O

Mercury B
is O
an O
element O
naturally O
occurring O
in O
the O
biosphere O
, O
but O
is O
also O
released O
into O
the O
environment O
by O
human O
activities O
, O
such O
as O
mining O
, O
smelting O
, O
and O
industrial O
discharge O
. O

Mercury B
is O
a O
biologically O
harmful O
element O
and O
any O
exposure O
of O
living O
organisms O
mainly O
due O
to O
contamination O
, O
can O
cause O
severe O
or O
even O
lethal O
side O
effects O
. O

In O
every O
form O
detected O
, O
elemental O
, O
inorganic O
, O
or O
organic O
, O
mercury B
exhibits O
toxicity O
associated O
with O
induced O
oxidative O
stress O
. O

Although O
the O
genotoxicity O
of O
mercury B
has O
been O
well O
demonstrated O
in O
mussels O
, O
little O
is O
known O
about O
its O
toxic O
effects O
on O
the O
translational O
machinery O
at O
the O
molecular O
level O
. O

To O
investigate O
possible O
effects O
, O
we O
exposed O
the O
common O
mussel O
Mytilus O
galloprovincialis O
in O
seawater O
supplemented O
by O
30 O
mu O
g O
/ O
L O
Hg B
( I
2 I
+ I
) I
for O
15 O
days O
. O

We O
observed O
that O
Hg B
( I
2 I
+ I
) I
was O
significantly O
accumulated O
in O
the O
digestive O
glands O
of O
mussels O
, O
reaching O
a O
level O
around O
80 O
mu O
g O
/ O
g O
tissue O
( O
dry O
weight O
) O
at O
the O
15th O
day O
of O
exposure O
. O

Exposure O
of O
mussels O
to O
Hg B
( I
2 I
+ I
) I
resulted O
in O
failure O
of O
redox O
homeostasis O
, O
as O
reflected O
on O
lipid O
peroxidation O
levels O
and O
superoxide B
dismutase O
activity O
in O
glands O
, O
and O
micronucleus O
frequency O
in O
gills O
. O

Extracts O
from O
digestive O
glands O
after O
15 O
- O
day O
exposure O
to O
Hg B
( I
2 I
+ I
) I
exhibited O
decreased O
tRNA O
aminoacylation O
ability O
and O
, O
moreover O
, O
a O
70 O
% O
reduction O
in O
the O
ability O
of O
40S O
ribosomal O
subunits O
to O
form O
the O
48S O
initiation O
ribosomal O
complex O
. O

A O
similar O
reduction O
was O
detected O
in O
the O
ability O
of O
ribosomes O
to O
translocate O
peptidyl O
- O
tRNA O
from O
the O
A O
- O
site O
to O
the O
P O
- O
site O
, O
an O
observation O
coinciding O
with O
the O
notion O
that O
regulation O
of O
protein O
synthesis O
by O
Hg B
( I
2 I
+ I
) I
mainly O
occurs O
at O
the O
initiation O
and O
elongation O
stages O
of O
translation O
. O

In O
conclusion O
, O
Hg B
( I
2 I
+ I
) I
apart O
from O
being O
a O
genotoxic O
ion O
acts O
as O
a O
modulator O
of O
protein O
synthesis O
in O
mussels O
, O
an O
observation O
probably O
related O
with O
its O
ability O
to O
induce O
oxidative O
stress O
. O

Lead O
, O
mercury B
, O
and O
cadmium B
in O
blood O
and O
their O
relation O
to O
diet O
among O
Swedish O
adults O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
body O
burden O
of O
lead O
( O
Pb B
) O
, O
mercury B
( O
Hg B
) O
, O
and O
cadmium B
( O
Cd B
) O
in O
blood O
among O
Swedish O
adults O
and O
the O
association O
between O
blood O
levels O
, O
diet O
and O
other O
lifestyle O
factors O
. O

Lead O
, O
Hg B
, O
and O
Cd B
were O
measured O
in O
whole O
blood O
, O
and O
Cd B
additionally O
in O
urine O
, O
by O
mass O
or O
fluorescence O
spectrometry O
methods O
. O

The O
median O
values O
( O
5 O
- O
95th O
percentiles O
) O
of O
the O
metals O
in O
blood O
were O
as O
follows O
; O
Pb B
: O
13 O
. O
4 O
( O
5 O
. O
8 O
- O
28 O
. O
6 O
) O
mu O
g O
/ O
L O
, O
Hg B
: O
1 O
. O
13 O
( O
0 O
. O
31 O
- O
3 O
. O
45 O
) O
mu O
g O
/ O
L O
, O
and O
Cd B
: O
0 O
. O
19 O
( O
0 O
. O
09 O
- O
1 O
. O
08 O
) O
mu O
g O
/ O
L O
. O

Lead O
levels O
in O
blood O
were O
positively O
associated O
with O
intakes O
of O
game O
and O
alcohol B
, O
Hg B
was O
related O
to O
fish O
intake O
, O
and O
blood O
Cd B
related O
to O
smoking O
and O
low O
iron B
stores O
and O
to O
a O
low O
meat O
intake O
. O

Body O
burdens O
of O
the O
studied O
metals O
were O
generally O
below O
health O
based O
reference O
values O
, O
but O
several O
individuals O
had O
blood O
Pb B
levels O
above O
the O
reference O
point O
for O
possible O
nephrotoxic O
and O
developmental O
neurotoxic O
effects O
. O

As O
health O
effects O
cannot O
be O
excluded O
, O
individuals O
with O
high O
Pb B
exposure O
should O
aim O
at O
decreasing O
their O
body O
burden O
, O
both O
from O
food O
and O
from O
other O
exposure O
routes O
. O

The O
involvement O
of O
heme B
oxygenase O
1 O
but O
not O
nitric B
oxide I
synthase O
2 O
in O
a O
hepatoprotective O
action O
of O
quercetin B
in O
lipopolysaccharide O
- O
induced O
hepatotoxicity O
of O
d B
- I
galactosamine I
sensitized O
rats O
. O

The O
objective O
of O
this O
study O
was O
to O
evaluate O
potential O
hepatoprotective O
capabilities O
of O
quercetin B
in O
relation O
to O
its O
modulation O
of O
the O
HO O
- O
1 O
and O
NOS O
- O
2 O
activities O
in O
an O
experimental O
model O
of O
fulminant O
liver O
failure O
. O

Liver O
insult O
was O
induced O
by O
in O
vivo O
administration O
of O
d B
- I
galactosamine I
( O
d B
- I
GalN I
, O
400mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lipopolysaccharide O
( O
LPS O
, O
10 O
mu O
g O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

The O
effects O
of O
quercetin B
( O
50mg O
/ O
kg O
, O
i O
. O
p O
) O
on O
d B
- I
GalN I
toxicity O
was O
evaluated O
by O
standard O
biochemical O
, O
RT O
- O
PCR O
and O
Western O
blot O
methods O
. O

Administration O
of O
d B
- I
GalN I
/ O
LPS O
combination O
resulted O
in O
significantly O
higher O
plasma O
levels O
of O
aminotransferases O
, O
as O
well O
as O
increased O
mRNA O
and O
protein O
expressions O
of O
both O
HO O
- O
1 O
and O
NOS O
- O
2 O
enzymes O
. O

Quercetin B
exhibited O
cytoprotective O
effects O
on O
the O
liver O
, O
as O
evidenced O
by O
decreased O
aminotransferase O
plasma O
levels O
. O

Additionally O
, O
quercetin B
treatment O
in O
d B
- I
GalN I
/ O
LPS O
treated O
rats O
significantly O
increased O
HO O
- O
1 O
mRNA O
and O
its O
protein O
expressions O
. O

On O
the O
contrary O
, O
quercetin B
did O
not O
exhibit O
any O
significant O
effects O
on O
the O
levels O
of O
nitrites O
, O
and O
NOS O
- O
2 O
mRNA O
and O
protein O
expressions O
in O
d B
- I
GalN I
/ O
LPS O
treated O
rats O
. O

Quercetin B
when O
given O
alone O
did O
not O
have O
any O
significant O
changes O
on O
liver O
enzymes O
nor O
HO O
- O
1 O
and O
NOS O
- O
2 O
mRNA O
and O
protein O
expressions O
. O

It O
can O
be O
concluded O
that O
the O
quercetin B
' O
s O
induction O
of O
HO O
- O
1 O
and O
its O
byproducts O
, O
without O
concomitant O
NOS O
- O
2 O
activity O
reduction O
, O
is O
among O
mechanisms O
contributing O
to O
the O
hepatoprotective O
effect O
in O
d B
- I
GalN I
/ O
LPS O
hepatotoxicity O
. O

Flame O
- O
generated O
organic O
carbon B
nanoparticles O
( O
OC O
NPs O
) O
provide O
interesting O
model O
nanoparticles O
that O
simulate O
fresh O
combustion O
emissions O
near O
roadways O
or O
combustion O
sources O
. O

Discovery O
of O
adamantane B
based O
highly O
potent O
HDAC O
inhibitors O
. O

A O
series O
of O
adamantane B
and O
nor O
- O
adamantane B
based O
HDAC O
inhibitors O
were O
designed O
, O
synthesized O
and O
screened O
for O
the O
inhibitory O
activity O
of O
HDAC O
. O

EZETIMIBE O
INCREASES O
HEPATIC O
IRON B
LEVELS O
IN O
MICE O
FED O
A O
HIGH O
- O
FAT O
DIET O
. O

Phlebotomy O
and O
dietary O
iron B
restriction O
reduces O
serum O
transaminase O
in O
NAFLD O
/ O
NASH O
patients O
. O

Recent O
studies O
showed O
that O
mutual O
effects O
exist O
between O
lipid O
metabolism O
and O
iron B
metabolism O
. O

Accordingly O
, O
the O
effects O
of O
ezetimibe O
on O
iron B
metabolism O
were O
examined O
in O
mice O
fed O
a O
high O
- O
fat O
diet O
with O
or O
without O
iron B
. O

In O
Experiment O
1 O
, O
hepatic O
iron B
levels O
were O
higher O
in O
HE O
than O
H O
, O
whereas O
there O
was O
no O
difference O
between O
C O
and O
CE O
. O

In O
Experiment O
2 O
, O
hepatic O
iron B
concentrations O
were O
higher O
in O
HIE O
than O
HI O
. O

Ezetimibe O
induced O
hepatic O
iron B
uptake O
transporter O
expression O
in O
mice O
fed O
a O
high O
- O
fat O
diet O
, O
causing O
increased O
hepatic O
iron B
concentrations O
. O

Astaxanthin B
Suppresses O
MPP B
+ I
- O
Induced O
Oxidative O
Damage O
in O
PC12 O
Cells O
through O
a O
Sp1 O
/ O
NR1 O
Signaling O
Pathway O
. O

Objective O
: O
To O
investigate O
astaxanthin B
( O
ATX O
) O
neuroprotection O
, O
and O
its O
mechanism O
, O
on O
a O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
pyridine O
ion O
( O
MPP B
+ I
) O
- O
induced O
cell O
model O
of O
Parkinson O
' O
s O
disease O
. O

Methods O
: O
Mature O
, O
differentiated O
PC12 O
cells O
treated O
with O
MPP B
+ I
were O
used O
as O
an O
in O
vitro O
cell O
model O
. O

The O
MTT B
assay O
was O
used O
to O
investigate O
cell O
viability O
after O
ATX O
treatment O
, O
and O
western O
blot O
analysis O
was O
used O
to O
observe O
Sp1 O
( O
activated O
transcription O
factor O
1 O
) O
and O
NR1 O
( O
NMDA B
receptor O
subunit O
1 O
) O
protein O
expression O
, O
real O
- O
time O
PCR O
was O
used O
to O
monitor O
Sp1 O
and O
NR1 O
mRNA O
, O
and O
cell O
immunofluorescence O
was O
used O
to O
determine O
the O
location O
of O
Sp1 O
and O
NR1 O
protein O
and O
the O
nuclear O
translocation O
of O
Sp1 O
. O

Results O
: O
PC12 O
cell O
viability O
was O
significantly O
reduced O
by O
MPP B
+ I
treatment O
. O

Following O
co O
- O
treatment O
with O
ATX O
and O
MPP B
+ I
, O
cell O
viability O
was O
significantly O
increased O
, O
and O
Sp1 O
and O
NR1 O
mRNA O
and O
protein O
were O
decreased O
, O
compared O
with O
the O
MPP B
+ I
groups O
( O
p O
< O
0 O
. O
01 O
) O
. O

In O
addition O
, O
mithracycin O
A O
protected O
PC12 O
cells O
from O
oxidative O
stress O
caused O
by O
MPP B
+ I
by O
specifically O
inhibiting O
the O
expression O
of O
Sp1 O
. O

Conclusion O
: O
ATX O
inhibited O
oxidative O
stress O
induced O
by O
MPP B
+ I
in O
PC12 O
cells O
, O
via O
the O
SP1 O
/ O
NR1 O
signaling O
pathway O
. O

The O
constitutive O
active O
/ O
androstane B
receptor O
( O
CAR O
) O
regulates O
hepatic O
drug O
metabolism O
by O
activating O
genes O
such O
as O
cytochrome O
P450 O
( O
CYP O
) O
and O
certain O
transferases O
. O

Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin B
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand O
- O
treated O
human O
primary O
hepatocytes O
. O

siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin B
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O

In O
addition O
to O
CYP2B6 O
, O
anisomycin B
co O
- O
treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O
UDP B
- O
glucuronosyltransfer O
1A1 O
mRNAs O
. O

Amphetamine B
, O
past O
and O
present O
- O
a O
pharmacological O
and O
clinical O
perspective O
. O

Amphetamine B
was O
discovered O
over O
100 O
years O
ago O
. O

This O
review O
describes O
the O
relationship O
between O
chemical O
structure O
and O
pharmacology O
of O
amphetamine B
and O
its O
congeners O
. O

Amphetamine B
' O
s O
diverse O
pharmacological O
actions O
translate O
not O
only O
into O
therapeutic O
efficacy O
, O
but O
also O
into O
the O
production O
of O
adverse O
events O
and O
liability O
for O
recreational O
abuse O
. O

The O
review O
charts O
advances O
in O
pharmaceutical O
development O
from O
the O
introduction O
of O
once O
- O
daily O
formulations O
of O
amphetamine B
through O
to O
lisdexamfetamine O
, O
which O
is O
the O
first O
d B
- I
amphetamine I
prodrug O
approved O
for O
the O
management O
of O
ADHD O
in O
children O
, O
adolescents O
and O
adults O
. O

The O
unusual O
metabolic O
route O
for O
lisdexamfetamine O
to O
deliver O
d B
- I
amphetamine I
makes O
an O
important O
contribution O
to O
its O
pharmacology O
. O

Using O
a O
structure O
based O
design O
approach O
we O
have O
identified O
a O
series O
of O
indazole B
substituted O
pyrrolopyrazines O
, O
which O
are O
potent O
inhibitors O
of O
JAK3 O
. O

Compounds O
bearing O
this O
conformation O
participated O
in O
a O
favorable O
hydrophobic O
interaction O
with O
a O
cysteine B
residue O
in O
the O
JAK3 O
binding O
pocket O
, O
which O
imparted O
high O
selectivity O
versus O
the O
kinome O
and O
improved O
selectivity O
within O
the O
JAK O
family O
. O

Copper B
- O
catalyzed O
diastereoselective O
arylation O
of O
tryptophan B
derivatives O
: O
total O
synthesis O
of O
( O
+ O
) O
- O
naseseazines O
a O
and O
B O
. O

A O
copper B
- O
catalyzed O
arylation O
of O
tryptophan B
derivatives O
is O
reported O
. O

Surface O
grafting O
of O
crystalline O
and O
ultrafine O
cellulose O
nanofibrils O
with O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
chains O
via O
ionic O
bonds O
was O
achieved O
by O
a O
simple O
ion O
- O
exchange O
treatment O
. O

The O
PEG B
- O
grafted O
cellulose O
nanofibrils O
exhibited O
nanodispersibility O
in O
organic O
solvents O
such O
as O
chloroform B
, O
toluene B
, O
and O
tetrahydrofuran B
. O

Then O
, O
the O
PEG B
- O
grafted O
cellulose O
nanofibril O
/ O
chloroform B
dispersion O
and O
poly B
( I
l I
- I
lactide I
) I
( O
PLLA B
) O
/ O
chloroform B
solution O
were O
mixed O
, O
and O
the O
PEG B
- O
grafted O
cellulose O
nanofibril O
/ O
PLLA B
composite O
films O
with O
various O
blend O
ratios O
were O
prepared O
by O
casting O
the O
mixtures O
on O
a O
plate O
and O
drying O
. O

The O
highly O
efficient O
nanocomposite O
effect O
was O
explained O
in O
terms O
of O
achievement O
of O
nanodispersion O
states O
of O
the O
PEG B
- O
grafted O
cellulose O
nanofibrils O
in O
the O
PLLA B
matrix O
. O

Moreover O
, O
some O
attractive O
interactions O
mediated O
by O
the O
PEG B
chains O
were O
likely O
to O
be O
formed O
between O
the O
cellulose O
nanofibrils O
and O
PLLA B
molecules O
in O
the O
composites O
, O
additionally O
enhancing O
the O
efficient O
nanocomposite O
effect O
. O

The O
present O
methodology O
is O
demonstrated O
by O
synthesizing O
a O
two O
- O
component O
CdSe B
/ O
CdS B
nanoparticle O
dimer O
, O
constructed O
in O
a O
way O
that O
both O
CdSe B
and O
CdS B
semiconductor O
domains O
are O
exposed O
to O
the O
external O
environment O
. O

Hydrogen B
production O
tests O
confirmed O
the O
improved O
catalytic O
activity O
of O
CdSe B
/ O
CdS B
dimers O
, O
which O
was O
enhanced O
3 O
- O
4 O
times O
upon O
etching O
treatment O
. O

Synergistic O
effects O
of O
diosmetin O
with O
erythromycin B
against O
ABC O
transporter O
over O
- O
expressed O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
RN4220 O
/ O
pUL5054 O
and O
inhibition O
of O
MRSA O
pyruvate B
kinase O
. O

Increasing O
prevalence O
of O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
worldwide O
with O
limited O
therapeutic O
options O
is O
a O
growing O
public O
health O
concern O
. O

Flavonoids B
from O
natural O
products O
have O
been O
shown O
to O
possess O
antibacterial O
actions O
against O
MRSA O
by O
antagonizing O
its O
resistance O
mechanisms O
. O

Diosmin O
and O
diosmetin O
are O
natural O
flavonoids B
found O
in O
a O
variety O
of O
citrus O
fruits O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
diosmin O
and O
diosmetin O
could O
inhibit O
the O
growth O
of O
MRSA O
and O
the O
in O
vitro O
enzymatic O
activity O
of O
a O
newly O
discovered O
MRSA O
drug O
target O
, O
pyruvate B
kinase O
( O
PK O
) O
. O

However O
, O
in O
checkerboard O
assay O
, O
we O
found O
that O
diosmetin O
together O
with O
erythromycin B
, O
could O
synergistically O
inhibit O
the O
growth O
of O
ABC O
- O
pump O
overexpressed O
MRSA O
- O
RN4220 O
/ O
pUL5054 O
, O
and O
time O
kill O
assay O
also O
showed O
that O
the O
antibacterial O
activities O
of O
diosmetin O
with O
erythromycin B
were O
bactericidal O
. O

In O
conclusion O
, O
the O
inhibition O
of O
MRSA O
PK O
by O
diosmetin O
could O
lead O
to O
a O
deficiency O
of O
ATP B
and O
affect O
the O
bacterial O
efflux O
pump O
which O
might O
contribute O
to O
the O
antibacterial O
actions O
of O
diosmetin O
against O
MRSA O
. O

Endothelin O
- O
3 O
Expression O
in O
the O
Subfornical O
Organ O
Enhances O
the O
Sensitivity O
of O
Nax O
, O
the O
Brain O
Sodium B
- O
Level O
Sensor O
, O
to O
Suppress O
Salt O
Intake O
. O

Here O
, O
we O
found O
that O
the O
sensitivity O
of O
Nax O
channels O
to O
[ O
Na B
( I
+ I
) I
] O
o O
is O
dose O
- O
dependently O
enhanced O
by O
endothelin O
- O
3 O
( O
ET O
- O
3 O
) O
. O

Nax O
channels O
began O
to O
open O
when O
[ O
Na B
( I
+ I
) I
] O
o O
exceeded O
~ O
150 O
mM O
without O
ET O
- O
3 O
, O
but O
opened O
fully O
at O
a O
physiological O
[ O
Na B
( I
+ I
) I
] O
o O
( O
135 O
- O
145 O
mM O
) O
with O
1 O
nM O
ET O
- O
3 O
. O

Pharmacological O
experiments O
revealed O
that O
endothelin O
receptor O
B O
( O
ETBR O
) O
signaling O
is O
involved O
in O
this O
modulation O
of O
Nax O
gating O
through O
protein O
kinase O
C O
and O
ERK1 O
/ O
2 O
activation O
. O
ETBR O
agonists O
increased O
the O
firing O
rate O
of O
GABAergic O
neurons O
via O
lactate B
in O
the O
SFO O
, O
and O
an O
ETBR O
antagonist O
attenuated O
salt O
aversion O
during O
dehydration O
. O

These O
results O
indicate O
that O
ET O
- O
3 O
expression O
in O
the O
SFO O
is O
tightly O
coupled O
with O
body O
- O
fluid O
homeostasis O
through O
modulation O
of O
the O
[ O
Na B
( I
+ I
) I
] O
o O
sensitivity O
of O
Nax O
. O

Muscle O
contractures O
to O
exogenous O
ACh B
and O
KCl B
were O
unaffected O
. O

- O
2 O
mV O
after O
120 O
min O
; O
n O
= O
5 O
; O
p O
< O
0 O
. O
05 O
] O
, O
with O
no O
significant O
change O
in O
the O
depolarizing O
response O
to O
exogenous O
carbachol B
. O

Selenium B
and O
mercury B
molar O
ratios O
in O
commercial O
fish O
from O
New O
Jersey O
and O
Illinois O
: O
Variation O
within O
species O
and O
relevance O
to O
risk O
communication O
. O

There O
is O
an O
emerging O
consensus O
that O
people O
consuming O
large O
amounts O
of O
fish O
with O
selenium B
: O
mercury B
ratios O
below O
1 O
are O
at O
higher O
risk O
from O
mercury B
toxicity O
. O

As O
the O
relative O
amount O
of O
selenium B
increases O
compared O
to O
mercury B
, O
risk O
may O
be O
lowered O
, O
but O
it O
is O
unclear O
how O
much O
excess O
selenium B
is O
required O
. O

It O
would O
be O
useful O
if O
the O
selenium B
: O
mercury B
ratio O
was O
relatively O
consistent O
within O
a O
species O
, O
but O
this O
has O
not O
been O
the O
case O
in O
our O
studies O
of O
wild O
- O
caught O
fish O
. O

Since O
most O
people O
in O
developed O
countries O
and O
urban O
areas O
obtain O
their O
fish O
and O
other O
seafood O
commercially O
, O
we O
examined O
selenium B
: O
mercury B
molar O
ratios O
in O
commercial O
fish O
purchased O
in O
stores O
and O
fish O
markets O
in O
central O
New O
Jersey O
and O
Chicago O
. O

Across O
species O
the O
selenium B
: O
mercury B
molar O
ratio O
decreased O
with O
increasing O
mean O
mercury B
levels O
, O
but O
selenium B
variation O
also O
contributed O
to O
the O
ratio O
. O

Few O
samples O
had O
selenium B
: O
mercury B
molar O
ratios O
below O
1 O
, O
but O
there O
was O
a O
wide O
range O
in O
ratios O
, O
complicating O
the O
interpretation O
for O
use O
in O
risk O
management O
and O
communication O
. O

Before O
ratios O
can O
be O
used O
in O
risk O
management O
, O
more O
information O
is O
needed O
on O
mercury B
: O
selenium B
interactions O
and O
mutual O
bioavailability O
, O
and O
on O
the O
relationship O
between O
molar O
ratios O
and O
health O
outcomes O
. O

Further O
, O
people O
who O
are O
selenium B
deficient O
may O
be O
more O
at O
risk O
from O
mercury B
toxicity O
than O
others O
. O

We O
demonstrate O
the O
difficulty O
of O
realising O
a O
phosphorylation O
step O
on O
the O
anomeric O
position O
of O
2 O
- O
deoxyribose O
, O
and O
we O
discover O
that O
introduction O
of O
fluorine B
atoms O
on O
the O
2 O
position O
of O
2 O
- O
deoxyribose O
enables O
the O
phosphorylation O
step O
: O
in O
fact O
, O
the O
stability O
of O
the O
prodrugs O
increases O
with O
the O
degree O
of O
2 O
- O
fluorination O
. O

Posttranslational O
mechanisms O
modulating O
the O
expression O
of O
the O
cytochrome O
P450 O
1A1 O
gene O
by O
methylmercury B
in O
HepG2 O
cells O
: O
A O
role O
of O
heme B
oxygenase O
- O
1 O
. O

Recently O
we O
demonstrated O
the O
ability O
of O
mercuric B
chloride I
( O
Hg B
( I
2 I
+ I
) I
) O
in O
human O
hepatoma O
HepG2 O
cells O
to O
significantly O
decrease O
the O
TCDD B
- O
mediated O
induction O
of O
Cytochrome O
P450 O
1A1 O
( O
CYP1A1 O
) O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O

In O
this O
study O
we O
investigated O
the O
effect O
of O
methylmercury B
( O
MeHg B
) O
on O
CYP1A1 O
in O
HepG2 O
cells O
. O

For O
this O
purpose O
, O
cells O
were O
co O
- O
exposed O
to O
MeHg B
and O
TCDD B
and O
the O
expression O
of O
CYP1A1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
were O
determined O
. O

Our O
results O
showed O
that O
MeHg B
did O
not O
alter O
the O
TCDD B
- O
mediated O
induction O
of O
CYP1A1 O
mRNA O
, O
or O
protein O
levels O
; O
however O
it O
was O
able O
to O
significantly O
decrease O
CYP1A1 O
catalytic O
activity O
levels O
in O
a O
concentration O
- O
dependent O
manner O
. O

Importantly O
, O
this O
inhibition O
was O
specific O
to O
CYP1A1and O
was O
not O
radiated O
to O
other O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
regulated O
genes O
, O
as O
MeHg B
induced O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
1 O
mRNA O
and O
protein O
levels O
. O

Mechanistically O
, O
the O
inhibitory O
effect O
of O
MeHg B
on O
the O
induction O
of O
CYP1A1 O
coincided O
with O
an O
increase O
in O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
mRNA O
levels O
. O

Furthermore O
, O
the O
inhibition O
of O
HO O
- O
1 O
activity O
, O
by O
tin O
mesoporphyrin O
, O
caused O
a O
complete O
restoration O
of O
MeHg B
- O
mediated O
inhibition O
of O
CYP1A1 O
activity O
, O
induced O
by O
TCDD B
. O

In O
addition O
, O
transfection O
of O
HepG2 O
cells O
with O
siRNA O
targeting O
the O
human O
HO O
- O
1 O
gene O
reversed O
the O
MeHg B
- O
mediated O
inhibition O
of O
TCDD B
- O
induced O
CYP1A1 O
. O

In O
conclusion O
, O
this O
study O
demonstrated O
that O
MeHg B
inhibited O
the O
TCDD B
- O
mediated O
induction O
of O
CYP1A1 O
through O
a O
posttranslational O
mechanism O
and O
confirms O
the O
role O
of O
HO O
- O
1 O
in O
a O
MeHg B
- O
mediated O
effect O
. O

The O
two O
C B
- O
terminal O
domains O
of O
the O
ScpB O
dimer O
primarily O
interact O
with O
different O
regions O
of O
ScpA O
with O
different O
affinities O
. O

Biodegradable O
oligo B
( I
poly I
( I
ethylene I
glycol I
) I
fumarate I
) I
( O
OPF B
) O
composite O
hydrogels O
have O
been O
investigated O
for O
the O
delivery O
of O
growth O
factors O
( O
GFs O
) O
with O
the O
aid O
of O
gelatin O
microparticles O
( O
GMPs O
) O
and O
stem O
cell O
populations O
for O
osteochondral O
tissue O
regeneration O
. O

In O
this O
study O
, O
a O
bilayered O
OPF B
composite O
hydrogel O
that O
mimics O
the O
distinctive O
hierarchical O
structure O
of O
native O
osteochondral O
tissue O
was O
utilized O
to O
investigate O
the O
effect O
of O
transforming O
growth O
factor O
- O
beta O
3 O
( O
TGF O
- O
beta O
3 O
) O
with O
varying O
release O
kinetics O
and O
/ O
or O
insulin O
- O
like O
growth O
factor O
- O
1 O
( O
IGF O
- O
1 O
) O
on O
osteochondral O
tissue O
regeneration O
in O
a O
rabbit O
full O
- O
thickness O
osteochondral O
defect O
model O
. O

The O
four O
groups O
investigated O
included O
( O
i O
) O
a O
blank O
control O
( O
no O
GFs O
) O
, O
( O
ii O
) O
GMP O
- O
loaded O
IGF O
- O
1 O
alone O
, O
( O
iii O
) O
GMP O
- O
loaded O
IGF O
- O
1 O
and O
gel O
- O
loaded O
TGF O
- O
beta O
3 O
, O
and O
( O
iv O
) O
GMP O
- O
loaded O
IGF O
- O
1 O
and O
GMP O
- O
loaded O
TGF O
- O
beta O
3 O
in O
OPF B
composite O
hydrogels O
. O

Second O
, O
the O
bioactive O
compounds O
identified O
( O
epimedin O
A O
, O
epimedin O
B O
, O
epimedin O
C O
and O
icariin B
) O
were O
fished O
and O
knocked O
out O
using O
high O
- O
speed O
counter O
- O
current O
chromatography O
and O
preparative O
HPLC O
. O

Potential O
diagnostic O
applications O
of O
side O
chain O
oxysterols B
analysis O
in O
plasma O
and O
cerebrospinal O
fluid O
. O

The O
neurospecific O
cholesterol B
24 O
- O
hydroxylase O
converts O
excess O
brain O
cholesterol B
into O
24S O
- O
hydroxycholesterol O
( O
24OHC O
) O
which O
, O
via O
the O
liver O
X O
receptor O
( O
LXR O
) O
, O
can O
increase O
the O
expression O
and O
synthesis O
of O
astrocyte O
ApoE O
. O

24OHC O
effluxes O
directly O
from O
brain O
into O
plasma O
where O
it O
is O
considered O
an O
indicator O
of O
brain O
cholesterol B
turnover O
. O

Less O
than O
1 O
% O
of O
the O
total O
brain O
excretion O
of O
24OHC O
occurs O
via O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
whereas O
almost O
all O
27 B
- I
hydroxycholesterol I
( O
27OHC B
) O
excretion O
is O
dependent O
on O
the O
function O
of O
the O
blood O
- O
cerebrospinal O
fluid O
barrier O
. O

Iincreased O
CSF O
oxysterols B
were O
found O
in O
patients O
with O
neurodegenerative O
and O
neuroinflammatory O
diseases O
in O
the O
presence O
of O
barrier O
dysfunction O
. O

In O
neurodegeneration O
, O
free O
cholesterol B
released O
from O
dying O
cells O
may O
engulf O
neurons O
. O

Cholesterol B
also O
increases O
Amyloid O
beta O
( O
A O
beta O
) O
deposition O
and O
tau O
pathology O
. O

Excess O
of O
cholesterol B
converted O
into O
24OHC O
may O
up O
- O
regulate O
ApoE O
synthesis O
which O
is O
a O
scavenger O
for O
A O
beta O
and O
Tau O
. O

In O
AD O
this O
protective O
mechanism O
seems O
to O
be O
inefficient O
, O
probably O
due O
to O
the O
presence O
of O
high O
concentrations O
of O
27OHC B
, O
microvascular O
dysfunction O
and O
the O
decreased O
efficiency O
of O
ApoE4 O
as O
lipid O
transporter O
and O
A O
beta O
scavenger O
. O

Analysis O
of O
side O
chain O
oxysterols B
in O
the O
CSF O
is O
likely O
to O
provided O
useful O
information O
about O
cholesterol B
metabolism O
and O
ApoE O
function O
in O
the O
pathogenesis O
of O
AD O
. O

The O
plant O
anti O
- O
inflammatory O
action O
was O
assessed O
by O
its O
capability O
in O
inhibiting O
cell O
migration O
, O
enzymatic O
activity O
of O
myeloperoxidase O
( O
MPO O
) O
and O
production O
of O
nitrite B
/ O
nitrate B
or O
edema O
. O

Ethanol B
extract O
of O
Adiantum O
capillus O
- O
veneris O
L O
. O
suppresses O
the O
production O
of O
inflammatory O
mediators O
by O
inhibiting O
NF O
- O
kappa O
B O
activation O
. O

MATERIALS O
AND O
METHODS O
: O
The O
plant O
ethanolic O
extracts O
were O
initially O
tested O
against O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
prostaglandin B
E2 I
( O
PGE2 B
) O
production O
in O
RAW264 O
. O
7 O
mouse O
macrophages O
, O
and O
interleukin O
6 O
( O
IL O
- O
6 O
) O
and O
tumor O
necrosis O
factor O
( O
TNF O
) O
production O
in O
human O
U937 O
monocytes O
. O

RESULTS O
: O
The O
plant O
ethanolic O
extracts O
effectively O
suppressed O
PGE2 B
, O
IL O
- O
6 O
and O
TNF O
release O
with O
an O
IC50 O
less O
than O
50 O
mu O
g O
/ O
ml O
. O

Neuroprotection O
by O
steroids B
after O
neurotrauma O
in O
organotypic O
spinal O
cord O
cultures O
: O
A O
key O
role O
for O
progesterone B
receptors O
and O
steroidal O
modulators O
of O
GABAA O
receptors O
. O

Progesterone B
is O
neuroprotective O
after O
spinal O
cord O
injury O
, O
however O
its O
mechanism O
of O
action O
remains O
unexplored O
. O

Here O
we O
used O
organotypic O
spinal O
cord O
slice O
cultures O
from O
3 O
weeks O
- O
old O
mice O
to O
evaluate O
the O
mechanisms O
of O
neuroprotection O
by O
progesterone B
and O
its O
5 O
alpha O
- O
reduced O
metabolites O
. O

Addition O
of O
10 O
mu O
M O
of O
progesterone B
, O
5 O
alpha O
- O
dihydroprogesterone O
( O
5 O
alpha O
- O
DHP O
) O
or O
allopregnanolone B
( O
3 O
alpha O
, O
5 O
alpha O
- O
tetrahydroprogestero O
) O
to O
the O
medium O
at O
the O
time O
of O
injury O
rescued O
the O
spinal O
cord O
slices O
from O
the O
effects O
of O
damage O
. O

Progesterone B
prevented O
membrane O
cell O
damage O
, O
motoneuron O
loss O
and O
cell O
death O
. O

These O
effects O
were O
not O
due O
to O
its O
bioconversion O
to O
5 O
alpha O
- O
DHP O
nor O
to O
allopregnanolone B
, O
as O
supported O
by O
the O
finasteride O
, O
an O
inhibitor O
of O
5 O
alpha O
- O
reductase O
enzymes O
, O
and O
by O
the O
absence O
of O
5 O
alpha O
- O
reduced O
progesterone B
metabolites O
in O
the O
slices O
analyzed O
by O
gas O
chromatography O
- O
mass O
spectrometry O
. O

The O
neuroprotective O
effects O
of O
progesterone B
required O
PR O
as O
they O
could O
not O
be O
observed O
in O
slices O
from O
homozygous O
knockout O
PR O
( O
- O
/ O
- O
) O
mice O
. O

Allopregnanolone B
treatment O
was O
also O
neuroprotective O
. O

Allopregnanolone B
effects O
involved O
GABAA O
receptors O
, O
as O
they O
were O
inhibited O
by O
the O
selective O
GABAA O
receptor O
antagonist O
Gabazine O
, O
in O
both O
PR O
( O
+ O
/ O
+ O
) O
and O
PR O
( O
- O
/ O
- O
) O
mice O
. O

Here O
, O
to O
resolve O
the O
neuronal O
circuitry O
mediating O
hemopressin O
' O
s O
actions O
, O
we O
have O
combined O
blood O
- O
oxygen B
- O
level O
- O
dependent O
, O
pharmacological O
- O
challenge O
magnetic O
resonance O
imaging O
with O
c O
- O
Fos O
functional O
activity O
mapping O
to O
compare O
brain O
regions O
responsive O
to O
systemic O
administration O
of O
hemopressin O
and O
the O
synthetic O
CB1 O
inverse O
agonist O
, O
AM251 O
. O

An O
intermediate O
GTX2 O
, O
3 O
- O
aldehyde O
was O
first O
synthesized O
by O
activating O
the O
NH2 B
group O
of O
the O
2nd O
and O
8th O
amino B
acid I
residues O
with O
three O
different O
aldehydes B
and O
two O
artificial O
complete O
antigens O
GTX2 O
, O
3 O
- O
aldehyde O
- O
bovine O
serum O
albumin O
( O
BSA O
) O
and O
GTX2 O
, O
3 O
- O
aldehyde O
- O
keyhole O
limpet O
hemocyanin O
( O
KLH O
) O
were O
then O
prepared O
by O
cross O
- O
linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O

Epidemiological O
and O
biochemical O
data O
have O
suggested O
a O
link O
between O
cholesterol B
content O
, O
APP O
( O
amyloid O
precursor O
protein O
) O
processing O
, O
A O
beta O
, O
inflammation O
and O
AD O
. O

Liver O
X O
receptors O
( O
LXRa O
and O
LXR O
beta O
) O
are O
oxysterol B
activated O
nuclear O
receptors O
that O
play O
essential O
role O
in O
lipid O
and O
glucose B
homeostasis O
, O
steroidogenesis O
and O
inflammatory O
responses O
. O

Studies O
also O
suggest O
that O
ligand O
activation O
of O
LXRs O
in O
Tg2576 O
mice O
enhanced O
, O
the O
expression O
of O
genes O
linked O
with O
cholesterol B
efflux O
e O
. O
g O
. O
apoe O
, O
abca O
- O
1 O
, O
down O
regulated O
APP O
processing O
and O
A O
beta O
production O
with O
significant O
improvement O
in O
memory O
functions O
. O

Mitochondrial O
complex O
I O
dysfunction O
induced O
by O
cocaine B
and O
cocaine B
plus O
morphine B
in O
brain O
and O
liver O
mitochondria O
. O

Mitochondrial O
function O
and O
energy O
metabolism O
are O
affected O
in O
brains O
of O
human O
cocaine B
abusers O
. O

Cocaine B
is O
known O
to O
induce O
mitochondrial O
dysfunction O
in O
cardiac O
and O
hepatic O
tissues O
, O
but O
its O
effects O
on O
brain O
bioenergetics O
are O
less O
documented O
. O

Furthermore O
, O
the O
combination O
of O
cocaine B
and O
opioids O
( O
speedball O
) O
was O
also O
shown O
to O
induce O
mitochondrial O
dysfunction O
. O

In O
this O
work O
, O
we O
compared O
the O
effects O
of O
cocaine B
and O
/ O
or O
morphine B
on O
the O
bioenergetics O
of O
isolated O
brain O
and O
liver O
mitochondria O
, O
to O
understand O
their O
specific O
effects O
in O
each O
tissue O
. O

Upon O
energization O
with O
complex O
I O
substrates O
, O
cocaine B
decreased O
state O
- O
3 O
respiration O
in O
brain O
( O
but O
not O
in O
liver O
) O
mitochondria O
and O
decreased O
uncoupled O
respiration O
and O
mitochondrial O
potential O
in O
both O
tissues O
, O
through O
a O
direct O
effect O
on O
complex O
I O
. O

Morphine B
presented O
only O
slight O
effects O
on O
brain O
and O
liver O
mitochondria O
, O
and O
the O
combination O
cocaine B
+ O
morphine B
had O
similar O
effects O
to O
cocaine B
alone O
, O
except O
for O
a O
greater O
decrease O
in O
state O
- O
3 O
respiration O
. O

In O
summary O
, O
cocaine B
and O
cocaine B
+ O
morphine B
induce O
mitochondrial O
complex O
I O
dysfunction O
in O
isolated O
brain O
and O
liver O
mitochondria O
, O
with O
specific O
effects O
in O
each O
tissue O
. O

Nicotine B
- O
Induced O
Structural O
Plasticity O
in O
Mesencephalic O
Dopaminergic O
Neurons O
Is O
Mediated O
by O
Dopamine B
D3 O
Receptors O
and O
Akt O
- O
mTORC1 O
Signalling O
. O

Though O
long O
- O
term O
exposure O
to O
nicotine B
is O
highly O
addictive O
, O
one O
" O
beneficial O
" O
consequence O
of O
chronic O
tobacco O
use O
is O
a O
reduced O
risk O
for O
Parkinson O
' O
s O
disease O
. O

Interestingly O
, O
these O
effects O
both O
reflect O
structural O
and O
functional O
plasticity O
of O
brain O
circuits O
controlling O
reward O
and O
motor O
behavior O
, O
and O
specifically O
recruitment O
of O
nicotinic O
acetylcholine B
receptors O
( O
nAChR O
) O
in O
mesencephalic O
dopaminergic O
neurons O
. O

Exposure O
to O
nicotine B
( O
1 O
- O
10 O
mu O
M O
) O
for O
72 O
hr O
in O
vitro O
increased O
dendritic O
arborization O
and O
soma O
size O
in O
primary O
cultures O
. O

These O
effects O
were O
blocked O
by O
mecamylamine B
and O
dihydro O
- O
beta O
- O
erythroidine O
, O
but O
not O
methyllycaconitine B
. O

The O
involvement O
of O
alpha O
4 O
beta O
2 O
nAChR O
was O
supported O
by O
the O
lack O
of O
nicotine B
- O
induced O
structural O
remodeling O
in O
neurons O
from O
alpha O
4 O
null O
mutant O
mice O
( O
KO O
) O
. O

Challenge O
with O
nicotine B
triggered O
phosphorylation O
of O
the O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
and O
the O
thymoma O
viral O
proto O
- O
oncogene O
( O
Akt O
) O
followed O
by O
activation O
of O
the O
mTORC1 O
- O
dependent O
p70 O
ribosomal O
S6 O
protein O
kinase O
. O

Upstream O
pathway O
blockade O
using O
the O
phosphatidylinositol B
3 O
- O
kinase O
inhibitor O
LY294002 B
resulted O
in O
suppression O
of O
nicotine B
- O
induced O
phosphorylations O
and O
structural O
plasticity O
. O

These O
effects O
were O
dependent O
upon O
functional O
DA O
D3 O
receptor O
( O
D3R O
) O
since O
nicotine B
was O
inactive O
both O
in O
cultures O
from O
D3R O
KO O
mice O
and O
following O
pharmacologic O
blockade O
with O
D3R O
antagonist O
SB O
- O
277011 O
- O
A O
( O
50 O
nM O
) O
. O

Finally O
, O
exposure O
to O
nicotine B
in O
utero O
( O
5 O
mg O
/ O
kg O
/ O
day O
for O
5 O
days O
) O
resulted O
in O
increased O
soma O
area O
of O
DAergic O
neurons O
of O
newborn O
mice O
, O
effects O
not O
observed O
in O
D3KO O
mice O
. O

These O
findings O
indicate O
that O
nicotine B
- O
induced O
structural O
plasticity O
in O
mesencephalic O
dopaminergic O
neurons O
involves O
alpha O
4 O
beta O
2 O
nAChRs O
together O
with O
dopamine B
D3R O
- O
mediated O
recruitment O
of O
ERK O
/ O
Akt O
- O
mTORC1 O
signaling O
. O

All O
women O
who O
attended O
the O
infertility O
clinic O
during O
this O
period O
were O
screened O
for O
hyperprolactinemia O
and O
only O
women O
with O
hyperprolactinemia O
and O
infertility O
were O
further O
studied O
for O
the O
presence O
of O
macroprolactin O
by O
polyethylene B
glycol I
precipitation O
assay O
. O

CX O
- O
4945 O
, O
a O
potent O
and O
selective O
orally O
bioavailable O
ATP B
- O
competitive O
inhibitor O
of O
CK2 O
, O
inhibits O
the O
oncogenic O
cellular O
events O
such O
as O
proliferation O
and O
angiogenesis O
, O
and O
the O
increase O
of O
tumor O
growth O
in O
mouse O
xenograft O
model O
. O

In O
hERG O
potassium B
channel O
inhibition O
assay O
, O
CX O
- O
4945 O
exhibited O
relatively O
low O
inhibition O
rate O
. O

Novel O
4 O
- O
( O
4 O
- O
bromophenyl O
) O
phthalazine O
derivatives O
connected O
via O
an O
alkyl B
spacer O
to O
amine B
or O
N O
- O
substituted O
piperazine O
were O
designed O
and O
synthesized O
as O
promising O
alpha O
- O
adrenoceptor O
antagonists O
. O

The O
structures O
of O
the O
phthalazine B
derivatives O
were O
established O
using O
elemental O
and O
spectral O
analyses O
. O

Nickel B
and O
Cobalt B
- O
Catalyzed O
Coupling O
of O
Alkyl O
Halides O
with O
Alkenes B
via O
Heck O
Reactions O
and O
Radical O
Conjugate O
Addition O
. O

Cross O
- O
coupling O
of O
alkyl O
halides O
with O
alkenes B
leading O
to O
Heck O
- O
type O
and O
addition O
products O
is O
summarized O
. O

The O
use O
of O
Ni B
- O
and O
Co B
- O
catalyzed O
protocols O
allowed O
efficient O
Heck O
coupling O
of O
activated O
and O
unactivated O
alkenes B
with O
1 O
( O
o O
) O
, O
2 O
( O
o O
) O
and O
3 O
( O
o O
) O
alkyl O
halides O
. O

In O
addition O
, O
radical O
conjugate O
addition O
to O
activated O
alkenes B
has O
become O
a O
well O
- O
established O
method O
that O
has O
led O
to O
efficient O
construction O
of O
many O
natural O
products O
. O

The O
utilization O
of O
Ni B
- O
and O
Co B
- O
catalyzed O
strategies O
would O
avoid O
toxic O
tin O
reagents O
, O
and O
therefore O
worth O
exploring O
. O

The O
recent O
development O
of O
Ni B
- O
and O
Co B
- O
catalyzed O
addition O
of O
alkyl O
halides O
to O
alkenes B
displays O
much O
improved O
reactivity O
and O
functional O
group O
tolerance O
. O

In O
this O
mini O
- O
review O
, O
we O
also O
attempt O
to O
overview O
the O
mechanisms O
that O
are O
proposed O
in O
the O
reactions O
, O
aiming O
at O
providing O
insight O
into O
the O
nickel B
and O
cobalt B
- O
catalyzed O
coupling O
of O
alkyl O
halides O
with O
alkenes B
. O

Pyrazoline O
is O
an O
important O
five O
membered O
nitrogen B
heterocycle O
, O
which O
has O
been O
extensively O
researched O
upon O
. O

Background O
: O
Levothyroxine B
has O
been O
shown O
to O
enhance O
pregnancy O
outcomes O
in O
women O
with O
hypothyroidism O
requiring O
In O
Vitro O
Fertilization O
( O
IVF O
) O
. O

In O
particular O
, O
it O
has O
yet O
to O
be O
clarified O
whether O
levothyroxine B
may O
fully O
overcome O
the O
detrimental O
effects O
of O
hypothyroidism O
or O
, O
conversely O
, O
whether O
affected O
women O
remain O
at O
reduced O
prognosis O
for O
pregnancy O
outcomes O
. O

Cases O
were O
deemed O
eligible O
if O
they O
were O
diagnosed O
with O
clinical O
or O
subclinical O
hypothyroidism O
and O
were O
receiving O
levothyroxine B
. O

In O
conclusion O
, O
adequate O
levothyroxine B
treatment O
maintaining O
TSH O
serum O
levels O
below O
2 O
. O
5 O
mIU O
/ O
L O
may O
overcome O
the O
detrimental O
effects O
of O
hypothyroidism O
. O

Chronic O
dietary O
exposure O
to O
chlorpyrifos B
causes O
behavioral O
impairments O
, O
low O
activity O
of O
brain O
membrane O
- O
bound O
acetylcholinesterase O
, O
and O
increased O
brain O
acetylcholinesterase O
- O
R O
mRNA O
. O

Chlorpyrifos B
( O
CPF O
) O
is O
an O
organophosphate B
( O
OP O
) O
insecticide O
that O
is O
metabolically O
activated O
to O
the O
highly O
toxic O
chlorpyrifos B
oxon I
. O

In O
vitro O
intestinal O
and O
hepatic O
metabolism O
of O
Di B
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
in O
human O
and O
rat O
. O

Species O
and O
organ O
differences O
in O
the O
intrinsic O
clearance O
and O
the O
enzymes O
involved O
in O
the O
metabolism O
of O
DEHP B
were O
examined O
in O
subcellular O
fractions O
of O
the O
intestine O
and O
liver O
as O
well O
as O
by O
recombinant O
cytochrome O
P450 O
( O
CYP O
) O
isoforms O
of O
human O
and O
rat O
. O

Estimated O
clearance O
( O
CLint O
) O
of O
DEHP B
via O
esterase O
- O
mediated O
pathway O
in O
human O
intestine O
was O
2 O
. O
4 O
- O
fold O
greater O
than O
that O
in O
human O
liver O
while O
its O
value O
in O
rat O
intestine O
was O
1 O
. O
7 O
- O
fold O
less O
than O
that O
in O
rat O
liver O
. O

Ranks O
of O
CLint O
for O
CYP O
- O
mediated O
oxidation O
/ O
dealkylation O
of O
MEHP B
were O
human O
liver O
> O
rat O
liver O
> O
human O
intestine O
> O
rat O
intestine O
. O

These O
species O
/ O
organ O
differences O
in O
major O
metabolic O
pathway O
and O
CYP O
isoforms O
should O
be O
considered O
for O
appraisal O
of O
the O
potential O
adverse O
health O
effects O
of O
DEHP B
. O

Electroactive O
nanoparticle O
directed O
assembly O
of O
functionalized O
graphene B
nanosheets O
into O
hierarchical O
structures O
with O
hybrid O
compositions O
for O
flexible O
supercapacitors O
. O

Here O
, O
we O
report O
the O
integrative O
assembly O
of O
chemically O
modified O
graphene B
( O
CMG O
) O
building O
blocks O
into O
hierarchical O
complex O
structures O
with O
the O
hybrid O
composition O
for O
high O
performance O
flexible O
pseudocapacitors O
. O

The O
formation O
mechanism O
of O
hierarchical O
CMG O
/ O
Nafion B
/ O
RuO2 O
( O
CMGNR O
) O
microspheres O
, O
which O
is O
triggered O
by O
the O
cooperative O
interplay O
during O
the O
in O
situ O
synthesis O
of O
RuO2 O
nanoparticles O
( O
NPs O
) O
, O
was O
extensively O
investigated O
. O

In O
particular O
, O
the O
hierarchical O
CMGNR O
microspheres O
consisting O
of O
the O
aggregates O
of O
CMG O
/ O
Nafion B
( O
CMGN O
) O
nanosheets O
and O
RuO2 O
NPs O
provided O
large O
surface O
area O
and O
facile O
ion O
accessibility O
to O
storage O
sites O
, O
while O
the O
interconnected O
nanosheets O
offered O
continuous O
electron O
pathways O
and O
mechanical O
integrity O
. O

Consequently O
, O
the O
CMGNR O
- O
SCs O
showed O
a O
specific O
capacitance O
as O
high O
as O
160 O
F O
g O
( O
- O
1 O
) O
, O
three O
- O
fold O
higher O
than O
that O
of O
conventional O
graphene B
SCs O
, O
and O
a O
capacitance O
retention O
of O
> O
95 O
% O
of O
the O
maximum O
value O
even O
after O
severe O
bending O
and O
1000 O
charge O
- O
discharge O
tests O
due O
to O
the O
structural O
and O
compositional O
features O
. O

While O
malondialdehyde B
, O
myeloperoxidase O
, O
lipid O
hyroperoxide O
, O
and O
total O
oxidant O
status O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
, O
reduced O
glutathione B
and O
total O
free O
sulfhydryl B
groups O
markedly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
in O
PF O
( O
alone O
) O
group O
when O
compared O
with O
PF O
+ O
EVOO O
group O
. O

Previously O
, O
we O
have O
confirmed O
that O
the O
antiviral O
activities O
of O
the O
chromone B
derivatives O
were O
controlled O
by O
the O
type O
as O
well O
as O
the O
position O
of O
the O
substituents O
attached O
to O
the O
chromone B
core O
structure O
. O

In O
the O
course O
of O
our O
ongoing O
efforts O
to O
optimize O
the O
antiviral O
activity O
of O
the O
chromone B
derivatives O
, O
we O
have O
been O
attempting O
to O
derivatize O
the O
chromone B
scaffold O
via O
introduction O
of O
various O
substituents O
. O

In O
this O
proof O
- O
of O
- O
concept O
study O
, O
we O
introduced O
a O
3 O
- O
amino O
- O
4 O
- O
piperazinylphenyl O
functionality O
to O
the O
chromone B
scaffold O
and O
evaluated O
the O
antiviral O
activities O
of O
the O
resulting O
chromone B
derivatives O
. O

In O
particular O
, O
the O
2 O
- O
pyridinylpiperazinyl O
substituents O
provided O
the O
resulting O
chromone B
derivatives O
with O
selective O
antiviral O
activity O
. O

Taken O
together O
, O
this O
result O
indicates O
the O
possible O
pharmacophoric O
role O
of O
the O
2 O
- O
pyridinylpiperazine O
functionality O
attached O
to O
the O
chromone B
scaffold O
, O
which O
warrants O
further O
in O
- O
depth O
structure O
- O
activity O
relationship O
study O
. O

Randomly O
amplified O
polymorphic O
- O
DNA O
analysis O
for O
detecting O
genotoxic O
effects O
of O
Boron B
on O
maize O
( O
Zea O
mays O
L O
. O
) O
. O

This O
study O
was O
carried O
out O
to O
investigate O
the O
genotoxic O
effect O
of O
boron B
( O
B B
) O
on O
maize O
using O
randomly O
amplified O
polymorphic O
DNA O
( O
RAPD O
) O
method O
. O

Experimental O
design O
was O
conducted O
under O
0 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
100 O
, O
125 O
, O
and O
150 O
ppm O
B B
exposures O
, O
and O
physiological O
changes O
have O
revealed O
a O
sharp O
decrease O
in O
root O
growth O
rates O
from O
28 O
% O
to O
85 O
% O
, O
starting O
from O
25 O
ppm O
to O
150 O
ppm O
, O
respectively O
. O

B B
- O
induced O
inhibition O
in O
root O
growth O
had O
a O
positive O
correlation O
with O
DNA O
alterations O
. O

Total O
soluble O
protein O
, O
root O
and O
stem O
lengths O
, O
and O
B B
content O
analysis O
in O
root O
and O
leaves O
encourage O
these O
results O
as O
a O
consequence O
. O

These O
preliminary O
findings O
reveal O
that O
B B
causes O
chromosomal O
aberration O
and O
genotoxic O
effects O
on O
maize O
. O

Meanwhile O
, O
usage O
of O
RAPD O
- O
PCR O
technique O
is O
a O
suitable O
biomarker O
to O
detect O
genotoxic O
effect O
of O
B B
on O
maize O
and O
other O
crops O
for O
the O
future O
. O

Exogenous O
PTHrP O
peptide O
( O
1 O
- O
34 O
) O
increased O
intracellular O
cAMP B
level O
in O
cultured O
BSMC O
. O

In O
organ O
bath O
study O
using O
bladder O
strips O
, O
the O
PTHrP O
peptide O
caused O
a O
marked O
reduction O
in O
the O
amplitude O
of O
spontaneous O
contraction O
, O
but O
caused O
only O
modest O
suppression O
for O
carbachol B
- O
induced O
contraction O
. O

17 B
beta I
- I
estradiol I
activates O
glucose B
uptake O
via O
GLUT4 O
translocation O
and O
PI3K O
/ O
Akt O
signaling O
pathway O
in O
MCF O
- O
7 O
cells O
. O

The O
relationship O
between O
estrogen B
and O
some O
types O
of O
breast O
cancer O
has O
been O
clearly O
established O
. O

However O
, O
although O
several O
studies O
have O
demonstrated O
the O
relationship O
between O
estrogen B
and O
glucose B
uptake O
via O
PI3K O
/ O
Akt O
in O
other O
tissues O
, O
not O
too O
much O
is O
known O
about O
the O
possible O
cross O
talk O
between O
them O
for O
development O
and O
maintenance O
of O
breast O
cancer O
. O

This O
study O
was O
designed O
to O
test O
the O
rapid O
effects O
of O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
or O
its O
membrane O
- O
impermeable O
form O
conjugated O
with O
bovine O
serum O
albumin O
( O
E2BSA O
) O
on O
glucose B
uptake O
in O
a O
positive O
estrogen B
receptor O
( O
ER O
) O
breast O
cancer O
cell O
line O
, O
through O
the O
possible O
relationship O
between O
key O
components O
of O
the O
PI3K O
/ O
Akt O
signaling O
pathway O
and O
acute O
steroid B
treatment O
. O

Then O
10nM O
of O
17 B
beta I
- I
estradiol I
or O
estradiol B
BSA O
conjugated O
were O
administrated O
before O
obtaining O
the O
cell O
lysates O
. O

To O
study O
the O
glucose B
uptake O
, O
the O
glucose B
fluorescent O
analogue O
2 O
- O
[ O
N O
- O
( O
7 O
- O
nitrobenz O
- O
2 O
- O
oxa O
- O
1 O
, O
3 O
- O
diazol O
- O
4 O
- O
yl O
) O
amino O
] O
- O
2 O
- O
deoxy O
- O
d O
- O
glucose O
was O
used O
. O

We O
report O
an O
ER O
- O
dependent O
activation O
of O
some O
of O
the O
key O
steps O
of O
the O
PI3K O
/ O
Akt O
signaling O
pathway O
cascade O
that O
leads O
cells O
to O
improve O
some O
mechanisms O
that O
finally O
increase O
glucose B
uptake O
capacity O
. O

Our O
data O
suggest O
that O
both O
E2 O
and O
E2BSA O
enhance O
the O
entrance O
of O
the O
fluorescent O
glucose B
analogue O
2 O
- O
NBDG O
, O
and O
also O
activates O
s O
PI3K O
/ O
Akt O
signaling O
pathway O
, O
leading O
to O
translocation O
of O
GLUT4 O
to O
the O
plasma O
membrane O
in O
an O
ER O
alpha O
dependent O
manner O
. O

E2 O
enhances O
ER O
- O
dependent O
rapid O
signaling O
triggered O
, O
partially O
in O
the O
plasma O
membrane O
, O
allowing O
ER O
alpha O
- O
positive O
MCF O
- O
7 O
breast O
cancer O
cells O
to O
increase O
glucose B
uptake O
, O
which O
could O
be O
essential O
to O
meet O
the O
energy O
demands O
of O
the O
high O
rate O
of O
proliferation O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
long O
- O
chain O
omega B
- I
3 I
polyunsaturated I
fatty I
acid I
( O
n O
- O
3 O
PUFA O
) O
supplementation O
on O
metabolic O
state O
and O
gene O
expression O
in O
subcutaneous O
adipose O
tissues O
of O
obese O
adolescents O
. O

Five O
times O
per O
day O
, O
subjects O
received O
a O
food O
supplement O
consisting O
of O
eicosapentaenoic B
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
( O
3 O
g O
per O
day O
, O
944 O
mg O
EPA B
, O
and O
2 O
, O
088 O
mg O
DHA B
) O
. O

and O
blood O
triglyceride B
levels O
( O
220 O
. O
8 O
+ O
/ O
- O
27 O
. O
4 O
vs O
. O
99 O
. O
7 O
+ O
/ O
- O
32 O
. O
7 O
mg O
/ O
dL O
; O
P O
< O
0 O
. O
001 O
) O
. O

Fatty B
acid I
supplementation O
/ O
n3 O
PUFA O
supplementation O
was O
associated O
with O
a O
downregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
gamma O
and O
PGC O
- O
1 O
alpha O
( O
P O
< O
0 O
. O
001 O
) O
, O
and O
an O
upregulated O
expression O
of O
the O
genes O
encoding O
PPAR O
alpha O
( O
P O
< O
0 O
. O
007 O
) O
and O
SREBP1 O
( O
P O
< O
0 O
. O
021 O
) O
. O

Our O
study O
demonstrated O
that O
n O
- O
3 O
PUFA O
consumption O
and O
dietary O
restriction O
improved O
the O
anthropometric O
parameters O
and O
decreased O
the O
triglycerides B
levels O
of O
the O
adolescents O
, O
suggesting O
a O
reduction O
in O
hypoxia O
in O
subcutaneous O
adipose O
tissue O
. O

FixK2 O
is O
an O
important O
regulatory O
protein O
that O
helps O
activating O
a O
large O
number O
of O
genes O
for O
the O
anoxic O
and O
microoxic O
, O
endosymbiotic O
and O
nitrogen B
- O
fixing O
life O
styles O
of O
the O
alpha O
- O
proteobacterium O
Bradyrhizobium O
japonicum O
. O

FixK2 O
belongs O
to O
the O
cyclic B
AMP I
receptor O
protein O
( O
CRP O
) O
superfamily O
. O

While O
most O
CRP O
- O
family O
members O
are O
co O
- O
regulated O
by O
effector O
molecules O
, O
the O
activity O
of O
FixK2 O
is O
negatively O
controlled O
by O
oxidation O
of O
its O
single O
cysteine B
( O
C183 O
) O
located O
next O
to O
the O
DNA O
binding O
domain O
, O
and O
possibly O
also O
by O
proteolysis O
. O

Crystallization O
succeeded O
only O
( O
i O
) O
when O
an O
oxidation O
- O
and O
protease O
- O
insensitive O
protein O
variant O
( O
C183S O
- O
FixK2His6 O
) O
was O
used O
, O
in O
which O
C183 O
was O
replaced O
by O
serine B
and O
the O
C B
- O
terminus O
fused O
with O
a O
hexa O
- O
histidine O
tag O
, O
and O
( O
ii O
) O
when O
this O
protein O
was O
allowed O
to O
form O
a O
complex O
with O
a O
30mer O
double O
- O
strand O
target O
DNA O
. O

The O
C B
- O
terminus O
is O
surface O
- O
exposed O
which O
might O
explain O
its O
sensitivity O
to O
specific O
cleavage O
and O
degradation O
. O

Analysis O
of O
the O
reaction O
progress O
by O
powder O
X O
- O
ray O
diffraction O
, O
solid O
- O
state O
( B
13 I
) I
C I
CPMAS O
NMR O
, O
solid O
- O
state O
FTIR O
spectroscopy O
, O
and O
thermal O
analysis O
has O
revealed O
that O
solid O
- O
to O
- O
solid O
reactions O
proceed O
either O
through O
metastable O
phases O
susceptible O
to O
amorphization O
or O
by O
mechanisms O
that O
involve O
a O
reconstructive O
phase O
transition O
that O
culminates O
in O
the O
formation O
of O
the O
stable O
phase O
of O
the O
product O
. O

Genetics O
of O
serotonin B
receptors O
and O
depression O
: O
state O
of O
the O
art O
. O

The O
present O
review O
is O
focused O
on O
the O
role O
of O
genes O
coding O
for O
serotonin B
receptors O
in O
MD O
pathogenesis O
, O
since O
the O
serotonin B
transporter O
and O
enzymes O
involved O
in O
serotonin B
metabolism O
have O
been O
reviewed O
elsewhere O
. O

Despite O
the O
large O
number O
of O
candidate O
gene O
studies O
focusing O
on O
genes O
coding O
for O
serotonin B
receptors O
, O
results O
have O
been O
inconsistent O
. O

Nucleoside B
inhibitors O
( O
NI O
) O
of O
HCV O
polymerase O
( O
NS5B O
) O
have O
demonstrated O
pan O
- O
genotypic O
activity O
and O
durable O
antiviral O
response O
in O
the O
clinic O
, O
and O
they O
are O
likely O
to O
become O
a O
key O
component O
of O
future O
treatment O
regimens O
. O

Exploration O
of O
adenosine B
analogs O
in O
this O
class O
identified O
1 O
' O
- O
cyano O
- O
2 O
' O
- O
C O
- O
methyl O
4 O
- O
aza O
- O
7 O
, O
9 O
- O
dideaza O
adenosine O
as O
a O
potent O
and O
selective O
inhibitor O
of O
NS5B O
. O

A O
monophosphate B
prodrug O
approach O
afforded O
a O
series O
of O
compounds O
showing O
submicromolar O
activity O
in O
HCV O
replicon O
assays O
. O

Further O
pharmacokinetic O
optimization O
for O
sufficient O
oral O
absorption O
and O
liver O
triphosphate B
loading O
led O
to O
identification O
of O
a O
clinical O
development O
candidate O
GS O
- O
6620 O
. O

Bioassay O
- O
guided O
fractionation O
of O
the O
leaves O
of O
Eugenia O
rigida O
yielded O
three O
stilbenes B
, O
( O
Z O
) O
- O
3 O
, O
4 O
, O
3 O
' O
, O
5 O
' O
- O
tetramethoxystilbene O
( O
1 O
) O
, O
( O
E O
) O
- O
3 O
, O
4 O
, O
3 O
' O
, O
5 O
' O
- O
tetramethoxystilbene O
( O
2 O
) O
, O
and O
( O
E O
) O
- O
3 O
, O
5 O
, O
4 O
' O
- O
trimethoxystilbene O
( O
3 O
) O
. O

Interestingly O
, O
2 O
showed O
antioxidant O
activity O
by O
inhibition O
of O
ROS O
generation O
to O
50 O
% O
at O
33 O
. O
3 O
mu O
M O
in O
PMA B
- O
induced O
HL O
- O
60 O
cells O
, O
while O
1 O
was O
inactive O
at O
100 O
mu O
M O
( O
vs O
Trolox B
1 O
. O
4 O
mu O
M O
) O
. O

Since O
the O
finding O
that O
salvinorin O
A O
exerts O
its O
potent O
psychotropic O
actions O
through O
the O
activation O
of O
opioid O
receptors O
, O
the O
site O
of O
action O
of O
morphine B
and O
related O
analogues O
, O
there O
has O
been O
much O
interest O
in O
elucidating O
the O
underlying O
mechanisms O
behind O
its O
effects O
. O

Formation O
of O
a O
tyrosine B
adduct O
involved O
in O
lignin O
degradation O
by O
Trametopsis O
cervina O
lignin O
peroxidase O
: O
A O
novel O
peroxidase O
activation O
mechanism O
. O

Lignin O
peroxidase O
( O
LiP O
) O
from O
Trametopsis O
cervina O
has O
an O
exposed O
catalytic O
tyrosine B
( O
Tyr B
- O
181 O
) O
instead O
of O
the O
conserved O
tryptophan B
of O
other O
lignin O
- O
degrading O
peroxidases O
. O

However O
, O
LiP O
after O
turnover O
with O
H2O2 B
/ O
VA O
( O
VA O
- O
LiP O
) O
lacked O
this O
lag O
, O
and O
H2O2 B
- O
pretreated O
LiP O
( O
H2O2 B
- O
LiP O
) O
was O
inactive O
. O

MS O
analyses O
revealed O
that O
VA O
- O
LiP O
includes O
one O
VA O
molecule O
covalently O
bound O
to O
the O
side O
- O
chain O
of O
Tyr B
- O
181 O
, O
whereas O
H2O2 B
- O
LiP O
contains O
hydroxylated O
Tyr B
- O
181 O
. O

Molecular O
docking O
showed O
that O
VA O
binding O
is O
favored O
by O
sandwich O
pi O
stacking O
with O
Tyr B
- O
181 O
and O
Phe B
- O
89 O
. O

EPR O
spectroscopy O
after O
peroxide B
activation O
of O
the O
pretreated O
LiPs O
showed O
other O
protein O
radicals O
than O
the O
tyrosine B
radical O
found O
in O
pristine O
LiP O
, O
which O
were O
assigned O
to O
a O
tyrosine B
/ O
VA O
adduct O
radical O
in O
VA O
- O
LiP O
and O
a O
dihydroxyphenyalanin O
radical O
in O
H2O2 B
- O
LiP O
. O

Both O
radicals O
are O
able O
to O
oxidize O
large O
low O
redox O
- O
potential O
substrates O
, O
but O
H2O2 B
- O
LiP O
is O
unable O
to O
oxidize O
high O
redox O
- O
potential O
substrates O
. O

Transient O
- O
state O
kinetics O
showed O
that O
the O
tyrosine B
/ O
VA O
adduct O
strongly O
promotes O
( O
> O
100 O
- O
fold O
) O
substrate O
oxidation O
by O
compound O
II O
, O
the O
rate O
- O
limiting O
step O
in O
catalysis O
. O

Nrf2 O
- O
dependent O
neuroprotective O
activity O
of O
diterpenoids B
isolated O
from O
Sideritis O
spp O
. O

Diterpenoids B
are O
one O
of O
the O
most O
abundant O
and O
important O
pharmacological O
interest O
of O
the O
classes O
of O
natural O
products O
presented O
in O
these O
medicinal O
plants O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
determine O
for O
the O
first O
time O
the O
neuroprotective O
effects O
, O
based O
on O
their O
antioxidant O
properties O
, O
of O
the O
three O
isolated O
major O
diterpenoids B
andalusol O
, O
conchitriol O
and O
lagascatriol O
in O
an O
oxidative O
stress O
model O
. O

MATERIALS O
AND O
METHODS O
: O
H2O2 B
was O
used O
as O
oxidant O
inductor O
and O
rat O
adrenal O
pheochromocytoma O
PC12 O
cells O
as O
cellular O
model O
. O

Cell O
viability O
was O
measured O
using O
MTT B
and O
LDH O
assays O
, O
lipid O
peroxidation O
was O
determined O
by O
HPLC O
, O
GSH B
and O
GSSG B
levels O
assessed O
by O
fluorometric O
techniques O
, O
enzymatic O
activity O
and O
protein O
expression O
were O
determined O
by O
spectrofometric O
techniques O
and O
Western O
blot O
, O
respectively O
. O

RESULTS O
: O
Pretreatments O
with O
the O
three O
diterpenoids B
significantly O
attenuated O
H2O2 B
- O
induced O
changes O
in O
mitochondrial O
integrity O
and O
activity O
( O
MTT B
assay O
) O
, O
in O
cell O
membrane O
integrity O
( O
LDH O
assay O
) O
and O
in O
cell O
morphology O
. O

Moreover O
, O
these O
diterpenoids B
inhibited O
intracellular O
ROS O
production O
H2O2 B
- O
induced O
, O
reduced O
lipid O
peroxidation O
and O
counteracted O
GSH B
/ O
GSSG B
changes O
. O

The O
Nrf2 O
pathway O
was O
involved O
, O
at O
least O
in O
part O
, O
in O
the O
protective O
effects O
of O
these O
diterpenoids B
. O

CONCLUSION O
: O
These O
findings O
suggest O
that O
these O
natural O
compounds O
provide O
significant O
antioxidant O
effects O
in O
PC12 O
under O
for O
counteracting O
the O
oxidative O
damage O
H2O2 B
- O
induced O
and O
their O
potential O
role O
as O
useful O
agents O
for O
the O
prevention O
of O
those O
oxidative O
stress O
- O
mediated O
dementia O
disorders O
. O

Andalusol O
was O
the O
most O
active O
compound O
among O
the O
studied O
diterpenoids B
. O

The O
putative O
JAK O
- O
STAT O
inhibitor O
AG490 B
exacerbates O
LPS O
- O
fever O
, O
reduces O
sickness O
behavior O
, O
and O
alters O
the O
expression O
of O
pro O
- O
and O
anti O
- O
inflammatory O
genes O
in O
the O
rat O
brain O
. O

Using O
AG490 B
, O
previously O
shown O
to O
inhibit O
the O
STAT3 O
- O
and O
NF O
- O
IL6 O
- O
signaling O
pathway O
, O
we O
therefore O
investigated O
the O
central O
involvement O
of O
these O
two O
signaling O
pathways O
in O
mediating O
sickness O
behavior O
, O
fever O
and O
accompanying O
brain O
inflammation O
induced O
by O
peripheral O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulation O
. O

Rats O
pre O
- O
treated O
i O
. O
c O
. O
v O
. O
with O
AG490 B
1 O
h O
before O
the O
i O
. O
p O
. O

The O
LPS O
- O
induced O
anorexia O
was O
not O
altered O
and O
AG490 B
did O
not O
have O
any O
effect O
on O
rats O
receiving O
PBS O
( O
i O
. O
p O
. O
) O
. O

We O
did O
observe O
effects O
of O
AG490 B
on O
STAT3 O
- O
signaling O
at O
4 O
h O
, O
while O
AG490 B
- O
mediated O
changes O
in O
brain O
activity O
of O
inflammatory O
transcription O
factors O
at O
8 O
h O
were O
not O
significant O
. O

Increased O
NF O
- O
IL6 O
and O
suppressor O
of O
cytokines O
3 O
mRNA O
- O
expression O
in O
AG490 B
/ O
LPS O
- O
treated O
rats O
were O
indicative O
of O
a O
compensative O
activation O
at O
24 O
h O
. O

Moreover O
, O
a O
significant O
decrease O
in O
hypothalamic O
anti O
- O
inflammatory O
IL O
- O
10 O
- O
expression O
and O
an O
increase O
in O
inflammatory O
microsomal O
prostaglandin B
E I
synthase O
( O
mPGES O
) O
mRNA O
- O
expression O
8 O
h O
after O
LPS O
- O
injection O
was O
revealed O
in O
AG490 B
pre O
- O
treated O
animals O
compared O
to O
solvent O
- O
treated O
LPS O
- O
controls O
. O

In O
summary O
, O
we O
have O
shown O
a O
dissociation O
between O
the O
effects O
of O
central O
AG490 B
treatment O
on O
fever O
and O
components O
of O
sickness O
behavior O
, O
which O
appears O
to O
be O
related O
to O
reduced O
IL O
- O
10 O
and O
increased O
mPGES O
- O
expression O
in O
the O
brain O
. O

Thus O
, O
AG490 B
might O
have O
therapeutic O
potential O
to O
reduce O
sickness O
behavior O
. O

Other O
endogenous O
ligands O
, O
also O
present O
in O
biological O
samples O
, O
include O
resolvins B
, O
amyloidogenic O
proteins O
, O
such O
as O
beta O
amyloid O
( O
A O
beta O
) O
- O
42 O
and O
prion O
protein O
( O
Prp O
) O
106 O
- O
126 O
, O
the O
neuroprotective O
peptide O
, O
humanin O
, O
antibacterial O
peptides O
, O
annexin O
1 O
- O
derived O
peptides O
, O
chemokine O
variants O
, O
the O
neuropeptides O
, O
vasoactive O
intestinal O
peptide O
( O
VIP O
) O
and O
pituitary O
adenylate B
cyclase O
activating O
polypeptide O
( O

Upon O
activation O
, O
intracellular O
domains O
of O
FPR2 O
mediate O
signaling O
to O
G O
- O
proteins O
, O
which O
trigger O
several O
agonist O
- O
dependent O
signal O
transduction O
pathways O
, O
including O
activation O
of O
phospholipase O
C O
( O
PLC O
) O
, O
protein O
kinase O
C O
( O
PKC O
) O
isoforms O
, O
the O
phosphoinositide B
3 O
- O
kinase O
( O
PI3K O
) O
/ O
protein O
kinase O
B O
( O
Akt O
) O
pathway O
, O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
pathway O
, O
p38MAPK O
, O
as O
well O
as O
the O
phosphorylation O
of O
cytosolic O
tyrosine B
kinases O
, O

tyrosine B
kinase O
receptor O
transactivation O
, O
phosphorylation O
and O
nuclear O
translocation O
of O
regulatory O
transcriptional O
factors O
, O
release O
of O
calcium B
and O
production O
of O
oxidants O
. O

Here O
, O
we O
review O
and O
discuss O
the O
most O
significant O
findings O
on O
the O
intracellular O
pathways O
and O
on O
the O
cross O
- O
communication O
between O
FPR2 O
and O
tyrosine B
kinase O
receptors O
triggered O
by O
different O
FPR2 O
agonists O
. O

Specific O
control O
of O
group O
IVA O
cytosolic O
phospholipase O
A2 O
( O
cPLA2 O
alpha O
or O
PLA2G4A O
) O
expression O
modulates O
arachidonic B
acid I
production O
, O
thus O
tightly O
regulating O
the O
downstream O
effects O
of O
pro O
- O
and O
anti O
- O
inflammatory O
eicosanoids O
. O

These O
data O
provide O
new O
and O
important O
contributions O
to O
the O
understanding O
of O
cPLA2 O
alpha O
regulation O
at O
the O
transcriptional O
level O
with O
implications O
to O
eicosanoid B
metabolism O
, O
cellular O
signaling O
and O
disease O
pathogenesis O
. O

Ultrahigh O
- O
efficiency O
photocatalysts O
based O
on O
mesoporous O
Pt B
- O
WO3 B
nanohybrids O
. O

A O
reliable O
nanocasting O
method O
has O
been O
developed O
to O
synthesize O
mesoporous O
hybrids O
of O
platinum B
( O
Pt B
) O
nanoparticles O
decorating O
tungsten O
trioxide O
( O
WO3 B
) O
. O

The O
process O
began O
with O
modification O
of O
the O
SBA B
- I
15 I
template O
with O
carbon B
polymers O
and O
Pt B
nanoparticles O
accompanied O
by O
adsorption O
of O
W O
( O
6 O
+ O
) O
, O
which O
was O
then O
converted O
into O
m O
- O
Pt O
- O
WO3 O
composites O
by O
heat O
treatment O
and O
subsequent O
template O
removal O
. O

The O
synthetic O
strategy O
can O
be O
easily O
extended O
to O
prepare O
other O
mesoporous O
nanohybrids O
with O
metal B
oxide I
loaded O
precious O
metal O
composites O
. O

When O
the O
photocatalytic O
properties O
of O
m O
- O
Pt O
- O
WO3 O
nanohybrids O
were O
systematically O
investigated O
, O
it O
was O
revealed O
that O
the O
m O
- O
Pt O
- O
WO3 O
nanohybrids O
showed O
great O
promise O
for O
degrading O
the O
organic O
dye O
under O
visible O
light O
irradiation O
, O
which O
shows O
an O
excellent O
photocatalytic O
activity O
that O
far O
exceeded O
those O
of O
pure O
phase O
mesoporous O
WO3 B
and O
commercial O
TiO2 B
( O
P25 O
) O
, O
and O
was O
10 O
- O
fold O
more O
active O
than O
that O
of O
the O
bulk O
Pt B
- O
WO3 B
catalyst O
. O

An O
Active O
Role O
for O
Steroid B
- O
binding O
Globulins O
: O
An O
Update O
. O

It O
has O
been O
7 O
years O
( O
can O
it O
really O
be O
that O
long O
? O
) O
since O
we O
co O
- O
edited O
a O
volume O
( O
# O
38 O
) O
of O
Hormone O
and O
Metabolic O
Research O
that O
focused O
on O
evidence O
that O
steroid B
- O
binding O
globulins O
play O
an O
active O
role O
in O
the O
actions O
of O
steroids B
. O

There O
has O
been O
considerable O
progress O
in O
identifying O
the O
location O
, O
the O
physiological O
actions O
, O
and O
of O
determining O
the O
role O
of O
binding O
globulins O
in O
the O
actions O
of O
steroids B
and O
identifying O
a O
membrane O
- O
associated O
receptor O
for O
a O
binding O
protein O
since O
then O
and O
this O
review O
will O
discuss O
this O
progress O
. O

This O
review O
summarizes O
selected O
mechanistic O
insight O
garnered O
from O
reactions O
that O
form O
bonds O
between O
main O
group O
elements O
with O
liberation O
of O
hydrogen B
, O
dehydrocoupling O
or O
dehydropolymerizatio O
reactions O
. O

The O
corrosion O
of O
CoCrMo O
, O
an O
alloy O
frequently O
used O
in O
orthopedic O
implants O
, O
was O
studied O
with O
an O
electrochemical O
quartz B
crystal O
microbalance O
( O
QCM O
) O
in O
three O
physiologically O
relevant O
solutions O
. O

Corrosion O
studies O
on O
pure O
Co B
, O
Cr B
, O
and O
Mo B
in O
protein O
solutions O
found O
material O
deposition O
only O
on O
Mo B
. O

Aromatic B
amino I
acids I
are O
known O
for O
their O
hydrophobicity O
and O
the O
active O
role O
they O
play O
in O
protein O
folding O
. O

Backbone O
NH B
amide B
groups O
surrounded O
by O
aromatic O
rings O
have O
also O
been O
evidenced O
and O
are O
found O
to O
contribute O
significantly O
to O
the O
stabilization O
of O
aromatic O
pairs O
. O

Sensitive O
determination O
of O
lead O
, O
cadmium B
and O
nickel B
in O
soil O
, O
water O
, O
vegetable O
and O
fruit O
samples O
using O
STAT O
- O
FAAS O
after O
preconcentration O
with O
activated O
carbon B
. O

In O
this O
study O
, O
lead O
( O
Pb B
) O
, O
cadmium B
( O
Cd B
) O
and O
nickel B
( O
Ni B
) O
were O
determined O
in O
soil O
, O
water O
, O
vegetable O
and O
fruit O
samples O
taken O
from O
around O
oil O
refinery O
region O
in O
Batman O
, O
Turkey O
. O

In O
order O
to O
determine O
Pb B
and O
Cd B
, O
slotted O
tube O
atom O
trap O
( O
STAT O
) O
was O
used O
to O
increase O
the O
sensitivity O
in O
atomic O
absorption O
spectrophotometry O
. O

Preconcentration O
procedure O
under O
the O
optimum O
conditions O
was O
applied O
to O
water O
, O
vegetable O
and O
fruit O
samples O
to O
determine O
Pb B
, O
Cd B
and O
Ni B
in O
trace O
levels O
. O

In O
soil O
samples O
, O
concentrations O
of O
analytes O
were O
found O
in O
the O
range O
of O
4 O
. O
0 O
+ O
/ O
- O
0 O
. O
2 O
- O
12 O
, O
000 O
+ O
/ O
- O
60 O
mg O
/ O
kg O
for O
Pb B
, O
0 O
. O
15 O
+ O
/ O
- O
0 O
. O
01 O
- O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
mg O
/ O
kg O
for O
Cd B
and O
21 O
+ O
/ O
- O
1 O
- O
65 O
+ O
/ O
- O
3 O
. O
4 O
mg O
/ O
kg O
for O
Ni B
. O

In O
all O
water O
samples O
, O
concentration O
of O
Ni B
was O
expressed O
as O
nanogram O
per O
milliliter O
( O
ng O
/ O
mL O
) O
and O
found O
to O
be O
higher O
than O
Pb B
and O
Cd B
levels O
. O

It O
was O
observed O
that O
Pb B
, O
Cd B
and O
Ni B
concentrations O
varied O
from O
both O
plant O
to O
plant O
and O
in O
same O
plants O
at O
different O
experimental O
sites O
. O

Pb B
concentrations O
in O
vegetable O
and O
fruit O
samples O
interested O
varied O
between O
20 O
+ O
/ O
- O
2 O
and O
160 O
+ O
/ O
- O
12 O
ng O
/ O
g O
, O
and O
the O
highest O
level O
of O
Pb B
was O
found O
to O
be O
in O
green O
pepper O
taken O
from O
1000 O
m O
away O
from O
refinery O
. O

UVA O
photoirradiation O
of O
benzo B
[ I
a I
] I
pyrene I
metabolites O
: O
induction O
of O
cytotoxicity O
, O
reactive O
oxygen B
species O
, O
and O
lipid O
peroxidation O
. O

Benzo B
[ I
a I
] I
pyrene I
( O
BaP B
) O
is O
a O
prototype O
for O
studying O
carcinogenesis O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
. O

We O
have O
long O
been O
interested O
in O
studying O
the O
phototoxicity O
of O
PAHs B
. O

In O
this O
study O
, O
we O
determined O
that O
metabolism O
of O
BaP B
by O
human O
skin O
HaCaT O
keratinocytes O
resulted O
in O
six O
identified O
phase O
I O
metabolites O
, O
for O
example O
, O
BaP O
trans O
- O
7 O
, O
8 O
- O
dihydrodiol O
( O
BaP O
t O
- O
7 O
, O
8 O
- O
diol O
) O
, O
BaP O
t O
- O
4 O
, O
5 O
- O
diol O
, O
BaP O
t O
- O
9 O
, O
10 O
- O
diol O
, O
3 O
- O
hydroxybenzo O
[ O
a O
] O
pyrene O
( O
3 O
- O
OH O
- O
BaP O
) O
, O
BaP O
( O
7 O
, O
10 O
/ O
8 O
, O
9 O
) O
tetrol O
, O
and O
BaP O
( O
7 O

When O
photoirradiation O
was O
conducted O
in O
the O
presence O
of O
a O
lipid O
( O
methyl O
linoleate O
) O
, O
BaP B
metabolites O
, O
BPDE O
, O
and O
three O
related O
PAHs B
, O
pyrene B
, O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
tetrahydro O
- O
BaP O
trans O
- O
7 O
, O
8 O
- O
diol O
, O
and O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
tetrahydro O
- O
BaP O
trans O
- O
9 O
, O
10 O
- O
diol O
, O
all O
induced O
lipid O
peroxidation O
. O

The O
formation O
of O
lipid O
peroxides O
by O
BaP O
t O
- O
7 O
, O
8 O
- O
diol O
was O
inhibited O
by O
NaN3 B
and O
enhanced O
by O
deuterated O
methanol O
, O
which O
suggests O
that O
singlet O
oxygen B
may O
be O
involved O
in O
the O
generation O
of O
lipid O
peroxides O
. O

The O
formation O
of O
lipid O
hydroperoxides O
was O
partially O
inhibited O
by O
superoxide B
dismutase O
( O
SOD O
) O
. O

Electron O
spin O
resonance O
spin O
trapping O
experiments O
indicated O
that O
both O
singlet O
oxygen B
and O
superoxide B
radical O
anion O
were O
generated O
from O
UVA O
photoirradiation O
of O
BPDE O
in O
a O
light O
dose O
responding O
manner O
. O

Rapid O
self O
- O
healable O
poly B
( I
ethylene I
glycol I
) I
hydrogels O
formed O
by O
selective O
metal O
- O
phosphate B
interactions O
. O

Rapid O
self O
- O
healable O
and O
biocompatible O
hydrogels O
were O
prepared O
using O
the O
selective O
formation O
of O
metal O
- O
ligand O
interactions O
between O
selected O
metal O
ions O
and O
phosphate B
end O
groups O
of O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
. O

The O
phosphate B
- O
terminated O
branch O
of O
PEG B
was O
synthesized O
via O
a O
substitution O
reaction O
of O
the O
hydroxyl B
end O
groups O
using O
phosphoryl O
chloride O
. O

Especially O
, O
the O
gels O
rapidly O
formed O
by O
trivalent O
metal O
ions O
such O
as O
Fe B
( I
3 I
+ I
) I
, O
V O
( O
3 O
+ O
) O
, O
Al B
( I
3 I
+ I
) I
, O
Ti O
( O
3 O
+ O
) O
, O
and O
Ga O
( O
3 O
+ O
) O
have O
relatively O
small O
ionic O
radii O
. O

We O
have O
also O
demonstrated O
a O
gel O
- O
sol O
/ O
sol O
- O
gel O
transition O
by O
switching O
the O
redox O
states O
of O
Fe B
( I
3 I
+ I
) I
/ O
Fe B
( I
2 I
+ I
) I
ions O
. O

Learning O
from O
biological O
systems O
, O
the O
proposed O
phosphate B
- O
metal O
ion O
based O
self O
- O
healable O
hydrogels O
could O
become O
an O
attractive O
candidate O
for O
various O
biomedical O
and O
environmental O
applications O
. O

This O
study O
aims O
to O
investigate O
potential O
diabetic O
retinopathy O
( O
DR O
) O
risk O
factors O
by O
evaluating O
the O
circulating O
levels O
of O
pentosidine O
, O
soluble O
receptor O
for O
advanced O
glycation O
end O
- O
product O
( O
sRAGE O
) O
, O
advanced O
oxidation O
protein O
product O
( O
AOPP O
) O
as O
well O
as O
glutathione B
peroxidase O
( O
GPx O
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
activities O
in O
DR O
patients O
. O

Results O
from O
4 B
' I
- I
6 I
- I
diamidino I
- I
2 I
- I
phenylindole I
and O
annexin O
- O
V O
/ O
PI O
double O
- O
staining O
assay O
showed O
that O
caspase O
- O
3 O
- O
and O
caspase O
- O
8 O
- O
dependent O
, O
and O
dose O
- O
dependent O
apoptoses O
were O
detected O
after O
a O
24 O
- O
h O
dioscin O
treatment O
. O

Blockade O
of O
autophagy O
with O
bafilomycin B
A1 I
or O
3 B
- I
methyladenine I
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O

METHODS O
: O
A O
PubMed O
literature O
search O
was O
conducted O
using O
the O
following O
key O
words O
: O
autism O
, O
pervasive O
developmental O
disorders O
, O
atypical O
antipsychotics O
, O
risperidone B
, O
aripiprazole O
, O
quetiapine B
, O
ziprasidone B
, O
olanzapine B
, O
clozapine B
, O
paliperidone B
, O
iloperidone O
, O
asenapine B
, O
and O
lurasidone O
. O

RESULTS O
: O
The O
efficacy O
and O
tolerability O
of O
risperidone B
and O
aripiprazole O
for O
the O
treatment O
of O
irritability O
in O
autism O
have O
been O
established O
with O
multi O
- O
site O
, O
randomized O
, O
controlled O
trials O
. O

Studies O
supporting O
the O
use O
of O
other O
atypical O
antipsychotics O
are O
either O
limited O
in O
scope O
or O
less O
robust O
in O
their O
findings O
, O
though O
newer O
agents O
such O
as O
ziprasidone B
and O
paliperidone B
show O
promise O
. O

Interleukin O
- O
1 O
( O
IL O
- O
1 O
) O
inhibitors O
potentially O
have O
a O
role O
as O
antiinflammatory O
agents O
in O
refractory O
gout O
or O
for O
patients O
who O
are O
unable O
to O
tolerate O
conventional O
therapy O
, O
such O
as O
nonsteroidal O
antiinflammatory O
drugs O
( O
NSAIDs O
) O
, O
colchicine B
, O
or O
glucocorticoids O
, O
for O
acute O
attacks O
. O

After O
NSAIDs O
, O
colchicine B
, O
and O
steroids B
, O
IL O
- O
1 O
inhibitors O
are O
beneficial O
as O
fourth O
- O
line O
therapy O
for O
acute O
gout O
attacks O
due O
to O
their O
high O
cost O
and O
limited O
clinical O
experience O
. O

We O
fit O
sex O
- O
specific O
multivariable O
regression O
models O
to O
compare O
bone O
outcomes O
between O
Asians O
and O
Caucasians O
, O
adjusting O
for O
age O
, O
age O
at O
menarche O
( O
girls O
) O
, O
lean O
mass O
, O
ulnar O
length O
, O
dietary O
calcium B
intake O
and O
physical O
activity O
. O

In O
this O
study O
, O
changes O
in O
gene O
expression O
at O
the O
transcription O
level O
were O
evaluated O
in O
HCT O
- O
116 O
colon O
cancer O
cells O
after O
exposure O
to O
P O
. O
americana O
ethanol B
extract O
and O
its O
water O
fraction O
using O
the O
Human O
Cancer O
Pathway O
Finder O
PCR O
Array O
. O

Of O
the O
genes O
significantly O
affected O
in O
HCT O
- O
116 O
cells O
exposed O
to O
the O
ethanol B
extract O
at O
3200 O
micro O
g O
/ O
ml O
, O
changes O
in O
expression O
of O
MYC O
, O
PLAU O
, O
and O
TEK O
may O
benefit O
the O
treatment O
of O
colon O
cancer O
. O

Furanodiene O
Presents O
Synergistic O
Anti O
- O
proliferative O
Activity O
With O
Paclitaxel B
Via O
Altering O
Cell O
Cycle O
and O
Integrin O
Signaling O
in O
95 O
- O
D O
Lung O
Cancer O
Cells O
. O

Furanodiene O
( O
FUR O
) O
is O
a O
natural O
terpenoid B
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well O
- O
known O
Chinese O
medicinal O
herb O
that O
presents O
anti O
- O
proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O

Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR O
with O
paclitaxel B
( O
TAX O
) O
showed O
synergetic O
anti O
- O
proliferative O
activities O
in O
95 O
- O
D O
lung O
cancer O
cells O
. O

Here O
we O
tested O
the O
effect O
of O
chronic O
supplementation O
with O
a O
mineral O
extract O
from O
red O
marine O
algae O
- O
rich O
in O
calcium B
( O
34 O
% O
) O
, O
magnesium B
, O
phosphorus B
, O
selenium B
and O
other O
trace O
minerals O
- O
in O
a O
clinically O
relevant O
model O
of O
spontaneous O
enterocolitis O
, O
interleukin O
( O
IL O
) O
- O
10 O
( O
- O
/ O
- O
) O
mice O
. O

Expression O
, O
purification O
and O
proteomic O
analysis O
of O
recombinant O
histone O
H4 O
acetylated O
at O
lysine B
16 O
. O

We O
have O
applied O
the O
amber O
stop O
codon O
/ O
suppressor O
tRNA O
strategy O
to O
the O
production O
of O
histone O
H4 O
acetylated O
at O
lysine B
16 O
, O
a O
particularly O
important O
isoform O
of O
this O
histone O
. O

Inexpensive O
components O
like O
a O
commercially O
available O
silazane O
and O
polyethylene B
are O
linked O
. O

Furthermore O
, O
the O
SiCN O
nanofibers O
introduced O
on O
page O
984 O
are O
a O
promising O
alternative O
to O
ultrathin O
carbon B
fibers O
, O
due O
to O
their O
oxidation O
resistance O
. O

Graphene B
in O
Light O
: O
Design O
, O
Synthesis O
and O
Applications O
of O
Photo O
- O
active O
Graphene B
and O
Graphene B
- O
Like O
Materials O
. O

Graphene B
functionalized O
with O
photo O
- O
active O
units O
has O
become O
one O
of O
the O
most O
exciting O
topics O
of O
research O
in O
the O
last O
few O
years O
, O
which O
remarkably O
sustains O
and O
expands O
the O
graphene B
boom O
. O

The O
rise O
of O
photo O
- O
active O
graphene B
in O
photonics O
and O
optoelectronics O
is O
evidenced O
by O
a O
spate O
of O
recent O
reports O
on O
topics O
ranging O
from O
photodetectors O
, O
photovoltaics O
, O
and O
optoelectronics O
to O
photocatalysis O
. O

For O
these O
applications O
, O
the O
fabrication O
of O
photo O
- O
active O
graphene B
through O
appropriate O
chemical O
functionalization O
strategies O
is O
essential O
as O
pristine O
graphene B
has O
zero O
bandgap O
and O
only O
weak O
absorption O
of O
photons O
. O

Written O
from O
the O
chemists O
' O
point O
of O
view O
, O
up O
- O
to O
- O
date O
chemical O
functionalization O
of O
graphene B
with O
various O
small O
organic O
molecules O
, O
conjugated O
polymers O
, O
rare O
- O
earth O
components O
, O
and O
inorganic O
semiconductors O
is O
reviewed O
. O

Particular O
attention O
is O
paid O
to O
the O
development O
of O
graphene B
functionalized O
with O
light O
- O
harvesting O
moieties O
, O
including O
materials O
synthesis O
, O
characterization O
, O
energy O
/ O
charge O
- O
transfer O
processes O
, O
and O
applications O
in O
photovoltaics O
. O

Amorphous O
Ni B
( I
OH I
) I
2 I
Nanoboxes O
: O
Fast O
Fabrication O
and O
Enhanced O
Sensing O
for O
Glucose B
. O

Inspired O
by O
Pearson O
' O
s O
hard O
and O
soft O
acid O
- O
base O
( O
HSAB O
) O
principle O
, O
uniform O
amorphous O
Ni B
( I
OH I
) I
2 I
nanoboxes O
with O
intact O
shell O
structures O
and O
various O
sizes O
are O
quickly O
fabricated O
by O
deliberately O
selecting O
S2 O
O3 O
( O
2 O
- O
) O
as O
the O
coordinating O
etchant O
toward O
Cu2 O
O O
templates O
and O
optimizing O
the O
reaction O
conditions O
. O

Ni B
( I
OH I
) I
2 I
nanoboxes O
, O
as O
an O
example O
, O
demonstrate O
an O
improved O
electrochemical O
sensing O
ability O
for O
glucose B
, O
which O
might O
be O
due O
to O
their O
amorphous O
and O
hollow O
structural O
features O
. O

A O
Thyroxine B
Absorption O
Test O
Followed O
by O
Weekly O
Thyroxine B
Administration O
: O
A O
Method O
to O
Assess O
Non O
- O
Adherence O
to O
Treatment O
. O

OBJECTIVE O
: O
For O
patients O
, O
who O
remain O
hypothyroid O
despite O
the O
administration O
of O
what O
would O
seem O
adequate O
doses O
of O
levothyroxine B
, O
the O
underlying O
cause O
can O
be O
difficult O
to O
determine O
. O

In O
this O
study O
we O
identified O
patients O
for O
whom O
known O
drug O
and O
pathological O
causes O
of O
levothyroxine B
malabsorption O
were O
excluded O
and O
despite O
often O
high O
doses O
of O
levothyroxine B
, O
the O
patients O
remained O
hypothyroid O
. O

DESIGN O
: O
Using O
a O
weight O
- O
determined O
oral O
levothyroxine B
bolus O
administration O
, O
absorption O
was O
initially O
assessed O
in O
twenty O
- O
three O
patients O
. O

This O
was O
then O
followed O
by O
the O
continued O
administration O
of O
a O
weekly O
thyroxine B
bolus O
for O
a O
four O
- O
week O
period O
after O
which O
TSH O
and O
free O
T4 O
levels O
were O
recorded O
. O

RESULTS O
: O
All O
patients O
showed O
a O
rise O
in O
free O
T4 O
at O
120mins O
following O
the O
administration O
of O
the O
levothyroxine B
bolus O
, O
with O
a O
mean O
increase O
of O
54 O
+ O
/ O
- O
3 O
% O
from O
baseline O
. O

Following O
the O
treatment O
period O
, O
using O
an O
equivalent O
weekly O
levothyroxine B
dose O
which O
was O
significantly O
less O
than O
that O
of O
the O
daily O
dose O
taken O
by O
the O
patients O
before O
the O
test O
, O
the O
TSH O
reduced O
from O
baseline O
in O
~ O
75 O
% O
of O
cases O
. O

hUII O
- O
induced O
MAP O
elevation O
and O
hemodynamic O
changes O
were O
inhibited O
by O
urantide O
, O
a O
UTR O
antagonist O
, O
but O
not O
losartan B
, O
a O
type O
1 O
angiotensin O
II O
receptor O
antagonist O
. O

U B
- I
73122 I
, O
a O
phospholipase O
C O
( O
PLC O
) O
inhibitor O
, O
and O
2 O
- O
aminoethoxydiphenyl O
borate O
, O
an O
inositol B
1 I
, I
4 I
, I
5 I
trisphosphate I
( O
IP3 O
) O
receptor O
antagonist O
, O
attenuated O
hUII O
- O
induced O
MAP O
and O
RVR O
elevations O
, O
RBF O
and O
CBF O
reductions O
, O
but O
not O
MBF O
increase O
. O

The O
present O
work O
demonstrates O
that O
hypothalamic O
integration O
of O
metabolic O
signals O
requires O
neuronal O
expression O
of O
glucosylceramide O
synthase O
( O
GCS O
; O
UDP B
- O
glucose B
: O
ceramide O
glucosyltransferase O
) O
. O

Consequently O
, O
mice O
with O
inducible O
forebrain O
neuron O
- O
specific O
deletion O
of O
the O
UDP B
- O
glucose B
: O
ceramide O
glucosyltransferase O
gene O
( O
Ugcg O
) O
display O
obesity O
, O
hypothermia O
, O
and O
lower O
sympathetic O
activity O
. O

Liposomes O
were O
composed O
of O
phosphatidylcholine B
, O
hydrogenated O
soy O
phosphatidylcholine B
( O
HSPC O
) O
, O
stearylamine O
, O
alpha B
- I
tocopherol I
and O
1 O
, O
2 O
- O
distearoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphoethanolamine O
- O
N O
- O
[ O
amino O
( O
polyethylene O
glycol O
) O
- O
2000 O
] O
( O
PEG B
- I
DSPE I
) O
or O
folate O
- O
polyethylene O
glycol O
- O
cholesteryl O
hemisuccinate O
( O
F O
- O

The O
cytotoxic O
activity O
of O
the O
encapsulated O
cyclic O
dipeptides O
was O
tested O
against O
HeLa O
, O
low O
folate B
HeLa O
and O
MCF O
- O
7 O
cells O
and O
found O
to O
have O
limited O
improvement O
in O
activity O
. O

However O
, O
modification O
of O
the O
polyethylene B
glycol I
with O
folic B
acid I
to O
target O
folate O
receptors O
significantly O
decreased O
the O
IC50 O
values O
recorded O
in O
all O
cells O
lines O
tested O
, O
particularly O
HeLa O
cells O
cultured O
in O
media O
containing O
physiological O
concentrations O
of O
folic B
acid I
with O
the O
lowest O
IC50 O
being O
recorded O
as O
0 O
. O
0962 O
mM O
for O
folate B
- O
targeted O
cyclo O
( O
His O
- O
Ala O
) O
. O

Dichloromethane B
, O
methanol B
and O
aqueous O
extracts O
of O
the O
fruiting O
bodies O
of O
25 O
species O
were O
screened O
in O
vitro O
for O
their O
antibacterial O
activities O
against O
three O
Gram O
- O
positive O
bacteria O
( O
Staphyloccocus O
aureus O
, O
Bacillus O
subtilis O
, O
Micrococcus O
flavus O
) O
and O
two O
Gram O
- O
negative O
bacteria O
( O
Escherichia O
coli O
, O
Pseudomonas O
aeruginosa O
) O
, O
against O
six O
human O
fungal O
pathogens O
( O
Candida O
albicans O
, O
Candida O
krusei O
, O
Aspergillus O
fumigatus O
, O

The O
methanol B
extracts O
of O
Agaricus O
cf O
. O
bernardii O
, O
Agrocybe O
pediades O
, O
Chlorophyllum O
molybdites O
, O
Coriolopsis O
polyzona O
, O
Ganoderma O
xylonoides O
, O
Pycnoporus O
sanguineus O
, O
Trametes O
lactinea O
and O
Trametes O
cingulata O
showed O
activity O
against O
all O
tested O
bacteria O
. O

The O
highest O
antibacterial O
activity O
was O
exhibited O
by O
methanol B
extracts O
from O
Chlorophyllum O
molybdites O
, O
Ganoderma O
xylonoides O
and O
Trametes O
cingulata O
and O
Agaricus O
cf O
. O
bernardii O
, O
Agrocybe O
pediades O
, O
Coriolopsis O
polyzona O
, O
Pycnoporus O
sanguineus O
and O
Trametes O
lactinea O
. O

The O
methanol B
extracts O
of O
Chlorophyllum O
molybdites O
, O
Ganoderma O
xylonoides O
and O
Pycnoporus O
sanguineus O
showed O
considerable O
antifungal O
activities O
against O
the O
tested O
fungal O
strains O
. O

Strong O
antioxidative O
effects O
employing O
the O
DPPH B
assay O
were O
exhibited O
by O
methanol B
extracts O
from O
Chlorophyllum O
molybdites O
, O
Ganoderma O
xylonoides O
, O
Hexagonia O
velutina O
, O
Pycnoporus O
sanguineus O
, O
Trametes O
lactinea O
and O
Trametes O
cingulata O
. O

A O
RCCSD O
( O
T O
) O
/ O
cc O
- O
pVQZ O
potential O
energy O
surface O
is O
constructed O
for O
the O
HOCO B
radical O
in O
the O
ground O
electronic O
state O
and O
used O
to O
compute O
rotation O
- O
vibration O
levels O
of O
HOCO B
and O
DOCO O
. O

The O
antioxidant O
capacities O
of O
the O
extract O
were O
evaluated O
using O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
, O
beta B
- I
carotene I
/ O
linoleic B
acid I
and O
reducing O
power O
and O
metal O
chelating O
activity O
assays O
. O

The O
amount O
of O
total O
phenolic O
content O
, O
flavonoids B
and O
condensed O
tannins B
was O
very O
high O
, O
and O
the O
correlation O
between O
the O
antioxidant O
activity O
potential O
and O
total O
phenolic O
level O
of O
the O
extract O
was O
pointed O
out O
. O

Galactose B
- O
Based O
Amphiphilic O
Block O
Copolymers O
: O
Synthesis O
, O
Micellization O
, O
and O
Bioapplication O
. O

Doxorubicin B
( O
DOX B
) O
could O
be O
encapsulated O
by O
P O
( O
MAGP O
- O
co O
- O
DMAEMA O
) O
- O
b O
- O
PPDSMA O
upon O
micellization O
and O
released O
upon O
adding O
glutathione B
( O
GSH B
) O
into O
the O
micelle O
solution O
. O

The O
galactose B
functional O
groups O
in O
the O
PMAGP O
block O
had O
specific O
interaction O
with O
HepG2 O
cells O
, O
and O
P O
( O
MAGP O
- O
co O
- O
DMAEMA O
) O
- O
b O
- O
PPDSMA O
can O
act O
as O
gene O
delivery O
vehicle O
. O

METHODS O
AND O
RESULTS O
: O
We O
measured O
CFR O
of O
65 O
subjects O
with O
prediabetes O
, O
45 O
patients O
with O
overt O
type O
2 O
diabetes O
, O
and O
43 O
sex O
and O
age O
matched O
normoglycemic O
healthy O
subjects O
with O
normal O
glucose B
tolerance O
. O

CFR O
was O
significantly O
and O
inversely O
correlated O
with O
age O
( O
r O
= O
- O
0 O
. O
15 O
, O
P O
= O
0 O
. O
04 O
) O
, O
fasting O
glucose B
level O
( O
r O
= O
- O
0 O
. O
27 O
, O
P O
= O
0 O
. O
001 O
) O
, O
postprandial O
glucose B
level O
( O
r O
= O
0 O
. O
43 O
, O
P O
< O
0 O
. O
001 O
) O
, O
hemoglobin O
A1C O
level O
( O
r O
= O
- O
0 O
. O
34 O
, O
P O
< O
0 O
. O
001 O
) O
, O
LDL O
cholesterol B
level O
( O
r O
= O
0 O
. O
22 O
, O
P O
= O
0 O
. O
009 O
) O
, O
mitral O
A O
velocity O
( O
r O
= O
- O
0 O
. O
27 O
, O
P O
= O

Does O
4 O
- O
tert O
- O
octylphenol O
affect O
estrogen B
signaling O
pathways O
in O
bank O
vole O
Leydig O
cells O
and O
tumor O
mouse O
Leydig O
cells O
in O
vitro O
? O

Leydig O
cells O
were O
treated O
with O
two O
concentrations O
of O
OP O
( O
10 O
( O
- O
4 O
) O
M O
, O
10 O
( O
- O
8 O
) O
M O
) O
alone O
or O
concomitantly O
with O
anti O
- O
estrogen B
ICI B
182 I
, I
780 I
( O
1 O
mu O
M O
) O
. O

In O
OP O
- O
treated O
bank O
vole O
Leydig O
cells O
, O
inhomogeneous O
staining O
of O
estrogen B
receptor O
alpha O
( O
ER O
alpha O
) O
within O
cell O
nuclei O
was O
found O
, O
whereas O
it O
was O
of O
various O
intensity O
among O
MA O
- O
10 O
Leydig O
cells O
. O

Dissimilar O
action O
of O
OP O
on O
cAMP B
and O
androgen B
production O
was O
also O
observed O
. O

Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin B
reduce O
albuminura O
in O
diabetes O
. O

High O
glucose B
( O
HG O
) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O

HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH B
oxidase O
activity O
. O

Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin B
decreases O
HG O
- O
induced O
Nox4 O
and O
Nox1 O
, O
NADPH B
oxidase O
activity O
and O
podocyte O
apoptosis O
. O

In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O
activation O
of O
mTOR O
with O
increase O
in O
Nox4 O
and O
NADPH B
oxidase O
activity O
. O

Inhibition O
of O
mTOR O
by O
small O
dose O
of O
rapamycin B
reduces O
podocyte O
apoptosis O
, O
attenuates O
glomerular O
injury O
and O
albuminuria O
. O

Thus O
mTOR O
and O
or O
NADPH B
oxidase O
inhibition O
may O
represent O
a O
therapeutic O
modality O
of O
diabetic O
kidney O
disease O
. O

Replacement O
of O
hydrogen B
with O
fluorine B
within O
three O
pairs O
of O
structurally O
similar O
small O
molecule O
inhibitors O
of O
heat O
shock O
protein O
90 O
( O
HSP90 O
) O
resulted O
in O
differences O
in O
inhibition O
constants O
( O
Ki O
) O
in O
vitro O
as O
well O
as O
marked O
differences O
in O
rat O
intravenous O
pharmacokinetic O
profiles O
. O

1 O
, O
3 O
, O
4 O
- O
Oxadiazol O
- O
2 O
- O
ones O
as O
fatty B
- I
acid I
amide I
hydrolase O
and O
monoacylglycerol B
lipase O
inhibitors O
: O
Synthesis O
, O
in O
vitro O
evaluation O
and O
insight O
into O
potency O
and O
selectivity O
determinants O
by O
molecular O
modelling O
. O

Inhibition O
of O
the O
key O
hydrolytic O
enzymes O
of O
the O
endocannabinoid O
system O
, O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
and O
monoacylglycerol B
lipase O
( O
MAGL O
) O
, O
has O
been O
proposed O
as O
potential O
mode O
of O
action O
for O
various O
therapeutic O
applications O
. O

Development O
of O
solid O
lipid O
nanoparticles O
based O
controlled O
release O
system O
for O
topical O
delivery O
of O
terbinafine B
hydrochloride I
. O

The O
study O
describes O
the O
development O
and O
evaluation O
of O
solid O
lipid O
nanoparticles O
( O
SLNs O
) O
of O
terbinafine B
hydrochloride I
( O
TH O
) O
for O
sustained O
release O
and O
skin O
targeting O
. O

Optimized O
SLNs O
were O
incorporated O
into O
Carbopol B
gel O
and O
evaluated O
for O
drug O
content O
, O
pH O
, O
in O
vitro O
release O
, O
ex O
vivo O
retention O
, O
in O
vivo O
pharmacodynamic O
and O
stability O
studies O
. O

It O
was O
concluded O
that O
SLNs O
incorporated O
Carbopol B
gel O
had O
skin O
targeting O
ability O
and O
may O
serve O
as O
a O
promising O
carrier O
in O
treatment O
of O
fungal O
skin O
infections O
. O

Antitumor O
effect O
of O
5 B
- I
fluorouracil I
is O
enhanced O
by O
rosemary O
extract O
in O
both O
drug O
sensitive O
and O
resistant O
colon O
cancer O
cells O
. O

5 B
- I
Fluorouracil I
( O
5 B
- I
FU I
) O
is O
the O
most O
used O
chemotherapeutic O
agent O
in O
colorectal O
cancer O
. O

The O
aim O
of O
this O
work O
was O
to O
determine O
the O
antitumor O
properties O
of O
a O
supercritical O
fluid O
rosemary O
extract O
( O
SFRE O
) O
, O
alone O
and O
in O
combination O
with O
5 B
- I
FU I
, O
as O
a O
potential O
adjuvant O
therapy O
useful O
for O
colon O
cancer O
patients O
. O

The O
effects O
of O
SFRE O
both O
alone O
and O
in O
combination O
with O
5 B
- I
FU I
were O
evaluated O
in O
different O
human O
colon O
cancer O
cells O
in O
terms O
of O
cell O
viability O
, O
cytotoxicity O
, O
and O
cell O
transformation O
. O

Additionally O
, O
colon O
cancer O
cells O
resistant O
to O
5 B
- I
FU I
were O
used O
to O
assay O
the O
effects O
of O
SFRE O
on O
drug O
resistance O
. O

Finally O
, O
qRT O
- O
PCR O
was O
performed O
to O
ascertain O
the O
mechanism O
by O
which O
SFRE O
potentiates O
the O
effect O
of O
5 B
- I
FU I
. O

Our O
results O
show O
that O
SFRE O
displays O
dose O
- O
dependent O
antitumor O
activities O
and O
exerts O
a O
synergistic O
effect O
in O
combination O
with O
5 B
- I
FU I
on O
colon O
cancer O
cells O
. O

Furthermore O
, O
SFRE O
sensitizes O
5 B
- I
FU I
- O
resistant O
cells O
to O
the O
therapeutic O
activity O
of O
this O
drug O
, O
constituting O
a O
beneficial O
agent O
against O
both O
5 B
- I
FU I
sensitive O
and O
resistant O
tumor O
cells O
. O

Gene O
expression O
analysis O
indicates O
that O
the O
enhancement O
of O
the O
effect O
of O
5 B
- I
FU I
by O
SFRE O
might O
be O
explained O
by O
the O
downregulation O
of O
TYMS O
and O
TK1 O
, O
enzymes O
related O
to O
5 B
- I
FU I
resistance O
. O

The O
improved O
protocol O
generates O
high O
quality O
data O
that O
can O
be O
used O
to O
identify O
differential O
expression O
in O
known O
and O
novel O
coding O
and O
non O
- O
coding O
transcripts O
, O
splice O
variants O
, O
mitochondrial O
genes O
and O
SNPs O
( O
single O
nucleotide B
polymorphisms O
) O
. O

We O
examined O
the O
concentration O
dependency O
and O
mechanism O
of O
action O
of O
DPHD O
relative O
to O
17 B
beta I
- I
estradiol I
in O
nontransformed O
human O
osteoblasts O
( O
h O
- O
OB O
) O
. O

Effects O
of O
DPHD O
were O
eliminated O
by O
the O
estrogen B
receptor O
antagonist O
ICI182780 O
. O

Subsequently O
, O
DPHD O
accelerated O
production O
of O
bone O
structural O
genes O
, O
including O
COL1A1 O
and O
osteocalcin O
comparably O
to O
17 B
beta I
- I
estradiol I
. O

In O
h O
- O
OB O
, O
DPHD O
increased O
the O
osteoprotegerin O
to O
RANKL O
ratio O
and O
supported O
mineralization O
more O
efficiently O
than O
10nM O
17 B
beta I
- I
estradiol I
. O

Four O
new O
cyclohexanone O
derivatives O
( O
2 O
- O
5 O
) O
and O
one O
known O
analog O
, O
( O
- O
) O
- O
Palitantin O
( O
1 O
) O
were O
isolated O
from O
the O
EtOAc B
extract O
of O
Penicillium O
commune O
, O
a O
fungal O
strain O
of O
low O
- O
temperature O
habitats O
. O

Native O
GLP O
- O
1 O
stimulates O
insulin O
secretion O
in O
a O
glucose B
- O
dependent O
manner O
, O
as O
well O
as O
suppressing O
glucagon O
production O
and O
slowing O
gastric O
emptying O
. O

After O
the O
first O
nucleotide B
is O
added O
by O
template O
slippage O
, O
however O
, O
hPol O
kappa O
can O
efficiently O
realign O
the O
primer O
- O
template O
duplex O
before O
continuing O
DNA O
synthesis O
. O

On O
non O
- O
repetitive O
sequences O
, O
we O
find O
that O
nucleotide B
misincorporation O
is O
slower O
if O
the O
incoming O
nucleotide B
can O
correctly O
basepair O
with O
the O
nucleotide B
immediately O
5 O
' O
to O
the O
templating O
base O
, O
thereby O
competing O
against O
the O
mispairing O
with O
the O
templating O
base O
. O

Finally O
, O
cyclosporine B
A I
( O
CsA O
) O
was O
used O
as O
an O
illustrative O
case O
to O
support O
applicability O
of O
ZFE O
in O
hepatotoxicity O
testing O
by O
comparing O
CsA O
- O
induced O
gene O
expression O
between O
ZFE O
, O
in O
vivo O
mouse O
liver O
and O
HepaRG O
cells O
on O
the O
levels O
of O
single O
genes O
, O
pathways O
and O
transcription O
factors O
. O

A O
series O
of O
sugar B
- O
modified O
derivatives O
of O
cytostatic O
7 O
- O
heteroaryl O
- O
7 O
- O
deazaadenosines O
( O
2 O
' O
- O
deoxy O
- O
2 O
' O
- O
fluororibo O
- O
and O
2 O
' O
- O
deoxy O
- O
2 O
' O
, O
2 O
' O
- O
difluororibonucleosi O
) O
bearing O
an O
aryl O
or O
heteroaryl O
group O
at O
position O
7 O
was O
prepared O
and O
screened O
for O
biological O
activity O
. O

The O
fluororibo O
derivatives O
were O
prepared O
by O
aqueous O
palladium B
- O
catalyzed O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
7 O
- O
iodo O
- O
7 O
- O
deazaadenine O
2 O
' O
- O
deoxy O
- O
2 O
' O
- O
fluororibonucleoside O
20 O
with O
( O
het O
) O
arylboronic O
acids O
. O

Some O
of O
the O
title O
nucleosides B
and O
7 O
- O
iodo O
- O
7 O
- O
deazaadenine O
intermediates O
showed O
micromolar O
cytostatic O
or O
anti O
- O
HCV O
activity O
. O

Modeling O
the O
Conformational O
Preference O
of O
the O
Carbon B
- O
Bonded O
Covalent O
Adduct O
Formed O
upon O
Exposure O
of O
2 O
' O
- O
Deoxyguanosine O
to O
Ochratoxin B
A I
. O

The O
conformational O
flexibility O
of O
the O
C8 O
- O
linked O
guanine B
adduct O
formed O
from O
attachment O
of O
ochratoxin B
A I
( O
OTA O
) O
was O
analyzed O
using O
a O
systematic O
computational O
approach O
and O
models O
ranging O
from O
the O
nucleobase B
to O
the O
adducted O
DNA O
helix O
. O

A O
focus O
was O
placed O
on O
the O
influence O
of O
the O
C8 O
- O
modification O
of O
2 O
' O
- O
deoxyguanosine O
( O
dG O
) O
on O
the O
preferred O
relative O
arrangement O
of O
the O
nucleobase B
and O
the O
C8 O
- O
substituent O
and O
, O
more O
importantly O
, O
the O
anti O
/ O
syn O
conformational O
preference O
with O
respect O
to O
the O
glycosidic O
bond O
. O

Although O
OTA O
is O
twisted O
with O
respect O
to O
the O
base O
in O
the O
nucleobase B
model O
, O
addition O
of O
the O
deoxyribose O
sugar O
induces O
a O
further O
twist O
and O
restricts O
rotation O
about O
the O
C B
- I
C I
linkage O
due O
to O
close O
contacts O
between O
OTA O
and O
the O
sugar O
. O

The O
nucleoside B
model O
preferentially O
adpots O
a O
syn O
orientation O
( O
by O
10 O
- O
20 O
kJ O
mol O
( O
- O
1 O
) O
depending O
on O
the O
OTA O
conformation O
) O
due O
to O
the O
presence O
of O
an O
O5 O
' O
- O
H B
. O
. O
. O
N3 O
interaction O
. O

However O
, O
when O
this O
hydrogen B
bond O
is O
eliminated O
, O
which O
better O
mimics O
the O
DNA O
environment O
, O
a O
small O
( O
< O
5 O
kJ O
mol O
( O
- O
1 O
) O
) O
anti O
/ O
syn O
energy O
difference O
is O
predicted O
. O

Inclusion O
of O
the O
5 O
' O
- O
monophosphate O
group O
leads O
to O
an O
up O
to O
20 O
kJ O
mol O
( O
- O
1 O
) O
preference O
for O
the O
syn O
( O
nucleotide O
) O
conformation O
due O
to O
stabilizing O
base O
- O
phosphate B
interactions O
involving O
the O
amino B
group O
of O
guanine B
. O

Nevertheless O
, O
MD O
simulations O
and O
free O
energy O
analysis O
predict O
that O
both O
syn O
- O
and O
anti O
- O
conformations O
of O
OTB O
- O
dG O
are O
equally O
stable O
in O
helices O
when O
paired O
opposite O
cytosine B
. O

These O
results O
indicate O
that O
the O
adduct O
will O
likely O
adopt O
a O
syn O
conformation O
in O
an O
isolated O
nucleoside B
and O
nucleotide B
, O
while O
a O
mixture O
of O
syn O
and O
anti O
conformations O
will O
be O
observed O
in O
DNA O
duplexes O
. O

This O
family O
, O
which O
does O
not O
contain O
the O
highly O
basic O
amino B
group O
usually O
present O
in O
other O
sigma O
1R O
ligands O
, O
showed O
high O
selectivity O
over O
the O
sigma O
2 O
receptor O
( O
sigma O
2R O
) O
. O

Compound O
32c O
also O
exhibited O
a O
good O
ADMET O
( O
absorption O
, O
distribution O
, O
metabolism O
, O
excretion O
, O
toxicity O
) O
profile O
and O
was O
identified O
as O
a O
sigma O
1R O
antagonist O
on O
the O
basis O
of O
its O
analgesic O
activity O
in O
the O
mouse O
capsaicin B
and O
formalin B
models O
of O
neurogenic O
pain O
. O

These O
compounds O
are O
indole B
- O
terpenes B
with O
a O
new O
skeleton O
uncommon O
in O
nature O
. O

To O
prepare O
DNA O
- O
loaded O
satellite O
assemblies O
, O
uniform O
gelatin O
microspheres O
are O
fabricated O
using O
microfluidics O
, O
loaded O
with O
15 O
base O
- O
long O
secondary O
DNA O
targets O
, O
capped O
with O
a O
polyelectrolyte O
bilayer O
, O
and O
finally O
coated O
with O
a O
monolayer O
of O
polystyrene B
microspheres O
functionalized O
with O
duplexes O
comprised O
of O
immobilized O
probes O
and O
soluble O
, O
13 O
base O
- O
long O
hybridization O
partner O
strands O
. O

Once O
warmed O
to O
37 O
degrees O
C O
, O
secondary O
DNA O
targets O
are O
released O
from O
the O
gelatin O
template O
and O
then O
competitively O
displace O
the O
shorter O
, O
original O
hybridization O
partners O
on O
the O
polystyrene B
microspheres O
. O

Quantitating O
the O
Lattice O
Strain O
Dependence O
of O
Monolayer O
Pt B
Shell O
Activity O
toward O
Oxygen B
Reduction O
. O

Lattice O
strain O
of O
Pt B
- O
based O
catalysts O
reflecting O
d O
- O
band O
status O
is O
the O
decisive O
factor O
of O
their O
catalytic O
activity O
toward O
oxygen B
reduction O
reaction O
( O
ORR O
) O
. O

For O
the O
newly O
arisen O
monolayer O
Pt B
system O
, O
however O
, O
no O
general O
strategy O
to O
isolate O
the O
lattice O
strain O
has O
been O
achieved O
due O
to O
the O
short O
- O
range O
ordering O
structure O
of O
monolayer O
Pt B
shells O
on O
different O
facets O
of O
core O
nanoparticles O
. O

Herein O
, O
based O
on O
the O
extended O
X O
- O
ray O
absorption O
fine O
structure O
of O
monolayer O
Pt B
atoms O
on O
various O
single O
crystal O
facets O
, O
we O
propose O
an O
effective O
methodology O
for O
evaluating O
the O
lattice O
strain O
of O
monolayer O
Pt B
shells O
on O
core O
nanoparticles O
. O

The O
quantitative O
lattice O
strain O
establishes O
a O
direct O
correlation O
to O
monolayer O
Pt B
shell O
ORR O
activity O
. O

Antioxidant O
capacity O
of O
anthocyanins B
from O
Rhodomyrtus O
tomentosa O
( O
Ait O
. O
) O
and O
identification O
of O
the O
major O
anthocyanins B
. O

The O
anthocyanins B
in O
the O
fruits O
of O
Rhodomyrtus O
tomentosa O
( O
ACN O
) O
were O
extracted O
by O
1 O
% O
TFA B
in O
methanol B
, O
and O
then O
purified O
by O
X O
- O
5 O
resin O
column O
and O
C18 O
( O
SPE O
) O
cartridges O
. O

The O
purified O
anthocyanin B
extract O
( O
ART O
) O
from O
the O
fruits O
of O
R O
. O
tomentosa O
showed O
strong O
antioxidant O
activities O
, O
including O
DPPH B
radical O
- O
scavenging O
capacity O
, O
ABTS B
radical O
scavenging O
capacity O
, O
reducing O
power O
and O
oxygen B
radical O
absorbance O
capacity O
( O
ORAC O
) O
. O

The O
purified O
anthocyanin B
extract O
was O
analyzed O
by O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
. O

The O
major O
anthocyanins B
were O
purified O
by O
semi O
- O
preparative O
HPLC O
and O
Sephadex O
LH O
- O
20 O
column O
chromatography O
, O
and O
were O
identified O
as O
cyanidin O
- O
3 O
- O
O O
- O
glucoside O
, O
peonidin O
- O
3 O
- O
O O
- O
glucoside O
, O
malvidin O
- O
3 O
- O
O O
- O
glucoside O
, O
petunidin O
- O
3 O
- O
O O
- O
glucoside O
, O
delphinidin O
- O
3 O
- O
O O
- O
glucoside O
and O
pelargonidin O
- O
3 O
- O
glucoside O
by O
HPLC O
- O
ESI O
/ O
MS O
and O
nuclear O

Cyanidin O
- O
3 O
- O
O O
- O
glucoside O
was O
considered O
as O
the O
most O
abundant O
anthocyanin B
, O
which O
was O
29 O
. O
4mg O
/ O
100g O
dry O
weight O
of O
R O
. O
tomentosa O
fruits O
. O

Additionally O
, O
all O
the O
major O
anthocyanins B
were O
identified O
from O
R O
. O
tomentosa O
fruit O
for O
the O
first O
time O
. O

Plums O
( O
Prunus O
domestica O
L O
. O
) O
are O
a O
good O
source O
of O
yeasts O
producing O
organic O
acids O
of O
industrial O
interest O
from O
glycerol B
. O

The O
production O
of O
organic O
acids O
from O
several O
yeasts O
isolated O
from O
mature O
plums O
on O
media O
containing O
glycerol B
as O
carbon B
source O
was O
analysed O
by O
HPLC O
- O
UV O
. O

The O
production O
from O
glycerol B
of O
succinic O
, O
acetic O
, O
citric O
, O
malic O
and O
oxalic O
acids O
from O
C O
. O
oleophila O
and O
W O
. O
anomalus O
, O
and O
that O
of O
succinic O
, O
oxalic O
and O
acetic O
acids O
by O
P O
. O
fermentans O
is O
reported O
for O
the O
first O
time O
in O
this O
work O
, O
as O
is O
the O
production O
of O
oxalic B
acid I
from O
glycerol B
in O
yeasts O
. O

Our O
results O
also O
showed O
that O
mature O
fruits O
can O
be O
a O
good O
source O
of O
new O
yeasts O
able O
to O
metabolise O
glycerol B
, O
producing O
different O
organic O
acids O
with O
industrial O
and O
biotechnological O
interest O
. O

Novel O
films O
of O
ethylene O
- O
vinyl O
alcohol O
copolymer O
( O
EVOH O
) O
containing O
flavonoid B
- O
rich O
cocoa O
were O
developed O
. O

Cocoa O
extract O
and O
the O
fraction O
obtained O
after O
in O
vitro O
gastrointestinal O
digestion O
presented O
antioxidant O
activity O
against O
oxidative O
stress O
induced O
by O
hydrogen B
peroxide I
in O
Caco O
- O
2 O
cells O
. O

In O
vivo O
and O
in O
vitro O
antioxidant O
activity O
and O
alpha O
- O
glucosidase O
, O
alpha O
- O
amylase O
inhibitory O
effects O
of O
flavonoids B
from O
Cichorium O
glandulosum O
seeds O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
antioxidant O
, O
anti O
- O
glucosidase O
and O
anti O
- O
amylase O
activities O
of O
total O
flavonoids B
( O
TFs O
) O
from O
Cichorium O
glandulosum O
seeds O
, O
and O
to O
analyse O
its O
chemical O
composition O
by O
HPLC O
- O
ESI O
/ O
MS O
. O

In O
vitro O
study O
, O
radical O
scavenging O
IC50 O
values O
of O
TFs O
were O
7 O
. O
33 O
+ O
/ O
- O
0 O
. O
093 O
, O
9 O
. O
24 O
+ O
/ O
- O
0 O
. O
100 O
, O
154 O
. O
33 O
+ O
/ O
- O
11 O
. O
38 O
and O
256 O
. O
7 O
+ O
/ O
- O
4 O
. O
86 O
mu O
g O
/ O
ml O
for O
DPPH B
, O
ABTS B
, O
hydroxyl B
radicals O
, O
and O
superoxide B
anion O
, O
respectively O
. O

In O
vivo O
, O
the O
treatment O
groups O
with O
TFs O
( O
100 O
, O
200 O
, O
400mg O
/ O
kg O
) O
showed O
a O
significant O
decrease O
in O
the O
malondialdehyde B
level O
, O
the O
superoxide B
dismutase O
and O
glutathione B
levels O
were O
restored O
to O
almost O
normal O
levels O
, O
and O
the O
catalase O
and O
glutathione B
peroxidase O
levels O
significantly O
increased O
compared O
to O
the O
CCl4 B
- O
intoxicated O
group O
in O
rats O
. O

Distribution O
, O
antioxidant O
and O
characterisation O
of O
phenolic B
compounds O
in O
soybeans O
, O
flaxseed O
and O
olives O
. O

The O
distribution O
of O
free O
and O
bound O
phenolic B
compounds O
present O
in O
soybean O
, O
flaxseed O
and O
olive O
were O
investigated O
. O

The O
phenolic B
compounds O
were O
fractionated O
on O
the O
basis O
on O
their O
solubility O
characteristics O
in O
water O
, O
alcohol B
, O
dilute O
base O
and O
dilute O
acid O
. O

Reversed O
phase O
high O
pressure O
liquid O
chromatography O
( O
RP O
- O
HPLC O
) O
and O
mass O
spectrometry O
( O
MS O
) O
were O
used O
for O
identification O
of O
individual O
components O
of O
phenolic B
compounds O
. O

Antioxidant O
activity O
( O
AA O
% O
) O
of O
free O
and O
bound O
phenolic B
compounds O
was O
measured O
using O
the O
linoleic B
acid I
/ O
beta B
- I
carotene I
assay O
. O

The O
water O
- O
soluble O
phenolic B
compound O
fractions O
represented O
68 O
- O
81 O
% O
, O
50 O
- O
72 O
% O
and O
46 O
- O
56 O
% O
of O
the O
total O
phenolic B
compounds O
measured O
in O
full O
- O
fat O
soybean O
, O
olive O
and O
flaxseed O
, O
respectively O
. O

Methanolic O
extraction O
of O
free O
phenolic B
compounds O
without O
heat O
, O
solubilised O
21 O
- O
56 O
% O
, O
42 O
- O
62 O
% O
and O
34 O
- O
51 O
% O
of O
the O
total O
phenolic B
compounds O
measured O
in O
soybean O
, O
olive O
and O
flaxseed O
, O
respectively O
; O
methanol B
extraction O
of O
free O
phenolic B
compounds O
with O
heat O
solubilised O
a O
further O
24 O
- O
34 O
% O
, O
31 O
- O
37 O
% O
and O
36 O
- O
37 O
% O
of O
phenolic B
compounds O
from O
soybean O
, O
olive O
and O
flaxseed O
, O
respectively O
. O

Further O
dilute O
alkali O
and O
dilute O
acid O
solubilised O
the O
remaining O
10 O
- O
40 O
% O
, O
1 O
- O
21 O
% O
and O
12 O
- O
29 O
% O
of O
the O
total O
phenolic B
compounds O
from O
soybean O
, O
olive O
and O
flaxseed O
, O
respectively O
. O

RP O
- O
HPLC O
and O
LC O
- O
MS O
/ O
MS O
profil1 O
for O
soybean O
, O
flaxseed O
and O
olive O
indicate O
two O
classes O
of O
phenolic B
compounds O
designated O
as O
free O
and O
bound O
phenolic B
compounds O
. O

The O
protective O
effects O
of O
maqui O
berry O
( O
Aristotelia O
chilensis O
) O
extract O
( O
MBE O
) O
and O
its O
major O
anthocyanins B
[ O
delphinidin O
3 O
, O
5 O
- O
O O
- O
diglucoside O
( O
D3G5G O
) O
and O
delphinidin O
3 O
- O
O O
- O
sambubioside O
- O
5 O
- O
O O
- O
glucoside O
( O
D3S5G O
) O
] O
against O
light O
- O
induced O
murine O
photoreceptor O
cells O
( O
661W O
) O
death O
were O
evaluated O
. O

Viability O
of O
661W O
after O
light O
treatment O
for O
24h O
, O
assessed O
by O
the O
tetrazolium B
salt O
( O
WST O
- O
8 O
) O
assay O
and O
Hoechst B
33342 I
nuclear O
staining O
, O
was O
improved O
by O
addition O
of O
MBE O
, O
D3G5G O
, O
and O
D3S5G O
. O

Intracellular O
radical O
activation O
in O
661W O
, O
evaluated O
using O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
- O
sensitive O
probe O
5 O
- O
( O
and O
- O
6 O
) O
- O
chloromethyl O
- O
2 O
, O
7 O
- O
dichlorodihydro O
fluorescein O
diacetate O
acetyl O
ester O
( O
CM O
- O
H2DCFDA O
) O
, O
was O
reduced O
by O
MBE O
and O
its O
anthocyanins B
. O

These O
findings O
indicate O
that O
MBE O
and O
its O
anthocyanidins B
suppress O
the O
light O
- O
induced O
photoreceptor O
cell O
death O
by O
inhibiting O
ROS O
production O
, O
suggesting O
that O
the O
inhibition O
of O
phosphorylated O
- O
p38 O
may O
be O
involved O
in O
the O
underlying O
mechanism O
. O

Encapsulation O
of O
indole O
- O
3 O
- O
carbinol O
and O
3 O
, O
3 O
' O
- O
diindolylmethane O
in O
zein O
/ O
carboxymethyl B
chitosan O
nanoparticles O
with O
controlled O
release O
property O
and O
improved O
stability O
. O

In O
this O
study O
, O
zein O
and O
zein O
/ O
carboxymethyl B
chitosan O
( O
CMCS O
) O
nanoparticles O
were O
prepared O
to O
encapsulate O
I3C O
and O
DIM O
by O
a O
combined O
liquid O
- O
liquid O
phase O
separation O
and O
ionic O
gelation O
method O
. O

The O
pH O
of O
both O
samples O
decreased O
during O
storage O
due O
to O
lactic B
acid I
production O
( O
post O
acidification O
) O
. O

Ligands O
affecting O
silver B
antimicrobial O
efficacy O
on O
Listeria O
monocytogenes O
and O
Salmonella O
enterica O
. O

Although O
silver B
is O
being O
extensively O
used O
in O
food O
or O
other O
applications O
as O
the O
key O
component O
to O
control O
microbial O
proliferation O
, O
many O
factors O
affecting O
its O
real O
potential O
are O
still O
unknown O
. O

In O
the O
present O
work O
, O
the O
presence O
of O
specific O
ligands O
or O
the O
contents O
in O
organic O
matter O
was O
correlated O
with O
silver B
speciation O
and O
its O
antibacterial O
performance O
. O

Silver B
was O
found O
to O
be O
only O
active O
in O
form O
of O
free O
silver B
ions O
( O
FSI O
) O
. O

The O
presence O
of O
chloride B
ions O
produced O
an O
equilibrium O
of O
stable O
silver B
chloride I
complexes O
which O
were O
void O
of O
antimicrobial O
efficacy O
. O

Low O
concentrations O
of O
thiol B
groups O
completely O
inactivated O
silver B
, O
while O
methylsulphur O
groups O
only O
affected O
its O
efficacy O
at O
very O
high O
concentrations O
. O

Thiol B
groups O
were O
nonetheless O
not O
found O
directly O
associated O
with O
the O
decrease O
in O
antimicrobial O
performance O
in O
a O
nutrient O
rich O
environment O
. O

These O
results O
point O
out O
the O
complexity O
of O
the O
antimicrobial O
systems O
based O
on O
silver B
and O
can O
have O
relevance O
in O
food O
or O
other O
applications O
of O
silver B
as O
an O
antimicrobial O
. O

Antioxidant O
capacity O
, O
polyphenolic B
content O
and O
tandem O
HPLC O
- O
DAD O
- O
ESI O
/ O
MS O
profiling O
of O
phenolic B
compounds O
from O
the O
South O
American O
berries O
Luma O
apiculata O
and O
L O
. O
chequ O
e O
n O
. O

The O
aerial O
parts O
and O
berries O
from O
Luma O
apiculata O
and O
Luma O
chequen O
were O
investigated O
for O
phenolic B
constituents O
and O
antioxidant O
capacity O
. O

A O
high O
performance O
electrospray O
ionisation O
mass O
spectrometry O
method O
was O
developed O
for O
the O
rapid O
identification O
of O
phenolics B
in O
polar O
extracts O
from O
both O
species O
. O

Thirty O
- O
one O
phenolic B
compounds O
were O
detected O
and O
27 O
were O
identified O
or O
tentatively O
characterised O
based O
on O
photodiode O
array O
UV O
- O
vis O
spectra O
( O
DAD O
) O
, O
ESI O
- O
MS O
- O
MS O
spectrometric O
data O
and O
spiking O
experiments O
with O
authentic O
standards O
. O

Twelve O
phenolic B
compounds O
were O
detected O
in O
L O
. O
apiculata O
fruits O
and O
12 O
in O
the O
aerial O
parts O
while O
L O
. O
chequen O
yielded O
10 O
compounds O
in O
fruits O
and O
16 O
in O
aerial O
parts O
, O
respectively O
. O

From O
the O
compounds O
occurring O
in O
both O
Luma O
species O
, O
seven O
were O
identified O
as O
tannins B
or O
their O
monomers O
, O
15 O
were O
flavonol B
derivatives O
and O
five O
were O
anthocyanins B
. O

The O
whole O
berry O
and O
aerial O
parts O
extracts O
presented O
high O
antioxidant O
capacity O
in O
the O
DPPH B
assay O
( O
IC50 O
of O
10 O
. O
41 O
+ O
/ O
- O
0 O
. O
02 O
and O
2 O
. O
44 O
+ O
/ O
- O
0 O
. O
03 O
mu O
g O
/ O
mL O
for O
L O
. O
apiculata O
, O
12 O
. O
89 O
+ O
/ O
- O
0 O
. O
05 O
and O
3 O
. O
22 O
+ O
/ O
- O
0 O
. O
05 O
for O
L O
. O
chequen O
, O
respectively O
) O
, O
which O
can O
be O
related O
to O
the O
diverse O
range O
of O
phenolics B
detected O
. O

The O
antioxidant O
capacity O
together O
with O
the O
high O
polyphenolic B
contents O
and O
compounds O
identified O
can O
support O
at O
least O
in O
part O
, O
their O
use O
as O
botanical O
drugs O
. O

From O
the O
compounds O
identified O
in O
both O
species O
, O
3 O
- O
O O
- O
( O
6 O
' O
' O
- O
O O
- O
galloyl O
) O
- O
hexose O
derivatives O
of O
myricetin B
, O
quercetin B
, O
laricitrin O
and O
isorhamnetin B
are O
reported O
for O
the O
first O
time O
for O
the O
genus O
Luma O
. O

Upon O
glycosylation O
, O
structural O
variations O
were O
significant O
at O
the O
disulfide B
, O
hydrophobic O
, O
amide B
III O
, O
amide B
II O
, O
and O
amide B
I O
regions O
. O

Ionisation O
of O
carboxyl B
groups O
at O
all O
tested O
pH O
values O
, O
and O
increased O
beta O
- O
sheet O
configuration O
were O
also O
observed O
. O

Changes O
in O
urocanic O
acid O
, O
histamine B
, O
putrescine B
and O
cadaverine O
levels O
in O
Indian O
mackerel O
( O
Rastrelliger O
kanagurta O
) O
during O
storage O
at O
different O
temperatures O
. O

Histamine B
, O
putrescine B
cadaverine O
and O
cis O
- O
urocanic O
acid O
( O
UCA O
) O
have O
all O
been O
implicated O
or O
suggested O
in O
scombroid O
fish O
poisoning O
. O

Histamine B
and O
putrescine B
were O
not O
detected O
. O

Histamine B
, O
putrescine B
and O
cadaverine O
levels O
increased O
significantly O
( O
P O
value O
< O
0 O
. O
05 O
) O
at O
all O
temperatures O
especially O
at O
23 O
degrees O
C O
. O

Fundamental O
studies O
on O
the O
structural O
functionality O
of O
whey O
protein O
isolate O
in O
the O
presence O
of O
small O
polyhydroxyl B
compounds O
as O
co O
- O
solute O
. O

The O
present O
work O
deals O
with O
the O
changing O
network O
morphology O
of O
whey O
protein O
isolate O
( O
15 O
% O
, O
w O
/ O
w O
) O
in O
the O
presence O
of O
glucose B
syrup O
( O
co O
- O
solute O
) O
with O
concentrations O
ranging O
from O
0 O
% O
to O
65 O
% O
( O
w O
/ O
w O
) O
in O
10mM O
CaCl2 B
solution O
, O
thus O
producing O
formulations O
with O
a O
total O
level O
of O
solids O
of O
up O
to O
80 O
% O
( O
w O
/ O
w O
) O
. O

A O
progression O
in O
the O
mechanical O
strength O
of O
protein O
aggregates O
was O
observed O
resulting O
from O
enhanced O
protein O
- O
protein O
interactions O
in O
the O
presence O
of O
glucose B
syrup O
. O

Observations O
are O
supported O
by O
micrographs O
showing O
coherent O
networks O
with O
reduced O
size O
of O
whey O
protein O
aggregates O
in O
the O
presence O
of O
high O
levels O
of O
glucose B
syrup O
, O
as O
opposed O
to O
thick O
and O
random O
clusters O
for O
systems O
of O
whey O
protein O
by O
itself O
. O

( O
Euphorbiaceae O
) O
stem O
bark O
essential O
oil O
as O
possible O
mutagen O
- O
protective O
food O
ingredient O
against O
heterocyclic B
amines I
from O
cooked O
food O
. O

The O
Amazonian O
Croton O
lechleri O
stem O
bark O
essential O
oil O
was O
tested O
for O
its O
anti O
- O
mutagenic O
potential O
by O
performing O
the O
Ames O
test O
against O
heterocyclic B
amines I
( O
HCAs B
) O
, O
in O
continuing O
research O
on O
applicative O
functional O
profile O
of O
this O
phytocomplex O
as O
food O
ingredient O
( O
Rossi O
et O
al O
. O
, O
2011 O
) O
. O

The O
anti O
- O
mutagenic O
properties O
was O
assayed O
with O
the O
following O
HCAs B
: O
2 O
- O
amino O
- O
3 O
- O
methylimidazo O
- O
[ O
4 O
, O
5 O
- O
f O
] O
quinoline O
( O
IQ O
) O
, O
2 O
- O
amino O
- O
3 O
, O
4 O
- O
dimethylimidazo O
- O
[ O
4 O
, O
5 O
- O
f O
] O
quinoline O
( O
MeIQ O
) O
, O
2 O
- O
amino O
- O
3 O
, O
8 O
- O
dimethylimidazo O
- O
[ O
4 O
, O
5 O
- O
f O
] O
quinoxaline O
( O
MeIQx O
) O
, O
the O
imidazoles O
2 O
- O
amino O
- O
6 O
- O

All O
HCAs B
with O
S9 O
induced O
mutagenicity O
at O
10 O
( O
- O
10 O
) O
mol O
/ O
plate O
. O

Characterisation O
of O
non O
- O
polar O
dimers O
formed O
during O
thermo O
- O
oxidative O
degradation O
of O
beta B
- I
sitosterol I
. O

Thermo O
- O
oxidative O
degradation O
of O
sterols B
at O
temperature O
typical O
for O
frying O
leads O
to O
the O
formation O
of O
oxidised O
derivatives O
, O
fragmented O
sterols B
and O
oligomers O
. O

Recent O
research O
on O
sterol B
oxidation O
focuses O
mainly O
on O
the O
oxysterol B
derivatives O
formation O
to O
the O
exclusion O
of O
compounds O
with O
high O
molecular O
mass O
. O

The O
aim O
of O
this O
work O
was O
to O
decipher O
the O
chemical O
structure O
of O
non O
- O
polar O
dimers O
formed O
during O
beta B
- I
sitosterol I
oxidation O
at O
180 O
degrees O
C O
in O
the O
presence O
of O
oxygen B
. O

The O
dimer O
fraction O
was O
separated O
by O
size O
- O
exclusion O
chromatography O
( O
SEC O
) O
after O
pre O
- O
fractionation O
on O
silica B
gel I
. O

NMR O
data O
confirmed O
that O
the O
predominant O
non O
- O
polar O
dimer O
formed O
during O
beta B
- I
sitosterol I
oxidative O
degradation O
has O
a O
configuration O
of O
3 O
beta O
, O
3 O
beta O
' O
- O
disitosteryl O
ether O
. O

Anthocyanins B
in O
the O
ripe O
fruits O
of O
Rubus O
coreanus O
Miquel O
and O
their O
protective O
effect O
on O
neuronal O
PC O
- O
12 O
cells O
. O

Phenolics B
of O
the O
fresh O
ripe O
fruits O
of O
Rubus O
coreanus O
Miquel O
were O
extracted O
and O
separated O
into O
anthocyanin B
and O
the O
non O
- O
anthocyanin B
fractions O
, O
which O
were O
used O
for O
the O
evaluation O
for O
antioxidant O
capacity O
and O
neuroprotective O
effects O
. O

The O
anthocyanin B
fraction O
accounted O
for O
approximately O
47 O
- O
55 O
% O
of O
the O
total O
antioxidant O
capacity O
of O
the O
whole O
extract O
and O
had O
significantly O
higher O
free O
radical O
- O
scavenging O
capacity O
than O
the O
non O
- O
anthocyanin B
fraction O
. O

Furthermore O
, O
the O
anthocyanins B
alleviated O
intracellular O
oxidative O
stress O
, O
as O
assayed O
by O
in O
vitro O
fluorescent O
measurements O
. O

The O
anthocyanins B
showed O
neuroprotective O
effects O
on O
PC O
- O
12 O
cells O
in O
vitro O
against O
oxidative O
stress O
in O
a O
dose O
- O
dependent O
manner O
. O

Triple O
quadrupole O
LC O
/ O
MS O
and O
Q O
- O
TOF O
LC O
/ O
MS O
analyses O
revealed O
four O
major O
anthocyanins B
; O
cyanidin O
3 O
- O
O O
- O
sambubioside O
, O
cyanidin O
3 O
- O
O O
- O
glucoside O
, O
cyanidin O
3 O
- O
O O
- O
xylosylrutinoside O
, O
and O
cyanidin O
3 O
- O
O O
- O
rutinoside O
in O
increasing O
order O
of O
amounts O
. O

These O
results O
demonstrated O
that O
anthocyanins B
are O
the O
major O
components O
and O
contributors O
to O
the O
antioxidant O
capacity O
of O
ripe O
R O
. O
coreanus O
Miquel O
fruits O
. O

Cell O
wall O
material O
from O
potato O
pulp O
by O
- O
product O
was O
used O
for O
the O
extraction O
of O
galactan O
- O
rich O
rhamnogalacturonan O
I O
( O
RG O
- O
I O
) O
type O
pectic O
polysaccharides O
using O
alkaline O
( O
NaOH B
and O
KOH B
) O
and O
enzymatic O
( O
endopolygalacturonas O
from O
Aspergillus O
niger O
) O
methods O
. O

TCC O
, O
lutein B
and O
zeaxanthin B
in O
germ O
fractions O
were O
higher O
in O
non O
- O
corn O
cereals O
than O
in O
corn O
. O

Lutein B
and O
zeaxanthin B
contents O
were O
lower O
in O
non O
- O
corn O
cereal O
endosperms O
. O

The O
aleurone O
layer O
had O
zeaxanthin B
levels O
2 O
- O
to O
5 O
- O
fold O
higher O
than O
lutein B
among O
the O
cereals O
. O

Positive O
significant O
correlations O
( O
p O
< O
0 O
. O
05 O
) O
were O
found O
between O
TCC O
, O
carotenoids O
analysed O
by O
HPLC O
and O
DPPH B
results O
. O

Aluminium B
and O
other O
elements O
in O
selected O
herbal O
tea O
plant O
species O
and O
their O
infusions O
. O

The O
determination O
of O
Al B
, O
B B
, O
Cu B
, O
Fe B
, O
Mn B
, O
Ni B
, O
P B
, O
Zn B
and O
Ca B
, O
K B
, O
Mg B
by O
inductively O
coupled O
plasma O
optical O
emission O
spectrometry O
( O
ICP O
- O
OES O
) O
and O
flame O
atomic O
absorption O
spectroscopy O
( O
FAAS O
) O
, O
respectively O
, O
in O
digests O
and O
infusions O
of O
Hibiscus O
sabdariffa O
( O
petals O
) O
, O
Rosa O
canina O
( O
receptacles O
) O
, O
Ginkgo O
biloba O
( O
leaves O
) O
, O
Cymbopogon O
citratus O
( O
leaves O
) O
, O
Aloe O
vera O
( O
leaves O
) O
and O
Panax O

Particular O
attention O
has O
been O
given O
to O
Al B
and O
heavy O
metals O
for O
the O
identification O
of O
possible O
raw O
material O
contaminants O
, O
their O
transformation O
into O
the O
infusion O
and O
for O
predicting O
their O
eventual O
role O
in O
the O
human O
diet O
during O
daily O
consumption O
. O

Additionally O
, O
Ion O
Chromatography O
( O
IC O
) O
speciation O
of O
Al B
in O
the O
leachates O
was O
carried O
out O
. O

In O
dry O
herbs O
, O
hibiscus O
and O
ginkgo O
appeared O
to O
contain O
the O
greatest O
contents O
of O
Al B
, O
Fe B
, O
K B
, O
Mn B
, O
Ni B
, O
Zn B
and O
B B
, O
Mg B
, O
P B
, O
respectively O
. O

A O
. O
vera O
contained O
the O
highest O
amount O
of O
Ca B
and O
highest O
values O
of O
Cu B
and O
P B
were O
observed O
in O
ginseng O
. O

In O
infusions O
, O
the O
topmost O
concentrations O
of O
Al B
, O
B B
, O
Cu B
, O
Fe B
, O
P B
, O
K B
, O
Mn B
, O
Ni B
, O
Zn B
were O
detected O
in O
those O
prepared O
from O
hibiscus O
petals O
, O
Ca B
from O
aloe O
leaves O
and O
Mg B
from O
leaves O
of O
ginkgo O
. O

It O
seems O
to O
be O
possibly O
one O
of O
the O
top O
contributors O
of O
B B
from O
food O
( O
up O
to O
5 O
. O
5 O
+ O
/ O
- O
0 O
. O
2mg O
/ O
L O
) O
. O

The O
Mg B
contained O
in O
the O
infusion O
( O
up O
to O
106 O
+ O
/ O
- O
5mg O
/ O
L O
) O
may O
be O
a O
contributor O
in O
the O
attenuation O
of O
blood O
pressure O
. O

A O
high O
amount O
of O
accessible O
Mn B
( O
up O
to O
17 O
. O
4 O
+ O
/ O
- O
1 O
. O
1mg O
/ O
L O
) O
can O
probably O
have O
an O
adverse O
effect O
in O
humans O
. O

The O
total O
Al B
allowance O
( O
up O
to O
1 O
. O
2 O
+ O
/ O
- O
0 O
. O
1mg O
/ O
L O
) O
suggests O
that O
no O
more O
than O
1L O
of O
the O
hibiscus O
infusion O
should O
be O
consumed O
per O
day O
by O
sensitive O
individuals O
including O
pregnant O
women O
and O
should O
be O
completely O
excluded O
from O
the O
diet O
of O
children O
under O
6months O
of O
age O
and O
children O
with O
chronic O
renal O
failure O
. O

KY O
had O
the O
highest O
phenolic B
content O
, O
and O
the O
strongest O
1 O
, O
1 O
- O
diphenyl O
- O
2 O
- O
pireyhydrazyl O
radical O
scavenging O
capacity O
and O
hydroxyl B
radical O
scavenging O
activity O
. O

From O
the O
high O
- O
performance O
liquid O
chromatography O
analysis O
, O
naringin B
and O
naringenin B
were O
the O
major O
flavonoids B
in O
the O
KT O
and O
TK O
cultivars O
. O

Six O
pomelo O
cultivars O
had O
antihyperlipidemic O
activities O
including O
the O
inhibition O
of O
pancreatic O
lipase O
and O
cholesterol B
esterase O
, O
as O
well O
as O
cholesterol B
micelle O
formation O
and O
bile B
acid I
binding O
. O

In O
addition O
, O
the O
total O
phenolics B
of O
the O
pomelo O
cultivars O
were O
significantly O
correlated O
with O
ferric B
reducing O
antioxidant O
power O
and O
Trolox B
equivalent O
antioxidant O
capacity O
. O

The O
active O
alkaloids O
vinblastine B
, O
vindoline B
, O
ajmalicine O
, O
catharanthine B
, O
and O
vinleurosine O
were O
identified O
by O
direct O
- O
injection O
ion O
trap O
- O
mass O
spectrometry O
( O
IT O
- O
MS O
) O
for O
collecting O
MS O
( O
1 O
- O
2 O
) O
spectra O
. O

The O
precursor O
ions O
and O
product O
ions O
for O
quantification O
of O
vinblastine B
, O
vindoline B
, O
ajmalicine O
, O
catharanthine B
, O
and O
vinleurosine O
were O
m O
/ O
z O
825 O
- O
- O
> O
807 O
, O
457 O
- O
- O
> O
397 O
, O
353 O
- O
- O
> O
144 O
, O
337 O
- O
- O
> O
144 O
and O
809 O
- O
- O
> O
748 O
by O
LC O
- O
IT O
- O
MS O
, O
respectively O
. O

In O
" O
pinking O
" O
of O
onion O
, O
E O
- O
( O
+ O
) O
- O
S O
- O
( O
1 O
- O
propenyl O
) O
- O
l O
- O
cysteine O
sulfoxide O
is O
first O
cleaved O
by O
alliinase O
to O
yield O
colour O
developers O
( O
CDs O
) O
, O
which O
react O
with O
amino B
acids I
, O
such O
as O
valine B
, O
to O
form O
pigment O
precursors O
( O
PPs O
) O
. O

The O
PPs O
react O
with O
naturally O
occurring O
carbonyls B
( O
NOCs O
) O
to O
form O
pigments O
. O

From O
the O
PP O
and O
formaldehyde B
as O
a O
NOC O
, O
two O
colourless O
and O
two O
pink O
compounds O
were O
derived O
. O

The O
total O
phenolic B
and O
flavonoid B
contents O
of O
the O
honey O
made O
from O
B O
. O
pilosa O
were O
significantly O
higher O
than O
those O
of O
the O
other O
honeys O
. O

The O
honey O
from O
B O
. O
pilosa O
also O
had O
significantly O
greater O
scavenging O
activities O
for O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
. I
) O
and O
hydroxyl B
radical O
, O
and O
substantially O
more O
reducing O
power O
. O

These O
findings O
suggest O
that O
the O
levels O
of O
antioxidant O
and O
antibacterial O
activities O
are O
attributable O
to O
the O
total O
phenolic B
and O
flavonoid B
contents O
of O
honeys O
, O
while O
the O
IL O
- O
8 O
inhibition O
is O
attributable O
to O
components O
other O
than O
phenols B
. O

Fatty B
acid I
profiling O
of O
the O
seed O
oils O
of O
some O
varieties O
of O
field O
peas O
( O
Pisum O
sativum O
) O
by O
RP O
- O
LC O
/ O
ESI O
- O
MS O
/ O
MS O
: O
Towards O
the O
development O
of O
an O
oilseed O
pea O
. O

Reversed O
- O
phase O
liquid O
chromatography O
coupled O
to O
negative O
- O
ion O
electrospray O
tandem O
mass O
spectrometry O
( O
RP O
- O
LC O
/ O
ESI O
- O
MS O
/ O
MS O
) O
was O
used O
to O
study O
the O
fatty B
acid I
profile O
from O
the O
oil O
of O
harvested O
field O
pea O
( O
Pisum O
sativum O
) O
varieties O
as O
part O
of O
a O
research O
project O
to O
develop O
this O
legume O
as O
a O
commercial O
oilseed O
for O
Canada O
. O

The O
seed O
oils O
from O
pea O
samples O
contained O
palmitic B
and I
stearic I
acids I
as O
major O
saturated B
fatty I
acids I
. O

Oleic O
, O
linoleic O
and O
linolenic O
acids O
were O
the O
major O
unsaturated B
fatty I
acids I
found O
. O

Small O
percentages O
of O
other O
long O
chain O
fatty B
acids I
were O
also O
detected O
. O

Fatty B
acid I
extracts O
did O
not O
require O
further O
manipulation O
before O
final O
analysis O
by O
RP O
- O
LC O
/ O
ESI O
- O
MS O
/ O
MS O
, O
indicating O
the O
utility O
and O
relative O
simplicity O
of O
this O
technique O
for O
future O
screening O
studies O
. O

Tert B
- I
butylhydroquinone I
recognition O
of O
molecular O
imprinting O
electrochemical O
sensor O
based O
on O
core O
- O
shell O
nanoparticles O
. O

One O
novel O
electrochemistry O
- O
molecular O
imprinting O
sensor O
for O
determining O
tert B
- I
butylhydroquinone I
( O
TBHQ B
) O
in O
foodstuff O
was O
developed O
. O

TBHQ B
- O
imprinted O
core O
- O
shell O
nanoparticles O
( O
TICSNs O
) O
were O
fabricated O
using O
silica B
nanoparticles O
as O
core O
material O
. O

The O
silica B
nanoparticles O
were O
modified O
with O
( O
3 O
- O
chloropropyl O
) O
trimethoxysilan O
and O
polyethylenimine B
, O
respectively O
, O
and O
polymerised O
to O
form O
the O
TICSNs O
with O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
. O

The O
sensor O
has O
been O
successfully O
applied O
to O
the O
determination O
of O
TBHQ B
in O
food O
samples O
and O
achieved O
high O
sensitivity O
and O
selectivity O
. O

Curcumin B
inhibits O
invasion O
and O
metastasis O
in O
K1 O
papillary O
thyroid O
cancer O
cells O
. O

Curcumin B
, O
the O
active O
constituent O
of O
dietary O
spice O
turmeric O
, O
possesses O
a O
strong O
potential O
for O
cancer O
prevention O
and O
treatment O
. O

However O
, O
there O
is O
no O
study O
to O
address O
the O
effects O
of O
curcumin B
on O
invasion O
and O
metastasis O
of O
thyroid O
cancers O
. O

Here O
, O
for O
the O
first O
time O
it O
has O
been O
reported O
that O
curcumin B
inhibit O
multiple O
metastasis O
steps O
of O
K1 O
papillary O
thyroid O
cancer O
cells O
. O

Curcumin B
dose O
- O
dependently O
suppressed O
viability O
of O
K1 O
cells O
as O
well O
as O
its O
cell O
attachment O
, O
spreading O
, O
migration O
and O
invasion O
abilities O
. O

Moreover O
, O
curcumin B
could O
also O
down O
- O
regulate O
the O
expression O
and O
activity O
of O
matrix O
metalloproteinase O
- O
9 O
( O
MMP O
- O
9 O
) O
. O

The O
findings O
showed O
that O
curcumin B
might O
be O
an O
effective O
tumouristatic O
agent O
for O
the O
treatment O
of O
aggressive O
papillary O
thyroid O
carcinomas O
. O

The O
potential O
of O
solvent O
- O
minimized O
extraction O
methods O
in O
the O
determination O
of O
polycyclic B
aromatic I
hydrocarbons I
in O
fish O
oils O
. O

The O
determination O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
in O
fish O
oils O
is O
complicated O
due O
to O
the O
fat O
matrix O
, O
which O
affects O
both O
extraction O
efficiency O
and O
analytical O
quality O
. O

This O
article O
reviews O
and O
addresses O
two O
of O
the O
most O
relevant O
analytical O
methods O
for O
determining O
11 O
mutagenic O
and O
carcinogenic O
PAHs B
, O
as O
well O
as O
two O
EPA O
indicator O
PAHs B
in O
fish O
oils O
. O

Clean O
- O
up O
of O
extracts O
was O
performed O
by O
solid O
- O
phase O
extraction O
using O
C18 O
and O
glass O
columns O
containing O
silica B
gel I
and O
florisil O
for O
USAE O
or O
only O
C18 O
for O
USAEME O
. O

Detection O
of O
the O
selected O
PAHs B
was O
carried O
out O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
with O
fluorescence O
detection O
for O
determination O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
time O
that O
USAEME O
has O
been O
applied O
to O
the O
determination O
of O
PAHs B
in O
food O
matrices O
, O
such O
as O
oil O
fish O
samples O
. O

The O
methods O
proposed O
were O
applied O
to O
the O
determination O
of O
the O
target O
PAHs B
in O
fish O
samples O
from O
different O
countries O
, O
and O
it O
was O
found O
that O
the O
low O
PAH B
contamination O
of O
the O
selected O
fish O
oils O
could O
mainly O
occur O
by O
atmospheric O
sources O
. O

Non O
- O
enzymatic O
glycation O
of O
natural O
actomyosin O
( O
NAM O
) O
with O
glucosamine B
in O
a O
liquid O
system O
at O
moderate O
temperatures O
. O

Actomyosin O
was O
conjugated O
with O
glucose B
or O
glucosamine B
in O
a O
liquid O
system O
at O
moderate O
temperatures O
( O
40 O
degrees O
C O
) O
. O

Sugar B
to O
protein O
conjugation O
was O
evident O
by O
UV O
- O
Vis O
spectral O
changes O
, O
with O
the O
glycation O
level O
determined O
by O
matrix O
assisted O
laser O
desorption O
/ O
ionisation O
mass O
spectrometry O
. O

The O
best O
glycation O
conditions O
were O
40 O
degrees O
C O
for O
8h O
at O
1 O
: O
3 O
protein O
: O
sugar B
ratio O
. O

Glucosamine B
was O
found O
to O
be O
more O
effective O
for O
glycation O
and O
provided O
higher O
protein O
functionality O
as O
compared O
to O
glucose B
. O

Mechanisms O
of O
saccharide B
protection O
against O
epigallocatechin B
- I
3 I
- I
gallate I
deterioration O
in O
aqueous O
solutions O
. O

We O
investigated O
the O
mechanisms O
of O
the O
protection O
conferred O
by O
sugars B
to O
epigallocatechin B
- I
3 I
- I
gallate I
( O
EGCG B
) O
against O
deterioration O
. O

Additionally O
, O
we O
present O
a O
rapid O
method O
for O
evaluating O
the O
deterioration O
rate O
of O
EGCG B
using O
absorbance O
spectroscopy O
. O

We O
found O
that O
various O
sugars B
provided O
different O
levels O
of O
protection O
at O
identical O
weight O
percentage O
, O
and O
the O
combination O
of O
sugars B
and O
beta O
- O
lactoglobulin O
nanocomplexes O
provided O
greater O
protection O
for O
EGCG B
than O
each O
protective O
component O
alone O
. O

We O
suggest O
that O
the O
concentration O
- O
dependent O
protection O
by O
sugars B
resulted O
from O
a O
combination O
of O
mechanisms O
, O
including O
: O
( O
1 O
) O
reduced O
aqueous O
O2 B
solubility O
, O
( O
2 O
) O
scavenging O
of O
reactive O
oxygen B
species O
, O
and O
( O
3 O
) O
chelation O
of O
traces O
of O
transition B
metal I
ions O
, O
which O
is O
suggested O
to O
be O
the O
main O
reason O
for O
the O
differences O
among O
the O
sugars B
. O

The O
observed O
protective O
effect O
of O
sugars B
can O
be O
easily O
applied O
by O
the O
industry O
in O
proper O
selection O
of O
sugars B
for O
enrichment O
of O
syrups O
or O
concentrates O
with O
EGCG B
and O
for O
the O
preparation O
of O
enriched O
beverages O
and O
foods O
for O
health O
promotion O
. O

Additional O
experiments O
with O
waxy O
maize O
starch O
led O
to O
the O
conclusion O
that O
SSL O
impacts O
swelling O
power O
and O
carbohydrate B
leaching O
more O
by O
covering O
the O
starch O
granule O
surface O
than O
by O
forming O
amylose O
- O
lipid O
complexes O
. O

All O
A O
. O
nomius O
and O
A O
. O
parasiticus O
isolates O
produced O
aflatoxins O
B O
and O
G O
, O
but O
not O
cyclopiazonic B
acid I
( O
CPA B
) O
. O

The O
rate O
of O
mycotoxigenic O
strains O
was O
high O
( O
92 O
. O
7 O
% O
) O
and O
mainly O
included O
A O
. O
flavus O
strains O
producing O
elevated O
levels O
of O
aflatoxins O
and O
CPA B
. O

These O
melons O
contain O
almost O
twice O
the O
amount O
of O
citric B
acid I
compared O
to O
standard O
melons O
and O
are O
described O
as O
' O
zesty O
and O
fresh O
' O
. O

GC O
- O
O O
revealed O
15 O
odour O
- O
active O
components O
in O
the O
headspace O
, O
with O
esters B
being O
consistently O
higher O
in O
the O
acidic O
variety O
. O

The O
compound O
, O
a O
non O
- O
palytoxin O
derivative O
, O
has O
a O
polyhydroxy O
chain O
ending O
with O
the O
primary O
amino O
group O
and O
contains O
an O
amide B
bond O
, O
along O
with O
two O
tetrahydropyran O
rings O
in O
the O
chain O
. O

Background O
Citronellyl O
acetate O
( O
CAT O
) O
, O
a O
monoterpene B
product O
of O
the O
secondary O
metabolism O
of O
plants O
, O
has O
been O
shown O
in O
the O
literature O
to O
possess O
several O
different O
biological O
activities O
. O

Methods O
The O
acetic B
acid I
- O
induced O
writhing O
test O
and O
the O
paw O
- O
licking O
test O
, O
in O
which O
paw O
licking O
was O
induced O
by O
glutamate B
and O
formalin B
, O
were O
performed O
to O
evaluate O
the O
antinociceptive O
action O
of O
CAT O
and O
to O
determine O
the O
involvement O
of O
PKC O
, O
PKA O
, O
TRPV1 O
, O
TRPA1 O
, O
TRPM8 O
and O
ASIC O
in O
its O
antinociceptive O
mechanism O
. O

Results O
CAT O
was O
administered O
intragastrically O
( O
25 O
, O
50 O
, O
75 O
, O
100 O
and O
200mg O
/ O
kg O
) O
, O
and O
the O
two O
higher O
doses O
caused O
antinociceptive O
effects O
in O
the O
acetic B
acid I
model O
; O
the O
highest O
dose O
reduced O
pain O
for O
4h O
after O
it O
was O
administered O
( O
200mg O
/ O
kg O
) O
. O

In O
the O
formalin B
test O
, O
two O
doses O
of O
CAT O
promoted O
antinociception O
in O
both O
the O
early O
and O
later O
phases O
of O
the O
test O
. O

The O
glutamate B
test O
showed O
that O
its O
receptors O
are O
involved O
in O
the O
antinociceptive O
mechanism O
of O
CAT O
. O

In O
an O
investigation O
into O
the O
participation O
of O
TRP O
channels O
and O
ASICs O
in O
CAT O
' O
s O
antinociceptive O
mechanism O
, O
we O
used O
capsaicin B
( O
2 O
. O
2 O
mu O
g O
/ O
paw O
) O
, O
cinnamaldehyde B
( O
10mmol O
/ O
paw O
) O
, O
menthol B
( O
1 O
. O
2mmol O
/ O
paw O
) O
and O
acidified O
saline O
( O
2 O
% O
acetic B
acid I
, O
pH O
1 O
. O
98 O
) O
. O

Conclusion O
The O
results O
of O
this O
work O
contribute O
information O
regarding O
the O
antinociceptive O
properties O
of O
CAT O
on O
acute O
pain O
and O
show O
that O
, O
at O
least O
in O
part O
, O
TRPV1 O
, O
TRPM8 O
, O
ASIC O
, O
glutamate B
receptors O
, O
PKC O
and O
PKA O
participate O
in O
CAT O
' O
s O
antinociceptive O
mechanism O
. O

Discovering O
and O
targeting O
the O
basic O
mechanism O
of O
neurodegeneration O
: O
The O
role O
of O
peptides O
from O
the O
C B
- O
terminus O
of O
acetylcholinesterase O
: O
Non O
- O
hydrolytic O
effects O
of O
ache O
: O
The O
actions O
of O
peptides O
derived O
from O
the O
C B
- O
terminal O
and O
their O
relevance O
to O
neurodegeneration O
. O

We O
have O
focussed O
on O
the O
observation O
that O
AChE O
, O
operating O
as O
a O
trophic O
agent O
independent O
of O
its O
enzymatic O
action O
, O
does O
indeed O
trigger O
calcium B
entry O
into O
neurons O
. O

We O
have O
identified O
two O
peptides O
that O
could O
be O
cleaved O
from O
the O
C B
- O
terminus O
of O
T O
- O
AChE O
, O
one O
( O
T14 O
) O
, O
within O
the O
other O
( O
T30 O
) O
, O
and O
which O
have O
a O
strong O
sequence O
homology O
to O
the O
comparable O
region O
of O
beta O
- O
amyloid O
whilst O
the O
inert O
residue O
within O
the O
T30 O
sequence O
( O
' O
T15 O
' O
) O
acts O
as O
a O
control O
, O
and O
is O
without O
effect O
. O

We O
have O
subsequently O
been O
able O
to O
ascribe O
the O
trophic O
- O
toxic O
actions O
of O
the O
both O
T14 O
and O
T30 O
peptides O
to O
the O
modulation O
of O
calcium B
influx O
via O
an O
allosteric O
site O
on O
the O
alpha O
- O
7 O
nicotinic O
acetylcholine B
receptor O
( O
alpha O
7 O
- O
nAChR O
) O
. O

Then O
, O
thermosensitive O
microspheres O
were O
prepared O
from O
preformed O
copolymers O
by O
chemical O
cross O
- O
linking O
of O
hydroxyl B
groups O
with O
glutaraldehyde B
at O
a O
temperature O
situated O
slightly O
below O
LCST O
of O
the O
copolymer O
solution O
. O

The O
microspheres O
were O
loaded O
with O
model O
drug O
indomethacin B
by O
the O
solvent O
evaporation O
method O
. O

On O
the O
contrary O
, O
microspheres O
with O
the O
diameter O
ranging O
between O
125 O
and O
220 O
mu O
m O
release O
a O
significantly O
higher O
amount O
of O
indomethacin B
below O
than O
above O
the O
VPTT O
. O

Carboxymethyl B
starch O
and O
lecithin O
complex O
as O
matrix O
for O
targeted O
drug O
delivery O
: O
I O
. O

This O
new O
preparation O
consists O
in O
the O
complexation O
between O
carboxymethyl B
starch O
( O
CMS O
) O
and O
Lecithin O
( O
L O
) O
. O

Crystallization O
of O
poly B
( I
ethylene I
oxide I
) I
with O
acetaminophen B
- O
A O
study O
on O
solubility O
, O
spherulitic O
growth O
, O
and O
morphology O
. O

A O
simple O
, O
sensitive O
, O
efficient O
, O
and O
novel O
method O
analyzing O
the O
number O
of O
spherulitic O
nuclei O
was O
proposed O
to O
estimate O
the O
solubility O
of O
a O
model O
drug O
acetaminophen B
( O
APAP B
) O
in O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
) O
. O

At O
high O
crystallization O
temperature O
( O
323K O
) O
, O
10 O
% O
APAP B
- O
PEO B
had O
the O
same O
low O
number O
of O
spherulitic O
nuclei O
as O
pure O
PEO B
, O
indicating O
that O
APAP B
and O
PEO B
were O
fully O
miscible O
. O

At O
low O
crystallization O
temperature O
( O
303K O
) O
, O
the O
number O
of O
nuclei O
for O
10 O
% O
APAP B
- O
PEO B
was O
significantly O
higher O
, O
suggesting O
that O
APAP B
was O
oversaturated O
and O
therefore O
recrystallized O
and O
acted O
as O
a O
nucleating O
agent O
. O

Based O
on O
the O
results O
obtained O
, O
the O
solubility O
of O
APAP B
in O
PEO B
is O
possibly O
between O
the O
concentration O
of O
0 O
. O
1 O
% O
and O
1 O
% O
at O
303K O
. O

The O
spherulitic O
growth O
rate O
G O
of O
PEO B
was O
found O
to O
decrease O
with O
increasing O
APAP B
concentration O
, O
suggesting O
that O
APAP B
is O
most O
likely O
functioning O
as O
a O
chemical O
defect O
and O
is O
either O
rejected O
from O
or O
included O
in O
the O
PEO B
crystals O
during O
chain O
folding O
. O

APAP B
could O
possibly O
locate O
in O
the O
inter O
- O
spherulitic O
, O
inter O
- O
fibrillar O
, O
inter O
- O
lamellar O
, O
or O
intra O
- O
lamellar O
regions O
of O
PEO B
. O

At O
323K O
, O
the O
morphology O
of O
10 O
% O
APAP B
- O
PEO B
is O
more O
dendritic O
than O
spherulitic O
with O
large O
unfilled O
space O
in O
between O
dendrites O
and O
spherulites O
, O
which O
is O
a O
sign O
of O
one O
or O
the O
combination O
of O
the O
four O
modes O
of O
segregation O
. O

The O
values O
of O
sigma O
e O
and O
q O
increased O
with O
APAP B
concentration O
, O
indicating O
that O
the O
chain O
folding O
of O
PEO B
was O
hindered O
by O
APAP B
. O

In O
this O
study O
, O
we O
describe O
the O
generation O
of O
chitosan O
imidazole B
/ O
siRNA O
nanoplexes O
( O
NPs O
) O
embedded O
in O
nano O
scope O
polyelectrolyte O
multilayers O
( O
PEMs O
) O
composed O
of O
hyaluronic O
acid O
and O
chitosan O
for O
sustained O
and O
localized O
drug O
delivery O
. O

Anti O
- O
inflammatory O
activity O
of O
hexane B
extracts O
from O
bones O
and O
internal O
organs O
of O
Anguilla O
japonica O
suppresses O
cyclooxygenase O
- O
2 O
- O
dependent O
prostaglandin B
D2 I
generation O
in O
mast O
cells O
and O
anaphylaxis O
in O
mice O
. O

The O
purpose O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
n B
- I
hexane I
extracts O
from O
bones O
and O
internal O
organs O
of O
Japanese O
eel O
, O
Anguilla O
japonica O
( O
HEE O
) O
, O
on O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
- O
dependent O
prostaglandin B
D2 I
( O
PGD2 O
) O
generation O
in O
stem O
cell O
factor O
( O
SCF O
) O
, O
IL O
- O
10 O
, O
plus O
LPS O
- O
induced O
mouse O
bone O
marrow O
- O
derived O
mast O
cells O
( O
BMMCs O
) O
and O
on O
passive O
cutaneous O
anaphylaxis O
( O
PCA O
) O
in O
mice O
. O

Moreover O
, O
oral O
administration O
of O
HEE O
inhibited O
anti O
- O
dinitrophenyl O
( O
DNP B
) O
IgE O
- O
induced O
PCA O
in O
a O
dose O
dependent O
manner O
. O

Vinblastine B
- O
induced O
apoptosis O
of O
melanoma O
cells O
is O
mediated O
by O
Ras O
homologous O
A O
protein O
( O
Rho O
A O
) O
via O
mitochondrial O
and O
non O
- O
mitochondrial O
- O
dependent O
mechanisms O
. O

In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine B
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase O
- O
9 O
and O
3 O
, O
and O
cleavage O
of O
Poly B
( I
ADP I
- I
ribose I
) I
- O
Polymerase O
. O

Also O
, O
vinblastine B
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen B
species O
, O
the O
release O
of O
intracellular O
Ca B
( I
2 I
+ I
) I
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal O
- O
regulating O
kinase O
1 O
, O
c O
- O
jun O
- O
N B
- O
terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaB O
alpha O
( O
I O
kappa O
B O
alpha O
) O
kinase O
, O
and O
inositol B
requiring O
enzyme O
1 O
alpha O
. O

In O
addition O
, O
vinblastine B
induces O
the O
DNA O
- O
binding O
activities O
of O
the O
transcription O
factor O
NF O
- O
kappa O
B O
, O
HSF1 O
, O
AP O
- O
1 O
, O
and O
ATF O
- O
2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O

Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine B
- O
induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non O
- O
mitochondrial O
- O
dependent O
mechanisms O
. O

In O
conclusion O
, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
role O
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine B
- O
induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine B
in O
melanoma O
treatment O
. O

We O
exposed O
juveniles O
of O
the O
water O
flea O
Daphnia O
magna O
for O
48 O
, O
96 O
and O
144 O
h O
to O
three O
stressors O
known O
to O
exert O
strong O
selection O
in O
natural O
populations O
of O
this O
species O
i O
. O
e O
. O
a O
sublethal O
concentration O
of O
the O
pesticide O
carbaryl B
, O
infective O
spores O
of O
the O
endoparasite O
Pasteuria O
ramosa O
, O
and O
fish O
predation O
risk O
mimicked O
by O
exposure O
to O
fish O
kairomones O
. O

Based O
on O
a O
PCA O
, O
the O
exposure O
treatments O
were O
separated O
into O
two O
main O
groups O
based O
on O
the O
extent O
of O
the O
transcriptional O
response O
: O
a O
low O
and O
a O
high O
( O
144 O
h O
of O
fish O
or O
carbaryl B
exposure O
and O
96 O
h O
of O
parasite O
exposure O
) O
stress O
group O
. O

Secondly O
, O
we O
observed O
treatment O
- O
specific O
responses O
including O
signs O
of O
migration O
to O
deeper O
water O
layers O
in O
response O
to O
fish O
predation O
, O
structural O
challenge O
of O
the O
cuticle O
in O
response O
to O
carbaryl B
exposure O
, O
and O
disturbance O
of O
the O
ATP B
production O
in O
parasite O
exposure O
. O

The O
peak O
of O
differentially O
expressed O
transcripts O
came O
only O
after O
144 O
h O
of O
fish O
exposure O
, O
while O
carbaryl B
exposure O
induced O
a O
more O
stable O
number O
of O
differently O
expressed O
gene O
fragments O
over O
time O
. O

Fourteen O
triphenylamine O
derivatives O
functionalized O
with O
fluorophenyl O
, O
methoxyphenyl B
, O
and O
pyridinyl O
groups O
as O
respective O
donors O
and O
acceptors O
were O
synthesized O
and O
characterized O
. O

Combinatorial O
Treatment O
of O
Tart O
Cherry O
Extract O
and O
Essential O
Fatty B
Acids I
Reduces O
Cognitive O
Impairments O
and O
Inflammation O
in O
the O
mu O
- O
p75 O
Saporin O
- O
Induced O
Mouse O
Model O
of O
Alzheimer O
' O
s O
Disease O
. O

The O
current O
study O
tested O
a O
combinatorial O
treatment O
of O
antioxidants O
from O
tart O
cherry O
extract O
and O
essential O
fatty B
acids I
from O
Nordic O
fish O
and O
emu O
oils O
for O
reducing O
cognitive O
deficits O
in O
the O
mu O
- O
p75 O
saporin O
( O
SAP O
) O
- O
induced O
mouse O
model O
of O
AD O
. O

Mice O
were O
given O
daily O
gavage O
treatments O
of O
Cerise O
( O
( O
R O
) O
) O
Total O
- O
Body O
- O
Rhythm O
( O
TM O
) O
( O
TBR O
; O
containing O
tart O
cherry O
extract O
, O
Nordic O
fish O
oil O
, O
and O
refined O
emu O
oil O
) O
or O
vehicle O
( O
methylcellulose O
) O
for O
2 O
weeks O
before O
intracerebroventricu O
injections O
of O
the O
cholinergic O
toxin O
, O
mu O
- O
p75 O
SAP O
, O
or O
phosphate B
- O
buffered O
saline O
. O

Results O
showed O
that O
oral O
administration O
of O
the O
Zhizhu O
decoction O
accelerated O
gastric O
emptying O
in O
mouse O
and O
protected O
gastric O
mucosa O
from O
ethanol B
- O
induced O
ulcers O
in O
rat O
. O

The O
immunomodulation O
effect O
of O
aronia O
extract O
lacks O
association O
with O
its O
antioxidant O
anthocyanins B
. O

Abstract O
Polyphenols B
comprise O
a O
diverse O
group O
of O
molecules O
with O
antioxidative O
and O
anti O
- O
inflammatory O
activities O
. O

To O
compare O
the O
antioxidative O
and O
anti O
- O
inflammatory O
capacity O
of O
Aronia O
melanocarpa O
berries O
( O
chokeberries O
) O
, O
recognized O
for O
their O
high O
content O
of O
anthocyanins B
, O
a O
noncytotoxic O
isolation O
method O
was O
developed O
to O
obtain O
high O
- O
purity O
anthocyanins B
in O
the O
extract O
. O

The O
antioxidative O
activity O
of O
the O
extract O
, O
the O
anthocyanin B
- O
rich O
fraction O
( O
AF O
) O
was O
determined O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
and O
ferric B
- O
reducing O
ability O
of O
plasma O
along O
with O
resveratrol B
as O
a O
reference O
. O

The O
isolated O
AF O
, O
containing O
six O
different O
anthocyanins B
, O
exhibited O
a O
stronger O
antioxidative O
capacity O
compared O
to O
resveratrol B
. O

Resveratrol B
enhanced O
tumor O
necrosis O
factor O
- O
alpha O
and O
reduced O
interleukin O
- O
10 O
( O
IL O
- O
10 O
) O
production O
by O
LPS O
, O
whereas O
AF O
only O
had O
a O
slight O
effect O
in O
reducing O
IL O
- O
10 O
. O

These O
results O
demonstrated O
that O
there O
was O
no O
major O
relationship O
between O
the O
antioxidative O
effect O
and O
immunomodulation O
capacities O
of O
AF O
and O
resveratrol B
. O

The O
immunomodulatory O
activity O
of O
the O
extract O
is O
associated O
with O
bioactive O
compounds O
in O
Aronia O
other O
than O
its O
anthocyanins B
. O

Novel O
sulfonamide B
compounds O
for O
inhibition O
of O
metastatic O
tumor O
growth O
( O
WO2012021963 O
) O
. O

High O
glucose B
, O
insulin O
and O
free O
fatty O
acid O
concentrations O
synergistically O
enhance O
perilipin O
3 O
expression O
and O
lipid O
accumulation O
in O
macrophages O
. O

Since O
metabolic O
derangements O
found O
in O
metabolic O
syndrome O
, O
such O
as O
high O
serum O
levels O
of O
glucose B
, O
insulin O
and O
free O
fatty O
acids O
( O
FFAs O
) O
, O
are O
major O
risk O
factors O
promoting O
atherosclerosis O
, O
we O
investigated O
whether O
PLIN3 O
expression O
is O
affected O
by O
glucose B
, O
insulin O
and O
oleic B
acid I
( O
OA O
) O
using O
RAW264 O
. O
7 O
cells O
. O

Oil O
- O
red O
O O
staining O
and O
Lipid O
Analysis O
were O
employed O
to O
measure O
cellular O
content O
of O
triacylglycerides O
( O
TAG B
) O
and O
cholesterol B
. O

RESULTS O
: O
PLIN3 O
mRNA O
was O
stimulated O
by O
high O
glucose B
or O
insulin O
concentrations O
individually O
, O
but O
not O
by O
OA O
. O

A O
combination O
of O
any O
two O
factors O
did O
not O
enhance O
PLIN3 O
expression O
any O
more O
than O
that O
evoked O
by O
glucose B
alone O
at O
24h O
. O

Inhibitors O
of O
Src O
family O
tyrosine B
kinase O
and O
/ O
or O
phosphatidylinositol B
3 O
- O
kinase O
, O
both O
of O
which O
are O
activated O
by O
insulin O
and O
FFA O
signaling O
, O
partially O
suppressed O
PLIN3 O
expression O
induced O
by O
the O
combination O
of O
the O
three O
factors O
. O

While O
simultaneous O
addition O
of O
glucose B
, O
insulin O
and O
OA O
remarkably O
increased O
the O
cellular O
content O
of O
TAG B
and O
cholesterol B
, O
knocking O
- O
down O
of O
PLIN3 O
predominantly O
reduced O
TAG B
content O
. O

CONCLUSIONS O
: O
These O
results O
indicate O
that O
PLIN3 O
expression O
is O
synergistically O
stimulated O
by O
high O
glucose B
, O
insulin O
and O
FFA O
concentrations O
, O
in O
parallel O
with O
TAG B
accumulation O
in O
macrophages O
. O

( B
1 I
) I
H I
NMR O
- O
based O
metabonomic O
analysis O
of O
the O
serum O
and O
urine O
of O
rats O
following O
subchronic O
exposure O
to O
dichlorvos B
, O
deltamethrin B
, O
or O
a O
combination O
of O
these O
two O
pesticides O
. O

Metabonomic O
analysis O
, O
clinical O
chemical O
analysis O
and O
histopathology O
were O
used O
to O
investigate O
the O
toxic O
effects O
of O
subchronic O
exposure O
to O
dichlorvos B
, O
deltamethrin B
, O
and O
a O
combination O
of O
these O
two O
pesticides O
, O
in O
rats O
. O

Weight O
loss O
, O
hind O
limb O
weakness O
and O
histopathological O
changes O
in O
kidney O
tissue O
were O
only O
observed O
in O
rats O
exposed O
to O
high O
doses O
of O
deltamethrin B
, O
or O
a O
combination O
of O
deltamethrin B
and O
dichlorvos B
. O

Urinary O
metabonomic O
analysis O
indicated O
that O
exposure O
to O
a O
mixture O
of O
dichlorvos B
and O
deltamethrin B
was O
followed O
by O
increases O
in O
urinary O
lactate B
, O
dimethylamine B
, O
N B
- O
glycoprotein O
( O
NAC O
) O
and O
glycine B
similar O
to O
those O
observed O
in O
rats O
treated O
with O
either O
dichlorvos B
or O
deltamethrin B
alone O
. O

Serum O
metabonomic O
analysis O
suggests O
that O
dichlorvos B
induced O
an O
increase O
in O
lactate B
and O
alanine B
and O
a O
decrease O
in O
dimethylglycine O
( O
DMG O
) O
, O
NAC O
and O
very O
low O
- O
and O
low O
- O
density O
lipoprotein O
( O
VLDL O
/ O
LDL O
) O
. O

High O
levels O
of O
lactate B
and O
low O
levels O
of O
NAC O
and O
VLDL O
/ O
LDL O
were O
observed O
in O
the O
deltamethrin B
treatment O
group O
. O

Treating O
rats O
with O
a O
mixture O
of O
dichlorvos B
and O
deltamethrin B
caused O
an O
increase O
in O
serum O
lactate B
, O
trimethylamine O
- O
N O
- O
oxide O
( O
TMAO O
) O
, O
choline B
and O
alanine B
, O
with O
the O
highest O
levels O
of O
these O
metabolites O
observed O
in O
those O
that O
received O
the O
highest O
dose O
. O

Exposure O
to O
a O
mixture O
of O
dichlorvos B
and O
deltamethrin B
also O
resulted O
in O
a O
decrease O
in O
serum O
acetone B
, O
DMG O
, O
NAC O
, O
and O
VLDL O
/ O
LDL O
. O

Changes O
in O
serum O
TMAO O
, O
alanine B
, O
choline B
and O
acetone B
in O
this O
treatment O
group O
were O
higher O
than O
in O
rats O
treated O
with O
either O
dichlorvos B
or O
deltamethrin B
. O

These O
results O
suggest O
that O
exposing O
rats O
to O
subchronic O
doses O
of O
dichlorvos B
, O
deltamethrin B
, O
or O
a O
combination O
of O
these O
pesticides O
, O
disrupted O
the O
energy O
metabolism O
of O
the O
liver O
and O
reduced O
kidney O
function O
. O

MATERIALS O
AND O
METHODS O
: O
Sixty O
- O
four O
samples O
with O
different O
proportions O
of O
compounds O
were O
prepared O
from O
Caesalpinia O
sappan O
L O
. O
by O
supercritical O
CO2 B
fluid O
extraction O
( O
SCFE O
) O
and O
refluxing O
. O

Ndonya O
, O
as O
it O
is O
colloquially O
known O
, O
refers O
to O
two O
products O
which O
look O
identical O
to O
the O
untrained O
eye O
- O
one O
is O
dyed O
table O
salt O
and O
the O
other O
is O
hexavalent B
chromium I
. O

Comparative O
study O
on O
transcriptional O
activity O
of O
17 O
parabens B
mediated O
by O
estrogen B
receptor O
alpha O
and O
beta O
and O
androgen B
receptor O
. O

The O
structure O
- O
activity O
relationships O
of O
parabens B
which O
are O
widely O
used O
as O
preservatives O
for O
transcriptional O
activities O
mediated O
by O
human O
estrogen B
receptor O
alpha O
( O
hER O
alpha O
) O
, O
hER O
beta O
and O
androgen B
receptor O
( O
hAR O
) O
were O
investigated O
. O

Fourteen O
of O
17 O
parabens B
exhibited O
hER O
alpha O
and O
/ O
or O
hER O
beta O
agonistic O
activity O
at O
concentrations O
of O
> O
= O
1 O
x O
10 O
( O
- O
5 O
) O
M O
, O
whereas O
none O
of O
the O
17 O
parabens B
showed O
AR O
agonistic O
or O
antagonistic O
activity O
. O

Among O
12 O
parabens B
with O
linear O
alkyl B
chains O
ranging O
in O
length O
from O
C1 O
to O
C12 O
, O
heptylparaben O
( O
C7 O
) O
and O
pentylparaben O
( O
C5 O
) O
showed O
the O
most O
potent O
ER O
alpha O
and O
ER O
beta O
agonistic O
activity O
in O
the O
order O
of O
10 O
( O
- O
7 O
) O
M O
and O
10 O
( O
- O
8 O
) O
M O
, O
respectively O
, O
and O
the O
activities O
decreased O
in O
a O
stepwise O
manner O
as O
the O
alkyl O
chain O
was O
shortened O
to O
C1 O
or O
lengthened O
to O
C12 O
. O

Most O
parabens B
showing O
estrogenic O
activity O
exhibited O
ER O
beta O
- O
agonistic O
activity O
at O
lower O
concentrations O
than O
those O
inducing O
ER O
alpha O
- O
agonistic O
activity O
. O

The O
estrogenic O
activity O
of O
butylparaben B
was O
markedly O
decreased O
by O
incubation O
with O
rat O
liver O
microsomes O
, O
and O
the O
decrease O
of O
activity O
was O
blocked O
by O
a O
carboxylesterase O
inhibitor O
. O

These O
results O
indicate O
that O
parabens B
are O
selective O
agonists O
for O
ER O
beta O
over O
ER O
alpha O
; O
their O
interactions O
with O
ER O
alpha O
/ O
beta O
are O
dependent O
on O
the O
size O
and O
bulkiness O
of O
the O
alkyl B
groups O
; O
and O
they O
are O
metabolized O
by O
carboxylesterases O
, O
leading O
to O
attenuation O
of O
their O
estrogenic O
activity O
. O

DICO O
, O
a O
novel O
nonaromatic O
B O
- O
ring O
flavonoid B
, O
induces O
G2 O
/ O
M O
cell O
cycle O
arrest O
and O
apoptosis O
in O
human O
hepatoma O
cells O
. O

DICO O
was O
a O
novel O
nonaromatic O
B O
- O
ring O
flavonoid B
obtained O
from O
Macrothelypteris O
torresiana O
. O

Chloroquine B
causes O
similar O
electroretinogram O
modifications O
, O
neuronal O
phospholipidosis O
and O
marked O
impairment O
of O
synaptic O
vesicle O
transport O
in O
Albino O
and O
Pigmented O
Rats O
. O

Retinal O
toxicity O
of O
chloroquine B
has O
been O
known O
for O
several O
years O
, O
but O
the O
mechanism O
( O
s O
) O
of O
toxicity O
remain O
controversial O
; O
some O
author O
support O
the O
idea O
that O
the O
binding O
of O
chloroquine B
to O
melanin O
pigments O
in O
the O
retinal O
pigmented O
epithelium O
( O
RPE O
) O
play O
a O
major O
toxic O
role O
by O
concentrating O
the O
drug O
in O
the O
eye O
. O

In O
our O
study O
, O
12 O
albinos O
Sprague O
- O
Dawley O
( O
SD O
) O
and O
12 O
pigmented O
Brown O
Norway O
( O
BN O
) O
rats O
were O
treated O
orally O
for O
3 O
months O
with O
chloroquine B
to O
compare O
functional O
and O
pathological O
findings O
. O

IHC O
analyses O
demonstrated O
a O
decrease O
in O
GABA B
expression O
in O
the O
inner O
nuclear O
layer O
. O

Comparable O
ERG O
modifications O
, O
histopathology O
and O
immunohistochemistry O
findings O
were O
observed O
in O
the O
retina O
of O
both O
rat O
strains O
suggesting O
that O
melanin O
pigment O
is O
unlikely O
involved O
. O
chloroquine B
- O
induced O
impairment O
of O
synaptic O
vesicle O
transport O
, O
likely O
related O
to O
disruption O
of O
neurofilaments O
was O
identified O
and O
non O
- O
previously O
reported O
. O

This O
new O
mechanism O
of O
toxicity O
may O
also O
be O
responsible O
for O
the O
burry O
vision O
described O
in O
humans O
chronically O
treated O
with O
chloroquine B
. O

Thiazolidin O
- O
4 O
- O
one O
and O
thiazinan O
- O
4 O
- O
one O
derivatives O
analogous O
to O
rosiglitazone B
as O
potential O
antihyperglycemic O
and O
antidyslipidemic O
agents O
. O

Among O
them O
the O
thiazinan O
- O
4 O
- O
one O
derivative O
4a O
showed O
maximal O
( O
45 O
% O
) O
improvement O
in O
oral O
glucose B
tolerance O
test O
in O
db O
/ O
db O
mice O
at O
30 O
mg O
/ O
kg O
oral O
dose O
. O

FLT3 O
and O
PDGFR O
tyrosine B
kinases O
are O
important O
targets O
for O
therapy O
of O
different O
types O
of O
leukemia O
. O

This O
effort O
led O
to O
the O
identification O
of O
five O
compounds O
that O
were O
confirmed O
to O
be O
active O
on O
additional O
FLT3 O
dependent O
cell O
lines O
( O
cellular O
EC50 O
values O
between O
35 O
and O
700 O
nM O
) O
, O
while O
having O
no O
significant O
effect O
on O
24 O
other O
tyrosine B
kinases O
. O

Transport O
of O
gabapentin B
by O
LAT1 O
( O
SLC7A5 O
) O
. O

Gabapentin B
is O
used O
in O
the O
treatment O
of O
epilepsy O
and O
neuropathic O
pain O
. O

Gabapentin B
has O
high O
and O
saturable O
permeability O
across O
the O
BBB O
, O
but O
no O
mechanistic O
studies O
underpinning O
this O
process O
have O
been O
reported O
. O

The O
aim O
of O
the O
current O
study O
was O
to O
investigate O
the O
transport O
of O
gabapentin B
in O
a O
model O
of O
the O
BBB O
, O
identify O
the O
important O
drug O
transporter O
( O
s O
) O
and O
to O
use O
mathematical O
modelling O
to O
quantify O
the O
processes O
involved O
. O

Gabapentin B
was O
demonstrated O
to O
be O
a O
LAT1 O
substrate O
in O
brain O
endothelial O
cells O
( O
LAT1 O
- O
process O
; O
Km O
= O
530 O
mu O
M O
and O
Vmax O
= O
7039pmoles O
/ O
million O
cells O
/ O
min O
versus O
other O
- O
processes O
; O
Km O
= O
923 O
mu O
M O
and O
Vmax O
= O
3656pmoles O
/ O
million O
cells O
/ O
min O
) O
and O
in O
transfected O
HEK O
293 O
LAT1 O
cells O
( O
LAT1 O
- O
process O
; O
Km O
= O
217 O
mu O
M O
and O
Vmax O
= O
5192pmoles O
/ O
million O
cells O
/ O
min O
versus O
otherprocesses O
; O

At O
physiological O
concentrations O
of O
gabapentin B
, O
LAT1 O
mediated O
transport O
was O
3 O
or O
~ O
10 O
- O
fold O
higher O
than O
the O
other O
transport O
processes O
in O
the O
two O
systems O
, O
respectively O
, O
demonstrating O
clear O
selectivity O
for O
gabapentin B
. O

Gabapentin B
was O
negative O
for O
OCT O
like O
transport O
and O
LAT2 O
activity O
in O
the O
hCMEC O
/ O
D3 O
and O
OCT1 O
transfected O
cells O
. O

Our O
data O
shows O
that O
gabapentin B
is O
a O
substrate O
for O
the O
influx O
transporter O
LAT1 O
at O
therapeutic O
concentrations O
. O

High O
- O
quality O
core O
/ O
shell O
CdSe B
/ O
CdS B
colloidal O
nanocrystals O
are O
demonstrated O
to O
be O
efficient O
sources O
of O
non O
- O
classical O
light O
. O

Light O
- O
Emitting O
Field O
- O
Effect O
Transistors O
Having O
Combined O
Organic O
Semiconductor O
and O
Metal B
Oxide I
Layers O
. O

A O
new O
organic O
light O
- O
emitting O
field O
- O
effect O
transistor O
characterized O
by O
a O
metal B
oxide I
layer O
inserted O
between O
the O
organic O
layer O
and O
the O
gate O
insulator O
is O
proposed O
. O

The O
metal B
oxide I
is O
indirectly O
connected O
with O
source O
and O
drain O
electrodes O
through O
the O
organic O
layer O
. O

METHODS O
: O
In O
Experiment O
1 O
, O
licking O
microstructure O
when O
consuming O
sucrose B
solution O
( O
2 O
to O
20 O
% O
) O
was O
compared O
in O
MOR O
knockout O
and O
wildtype O
mice O
as O
a O
function O
of O
sucrose B
concentration O
and O
level O
of O
food O
deprivation O
. O

RESULTS O
: O
In O
Experiment O
1 O
, O
MOR O
knockout O
mice O
exhibited O
several O
alterations O
in O
sucrose B
licking O
. O

Although O
wildtype O
mice O
exhibited O
a O
twofold O
increase O
in O
the O
burst O
length O
when O
food O
deprived O
, O
relative O
to O
the O
nondeprived O
test O
, O
this O
aspect O
of O
sucrose B
licking O
was O
generally O
insensitive O
to O
manipulations O
of O
food O
deprivation O
for O
MOR O
knockout O
mice O
. O

Furthermore O
, O
during O
concentration O
testing O
, O
their O
rate O
of O
sucrose B
licking O
was O
less O
than O
half O
that O
of O
wildtype O
mice O
. O

Non O
- O
classical O
Pharmacology O
of O
the O
Dopamine B
Transporter O
: O
Atypical O
Inhibitors O
, O
Allosteric O
Modulators O
and O
Partial O
Substrates O
. O

The O
dopamine B
transporter O
( O
DAT O
) O
is O
a O
sodium B
- O
coupled O
symporter O
protein O
responsible O
for O
modulating O
the O
concentration O
of O
extraneuronal O
dopamine B
in O
the O
brain O
. O

The O
DAT O
is O
a O
principle O
target O
of O
various O
psychostimulant O
, O
nootropic O
and O
antidepressant O
drugs O
, O
as O
well O
as O
certain O
drugs O
used O
recreationally O
, O
including O
the O
notoriously O
addictive O
stimulant O
cocaine B
. O

DAT O
ligands O
have O
traditionally O
been O
divided O
into O
two O
categories O
: O
cocaine B
- O
like O
inhibitors O
and O
amphetamine B
- O
like O
substrates O
. O

Whereas O
inhibitors O
block O
monoamine B
uptake O
by O
the O
DAT O
, O
but O
are O
not O
translocated O
across O
the O
membrane O
, O
substrates O
are O
actively O
translocated O
and O
trigger O
DAT O
- O
mediated O
release O
of O
dopamine B
by O
reversal O
of O
the O
translocation O
cycle O
. O

As O
both O
inhibitors O
and O
substrates O
increase O
extraneuronal O
dopamine B
levels O
, O
it O
is O
often O
assumed O
that O
all O
DAT O
ligands O
posses O
an O
addictive O
liability O
equivalent O
to O
cocaine B
. O

However O
, O
the O
recent O
development O
of O
novel O
' O
atypical O
' O
inhibitors O
and O
' O
partial O
substrate O
' O
ligands O
with O
reduced O
or O
even O
a O
complete O
lack O
of O
cocaine B
- O
like O
rewarding O
effects O
suggests O
that O
addictiveness O
is O
not O
a O
constant O
property O
of O
DAT O
- O
affecting O
compounds O
. O

The O
present O
overview O
discusses O
compounds O
with O
conformation O
- O
specific O
activity O
, O
useful O
not O
only O
as O
tools O
for O
studying O
the O
mechanics O
of O
dopamine B
transport O
, O
but O
also O
as O
leads O
for O
medication O
development O
in O
addictive O
disorders O
. O

Molecular O
Identification O
and O
Characterization O
of O
an O
Essential O
Pyruvate B
Transporter O
from O
Trypanosoma O
brucei O
. O

Pyruvate B
export O
is O
an O
essential O
physiological O
process O
for O
the O
bloodstream O
form O
of O
T O
. O
brucei O
as O
the O
parasite O
would O
otherwise O
accumulate O
this O
end O
product O
of O
glucose B
metabolism O
to O
toxic O
levels O
. O

In O
the O
studies O
reported O
here O
genetic O
complementation O
in O
Saccharomyces O
cerevisiae O
has O
been O
employed O
to O
identify O
a O
gene O
( O
TbPT0 O
) O
that O
encodes O
this O
vital O
pyruvate B
transporter O
from O
T O
. O
brucei O
. O

Expression O
of O
TbPT0 O
in O
S O
. O
cerevisiae O
reveals O
that O
TbPT0 O
is O
a O
high O
affinity O
pyruvate B
transporter O
. O

Interestingly O
, O
TbPT O
family O
permeases O
are O
related O
to O
polytopic O
proteins O
from O
plants O
but O
not O
to O
characterized O
monocarboxylate B
transporters O
from O
mammals O
. O

The O
discovery O
of O
TbPT0 O
reveals O
for O
the O
first O
time O
the O
identity O
of O
the O
essential O
pyruvate B
transporter O
and O
provides O
a O
potential O
drug O
target O
against O
the O
mammalian O
life O
cycle O
stage O
of O
T O
. O
brucei O
. O

Six O
new O
sesquiterpenoids B
, O
aristoyunnolins O
A O
- O
F O
( O
1 O
- O
6 O
) O
, O
an O
artifact O
of O
isolation O
[ O
7 O
- O
O O
- O
ethyl O
madolin O
W O
( O
7 O
) O
] O
, O
and O
12 O
known O
analogues O
were O
isolated O
from O
stems O
of O
Aristolochia O
yunnanensis O
. O

Compounds O
16 O
and O
19 O
were O
more O
active O
than O
the O
positive O
control O
PD98059 B
, O
a O
known O
inhibitor O
of O
the O
ERK1 O
/ O
2 O
signaling O
pathway O
. O

Different O
levels O
of O
prenatal O
zinc B
and O
selenium B
had O
different O
effects O
on O
neonatal O
neurobehavioral O
development O
. O

Effects O
of O
different O
levels O
of O
prenatal O
zinc B
( O
Zn B
) O
and O
selenium B
( O
Se B
) O
on O
fetal O
neurobehavioral O
development O
remain O
unclear O
. O

To O
determine O
the O
effects O
of O
different O
cord O
serum O
levels O
of O
Zn B
and O
Se B
on O
neurobehavioral O
development O
in O
neonates O
and O
to O
explore O
possible O
threshold O
level O
of O
Zn B
and O
Se B
based O
on O
fetal O
neurodevelopment O
, O
we O
conducted O
this O
epidemiological O
research O
. O

Umbilical O
cord O
serum O
concentrations O
of O
Zn B
and O
Se B
were O
measured O
and O
Neonatal O
Behavioral O
Neurological O
Assessment O
( O
NBNA O
) O
tests O
were O
conducted O
. O

The O
median O
cord O
serum O
Zn B
and O
Se B
concentrations O
were O
794 O
. O
3 O
mu O
g O
/ O
L O
and O
63 O
. O
1 O
mu O
g O
/ O
L O
, O
respectively O
. O

A O
nonlinear O
relationship O
was O
observed O
between O
cord O
serum O
Zn B
and O
NBNA O
after O
adjusting O
for O
potential O
confounders O
. O

NBNA O
score O
decreased O
with O
increasing O
Zn B
levels O
after O
794 O
. O
3 O
mu O
g O
/ O
L O
( O
adjusted O
beta O
= O
- O
3 O
. O
0 O
, O
95 O
% O
CI O
: O
- O
3 O
. O
6 O
to O
- O
2 O
. O
4 O
, O
p O
< O
0 O
. O
001 O
) O
. O

Additionally O
, O
an O
invert O
U O
- O
shape O
with O
a O
threshold O
Se B
of O
100 O
mu O
g O
/ O
L O
was O
observed O
between O
cord O
serum O
Se B
and O
NBNA O
. O

The O
adjusted O
regression O
coefficient O
was O
4 O
. O
4 O
( O
95 O
% O
CI O
: O
3 O
. O
6 O
- O
5 O
. O
2 O
, O
p O
< O
0 O
. O
001 O
) O
for O
Se B
< O
100 O
mu O
g O
/ O
L O
while O
- O
3 O
. O
6 O
( O
95 O
% O
CI O
: O
- O
6 O
. O
1 O
to O
- O
1 O
. O
1 O
, O
p O
< O
0 O
. O
01 O
) O
for O
Se B
> O
= O
100 O
mu O
g O
/ O
L O
. O

Of O
the O
927 O
infants O
, O
50 O
% O
had O
a O
high O
level O
Zn B
( O
> O
= O
794 O
. O
3 O
mu O
g O
/ O
L O
) O
and O
8 O
. O
6 O
% O
had O
a O
high O
level O
Se B
( O
> O
= O
100 O
mu O
g O
/ O
L O
) O
. O

High O
levels O
of O
both O
Zn B
and O
Se B
mainly O
had O
adverse O
effects O
on O
behavior O
and O
passive O
tone O
( O
p O
< O
0 O
. O
001 O
) O
. O

Taken O
together O
, O
our O
study O
suggested O
that O
a O
threshold O
of O
cord O
blood O
Zn B
and O
Se B
was O
existed O
for O
fetal O
neurodevelopment O
and O
the O
prevalence O
of O
excessive O
Zn B
was O
high O
. O

Thus O
, O
the O
supplementation O
of O
Zn B
during O
pregnancy O
should O
be O
considered O
with O
caution O
in O
Shanghai O
, O
China O
. O

Substituted O
imidazopyridazines O
are O
potent O
and O
selective O
inhibitors O
of O
Plasmodium O
falciparum O
calcium B
- O
dependent O
protein O
kinase O
1 O
( O
PfCDPK1 O
) O
. O

A O
series O
of O
imidazopyridazines O
which O
are O
potent O
inhibitors O
of O
Plasmodium O
falciparum O
calcium B
- O
dependent O
protein O
kinase O
1 O
( O
PfCDPK1 O
) O
was O
identified O
from O
a O
high O
- O
throughput O
screen O
against O
the O
isolated O
enzyme O
. O

Using O
structurally O
diverse O
model O
compounds O
from O
the O
Pfizer O
drug O
library O
, O
including O
ingliforib O
, O
furosemide B
and O
celecoxib B
, O
we O
successfully O
prepared O
stable O
solid O
nanodispersions O
( O
SNDs O
) O
without O
the O
use O
of O
solvent O
or O
heat O
. O

Stable O
colloidal O
particles O
( O
< O
350nm O
) O
containing O
drug O
, O
polyvinylpyrrolidone B
( O
PVP O
) O
K12 O
and O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
in O
1 O
: O
2 O
. O
75 O
: O
0 O
. O
25 O
ratio O
were O
produced O
after O
2h O
of O
co O
- O
grinding O
. O

Using O
furosemide B
( O
BCS O
class O
IV O
compound O
) O
as O
a O
model O
compound O
, O
we O
conducted O
transport O
studies O
with O
Madin O
- O
Darby O
canine O
kidney O
cells O
transfected O
with O
human O
MDR1 O
gene O
( O
MDCK O
/ O
MDR1 O
) O
, O
followed O
by O
pharmacokinetics O
studies O
in O
rats O
. O

Results O
showed O
that O
the O
SND O
formulation O
enhanced O
the O
absorptive O
flux O
of O
furosemide B
by O
more O
than O
3 O
- O
fold O
. O

In O
the O
pharmacokinetics O
studies O
, O
the O
SND O
formulation O
increased O
Cmax O
and O
AUC O
of O
furosemide B
by O
36 O
. O
6 O
and O
43 O
. O
2 O
fold O
respectively O
, O
relative O
to O
Methocel O
formulation O
. O

Interestingly O
, O
physical O
mixture O
containing O
furosemide B
, O
PVP O
K12 O
and O
SDS B
produced O
a O
similar O
level O
of O
oral O
exposure O
as O
the O
SNDs O
, O
albeit O
with O
a O
longer O
Tmax O
than O
the O
SND O
formulation O
. O

The O
results O
suggest O
that O
PVP O
K12 O
and O
SDS B
were O
able O
to O
increase O
the O
furosemide B
free O
fraction O
available O
for O
oral O
absorption O
. O

Low O
solubility O
, O
poor O
permeability O
, O
and O
high O
first O
- O
pass O
effect O
of O
furosemide B
may O
also O
have O
produced O
the O
effect O
that O
small O
improvements O
in O
solubilization O
resulted O
in O
significant O
potentiation O
of O
the O
oral O
exposure O
of O
the O
physical O
mixture O
. O

Cellular O
content O
of O
granuloma O
was O
measured O
by O
assaying O
activity O
of O
N B
- I
acetyl I
glucosaminidase O
( O
NAG O
) O
and O
total O
nucleic O
acid O
content O
. O

PPG O
had O
a O
more O
effective O
response O
than O
the O
reference O
drug O
diclofenac B
sodium I
in O
both O
the O
models O
of O
inflammation O
. O

Data O
on O
base O
excision O
repair O
( O
BER O
) O
, O
direct O
reversal O
with O
O O
( O
6 O
) O
- O
alkylguanine O
transferase O
and O
double O
strand O
breaks O
repair O
, O
although O
rather O
scarce O
, O
are O
being O
reviewed O
, O
as O
well O
as O
nucleotide B
excision O
repair O
( O
NER O
) O
and O
photoreactivation O
repair O
( O
PER O
) O
, O
which O
are O
by O
far O
the O
most O
studied O
repair O
mechanisms O
in O
fish O
. O

We O
provide O
here O
evidence O
that O
neurofibromin O
, O
via O
its O
Ras O
guanosine B
triphosphatase O
- O
activating O
activity O
, O
controls O
ERK1 O
/ O
2 O
- O
dependent O
fibroblast O
growth O
factor O
receptor O
( O
FGFR O
) O
signaling O
in O
chondrocytes O
. O

Stereoselective O
Glucuronidation O
of O
Ornidazole O
in O
Humans O
: O
Predominant O
Contribution O
of O
UDP B
- O
Glucuronosyltransfer O
1A9 O
and O
2B7 O
. O

Screening O
assays O
with O
12 O
available O
human O
recombinant O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
demonstrated O
that O
UGT1A9 O
was O
the O
predominant O
UGT O
isoform O
involved O
in O
R O
- O
ornidazole O
glucuronidation O
, O
whereas O
S O
- O
ornidazole O
glucuronidation O
was O
almost O
exclusively O
catalyzed O
by O
UGT2B7 O
. O

Hydroxylated O
metabolites O
often O
retain O
the O
pharmacological O
activity O
of O
parent O
compound O
, O
and O
the O
position O
of O
hydroxylation O
determines O
the O
formation O
of O
chemically O
reactive O
intermediates O
such O
as O
quinones B
and O
analogues O
from O
para O
- O
and O
/ O
or O
ortho O
- O
hydroxylation O
of O
phenols B
or O
arylamines O
. O

In O
the O
present O
study O
, O
a O
chemical O
derivatization O
of O
isomeric O
hydroxylated O
metabolites O
with O
2 O
- O
fluoro O
- O
N O
- O
methyl O
pyridinium O
p O
- O
toluenesulfonate O
was O
found O
to O
confer O
distinct O
theoretical O
CCS O
value O
on O
each O
isomer O
by O
forming O
corresponding O
N O
- O
methyl O
pyridine O
( O
NMP B
) O
derivative O
. O

The O
regression O
lines O
established O
by O
the O
comparison O
between O
theoretical O
CCS O
values O
and O
observed O
drift O
times O
from O
IMS O
for O
each O
set O
of O
parent O
compound O
( O
labetalol O
, O
ezetimibe O
, O
atorvastatin B
and O
warfarin B
) O
and O
its O
MS O
/ O
MS O
product O
ions O
accurately O
and O
selectively O
projected O
the O
actual O
drift O
times O
of O
NMP B
derivatives O
of O
corresponding O
aromatic O
or O
isomeric O
hydroxylated O
metabolites O
. O

The O
established O
method O
was O
used O
for O
the O
accurate O
assignment O
of O
predominant O
formation O
of O
2 O
- O
hydroxylated O
metabolite O
from O
imipramine B
in O
NADPH B
- O
fortified O
human O
liver O
microsomes O
. O

The O
current O
study O
was O
aimed O
to O
scrutinize O
acetylcholinesterase O
( O
AchE O
) O
inhibitory O
profile O
of O
two O
antidepressants O
, O
diazepam B
and O
phenobarbitone O
. O

The O
results O
showed O
marked O
inhibition O
of O
AchE O
by O
diazepam B
and O
the O
values O
of O
aKm O
and O
aVm O
were O
65 O
. O
5 O
% O
and O
52 O
. O
63 O
% O
, O
respectively O
. O

These O
values O
suggested O
a O
competitive O
type O
of O
antagonism O
for O
diazepam B
. O

It O
is O
concluded O
that O
diazepam B
and O
phenobarbitone O
exhibited O
prominent O
AchE O
attenuation O
apart O
from O
their O
well O
- O
established O
antidepressant O
activity O
, O
which O
could O
be O
more O
useful O
in O
related O
diseased O
conditions O
. O

A O
Role O
for O
Cargo O
in O
the O
Activation O
of O
ADP B
- O
Ribosylation O
Factors O
( O
Arf O
) O
and O
Adaptor O
Recruitment O
. O

We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf O
- O
dependent O
adaptors O
( O
AP O
- O
1 O
and O
GGAs O
) O
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo O
proteins O
( O
furin O
, O
mannose O
- O
6 O
- O
phosphate O
receptor O
( O
M6PR O
) O
and O
M6PR O
lacking O
a O
C B
- O
terminal O
domain O
M6PR O
Delta O
C O
) O
. O

Using O
temperature O
block O
, O
Brefeldin B
A I
, O
and O
recovery O
from O
each O
, O
we O
found O
that O
the O
cytoplasmic O
tail O
of O
M6PR O
causes O
the O
recruitment O
of O
AP O
- O
1 O
and O
GGAs O
to O
recycling O
endosomes O
and O
not O
at O
the O
Golgi O
, O
as O
predicted O
by O
steady O
state O
staining O
profiles O
. O

Three O
metal O
complexes O
consisting O
of O
Li B
( I
+ I
) I
, O
Zn B
( I
2 I
+ I
) I
, O
and O
Al B
( I
3 I
+ I
) I
and O
quinolinol O
- O
functionalized O
l O
- O
glutamides O
( O
HQLG O
) O
, O
( O
abbreviated O
as O
LiHQLG O
, O
Zn O
( O
HQLG O
) O
2 O
, O
and O
Al O
( O
HQLG O
) O
3 O
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

Effects O
of O
17 O
alpha O
- O
ethynylestradiol O
- O
induced O
cholestasis O
on O
the O
pharmacokinetics O
of O
doxorubicin B
in O
rats O
: O
reduced O
biliary O
excretion O
and O
hepatic O
metabolism O
of O
doxorubicin B
. O

Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen B
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17 O
alpha O
- O
ethynylestradiol O
( O
EE O
, O
an O
oral O
contraceptive O
) O
and O
doxorubicin B
( O
an O
anticancer O
drug O
) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O

Doxorubicin B
is O
mainly O
excreted O
into O
the O
bile O
via O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
and O
multidrug O
resistance O
- O
associated O
protein O
2 O
( O
Mrp2 O
) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
( O
CYP O
) O
3A O
subfamily O
. O

Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O
changes O
of O
doxorubicin B
with O
respect O
to O
the O
changes O
in O
its O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
EEC O
rats O
. O

The O
pharmacokinetic O
study O
of O
doxorubicin B
after O
intravenous O
administration O
of O
its O
hydrochloride B
was O
conducted O
along O
with O
the O
investigation O
of O
bile O
flow O
rate O
and O
hepatobiliary O
excretion O
of O
doxorubicin B
in O
control O
and O
EEC O
rats O
. O

The O
significantly O
greater O
AUC O
( O
58 O
. O
7 O
% O
increase O
) O
of O
doxorubicin B
in O
EEC O
rats O
was O
due O
to O
the O
slower O
CL O
( O
32 O
. O
9 O
% O
decrease O
) O
. O

The O
slower O
CL O
was O
due O
to O
the O
reduction O
of O
hepatic O
biliary O
excretion O
( O
67 O
. O
0 O
% O
decrease O
) O
and O
hepatic O
CYP3A O
subfamily O
- O
mediated O
metabolism O
( O
21 O
. O
9 O
% O
decrease O
) O
of O
doxorubicin B
. O

These O
results O
might O
have O
broader O
implications O
to O
understand O
the O
altered O
pharmacokinetics O
and O
/ O
or O
pharmacologic O
effects O
of O
doxorubicin B
via O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
experimental O
and O
clinical O
estrogen B
- O
induced O
cholestasis O
. O

Oxidation O
of O
CO B
by O
Nickel B
Oxide I
Clusters O
Revealed O
by O
Post O
Heating O
. O

Reactions O
of O
nickel B
oxide I
cluster O
ions O
, O
NinOn O
+ O
x O
( O
+ O
) O
( O
n O
= O
4 O
- O
10 O
, O
x O
= O
- O
1 O
~ O
+ O
3 O
) O
, O
with O
CO B
in O
a O
He B
buffer O
gas O
were O
investigated O
using O
mass O
spectrometry O
. O

When O
the O
cluster O
ions O
react O
at O
room O
temperature O
, O
a O
CO B
molecule O
tends O
to O
attach O
readily O
to O
NinOn O
+ O
x O
( O
+ O
) O
for O
all O
of O
the O
cluster O
ions O
with O
different O
stoichiometry O
, O
although O
rate O
constants O
of O
the O
CO B
attachment O
reaction O
are O
more O
or O
less O
stoichiometry O
- O
dependent O
. O

However O
, O
CO B
was O
found O
to O
be O
released O
from O
the O
cluster O
ions O
when O
the O
cluster O
ions O
were O
heated O
up O
to O
523 O
K O
after O
the O
reaction O
. O

This O
finding O
is O
interpreted O
such O
that O
the O
CO B
molecule O
that O
physisorbs O
weakly O
to O
NinOn O
+ O
x O
( O
+ O
) O
at O
room O
temperature O
desorbs O
into O
the O
gas O
phase O
by O
the O
post O
heating O
. O

In O
addition O
, O
we O
found O
that O
an O
oxygen B
extraction O
reaction O
by O
a O
CO B
molecule O
actually O
occurs O
for O
oxygen B
- O
rich O
clusters O
such O
as O
Ni6O7 O
( O
+ O
) O
and O
Ni8O9 O
( O
+ O
) O
. O

As O
the O
oxygen B
extraction O
reaction O
is O
one O
order O
of O
magnitude O
slower O
than O
physisorption O
, O
it O
lies O
hidden O
underneath O
of O
the O
faster O
physisorption O
processes O
in O
the O
mass O
spectrum O
but O
is O
revealed O
by O
the O
elimination O
of O
physisorption O
through O
the O
post O
heating O
. O

Benchmark O
quantum O
- O
chemical O
calculations O
on O
a O
complete O
set O
of O
rotameric O
families O
of O
the O
DNA O
sugar B
- O
phosphate B
backbone O
and O
their O
comparison O
with O
modern O
density O
functional O
theory O
. O

The O
DNA O
sugar B
- O
phosphate B
backbone O
has O
a O
substantial O
influence O
on O
the O
DNA O
structural O
dynamics O
. O

We O
utilize O
an O
electronically O
sufficiently O
complete O
DNA O
sugar B
- O
phosphate B
- O
sugar B
( O
) O
backbone O
model O
system O
truncated O
to O
prevent O
undesired O
intramolecular O
interactions O
. O

The O
Appraisal O
Committee O
concluded O
that O
golimumab O
should O
be O
recommended O
in O
combination O
with O
methotrexate B
as O
an O
option O
for O
patients O
with O
severe O
active O
RA O
who O
have O
failed O
on O
conventional O
DMARDs O
, O
or O
who O
have O
failed O
on O
a O
TNF O
- O
alpha O
inhibitor O
and O
are O
contraindicated O
to O
or O
withdrawn O
from O
rituximab O
. O

Evolutionary O
concepts O
in O
ecotoxicology O
: O
tracing O
the O
genetic O
background O
of O
differential O
cadmium B
sensitivities O
in O
invertebrate O
lineages O
. O

In O
this O
article O
, O
the O
genetic O
and O
evolutionary O
background O
of O
differential O
Cd B
sensitivities O
among O
invertebrate O
populations O
and O
species O
and O
their O
potential O
of O
adaptation O
to O
environmental O
Cd B
exposure O
will O
be O
highlighted O
. O

Important O
evolutionary O
and O
population O
genetic O
concepts O
such O
as O
genome O
structure O
and O
their O
importance O
for O
evolutionary O
adaptation O
, O
population O
structure O
of O
affected O
individuals O
, O
as O
well O
as O
micro O
and O
macroevolutionary O
mechanisms O
of O
Cd B
resistance O
in O
invertebrate O
lineages O
will O
be O
stressed O
by O
discussing O
examples O
of O
work O
from O
our O
own O
laboratory O
along O
with O
a O
review O
of O
relevant O
literature O
data O
and O
a O
brief O
discussion O
of O
open O
questions O
along O
with O
some O
perspectives O
for O
further O
research O
. O

Both O
, O
differences O
and O
similarities O
in O
Cd B
sensitivity O
traits O
of O
related O
invertebrate O
species O
can O
only O
be O
understood O
if O
we O
consider O
the O
underlying O
evolutionary O
processes O
and O
genetic O
( O
or O
epigenetic O
) O
mechanisms O
. O

A O
Platform O
for O
Large O
- O
Scale O
Graphene B
Electronics O
- O
CVD O
Growth O
of O
Single O
- O
Layer O
Graphene B
on O
CVD O
- O
Grown O
Hexagonal O
Boron O
Nitride O
. O

Direct O
chemical O
vapor O
deposition O
( O
CVD O
) O
growth O
of O
single O
- O
layer O
graphene B
on O
CVD O
- O
grown O
hexagonal O
boron O
nitride O
( O
h O
- O
BN O
) O
film O
can O
suggest O
a O
large O
- O
scale O
and O
high O
- O
quality O
graphene B
/ O
h O
- O
BN O
film O
hybrid O
structure O
with O
a O
defect O
- O
free O
interface O
. O

This O
sequentially O
grown O
graphene B
/ O
h O
- O
BN O
film O
shows O
better O
electronic O
properties O
than O
that O
of O
graphene B
/ O
SiO2 B
or O
graphene B
transferred O
on O
h O
- O
BN O
film O
, O
and O
suggests O
a O
new O
promising O
template O
for O
graphene B
device O
fabrication O
. O

The O
cation O
- O
pi O
box O
is O
a O
specific O
phosphatidylcholine B
membrane O
targeting O
motif O
. O

While O
molecular O
determinants O
of O
specificity O
for O
several O
headgroups O
, O
including O
phosphatidylserine B
and O
phosphoinositides B
are O
well O
defined O
, O
specific O
recognition O
of O
the O
headgroup O
of O
the O
zwitterionic O
phosphatidylcholine B
( O
PC O
) O
is O
less O
well O
understood O
. O

In O
cytosolic O
proteins O
the O
cation O
- O
pi O
box O
provides O
a O
suitable O
receptor O
for O
choline B
recognition O
and O
binding O
through O
the O
trimethylammonium O
moiety O
. O

We O
prove O
this O
hypothesis O
by O
engineering O
the O
cation O
- O
pi O
box O
into O
secreted O
phosphatidylinositol B
- O
specific O
phospholipase O
C O
from O
Staphylococcus O
aureus O
, O
which O
lacks O
specific O
PC O
recognition O
. O

The O
N254Y O
/ O
H258Y O
variant O
selectively O
binds O
PC O
- O
enriched O
vesicles O
, O
and O
X O
- O
ray O
crystallography O
reveals O
N254Y O
/ O
H258Y O
binds O
choline B
and O
dibutyroylphosphatid O
within O
the O
cation O
- O
pi O
motif O
. O

Theoretical O
Investigation O
of O
Generator O
- O
Collector O
Microwell O
Arrays O
for O
Improving O
Electroanalytical O
Selectivity O
: O
Application O
to O
Selective O
Dopamine B
Detection O
in O
the O
Presence O
of O
Ascorbic B
Acid I
. O

Recessed O
generator O
- O
collector O
assemblies O
consisting O
of O
an O
array O
of O
recessed O
disks O
( O
generator O
electrodes O
) O
with O
a O
gold O
layer O
( O
collector O
electrode O
) O
deposited O
over O
the O
top O
- O
plane O
insulator O
reportedly O
allow O
increased O
selectivity O
and O
sensitivity O
during O
electrochemical O
detection O
of O
dopamine B
( O
DA O
) O
in O
the O
presence O
of O
ascorbic B
acid I
( O
AA O
) O
, O
a O
situation O
which O
is O
frequently O
encountered O
. O

Tuning O
the O
Electrical O
and O
Optical O
Properties O
of O
Graphene B
by O
Ozone B
Treatment O
for O
Patterning O
Monolithic O
Transparent O
Electrodes O
. O

Tunable O
electrical O
and O
optical O
properties O
of O
graphene B
are O
vital O
to O
promote O
its O
use O
as O
film O
electrodes O
in O
a O
variety O
of O
devices O
. O

We O
developed O
an O
etching O
- O
free O
ozone B
treatment O
method O
to O
continuously O
tune O
the O
electrical O
resistance O
and O
optical O
transmittance O
of O
graphene B
films O
by O
simply O
varying O
the O
time O
and O
temperature O
of O
graphene B
exposure O
to O
ozone B
. O

Initially O
, O
ozone B
exposure O
dramatically O
decreases O
the O
electrical O
resistance O
of O
graphene B
films O
by O
p O
- O
doping O
, O
but O
this O
is O
followed O
by O
increases O
in O
the O
resistance O
and O
optical O
transmittance O
as O
a O
result O
of O
surface O
oxidation O
. O

The O
ozone B
- O
oxidized O
graphene O
is O
not O
removed O
but O
is O
gradually O
transformed O
to O
graphene B
oxide I
( O
GO O
) O
. O

On O
the O
basis O
of O
such O
effects O
of O
ozone B
treatment O
, O
we O
demonstrate O
a O
well O
- O
defined O
graphene B
pattern O
by O
using O
ozone B
photolithography O
, O
in O
which O
the O
ozone B
- O
treated O
graphene B
electrodes O
are O
monolithic O
but O
separated O
by O
insulating O
GO O
regions O
. O

Such O
a O
monolithic O
graphene B
pattern O
shows O
low O
optical O
contrast O
, O
a O
clean O
and O
more O
hydrophilic O
surface O
, O
indicating O
the O
promising O
use O
of O
ozone B
treatment O
to O
achieve O
high O
- O
performance O
graphene B
- O
based O
optoelectronic O
devices O
. O

Asymmetric O
dimethylarginine O
predicts O
decline O
of O
glucose B
tolerance O
in O
men O
with O
stable O
coronary O
artery O
disease O
: O
a O
4 O
. O
5 O
- O
year O
follow O
- O
up O
study O
. O

BACKGROUND O
: O
Endothelial O
dysfunction O
, O
largely O
dependent O
on O
impaired O
nitric B
oxide I
bioavailability O
, O
has O
been O
reportedly O
associated O
with O
incident O
type O
2 O
diabetes O
. O

Our O
aim O
was O
to O
test O
the O
hypothesis O
that O
asymmetric O
dimethylarginine O
( O
ADMA O
) O
, O
an O
endogenous O
inhibitor O
of O
nitric B
oxide I
formation O
, O
might O
be O
linked O
to O
future O
deterioration O
in O
glucose B
tolerance O
in O
stable O
coronary O
artery O
disease O
( O
CAD O
) O
. O

An O
estimate O
of O
insulin O
resistance O
by O
homeostasis O
model O
assessment O
( O
HOMA O
- O
IR O
index O
) O
was O
calculated O
from O
fasting O
insulin O
and O
glucose B
. O

Deterioration O
in O
glucose B
tolerance O
was O
defined O
as O
development O
of O
type O
2 O
diabetes O
or O
progression O
from O
a O
normal O
glucose B
tolerance O
to O
impaired O
fasting O
glucose B
. O

RESULTS O
: O
Over O
a O
median O
follow O
- O
up O
of O
55 O
months O
11 O
subjects O
developed O
type O
2 O
diabetes O
and O
13 O
progressed O
to O
impaired O
fasting O
glucose B
. O

Incident O
deterioration O
of O
glucose B
tolerance O
was O
associated O
with O
ADMA O
( O
hazard O
ratio O
[ O
HR O
] O
per O
1 O
- O
SD O
increment O
1 O
. O
64 O
[ O
95 O
% O
CI O
: O
1 O
. O
14 O
- O
- O
2 O
. O
35 O
] O
; O
P O
= O
0 O
. O
007 O
) O
, O
log O
( O
HOMA O
- O
IR O
index O
) O
( O
HR O
= O
1 O
. O
60 O
[ O
1 O
. O
16 O
- O
- O
2 O
. O
20 O
] O
; O
P O
= O
0 O
. O
004 O
) O
and O
body O
- O
mass O
index O
( O
HR O
= O
1 O
. O
44 O
[ O
0 O
. O
95 O
- O
- O
2 O
. O
17 O
] O
; O
P O
= O
0 O
. O
08 O
) O
by O
univariate O
Cox O
regression O

ADMA O
( O
HR O
= O
1 O
. O
65 O
[ O
1 O
. O
14 O
- O
- O
2 O
. O
38 O
] O
; O
p O
= O
0 O
. O
008 O
) O
and O
log O
( O
HOMA O
- O
IR O
index O
) O
( O
HR O
= O
1 O
. O
55 O
[ O
1 O
. O
10 O
- O
- O
2 O
. O
17 O
] O
; O
P O
= O
0 O
. O
01 O
) O
were O
multivariate O
predictors O
of O
a O
decline O
in O
glucose B
tolerance O
. O

ADMA O
and O
SDMA O
were O
unrelated O
to O
body O
- O
mass O
index O
, O
HOMA O
- O
IR O
index O
, O
insulin O
or O
glucose B
. O

CONCLUSIONS O
: O
ADMA O
predicts O
future O
deterioration O
of O
glucose B
tolerance O
independently O
of O
baseline O
insulin O
resistance O
in O
men O
with O
stable O
CAD O
. O

Sodium B
fluoride I
induces O
apoptosis O
in O
odontoblasts O
via O
a O
JNK O
- O
dependent O
mechanism O
. O

Sodium B
fluoride I
( O
NaF B
) O
is O
widely O
used O
for O
the O
treatment O
of O
dental O
caries O
and O
dentin O
hypersensitivity O
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
pro O
- O
apoptotic O
effects O
of O
NaF B
in O
odontoblasts O
and O
elucidate O
the O
possible O
underlying O
molecular O
mechanisms O
. O

NaF B
generated O
cytotoxic O
effects O
in O
odontoblast O
- O
lineage O
cell O
( O
OLC O
) O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
. O

Exposure O
of O
cells O
to O
4mM O
NaF B
for O
24h O
induced O
caspase O
- O
3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter O
- O
membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride B
- O
mediated O
apoptosis O
is O
mitochondria O
- O
dependent O
. O

Fluoride B
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride B
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
NaF B
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK O
- O
dependent O
mitochondrial O
pathway O
. O

Perinatal O
exposure O
to O
BDE B
- I
99 I
causes O
learning O
disorders O
and O
decreases O
serum O
thyroid B
hormone I
levels O
and O
BDNF O
gene O
expression O
in O
hippocampus O
in O
rat O
offspring O
. O

Exposure O
of O
pregnant O
women O
to O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
may O
mean O
serious O
health O
risks O
. O

The O
main O
goal O
of O
the O
present O
study O
was O
to O
examine O
the O
neurobehavioral O
changes O
in O
rat O
offspring O
that O
were O
perinatally O
exposed O
to O
one O
of O
the O
most O
prevalent O
PBDEs B
congeners O
found O
in O
humans O
, O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
- O
pentaBDE O
( O
BDE B
- I
99 I
) O
. O

Rat O
dams O
were O
exposed O
to O
0 O
, O
1 O
and O
2mg O
/ O
kg O
/ O
day O
of O
BDE B
- I
99 I
from O
gestation O
day O
6 O
to O
post O
- O
natal O
day O
21 O
. O

When O
pups O
were O
weaning O
, O
cortex O
and O
hippocampal O
gene O
expressions O
of O
brain O
- O
derived O
neurotrophic O
factor O
( O
BDNF O
) O
of O
the O
different O
isoforms O
of O
the O
thyroid B
hormone I
( O
TH O
) O
receptors O
( O
TRs O
) O
were O
evaluated O
. O

The O
results O
showed O
that O
maternal O
transference O
of O
BDE B
- I
99 I
produced O
a O
delay O
in O
the O
spatial O
learning O
task O
in O
the O
water O
maze O
test O
. O

It O
was O
also O
found O
that O
the O
serum O
levels O
of O
triiodothyronine B
( O
T3 O
) O
, O
tetraiiodothyronine O
( O
T4 O
) O
and O
free O
- O
T4 O
( O
FT4 O
) O
decreased O
. O

These O
results O
indicate O
a O
clear O
signal O
disruption O
of O
TH O
and O
reinforce O
previous O
studies O
in O
which O
neurotoxic O
effects O
of O
PBDEs B
in O
animal O
research O
were O
observed O
at O
levels O
comparable O
to O
those O
found O
in O
humans O
. O

Reward O
and O
aversion O
in O
a O
heterogeneous O
midbrain O
dopamine B
system O
. O

Abnormalities O
in O
the O
function O
of O
VTA O
dopamine B
( O
DA O
) O
neurons O
and O
the O
targets O
they O
influence O
are O
implicated O
in O
several O
prominent O
neuropsychiatric O
disorders O
including O
addiction O
and O
depression O
. O

Here O
we O
will O
focus O
on O
recent O
advances O
in O
understanding O
the O
neural O
circuits O
mediating O
reward O
and O
aversion O
in O
the O
VTA O
and O
how O
stress O
as O
well O
as O
drugs O
of O
abuse O
, O
in O
particular O
cocaine B
, O
alter O
circuit O
function O
within O
a O
heterogeneous O
midbrain O
DA O
system O
. O

Anatoxin O
- O
a O
is O
one O
of O
the O
common O
and O
major O
cyanobacterial O
neurotoxins O
acting O
as O
a O
powerful O
agonist O
at O
nicotinic O
acetylcholine B
receptors O
( O
nAChR O
) O
. O

The O
numerous O
researches O
have O
been O
actively O
conducted O
with O
respect O
to O
the O
toxic O
effects O
of O
anatoxin O
- O
a O
on O
mammals O
; O
however O
, O
little O
research O
has O
aimed O
at O
its O
possible O
effects O
on O
aquatic O
plants O
, O
wherein O
well O
- O
structured O
nervous O
system O
is O
absent O
with O
the O
lack O
of O
various O
components O
of O
the O
acetylcholine B
mechanism O
. O

In O
this O
study O
, O
submerged O
macrophyte O
Ceratophyllum O
demersum O
( O
C O
. O
demersum O
) O
was O
adopted O
to O
examine O
the O
effects O
of O
anatoxin O
- O
a O
on O
morphological O
( O
growth O
) O
, O
physiological O
( O
photosynthetic O
pigment O
contents O
) O
and O
biochemical O
( O
hydrogen B
peroxide I
level O
, O
biotransformation O
and O
antioxidative O
enzymes O
) O
responses O
in O
the O
aquatic O
plant O
at O
environmentally O
relevant O
concentrations O
( O
0 O
. O
005 O
, O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mu O
g O
/ O
L O
) O
. O

The O
significant O
elevation O
of O
antioxidative O
enzymes O
in O
parallel O
with O
increased O
formation O
of O
hydrogen B
peroxide I
appeared O
from O
0 O
. O
5 O
mu O
g O
/ O
L O
of O
anatoxin O
- O
a O
. O

In O
the O
measurement O
of O
photosynthetic O
pigments O
, O
the O
decrease O
in O
chlorophyll B
a I
content O
was O
detected O
at O
5 O
and O
50 O
mu O
g O
/ O
L O
, O
whereas O
the O
increase O
in O
carotenoids O
/ O
total O
chlorophyll B
was O
observed O
from O
0 O
. O
05 O
mu O
g O
/ O
L O
. O

The O
next O
generation O
of O
novel O
low O
- O
density O
lipoprotein O
cholesterol B
- O
lowering O
agents O
: O
Proprotein O
convertase O
subtilisin O
/ O
kexin O
9 O
inhibitors O
. O

Gain O
- O
of O
- O
function O
mutations O
promote O
the O
development O
of O
familial O
hypercholesterolemia O
, O
whereas O
loss O
- O
of O
- O
function O
mutations O
are O
associated O
with O
lower O
levels O
of O
circulating O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
and O
significant O
protection O
against O
coronary O
heart O
disease O
. O

Therefore O
, O
PCSK9 O
is O
an O
attractive O
therapeutic O
target O
for O
the O
new O
generation O
of O
cholesterol B
- O
lowering O
drugs O
. O

Role O
of O
plant O
stanol B
derivatives O
in O
the O
modulation O
of O
cholesterol B
metabolism O
and O
liver O
gene O
expression O
in O
mice O
. O

The O
present O
study O
was O
to O
evaluate O
the O
cholesterol B
- O
lowering O
effect O
of O
two O
novel O
plant O
stanol B
derivatives O
and O
its O
potential O
molecular O
mechanism O
in O
hyper O
- O
cholesterol B
mice O
induced O
by O
a O
high O
- O
cholesterol B
diet O
. O

Results O
showed O
that O
oral O
administration O
of O
plant O
stanyl O
hemisuccinate O
( O
2 O
x O
, O
5 O
x O
) O
and O
plant O
stanyl O
sorbitol O
succinate O
( O
2 O
x O
, O
5 O
x O
) O
effectively O
attenuated O
the O
serum O
total O
cholesterol B
and O
low O
density O
lipoprotein O
cholesterol B
levels O
, O
while O
had O
no O
effect O
on O
the O
serum O
triacylglycerol B
and O
high O
density O
lipoprotein O
cholesterol B
. O

And O
plant O
stanol B
derivatives O
decreased O
liver O
cholesterol B
concentration O
and O
increased O
faecal O
cholesterol B
output O
. O

Meanwhile O
, O
both O
plant O
stanyl O
hemisuccinate O
and O
plant O
stanyl O
sorbitol O
succinate O
could O
remarkably O
promote O
liver O
X O
receptor O
alpha O
( O
LXR O
alpha O
) O
expression O
, O
and O
increased O
cholesterol B
7 O
alpha O
- O
hydroxylase O
( O
CYP7A1 O
) O
expression O
and O
faecal O
total O
bile B
acid I
output O
to O
varying O
degrees O
. O

These O
results O
suggested O
two O
novel O
plant O
stanol B
derivatives O
possessed O
hypocholesterolemic O
effect O
, O
and O
the O
cholesterol B
- O
lowering O
action O
of O
plant O
stanol B
derivatives O
may O
be O
through O
activating O
the O
potential O
LXR O
alpha O
- O
CYP7A1 O
- O
bile B
acid I
excretion O
pathway O
. O

An O
optimised O
method O
for O
the O
accurate O
determination O
of O
zeranol O
and O
diethylstilbestrol B
in O
animal O
tissues O
using O
isotope O
dilution O
- O
liquid O
chromatography O
/ O
mass O
spectrometry O
. O

The O
sensitivity O
difference O
of O
trans O
- O
and O
cis O
- O
diethylstilbestrol O
( O
isomerizing O
in O
sample O
preparation O
processes O
) O
by O
the O
LC O
/ O
MS O
was O
measured O
by O
running O
a O
trans O
/ O
cis O
mixture O
( O
ratio O
measured O
by O
a O
quantitative O
NMR O
) O
with O
and O
without O
sample O
matrices O
, O
and O
applied O
for O
the O
determination O
of O
total O
diethylstilbestrol B
. O

Wines O
stored O
at O
5 O
degrees O
C O
for O
6months O
did O
not O
show O
significant O
changes O
in O
flavor O
; O
otherwise O
, O
the O
samples O
stored O
at O
15 O
and O
25 O
degrees O
C O
, O
showed O
a O
significant O
decrease O
in O
linalool B
, O
beta O
- O
damascenone O
, O
ethyl O
hexanoate O
, O
and O
ethyl O
octanoate O
levels O
. O

In O
these O
last O
samples O
, O
alpha B
- I
terpineol I
, O
hotrienol O
, O
nerol O
oxide O
, O
furanic O
linalool O
oxides O
A O
/ O
B O
and O
rose O
oxide O
concentrations O
significantly O
increased O
. O

Similarly O
, O
the O
total O
phenolic B
, O
flavonoids B
and O
tartaric O
esters O
content O
and O
the O
composition O
of O
organic O
acids O
did O
not O
show O
significant O
differences O
( O
p O
< O
0 O
. O
05 O
) O
during O
the O
process O
. O

On O
the O
contrary O
, O
colour O
intensity O
and O
tonality O
of O
wine O
samples O
changed O
significantly O
when O
the O
alcohol B
reduction O
was O
over O
the O
6 O
. O
5vol O
. O
% O
. O

The O
impact O
of O
catechin B
and O
epicatechin B
, O
total O
phenols B
and O
PPO O
activity O
on O
the O
Mal O
d O
1 O
content O
in O
apple O
fruit O
. O

Apples O
are O
a O
very O
important O
source O
of O
secondary O
plant O
metabolites O
like O
polyphenols B
in O
human O
nutrition O
. O

The O
most O
important O
phenols B
in O
apple O
are O
epicatechin B
, O
catechin B
and O
their O
polymeric O
structures O
, O
which O
have O
been O
identified O
as O
substrates O
of O
the O
polyphenoloxidase O
( O
PPO O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
influence O
of O
naturally O
occurring O
catechin B
and O
epicatechin B
contents O
in O
apple O
on O
the O
allergenicity O
of O
apple O
fruits O
. O

Mal O
d O
1 O
- O
, O
catechin B
- O
, O
epicatechin B
- O
and O
total O
phenol B
content O
as O
well O
as O
the O
activity O
of O
PPO O
were O
determined O
. O

Correlation O
analysis O
showed O
that O
naturally O
occurring O
catechin B
as O
well O
as O
epicatechin B
has O
no O
impact O
on O
the O
Mal O
d O
1 O
content O
of O
the O
tested O
cultivars O
: O
correlation O
coefficient O
ranged O
from O
- O
0 O
. O
203 O
to O
0 O
. O
501 O
for O
the O
correlation O
between O
Mal O
d O
1 O
and O
catechin B
. O

The O
results O
further O
indicated O
that O
the O
activity O
of O
PPO O
is O
more O
important O
than O
the O
content O
of O
total O
phenols B
to O
reduce O
the O
Mal O
d O
1 O
level O
. O

If O
there O
is O
a O
high O
PPO O
activity O
, O
Mal O
d O
1 O
could O
be O
reduced O
even O
if O
the O
total O
phenol B
concentration O
is O
low O
. O

A O
new O
method O
for O
the O
detection O
of O
alternariol B
( O
AOH B
) O
, O
alternariol B
monomethyl I
ether I
( O
AME B
) O
, O
altenuene O
( O
ALT O
) O
, O
tentoxin O
( O
TEN O
) O
, O
and O
tenuazonic O
acid O
( O
TeA B
) O
, O
five O
alternaria O
toxins O
( O
ATs O
) O
was O
developed O
by O
liquid O
chromatography O
- O
triple O
quadrupole O
mass O
spectrometry O
equipped O
with O
atmospheric O
pressure O
chemical O
ionisation O
( O
APCI O
) O
. O

AOH B
was O
the O
most O
common O
AT O
( O
14 O
samples O
) O
, O
followed O
by O
ALT O
( O
10 O
samples O
) O
. O

Globally O
, O
volatile O
phenols B
together O
with O
aldehydes B
, O
phenols B
and O
lactones B
showed O
an O
increase O
with O
increasing O
maceration O
time O
. O

Lactones B
induced O
positive O
sweetness O
sensations O
, O
whereas O
furanic O
and O
guaiacol O
compounds O
influenced O
bitterness O
and O
astringency O
. O

Spicy O
and O
vanilla O
descriptors O
were O
related O
to O
eugenol B
, O
vanillin B
and O
other O
odorous O
chemicals O
. O

Selenium B
bioaccessibility O
and O
speciation O
in O
biofortified O
Pleurotus O
mushrooms O
grown O
on O
selenium B
- O
rich O
agricultural O
residues O
. O

Cultivation O
of O
saprophytic O
fungi O
on O
selenium B
- O
rich O
substrates O
can O
be O
an O
effective O
means O
to O
produce O
selenium B
- O
fortified O
food O
. O

Pleurotus O
florida O
, O
an O
edible O
species O
of O
oyster O
mushrooms O
, O
was O
grown O
on O
wheat O
straw O
from O
the O
seleniferous O
belt O
of O
Punjab O
( O
India O
) O
and O
its O
potential O
to O
mobilize O
and O
accumulate O
selenium B
from O
the O
growth O
substrate O
was O
studied O
. O

Selenium B
concentration O
in O
biofortified O
mushrooms O
was O
800 O
times O
higher O
compared O
with O
control O
samples O
grown O
on O
wheat O
straw O
from O
non O
selenium B
- O
rich O
areas O
( O
141 O
vs O
0 O
. O
17 O
mu O
gSeg O
( O
- O
1 O
) O
dry O
weight O
) O
. O

Seventy O
- O
five O
percent O
of O
the O
selenium B
was O
extracted O
after O
in O
vitro O
simulated O
gastrointestinal O
digestion O
and O
investigation O
of O
the O
selenium B
molecular O
fractions O
by O
size O
exclusion O
HPLC O
- O
ICP O
- O
MS O
revealed O
that O
proteins O
and O
any O
other O
high O
molecular O
weight O
selenium B
- O
containing O
molecule O
were O
hydrolyzed O
to O
peptides O
and O
low O
molecular O
weight O
selenocompounds O
. O

Analysis O
of O
the O
gastrointestinal O
hydrolysates O
by O
anion O
exchange O
HPLC O
- O
ICP O
- O
MS O
showed O
that O
the O
bioaccessible O
selenium B
was O
mainly O
present O
as O
selenomethionine B
, O
a O
good O
bioavailable O
source O
of O
selenium B
, O
which O
accounted O
for O
73 O
% O
of O
the O
sum O
of O
the O
detected O
species O
. O

This O
study O
demonstrates O
the O
feasibility O
of O
producing O
selenium B
- O
biofortified O
edible O
mushrooms O
using O
selenium B
- O
rich O
agricultural O
by O
- O
products O
as O
growth O
substrates O
. O

The O
proposed O
approach O
can O
be O
used O
to O
evaluate O
whether O
selenium B
- O
contaminated O
plant O
waste O
materials O
harvested O
from O
high O
- O
selenium B
areas O
may O
be O
used O
to O
produce O
selenium B
- O
biofortified O
edible O
mushrooms O
based O
on O
the O
concentration O
, O
bioaccessibility O
and O
speciation O
of O
selenium B
in O
the O
mushrooms O
. O

Ca B
, O
K B
, O
Mg B
and O
Na B
were O
the O
most O
abundant O
elements O
, O
with O
mean O
contents O
of O
219 O
. O
38 O
, O
446 O
. O
93 O
, O
49 O
. O
06 O
and O
95 O
. O
91mgkg O
( O
- O
1 O
) O
respectively O
. O

The O
first O
most O
important O
principal O
component O
( O
PC O
) O
was O
strongly O
associated O
with O
the O
value O
of O
Al B
, O
B B
, O
Cd B
and O
Co B
. O

Flavonol O
glycosides O
with O
lipid O
accumulation O
inhibitory O
activity O
and O
simultaneous O
quantitative O
analysis O
of O
15 O
polyphenols B
and O
caffeine B
in O
the O
flower O
buds O
of O
Camellia O
sinensis O
from O
different O
regions O
by O
LCMS O
. O

A O
simultaneous O
quantitative O
analytical O
method O
for O
15 O
major O
polyphenols B
, O
e O
. O
g O
. O
five O
catechins B
( O
1 O
- O
5 O
) O
and O
10 O
flavonols B
( O
6 O
- O
15 O
) O
, O
as O
functional O
constituents O
in O
the O
extracts O
of O
" O
tea O
flowers O
" O
, O
the O
flower O
buds O
of O
Camellia O
sinensis O
( O
Theaceae O
) O
, O
has O
been O
developed O
. O

The O
content O
of O
caffeine B
( O
16 O
) O
, O
which O
showed O
similar O
chromatographic O
behaviour O
under O
the O
analytical O
conditions O
, O
was O
also O
determined O
. O

The O
results O
indicated O
that O
the O
assay O
was O
reproducible O
and O
precise O
, O
and O
could O
be O
readily O
underutilised O
for O
the O
quality O
evaluation O
of O
tea O
flowers O
on O
the O
basis O
of O
polyphenols B
' O
contents O
. O

A O
new O
flavonol O
glycoside O
, O
chakaflavonoside O
B O
( O
17 O
) O
, O
which O
was O
isolated O
in O
the O
course O
of O
this O
analytical O
study O
, O
was O
found O
to O
show O
oleic B
acid I
- O
albumin O
- O
induced O
lipid O
accumulation O
inhibitory O
activity O
. O

Over O
the O
last O
number O
of O
years O
, O
the O
oxygen B
carrier O
hemocyanin O
, O
has O
demonstrated O
several O
immune O
- O
and O
physiological O
functionalities O
, O
most O
notably O
, O
inducible O
phenoloxidase O
activity O
. O

The O
main O
differences O
found O
in O
the O
volatile O
composition O
of O
the O
cvs O
, O
concerned O
the O
relative O
abundance O
of O
esters B
. O

Instead O
, O
a O
lower O
relative O
content O
of O
methyl B
esters I
, O
such O
as O
methyl O
hexanoate O
and O
methyl O
octanoate O
, O
known O
to O
act O
as O
medfly O
pheromone O
and O
attractant O
respectively O
, O
was O
found O
in O
the O
least O
susceptible O
cvs O
. O

This O
report O
is O
aimed O
at O
intra O
- O
laboratory O
and O
inter O
- O
laboratory O
comparison O
of O
the O
results O
obtained O
during O
spectrophotometric O
and O
HPLC O
analyses O
of O
lycopene B
, O
beta B
- I
carotene I
and O
total O
carotenoids O
in O
tomato O
products O
and O
yellow O
maize O
flours O
/ O
grits O
. O

Montmorillonite B
based O
clays O
have O
a O
wide O
range O
of O
applications O
that O
are O
going O
to O
contribute O
to O
increase O
human O
exposure O
to O
these O
materials O
. O

In O
the O
present O
study O
, O
the O
cytotoxic O
effects O
of O
a O
non O
- O
modified O
clay O
( O
Cloisite O
( O
R O
) O
Na B
+ I
) O
and O
an O
organoclay O
( O
Cloisite O
( O
R O
) O
30B O
) O
have O
been O
investigated O
in O
the O
hepatic O
cell O
line O
HepG2 O
. O

Results O
showed O
genotoxic O
effects O
and O
glutathione B
decrease O
. O

Mechanisms O
of O
Glucose B
Lowering O
of O
Dipeptidyl O
Peptidase O
- O
4 O
Inhibitor O
Sitagliptin B
When O
Used O
Alone O
or O
With O
Metformin B
in O
Type O
2 O
Diabetes O
: O
A O
double O
- O
tracer O
study O
. O

OBJECTIVETo O
assess O
glucose B
- O
lowering O
mechanisms O
of O
sitagliptin B
( O
S O
) O
, O
metformin B
( O
M O
) O
, O
and O
the O
two O
combined O
( O
M O
+ O
S O
) O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
randomized O
16 O
patients O
with O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
to O
four O
6 O
- O
week O
treatments O
with O
placebo O
( O
P O
) O
, O
M O
, O
S O
, O
and O
M O
+ O
S O
. O

After O
each O
period O
, O
subjects O
received O
a O
6 O
- O
h O
meal O
tolerance O
test O
( O
MTT B
) O
with O
[ B
( I
14 I
) I
C I
] I
glucose I
to O
calculate O
glucose B
kinetics O
. O

Fasting O
plasma O
glucose B
( O
FPG O
) O
, O
fasting O
plasma O
insulin O
, O
C B
- O
peptide O
( O
insulin O
secretory O
rate O
[ O
ISR O
] O
) O
, O
fasting O
plasma O
glucagon O
, O
and O
bioactive O
glucagon O
- O
like O
peptide O
( O
GLP O
- O
1 O
) O
and O
gastrointestinal O
insulinotropic O
peptide O
( O
GIP O
) O
was O
measured O
. O
RESULTSFPG O
decreased O
from O
P O
, O
160 O
+ O
/ O
- O
4 O
to O
M O
, O
150 O
+ O
/ O
- O
4 O
; O
S O
, O
154 O
+ O
/ O
- O
4 O
; O
and O
M O
+ O
S O
, O
125 O
+ O
/ O
- O
3 O
mg O
/ O
dL O
. O

Mean O
post O
- O
MTT B
PG O
decreased O
from O
P O
, O
207 O
+ O
/ O
- O
5 O
to O
M O
, O
191 O
+ O
/ O
- O
4 O
; O
S O
, O
195 O
+ O
/ O
- O
4 O
; O
and O
M O
+ O
S O
, O
161 O
+ O
/ O
- O
3 O
mg O
/ O
dL O
( O
P O
< O
0 O
. O
01 O
] O
. O

The O
increase O
in O
mean O
post O
- O
MTT B
plasma O
insulin O
and O
in O
ISR O
was O
similar O
in O
P O
, O
M O
, O
and O
S O
and O
slightly O
greater O
in O
M O
+ O
S O
. O

Fasting O
and O
mean O
post O
- O
MTT B
plasma O
bioactive O
GLP O
- O
1 O
were O
higher O
( O
P O
< O
0 O
. O
01 O
) O
after O
S O
and O
M O
+ O
S O
vs O
. O
M O
and O
P O
. O

Basal O
endogenous O
glucose B
production O
( O
EGP O
) O
fell O
from O
P O
2 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
to O
S O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
1 O
mg O
/ O
kg O
. O
min O
, O
M O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
2 O
mg O
/ O
kg O
. O
min O
[ O
both O
P O
< O
0 O
. O
05 O
vs O
. O
P O
) O
, O
and O
M O
+ O
S O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
1 O
mg O
/ O
kg O
. O
min O
( O
P O
< O
0 O
. O
01 O
vs O
. O
P O
) O
. O

Involvement O
of O
nNOS O
/ O
NO O
/ O
sGC O
/ O
cGMP O
signaling O
pathway O
in O
cocaine B
sensitization O
and O
in O
the O
associated O
hippocampal O
alterations O
: O
does O
phosphodiesterase O
5 O
inhibition O
help O
to O
drug O
vulnerability O
? O

RATIONALE O
: O
Repeated O
cocaine B
administration O
induces O
behavioral O
sensitization O
in O
about O
50 O
% O
of O
treated O
animals O
. O

Nitric B
oxide I
could O
be O
involved O
in O
the O
acquisition O
and O
maintenance O
of O
behavioral O
cocaine B
effects O
, O
probably O
by O
activation O
of O
neuronal O
nitric B
oxide I
synthase O
( O
nNOS O
) O
/ O
NO B
/ O
soluble O
guanylyl O
cyclase O
( O
sGC O
) O
/ O
cyclic O
guanosine O
monophosphate O
( O
cGMP B
) O
signaling O
pathway O
, O
since O
inhibition O
of O
the O
nNOS O
enzyme O
attenuates O
development O
of O
sensitization O
in O
rats O
. O

On O
the O
other O
hand O
, O
increased O
cGMP B
availability O
by O
phosphodiesterase O
5 O
inhibitors O
has O
been O
correlated O
to O
the O
misuse O
and O
recreational O
use O
of O
these O
agents O
and O
also O
to O
the O
concomitant O
use O
with O
illicit O
drugs O
in O
humans O
. O

Moreover O
, O
cocaine B
and O
other O
drugs O
of O
abuse O
can O
affect O
the O
strength O
of O
glutamate B
synapses O
in O
this O
structure O
, O
lastly O
modifying O
neuronal O
activity O
in O
main O
regions O
of O
the O
reward O
circuitry O
. O

OBJECTIVE O
: O
The O
objective O
of O
this O
study O
is O
to O
determine O
whether O
the O
pharmacological O
manipulation O
of O
nNOS O
/ O
NO B
/ O
sGC O
/ O
cGMP B
signaling O
pathway O
altered O
changes O
induced O
by O
repeated O
cocaine B
exposure O
. O

RESULTS O
: O
The O
present O
investigation O
showed O
a O
relationship O
between O
behavioral O
cocaine B
sensitization O
, O
reduced O
threshold O
to O
generate O
long O
- O
term O
potentiation O
( O
LTP O
) O
in O
hippocampal O
dentate O
gyrus O
, O
and O
increased O
nNOS O
activity O
in O
this O
structure O
. O

The O
opposite O
occurred O
when O
cGMP B
availability O
was O
increased O
. O

CONCLUSION O
: O
We O
demonstrate O
a O
key O
role O
of O
the O
nNOS O
activity O
and O
NO B
/ O
sGC O
/ O
cGMP B
signaling O
pathway O
in O
the O
development O
of O
cocaine B
sensitization O
and O
in O
the O
associated O
enhancement O
of O
hippocampal O
synaptic O
transmission O
. O

A O
statistical O
approach O
for O
analyzing O
the O
development O
of O
( B
1 I
) I
H I
multiple O
- O
quantum O
coherence O
in O
solids O
. O

A O
novel O
statistical O
approach O
for O
analyzing O
( B
1 I
) I
H I
multiple O
- O
quantum O
( O
MQ O
) O
spin O
dynamics O
in O
so O
- O
called O
spin O
- O
counting O
solid O
- O
state O
NMR O
experiments O
is O
presented O
. O

The O
statistical O
approach O
is O
based O
on O
the O
percolation O
theory O
with O
Monte O
Carlo O
methods O
and O
is O
examined O
by O
applying O
it O
to O
the O
experimental O
results O
of O
three O
solid O
samples O
having O
unique O
hydrogen B
arrangement O
for O
1 O
- O
3 O
dimensions O
: O
the O
n O
- O
alkane O
/ O
d O
- O
urea O
inclusion O
complex O
as O
a O
one O
- O
dimensional O
( O
1D O
) O
system O
, O
whose O
( B
1 I
) I
H I
nuclei O
align O
approximately O
in O
1D O
, O
and O
magnesium O
hydroxide O
and O
adamantane B
as O
a O
two O
- O
dimensional O
( O
2D O
) O
and O
a O
three O
- O
dimensional O
( O
3D O
) O
system O
, O
respectively O
. O

Four O
lattice O
models O
, O
linear O
, O
honeycomb O
, O
square O
and O
cubic O
, O
are O
used O
to O
represent O
the O
( B
1 I
) I
H I
arrangement O
of O
the O
three O
samples O
. O

It O
is O
shown O
that O
the O
MQ O
dynamics O
in O
adamantane B
is O
consistent O
with O
that O
calculated O
using O
the O
cubic O
lattice O
and O
that O
in O
Mg O
( O
OH O
) O
2 O
with O
that O
calculated O
using O
the O
honeycomb O
and O
the O
square O
lattices O
. O

It O
is O
shown O
that O
a O
more O
realistic O
model O
representing O
the O
( B
1 I
) I
H I
arrangement O
of O
n O
- O
C20H42 O
/ O
d O
- O
urea O
can O
describe O
the O
result O
. O

The O
present O
approach O
can O
thus O
be O
used O
to O
determine O
( B
1 I
) I
H I
arrangement O
in O
solids O
. O

Graphene B
sheets O
: O
gram O
- O
scale O
synthesis O
of O
graphene B
sheets O
by O
a O
catalytic O
arc O
- O
discharge O
method O
( O
small O
8 O
/ O
2013 O
) O
. O

Gram O
- O
scale O
amounts O
of O
high O
- O
quality O
graphene B
sheets O
are O
synthesized O
on O
page O
1330 O
through O
an O
arc O
- O
discharge O
method O
. O

An O
arc O
, O
which O
is O
generated O
between O
two O
graphite B
rods O
when O
a O
high O
voltage O
is O
applied O
by O
Y O
. O

Liu O
and O
co O
- O
workers O
, O
can O
cause O
the O
graphite B
layers O
to O
separate O
into O
graphene B
sheets O
via O
a O
high O
- O
temperature O
exfoliation O
, O
or O
even O
broken O
into O
small O
clusters O
/ O
atoms O
, O
which O
then O
form O
graphene B
sheets O
by O
catalytic O
growth O
, O
demonstrating O
that O
two O
mechanisms O
exist O
in O
an O
arc O
discharge O
process O
simultaneously O
. O

Free O
radicals O
: O
free O
radical O
reactions O
in O
two O
dimensions O
: O
a O
case O
study O
on O
photochlorination O
of O
graphene B
( O
small O
8 O
/ O
2013 O
) O
. O

Graphene B
is O
a O
2D O
giant O
polycyclic O
aromatic O
molecule O
that O
provides O
opportunities O
for O
studying O
chemical O
reactions O
in O
two O
dimensions O
. O

Liu O
, O
and O
co O
- O
workers O
have O
systematically O
investigated O
the O
influence O
of O
specific O
features O
of O
2D O
molecules O
, O
such O
as O
their O
thickness O
, O
stacking O
order O
, O
single O
- O
and O
double O
- O
side O
upon O
graphene B
' O
s O
radical O
reactivity O
by O
utilizing O
a O
free O
radical O
photochlorination O
as O
a O
probe O
. O

The O
result O
, O
described O
on O
page O
1388 O
, O
can O
contribute O
to O
a O
deeper O
understanding O
of O
dimensionality O
effects O
for O
the O
chemistry O
of O
2D O
graphene B
. O

The O
interaction O
between O
the O
proteins O
ERCC1 O
and O
XPF O
, O
involves O
two O
major O
components O
of O
the O
nucleotide B
excision O
repair O
pathway O
. O

In O
particular O
, O
the O
compound O
labeled O
NSC130813 O
was O
shown O
to O
act O
synergistically O
with O
cisplatin B
and O
mitomycin B
C I
, O
to O
increase O
UVC O
mediated O
cytotoxicity O
, O
to O
modify O
DNA O
repair O
as O
indicated O
by O
the O
staining O
of O
phosphorylated O
H2AX O
and O
to O
disrupt O
interaction O
between O
ERCC1 O
and O
XPF O
in O
cells O
. O

A O
sub O
- O
monolayer O
distribution O
of O
isolated O
molecular O
Fe14 O
( O
bta O
) O
6 O
nanomagnets O
is O
deposited O
intact O
on O
a O
Au B
( I
111 I
) I
surface O
and O
investigated O
by O
X O
- O
ray O
magnetic O
circular O
dichroism O
spectroscopy O
. O

A O
His B
- O
tag O
was O
cloned O
at O
the O
N B
- O
terminus O
, O
along O
with O
R403Q O
, O
to O
facilitate O
isolation O
of O
myosin O
subfragment O
- O
1 O
( O
S1 O
) O
. O

Stopped O
- O
flow O
kinetics O
were O
used O
to O
measure O
the O
equilibrium O
constants O
and O
rates O
of O
nucleotide B
binding O
and O
release O
for O
the O
mouse O
S1 O
isoforms O
bound O
to O
actin O
. O

Introducing O
the O
R403Q O
mutation O
caused O
only O
a O
minor O
reduction O
in O
kinetics O
for O
beta O
- O
S1 O
, O
but O
R403Q O
in O
alpha O
- O
S1 O
caused O
the O
ADP B
release O
rate O
to O
increase O
by O
20 O
% O
( O
430 O
s O
- O
1 O
) O
. O

A O
new O
isobenzofuranone O
, O
4 O
- O
( O
methoxymethyl O
) O
- O
7 O
- O
methoxy O
- O
6 O
- O
methyl O
- O
1 O
( O
3H O
) O
- O
isobenzofuranone O
( O
1 O
) O
, O
together O
with O
seven O
known O
compounds O
, O
dilation O
( O
2 O
) O
, O
lumichrome O
( O
3 O
) O
, O
curvulari O
( O
4 O
) O
, O
5 O
, O
5 O
' O
- O
oxy O
- O
dimethylene O
- O
bis O
( O
2 O
- O
furaldehyde O
) O
( O
5 O
) O
, O
chromone B
( O
6 O
) O
, O
harman O
( O
1 O
- O
methyl O
- O
beta O
- O
carboline O
) O

( O
Aminoalkyl O
) O
fluoroindole O
derivatives O
were O
detected O
to O
be O
very O
potent O
MPO O
inhibitors O
; O
however O
, O
they O
also O
promote O
inhibition O
of O
the O
serotonin B
reuptake O
transporter O
( O
SERT O
) O
at O
the O
same O
concentration O
range O
. O

Via O
structure O
- O
based O
drug O
design O
, O
a O
new O
series O
of O
MPO O
inhibitors O
derived O
from O
3 O
- O
alkylindole O
were O
synthesized O
and O
their O
effects O
were O
assessed O
on O
MPO O
- O
mediated O
taurine B
chlorination O
and O
low O
- O
density O
lipoprotein O
oxidation O
as O
well O
as O
on O
inhibition O
of O
SERT O
. O

The O
fluoroindole O
compound O
with O
three O
carbons B
in O
the O
side O
chain O
and O
one O
amide B
group O
exhibited O
a O
selectivity O
index O
of O
35 O
( O
Ki O
/ O
IC50 O
) O
with O
high O
inhibition O
of O
MPO O
activity O
( O
IC50 O
= O
18 O
nM O
) O
, O
whereas O
its O
effect O
on O
SERT O
was O
in O
the O
micromolar O
range O
. O

Sacchathridine O
A O
, O
a O
Prostaglandin B
Release O
Inhibitor O
from O
Saccharothrix O
sp O
. O

Compound O
1 O
showed O
inhibitory O
activity O
of O
prostaglandin B
E2 I
release O
in O
a O
concentration O
- O
dependent O
manner O
from O
human O
synovial O
sarcoma O
cells O
, O
SW982 O
, O
with O
an O
IC50 O
value O
of O
1 O
. O
0 O
mu O
M O
, O
but O
had O
no O
effect O
on O
cell O
growth O
up O
to O
30 O
mu O
M O
. O

Design O
and O
synthesis O
of O
a O
tetrahydroisoquinoli B
- O
based O
hydroxamate B
derivative O
( O
ZYJ O
- O
34v O
) O
, O
an O
oral O
active O
histone O
deacetylase O
inhibitor O
with O
potent O
antitumor O
activity O
. O

In O
our O
previous O
study O
we O
developed O
a O
novel O
series O
of O
tetrahydroisoquinoli B
- O
based O
hydroxamic B
acid I
derivatives O
as O
histone O
deacetylase O
( O
HDAC O
) O
inhibitors O
( O
Bioorg O
. O
Med O
. O
Chem O
. O
, O
2010 O
, O
18 O
, O
1761 O
- O
1772 O
. O
, O
J O
. O
Med O
. O
Chem O
. O
, O
2011 O
, O
54 O
, O
2823 O
- O
2838 O
. O
) O
, O
among O
which O
compound O
ZYJ O
- O
34c O
( O
1 O
) O
was O
identified O
and O
validated O
as O
the O
most O
potent O
one O
with O
marked O
in O
vitro O
and O
in O
vivo O
antitumor O
potency O
( O
J O
. O
Med O
. O

Most O
importantly O
, O
compound O
2 O
exhibited O
similar O
even O
more O
potent O
in O
vitro O
and O
in O
vivo O
antitumor O
activities O
relative O
to O
the O
approved O
HDAC O
inhibitor O
SAHA B
This O
article O
is O
protected O
by O
copyright O
. O

Metabolism O
of O
2 O
, O
2 O
' O
, O
3 O
, O
3 O
' O
, O
6 O
, O
6 O
' O
- O
hexachlorobiphenyl O
( O
PCB O
136 O
) O
atropisomers O
in O
tissue O
slices O
from O
phenobarbital B
or O
dexamethasone B
- O
induced O
rats O
is O
sex O
- O
dependent O
. O

Chiral O
polychlorinated B
biphenyls I
( O
PCBs B
) O
such O
as O
PCB O
136 O
enantioselectively O
sensitize O
the O
ryanodine B
receptor O
( O
RyR O
) O
. O

In O
light O
of O
recent O
evidence O
that O
PCBs B
cause O
developmental O
neurotoxicity O
via O
RyR O
- O
dependent O
mechanisms O
, O
this O
suggests O
that O
enantioselective O
PCB B
metabolism O
may O
influence O
the O
developmental O
neurotoxicity O
of O
chiral O
PCBs B
. O

However O
, O
enantioselective O
disposition O
of O
PCBs B
has O
not O
been O
fully O
characterized O
. O

The O
effect O
of O
sex O
and O
cytochrome O
P450 O
( O
P450 O
) O
enzyme O
induction O
on O
the O
enantioselective O
metabolism O
of O
PCB O
136 O
was O
studied O
using O
liver O
tissue O
slices O
prepared O
from O
na O
i O
ve O
control O
( O
CTL O
) O
, O
phenobarbital B
( O
PB O
; O
CYP2B O
inducer O
) O
or O
dexamethasone B
( O
DEX B
; O
CYP3A O
inducer O
) O
pretreated O
adult O
Sprague O
- O
Dawley O
rats O
. O

In O
liver O
tissue O
slices O
, O
hydroxylated O
PCB O
( O
OH O
- O
PCB O
) O
profiles O
depended O
on O
sex O
and O
inducer O
pretreatment O
, O
and O
OH O
- O
PCB O
levels O
followed O
the O
rank O
orders O
male O
> O
female O
and O
PB O
> O
DEX B
> O
CTL O
. O

Our O
results O
suggest O
that O
enantioselective O
metabolism O
, O
sex O
and O
induction O
status O
of O
P450 O
enzymes O
in O
the O
liver O
may O
modulate O
the O
neurotoxic O
outcomes O
of O
developmental O
exposure O
to O
chiral O
PCBs B
. O

Two O
monomers O
that O
undergo O
different O
click O
reactions O
, O
pentafluorophenyl O
acrylate O
( O
PFPA O
) O
and O
4 O
- O
( O
trimethylsilyl O
) O
ethynylstyrene O
( O
TMSES O
) O
, O
were O
sequentially O
polymerized O
from O
a O
silicon B
surface O
in O
the O
presence O
of O
a O
shadowmask O
with O
UV O
light O
, O
generating O
12 O
. O
5 O
and O
62 O
mu O
m O
pitch O
patterns O
. O

Two O
different O
dyes O
, O
1 O
- O
aminomethylpyrene O
( O
AMP B
) O
and O
5 O
- O
azidofluorescein O
( O
AF O
) O
, O
were O
covalently O
attached O
to O
the O
polymer O
brushes O
through O
aminolysis O
and O
dual O
desilylation O
/ O
copper B
( I
I I
) I
- O
catalyzed O
alkyne B
/ O
azide B
cycloaddition O
( O
CuAAC O
) O
in O
one O
pot O
. O

Agonism O
of O
human O
pregnane B
X O
receptor O
by O
rilpivirine O
and O
etravirine O
: O
Comparison O
with O
first O
generation O
non O
- O
nucleoside B
reverse O
transcriptase O
inhibitors O
. O

Rilpivirine O
and O
etravirine O
are O
second O
generation O
non O
- O
nucleoside B
reverse O
transcriptase O
inhibitors O
approved O
recently O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
- O
1 O
infection O
. O

Pregnane B
X O
receptor O
( O
PXR O
) O
is O
a O
member O
of O
the O
superfamily O
of O
nuclear O
receptors O
that O
regulate O
the O
expression O
of O
various O
genes O
controlling O
diverse O
biological O
functions O
. O

The O
present O
study O
investigated O
the O
effects O
of O
rilpivirine O
and O
etravirine O
on O
the O
activity O
of O
human O
PXR O
( O
hPXR O
) O
, O
including O
the O
mode O
of O
activation O
, O
and O
compared O
them O
to O
those O
of O
efavirenz O
, O
nevirapine B
, O
and O
delavirdine O
, O
which O
are O
first O
generation O
non O
- O
nucleoside B
reverse O
transcriptase O
inhibitors O
. O

In O
transiently O
transfected O
HepG2 O
cells O
, O
rilpivirine O
, O
etravirine O
, O
and O
efavirenz O
, O
but O
not O
nevirapine B
or O
delavirdine O
, O
activated O
human O
, O
mouse O
, O
and O
rat O
PXR O
. O

Results O
from O
mechanistic O
studies O
indicated O
that O
rilpivirine O
, O
etravirine O
, O
and O
efavirenz O
, O
but O
not O
nevirapine B
or O
delavirdine O
, O
bound O
to O
the O
ligand O
- O
binding O
domain O
of O
hPXR O
, O
as O
assessed O
by O
a O
transactivation O
assay O
and O
by O
a O
competitive O
ligand O
- O
binding O
assay O
using O
time O
- O
resolved O
fluorescence O
resonance O
energy O
transfer O
; O
triggered O
nuclear O
translocation O
of O
a O
green O
fluorescence O
protein O
- O
tagged O
hPXR O
, O
as O
visualized O
by O
confocal O
imaging O
; O
and O
recruited O
steroid B
receptor O
coactivator O
- O
1 O
( O

Rilpivirine O
, O
etravirine O
, O
and O
efavirenz O
, O
but O
not O
nevirapine B
or O
delavirdine O
, O
increased O
hPXR O
target O
gene O
( O
CYP3A4 O
) O
expression O
in O
primary O
cultures O
of O
human O
hepatocytes O
. O

In O
summary O
, O
select O
non O
- O
nucleoside B
reverse O
transcriptase O
inhibitors O
activated O
human O
and O
rodent O
PXR O
. O

Rilpivirine O
, O
etravirine O
, O
and O
efavirenz O
, O
but O
not O
nevirapine B
or O
delavirdine O
, O
were O
identified O
as O
agonists O
of O
hPXR O
, O
as O
assessed O
in O
mechanistic O
experiments O
, O
and O
inducers O
of O
CYP3A4 O
, O
as O
determined O
in O
primary O
cultures O
of O
human O
hepatocytes O
. O

The O
IC50 O
values O
were O
1 O
. O
61 O
mu O
g O
/ O
mL O
, O
20 O
. O
06 O
mu O
g O
/ O
mL O
, O
34 O
. O
76 O
mu O
g O
/ O
mL O
( O
CYP3A4 O
/ O
midazolam B
) O
, O
46 O
. O
73 O
mu O
g O
/ O
mL O
( O
CYP3A4 O
/ O
testosterone B
) O
, O
and O
54 O
. O
52 O
mu O
g O
/ O
mL O
, O
respectively O
. O

The O
synthesis O
of O
racemic O
tetrahydrocurcumin O
- O
( O
THC B
- O
) O
, O
tetrahydrodemethoxyc O
- O
( O
THDC O
- O
) O
and O
tetrahydrobisdemetho O
- O
( O
THBDC O
- O
) O
dihydropyrimidinone O
( O
DHPM O
) O
analogues O
was O
achieved O
by O
utilizing O
the O
multi O
- O
component O
Biginelli O
reaction O
in O
the O
presence O
of O
copper O
sulphate O
as O
a O
catalyst O
. O

THBDC O
- O
DHPM O
demonstrated O
the O
most O
potent O
inhibitory O
activity O
with O
an O
IC50 O
value O
of O
1 O
. O
34 O
+ O
/ O
- O
0 O
. O
03 O
mu O
M O
which O
was O
more O
active O
than O
the O
approved O
drug O
galanthamine B
( O
IC50 O
= O
1 O
. O
45 O
+ O
/ O
- O
0 O
. O
04 O
mu O
M O
) O
. O

Design O
considerations O
for O
PAMAM B
dendrimer O
therapeutics O
. O

We O
have O
previously O
shown O
that O
methotrexate B
( O
MTX B
) O
conjugated O
to O
a O
cancer O
- O
specific O
poly O
amido O
amine O
( O
PAMAM B
) O
dendrimer O
has O
a O
higher O
therapeutic O
index O
than O
MTX B
alone O
. O

We O
wished O
to O
address O
these O
obstacles O
by O
using O
copper B
- O
free O
click O
chemistry O
to O
functionalize O
the O
dendrimer O
scaffolds O
and O
to O
exploring O
the O
effects O
of O
two O
dendrimer O
properties O
( O
the O
targeting O
ligand O
and O
drug O
linkage O
) O
on O
cytotoxicity O
. O

We O
conjugated O
either O
ester B
or O
amide B
- O
linker O
modified O
MTX B
to O
dendrimer O
scaffolds O
with O
or O
without O
folic B
acid I
( O
FA O
) O
. O

Because O
of O
multivalency O
, O
the O
FA O
and O
MTX B
functionalized O
dendrimers O
had O
similar O
capacities O
to O
target O
the O
folate B
receptor O
on O
cancer O
cells O
. O

Additionally O
, O
we O
found O
that O
the O
ester B
- O
and O
amide B
- O
linker O
modified O
MTX B
compounds O
had O
similar O
cytotoxicity O
but O
the O
dendrimer O
- O
ester B
MTX B
conjugates O
were O
much O
more O
cytotoxic O
than O
the O
dendrimer O
- O
amide B
MTX B
conjugates O
. O

The O
results O
suggested O
that O
UPLC O
/ O
MS O
- O
based O
metabolic O
profiling O
of O
rat O
urine O
identifies O
impaired O
tryptophan B
metabolism O
as O
the O
mechanism O
of O
yeast O
- O
induced O
fever O
. O

This O
research O
provided O
informative O
data O
that O
the O
impaired O
tryptophan B
metabolism O
might O
be O
one O
of O
the O
important O
reasons O
in O
elucidating O
the O
biochemical O
basis O
of O
the O
febrile O
response O
. O

Melanoidins O
are O
brown O
, O
nitrogen B
containing O
, O
high O
molecular O
weight O
end O
products O
of O
Maillard O
reaction O
with O
poorly O
established O
activity O
towards O
tumor O
cells O
. O

Short O
- O
term O
heating O
reduces O
the O
anti O
- O
inflammatory O
effects O
of O
fresh O
raw O
garlic O
extracts O
on O
the O
LPS O
- O
induced O
production O
of O
NO B
and O
pro O
- O
inflammatory O
cytokines O
by O
downregulating O
allicin O
activity O
in O
RAW O
264 O
. O
7 O
macrophages O
. O

Treatment O
with O
FRGE O
and O
HRGE O
significantly O
reduced O
the O
LPS O
- O
induced O
increase O
in O
the O
pro O
- O
inflammatory O
cytokine O
concentration O
( O
TNF O
- O
alpha O
, O
IL O
- O
1 O
beta O
, O
and O
IL O
- O
6 O
) O
and O
NO B
through O
HO O
- O
1 O
upregulation O
in O
RAW O
264 O
. O
7 O
macrophages O
. O

Allicin O
treatment O
showed O
reduced O
production O
of O
pro O
- O
inflammatory O
cytokines O
and O
NO B
and O
increased O
HO O
- O
1 O
activity O
. O

The O
results O
show O
that O
the O
decrease O
in O
LPS O
- O
induced O
NO B
and O
pro O
- O
inflammatory O
cytokines O
in O
RAW O
264 O
. O
7 O
macrophages O
through O
HO O
- O
1 O
induction O
was O
greater O
for O
FRGE O
compared O
with O
HRGE O
. O

Recently O
, O
the O
P2X7 O
receptor O
for O
ATP B
was O
reported O
to O
display O
neurotoxic O
potential O
in O
motor O
neuron O
disorders O
, O
and O
antagonism O
of O
the O
receptor O
has O
been O
suggested O
to O
be O
helpful O
in O
these O
disorders O
. O

Studying O
transgenic O
mice O
with O
superoxide B
dismutase O
1 O
gene O
mutations O
, O
widely O
used O
as O
model O
for O
ALS O
, O
may O
provide O
a O
better O
understanding O
of O
pathogenic O
mechanisms O
and O
of O
toxicity O
towards O
motor O
neurons O
, O
also O
possibly O
helping O
to O
understand O
whether O
treatments O
for O
ALS O
should O
take O
into O
account O
sexual O
dimorphism O
. O

The O
aim O
of O
the O
work O
was O
( O
1 O
) O
investigating O
on O
gender O
- O
dependence O
of O
disease O
progression O
in O
the O
standard O
model O
for O
ALS O
- O
the O
transgenic O
mouse O
bearing O
superoxide B
dismutase O
1 O
gene O
mutations O
- O
and O
( O
2 O
) O
assessing O
if O
a O
P2X7 O
receptor O
antagonist O
treatment O
should O
take O
into O
account O
sexual O
dimorphism O
. O

We O
evaluated O
if O
gender O
affect O
the O
disease O
course O
, O
the O
motor O
performance O
, O
the O
weight O
loss O
and O
the O
lifespan O
in O
mice O
overexpressing O
mutant O
superoxide B
dismutase O
1 O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
- O
induced O
inflammatory O
activation O
is O
mediated O
by O
intracellular O
free O
calcium B
in O
microglial O
cells O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues O
. O

However O
, O
the O
adverse O
effects O
of O
TCDD B
on O
the O
central O
nervous O
system O
( O
CNS O
) O
have O
not O
been O
entirely O
elucidated O
. O

In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
( O
RT O
- O
PCR O
) O
and O
ELISA O
, O
we O
showed O
that O
TCDD B
up O
- O
regulated O
the O
expression O
and O
secretion O
of O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
in O
a O
time O
- O
dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O

TCDD B
also O
caused O
a O
fast O
( O
within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level O
) O
activation O
of O
cytosolic O
phospholipase O
A2 O
( O
cPLA2 O
) O
. O

This O
initial O
action O
was O
accompanied O
by O
up O
- O
regulation O
of O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD B
treatment O
. O

These O
pro O
- O
inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca B
( I
2 I
+ I
) I
blockers O
, O
bis O
- O
( O
o O
- O
aminophenoxy O
) O
ethane O
- O
N O
, O
N O
, O
N O
' O
, O
N O
' O
- O
tetra O
- O
acetic O
acid O
acetoxymethyl O
ester O
( O
BAPTA B
- I
AM I
) O
and O
nifedipine B
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca B
( I
2 I
+ I
) I
( O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
) O
. O

Further O
, O
TCDD B
exposure O
could O
induce O
phosphorylation O
- O
and O
ubiquitination O
- O
dependent O
degradation O
of O
I O
k O
B O
alpha O
, O
and O
the O
translocation O
of O
NF O
- O
kappa O
B O
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O

Thus O
, O
the O
NF O
- O
kappa O
B O
signaling O
pathway O
can O
be O
activated O
after O
TCDD B
treatment O
. O

However O
, O
Ca B
( I
2 I
+ I
) I
blockers O
also O
obviously O
attenuated O
NF O
- O
kappa O
B O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD B
. O

In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro O
- O
inflammatory O
cytokine O
and O
NF O
- O
kappa O
B O
activation O
induced O
by O
TCDD B
can O
be O
mediated O
by O
elevation O
of O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
in O
HAPI O
microglial O
cells O
. O

MATERIAL O
AND O
METHODS O
: O
The O
antioxidant O
activity O
of O
MPG O
leaf O
hydromethanolic O
extract O
was O
determined O
by O
using O
both O
the O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
radical O
scavenging O
and O
the O
oxygen B
radical O
absorbance O
capacity O
in O
vitro O
assays O
. O

The O
vasorelaxant O
effect O
of O
MPG O
extract O
was O
studied O
on O
rat O
arterial O
rings O
pre O
- O
contracted O
with O
phenylephrine B
( O
1 O
mu O
M O
) O
in O
the O
presence O
or O
absence O
of O
the O
endothelium O
. O

It O
induced O
endothelium O
- O
dependent O
, O
NO B
- O
mediated O
relaxation O
of O
rat O
aorta O
and O
pulmonary O
artery O
. O

This O
effect O
was O
associated O
with O
a O
restoration O
of O
endothelium O
function O
and O
a O
2 O
. O
3 O
- O
fold O
increase O
in O
endothelial O
NO B
synthase O
phosphorylation O
. O

MPG O
leaf O
hydromethanolic O
extract O
contained O
tryptophan B
and O
flavonoids B
, O
including O
quercetin B
glycosides I
. O

The O
ATP B
required O
for O
potentiation O
of O
skeletal O
muscle O
contraction O
is O
released O
via O
pannexin O
hemichannels O
. O

During O
repetitive O
stimulation O
of O
skeletal O
muscle O
, O
extracellular O
ATP B
levels O
raise O
, O
activating O
purinergic O
receptors O
, O
increasing O
Ca B
( I
2 I
+ I
) I
influx O
, O
and O
enhancing O
contractile O
force O
, O
a O
response O
called O
potentiation O
. O

We O
found O
that O
ATP B
appears O
to O
be O
released O
through O
pannexin1 O
hemichannels O
( O
Panx1 O
HCs O
) O
. O

Immunocytochemical O
analyses O
and O
function O
were O
consistent O
with O
pannexin1 O
localization O
to O
T O
- O
tubules O
intercalated O
with O
dihydropyridine B
and O
ryanodine B
receptors O
in O
slow O
( O
soleus O
) O
and O
fast O
( O
extensor O
digitorum O
longus O
, O
EDL O
) O
muscles O
. O

Isolated O
myofibers O
took O
up O
ethidium O
( O
Etd O
( O
+ O
) O
) O
and O
released O
small O
molecules O
( O
as O
ATP B
) O
during O
electrical O
stimulation O
. O

Consistent O
with O
two O
glucose B
uptake O
pathways O
, O
induced O
uptake O
of O
2 O
- O
NBDG O
, O
a O
fluorescent O
glucose B
derivative O
, O
was O
decreased O
by O
inhibition O
of O
HCs O
or O
glucose B
transporter O
( O
GLUT4 O
) O
, O
and O
blocked O
by O
dual O
blockade O
. O

ATP B
release O
, O
Etd O
( O
+ O
) O
uptake O
, O
and O
potentiation O
induced O
by O
repetitive O
electrical O
stimulation O
were O
blocked O
by O
HC O
blockers O
and O
did O
not O
occur O
in O
muscles O
of O
pannexin1 O
knockout O
mice O
. O

MRS2179 O
, O
a O
P2Y1R O
blocker O
, O
prevented O
potentiation O
in O
EDL O
, O
but O
not O
soleus O
muscles O
, O
suggesting O
that O
in O
fast O
muscles O
ATP B
activates O
P2Y1 O
but O
not O
P2X O
receptors O
. O

Phosphorylation O
on O
Ser B
and O
Thr B
residues O
of O
pannexin1 O
was O
increased O
during O
potentiation O
, O
possibly O
mediating O
HC O
opening O
. O

Opening O
of O
Panx1 O
HCs O
during O
repetitive O
activation O
allows O
efflux O
of O
ATP B
, O
influx O
of O
glucose B
and O
possibly O
Ca B
( I
2 I
+ I
) I
too O
, O
which O
are O
required O
for O
potentiation O
of O
contraction O
. O

Genetic O
deletion O
of O
the O
adenosine B
A2A O
receptor O
prevents O
nicotine B
- O
induced O
upregulation O
of O
alpha O
7 O
, O
but O
not O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine B
receptor O
binding O
in O
the O
brain O
. O

Considerable O
evidence O
indicates O
that O
adenosine B
A2A O
receptors O
( O
A2ARs O
) O
modulate O
cholinergic O
neurotransmission O
, O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
function O
, O
and O
nicotine B
- O
induced O
behavioural O
effects O
. O

To O
explore O
the O
interaction O
between O
A2A O
and O
nAChRs O
, O
we O
examined O
if O
the O
complete O
genetic O
deletion O
of O
adenosine B
A2ARs O
in O
mice O
induces O
compensatory O
alterations O
in O
the O
binding O
of O
different O
nAChR O
subtypes O
, O
and O
whether O
the O
long O
- O
term O
effects O
of O
nicotine B
on O
nAChR O
regulation O
are O
altered O
in O
the O
absence O
of O
the O
A2AR O
gene O
. O

Quantitative O
autoradiography O
was O
used O
to O
measure O
cytisine O
- O
sensitive O
[ O
( O
125 O
) O
I O
] O
epibatidine O
and O
[ O
( B
125 I
) I
I I
] O
alpha O
- O
bungarotoxin O
binding O
to O
alpha O
4 O
beta O
2 O
* O
and O
alpha O
7 O
nAChRs O
, O
respectively O
, O
in O
brain O
sections O
of O
drug O
- O
na O
i O
ve O
( O
n O
= O
6 O
) O
or O
nicotine B
treated O
( O
n O
= O
5 O
- O
7 O
) O
, O
wild O
- O
type O
and O
adenosine B
A2AR O
knockout O
mice O
. O

Saline O
or O
nicotine B
( O
7 O
. O
8 O
mg O
/ O
kg O
/ O
day O
; O
free O
- O
base O
weight O
) O
were O
administered O
to O
male O
CD1 O
mice O
via O
subcutaneous O
osmotic O
minipumps O
for O
a O
period O
of O
14 O
days O
. O

Blood O
plasma O
levels O
of O
nicotine B
and O
cotinine B
were O
measured O
at O
the O
end O
of O
treatment O
. O

In O
nicotine B
treated O
wild O
- O
type O
mice O
, O
both O
alpha O
4 O
beta O
2 O
* O
and O
alpha O
7 O
nAChR O
binding O
sites O
were O
increased O
compared O
with O
saline O
treated O
controls O
. O

The O
genetic O
ablation O
of O
adenosine B
A2ARs O
prevented O
nicotine B
- O
induced O
upregulation O
of O
alpha O
7 O
nAChRs O
, O
without O
affecting O
alpha O
4 O
beta O
2 O
* O
receptor O
upregulation O
. O

This O
selective O
effect O
was O
observed O
at O
plasma O
levels O
of O
nicotine B
that O
were O
within O
the O
range O
reported O
for O
smokers O
( O
10 O
- O
50 O
ng O
ml O
( O
- O
1 O
) O
) O
. O

Our O
data O
highlight O
the O
involvement O
of O
adenosine B
A2ARs O
in O
the O
mechanisms O
of O
nicotine B
- O
induced O
alpha O
7 O
nAChR O
upregulation O
, O
and O
identify O
A2ARs O
as O
novel O
pharmacological O
targets O
for O
modulating O
the O
long O
- O
term O
effects O
of O
nicotine B
on O
alpha O
7 O
receptors O
. O

Simultaneous O
determination O
of O
methanol B
, O
acetaldehyde B
, O
acetone B
, O
and O
ethanol B
in O
human O
blood O
by O
gas O
chromatography O
with O
flame O
ionization O
detection O
. O

Background O
: O
Methanol B
, O
acetaldehyde B
, O
acetone B
, O
and O
ethanol B
, O
which O
are O
commonly O
used O
as O
biomarkers O
of O
several O
diseases O
, O
in O
acute O
intoxications O
, O
and O
forensic O
settings O
, O
can O
be O
detected O
and O
quantified O
in O
biological O
fluids O
. O

Gas O
chromatographic O
determinations O
of O
ethanol B
, O
methanol B
, O
and O
acetone B
have O
been O
reported O
in O
one O
study O
with O
suboptimal O
accuracy O
. O

We O
used O
a O
dimethylpolysiloxane O
capillary O
column O
of O
30 O
m O
0 O
. O
25 O
mm O
0 O
. O
25 O
micro O
m O
. O
Results O
: O
We O
observed O
linear O
correlations O
from O
7 O
. O
5 O
to O
240 O
mg O
/ O
l O
for O
methanol B
, O
acetaldehyde B
, O
and O
acetone B
and O
from O
75 O
to O
2400 O
mg O
/ O
l O
for O
ethanol B
. O

Precision O
at O
concentrations O
15 O
, O
60 O
, O
and O
120 O
mg O
/ O
l O
for O
methanol B
, O
acetaldehyde B
, O
and O
acetone B
and O
150 O
, O
600 O
, O
and O
1200 O
mg O
/ O
ml O
for O
ethanol B
were O
0 O
. O
8 O
- O
6 O
. O
9 O
% O
. O

Ranges O
of O
accuracy O
were O
94 O
. O
7 O
- O
98 O
. O
9 O
% O
for O
methanol B
, O
91 O
. O
2 O
- O
97 O
. O
4 O
% O
for O
acetaldehyde B
, O
96 O
. O
1 O
- O
98 O
. O
7 O
% O
for O
acetone B
, O
and O
105 O
. O
5 O
- O
111 O
. O
6 O
% O
for O
ethanol B
. O

Limits O
of O
detection O
were O
0 O
. O
80 O
mg O
/ O
l O
for O
methanol B
, O
0 O
. O
61 O
mg O
/ O
l O
for O
acetaldehyde B
, O
0 O
. O
58 O
mg O
/ O
l O
for O
acetone B
, O
and O
0 O
. O
53 O
mg O
/ O
l O
for O
ethanol B
. O
Conclusion O
: O
This O
method O
is O
suitable O
for O
routine O
clinical O
and O
forensic O
practices O
. O

There O
is O
acceptance O
of O
prediabetes O
defined O
by O
impaired O
fasting O
glucose B
( O
IFG O
) O
and O
impaired O
glucose B
tolerance O
( O
IGT O
) O
, O
but O
there O
is O
some O
controversy O
surrounding O
HbA1c O
- O
defined O
prediabetes O
ranges O
, O
with O
some O
favouring O
6 O
. O
0 O
- O
6 O
. O
4 O
% O
( O
42 O
- O
46 O
mmol O
/ O
mol O
) O
. O

Antibacterial O
oxazolidinone B
analogues O
having O
a O
N O
- O
hydroxyacetyl O
- O
substituted O
seven O
- O
membered O
[ O
1 O
, O
2 O
, O
5 O
] O
triazepane O
or O
[ O
1 O
, O
2 O
, O
5 O
] O
oxadiazepane O
C B
- O
ring O
unit O
. O

We O
synthesized O
a O
series O
of O
oxazolidinone B
analogues O
bearing O
a O
N O
- O
hydroxyacetyl O
- O
substituted O
[ O
1 O
, O
2 O
, O
5 O
] O
triazepane O
or O
[ O
1 O
, O
2 O
, O
5 O
] O
oxadiazepane O
C B
- O
ring O
unit O
as O
homologues O
of O
an O
earlier O
drug O
candidate O
, O
eperezolid O
. O

Several O
of O
these O
compounds O
exhibited O
potent O
in O
vitro O
antibacterial O
activities O
towards O
not O
only O
Gram O
- O
positive O
, O
but O
also O
Gram O
- O
negative O
and O
linezolid B
- O
resistant O
pathogens O
. O

Compounds O
21a O
and O
21b O
, O
bearing O
a O
thiocarbamate O
side O
chain O
, O
showed O
high O
in O
vivo O
activity O
against O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
SR3637 O
, O
together O
with O
a O
promising O
safety O
profile O
in O
terms O
of O
weak O
inhibition O
of O
monoamine B
oxidase O
and O
cytochrome O
P450 O
isozymes O
. O

Proteasomal O
cleavage O
site O
prediction O
of O
protein O
antigen O
using O
BP O
neural O
network O
based O
on O
a O
new O
set O
of O
amino B
acid I
descriptor O
. O

The O
accuracy O
of O
the O
prediction O
model O
, O
which O
depends O
on O
the O
window O
sizes O
of O
the O
cleavage O
, O
reaches O
95 O
. O
454 O
% O
for O
the O
N B
- O
terminus O
and O
95 O
. O
011 O
% O
for O
the O
C B
- O
terminus O
. O

The O
results O
show O
that O
the O
identification O
of O
proteasomal O
cleavage O
sites O
depends O
on O
the O
sequence O
next O
to O
it O
and O
that O
the O
prediction O
performance O
of O
the O
C B
- O
terminus O
is O
better O
than O
that O
of O
the O
N B
- O
terminus O
on O
average O
. O

Thus O
, O
models O
based O
on O
the O
properties O
of O
amino B
acids I
can O
be O
highly O
reliable O
and O
reflect O
the O
structural O
features O
of O
interactions O
between O
proteasomes O
and O
peptide O
sequences O
. O

Effects O
of O
Dietary O
Factors O
on O
the O
Pharmacokinetics O
of O
( O
58 O
) O
Fe O
- O
labeled O
Hemin O
After O
Oral O
Administration O
in O
Normal O
Rats O
and O
the O
Iron B
- O
deficient O
Rats O
. O

Hemin O
, O
iron O
( O
III O
) O
protoporphyrin O
chloride O
( O
IX O
) O
, O
as O
a O
stable O
form O
of O
heme B
iron B
, O
has O
been O
used O
in O
iron B
absorption O
studies O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
elucidate O
the O
influences O
of O
body O
iron B
status O
and O
three O
dietary O
factors O
( O
green O
tea O
extract O
, O
ascorbic B
acid I
, O
and O
calcium B
) O
on O
the O
pharmacokinetics O
of O
hemin O
using O
stable O
isotope O
labeling O
methods O
followed O
by O
ICP O
- O
MS O
measurement O
. O

In O
this O
study O
, O
a O
rapid O
, O
sensitive O
, O
and O
specific O
ICP O
- O
MS O
method O
for O
the O
determination O
of O
( O
58 O
) O
Fe O
originating O
from O
hemin O
in O
rat O
plasma O
was O
developed O
and O
a O
rat O
model O
of O
iron B
deficiency O
anemia O
was O
established O
. O

It O
was O
found O
that O
hemin O
iron B
absorption O
increased O
significantly O
under O
iron B
deficiency O
anemia O
status O
, O
with O
AUC0 O
- O
t O
and O
AUC0 O
- O
infinity O
showing O
significant O
increase O
in O
anemic O
rats O
compared O
to O
normal O
ones O
. O

Green O
tea O
extract O
strongly O
inhibited O
hemin O
iron B
absorption O
in O
both O
normal O
rats O
and O
iron B
- O
deficient O
rats O
. O

On O
the O
other O
hand O
, O
ascorbic B
acid I
significantly O
affected O
hemin O
iron B
absorption O
only O
in O
iron B
- O
deficient O
rats O
, O
in O
which O
C O
max O
showed O
a O
significant O
increase O
. O

Interestingly O
, O
calcium B
slowed O
down O
the O
hemin O
iron B
absorption O
rate O
in O
normal O
rats O
, O
MRT0 O
- O
t O
being O
significantly O
different O
in O
calcium B
- O
treated O
animals O
compared O
to O
untreated O
ones O
. O

This O
trend O
also O
appeared O
in O
the O
iron B
- O
deficient O
group O
but O
it O
did O
not O
reach O
statistical O
significance O
. O

Our O
data O
suggest O
that O
the O
mechanism O
of O
hemin O
iron B
absorption O
is O
regulated O
by O
body O
iron B
status O
and O
dietary O
factors O
can O
influence O
hemin O
iron B
absorption O
to O
varying O
degrees O
. O

Moreover O
, O
these O
results O
may O
also O
have O
general O
implication O
in O
the O
iron B
deficiency O
treatment O
with O
iron B
supplements O
and O
fortification O
of O
foods O
. O

Two O
highly O
engineered O
halohydrin O
dehalogenase O
variants O
were O
characterized O
in O
terms O
of O
their O
performance O
in O
dehalogenation O
and O
epoxide B
cyanolysis O
reactions O
. O

Crystal O
structures O
of O
this O
enzyme O
were O
elucidated O
with O
chloride B
and O
ethyl O
( O
S O
) O
- O
3 O
, O
4 O
- O
epoxybutyrate O
or O
with O
ethyl O
( O
R O
) O
- O
4 O
- O
cyano O
- O
3 O
- O
hydroxybutyrate O
bound O
in O
the O
active O
site O
. O

Fine O
Tuning O
of O
the O
Structure O
of O
Pt O
- O
Cu O
Alloy O
Nanocrystals O
by O
Glycine B
- O
Mediated O
Sequential O
Reduction O
Kinetics O
. O

Uniform O
Pt O
- O
Cu O
alloy O
nanocrystals O
in O
the O
shape O
of O
dendrite O
, O
, O
yolk O
- O
cage O
, O
and O
box O
structures O
are O
prepared O
via O
a O
facile O
wet O
- O
chemical O
reduction O
route O
in O
which O
glycine B
is O
demonstrated O
to O
alter O
the O
reduction O
kinetics O
of O
metal O
cations O
, O
critical O
to O
the O
morphology O
of O
the O
obtained O
product O
. O

These O
alloy O
nanocrystals O
exhibit O
superior O
specific O
activity O
and O
stability O
in O
the O
electro O
- O
oxidation O
of O
methanol B
. O

OBJECTIVE O
: O
Low O
thyroid O
function O
may O
be O
associated O
with O
a O
reduced O
glomerular O
filtration O
rate O
( O
GFR O
) O
calculated O
on O
the O
basis O
of O
creatinine B
metabolism O
. O

Thyroid B
hormone I
directly O
affects O
serum O
creatinine B
in O
muscle O
and O
low O
thyroid O
function O
might O
exert O
a O
similar O
direct O
effect O
in O
the O
kidney O
. O

PATIENTS O
AND O
METHODS O
: O
Renal O
and O
glomerular O
hemodynamics O
were O
assessed O
by O
simultaneous O
measurements O
of O
plasma O
clearance O
of O
para O
- O
aminohippurate O
( O
CPAH O
) O
and O
inulin O
( O
Cin O
) O
in O
26 O
patients O
with O
serum O
creatinine B
< O
1 O
. O
00 O
mg O
/ O
dl O
and O
without O
thyroid O
disease O
. O

All O
subjects O
were O
normotensive O
with O
or O
without O
antihypertensive O
treatment O
and O
were O
kept O
in O
a O
sodium B
- O
replete O
state O
. O

Molecular O
- O
Beam O
Optical O
Stark O
and O
Zeeman O
Study O
of O
the O
[ O
17 O
. O
8 O
] O
0 O
( O
+ O
) O
- O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
( O
0 O
, O
0 O
) O
Band O
System O
of O
AuF B
. O

The O
[ O
17 O
. O
8 O
] O
0 O
( O
+ O
) O
- O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
( O
0 O
, O
0 O
) O
band O
of O
gold O
monofluoride O
, O
AuF B
, O
has O
been O
recorded O
at O
a O
resolution O
of O
40 O
MHz O
both O
field O
free O
and O
in O
the O
presence O
of O
a O
static O
electric O
and O
magnetic O
field O
. O

Dynamic O
and O
Electronic O
Transport O
Properties O
of O
DNA O
Translocation O
through O
Graphene B
Nanopores O
. O

Graphene B
layers O
have O
been O
targeted O
in O
the O
last O
years O
as O
excellent O
host O
materials O
for O
sensing O
a O
remarkable O
variety O
of O
gases O
and O
molecules O
. O

This O
has O
automatically O
led O
scientists O
to O
probe O
graphene B
as O
a O
potential O
platform O
for O
sequencing O
DNA O
strands O
. O

In O
this O
work O
, O
we O
use O
robust O
numerical O
tools O
to O
model O
the O
dynamic O
and O
electronic O
properties O
of O
molecular O
sensor O
devices O
composed O
of O
a O
graphene B
nanopore O
through O
which O
DNA O
molecules O
are O
driven O
by O
external O
electric O
fields O
. O

Our O
results O
reveal O
that O
one O
can O
have O
extra O
control O
on O
the O
DNA O
passage O
when O
four O
additional O
graphene B
layers O
are O
deposited O
on O
the O
top O
of O
the O
main O
graphene B
platform O
containing O
the O
pore O
in O
a O
2 O
x O
2 O
grid O
arrangement O
. O

The O
transmission O
obtained O
along O
the O
graphene B
sensor O
at O
the O
Fermi O
level O
is O
affected O
by O
the O
presence O
of O
the O
DNA O
. O

However O
, O
it O
is O
rather O
hard O
to O
distinguish O
the O
respective O
nucleobases B
. O

This O
scenario O
can O
be O
significantly O
altered O
when O
the O
transport O
is O
conducted O
away O
from O
the O
Fermi O
level O
of O
the O
graphene B
platform O
. O

Under O
an O
energy O
shift O
, O
we O
observed O
that O
the O
graphene B
pore O
manifests O
selectiveness O
toward O
DNA O
nucleobases B
. O

Upon O
their O
discovery O
almost O
40 O
years O
ago O
, O
isoforms O
of O
the O
lipid O
- O
activated O
protein O
kinase O
C O
( O
PKC O
) O
family O
were O
initially O
regarded O
only O
as O
downstream O
effectors O
of O
the O
second O
messengers O
calcium B
and O
diacylglycerol B
, O
undergoing O
activation O
upon O
phospholipid O
hydrolysis O
in O
response O
to O
acute O
stimuli O
. O

Subsequently O
, O
several O
isoforms O
were O
found O
to O
be O
associated O
with O
the O
inhibitory O
effects O
of O
lipid O
over O
- O
supply O
on O
glucose B
homeostasis O
, O
especially O
the O
negative O
cross O
- O
talk O
with O
insulin O
signal O
transduction O
, O
observed O
upon O
accumulation O
of O
diacylglycerol B
in O
insulin O
target O
tissues O
. O

Although O
PKCs O
may O
inhibit O
insulin O
signal O
transduction O
, O
these O
enzymes O
are O
not O
merely O
downstream O
effectors O
of O
lipid O
accumulation O
, O
but O
in O
fact O
control O
the O
fate O
of O
fatty B
acids I
, O
thus O
the O
tail O
wags O
the O
dog O
. O

Inhibition O
of O
TrkB O
tyrosine B
kinase O
signaling O
with O
k252a O
, O
or O
with O
the O
selective O
BDNF O
scavenger O
TrkB O
- O
Fc O
, O
both O
inhibited O
MF O
- O
LTP O
to O
the O
same O
extent O
as O
observed O
in O
BDNF O
+ O
/ O
- O
mice O
. O

Structure O
- O
activity O
relationships O
of O
hybrid O
annonaceous O
acetogenins O
: O
Powerful O
growth O
inhibitory O
effects O
of O
their O
connecting O
groups O
between O
heterocycle O
and O
hydrophobic O
carbon B
chain O
bearing O
THF B
ring O
on O
human O
cancer O
cell O
lines O
. O

It O
was O
revealed O
that O
the O
connecting O
group O
between O
the O
N O
- O
methylpyrazole O
part O
and O
the O
hydrophobic O
alkyl B
chain O
bearing O
the O
THF B
ring O
influenced O
their O
biological O
activities O
significantly O
. O

Amide B
- O
connected O
analog O
2 O
, O
in O
particular O
, O
showed O
selective O
and O
very O
potent O
activity O
( O
< O
10 O
nM O
) O
against O
some O
cancer O
cell O
lines O
. O

Antiulcer O
and O
gastric O
antisecretory O
effects O
of O
dichloromethane B
fraction O
and O
piplartine O
obtained O
from O
fruits O
of O
Piper O
tuberculatum O
Jacq O
. O
in O
rats O
. O

Thus O
, O
the O
current O
study O
aimed O
to O
investigate O
the O
gastroprotective O
and O
antisecretory O
properties O
of O
the O
dichloromethane B
fraction O
of O
the O
fruit O
of O
Piper O
tuberculatum O
( O
DFPT O
) O
and O
piplartine O
, O
a O
compound O
isolated O
from O
the O
DFPT O
, O
in O
rats O
. O

MATERIALS O
AND O
METHODS O
: O
Gastric O
ulcers O
were O
induced O
in O
fasted O
rats O
by O
oral O
administration O
of O
absolute O
ethanol B
and O
then O
mucus O
content O
and O
glutathione B
( O
GSH B
) O
levels O
were O
measured O
. O

Mechanisms O
underlying O
the O
antisecretory O
action O
were O
studied O
through O
gastric O
H B
( I
+ I
) I
, O
K B
( I
+ I
) I
- O
ATPase O
activity O
of O
highly O
purified O
rabbit O
gastric O
microsomes O
and O
pylorus O
ligature O
method O
in O
rats O
. O

The O
DFPT O
( O
ED50 O
= O
29mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
and O
piplartine O
( O
4 O
. O
5mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
promoted O
gastroprotection O
against O
acute O
lesions O
induced O
by O
ethanol B
, O
effect O
that O
could O
be O
related O
with O
the O
maintenance O
of O
GSH B
levels O
in O
the O
gastric O
mucosa O
. O

In O
vitro O
, O
the O
DFPT O
and O
piplartine O
inhibited O
the O
H B
( I
+ I
) I
, O
K B
( I
+ I
) I
- O
ATPase O
activity O
and O
, O
in O
vivo O
DFPT O
and O
piplartine O
also O
reduced O
basal O
gastric O
acid O
secretion O
, O
as O
well O
as O
that O
stimulated O
by O
pentagastrin O
. O

CONCLUSIONS O
: O
These O
results O
demonstrate O
that O
DFPT O
and O
piplatine O
cause O
marked O
gastroprotective O
effects O
accompanied O
by O
the O
increase O
and O
maintenance O
of O
gastric O
mucus O
and O
GSH B
levels O
, O
as O
well O
as O
a O
reduction O
in O
gastric O
acid O
secretion O
through O
the O
gastrinergic O
pathway O
. O

The O
bile B
salt I
export O
pump O
( O
BSEP O
or O
ABCB11 O
) O
prevents O
accumulation O
of O
toxic O
bile B
salt I
concentrations O
in O
hepatocytes O
, O
and O
BSEP O
inhibition O
or O
deficiency O
may O
cause O
cholestasis O
and O
liver O
injury O
. O

Additionally O
, O
examples O
are O
presented O
on O
the O
roles O
of O
nucleoside B
and O
peptide O
transporters O
in O
drug O
targeting O
and O
disposition O
. O
Clinical O
Pharmacology O
& O
Therapeutics O
( O
2013 O
) O
; O
accepted O
article O
preview O
online O
8 O
April O
2013 O
doi O
: O
10 O
. O
1038 O
/ O
clpt O
. O
2013 O
. O
74 O
. O

The O
self O
- O
assembly O
of O
short O
amino B
acid I
chains O
appears O
to O
be O
one O
of O
the O
most O
promising O
strategies O
for O
the O
fabrication O
of O
nanostructures O
. O

Their O
solubility O
in O
water O
and O
the O
possibility O
of O
chemical O
modification O
by O
targeting O
the O
amino B
or O
carboxyl B
terminus O
give O
peptide O
- O
based O
nanostructures O
several O
advantages O
over O
carbon B
nanotube O
nanostructures O
. O

Low O
allopurinol B
doses O
are O
sufficient O
to O
optimize O
azathioprine O
therapy O
in O
inflammatory O
bowel O
disease O
patients O
with O
inadequate O
thiopurine O
metabolite O
concentrations O
. O

PURPOSE O
: O
Recent O
studies O
in O
patients O
with O
inflammatory O
bowel O
diseases O
( O
IBD O
) O
on O
thiopurine O
therapy O
suggest O
that O
too O
low O
6 O
- O
thioguanine O
nucleotide O
concentrations O
( O
6 O
- O
TGN O
) O
and O
too O
high O
methylmercaptopurine O
nucleotide O
concentrations O
( O
MMPN O
) O
can O
be O
reversed O
by O
a O
combination O
therapy O
of O
allopurinol B
and O
low O
- O
dose O
thiopurines O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
minimal O
allopurinol B
doses O
necessary O
to O
achieve O
adequate O
6 O
- O
TGN O
concentrations O
in O
combination O
with O
low O
- O
dose O
azathioprine O
. O

METHODS O
: O
A O
stepwise O
dose O
- O
escalation O
of O
allopurinol B
was O
performed O
in O
11 O
azathioprine O
- O
pretreated O
IBD O
patients O
with O
inadequately O
low O
6 O
- O
TGN O
concentrations O
( O
< O
235 O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
) O
and O
/ O
or O
elevated O
MMPN O
concentrations O
( O
> O
5 O
, O
000 O
pmol O
/ O
8 O
x O
10 O
( O
8 O
) O
erythrocytes O
) O
and O
/ O
or O
elevated O
liver O
enzymes O
( O
alanine B
aminotransferase O
and O
/ O
or O
aspartate B
aminotransferase O
levels O
one O
- O
to O
threefold O
the O
upper O
limit O
of O

RESULTS O
: O
Adequate O
6 O
- O
TGN O
concentrations O
were O
achieved O
with O
a O
combination O
of O
25 O
mg O
allopurinol B
and O
50 O
mg O
azathioprine O
in O
one O
patient O
and O
with O
50 O
mg O
allopurinol B
and O
50 O
mg O
azathioprine O
in O
nine O
patients O
. O

CONCLUSIONS O
: O
Combination O
therapy O
with O
only O
50 O
mg O
allopurinol B
and O
50 O
mg O
azathioprine O
daily O
is O
sufficient O
, O
efficacious O
and O
safe O
in O
most O
IBD O
patients O
with O
inadequate O
thiopurine O
metabolite O
concentrations O
to O
optimize O
azathioprine O
- O
based O
IBD O
therapy O
. O

Population O
pharmacokinetics O
analysis O
of O
cyclophosphamide B
with O
genetic O
effects O
in O
patients O
undergoing O
hematopoietic O
stem O
cell O
transplantation O
. O

PURPOSE O
: O
To O
build O
a O
population O
pharmacokinetic O
( O
PK O
) O
model O
of O
cyclophosphamide B
( O
CY O
) O
and O
its O
metabolite O
, O
4 O
- O
hydroxycyclophospham O
( O
HCY O
) O
, O
in O
patients O
undergoing O
allogeneic O
haematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
and O
to O
identify O
covariates O
, O
including O
genetic O
polymorphisms O
, O
which O
affect O
CY O
and O
HCY O
PK O
parameters O
. O

RESULTS O
: O
A O
population O
PK O
analysis O
showed O
that O
the O
ABCC2 O
1249 O
genotype O
and O
aspartate B
aminotransferase O
levels O
significantly O
affected O
non O
- O
induced O
clearance O
( O
CL O
UI O
) O
and O
induced O
clearance O
( O
CL O
I O
) O
of O
CY O
, O
respectively O
. O

Synthesis O
, O
characterization O
and O
organic O
field O
effect O
transistor O
performance O
of O
a O
diketopyrrolopyrrole O
- O
fluorenone B
copolymer O
. O

A O
diketopyrrolopyrrole O
( O
DPP O
) O
with O
fluorenone B
( O
FN O
) O
based O
low O
band O
gap O
alternating O
copolymer O
( O
PDPPT O
- O
alt O
- O
FN O
) O
has O
been O
synthesized O
via O
Suzuki O
coupling O
. O

Aim O
: O
Present O
study O
was O
conducted O
to O
evaluate O
the O
dermatoprotective O
effects O
of O
plant O
extracts O
( O
Ficus O
religiosa O
, O
Ficus O
benghalensis O
, O
and O
Ficus O
racemosa O
) O
against O
known O
irritants O
such O
as O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
atrazine B
, O
and O
petrol O
. O

Ethanol B
extracts O
of O
plants O
were O
obtained O
through O
Soxhlet O
. O

All O
irritants O
and O
Ficus O
extracts O
were O
topically O
applied O
to O
the O
backs O
of O
rabbits O
daily O
for O
4 O
days O
, O
while O
pure O
ethanol B
served O
as O
control O
. O

The O
mean O
+ O
/ O
- O
SEM O
epidermal O
thickness O
( O
micrometer O
) O
with O
SDS B
was O
45 O
. O
40 O
+ O
/ O
- O
1 O
. O
89 O
, O
F O
. O
religiosa O
+ O
SDS B
was O
18 O
. O
60 O
+ O
/ O
- O
0 O
. O
51 O
, O
F O
. O
benghalensis O
+ O
SDS B
was O
18 O
. O
40 O
+ O
/ O
- O
0 O
. O
25 O
, O
F O
. O
racemosa O
+ O
SDS B
was O
18 O
. O
80 O
+ O
/ O
- O
0 O
. O
37 O
, O
and O
mixture O
of O
three O
Ficus O
species O
+ O
SDS B
was O
16 O
. O
80 O
+ O
/ O
- O
0 O
. O
37 O
. O

Similar O
findings O
were O
revealed O
after O
using O
plant O
extracts O
with O
atrazine B
and O
petrol O
. O

The O
mean O
+ O
/ O
- O
SEM O
epidermal O
layer O
count O
for O
SDS B
was O
3 O
. O
60 O
+ O
/ O
- O
0 O
. O
25 O
, O
atrazine B
was O
3 O
. O
40 O
+ O
/ O
- O
0 O
. O
25 O
, O
petrol O
was O
3 O
. O
40 O
+ O
/ O
- O
0 O
. O
25 O
, O
and O
ethanol B
( O
control O
) O
was O
1 O
. O
00 O
+ O
/ O
- O
0 O
. O
20 O
. O

This O
count O
reduced O
to O
1 O
. O
20 O
+ O
/ O
- O
0 O
. O
20 O
for O
three O
Ficus O
species O
+ O
SDS B
, O
1 O
. O
40 O
+ O
/ O
- O
0 O
. O
25 O
for O
Ficus O
species O
+ O
atrazine B
, O
and O
1 O
. O
40 O
+ O
/ O
- O
0 O
. O
25 O
for O
Ficus O
species O
+ O
petrol O
. O

Protective O
effects O
of O
caffeic B
acid I
phenethyl I
ester I
on O
dose O
- O
dependent O
intoxication O
of O
rats O
with O
paraquat B
. O

PURPOSE O
: O
Paraquat B
( O
PQ O
; O
1 O
, O
1 O
' O
dimethyl O
- O
bipyridilium O
4 O
, O
4 O
' O
- O
dichloride O
) O
, O
which O
is O
used O
extensively O
throughout O
the O
world O
, O
is O
highly O
toxic O
to O
humans O
. O

We O
aimed O
to O
investigate O
the O
protective O
effects O
of O
different O
doses O
of O
caffeic B
acid I
phenethyl I
ester I
( O
CAPE B
) O
on O
PQ O
- O
intoxicated O
rats O
. O
Materials O
and O
methods O
: O
A O
total O
of O
80 O
rats O
were O
divided O
into O
the O
following O
eight O
groups O
, O
comprising O
10 O
rats O
in O
each O
group O
: O
group O
1 O
: O
control O
; O
group O
2 O
: O
administered O
with O
CAPE B
( O
10 O
micro O
mol O
/ O
kg O
) O
; O
group O
3 O
: O
administered O
with O
15 O
mg O
/ O
kg O
PQ O
( O
PQ15 O
group O
) O
; O
group O
4 O
: O
administered O
with O
30 O
mg O
/ O
kg O
PQ O
( O
PQ30 O
group O
) O
; O
group O
5 O
: O
administered O
with O
45 O
mg O
/ O
kg O

PQ O
( O
PQ45 O
group O
) O
; O
group O
6 O
: O
administered O
with O
15 O
mg O
/ O
kg O
PQ O
+ O
CAPE B
; O
group O
7 O
: O
administered O
with O
30 O
mg O
/ O
kg O
PQ O
+ O
CAPE B
and O
group O
8 O
: O
administered O
with O
45 O
mg O
/ O
kg O
PQ O
+ O
CAPE B
. O

Both O
PQ O
and O
CAPE B
were O
injected O
intraperitoneally O
. O

Pancreatic O
tissue O
was O
examined O
with O
both O
haematoxylin B
and O
eosin B
and O
immunochemical O
staining O
. O

RESULTS O
: O
The O
ratio O
of O
the O
immunohistochemical O
staining O
area O
to O
the O
total O
pancreatic O
area O
of O
the O
beta O
cells O
revealed O
that O
statistically O
significant O
differences O
were O
observed O
only O
between O
the O
PQ O
and O
PQ O
+ O
CAPE B
groups O
( O
p O
< O
0 O
. O
05 O
) O
. O

Discussion O
: O
The O
evaluation O
of O
the O
data O
suggests O
that O
CAPE B
can O
be O
used O
to O
prevent O
acute O
effects O
of O
PQ O
intoxication O
. O

Modulation O
of O
carbon B
tetrachloride I
- O
induced O
nephrotoxicity O
in O
rats O
by O
n B
- I
hexane I
extract O
of O
Sonchus O
asper O
. O

In O
the O
present O
study O
, O
protective O
effects O
of O
S O
. O
asper O
against O
carbon B
tetrachloride I
( O
CCl4 B
) O
- O
induced O
nephrotoxicity O
of O
rats O
were O
determined O
. O

Group O
I O
( O
control O
group O
) O
was O
given O
saline O
( O
1 O
ml O
/ O
kg O
body O
weight O
( O
b O
. O
w O
. O
) O
, O
0 O
. O
85 O
% O
NaCl B
) O
and O
dimethyl B
sulfoxide I
( O
1 O
ml O
/ O
kg O
b O
. O
w O
. O
) O
; O
group O
II O
was O
treated O
with O
CCl4 B
( O
1 O
ml O
/ O
kg O
b O
. O
w O
. O
intraperitoneally O
) O
; O
groups O
III O
and O
IV O
were O
administered O
with O
CCl4 B
and O
after O
48 O
h O
with O
S O
. O
asper O
n B
- I
hexane I
extract O
( O
SHE O
; O
100 O
and O
200 O
mg O
/ O
kg O
b O
. O
w O
. O
) O
. O

The O
results O
revealed O
that O
CCl4 B
- O
induced O
oxidative O
stress O
as O
evidenced O
by O
the O
significant O
depletion O
of O
antioxidant O
enzymes O
, O
namely O
, O
superoxide B
dismutase O
, O
catalase O
, O
peroxidase O
, O
glutathione B
- O
S B
- O
transferase O
, O
glutathione B
peroxidase O
, O
glutathione B
reductase O
, O
and O
glutathione B
contents O
, O
while O
increased O
lipid O
peroxidation O
( O
thiobarbituric B
acid I
- O
reactive O
substances O
contents O
) O
. O

Coadministration O
revealed O
that O
S O
. O
asper O
extract O
can O
protect O
the O
kidney O
against O
CCl4 B
- O
mediated O
oxidative O
damage O
by O
restoring O
the O
activity O
of O
antioxidant O
enzyme O
, O
due O
to O
the O
presence O
of O
plant O
bioactive O
constituents O
. O

The O
membranes O
could O
be O
easily O
detached O
from O
polystyrene B
or O
polypropylene B
substrate O
without O
any O
postprocessing O
step O
. O

Concentration O
- O
Dependent O
Supramolecular O
Engineering O
of O
Hydrogen B
- O
Bonded O
Nanostructures O
at O
Surfaces O
: O
Predicting O
Self O
- O
Assembly O
in O
2D O
. O

As O
a O
model O
system O
we O
have O
chosen O
a O
rigid O
molecular O
module O
, O
1 O
, O
3 O
, O
5 O
- O
tris O
( O
pyridine O
- O
4 O
- O
ylethynyl O
) O
benzene O
, O
which O
can O
undergo O
self O
- O
association O
via O
hydrogen B
bonding O
( O
H B
- O
bonding O
) O
to O
form O
ordered O
2D O
nanostructures O
. O

We O
analyzed O
the O
stability O
of O
different O
weak O
H B
- O
bonded O
patterns O
and O
the O
influence O
of O
the O
concentration O
of O
the O
starting O
molecule O
on O
the O
2D O
supramolecular O
packing O
. O

A O
concentration O
- O
dependent O
scanning O
tunneling O
microscopy O
investigation O
of O
the O
molecular O
self O
- O
assembly O
at O
a O
graphite B
- O
solution O
interface O
revealed O
supramolecular O
motifs O
, O
which O
are O
in O
perfect O
agreement O
with O
those O
obtained O
by O
simulations O
. O

Theoretical O
and O
Kinetic O
Study O
of O
the O
Reaction O
of O
Ethyl O
Methyl O
Ketone O
with O
HO2 B
for O
T O
= O
600 O
- O
1 O
, O
600 O
K O
. O

The O
temperature O
and O
pressure O
dependence O
of O
the O
addition O
reaction O
of O
ethyl O
methyl O
ketone O
( O
EMK O
) O
with O
HO2 B
radical O
has O
been O
calculated O
with O
the O
master O
equation O
method O
employing O
conventional O
transition O
state O
theory O
estimates O
for O
the O
microcanonical O
rate O
coefficients O
in O
the O
temperature O
range O
of O
600 O
- O
1600 O
K O
. O

Our O
calculated O
results O
show O
that O
the O
four O
reaction O
channels O
forming O
1 O
- O
buten O
- O
2 O
- O
ol O
+ O
H O
y O
O2 O
radical O
( O
R5 O
) O
, O
2 O
- O
buten O
- O
2 O
- O
ol O
+ O
H O
y O
O2 O
radical O
( O
R10 O
) O
, O
acetic B
acid I
+ O
ethylene B
+ O
y O
O B
H I
radical O
( O
R13 O
) O
, O
2 O
- O
methyl O
- O
2 O
- O
oxetanol O
+ O
y O
OH B
radical O
( O
R15 O
) O
are O
the O
dominant O
channels O
. O

When O
the O
temperature O
is O
below O
1000 O
K O
, O
the O
reaction O
R15 O
forming O
the O
cyclic O
ether O
, O
2 O
- O
methyl O
- O
2 O
- O
oxetanol O
, O
is O
dominant O
; O
while O
the O
reaction O
R13 O
forming O
acetic B
acid I
+ O
ethylene B
+ O
y O
OH B
radical O
becomes O
increasingly O
dominant O
at O
temperatures O
above O
1000 O
K O
. O

The O
other O
two O
channels O
forming O
1 O
- O
buten O
- O
2 O
- O
ol O
, O
2 O
- O
buten O
- O
2 O
- O
ol O
and O
HO2 B
radical O
are O
not O
dominant O
but O
are O
still O
important O
product O
channels O
over O
the O
whole O
temperature O
range O
investigated O
here O
. O

No O
pressure O
dependence O
has O
been O
found O
for O
the O
reaction O
channels O
forming O
2 O
- O
methyl O
- O
2 O
- O
oxetanol O
+ O
OH B
radical O
and O
acetic B
acid I
+ O
ethylene B
+ O
OH B
radical O
. O

comparison O
of O
the O
total O
rate O
constants O
for O
the O
addition O
of O
HO2 B
radical O
to O
EMK O
and O
that O
for O
H B
- O
atom O
abstraction O
by O
HO2 B
radical O
from O
EMK O
has O
also O
been O
carried O
out O
. O

12 O
- O
HSA O
xerogels O
made O
from O
12 O
- O
HSA O
- O
acetronitrile O
organogels O
are O
more O
effective O
than O
12 O
- O
HSA O
xerogels O
made O
from O
12 O
- O
HSA O
- O
pentane O
organogels O
because O
of O
the O
highly O
branched O
fibrillar O
networks O
established O
in O
acetonitrile B
molecular O
gels O
. O

Electrophysiological O
evidence O
for O
4 O
- O
isobutyl O
- O
3 O
- O
isopropylbicyclophos O
as O
a O
selective O
blocker O
of O
insect O
GABA B
- O
gated O
chloride B
channels O
. O

Invertebrate O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
- O
gated O
chloride B
channels O
( O
GABACls O
) O
and O
glutamate B
- O
gated O
chloride B
channels O
( O
GluCls O
) O
, O
which O
function O
as O
inhibitory O
neurotransmitter O
receptors O
, O
are O
important O
targets O
of O
insecticides O
and O
antiparasitic O
agents O
. O

PS O
- O
14 O
represents O
a O
useful O
probe O
for O
the O
study O
of O
insect O
GABA B
receptors O
. O

The O
synthesis O
of O
novel O
pyrimidine O
deoxyapiothionucleos O
of O
d O
- O
and O
l O
- O
series O
was O
realized O
following O
application O
of O
a O
versatile O
and O
high O
- O
yielding O
scheme O
, O
which O
utilized O
inexpensive O
l O
- O
and O
d O
- O
arabinose O
as O
starting O
materials O
, O
respectively O
, O
and O
which O
makes O
use O
of O
a O
regio O
- O
and O
stereo O
- O
selective O
Pummerer O
rearrangement O
reaction O
for O
the O
coupling O
of O
the O
nucleobase B
with O
the O
thiosugar O
moiety O
. O

Oxidative O
stress O
and O
MAPK O
involved O
into O
ATF2 O
expression O
in O
immortalized O
human O
urothelial O
cells O
treated O
by O
arsenic B
. O

However O
, O
little O
is O
known O
about O
the O
effect O
of O
arsenic B
on O
expression O
of O
ATF2 O
and O
regulatory O
pathways O
in O
human O
urothelial O
cells O
. O

In O
this O
study O
, O
ATF2 O
expression O
was O
measured O
in O
NaAsO2 O
- O
treated O
human O
uroepithelial O
cell O
line O
( O
SV O
- O
HUC O
- O
1 O
) O
with O
1 O
, O
2 O
, O
4 O
, O
8 O
and O
10 O
mu O
M O
concentrations O
in O
order O
to O
provide O
some O
basis O
data O
for O
the O
study O
on O
mechanism O
of O
bladder O
cancer O
induced O
by O
arsenic B
. O

We O
found O
that O
ATF2 O
expression O
levels O
at O
2 O
, O
4 O
, O
8 O
and O
10 O
mu O
M O
arsenic B
- O
treated O
cells O
were O
significantly O
higher O
than O
those O
of O
control O
cells O
, O
and O
the O
strongest O
expression O
occurred O
in O
4 O
mu O
M O
NaAsO2 O
- O
treated O
cells O
. O

Antioxidants O
( O
melatonin B
) O
and O
JNK O
or O
p38 O
inhibitors O
decreased O
significantly O
arsenic B
- O
induced O
ATF2 O
expression O
. O

Taken O
together O
, O
these O
data O
indicated O
that O
the O
increasing O
of O
ATF2 O
expression O
is O
mediated O
via O
oxidative O
stress O
induced O
by O
arsenic B
in O
SV O
- O
HUC O
- O
1 O
cells O
, O
and O
JNK O
or O
p38 O
rather O
than O
ERK O
is O
responsible O
for O
arsenic B
- O
induced O
ATF2 O
expression O
. O

ROS O
were O
also O
involved O
in O
arsenic B
induced O
the O
activation O
of O
JNK O
and O
p38 O
MAPK O
signaling O
pathway O
. O

Two O
Common O
Bean O
Genotypes O
with O
Contrasting O
Response O
to O
Phosphorus B
Deficiency O
Show O
Variations O
in O
the O
microRNA O
399 O
- O
Mediated O
PvPHO2 O
Regulation O
within O
the O
PvPHR1 O
Signaling O
Pathway O
. O

Crop O
production O
of O
the O
important O
legume O
, O
the O
common O
bean O
( O
Phaseolus O
vulgaris O
) O
, O
is O
often O
limited O
by O
low O
phosphorus B
( O
P B
) O
in O
the O
soil O
. O

The O
genotypes O
, O
BAT477 O
and O
DOR364 O
, O
of O
the O
common O
bean O
have O
contrasting O
responses O
to O
P B
starvation O
. O

Plants O
from O
the O
BAT477 O
P B
deficiency O
tolerant O
genotype O
showed O
higher O
phosphate B
content O
and O
root O
biomass O
as O
compared O
to O
the O
DOR364 O
plants O
under O
P B
starvation O
. O

The O
PvPHR1 O
transcription O
factor O
- O
signaling O
pathway O
plays O
an O
essential O
role O
in O
the O
response O
to O
P B
starvation O
. O

PvPHO2 O
, O
a O
negative O
regulator O
of O
this O
pathway O
, O
encodes O
an O
ubiquitin O
E2 O
conjugase O
that O
promotes O
degradation O
of O
P B
- O
responsive O
proteins O
and O
is O
the O
target O
gene O
of O
PvmiR399 O
. O

PvPHO2 O
is O
downregulated O
in O
BAT477 O
plants O
under O
P B
deficiency O
, O
while O
such O
a O
response O
is O
not O
observed O
in O
P B
- O
starved O
DOR364 O
plants O
. O

Modified O
5 O
' O
RACE O
experiments O
indicated O
that O
PvmiR399 O
binding O
and O
/ O
or O
processing O
was O
affected O
in O
DOR364 O
P B
- O
starved O
plants O
. O

We O
propose O
that O
a O
less O
efficient O
cleavage O
of O
the O
PvPHO2 O
mRNA O
directed O
by O
PvmiR399 O
would O
result O
in O
a O
higher O
PvPHO2 O
- O
mediated O
degradation O
of O
P B
- O
responsive O
proteins O
in O
the O
DOR364 O
genotype O
with O
decreased O
P O
deficiency O
tolerance O
. O

We O
synthesized O
a O
serotonin B
derivative O
to O
enable O
selective O
tagging O
of O
serotonylation O
and O
to O
investigate O
its O
effect O
on O
Ras O
; O
the O
latter O
displayed O
undisrupted O
interaction O
with O
Raf O
- O
1 O
at O
the O
Ras O
binding O
domain O
. O

A O
Surgical O
Model O
in O
Male O
Obese O
Rats O
Uncovers O
Protective O
Effects O
of O
Bile B
Acids I
Post O
- O
Bariatric O
Surgery O
. O

Bariatric O
surgery O
elevates O
serum O
bile B
acids I
. O

Conjugated O
bile B
acid I
administration O
, O
such O
as O
tauroursodeoxycholic O
acid O
( O
TUDCA O
) O
, O
improves O
insulin O
sensitivity O
, O
while O
short O
- O
circuiting O
bile B
acid I
circulation O
through O
ileal O
interposition O
surgery O
in O
rats O
raises O
TUDCA O
levels O
. O

Glucose B
tolerance O
, O
insulin O
and O
glucagon O
- O
like O
peptide O
- O
1 O
( O
GLP O
- O
1 O
) O
response O
, O
hepatic O
steatosis O
and O
endoplasmic O
reticulum O
( O
ER O
) O
stress O
were O
measured O
. O

BD O
rats O
had O
improved O
glucose B
tolerance O
, O
increased O
higher O
post O
- O
prandial O
GLP O
- O
1 O
response O
and O
serum O
bile B
acids I
but O
less O
liver O
steatosis O
. O

Serum O
bile B
acid I
levels O
including O
TUDCA O
concentrations O
were O
higher O
in O
BD O
compared O
to O
SH O
pair O
- O
fed O
rats O
. O

Fecal O
bile B
acid I
levels O
were O
not O
different O
. O

Bile B
acid I
gavage O
( O
TUDCA O
/ O
UDCA O
) O
in O
diet O
- O
induced O
obese O
rats O
, O
elevated O
serum O
TUDCA O
and O
concomitantly O
reduced O
hepatic O
steatosis O
and O
ER O
stress O
( O
CHOP O
mRNA O
) O
. O

These O
data O
demonstrate O
the O
ability O
of O
alterations O
in O
bile B
acids I
to O
recapitulate O
important O
metabolic O
improvements O
seen O
after O
bariatric O
surgery O
. O

Further O
, O
our O
work O
establishes O
a O
model O
for O
focused O
study O
of O
bile B
acids I
in O
the O
context O
of O
bariatric O
surgery O
that O
may O
lead O
to O
the O
identification O
of O
therapeutics O
for O
metabolic O
disease O
. O

Silver B
nanoparticles O
enhance O
Pseudomonas O
aeruginosa O
PAO1 O
biofilm O
detachment O
. O

Abstract O
Objectives O
: O
Silver B
nanoparticles O
( O
AgNPs O
) O
with O
a O
size O
ranging O
from O
7 O
to O
70 O
nm O
were O
synthesized O
using O
the O
ascorbic B
acid I
- O
citrate B
seed O
- O
mediated O
growth O
approach O
at O
room O
temperature O
. O

Methods O
: O
The O
8 O
nm O
silver B
particles O
were O
prepared O
using O
gallic B
acid I
in O
alkaline O
conditions O
and O
used O
as O
seed O
to O
prepare O
AgNPs O
. O

Results O
: O
The O
presence O
of O
ascorbic B
acid I
and O
citrate B
allows O
the O
regulation O
of O
size O
and O
size O
distribution O
of O
the O
nanoparticles O
. O

The O
increase O
in O
free O
silver B
ion O
- O
to O
- O
seed O
ratio O
( O
Ag B
( I
+ I
) I
/ O
Ag O
( O
0 O
) O
) O
resulted O
in O
changes O
of O
particle O
shape O
from O
spherical O
to O
pseudo O
- O
spherical O
and O
minor O
cylindrical O
shape O
. O

Citrate B
- O
capped O
AgNPs O
were O
stable O
and O
did O
not O
agglomerate O
upon O
centrifugation O
. O

Bacteriolysis O
by O
vancomycin B
- O
conjugated O
acryl O
nanoparticles O
and O
morphological O
component O
analysis O
. O

In O
this O
study O
, O
vancomycin B
- O
conjugated O
nanoparticles O
( O
VCM O
NPs O
) O
were O
prepared O
. O

The O
antibacterial O
activity O
of O
VCM O
NPs O
was O
compared O
with O
that O
of O
VCM O
alone O
by O
exposure O
to O
vancomycin B
- O
resistant O
enterococci O
( O
VRE O
) O
. O

VCM O
NPs O
were O
found O
to O
have O
more O
potent O
antibacterial O
activity O
against O
VRE O
compared O
to O
VCM O
alone O
, O
but O
the O
activity O
against O
vancomycin B
- O
sensitive O
enterococci O
( O
VSE O
) O
remained O
the O
same O
. O

Gas O
Chromatography O
- O
Electron O
Impact O
Mass O
Spectrometry O
analyses O
of O
the O
three O
EOs O
showed O
that O
H O
. O
suaveolens O
EO O
was O
dominated O
by O
monoterpene B
and O
sesquiterpene O
hydrocarbons O
. O

Oxygenated B
monoterpenes I
were O
the O
main O
chemical O
class O
in O
R O
. O
officinalis O
and O
L O
. O
angustifolia O
EOs O
. O

The O
seemingly O
disparate O
areas O
of O
oxygen B
toxicity O
, O
radiation O
exposure O
, O
and O
aging O
are O
now O
recognized O
to O
share O
a O
common O
feature O
- O
the O
aberrant O
production O
and O
/ O
or O
removal O
of O
biologically O
derived O
free O
radicals O
and O
other O
reactive O
oxygen B
and O
nitrogen B
species O
( O
ROS O
/ O
RNS O
) O
. O

1D O
and O
2D O
NMR O
spectroscopy O
revealed O
that O
the O
O B
- O
specific O
polysaccharide O
( O
OPS O
) O
of O
A O
. O
bestiarum O
K296 O
consists O
of O
a O
branched O
tetrasaccharide B
repeating O
unit O
containing O
two O
6 O
- O
deoxy O
- O
l O
- O
talose O
( O
6dTalp O
) O
, O
one O
Manp O
and O
one O
GalpNAc O
residues O
; O
thus O
, O
it O
is O
similar O
to O
that O
of O
the O
OPS O
of O
A O
. O
hydrophila O
AH O
- O
3 O
( O
serotype O
O34 O
) O
in O
both O
the O
sugar B
composition O
and O
the O
glycosylation O
pattern O
. O

The O
very O
weak O
reaction O
of O
the O
anti O
- O
O34 O
serum O
with O
the O
O B
- O
deacylated O
LPS O
of O
A O
. O
bestiarum O
K296 O
might O
have O
been O
due O
to O
the O
different O
O B
- O
acetylation O
pattern O
of O
the O
terminal O
6dTalp O
. O

Palbinone O
from O
Paeonia O
suffruticosa O
Protects O
Hepatic O
Cells O
via O
Up O
- O
regulation O
of O
Heme B
Oxygenase O
- O
1 O
. O

The O
pathways O
by O
which O
palbinone O
( O
PB O
) O
isolated O
from O
P O
. O
suffruticosa O
mediates O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
induction O
were O
investigated O
using O
the O
specific O
inhibitors O
for O
PI3K O
and O
mitogen O
activated O
protein O
kinases O
pathways O
. O

We O
previously O
identified O
a O
cluster O
of O
quantitative O
trait O
loci O
( O
QTL O
) O
on O
baboon O
chromosome O
11 O
for O
multiple O
related O
quantitative O
traits O
for O
serum O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
. O

We O
performed O
hepatic O
whole O
genome O
expression O
profiling O
for O
LDL O
- O
C O
discordant O
baboons O
fed O
a O
high O
- O
cholesterol B
, O
high O
- O
fat O
( O
HCHF O
) O
diet O
for O
7 O
weeks O
. O

We O
demonstrated O
recently O
that O
the O
4 O
- O
anilinoquinazolines O
lapatinib B
( O
GW572016 O
, O
1 O
) O
and O
canertinib O
( O
CI O
- O
1033 O
) O
kill O
T O
. O
brucei O
with O
low O
micromolar O
EC50 O
values O
. O

Molecular O
Mechanisms O
in O
the O
Pyrolysis O
of O
Unsaturated O
Chlorinated O
Hydrocarbons O
: O
Formation O
of O
Benzene B
Rings O
Part O
II O
- O
Experimental O
and O
Kinetic O
Modeling O
Studies O
. O

The O
mechanism O
of O
formation O
of O
benzene B
rings O
during O
the O
pyrolysis O
of O
dichloro O
- O
and O
trichloroethylene O
has O
been O
investigated O
by O
the O
method O
of O
Laser O
Powered O
Homogeneous O
Pyrolysis O
coupled O
with O
product O
analysis O
by O
gas O
chromatography O
. O

Additionally O
, O
selected O
( O
co O
) O
- O
pyrolyses O
between O
the O
chlorinated O
ethylenes O
, O
CH2Cl2 B
, O
C4Cl4 O
, O
C4Cl6 O
, O
and O
C2H2 O
have O
been O
performed O
to O
explicitly O
probe O
the O
roles O
of O
2C3 O
and O
C4 O
/ O
C2 B
reaction O
pairs O
in O
aromatic O
growth O
. O

The O
presence O
of O
odd O
- O
carbon B
products O
in O
neat O
C4Cl6 O
pyrolyses O
indicates O
2C3 O
processes O
are O
operative O
in O
these O
systems O
; O
however O
, O
comparison O
with O
product O
yields O
from O
C2HCl3 O
suggests O
C4 O
/ O
C2 B
processes O
dominate O
most O
other O
systems O
. O

This O
is O
further O
evidenced O
by O
an O
absence O
of O
C3 O
and O
other O
odd O
- O
carbon B
species O
in O
( O
co O
) O
- O
pyrolyses O
with O
dichloromethane B
which O
should O
seed O
C3 O
- O
based O
growth O
. O

The O
experimental O
and O
theoretical O
results O
strongly O
suggest O
that O
, O
at O
moderate O
temperatures O
, O
aromatic O
ring O
formation O
from O
chlorinated O
ethylenes O
normally O
follows O
a O
Diels O
- O
Alder O
coupling O
of O
C4 O
and O
C2 B
molecular O
units O
followed O
by O
internal O
shifts O
; O
the O
one O
exception O
is O
the O
C4Cl4 O
+ O
C2Cl2 O
system O
, O
where O
steric O
factors O
lead O
to O
the O
formation O
of O
non O
- O
aromatic O
products O
. O

Reduction O
of O
the O
bioreductive O
group O
nitro B
moiety O
, O
under O
hypoxic O
conditions O
, O
reveals O
an O
electron O
- O
donating O
substituent O
that O
leads O
to O
fragmentation O
of O
the O
molecule O
, O
affording O
the O
active O
inhibitor O
. O

Wool O
was O
dissolved O
in O
sodium B
hydroxide I
solution O
, O
the O
pH O
value O
of O
the O
solution O
was O
adjusted O
to O
5 O
. O
55 O
and O
the O
precipitate O
was O
harvested O
as O
wool O
polypeptide O
. O

After O
4weeks O
of O
DMH O
administrations O
, O
the O
groups O
were O
fed O
with O
standard O
diet O
, O
a O
diet O
containing O
2 O
. O
5 O
% O
or O
5 O
. O
0 O
% O
AP O
or O
a O
diet O
containing O
0 O
. O
2 O
% O
N B
- I
acetylcysteine I
( O
NAC B
) O
for O
10weeks O
, O
using O
aberrant O
crypt O
foci O
( O
ACF O
) O
as O
the O
endpoint O
. O

In O
ACF O
assay O
, O
a O
reduction O
in O
the O
number O
of O
aberrant O
crypts O
( O
ACs O
) O
and O
ACF O
( O
1 O
- O
3 O
AC O
) O
were O
observed O
in O
the O
groups O
fed O
with O
5 O
. O
0 O
% O
AP O
( O
37 O
% O
AC O
and O
47 O
% O
ACF O
inhibition O
, O
p O
= O
0 O
. O
036 O
) O
and O
0 O
. O
2 O
% O
NAC B
( O
39 O
% O
AC O
and O
41 O
% O
ACF O
inhibition O
, O
p O
= O
0 O
. O
042 O
) O
. O

1 O
, O
1 O
- O
Difluoroethyl O
- O
substituted O
triazolothienopyrimi O
as O
inhibitors O
of O
a O
human O
urea B
transport O
protein O
( O
UT O
- O
B O
) O
: O
New O
analogs O
and O
binding O
model O
. O

The O
kidney O
urea B
transport O
protein O
UT O
- O
B O
is O
an O
attractive O
target O
for O
the O
development O
of O
small O
- O
molecule O
inhibitors O
with O
a O
novel O
diuretic O
( O
' O
urearetic O
' O
) O
action O
. O

Compound O
1c O
incorporates O
a O
1 O
, O
1 O
- O
difluoroethyl O
group O
, O
which O
affords O
improved O
microsomal O
stability O
when O
compared O
to O
the O
corresponding O
ethyl B
- O
substituted O
compound O
1a O
. O

Here O
, O
a O
small O
focused O
library O
( O
4a O
- O
4f O
) O
was O
developed O
around O
lead O
inhibitor O
1c O
to O
investigate O
the O
requirement O
of O
an O
amidine B
- O
linked O
thiophene B
in O
the O
inhibitor O
scaffold O
. O

Greater O
impairment O
of O
postprandial O
triacylglycerol B
than O
glucose B
response O
in O
metabolic O
syndrome O
subjects O
with O
fasting O
hyperglycaemia O
. O

Our O
aim O
was O
to O
examine O
the O
impact O
of O
the O
presence O
of O
raised O
fasting O
glucose B
as O
a O
MetS O
component O
on O
postprandial O
lipaemia O
. O

Lipids O
, O
glucose B
and O
insulin O
were O
measured O
in O
the O
fasting O
and O
postprandial O
samples O
. O

Fasting O
lipids O
and O
insulin O
were O
similar O
in O
the O
two O
groups O
, O
with O
glucose B
significantly O
higher O
in O
the O
men O
with O
glucose B
as O
a O
MetS O
component O
( O
P O
< O
0 O
. O
001 O
) O
. O

Following O
the O
test O
meals O
, O
there O
were O
higher O
maximum O
concentration O
( O
maxC O
) O
, O
area O
under O
the O
curve O
( O
AUC O
) O
and O
incremental O
AUC O
( O
P O
< O
= O
0 O
. O
016 O
) O
for O
the O
postprandial O
triacylglycerol B
( O
TAG B
) O
response O
in O
men O
with O
fasting O
hyperglycaemia O
. O

Greater O
glucose B
AUC O
( O
P O
< O
0 O
. O
001 O
) O
and O
insulin O
maxC O
( O
P O
= O
0 O
. O
010 O
) O
were O
also O
observed O
in O
these O
individuals O
after O
the O
test O
meals O
. O

Multiple O
regression O
analysis O
revealed O
fasting O
glucose B
to O
be O
an O
important O
predictor O
of O
the O
postprandial O
TAG B
and O
glucose B
response O
. O

CONCLUSION O
: O
Our O
data O
analysis O
has O
revealed O
a O
greater O
impairment O
of O
postprandial O
TAG B
than O
glucose B
response O
in O
MetS O
subjects O
with O
raised O
fasting O
glucose B
. O

New O
Diterpenes B
from O
a O
Godavari O
Mangrove O
, O
Ceriops O
decandra O
. O

Eleven O
new O
diterpenes B
, O
named O
decandrins O
A O
- O
K O
( O
1 O
- O
11 O
) O
, O
including O
nine O
abietanes O
( O
1 O
- O
9 O
) O
and O
two O
podocarpanes B
( O
10 O
- O
11 O
) O
, O
were O
isolated O
from O
the O
barks O
of O
an O
Indian O
mangrove O
, O
Ceriops O
decandra O
, O
collected O
in O
the O
mangrove O
swamp O
of O
Godavari O
estuary O
, O
Andhra O
Pradesh O
, O
together O
with O
four O
known O
abietanes O
. O

This O
is O
the O
first O
report O
of O
abietane B
and O
podocarpane B
diterpenoids B
from O
C O
. O
decandra O
. O

Concentration O
and O
Strain O
Fields O
inside O
a O
Ag B
/ O
Au B
Core O
- O
Shell O
Nanowire O
Studied O
by O
Coherent O
X O
- O
ray O
Diffraction O
. O

Three O
- O
dimensional O
coherent O
diffraction O
patterns O
of O
an O
isolated O
, O
single O
- O
crystalline O
Ag B
/ O
Au B
core O
- O
shell O
nanowire O
were O
recorded O
at O
different O
X O
- O
ray O
beam O
energies O
close O
to O
the O
Au B
LIII O
absorption O
edge O
. O

Molecular O
dynamics O
( O
MD O
) O
provided O
ensembles O
of O
conformations O
in O
water O
and O
water O
- O
saturated O
octanol B
. O

The O
performance O
of O
the O
implicit O
models O
was O
tested O
by O
a O
comparison O
with O
experimental O
water O
- O
octanol B
transfer O
free O
energies O
( O
Delta O
Gow O
) O
by O
using O
single O
- O
and O
multiconformation O
approaches O
. O

We O
demonstrate O
in O
this O
article O
efficient O
photon O
transfer O
in O
discrete O
optoplasmonic O
molecules O
comprising O
gold O
nanoparticle O
( O
NP O
) O
dimer O
antennas O
located O
in O
the O
evanescent O
field O
of O
a O
2 O
mu O
m O
diameter O
polystyrene B
bead O
, O
which O
served O
as O
an O
optical O
microcavity O
( O
OM O
) O
. O

The O
optoplasmonic O
molecules O
were O
generated O
through O
a O
guided O
self O
- O
assembly O
strategy O
in O
which O
the O
OMs O
were O
immobilized O
in O
binding O
sites O
generated O
by O
quartz B
( O
SiO2 B
) O
or O
silicon B
posts O
that O
contained O
plasmonic O
nanoantennas O
on O
their O
tips O
. O

Abstract O
Aim O
: O
In O
order O
to O
avoid O
gastric O
irritation O
caused O
by O
tolmetin O
sodium O
( O
TS O
) O
, O
gastro O
resistant O
Eudragit B
( O
R O
) O
S O
100 O
microsphere O
formulations O
were O
prepared O
with O
the O
emulsion O
/ O
solvent O
diffusion O
method O
. O

Materials O
: O
Considering O
the O
high O
water O
solubility O
of O
the O
TS O
molecule O
, O
the O
effects O
of O
the O
presence O
of O
inorganic O
salt O
( O
NaCl B
, O
NaBr O
and O
KH2PO4 O
; O
0 O
. O
1 O
M O
and O
1 O
. O
0 O
M O
) O
in O
external O
phase O
and O
external O
phase O
pH O
on O
the O
encapsulation O
efficiency O
were O
evaluated O
. O

Improvement O
in O
encapsulation O
efficiency O
was O
determined O
by O
increasing O
concentrations O
of O
NaCl B
, O
NaBr O
and O
KH2PO4 O
. O

Conclusion O
: O
Conclusively O
, O
drug O
release O
in O
stomach O
pH O
was O
significantly O
prevented O
by O
the O
microspheres O
prepared O
using O
Eudragit B
( O
R O
) O
S O
100 O
polymer O
, O
and O
these O
formulations O
are O
considered O
to O
be O
a O
model O
for O
other O
orally O
administered O
drugs O
with O
similar O
problems O
. O

Materials O
and O
methods O
: O
With O
bovine O
albumin O
- O
fluorescein B
isothiocyanate I
conjugate O
( O
FITC B
- O
BSA O
) O
as O
a O
vaccine O
model O
, O
formulations O
were O
selected O
with O
the O
construction O
of O
pseudo O
- O
ternary O
phase O
diagrams O
and O
a O
short O
- O
term O
stability O
study O
. O

Different O
drug O
concentrations O
were O
compared O
, O
and O
the O
effect O
of O
the O
nanoemulsion O
excipients O
on O
the O
permeation O
of O
the O
FITC B
- O
BSA O
was O
also O
studied O
. O

In O
vitro O
skin O
diffusion O
studies O
show O
that O
the O
optimized O
formulation O
improves O
the O
permeation O
of O
FITC B
- O
BSA O
through O
skin O
with O
an O
enhancement O
ratio O
of O
4 O
. O
2 O
compared O
to O
a O
neat O
control O
solution O
. O

The O
attachment O
of O
inert O
polymers O
, O
such O
as O
polyethyleneglycol B
, O
to O
proteins O
has O
driven O
the O
emergence O
of O
a O
multibillion O
dollar O
biotechnology O
industry O
. O

Two O
new O
isoflavone O
glycosides O
, O
ammopiptanosides O
A O
and O
B O
, O
have O
been O
isolated O
from O
the O
95 O
% O
EtOH B
extract O
of O
the O
twigs O
of O
Ammopiptanthus O
nanus O
( O
M O
. O
Pop O
. O
) O
Cheng O
f O
. O
, O
together O
with O
six O
known O
compounds O
, O
and O
their O
structures O
were O
characterized O
by O
spectroscopic O
methods O
and O
compared O
with O
the O
data O
in O
the O
literature O
. O

Catecholamine B
mimetic O
EDTA O
- O
bis O
( O
tyramide O
) O
was O
synthesized O
and O
characterized O
by O
various O
spectroscopic O
techniques O
( O
NMR O
, O
Mass O
spectroscopy O
) O
and O
lambda O
em O
310 O
nm O
for O
the O
excitation O
at O
270 O
nm O
. O

Molecular O
docking O
studies O
were O
performed O
with O
Human O
Serum O
Albumin O
( O
HSA O
: O
PDB O
1E78 O
) O
, O
showing O
binding O
pattern O
with O
amino B
acid I
residues O
Arg218 O
, O
Arg222 O
and O
Lys444 O
, O
identifies O
the O
ligand O
- O
HSA O
interaction O
for O
the O
transportation O
affinity O
of O
the O
ligand O
at O
the O
specific O
site O
of O
the O
target O
. O

Finally O
, O
EDTA O
- O
bis O
( O
tyramide O
) O
labeled O
with O
( B
99m I
) I
Tc I
to O
investigate O
its O
in O
- O
vivo O
radiopharmaceutical O
efficiency O
, O
having O
97 O
% O
binding O
affinity O
with O
98 O
% O
radiochemical O
purity O
. O

Overexpression O
of O
neurotrophin O
receptors O
of O
the O
tyrosine B
kinase O
( O
Trk O
) O
family O
has O
been O
identified O
as O
a O
major O
prognostic O
and O
biological O
factor O
for O
this O
disease O
. O

Health O
benefits O
of O
seafood O
; O
Is O
it O
just O
the O
fatty B
acids I
? O

This O
paper O
reviews O
our O
current O
knowledge O
of O
the O
beneficial O
nutrient O
composition O
of O
seafood O
, O
in O
particular O
omega B
- I
3 I
fatty I
acids I
, O
selenium B
, O
taurine B
, O
vitamins O
D O
and O
B12 O
, O
in O
the O
context O
of O
the O
development O
of O
environmentally O
sustainable O
aquaculture O
. O

Assessing O
caffeine B
intake O
in O
the O
United O
Kingdom O
diet O
. O

Caffeine B
occurs O
naturally O
in O
the O
leaves O
and O
seeds O
of O
many O
plants O
and O
is O
artificially O
added O
to O
some O
beverages O
. O

Consumption O
of O
caffeine B
has O
been O
linked O
to O
both O
positive O
and O
adverse O
health O
outcomes O
. O

We O
incorporated O
estimates O
of O
caffeine B
content O
( O
mg O
/ O
100g O
or O
ml O
) O
of O
foods O
and O
drinks O
, O
taken O
from O
the O
published O
literature O
, O
to O
provide O
a O
preliminary O
estimate O
of O
caffeine B
intake O
for O
the O
UK O
population O
, O
based O
on O
data O
collected O
in O
the O
National O
Diet O
and O
Nutrition O
Survey O
2008 O
- O
10 O
. O

Among O
consumers O
mean O
total O
caffeine B
intakes O
of O
adult O
men O
19 O
+ O
y O
were O
significantly O
greater O
than O
intakes O
by O
boys O
4 O
- O
10y O
and O
11 O
- O
18y O
( O
p O
< O
0 O
. O
05 O
) O
, O
with O
the O
same O
age O
- O
related O
differences O
seen O
for O
females O
. O

4 O
. O
1 O
% O
of O
men O
19 O
+ O
y O
and O
3 O
. O
8 O
% O
of O
women O
19 O
+ O
y O
had O
caffeine B
intakes O
in O
excess O
of O
300mg O
/ O
d O
. O

The O
addition O
of O
caffeine B
to O
UK O
food O
composition O
databases O
will O
allow O
more O
detailed O
study O
of O
the O
health O
effects O
of O
caffeine B
consumption O
. O

The O
results O
showed O
that O
Phyllanthus O
emblica O
L O
. O
exhibited O
the O
highest O
levels O
of O
vitamin B
C I
( O
575 O
+ O
/ O
- O
452mg O
/ O
100g O
) O
, O
total O
phenolics B
( O
TP O
) O
( O
3703 O
+ O
/ O
- O
1244mGAE O
/ O
100g O
) O
, O
and O
antioxidant O
activities O
, O
as O
measured O
by O
DPPH B
, O
FRAP O
and O
ORAC O
assays O
. O

Compared O
to O
the O
other O
two O
fruits O
, O
Antidesma O
velutinosum O
Blume O
contained O
higher O
levels O
of O
most O
nutrients O
and O
dietary O
fibre O
( O
15 O
. O
6 O
+ O
/ O
- O
5 O
. O
9g O
/ O
100g O
) O
, O
as O
well O
as O
carotenoids O
( O
335 O
+ O
/ O
- O
98 O
mu O
g O
/ O
100g O
) O
and O
phytosterols B
( O
22 O
. O
1 O
+ O
/ O
- O
3 O
. O
9mg O
/ O
100g O
) O
. O

Spondias O
pinnata O
( O
L O
. O
f O
. O
) O
Kurz O
was O
high O
in O
total O
phenolics B
( O
3178 O
+ O
/ O
- O
887mGAE O
/ O
100g O
) O
and O
antioxidant O
activity O
. O

Effect O
of O
different O
maize O
meal O
diets O
on O
growth O
and O
vitamin B
A I
: O
Case O
- O
study O
on O
chickens O
. O

However O
, O
it O
was O
reported O
, O
in O
2008 O
, O
that O
vitamin B
A I
deficiency O
increased O
despite O
the O
mandatory O
fortification O
programme O
. O

This O
motivates O
an O
investigation O
into O
the O
absorption O
of O
vitamin B
A I
as O
fortificant O
in O
the O
maize O
meal O
. O

Relative O
absorption O
, O
in O
chickens O
as O
the O
biological O
model O
, O
was O
determined O
by O
evaluating O
growth O
and O
vitamin B
A I
status O
. O

The O
weight O
, O
cumulative O
feed O
intake O
and O
liver O
retinol B
stores O
of O
chickens O
on O
different O
diets O
were O
measured O
over O
a O
6week O
period O
. O

The O
fortified O
white O
maize O
meal O
diet O
was O
able O
to O
maintain O
the O
vitamin B
A I
status O
of O
the O
chickens O
. O

Poor O
absorption O
of O
the O
fortificant O
vitamin B
A I
is O
therefore O
not O
a O
constraint O
in O
combating O
vitamin B
A I
deficiency O
. O

Voluntary O
food O
fortification O
with O
folic B
acid I
in O
Spain O
: O
Predicted O
contribution O
to O
children O
' O
s O
dietary O
intakes O
as O
assessed O
with O
new O
food O
folate B
composition O
data O
. O

The O
Spanish O
market O
offers O
a O
significant O
number O
of O
folic B
acid I
( O
FA O
) O
voluntarily O
fortified O
foods O
. O

Contribution O
to O
potential O
FA O
intakes O
for O
children O
aged O
2 O
- O
13years O
, O
was O
assessed O
using O
food O
consumption O
data O
from O
a O
representative O
nationwide O
study O
, O
folate B
Recommended O
Dietary O
Intakes O
( O
RDI O
) O
, O
and O
Upper O
Levels O
( O
UL O
) O
. O

Total O
nitrogen B
vs O
. O
amino B
- I
acid I
profile O
as O
indicator O
of O
protein O
content O
of O
beef O
. O

In O
most O
cited O
food O
composition O
studies O
and O
tables O
, O
the O
proximate O
system O
measures O
protein O
as O
total O
nitrogen B
( O
N B
) O
( O
determined O
by O
Kjeldahl O
or O
Dumas O
method O
) O
multiplied O
by O
a O
specific O
factor O
. O

A O
factor O
of O
6 O
. O
25 O
is O
used O
for O
determining O
total O
protein O
from O
total O
N B
( O
Jones O
, O
Munsey O
, O
& O
Walker O
, O
1942 O
) O
. O

Although O
more O
expensive O
, O
it O
is O
considered O
more O
accurate O
to O
base O
protein O
content O
of O
foods O
on O
amino B
acid I
data O
( O
Greenfield O
& O
Southgate O
, O
2003 O
) O
. O

A O
study O
on O
the O
nutrient O
composition O
of O
beef O
analysed O
the O
full O
amino B
- I
acid I
profile O
of O
fifteen O
retail O
cuts O
from O
three O
age O
groups O
and O
six O
fat O
codes O
, O
as O
well O
as O
determined O
total O
nitrogen B
content O
to O
determine O
proximate O
protein O
composition O
. O

For O
all O
cuts O
, O
the O
correlation O
coefficient O
of O
total O
amino B
acids I
to O
protein O
( O
N O
x O
6 O
. O
25 O
) O
was O
0 O
. O
635 O
. O

This O
indicates O
a O
poor O
correlation O
for O
predicting O
actual O
protein O
content O
( O
as O
determined O
by O
total O
amino B
acid I
count O
) O
, O
based O
on O
the O
nitrogen B
factor O
of O
6 O
. O
25 O
. O

On O
average O
, O
the O
sum O
of O
amino B
acids I
per O
cut O
amounted O
to O
91 O
% O
of O
total O
determined O
protein O
( O
N O
x O
6 O
. O
25 O
) O
for O
the O
same O
cut O
. O

ActVA O
- O
ORF5 O
, O
a O
flavin B
- O
dependent O
monooxygenase O
( O
FMO O
) O
essential O
for O
ACT O
biosynthesis O
, O
forms O
a O
two O
- O
component O
enzyme O
system O
in O
combination O
with O
a O
flavin B
: O
NADH B
oxidoreductase O
, O
ActVB O
. O

The O
genes O
for O
homologous O
two O
- O
component O
FMOs O
are O
found O
in O
the O
biosynthetic O
gene O
clusters O
for O
two O
other O
BIQs O
, O
granaticin O
( O
GRA O
) O
and O
medermycin O
( O
MED O
) O
, O
and O
a O
closely O
related O
antibiotic O
, O
alnumycin O
( O
ALN B
) O
. O

No O
p O
- O
quinone O
formation O
on O
a O
BIQ O
substrate O
was O
observed O
for O
AlnT O
, O
which O
is O
involved O
in O
lateral O
p O
- O
quinone O
formation O
in O
ALN B
. O

Genome O
- O
wide O
Analysis O
Reveals O
TET O
- O
and O
TDG O
- O
Dependent O
5 B
- I
Methylcytosine I
Oxidation O
Dynamics O
. O

TET O
dioxygenases O
successively O
oxidize O
5 B
- I
methylcytosine I
( O
5mC O
) O
in O
mammalian O
genomes O
to O
5 B
- I
hydroxymethylcytosin I
( O
5hmC O
) O
, O
5 O
- O
formylcytosine O
( O
5fC O
) O
, O
and O
5 B
- I
carboxylcytosine I
( O
5caC O
) O
. O

5fC O
/ O
5caC O
can O
be O
excised O
and O
repaired O
to O
regenerate O
unmodified O
cytosines B
by O
thymine B
- O
DNA O
glycosylase O
( O
TDG O
) O
and O
base O
excision O
repair O
( O
BER O
) O
pathway O
, O
but O
it O
is O
unclear O
to O
what O
extent O
and O
at O
which O
part O
of O
the O
genome O
this O
active O
demethylation O
process O
takes O
place O
. O

We O
further O
selected O
the O
5 O
- O
chloroindolin O
- O
2 O
- O
one O
moiety O
for O
the O
extension O
to O
another O
series O
of O
compounds O
by O
varying O
the O
substituents O
( O
R O
( O
2 O
) O
) O
at O
the O
phenyl B
group O
connected O
with O
the O
piperazine B
ring O
. O

Among O
all O
the O
compounds O
synthesized O
, O
6d O
and O
6l O
were O
most O
potent O
with O
IC50 O
values O
of O
3 O
. O
59 O
and O
5 O
. O
58 O
mu O
M O
, O
respectively O
against O
A549 O
lung O
cancer O
cells O
, O
while O
5f O
and O
6l O
possessed O
IC50 O
values O
of O
3 O
. O
49 O
and O
4 O
. O
57 O
mu O
M O
, O
respectively O
against O
HCT O
- O
116 O
colon O
cancer O
cells O
which O
were O
comparable O
to O
that O
of O
Sunitinib B
, O
an O
indolin O
- O
2 O
- O
one O
derivative O
in O
cancer O
therapy O
. O

The O
effects O
of O
BDNF O
in O
LTP O
are O
mediated O
by O
TrkB O
( O
tropomyosin O
- O
related O
kinase O
B O
) O
receptors O
, O
which O
are O
known O
to O
be O
coupled O
to O
the O
activation O
of O
the O
Ras O
/ O
ERK O
, O
phosphatidylinositol B
3 O
- O
kinase O
/ O
Akt O
and O
phospholipase O
C O
- O
gamma O
( O
PLC O
- O
gamma O
) O
pathways O
. O

Protective O
effects O
of O
naringin B
against O
paraquat B
- O
induced O
acute O
lung O
injury O
and O
pulmonary O
fibrosis O
in O
mice O
. O

The O
present O
study O
evaluates O
protective O
effects O
of O
naringin B
against O
paraquat B
( O
PQ O
) O
- O
induced O
acute O
lung O
injury O
( O
ALI O
) O
and O
pulmonary O
fibrosis O
in O
mice O
. O

Results O
showed O
that O
survival O
rates O
of O
mice O
exposed O
to O
PQ O
only O
( O
50mg O
/ O
kg O
within O
7days O
) O
were O
much O
lower O
than O
that O
in O
mice O
daily O
treatment O
with O
NAC B
or O
naringin B
. O

Moreover O
, O
protection O
against O
PQ O
- O
induced O
ALI O
was O
tested O
by O
daily O
pretreatment O
mice O
with O
saline O
, O
NAC B
or O
naringin B
for O
3days O
before O
PQ O
( O
30mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

Results O
showed O
that O
increase O
in O
leukocytes O
infiltration O
and O
overexpressions O
of O
TNF O
- O
alpha O
and O
TGF O
- O
beta O
1 O
caused O
by O
8h O
of O
PQ O
exposure O
were O
dose O
- O
dependently O
ameliorated O
by O
naringin B
. O

Furthermore O
, O
protection O
against O
PQ O
- O
induced O
pulmonary O
fibrosis O
was O
tested O
by O
pretreatment O
mice O
with O
PQ O
( O
20mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
and O
then O
daily O
administration O
with O
saline O
, O
NAC B
or O
naringin B
for O
prolonged O
21days O
. O

Results O
showed O
that O
naringin B
of O
60 O
and O
120mg O
/ O
kg O
significantly O
reduced O
PQ O
- O
induced O
upregulations O
of O
TNF O
- O
alpha O
, O
TGF O
- O
beta O
1 O
, O
MMP O
- O
9 O
and O
TIMP O
- O
1 O
, O
levels O
of O
pulmonary O
malonaldehyde B
and O
hydroxyproline B
, O
as O
well O
as O
pulmonary O
fibrosis O
deposition O
, O
while O
increased O
activities O
of O
SOD O
, O
GSH B
- O
Px O
and O
HO O
- O
1 O
. O

These O
results O
indicated O
that O
naringin B
had O
effective O
protection O
against O
PQ O
- O
induced O
ALI O
and O
pulmonary O
fibrosis O
. O

Immunotoxicological O
effects O
of O
inorganic O
arsenic B
on O
gilthead O
seabream O
( O
Sparus O
aurata O
L O
. O
) O
. O

Arsenic B
( O
As B
) O
has O
been O
associated O
with O
multitude O
of O
animal O
and O
human O
health O
problems O
; O
however O
, O
its O
impact O
on O
host O
immune O
system O
has O
not O
been O
extensively O
investigated O
. O

In O
fish O
, O
there O
are O
very O
few O
works O
on O
the O
potential O
risks O
or O
problems O
associated O
to O
the O
presence O
of O
arsenic B
. O

In O
the O
present O
study O
we O
have O
evaluated O
the O
effects O
of O
exposure O
( O
30 O
days O
) O
to O
sub O
- O
lethal O
concentrations O
of O
arsenic B
( O
5 O
mu O
M O
As2O3 O
) O
in O
the O
teleost O
fish O
gilthead O
seabream O
( O
Sparus O
aurata O
) O
, O
with O
special O
emphasis O
in O
the O
innate O
immune O
response O
. O

The O
arsenic B
concentration O
was O
determined O
using O
atomic O
fluorescence O
spectrometry O
( O
AFS O
) O
in O
liver O
and O
muscle O
of O
exposed O
fish O
showing O
As B
accumulation O
in O
the O
liver O
after O
30 O
days O
of O
exposure O
. O

Overall O
, O
As B
- O
exposure O
in O
the O
seabream O
affects O
the O
immune O
system O
. O

This O
paper O
describes O
, O
for O
the O
first O
time O
, O
the O
immunotoxicological O
effects O
of O
arsenic B
exposure O
in O
the O
gilthead O
seabream O
, O
which O
is O
a O
species O
with O
the O
largest O
production O
in O
Mediterranean O
aquaculture O
. O

Evaluation O
of O
mechanisms O
involved O
in O
the O
antinociception O
of O
the O
ethanol B
extract O
from O
the O
inner O
bark O
of O
Caesalpinia O
pyramidalis O
in O
mice O
. O

MATERIALS O
AND O
METHODS O
: O
The O
ethanol B
extract O
of O
Caesalpinia O
pyramidalis O
inner O
bark O
was O
used O
in O
mice O
via O
oral O
route O
, O
at O
the O
doses O
of O
10 O
, O
30 O
, O
and O
100mg O
/ O
kg O
, O
in O
behavioral O
models O
of O
nociception O
and O
investigates O
some O
of O
the O
mechanisms O
underlying O
this O
effect O
. O

RESULTS O
: O
The O
ethanol B
extract O
( O
30 O
and O
100mg O
/ O
kg O
, O
P O
< O
0 O
. O
001 O
) O
, O
given O
orally O
, O
produced O
dose O
dependent O
inhibition O
of O
acetic B
acid I
- O
induced O
visceral O
pain O
. O

The O
ethanol B
extract O
also O
caused O
significant O
and O
dose O
- O
dependent O
inhibition O
of O
capsaicin B
- O
( O
100mg O
/ O
kg O
, O
P O
< O
0 O
. O
001 O
) O
and O
glutamate B
- O
( O
10 O
, O
30 O
, O
and O
100mg O
/ O
kg O
, O
P O
< O
0 O
. O
01 O
) O
induced O
pain O
. O

The O
antinociception O
caused O
by O
the O
ethanol B
extract O
( O
30mg O
/ O
kg O
) O
in O
the O
abdominal O
constriction O
test O
was O
significantly O
attenuated O
( O
P O
< O
0 O
. O
001 O
) O
by O
intraperitoneal O
treatment O
of O
mice O
with O
l B
- I
arginine I
( O
600mg O
/ O
kg O
) O
. O

CONCLUSIONS O
: O
Collectively O
, O
the O
present O
results O
suggest O
that O
the O
ethanol B
extract O
of O
Caesalpinia O
pyramidalis O
produced O
dose O
- O
related O
antinociception O
in O
several O
models O
of O
pain O
through O
mechanisms O
that O
involved O
both O
glutamatergic O
system O
and O
/ O
or O
the O
l O
- O
arginine O
- O
nitric O
oxide O
pathway O
, O
supporting O
the O
folkloric O
usage O
of O
the O
plant O
to O
treat O
various O
painful O
processes O
. O

Increasing O
evidence O
points O
to O
a O
role O
of O
glutamate B
in O
anxiety O
. O

The O
group O
III O
metabotropic O
glutamate B
receptors O
( O
mGlu4 O
, O
mGlu6 O
, O
mGlu7 O
and O
mGlu8 O
receptors O
) O
remain O
the O
least O
investigated O
glutamate B
receptor O
subtypes O
partially O
due O
to O
a O
delay O
in O
the O
development O
of O
specific O
pharmacological O
tools O
. O

Protective O
effects O
of O
selenium B
on O
oxidative O
damage O
and O
oxidative O
stress O
related O
gene O
expression O
in O
rat O
liver O
under O
chronic O
poisoning O
of O
arsenic B
. O

Arsenic B
( O
As B
) O
is O
a O
toxic O
metalloid O
existing O
widely O
in O
the O
environment O
, O
and O
chronic O
exposure O
to O
it O
through O
contaminated O
drinking O
water O
has O
become O
a O
global O
problem O
of O
public O
health O
. O

The O
present O
study O
focused O
on O
the O
protective O
effects O
of O
selenium B
on O
oxidative O
damage O
of O
chronic O
arsenic B
poisoning O
in O
rat O
liver O
. O

Compared O
to O
the O
control O
and O
Na2SeO3 O
groups O
, O
the O
MDA B
content O
in O
liver O
tissue O
was O
decreased O
and O
the O
activities O
of O
antioxidant O
enzymes O
were O
increased O
in O
the O
Na2SeO3 O
intervention O
group O
. O

This O
work O
aimed O
to O
evaluate O
and O
compare O
the O
phenolic O
profile O
and O
some O
biological O
properties O
of O
the O
ripe O
" O
berries O
" O
methanol B
extracts O
of O
Juniperus O
oxycedrus O
L O
. O
subsp O
. O

The O
total O
phenolic B
content O
resulted O
about O
3 O
- O
fold O
higher O
in O
Jom O
( O
17 O
. O
89 O
+ O
/ O
- O
0 O
. O
23mg O
GAE O
/ O
g O
extract O
) O
than O
in O
Joo O
( O
5 O
. O
14 O
+ O
/ O
- O
0 O
. O
06mg O
GAE O
/ O
g O
extract O
) O
. O

The O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
analysis O
revealed O
a O
similar O
flavonoid B
fingerprint O
in O
Joo O
and O
Jom O
, O
whereas O
a O
difference O
in O
their O
quantitative O
content O
was O
found O
( O
4632 O
mu O
g O
/ O
g O
extract O
and O
12 O
, O
644 O
mu O
g O
/ O
g O
extract O
) O
. O

In O
addition O
, O
three O
phenolic B
acids I
were O
detected O
in O
Jom O
only O
( O
5765 O
mu O
g O
/ O
g O
extract O
) O
, O
and O
protocatechuic B
acid I
was O
the O
most O
abundant O
one O
. O

The O
antioxidant O
capacity O
of O
the O
extracts O
was O
evaluated O
by O
different O
in O
vitro O
assays O
: O
in O
the O
DPPH B
and O
in O
the O
TBA O
tests O
a O
stronger O
activity O
in O
Jom O
was O
highlighted O
, O
while O
Joo O
exhibited O
higher O
reducing O
power O
and O
metal O
chelating O
activity O
. O

The O
targeted O
compounds O
were O
converted O
in O
the O
desired O
water O
soluble O
dihydrochloride B
salts O
by O
reaction O
of O
appropriate O
free O
base O
with O
concd O
HCl B
in O
ethanol B
or O
acetic B
acid I
. O

Large O
networks O
of O
vertical O
multi O
- O
layer O
graphenes B
with O
morphology O
- O
tunable O
magnetoresistance O
. O

We O
report O
on O
the O
comparative O
study O
of O
magnetotransport O
properties O
of O
large O
- O
area O
vertical O
few O
- O
layer O
graphene B
networks O
with O
different O
morphologies O
, O
measured O
in O
a O
strong O
( O
up O
to O
10 O
T O
) O
magnetic O
field O
over O
a O
wide O
temperature O
range O
. O

The O
petal O
- O
like O
and O
tree O
- O
like O
graphene B
networks O
grown O
by O
a O
plasma O
enhanced O
CVD O
process O
on O
a O
thin O
( O
500 O
nm O
) O
silicon O
oxide O
layer O
supported O
by O
a O
silicon B
wafer O
demonstrate O
a O
significant O
difference O
in O
the O
resistance O
- O
magnetic O
field O
dependencies O
at O
temperatures O
ranging O
from O
2 O
to O
200 O
K O
. O

This O
behaviour O
is O
explained O
in O
terms O
of O
the O
effect O
of O
electron O
scattering O
at O
ultra O
- O
long O
reactive O
edges O
and O
ultra O
- O
dense O
boundaries O
of O
the O
graphene B
nanowalls O
. O

Our O
results O
pave O
a O
way O
towards O
three O
- O
dimensional O
vertical O
graphene B
- O
based O
magnetoelectronic O
nanodevices O
with O
morphology O
- O
tuneable O
anisotropic O
magnetic O
properties O
. O

The O
structure O
of O
the O
biliverdin B
cofactor O
in O
the O
Pfr O
state O
of O
bathy O
and O
prototypical O
phytochromes O
. O

The O
structures O
of O
the O
chromophore O
binding O
pockets O
in O
the O
Pfr O
states O
of O
various O
bathy O
and O
prototypical O
biliverdin B
- O
binding O
phytochromes O
were O
analysed O
by O
using O
a O
combined O
spectroscopic O
- O
theoretical O
approach O
. O

For O
the O
Pfr O
state O
of O
the O
bathy O
phytochrome O
from O
Pseudomonas O
aeruginosa O
( O
PaBphP O
) O
the O
very O
good O
agreement O
between O
calculated O
Raman O
spectra O
of O
the O
tetrapyrrole O
cofactor O
, O
obtained O
by O
quantum O
- O
mechanical O
/ O
molecular O
- O
mechanical O
hybrid O
methods O
, O
and O
the O
experimental O
resonance O
Raman O
( O
RR O
) O
spectra O
confirms O
important O
conclusions O
derived O
from O
the O
previous O
crystallographic O
analyses O
, O
particularly O
the O
ZZEssa O
configuration O
of O
the O
chromophore O
and O
its O
attachment O
to O
the O
thiol B
side O
chain O
of O
Cys12 O
via O
the O
exocyclic O
vinyl B
group O
of O
ring O

The O
Pfr O
states O
of O
prototypical O
phytochromes O
, O
thoroughly O
studied O
for O
Agp1 O
( O
A O
. O
tumefaciens O
) O
, O
display O
conformational O
equilibria O
between O
two O
sub O
- O
states O
differing O
with O
respect O
to O
the O
CD O
methine B
bridge O
torsional O
angle O
and O
the O
AB O
methine B
bridge O
geometry O
. O

These O
differences O
may O
mainly O
root O
in O
the O
interactions O
of O
the O
cofactor O
with O
the O
highly O
conserved O
Asp194 O
( O
PaBphP O
) O
that O
occur O
via O
its O
carboxylate B
function O
in O
bathy O
phytochromes O
. O

The O
weaker O
interactions O
via O
the O
carbonyl B
function O
in O
prototypical O
phytochromes O
may O
lead O
to O
a O
higher O
structural O
flexibility O
of O
the O
chromophore O
binding O
pocket O
that O
opens O
the O
reaction O
channel O
for O
the O
thermal O
( O
ZZE O
- O
- O
> O
ZZZ O
) O
Pfr O
- O
to O
- O
Pr O
back O
- O
conversion O
. O

The O
properties O
of O
graphdiyne O
under O
strains O
are O
found O
to O
differ O
remarkably O
from O
that O
of O
graphene B
. O

Antifungal O
Azoles B
: O
Structural O
Insights O
into O
Undesired O
Tight O
Binding O
to O
Cholesterol B
- O
Metabolizing O
CYP46A1 O
. O

Although O
there O
are O
currently O
three O
generations O
of O
antifungal O
azoles B
on O
the O
market O
, O
even O
the O
third O
generation O
agents O
show O
undesired O
interactions O
with O
human O
cytochrome O
P450 O
enzymes O
. O

CYP46A1 O
is O
a O
cholesterol B
- O
metabolizing O
P450 O
in O
the O
brain O
tightly O
binding O
a O
number O
of O
structurally O
distinct O
azoles B
. O

This O
long O
antifungal O
drug O
coordinates O
the O
P450 O
heme B
iron B
with O
the O
nitrogen B
atom O
of O
its O
terminal O
azole B
ring O
and O
adopts O
a O
linear O
configuration O
occupying O
the O
whole O
length O
of O
the O
substrate O
access O
channel O
and O
extending O
beyond O
the O
protein O
surface O
. O

These O
and O
the O
solution O
studies O
with O
different O
marketed O
azoles B
, O
collectively O
, O
allowed O
us O
to O
identify O
the O
determinants O
of O
tight O
azole B
binding O
to O
CYP46A1 O
and O
generate O
an O
overall O
picture O
of O
azole B
binding O
to O
this O
important O
P450 O
. O

Therefore O
, O
structural O
understanding O
of O
the O
azole B
binding O
not O
only O
to O
CYPs O
51 O
from O
the O
pathogenic O
species O
but O
also O
to O
different O
human O
P450s O
is O
required O
to O
deal O
efficiently O
with O
this O
challenge O
. O

METHODS O
: O
For O
CTA O
, O
water O
- O
restricted O
rats O
were O
administered O
U62 O
, O
066 O
following O
30 O
min O
access O
to O
a O
saccharin B
solution O
, O
with O
subsequent O
saccharin B
consumption O
used O
to O
index O
aversion O
. O

Methylphenidate B
reduces O
functional O
connectivity O
of O
nucleus O
accumbens O
in O
brain O
reward O
circuit O
. O

Release O
of O
dopamine B
in O
the O
nucleus O
accumbens O
( O
NAcc O
) O
is O
essential O
for O
acute O
drug O
reward O
. O

The O
present O
study O
was O
designed O
to O
trace O
the O
reinforcing O
effect O
of O
dopamine B
release O
by O
measuring O
the O
functional O
connectivity O
( O
FC O
) O
between O
the O
NAcc O
and O
brain O
regions O
involved O
in O
a O
limbic O
cortical O
- O
subcortical O
circuit O
during O
a O
dopaminergic O
challenge O
. O

Twenty O
healthy O
volunteers O
received O
single O
doses O
of O
methylphenidate B
( O
40 O
mg O
) O
and O
placebo O
on O
separate O
test O
days O
according O
to O
a O
double O
- O
blind O
, O
cross O
- O
over O
study O
design O
. O

Methylphenidate B
significantly O
reduced O
FC O
between O
the O
NAcc O
and O
the O
basal O
ganglia O
( O
i O
. O
e O
. O
, O
subthalamic O
nucleus O
and O
ventral O
pallidum O
( O
VP O
) O
) O
, O
relative O
to O
placebo O
. O

Methylphenidate B
also O
decreased O
FC O
between O
the O
NAcc O
and O
the O
medial O
prefrontal O
cortex O
( O
mPFC O
) O
as O
well O
as O
the O
temporal O
cortex O
. O

Methylphenidate B
did O
not O
affect O
FC O
between O
MDN O
and O
the O
limbic O
circuit O
. O

It O
is O
concluded O
that O
methylphenidate B
directly O
affects O
the O
limbic O
reward O
circuit O
. O

Here O
we O
show O
that O
the O
QYs O
of O
Yb B
( I
3 I
+ I
) I
sensitized O
two O
- O
photon O
upconversion O
emissions O
can O
be O
well O
characterized O
by O
the O
balancing O
power O
density O
, O
at O
which O
the O
ETU O
rate O
and O
the O
linear O
decay O
rate O
have O
equal O
contributions O
, O
and O
its O
corresponding O
QY O
. O

Sparstolonin O
B O
( O
SsnB O
) O
is O
an O
isocoumarin B
compound O
isolated O
from O
the O
tubers O
of O
both O
Sparganium O
stoloniferum O
and O
Scirpus O
yagara O
. O

Cytochrome O
p450 O
- O
mediated O
changes O
in O
oxycodone B
pharmacokinetics O
/ O
pharmacodynamics O
and O
their O
clinical O
implications O
. O

In O
recent O
years O
the O
use O
of O
the O
opioid O
oxycodone B
has O
increased O
markedly O
and O
replacing O
morphine B
as O
the O
first O
- O
line O
choice O
of O
opioid O
in O
several O
countries O
. O

The O
bioavailability O
is O
higher O
than O
for O
morphine B
and O
less O
variable O
. O

Oxycodone B
is O
primarily O
metabolized O
in O
the O
liver O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
enzymes O
with O
CYP3A O
as O
the O
major O
metabolic O
pathway O
and O
CYP2D6 O
as O
the O
minor O
metabolic O
pathway O
to O
noroxycodone B
, O
oxymorphone B
and O
noroxymorphone O
. O

Oxycodone B
exerts O
its O
analgesic O
effect O
via O
the O
micro O
- O
opioid O
receptor O
. O

On O
the O
basis O
of O
studies O
performed O
thus O
far O
, O
oxycodone B
concentrations O
in O
comparison O
with O
EM O
are O
similar O
in O
PM O
and O
reduced O
in O
UM O
. O

Simultaneous O
inhibition O
of O
both O
CYP3A O
and O
CYP2D6 O
results O
in O
increased O
oxycodone B
concentrations O
and O
such O
a O
combination O
should O
be O
avoided O
. O

Concomitant O
use O
of O
enzyme O
inducers O
such O
as O
rifampicin B
, O
St O
John O
' O
s O
wort O
and O
carbamazepine B
should O
be O
avoided O
because O
of O
the O
risk O
of O
subtherapeutic O
concentrations O
of O
oxycodone B
. O

When O
the O
dosage O
of O
morphine B
may O
result O
in O
unpredictable O
bioavailability O
, O
like O
in O
patients O
with O
severe O
hepatic O
cirrhosis O
, O
oxycodone B
might O
be O
beneficial O
because O
it O
has O
higher O
and O
less O
variability O
in O
bioavailability O
between O
patients O
than O
morphine B
. O

Promising O
results O
were O
also O
observed O
in O
estrogen B
receptor O
( O
ER O
) O
- O
positive O
, O
HER2 O
- O
negative O
breast O
cancer O
using O
a O
mammalian O
target O
of O
rapamycin B
inhibitor O
with O
tamoxifen B
or O
an O
aromatase O
inhibitor O
( O
AI O
) O
in O
the O
preoperative O
setting O
and O
for O
patients O
with O
metastatic O
breast O
cancer O
that O
had O
previously O
progressed O
on O
endocrine O
therapy O
alone O
. O

On O
the O
basis O
of O
preclinical O
data O
, O
clinical O
trials O
have O
examined O
combinations O
of O
hormonal O
agents O
such O
as O
fulvestrant B
with O
an O
AI O
. O

Early O
data O
indicated O
that O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
inhibitors O
exploiting O
the O
concept O
of O
synthetic O
lethality O
would O
offer O
improved O
outcomes O
for O
patients O
with O
ER O
- O
negative O
, O
progesterone B
receptor O
( O
PR O
) O
- O
negative O
, O
HER2 O
- O
negative O
breast O
cancer O
often O
referred O
to O
as O
triple O
negative O
breast O
cancer O
( O
TNBC O
) O
; O
however O
, O
data O
in O
the O
phase O
III O
setting O
failed O
to O
confirm O
these O
findings O
but O
this O
may O
be O
because O
the O
drug O
was O
not O
a O
true O
PARP O
inhibitor O
. O

Morphological O
Change O
and O
Mobility O
Enhancement O
in O
PEDOT B
: O
PSS O
by O
Adding O
Co O
- O
solvents O
. O

Adding O
ethylene B
glycol I
( O
EG O
) O
to O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
: O
poly O
( O
styrenesulfonate O
) O
( O
PEDOT B
: O
PSS O
) O
solution O
improves O
the O
crystallinity O
of O
the O
PEDOT B
and O
the O
ordering O
of O
the O
PEDOT B
nanocrystals O
in O
solid O
films O
. O

3D O
Graphene B
Foams O
Cross O
- O
linked O
with O
Pre O
- O
encapsulated O
Fe3 O
O4 O
Nanospheres O
for O
Enhanced O
Lithium B
Storage O
. O

Electrostatic O
assembly O
between O
Fe3 O
O4 O
nanospheres O
and O
graphene B
oxide I
, O
and O
subsequent O
hydrothermal O
assembly O
with O
additional O
graphene B
sheets O
, O
leads O
to O
Fe3 O
O4 O
nanospheres O
encapsulated O
in O
the O
graphene B
shells O
and O
interconnected O
by O
the O
graphene B
networks O
. O

Such O
3D O
Fe3 O
O4 O
/ O
graphene B
foams O
exhibit O
enhanced O
lithium B
storage O
with O
excellent O
cycling O
performance O
and O
rate O
capability O
. O

Morphological O
and O
histological O
examinations O
and O
terminal O
deoxynucleotidyl O
transferase O
dUTP B
nick O
end O
labeling O
( O
TUNEL O
) O
assays O
were O
performed O
. O

Prolonged O
- O
release O
fampridine O
( O
fampridine O
PR O
) O
is O
a O
potassium B
channel O
blocker O
that O
improves O
conductivity O
of O
signal O
on O
demyelinated O
axons O
in O
central O
nervous O
system O
. O

Synaptotagmin O
1 O
is O
required O
for O
vesicular O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
. O

A O
low O
- O
affinity O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
was O
described O
in O
the O
membrane O
of O
mammalian O
brain O
synaptic O
vesicles O
. O

Synaptotagmin O
- O
1 O
, O
a O
vesicular O
protein O
interacting O
with O
membranes O
upon O
low O
- O
affinity O
Ca B
( I
2 I
+ I
) I
- O
binding O
, O
plays O
a O
major O
role O
in O
excitation O
- O
release O
coupling O
, O
by O
synchronizing O
calcium B
entry O
with O
fast O
neurotransmitter O
release O
. O

Here O
, O
we O
report O
that O
synaptotagmin O
- O
1 O
is O
necessary O
for O
expression O
of O
the O
vesicular O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
. O

We O
measured O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
in O
vesicles O
and O
granules O
of O
pheochromocytoma O
PC12 O
cells O
by O
three O
methods O
: O
( O
1 O
) O
Ca B
( I
2 I
+ I
) I
- O
induced O
dissipation O
of O
the O
vesicular O
H B
( I
+ I
) I
- O
gradient O
; O
( O
2 O
) O
bafilomycin O
- O
sensitive O
calcium B
accumulation O
and O
( O
3 O
) O
pH O
- O
jump O
- O
induced O
calcium B
accumulation O
. O

The O
results O
were O
congruent O
and O
highly O
significant O
: O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
is O
detectable O
only O
in O
acidic O
organelles O
expressing O
functional O
synaptotagmin O
- O
1 O
. O

In O
contrast O
, O
synaptotagmin O
- O
1 O
- O
deficient O
cells O
- O
and O
cells O
where O
transgenically O
encoded O
synaptotagmin O
- O
1 O
was O
acutely O
photo O
- O
inactivated O
- O
were O
devoid O
of O
any O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
- O
antiport O
activity O
. O

Therefore O
, O
in O
addition O
to O
its O
previously O
described O
functions O
, O
synaptotagmin O
- O
1 O
is O
involved O
in O
a O
rapid O
vesicular O
Ca B
( I
2 I
+ I
) I
sequestration O
through O
a O
Ca B
( I
2 I
+ I
) I
/ O
H B
( I
+ I
) I
antiport O
. O

Concentration O
- O
and O
size O
- O
dependent O
superoxide B
formation O
, O
measured O
by O
electron O
paramagnetic O
resonance O
( O
EPR O
) O
, O
was O
observed O
. O

Furthermore O
, O
we O
could O
show O
that O
the O
GSH B
level O
decreased O
significantly O
after O
exposure O
to O
magnetite O
particles O
, O
while O
catalase O
( O
CAT O
) O
activity O
was O
increased O
. O

We O
were O
able O
to O
show O
that O
incubation O
of O
A549 O
cells O
prior O
to O
particle O
treatment O
with O
diphenyleneiodonium B
( O
DPI B
) O
, O
a O
NADPH B
- O
oxidase O
( O
NOX O
) O
inhibitor O
, O
leads O
to O
decreased O
ROS O
formation O
, O
but O
this O
effect O
was O
not O
observed O
for O
the O
NOX O
inhibitor O
apocynin B
. O

Soluble O
iron B
does O
not O
contribute O
considerably O
to O
ROS O
production O
. O

Progesterone B
receptor O
( O
PR O
) O
plays O
a O
key O
role O
in O
reproductive O
functions O
, O
and O
compounds O
that O
inhibit O
progesterone B
action O
( O
antiprogestins O
) O
have O
potential O
use O
in O
the O
treatment O
of O
estrogen B
- O
and O
progesterone B
- O
dependent O
diseases O
, O
including O
uterine O
leiomyomas O
and O
breast O
cancer O
. O

The O
increases O
in O
blood O
urea B
nitrogen B
( O
BUN O
) O
and O
creatinine B
( O
CR O
) O
in O
both O
dose O
groups O
further O
revealed O
severe O
impairment O
occurred O
in O
the O
kidney O
of O
crucian O
carp O
. O

Glucose B
- O
induced O
insulin O
secretion O
from O
pancreatic O
beta O
- O
cells O
depends O
critically O
on O
activity O
of O
ATP B
- O
sensitive O
K B
+ I
channels O
( O
KATP O
channel O
) O
. O

We O
previously O
generated O
mice O
lacking O
Kir6 O
. O
2 O
, O
the O
pore O
subunit O
of O
the O
beta O
- O
cell O
KATP O
channel O
( O
Kir6 O
. O
2 O
- O
/ O
- O
) O
, O
that O
show O
almost O
no O
insulin O
secretion O
in O
response O
to O
glucose B
in O
vitro O
. O

Under O
ad O
libitum O
feeding O
or O
during O
voluntary O
feeding O
of O
standard O
chow O
, O
blood O
glucose B
levels O
and O
plasma O
insulin O
levels O
were O
similar O
in O
Kir6 O
. O
2 O
+ O
/ O
+ O
and O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
. O

By O
voluntary O
feeding O
of O
carbohydrate B
alone O
, O
insulin O
secretion O
was O
induced O
significantly O
in O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
, O
but O
was O
markedly O
attenuated O
compared O
to O
that O
in O
Kir6 O
. O
2 O
+ O
/ O
+ O
mice O
. O

On O
forced O
feeding O
of O
standard O
chow O
or O
carbohydrate B
alone O
, O
the O
insulin O
secretory O
response O
was O
markedly O
impaired O
or O
completely O
absent O
in O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
. O

Pre O
- O
treatment O
of O
a O
muscarine O
receptor O
antagonist O
, O
atropine O
methyl O
nitrate O
, O
which O
does O
not O
cross O
the O
blood O
- O
brain O
barrier O
, O
almost O
completely O
blocked O
insulin O
secretion O
induced O
by O
voluntary O
feeding O
of O
standard O
chow O
or O
carbohydrate B
in O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
. O

Substantial O
glucose B
- O
induced O
insulin O
secretion O
was O
induced O
in O
pancreas O
perfusion O
study O
of O
Kir6 O
. O
2 O
- O
/ O
- O
mice O
only O
in O
the O
presence O
of O
carbamylcholine O
. O

Using O
reporter O
gene O
and O
electrophoretic O
gel O
mobility O
shift O
assays O
we O
demonstrated O
that O
MK2 O
catalytic O
activity O
directly O
regulated O
the O
promoters O
of O
the O
fast O
fiber O
- O
specific O
myosin O
heavy O
chain O
IId O
/ O
x O
and O
the O
slow O
fiber O
- O
specific O
sarco O
/ O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
- O
ATPase O
( O
SERCA O
) O
2 O
gene O
. O

These O
results O
link O
MK2 O
/ O
3 O
to O
the O
regulation O
of O
calcium B
dynamics O
and O
identify O
enzymatic O
activity O
of O
MK2 O
/ O
3 O
as O
a O
critical O
factor O
for O
modulating O
cross O
- O
striated O
muscle O
function O
by O
generating O
a O
unique O
muscle O
phenotype O
exhibiting O
both O
, O
reduced O
fatigability O
and O
enhanced O
force O
in O
MK2 O
/ O
3 O
( O
- O
/ O
- O
) O
mice O
. O

N B
- O
alkylation O
of O
highly O
quaternized O
chitosan O
derivatives O
affects O
the O
paracellular O
permeation O
enhancement O
in O
bronchial O
epithelia O
in O
vitro O
. O

This O
study O
describes O
the O
structure O
- O
activity O
relationship O
for O
carefully O
characterized O
N O
- O
alkyl O
- O
N B
- O
quaternary O
chitosan O
derivatives O
as O
permeation O
enhancers O
for O
drugs O
that O
are O
mainly O
absorbed O
through O
the O
paracellular O
pathway O
, O
such O
as O
macromolecular O
drugs O
and O
hydrophilic O
drugs O
, O
in O
a O
well O
defined O
bronchial O
epithelial O
cell O
line O
. O

The O
structure O
- O
activity O
relationship O
suggests O
that O
more O
lipophilic O
derivatives O
show O
more O
permeation O
enhancement O
, O
TJ O
disassembly O
, O
and O
less O
viability O
in O
the O
order O
of O
hexyl O
= O
~ O
butyl B
> O
propyl B
> O
methyl B
and O
demonstrates O
that O
the O
permeation O
effect O
is O
not O
only O
mediated O
by O
permanent O
positive O
charge O
but O
also O
through O
by O
the O
extent O
of O
N B
- O
alkylation O
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
association O
of O
PON1 O
genetic O
variants O
with O
the O
susceptibility O
to O
coronary O
artery O
disease O
( O
CAD O
) O
and O
with O
the O
clinical O
endpoints O
in O
aspirin B
and O
clopidogrel B
( O
dual O
antiplatelet O
therapy O
) O
- O
treated O
Han O
Chinese O
patients O
with O
CAD O
after O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O

The O
geometrical O
structures O
and O
energies O
of O
mixed O
Ar B
- O
Kr O
- O
Xe B
clusters O
were O
investigated O
using O
ternary O
Lennard O
- O
Jones O
( O
TLJ O
) O
potential O
. O

The O
inner O
core O
of O
all O
these O
clusters O
is O
composed O
mainly O
of O
Ar B
atoms O
, O
and O
Kr O
and O
Xe B
atoms O
are O
distributed O
on O
the O
surface O
with O
well O
mixed O
pattern O
for O
polytetrahedral O
and O
segregate O
pattern O
for O
six O
- O
fold O
pancake O
configurations O
. O

The O
relative O
stability O
property O
of O
Ar B
- O
Kr O
- O
Xe B
clusters O
with O
a O
certain O
composition O
is O
discussed O
. O

Moreover O
, O
the O
role O
of O
heterogeneity O
on O
the O
strain O
was O
investigated O
, O
and O
reduced O
strain O
energies O
in O
Ar B
- O
Kr O
- O
Xe B
clusters O
were O
studied O
to O
find O
possible O
ways O
of O
reducing O
strain O
. O

The O
results O
showed O
that O
the O
strain O
energies O
were O
affected O
mainly O
by O
Ar B
- O
Ar B
, O
Ar B
- O
Kr O
, O
and O
Xe B
- O
Xe B
bonds O
. O

Region O
- O
specific O
regulation O
of O
5 O
- O
HT1B O
receptors O
in O
the O
rat O
brain O
by O
chronic O
venlafaxine B
treatment O
. O

RATIONALE O
: O
Venlafaxine B
is O
a O
non O
- O
selective O
serotonin B
and O
noradrenaline B
reuptake O
inhibitor O
antidepressant O
drug O
for O
which O
clinical O
studies O
have O
suggested O
a O
high O
level O
efficacy O
and O
a O
possible O
early O
action O
onset O
compared O
to O
the O
classical O
antidepressants O
. O

Its O
therapeutic O
effects O
might O
be O
due O
, O
at O
least O
in O
part O
, O
to O
adaptive O
changes O
in O
serotonergic O
neurotransmission O
, O
through O
the O
activation O
of O
the O
different O
5 B
- I
HT I
receptor O
subtypes O
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
venlafaxine B
( O
10 O
mg O
kg O
( O
- O
1 O
) O
day O
( O
- O
1 O
) O
, O
p O
. O
o O
. O
) O
after O
21 O
days O
of O
treatment O
on O
the O
density O
of O
5 O
- O
HT1B O
receptors O
and O
their O
functionality O
in O
rat O
brain O
. O

METHODS O
: O
Effects O
of O
chronic O
venlafaxine B
were O
evaluated O
at O
different O
levels O
of O
5 O
- O
HT1B O
receptor O
by O
using O
receptor O
autoradiography O
, O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
, O
and O
the O
regulation O
of O
body O
temperature O
induced O
by O
selective O
5 O
- O
HT1B O
agonist O
. O

RESULTS O
: O
Our O
results O
show O
that O
venlafaxine B
induced O
an O
increase O
in O
sensitivity O
of O
5 O
- O
HT1B O
receptors O
in O
hypothalamus O
both O
at O
G O
- O
protein O
level O
and O
the O
control O
of O
core O
temperature O
without O
affecting O
the O
receptor O
density O
. O

CONCLUSIONS O
: O
These O
results O
demonstrate O
that O
adaptive O
changes O
on O
5 O
- O
HT1B O
receptors O
induced O
by O
chronic O
administration O
of O
venlafaxine B
exhibit O
regional O
differences O
suggesting O
that O
the O
hypothalamus O
might O
be O
an O
important O
site O
of O
drug O
action O
. O

A O
library O
of O
ten O
2 O
- O
aminoimidazolone O
products O
( O
3 O
- O
12 O
) O
was O
prepared O
by O
coupling O
glycocyamidine O
and O
a O
variety O
of O
aldehydes B
using O
a O
one O
- O
step O
stereoselective O
aldol O
condensation O
reaction O
under O
microwave O
conditions O
. O

Resultant O
cells O
were O
able O
to O
secrete O
insulin O
in O
response O
to O
glucose B
and O
on O
transplantation O
, O
to O
normalise O
blood O
glucose B
levels O
in O
streptozotocin B
diabetic O
NOD O
/ O
Scid O
mice O
. O

OBJECTIVETo O
examine O
factors O
associated O
with O
clinical O
microalbuminuria O
( O
MA O
) O
diagnosis O
in O
children O
and O
adolescents O
in O
the O
T1D O
Exchange O
clinic O
registry O
. O
RESEARCH O
DESIGN O
AND O
METHODST1D O
Exchange O
participants O
< O
20 O
years O
of O
age O
with O
type O
1 O
diabetes O
> O
= O
1 O
year O
and O
urinary O
albumin O
- O
to O
- O
creatinine B
ratio O
( O
ACR O
) O
measured O
within O
the O
prior O
2 O
years O
were O
included O
in O
the O
analysis O
. O

Some O
of O
the O
most O
commonly O
affected O
assays O
were O
CYPs O
( O
CYP2C9 O
, O
CYP2C19 O
) O
, O
transporters O
( O
mitochondrial O
TSPO O
, O
norepinephrine B
, O
dopaminergic O
) O
, O
and O
GPCRs O
( O
aminergic O
) O
. O

Heavy O
metals O
, O
surfactants O
, O
and O
dithiocarbamate B
fungicides O
showed O
promiscuous O
, O
but O
distinctly O
different O
patterns O
of O
activity O
whereas O
many O
of O
the O
pharma O
compounds O
showed O
promiscuous O
activity O
across O
GPCRs O
. O

Herein O
, O
the O
polarized O
energy O
transfer O
up O
- O
conversion O
from O
REs O
doped O
fluoride B
nanorods O
is O
demonstrated O
in O
a O
single O
particle O
spectroscopy O
mode O
for O
the O
first O
time O
. O

Taking O
advantage O
of O
the O
REs O
based O
up O
- O
conversion O
, O
potential O
application O
in O
polarized O
microscopic O
multi O
- O
information O
transportation O
is O
suggested O
for O
the O
polarization O
anisotropy O
from O
REs O
doped O
fluoride B
single O
nanorod O
or O
nanorod O
array O
. O

Stability O
of O
sulforaphane B
for O
topical O
formulation O
. O

Abstract O
Context O
: O
Sulforaphane B
( O
SFN B
) O
is O
a O
natural O
compound O
that O
has O
been O
investigated O
as O
a O
chemopreventive O
agent O
. O

SFN B
has O
been O
shown O
to O
inhibit O
the O
activator O
- O
protein O
- O
1 O
( O
AP O
- O
1 O
) O
transcription O
factor O
and O
may O
be O
effective O
for O
inhibition O
of O
ultraviolet O
( O
UV O
) O
induced O
skin O
carcinogenesis O
. O

This O
study O
was O
designed O
to O
investigate O
the O
stability O
of O
SFN B
as O
a O
function O
of O
pH O
, O
temperature O
and O
in O
various O
solvents O
and O
formulations O
. O

Results O
: O
SFN B
was O
determined O
to O
undergo O
apparent O
first O
- O
order O
degradation O
kinetics O
for O
the O
conditions O
explored O
. O

It O
was O
observed O
that O
SFN B
undergoes O
base O
catalyzed O
degradation O
. O

SFN B
was O
found O
to O
be O
very O
sensitive O
to O
temperature O
with O
degradation O
rate O
changing O
by O
a O
factor O
of O
nearly O
3 O
. O
1 O
for O
every O
10 O
degrees O
C O
change O
in O
temperature O
( O
at O
pH O
4 O
. O
0 O
) O
. O

SFN B
completely O
degraded O
after O
30 O
days O
in O
a O
conventional O
pharmaceutical O
cream O
formulation O
. O

Stability O
studies O
were O
conducted O
on O
two O
nonaqueous O
topical O
formulations O
: O
a O
polyethylene B
glycol I
( O
PEG B
) O
ointment O
base O
and O
an O
organic O
oleaginous O
base O
. O

Conclusion O
: O
Topically O
applied O
SFN B
in O
the O
PEG B
base O
formulation O
significantly O
reduced O
AP O
- O
1 O
activation O
after O
UV O
stimulation O
in O
the O
skin O
of O
a O
transgenic O
mouse O
model O
, O
indicating O
that O
SFN B
in O
this O
formulation O
retains O
efficacy O
in O
vivo O
. O

Spontaneous O
partition O
of O
carbon B
nanotubes O
in O
polymer O
- O
modified O
aqueous O
phases O
. O

Here O
, O
we O
study O
distribution O
of O
carbon B
nanotubes O
( O
CNTs O
) O
in O
two O
immiscible O
aqueous O
phases O
formed O
by O
the O
addition O
of O
polyethylene B
glycol I
( O
PEG B
) O
and O
dextran O
. O

This O
well O
- O
defined O
model O
system O
exhibits O
a O
strikingly O
robust O
phenomenon O
: O
CNTs O
spontaneously O
partition O
between O
the O
PEG B
- O
and O
the O
dextran O
- O
rich O
phases O
according O
to O
nanotube O
' O
s O
diameter O
and O
metallicity O
. O

Structural O
insights O
obtained O
from O
the O
EGFR O
/ O
2a O
complex O
suggested O
that O
an O
extension O
from O
the O
meta O
- O
position O
on O
the O
phenyl B
group O
( O
ring O
- O
5 O
) O
would O
improve O
interactions O
with O
the O
DFG O
motif O
. O

Over O
the O
last O
decade O
, O
selective O
phosphopeptide O
enrichment O
methods O
including O
IMAC O
and O
metal B
oxides I
( O
TiO2 B
and O
ZrO2 O
) O
have O
been O
developed O
and O
greatly O
facilitate O
large O
scale O
phosphoproteome O
analysis O
of O
various O
cells O
, O
tissues O
and O
living O
organisms O
, O
in O
combination O
with O
modern O
mass O
spectrometers O
featuring O
high O
mass O
accuracy O
and O
high O
mass O
resolution O
. O

We O
describe O
common O
strategies O
for O
mass O
spectrometric O
analysis O
of O
stable O
isotope O
labeled O
samples O
, O
as O
well O
as O
two O
widely O
applied O
phosphopeptide O
enrichment O
methods O
based O
on O
IMAC O
( O
NTA O
- O
Fe O
( O
3 O
+ O
) O
) O
and O
metal B
oxide I
( O
ZrO2 O
) O
. O

Molecular O
docking O
studies O
suggested O
that O
SB O
has O
a O
good O
affinity O
towards O
vinblastine B
- O
binding O
site O
on O
beta O
- O
tubulin O
subunit O
. O

The O
inhibition O
of O
wogonoside O
against O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
cells O
were O
measured O
. O

Additionally O
, O
the O
effects O
of O
wogonoside O
on O
mRNA O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
2 O
( O
COX2 O
) O
, O
TNF O
- O
alpha O
and O
IL O
- O
6 O
were O
also O
investigated O
. O

RESULTS O
AND O
DISCUSSION O
: O
Wogonoside O
not O
only O
dose O
- O
dependently O
decreased O
the O
production O
of O
inflammatory O
mediators O
including O
NO B
and O
PGE2 B
but O
also O
inhibited O
the O
release O
of O
pro O
- O
inflammatory O
cytokines O
including O
TNF O
- O
alpha O
and O
IL O
- O
6 O
in O
LPS O
- O
induced O
RAW264 O
. O
7 O
cells O
. O

Relations O
between O
stimulation O
of O
mesolimbic O
dopamine B
and O
place O
conditioning O
in O
rats O
produced O
by O
cocaine B
or O
drugs O
that O
are O
tolerant O
to O
dopamine B
transporter O
conformational O
change O
. O

RATIONALE O
: O
Dopamine B
transporter O
( O
DAT O
) O
conformation O
plays O
a O
role O
in O
the O
effectiveness O
of O
cocaine B
- O
like O
and O
other O
DAT O
inhibitors O
. O

Cocaine B
- O
like O
stimulants O
are O
intolerant O
to O
DAT O
conformation O
changes O
having O
decreased O
potency O
in O
cells O
transfected O
with O
DAT O
constructs O
that O
face O
the O
cytosol O
compared O
to O
wild O
- O
type O
DAT O
. O

METHODS O
: O
We O
compared O
the O
displacement O
of O
radioligand O
binding O
to O
various O
mammalian O
CNS O
sites O
, O
acute O
stimulation O
of O
accumbens O
shell O
dopamine B
levels O
, O
and O
place O
conditioning O
in O
rats O
among O
cocaine B
and O
four O
BZT O
analogs O
with O
Cl B
substitutions O
on O
the O
diphenyl O
- O
ether O
system O
including O
two O
with O
carboalkoxy O
substitutions O
at O
the O
2 O
- O
position O
of O
the O
tropane B
ring O
. O

RESULTS O
: O
Binding O
assays O
confirmed O
high O
- O
affinity O
and O
selectivity O
for O
the O
DAT O
with O
the O
BZT O
analogs O
which O
also O
produced O
significant O
stimulation O
of O
mesolimbic O
dopamine B
efflux O
. O

Because O
BZT O
analogs O
produced O
temporal O
patterns O
of O
extracellular O
dopamine B
levels O
different O
from O
those O
by O
cocaine B
( O
3 O
- O
10 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
the O
place O
conditioning O
produced O
by O
BZT O
analogs O
and O
cocaine B
was O
compared O
at O
doses O
and O
times O
at O
which O
both O
the O
increase O
in O
dopamine B
levels O
and O
rates O
of O
increase O
were O
similar O
to O
those O
produced O
by O
an O
effective O
dose O
of O
cocaine B
. O

CONCLUSIONS O
: O
The O
present O
results O
extend O
previous O
findings O
suggesting O
that O
cocaine B
- O
like O
actions O
are O
dependent O
on O
a O
binding O
equilibrium O
that O
favors O
the O
outward O
conformational O
state O
of O
the O
DAT O
. O

In O
contrast O
, O
BZT O
analogs O
with O
reduced O
dependence O
on O
DAT O
conformation O
have O
reduced O
cocaine B
- O
like O
behavioral O
effects O
and O
may O
prove O
useful O
in O
development O
of O
medications O
for O
stimulant O
abuse O
. O

Decreased O
Permeability O
Surface O
Area O
for O
Glucose B
in O
Obese O
Women O
with O
Postprandial O
Hyperglycemia O
: O
No O
Effect O
of O
Phosphodiesterase O
- O
5 O
( O
PDE O
- O
5 O
) O
Inhibition O
. O

In O
this O
study O
, O
we O
compared O
a O
marker O
of O
microvascular O
function O
, O
the O
permeability O
surface O
area O
for O
glucose B
( O
PSglu O
) O
, O
and O
forearm O
glucose B
uptake O
after O
an O
OGTT O
in O
obese O
women O
with O
impaired O
glucose B
metabolism O
and O
healthy O
lean O
nondiabetic O
women O
, O
with O
the O
aim O
to O
characterize O
whether O
decreased O
permeability O
surface O
area O
for O
glucose B
or O
decreased O
glucose B
uptake O
may O
contribute O
to O
postprandial O
hyperglycemia O
in O
the O
obese O
group O
. O

In O
addition O
, O
we O
evaluated O
whether O
the O
phosphodiesterase O
- O
5 O
( O
PDE O
- O
5 O
) O
inhibitor O
tadalafil B
, O
in O
a O
randomized O
double O
blind O
placebo O
controlled O
design O
, O
might O
attenuate O
postprandial O
glucose B
levels O
in O
obese O
women O
. O

The O
results O
showed O
an O
impaired O
permeability O
surface O
area O
for O
glucose B
( O
IAUC O
PSglu O
31 O
+ O
/ O
- O
13 O
vs O
. O
124 O
+ O
/ O
- O
31 O
; O
p O
< O
0 O
. O
05 O
) O
in O
obese O
when O
compared O
with O
lean O
participants O
, O
but O
no O
differences O
in O
forearm O
glucose B
uptake O
appeared O
between O
the O
groups O
. O

Furthermore O
, O
a O
single O
dose O
of O
tadalafil B
10 O
mg O
showed O
no O
improvement O
of O
the O
permeability O
surface O
area O
for O
glucose B
, O
glucose B
uptake O
, O
or O
circulating O
glucose B
levels O
in O
obese O
participants O
. O

However O
, O
we O
were O
unable O
to O
demonstrate O
any O
acute O
effect O
on O
either O
vascular O
function O
or O
glucose B
uptake O
of O
the O
phosphodiesterase O
- O
5 O
( O
PDE O
- O
5 O
) O
inhibitor O
tadalafil B
. O

Dietary O
Flaxseed O
Oil O
Supplementation O
Mitigates O
the O
Effect O
of O
Lead O
on O
the O
Enzymes O
of O
Carbohydrate B
Metabolism O
, O
Brush O
Border O
Membrane O
, O
and O
Oxidative O
Stress O
in O
Rat O
Kidney O
Tissues O
. O

Recently O
, O
flaxseed O
oil O
( O
FXO O
) O
, O
a O
rich O
source O
of O
omega B
- I
3 I
fatty I
acids I
and O
lignans B
, O
has O
been O
shown O
to O
prevent O
/ O
reduce O
the O
progression O
of O
certain O
types O
of O
cardiovascular O
and O
renal O
disorders O
. O

Various O
serum O
parameters O
, O
enzymes O
of O
carbohydrate B
metabolism O
, O
brush O
border O
membrane O
( O
BBM O
) O
, O
and O
oxidative O
stress O
were O
analyzed O
in O
rat O
kidney O
. O

PbAc O
nephrotoxicity O
was O
characterized O
by O
increased O
serum O
creatinine B
and O
blood O
urea B
nitrogen B
. O

PbAc O
increased O
the O
activities O
of O
lactate B
dehydrogenase O
and O
NADP B
- O
malic O
enzyme O
, O
whereas O
it O
decreased O
malate B
and O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
, O
glucose B
- O
6 O
- O
phosphatase O
, O
fructose B
- O
1 O
, O
6 O
- O
bisphosphatase O
, O
and O
BBM O
enzyme O
activities O
. O

PbAc O
caused O
oxidant O
/ O
antioxidant O
imbalances O
as O
reflected O
by O
increased O
lipid O
peroxidation O
and O
decreased O
activities O
of O
superoxide B
dismutase O
, O
glutathione B
peroxidase O
, O
and O
catalase O
. O

In O
contrast O
, O
FXO O
alone O
enhanced O
the O
enzyme O
activities O
of O
carbohydrate B
metabolism O
, O
BBM O
, O
and O
antioxidant O
defense O
system O
. O

Biosensing O
with O
virus O
- O
PEDOT B
films O
provides O
a O
100 O
pM O
limit O
of O
detection O
for O
PSMA O
in O
synthetic O
urine O
without O
requiring O
enzymatic O
or O
other O
amplification O
. O

In O
the O
present O
study O
, O
we O
examined O
oxidative O
stress O
and O
genotoxic O
effects O
of O
sub O
- O
chronic O
low O
- O
dose O
VOCs O
mixture O
( O
formaldehyde B
, O
benzene B
, O
toluene B
and O
xylene B
) O
. O

Results O
showed O
that O
exposure O
to O
VOCs O
( O
IAQS O
dose O
) O
resulted O
in O
oxidative O
damages O
of O
lung O
, O
which O
were O
supported O
by O
the O
significant O
changes O
on O
reactive O
oxygen B
species O
, O
reduced B
glutathione I
( O
GSH B
) O
, O
GSH B
S B
- O
transferase O
, O
total O
antioxidative O
capacity O
, O
malondialdehyde B
, O
protein O
carbonyl B
and O
nitric B
oxide I
( O
NO B
) O
. O

Moreover O
, O
oxidative O
stress O
markers O
in O
group O
5S O
and O
10S O
( O
except O
NO B
) O
in O
lung O
were O
affected O
significantly O
. O

Both O
nitrobenzene B
and O
1 O
, O
4 O
- O
dinitrobenzene O
decreased O
fluorescence O
intensity O
and O
molecular O
conductivity O
, O
while O
toluene B
had O
no O
effect O
. O

In O
vitro O
effect O
of O
N B
- I
acetylcysteine I
on O
hepatocyte O
injury O
caused O
by O
dichlorodiphenyltric B
and O
its O
metabolites O
. O

The O
organochlorine B
pesticide O
, O
dichlorodiphenyltric B
( O
DDT B
) O
, O
is O
still O
used O
to O
combat O
the O
spread O
of O
malaria O
in O
several O
developing O
countries O
despite O
its O
accumulation O
and O
known O
hepatotoxic O
effects O
that O
have O
been O
demonstrated O
both O
in O
vitro O
and O
in O
vivo O
. O

N B
- I
Acetylcysteine I
( O
NAC B
) O
is O
a O
recognized O
hepatoprotective O
agent O
that O
has O
been O
reported O
to O
reduce O
hepatotoxicity O
initiated O
by O
many O
different O
compounds O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
NAC B
could O
counter O
in O
vitro O
hepatocyte O
injury O
induced O
by O
DDT B
or O
its O
two O
major O
metabolites O
, O
dichlorodiphenyldich B
and O
dichlorodiphenyldich B
. O

HepG2 O
cell O
cultures O
were O
used O
to O
assess O
the O
following O
parameters O
of O
toxicity O
: O
cellular O
viability O
, O
intracellular O
levels O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
mitochondrial O
membrane O
potential O
and O
initiation O
of O
apoptosis O
. O

None O
of O
the O
three O
test O
compounds O
induced O
ROS O
generation O
, O
yet O
exposure O
to O
any O
of O
the O
three O
compounds O
produced O
mitochondrial O
hyperpolarization O
, O
which O
was O
countered O
by O
NAC B
pretreatment O
. O

All O
three O
test O
compounds O
also O
induced O
apoptotic O
cell O
death O
, O
which O
was O
inhibited O
by O
NAC B
. O

Despite O
NAC B
counteracting O
some O
adverse O
intracellular O
changes O
due O
to O
organochlorine B
exposure O
, O
it O
appeared O
to O
aggravate O
the O
cytotoxic O
effects O
of O
the O
organochlorine B
compounds O
at O
low O
test O
concentrations O
. O

As O
the O
same O
outcome O
may O
also O
occur O
in O
vivo O
, O
results O
from O
the O
present O
study O
raise O
concern O
about O
the O
use O
of O
NAC B
as O
treatment O
for O
DDT B
- O
induced O
hepatotoxicity O
. O

Current O
knowledge O
of O
the O
physiology O
and O
phylogeny O
of O
polycyclic O
aromatic O
hydrocarbon O
( O
PAH B
) O
degrading O
bacteria O
often O
relies O
on O
laboratory O
enrichments O
and O
isolations O
. O

In O
the O
present O
study O
, O
in O
situ O
microcosms O
consisting O
of O
activated O
carbon B
pellets O
( O
BACTRAP O
( O
R O
) O
s O
) O
were O
loaded O
with O
either O
( O
13 O
) O
C O
- O
naphthalene O
or O
( O
13 O
) O
C O
- O
fluorene O
and O
were O
subsequently O
exposed O
in O
the O
contaminant O
source O
and O
plume O
fringe O
region O
of O
an O
PAH B
contaminated O
aquifer O
. O

Proteins O
identified O
of O
the O
naphthalene B
degradation O
pathway O
showed O
a O
relative O
( B
13 I
) I
C I
isotope O
abundance O
of O
approximately O
50 O
atom O
% O
demonstrating O
that O
the O
identified O
naphthalene B
degrading O
bacteria O
gained O
at O
least O
80 O
% O
of O
their O
carbon B
by O
PAH B
degradation O
. O

Although O
the O
microbial O
community O
grown O
on O
the O
fluorene B
- O
BACTRAPs O
showed O
a O
structure O
similar O
to O
the O
naphthalene B
- O
BACTRAPs O
, O
the O
identification O
of O
fluorene B
degraders O
and O
degradation O
pathways O
failed O
in O
situ O
. O

In O
complementary O
laboratory O
microcosms O
, O
a O
clear O
enrichment O
in O
proteins O
related O
to O
Rhodococcus O
and O
possible O
fluorene B
degradation O
enzymes O
was O
observed O
. O

Folate B
- O
Conjugated O
PEG B
on O
Single O
Walled O
Carbon B
Nanotubes O
for O
Targeting O
Delivery O
of O
Doxorubicin B
to O
Cancer O
Cells O
. O

A O
highly O
effective O
drug O
carrier O
is O
constructed O
by O
coating O
folic B
acid I
- O
terminated O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
- O
FA O
) O
on O
single O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
in O
a O
facile O
non O
- O
covalent O
method O
. O

The O
anti O
- O
cancer O
drug O
, O
doxorubicin B
( O
DOX B
) O
, O
is O
further O
loaded O
on O
the O
surface O
of O
SWNTs O
at O
a O
very O
high O
loading O
efficiency O
, O
149 O
. O
3 O
+ O
/ O
- O
4 O
. O
1 O
% O
. O

The O
drug O
system O
( O
DOX B
/ O
PEG B
- O
FA O
/ O
SWNTs O
) O
exhibits O
excellent O
stability O
under O
neutral O
pH O
conditions O
such O
as O
serum O
, O
but O
dramatically O
releases O
DOX B
at O
reduced O
pH O
typical O
of O
the O
tumour O
environment O
and O
intracellular O
lysosomes O
and O
endosomes O
. O

With O
the O
help O
of O
FA O
, O
DOX B
/ O
PEG B
- O
FA O
/ O
SWNTs O
tend O
to O
selectively O
attach O
onto O
cancer O
cells O
and O
enter O
the O
lysosomes O
or O
endosomes O
by O
clathrin O
- O
mediated O
endocytosis O
. O

Analysis O
by O
gas O
chromatography O
showed O
LPS1 O
was O
a O
homopolysaccharide O
of O
glucose B
with O
glycosidic O
linkage O
of O
- O
- O
> O
6 O
) O
- O
D O
- O
Glc O
- O
( O
1 O
- O
- O
> O
. O

Nuclear O
magnetic O
resonance O
( O
NMR O
) O
spectra O
indicated O
that O
the O
con O
fi O
guration O
of O
anomeric O
carbon B
in O
glucose B
residual O
was O
alpha O
- O
form O
. O

The O
molecular O
weight O
of O
LPS1 O
was O
calculated O
to O
be O
108 O
kDa O
, O
which O
had O
661 O
glucose B
residuals O
. O

Hybrid O
Molecule O
from O
O O
( O
2 O
) O
- O
( O
2 O
, O
4 O
- O
Dinitrophenyl O
) O
diazeniumdiolate O
and O
Oleanolic B
Acid I
: O
a O
GST O
pi O
Activated O
Nitric B
Oxide I
Prodrug O
with O
Selective O
Anti O
- O
human O
Hepatocellular O
Carcinoma O
Activity O
and O
Improved O
Stability O
. O

A O
series O
of O
hybrids O
from O
O O
( O
2 O
) O
- O
( O
2 O
, O
4 O
- O
dinitrophenyl O
) O
diazeniumdiolate O
and O
oleanolic B
acid I
( O
OA O
) O
were O
designed O
, O
synthesized O
, O
and O
biologically O
evaluated O
as O
novel O
nitric B
oxide I
( O
NO B
) O
releasing O
prodrugs O
which O
could O
be O
activated O
by O
glutathione B
S O
- O
transferase O
pi O
( O
GST O
pi O
) O
overexpressed O
in O
a O
number O
of O
cancer O
cells O
. O

It O
was O
discovered O
that O
the O
most O
active O
compound O
21 O
released O
high O
levels O
of O
NO B
selectively O
in O
HCC O
cells O
but O
not O
in O
the O
normal O
cells O
, O
and O
exhibited O
potent O
antiproliferative O
activity O
in O
vitro O
as O
well O
as O
remarkable O
tumor O
- O
retarding O
effects O
in O
vivo O
. O

Compared O
with O
the O
reported O
GST O
pi O
- O
activated O
prodrugs O
JS O
- O
K O
and O
PABA O
/ O
NO B
, O
21 O
exhibited O
remarkably O
improved O
stability O
in O
the O
absence O
of O
GST O
pi O
. O

Rationale O
for O
the O
higher O
reactivity O
of O
interfacial O
sites O
in O
methanol B
decomposition O
on O
Au13 O
/ O
TiO2 O
( O
110 O
) O
. O

We O
find O
that O
the O
higher O
activity O
of O
interfacial O
sites O
in O
Au13 O
/ O
TiO2 O
( O
110 O
) O
towards O
methanol B
decomposition O
originates O
from O
charge O
- O
transfer O
- O
induced O
Coulomb O
interaction O
among O
the O
gold O
, O
reactant O
, O
and O
reducible O
TiO2 B
support O
, O
brought O
about O
through O
the O
formation O
of O
an O
ionic O
O O
- O
Au O
bond O
between O
gold O
and O
methoxy B
in O
such O
sites O
, O
which O
turns O
the O
participating O
perimeter O
gold O
atom O
cationic O
. O

A O
direct O
result O
of O
such O
charge O
- O
transfer O
- O
induced O
repulsive O
interaction O
between O
cationic O
gold O
and O
positively O
charged O
C B
moiety O
of O
methoxy B
is O
activation O
of O
the O
positively O
charged O
C B
moiety O
of O
methoxy B
, O
as O
manifested O
by O
the O
pronounced O
elongation O
of O
O B
- I
C I
bond O
length O
and O
the O
tilting O
of O
the O
methoxy B
axis O
, O
which O
facilitate O
reaction O
of O
methoxy B
through O
C B
- I
H I
scission O
with O
the O
bridge O
oxygen B
atoms O
that O
are O
readily O
available O
from O
the O
reducible O
support O
. O

More O
generally O
, O
our O
proposed O
mechanism O
for O
the O
reactivity O
of O
the O
gold O
/ O
TiO2 B
interface O
should O
hold O
for O
oxidation O
of O
organic O
molecules O
with O
the O
structure O
of O
R O
- O
O O
- O
R O
' O
, O
where O
R O
and O
R O
' O
are O
( O
saturated O
) O
hydrocarbons O
. O

Cadmium B
- O
Based O
Quantum O
Dot O
Induced O
Autophagy O
Formation O
for O
Cell O
Survival O
via O
Oxidative O
Stress O
. O

QDs O
in O
RAG O
cells O
increased O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
levels O
and O
induced O
autophagy O
at O
6 O
h O
, O
leading O
to O
subsequent O
apoptosis O
at O
24 O
h O
. O

N B
- I
Acetylcysteine I
, O
an O
antioxidant O
agent O
, O
reduced O
intracellular O
ROS O
levels O
and O
decreased O
QD O
- O
induced O
autophagy O
but O
enhanced O
QD O
- O
induced O
cell O
death O
. O

Nasal O
dosimetry O
of O
inspired O
naphthalene B
vapor O
in O
the O
male O
and O
female O
B6C3F1 O
mouse O
. O

Naphthalene B
vapor O
is O
a O
nasal O
cytotoxicant O
in O
the O
rat O
and O
mouse O
but O
is O
a O
nasal O
carcinogen O
in O
only O
the O
rat O
. O

To O
define O
the O
nasal O
dosimetry O
of O
naphthalene B
in O
the O
B6C3F1 O
male O
and O
female O
mouse O
, O
uptake O
of O
naphthalene B
vapor O
was O
measured O
in O
the O
surgically O
isolated O
upper O
respiratory O
tract O
( O
URT O
) O
at O
inspiratory O
flow O
rates O
of O
25 O
or O
50ml O
/ O
min O
. O

Both O
uptake O
efficiency O
and O
the O
concentration O
dependence O
of O
uptake O
were O
significantly O
diminished O
by O
5 O
- O
phenyl O
- O
1 O
- O
pentyne O
indicating O
inspired O
naphthalene B
vapor O
is O
extensively O
metabolized O
in O
the O
mouse O
nose O
with O
saturation O
of O
metabolism O
occurring O
at O
the O
higher O
concentrations O
. O

Overall O
, O
the O
high O
URT O
uptake O
efficiency O
of O
naphthalene B
in O
the O
mouse O
nose O
indicates O
the O
absence O
of O
a O
tumorigenic O
response O
is O
not O
attributable O
to O
low O
delivered O
dose O
rates O
in O
this O
species O
. O

Exposure O
to O
DEHP B
decreased O
four O
fatty B
acid I
levels O
in O
plasma O
of O
prepartum O
mice O
. O

Maternal O
exposure O
to O
di B
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
decreased O
the O
plasma O
triglyceride B
in O
prepartum O
mice O
. O

To O
identify O
the O
fatty B
acid I
( O
FA O
) O
species O
involved O
and O
to O
understand O
the O
underlying O
mechanisms O
, O
pregnant O
Sv O
/ O
129 O
wild O
- O
type O
( O
mPPAR O
alpha O
) O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
- O
null O
( O
Ppar O
alpha O
- O
null O
) O
and O
humanized O
PPAR O
alpha O
( O
hPPAR O
alpha O
) O
mice O
were O
treated O
with O
diets O
containing O
0 O
% O
, O
0 O
. O
01 O
% O
, O
0 O
. O
05 O
% O
or O
0 O
. O
1 O
% O
DEHP B
. O

The O
plasma O
levels O
of O
linoleic B
acid I
, O
alpha O
- O
linolenic O
acid O
, O
palmitic B
acid I
and O
oleic B
acid I
were O
higher O
in O
the O
pregnant O
control O
mPPARa O
mice O
than O
in O
Ppara O
- O
null O
and O
hPPARa O
mice O
. O

DEHP B
exposure O
significantly O
decreased O
the O
levels O
of O
these O
four O
FAs O
only O
in O
pregnant O
mPPAR O
alpha O
mice O
. O

DEHP B
exposure O
slightly O
increased O
hepatic O
arachidonic B
acid I
, O
alpha O
- O
linolenic O
acid O
, O
palmitoleic O
acid O
and O
oleic B
acid I
in O
fetuses O
, O
but O
not O
in O
pups O
. O

However O
, O
DEHP B
exposure O
did O
not O
clearly O
influence O
FA O
desaturase O
1 O
and O
2 O
nor O
elongase O
2 O
and O
5 O
expressions O
in O
the O
liver O
of O
all O
maternal O
mice O
. O

Taken O
together O
, O
the O
levels O
of O
plasma O
four O
FAs O
with O
shorter O
carbon B
chains O
were O
higher O
in O
pregnant O
mPPAR O
alpha O
mice O
than O
in O
other O
genotypes O
, O
and O
DEHP B
exposure O
decreased O
these O
specific O
FA O
concentrations O
only O
in O
mPPAR O
alpha O
mice O
, O
similarly O
to O
triglyceride B
levels O
. O

The O
role O
of O
methyl B
- O
CpG B
binding O
protein O
2 O
in O
liver O
fibrosis O
. O

Liver O
injure O
is O
induced O
by O
various O
insults O
such O
as O
alcohol B
abuse O
, O
if O
insults O
persistent O
, O
may O
result O
in O
the O
formation O
of O
liver O
fibrosis O
. O

In O
this O
review O
we O
focus O
on O
the O
role O
of O
the O
methyl B
- O
CpG B
binding O
protein O
2 O
( O
MeCP2 O
) O
transcriptional O
regulation O
of O
different O
target O
genes O
and O
the O
interaction O
MeCP2 O
with O
microRNAs O
( O
miRNAs O
) O
during O
liver O
fibrosis O
. O

Dabigatran B
for O
the O
Prevention O
of O
Stroke O
and O
Systemic O
Embolism O
in O
Atrial O
Fibrillation O
: O
A O
NICE O
Single O
Technology O
Appraisal O
. O

The O
National O
Institute O
for O
Health O
and O
Clinical O
Excellence O
( O
NICE O
) O
invited O
the O
manufacturer O
of O
dabigatran B
etexilate I
( O
Boehringer O
Ingelheim O
Ltd O
, O
UK O
) O
to O
submit O
evidence O
for O
the O
clinical O
and O
cost O
- O
effectiveness O
of O
this O
drug O
for O
the O
prevention O
of O
stroke O
and O
systemic O
embolism O
in O
patients O
with O
non O
- O
valvular O
atrial O
fibrillation O
( O
AF O
) O
as O
part O
of O
the O
NICE O
single O
technology O
appraisal O
process O
. O

This O
article O
presents O
a O
summary O
of O
the O
manufacturer O
' O
s O
submission O
, O
the O
ERG O
report O
and O
the O
subsequent O
development O
of O
NICE O
guidance O
for O
the O
use O
of O
dabigatran B
within O
the O
UK O
National O
Health O
Service O
. O

Dabigatran B
was O
granted O
marketing O
authorisation O
by O
the O
European O
Medicines O
Agency O
for O
a O
sequential O
dosing O
regimen O
( O
DBG O
sequential O
) O
, O
in O
which O
patients O
under O
80 O
years O
are O
treated O
with O
dabigatran B
150 O
mg O
twice O
daily O
( O
DBG150 O
) O
and O
patients O
80 O
years O
and O
over O
are O
given O
dabigatran B
110 O
mg O
twice O
daily O
( O
DBG110 O
) O
. O

NICE O
decisions O
are O
bound O
by O
the O
marketing O
authorisation O
; O
therefore O
, O
the O
decision O
problem O
faced O
by O
the O
committee O
was O
whether O
the O
DBG O
sequential O
regimen O
was O
effective O
and O
cost O
- O
effective O
compared O
with O
warfarin B
or O
aspirin B
for O
patients O
with O
non O
- O
valvular O
AF O
and O
one O
or O
more O
risk O
factors O
. O

DBG150 O
was O
shown O
to O
be O
non O
- O
inferior O
, O
and O
subsequently O
superior O
to O
warfarin B
, O
for O
the O
primary O
outcome O
of O
all O
stroke O
/ O
systemic O
embolism O
. O

DBG110 O
was O
found O
to O
be O
non O
- O
inferior O
to O
warfarin B
. O

Results O
were O
presented O
for O
a O
post O
hoc O
subgroup O
analysis O
for O
patients O
under O
and O
over O
80 O
years O
of O
age O
, O
where O
DBG110 O
showed O
a O
statistically O
significant O
reduction O
of O
haemorrhagic O
stroke O
and O
intracranial O
haemorrhage O
in O
comparison O
to O
warfarin B
in O
patients O
over O
80 O
years O
of O
age O
. O

The O
economic O
evaluation O
compared O
the O
costs O
and O
outcomes O
of O
DBG110 O
, O
DBG150 O
and O
DBG O
sequential O
against O
warfarin B
, O
aspirin B
, O
and O
aspirin B
plus O
clopidogrel B
. O

Across O
the O
three O
dosing O
regimens O
, O
dabigatran B
was O
associated O
with O
greater O
costs O
and O
better O
health O
outcomes O
than O
warfarin B
; O
however O
, O
DBG150 O
offered O
the O
most O
benefits O
and O
dominated O
DBG110 O
and O
DBG O
sequential O
( O
i O
. O
e O
. O
less O
costly O
and O
more O
effective O
) O
. O

The O
cost O
- O
effectiveness O
of O
DBG150 O
was O
less O
favourable O
for O
patients O
well O
controlled O
on O
warfarin B
. O

These O
additional O
analyses O
indicated O
that O
the O
incremental O
cost O
- O
effectiveness O
ratio O
( O
ICER O
) O
of O
the O
DBG O
sequential O
regimen O
compared O
with O
warfarin B
ranged O
from O
pound O
8 O
, O
388 O
to O
pound O
18 O
, O
987 O
per O
quality O
- O
adjusted O
life O
year O
( O
QALY O
) O
gained O
depending O
on O
the O
level O
of O
monitoring O
costs O
assumed O
for O
warfarin B
. O

Patients O
on O
warfarin B
would O
need O
to O
be O
within O
therapeutic O
range O
83 O
- O
85 O
% O
of O
the O
time O
for O
the O
ICER O
to O
exceed O
pound O
30 O
, O
000 O
per O
additional O
QALY O
. O

Following O
consideration O
of O
the O
additional O
evidence O
and O
the O
responses O
from O
a O
large O
number O
of O
consultees O
and O
commentators O
, O
the O
committee O
recommended O
dabigatran B
as O
DBG O
sequential O
as O
an O
option O
for O
the O
prevention O
of O
stroke O
and O
systemic O
embolism O
in O
people O
with O
non O
- O
valvular O
AF O
with O
one O
or O
more O
risk O
factors O
for O
ischaemic O
stroke O
. O

Asymmetric O
zinc B
- O
catalyzed O
hydrosilylation O
of O
ketones B
and O
the O
effect O
of O
carboxylate B
on O
the O
enantioselectivity O
. O

Several O
chiral O
ligands O
containing O
( O
R O
, O
R O
) O
- O
diaminocyclohexane O
moieties O
and O
pyrrole B
, O
furan B
, O
or O
benzene B
have O
been O
synthesized O
. O

These O
ligands O
were O
tested O
in O
enantioselective O
zinc B
- O
catalyzed O
hydrosilylation O
reactions O
; O
excellent O
enantioselectivities O
were O
obtained O
when O
the O
ligands O
containing O
( O
R O
, O
R O
) O
- O
diaminocyclohexane O
moieties O
and O
furan B
rings O
were O
used O
. O

For O
comparison O
, O
zinc B
chloride I
combined O
with O
different O
potassium O
carboxylate O
salts O
and O
ligands O
were O
also O
tested O
for O
catalytic O
hydrosilylation O
reactions O
. O

The O
difference O
in O
IC50 O
values O
for O
each O
of O
the O
inhibitors O
across O
all O
test O
systems O
and O
equations O
ranged O
from O
a O
minimum O
of O
20 O
- O
and O
24 O
- O
fold O
between O
lowest O
and O
highest O
IC50 O
values O
for O
sertraline O
and O
isradipine O
, O
to O
a O
maximum O
of O
407 O
- O
and O
796 O
- O
fold O
for O
telmisartan B
and O
verapamil B
, O
respectively O
. O

For O
telmisartan B
and O
verapamil B
, O
variability O
was O
greatly O
influenced O
by O
data O
from O
one O
laboratory O
in O
each O
case O
. O

Excluding O
these O
two O
data O
sets O
brings O
the O
range O
in O
IC50 O
values O
for O
telmisartan B
and O
verapamil B
down O
to O
69 O
- O
and O
159 O
- O
fold O
. O

Study O
of O
Charge O
- O
Dependent O
Transport O
and O
Toxicity O
of O
Peptide O
- O
Functionalized O
Silver B
Nanoparticles O
Using O
Zebrafish O
Embryos O
and O
Single O
Nanoparticle O
Plasmonic O
Spectroscopy O
. O

In O
this O
study O
, O
we O
have O
functionalized O
the O
surfaces O
of O
silver B
nanoparticles O
( O
Ag B
NPs O
, O
11 O
. O
7 O
+ O
/ O
- O
2 O
. O
7 O
nm O
in O
diameters O
) O
with O
three O
biocompatible O
peptides O
( O
CALNNK O
, O
CALNNS O
, O
CALNNE O
) O
to O
prepare O
positively O
( O
Ag B
- O
CALNNK O
NPs O
+ O
zeta O
) O
, O
negatively O
( O
Ag B
- O
CALNNS O
NPs O
- O
2 O
zeta O
) O
, O
and O
more O
negatively O
charged O
NPs O
( O
Ag B
- O
CALNNE O
NPs O
- O
4 O
zeta O
) O
, O
respectively O
. O

Each O
peptide O
differs O
in O
a O
single O
amino B
acid I
at O
its O
C B
- O
terminus O
, O
which O
minimizes O
the O
effects O
of O
peptide O
sequences O
and O
serves O
as O
a O
model O
molecule O
to O
create O
positive O
, O
neutral O
and O
negative O
charges O
on O
the O
surface O
of O
the O
NPs O
at O
pH O
4 O
- O
10 O
. O

We O
found O
that O
all O
three O
Ag B
- O
peptide O
NPs O
passively O
diffused O
into O
the O
embryos O
via O
their O
chorionic O
pore O
canals O
, O
and O
stayed O
inside O
the O
embryos O
throughout O
their O
entire O
development O
( O
120 O
h O
) O
, O
showing O
charge O
- O
independent O
diffusion O
modes O
and O
charge O
- O
dependent O
diffusion O
coefficients O
. O

Notably O
, O
the O
NPs O
create O
charge O
- O
dependent O
toxic O
effects O
on O
embryonic O
development O
, O
showing O
that O
the O
Ag B
- O
CALNNK O
NPs O
+ O
zeta O
( O
positively O
charged O
) O
are O
the O
most O
biocompatible O
while O
the O
Ag B
- O
CALNNE O
NPs O
- O
4 O
zeta O
( O
more O
negatively O
charged O
) O
are O
the O
most O
toxic O
. O

By O
comparing O
with O
our O
previous O
studies O
of O
the O
same O
sized O
citrated O
Ag B
and O
Au B
NPs O
, O
the O
Ag B
- O
peptide O
NPs O
are O
much O
more O
biocompatible O
than O
the O
citrated O
Ag B
NPs O
, O
and O
nearly O
as O
biocompatible O
as O
the O
Au B
NPs O
, O
showing O
the O
dependence O
of O
nanotoxicity O
upon O
the O
surface O
charges O
, O
surface O
functional O
groups O
and O
chemical O
compositions O
of O
the O
NPs O
. O

Two O
new O
vinblastine B
- O
type O
N O
- O
oxide O
alkaloids O
from O
Catharanthus O
roseus O
. O

Two O
new O
vinblastine B
- O
type O
N O
- O
oxide O
alkaloids O
, O
17 O
- O
desacetoxyvinblastin O
[ O
Formula O
: O
see O
text O
] O
- O
oxide B
( O
1 O
) O
and O
20 O
' O
- O
deoxyvinblastine O
[ O
Formula O
: O
see O
text O
] O
- O
oxide B
( O
2 O
) O
, O
were O
isolated O
from O
the O
leaves O
of O
Catharanthus O
roseus O
. O

All O
alkaloids O
were O
evaluated O
for O
their O
cytotoxic O
activities O
against O
the O
human O
hepatocellular O
carcinoma O
( O
HepG2 O
) O
cell O
line O
, O
human O
colorectal O
carcinoma O
( O
Lovo O
) O
cell O
line O
and O
human O
breast O
carcinoma O
( O
MCF O
- O
7 O
) O
cell O
line O
by O
the O
MTT B
method O
in O
vitro O
, O
respectively O
. O

A O
photocaged O
lysine B
analogue O
was O
site O
- O
specifically O
incorporated O
into O
fLuc O
to O
replace O
its O
key O
catalytic O
lysine B
residue O
- O
Lys529 O
, O
rendering O
fLuc O
inactive O
until O
light O
- O
triggered O
removal O
of O
the O
caging O
group O
. O

This O
photo O
- O
induced O
gain O
- O
of O
- O
luminescence O
provides O
a O
facile O
approach O
for O
assessing O
the O
photolysis O
efficiency O
of O
this O
valuable O
photosensitive O
lysine B
analogue O
within O
the O
context O
of O
its O
carrier O
protein O
in O
vitro O
and O
in O
living O
cells O
. O

We O
further O
took O
advantage O
of O
the O
spatial O
and O
temporal O
activation O
feature O
of O
pfLuc O
for O
intracellular O
measurement O
of O
labile O
ATP B
levels O
without O
impairment O
of O
a O
cell O
' O
s O
physiology O
. O

CYP2D O
metabolizes O
codeine O
to O
the O
active O
morphine B
metabolite O
. O

Rats O
received O
intracerebroventricu O
injections O
of O
CYP2D O
inhibitors O
( O
20 O
mu O
g O
propranolol B
or O
40 O
mu O
g O
propafenone O
) O
or O
vehicle O
controls O
. O

Compared O
to O
vehicle O
- O
pretreated O
rats O
, O
inhibitor O
- O
pretreated O
rats O
had O
: O
a O
) O
lower O
analgesia O
in O
the O
tail O
- O
flick O
test O
( O
p O
< O
0 O
. O
05 O
) O
and O
lower O
areas O
under O
the O
analgesia O
- O
time O
curve O
( O
p O
< O
0 O
. O
02 O
) O
within O
the O
first O
hour O
after O
30mg O
/ O
kg O
subcutaneous O
codeine O
, O
b O
) O
lower O
morphine B
concentrations O
and O
morphine B
to O
codeine O
ratios O
in O
the O
brain O
( O
p O
< O
0 O
. O
02 O
and O
p O
< O
0 O
. O
05 O
, O
respectively O
) O
, O
but O
not O
in O
plasma O
( O
p O
> O
0 O
. O
6 O
and O
p O
> O
0 O
. O
7 O
, O
respectively O
) O
, O
tested O
at O

30min O
after O
30mg O
/ O
kg O
subcutaneous O
codeine O
, O
and O
c O
) O
lower O
morphine B
formation O
from O
codeine O
ex O
vivo O
by O
brain O
membranes O
( O
p O
< O
0 O
. O
04 O
) O
, O
but O
not O
by O
liver O
microsomes O
( O
p O
> O
0 O
. O
9 O
) O
. O

Analgesia O
trended O
toward O
a O
correlation O
with O
brain O
morphine B
concentrations O
( O
p O
= O
0 O
. O
07 O
) O
and O
correlated O
with O
brain O
morphine B
to O
codeine O
ratios O
( O
p O
< O
0 O
. O
005 O
) O
, O
but O
not O
with O
plasma O
morphine B
concentrations O
( O
p O
> O
0 O
. O
8 O
) O
or O
plasma O
morphine B
to O
codeine O
ratios O
( O
p O
> O
0 O
. O
8 O
) O
. O

Our O
findings O
suggest O
that O
brain O
CYP2D O
affects O
brain O
morphine B
levels O
after O
peripheral O
codeine O
administration O
, O
and O
may O
thereby O
alter O
codeine O
' O
s O
therapeutic O
efficacy O
, O
side O
- O
effect O
profile O
and O
abuse O
liability O
. O

BDFI O
using O
MTS B
assay O
was O
applied O
to O
determine O
the O
active O
anticancer O
extracts O
, O
fractions O
, O
and O
finally O
discrete O
compounds O
. O

) O
, O
2 O
- O
hydroxy O
- O
3 O
- O
methyl O
- O
1 O
- O
methoxyanthraquinone O
( O
7 O
) O
, O
oleanolic B
acid I
( O
8 O
) O
, O
ursolic B
acid I
( O
9 O
) O
, O
stigmasterol B
( O
10 O
) O
and O
docosanoic O
acid O
( O
11 O
) O
, O
were O
isolated O
and O
identified O
. O

High O
expression O
of O
Cyr61 O
, O
an O
extracellular O
cysteine B
- O
rich O
heparin O
- O
binding O
protein O
, O
has O
been O
associated O
with O
a O
malignant O
cell O
phenotype O
and O
poor O
outcome O
in O
prostate O
cancers O
. O

Although O
Cyr61 O
was O
found O
by O
us O
to O
be O
overproduced O
in O
androgen B
- O
independent O
PC O
- O
3 O
cells O
treated O
with O
N B
- I
acetylcysteine I
( O
NAC B
) O
, O
its O
significance O
is O
still O
unclear O
. O

We O
therefore O
aimed O
to O
determine O
how O
and O
why O
Cyr61 O
protein O
is O
overexpressed O
in O
NAC B
- O
treated O
cells O
. O

Here O
, O
we O
found O
that O
Cyr61 O
protein O
level O
markedly O
increased O
in O
cells O
treated O
with O
NAC B
at O
high O
cell O
seeding O
density O
. O

NAC B
treatment O
caused O
a O
reduction O
of O
extracellular O
medium O
pH O
to O
acidic O
and O
an O
increase O
in O
Akt O
phosphorylation O
, O
after O
which O
the O
replacement O
with O
NAC B
- O
free O
medium O
returned O
them O
to O
control O
levels O
within O
24h O
. O

Comparative O
evaluation O
of O
oral O
and O
dermal O
cypermethrin B
exposure O
on O
antioxidant O
profile O
in O
Bubalus O
bubalis O
. O

Cypermethrin B
, O
a O
type O
II O
synthetic O
pyrethroid B
insecticide O
, O
@ O
0 O
. O
5mg O
/ O
kg O
/ O
day O
for O
14 O
consecutive O
weeks O
produced O
mild O
signs O
of O
toxicity O
in O
buffalo O
calves O
. O

There O
was O
a O
marked O
increase O
in O
the O
extent O
of O
lipid O
peroxidation O
( O
33 O
. O
9 O
% O
) O
and O
enzymic O
activity O
of O
glutathione B
peroxidase O
( O
6 O
. O
7 O
% O
) O
, O
superoxide B
dismutase O
( O
35 O
. O
0 O
% O
) O
, O
catalase O
( O
43 O
. O
7 O
% O
) O
, O
glutathione B
- O
S O
- O
transferase O
( O
64 O
. O
4 O
% O
) O
, O
glutathione B
reductase O
( O
36 O
. O
7 O
% O
) O
and O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase O
( O
32 O
. O
1 O
% O
) O
. O

A O
significant O
decrease O
in O
blood O
glutathione B
( O
16 O
. O
7 O
% O
) O
, O
total O
antioxidant O
activity O
( O
45 O
. O
4 O
% O
) O
and O
vitamin B
E I
( O
40 O
. O
8 O
% O
) O
was O
observed O
and O
no O
significant O
effect O
was O
found O
on O
blood O
selenium B
levels O
. O

However O
, O
the O
extent O
of O
lipid O
peroxidation O
( O
42 O
% O
) O
and O
the O
depletion O
of O
glutathione B
( O
28 O
. O
8 O
% O
) O
was O
greater O
after O
dermal O
sub O
- O
acute O
toxicity O
of O
cypermethrin B
( O
0 O
. O
25 O
% O
) O
for O
14 O
consecutive O
days O
. O

Similarly O
, O
it O
was O
observed O
that O
the O
incline O
in O
the O
enzymic O
activity O
of O
glutathione B
peroxidase O
( O
29 O
. O
7 O
% O
) O
, O
superoxide B
dismutase O
( O
38 O
. O
3 O
% O
) O
and O
glutathione B
reductase O
( O
38 O
. O
3 O
% O
) O
was O
higher O
in O
dermally O
cypermethrin B
exposed O
animals O
. O

Thus O
, O
the O
present O
investigation O
contemplates O
that O
oxidative O
stress O
is O
the O
important O
mechanisms O
involved O
in O
cypermethrin B
- O
induced O
toxicity O
and O
the O
oxidative O
insult O
produced O
by O
dermal O
route O
is O
more O
severe O
as O
compared O
to O
oral O
intoxication O
. O

Biological O
effects O
induced O
by O
BSA O
- O
stabilized O
silica B
nanoparticles O
in O
mammalian O
cell O
lines O
. O

E O
. O
g O
. O
, O
the O
effects O
of O
exposure O
to O
silica B
dust O
particles O
have O
been O
studied O
intensely O
due O
to O
the O
carcinogenicity O
of O
crystalline O
silica B
. O

However O
, O
the O
increasing O
usage O
of O
engineered O
amorphous O
silica B
NPs O
has O
emphasized O
the O
need O
for O
further O
mechanistic O
insight O
to O
predict O
the O
consequences O
of O
exposure O
to O
the O
amorphous O
type O
of O
silica B
NPs O
. O

The O
present O
study O
focused O
on O
the O
in O
vitro O
biological O
effects O
following O
exposure O
to O
well O
- O
dispersed O
, O
BSA O
- O
stabilized O
, O
amorphous O
silica B
NPs O
whereas O
unmodified O
silica B
NPs O
where O
included O
for O
reasons O
of O
comparison O
. O

The O
cytotoxicity O
of O
the O
silica B
NPs O
was O
investigated O
in O
six O
different O
cell O
lines O
( O
A549 O
, O
THP O
- O
1 O
, O
CaCo O
- O
2 O
, O
ASB O
- O
XIV O
, O
J O
- O
774A O
. O
1 O
, O
and O
Colon O
- O
26 O
) O
selected O
to O
explore O
the O
significance O
of O
organ O
and O
species O
sensitivity O
in O
vitro O
. O

Viability O
data O
demonstrated O
that O
macrophages O
were O
most O
sensitive O
to O
silica B
NP O
and O
interestingly O
, O
murine O
cell O
lines O
were O
generally O
found O
to O
be O
more O
sensitive O
than O
comparable O
human O
cell O
lines O
. O

Further O
studies O
were O
conducted O
in O
the O
human O
epithelial O
lung O
cell O
line O
, O
A549 O
, O
to O
explore O
the O
molecular O
mechanism O
of O
silica B
toxicity O
. O

Generation O
of O
reactive O
oxygen B
species O
, O
one O
of O
the O
proposed O
toxicological O
mechanisms O
of O
NPs O
, O
was O
investigated O
in O
A549 O
cells O
by O
the O
dichlorofluorescin O
( O
DCF B
) O
assay O
to O
be O
significantly O
induced O
at O
NP O
concentrations O
above O
113 O
mu O
g O
/ O
mL O
. O

However O
, O
induction O
of O
oxidative O
stress O
related O
pathways O
was O
not O
found O
after O
silica B
NP O
exposure O
for O
24h O
in O
gene O
array O
studies O
conducted O
in O
A549 O
cells O
at O
a O
relatively O
low O
NP O
concentration O
( O
EC20 O
) O
. O

Thus O
, O
gene O
expression O
data O
proposes O
that O
several O
cellular O
processes O
other O
than O
oxidative O
stress O
could O
be O
affected O
by O
exposure O
to O
silica B
NPs O
. O

The O
anthelmintic O
bioassay O
tests O
of O
Arisaema O
franchetianum O
and O
Arisaema O
lobatum O
essential O
oil O
, O
linalool B
and O
carvacrol B
were O
performed O
using O
egg O
hatch O
assay O
( O
EHA O
) O
, O
larval O
development O
assay O
( O
LDA O
) O
and O
larval O
migration O
inhibition O
assay O
( O
LMIA O
) O
. O

Carvacrol B
and O
linalool B
were O
found O
to O
be O
the O
major O
constituents O
of O
two O
oils O
. O

Carvacrol B
exhibited O
similar O
activity O
to O
Arisaema O
lobatum O
essential O
oil O
and O
linalool B
did O
not O
show O
high O
activity O
in O
every O
assay O
. O

Sciadopitysin B
protects O
osteoblast O
function O
via O
its O
antioxidant O
activity O
in O
MC3T3 O
- O
E1 O
cells O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
sciadopitysin B
, O
a O
type O
of O
biflavonoids O
, O
on O
osteoblast O
function O
was O
investigated O
in O
osteoblastic O
MC3T3 O
- O
E1 O
cells O
. O

Sciadopitysin B
caused O
a O
significant O
elevation O
of O
alkaline O
phosphatase O
activity O
, O
collagen O
synthesis O
, O
osteocalcin O
production O
, O
mineralization O
, O
and O
glutathione B
content O
in O
the O
cells O
( O
P O
< O
0 O
. O
05 O
) O
. O

Sciadopitysin B
also O
decreased O
the O
production O
of O
tumor O
necrosis O
factor O
- O
a O
( O
TNF O
- O
alpha O
) O
induced O
by O
antimycin O
A O
, O
a O
mitochondrial O
electron O
transport O
inhibitor O
. O

We O
investigated O
the O
protective O
effects O
of O
sciadopitysin B
on O
antimycin O
A O
- O
induced O
toxicity O
in O
osteoblastic O
MC3T3 O
- O
E1 O
cells O
. O

However O
, O
pretreatment O
with O
sciadopitysin B
prior O
to O
antimycin O
A O
exposure O
significantly O
reduced O
antimycin O
A O
- O
induced O
cell O
damage O
by O
preventing O
mitochondrial O
membrane O
potential O
dissipation O
, O
adenosine B
triphosphate I
( O
ATP B
) O
loss O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
release O
, O
and O
nitrotyrosine O
increase O
, O
suggesting O
that O
sciadopitysin B
may O
be O
useful O
for O
protecting O
mitochondria O
against O
a O
burst O
of O
oxidative O
stress O
. O

Moreover O
, O
sciadopitysin B
increased O
phosphorylation O
of O
cAMP B
- O
response O
element O
- O
binding O
protein O
( O
CREB O
) O
inhibited O
by O
antimycin O
A O
. O

Our O
results O
demonstrate O
that O
sciadopitysin B
may O
reduce O
or O
prevent O
osteoblasts O
degeneration O
. O

In O
vitro O
binding O
affinities O
of O
a O
series O
of O
flavonoids B
for O
mu O
- O
opioid O
receptors O
. O

Antinociceptive O
effect O
of O
the O
synthetic O
flavonoid B
3 O
, O
3 O
- O
dibromoflavanone O
in O
mice O
. O

In O
the O
present O
work O
the O
capacity O
of O
a O
series O
of O
flavonoids B
to O
bind O
to O
the O
mu O
opioid O
receptor O
was O
evaluated O
. O

The O
most O
active O
compound O
, O
3 O
, O
3 O
- O
dibromoflavanone O
( O
31 O
) O
, O
a O
synthetic O
flavonoid B
, O
presented O
a O
significant O
inhibition O
of O
the O
binding O
of O
the O
selective O
mu O
opioid O
ligand O
[ O
( O
3 O
) O
H O
] O
DAMGO O
, O
with O
a O
Ki O
of O
0 O
. O
846 O
+ O
/ O
- O
0 O
. O
263 O
mu O
M O
. O

It O
evidenced O
antinociceptive O
activity O
on O
the O
acetic B
acid I
- O
induced O
nociception O
, O
hot O
plate O
and O
formalin B
tests O
( O
at O
10 O
mg O
/ O
kg O
and O
30 O
mg O
/ O
kg O
) O
. O

Naltrexone O
, O
a O
nonselective O
opioid O
receptors O
antagonist O
, O
totally O
blocked O
compound O
31 O
antinociceptive O
effects O
on O
the O
hot O
plate O
test O
, O
but O
naltrindole B
( O
delta O
opioid O
antagonist O
) O
and O
nor O
- O
binaltorphimine O
( O
kappa O
opioid O
antagonist O
) O
did O
not O
. O

Developmental O
toxicity O
and O
estrogenic O
potency O
of O
zearalenone B
in O
zebrafish O
( O
Danio O
rerio O
) O
. O

Zearalenone B
( O
ZEA B
, O
F2 O
) O
is O
one O
of O
the O
most O
common O
mycotoxins O
and O
the O
only O
known O
mycoestrogen O
. O

Effects O
of O
early O
ZEA B
exposure O
were O
concentration O
- O
dependent O
with O
LC50 O
and O
LC10 O
values O
of O
893 O
and O
335 O
mu O
g O
/ O
L O
. O

In O
larvae O
exposed O
to O
500 O
mu O
g O
/ O
L O
and O
above O
, O
ZEA B
induced O
similar O
phenotype O
to O
has O
( O
heart O
- O
and O
soul O
) O
showing O
defects O
in O
heart O
and O
eye O
development O
and O
upward O
curvature O
of O
the O
body O
axis O
. O

qRT O
- O
PCR O
in O
larvae O
proved O
to O
be O
sufficient O
substitute O
to O
adult O
tests O
and O
sensitive O
enough O
to O
detect O
ZEA B
in O
0 O
. O
1 O
mu O
g O
/ O
L O
concentrations O
, O
that O
is O
close O
to O
levels O
observed O
in O
wastewaters O
. O

Developmental O
defects O
reveal O
that O
besides O
direct O
estrogenic O
effects O
, O
zearalenone B
might O
interact O
with O
other O
ontogenic O
pathways O
. O

Effects O
of O
intravenous O
nicotine B
on O
prepulse O
inhibition O
in O
smokers O
and O
non O
- O
smokers O
: O
relationship O
with O
familial O
smoking O
. O

RATIONALE O
: O
The O
reinforcing O
properties O
of O
nicotine B
may O
be O
, O
in O
part O
, O
derived O
from O
its O
ability O
to O
enhance O
certain O
forms O
of O
cognitive O
processing O
. O

Several O
animal O
and O
human O
studies O
have O
shown O
that O
nicotine B
increases O
prepulse O
inhibition O
( O
PPI O
) O
of O
the O
startle O
reflex O
. O

OBJECTIVES O
: O
The O
current O
study O
examined O
the O
effects O
of O
intravenously O
delivered O
nicotine B
on O
PPI O
in O
smokers O
and O
non O
- O
smokers O
, O
as O
well O
as O
its O
association O
with O
a O
quantitative O
index O
of O
familial O
smoking O
. O

METHODS O
: O
The O
sample O
consisted O
of O
30 O
non O
- O
smokers O
and O
16 O
smokers O
, O
who O
completed O
an O
initial O
assessment O
, O
followed O
on O
a O
separate O
day O
by O
a O
laboratory O
assessment O
of O
PPI O
prior O
to O
and O
following O
each O
of O
two O
intravenous O
nicotine B
infusions O
. O

RESULTS O
: O
Analyses O
indicated O
that O
both O
nicotine B
infusions O
acutely O
enhanced O
PPI O
among O
non O
- O
smokers O
, O
and O
this O
enhancement O
was O
positively O
related O
to O
the O
degree O
of O
smoking O
among O
first O
and O
second O
- O
degree O
relatives O
. O

Ventral O
tegmental O
area O
alpha O
6 O
beta O
2 O
nicotinic O
acetylcholine B
receptors O
modulate O
phasic O
dopamine B
release O
in O
the O
nucleus O
accumbens O
core O
. O

RATIONALE O
: O
Phasic O
dopamine B
( O
DA O
) O
signaling O
underlies O
reward O
learning O
. O

OBJECTIVE O
: O
The O
goal O
was O
to O
determine O
the O
role O
of O
VTA O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
( O
NMDARs O
) O
and O
specific O
subtypes O
of O
nicotinic O
acetylcholine B
receptors O
( O
nAChRs O
) O
in O
regulating O
phasic O
DA O
release O
in O
the O
NAc O
core O
. O

RESULTS O
: O
VTA O
NMDAR O
blockade O
with O
AP O
- O
5 O
decreased O
, O
while O
VTA O
NMDAR O
activation O
with O
NMDA B
increased O
NAc O
peak O
phasic O
DA O
release O
. O

Intra O
- O
VTA O
administration O
of O
the O
nonspecific O
nAChR O
antagonist O
mecamylamine B
produced O
a O
persistent O
decrease O
in O
phasic O
DA O
release O
. O

Infusion O
of O
the O
alpha O
6 O
- O
selective O
antagonist O
alpha O
- O
conotoxin O
MII O
( O
alpha O
- O
ctx O
MII O
) O
produced O
a O
robust O
, O
but O
transient O
decrease O
in O
phasic O
DA O
, O
whereas O
infusion O
of O
selective O
doses O
of O
either O
the O
alpha O
4 O
beta O
2 O
- O
selective O
antagonist O
, O
dihydro O
- O
beta O
- O
erythroidine O
, O
or O
the O
alpha O
7 O
antagonist O
, O
methyllycaconitine B
, O
had O
no O
effect O
. O

CONCLUSIONS O
: O
The O
results O
suggest O
that O
VTA O
alpha O
6 O
beta O
2 O
nAChRs O
, O
but O
not O
alpha O
4 O
beta O
2 O
or O
alpha O
7 O
nAChRs O
, O
regulate O
phasic O
DA O
release O
in O
the O
NAc O
core O
and O
that O
VTA O
alpha O
6 O
beta O
2 O
nAChRs O
and O
NMDA B
receptors O
act O
at O
a O
common O
site O
or O
target O
to O
regulate O
NAc O
phasic O
DA O
signaling O
. O

Glycolytic O
pyruvate B
kinase O
isoenzyme O
type O
M2 O
( O
M2 O
- O
PK O
) O
plays O
a O
key O
role O
in O
tumor O
metabolism O
and O
energy O
production O
. O

The O
background O
concentration O
of O
Se B
in O
soil O
has O
a O
significant O
positive O
correlation O
with O
longevity O
index O
, O
while O
Ba O
and O
Ni B
have O
a O
significant O
negative O
correlation O
with O
longevity O
indexes O
. O

By O
regression O
analysis O
, O
longevity O
index O
C O
/ O
100 O
, O
000 O
can O
be O
expressed O
as O
C O
/ O
100 O
, O
000 O
= O
1 O
. O
679 O
- O
0 O
. O
205 O
Ni B
+ O
0 O
. O
413 O
Co B
+ O
0 O
. O
006 O
Se B
( O
with O
R O
( O
2 O
) O
= O
0 O
. O
402 O
and O
p O
< O
0 O
. O
01 O
) O
, O
C O
/ O
65 O
+ O
can O
be O
expressed O
as O
C O
/ O
65 O
+ O
= O
3 O
. O
425 O
- O
0 O
. O
262 O
Ni B
+ O
0 O
. O
435 O
Co B
+ O
0 O
. O
006 O
Se B
( O
with O
R O
( O
2 O
) O
= O
0 O
. O
369 O
and O
p O
< O
0 O
. O
01 O
) O
. O

Glomerular O
Filtration O
Rate O
Equations O
Overestimate O
Creatinine B
Clearance O
in O
Older O
Individuals O
Enrolled O
in O
the O
Baltimore O
Longitudinal O
Study O
on O
Aging O
: O
Impact O
on O
Renal O
Drug O
Dosing O
. O

SUBJECTS O
: O
A O
total O
of O
269 O
men O
and O
women O
with O
a O
mean O
+ O
/ O
- O
SD O
age O
of O
81 O
+ O
/ O
- O
6 O
years O
, O
mean O
serum O
creatinine B
concentration O
( O
Scr O
) O
of O
1 O
. O
1 O
+ O
/ O
- O
0 O
. O
4 O
mg O
/ O
dl O
, O
and O
mean O
24 O
- O
hour O
measured O
creatinine B
clearance O
( O
mClcr O
) O
of O
53 O
+ O
/ O
- O
13 O
ml O
/ O
minute O
. O

CONCLUSION O
: O
The O
MDRD O
and O
CKD O
- O
EPI O
equations O
significantly O
overestimated O
creatinine B
clearance O
( O
mClcr O
and O
CG O
) O
in O
elderly O
individuals O
. O

Multiple O
Site O
- O
Selective O
Insertions O
of O
Noncanonical O
Amino B
Acids I
into O
Sequence O
- O
Repetitive O
Polypeptides O
. O

A O
simple O
and O
efficient O
method O
is O
described O
for O
the O
introduction O
of O
noncanonical O
amino B
acids I
at O
multiple O
, O
defined O
sites O
within O
recombinant O
polypeptide O
sequences O
. O

Escherichia O
coli O
MRA30 O
, O
a O
bacterial O
host O
strain O
with O
attenuated O
activity O
of O
release O
factor O
1 O
( O
RF1 O
) O
, O
was O
assessed O
for O
its O
ability O
to O
support O
incorporation O
of O
a O
diverse O
range O
of O
noncanonical O
amino B
acids I
in O
response O
to O
multiple O
encoded O
amber O
( O
TAG O
) O
codons O
within O
genes O
derived O
from O
superfolder O
GFP O
and O
an O
elastin O
- O
mimetic O
protein O
polymer O
. O

Suppression O
efficiency O
and O
protein O
yield O
depended O
on O
the O
identity O
of O
the O
orthogonal O
aminoacyl B
- O
tRNA O
synthetase O
/ O
tRNA O
( O
CUA O
) O
pair O
and O
the O
noncanonical O
amino B
acid I
. O

Elastin O
- O
mimetic O
protein O
polymers O
were O
prepared O
in O
which O
noncanonical O
amino B
acid I
derivatives O
were O
incorporated O
at O
up O
to O
22 O
specific O
sites O
within O
the O
polypeptide O
sequence O
with O
high O
substitution O
efficiency O
. O

OBJECTIVE O
: O
To O
investigate O
the O
antioxidant O
role O
in O
reversing O
cytogenetic O
changes O
caused O
by O
solvent O
exposure O
in O
paint O
industry O
. O
Subjects O
and O
METHODS O
: O
A O
prospective O
controlled O
clinical O
trial O
was O
performed O
on O
39 O
workers O
exposed O
to O
solvents O
and O
39 O
workers O
not O
exposed O
to O
solvents O
by O
supplying O
a O
mixture O
of O
antioxidant O
vitamins O
( O
A O
, O
C O
, O
E O
and O
selenium B
) O
and O
the O
after O
effects O
of O
such O
regimen O
were O
analyzed O
. O

1 B
, I
1 I
- I
Diphenyl I
, I
2 I
- I
picrylhydrazyl I
free O
radical O
scavenging O
, O
bactericidal O
, O
fungicidal O
and O
leishmanicidal O
properties O
of O
Teucrium O
stocksianum O
. O

The O
crude O
extract O
of O
T O
. O
stocksianum O
( O
Ts O
. O
Cr O
) O
and O
its O
subsequent O
organic O
fractions O
: O
n B
- I
hexane I
( O
Ts O
. O
Hex B
) O
, O
chloroform B
( O
Ts O
. O
CHCl3 B
) O
and O
ethyl B
acetate I
( O
Ts O
. O
EtAc O
) O
exhibited O
1 B
, I
1 I
- I
diphenyl I
, I
2 I
- I
picrylhydrazyl I
free O
radical O
scavenging O
activity O
with O
different O
potencies O
. O

Ts O
. O
Cr O
, O
Ts O
. O
Hex B
, O
Ts O
. O
CHCl3 B
and O
Ts O
. O
EtAc O
showed O
significant O
bactericidal O
activity O
against O
Escherichia O
coli O
, O
Staphylococcus O
aureus O
, O
Salmonella O
typhi O
, O
Shigella O
flexneri O
and O
Bacillus O
subtilis O
at O
their O
extent O
. O

Ts O
. O
Cr O
, O
Ts O
. O
Hex B
, O
Ts O
. O
CHCl3 B
and O
Ts O
. O
EtAc O
displayed O
fungicidal O
action O
against O
Aspergillus O
niger O
, O
Aspergillus O
flavus O
, O
Aspergillus O
fumigatus O
and O
Fusarium O
solani O
at O
various O
minimum O
inhibitory O
concentrations O
. O

Effect O
of O
paraoxonase O
1 O
192 O
Q O
/ O
R O
polymorphism O
on O
paraoxonase O
and O
acetylcholinesterase O
enzyme O
activities O
in O
Turkish O
population O
exposed O
to O
organophosphate B
. O

Organophosphate B
( O
OP O
) O
compounds O
are O
the O
most O
commonly O
used O
pesticide O
groups O
and O
they O
are O
commercially O
used O
in O
the O
market O
for O
local O
and O
industrial O
purposes O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
PON1 O
gene O
polymorphism O
and O
its O
effects O
on O
PON O
and O
AChE O
enzyme O
activities O
in O
individuals O
who O
were O
exposed O
to O
organophosphorus B
insecticides O
due O
to O
occupational O
reasons O
, O
and O
to O
profile O
the O
probability O
of O
susceptibility O
to O
organophosphorus B
compounds O
. O

Structural O
Determinants O
of O
Agonist O
Efficacy O
at O
the O
Glutamate B
Binding O
Site O
of O
NMDA B
Receptors O
. O

NMDA B
receptors O
are O
ligand O
- O
gated O
ion O
channels O
assembled O
from O
GluN1 O
and O
GluN2 O
subunits O
. O

We O
utilized O
a O
series O
of O
N O
- O
hydroxypyrazole O
- O
5 O
- O
glycine O
( O
NHP5G O
) O
partial O
agonists O
at O
the O
GluN2 O
glutamate B
binding O
site O
as O
tools O
to O
study O
activation O
of O
GluN1 O
/ O
GluN2A O
and O
GluN1 O
/ O
GluN2D O
NMDA B
receptor O
subtypes O
. O

We O
show O
using O
two O
- O
electrode O
voltage O
- O
clamp O
electrophysiology O
, O
fast O
- O
application O
patch O
- O
clamp O
, O
and O
single O
channel O
recordings O
that O
propyl O
- O
and O
ethyl O
- O
substituted O
NHP5G O
agonists O
have O
a O
broad O
range O
of O
agonist O
efficacies O
relative O
to O
the O
full O
agonist O
glutamate B
( O
< O
1 O
% O
- O
72 O
% O
) O
. O

Crystal O
structures O
of O
the O
agonist O
binding O
domains O
( O
ABDs O
) O
of O
GluN2A O
and O
GluN2D O
do O
not O
reveal O
any O
differences O
in O
the O
overall O
domain O
conformation O
induced O
by O
binding O
of O
the O
full O
agonist O
glutamate B
or O
the O
partial O
agonist O
propyl O
- O
NHP5G O
, O
which O
is O
strikingly O
different O
from O
ABD O
structures O
of O
AMPA B
and O
kainate B
receptors O
bound O
to O
full O
and O
partial O
agonists O
. O

Subsequent O
evaluation O
of O
relative O
NHP5G O
agonist O
efficacy O
at O
GluN2A O
- O
GluN2D O
chimeric O
subunits O
implicates O
the O
amino B
- O
terminal O
domain O
( O
ATD O
) O
as O
a O
strong O
determinant O
of O
agonist O
efficacy O
, O
suggesting O
that O
interdomain O
interactions O
between O
the O
ABD O
and O
the O
ATD O
may O
be O
a O
central O
element O
in O
controlling O
the O
manner O
by O
which O
agonist O
binding O
leads O
to O
channel O
opening O
. O

Self O
- O
Assembly O
and O
Near O
Perfect O
Macroscopic O
Alignment O
of O
Fluorescent O
Triangulenium O
Salt O
in O
Spin O
Cast O
Thin O
Films O
on O
PTFE B
. O

Highly O
fluorescent O
, O
discotic O
trioxatriangulenium O
dyes O
were O
aligned O
by O
simple O
spin O
casting O
on O
substrates O
with O
friction O
transferred O
PTFE B
layers O
. O

Gracing O
Incidence O
X O
- O
ray O
Diffraction O
( O
GIXD O
) O
unambiguously O
allowed O
to O
determine O
a O
long O
range O
order O
unit O
cell O
as O
well O
as O
its O
orientation O
with O
respect O
to O
the O
PTFE B
fibers O
. O

Further O
analysis O
of O
the O
X O
- O
ray O
data O
, O
in O
conjunction O
with O
polarized O
absorption O
spectroscopy O
, O
suggest O
a O
lamellar O
packing O
model O
with O
alternating O
layers O
of O
alkyl B
chains O
and O
ionic O
dyes O
oriented O
parallel O
to O
the O
substrate O
. O

The O
bright O
fluorescence O
from O
the O
films O
is O
also O
polarized O
parallel O
to O
the O
PTFE B
alignment O
layer O
. O

Eighty O
( O
31 O
. O
7 O
% O
) O
women O
who O
were O
not O
at O
high O
cardiovascular O
risk O
presented O
at O
least O
one O
classical O
risk O
factor O
( O
arterial O
hypertension O
, O
elevated O
level O
of O
low O
- O
density O
lipoprotein O
- O
cholesterol B
or O
low O
level O
of O
high O
- O
density O
lipoprotein O
- O
cholesterol B
, O
smoking O
, O
or O
first O
- O
degree O
family O
history O
of O
premature O
coronary O
artery O
disease O
) O
. O

Conclusions O
: O
According O
to O
the O
new O
ATA O
and O
AACE O
guidelines O
, O
L B
- I
T4 I
therapy O
would O
be O
considered O
for O
92 O
% O
of O
women O
with O
SCH O
and O
TSH O
< O
= O
10 O
mIU O
/ O
L O
. O

NMDA B
receptors O
and O
memory O
encoding O
. O

This O
dissociation O
was O
one O
of O
the O
key O
triggers O
for O
an O
explosion O
of O
interest O
in O
glutamate B
receptors O
, O
and O
much O
has O
been O
discovered O
since O
that O
collectively O
contributes O
to O
our O
contemporary O
understanding O
of O
glutamatergic O
synapses O
- O
their O
biophysics O
and O
subunit O
composition O
, O
of O
the O
agonists O
and O
antagonists O
acting O
on O
them O
, O
and O
their O
diverse O
functions O
in O
different O
networks O
of O
the O
brain O
and O
spinal O
cord O
. O

It O
can O
be O
fairly O
said O
that O
Collingridge O
et O
al O
. O
' O
s O
( O
1983 O
) O
observation O
was O
the O
stimulus O
that O
has O
led O
, O
on O
the O
one O
hand O
, O
to O
structural O
biological O
work O
at O
the O
atomic O
scale O
describing O
the O
key O
features O
of O
NMDA B
receptors O
that O
enables O
their O
coincidence O
function O
to O
happen O
; O
and O
, O
on O
the O
other O
, O
to O
work O
with O
whole O
animals O
investigating O
the O
contributions O
that O
calcium B
signalling O
via O
this O
receptor O
can O
have O
on O
rhythmical O
activities O
controlled O
by O
spinal O
circuits O
, O
memory O
encoding O
in O
the O
hippocampus O
( O
the O
topic O
of O
this O
article O
) O
, O
visual O
cortical O
plasticity O
, O
sensitization O
in O
pain O
, O
and O
other O
functions O
. O

The O
idea O
that O
NMDA B
receptor O
activation O
is O
essential O
for O
memory O
encoding O
, O
though O
not O
for O
storage O
, O
took O
time O
to O
develop O
and O
to O
be O
accepted O
. O

Along O
the O
way O
, O
there O
have O
been O
confusions O
, O
challenges O
, O
and O
surprises O
surrounding O
the O
idea O
that O
activation O
of O
NMDA B
receptors O
can O
trigger O
memory O
. O

Last O
, O
I O
touch O
on O
some O
new O
directions O
of O
interest O
with O
respect O
to O
the O
functional O
role O
of O
the O
NMDA B
receptor O
in O
cognition O
. O

AIM O
OF O
THE O
STUDY O
: O
The O
present O
study O
was O
aimed O
to O
establish O
a O
scientific O
evidence O
for O
anti O
obesity O
efficiency O
of O
ethyl B
acetate I
extract O
of O
Tecomella O
undulata O
bark O
( O
EATUB O
) O
. O

In O
- O
vivo O
studies O
of O
F1 O
in O
HFD O
induced O
obese O
mice O
showed O
significant O
improvement O
in O
lipid O
profile O
and O
glucose B
levels O
. O

The O
bioactive O
fraction O
( O
F1 O
) O
was O
determined O
to O
possess O
4 O
. O
95 O
% O
of O
ferulic B
acid I
. O

Ferulic B
acid I
and O
rutin B
are O
being O
reported O
and O
quantified O
for O
the O
first O
time O
from O
the O
bark O
of O
Tecomella O
undulata O
. O

Cytotoxic O
effects O
of O
amphetamine B
mixtures O
in O
primary O
hepatocytes O
are O
severely O
aggravated O
under O
hyperthermic O
conditions O
. O

Amphetamine B
consumers O
are O
often O
, O
deliberately O
or O
not O
, O
polydrug O
abusers O
. O

We O
previously O
reported O
that O
joint O
effects O
of O
3 B
, I
4 I
- I
methylenedioxymetham I
( O
MDMA B
, O
ecstasy B
) O
and O
three O
other O
often O
co O
- O
ingested O
amphetamines B
( O
methamphetamine B
, O
4 O
- O
methylthyoamphetamin O
and O
D B
- I
amphetamine I
) O
could O
be O
predicted O
by O
the O
concentration O
addition O
( O
CA O
) O
model O
in O
HepG2 O
cells O
. O

Detailed O
cytotoxic O
information O
of O
the O
four O
individual O
amphetamines B
on O
primary O
rat O
hepatocytes O
was O
recorded O
by O
the O
MTT B
assay O
, O
at O
37 O
degrees O
C O
and O
40 O
. O
5 O
degrees O
C O
, O
simulating O
the O
rise O
in O
body O
temperature O
that O
could O
be O
induced O
following O
amphetamine B
intake O
. O

Our O
findings O
provide O
evidence O
of O
the O
increased O
risks O
associated O
with O
the O
abuse O
of O
amphetamine B
mixtures O
, O
especially O
during O
hyperthermia O
, O
emphasising O
the O
need O
to O
increase O
awareness O
of O
misinformed O
users O
who O
believe O
these O
drugs O
are O
safe O
. O

Recent O
findings O
have O
revealed O
that O
[ O
S3 O
] O
. O
( O
- O
) O
has O
a O
multi O
- O
faceted O
role O
in O
a O
variety O
of O
media O
, O
including O
alkali O
metal O
- O
sulfur B
batteries O
, O
aqueous O
solutions O
at O
high O
temperatures O
and O
pressures O
, O
and O
ionic O
liquids O
; O
it O
has O
also O
been O
used O
to O
detect O
trace O
amounts O
of O
water O
in O
organic O
solvents O
. O

The O
following O
components O
were O
investigated O
: O
alpha O
- O
amylase O
, O
lysozyme O
, O
acid O
phosphatase O
, O
and O
urea B
. O

Simple O
and O
Rapid O
Synthesis O
of O
Magnetite O
/ O
Hydroxyapatite B
Composites O
for O
Hyperthermia O
Treatments O
via O
a O
Mechanochemical O
Route O
. O

This O
paper O
presents O
a O
simple O
method O
for O
the O
rapid O
synthesis O
of O
magnetite O
/ O
hydroxyapatite B
composite O
particles O
. O

In O
this O
method O
, O
superparamagnetic O
magnetite O
nanoparticles O
are O
first O
synthesized O
by O
coprecipitation O
using O
ferrous O
chloride O
and O
ferric B
chloride I
. O

Immediately O
following O
the O
synthesis O
, O
carbonate B
- O
substituted O
( O
B O
- O
type O
) O
hydroxyapatite B
particles O
are O
mechanochemically O
synthesized O
by O
wet O
milling O
dicalcium O
phosphate O
dihydrate O
and O
calcium B
carbonate I
in O
a O
dispersed O
suspension O
of O
magnetite O
nanoparticles O
, O
during O
which O
the O
magnetite O
nanoparticles O
are O
incorporated O
into O
the O
hydroxyapatite B
matrix O
. O

We O
observed O
that O
the O
resultant O
magnetite O
/ O
hydroxyapatite B
composites O
possessed O
a O
homogeneous O
dispersion O
of O
magnetite O
nanoparticles O
, O
characterized O
by O
an O
absence O
of O
large O
aggregates O
. O

A O
Detailed O
Experimental O
and O
Theoretical O
Study O
into O
the O
Properties O
of O
C60 B
Dumbbell O
Junctions O
. O

A O
combined O
experimental O
and O
theoretical O
investigation O
is O
carried O
out O
into O
the O
electrical O
transport O
across O
a O
fullerene B
dumbbell O
one O
- O
molecule O
junction O
. O

The O
newly O
designed O
molecule O
comprises O
two O
C60 B
s O
connected O
to O
a O
fluorene B
backbone O
via O
cyclopropyl B
groups O
. O

It O
is O
wired O
between O
gold O
electrodes O
under O
ambient O
conditions O
by O
pressing O
the O
tip O
of O
a O
scanning O
tunnelling O
microscope O
( O
STM O
) O
onto O
one O
of O
the O
C60 B
groups O
. O

Theoretical O
analysis O
indicates O
that O
the O
molecule O
is O
connected O
directly O
to O
one O
electrode O
through O
the O
central O
fluorene B
, O
and O
that O
to O
bind O
it O
to O
the O
gold O
fully O
it O
has O
to O
be O
pushed O
through O
a O
layer O
of O
adsorbates O
naturally O
present O
in O
the O
experiment O
. O

PICK1 O
Deficiency O
Impairs O
Secretory O
Vesicle O
Biogenesis O
and O
Leads O
to O
Growth O
Retardation O
and O
Decreased O
Glucose B
Tolerance O
. O

Evidence O
was O
also O
obtained O
for O
impaired O
insulin O
secretion O
associated O
with O
decreased O
glucose B
tolerance O
. O

An O
interesting O
system O
of O
intramolecular O
hydrogen B
bonds O
and O
weak O
intermolecular O
CH B
. O
. O
. O
O B
type O
hydrogen B
bond O
was O
observed O
in O
the O
solid O
state O
. O

" O
Strange O
Kinetics O
" O
in O
the O
Temperature O
Dependence O
of O
Methionine B
Ligand O
Rebinding O
Dynamics O
in O
Cytochrome O
c O
. O

Temperature O
dependence O
of O
methionine B
ligand O
dissociation O
and O
rebinding O
dynamics O
in O
cytochrome O
c O
in O
aqueous O
solution O
has O
been O
studied O
using O
classical O
molecular O
dynamics O
simulation O
. O

While O
fast O
rebinding O
occurs O
from O
a O
" O
downward O
" O
( O
heme B
pointing O
) O
substate O
of O
the O
methionine B
, O
the O
slow O
rebinding O
involves O
interconversion O
between O
an O
" O
upward O
" O
substate O
, O
from O
which O
rebinding O
cannot O
occur O
, O
and O
the O
downward O
substate O
. O

Suggestions O
for O
future O
experiments O
to O
further O
probe O
the O
role O
of O
dynamic O
heterogeneity O
in O
the O
kinetics O
of O
methionine B
ligand O
binding O
in O
cytochrome O
c O
protein O
are O
proposed O
. O

( O
De O
) O
Lithiation O
Mechanism O
of O
Li B
/ O
SeSx O
( O
x O
= O
0 O
- O
7 O
) O
Batteries O
Determined O
by O
In O
- O
situ O
Synchrotron O
X O
- O
ray O
Diffraction O
and O
X O
- O
ray O
Absorption O
Spectroscopy O
. O

Electrical O
energy O
storage O
for O
transportation O
has O
going O
beyond O
the O
limit O
of O
converntional O
lithium B
- O
ion O
batteries O
currently O
. O

A O
series O
of O
SeSx O
- O
carbon B
( O
x O
= O
0 O
- O
7 O
) O
composite O
materials O
has O
been O
prepared O
and O
evaluated O
as O
the O
positive O
electrodes O
in O
secondary O
lithium B
cells O
with O
ether B
- O
based O
electrolyte O
. O

Complementary O
, O
in O
- O
situ O
Se B
K O
- O
edge O
X O
- O
ray O
absorption O
near O
edge O
structure O
analysis O
was O
used O
to O
track O
the O
evolution O
of O
the O
Se B
valence O
state O
for O
both O
crystalline O
and O
non O
- O
crystalline O
phases O
, O
including O
amorphous O
and O
electrolyte O
- O
dissolved O
phases O
in O
the O
( O
de O
) O
lithiation O
process O
. O

On O
the O
basis O
of O
these O
reuslts O
, O
a O
mechanism O
for O
the O
( O
de O
) O
lithiation O
process O
is O
proposed O
, O
where O
Se B
is O
reduced O
to O
the O
polyselenides O
, O
Li2Sen O
( O
n O
> O
= O
4 O
) O
, O
Li2Se2 O
, O
and O
Li2Se O
sequentially O
during O
the O
lithiation O
, O
and O
Li2Se O
is O
oxidized O
to O
Se B
through O
Li2Sen O
( O
n O
> O
= O
4 O
) O
during O
the O
delithiation O
. O

In O
addition O
, O
X O
- O
ray O
photoelectron O
spectroscopy O
and O
electrochemical O
impedance O
spectroscopy O
demonstrated O
the O
reversibility O
of O
the O
Li B
/ O
Se B
system O
in O
ether B
- O
based O
electrolyte O
and O
the O
presence O
of O
side O
products O
in O
the O
carbonate B
- O
based O
electrolytes O
. O

For O
Li B
/ O
SeS2 O
and O
Li B
/ O
SeS7 O
cells O
, O
Li2Se O
and O
Li2S O
are O
the O
discharged O
products O
with O
the O
presence O
of O
Se B
only O
as O
the O
crystalline O
phase O
in O
the O
end O
of O
charge O
. O

The O
Governing O
Role O
of O
Surface O
Hydration O
in O
Ion O
Specific O
Adsorption O
to O
Silica B
- O
an O
AFM O
Based O
Account O
of O
the O
Hofmeister O
Universality O
and O
its O
Reversal O
. O

AFM O
measurements O
of O
the O
force O
acting O
between O
silica B
surfaces O
in O
the O
presence O
of O
varied O
alkali O
- O
chloride O
salts O
and O
pH O
' O
s O
elucidate O
the O
origin O
of O
the O
Hofmeister O
adsorption O
series O
and O
its O
reversal O
. O

The O
preferential O
adsorption O
of O
Cs B
+ I
to O
the O
silica B
surface O
is O
traced O
to O
the O
weak O
hydration O
of O
neutral O
silanols O
and O
the O
resulting O
hydrophobic O
expulsion O
of O
weakly O
hydrated O
ions O
from O
bulk O
solution O
to O
the O
interface O
. O

The O
same O
interactions O
keep O
the O
strongly O
hydrated O
Li B
+ I
and O
Na B
+ I
in O
solution O
. O

Cs B
+ I
is O
correspondingly O
expelled O
from O
the O
surface O
and O
adsorption O
of O
small O
ions O
is O
encouraged O
. O

The O
deduced O
role O
of O
surface O
hydration O
is O
corroborated O
by O
hydration O
repulsion O
observed O
at O
high O
pH O
, O
surface O
over O
- O
charging O
at O
low O
pH O
, O
and O
data O
in O
other O
oxides B
. O

Fungal O
ABC O
Transporter O
- O
Associated O
Activity O
of O
Isoflavonoids B
from O
the O
Root O
Extract O
of O
Dalea O
formosa O
. O

We O
observed O
strong O
antifungal O
growth O
inhibitory O
activity O
in O
the O
methanol B
extract O
of O
Dalea O
formosa O
roots O
. O

This O
extract O
afforded O
six O
new O
isoflavonoids B
, O
sedonans O
A O
- O
F O
( O
1 O
- O
6 O
) O
, O
a O
new O
but O
- O
2 O
- O
enolide O
, O
4 O
' O
- O
O O
- O
methylpuerol O
A O
( O
7 O
) O
, O
and O
the O
new O
pterocarpan O
ent O
- O
sandwicensin O
( O
8 O
) O
. O

The O
direct O
antifungal O
activity O
of O
1 O
against O
C O
. O
glabrata O
( O
MIC O
= O
20 O
mu O
M O
) O
was O
higher O
than O
that O
of O
fluconazole B
. O

A O
Chemometric O
Approach O
to O
Distribution O
of O
Selenium B
in O
Medicinal O
Plants O
Cultivated O
in O
Poland O
. O

Abstract O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
level O
of O
selenium B
( O
Se B
) O
in O
common O
raw O
plant O
materials O
( O
herbs O
, O
leaves O
, O
flowers O
, O
fruits O
, O
and O
roots O
) O
obtained O
from O
medicinal O
plants O
cultivated O
in O
Poland O
. O

Furthermore O
, O
the O
relationship O
between O
the O
morphological O
part O
of O
a O
plant O
and O
its O
species O
was O
examined O
, O
and O
the O
concentration O
of O
Se B
in O
it O
was O
measured O
. O

Spectrofluorimetric O
determination O
of O
Se B
in O
148 O
samples O
of O
44 O
plant O
species O
revealed O
that O
the O
majority O
of O
the O
plants O
contained O
Se B
at O
a O
level O
from O
several O
to O
several O
tens O
of O
mu O
g O
/ O
kg O
dry O
weight O
( O
d O
. O
w O
. O
) O
. O

A O
relatively O
high O
Se B
concentration O
, O
in O
the O
order O
of O
50 O
mu O
g O
/ O
kg O
d O
. O
w O
. O
, O
was O
found O
in O
Majoranae O
herba O
, O
Crataegi O
fructus O
, O
and O
Lini O
semen O
. O

An O
especially O
high O
Se B
level O
, O
> O
100 O
mu O
g O
/ O
kg O
d O
. O
w O
. O
, O
was O
found O
in O
only O
three O
plants O
- O
Equiseti O
herba O
, O
Farfarae O
folium O
, O
and O
Cichorii O
radix O
. O

Application O
of O
a O
nonparametric O
Kruskal O
- O
Wallis O
analysis O
of O
variance O
test O
indicates O
that O
the O
morphological O
variable O
influences O
the O
level O
of O
Se B
in O
the O
studied O
groups O
of O
raw O
plant O
materials O
. O

The O
mean O
concentration O
of O
Se B
in O
fruits O
differs O
significantly O
from O
that O
found O
in O
flowers O
and O
roots O
. O

However O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
the O
Se B
content O
in O
herbs O
and O
leaves O
and O
its O
levels O
in O
fruits O
, O
flowers O
, O
and O
roots O
. O

Cluster O
analysis O
and O
principal O
component O
analysis O
calculations O
show O
that O
it O
is O
possible O
to O
relate O
the O
Se B
concentration O
in O
plant O
material O
to O
the O
plant O
species O
and O
botanical O
family O
of O
the O
medicinal O
plant O
in O
only O
a O
few O
cases O
. O

Analysis O
of O
average O
Se B
levels O
in O
the O
plant O
species O
showed O
that O
the O
plants O
belonging O
to O
the O
Apiaceae O
and O
Labiatae O
are O
more O
Se B
- O
rich O
than O
those O
belonging O
to O
Rosaceae O
botanical O
families O
. O

In O
addition O
, O
the O
MRI O
examination O
enables O
the O
detection O
of O
creaming O
occurring O
in O
a O
polyethylene B
tube O
, O
which O
is O
commonly O
used O
for O
commercial O
products O
, O
without O
losing O
any O
image O
quality O
. O

Recent O
structural O
data O
revealed O
that O
the O
CP29 O
protein O
of O
higher O
plant O
Photosystem O
II O
( O
PSII O
) O
contains O
13 O
chlorophylls B
( O
Chls O
) O
per O
complex O
[ O
Pan O
et O
al O
. O
, O
Nat O
. O
Struct O
. O
Mol O
. O
Biol O
. O
2011 O
, O
18 O
, O
309 O
] O
, O
i O
. O
e O
. O
, O
five O
Chls O
more O
than O
in O
the O
predicted O
CP29 O
homology O
- O
based O
structure O
model O
[ O
Bassi O
et O
al O
. O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
1999 O
, O
96 O
, O
10056 O
] O
. O

We O
argue O
that O
CP29 O
proteins O
previously O
studied O
by O
HB O
spectroscopy O
lacked O
at O
least O
one O
Chl B
a I
molecule O
( O
i O
. O
e O
. O
, O
a615 O
or O
a611 O
) O
, O
which O
along O
with O
Chl O
a612 O
contribute O
to O
the O
lowest O
energy O
state O
in O
more O
intact O
CP29 O
, O
and O
one O
Chl O
b O
( O
most O
likely O
b607 O
) O
. O

[ O
Photochem O
. O
Photobiol O
. O
2000 O
, O
71 O
, O
574 O
] O
were O
blueshifted O
by O
~ O
1 O
nm O
, O
the O
low O
- O
energy O
state O
appeared O
to O
be O
highly O
localized O
on O
a O
single O
Chl B
a I
molecule O
, O
and O
the O
position O
of O
the O
low O
- O
energy O
state O
was O
independent O
of O
burning O
fluence O
. O

Zero O
- O
phonon O
hole O
widths O
obtained O
for O
the O
Chl O
b O
band O
at O
638 O
. O
5 O
nm O
( O
5 O
K O
) O
revealed O
two O
independent O
Chl O
b O
- O
- O
> O
Chl B
a I
EET O
times O
, O
i O
. O
e O
. O
, O
4 O
+ O
/ O
- O
0 O
. O
5 O
ps O
and O
0 O
. O
4 O
+ O
/ O
- O
0 O
. O
1 O
ps O
. O

EET O
time O
from O
650 O
nm O
Chl O
b O
- O
- O
> O
Chl B
a I
and O
downward O
EET O
from O
Chl O
( O
s O
) O
a O
state O
( O
s O
) O
at O
665 O
nm O
occurs O
in O
4 O
. O
9 O
+ O
/ O
- O
0 O
. O
7 O
ps O
. O

The O
available O
3 O
- O
dimensional O
structures O
of O
these O
enzymes O
reveal O
a O
typical O
sortase O
fold O
, O
except O
for O
the O
presence O
of O
a O
unique O
feature O
represented O
by O
an O
N B
- O
terminal O
highly O
flexible O
loop O
known O
as O
the O
" O
lid O
. O
" O
This O
region O
interacts O
with O
the O
residues O
composing O
the O
catalytic O
triad O
and O
covers O
the O
active O
site O
, O
thus O
maintaining O
the O
enzyme O
in O
an O
autoinhibited O
state O
and O
preventing O
the O
accessibility O
to O
the O
substrate O
. O

Anti O
- O
allergic O
actions O
of O
rottlerin B
from O
Mallotus O
philippinensis O
in O
experimental O
mast O
cell O
- O
mediated O
anaphylactic O
models O
. O

Rottlerin B
is O
an O
active O
molecule O
isolated O
from O
Mallotus O
philippinensis O
, O
a O
medicinal O
plant O
used O
in O
Ayurvedic O
Medicine O
System O
for O
anti O
- O
allergic O
and O
anti O
- O
helminthic O
treatments O
. O

The O
present O
study O
investigated O
potential O
anti O
- O
allergic O
effects O
of O
rottlerin B
in O
animal O
models O
of O
IgE O
- O
dependent O
anaphylaxis O
and O
the O
anti O
- O
allergic O
mechanisms O
of O
action O
of O
rottlerin B
in O
mast O
cells O
. O

Anti O
- O
allergic O
actions O
of O
rottlerin B
were O
evaluated O
in O
passive O
cutaneous O
anaphylaxis O
and O
passive O
systemic O
anaphylaxis O
mouse O
models O
, O
and O
in O
anaphylactic O
contraction O
of O
bronchial O
rings O
isolated O
from O
sensitized O
guinea O
pigs O
. O

Direct O
mast O
cell O
- O
stabilizing O
effect O
of O
rottlerin B
was O
examined O
in O
RBL O
- O
2H3 O
mast O
cell O
line O
. O

Anti O
- O
allergic O
signaling O
mechanisms O
of O
action O
of O
rottlerin B
in O
mast O
cells O
were O
also O
examined O
. O

Rottlerin B
prevented O
IgE O
- O
mediated O
cutaneous O
vascular O
extravasation O
, O
hypothermia O
, O
elevation O
in O
plasma O
histamine B
level O
and O
tracheal O
tissue O
mast O
cell O
degranulation O
in O
mice O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
addition O
, O
rottlerin B
suppressed O
ovalbumin O
- O
induced O
guinea O
pig O
bronchial O
smooth O
muscle O
contraction O
. O

Furthermore O
, O
rottlerin B
concentration O
- O
dependently O
blocked O
IgE O
- O
mediated O
immediate O
release O
of O
beta O
- O
hexosaminidase O
from O
RBL O
- O
2H3 O
mast O
cells O
. O

Rottlerin B
was O
found O
to O
inhibit O
IgE O
- O
induced O
PLC O
gamma O
1 O
and O
Akt O
phosphorylation O
, O
production O
of O
IP3 O
and O
rise O
in O
cytosolic O
Ca B
( I
2 I
+ I
) I
level O
in O
mast O
cells O
. O

We O
report O
here O
for O
the O
first O
time O
that O
rottlerin B
possesses O
anti O
- O
allergic O
activity O
by O
blocking O
IgE O
- O
induced O
mast O
cell O
degranulation O
, O
providing O
a O
foundation O
for O
developing O
rottlerin B
for O
the O
treatment O
of O
allergic O
asthma O
and O
other O
mast O
cell O
- O
mediated O
allergic O
disorders O
. O

Clock O
Gene O
Expression O
in O
the O
Liver O
of O
Streptozotocin B
- O
induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats O
. O

We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock O
- O
controlled O
genes O
( O
CCGs O
) O
in O
3 O
- O
hour O
intervals O
for O
a O
24 O
- O
h O
period O
in O
the O
livers O
of O
male O
streptozotocin B
( O
STZ B
) O
- O
treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW O
. O
1AR1 O
- O
iddm O
( O
Iddm O
) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O

Diabetic O
STZ B
and O
Iddm O
rats O
, O
as O
well O
as O
insulin O
- O
substituted O
Iddm O
rats O
, O
exhibited O
a O
significant O
diurnal O
expression O
pattern O
of O
clock O
genes O
as O
determined O
by O
Cosinor O
analysis O
; O
however O
, O
the O
MESOR O
( O
midline O
estimating O
statistic O
of O
rhythm O
) O
of O
Bmal1 O
, O
Per2 O
, O
and O
Clock O
transcript O
expression O
was O
altered O
in O
Iddm O
and O
insulin O
- O
substituted O
Iddm O
rats O
. O

Cosinor O
analysis O
indicated O
no O
diurnal O
rhythm O
of O
Ppar O
gamma O
expression O
in O
the O
livers O
of O
diabetic O
STZ B
or O
Iddm O
rats O
or O
in O
those O
of O
insulin O
- O
substituted O
Iddm O
rats O
. O

Studies O
on O
the O
Himbert O
Intramolecular O
Arene B
/ O
Allene O
Diels O
- O
Alder O
Cycloaddition O
. O

Mechanistic O
Studies O
and O
Expansion O
of O
Scope O
to O
All O
- O
Carbon B
Tethers O
. O

The O
unusual O
intramolecular O
arene B
/ O
allene O
cycloaddition O
described O
30 O
years O
ago O
by O
Himbert O
permits O
rapid O
access O
to O
strained O
polycyclic O
compounds O
that O
offer O
great O
potential O
for O
the O
synthesis O
of O
complex O
scaffolds O
. O

Compared O
to O
carbon B
- O
based O
compliant O
electrodes O
, O
networks O
of O
metal O
nanowires O
can O
actuate O
across O
a O
broader O
range O
of O
optical O
transmittance O
. O

Piezotronic O
Effect O
in O
Solution O
- O
Grown O
p O
- O
Type O
ZnO B
Nanowires O
and O
Films O
. O

Using O
a O
low O
temperature O
solution O
method O
, O
we O
were O
able O
to O
produce O
ultralong O
( O
up O
to O
60 O
mu O
m O
in O
length O
) O
Sb O
doped O
p O
- O
type O
ZnO B
nanowires O
on O
both O
rigid O
and O
flexible O
substrates O
. O

We O
further O
investigated O
the O
universality O
of O
piezotronic O
effect O
in O
the O
as O
- O
synthesized O
Sb O
- O
doped O
p O
- O
type O
ZnO B
NWs O
and O
reported O
for O
the O
first O
time O
strain O
- O
gated O
piezotronic O
transistors O
as O
well O
as O
piezopotential O
- O
driven O
mechanical O
energy O
harvesting O
based O
on O
solution O
- O
grown O
p O
- O
type O
ZnO B
NWs O
. O

Sub O
- O
micron O
surface O
topography O
generated O
via O
hot O
- O
embossing O
onto O
a O
track O
- O
etched O
polycarbonate B
membrane O
, O
fully O
replicated O
topographical O
features O
and O
preserved O
porous O
architecture O
. O

Considerable O
differences O
were O
noticed O
in O
mitochondrial O
membrane O
lipid O
composition O
, O
namely O
in O
terms O
of O
fatty O
acyl O
chains O
and O
relative O
proportions O
of O
phospholipid O
classes O
, O
the O
modified O
diet O
inducing O
a O
decrease O
in O
the O
saturated O
to O
unsaturated O
molar O
ratio O
and O
an O
increase O
in O
the O
phosphatidylcholine B
to O
phosphatidylethanola B
molar O
ratio O
. O

Mass O
spectrometry O
lipid O
analysis O
showed O
significant O
differences O
in O
the O
major O
species O
of O
cardiolipin B
, O
with O
an O
apparent O
increased O
incorporation O
of O
oleic B
acid I
as O
a O
result O
of O
exposure O
to O
the O
modified O
diet O
. O

Rats O
fed O
the O
modified O
diet O
during O
22 O
days O
showed O
decreased O
hepatic O
mitochondrial O
state O
3 O
respiration O
and O
were O
more O
susceptible O
to O
Ca B
( I
2 I
+ I
) I
- O
induced O
transition O
pore O
opening O
. O

Rapeseed O
oil O
- O
enriched O
diet O
also O
appeared O
to O
promote O
a O
decrease O
in O
hydroperoxide B
production O
by O
the O
respiratory O
chain O
, O
although O
a O
simultaneous O
decrease O
in O
vitamin B
E I
content O
was O
detected O
. O

Individual O
multi O
- O
locus O
heterozygosity O
is O
associated O
with O
lower O
morning O
plasma O
cortisol B
concentration O
. O

STRESS O
IS O
IMPLICATED O
AS O
A O
RISK O
FACTOR O
FOR O
NUMEROUS O
ILLNESSES O
IN O
HUMANS O
, O
PUTATIVELY O
IN O
PART O
MEDIATED O
BY O
BIOLOGICAL O
RESPONSES O
TO O
STRESS O
, O
SUCH O
AS O
ELEVATED O
CORTISOL B
. O

WE O
HYPOTHESIZED O
THAT O
HETEROZYGOSITY O
AMELIORATES O
THE O
BIOLOGICAL O
RESPONSE O
TO O
A O
GIVEN O
LEVEL O
OF O
PERCEIVED O
STRESS O
, O
REFLECTED O
IN O
LOWER O
PLASMA O
CORTISOL B
CONCENTRATIONS O
. O
DESIGN O
. O

WE O
EXAMINE O
THE O
ROLE O
OF O
HETEROZYGOSITY O
ON O
THE O
ASSOCIATION O
BETWEEN O
PERCEIVED O
PSYCHOLOGICAL O
STRESS O
AND O
MORNING O
CORTISOL B
CONCENTRATIONS O
IN O
854 O
INDIVIDUALS O
FROM O
THE O
ISOLATED O
ISLAND O
OF O
VIS O
, O
CROATIA O
. O
METHODS O
. O

CORTISOL B
WAS O
MEASURED O
IN O
MORNING O
PLASMA O
SAMPLES O
. O

Cortisol B
was O
positively O
associated O
with O
psychological O
distress O
( O
beta O
= O
2 O
. O
20 O
, O
p O
= O
0 O
. O
01 O
) O
. O

In O
a O
regression O
model O
adjusting O
for O
age O
, O
BMI O
, O
education O
and O
GHQ O
- O
30 O
score O
, O
multi O
- O
locus O
heterozygosity O
was O
independently O
and O
inversely O
associated O
with O
morning O
plasma O
cortisol B
( O
p O
= O
0 O
. O
005 O
) O
. O
Conclusion O
. O

More O
heterozygous O
individuals O
, O
as O
measured O
by O
microsatellite O
markers O
, O
had O
lower O
morning O
plasma O
cortisol B
concentrations O
for O
a O
given O
level O
of O
perceived O
psychological O
stress O
. O

This O
may O
be O
important O
, O
as O
higher O
cortisol B
concentrations O
may O
increase O
allostatic O
load O
and O
be O
associated O
with O
higher O
risk O
of O
stress O
- O
related O
illness O
. O

3D O
TiO2 B
photoanodes O
in O
dye O
- O
sensitized O
solar O
cells O
( O
DSCs O
) O
are O
fabricated O
by O
the O
soft O
lithographic O
technique O
for O
efficient O
light O
trapping O
. O

An O
extended O
strategy O
to O
the O
construction O
of O
randomized O
pyramid O
structure O
is O
developed O
by O
the O
conventional O
wet O
- O
etching O
of O
a O
silicon B
wafer O
for O
low O
- O
cost O
fabrication O
. O

Upgraded O
Silicon B
Nanowires O
by O
Metal O
- O
Assisted O
Etching O
of O
Metallurgical O
Silicon B
: O
A O
New O
Route O
to O
Nanostructured O
Solar O
- O
Grade O
Silicon B
. O

Through O
metal O
assisted O
chemical O
etching O
( O
MaCE O
) O
, O
superior O
purification O
of O
dirty O
Si B
was O
observed O
, O
from O
99 O
. O
74 O
to O
99 O
. O
9884 O
% O
for O
metallurgical O
Si B
and O
from O
99 O
. O
999772 O
to O
99 O
. O
999899 O
% O
for O
upgraded O
metallurgical O
Si B
. O

Meanwhile O
, O
large O
area O
of O
silicon B
nanowires O
( O
SiNW O
) O
was O
fabricated O
. O

In O
this O
contribution O
, O
high O
- O
performance O
vertical O
organic O
transistors O
comprising O
pentacene O
for O
p O
- O
type O
operation O
and O
C60 B
for O
n O
- O
type O
operation O
are O
presented O
. O

Recent O
literature O
shows O
that O
Brassica O
vegetables O
( O
Cruciferae O
) O
possess O
therapeutic O
effects O
particularly O
ascribed O
due O
to O
their O
content O
in O
glucosinolates B
, O
which O
upon O
myrosinase O
hydrolysis O
release O
the O
corresponding O
isothiocyanates B
. O

Anti O
- O
HIV O
and O
NO B
production O
inhibition O
activities O
of O
epi O
- O
aleuritolic O
acid O
derivatives O
. O

Fifteen O
epi O
- O
aleuritolic O
acid O
derivatives O
were O
synthesized O
and O
evaluated O
for O
anti O
- O
HIV O
activity O
in O
293 O
T O
cells O
and O
NO B
production O
inhibition O
activity O
. O

Compounds O
1 O
, O
3 O
, O
4 O
, O
and O
11 O
showed O
NO B
inhibition O
activity O
, O
with O
IC50 O
values O
ranging O
from O
3 O
. O
40 O
to O
7 O
. O
10 O
mu O
M O
and O
compound O
1 O
inhibited O
NO B
production O
with O
an O
IC50 O
value O
of O
3 O
. O
40 O
mu O
M O
. O

LC O
- O
MS O
( O
n O
) O
analysis O
on O
the O
extract O
revealed O
the O
presence O
of O
other O
myricetin O
, O
quercetin B
, O
isorhamnetin O
glycosides O
, O
simple O
phenolic B
acids I
and O
esters B
. O

Skeletal O
muscle O
, O
responsible O
for O
up O
to O
80 O
% O
of O
the O
glucose B
disposal O
from O
the O
peripheral O
circulation O
, O
is O
particularly O
vulnerable O
to O
increased O
levels O
of O
saturated O
FFAs O
. O

Palmitate O
- O
induced O
insulin O
resistant O
C2C12 O
cells O
were O
treated O
with O
an O
aspalathin O
- O
enriched O
green O
( O
unfermented O
) O
rooibos O
extract O
( O
GRE O
) O
, O
previously O
shown O
for O
its O
blood O
glucose B
lowering O
effect O
in O
vitro O
and O
in O
vivo O
or O
an O
aqueous O
extract O
of O
fermented O
rooibos O
( O
FRE O
) O
. O

Glucose B
uptake O
and O
mitochondrial O
activity O
were O
measured O
using O
2 O
- O
deoxy O
- O
[ O
( O
3 O
) O
H O
] O
- O
d O
- O
glucose O
, O
MTT B
and O
ATP B
assays O
, O
respectively O
. O

Expression O
of O
proteins O
relevant O
to O
glucose B
metabolism O
was O
analysed O
by O
Western O
blot O
. O

GRE O
contained O
higher O
levels O
of O
all O
compounds O
, O
except O
the O
enolic O
phenylpyruvic O
acid O
- O
2 O
- O
O O
- O
glucoside O
and O
luteolin B
- I
7 I
- I
O I
- I
glucoside I
. O

Both O
rooibos O
extracts O
increased O
glucose B
uptake O
, O
mitochondrial O
activity O
and O
ATP B
production O
. O

Compared O
to O
FRE O
, O
GRE O
was O
more O
effective O
at O
increasing O
glucose B
uptake O
and O
ATP B
production O
. O

Protein O
levels O
of O
the O
glucose B
transporter O
( O
GLUT4 O
) O
involved O
in O
glucose B
transport O
via O
these O
two O
pathways O
were O
also O
increased O
. O

Coumarin B
( O
1 O
, O
2 O
- O
benzopyrone O
) O
was O
previously O
reported O
as O
responsible O
for O
some O
biological O
activities O
of O
this O
plant O
species O
. O

Here O
, O
the O
extracts O
were O
evaluated O
by O
their O
cytotoxic O
activity O
against O
tumor O
( O
Hep O
- O
2 O
, O
HeLa O
) O
and O
non O
tumor O
( O
MRC O
- O
5 O
) O
cell O
lines O
, O
presenting O
significant O
inhibitory O
activity O
of O
cell O
growth O
in O
all O
extracts O
analyzed O
, O
chloroform B
, O
ethyl B
acetate I
, O
hexane B
, O
ethanol B
, O
which O
is O
related O
to O
its O
chemical O
composition O
. O

From O
the O
four O
different O
extracts O
here O
tested O
, O
two O
of O
them O
, O
hexane B
and O
ethanol B
, O
presented O
a O
clear O
selectivity O
against O
both O
tumor O
cells O
lines O
investigated O
. O

This O
can O
be O
explained O
by O
variances O
and O
increase O
of O
phenolic B
compounds O
in O
the O
ethanol B
fraction O
and O
an O
association O
of O
molecules O
with O
coumarin B
found O
in O
the O
hexane B
fraction O
. O

RESULTS O
: O
Rats O
given O
Hachimi O
- O
jio O
- O
gan O
and O
Bakumi O
- O
jio O
- O
gan O
showed O
an O
improvement O
of O
renal O
functional O
parameters O
such O
as O
serum O
urea B
nitrogen B
, O
creatinine B
, O
creatinine B
clearance O
, O
and O
urinary O
protein O
. O

The O
increased O
triglyceride B
, O
total O
cholesterol B
, O
non O
- O
esterified O
fatty B
acid I
, O
high O
- O
density O
lipoprotein O
cholesterol B
, O
and O
very O
low O
- O
density O
lipoprotein O
cholesterol B
/ O
low O
- O
density O
lipoprotein O
cholesterol B
levels O
in O
serum O
, O
and O
triglyceride B
and O
total O
cholesterol B
contents O
in O
the O
kidney O
of O
nephrectomized O
rats O
were O
significantly O
decreased O
by O
Hachimi O
- O
jio O
- O
gan O
and O
Bakumi O
- O
jio O
- O
gan O
administration O
. O

Furthermore O
, O
Hachimi O
- O
jio O
- O
gan O
acts O
as O
a O
regulator O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
, O
sterol B
regulatory O
element O
binding O
protein O
( O
SREBP O
) O
- O
1 O
, O
and O
SREBP O
- O
2 O
. O

On O
the O
contrary O
, O
the O
increased O
reactive O
oxygen B
species O
and O
thiobarbituric B
acid I
- O
reactive O
substance O
were O
decreased O
, O
while O
superoxide B
dismutase O
and O
the O
reduced B
glutathione I
/ O
oxidized B
glutathione I
ratio O
were O
augmented O
by O
Hachimi O
- O
jio O
- O
gan O
rather O
than O
Bakumi O
- O
jio O
- O
gan O
. O

The O
improvement O
of O
nuclear O
factor O
- O
kappa O
Bp65 O
, O
cyclooxygenase O
- O
2 O
, O
inducible O
nitric B
oxide I
synthase O
, O
NF O
- O
E2 O
- O
related O
factor O
2 O
, O
and O
heme B
oxygenase O
- O
1 O
was O
marked O
in O
the O
group O
administered O
Bakumi O
- O
jio O
- O
gan O
. O

Cyperi O
Rhizoma O
inhibits O
the O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
- O
induced O
reduction O
in O
nigrostriatal O
dopaminergenic O
neurons O
in O
estrogen B
- O
deprived O
mice O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
estrogenic O
properties O
and O
neuroprotective O
effects O
of O
Cyperi O
Rhizoma O
under O
estrogen B
- O
deprived O
condition O
in O
female O
mice O
. O

MATERIALS O
AND O
METHODS O
: O
To O
determine O
the O
estrogen B
- O
like O
effect O
of O
Cyperi O
Rhizoma O
extract O
( O
CRE O
) O
, O
we O
measured O
luciferase O
expression O
after O
transfection O
of O
a O
promoter O
construct O
containing O
an O
estrogen B
response O
element O
( O
ERE O
) O
and O
treatment O
of O
CRE O
. O

To O
evaluate O
the O
neuroprotective O
effect O
of O
CRE O
, O
we O
measured O
striatal O
dopamine B
, O
movement O
ability O
, O
tyrosine B
hydroxylase O
( O
TH O
) O
immunoreactivity O
, O
and O
apoptosis O
- O
related O
protein O
expression O
levels O
after O
treatment O
of O
CRE O
either O
with O
or O
without O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
in O
ovariectomized O
female O
mice O
. O

In O
mice O
, O
MPTP B
significantly O
decreased O
the O
levels O
of O
dopamine B
in O
the O
striatum O
and O
behavior O
performance O
; O
in O
contrast O
, O
both O
CRE O
and O
17 O
beta O
- O
estradiol O
benzoate O
( O
EB O
) O
recovered O
these O
parameters O
to O
normal O
levels O
. O

CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP B
toxicity O
. O

Additionally O
, O
MPTP B
significantly O
down O
- O
regulated O
Bcl O
- O
2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax O
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved O
- O
caspase O
- O
3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O

CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen B
- O
like O
and O
neuroprotective O
effects O
on O
dopaminergic O
neurons O
in O
estrogen B
- O
deprived O
mice O
treated O
with O
MPTP B
- O
toxin O
. O

Fusidic O
acid O
and O
rifampicin B
co O
- O
loaded O
PLGA B
nanofibers O
for O
the O
prevention O
of O
orthopedic O
implant O
associated O
infections O
. O

Here O
we O
report O
the O
development O
of O
a O
biodegradable O
localized O
delivery O
system O
using O
poly O
( O
D O
, O
L O
- O
lactic O
acid O
- O
co O
- O
glycolic O
acid O
) O
( O
PLGA B
) O
for O
the O
combinatorial O
release O
of O
fusidic O
acid O
( O
FA O
) O
( O
or O
its O
sodium B
salt O
; O
SF O
) O
and O
rifampicin B
( O
RIF O
) O
using O
electrospinning O
. O

All O
dual O
- O
loaded O
formulations O
showed O
direct O
antimicrobial O
activity O
in O
vitro O
against O
Staphylococcus O
epidermidis O
, O
and O
two O
strains O
of O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
. O

Synthesis O
of O
some O
novel O
biologically O
active O
piperidin O
- O
4 O
- O
one O
oxime O
carbonates O
from O
1 O
- O
methyl O
- O
3alkyl O
- O
2 O
, O
6 O
- O
diphenylpiperidin O
- O
4 O
- O
one O
oximes O
and O
substituted O
chloroformates O
was O
carried O
out O
in O
the O
presence O
of O
potassium B
carbonate I
as O
base O
and O
tetrabutylammonium O
bromide O
( O
TBAB O
) O
as O
catalyst O
. O

The O
newly O
synthesized O
compounds O
were O
characterized O
by O
IR O
, O
( B
1 I
) I
H I
, O
( B
13 I
) I
C I
NMR O
and O
LC O
- O
mass O
spectra O
. O

Based O
on O
the O
( B
1 I
) I
H I
NMR O
analysis O
, O
all O
the O
compounds O
were O
found O
to O
adopt O
normal O
chair O
conformation O
with O
equatorial O
orientation O
of O
all O
the O
substituents O
. O

For O
all O
the O
synthesized O
compounds O
( O
5a O
- O
5l O
) O
antimicrobial O
activity O
has O
been O
tested O
against O
bacterial O
and O
fungal O
strains O
using O
Streptomycin O
and O
Amphotericin B
B I
as O
standards O
. O

Synthesis O
of O
proline B
analogues O
as O
potent O
and O
selective O
cathepsin O
S O
inhibitors O
. O

A O
series O
of O
proline B
derived O
compounds O
were O
synthesized O
and O
evaluated O
as O
cathepsin O
S O
inhibitors O
. O

We O
discovered O
potent O
cathepsin O
S O
inhibitors O
through O
structure O
- O
activity O
relationship O
studies O
of O
proline B
analogues O
. O

The O
preventive O
effect O
of O
uncarboxylated O
osteocalcin O
against O
free O
fatty O
acid O
- O
induced O
endothelial O
apoptosis O
through O
the O
activation O
of O
phosphatidylinositol B
3 O
- O
kinase O
/ O
Akt O
signaling O
pathway O
: O
Uncarboxylated O
osteocalcin O
and O
endothelial O
apoptosis O
. O

Linoleic B
acid I
( O
LA O
) O
was O
used O
as O
a O
representative O
free O
fatty O
acid O
. O

Apoptosis O
was O
evaluated O
using O
various O
methods O
including O
a O
terminal O
deoxyribonucleotide O
transferase O
- O
mediated O
deoxyuridine B
triphosphate I
nick O
- O
end O
labeling O
analysis O
kit O
and O
Western O
blotting O
for O
cleaved O
caspase O
3 O
, O
cleaved O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
Bcl O
- O
xL O
. O

The O
phosphorylations O
of O
Akt O
and O
endothelial O
nitric B
oxide I
synthase O
( O
eNOS O
) O
as O
well O
as O
the O
level O
of O
NO B
were O
measured O
to O
confirm O
the O
effect O
of O
ucOC O
on O
insulin O
signaling O
pathway O
. O

RESULTS O
: O
Pretreatment O
of O
ucOC O
( O
30ng O
/ O
ml O
) O
prevented O
LA O
- O
induced O
apoptosis O
in O
insulin O
- O
stimulated O
endothelial O
cells O
; O
effects O
were O
abolished O
by O
pretreatment O
with O
the O
phosphatidylinositol B
3 O
- O
kinase O
( O
PI3 O
- O
kinase O
) O
inhibitor O
, O
wortmannin B
. O

Treatment O
of O
ucOC O
( O
ranged O
from O
0 O
. O
3 O
to O
30ng O
/ O
ml O
) O
significantly O
increased O
the O
phosphorylation O
of O
Akt O
and O
eNOS O
and O
nitric B
oxide I
secretion O
from O
endothelial O
cells O
in O
a O
PI3 O
- O
kinase O
dependent O
manner O
. O

Analyses O
of O
these O
genes O
identified O
over O
- O
represented O
functions O
associated O
with O
insulin O
signaling O
pathway O
, O
glucose B
metabolism O
, O
cell O
cycle O
, O
oxidative O
stress O
and O
apoptosis O
, O
which O
were O
consistent O
with O
the O
results O
of O
significant O
increase O
of O
Caspase O
- O
3 O
activity O
and O
reduction O
of O
serum O
glucose B
, O
GSH B
/ O
GSSG B
ratio O
, O
glucose B
- O
6 O
- O
phosphatase O
and O
phosphoenolpyruvate B
carboxykinase O
activities O
, O
liver O
glycogen O
. O

These O
data O
suggest O
that O
TP O
treatment O
could O
alter O
the O
hepatic O
redox O
status O
, O
reduce O
serum O
glucose B
and O
induce O
hepatocyte O
apoptosis O
, O
consistent O
with O
the O
differential O
expression O
of O
genes O
involved O
in O
insulin O
signaling O
pathway O
, O
glucose B
metabolism O
pathway O
and O
cell O
stress O
pathway O
, O
all O
of O
which O
might O
contribute O
to O
the O
overall O
TP O
- O
induced O
hepatotoxicity O
. O

TCDD B
induces O
the O
expression O
of O
insulin O
- O
like O
growth O
factor O
binding O
protein O
4 O
in O
5L O
rat O
hepatoma O
cells O
: O
a O
cautionary O
tale O
of O
the O
use O
of O
this O
cell O
line O
in O
studies O
on O
dioxin B
toxicity O
. O

Previous O
quantitative O
proteomic O
studies O
on O
the O
actions O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
in O
5L O
rat O
hepatoma O
cells O
, O
a O
cell O
model O
frequently O
used O
for O
investigating O
the O
mechanisms O
of O
TCDD B
toxicity O
, O
had O
indicated O
that O
dioxin B
exposure O
reduced O
the O
abundance O
of O
numerous O
proteins O
which O
are O
regulated O
at O
the O
level O
of O
protein O
synthesis O
initiation O
. O

TCDD B
treatment O
of O
the O
cells O
largely O
prevented O
the O
activation O
of O
eukaryotic O
translation O
initiation O
factor O
4E O
- O
binding O
protein O
1 O
, O
a O
regulator O
of O
translation O
initiation O
and O
substrate O
of O
the O
mammalian O
target O
of O
rapamycin B
( O
mTOR O
) O
. O

By O
" O
working O
upwards O
" O
from O
mTOR O
, O
we O
observed O
that O
TCDD B
inhibited O
endogenous O
and O
IGF O
- O
I O
- O
induced O
AKT O
and O
ERK O
activation O
by O
interfering O
with O
tyrosine B
phosphorylation O
of O
insulin O
receptor O
substrate O
1 O
. O

This O
inhibition O
was O
mediated O
by O
a O
TCDD B
- O
induced O
secreted O
factor O
which O
was O
identified O
as O
insulin O
- O
like O
growth O
factor O
binding O
protein O
4 O
( O
IGFBP O
- O
4 O
) O
. O

The O
induction O
of O
IGFBP O
- O
4 O
protein O
was O
dependent O
on O
a O
functional O
aryl B
hydrocarbon I
receptor O
and O
was O
preceded O
by O
a O
rapid O
increase O
in O
the O
level O
of O
IGFBP O
- O
4 O
mRNA O
indicating O
that O
IGFBP O
- O
4 O
is O
a O
previously O
unknown O
transcriptional O
target O
of O
TCDD B
in O
5L O
cells O
. O

IGFBP O
- O
4 O
was O
not O
induced O
by O
TCDD B
in O
the O
parental O
cell O
line O
of O
5L O
cells O
, O
Fao O
, O
and O
in O
various O
closely O
related O
rat O
hepatoma O
cell O
lines O
as O
well O
as O
in O
other O
unrelated O
cell O
types O
. O

The O
observations O
suggest O
that O
in O
5L O
cells O
the O
Igfbp O
- O
4 O
gene O
may O
have O
got O
under O
the O
control O
of O
a O
promoter O
containing O
dioxin B
responsive O
element O
( O
s O
) O
leading O
to O
the O
induction O
of O
IGFBP O
- O
4 O
by O
TCDD B
. O

These O
findings O
emphasise O
a O
particular O
caution O
when O
interpreting O
and O
extrapolating O
results O
on O
the O
action O
mechanisms O
of O
TCDD B
obtained O
in O
studies O
using O
5L O
cells O
as O
a O
model O
system O
. O

Pyrazole B
derivatives O
as O
inhibitors O
of O
arachidonic B
acid I
- O
induced O
platelet O
aggregation O
. O

Analogs O
from O
this O
series O
demonstrated O
potent O
anti O
- O
aggregatory O
activities O
against O
arachidonic B
acid I
- O
induced O
platelet O
aggregation O
, O
as O
measured O
by O
turbidimetric O
method O
of O
Born O
. O

1 O
, O
5 O
- O
Diarylpyrazole O
- O
3 O
- O
carboxamides O
obtained O
with O
small O
- O
basic O
amines B
( O
7 O
, O
8 O
, O
50 O
, O
51 O
, O
61 O
, O
62 O
) O
displayed O
the O
strongest O
activity O
with O
IC50 O
values O
in O
low O
nanomolar O
range O
( O
5 O
. O
7 O
- O
83 O
nM O
) O
. O

On O
the O
basis O
of O
their O
high O
potency O
in O
cellular O
environment O
, O
these O
straightforward O
pyrazole B
derivatives O
may O
possess O
potential O
in O
the O
design O
of O
more O
potent O
compounds O
for O
intervention O
with O
cardiovascular O
diseases O
. O

In O
HEK293 O
cells O
stably O
expressing O
human O
GPR55 O
( O
HEK O
- O
GPR55 O
) O
, O
the O
compound O
behaved O
as O
an O
antagonist O
on O
LPI O
- O
mediated O
Ca2 B
+ I
release O
and O
extracellular O
signal O
- O
regulated O
kinases O
( O
ERK1 O
/ O
2 O
) O
activation O
, O
but O
not O
in O
HEK293 O
cells O
expressing O
cannabinoid O
receptor O
1 O
or O
2 O
( O
CB1 O
or O
CB2 O
) O
. O

Prostaglandin B
E2 I
acts O
via O
bone O
marrow O
macrophages O
to O
block O
PTH O
- O
stimulated O
osteoblast O
differentiation O
in O
vitro O
. O

PTH O
also O
induces O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
producing O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
that O
can O
act O
on O
both O
OBs O
and O
osteoclasts O
( O
OCs O
) O
. O

We O
compared O
effects O
of O
continuous O
PTH O
on O
bone O
marrow O
stromal O
cells O
( O
BMSCs O
) O
and O
primary O
OBs O
( O
POBs O
) O
from O
Cox O
- O
2 O
KO O
mice O
, O
mice O
with O
deletion O
of O
PGE2 B
receptors O
( O
Ptger4 O
and O
Ptger2 O
KO O
mice O
) O
, O
and O
WT O
controls O
. O

In O
Cox O
- O
2 O
KO O
BMSCs O
, O
PTH O
- O
stimulated O
differentiation O
was O
prevented O
by O
adding O
PGE2 B
to O
cultures O
. O

Co O
- O
culture O
of O
POBs O
with O
M O
- O
CSF O
- O
expanded O
bone O
marrow O
macrophages O
( O
BMMs O
) O
showed O
that O
the O
inhibition O
of O
PTH O
- O
stimulated O
OB O
differentiation O
required O
not O
only O
COX O
- O
2 O
or O
PGE2 B
but O
also O
BMMs O
. O

Sufficient O
PGE2 B
to O
mediate O
the O
inhibitory O
effect O
was O
made O
by O
either O
WT O
POBs O
or O
WT O
BMMs O
. O

The O
inhibitory O
effect O
mediated O
by O
COX O
- O
2 O
/ O
PGE2 B
was O
transferred O
by O
conditioned O
media O
from O
RANKL O
- O
treated O
BMMs O
and O
could O
be O
blocked O
by O
osteoprotegerin O
, O
which O
interferes O
with O
RANKL O
binding O
to O
its O
receptor O
on O
OC O
lineage O
cells O
. O

As O
expected O
, O
PGE2 B
also O
stimulated O
OB O
differentiation O
, O
but O
when O
given O
in O
combination O
with O
PTH O
, O
the O
stimulatory O
effects O
of O
both O
were O
abrogated O
. O

These O
data O
suggest O
that O
PGE2 B
, O
acting O
via O
EP4R O
on O
BMMs O
committed O
to O
the O
OC O
lineage O
, O
stimulated O
secretion O
of O
a O
factor O
or O
factors O
that O
acted O
to O
suppress O
PTH O
- O
stimulated O
OB O
differentiation O
. O

Zno B
nanoparticle O
based O
highly O
efficient O
CdS B
/ O
CdSe B
quantum O
dot O
- O
sensitized O
solar O
cells O
. O

20 O
nm O
ZnO B
nanoparticles O
are O
used O
to O
fabricate O
the O
mesoporous O
photoanode O
of O
the O
CdS B
/ O
CdSe B
quantum O
dot O
- O
sensitized O
solar O
cells O
by O
the O
simple O
doctor O
blade O
method O
. O

A O
maximum O
power O
conversion O
efficiency O
of O
4 O
. O
46 O
% O
has O
been O
achieved O
, O
which O
indicated O
exciting O
prospects O
for O
ZnO B
nanoparticle O
based O
quantum O
dot O
- O
sensitized O
solar O
cells O
. O

A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
crossover O
study O
of O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine B
receptor O
agonist O
AZD1446 O
( O
TC O
- O
6683 O
) O
in O
adults O
with O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

AZD1446 O
is O
a O
selective O
alpha O
4 O
beta O
2 O
* O
nicotinic O
acetylcholine B
receptor O
agonist O
with O
potential O
effect O
on O
the O
symptoms O
of O
ADHD O
. O

Participants O
were O
79 O
adults O
with O
ADHD O
, O
grouped O
according O
to O
their O
use O
of O
nicotine B
- O
containing O
products O
. O

Nicotine B
non O
- O
users O
received O
placebo O
and O
two O
of O
three O
AZD1446 O
treatment O
regimens O
( O
80 O
mg O
tid O
, O
80 O
mg O
qd O
, O
10 O
mg O
tid O
) O
. O

Nicotine B
users O
received O
placebo O
, O
AZD1446 O
80 O
mg O
tid O
and O
80 O
mg O
qd O
. O

RESULTS O
: O
There O
was O
no O
significant O
effect O
of O
AZD1446 O
on O
any O
of O
the O
clinical O
scores O
irrespective O
of O
dose O
, O
schedule O
, O
or O
concomitant O
use O
of O
nicotine B
products O
. O

A O
statistically O
significant O
improvement O
was O
seen O
on O
the O
Groton O
Maze O
Learning O
Task O
, O
a O
measure O
of O
executive O
functioning O
, O
in O
nicotine B
non O
- O
users O
after O
treatment O
with O
AZD1446 O
80 O
mg O
qd O
. O

To O
directly O
address O
the O
role O
of O
OAT1 O
ubiquitination O
, O
we O
then O
generated O
two O
OAT1 O
mutants O
, O
each O
having O
multiple O
lysines B
( O
K O
) O
simultaneously O
mutated O
to O
arginine B
( O
R O
) O
. O

Further O
dissecting O
each O
lysine B
within O
this O
mutant O
, O
we O
identified O
Lys297 O
, O
Lys303 O
and O
Lys315 O
being O
the O
ubiquitin O
- O
conjugation O
sites O
. O

Interestingly O
, O
mutating O
any O
one O
of O
the O
three O
lysines B
prevented O
the O
ubiquitin O
- O
conjugation O
to O
the O
other O
two O
lysines B
, O
suggesting O
that O
Lys297 O
, O
Lys303 O
and O
Lys315 O
may O
form O
an O
optimal O
structure O
to O
interact O
with O
ubiquitination O
machineries O
. O

Progesterone B
receptor O
induces O
bcl O
- O
x O
expression O
through O
intragenic O
binding O
sites O
favoring O
RNA O
polymerase O
II O
elongation O
. O

Steroid B
receptors O
were O
classically O
described O
for O
regulating O
transcription O
by O
binding O
to O
target O
gene O
promoters O
. O

However O
, O
genome O
- O
wide O
studies O
reveal O
that O
steroid B
receptors O
- O
binding O
sites O
are O
mainly O
located O
at O
intragenic O
regions O
. O

To O
determine O
the O
role O
of O
these O
sites O
, O
we O
examined O
the O
effect O
of O
progestins O
on O
the O
transcription O
of O
the O
bcl O
- O
x O
gene O
, O
where O
only O
intragenic O
progesterone B
receptor O
- O
binding O
sites O
( O
PRbs O
) O
were O
identified O
. O

Seawater O
- O
driven O
magnesium B
based O
Janus O
micromotors O
for O
environmental O
remediation O
. O

The O
new O
micromotors O
consist O
of O
biodegradable O
and O
environmentally O
friendly O
magnesium B
microparticles O
and O
a O
nickel B
- O
gold O
bilayer O
patch O
for O
magnetic O
guidance O
and O
surface O
modification O
. O

Such O
seawater O
- O
driven O
micromotors O
, O
which O
utilize O
macrogalvanic O
corrosion O
and O
chloride B
pitting O
corrosion O
processes O
, O
eliminate O
the O
need O
for O
external O
fuels O
to O
offer O
efficient O
and O
prolonged O
propulsion O
towards O
diverse O
applications O
in O
aquatic O
environments O
. O

Electrically O
driven O
ultraviolet O
random O
lasing O
from O
an O
n O
- O
MgZnO O
/ O
i O
- O
ZnO B
/ O
SiO2 B
/ O
p O
- O
Si B
asymmetric O
double O
heterojunction O
. O

Electrically O
pumped O
lasing O
action O
has O
been O
realized O
in O
ZnO B
from O
an O
n O
- O
MgZnO O
/ O
i O
- O
ZnO B
/ O
SiO2 B
/ O
p O
- O
Si B
asymmetric O
double O
heterostructure O
, O
an O
ultralow O
threshold O
of O
3 O
. O
9 O
mA O
was O
obtained O
. O

The O
mechanism O
of O
the O
laser O
is O
associated O
with O
the O
in O
- O
plane O
random O
resonator O
cavities O
formed O
in O
the O
ZnO B
films O
and O
the O
elaborate O
hollow O
- O
shaped O
SiO2 B
cladding O
pattern O
, O
which O
prevent O
the O
lateral O
diffusion O
of O
injection O
current O
and O
ultimately O
lower O
the O
threshold O
current O
of O
the O
laser O
diode O
. O

In O
addition O
, O
a O
waveguide O
mechanism O
due O
to O
different O
refractive O
indices O
of O
three O
epilayers O
enhances O
the O
guided O
optical O
field O
on O
the O
ZnO B
side O
, O
resulting O
in O
an O
improved O
light O
extraction O
efficiency O
. O

Recently O
, O
antidiabetic O
thiazolidinediones B
have O
been O
implicated O
in O
the O
development O
of O
macular O
edema O
, O
and O
a O
review O
of O
the O
English O
literature O
revealed O
that O
other O
systemically O
administered O
drugs O
like O
fingolimod B
, O
recently O
approved O
for O
relapsing O
forms O
of O
multiple O
sclerosis O
, O
the O
anticancer O
agents O
tamoxifen B
and O
the O
taxanes B
, O
as O
well O
as O
niacin O
and O
interferons O
have O
been O
reported O
to O
cause O
macular O
edema O
. O

Ophthalmologic O
pharmaceutical O
agents O
, O
like O
prostaglandin B
analogs O
, O
epinephrine B
, O
timolol B
, O
and O
ophthalmic O
preparation O
preservatives O
have O
also O
been O
reported O
to O
cause O
macular O
edema O
as O
an O
adverse O
event O
. O

Oxygen B
- O
functionalized O
few O
- O
layer O
graphene B
sheets O
as O
active O
catalysts O
for O
oxidative O
dehydrogenation O
reactions O
. O

The O
illustration O
is O
of O
the O
catalytic O
activity O
of O
the O
reported O
oxygen B
- O
functionalized O
few O
- O
layer O
graphenes B
, O
whereas O
the O
micrograph O
background O
image O
is O
of O
the O
same O
graphenes B
recorded O
by O
the O
authors O
using O
a O
new O
helium B
- O
ion O
microscope O
at O
the O
CNMS O
. O

NUCLEOSIDE B
REVERSE O
TRANSCRIPTASE O
INHIBITORS O
INDUCE O
A O
MITOPHAGY O
- O
ASSOCIATED O
ENDOTHELIAL O
DYSFUNCTION O
THAT O
IS O
REVERSED O
BY O
COENZYME O
Q10 O
CO O
- O
TREATMENT O
. O

Nucleoside B
reverse O
transcriptase O
inhibitors O
( O
NRTI O
) O
are O
antiretrovirals O
known O
to O
induce O
mitochondrial O
damage O
in O
endothelial O
cells O
, O
culminating O
in O
endothelial O
dysfunction O
, O
an O
initiating O
event O
in O
atherogenesis O
. O

To O
further O
delineate O
the O
mechanism O
of O
toxicity O
, O
endothelial O
cells O
were O
treated O
with O
NRTI O
of O
varying O
subclasses O
, O
and O
the O
level O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
mitochondrial O
function O
were O
assessed O
. O

At O
4 O
- O
6h O
, O
NRTI O
increased O
levels O
of O
ROS O
but O
decreased O
the O
activities O
of O
electron O
transport O
chain O
complexes O
I O
- O
IV O
, O
levels O
of O
ATP B
and O
the O
NAD B
/ O
NADH B
ratio O
. O

Moreover O
, O
nitric B
oxide I
levels O
were O
decreased O
, O
while O
endothelin O
- O
1 O
release O
was O
increased O
. O

The O
structure O
of O
AFUEI O
shows O
remarkable O
similarity O
to O
serine B
protease O
inhibitors O
of O
the O
potato O
inhibitor O
I O
family O
, O
although O
they O
are O
classified O
into O
different O
inhibitor O
families O
. O

We O
have O
in O
a O
one O
- O
pot O
reaction O
synthesized O
a O
series O
of O
amorphous O
and O
degradable O
polyester B
- O
based O
copolymers O
with O
active O
functional O
groups O
by O
copolymerization O
of O
2 O
- O
methylene O
- O
1 O
, O
3 O
- O
dioxepane O
and O
glycidyl O
methacrylate O
. O

Influence O
of O
histidine B
incorporation O
on O
buffer O
capacity O
and O
gene O
transfection O
efficiency O
of O
HPMA B
- O
co O
- O
oligolysine O
brush O
polymers O
. O

The O
incorporation O
of O
histidine B
residues O
into O
polymeric O
constructs O
has O
been O
found O
to O
increase O
endosomal O
escape O
via O
the O
proton O
sponge O
effect O
. O

Statistical O
and O
diblock O
copolymers O
of O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
, O
oligolysine O
, O
and O
oligohistidine O
were O
synthesized O
via O
reversible O
- O
addition O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
, O
and O
tested O
for O
in O
vitro O
transfection O
efficiency O
, O
buffering O
ability O
, O
and O
polyplex O
uptake O
mechanism O
via O
the O
use O
of O
chemical O
endocytic O
inhibitors O
. O

Interestingly O
, O
histidine B
- O
containing O
statistical O
and O
diblock O
polymers O
exhibited O
increased O
buffer O
capacity O
in O
different O
endosomal O
pH O
ranges O
. O

Statistical O
copolymers O
transfected O
better O
than O
block O
copolymers O
that O
contained O
similar O
amounts O
of O
histidine B
. O

In O
addition O
, O
only O
the O
polymer O
containing O
the O
highest O
incorporation O
of O
oligohistidine O
residues O
led O
to O
increases O
in O
transfection O
efficiency O
over O
the O
HPMA B
- O
oligolysine O
base O
polymer O
. O

Thus O
, O
for O
these O
polymer O
architectures O
, O
high O
histidine B
incorporation O
may O
be O
required O
for O
efficient O
endosomal O
escape O
. O

Furthermore O
, O
uptake O
studies O
indicate O
that O
non O
- O
acidified O
caveolae O
- O
mediated O
endocytosis O
may O
be O
the O
primary O
route O
of O
transfection O
for O
these O
copolymers O
, O
suggesting O
that O
alternative O
approaches O
for O
increasing O
endosomal O
escape O
may O
be O
beneficial O
for O
enhancing O
transfection O
efficiency O
with O
these O
HPMA B
- O
oligolysine O
copolymers O
. O

The O
model O
organism O
S O
. O
cerevisiae O
and O
this O
particular O
enzyme O
may O
be O
useful O
for O
detecting O
antifungals O
with O
a O
novel O
mechanism O
of O
action O
compared O
to O
the O
classical O
azole B
drugs O
to O
which O
significant O
drug O
resistance O
emerged O
. O

Indeed O
, O
some O
of O
these O
sulfonamides B
inhibited O
the O
growth O
of O
the O
yeast O
with O
CC50 O
- O
s O
in O
the O
range O
of O
0 O
. O
73 O
- O
6 O
. O
54 O
mu O
M O
. O

Thirteen O
compounds O
belonging O
to O
different O
classes O
of O
alkaloids O
( O
1 O
- O
9 O
) O
and O
lignans B
( O
10 O
- O
13 O
) O
, O
isolated O
from O
the O
methanol B
extract O
of O
roots O
of O
the O
African O
medicinal O
plant O
Zanthoxylum O
capense O
, O
were O
assayed O
for O
their O
ability O
as O
apoptosis O
inducers O
in O
HCT116 O
colon O
carcinoma O
cells O
. O

The O
cytotoxicity O
of O
these O
compounds O
was O
evaluated O
in O
HCT116 O
colon O
carcinoma O
cells O
by O
the O
MTS B
assay O
. O

Morphologic O
evaluation O
of O
HCT116 O
nuclei O
following O
Hoechst O
staining O
and O
fluorescence O
microscopy O
revealed O
that O
compounds O
1 O
, O
4 O
, O
7 O
, O
10 O
, O
12 O
, O
and O
13 O
induced O
apoptosis O
in O
HCT116 O
colon O
carcinoma O
cells O
, O
producing O
similar O
, O
or O
higher O
, O
apoptosis O
levels O
when O
compared O
with O
5 B
- I
fluorouracil I
( O
5 B
- I
FU I
) O
, O
the O
cornerstone O
cytotoxic O
used O
in O
colon O
cancer O
treatment O
for O
several O
decades O
. O

Importantly O
, O
compounds O
4 O
and O
13 O
at O
20 O
mu O
M O
were O
the O
most O
promising O
in O
this O
study O
, O
inducing O
respectively O
~ O
11 O
- O
and O
7 O
- O
fold O
increases O
in O
apoptotic O
cells O
as O
compared O
to O
vehicle O
control O
, O
whereas O
5 B
- I
FU I
increased O
apoptosis O
by O
~ O
2 O
- O
fold O
. O

Pharmacokinetic O
study O
of O
four O
flavones B
of O
Glycyrrhiza O
in O
rat O
plasma O
using O
HPLC O
- O
MS O
. O

AIM O
OF O
THE O
STUDY O
: O
This O
study O
aimed O
to O
develop O
a O
specific O
HPLC O
- O
MS O
method O
for O
simultaneous O
quantification O
of O
four O
flavones B
of O
Glycyrrhiza O
in O
rat O
plasma O
after O
oral O
administration O
and O
to O
describe O
the O
pharmacokinetics O
of O
four O
flavones B
in O
rat O
plasma O
. O

MATERIALS O
AND O
METHODS O
: O
A O
simple O
, O
sensitive O
and O
selective O
method O
for O
simultaneous O
determination O
of O
four O
flavones B
of O
Glycyrrhiza O
in O
rat O
plasma O
, O
i O
. O
e O
. O
, O
liquiritin O
, O
isoliquiritin O
, O
liquiritigenin B
, O
isoliquiritigenin O
, O
by O
high O
performance O
liquid O
chromato O
- O
graphy O
- O
tandem O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
with O
negative O
electrospray O
ionization O
mode O
, O
was O
developed O
and O
validated O
. O

The O
method O
was O
applied O
to O
investigate O
the O
pharmacokinetics O
of O
four O
flavones B
in O
rat O
plasma O
after O
oral O
administration O
of O
Glycyrrhiza O
flavones B
. O

Chromatographic O
separation O
was O
accomplished O
on O
an O
Agilent O
TC O
- O
C18 O
column O
( O
4 O
. O
6mm O
x O
250mm O
, O
5 O
mu O
m O
) O
, O
with O
gradient O
elution O
by O
using O
a O
mixture O
of O
methanoic O
acid O
( O
A O
) O
and O
acetonitrile B
( O
B O
) O
as O
the O
mobile O
phase O
at O
a O
flow O
rate O
of O
0 O
. O
8mL O
/ O
min O
. O

RESULTS O
: O
The O
calibration O
curves O
for O
four O
flavones B
had O
good O
linearity O
in O
the O
measured O
range O
with O
higher O
than O
0 O
. O
997 O
. O

The O
pharmacokinetic O
profile O
of O
four O
flavones B
in O
rat O
plasma O
was O
fitted O
with O
a O
two O
- O
compartment O
model O
detected O
by O
a O
simple O
, O
rapid O
and O
accurate O
HPLC O
- O
MS O
method O
. O

Time O
( O
h O
) O
to O
reach O
peak O
concentration O
( O
mu O
g O
/ O
mL O
) O
of O
liquiritin O
( O
2 O
. O
69 O
+ O
/ O
- O
0 O
. O
04 O
) O
, O
isoliquiritin O
( O
10 O
. O
16 O
+ O
/ O
- O
0 O
. O
02 O
) O
, O
liquiritigenin B
( O
2 O
. O
83 O
+ O
/ O
- O
0 O
. O
02 O
) O
, O
isoliquiritigenin O
( O
0 O
. O
28 O
+ O
/ O
- O
0 O
. O
01 O
) O
were O
2 O
. O
02 O
+ O
/ O
- O
0 O
. O
23 O
, O
1 O
. O
97 O
+ O
/ O
- O
0 O
. O
20 O
, O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
02 O
, O
1 O
. O
93 O
+ O
/ O
- O
0 O
. O
36 O

The O
distribution O
and O
elimination O
half O
- O
life O
( O
h O
) O
and O
area O
under O
the O
concentration O
- O
time O
curve O
( O
mu O
g O
/ O
mL O
* O
h O
) O
from O
t O
= O
0 O
to O
last O
time O
of O
liquiritin O
, O
isoliquiritin O
, O
liquiritigenin B
, O
isoliquiritigenin O
were O
1 O
. O
02 O
+ O
/ O
- O
0 O
. O
48 O
/ O
2 O
. O
27 O
+ O
/ O
- O
0 O
. O
53 O
/ O
16 O
. O
97 O
+ O
/ O
- O
0 O
. O
43 O
, O
2 O
. O
04 O
+ O
/ O
- O
1 O
. O
01 O
/ O
2 O
. O
38 O
+ O
/ O
- O
0 O
. O
80 O
/ O
69 O
. O
20 O
+ O
/ O
- O
5 O
. O
24 O
, O
0 O
. O
35 O
+ O

Liquiritigenin B
had O
the O
fastest O
absorption O
and O
distribution O
rate O
and O
the O
lowest O
elimination O
rate O
according O
to O
Tmax O
, O
t1 O
/ O
2 O
alpha O
, O
t1 O
/ O
2 O
beta O
. O

CONCLUSIONS O
: O
This O
paper O
first O
reported O
on O
identification O
and O
determination O
of O
four O
flavones B
of O
Glycyrrhiza O
in O
rat O
plasma O
and O
their O
respective O
pharmacokinetic O
characteristics O
. O

Evaluation O
of O
genotoxicity O
of O
nitrile B
fragrance O
ingredients O
using O
in O
vitro O
and O
in O
vivo O
assays O
. O

Genotoxicity O
studies O
were O
conducted O
on O
a O
group O
of O
8 O
fragrance O
ingredients O
that O
belong O
to O
the O
nitrile B
family O
. O

The O
remaining O
two O
nitriles O
( O
benzonitrile B
and O
alpha O
- O
cyclohexylidene O
benzeneacetonitrile O
) O
were O
negative O
in O
the O
in O
- O
vivo O
micronucleus O
test O
. O

The O
low O
lipophilicity O
of O
hydroxytyrosol B
( O
HT O
) O
has O
motivated O
efforts O
to O
synthesize O
homologous O
series O
with O
better O
lipid O
solubility O
, O
such O
as O
the O
ethers B
, O
which O
are O
more O
lipophilic O
than O
HT O
. O

Because O
HT O
inhibits O
platelet O
aggregation O
, O
the O
aim O
of O
the O
study O
was O
to O
assess O
the O
possible O
anti O
- O
platelet O
effect O
of O
five O
HT O
ether B
derivatives O
( O
ethyl B
, O
butyl B
, O
hexyl O
, O
octyl O
and O
dodecyl B
) O
after O
oral O
administration O
to O
rats O
. O

Whole O
blood O
collagen O
- O
induced O
platelet O
aggregation O
and O
calcium B
- O
induced O
thromboxane O
B2 O
( O
TxB2 O
) O
, O
aortic O
6 O
- O
keto O
- O
prostaglandin O
F1 O
alpha O
( O
6 O
- O
keto O
- O
PGF1 O
alpha O
) O
and O
nitrites O
+ O
nitrates B
, O
plasma O
concentration O
of O
lipid O
peroxides B
( O
TBARS O
) O
and O
red O
blood O
cell O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
were O
measured O
. O

The O
administration O
of O
20 O
mg O
/ O
kg O
/ O
day O
inhibited O
platelet O
aggregation O
, O
TxB2 O
and O
TBARS O
in O
a O
non O
- O
linear O
manner O
related O
to O
the O
length O
of O
the O
carbon B
chain O
, O
with O
a O
cut O
- O
off O
effect O
in O
the O
hexyl O
derivative O
. O

Aortic O
nitrite B
and O
red O
blood O
cell O
GSH B
production O
were O
also O
increased O
. O

The O
aortic O
production O
of O
6 O
- O
keto O
- O
PGF1 O
alpha O
was O
unaltered O
except O
in O
the O
group O
treated O
with O
the O
dodecyl B
derivative O
. O

In O
conclusion O
, O
HT O
ethers B
, O
especially O
the O
hexyl O
derivative O
, O
are O
a O
potential O
alternative O
to O
hydroxytyrosol B
, O
and O
their O
effect O
merits O
additional O
research O
to O
determine O
their O
role O
in O
the O
prophylaxis O
of O
vascular O
disease O
. O

Cyclooxygenase O
activity O
contributes O
to O
the O
monoaminergic O
damage O
caused O
by O
serial O
exposure O
to O
stress O
and O
methamphetamine B
. O

Methamphetamine B
( O
Meth B
) O
is O
a O
widely O
abused O
psychostimulant O
that O
causes O
long O
- O
term O
dopamine B
( O
DA O
) O
and O
serotonin B
( O
5 B
- I
HT I
) O
depletions O
. O

Stress O
and O
Meth B
abuse O
are O
comorbid O
events O
in O
society O
and O
stress O
exacerbates O
Meth B
- O
induced O
monoaminergic O
terminal O
damage O
. O

This O
study O
examined O
the O
role O
of O
the O
neuroinflammatory O
mediator O
, O
cyclooxygenase O
( O
COX O
) O
, O
in O
the O
depletions O
of O
monoamines B
caused O
by O
serial O
exposure O
to O
chronic O
unpredictable O
stress O
( O
CUS O
) O
and O
Meth B
. O

CUS O
produced O
an O
increase O
in O
COX O
- O
2 O
protein O
expression O
and O
enhanced O
Meth B
- O
induced O
monoaminergic O
depletions O
in O
the O
striatum O
and O
hippocampus O
. O

The O
enhanced O
DA O
and O
5 B
- I
HT I
depletions O
in O
the O
striatum O
, O
but O
not O
the O
hippocampus O
, O
were O
prevented O
by O
pretreatment O
with O
COX O
inhibitor O
, O
ketoprofen B
, O
during O
stress O
or O
during O
Meth B
; O
however O
, O
ketoprofen B
did O
not O
attenuate O
the O
monoaminergic O
damage O
caused O
by O
Meth B
alone O
. O

The O
COX O
- O
dependent O
enhancement O
by O
stress O
of O
Meth B
- O
induced O
monoaminergic O
depletions O
was O
independent O
of O
hyperthermia O
, O
as O
ketoprofen B
did O
not O
attenuate O
Meth B
- O
induced O
hyperthermia O
. O

In O
addition O
, O
the O
EP1 O
receptor O
antagonist O
, O
SC O
- O
51089 O
, O
did O
not O
attenuate O
DA O
or O
5 B
- I
HT I
depletions O
caused O
by O
stress O
and O
Meth B
. O

These O
findings O
illustrate O
that O
COX O
activity O
, O
but O
not O
activation O
of O
the O
EP1 O
receptor O
, O
is O
responsible O
for O
the O
potentiation O
of O
Meth B
- O
induced O
damage O
to O
striatal O
monoamine B
terminals O
by O
stress O
and O
suggests O
the O
use O
of O
anti O
- O
inflammatory O
drugs O
for O
mitigating O
the O
neurotoxic O
effects O
associated O
with O
the O
combination O
of O
stress O
and O
Meth B
. O

Upregulation O
of O
the O
dorsal O
raphe O
nucleus O
- O
prefrontal O
cortex O
serotonin B
system O
by O
chronic O
treatment O
with O
escitalopram B
in O
hyposerotonergic O
Wistar O
- O
Kyoto O
rats O
. O

Dorsal O
raphe O
nucleus O
( O
DRN O
) O
serotonin B
( O
5 B
- I
HT I
) O
neurons O
projecting O
to O
the O
prefrontal O
cortex O
( O
PFC O
) O
comprise O
the O
important O
neurocircuitry O
underlying O
the O
pathophysiology O
of O
depression O
. O

To O
evaluate O
the O
DRN O
- O
PFC O
5 B
- I
HT I
system O
in O
WKY O
rats O
, O
we O
examined O
the O
effects O
of O
escitalopram B
( O
ESCIT O
) O
on O
the O
extracellular O
5 B
- I
HT I
level O
in O
comparison O
with O
Wistar O
rats O
using O
dual O
- O
probe O
microdialysis O
. O

The O
basal O
levels O
of O
5 B
- I
HT I
in O
the O
DRN O
, O
but O
not O
in O
the O
PFC O
, O
in O
WKY O
rats O
was O
reduced O
as O
low O
as O
30 O
% O
of O
Wistar O
rats O
. O

Responses O
of O
5 B
- I
HT I
in O
the O
DRN O
and O
PFC O
to O
ESCIT O
administered O
systemically O
and O
locally O
were O
attenuated O
in O
WKY O
rats O
. O

Feedback O
inhibition O
of O
DRN O
5 B
- I
HT I
release O
induced O
by O
ESCIT O
into O
the O
PFC O
was O
also O
attenuated O
in O
WKY O
rats O
. O

Chronic O
ESCIT O
induced O
upregulation O
of O
the O
DRN O
- O
PFC O
5 B
- I
HT I
system O
in O
WKY O
rats O
, O
with O
increases O
in O
basal O
5 B
- I
HT I
in O
the O
DRN O
, O
responsiveness O
to O
ESCIT O
in O
the O
DRN O
and O
PFC O
, O
and O
feedback O
inhibition O
, O
whereas O
downregulation O
of O
these O
effects O
was O
induced O
in O
Wistar O
rats O
. O

The O
finding O
that O
chronic O
ESCIT O
upregulates O
the O
5 B
- I
HT I
system O
in O
hyposerotonergic O
WKY O
rats O
may O
contribute O
to O
improved O
understanding O
of O
mechanisms O
of O
action O
of O
antidepressants O
, O
especially O
in O
depression O
with O
5 B
- I
HT I
deficiency O
. O

Bioconcentration O
of O
chromium B
in O
edible O
mushrooms O
: O
influence O
of O
environmental O
and O
genetic O
factors O
. O

Chromium B
concentrations O
were O
determined O
in O
167 O
samples O
of O
wild O
edible O
mushrooms O
, O
collected O
from O
three O
different O
sites O
( O
urban O
, O
traffic O
and O
pastureland O
areas O
) O
in O
Lugo O
( O
NW O
Spain O
) O
. O

The O
highest O
mean O
chromium B
levels O
( O
mg O
/ O
kg O
dry O
weight O
) O
of O
3 O
. O
5 O
and O
8 O
. O
0 O
, O
4 O
. O
5 O
and O
6 O
. O
2 O
, O
and O
6 O
. O
2 O
and O
4 O
. O
3 O
were O
found O
in O
Lycoperdon O
utriforme O
, O
Coprinus O
comatus O
and O
Agaricus O
campestris O
in O
H O
and O
RFB O
, O
respectively O
. O

The O
highest O
concentrations O
of O
chromium B
were O
observed O
in O
terrestrial O
saprophytic O
species O
in O
relation O
to O
mycorrhizal O
species O
. O

With O
respect O
to O
the O
underlying O
substrates O
, O
chromium B
concentration O
was O
lowest O
in O
the O
pastureland O
area O
( O
24 O
. O
6 O
mg O
/ O
kg O
dw O
) O
. O

All O
mushroom O
species O
were O
bioexclusors O
of O
chromium B
( O
BCF O
< O
1 O
) O
with O
statistically O
significant O
differences O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
consumption O
of O
mushrooms O
harvested O
from O
the O
areas O
investigated O
poses O
no O
toxicological O
risk O
to O
human O
health O
due O
to O
chromium B
. O

Synthetic O
pathway O
to O
22 O
, O
23 O
- O
dioxocholestanic O
chain O
derivatives O
and O
their O
usefulness O
for O
obtaining O
brassinosteroid B
analogues O
. O

Recognizing O
the O
functionality O
of O
the O
pentacyclic O
steroidal O
derivative O
7a O
as O
important O
synthon O
to O
obtain O
new O
brassinosteroid B
analogs O
, O
we O
have O
accomplished O
the O
derivatization O
of O
hecogenin B
, O
a O
sapogenin O
from O
the O
25R O
serie O
containing O
a O
carbonyl B
group O
at O
C O
- O
12 O
, O
to O
a O
22 O
, O
23 O
- O
dioxocholestanic O
chain O
derivative O
. O

Starting O
from O
hecogenin B
acetate I
( O
5a O
) O
or O
hecogenin O
tosylate O
( O
5b O
) O
, O
we O
obtained O
two O
pentacyclic O
derivatives O
( O
7a O
and O
7b O
) O
which O
were O
subjected O
to O
an O
oxidation O
reaction O
on O
the O
double O
bond O
at O
C O
- O
12 O
( O
23 O
) O
to O
obtain O
a O
22 O
, O
23 O
- O
dioxocholestanic O
chain O
, O
with O
the O
regeneration O
of O
the O
carbonyl B
group O
at O
C O
- O
12 O
. O

Reduction O
of O
the O
carbonyl B
groups O
lead O
to O
the O
20 O
- O
epi O
- O
12 O
, O
23 O
- O
dihydroxy O
- O
22 O
- O
oxo O
system O
11a O
- O
b O
. O

Designing O
, O
structural O
elucidation O
, O
comparison O
of O
DNA O
binding O
, O
cleavage O
, O
radical O
scavenging O
activity O
and O
anticancer O
activity O
of O
copper B
( I
I I
) I
complex O
with O
5 O
- O
dimethyl O
- O
2 O
- O
phenyl O
- O
4 O
- O
[ O
( O
pyridin O
- O
2 O
- O
ylmethylene O
) O
- O
amino O
] O
- O
1 O
, O
2 O
- O
dihydro O
- O
pyrazol O
- O
3 O
- O
one O
Schiff B
base I
ligand O
. O

Single O
crystal O
X O
- O
ray O
diffraction O
studies O
revealed O
that O
the O
copper B
( I
I I
) I
complex O
[ O
CuCl O
( O
PPh3 O
) O
L O
] O
has O
a O
distorted O
tetrahedral O
geometry O
around O
the O
central O
copper B
( I
I I
) I
ion O
. O

The O
antioxidative O
properties O
showed O
that O
the O
copper B
( I
I I
) I
complex O
has O
a O
strong O
radical O
- O
scavenging O
potency O
than O
ligands O
. O

Synthesis O
and O
biological O
evaluation O
of O
novel O
phosphatidylinositol B
3 O
- O
kinase O
inhibitors O
: O
Solubilized O
4 O
- O
substituted O
benzimidazole O
analogs O
of O
2 O
- O
( O
difluoromethyl O
) O
- O
1 O
- O
[ O
4 O
, O
6 O
- O
di O
( O
4 O
- O
morpholinyl O
) O
- O
1 O
, O
3 O
, O
5 O
- O
triazin O
- O
2 O
- O
yl O
] O
- O
1H O
- O
benzimidazole O
( O
ZSTK474 B
) O
. O

A O
range O
of O
4 O
- O
substituted O
derivatives O
of O
the O
pan O
class O
I O
PI O
3 O
- O
kinase O
inhibitor O
2 O
- O
( O
difluoromethyl O
) O
- O
1 O
- O
[ O
4 O
, O
6 O
- O
di O
- O
( O
4 O
- O
morpholinyl O
) O
- O
1 O
, O
3 O
, O
5 O
- O
triazin O
- O
2 O
- O
yl O
] O
- O
1H O
- O
benzimidazole O
( O
ZSTK474 B
) O
were O
prepared O
in O
a O
search O
for O
more O
soluble O
analogs O
. O

4 O
- O
Aminoalkoxy O
substituents O
provided O
the O
most O
potent O
derivatives O
, O
with O
the O
4 O
- O
O O
( O
CH2 O
) O
3NMe2 O
analog O
( O
compound O
14 O
) O
being O
identified O
as O
displaying O
the O
best O
overall O
activity O
in O
combination O
with O
good O
aqueous O
solubility O
( O
25 O
mg O
/ O
mL O
for O
the O
hydrochloride B
salt O
) O
. O

This O
compound O
was O
tested O
in O
a O
U87MG O
xenograft O
model O
, O
but O
displayed O
less O
potency O
than O
ZSTK474 B
as O
a O
result O
of O
an O
unfavorable O
pharmacokinetic O
profile O
. O

Two O
series O
of O
compounds O
with O
hydrazone B
derivatives O
( O
HZ1 O
- O
HZl2 O
, O
series O
1 O
) O
and O
oxadiazoline O
derivatives O
( O
OZ1 O
- O
OZ12 O
, O
series O
2 O
) O
of O
the O
2 O
- O
methyl O
- O
5 O
- O
nitro O
- O
1H O
- O
imidazole O
scaffold O
were O
designed O
and O
synthesized O
. O

Physicochemical O
properties O
and O
Lipophilic O
efficiency O
( O
LipE O
) O
analysis O
predicted O
higher O
intrinsic O
quality O
of O
the O
acylhydrazone B
derivatives O
( O
series O
1 O
) O
than O
their O
corresponding O
oxadiazoline O
analogues O
( O
series O
2 O
) O
. O

In O
vitro O
antiamoebic O
results O
supported O
the O
above O
findings O
and O
validated O
that O
the O
acylhydrazone B
derivatives O
( O
HZ1 O
- O
HZl2 O
) O
show O
better O
activity O
than O
the O
oxadiazoline O
derivatives O
( O
OZ1 O
- O
OZ12 O
) O
. O

MTT B
assay O
, O
using O
HepG2 O
cell O
line O
, O
revealed O
noncytotoxic O
nature O
of O
the O
compounds O
. O

Enmein O
- O
type O
diterpenoid B
analogs O
from O
natural O
kaurene O
- O
type O
oridonin O
: O
Synthesis O
and O
their O
antitumor O
biological O
evaluation O
. O

A O
series O
of O
enmein O
- O
type O
diterpenoid B
analogs O
( O
11 O
- O
20 O
) O
derived O
from O
natural O
kaurene O
- O
type O
diterpenoid O
oridonin O
were O
synthesized O
and O
biologically O
evaluated O
. O

Some O
compounds O
were O
more O
potent O
than O
positive O
control O
Taxol B
. O

The O
effect O
of O
intranasal O
oxytocin B
treatment O
on O
conditioned O
fear O
extinction O
and O
recall O
in O
a O
healthy O
human O
sample O
. O

Oxytocin B
( O
OT O
) O
is O
a O
mammalian O
neuropeptide O
that O
modulates O
activation O
of O
fear O
extinction O
- O
based O
neural O
circuits O
and O
fear O
responses O
. O

Role O
of O
quercetin B
in O
cadmium B
- O
induced O
oxidative O
stress O
, O
neuronal O
damage O
, O
and O
apoptosis O
in O
rats O
. O

The O
present O
study O
was O
carried O
out O
to O
evaluate O
the O
neuroprotective O
effect O
of O
quercetin B
( O
QE O
) O
in O
protecting O
the O
cadmium B
( O
Cd B
) O
- O
induced O
neuronal O
injury O
in O
frontal O
cortex O
of O
rats O
. O

A O
total O
of O
30 O
adult O
male O
Sprague O
- O
Dawley O
rats O
were O
randomly O
divided O
into O
three O
groups O
of O
10 O
animals O
each O
: O
control O
, O
Cd B
treated O
and O
Cd B
treated O
with O
QE O
. O

The O
Cd B
- O
treated O
group O
was O
injected O
subcutaneously O
with O
cadmium B
chloride I
( O
CdCl2 B
) O
dissolved O
in O
saline O
at O
a O
dose O
of O
2 O
ml O
/ O
kg O
/ O
day O
for O
30 O
days O
, O
resulting O
in O
a O
dosage O
of O
1 O
mg O
/ O
kg O
Cd B
. O

The O
rats O
in O
QE O
- O
treated O
groups O
were O
given O
QE O
( O
15 O
mg O
/ O
kg O
body O
weight O
) O
once O
a O
day O
intraperitoneally O
starting O
2 O
days O
prior O
to O
Cd B
injection O
, O
during O
the O
study O
period O
. O

To O
date O
, O
there O
is O
no O
available O
information O
on O
the O
effect O
of O
QE O
on O
neuronal O
injury O
after O
Cd B
exposure O
. O

Rats O
intoxicated O
with O
Cd B
for O
30 O
days O
, O
significantly O
increased O
tissue O
malondialdehyde B
( O
MDA B
) O
levels O
and O
significantly O
decreased O
enzymatic O
antioxidants O
superoxide B
dismutase O
, O
glutathione B
peroxidase O
and O
catalase O
in O
the O
frontal O
cortex O
tissue O
. O

Administration O
of O
QE O
with O
Cd B
significantly O
diminished O
the O
levels O
of O
MDA B
and O
significantly O
elevated O
the O
levels O
of O
enzymatic O
antioxidants O
in O
the O
frontal O
cortex O
tissue O
. O

The O
histopathological O
studies O
in O
the O
brain O
of O
rats O
also O
supported O
that O
QE O
markedly O
reduced O
the O
Cd B
- O
induced O
histopathological O
changes O
and O
well O
preserved O
the O
normal O
histological O
architecture O
of O
the O
frontal O
cortex O
tissue O
. O

The O
caspase O
- O
3 O
immunopositivity O
was O
increased O
in O
degenerating O
neurons O
of O
the O
Cd B
group O
. O

In O
conclusion O
, O
the O
results O
of O
the O
current O
study O
suggest O
that O
QE O
may O
be O
beneficial O
in O
combating O
the O
Cd B
- O
induced O
neurotoxicity O
in O
the O
brain O
of O
rats O
. O

We O
believe O
that O
further O
preclinical O
research O
into O
the O
utility O
of O
QE O
may O
indicate O
its O
usefulness O
as O
a O
potential O
treatment O
for O
neurodegeneration O
after O
Cd B
exposure O
in O
rats O
. O

Analysis O
of O
the O
inhibitory O
activity O
of O
Abeliophyllum O
distichum O
leaf O
constituents O
against O
aldose B
reductase O
by O
using O
high O
- O
speed O
counter O
current O
chromatography O
. O

We O
isolated O
five O
phenolic B
glycosides I
( O
acteoside O
, O
eutigoside O
B O
, O
isoacteoside O
, O
rutin B
and O
cornoside O
) O
from O
Abeliophyllum O
distichum O
leaves O
by O
high O
- O
speed O
counter O
current O
chromatography O
( O
HSCCC O
) O
using O
a O
solvent O
system O
of O
ethyl B
acetate I
: O
n B
- I
butanol I
: O
water O
( O
8 O
: O
0 O
. O
7 O
: O
5 O
) O
. O

We O
examined O
the O
inhibitory O
effect O
of O
these O
compounds O
on O
rat O
lens O
aldose B
reductase O
. O

The O
inhibitory O
effect O
of O
1 O
was O
5 O
. O
0 O
times O
greater O
than O
that O
of O
quercetin B
( O
7 O
. O
05 O
mu O
M O
) O
, O
which O
was O
used O
as O
a O
positive O
control O
. O

Pharmacologic O
inhibitor O
studies O
implicated O
several O
signaling O
mediators O
, O
including O
calmodulin O
and O
calcineurin O
, O
supporting O
the O
importance O
of O
TRPC6 O
- O
mediated O
calcium B
influx O
in O
this O
process O
. O

The O
inhibitors O
KN O
- O
92 O
and O
H89 O
were O
able O
to O
block O
both O
pathways O
in O
mutant O
TRPC6 O
expressing O
cells O
, O
as O
well O
as O
the O
prolonged O
elevation O
of O
intracellular O
calcium B
levels O
upon O
carbachol B
stimulation O
seen O
in O
these O
cells O
. O

